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AN EMPIRICAL EVALUATION OF THE ARIZONA
SEXUAL EXPERIENCE SCALE (ASEX) QUESTION-
NAIRE TO IDENTIFY SEXUAL DYSFUNCTION IN
PATIENTS OF THE SCHIZOPHRENIA SPECTRUM
Luciana Vargas Nunes, L. H. Dieckmann, F. S. Lacaz,
A. M. Costa, C. Daltio, R. A. Bressan, S. V. Nunes, J. J. Mari
Psychiatry, UNIFESP-Universidade Federal de Sa˜o Paulo, Sa˜o
Paulo, Brazil
Objective: The main aims of this paper are threefold: a) to assess the fre-
quency of sexual dysfunction in a sample of out-patients with schizophre-
nia and schizoaffective disorder under antipsychotic therapy; b) to
investigate the effect of different antipsychotics on sexual function;
and c) to evaluate the accuracy of the Arizona Sexual Experience Scale
(ASEX) to identify sexual dysfunction. Method: A cross-sectional study
of sexual function was conducted with one-year consecutive outpatients
from the Schizophrenia Program of the Universidade Federal de Sao
Paulo (Proesq), from February 2007 to January 2008. Patients, who
met DSM IV criteria for schizophrenia or schizoaffective disorder,
were asked to fulfill both the Arizona Sexual Experience Scale (ASEX)
and the Dickson Glazer Scale for the Assessment of Sexual Functioning
Inventory (DGSFi) at a single interview. Results: 137 patients entered the
study (86 were males and 51 were females). The sensitivity and specificity
of the ASEX at identification of sexual dysfunction in relation with
DGSFi scores were respectively: 80.8%, (95% CI = 70.0%–88.5%) and
88.1% (95% CI = 76.5%–94.7%), and the misclassification rate was
9,5%. The ROC curve comparing the ASEX and the DGSFi scores
revealed a value of 0.93 (CI = 0.879–0.970), with the optimum cutoff
point of ASEX for sexual dysfunction being 14/15. Sexual dysfunction
measured by ASEX was higher among females (79.2%) than for
males (33.3%), and this difference was statistically significant (v2 =
27.41, df = 1, P < .001). Conclusion: Patients under antipsychotic treat-
ment showed a high level of sexual complaints, and the ASEX question-
naire showed to be an accurate instrument to identify sexual dysfunction
in an out-patient sample of patients with schizophrenia and schizoaffec-
tive disorders. Females showed a higher frequency of sexual dysfunctions
than males and sexual drive and ability to reach orgasm were the most
affected areas. The use of antipsychotics, especially the combinations
of medications, was more likely to impair sexual functioning.
ID: 540733
METHODS FOR DETERMINING INTER-RATER
RELIABILITY OF THE PANSS: A REVIEW OF THE
LITERATURE
Kia Crittenden, C. Yavorsky, F. Ockun, K. Wolanski, K. Kobak
Clinical Operations, MedAvante, Inc., Hamilton, NJ, USA
Inter-rater reliability (IRR) is an important consideration in CNS trials,
as poor reliability increases error variance, which reduces study power
and increases the risk for type II errors. The increasing placebo response
in schizophrenia points to renewed examination of the role of clinical
ratings. The method for evaluating reliability impacts the reliability fig-
ures, eg, observation of tapes results in artificially higher IRR than in-
dependent interviews, as the former artificially reduces information
variance. Thus, the methodology for determining IRR is a critical factor
in interpreting a study’s results. To date there has been no systematic
review of the methods used in determining reliability of the PANSS,
and the relationship between method and level of IRR. We searched
Pub Med using keywords ‘‘PANSS’’ and ‘‘reliability.’’ In only 53% of
studies (18/34), the method for determining reliability was described:
these included rating tapes (9/34;26%), joint interviews (8/34;24%),
and a combination of both methods (1/34;3%). No studies used indepen-
dent interviews. Rater training was done in 56% (19/34) of studies. IRR
total PANSS score ranged from 0.63 to 0.71 for tapes and from 0.92 to
0.99 for joint interviews. The positive subscale ranged from 0.56 to 0.99
(tapes) and 0.72 to 0.99 for joint interviews, and the negative subscale
ranged from 0.27 to 0.90 for tapes and from 0.63 to 0.92 for joint inter-
views. Methodology for testing IRR is not often cited. Tape rating is the
most common method reported. Reliability on the PANSS using joint
methods is good, but unknown with independent assessments.
ID: 550710
COMPARING SCHIZOPHRENIA AND BIPOLAR
PROBANDS: NEUROPSYCHOLOGY,
NEUROPHYSIOLOGY AND FMRI
John A. Sweeney
Psychiatry, University of Illinois, Chicago, IL, USA
A better characterization of similarities and differences between schizo-
phrenia and affective psychoses is needed to define their diagnostic
boundaries and to clarify their overlapping and unique pathophysiolo-
gies. We contrasted untreated first episode patients with schizophrenia,
bipolar disorder and psychotic depression, and matched controls, on
a battery of neuropsychological, oculomotor and fMRI measures. Pre-
viously published data from the Pittsburgh first episode study will be pre-
sented together with data from our new sample from Chicago that now
includes 40 schizophrenia patients, 22 bipolar patients and 15 unipolar
depression patients. In both samples, neuropsychological data indicate
similar profiles of deficit across cognitive domains across disorders
that were more severe in schizophrenia patients. Profiles of oculomotor
deficit were more variable. Measures most heavily dependent on prefron-
tal systems were impaired in all groups but showed greater deficit in
schizophrenia. Preliminary analyses of fMRI data with oculomotor tasks
also suggest greater deficits in prefrontal systems in schizophrenia. Some
attention-dependent and sensorimotor tasks were equally or more im-
paired in one or both groups of patients with affective psychoses than
in schizophrenia. Patients with psychotic depression generally had the
least severe cognitive deficits, but uniquely manifested some specific mo-
tor system dysfunctions. These findings document neurobehavioral def-
icits in both affective and nonaffective psychotic disorders. The
similarities and differences in their severity and profile suggest that
the illnesses have somewhat different impacts across functional neural
systems, and also suggest promising phenotypic approaches for charac-
terizing unique and common neurocognitive deficits associated with
schizophrenia and psychotic affective disorders.
ID: 550510
MAJOR DEPRESSIVE EPISODES IN FIRST EPISODE
PSYCHOSIS
Kristin Lie Romm2, J. I. Rossberg1,2, O. A. Andreassen1,2,
E. A. Barrett3, A. Faerden2, I. Melle1,2
1Institute of Psychiatry, University of Oslo, Oslo, Norway;
2Department of Research and Education, Division of Psychiatry,
Ullevaal University Hospital, Oslo, Norway; 3Division of
Psychiatry, Aker University Hospital, Oslo, Norway
There are clear indications that depressive symptoms contribute to increased
morbidity and mortality in patients with schizophrenia spectrum disorders,
but the actual rate of patients experiencing clinically significant depressive
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symptoms in the early phases of the disorder (from before onset of psychotic
symptoms until start of first treatment) is not known. The main aims of this
study were to examine the prevalence of lifetime DSM-IV Major Depressive
Episode in a sample of patients with first episode schizophrenia spectrum
disorders, and to examine the demographic and clinical characteristics dis-
tinguishing this patient group (MDE) from patients that never had experi-
enced a Major Depressive Episode (Non-MDE). A total of 123 patients (age
18–65) from the ongoing longitudinal Thematic Organized Psychosis re-
search study (TOP) were included at the time of their first treatment. Diag-
noses were set according to SCID-I for DSM-IV (schizophrenia,
schizophreniform disorder, schizoaffective disorder and psychosis NOS).
Present symptom level was assessed by the Positive and Negative Syndrome
Scale (PANSS) and the Global Assessment of Functioning scale (GAF). Pre-
morbid functioning was measured by the Premorbid Adjustment Scale
(PAS). The duration of untreated psychosis (DUP) was measured as weeks
from first psychotic symptoms until start of first treatment. A total of 59
(48%) patients had experienced one or more MDE. Poor premorbid adjust-
ment in childhood and adolescence was significantly associated with more
depressive episodes. There were no significant differences between the MDE
and Non-MDE group for age, gender and DUP. With the exception of the
PANSS general score (which was higher in the MDE group), there were no
differences between the groups concerning positive and negative symptom
scores or GAF scores. This study shed more light on the frequency of MDE
among patients with first episode psychosis. The fact that as many as 48% of
the patients met the MDE criteria shows the importance of achieving more
knowledge about depressive symptoms among patients with first episode
psychosis.
ID: 550371
HEIGHTENED RATES OF SCHIZOAFFECTIVE
DISORDER AMONG IMMIGRANTS? A CROSS-
SECTIONAL STUDY
Akiah A. O. Berg1, I. Melle1,2, S. R. Aminoff1,
O. A. Andreassen1,2, E. Hauff1
,2
1Institute of Psychiatry, University of Oslo, Oslo, Norway;
2Department of Research and Education, Division of Psychiatry,
Ullevaal University Hospital, Oslo, Norway
Migration has been found to be a relevant risk factor in the development
of schizophrenia and other psychotic disorders. The purpose of this
study is to explore if migration is associated with particular symptoms
among psychosis patients exposed to migration (IM) compared to non-
immigrants (NI) patients. Our main hypothesis is that among an IM
group we will find a higher rate of schizophrenia-like psychotic symp-
toms in connection with mood episodes, suggesting possible heightened
rates of schizoaffective (SA) disorder compared to NI. We used natural-
istic cross-sectional data from a cohort of patients being treated for
schizophrenia- or bipolar-spectrum disorders in the greater Oslo region
(Thematic Organized Psychosis research (TOP) study). Exclusion crite-
ria was drug-induced psychosis, IQ < 70, or limited Scandinavian lan-
guage skills. Participants (age 18–65) received a DSM-IV diagnosis on
the basis of a SCID-I interview. Present symptom level was assessed
by the Positive and Negative Syndrome Scale (PANSS). Immigration
status was based on observed ethnicity, country of birth, mother tongue
and immigrant status of parents. The sample consisted of 435 partici-
pants with lifetime psychosis symptoms, whereof 27 % were 1st. or
2nd. generation IM. We found more IM with a DSM-IV diagnosis of
SA disorder (v2 = 8214, df = 1; P < .005), and more NI with a diagnosis
of Bipolar I (BPI) (v2 = 12,915, df = 1; P < .001). Logistic regression was
performed to explore main effects of diagnostic grouping for SA and BPI
in the context of independent variables. Results indicated that IM had
a 7,2 (CI = 2,4–21,6) times higher risk of receiving a SA disorder diag-
nosis (Wald = 12,609, df = 1, P < .001) than NI. ANOVA analyses of the
three PANSS subscales (positive, negative and general) showed similar
symptom patterns for IM and NI in the SA group, but significantly higher
positive (F = 18,848, df = 3, P< .001), and general symptoms (F = 9,396, df =
3, P < .001) for the BPI-IM group compared to the BPI-NI group. In con-
clusion we found that immigrant status was a significant predictor of re-
ceiving a SA diagnosis in our sample. Comparisons of symptom
patterns within diagnostic categories suggests that this finding was not
due to misclassification of affective disorders as belonging to the schizo-
phrenia spectrum in the IM group, but rather supports the hypothesis
that aspects of the migration experience are associated with specific clinical
symptom expression.
ID: 550226
IS SCREENING FOR PSYCHOSIS POSSIBLE IN
GENERAL POPULATION SAMPLES?
Tyrone D. Cannon1,2, R. Loewy3, C. E. Bearden2
1Psychology, UCLA, Los Angeles, CA, USA; 2Psychiatry and
Biobehavioral Sciences, UCLA, Los Angeles, CA, USA; 3Psychi-
atry, UCSF, San Francisco, CA, USA
The criteria used to ascertain youth at high clinical risk for psychosis em-
phasize the recent onset of sub-psychotic intensity psychotic-like symp-
toms. We have developed a self-report screening instrument (the
Prodromal Questionnaire or PQ) to provide an efficient screen for these
symptoms. Adolescents and young adults referred to a prodromal psychosis
research clinic completed the PQ and the Structured Interview for Prodro-
mal Syndromes. PQ positive symptom scores predicted a concurrent pro-
dromal or psychotic diagnosis with 92% sensitivity and 42% specificity. The
PQ thus shows good preliminary validity in detecting individuals with an
interview-based diagnosis of a prodromal or psychotic syndrome, but is not
sensitive to the threshold between prodromal and full psychosis. We also
assessed the rates of self-reported ‘‘prodromal’’ psychotic symptoms and
related distress in a college population (N = 1020). Participants’ responses
to the PQ were highly similar to the responses of non-psychotic-spectrum
patients in the original PQ validation sample, suggesting that the PQ may
perform similarly with a variety of populations. Applying the cutoff pro-
posed for screening treatment-seeking patients identified 43% of students,
while comparatively fewer participants (25%) endorsed items at the fre-
quency required for prodromal syndrome diagnosis by interview (ie,
weekly), and only 2% endorsed the positive symptom items as distressing.
Although attenuated psychotic experiences are commonly reported by
‘‘normal’’ young adults, frequent and distressing items identify a proportion
of students more consistent with the prevalence of psychotic-spectrum dis-
orders in the general population, which suggests a potential for future
screening of unselected samples.
ID: 550092
IMPRESSION-MANAGEMENT EFFECTS IN
PARANOIA ASSESSMENT
David Leland Roberts, J. M. Fiszdon, P. C. DeGeorge, C. Tek
Psychiatry, Yale University, New Haven, CT, USA
It is challenging to objectively measure undesirable personal characteristics
(eg, racism) due to participants’ tendency to portray a positive impression.
However, impression-management effects can be overcome with the use
of non-obvious measures. In schizophrenia, there is evidence linking para-
noia with an Externalizing-Personalizing Bias (EPB), a tendency to blame
negative experiences on the hostile intentions of others. However, this
finding is inconsistent, possibly due to participants’ efforts to appear
non-paranoid. The Social Cognition Screening Questionnaire (SCSQ)
uses non-obvious measurement to assess both EPB and efforts to under-
endorse EPB. The SCSQ is presented as a memory task consisting of
ten verbally-presented, second-person vignettes describing unpleasant
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social interactions. Each is followed by three Yes-or-No ‘‘memory’’ ques-
tions, one of which tacitly elicits a judgment about whether story characters
had negative intentionality toward the participant (eg, ‘‘Was the manager
trying to be rude to you?’’). Five of the vignettes include explicit evidence of
negative intentionality toward the participant, while five include no such
evidence. The SCSQ yields two scores: 1) An EPB score reflects endorse-
ment of negative intentionality in vignettes in which it is not present;
2) A Disavowal of Negative Intentionality (DNI) score reflects non-
endorsement of negative intentionality in vignettes in which it is present.
Outpatients with schizophrenia completed the SCSQ and PANSS (n =
38), and two established measures of paranoid attributional bias (n =
19). Convergent validity of the EPB score was supported by its correlations
with existing measures of paranoid attributional bias (r = .598; P = .011; and
r = .574; P = .010). The DNI score correlated significantly with the PANSS
suspiciousness item (r = .357; P = .033), whereas the EPB score did not (r =
.257; NS). Additionally, the DNI score discriminated between schizophre-
nia subgroups that were high (> 3; n = 14) versus low (< 3; n = 12) on the
PANSS suspiciousness item (t = 2.15; P = .042), whereas the EPB score did
not (t = 1.61; NS). This study provides preliminary evidence that individuals
with paranoia may under-report inferences of negative intentionality, and
that objective measurement of this effect may add incremental validity to
paranoia assessment in schizophrenia.
ID: 549924
ANTIDEPRESSANT EFFECT OF ANTIPSYCHOTICS
IN SCHIZOPHRENIA: COMPARISON OF TYPICAL
AND ATYPICAL ANTIPSYCHOTIC DRUGS
Antonio Reis Sa´, B. Avrichir, H. Elkis
Department and Institute of Psychiatry., Clinical Hospital, Faculty
of Medicine, University of Sa˜o, Brazil., Sa˜o Paulo, Brazil
Objective: Despite progress in the treatment of schizophrenia the efficacy of
atypical antipsychotics on depressive symptoms in schizophrenia is not well
established and for clarify this question we examined the effects of atypical
versus typical antipsychotics on depressive symptoms in a cohort study in
patients with schizophrenia. Methods: The data were drawn from a cohort,
naturalistic, observational study with 96 subjects diagnosed as being af-
fected by schizophrenia during a re-exacerbation phase. The patients
were taking typical or atypical antipsychotics. All subjects completed the
Calgary Depression Scale for Schizophrenia (CDSS) to rate the severity
of the depressive symptoms. The severity of schizophrenic symptoms
was rated by the Positive and Negative Syndrome Scale (PANSS) and
the Clinical Global Impression (CGI) severity and improvement scales.
Assessments of scales above were undertaken at baseline, 8 weeks, 16 weeks
and 24 weeks. Results: The PANSS total score higher than 70 and female
gender were significantly associated with the presence of depressive
symptoms. Global improvement of depressive symptoms was associated
with use of antipsychotics in general, however atypical antipsychotics
showed a statistically significant effect when compared to typical antipsy-
chotics. Conclusion: This observational study provides evidence that
atypical antipsychotics are more effective than typical antipsychotics on
the depressive symptoms in patients with schizophrenia.
ID: 549525
AFFECT IN SCHIZOPHRENIA: IMPLICATIONS FOR
DSM V AND RESEARCH
Dolores Malaspina1,2, J. W. Messinger1,3, V. Prudent1,
E. Mendelsohn4, D. Antonius1
1Psychiatry, New York University School of Medicine, New York,
NY, USA; 2Psychiatry, Columbia University, College of Physicians
and Surgeons, New York, NY, USA; 3Psychology, Long Island
University, Brooklyn, NY, USA; 4Psychology, Emory University,
Atlanta, GA, USA
A flat or inappropriate facial affect has been a consistent finding among
a portion of people with schizophrenia from the earliest descriptions of
the disease. Flat affect (restricted, blunted) describes a lack of observable
emotional reactivity and inappropriate affect is the term for an incongruous
facial emotional expression. Kraepelin viewed flat affect as indicative of
a lack of emotional experience. Bleuler also observed incongruence between
emotional expression and self-reported experience in his schizophrenia
patients. Both Kraepelin and Bleuler agreed that abnormalities in affect
denoted a defective or diminished emotional expression. As such, anchored
ratings of the magnitude of affect abnormalities may be important indica-
tors of the success of new treatments for the core emotional deficits in the
disease. Additionally, as the truly heterogeneous nature of the schizophrenia
syndrome has been better appreciated, the possibility of using stable flat af-
fect as a categorical tool for subtyping schizophrenia has been supported in
numerous studies.
ID: 549399
ANTI-GAD65, NMDAR AND VGKC ANTIBODIES
DETECTED IN FIRST EPISODE PSYCHOSIS
Belinda Lennox1,2, M. Zandi3, S. Irani4, A. J. Coles3, A. Vincent4
1Psychiatry, University of Cambridge, Cambridge, United Kingdom;
2Cameo, Early Intervention for Psychosis service, Cambridgeshire
and Peterborough NHS Foundation Trust, Cambridge, United
Kingdom; 3Neurology, University of Cambridge, Cambridge, United
Kingdom; 4Neuro-Immunology, University of Oxford, Oxford,
United Kingdom
There are many lines of evidence to suggest that schizophrenia may be
an autoimmune disorder. To date there have been no reports of path-
ogenic antibodies in cases of pure psychosis. However in cases of lim-
bic encephalitis, where psychosis is often present, there have been new
serum autoantibodies identified, which have been responsive to immu-
notherapy. Our aim was to screen serum from cases of first episode
psychosis for these antibodies. Methods: 16 patients under the care of
Cameo (www.cameo.nhs.uk). Serum collected within six months of
symptoms (range 2–26 weeks, mean 8 weeks). Serum was also col-
lected from 22 patients with chronic schizophrenia (length illness
>2 years) and 23 healthy controls. Voltage gated potassium channel
(VGKC)-Ab titres were measured by radioimmunoassay (Vincent et
al. 2004), and anti GAD65 antibodies measured by radio-immunopre-
cipitation assay using 125I (RSR Cardiff). Anti-NMDAR antibodies
were measured:HEK cells were transfected with NR1 and NR2B sub-
units and incubated with patient serum and a fluorescent antihuman
secondary to detect cell surface binding. Results: One case with
raised NMDAR antibodies, one with raised VGKC antibodies and
three with raised GAD antibodies were identified in the first episode
group. No antibodies were found in the chronic patients, or controls.
Discussion: These cases were all under the care of a first episode
psychosis service. None had any signs of organic illness. None had
features suggestive of limbic encephalitis. No antibodies were identi-
fied in chronic group, in keeping with other studies of autoimmune
mediated neurological disorders. Each of these antibodies identified
has validity in having an aetiological role in schizophrenia. If the
incidence found in this group is replicated, 31% of schizophrenia
may be autoimmune, and amenable to immunotherapy. We should
now aim to establish the frequency of these antibodies in all cases
of first episode psychosis, and introduce early recognition and
treatment.
ID: 549060
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NEUROPSYCHOLOGICAL TESTING AND
STRUCTURAL MAGNETIC RESONANCE IMAGING
IN THE DIAGNOSIS OF SCHIZOPHRENIA AFTER
A FIRST PSYCHOTIC EPISODE
Elissaios Karageorgiou1, R. Gollub3, N. Andreasen4, B.-C. Ho4,
J. Lauriello5, V. Calhoun5, S. C. Schulz2, A. P. Georgopoulos1,2
1Neuroscience, University of Minnesota, Minneapolis, MN, USA;
2Psychiatry, University of Minnesota, Minneapolis, MN, USA;
3Harvard University, Boston, MA, USA; 4University of Iowa, Iowa
city, IA, USA; 5University of New Mexico, Albuquerque, NM, USA
Introduction: Making an accurate diagnosis after a first psychotic episode
is important for initiating treatment and counseling patients and families.
Previous work by our group demonstrated the potential of applying linear
discriminant analysis (LDA) to structural magnetic resonance imaging
(sMRI) and neuropsychological (NP) testing in adolescents (Pardo et al.
2006). In this study, we developed sMRI and NP models for disease diag-
nosis and, additionally, cross-validated the accuracy of our modeling algo-
rithms. The analysis was made on a subject subsample characterized by
a first psychotic episode from the larger MIND Clinical Imaging Consor-
tium (MCIC) sample. Methods: Prospective first-episode schizophrenic
patients (47 controls; 28 patients) underwent structured interview evalua-
tions, sMRI scanning and NP testing. In the ensuing analysis 75 NP and 95
sMRI variables were used. We developed diagnostic models based on the
following algorithms. First, a stepwise-LDA was performed, where subsets
of the original variables were used in the final models. Second, an LDA was
performed on latent variables, which were in turn created by Principal
Component Analysis (PCA) and selected according to Humphrey-Ilgen
parallel analysis. Error estimation of the modeling algorithms was evalu-
ated by leave-one-out external-cross-validation. The described analyses
were performed on NP and sMRI variables both in combination and sep-
arately. Results: The following cross-validation results were obtained.
sMRI only. a) Stepwise-LDA: 53.6% sensitivity and 74.5% specificity, b)
PCA-LDA: 67.9% sensitivity and 72.3% specificity. NP only. a) Step-
wise-LDA: 78.5% sensitivity and 85.1% specificity, b) PCA-LDA: 78.5%
sensitivity and 91.5% specificity. Combined sMRI-NP. a) Stepwise-
LDA: 60.7% sensitivity and 72.3% specificity, b) PCA-LDA: 89.3% sensi-
tivity and 93.6% specificity. Conclusions: These results reveal that a) the
combination of sMRI and NP variables can significantly improve diagnos-
tic accuracy, b) the PCA-LDA approach accounting for more of the var-
iance in the data is more robust than Stepwise-LDA, c) NP variables are
more informative than sMRI indicating that cognitive deficits precede
structural anomalies. This work verifies the accuracy of the applied mod-
eling algorithms and, by extension, any of the models produced in the pro-
cess. To obtain an error estimate for a specific model to be used in clinical
practice, that model will have to be tested on a separate test sample.
ID: 548502
A PARADIGM SHIFT: CRITICAL CHANGES
ANTICIPATED IN THE CLASSIFICATION OF
PSYCHOTIC DISORDERS
William T. Carpenter1,2
1Psychiatry, University of Maryland School of Medicine, Baltimore,
MD, USA; 2Maryland Psychiatric Research Center, University of
Maryland School of Medicine, Baltimore, MD, USA
DSM-V, when published in 2012, will shape the clinical care, education, and
research agendas for psychotic illnesses for the following decade. It was pre-
viously hoped that classification would be reorganized based on etiological
and pathophysiological evidence that would move diagnoses from syn-
dromes to disease entities. In the absence of sufficient evidence, critical issues
related to a more modest modification of DSM-IV are addressed. These
issues, briefly stated, are: 1) Criteria emphasize reality distortion and neglect
avolition, psychomotor and cognitive pathology; 2) Schizoaffective schizo-
phrenia is weak on validity and reliability, but is clinically useful; 3) Psycho-
sis NOS is over-utilized, and there is inadequate data on psychotic disorders
other than schizophrenia; 4) Data from early detection studies has not been
integrated with classification; 5) Similarities between cases of schizophrenia
and cases on the diagnostic borders raise questions regarding bipolar disor-
ders and schizophrenia spectrum personality disorders; and 6) The role of
affect pathology in classification of psychotic disorders. Addressing these
issues is an important challenge, but a more substantial basis for advancing
classification relates to a proposed paradigm shift. A dimensional system
may augmentdiagnostic classes. This presentation will outline psychopath-
ological dimensions based on evidence that domains of pathology represent
critical issues for clinical care and education, and provide a more heuristic
framework for research. Individual cases within a class vary in which
domains of pathology are manifest, and domains of pathology may better
explain across boundary similarities. Dimensions include some diagnostic
criteria (eg, negative symptoms) and some additional features (eg, depres-
sion, cognition). A tentative model for diagnostic criteria and pathological
dimensions for schizophrenia will be presented for audience critique.
ID: 548047
THE AUSTRALIAN SCHIZOPHRENIA RESEARCH
BANK (ASRB): THE DEVELOPMENT OF AN ELEC-
TRONICALLY DELIVERED CLINICAL ASSESS-
MENT BATTERY
Carmel Maree Loughland1,2, J. Richards1,2, M. Aphale1,2,
F. Henskens1,2, V. J. Carr1,2, S. V. Catts1,4, A. Jablensky1,3,
P. Michie1,2, B. J. Mowrey1,4, C. Pantelis1,5, U. Schall1,2,
R. J. Scott1,2, T. J. Lewin1,2
1Centre for Brain and Mental Health Research, Schizophrenia
Research Institute, Newcastle, NSW, Australia; 2University of
Table.
sex/
age antibody
assay
level
(normal
range)
clinical
features
other
diagnostic
tests outcome
F/20 GAD65 3904cpm
(<2500)
3/7 elated
mood,
paranoid
psychosis
repeat GAD
after 18/
12 < 3u/l
remitting course
for 6 months,
treated with
Risperidone.
well since
M/20 GAD65 5581cpm
(<2500)
2/12
paranoid
psychosis,
catatonia
5/12 admission,
continued
negative
symptoms
M/25 GAD65 21622cpm
(<2500)
2/52
paranoid
psychosis
improved after
2/12 on
Olanzapine
disengaged
from follow up
F/22 VGKC 2300 at
1ul cpm
(<100)
2/52 paranoid
psychosis,
insomnia,
overactivity
MRI normal,
Naþ normal,
no evidence
paraneoplastic
syndrome
gradual
improvement
over 3/12 on
Risperidone
M/21 NMDAR þve 2/52 insomnia,
elated mood,
paranoid
and grandiose
delusions
No evidence
teratoma
Improved after
3/12
Olanzapine
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Newcastle, Newcastle, NSW, Australia; 3University of Western
Australia, Perth, WA, Australia; 4University of Queensland, Bris-
bane, QLD, Australia; 5University of Melbourne, Melbourne, VIC,
Australia
The Australian Schizophrenia Research Bank (ASRB) was established in
2007 to collect cross referenced diagnostic, neuropsychological, anatomical
(MRI) and genetic data from 2000 people with schizophrenia and 2000
healthy age and gender matched controls. A clinical assessment battery
(CAB), administered over 3 hours, was developed and consists of a struc-
tured diagnostic interview, clinical and family history, measures of neuro-
psychological and cognitive performance (WTAR, WASI, RBANS,
COWAT), symptom (SANS) and general functioning (GAF) ratings.
This large scale data collection across multiple Australian sites necessitated
a quality-controlled, time and cost effective data collection strategy. To this
end, the ASRB has developed an electronic version of the assessment bat-
tery called eCAB. The eCAB was developed using SQL programming. Data
is entered directly into the software by assessment officers using a lap top
computer. Each assessment item is presented in a question and answer for-
mat, and the program allows navigation through questions with comment
boxes for note taking. Quality control parameters for data input and
a checking mechanism at the end of the assessment ensure all questions
are answered. Scoring formulae embedded into the program calculate
raw scores, standard scores and factor scores for the neuropsychological
evaluations and rating scales, reducing scoring time and error. The
OPCRIT algorithm (Craddock et al., 2006) is used to derive diagnostic con-
firmation based on DIP answers. Completed assessments are uploaded to
the ASRB central server in encrypted format for access by researchers. The
eCAB is a time and cost efficient method for collecting research data, and
significantly reduces data handling errors through automatic score calcu-
lations. It is well tolerated by patients and controls alike, and eliminates the
need for paper assessment storage in large scale projects such as the ASRB.
ID: 550847
A NEW DIAGNOSTIC CLASS: THE PRODROMAL
RISK SYNDROME FOR FIRST PSYCHOSIS
Thomas McGlashan1, J. Addington2, K. S. Cadenhead3,
T. D. Cannon4, B. A. Cornblatt5, R. Heinssen6, D. O. Perkins7,
L. J. Seidman8, M. T. Tsuang3,8, E. F. Walker9, S. W. Woods1
1Psychiatry/Medicine, Yale University, Branford, CT, USA;
2Psychiatry, University of Toronto, Toronto, ON, Canada; 3Psy-
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Behavioral Sciences, UCLA, Los Angeles, CA, USA; 5Psychiatry,
Zucker Hillside Hospital, Long Island, NY, USA; 6Schizophrenia
Spectrum Disorders Research Program, NIMH, Bethesda, MD,
USA; 7Psychiatry, University of North Carolina, Chapel Hill, NC,
USA; 8Psychiatry, Harvard Medical School, Boston, MA, USA;
9Psychology/Psychiatry, Emory University, Atlanta, GA, USA
Since Falloon’s seminal pilot study in 1992 (1), research on early detection
and intervention in psychotic disorders has demonstrated that reliably iden-
tifiable clinical syndromes can be identified in help-seeking persons which
are also ‘‘prodromal’’, meaning they signal a very high risk for developing
(converting to) psychosis in the near future, ie, within 2–3 years (2). A Scale
of Prodromal Symptoms (SOPS) embedded within a Structured Interview
for Prodromal Syndromes (SIPS) has been developed by the presenter and
colleagues and used in ‘‘prodromal’’ clinics nationally, and internationally
in studies of the natural course and treatment of these clinical high risk
syndromes (3). This presentation will include: 1) a review of prodromal as-
sessment from Falloon (1) to Yung and McGorry (4) to Miller and McGla-
shan (3), 2) reliability studies of the SIPS and SOPS prodromal syndromes
(5), 3) early longitudinal studies validating high risk for psychosis in these
syndromes (4), 4) a later study of 372 patients meeting SIPS/SOPS prodro-
mal criteria (6) showing predictive accuracy for psychosis comparable to
other areas of preventive medicine and (7) an unpublished study comparing
the NAPLS prodromal sample with a) 195 natural subjects, b) 200 help-
seeking persons who do not develop psychosis, c) 40 familial (genetic)
high risk subjects, and d) 53 persons with Schizotypal personality disorder.
The groups are compared across the symptoms, functioning, comorbidity,
family history, and course of illness domains originally identified by Robins
and Guze as validating psychiatric syndromes. The data from these studies
collectively support the inclusion of the Prodromal Risk Syndromes for
First Psychosis in DSM-IV alongside traditional diagnoses in the Psychotic
Disorders spectrum. Specific criteria have been formulated. The clinical,
therapeutic, scientific, ethical, and political issues involved in adding a re-
liably identifiable and potentially treatable risk syndrome to the DSM-V
psychotic disorders will also be discussed (8).
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A TAXOMETRIC ANALYSIS OF NEGATIVE
SYMPTOMS IN THE WHO TEN-COUNTRY STUDY
OF SCHIZOPHRENIA
Amy Lynn Wilson, J. J. Blanchard
Psychology, University of Maryland, College Park, College Park,
MD, USA
It has been proposed that enduring primary negative symptoms, or deficit
symptoms, reflect a distinct subtype of schizophrenia—the deficit syndrome
(Carpenter et al., 1988). Although differences between deficit and nondeficit
schizophrenics are suggestive of a distinct and separate disease process
(Buchanan and Carpenter, 1994), these findings are also consistent with a
dimensional-only model where the deficit syndrome merely reflects an ex-
treme on a continuum of severity. Taxometric statistical methods (Waller
and Meehl, 1998) allow for a quantitative examination of whether a taxonic
or latent class model best describes negative symptoms in schizophrenia. Us-
ing suchmethodsBlanchardet al. (2005) haveshown thatnegative symptoms
are taxonic. In this study we sought to replicate these findings in a larger and
more diverse sample. The current investigation is a taxometric analysis of the
World Health Organization Ten-Country Study of Schizophrenia (Jablensky,
et al., 1992). Negative symptom data from a subset of 694 schizophrenia par-
ticipants within the WHO study were analyzed using the taxometric methods
of maximum covariance analysis (MAXCOV) and mean above minus below
a cut (MAMBAC). Results from MAXCOV and MAMBAC indicated a
latent class with base rates of 16% and 18%, respectively. These results
are consistentwith a categorical view of negative symptoms in schizophrenia.
ID: 551893
SCHIZOPHRENIA COLLABORATIVE RESOURCE
(SCORE) TOOL: TRACKING PATIENT PROGRESS
Stephen Rodriguez1, C. A. Bossie1, W. Macfadden1,
J. T. Haskins1, J. Docherty2
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA;
2Joan and Sanford I. Weill Medical College and Graduate School of
Medical Sciences of Cornell University, White Plains, NY, USA
Unlike many other chronic disorders, stages of illness and disease progres-
sion for patients with schizophrenia are not well characterized. This gap in
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understanding the course and stages of the illness impacts expectations, goal
setting, recognition of clinically relevant change, and ultimately overall pa-
tient management. We describe software, entitled the Schizophrenia Collab-
orative Resource Tool (SCoRe), that identifies the stage of illness, creates
a personalized patient profile, and tracks patient progress over time. A
group of clinicians who are experts in the treatment of patients with schizo-
phrenia were involved in the development of this tool. Literature reviews
were conducted and data from clinical trials were analyzed to guide the clini-
cians in describing stages of illness and associated symptom severity and
level of functioning. A software tool designed to capture information about
the status of patients with schizophrenia was then developed for use in clin-
ical practice. This interactive program captures information (from both cli-
nician and patient) on current interventions, symptom severity, social
functioning, stress tolerance, cognition, and physical health. The patient’s
illness is staged according to an algorithm that considers the type of clinical
intervention needed and the severity of core symptoms of schizophrenia.
Four stages of illness were defined based on both clinician input and
data analysis: 1) acute, 2) stabilization, 3) stable, and 4) remission. These
stages are reassessed at each subsequent visit. This information can then
be used to develop treatment goals and to track patient progress over
time. The program can also provide graphical outputs of an individual
patient’s clinical profile over time. SCoRe may help in the management
of patients with schizophrenia. It can identify milestones for improvement
throughout the course of illness toward which both the patient and clinician
can strive to achieve. Additionally, this software provides physicians with
a mechanism to record and track patient progress and assist with the
development of treatment goals. Supported by funding from Ortho-McNeil
Janssen Scientific Affairs, LLC.
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DEVELOPMENT AND INITIAL PSYCHOMETRIC
EXPLORATION OF A CLINICAL GLOBAL
IMPRESSION SCALE FOR SCHIZOAFFECTIVE
DISORDER (CGI-SCA)
Michael Allen1, J. Bartko2, J. P. Lindenmayer3, D. G. Daniel4,
C. M. Canuso5, C. Kosik-Gonzalez5, J. Adams6, D. Revicki7,
G. Garibaldi8
1University of Colorado School of Medicine, Denver, CO, USA;
2Independent Consultant, Newville, PA, USA; 3New York Univer-
sity School of Medicine, New York, NY, USA; 4United BioSource
Corporation, McLean, VA, USA; 5Ortho-McNeil Janssen Scientific
Affairs, LLC, Titusville, NJ, USA; 6i3 Research, Midland, MI,
USA; 7United BioSource Corporation, Bethesda, MD, USA;
8Roche Pharmaceuticals, Nutley, NJ, USA
Currently, there is no rating scale specific to schizoaffective disorder (SCA).
This study tests the psychometric properties of a new scale, the Clinical
Global Impression for Schizoaffective Disorder (CGI-SCA), using the fa-
miliar 7-point format to measure positive, negative, manic, depressive
and global severity and change. Experts adapted the CGI and developed
a manual for evaluation of patients with SCA. Data for psychometric ex-
ploration of the CGI-SCA were gathered during training for an interna-
tional multicenter drug trial using the CGI, PANSS, HAM-D-21 and
YMRS. Exploratory data were obtained using 132 investigators from the
United States (N = 41), India (N = 35) and Eastern Europe (N = 56) rating
2 videotapes. Inter-rater reliability was initially evaluated using intra-class
correlation (ICC) and convergent and divergent validity using Cramer’s V.
Effect sizes were calculated for sensitivity to change. A questionnaire exam-
ined content validity. Power analysis using the training data suggested that
with sufficient variability among subjects, inter-rater reliability could be
demonstrated with 2 raters and 12 subjects. This formal assessment was ac-
complished using 12 sets of videotaped interviews and 2 additional raters.
Test-retest reliability was assessed with 10 randomly selected raters from
each region rating the same tapes on 2 occasions separated by a minimum
of 2 weeks and maximum of 4 weeks. Inter-rater reliability varied across the
3 geographic regions. ICC ranges: CGI-Manic, 0.829–0.948; CGI-Depres-
sive, 0.916–0.972; CGI-Positive, 0.245–0.759; CGI-Negative, 0.464–0.624;
CGI-Global, 0.005–0.428. Pairs of ratings, eg, YMRS and CGI-Manic,
converged in 5 of 6 cases (Cramer’s V 0.44–0.82) and diverged in 3 of 5,
eg, CGI-Positive vs CGI-Manic (Cramer’s V 0.64–0.76). Sensitivity to
change ranged in effect size from 2.7 to 12.7. Overall, raters in each region
concurred that the CGI-SCA was useful, with 90% or more agreeing that the
CGI-SCA captured a large fraction of the variance. Formal testing of inter-
rater reliability found ICCs of 0.5–0.883. Test-retest reliability ranged from
0.444 to 0.888. Initial psychometric examination indicates at least moderate
inter-rater and test-retest reliability for these symptom domains and good
sensitivity to change. Content validity was high in the United States, India
and Europe. These results suggest that the CGI-SCA may be useful in
clinical trials. Supported by Ortho-McNeil Janssen Scientific Affairs, LLC.
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DIMENSIONAL CLASSIFICATION OF SCHIZO-
PHRENIA
Patricia Beatriz Estani, P. B. Estani
Department of Neurocognition and Neurobiology of Schizophrenia,
Neuropsychiatric Medical Hospital Dr. L.S. Morra, Cordoba,
Argentina
Introduction: The objective of this research is to propose a simple, dimen-
sional classification of schizophrenia, based on the concept of endopheno-
types (Gottesman, 2003). Methods: A total of 1200 participants were the
subjects. Neuropsychological tests were applied . We operationalized two
neurocognitive endophenotypes: sensorial gating and cognitive perfor-
mance. Results: A: Dimensional Classification of Schizophrenia: Structural
dimensions. A1: Genetically-defined Dimensions, as a WorkingGroup1. Neg-
ative Schizophrenia and 2. Positive Schizophrenia. B. The Longitudinal Diag-
nosis of the Disease: Longitudinal Dimensions. B1. The Continuous
Dimensions: The dimensions as phasesof a continuum from a pre-clinical state
to a more chronic, pathological state. 1) the schizophrenia prodrome. 2) first
episodeof illness.3)TheSpontaneousAmileorationSyndrome:typicallyactive
phase or positive symptoms. 4) A progressive neurodegeneration and neuro-
deterioration phase. 5) Deficit Syndrome. Conclusions: The classification
allows full inclusion of the neurocognitive endophenotypes in the classification
ofschizophrenia,definingthegenotypestobenefit theunderstandingandtreat-
ment of schizophrenia. The full explanation of this categorization will be pre-
sented along with the results of this pilot sample.
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SCHIZOPHRENIA AT THE BORDERS WITH
BIPOLAR DISORDER AND SCHIZOTYPAL
PERSONALITY
Larry J. Siever
Psychiatry, Mt. Sinai School of Medicine, New York, NY, USA
In order to delineate similarities and differences between schizophrenia
(SCZ) and schizophrenia spectrum personality pathology, on the one
hand, and SCZ and bipolar disorder (BD), on the other for the purposes
of defining the relationship between these disorders in DSM-V, external
validators, evaluated by imaging methodology including functional
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imaging and measurement of D1 binding and raclopride displacement, bio-
markers, physiologic measures, cognitive status, genetic data, environmen-
tal risk factors, course, and treatment response will be compared between
schizotypal personality disorder (SPD) and SCZ and between BP and SCZ
incorporating new data from our and other laboratories. These studies sug-
gest that SCZ and SPD share structural and functional imaging character-
istics, cognitive profile, and asociality but are distinguished by the
neurobiology of dopaminergic activity, course of illness, comorbidity,
and treatment response. SPD and schizophrenic patients both show volume
decreases, with sparing of frontal lobe in SPD. SPD patients, in contrast to
schizophrenia patients overactivate instead of underactivate prefrontal cor-
tex, recruit compensatory regions (eg, BA10) doing cognitive tasks, are
more vigilance on a startle-blink task, and evidence lesser activation of
the dopamine system on provocation than SCZ patients. In contrast,
SCZ and BD, both of which may be characterized by psychosis, appear
to share dopaminergic hyperactivity and reduced gabaminergic markers
as measured in imaging and neurochemical studies, treatment response
to dopamine antagonists, genetic antecedents such as neuroregulin 1,
and altered physiology. BP and SCZ patients both share decreases in
grey matter, greater in SCZ patients, reduced NAA on MRS, abnormal
PPI, P300, and pursuit maintenance, while BP patients have better pre-
served cognitive function and intact MMN. SPD thus appears to be related
to schizophrenia as reflected as part of the schizophrenia spectrum while
bipolar disorder and schizophrenia share complementary characteristics
reflecting a diathesis to psychosis, reflected in neurotransmitter (DA,
GABA) abnormalities.
ID: 551702
STRESS REACTIVITY IN ULTRA-HIGH RISK
PATIENTS: THE INFLUENCE OF CLINICAL
SYMPTOM LEVELS, LIFE STRESS, SOCIAL
SUPPORT AND OTHER PSYCHOSOCIAL FACTORS
Gretchen Louise Sholty1, J. C. Sun1, K. I. Mathis1, P. Bachman1,
T. J. Williams1,2, S. E. Taylor1, K. H. Nuechterlein1,2,
T. D. Cannon1,2, C. E. Bearden2, C. M. Yee1,2
1Psychology, UCLA, Los Angeles, CA, USA; 2Psychiatry and
Biobehavioral Sciences, UCLA, Los Angeles, CA, USA
From the perspective of the diathesis-stress model of schizophrenia, life
stress is likely a critical factor in the development of psychosis. It has been
suggested that the hypothalamic-pituitary-adrenal (HPA) axis may serve
as a biological pathway underlying the relationship between stress and
illness expression (eg, Corcoran et al., 2003). The present study sought
to elucidate this relationship in individuals at ultra-high risk (UHR)
for psychosis by examining HPA activity at rest and in response to a psy-
chosocial stressor. Previous studies investigating the stress response in
schizophrenia have shown that patients display higher resting cortisol rel-
ative to healthy individuals and a blunted response to stress (eg, Jansen
et al., 2000). Heightened resting cortisol levels also have been observed in
schizotypal personality disorder, possibly reflecting vulnerability to
schizophrenia (Walker et al., 1996). Although prior research has exam-
ined cortisol reactivity in patients with schizophrenia-spectrum disorders,
less is known about the relationship between risk status for psychosis and
the stress response. In the present study, the Trier Social Stress Test
(TSST) was administered to 33 UHR individuals, as determined by the
Structured Interview for Prodromal States (Miller et al., 2002), and 20
healthy comparison subjects. Salivary cortisol was sampled before and
immediately after the TSST. UHR participants were later subdivided
into those who subsequently developed a psychotic disorder (n = 10)
and those who did not (n = 23) over the following 12–24 months. Initial
results suggest that among the UHR individuals, those who converted to
psychosis had higher resting cortisol relative to non-converters and
healthy participants. Both UHR groups showed blunted cortisol reactiv-
ity to the TSST as compared to healthy individuals, who exhibited a robust
response to the stressor. These findings support the view that the stress
response may be a marker of evolving psychosis. It is unclear, however,
if the distinct patterns of HPA reactivity among UHR patients who con-
verted might be due to their vulnerability for psychosis, the acuity of their
illness and related increases in life stress, or a combination of these factors.
Behavioral ratings of life stress, clinical symptom levels and their rele-
vance to this hypothesis are examined, as well as relationships between
cortisol reactivity and self-report measures of coping style, social support,
and early life adversity.
ID: 551667
PERSONALITY TRAITS PREDICT PSYCHOTIC
TRANSITION IN ULTRA HIGH RISK
Peter M. Dingemans, R. van de Flierte, H. Becker, D. Nieman,
D. Linszen
Psychiatry, Academic Medical Center, Amsterdam Z.-O.,
Netherlands
This is the first study to deal with personality traits in the transition of Ultra
High Risk Subjects. In a Ultra High Risk group for psychosis (Dutch Pre-
diction Study for Psychosis: subjects (n = 77) rated the Schizotypal Person-
ality Questionnaire (SPQ) and a DSM-IV screener (PDQ-R)for personality
disorders at the start of the study. After a median follow up time of 24 months
transitioners were compared with non-transitioners on the SPC en SCID-II
subscales with regard to transition (yes/no) and time to transition (multivar-
iate survival with correction; two sided P = .10). SPQ-factors 2 (negative
schizotypy) and factor 3 (desorganization)turned out to be the best predic-
tors for transition (yes versus no) and speed of transition. Conclusion is that:
1) personality traits influence transition into psychosis; 2) schizotypy
concept is applicable to UHR, 3) SPQ is a better predictor for transition
than PDQ-R.
ID: 551291
AN INNOVATING TOOL FOR THE EARLY
DIAGNOSIS OF SCHIZOPHRENIA AND OTHER
PSYCHIATRIC DISORDERS
Helene Wilquin1,2, Y. Delevoye-Turrell1
1Lab. URECA, University of Lille Nord de France, Villeneuve
d’Ascq, France; 2Clinic Lautreamont, Loos, France
The phase before the emergence of a first episode psychosis is today at-
tract a widespread interest in the field of clinical research of schizophrenia.
Indeed, it has been shown that the earlier patients are treated, the better
their outcome. It is also important from a preventive perspective. How-
ever, the prodromal phase is difficult to detect as it is characterised by
many none specific behavioural and cognitive deficits. The most widely
used approach is an interview for the detection of ultra-high risk
(UHR) patients (McGorry, Yung 1996). This test combines symptoms
and signs with other risk factors, eg, age, family history, personality dis-
order. This approach has revealed to be promising but its time consuming.
The aim of our work was to see if non-verbal motor tasks could be as
efficient in dissociating UHR, first episode and chronic patients with
schizophrenia. A load cell was used to quantify those motor disorders
and agency impairments that are known to be affected in schizophrenia
(Bulot et al. 2007; Delevoye-Turrell et al. 2003). The CAARMS (Compre-
hensive Assessment of At Risk Mental State—Yung et al., 2003) was used
International Congress on Schizophrenia Research
1. 1 Diagnosis 7
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
to divided the young patients into two distinct groups: UHR patients (n =
10) and patients after the onset of fully fledged psychosis (n = 10). Control
subjects included healthy and schizophrenic adults. The subjects’ task was
to use an object to hit (task 1) or resist (task 2) impacts produced by a col-
lision between the hand held object and a pendulum. The results of the hit
task provided the means to quantify motor preparation, motor prediction
and motor coordination. For the resist task, we further contrasted the case
when the pendulum was self released and released by the experimenter in
order to evaluate agency. The two groups of patients were impaired in the
execution of motor control. However, the pattern of the deficit was dif-
ferent compared to both healthy and chronic schizophrenic adults. A def-
icit of agency was observed only in the group of patients after the onset of
fully fledged psychosis. This deficit was similar to that observed in the
chronic schizophrenic; the UHR had similar results than that observed
in the healthy controls. Motor deficits are present very early in the evo-
lution of psychosis development while the agency deficit seems to be the
result of a first episode psychosis. These first results suggest that non-ver-
bal motor tasks may reveal an efficient tool to help for an early diagnosis
of schizophrenia.
ID: 551186
KRAEPELIN’S INFLUENCE ON THE
SCHIZOPHRENIA CONCEPT IN DSM
Stephan Heckers
Psychiatry, Vanderbilt University, Nashville, TN, USA
Emil Kraepelin has shaped diagnostic systems and research strategies in
psychiatry with the introduction of the diagnoses dementia praecox and
manic-depressive illness. He conjectured that clinical observation, exper-
imental studies of patients, and basic studies of disease mechanisms will
identify psychiatric disorders, with clearly delineated etiology, mecha-
nisms, and outcome. However, his separation of diagnostic classes and
the reliance on disease course and outcome for diagnostic classification
have been challenged repeatedly. Despite these concerns, DSM-III and
DSM-IV have continued a categorical classification of psychotic disor-
ders in the tradition of Kraepelin, emphasizing outcome and affective
symptoms for the subtyping of psychotic disorders and minimizing the
importance of psychomotor changes and avolition. The presentation
will review in detail how Kraepelin’s dementia praecox concept: 1) evolved
over several decades, 2) emphasized avolition and cognitive deficits and
deemphasized psychotic symptoms, and 3) continues to fuel schizophrenia
research even today. The presentation will review the implications of
Kraepelin’s scientific biases for the current DSM and will outline options
for DSM-V.
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VALIDATION OF ‘‘PRODROMAL’’ CRITERIA TO
DETECT INDIVIDUALS AT ULTRA HIGH RISK OF
PSYCHOSIS: 2 YEAR FOLLOW UP
Alison Yung1,2, B. Nelson1,2, C. Stanford1, M. Simmons1,2,
E. Cosgrave1,2, E. Killackey1, L. Phillips1, A. Bechdolf1,
J. Buckby1, P. McGorry1,2
1Orygen Research Centre, Parkville, VIC, Australia; 2Psychiatry,
University of Melbourne, Melbourne, VIC, Australia
Background: Identification of individuals ‘‘prodromal’’ for schizophrenia
and other psychotic disorders relies on criteria that predict onset within
a brief period. Previous trials and biological research have been predicated
on the view that certain ‘‘ultra high risk’’ (UHR) criteria detect ‘‘the pro-
drome’’, but there is a need to test the validity of these criteria. Also, it
may be the fact of seeking help from a UHR service, rather than the UHR
criteria per se, which predicts onset of psychosis. Aim: To assess the pre-
dictive validity of the UHR criteria in a clinical population. A secondary
aim was to assess clinicians’ ability to detect UHR criteria. Method: Pres-
ence of UHR criteria was determined in 292 individuals at baseline. At 2
year follow up the number of new cases of psychotic disorder was assessed
in those meeting and not meeting the UHR criteria. Results: Help-seeking
per se was not a risk factor for development of psychotic disorder, rather
it was the UHRþ status at baseline that predicted psychosis onset within
2 years. The transition rate of 16% was much lower than in initial cohorts
(over 40%). Clinicians frequently missed UHRþve individuals and failed
to diagnose the UHR criteria in others. Conclusions: Although young
help-seekers meeting UHR criteria are at greater risk of psychotic disor-
der than those who do not meet them, caution is needed in their manage-
ment, since a high transition rate can no longer be assumed. Training
with a structured assessment tool may aid clinicians in detecting the
UHR criteria.
ID: 550971
IS LATE-ONSET SCHIZOPHRENIA A DISTINCT
SUBTYPE OF SCHIZOPHRENIA?
Dilip V. Jeste1,2, I. Vahia1, S. Golshan1, I. Fellows1, H. Kraemer3,
B. Palmer1
1Psychiatry, University of California, San Diego and VA San Diego
Healthcare System, La Jolla, CA, USA; 2Psychiatry, VA San Diego
Healthcare System, San Diego, CA, USA; 3Psychiatry, Stanford
University, Stanford, CA, USA
Introduction: Onset of schizophrenia in later life has been a controversial
topic. Different versions of DSM have taken varying positions on this issue,
usually without adequate data. An International Consensus Statement by
researchers in late-life schizophrenia recommended that age 40 be used as
the lower age cutoff for defining late-onset schizophrenia (LOS). Yet,
whether LOS is a distinct subtype of schizophrenia remains unsettled.
Methods: We analyzed data from over 800 community-dwelling patients
age > 40 years with DSM-III-R or DSM-IV diagnosis of schizophrenia
or schizoaffective disorder, studied at our NIMH-funded research center
at UCSD over a 12-year period. These included more than 700 patients
with EOS, and about 100 with LOS, using age of 40 at first manifestation
of prodromal symptoms as the cutoff. Baseline assessments included stan-
dardized instruments for psychopathology (Positive And Negative Syn-
drome Scale, Hamilton’s Depression scale), motor abnormalities
(Abnormal Involuntary Movement Scale), cognition (including Wechsler
Adult Intelligence Scale—Revised, California Verbal Learning Test, Wis-
consin Card Sorting Test), and health-related quality of life (Quality of
Well-Being scale). The patients were followed annually. Results: Compared
to EOS, the LOS patients were older, had a greater proportion of women,
shorter duration of illness, less severe positive symptoms, better perfor-
mance on abstraction/cognitive flexibility and psychomotor speed, and bet-
ter health-related quality of life. Most of these differences remained
significant after controlling for age, gender, and severity of negative symp-
toms. The EOS and LOS groups did not differ in education, ethnicity, se-
verity of depressive, negative, or motor symptoms, proportion of patients
with deficit syndrome, or in crystallized verbal knowledge and perceptual-
organization/visual construction. The diagnosis of most of the patients fol-
lowed longitudinally did not change. Discussion: Our results support the
notion that LOS may be a distinct subtype of schizophrenia. Limitations
of our study will be discussed. The implications of the results are clinical as
well as theoretical in that they may relate to pathophysiologic factors pres-
ent at menopausal or post-menopausal age of onset of LOS. Biological re-
search on identifying factors responsible for a delayed onset of
schizophrenia could be useful in opening possible new leads in prevention
and intervention strategies for schizophrenia.
ID: 552223
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2. 2. Phenomenology
BILINGUAL LANGUAGE UNDERSTANDING IN
SCHIZOPHRENIA
Debra Titone1, M. Libben1, V. Whitford1, A. Malla2, R. Joober2
1Psychology, McGill University, Montreal, QC, Canada; 2Douglas
Hospital, McGill University, Montre´al, QC, Canada
Investigations of language in people with schizophrenia date back to the first
scientific accounts of the disorder. Virtually all of this work has focussed on
language in monolingual people despite the fact that bilingualism is more
prevalent globally than monolingualism. Basic studies of bilingualism are
relevant to theories of language and neurocognitive dysfunction in schizo-
phrenia, and to both the clinical assessment and treatment of bilingual indi-
viduals with schizophrenia. We present preliminary data from a study of
language in four French-English bilingual people diagnosed with schizo-
phrenia and four matched bilingual non-psychiatric controls. Participants
read short English sentences that were literally plausible (‘‘She kept her
desk’’), idiomatic (‘‘He had a lark’’), or anomalous (‘‘He hired the debt’’),
and they made speeded decisions about the sensibility of each sentence. These
sentences also varied in the contextual constraint of the final word of literal
and idiomatic sentences (eg, ‘‘She drove the car’’ vs. ‘‘He bought the knife’’).
Further, a common feature of bilingual communicative interaction, code-
mixing,was experimentally simulated by replacing the final word of each sen-
tence with its French translation equivalent (eg, ‘‘He used his comb’’ vs. ‘‘He
used his peigne’’). Mixed design analysis of variance revealed that bilingual
people with schizophrenia were slower to make sensibility judgments overall,
less able to comprehend idiomatic language, and were less likely to capitalize
on high contextual constraint than bilingual non-psychiatric controls (all rel-
evant group interactions, P< .05). Thus, several of the most replicated find-
ings observed for monolingual people with schizophrenia were evident in this
preliminary bilingual sample. Moreover, comprehension of code-mixed sen-
tences was less accurate and slower for bilingual people with schizophrenia
than for non-psychiatric controls, especially for contextually constrained
sentences (all relevant group interactions, P < .05). This novel finding sug-
gests that language impairment in schizophrenia may be especially pro-
nounced under conditions that simulate normal bilingual communicative
interaction. Whether bilingual people with schizophrenia engage in less
cross-language interactionthan normal, or experiencemore difficulty resolv-
ing cross-language interaction is a topic of future investigation.
ID: 539076
SELF-ESTEEM, ANXIETY, AND DEFEATIST PER-
FORMANCE BELIEFS AS RISK FACTORS FOR
PARANOIA
Dror Ben-Zeev1, E. Granholm1,2
1Department of Psychiatry, University of California, San Diego, San
Diego, CA, USA; 2Psychology Service, VA San Diego Healthcare
System, San Diego, CA, USA
Paranoid delusions are one of the most prevalent psychiatric symptoms in
individuals suffering from psychosis. Psychological theories have implicated
a number of variables in the formation and maintenance of paranoid beliefs,
including self-esteem, anxiety, and negative beliefs about the self. Empirical
studies evaluating the relationship between paranoia and self-esteem in
clinical samples have yielded inconsistent findings. This may be due to
differential mechanisms in various symptomatic subgroups. The current
cross-sectional study examined the interrelationships between predictors
of persecutory ideation in people with psychosis who range across the con-
tinuum of paranoid symptom intensity. One hundred and ninety-nine com-
munity-dwelling people with schizophrenia (n = 140) or schizoaffective
disorder (n = 59) completed measures of psychotic symptoms (PANSS),
paranoia (Paranoia Scale-PS), anxiety (Beck Anxiety Inventory- BAI),
self-esteem (Self-Esteem Rating Scale, Sort Version-SERS-SF), and defeatist
performance beliefs (Performance Evaluation factor from the Dysfunctional
Attitudes Scale-DPAS). Participants were divided in to 3 groups: Paranoid
(PANSS ‘‘suspiciousness’’ score of 4 or more), Non Paranoid (PANSS ‘‘Sus-
piciousness’’ score of 3 or less, and a score of 4 or more on one of the PANSS
items ‘‘delusions’’, ‘‘hallucinatory behavior’’, ‘‘grandiosity’’, and ‘‘unusual
thought content’’), and Remitted (score of 3 or less on all described PANNS
items).Multiple regressionanalyses showed that inall three groupsself-esteem
predicted paranoia. In the paranoid group the relationship between self-
esteem and paranoia was mediated by anxiety and not defeatist performance
beliefs, whereas in the other two groups this relationship was mediated by de-
featist performance beliefs but not anxiety. Participants from the paranoid
group were significantly more anxious than non paranoid and remitted par-
ticipants. Defeatist performance beliefs did not differ significantly across
groups. The findings suggest different treatment strategies for different
groups, and highlight the importance of anxiety reduction as a potential treat-
ment target for patients with more severe paranoia.
ID: 550695
EMOTION RECOGNITION AND SCHIZOPHRENIA
Maite Ferrin1,3, J. L. Rubio1, M. Ruiz-Veguilla1, M. L. Barrigon2,
L. Hernandez1
1Unidad de Investigacio´n de Neuropsiquiatria del desarrollo, Com-
plejo Hospitalario de Jae´n, Jaen, Spain; 2Unidad de Investigacio´n de
Neuropsiquiatria del desarrollo, Hospital de Santa Ana, Motril,
Spain; 3Department of child and adolescent psychiatry, Institute of
Psychiatry, London, United Kingdom
Schizophrenia is associated with deficits in the processing of affective infor-
mationfrom facial expressionsandother social cues.The purposeof thepres-
ent study was to explore whether schizophrenia patients show deficits in
recognition of specific facial expressions. Healthy comparison subjects, un-
affected siblings of schizophrenia patients, and schizophrenia patients were
tested with a computerized test of degraded facial affect recognition. Patients
demonstrated a worse recognition of facial expressions. Specifically with
greater impairments of matched positive (happy) and negative (angry)
whereas healthy subjects and unaffected siblings recognized negative and
positive expressions at an equal level of accuracy. These results suggest
that deficits in the processing of facial emotion recognition from social
cues may contribute to poor social functioning in schizophrenia patients
and must be identified as an important target for clinical intervention.
ID: 550494
SENSE OF HUMOR IN PATIENTS WITH
SCHIZOPHRENIA
Irina Falkenberg1,2, K. Kluegel2, M. Bartels2, B. Wild2
1Psychiatry and Psychotherapy, RWTH Aachen University,
Aachen, Germany; 2Psychiatry and Psychotherapy, Tu¨bingen
University, Tu¨bingen, Germany
Introduction: Sense of humor is an important social skill. It can facilitate
social interaction and can help to cope with adverse situations. So far, it has
not been studied systematically in patients with schizophrenia. Methods: 18
patients with schizophrenia and 18 healthy controls were examined with
standardized self-assessment questionnaires to study potential group differ-
ences in humor type preferences, state and trait cheerfulness, seriousness
and bad mood as well as the use of humour as a coping strategy. Results:
The patients had more difficulties in understanding the test joke items but
patients and controls did not differ in their humor type preferences and
their use of humor as a coping strategy. The patients’ readiness to react
to funny stimuli with exhilaration was negatively correlated with the
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severity of accompanying depressive symptoms. Conclusion: If understood
and if no additional depression is present, patients with schizophrenia can
enjoy humorous stimuli as controls do. This indicates a close connection
between exhilaration and hedonia. The ability to use humour as a coping
strategy is unaffected by the disorder.
ID: 550463
FEWER NEUROLOGICAL SOFT SIGNS AMONG
FIRST EPISODE PSYCHOSIS PATIENTS WITH
HEAVY CANNABIS USE
Miguel Ruiz-Veguilla1, M. Ferrin1,2, M. L. Barrigon-Esteve3,
J. L. Rubio1, J. A. Becerra1, M. Gurpegui5, J. Cervilla4
1Unidad de Investigacion de Neuropsiquiatrı´a del Desarrollo,
Complejo Hospitalario de Jae´n, Jaen, Spain; 2Department of Child
and Adolescent Psychiatry, Institute of Psychiatry, London, United
Kingdom; 3Unidad de Investigacion de Neuropsiquiatria del
Desarrollo, Hospital de Santa Ana, Motril, Spain; 4CIBERSAM
Granada (CIB07/09/0036), Division of Psychiatry and Institute of
Neurosciences, University of Granada, Granada, Spain; 5Psychiatry
and Neurosciences Research Group (CTS-549), Institute of
Neurosciences, University of Granada, Granada, Spain
Background: Although neurological soft signs (NSS) have been consis-
tently associated with schizophrenia and a variety of risk factors, few stud-
ies have focused on the association between NSS and environmental factors
such as cannabis use, particularly in first episode patients. Methods: We
administered the Neurological Evaluation Scale (NES) to 92 patients dur-
ing their first episode of functional psychosis. Psychopathology was
assessed with the Positive And Negative Syndrome Scale (PANSS) and
the family history of psychotic disorder was established on the basis of
the Family Interview for Genetic Studies (FIGS). We also assessed lifetime
cannabis and cocaine use utilizing that specific section of the Composite
International 28 Diagnostic Interview. The outcome variable was the pres-
ence of high NSS, defined by a score above the median split of the NES
score (N21). Results: Most patients (80/92, 87%) presented a non-affective
psychosis. The presence of high NSS showed a significant independent as-
sociation with not having been a heavy cannabis user (OR = 8.3; 95% CI =
2.4–33.3), family history of psychosis (OR = 4.3; 95% CI = 1.2–14.9), male
sex 33 (OR = 4.0; 95% CI = 1.2–14.0), lower score in verbal fluency and
higher score in negative symptoms (both P < .01). Conclusion: Our cross-
sectional results support the hypothesis that potentially different pathways
associated with the emergence of first episode psychosis may exist, includ-
ing neurological premorbid alteration and environmental cannabis abuse.
ID: 550355
INITIAL RELIABILITY AND VALIDITY OF THE
NEW NIMH-MATRICS NEGATIVE SYMPTOM
RATING SCALE
Jack J. Blanchard1, C. Forbes1, A. Wilson1, B. Baker1, R. Gur2,
W. P. Horan3, A. Kring4, M. E. Bennett5
1Psychology, University of Maryland, College Park, MD, USA;
2Psychiatry, University of Pennsylvania, Philadelphia, PA, USA;
3Psychiatry, UCLA, Los Angeles, CA, USA; 4Psychology, UC-
Berkeley, Berkeley, CA, USA; 5Psychiatry, University of Maryland
School of Medicine, Baltimore, MD, USA
Negative symptoms in schizophrenia are a major determinant of the func-
tional impairments that characterize the disorder as well as a significant
source of distress for caregivers. Unfortunately, negative symptoms repre-
sent an unmet therapeutic need as no medications have shown to be effec-
tive in their treatment. One outcome of an NIMH consensus development
conference on negative symptoms (Kirkpatrick et al., 2006) was the recom-
mendation for the development of a new negative symptom assessment in-
strument that addresses conceptual and psychometric limitations of
existing instruments. The NIMH-MATRICS negative symptom work-
group has developed a new instrument, the Negative Symptom Rating
Scale (NSRS), which represents a substantial step forward in the assessment
of this critical symptom domain. The current study is the first assessment of
the newly developed NSRS. Forty individuals diagnosed with schizophre-
nia or schizoaffective disorder completed assessments of current symptoms
and social functioning. To examine convergent validity of the NSRS, in-
dependent assessments of negative symptoms were obtained with the Scale
for the Assessment of Negative Symptoms (SANS). Discriminant validity
was examined by assessing the independence of the NSRS ratings from psy-
chotic and depressed symptoms. Finally, it was expected that the NSRS
ratings would be related to assessments of social functioning in the com-
munity. Analyses indicated that the NSRS has high internal consistency
reliability (total scale alpha = .86) and high convergent correlations with
SANS scales (median r = .52, P< .01). The NSRS ratings were uncorrelated
with either psychotic or affective symptoms (all ps > .05). The NSRS dem-
onstrated significant correlations with social functioning in the community.
These initial findings indicate that the NSRS holds promise as a next-gen-
eration negative symptom scale.
ID: 550319
INSTRUMENTAL ASSESSMENT OF MOVEMENT
DISORDERS IN PATIENTS WITH SCHIZOPHRENIA,
THEIR HEALTHY SIBLINGS AND CONTROLS
J. Koning1,2, P. N. van Harten1, R. S. Kahn2
1Psychiatric Centre, Symfora Groep, Amersfoort, Netherlands;
2Psychiatry, Rudolf Magnus Institute of Neuroscience, University
Medical Centre Utrecht, Utrecht, Netherlands
Background: Movement disorders as dyskinesia and parkinsonism are
regarded as core features of schizophrenia and highly related to the dopa-
mine system. Several studies suggested that the presence of these movement
disorders in siblings of patients would constitute (genetic) markers of vul-
nerability. However, most individual studies on first degree-relatives failed
to find this association, possibly due to insufficient sensitivity of the applied
clinical rating scales. Quantitative instrumental measurements can be more
sensitive to detect subclinical movement disorders (Cortese 2005). This
study compares prevalences of dyskinesia and parkinsonism in patients
with schizophrenia, healthy siblings and matched controls using instrumen-
tal assessments. Methods: Instrumental measurements of tongue and finger
instability as a measure of dyskinesia and resting tremor of the finger as
a measure of parkinsonism were carried out in 44 medicated patients
with a non-affective psychosis (70% schizophrenia), 44 healthy siblings
and 32 controls. Dyskinesia and parkinsonism were quantified using instru-
mental force variability, a method to measure the percentage of motor in-
stability and tremor (Caligiuri 1994). All subjects were screened for Axis-1
pathology using CASH-interviews. Siblings and controls were matched
according to age, sex and years of education. Results: Siblings displayed
significantly more finger instability and resting tremor than controls
(2.35% vs.1.97%; P = .02 and 0.30% vs. 0.25%; P = .01 respectively). There
was no difference in tongue instability (16.7% vs 16.9%; P = .88). In addi-
tion, patients not only demonstrated more finger instability and resting
tremor than siblings (2.80% vs. 2.35%; P = .03 and 0.43% vs 0.30% P <
.01 respectively), but also more tongue instability (21.2% vs. 16.7%; P <
.01). Demographic information of patients, siblings and controls are given
for age, years of education and percentage of males (27.2, 27.7 and 25.7
years), (12.1, 14.2 and 14.7 years) and (82%, 55% and 50%). Conclusion:
This is the first study that used instrumental assessments to compare prev-
alences of motor disorders between patients with schizophrenia, healthy
siblings and controls. It clearly shows that siblings have more dyskinetic
and parkinsonian movements of the fingers than controls suggesting a
(genetic) risk of developing schizophrenia. Instrumental measurement
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can be used for detecting subclinical movement disorders in high risk
populations.
ID: 550265
ASSESSING AUDITORY VOCAL HALLUCINA-
TIONS: THE PSYCHOMETRIC EVALUATION OF
THE AUDITORY VOCAL HALLUCINATION
RATING SCALE (AVHRS)
Agna A. Bartels, G. Van de Willige, J. A. Jenner, D. Wiersma
University Center for Psychiatry, University Medical Center
Groningen, Groningen, Netherlands
Introduction: Assessing auditory vocal hallucinations (AVH) is important,
both for clinical practice and research purposes. Questioning patients thor-
oughly about different dimensions of their voices may offer a solid base for
therapeutic interventions, whereas reliable instruments are useful for out-
come assessment and research. Our aim is to examine the inter-rater reli-
ability and concurrent validity of the Auditory Vocal Hallucination Rating
Scale (AVHRS), a more extensive version of an existing scale to assess voi-
ces. Methods: To examine the inter-rater reliability (IRR) 23 patients of the
Voices Outpatient Department (VOPD) of the University Medical Center
Groningen (the Netherlands) were assessed with the AVHRS, both about
the past month and about lifetime. AVHRS total scores were compared
with available PANSS scores—of all patients from September 2006 till Sep-
tember 2008—to investigate concurrent validity. Results: The IRR of the
AVHRS was good (lifetime) to excellent (past month). Correlations with
the PANSS will be presented at the conference. Face validity was excellent.
Conclusions: So far, we consider the AVHRS to be a very comprehensive
scale with favourable psychometric properties. The instrument is useful for
both clinical therapy and research.
References
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sure dimensions of hallucinations and delusions: The psychotic symptom
rating scale (PSYRATS). Psychological Medicine. 1999;29:879–889.
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SOCIAL ANXIETY AND IDEAS OF REFERENCE IN
EARLY PSYCHOSIS
Gloria H. Y. Wong1, C. Hui1, C. Chiu2, E. Chen1
1Department of Psychiatry, The University of Hong Kong, Hong
Kong, China; 2Department of Psychiatry, Queen Mary Hospital,
Hong Kong, China
An increased prevalence of social anxiety disorder is observed in patients
with psychosis (16%–38%, compared with 13% in the general popula-
tion). Despite important treatment implications, previous attempts in
understanding the comorbidity have been inconclusive. This study
aims to explore the relationship between social anxiety and other psycho-
pathological characteristics in psychotic disorders, with a conceptually
driven focus on the possible linkage between social anxiety and the sub-
threshold symptom ideas of reference. A consecutive sample of 137 out-
patients with early psychosis was assessed for social anxiety using the
Liebowitz Social Anxiety Scale (LSAS), and for ideas of reference using
a new instrument Ideas of Reference Interview Schedule (IRIS). Positive
symptoms, negative symptoms, depression and insight were measured
using the Scale for the Assessment of Positive Symptoms in Schizophre-
nia (SAPS), the Scale for the Assessment of Negative Symptoms in
Schizophrenia (SANS), Calgary Depression Scale for Schizophrenia
(CDSS) and the Scale to Assess Unawareness of Illness (SUMD). To
identify potential explanatory variables for social anxiety, univariate
analyses were first carried out between LSAS and age, sex and all symp-
tom subscales. Variables that displayed simple correlation with LSAS
(based on a lax criterion of P < .1) were then entered as independent
variables into a stepwise multiple regression analysis to determine the
symptoms specifically correlated with LSAS. Results suggested
a three-factor model, with IRIS included as the strongest explanatory
factor, while avolition and blunting were also related (adjust R2 =
0.18; P = .00). The association observed between social anxiety and neg-
ative symptoms is consistent with previous findings. This is the first
study to demonstrate that a proportion of social anxiety covaries
with ideas of reference. The nature of their relationship and the extent
to which ideas of reference may explain for the excess of social anxiety
prevalence in early psychosis need to be further investigated.
ID: 550218
CHARACTERISTICS OF HIGH FUNCTIONING
INDIVIDUALS WITH SCHIZOPHRENIA
Stephen R. Marder1,2, A. N. Cohen1,2, A. Hamilton1,4, E. Saks3,
S. Glynn1,2, D. Hollan4, J. Brekke5
1Psychiatry, Semel Institute at UCLA, Los Angeles, CA, USA;
2Mental Illness Research, Education, and Clinical Center, VA
Greater Los Angeles, Los Angeles, CA, USA; 3School of Law,
University of Southern California, Los Angeles, CA, USA;
4Department of Anthropology, UCLA, Los Angeles, CA, USA;
5School of Social Work, University of Southern California, Los
Angeles, CA, USA
Recent attention has focused on individuals who live remarkably produc-
tive lives with rich interpersonal relationships despite active symptoms. We
know very little about how these ‘‘high functioning’’ individuals with
schizophrenia successfully cope with their illness to achieve occupational
and social success. Therefore, we initiated a qualitative study of high func-
tioning individuals with schizophrenia who are living in Los Angeles. For
this study, ‘‘high functioning’’ was defined as employment in a professional,
technical, or managerial occupation or high-level functionality as a stay-at-
home caretaker or full-time student. Method: Subjects who responded to
flyers were evaluated according to entry criteria. Following informed con-
sent, subjects were evaluated using the SCID, the PANSS, a background
survey, and the BASIS-24. This was followed by a Person-centered Inter-
view. This interview uses a method that is used in psychological anthropol-
ogy to obtain in-depth, phenomenological perspectives. Results: Fourteen
subjects qualified for the study and were interviewed. Subjects included 1
MD, 2 PhD’s, 2 MA’s as well as 4 BA’s. The majority had managerial or
supervisory responsibilities in their current job. Nearly all of the subjects
had active symptoms that affected their everyday life. The majority could
point to cognitive or behavioral techniques used to manage symptoms
in the face of these responsibilities. Participants tended to be very familiar
with mental health recovery concepts and articulated the ways in which
these concepts interfaced with their ideas about their own mental health
experiences.
ID: 549746
AN EXPERIENCE SAMPLING STUDY OF THE
EXPRESSION OF POSITIVE AND NEGATIVE
SCHIZOTYPY IN DAILY LIFE
Thomas R. Kwapil1, N. Barrantes-Vidal2, L. H. Brown1,
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Psychometrically identified positive and negative schizotypy are differen-
tially related to psychopathology, personality, and social functioning. How-
ever, little isknownabouttheexperienceandexpressionofschizotypyindaily
life. The present study employed the experience sampling method (ESM) to
assess positive and negative schizotypy in daily life in a nonclinical sample of
412 young adults. ESM is a structured diary technique in which participants
are prompted at random times during the day to complete an assessment of
their current experiences. As hypothesized, positive schizotypy was associ-
atedwith increasednegativeaffect, thought impairment, suspiciousness,neg-
ative beliefs about current activities, and feelings of rejection, but not with
social disinterest or decreased positive affect. Negative schizotypy, on the
otherhand,wasassociatedwithdecreasedpositiveaffectandpleasureindaily
life, increased negative affect, and marked decreases in social contact and in-
terest. Both positive and negative schizotypy were associated with the desire
to be alone when with others. However, this desire appeared to be moderated
by anxiety in positive schizotypyand bydiminishedpositiveaffect innegative
schizotypy.The findingssupport theconstructvalidityofa multidimensional
model of schizotypy and the use of psychometric inventories for assessing
these dimensions. ESM appears to be a promising method for examining
the daily life experiences of schizotypic individuals.
ID: 549731
EFFECTS OF PRE-ONSET CANNABIS USE ON
EARLY-COURSE FEATURES OF FIRST-EPISODE
NONAFFECTIVE PSYCHOSIS: PREMORBID
FUNCTIONING, THE PRODROME, AND ONSET OF
PSYCHOSIS
Michael T. Compton1, M. Pringle1, S. M. Goulding1,
M. L. Esterberg2, M. Kelley3, T. Stewart4, E. F. Walker2
1Department of Psychiatry and Behavioral Sciences, Emory University
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Background: Several studies suggest that pre-onset cannabis use results in
an earlier age at onset of psychosis, independent of effects of gender and use
of other drugs. However, little is known about the influence of prior can-
nabis use on other early-course epochs, including the premorbid and pro-
dromal phases. We examined the effects of prior cannabis use on: (1) early
adolescent (12–15 years) premorbid functioning, (2) late adolescent (16–18
years) premorbid functioning, (3) four features of the prodrome, and (4)
mode of onset and age at onset of psychosis. Methods: Participants in-
cluded urban, low-income, predominantly African American, first-episode
patients (n = 109) in a public-sector hospital. The assessment included the
Premorbid Adjustment Scale (PAS) and the Symptom Onset in Schizophre-
nia inventory, along with other measures. Potential confounders, including
gender, family history of psychosis, and prior nicotine and alcohol use, were
considered. Results: Those having used cannabis before or at age 15 years
had a mean PAS early adolescence social score of 1.21 6 0.85, compared to
1.75 6 1.27 in those who had not (t = 2.46, P = .02), indicating better social
functioning among those having used cannabis. On the other hand, those
having used cannabis before or at age 18 had a mean PAS late adolescence
academic score of 3.59 6 1.46, compared to 2.00 6 1.33 (t = 4.52, P <
.001), indicating poorer academic functioning among those having used
cannabis. Cannabis use prior to onset of psychotic symptoms was not as-
sociated with having had a prodrome, duration of prodrome, or number of
prodromal features experienced. Whereas 16 (42.1%) of those having used
cannabis daily had an acute mode of onset of psychosis, only 12 (20.0%) of
those without past daily use had an acute mode (v2 = 6.53, P = .04).
Conversely, 9 (23.7%) of those who had used daily had a subacute
mode, compared to 26 (43.3%) of those who had not used daily. Pre-onset
cannabis use was associated with an earlier age at onset of psychotic as well
as prodromal symptoms. Conclusions: We replicated the finding that pre-
onset cannabis use is associated with an earlier age at onset. Further, these
findings suggest that cannabis use is associated with poorer premorbid so-
cial and academic functioning and an acute mode of onset of psychosis.
Further research is warranted to further elucidate the complex associations
between early-course features and cannabis use.
ID: 549715
THE RELATIONSHIP BETWEEN AWARENESS OF
TARDIVE DYSKINESIA AND INSIGHT INTO
MENTAL ILLNESS IN SCHIZOPHRENIA
Robin Emsley, D. J. Niehaus, P. P. Oosthuizen, L. Koen,
B. Chiliza
Psychiatry, Stellenbosch University, Cae Town, South Africa
Background: A striking feature of tardive dyskinesia TD is that a large per-
centage of patients display an unawareness or lack of concern for the move-
ment disorder, with reported rates ranging between 44% and 95%.5;6 Poor
insight into their mental illness is also a common and often striking symp-
tom in schizophrenia, with an estimated 50% to 80% of such individuals not
being convinced that they have a disorder.12 Both phenomena have been
likened to anosognosia, a neurological deficit characterised by unawareness
or denial of an impairment, and associated with damage to specific brain
areas.6 We investigated whether poor awareness of TD is related to poor
insight into mental illness and examined their clinical correlates. Methods:
The sample comprised 84 men and 46 women aged 45 6 11.4 yrs with
schizophrenia and TD. Motor disorders were assessed by means of the Ex-
trapyramidal Symptom Rating Scale (ESRS)18 and schizophrenia psycho-
pathology by means of the Positive and Negative Syndrome Scale
(PANSS)19. The level of awareness of TD was calculated by the sum of
two items on the ESRS scale that rate the patient’s subjective evaluation
of the intensity of dyskinesia of extremities. For assessing insight into men-
tal illness we used a single item on the PANSS scale (item G 12). Results: We
found high rates of poor awareness of TD (52%) and poor insight into their
mental illness (72%). Poor of awareness of TD and impairment of insight
into mental illness were significantly related, although regression analysis
indicated that relatively little variance is shared between them. In fact, cor-
relation profiles for level of awareness of TD and the level of impairment of
insight into the mental illness were very different, suggesting that the two
phenomena are not related. Discussion: Insight into mental illness was re-
lated to the presence and severity of core psychosis symptoms, while aware-
ness of TD was related to severity of TD and the presence of parkinsonism.
ID: 549413
SCHIZOTYPY: PSYCHOMETRIC PROPERTIES AND
FACTORIAL STRUCTURE OF THREE SELF-
REPORT RATING SCALES, DEMOGRAPHIC
CORRELATES, AND ASSOCIATIONS WITH
NICOTINE, ALCOHOL, AND CANNABIS USE
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Introduction: Schizotypy and schizotypal personality disorder are thought
to be genetically related to schizophrenia given that relatives of people
with schizophrenia are more likely to exhibit schizotypal traits than indi-
viduals without a family history of schizophrenia. This presentation gives
an overview of a recent survey of undergraduate students, focusing on: (1)
measurement issues regarding self-report rating scales of schizotypy, (2)
demographic correlates of schizotypy scores, and (3) associations between
self-reported schizotypy and reports of nicotine, alcohol, and cannabis
use. Methods: A survey was conducted with 825 undergraduate college
students. Measures included the Schizotypal Personality Questionnaire
(SPQ), the Perceptual Aberration Scale (PAS), and the Social Anhedonia
Scale (SAS). Demographic characteristics and substance use variables also
were assessed. Results: Confirmatory factor analysis (CFA) supported
a 4-factor structure of the SPQ in this sample. Correlations between scores
on the three schizotypy measures were relatively modest, though inter-
correlations among the four SPQ subscales were fairly high. Internal con-
sistency reliability coefficients were acceptable for all instruments. A CFA
of an abbreviated version of the SPQ (SPQ-B) revealed that the standard
3-factor solution may not fit the data better than a 1-factor solution. Male
gender was significantly associated with higher SAS scores, and race was
associated with several schizotypy measures. Students reporting past use
of cigarettes, alcohol, or cannabis generally had higher schizotypy scores
than those without past use of these substances. Specifically, higher levels
of disorganized schizotypy were associated with greater indices of use of
all three substances. Furthermore, lower negative schizotypy and higher
cognitive-perceptual schizotypy were selectively associated with nicotine
and cannabis use, respectively. Discussion: These findings indicate that
commonly used measures of schizotypy have adequate psychometric
properties in this sample; that scores on some dimensions of schizotypy
may differ by gender and race; and that the use of nicotine, alcohol, and
cannabis are associated with schizotypal features. Greater elucidation of
these associations, ideally using longitudinal research designs, could pro-
vide crucial information not only on the connection between substance
use and schizotypy, but also between substance use and schizophrenia.
ID: 549144
PARANOIA AND HALLUCINATIONS IN THE
CONTEXT OF DAILY LIFE: THE ROLE OF
EMOTIONAL EXPERIENCES AND SELF-ESTEEM
Viviane Thewissen1,2, R. Bentall3, J. a` Campo4, T. van Lierop4,
J. van Os2,5, I. Myin-Germeys2,4
1Faculty of Psychology, Open University of the Netherlands,
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Kingdom; 4Section Social Cognition, Mondriaan Zorggroep,
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Emotional experiences—anxiety in particular—and self-esteem are consid-
ered to play an important role in the generation and maintenance of para-
noia. The goal of current study was to explore the dynamic association
between emotional experiences (anxiety, anger, depression) and self-esteem
on the one hand and paranoia on the other. In addition, it was investigated
whether the association is symptom-specific by looking at hallucinations as
well. The Experience Sampling Method, a structured self-assessment diary
technique, was used to examine the alleged association in the daily life of
158 individuals who ranged across the paranoia continuum. Multilevel re-
gression analyses were performed to investigate the association between
self-esteem and emotional experiences and paranoia / hallucinatory epi-
sodes ( = uninterrupted series of occurrence of paranoia / hallucination).
Results showed that self-esteem plays a significant role in the onset of
both paranoia and hallucinatory episodes. In addition, level of self-esteem
is significantly lower during both paranoia and hallucinatory episodes.
However, self-esteem only plays a significant maintaining role in the
duration of a paranoia episode. Paranoia and hallucinatory episodes are
both characterised by higher levels of anxiety and depression. However,
anxiety is most strongly associated with paranoia. Only paranoia episodes
are characterised by higher levels of anger. It can be concluded that emo-
tional experiences and self-esteem are associated with both paranoia and
hallucinations. The findings give support to the postulation that especially
anxiety is important in the relationship with paranoia, probably because
both anxiety and paranoia can be seen as treat beliefs.
ID: 549120
PHENOMENOLOGY OF SCHIZOPHRENIA AND
AFFECTIVE FIRST EPISODE PSYCHOSIS
Cherise Rosen, R. Marvin, J. L. Reilly, O. A. DeLeon,
P. J. Weiden, S. K. Keedy, M. S. Harris, H. Solari, J. A. Sweeney
Psychiatry/Center for Cognitive Medicine, University of Illinois at
Chicago, Chicago, IL, USA
Objective: This study compares the phenomenological dimensions of psy-
chotic disorders at initial presentation of first episode psychosis in both
schizophrenia and affective psychotic disorders. Method: Patients were
recruited from the University of Illinois Medical Center. Lifetime exposure
to psychotropics in all patients was less than 16 weeks, and patients were
evaluated free of pharmacological treatment. Diagnosis was determined us-
ing the DSM-IVtr and consensus procedure including treating clinicians.
All patients were assessed on standardized research instruments evaluating
symptoms and global functioning prior to starting drug treatment. 5-factor
scoring of PANNS dimensions included positive, negative, cognitive, ex-
citement, and depression. A composite Cluster score for PANNS dimen-
sions assessed anergia, thought disturbance, activation, paranoia and
depression. Results: Of the 110 first episode psychosis subjects who partic-
ipated, 56 were diagnosed with schizophrenia, 30 with bipolar disorder, and
24 with unipolar depression. PANSS 5-factor scores at baseline demon-
strated that schizophrenia and bipolar patients showed significantly
more positive symptoms than depressed patients (P < .001) while schizo-
phrenia and depressed patients demonstrated significantly more negative
symptoms than bipolar patients (P < .001). Additionally, patients with
schizophrenia reported greater cognitive symptoms than patients with ei-
ther bipolar or depression (P< .001). Lastly, PANSS cluster scores showed
that schizophrenia and bipolar patients exhibited significantly more
thought disturbance (P = .007), activation (P < .05), and paranoia (P =
.02) than patients with depression. Schizophrenia and depressed patients
exhibited greater anergia (P < .001) than bipolar patients. Conclusions:
This study compared patients with schizophrenia, bipolar disorder and uni-
polar depression at the time of their initial clinical presentation of psycho-
sis. Data emerging from this study suggests that phenomenology of these
disorders is overlapping with a broad co-occurrence of psychopathological
symptom dimensions. However, differences across groups were observed
with acute psychosis severity being greater in schizophrenia and bipolar
disorder than depression. The similarities of psychotic symptoms in schizo-
phrenia and bipolar disorder may suggest some common mechanisms un-
derlying psychosis in these disorders.
ID: 548869
A PHENOMENOLOGICAL STUDY OF NEGATIVE
SYMPTOMS IN SCHIZOPHRENIA: AMOTIVATION
AND ITS RELATIONSHIP TO FUNCTIONING
George Foussias1,2, S. Mann1,2, G. Remington1,2
1Centre for Addiction and Mental Health, Toronto, ON, Canada;
2Department of Psychiatry and Institute of Medical Science, Faculty
of Medicine, University of Toronto, Toronto, ON, Canada
The negative symptoms of schizophrenia are comprised of two key symp-
tom subdomains: 1) diminished expression (affective flattening and
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poverty of speech); and 2) amotivation (apathy and anhedonia), and
contribute to functional impairment in this illness. Of note, there is ev-
idence that individuals with schizophrenia do not, in fact, experience an-
hedonia (ie. a consummatory pleasure deficit), but rather deficits in
anticipating pleasure. To date we are unaware of any investigation
that has concurrently examined amotivation and these different facets
of the experience of pleasure, and their relationship with functioning
in schizophrenia. This study aims to specifically examine these relation-
ships, with the hypothesis that amotivation bears the strongest relation-
ship to functional outcomes. Outpatients between the ages of 18 and 55
with a diagnosis of schizophrenia, on stable doses of antipsychotic med-
ication, were evaluated with the Scales for the Assessment of Positive
Symptoms (SAPS) and Negative Symptoms (SANS). Amotivation
was assessed with the Apathy Evaluation Scale—Clinician version
(AES-C), anticipatory/consummatory pleasure with the Temporal Expe-
rience of Pleasure Scale (TEPS), and cognition with the Brief Assessment
of Cognition in Schizophrenia (BACS). The Quality of Life Scale
(QLS) was used to evaluate current functioning. Analysis of data
from 11 subjects (mean age of 38, mean duration of illness of 13 years)
revealed significant relationships between QLS scores and total SANS
(r = .645, P = .032), Amotivation subdomain (r = .704, P = .016),
and AES-C (r = .771, P = .005). Other measures including SAPS total
score, Diminished Expression subdomain score, TEPS anticipatory/con-
summatory pleasure scores, and BACS composite score did not exhibit
any significant association with functional status. Negative symptoms
have been implicated in poor functional outcome, reflected here as
well with total SANS and QLS scores. The present data, albeit prelim-
inary, take this issue a step further though, examining different aspects of
the negative symptom domain. Amotivation was strongly correlated
with current functioning, whereas this was not the case for the expressive
component of negative symptoms, or for anticipatory or consummatory
pleasure. These preliminary findings suggest that it is loss of drive, rather
than pleasure, that links negative symptoms to poor functional outcome.
ID: 546949
A META-ANALYSIS AND QUALITATIVE REVIEW
OF THE IMPACT OF FAMILY HISTORY OF
PSYCHOSIS ON PRESENTATION AND COURSE
OF ILLNESS IN SCHIZOPHRENIA
Michelle Esterberg, H. D. Trotman, E. F. Walker
Psychology, Emory University, Atlanta, GA, USA
Research on the influence of a positive family history of psychosis on pre-
sentation and course of illness in schizophrenia has been mixed, and to
date, there have been no comprehensive reviews that have attempted to
bring together this large area of research and determine the exact impact
of this potentially important etiologic factor. Therefore, the current re-
view qualitatively and quantitatively reviews four areas of research rela-
tive to positive family history: age at onset, presentation of positive and
negative symptoms, course of positive and negative symptoms, and treat-
ment response. Results showed that positive family history of psychosis
has a small but significant impact on several of these areas, including age
at onset and its relationship with gender, negative symptoms, course, and
treatment response. While only one moderator analysis was significant,
there were several interesting trends. The findings of the current review
are discussed in light of an extension of the diathesis-stress model for
the development of schizophrenia. Theoretical assumptions and empirical
research are reviewed to support the notion that family history operates
to influence presentation and course through the same mechanisms it
operates through to influence susceptibility. Finally, implications of
the current findings, limitations of the review, and directions for future
research are highlighted.
ID: 546059
AN ALTERNATE EXPLANATION TO ‘‘COGNITIVE
DYSMETRIA’’ IN SCHIZOPHRENIA
Robert G. Bota
Psychiatry, UMKC, Kansas City, MO, USA
Background: Schizophrenia is considered to be an illness in which there is
a generalized ‘‘cognitive dysmetria’’ in which cortical-cerebelar-thalmic-
cortical circuitry shows impairments when compared with individuals with-
out mental illness. Method: We reviewed the literature pertinent to circuitry
abnormalities in schizophrenia. Also, we looked for correlates with severity
of illness. Further we focused on described impairments in various domains
of insight in schizophrenia. Results: Form the data gathered we observed
that insight into the symptoms is less often impaired than insight into the
illness and the consequences of illness. Experiential aspect of perception is
obtained from processing primitive awareness through working memory
and referenced through the association areas. The reported difficulties
for schizophrenia in processing and encoding would lead in time to incre-
mental deteriorations in reality testing. Thinking can be understood as re-
lated to perception (impure cognition) and not related to experience (pure
cognition, eg, close systems such as matematics). We propose that even
though are severe dysfunction in each of the presented domains, they occur
at different degree of severity. The cognitive dysmetria can be explained as
a ‘‘schism’’ in the interplay of impaired perception and faulty cognition.
Discussion: Despite the fact that is a vast literature discussing neurological
abnormalities in schizophrenia, very limited integrative work was done.
Our hypothesis suggests a different way of assessing and understanding
each individual affected with this illness and ultimately proposes to correct
the specific dysfunctions to reduce the decalage between levels of cognition
and perception.
ID: 543795
IMPULSIVITY IN CO-OCCURING SCHIZOPHRENIA
AND SUBSTANCE USE
Stephanie C. Marcello1,2, R. Spiga2, S. Silverstein1
1Division of Schizophrenia Research, University of Medicine and
Dentistry of New Jersey- University Behavioral HealthCare,
Piscataway, NJ, USA; 2Department of Behavioral Research,
Temple University Hospital, Philadelphia, OR, USA
Impulsivity is a risk factor associated with substance use disorders. On
paper-and-pencil measures, people with schizophrenia and substance use
disorders have been shown to be more impulsive than their non-using
counterparts. However, there has been little research elucidating the vari-
ous behavioral components which often define the concept of impulsivity.
These components include: temporal discounting, risk taking, underesti-
mating time and failure to inhibit extraneous responding. Specifically,
the study compared people with schizophrenia who did and did not use
cocaine on these behavioral impulsivity measures. One group had a positive
urine drug screen (UDS) for cocaine (N = 20). A second group had a neg-
ative UDS, but a positive cocaine history (N = 20). Finally, the third group
had no history of cocaine use (N = 20). Participants were assessed using
computer-based tasks. Those with a current or past history of cocaine
use had greater means on the Balloon Analogue Risk Task and engaged
in more risk-taking behaviors. People with schizophrenia with a current
or drug use history seemed to be less affected by loss and more attuned
to monetary gains. Contrary to our hypothesis, the study found that
patients with a positive UDS for cocaine selected larger, delayed rewards
over the smaller, immediate rewards. Performances on the immediate/delay
task also suggest greater attentiveness to magnitude of the monetary re-
ward. On the GoStop computer task, a trend was found toward significant
differences between the means for inhibited responses and total number of
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responses. However, no significant differences were found between groups
for time estimation. These data indicate that depending on the conditions,
people with comorbid schizophrenia and cocaine abuse may demonstrate
more or less impulsivity than people with either disorder alone. Implica-
tions for understanding the interaction between the CNS effects of cocaine
and psychosis will be discussed.
ID: 541250
INSIGHT INTO DEFICITS? THE DEFICIT SYN-
DROME IN FIRST-EPISODE SCHIZOPHRENIA
Hanan D. Trotman1,2, M. T. Compton3
1Department of Psychiatry and Health Behavior, Medical College of
Georgia, Augusta, GA, USA; 2Department of Veterans Affairs,
Charlie Norwood VA Medical Center, Augusta, GA, USA;
3Department of Psychiatry and Behavioral Sciences, Emory
University School of Medicine, Atlanta, GA, USA
Schizophrenia as it is currently conceptualized is a markedly heterogeneous
disorder. Researchers have long attempted to decrease this variability to
allow greater predictive power regarding illness course and treatment re-
sponse. The aim of the current research is to examine the deficit syndrome,
a category gaining increasing support in the literature. Studies of deficit
syndrome patients have indicated a history of poor functioning (Tiryaki
et al., 2003), but decreased clinical distress (Kirkpatrick et al., 1994, Fenton
and McGlashan et al., 1994) compared to nondeficit patients. Poor insight
in patients with deficit schizophrenia may be one explanation for these find-
ings. One study in a sample of patients with chronic illness found that deficit
patients had poor insight compared to nondeficit patients (Kirkpatrick
et al., 2000). We hypothesized that poor insight would be present early
in the course of illness in deficit patients. Selected clinical correlates of
the deficit syndrome were also examined. We used the Proxy for the Deficit
Syndrome (PDS) to categorize 109 newly diagnosed patients with nonaf-
fective psychosis into deficit (N = 31) and nondeficit (N = 78) groups
(Kirkpatrick et al., 1993) based on Positive and Negative Syndrome Scale
scores. Results indicate that first-episode deficit patients have poorer in-
sight than first-episode nondeficit patients after accounting for age, gender,
hallucinatory behavior, and delusional thinking. Deficit patients exhibited
greater negative symptoms, less severe positive symptoms, and less distress.
Deficit patients also demonstrated greater impairments in global indicators
of functioning (education, marital/relationship status, employment status).
These results were not confounded by greater substance abuse in the deficit
group. Results from the current study further validate the deficit syndrome
as a useful subcategory of schizophrenia in a sample of first-episode
patients. Results also suggest that the treatment of deficit patients may
be complicated by poor insight. Understanding heterogeneity in the early
course of schizophrenia may hasten treatment interventions and enhance
the development of new treatment targets.
ID: 550901
TRAUMA EXPOSURE AND POSITIVE SYMPTOM
SEVERITY IN PRODROMAL PATIENTS
Cheryl Corcoran, J. Thompson, D. Kimhy, S. Schobel,
D. Malaspina
Columbia, New York, NY, USA
Introduction: Although traumatic childhood experiences are commonly en-
dorsed by individuals with schizophrenia, and associated with psychotic
symptoms, little is known about childhood trauma in prodromal or clinical
high risk samples. Methods: We examined the prevalence of childhood
trauma and its symptom correlates in 30 clinical high risk patients, includ-
ing prodromal and depressive symptoms. Results: All forms of childhood
abuse were prevalent, particularly among ethnic minority participants,
among whom trauma was associated with subthreshold psychotic symp-
toms, in particular grandiosity. By contrast, childhood trauma was associ-
ated with depression only in Caucasian participants at heightened risk for
psychosis. Discussion: This exploratory study suggests childhood trauma is
common among prodromal patients and related to symptoms. Further
studies will entail the predictive value of traumatic experiences and their
neuroendocrine correlates.
ID: 551921
THE WINTER BLUES: SEASON OF BIRTH
PATTERNS IN SCHIZOTYPY
Bianca Iglesias, A. S. Cohen
Psychology, Louisiana State University, Baton Rouge, LA, USA
The season of birth effect, defined in terms of an elevated incidence of birth
during certain months, is one of the most replicated findings in schizophrenia
research.Themajority of researchhas reported elevated rates of winterbirths
for individuals with schizophrenia dating back to 1929. Many theories have
attempted to explain this effect by including risk factors such as maternal
stress and influenza exposure during pregnancy. Although this effect has
been extensively studied in individuals with schizophrenia, it has not been
examined on individuals with schizotypy—those with a putative genetic vul-
nerability who don’t manifest symptomatology. In the current study, we ex-
amined individuals with schizotypy to see whether a pattern of birth rates is
exhibited.Theschizotypalpersonalityquestionnaire(SPQ)wasadministered
to 1135 undergraduates and comptuted dimensional positive, negative, and
disorganization scores for each individual, We examined 2 issues: 1) whether
schizotypal features were associated with season of birth and 2) how gender
differencesmightmoderatethisrelationship.Wefoundthatthosewithhigher
positive schizotypy scores showed a higher incidenceofwinter birth, however
only within males. This study has replicated in schizotypy what has been
foundinschizophrenia—thatwinterbirthsareassociatedwithpositivesymp-
tomotology. However, this relationship was only present for males.
ID: 551862
THEORY OF MIND ABILITIES AND SELF-
CONFIDENCE IN SCHIZOTYPY
Laura Brown, A. S. Cohen
Department of Psychology, Louisiana State University, Baton
Rouge, LA, USA
Social cognitive deficits have been well established in schizophrenia. How-
ever, there have been mixed results in research on social cognition in indi-
viduals with schizotypy, those with the underlying genetic vulnerability that
do not exhibit full-blown symptomology. The current study investigated
theory of mind, one component of social cognition involving the ability
to infer mental states. Participants included 81 psychometrically-identified
schizotypes and 35 controls who completed a computerized theory of mind
task (TOM). This task was designed to be more sensitive than those used in
previous research, and was composed of items from an existing published
hinting task with a true/false response format. We also has participants rate
how confident they were that their answers were correct. Schizotypes per-
formed similarly to controls on TOM, although they were significantly less
confident. Confidence ratings were not related to overall performance but
were positively correlated with performance on true/false items in which
a correct social inference was made. Results suggest that although schizo-
types may have intact theory of mind, they are less confident in their abil-
ities. Among possible interpretations are that: 1) social cognitive deficits
seen in patients with schizophrenia stem from later decline in general cog-
nition in conjunction with lower confidence in social abilities, 2) social cog-
nitive abilities serve as a resilience factor buffering against the eventual
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decline into psychosis, and that 3) schizotypes may be employing a compen-
satory strategy leading them to the correct responses.
ID: 551824
EVALUATION OF SPEECH MISATTRIBUTION BIAS
IN SCHIZOPHRENIA
Massoud Stephane1,2, M. Kuskowski1,2, K. McClannahan3,
C. Surerus1
1Psychiatry, VA Medical Center, Minneapolis, MN, USA;
2Psychiatry, University of Minnesota, Minneapolis, MN, USA;
3Psychiatry, University of Washington, seattle, WA, USA
Background: Attributing self-generated speech to others could explain the
experience of verbal hallucinations. This theory was based on experiments
that used non-linguistic, or speech perception paradigms. Speech genera-
tion paradigms compared self-other to other-self misattribution errors. Im-
pairment in the self-other distinction could cause both types of errors. In
this study we compare both self-other and other-self misattribution errors
to errors that are not related to the self-other distinction. Methods: 39
schizophrenia patients and 26 matched healthy controls were required to
distinguish between self-generated, other-generated, and non-generated
(self or other) sentences. The sentences were in the first, second or third
person and read in a male or female voice in equal proportion. Mixed mul-
tilevel logistic regression models were used to investigate the effect of group,
sentence source, pronoun, and gender of the heard sentences on response
accuracy. Results: Patients differed from controls in the recognition of self-
generated and other- generated sentences, but not in general recognition
ability. Pronoun was a significant predictor of response accuracy but with-
out any significant interaction with group. The gender of heard sentences
variable was not significant. Misattribution bias differentiated groups only
in the self-other direction. Conclusions: These data support the theory that
misattributing self-generated speech to other could result in verbal halluci-
nations. Syntactic (pronoun) but not acoustic (gender) manipulations affect
the recognition of self and other generated speech. This indirectly implicates
language, rather than sensory, disorder in the pathogenesis of AVH.
ID: 551803
THC ELICITS NEGATIVE SYMPTOMS IN HEALTHY
CONTROLS: AN EXPERIMENTAL STUDY
Paul D. Morrison, S. Kapur, R. M. Murray
Psychological Medicine, Institute of Psychiatry, London, United
Kingdom
Background: It is well recognised that cannabis can induce transient
positive psychotic symptoms in healthy subjects and in people with schizo-
phrenia. The psychotogenic effects are attributable to the molecule delta-9-
tetrahydrocannibinol (THC). Less well understood is the effect of cannabis/
THC on the negative dimension. It has been suggested that patients who use
cannabis experience less negative symptomatology compared to those who
don’t. In contrast, there is some experimental evidence that THC may ac-
tually induce schizophrenia-like negative symptoms. Here we report the
effects of pure THC on the negative dimension in a sample of healthy
male subjects. Method: A validated structured instrument, The Community
Assessment of Psychic Experiences (CAPE-state version) was used to assess
drug effects on the negative dimension in 22 participants. The CAPE dis-
tinguishes between positive, negative and depressive dimensions. Pharma-
ceuticals were administered by intravenous injection under randomised,
double-blind placebo controlled conditions. The dose of THC (2.5 mg)
was chosen on the basis of previous studies. Ratings were made at baseline
and at 30, 80 and 120 minutes post-injection. Plasma levels of THC and its
major metabolites were measured over the course of the experiment.
Results: Nineteen participants completed the paradigm. Overall, subject-
rated scores on the CAPE negative dimension were increased from baseline
following THC but not placebo administration (Friedman’s v2 = 25.3, df =
7, P = .001). At 30 minutes post THC, CAPE negative scores had increased
by a mean of 4 points, returning to baseline levels by 120 minutes post-in-
jection. There was wide inter-individual variation in responses to THC.
Overall, 70% of subjects reported an increase in the CAPE negative dimen-
sion following THC whilst 15% showed no change and 15% reported a de-
crease. Plasma levels of THC were similar to those observed following
inhalational use of cannabis. Conclusion: In a majority of healthy subjects,
pure THC elicits negative symptoms. Further work to explore the under-
lying mechanism is underway in our lab.
ID: 551761
PERSISTENCE OF RATER TRAINING EFFECTS IN
SCHIZOPHRENIA CLINICAL TRIALS
David Gordon Daniel1, J. J. Bartko2, M. H. Allen3
1Training and Education, UBC, McLean, VA, USA; 2Statistics,
Private Consultant, Newville, PA, USA; 3Psychiatry, University
of Colorado Health Sciences Center, Denver, CO, USA
Background: We report a retrospective assessment of rater drift in 9 CNS
trials involving the Positive and Negative Syndrome Scale (PANSS) and
Negative Symptom Assessment Scale (NSA-16) in schizophrenia. We hy-
pothesized that measures of rater adherence to scoring would be signifi-
cantly lower at study mid-point than at initiation. Method: All trials
included had at least one post-investigator meeting recertification or re-
fresher procedure at least 6 months (range approximately 6–19 months) af-
ter the initial approval. For each scale, raters were trained to rate these
scales by viewing at least one training lecture and viewing and rating at least
one videotaped practice subject interview using the scale, followed by de-
tailed feedback on proper scoring from an expert trainer utilizing an audi-
ence response system and expert panel consensus scoring explanations.
Subsequently, in order to be approved to rate, investigators were evaluated
on their ratings of an additional videotaped subject interview. Approxi-
mately 9–16 months later, raters were required to complete a self-
instructional review of rater scoring technique using internet based training
or instructional CD and retested on their ability to properly score a video-
taped interview. For purposes of this analysis, rater performance was eval-
uated as passing if 80% of the scale items were scored within one point of the
modal score or within 1 point of the expert consensus. The proportion of all
raters who scored within one point of the modal score or panel expert con-
sensus on at least 80% of the scale items was compared at study initiation
and mid-study using the chi-square statistic. Results: For schizophrenia
(PANSS and NSA-16), rater performance at mid-study compared to study
initiation was not statistically significant (v2 =2.66; P NS; df = 1). At initial
testing 85.9% (n = 1198) of raters met criteria considered acceptable for
passing and 14.1 % (n = 197) did not. At retesting 88.6% (n = 528) of raters
met criteria considered acceptable for passing and 11.4% (n = 68) did not.
Discussion: A retrospective analysis of 9 CNS clinical trials in schizophre-
nia suggests relatively high levels of rater agreement may be sustainable 6–
19 months after initial training with an instructional review at mid-study.
ID: 551757
EXPLORING THE INTERPLAY BETWEEN
MARIJUANA USE, MEDICATION ADHERENCE,
AND PSYCHOTIC SYMPTOMS IN FIRST-EPISODE
PSYCHOSIS
Kia Faridi1,2, A. Malla1,2
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1Department of Psychiatry, McGill University, Montreal, QC,
Canada; 2Clinical Research Division, Douglas Mental Health
University Institute, Montreal, QC, Canada
Marijuana use is a frequently present co-morbidity among people with a
first episode of psychosis (FEP), and has an impact on symptoms and on
outcome. The objective of this study was to examine, in the context of
a FEP program, the proportion of marijuana users who persist in using
during the first year in treatment. The study also examined the interaction
between drug use, medication compliance, and symptomatology. The
study was conducted at PEPP-Montreal, a specialized integrated treat-
ment service for all incident FEP cases within a defined area. Subjects
were 192 consecutive admissions, aged between 14 and 30, suffering
from at least two weeks of psychotic symptoms meeting DSM-IV syndro-
mal criteria, and with no history of antipsychotic treatment. Diagnoses,
including co-morbid substance use diagnoses, were determined using the
Structured Clinical Interview for DSM-IV (SCID-I), administered shortly
after program admission, and again at one year. Symptoms were evalu-
ated at regular intervals through one year of follow-up using the Positive
and Negative Symptom Scale (PANSS). Antipsychotic medication com-
pliance was also evaluated regularly based on patient report and corrob-
orated by collateral report and clinical notes. 56 subjects (29.2%) had
a current cannabis use disorder at baseline. Of the cannabis-using subjects
for whom information was available at one year (50), 29 (58.0%) had con-
tinued to use marijuana, while 21 (42.0%) had stopped. PANSS total score
did not differ between stable users compared to those who abstained,
either at baseline (75.1 vs. 77.6, t = 0.47, P = .64) or at one year
(56.2 vs. 50.3, t = 1.40, P = .17). The groups did not differ in their rate
of compliance at baseline (85.2% vs. 90.5%, Fisher’s P = .68). However,
at month 12 stable users were significantly more compliant than cannabis
users who had stopped (92.3% vs. 60.0%, Fisher’s P = .01). An ANCOVA
revealed that PANSS total at 12 months was associated with compliance
at 12 months, F1,39 = 5.28, P = .03, but that the effect of stability of mar-
ijuana consumption remained significant after controlling for this covari-
ance, F2,39 = 17.16, P < .001. These results suggest that FEP patients who
continue to use marijuana are more adherent to medications than abstaining
users, and that this effect is not explained by patients who, having stopped
marijuana, felt they no longer need medications to control symptoms.
ID: 551746
DEFINING THE RELATIONSHIP BETWEEN
CLINICAL RATINGS OF BLUNTED AFFECT AND
BEHAVIORAL CODING OF FACIAL AFFECT:
FREQUENCY, INTENSITY, OR DURATION?
Bryann Renee Baker, K. Llerena, S. Lin, C. Forbes,
J. J. Blanchard
University of Maryland, College Park, College Park, MD, USA
Negative symptoms within schizophrenia include profound changes in the
expression of emotion as reflected in the symptom domain of flat or
blunted affect. Despite the importance of this domain it remains unclear
how expression is altered. Specifically, it is not yet known whether dimin-
ished expression reflects changes in the frequency, duration, or intensity of
emotional expression. In order to better understand the nature of blunted
affect, the present study conducted a detailed assessment of facial affect
using the Facial Affect Coding System (FACES; Kring and Sloan, 2007).
A further refinement in this study was the use of the newly developed
NIMH-MATRICS Negative Symptom Rating Scale (NSRS) for the as-
sessment of negative symptoms. 40 outpatient schizophrenics were
assessed with diagnostic and symptom interviews including the NSRS
and BPRS. Videotaped interviews were subsequently rated for facial af-
fective displays using the FACES. Data analyses will examine the relation-
ship between clinical ratings of blunted affect and behavioral coding of
the frequency, duration, and intensity of facial affective displays. Further,
the association between other negative, psychotic, and affective symptoms
will be examined.
ID: 551706
CANNABIS USE AND CLINICAL AND
FUNCTIONAL OUTCOME IN PRODROMAL
ADOLESCENTS AND YOUNG ADULTS
Andrea Auther1,2, C. Smith1,2, P. Nagachandran1,2,
M. Akerman1,2, K. Candenhead3, B. Cornblatt1,2
1Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks,
NY, USA; 2Center for Translational Psychiatry, Feinstein Institute
for Medical Research, Manhasset, NY, USA; 3Department of
Psychiatry, University of California, San Diego, San Diego, CA,
USA
The Recognition and Prevention Program has recently found that can-
nabis use is not related to worsening of positive symptoms or to conver-
sion to psychosis. However, the North American Prodromal
Longitudinal Study (NAPLS), a consortium of eight longitudinal pro-
dromal programs, has found that drug use in general is related to con-
version (Cannon et al. 2008). This poster will involve a more intensive
evaluation of the relationship between cannabis use and prodromal
symptoms, social and role functioning, and conversion to psychosis uti-
lizing the NAPLS retrospective database. Subjects include 330 prodro-
mal individuals who met criteria for Attenuated Positive Symptom
Syndrome according to the Scale of Prodromal Symptoms. Level of can-
nabis use was divided into those with no or low use and those with abuse
or dependence. Social and role functioning was assessed with rating
scales developed for NAPLS. Baseline and 12 month follow up data
were utilized. Of the 330 participants, 64 (19.4%) met the criteria for can-
nabis abuse or dependence and the remainder reported no or low levels of
cannabis use. Cannabis misusers were older at baseline but did not differ
from no/low users on other demographic variables. In terms of prodro-
mal symptoms, there were no significant differences between cannabis
misusers and no/low users on attenuated positive or negative symptoms
at baseline. However, cannabis misusers were significantly more likely to
convert to psychosis over follow up (38.2% vs. 24.9%; P = .038). 33% of
participants with follow up cannabis data (68/205) changed their level of
cannabis use over the follow up period. In terms of functioning, subjects
with cannabis misuse at baseline had significantly better social function-
ing than those who had no/low use (P = .021), but there were no differ-
ences on role functioning. These results indicate that cannabis misuse is
related to conversion to psychosis in the NAPLS retrospective sample,
although cannabis misusers could not be distinguished from no/low users
on attenuated symptoms at baseline. Cannabis misusers were older
and had better social functioning. Further analyses will examine
whether prodromal symptoms and cannabis use fluctuate in relation
to each other.
ID: 551705
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ASSESSMENT OF NEUROLOGICAL SOFT SIGNS IN
POSITIVE AND NEGATIVE SCHIZOTYPY
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1Psychology, University of North Carolina at Greensboro, Greens-
boro, NC, USA; 2Departament de Psicologia Clı´nica i de la Salut,
Universitat Autonoma de Barcelona, Barcelona, Spain
Patients with schizophrenia often exhibit structural brain abnormalities, as
well as neurological soft signs, consistent with the conceptualization of
schizophrenia as a neurodevelopmental disorder. Neurological soft signs
are mild, presumably nonlocalizing, neurological impairments that are
inferred from performance deficits in domains such as sensory integration,
motor coordination, and motor sequencing. The vulnerability for schizo-
phrenia is presumed to be expressed across a broad continuum of impair-
ment referred to as schizotypy. It is hypothesized that nonpsychotic people
along the schizotypy continuum should exhibit elevated rates of neurolog-
ical soft signs. The present study examined the relation between psychomet-
rically identified positive and negative schizotypy and neurological soft
signs in a nonclinically ascertained sample of young adults (n = 177). Pos-
itive and negative schizotypy dimensional scores were derived from the Per-
ceptual Aberration, Magical Ideation, Physical Anhedonia and Revised
Social Anhedonia Scales. The neurological assessment was conducted using
the Neurological Evaluation Scale (NES). The battery consists of 26 tasks
that tap three neurological soft sign domains including sensory integration,
motor coordination, and motor sequencing. As hypothesized, negative, but
not positive, schizotypy was related to increased neurological soft signs as-
sociated with deficits in tasks related to fine and gross motor coordination,
motor sequencing, eye movement abnormalities, and memory recall. How-
ever, positive schizotypy was associated with deficits in a few tasks related
to sensory integration dysfunction. In general, the positive x negative schiz-
otypy interaction term was unrelated to soft signs. Recommendations are
offered to strengthen the utility of the NES for use with nonclinical samples,
including using a modified version of the battery and a continuous scoring
system. The findings support: a) the theory that the vulnerability for schizo-
phrenia is expressed across a broad continuum of subclinical and clinical
impairment referred to as schizotypy; b) the multidimensional structure of
schizotypy; and c) the notion that schizotypy may be a more appropriate
construct for understanding the etiology and development of spectrum psy-
chopathology than full-blown schizophrenia.
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ASSESSING SUICIDIDAL BEHAVIOR IN SCHIZO-
PHRENIA: PSYCHOMETRIC PROPERTIES OF
A BRIEF SELF-REPORT MEASURE
Jill Harkavy-Friedman
Psychiatry, Columbia University, NYSPI, New York, NY, USA
Individuals with schizophrenia are at risk for suicidal behavior. Careful and
ongoing assessment is important for detecting risk.The HASS is a 21-item
self-report measure of suicidal behavior assessing suicidal behavior over
the past 2 weeks (HASS I) and the patient’s whole life except the past 2 weeks
(HASS II). The strong psychometric properties and the application of this
measure will be presented. Data will be presented demonstrating the efficacy
of the HASS at identifying suicidal behavior and measuring change with
treatment. Over 140 individuals with Sz/SA disorder completed the
HASS. Three factors accounting for 59% of the variance were identified
for the HASS I: 1) thoughts of life, death and suicide; 2) suicidal behaviors
including attempts; 3) substance use. Four factors were identified for the
HASS II accounting for almost 67% of the variance: 1) Thoughts of suicide;
2) suicidal plans and actions; 3) substance use; and 4) thoughts of impulsive
suicidal behavior. Data will be presented regarding relationships with de-
pression, psychotic symptoms, impulsivity, aggression and the Beck Scale
for Suicidal Ideation. The findings will be compared with a sample of
adolescent high school students and with a sample of adolescents hospital-
ized for suicidal behavior in order to demonstrate the external validity of the
instrument. Sixty-five individuals were administered the HASS I on admis-
sion and discharge to the Schizophrenia Research Unit at New York State
Psychiatric Institute and the HASS II was administered on admission. The
HASS I detected attempts during the 2 weeks prior to admission and coupled
with the HASS II identified 100% of documented attempters in the sample.
There was a significant decrease in suicidal behavior from admission to
discharge (P < .001). The relationship between change in suicidal behavior
and change in other symptoms will be presented. The ability to assess suicidal
behavior in Sz regularly and thoroughly is important. The HASS is the only
self-report measure in the literature available at this time. The reliability is
excellent and a significant amount of validity data has been accrued. The
hope is that the availability of this measure will increase the likelihood
of the assessment of suicidal behavior in research as well as clinically. Sup-
ported by NIMH RO1 MH 56422-O1A, 2 P30 MH4674.
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THE PSYCHOTIC BRAIN-MIND BEYOND THE
KRAEPELINIAN DICHOTOMY: SIMILAR LEVELS
OF COGNITIVE BIZARRENESS FOUND IN THE
DREAM AND WAKING MENTATION OF PATIENTS
DIAGNOSED WITH BIPOLAR DISORDER AND
SCHIZOPHRENIA
Ivan Limosani, A. D’Agostino, M. L. Manzone, S. Scarone
Department of Psychiatry, Universita` degli Studi di Milano Azienda
Ospedaliera San Paolo, Milano, Italy
Similarities and differences were evaluated in terms of structural organiza-
tion of thought across two diagnostically distinct groups of actively psy-
chotic subjects, by measuring cognitive bizarreness in their dream and
waking mentation. Dreams reported upon awakening and narrative
responses to a standardized projective stimulus, the Thematic Apperception
Test (TAT), were collected from 20 acutely manic inpatients with psychotic
symptoms, 20 actively psychotic schizophrenic inpatients and 20 subjects
with no present or past history of mental illness, all adequately matched
in terms of age and education. The material was scored by two highly-trained
judges who evaluated the degree of bizarre elements referred to the formal
architecture of verbalized thoughts according to the dream bizarreness scale
(Scarone et al., 2008). A mean Bizarreness Density Index (BDI) was then
elaborated for each of the three experimental groups’ sets of dream and
TAT reports; analysis of the data indicated a substantial similarity in terms
of cognitive bizarreness in all reports, with the only statistically significant
outlier being the control group’s waking mentation (see Table). Cognitive
bizarreness can be interpreted as the phenomenological correlate of the spe-
cific activation pattern occurring in the brain during REM sleep, where
dream imagery is more vivid and storylines more articulated and incongru-
ous. Similar experimentally measurable and clinically objectivable depar-
tures from the physiological functioning of the brain-mind have been
shown to underlie dreaming and schizophrenia (Scarone et al., 2008).
The results found in this study support the view of psychotic mentation
as a correlate of the same type of neurobiological activation underlying
dream sleep. Moreover, waking levels of cognitive bizarreness appear to
be shared amongst acutely manic bipolar patients and actively psychotic
schizophrenic subjects, linking psychosis to a specific shift in brain-mind
functioning independent of diagnostic categories.
Reference
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Table. Descriptive statistics (Mean BDI Standard Deviation)
DREAM BDI TAT BDI
Control subjects 0.29 6 0.20 0.11 6 0.11
Schizophrenic subjects 0.32 6 0.13 0.32 6 0.19
Manic bipolar subjects 0.33 6 0.11 0.29 6 0.15
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HIGH FREQUENCY BAND ACTIVITY IN RESTING
EEG AND THE RELATIONSHIP WITH SMOKING IN
SCHIZOPHRENIA
Alice Saperstein1, A. Summerfelt2, L. E. Hong2, R. Buchanan2,
G. K. Thaker2
1Psychology, University of Maryland, College Park, MD, USA;
2Psychiatry, University of Maryland School of Medicine, Baltimore,
MD, USA
Evidence suggests that high nicotine dependence observed in schizophrenia
is related to its core neuronal deficits such as abnormalities in neural syn-
chronization and sensory gating deficits. Some of these neuronal deficits are
shown to mark schizophrenia liability, raising the possibility that the in-
creased nicotine dependence in schizophrenia is related to its etiological fac-
tors. In an ongoing study, we are examining the rates of nicotine
dependence in families of schizophrenia probands using the Fagerstrom
Test for Nicotine Dependence, and the relationships between nicotine de-
pendence and schizophrenia endophenotypes in these subjects. Rates of nic-
otine use were significantly greater in patients (n = 103) than controls (n =
77) with respect to a history of ever smoking (69.9% vs 46.8%) and current
smoking (58.3% vs 23.4%) with patients reporting greater levels of nicotine
dependence (FTND; F1,103 = 20.33, P< .001). The two phenotypes, ie, ever
smoking and current smoking, were associated with moderate to high her-
itability among schizophrenia families (heritability estimates > 0.9) and
control families (> 0.5). We are in the process of examining their relation-
ships with schizophrenia endophenotypes; at present data are available only
in schizophrenia probands and control subjects on resting EEG measures
and P50 gating. Resting EEG (5 min. sample) were analyzed to yield ab-
solute power averages in alpha (8–10Hz), beta (12–28Hz) and gamma (30–
50Hz) frequency bands examined at electrode sites Cz and Fz with repeated
measures ANOVA to test for diagnostic differences and interactions with
smoking status. No main effect of diagnosis was found for power in the
alpha, beta, or gamma bands (all p values > 0.20), but classification by
never, former, or current smoker yielded a significant main effect in the
gamma band (F2,173 = 3.34, P = .038) and a trend towards significance
for the beta band (F2,174 = 2.62, P = .076); post-hoc tests demonstrated sig-
nificantly lower gamma band activity in current smokers than former
smokers (P = .037). There was a significant group by smoking status inter-
action for P50 ratio (F1,81 = 9.12, P = .003) whereby sensory gating deficits
were normalized in patient but not control smokers. We are in the process
of analyzing data in the relatives. These results suggest that further analysis
of high frequency bandpower in resting EEG may provide important links
between neurophysiological deficits associated with schizophrenia and
smoking.
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SELF-DISORDERS IN THE PRODROME: A PILOT
STUDY AMONG HELP-SEEKING ADOLESCENTS
Danny Koren1, N. Reznik1, M. Herman1, R. Rozilio1, J. Parnas2
1Psychology, University of Haifa, Haifa, Israel; 2Psychiatry,
University of Copenhagen, Copenhagen, Denmark
The overarching objective of this pilot study was to lay the ground for
a large-scale, community-based, prospective study that will examine the po-
tential of anomalous self-experiences as an early, pre-psychotic phenotype
of emerging schizophrenia. More specifically, the present study had two
interrelated goals: 1) to demonstrate the feasibility of identification of
anomalous self-experiences among non-psychotic help-seeking adolescents,
and 2) to examine the potential of these experiences to serve as an early risk
marker by examining their relationship with level of worry for a future psy-
chotic illness as rated by an experienced child psychiatrist, presence and
severity of prodromal symptoms, and decline in level of functioning.
The study was motivated by the view that present research is not guided
by a comprehensive psychopathological theory regarding the nature of
the pre-psychotic phase. To accomplish these goals we administered the Ex-
amination of Anomalous Self-Experience (EASE: Parnas et al. 2005) to
a group of 30 adolescents seeking help for emotional and behavioral prob-
lems. In addition, all participants were assessed with an extensive battery
measuring conventional genetic and clinical risk factors such as familial
predisposition, prodromal symptoms, emotional distress, psychosocial
functioning, and (meta-)cognitive functioning. All assessments were carried
out in complete blindness to the level of worry for future psychotic illness as
assessed by the intake psychiatrist. A wide range of anomalous self expe-
riences has been observed in about two thirds of the sample. The prevalence
and level of severity of these experiences were significantly correlated with
level of worry as assessed by the child psychiatrist, as well as with level of
prodromal symptoms, emotional distress, and depth of cognitive and meta-
cognitive deficits. If further validated, these preliminary findings suggest
that anomalous self-experiences can enrich current early detection models
by expanding the focus to the subjective experiences that may antecede the
more descriptive-observational at-risk phenomena.
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RATES AND CORRELATES OF PAST INCAR-
CERATION AMONG PATIENTS HOSPITALIZED
FOR A FIRST-EPISODE OF NONAFFECTIVE
PSYCHOSIS
Claire Ramsay, S. M. Goulding, B. Broussard, S. Cristofaro,
G. Abedi, M. T. Compton
Department of Psychiatry and Behavioral Sciences, Emory
University School of Medicine, Atlanta, GA, USA
Background: Population-based and clinical studies attest to the fact that
individuals with schizophrenia have high rates of arrest and incarceration.
However, little is known about the prevalence of arrest and incarceration in
first-episode psychosis samples, or social and clinical correlates of such le-
gal system involvement occurring prior to initial treatment seeking. This
study examined prevalence of arrest/incarceration and associations be-
tween incarceration and demographic, premorbid functioning, and clinical
variables in a first-episode sample. Methods: The sample consisted of 109
urban, predominantly African American patients with first-episode
nonaffective psychosis, hospitalized in a public-sector setting. Assessments
included the Premorbid Adjustment Scale and the Positive and Negative
Syndrome Scale (PANSS), along with a number of other measures. Results:
Rates of past arrest and incarceration were very high in this sample (77%
and 63%, respectively). Patients with a history of incarceration had
completed fewer years of education (10.9 6 2.1) compared to those who
had not been incarcerated (12.6 6 2.4; t = 3.9, P < .001). Past incarceration
was associated with poorer academic functioning in early (P = .020) and late
adolescence (P = .007), though no association was found with academic
functioning before the age of 11 years or social functioning during any pre-
morbid period. Past incarceration was significantly associated with the
presence of alcohol (P = .017) and cannabis (P = .003) abuse or dependence.
Of those having ever used cannabis, patients who had been previously in-
carcerated had a mean age at first reported cannabis use of 15.2 6 4.1, com-
pared to those who had not been arrested (17.0 6 3.6; t = 2.0, P = .049).
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There was a significant association between past incarceration and the total
number of Axis IV psychosocial and environmental stressors (P = .002),
PANSS positive symptoms, and PANSS general symptoms, each indicating
poorer functioning among those having been previously incarcerated. Dis-
cussion: Although criminalization of individuals with serious mental ill-
nesses is a widely recognized problem, it is typically conceptualized as
a function of chronicity of illness. These data indicate that even prior to
the first treatment contact, this sample had already accumulated substantial
psychosocial consequences in terms of arrest/incarceration. Each signifi-
cant correlate of past incarceration suggested grave implications for symp-
tomatic and social functioning.
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DIFFERENTIAL HEDONIC CAPACITY IN
SCHIZOPHRENIA AND BIPOLAR DISORDER.
Tyler Barrett Grove, I. F. Tso, S. F. Taylor
Psychiatry, University of Michigan, Ann Arbor, MI, USA
Emotional abnormalities characterize both affective and non-affective psy-
chosis, and both schizophrenia and bipolar disorder have poor functional
outcomes. However, socio-emotional and volitional impairment are central
to the Kraepelinian distinction between the groups, suggesting that emo-
tional measures should differentiate them. To investigate this question,
we administered several emotion function scales to patients with affective
and non-affective psychosis in order to differentiate hedonic capacity. Sta-
ble outpatients (43 with schizophrenia/schizoaffective disorder [SCZ]; 27
with bipolar disorder I/II [BP]) and 36 matched healthy subjects (HC)
were administered tests of hedonic capacity (Physical and revised Social
Anhedonia scales[PAS, RSAS]), basic drive and inhibition (Behavioral In-
hibition and Activation Scales [BIS-BAS]), and consummatory/anticipa-
tory hedonic capacity (Temporal Experience of Pleasure Scale –TEPS).
Subjects also completed a measure of anxiety/negative affect (State-trait
anxiety, STAI) and the Social Adjustment Scale (SAS). Twelve-month fol-
low-up data is reported from 33 SCZ and 18 BP subjects. Internal reliability
of the self-rating scales was favorable for both groups (alpha > 0.75). Both
patient groups exhibited significant negative affect (STAI: F = 26.7, P <
.000, SCZ = BP > HC), and significant functional social impairment
(SAS: F = 20.9, P < .000; SCZ = B, P < HC). On traditional anhedonia
measures, both groups were impaired (PAS: F = 14.7, P < .000, SCZ =
BP > HC; RSAS: F = 9.7, P < .000, SCZ = BP > HC). However, the
TEPS differentiated the groups (F = 5.8, P = .004, SCZ<B, P < HC), as
did BAS reward reinforcement (F = 6.8, P = .002, SCZ < BP = HC)
and BAS drive (F = 4.7, P = .01, SCZ< BP = HC). The BP group exhibited
greater inhibition than the HC group (F = 6.2, P = .003, BP > HC). The
TEPS did not show differential impairment according to anticipatory or
consummatory pleasure, i. e. no group by subscale interaction (P > .5).
However, in SCZ only the TEPS anticipatory subscale correlated with cli-
nician-rated anhedonia (r = .33, P < .05), predicted current social adjust-
ment (r = .35, P< .05), and predicted social adjustment at 12 months (r =
.45, P < .01). Negative affect (STAI) predicted social adjustment in SCZ
(r = .58, P < .01) and BP (r = .56, P < .05). The findings illustrate the phe-
notypic overlap of the two groups, but also support the Kraepelinian poles
of affective and non-affective psychosis by way of hedonic capacity and
emotional drive.
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AN INVESTIGATION OF NEGATIVE AFFECT AND
POSITIVE SYMPTOMS OF PSYCHOSIS
Audra Crutchfield1, C. Neumann2, P. Wupperman3
1Psychology, University of North Texas, Denton, TX, USA;
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Disturbances of negative affect, such as depression and anxiety, are con-
sistently identified as core features of both psychotic and psychosis-prone
(at-risk) individuals and represent important treatment considerations for
individuals with psychotic disorders. Vulnerability-stress models suggest
that individuals with a predisposition to psychosis may have heightened
emotional reactivity to environmental, biological, and psychosocial stres-
sors – and therefore may be more susceptible to negative affective states
(Asarnaw, Cromwell, and Rennick, 1978; Meehl, 1962; Walker and Difor-
io, 1997). Additionally, emerging evidence suggests a cross-sectional as-
sociation between negative affect and positive symptoms of psychosis,
such as hallucinations, delusions, and thought disorder; however, few lon-
gitudinal studies have examined these relationships (eg, Docherty, Grosh,
and Wexler, 1996; Docherty, Rhinewine, Nienow, and Cohen, 2001). The
current study examined cross-sectional and longitudinal associations be-
tween disturbances in negative affect (depression and anxiety) and posi-
tive symptoms of psychosis (hallucinations, delusions, and thought
disorder). Specifically, we hypothesized synchronous (cross-sectional)
associations between negative affect and positive psychosis and believed
these associations would remain stable over time after accounting for
baseline levels. It was also hypothesized that negative affective traits at
baseline would predict an increase in severity of positive symptoms of psy-
chosis among those individuals with a diagnosis of psychotic disorder at
subsequent time frames (10 and 20 weeks). Data were drawn from the
MacArthur Violence Risk Assessment study and included individuals
(N = 245) with a diagnosis of psychotic disorder and scores of individual
items on the Brief Psychiatric Rating Scale. Results of Confirmatory Fac-
tor Analysis and Structural Equation Modeling suggested good fit to the
data (CFI = .94, RMSEA = .05, SRMR = .05, BIC = 12023). Analyses
revealed moderately strong, statistically significant cross-sectional asso-
ciations between negative affect (Depression-Anxiety) and positive symp-
toms of psychosis. These correlations remained stable over time after
accounting for baseline and previous effects of the latent variables. Con-
trary to hypotheses, no significant cross-lagged effect was identified,
suggesting no directional relationship between negative affect and positive
psychotic symptoms.
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22Q11DELETION SYNDROME AND SCHIZOTYPAL
PERSONALITY DISORDER: BEHAVIORAL AND
PRODROMAL SYMPTOMS IN INDIVIDUALS AT
HIGH RISK FOR PSYCHOSIS
Daniel Shapiro1, J. F. Cubells2, K. Rockers2, O. Ousley2,
E. F. Walker1
1Department of Psychology, Emory University, Atlanta, GA,
USA; 2Department of Psychiatry and Behavrioal Sciences, Emory
Autism Center, Emory University School of Medicine, Atlanta,
GA, USA
Adolescents with 22q11 Deletion Syndrome (22q11DS) and Schizotypal
Personality Disorder (SPD) are at increased risk for the development of
psychosis. This is evidenced by rates of illness much higher than those in
the general population, as well as by the presence, in both, of subthresh-
old psychotic symptoms. The current study compares the behavioral and
prodromal symptom profiles of adolescents in genetic (22q11DS) and
behavioral (SPD) high risk groups. While many studies have investigated
the behavioral and symptom profiles in each of these groups, no pub-
lished report has directly compared them with each other. Doing so
can potentially shed light on the relevance of etiological subtypes for un-
derstanding the pathogenesis of schizophrenia. The current study used
two measures: the Achenbach Child Behavior Checklist (CBCL; SPD:
n = 13, 22q11DS: n = 13), and the Structured Interview for Prodromal
Syndromes (SIPS; SPD: n = 23, 22q11DS: n = 23). The two risk groups
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were matched on age, gender, and where possible, ethnicity. PRELIM-
INARY RESULTS: CBCL—Individuals in the SPD group had scores
that were in the clinically significant range, and higher than those in
the 22q11DS group on the anxious/depressed, social problems, thought
problems, attention problems, internalizing problems, and total prob-
lems scales. The 22q11DS group did not have any scores in the clinically
significant range. SIPS—individuals in the SPD group had more positive
symptoms and attenuated ideational richness, as well as fewer motor
problems. Both groups also showed heightened attention problems
and elevated anhedonia scores. Thus, results show both similarities
and differences between these two high risk groups, suggesting that
individuals with 22q11DS and those with SPD may share some of the
same risk factors for the development of schizophrenia. Results are
consistent with the notion that genes mapping the 22q11 chromosomal
region are involved in the pathogenesis of schizophrenia and
spectrum disorders.
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THE PATTERN OF CANNABIS USE AND WITH-
DRAWAL SYMPTOMS IN PEOPLE WITH SCHIZO-
PHRENIA
Douglas Lee Boggs1, D. L. Kelly1, J. Linthicum1, F. Liu1,
R. P. McMahon1, D. A. Gorelick2
1School of Medicine, Psychiatry, Maryland Psychiatric Research
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2Office of the Scientific Director, Intramural Research Program,
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Chronic users of cannabis often report withdrawal symptoms after ab-
stinence from use (1), but it is unknown whether this occurs in people
with schizophrenia. This study used a structured questionnaire (Mari-
juana Quit Questionnaire (1)) to examine behavioral patterns of canna-
bis use and withdrawal symptoms. Fifty-four people in treatment for
schizophrenia or schizoaffective disorder who were > 18 years old
and reported at least one serious cannabis quit attempt participated
in the study. Volunteers were 40.1 6 10.9 years old (mean 6 SD),
66.76% male, 54% Caucasian, and 37% African-American. First
reported age of cannabis use was 16.5 6 6.1 yrs, and reported age of
onset of psychotic symptoms (n = 50) was 21.0 6 5.6 yrs. Ninety-two
percent (46/50) reported using cannabis before the onset of psychotic
symptoms. The number of lifetime uses of cannabis ranged from 1 to
> 10 000 (63% reported at least 500 uses). Seventeen percent met criteria
for cannabis abuse; 74% met surrogate criteria for cannabis dependence.
Cannabis use had a negative effect on quality of life: 87% (46/53)
reported experiencing psychological or emotional problems and 60%
(32/54) reported physical health problems related to cannabis use. With-
drawal symptoms were reported by 93%; 52% reported between 1–5
withdrawal symptoms, 28% reported 6–10 symptoms, and 20% reported
> 10 symptoms. The most common reported withdrawal symptoms
were: anxiety (50%), depression (46%), craving for cannabis (44%),
and boredom (39%), similar to the symptoms reported by users without
psychiatric comorbidity (1). Ten percent reported using cannabis to re-
lieve withdrawal symptoms. This suggests that withdrawal is a negative
reinforcer for relapse. We conclude that most people with schizophrenia
who use cannabis begin before the onset of psychosis and that with-
drawal symptoms are common in those who have attempted to quit.
Withdrawal symptoms are important in the clinical treatment of schizo-
phrenia and comorbid cannabis use disorders. Supported by the Intra-
mural Research Program, NIH, National Institute on Drug Abuse and
the NIDA Residential Research Support Services Contract
HHSN271200599091CADB.
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SOCIAL WORLD INTERACTIONS: HOW COMPANY
CONNECTS TO PARANOIA
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Background: Many surveys and experimental studies have indicated that
social contact, even when it is neutral, triggers paranoid thinking in people
who score high on clinical or sub-clinical paranoia. However, little is known
about the relationship between paranoia and social environmental effects in
the context of daily life reality. The current study aims to investigate
whether contextual variables are predictive of momentary increases in
the intensity of paranoid thinking in a sample of subjects with clinical
and non-clinical paranoia. Methods: A sample of 37 control subjects, 37
high-schizotypy participants, and 33 paranoid patients were assessed
with the Experience Sampling Method (a structured diary technique)
assessing momentary social context, appraisal of social company, perceived
social threat and paranoia in daily life. Results: Multilevel analyses revealed
a significant interaction effect between group and being alone in the model
of momentary paranoia (v2 (2) = 20.22, P < .00). Patients reported lower
levels of paranoia when in company than when alone (v2 (1) = 13.84, P <
.000), whereas no such difference was found in the high-schizotypy group or
controls. With regard to the type of social company, differential associa-
tions were found for momentary paranoia (v2 (2) = 28.83, P < .000), and
perceived social threat (v2 (2) = 41.88, P< .000) in the three groups. Controls
and high-schizotypy individuals reported higher levels of perceived social
threat when with non-familiar compared to familiar individuals. Moreover,
the high-schizotypy group reported more paranoia in non-familiar com-
pany. The patients, on the other hand, reported no difference in the per-
ception of social threat between familiar and non-familiar contacts.
They even reported less paranoia when in non-familiar compared to famil-
iar company. Discussion: The data suggest that the development of
sub-clinical momentary paranoia is context-dependent. However, once
in a full-blown paranoid episode, momentary paranoia seems to become
more autonomous and independent of the social reality. Being with other
people, especially with non-familiar individuals, may then even serve as a
protective factor.
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DEVELOPMENT OF AN INTERVIEW-BASED
‘‘CO-PRIMARY’’ MEASURE OF COGNITION
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Background: The MATRICS initiative has reached a consensus that prac-
tical, reliable ‘‘co-primary’’ measures of cognition are needed to evaluate
change in cognitive functioning after new drug interventions (Green
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et al., 2008). However, for data to be meaningful there should be evidence
that the co-primary instrument effectively measures the appropriate
concept. Method: Data were collected as part of the MATRICS initiative
(n = 176) with the (SCoRS and CGI-CogS; total of 41 items), two interview-
based measures of cognition. Sources of information included a patient,
a caregiver, and the rater. The aim of these analyses was to develop a valid
but brief co-primary measure of cognition. The study investigators used
classical test theory (CTT) including factor analysis and modern test theory
approaches, such as Item Response Theory (IRT) and developed a 10-item
Cognitive Assessment Interview (CAI). The validity analysis focused on the
relationship between the CAI and objective measures of cognitive function-
ing (MCCB), functional outcome (Birchwood Social Functioning Scale),
and psychiatric symptoms (BPRS). Results: For the CAI, both the patient
(r = .82) and the caregiver (r = .95) ratings were highly correlated with the
rater’s composite. The 10-item CAI correlates highly (r = .87) with the com-
bined set of parent instruments (CGI-CogS and SCoRS; 41 items). In ad-
dition, the CAI is moderately correlated with objectively measured
cognition (r = .32) and with functional outcomes (r = .31) at levels
that are comparable the parent instruments. The CAI was correlated
with positive symptoms (r = .28), but not with depression (r = .06) or neg-
ative symptoms (r = .09). Conclusions: The CAI allows a rater to use expert
judgment to evaluate the patient’s or the caregiver’s report of cognitive
functioning. The CAI is experience-near, and given the moderate correla-
tion with neurocognition and functional outcome, shows indications of be-
ing valid. Although the CAI is correlated with positive symptoms, the
ratings are not unduly influenced by all types of symptoms. The CAI is brief
and repeatable, and therefore might be a valuable tool for assessing cog-
nitive functioning for schizophrenia patients who are participating in clin-
ical trials.
ID: 551133
THE ECOLOGICAL VALIDITY OF NEGATIVE
SYMPTOMS
Margreet Oorschot1, V. Thewissen1,2, J. van Os1,3,
I. Myin-Germeys1,4
1Department of Psychiatry and Neuropsychology, South Limburg
Mental Health Research and Teaching Network, EURON, Maas-
tricht University, Maastricht, Netherlands; 2Faculty of Psychology,
Open Universiteit Nederland, Heerlen, Netherlands; 3Division of
Psychological Medicine, Institute of Psychiatry, London, United
Kingdom; 4School of Psychological Sciences, University of Man-
chester, Manchester, United Kingdom
Flat affect and social anhedonia are assumed to be key characteristics of
negative symptomatology in psychotic disorders. However, the ecological
validity of these concepts remains unclear. This study compared flat affect
and social anhedonia as measured by a structured interview to emotional
experience and social behavior in the realm of daily life. In the current
study, emotional experience and social behavior of 178 patients diagnosed
with psychotic spectrum disorders and 164 controls were explored using the
Experience Sampling Method (a structured diary method). Social
anhedonic and blunted patients were identified using the Positive and Neg-
ative Symptom Scale. Flat affect in daily life was defined as diminished
emotional intensity. Social anhedonia in daily life was conceptualized using
1) frequency of being in company, 2) preference of being alone while in
company and 3) emotional reward of being in company. Multilevel regres-
sion analyses revealed that the patient group as a whole experienced more
intense negative and less intense positive emotions than controls. Blunted
patients, however, did not differ from non-blunted patients in emotional
intensity. Compared to controls, patients were more often alone and
showed a higher preference of being alone when in company. However, so-
cial company was associated with more positive and less negative emotions
in both patients and controls. No differences between social anhedonic and
non-anhedonic patients were found on all three indicators of social anhe-
donia. These results suggest that patients may experience problems with
positive emotions and social isolation in normal reality of daily life. How-
ever, these problems were not validly captured using a structured interview,
since no differences on social anhedonia and flat affect in daily life were
found between patients scoring high or low on the negative symptom items
of the structured interview.
ID: 551083
PRODROMAL SYMPTOMS IN CANNABIS,
KETAMINE AND COCAINE USERS
Celia J. A. Morgan1, S. Duffen2, S. Hunt2, L. Monaghan2,
O. J. Mason2, H. V. Curran1
1Clinical Psychopharmacology Unit, University College London,
London, United Kingdom; 2Psychology, Univerisity College London,
London, United Kingdom
Three classes of drugs have been repeatedly associated with psychotic phe-
nomena: cannabis, the stimulants (cocaine and amphetamine), and the dis-
sociative anaesthetics (PCP and ketamine) but their users have never been
directly compared on psychotic symptoms. We used a pre-clinical or pro-
dromal measure of symptoms to compare non-psychotic users of these three
groups of drugs. 130 volunteers were rated on the Schizophrenia Proneness
Instrument-Adult (Schulz-Lutter et al. 2008; SPI-A): 29 dependent ‘skunk’
(high potency cannabis) users, 22 dependent cocaine users, 21 dependent
ketamine users, along with 28 ‘recreational’ poly-drug (ketamine, cannabis
and cocaine) users, and 30 drug-naı¨ve controls. Group membership was
verified by hair and urine analysis. The SPI-A yields 6 basic symptom ‘fac-
tors’: affective symptoms, attentional symptoms, cognitive disturbances,
perception of self and surroundings, body perception and general percep-
tual changes. SPI-A data were also compared with existing data on prodro-
mal individuals (Kloster-Kotter et al., 2007). Ketamine users showed the
greatest number of affective and perceptual symptoms. Both ketamine
and cannabis users manifested the greatest levels of attentional problems
and cognitive disturbances. Cocaine users showed greater perceptual dis-
turbances than the cannabis group but fewer than ketamine users. Overall
dependent drug users exhibited more symptoms than recreational users on
every factor except disturbances in body perception. Recreational drug
users did not differ from non-drug users in affective symptoms and other
perceptual disturbances. Of the dependent groups, ketamine users pre-
sented with basic symptoms which were the most similar to prodromal indi-
viduals; ‘cognitive’ basic symptoms were also prominent in dependent
cannabis users; the symptom profile of cocaine users was the most subtle.
The drug-related elevation in symptoms was restricted largely to dependent
drug users, with much lower levels of symptoms in recreational drug users.
Few of these drug-dependent individuals will likely transition to psychosis
but these drug induced increases in basic symptoms may represent mech-
anism of risk in people with a predisposition to the disorder. In addition,
clinicians should be aware of the similarity of symptoms observed in drug
users who will likely not transition to psychosis and genuinely prodromal
individuals.
ID: 550978
CHILDHOOD TRAUMA, CORTISOL LEVELS AND
HPA AXIS FUNCTION IN DRUG-NAI¨VE FIRST
EPISODE PSYCHOSIS PATIENTS
Belinda Garner1, C. Phassouliotis1, L. J. Phillips2, Y. Yun1,
C. Markulev1, S. Bendall1, R. Parslow1, C. Leong2,
P. D. McGorry3
1Psychiatry, ORYGEN Research Centre, Melbourne, VIC,
Australia; 2School of Behavioural Sciences, University of
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Melbourne, Melbourne, VIC, Australia; 3ORYGEN Youth Health,
NorthWestern Mental Health, Melbourne, VIC, Australia
Early life trauma is associated with increased vulnerability for psychiatric
disorders, possibly mediated by alterations in the hypothalamic-pituitary-
adrenal (HPA) axis. This study examined the relationship between child-
hood trauma and HPA axis function in 17 first-episode psychosis (FEP)
patients and 19 healthy controls using the low dose (0.25mg) Dexametha-
sone Suppression Test (DST). Blood samples were obtained at 9am before
and after administration of 0.25mg oral dexamethasone at 11pm. Suppres-
sion was defined as a cortisol level <5ug/dL. Childhood trauma was
assessed using the Childhood Trauma Questionnaire (CTQ). FEP patients
had significantly higher CTQ scores for emotional abuse (P< .001), sexual
abuse (P = .043) and physical neglect (P = .01) compared to controls. Base-
line cortisol levels tended to be lower in FEP patients compared to controls
(mean (SEM): FEP = 16.4 (1.4) ug/dL; controls = 20.6 (1.4) ug/dL; P = .054).
Six out of 17 FEP patients (35.3%) suppressed cortisol following ingestion
of dexamethasone compared to 2 out of 19 (10.5%) control participants
(x2=3.18; P = .07). In the entire sample, there was a non-significant negative
correlation between baseline cortisol levels and total CTQ scores (0.2; P =
.2). In the low dose DST, percent cortisol suppression was significantly cor-
related with emotional abuse in FEP patients (r = .58, P = .038), but not in
control participants (r = .05; P = .8). No significant correlations were ob-
served for the other CTQ dimension scores. These preliminary findings
show for the first time that a subset of FEP patients have enhanced feed-
back inhibition of the HPA axis, which might be linked to prior exposure to
childhood trauma. Further studies with larger sample sizes are needed. Ex-
amination of the relationship between childhood trauma, HPA function
and the development of PTSD symptoms following the first psychotic
episode is currently underway.
ID: 550972
SEPARABLE DEVELOPMENTAL TRAJECTORIES IN
SCHIZOPHRENIA FROM WOMB TO GRAVE.
RESULTS FROM THE NORTHERN FINLAND 1966
BIRTH COHORT
Matti K. Isohanni1, P. Tanskanen2, A. Alara¨isa¨nen1,
E. Ja¨a¨skela¨inen1, I. Isohanni3, J. Miettunen1
1Psychiatry, University of Oulu, Oulu, Finland; 2Radiology,
University of Oulu, Oulu, Finland; 3Oulu Polytechnic, Oulu, Finland
Subtle developmental (motor, emotional, structural, cognitive and behav-
ioural) abnormalities are often present in individuals who later develop psy-
chosis suggesting that some aspects of causation are established before
overt psychosis. However, their effect size and predictive power are small,
and the longitudinal trajectory of developmental factors can be difficult to
tease apart. The Northern Finland 1966 Birth Cohort Study examines the
pre- and postmorbid life-span developmental trajectory for schizophrenia
in a population-based cohort. We studied developmental pathways across
diagnostic groups using developmental markers at birth, at ages 1, 16, and
at ages 31, 34 and (in progress) 43 (genetics, brain morphology, cognitive
capacity, clinical status). The main results were: the schizophrenia group
had excess of achieved developmental milestones later and showed altered
patterns of development over time when compared with non-psychotic
controls. The associations between early development and post-onset
cognition/brain morphology differed in various diagnostic groups. Further-
more, we have identified evidence of progressive dysfunction in a distributed
network involving a fronto-striatal-cerebellar circuit (‘‘developmental dys-
metria’’) in schizophrenia. This is akin to the system underpinning the cog-
nitive dysmetria of schizophrenia and provides a mechanistic link between
the developmental dysmetria prior to schizophrenia. Schizophrenic persons
experience different trails also after the illness onset: separable outcomes in
terms of psychiatric symptomatology, somatic health and mortality. We
conclude that the developmental trajectories in schizophrenia from
womb to grave are distinctly different compared to controls and also within
the schizophrenia group. These findings emphasize both neurodevelopmen-
tal and neurodegenerative aspects of schizophrenia and the scientific value
of pathway variables collected in longitudinal birth cohort studies.
ID: 550963
THE RELATIONSHIP AMONG CHILDHOOD
TRAUMA, STRESS AND COPING IN THE FIRST
EPISODE PSYCHOTIC POPULATION:
PRELIMINARY RESULTS FROM SHARP STUDY
Yang Yun Master1,2, R. Parslow2, B. Garner1,2, L. Phillips2,
C. Phassouliotis2, C. Markulev1, C. Leong2, S. Bendall1,2,
G. Berger2,3, P. McGorry1,2
1ORYGEN Research Centre, Melbourne, VIC, Australia;
2Department of Psychiatry, University of Melbourne, Melbourne,
VIC, Australia; 3Department of Psychiatry, University Hospital,
Basel, Switzerland
SHARP (Stress, HPA function And Related Psychosis) is a project to inves-
tigate the relationship among childhood trauma, stress, coping, psychopa-
thology, HPA function, neuro-cognition, brain structure and medical
compliance in the first episode psychotic (FEP) population. This abstract
is the results about childhood trauma, stress, coping, medical compliance
and psychopathology. 50 first episode psychosis drug naı¨ve or early treated
(less than 7 days of antipsychotic or antidepressant) patients and 40 matched
healthy controls were recruited from the ORYGEN Youth Health in Mel-
bourne, Australia. Their psychopathology (BPRS, SANS, HAMA and
HAMD), social function (GAF and SOFAS), medical compliance (Clinical
rating scale, Drug attitude Inventory), NEO personality inventory, trauma
(Childhood Trauma Questionnaire and List of Threatening Experiences)
and Stress and coping (Coping Inventory for Stressful Situations, Daily Has-
sles Scale, Perceived Stress Scale and Connor-Davidson Resilience Scale)
were measured at baseline and after 12 weeks follow up. The prevalence
of childhood trauma in FEP group is higher than in the control group. In
the FEP group, the level of daily hassle is positively correlated to perceived
distress at baseline. The bigger change of hassle total score and severity of
hassle is linked to the more severe negative symptoms at 12 week follow up.
Perceived stress at baseline is correlated to less severe negative symptom,
higher hassle and hassle severity and poor clinical rating score. Also higher
CTQ is linked to higher baseline hassle total score, severity of hassle and
higher perceived stress. It also related to lower mood symptom in the
FEP group. FEP with childhood traumatic history might experiences
more hassle, more severe hassles and perceived more stress when they
were suffering from the psychosis, also might report less mood symptom.
ID: 550957
DISORGANIZATION IN SCHIZOPHRENIA:
POSITIVE SYMPTOM OR NEUROCOGNITIVE
DEFICIT?
Joseph Ventura1, A. D. Thames2, G. S. Hellemann1
1Psychiatry, UCLA, Los Angeles, CA, USA; 2Psychology, Alliant
International University, Los Angeles, CA, USA
Background: Several factor analytic studies have shown that in schizophre-
nia patients, disorganization is a separate dimension from positive (non-
disorganizing) symptoms termed, reality distortion. A prior meta-analysis
found that the strength of the relationship between positive symptoms and
neurocognition can vary depending on whether researchers were examining
‘‘reality distortion’’ or ‘‘disorganization’’ (Nieuwenstein et al., 2001). Sev-
eral studies on this topic have now been added to the literature. Methods:
Meta-analysis of 58 studies published in the English language (combined
n = 5,029) was conducted to determine the magnitude of the relationship
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between neurocognition and reality distortion, eg, delusions and hallucina-
tions as compared to disorganization, eg, formal thought disorder. Addi-
tional analyses were conducted to determine whether the strength of these
relationships differed depending on the neurocognitive domain under in-
vestigation. Results: The effect size of relationship between neurocognition
and reality distortion was small (r = .16) as compared to disorganization
which was moderately associated with neurocognition (r =.26). In four of
five MATRICS domains that were examined, neurocognition was more
closely related to disorganization (r’s range from .20 to .28) than
was reality distortion (r’s = .08 to .15). For disorganization, moderate
effects were found for reasoning and problem solving (r = .26) and verbal
memory (r =.28). Conclusions: The effect size of the relationship between
neurocognition and reality distortion was small compared to disorganiza-
tion which was moderately related in several MATRICS domains. These
findings support a dimensional view of positive symptoms indicating
that the strongest relationship to neurocognitive deficits is shown by the
category of disorganization. The cognitive domains of reasoning and prob-
lem solving, and verbal memory appear to be more conceptually linked to
disorganization than to reality distortion.
ID: 550927
DECREASED BDNF IN PATIENTS WITH FIRST
EPISODE TREATMENT NAI¨VE PSYCHOSIS
Ripu D. Jindal1, A. K. Pillai2, S. R. Mahadik2, M. S. Keshavan1,3
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Psychiatry, medical College of Georgia, Augusta, GA, USA;
3Psychiatry, Harvard Medical School (BIDMC), Boston,
MA, USA
Objective: Brain-derived neurotrophic factor (BDNF) is a key factor that
may mediate neuronal proliferation, differentiation, survival and response
to stress. Several small studies show a decrease in BDNF levels in patients
with psychosis. However, studies of effect of antipsychotic agents on
BDNF have yielded conflicting results. Herein we report on BDNF levels
in first-episode treatment naı¨ve psychosis. Method: Fasting serum BDNF
levels were measured in .43.patients with treatment naı¨ve first episode psy-
chosis and 42 age matched healthy controls. Baseline levels in the 9 patients
were compared with their levels after 4–8 weeks of antipsychotic treatment
with second generation antipsychotic agents. Data were square root trans-
formed to ensure normality of distribution. Results: Serum BDNF levels
(square root) were reduced in the patients (9.95 þ 1.5) versus controls
(10.70 þ 1.6) (Mann Whitney U = 670.5; P = .04). The levels did not sig-
nificantly differ after treatment (before treatment 9 þ 1.43) versus after
treatment (8.9 þ 1.17); Mann Whitney U = 39.5; P = .93) Conclusions:
Low BDNF levels at the onset of psychosis suggest a possible role in
the pathogenesis of schizophrenia. Our failure to detect treatment may ei-
ther reflect inadequate statistical power, or a true lack of effect of the atyp-
ical antipsychotic agents on BDNF. The inadequacy of contemporary
treatments in addressing the core pathology of schizophrenia highlights
the need to examine alternative treatment targets. This publication was sup-
ported by funds received from AAGP SRI Alumni Award (P.I Ripu Jindal)
and the NIH/NCRR/GCRC grant #M01 RR00056.The clinical core staff
of the Center for the Neuroscience of Mental Disorders (MH45156) assisted
in diagnostic assessments.
ID: 551937
CHILDHOOD BEHAVIOR AND SCHIZOPHRENIA
SPECTRUM PSYCHOPATHOLOGY IN YOUNG GE-
NETIC HIGH-RISK RELATIVES
Srihari S. Bangalore1, D. M. Montrose1, D. Mermon1,
J. Miewald1, S. Eack1, K. Prasad1, V. Diwadkar1,2, M. Abela2,
R. Rajarethinam2, M. Keshavan1,2
1Psychiatry, University of Pittsburgh Medical Center, Pittsburgh,
PA, USA; 2Psychiatry, Wayne State University, Detroit, MI, USA
Introduction: High frequency of psychopathological disorders are seen
among offsprings of schizophrenia and bipolar disorder. The Child Behav-
ior Checklist (CBCL) is a reliable measure of the assessment of changes in
behavior over a period of time as reported by parents and subjects. Schiz-
otypy scores in high risk patients have been shown to be related to premor-
bid psychopathological traits and is a specific predictor of later
development of schizophrenia spectrum disorder. We wanted to examine
the relation between schizotypy and CBCL scores as reported by parents
and subjects. Methods: Subjects for this study were recruited from the Pitts-
burgh Risk Evaluation Program (PREP) at the Western Psychiatric Insti-
tute and Clinic of the University of Pittsburgh Medical Center , as well as
Wayne State University, Detroit. The Chapman subscales evaluating mag-
ical ideation (MA), perceptual aberration (PA) and social anhedonia (SA)
were used to evaluate schizotypy scores using the Chapman psychosis
proneness scale. Internalizing and externalizing symptoms were evaluated
using the parent and child version of the CBCL. Seventy-four young rel-
atives, with a first-degree family history of schizophrenia or bipolar disor-
der, aged 10 to 24 years were evaluated. Results: Cross-sectional analyses
revealed that child internalizing subscale correlated with Chapman sub-
scales of magical ideation (Spearman r = 0.31, P = .007), perceptual aber-
ration (Spearman r = 0.29, P = .038), and social anhedonia (Spearman r =
0.438, P = .004). Strong correlations were also seen the child externalizing
subscales and Chapman subscales of magical ideation (Spearman r = 0.41,
P = .0004), perceptual aberration (Spearman r = 0.23, P = .052), and social
anhedonia (Spearman r = 0.37, P = .005). There was no correlation between
the Parent version of CBCL and Chapman subscales. Conclusions: Child
version of CBCL correlates better than parent version with schizotypy.
Given that schizotypy scores may reliably predict progression towards fu-
ture schizophrenia spectrum disorders, it is prudent to recognize and treat
internalizing and externalizing symptoms early into the prodrome. High-
risk offsprings may be better able to state and recognize their problems ear-
lier on before their parents could recognize it. The CBCL may be used as an
effective tool to screen these high risk children to aid early detection and
predict progression of the illness. This work was supported by MH064023
(Keshavan).
ID: 555210
SCHIZOTYPAL INDIVIDUALS DISPLAY DEFICITS
IN SOCIAL COGNITION
Diane C. Gooding, J. S. Peterman
Psychology, University of Wisconsin-Madison, Madison, WI, USA
Deficits in social information processing have been consistently observed in
schizophrenia patients. Social cognition is a multifaceted construct that
includes the ability to perceive others’ mental states (Theory of Mind), rec-
ognize affect, and accurately identify and interpret emotional meanings
from the environmental milieu. The extent to which these social cognition
deficits are present in individuals at risk for schizophrenia is not clear. The
purpose of the present study was to compare psychometrically-identified
individuals at heightened risk for the later development of schizophrenia
and spectrum disorders with controls in terms of their performance on
two tasks tapping social cognition. Individuals with excessively high (n =
33) and normal (n = 62) scores on the revised Social Anhedonia Scale
were administered the Reading the Mind in the Eyes Task (RMET) and
the Facial Affect and Social Cue Test (FASC). The Social Anhedonia group
showed significantly poorer performance on the RMET relative to the con-
trols, t(93) = 2.34, P < .05. The two groups did not differ in terms of the
FASC. We observed a small but significant association between the
two measures of social cognition. These findings indicate that individuals
at heightened risk for the later development of schizophrenia and schizo-
phrenia-spectrum disorders display deficits in social cognition. It is possi-
ble, however, that the deficits in social information processing are more
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circumscribed in at-risk samples. Our results will be considered in the larger
context of social cognition and social functioning deficits in the premorbid
and prodromal stages of schizophrenia.
ID: 553487
REEXAMINING THEORY OF MIND IMPAIRMENT
AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA:
A ROLE FOR ATTENTIONAL DYSFUNCTION?
Aaron Leonard Mishara, T. C. Greig, S. S. Nicholls, M. D. Bell
Psychiatry, Yale University School of Medicine, New Haven,
CT, USA
Abstract: Patients with prominent negative symptoms consistently perform
worse than other clinical groups on Theory of Mind (ToM) tasks. How-
ever, the nature of this relationship has not been closely examined. In this
study, we investigated the relationship between ToM and the Scale for the
Assessment of Negative Symptoms (SANS) components. We replicated
our findings in two independent samples and at two timepoints. Methods:
227 patients with DSM-III-R diagnosis of schizophrenia or schizoaffective
disorder in two independent samples were administered the Hinting Task
and the SANS. One sample (n = 137) was reassessed at 6 months. Pear-
son’s correlations were used to examine the relationships between the
Hinting Task and the SANS subscales and total scores. Subscale scores
that were significantly correlated with the Hinting task were entered
into a stepwise multiple regression to determine how much of the variance
they explained. Results: Results indicate a modest but significant relation-
ship between negative symptoms and the Hinting Task. Examination of
the components revealed that Attention is largely responsible. Alogia
made a minor contribution. Conclusions: ToM deficits are associated
with negative symptoms. A common mechanism may be the allocation
of attention to social events and socially relevant stimuli. Disrupted pro-
cessing at the level of implicit, ‘‘on line’’ representations may contribute to
impairments in attentional function as assessed by the SANS as well as
contributing to impaired ToM performance on the Hinting Task. The cur-
rent findings indicate that we should reexamine ToM impairment in
patients with negative symptoms and how it might be targeted in thera-
peutic interventions.
ID: 551995
TOWARD A COMPREHENSIVE MODEL OF
NEUROLOGICAL SOFT-SIGNS AND PSYCHO-
PATHOLOGY IN SCHIZOPHRENIA
Marie-Odile Krebs1,2, D. Gourion1, M. C. Bourdel1,2, I. Amado1,2,
J. O. Olie´1,2
1Lab Physiopathologie of Psychiatric Diseases, Inserm, Paris,
France; 2SHU, Hoˆpital Sainte Anne, Paris, France
The goal of this study was to explore interrelations between core dimen-
sions of schizophrenia, neurological soft-signs and age at onset, by using
structural modeling. Two hundred and thirty four patients with a DSM-IV
diagnosis of schizophrenia were included in the study. All subjects were
administered a semi-structured interview (DIGS) for diagnosis and age
at psychotic onset, the Positive and Negative Syndrome Scale (PANSS),
and neurological signs were assessed with a standardized scaleSeveral
structural equations analyses were performed. The best structural model
in terms of fit indices incorporated two latent components of the disease
and nine observed variables (TLI: 0.86; RMSEA:0.064). The first latent
component, Neurological Loading (NL), was mostly related to abnormal
motor coordination and motor integration scores (structural coefficients:
respectively .81 and .72). The second latent component, Schizophrenic Psy-
chopathology (SP), was strongly linked to the dimension of disorganisation
(.99). NL and SP were significantly inter-correlated (.49; P < .001).Age at
onset was significantly correlated to SP but not to NL. The close association
of neurological abnormalities with core schizophrenic dimensions, partic-
ularly disorganisation, suggest common physiopathological pathways.
ID: 551957
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3. 3. Drug Side Effects and Physical Illness
ANTIPSYCHOTIC STAY VS. SWITCH FOR
METABOLIC BENEFIT: PSYCHIATRIC COST
Jonathan M. Meyer,1, R. R. Henry2, D. L. Braff1
1Psychiatry, UCSD, San Diego, CA, USA; 2Medicine, UCSD and
VA San Diego, San Diego, CA, USA
Background: Switching antipsychotics is one option for patients with an-
tipsychotic-induced metabolic effects,1 yet there is concern that switching
stable patients carries a psychiatric cost, and may result in exacerbation.2
Methods: Data were analyzed from a randomized, 6-month, open-label
switch study for overweight or obese nondiabetic schizophrenia patients
taking risperidone or olanzapine. Eligible subjects were randomized to
usual care non-switch (UC) or open-label switch (S) to ziprasidone.
Arms were balanced for gender and race/ethnicity. Imaging measures
of adiposity and endocrine measures were obtained at baseline and
6 months. The primary psychiatric outcome measure was total hospital
days in each arm, while secondary analyses examined change in total
PANSS and PANSS subscale scores. Results: To date, 51 subjects
have entered the randomization phase of the study: UC n = 22; S n =
29. Mean age of randomized subjects was 47.3, 78.4% were male,
66.7% white and 9.8% Hispanic. Mean BMI was 33.4 kg/m2, 63% smoked,
and 15.7% reported a 1st-degree family history of diabetes. Baseline total
PANSS score was 64, positive subscale 18, and negative subscale 15. At
baseline there were no significant between-group differences on any de-
mographic, adiposity or laboratory variable, nor on total PANSS, posi-
tive or negative subscale symptom scores. There were no significant
differences in total hospital days between the UC arm (26 days), and
the S arm (25 days), or in proportion of subjects hospitalized: UC
(14%) vs. S (21%) (v2 = .338, P = .561). In a linear regression model
with change in total PANSS score from baseline to week 26 as the de-
pendent variable, neither treatment arm, nor baseline antipsychotic signif-
icantly predicted the outcome variable. Conclusions: Contrary to many
assumptions, in this 6-month, open-label, randomized trial, the hospital-
ization rate and total hospital days in non-switchers did not significantly
exceed that seen with careful antipsychotic switching. This inherent re-
lapse rate among stable patients with schizophrenia must be factored
into the stay vs. switch decision to change antipsychotic treatment for
possible metabolic benefit.
References
1. Meyer JM, et al. Change in metabolic syndrome parameters with anti-
psychotic treatment in the CATIE Schizophrenia Trial: prospective
data from phase 1. Schizophr Res 2008;101:273–86.
2. Essock S, et al. Effectiveness of switching antipsychotic medications.
Am J Psychiatry 2006;163:2090–5.
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REDUCED EPS RISK WITH LURASIDONE, A NOVEL
PSYCHOTROPIC AGENT UNDER DEVELOPMENT
FOR SCHIZOPHRENIA AND BIPOLAR DISORDER
Hiroyuki Nishikawa1, T. Ishibashi1, K. Tokuda1, T. Matsumoto1,
M. Ogasa2
1Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; 2Dainippon
Sumitomo Pharma America, Fort Lee, NJ, USA
Background: Lurasidone is a novel psychotropic agent with affinity for
dopamine D2 and serotonin 5-HT2A receptors. Compared with other atyp-
ical antipsychotics, lurasidone has high affinity at serotonin 5-HT7, 5-
HT1A, and noradrenaline a2c receptors; minimal affinity for a1 adrenocep-
tors, dopamine D1 and D3 receptors, serotonin 5-HT2C receptors, and a2A
adrenoceptors; and no affinity for histamine H1 and cholinergic M1 recep-
tors. The goal of the current series of studies was to evaluate the EPS-pro-
ducing potential of lurasidone compared to other antipsychotics in
standard animal models. Methods: The EPS potential of lurasidone
was evaluated in animal models. The mouse pole-test was used to measure
bradykinesia-inducing activity. The rat and mouse catalepsy was measured
by duration of immobility induced by lurasidone in a catalepsy apparatus.
The rat paw test was used to measure forepaw retraction time. Results: As
summarized in Table 1, below, lurasidone was much weaker than other
antipsychotic drugs in inducing catalepsy in both rats and mice. In the
mouse pole test, lurasidone was also far weaker than other antipsychotics
in inducing bradykinesia, and failed to cause a significant motor impair-
ment (delay in turning and pole-descending behaviors) even at 1000 mg/kg
(Table 1). Finally, in the rat paw test, even high doses of lurasidone did not
increase the forepaw retraction time. In contrast, other antipsychotic
drugs were associated with increased retraction times even at relatively
low doses (Table 1). Conclusion: The results of these pre-clinical studies
suggest that lurasidone has a low potential for causing clinically significant
EPS.
Table1. Comparative ED50 (mg/kg) for induction of extrapyramidal side
effects across 4 animal models
Drug
Rat
Catalepsy
Mouse
Catalepsy
Mouse Pole
Test
Bradykinesia
Rat Paw
Test
Lurasidone >1000 >1000 >1000 >1000
Risperidone 20 0.85 3 30
Olanzapine 28 >10 10 30
Sertindole >300 >30 10 >1000
Quetiapine NT >300 NT NT
Ziprasidone 97 63 30 100
Clozapine >300 >30 >30 300
Haloperidol 12 2.0 1 1
Chlorpromazine 25 7.3 10 30
Thioridazine 890 42 30 >1000
ID: 550540
PREDICTORS OF CARDIOVASCULAR MORTALITY
IN HOSPITALIZED PATIENTS WITH SEVERE
MENTAL ILLNESS
Kimberly R. Warren1, F. Liu1, R. P. McMahon1,
H. J. Wehring1, R. C. Love2, K. M. Mackowick1, J. C. Shim3,
D. L. Kelly1
1Maryland Psychiatric Research Center, University of Maryland
School of Medicine, Catonsville, MD, USA; 2Department of
Pharmacy Practice and Science, University of Maryland School of
Pharmacy, Baltimore, MD, USA; 3Paik Hospital, Inje University,
Gimhae, South Korea
People with mental illness have an increased risk of comorbid medical
conditions (Sokal, et al., 2004) and premature death (Harris and Barra-
clough, 1998). Cardiovascular (CV) disease is the second leading cause of
death in patients with schizophrenia (Osbey et al., 2000). The present
study investigated predictors of CV mortality in hospitalized people
with severe mental illness: psychosis (predominantly schizophrenia
(SZ)), bipolar disorder (BD), or other mental illness (predominantly
depression and anxiety disorders ([OTH]). Clinical chart data was
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abstracted and available on 1828 patients (nSZ = 1443, nBD = 165, nOTH =
220) from inpatient State psychiatric hospitals between 1994 and 2000 in
order to assess risk factors for cardiovascular (CV) mortality. Deaths were
identified from the Social Security Death Index and death records were
collected for all decedents. Males (n = 1065) and females (n = 762) between
the ages of 35–65 were included. Groups were similar in age, smoking
status, and sex, however, the SZ group had more non-whites (41%)
than BD (29%) or OTH (22%). There were 60 (nmale = 30, nfemale =
30) deaths in this sample. A Cox proportional hazards model, including
age>55, race (white vs. non-white), sex, smoking status, and diagnosis,
was used for multivariate survival analysis. Increased CV mortality
was associated with age>55 (hazard ratio (HR) = 4.1, v2 = 15.76,
P < 0.001), white race (HR = 2.4, v2 = 4.07, P < 0.05), and smoking
(HR = 2.0, v2 = 3.63, P = .057). Compared with patients with SZ, increase
in CV mortality was not significant in patients with bipolar disorder
(HR = 1.7, v2 = 0.71, P = .399), and was marginally elevated in the
OTH group (HR = 2.7 v2 = 3.30, P = .069). Sex was not significantly
associated with CV mortality, P = .25. These findings are consistent
with numerous studies that suggest that older age and smoking are
risk factors for heart disease (Hennekens, 2007). Previous studies have
also indicated greater CV mortality risks for patients with anxiety and
depressive disorders than patients with schizophrenia (Harris and
Barraclough, 1998). Racial differences in CV mortality in patients with
severe mental illness require further investigation. This project was funded
by the National Institutes of Mental Health (NIMH R03 MH069871-01;
Kelly, PI) and the Advanced Centers for Intervention and Services
Research (NIMH P50 MH40279; Carpenter, PI).
ID: 550530
THE RELATIONSHIP OF BRAIN WEIGHT TO BODY
MASS INDEX (BMI) UPON AUTOPSY IN PEOPLE
WITH SEVERE MENTAL ILLNESS
Heidi Wehring 1, F. Liu1, R. P. McMahon1, D. L. Boggs1,
R. C. Love2, D. Dickinson3,4, J. C. Shim5, D. Fowler6, D. L. Kelly1
1Maryland Psychiatric Research Center, University of Maryland
School of Medicine, Baltimore, MD, USA; 2Pharmacy Practice and
Science, University of Maryland School of Pharmacy, Baltimore,
MD, USA; 3University of Maryland School of Medicine, Baltimore,
MD, USA; 4Research Core, VISN 5 Mental Illness Research,
Education, and Clinical Center, Baltimore, MD, USA; 5Paik
Hospital, Inje University, Gimhae, South Korea; 6Office of the Chief
Medical Examiner (OCME), Baltimore, MD, USA
Weight gain and other metabolic adverse effects of antipsychotic medica-
tions have been of concern in maintaining the physical health of patients
with schizophrenia. However, the potential effects of possible brain
changes during weight gain have received less attention. In the non-
schizophrenia population, it has been observed that an association exists
between high body mass index (BMI) and reduced gray matter, and BMI
has also been found to be inversely related to brain volume measured by
MRI. This association has not been reported thus far in patients with
schizophrenia. Also, people with first episode schizophrenia have been
shown to undergo changes in gray matter and ventricular volume over
time and some evidence suggests that brain volume changes may occur
with some antipsychotic medications. This study examined the relationship
between BMI and brain weight upon autopsy in 60 patients with severe
mental illness treated with antipsychotics. The population was 67% Cau-
casian, 70% male, with a mean age of 38.2 6 9.6 years. The mean BMI and
brain weights were 29.64 6 8.71 kg/m2 and 1322.58 6 162.23 gm, respec-
tively. Mean brain weight was significantly higher in men as compared to
women, despite no gender differences in BMI (Kruskal-Wallis test,
v2=12.28, df = 1, P = .0005). No racial differences were evident. Normal
weight subjects (BMI = 18.5–24.9 kg/m2; n = 19) had a significantly greater
mean brain weight (1357.4 6 141.7 gm) as compared to those who were
considered obese (BMI  30 kg/m2) (1299.0 6 194.0 gm; n = 29)
(Kruskal-Wallis test, v2 = 33.8, df = 1, P< .0001). Further characterization
found that in those with morbid obesity (Obesity class III BMI 40 kg/m2;
n = 5), the mean brain weight was the smallest among all obese categories
(1186.0 6 286.2 gm). There were no differences in brain weight by antipsy-
chotic treatment and no correlations between brain weight and body
weight were found by race, gender or drug treatment. The results of
this study suggest that further research is needed regarding the effects
of obesity on brain changes in people with severe mental illness. This pro-
ject was funded by the National Institutes of Mental Health (NIMH R03
MH069871-01; Kelly, PI) and the Advanced Centers for Intervention and
Services Research (NIMH P50 MH40279; Carpenter, PI).
ID: 550511
METHODS USED TO ASSESS ADVERSE EFFECTS IN
A SAMPLE OF REPORTS OF CLINICAL STUDIES OF
ANTIPSYCHOTIC MEDICATION
Alison Pope1, C. Adams2, C. Paton1, T. Weaver1, T. R. Barnes1
1Psychological Medicine, Imperial College London, London, United
Kingdom; 2Cochrane Schizophrenia Group, Nottingham, United
Kingdom
Evidence-based decisions regarding the selection of antipsychotics (APs)
for the long-term treatment of schizophrenia are influenced by existing
knowledge regarding the relative safety and tolerability profiles of differ-
ent agents. However, collecting information about AP safety is method-
ologically challenging because there is no single assessment approach
capable of capturing the full range of adverse effects. Different methods
for collecting information about adverse effects have been shown to result
in different prevalence figures, which may represent a source of bias in
reports of AP safety and tolerability. To identify how investigators typ-
ically collect and report information about AP safety, we surveyed eligible
journal articles. To generate a representative sample, we searched the
Cochrane Schizophrenia Group’s register. Reports on 103 eligible clinical
studies of antipsychotic drug treatment (90 of which were double-blind)
were identified. The findings revealed that published rating scales were
frequently used to evaluate drug-induced extrapyramidal symptoms
(EPS), although relatively few studies employed several measures to assess
the full range of EPS. In contrast, published scales were rarely used to
assess general treatment emergent adverse effects and a large number
of reports failed to specify how such information had been collected. De-
spite broad uniformity in the choice of measures used to evaluate EPS,
findings from different studies remain difficult to interpret due to varia-
tions in reporting. Scores derived from rating scales tended to be presented
as statistics such as mean change, which do not provide clinicians with
meaningful information about the clinical or functional impact of the
movement abnormalities observed. After EPS, weight gain was the second
most frequently reported adverse effect. Despite increasing concerns about
other metabolic risks associated with APs, relatively few studies explicitly
referred to collecting data regarding markers of the metabolic syndrome.
Only a small minority of studies reported assessing adverse effects that
may be of particular concern to patients, eg, sexual dysfunction and aver-
sive subjective experiences. These findings highlight the need for more con-
sistent approaches to collecting and reporting information about the
adverse effects of APs. Such information is vital if meaningful compari-
sons are to be made between the safety and tolerability profiles of different
APs.
ID: 550476
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GENE PROFILING REVEALS MAJOR
DIFFERENCES IN THE EFFECT OF ANTI-
PSYCHOTICS ON LIPID METABOLISM
Aouatef Bellamine1, C. Elosua1, C. Cao1, R. Baker1, A. Pikalov2,
O. Flint1
1Research and Development, Bristol-Myers Squibb, Princeton, NJ,
USA; 2Mediacl Affairs, Otsuka America Pharmaceuticals,
Rockville, MD, USA
Background: Some anti-psychotics (APs) are associated with metabolic side
effects. We investigated the effect of aripiprazole and other APs on
gene expression in human hepatoma cells (HepG2) and primary human
adipocytes. Methods: Cultured HepG2 and differentiated human adipo-
cytes were exposed to Cmax and 10-fold Cmax of aripiprazole (ARI),
olanzapine (OLZ), quetiapine (QUE), risperidone (RIS), 9-OH risperi-
done (9-OH-RIS) or ziprasidone (ZIP) for 6 or 24 hrs. Total RNA
was isolated and used to evaluate expression levels for the treated vs ve-
hicle control. GeneChip hybridization Array technology (Affymetrix) (P
 0.01) was used. Statistical comparisons were made by ANOVA with
Dunnet’s correction. Results: In adipocytes, OLZ and QUE induced
genes involved in cholesterol transport and lipid synthesis. These genes
are unchanged by other APs and down-regulated by ARI. In HepG2,
PCA analysis grouped OLZ/QUE together but only QUE treatment
resulted in the up-regulation of squalene epoxidase, an enzyme convert-
ing cholesterol to oxysterols. ARI treatment led to the down-regulation
of this gene. Furthermore, in lipid synthesis studies, QUE treatment
shifted the cholesterol band to a higher molecular weight product cor-
responding to an oxysterol. Conclusions: AP treatment of both
HepG2 and adipocytes resulted in changes in expression levels of genes
involved in lipid metabolism and cholesterol reverse transport. In addi-
tion, in HepG2 QUE led to the shunt of cholesterol pathway to oxyster-
ols, known LXR ligands. The possible activation of the transcription
factor LXR by oxysterols could be the reason for the observed gene
up-regulation, contributing potentially to an increase in plasma lipids lev-
els and cardiovascular risks.
ID: 550415
PHARMACOGENETICS OF FOLIC ACID METABO-
LISM AND METABOLIC DISTURBANCES IN
SCHIZOPHRENIA
Vicki Ellingrod1, T. Grove1, S. F. Taylor1, J. Moline3,
D. D. Miller2, T. Holman2, J. Kerr2
1University of Michigan, Ann Arbor, MI, USA; 2University of Iowa,
Iowa City, IA, USA; 3Cleveland Clinics, Cleveland, OH, USA
Purpose: To examine the relationship between the methylenetetrahydrofo-
late reductase (MTHFR) 677C/T variant and metabolic syndrome in
schizophrenia subjects receiving antipsychotics for  12 months. This var-
iant is associated with aberrant folic acid metabolism and cardiovascular
disease risk due to alterations in the Aldomet cycle associated with homo-
cysteine and folic acid metabolism. Methods: 121 subjects were recruited
from the Universities of Iowa and Michigan for this cross-sectional anal-
ysis. They were screened for the metabolic syndrome (NCEP ATP-III cri-
teria) and genotyped for MTHFR 677C/T. Additionally serum folate,
vitamin B12, leptin, and homocysteine were measured in some subjects.
Results: 49 subjects (40%) met metabolic syndrome criteria. The groups
mean age (6 s.d.) was 41.05 6 11.17 years, 78% (n = 94) were Caucasian,
61% (n = 74) were male, and 71% (n = 84) were receiving clozapine, olan-
zapine, risperidone or quetiapine. There were no differences in age, gender,
race, or antipsychotic exposure, between the genotype groups. The geno-
types were CC (53%), CT (395), TT (8%) and are in Hardy Weinberg (v2 =
0.11, P = .74) Overall, for those receiving an atypical antipsychotic (AAP)
a significant relationship was found between metabolic syndrome and the
MTHFR TT genotype (v2 = 6.81, P = .009). Specifically, subjects with this
genotype receiving an AAP had a relative risk of 2.42 (95% CI: 1.87–3.14)
for meeting metabolic syndrome criteria compared to those without this
genotype receiving AAPs. For subjects not receiving AAPs no relationship
between MTHFR genotype and metabolic syndrome was found (v2 = 0.47,
P = .49). No statistically significant relationship between MTHFR geno-
type and homocysteine was found, however subjects with the TT genotype
did have higher levels (9.6 vs 10.3, P = .7). Conclusion: Overall, these
results confirm our group’s previous data. Aberrant function in MTHFR
related to poor folic acid metabolism and hyperhomocysteinemia may be
associated with antipsychotic associated metabolic complications. How-
ever, these results should be taken cautiously due to the small sample
size included in this study. Acknowledgements: This project was sup-
ported by the NIMH (K08MH64158), the NIH-NCRR, General Clinical
Research Centers Program (M01-RR-59 and UL1RR024986), a University
of Michigan College of Pharmacy Vahlteich Award, and Washtenaw
Community Health Organization (WCHO).
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SUBJECTIVE WELL-BEING AND D2 RECEPTOR
OCCUPANCY IN PSYCHOTIC PATIENTS TREATED
WITH ANTIPSYCHOTICS: AN EXPERIENCE
SAMPLING STUDY
Johan Lataster1, J. van Os1,2, L. de Haan3, I. Myin-Germeys1,4
1Department of Psychiatry and Neuropsychology, South Limburg
Mental Health Research and Teaching Network, EURON, Maas-
tricht University Medical Center, Maastricht, Netherlands; 2Divi-
sion of Psychological Medicine, Institute of Psychiatry, London,
United Kingdom; 3Department of Psychiatry, Academic Medical
Center/de Meren, Amsterdam, Netherlands; 4School of Psycho-
logical Sciences, University of Manchester, Manchester, United
Kingdom
Background: Blockade of dopamine D2 receptors is a key element in the
therapeutic activity of antipsychotic medication, but may also reduce mo-
tivation and subjective well-being. Previous laboratory studies have related
D2 receptor occupancy to subjective well-being measured with question-
naires. The current study aims to extend these findings to a broader domain
of well-being assessed in the realm of daily life. In addition, antipsychotic
agents differ in how tightly they bind to the D2 receptor, possibly resulting
in different effects on subjective well-being. The differential effect of ‘tight’
and ‘loose’ binding drugs will be investigated. Methods: The Experience
Sampling Method (a structured diary technique) was used to assess
subjective experience in daily life in 111 patients with a diagnosis of
psychotic disorder. Patients were on current antipsychotic medication
and were divided into a loose (olanzapine; n = 41) and tight (haloperidol,-
risperidone; n = 70) binding agent user group based on the agents’ disso-
ciation constants at the D2 receptor. D2 occupancy values were estimated
using occupancy formulas extracted from previous literature. Based on the
tertiles, a three level D2 occupancy variable was defined. Results: Multilevel
analyses showed a significant interaction between binding group and D2
receptor occupancy (positive affect (PA):b = .05 (SE = .02), P < .009; neg-
ative affect (NA):b =.04(SE = .02), P< .03). For tight binding agent users,
a significant effect was found of D2 receptor binding on PA and NA (PA:
v2(2) = 6.41, P< .042; NA:v2(2) = 29.73, P< .0001). There was a decrease in
PA in the middle group and an even larger decrease in the group with the
most D2 receptor occupancy. A significant increase in NA was found in the
group with the most D2 receptor occupancy. For loose binding agent users,
no main effect of D2 occupancy on PA or NA was found. Although related
to symptom severity, effects could not be entirely explained in terms of clin-
ical symptom scores. Conclusions: These findings add ecological validity to
previous laboratory findings showing an association between D2 receptor
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occupancy and subjective well-being, particularly pertaining to the tight
binding agents. Furthermore, given that tight and loose binding agents
showed overlap in terms of overall receptor occupancy estimates, our
results suggest that the mechanism of dissociation from the D2 receptor
rather than mere occupancy levels of the drug may determine a drug’s im-
pact on subjective well-being.
ID: 550288
THE NATIONAL REGISTER OF ANTIPSYCHOTIC
MEDICATION IN PREGNANCY (NRAMP)
Heather Gilbert, N. Marston, C. Gurvich, A. de Castella,
K. McCauley, J. Kulkarni
Monash Alfred Psychiatry Research Centre, The Alfred Hospital
and School of Psychology, Psychiatry and Psychological Medicine,
Monash University, Melbourne, VIC, Australia
Current data on the use of antipsychotic medication in pregnancy is limited.
Establishment of The National Register of Antipsychotic Medication in
Pregnancy (NRAMP) will provide evidence-based clinical guidelines for
the safest use of antipsychotic medication during pregnancy and for one
year postnatally. NRAMP is an Australia-wide observational, non-
interventional study involving female participants with a history of mental
illness, who take antipsychotic medication and who become pregnant or
have had a baby in the last 12 months. Information is collected via tele-
phone or face to face interviews during the pregnancy and for the first
year postpartum and includes demographic, social, family, medical, psychi-
atric, medication and obstetric history, as well as information on general
health and wellbeing for both mother and baby. This observational study is
current and ongoing, with 66 consented participants at different stages on
the study timeline; that is, either antenatal or postnatal. This is reflected in
the results to date, with regard to consenting data, pregnancy outcomes and
maternal and neonatal complications. Preliminary interpretation of these
results will therefore be spread across various time points: the antenatal
period, post-delivery and for one year postnatally. The resultant evi-
dence-based guidelines arising from The National Register of Antipsy-
chotic Medication in Pregnancy (NRAMP) have the potential to
provide regular, contemporary updates to clinical treating teams for the
management of women in this vulnerable population group. We plan to
fill a void in mental health services where currently there is a distinct
lack of information available to treating clinicians, with regard to providing
safe and timely care of women who take antipsychotic medication and be-
come pregnant. This study is supported by AstraZeneca, Janssen-Cilag,
Mayne Pharmaceuticals and the Australian Rotary Health Research Fund.
ID: 550183
THE INCIDENCE OF OBESITY AND DIABETES IN
PATIENTS TREATED WITH CLOZAPINE
Rammohan Rao Malesu1,2, N. Limet1
1Psychiatry, Blacktown Hospital, Blacktown, Sydney, NSW,
Australia; 2Psychiatry, University of sydney, Sydney, NSW,
Australia
This is a 15 year retrospective study to determine the correlation between
Clozapine treatment and the development of diabetes and obesity . The
study cohort consisted of all 136 patients (77M;59F) registered at the Clo-
zapine outpatients clinic of the Blacktown Hospital in Sydney. All patients
were suffering from drug resistant Schizophrenia and were on Clozapine.
The data was collected from patient records, which included demographic
details, duration of Clozapine treatment, vital signs including weight, Blood
levels for Glucose, Cholesterol and Triglycerides. Patients were on Cloza-
pine treatment for between 1–15 years(mean 5.6 years) of which 24 patients
were on Clozapine for 10 years or more. As per the protocol, all patients
had routine investigations including blood levels for glucose, cholesterol
and triglycerides. Their weight was also recorded at least once a month.
Of this cohort, 10(5M:5F) had consistently elevated blood glucose levels,
34 (19M:15F) had high cholesterol and 55(39M:16F) had high triglycerides.
All the patients who had high glucose levels also had high cholesterol and
triglycerides and were overweight. These figures were compared to the prev-
alence of obesity and Type II diabetes in the general population of Austral-
ia. These figures support the fact that there is a higher incidence of obesity
and diabetes in patients treated with Clozapine even after adjusting for age
and gender.
ID: 550161
EFFECTS OF CLOZAPINE AND HALOPERIDOL ON
EXPRESSION OF DOWNSTREAM EFFECTORS OF
INSULINE SIGNALING: FOCUS ON Ped/Pea-15
Fabio Panariello1, G. Perruolo2, P. Formisano2, G. Muscettola1,
A. de Bartolomeis1
1Neuroscience, University of Neaples ‘‘Federico II’’, Neaples, Italy;
2Dipartimento di Biologia e Patologia Cellulare e Molecolare and
Istituto di Endocrinologia ed Oncologia Sperimentale del CNR,
University of Neaples ‘‘Federico II’’, Neaples, Italy
Schizophrenia is a major highly debilitating psychiatric disorder with
a prevalence of about 1% (Mueser and McGurk, 2004). Several lines of
evidence have indicated that schizophrenic patients have an higher prev-
alence of impaired glucose tolerance, insulin-resistance, and type-2 diabe-
tes mellitus than general population (Citrome et al., 2005). Clinical and
experimental evidence indicates that first and second generation antipsy-
chotic drugs may contribute to impair glucose metabolism (Haupt and
Kane 2007). In our study we have shown, by in vitro (PC12 transplantable
rat pheochromocytoma cells and L6 skeletal muscle cells) paradigm, that
both haloperidol and clozapine reduced insulin-stimulated glucose uptake
in PC12 neuronal cells and in L6 skeletal muscle cells. Pre-treatment with
clozapine, but not with haloperidol, also prevented insulin effect on insulin
receptor and IRS-1/2 tyrosine phosphorylation. Furthermore in neurons
and skeletal muscle cells, both haloperidol and clozapine led to the acti-
vation of Akt and to increased expression of the Ped/Pea-15 protein, an
Akt substrate. This is paralleled by decreased PKC-f activity and deranged
insulin-stimulated glucose uptake. Similarly increased Akt activity and
Ped/Pea-15 levels, as well as reduced PKC-1 activity, were detected in cau-
date-putamen and in skeletal muscle of mice (3-months-old male C57/BL/
KsJ mice) treated with either haloperidol or clozapine. Our data suggest
that first and second generation antipsychotics may contribute to the im-
pairment of glucose metabolism by reducing insulin-mediated glucose up-
take in insulin-targeted tissues. The molecular mechanism implicated in
this effect involves intracellular effectors of the insulin signaling cascade.
For instance, the increase of phosphorilated Akt enhances Ped/Pea-15 lev-
els by increasing its phosphorylation on Ser-116; as a consequence, Ped/
Pea-15 inhibits the activation of atypical PKC-f and prevents insulin-
stimulated glucose uptake.
References
1. Citrome L, Blonde L, Damatarca C. Metabolic issues in patients with
severe mental illness. South Med J. 2005;98(7):714–20.
2. Haupt DW, Kane JM. Metabolic risks and effects of atypical antipsy-
chotic treatment. J Clin Psychiatry. 2007;68(10):e24.
3. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;19:363(9426):
2063–2072.
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PHARMACOGENETICS OF THE METABOLIC
CONSEQUENCES OF ANTIPSYCHOTIC
TREATMENT - PREDICTION AND MECHANISM
Gavin P. Reynolds
Department of Psychiatry, Queen’s University Belfast, Belfast,
United Kingdom
There are substantial differences between individuals in the effects of an-
tipsychotic drugs. This is particularly true in the weight gain apparent fol-
lowing treatment with many of the second generation, as well as some of the
first generation, antipsychotics; equivalent treatment regimes can cause
profound fat deposition in some patients but minimal effects in others.
Such weight gain can lead to further morbidity as indicated by the devel-
opment of metabolic syndrome, identifying a set of risk factors for cardio-
vascular disease and diabetes. The pharmacology of antipsychotic-induced
weight gain is not fully defined, but antagonist action at 5-HT2C receptors,
as well as at histamine H1 and some other receptors, is strongly implicated.
The underlying mechanisms too are unclear but may involve hypothalamic
receptor antagonism interfering with the signalling of circulating hormones
such as leptin. These receptors and hormonal hypotheses provide good can-
didate genes for pharmacogenetic study of antipsychotic drug-induced
weight gain. In two pharmacogenetic studies of antipsychotic-induced
weight gain in initially drug-naive patients, we demonstrated a strong as-
sociation with weight gain of a promoter region polymorphism of the 5-
HT2C receptor, which we have also shown to influence gene expression
in neuronal cells in culture. The leptin gene also shows a functional pro-
moter polymorphism and this too is associated with antipsychotic-induced
weight gain, particularly in the longer term. Findings in a population of
chronically-treated patients with schizophrenia have revealed interacting
effects of the two polymorphisms on measures of obesity, and particularly
association of the leptin gene polymorphism with the incidence of metabolic
syndrome. This supports the interpretation that the leptin polymorphism
may have longer-term effects on these metabolic consequences of antipsy-
chotic treatment. Interestingly, not only the leptin polymorphism but also
that of the 5-HT2C receptor gene was associated with blood leptin concen-
trations prior to treatment. These findings point towards underlying mech-
anisms, as well as indicating the potential for genetic testing for the
propensity to develop weight gain and its severe metabolic consequences.
ID: 549828
COMPARISON OF LEPTIN LEVELS AND OBESITY
BETWEEN DRUG-NAI¨VE FIRST-EPISODE
SCHIZOPHRENIA PATIENTS AND CHRONICALLY
MEDICATED PATIENTS
Peter F. Buckley1, S. P. Mahadik1,2, M. M. Khan1,
D. R. Evans1,2
1Department of Psychiatry, Medical College of Georgia, Augusta,
GA, USA; 2Mental Health Section, Charlie Norwood VA Medical
Center, Augusta, GA, USA
Weight gain and metabolic disturbances now predominate the psychophar-
macology of schizophrenia. In this study, plasma levels of leptin were eval-
uated in relation to weight and psychopathology measures in never-
medicated first episode of psychosis patients (FEP; N = 23), patients
with chronic schizophrenia who were receiving clozapine, (N = 21), and nor-
mal subjects (N = 11). Patients were clinically assessed using the PANSS and
BPRS. Plasma leptin levels were determined by commercially available En-
zyme Linked ImmunoSorbent (ELISA) kits. Plasma leptin levels were not
significantly different between never-medicated FEP and matched normal
controls. However leptin levels were significantly higher in patients treated
with clozapine than in either control subjects or FEP patients (P = .065 and
.016, respectively). While not surprisingly, clozapine-treated patients had
significantly higher BMI than FEP patients or controls (29.86 6 3.6 vs
25.1 6 2.61 and 23.2 6 2.14, respectively), higher leptin levels in these
chronic schizophrenia patients did not correlate with higher BMI but
did correlate with psychopathology measures. In some contrast, leptin lev-
els in FEP patients were inversely related to psychopathology measures.
Consistent with the emergent literature, leptin levels may be a useful mea-
sure for examining energy metabolism and relationships to antipsychotic-
induced weight and metabolic disturbances in schizophrenia.
ID: 549709
PROLACTIN LEVELS AND SEXUAL SIDE EFFECTS
IN SCHIZOPHRENIA PATIENTS DURING
ANTIPSYCHOTIC TREATMENT
Falko Biedermann, M. Rettenbacher, A. Hofer, C. Ebenbichler,
S. Baumgartner, M. Edlinger, M. Hummer, G. Kemmler,
W. W. Fleischhacker
Biological Psychiatry of Innsbruck, Medical University of
Innsbruck, INNSBRUCK, Austria
Introduction: Sexual dysfunction occurs frequently in schizophrenia
patients treated with antipsychotic drugs. Prolactin levels can be elevated
under antipsychotic treatment and have been suggested to impair sexual
functioning through an action on the hypothalamic-pituitary-gonadal
axis altering sex hormone release. As there is limited evidence about the
association between prolactin levels and sexual dysfunction in schizophre-
nia patients receiving antipsychotic treatment we have prospectively inves-
tigated patients during treatment with second generation antipsychotics.
Methods: Thirty-nine schizophrenia patients (diagnosed according to
ICD 10) treated with amisulpride, clozapine, quetiapine, olazapine, risper-
idone or ziprasidone were included in a 4 week study. To quantify antipsy-
chotic side effects we used the Udyalg for Klinske Undersogelser (UKU)
Side Effect Scale. Prolactin levels were determined weekly. Results: Prolac-
tin levels in males rose significantly while no significant changes in prolactin
levels were observed in female patients from baseline to week 4. Men reported
diminished sexual desire most frequently followed by orgastic dysfunction
and ejaculatory dysfunction. Women most often complained about dimin-
ished sexual desire, amenorrhea or orgastic dysfunction. The incidence of
sexual adverse events did not change significantly from baseline to week
4. At baseline a significant association was found between diminished sexual
desire and prolactin levels in men. At week 4 orgastic dysfunction and higher
prolactin levels showed a correlation in male and female patients. In addition
a relationship between changes of prolactin concentration and diminished
sexual desire was detected in female patients. Conclusion: Further studies,
including more Patients, which need to be studied over a larger observation
period, will be necessary to shed more light on sexual functioning in schizo-
phrenia patients and to differentiate between antipsychotics, which was not
the aim of this study.
ID: 549658
PROSPECTIVE LONG-TERM EVALUATION OF
SERUM CREATINE KINASE LEVELS AND
NEUROMUSCULAR DYSFUNCTION IN
SCHIZOPHRENIA PATIENTS: NEW RESULTS OF
FOLLOW-UP STUDY
Ilya Reznik1, L. Volchek2, M. Reznik3, H. Y. Meltzer4,
A. Weizman1
1Laboratory of Biological Psychiatry, Felsenstein Medical Research
Center, Bat-Yam, Israel; 2Neurology Department, Barzilay Medical
Center, affiliated to Ben Gurion University, Ashkelon, Israel;
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Gurion University, Ashkelon, Israel; 4Division of Psychopharma-
cology, Vanderbilt University Medical Center, Nashville, TN, USA
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Background: There are multiple causes of hyper-CKemia (HCK)—the el-
evation of serum creatine kinase (SCK) activity above upper limits. These
increases may be related to underlying trait-like biological abnormalities in
psychosis, phasic episodes related biological abnormalities, or the effect of
drug treatment. Previously we found, that among HCKemic patients, the
majority was treated with atypical antipsychotic drug (AAPD) and some
of them had neuromuscular complaints. The purposes of this study were to
follow-up prospectively and to estimate the incidence and severity of prob-
able neuromuscular dysfunction in HCKemic schizophrenia and schizoaf-
fective patients. Methods: For this study, we selected 39 HCK-emic
patients suffering from schizophrenia or schizoaffective disorder. Eleven
patients, treated either with clozapine, olanzapine or perphenazine had
persistent/recurrent hyper-CKemia (PHCK). 25 patients had occasional
HCKemia (OHCK). Blood samples for CK determinations were collected
up to three years of follow-up. Each year, all patients were assessed neu-
rologically for possible muscular and peripheral nervous systems involve-
ment. Results: During the study, SCK activity in PHCK patients was
found to be persistently elevated: 400 6 200 (mean 6 SD) in range
250–950 IU/L. Five of these patients had complaints of muscular weak-
ness, early fatigue on exercise, some muscular pains and cramps. In two of
them clinical assessment revealed mild general muscular weakness, espe-
cially in the proximal parts of the limbs. This pattern was diagnosed as
probable mild myopathy. In majority of OHCK patients SCK activity
was reduced to the normal levels range. Some patients remained with oc-
casional HCK without any kind of neuromuscular pathology. Conclu-
sions: The results of this first long-term large-scale prospective
comparative study indicate that among HCK-emic schizophrenia and
schizoaffective patients, only PHCK pattern may consider to be a bio-
chemical marker of the neuromuscular dysfunction. Meanwhile, OHCK
is likely to be a benign phenomenon, has no clinical manifestations,
and does not need to be followed-up routinely. Further investigation of
neuromuscular dysfunction, its mechanisms, pathophysiological signifi-
cance and possible pharmacogenetics associations in schizophrenia
patients is certainly indicated. The relationship of HCK to mutations
in neuregulin, dysbindin or reelin—the genes related both to schizophrenia
and to muscle, is also of interest.
ID: 549626
CHANGES IN BODY MASS INDEX (BMI) DURING
TREATMENT WITH OLANZAPINE VERSUS
AMISULPRIDE: A PROSPECTIVE STUDY
Christian Georg Widschwendter, A. Hofer, S. Baumgartner,
M. Edlinger, M. A. Rettenbacher, W. W. Fleischhacker
Biological Psychiatry, Medical University Innsbruck, Innsbruck,
Austria
Adiposity (body mass index [BMI]  30), hyperlipidemia, hypertension
and increased blood glucose levels, which define the metabolic syndrome,
are common side effects of atypical antipsychotic treatment. The aim of
this prospective study was to examine changes in BMI during treatment
with olanzapine versus amisulpride over a twelve-week period (day 0,
week 4, week 8, week 12). 46 patients with schizophrenia (ICD-10) were
included into the study (olanzapine: n = 25, amisulpride: n = 21), 32 patients
(olanzapine: n = 14, amisulpride: n = 18) completed the trial. BMI increased
by 1.81 6 1.0 in the olanzapine group (baseline-BMI = 23.7 6 4.8), whereas
BMI decreased by 0.21 6 1.6 in the amisulpride group (baseline-BMI =
28.5 6 8.0). Analysis of covariance (adjustment for baseline differences)
showed a significant difference (P = .01) in BMI change to the disadvan-
tage of Olanzapine. These results support differences in metabolic
side effects of olanzapine and amisulpride and further emphasize the
need for a risk-benefit analysis regarding the choice of antipsychotics in
schizophrenia.
ID: 549363
RELATIONSHIP BETWEEN THE ADIPONECTIN
(APM1) 276G/T VARIANT AND METABOLIC
DISTURBANCES IN A SCHIZOPHRENIA
POPULATION RECEIVING ANTIPSYCHOTICS
Vicki Ellingrod1, M. Meden1, T. B. Grove1, S. F. Taylor1,
J. Moline3, D. D. Miller2, T. L. Holman2, J. Kerr2
1University of Michigan, Ann Arbor, MI, USA; 2University of Iowa,
Iowa City, IA, USA; 3Cleveland Clinics, Cleveland, OH, USA
Purpose: To explore the relationship between the adiponectin (APM1)
276G>T (rs1501299) variant and metabolic abnormalities in schizophrenia
subjects receiving antipsychotics. Methods: Subjects with schizophrenia, re-
ceiving antipsychotic treatment for 12 months were screened for the met-
abolic syndrome (NCEP ATP-III criteria), including blood pressure, height,
weight, and fasting laboratory measures (cholesterol panel, glucose, insulin,
hemoglobin A1C), and a DNA sample. From these measures, body mass
index (BMI) and a Homeostasis Model Assessment Insulin Resistance
(HOMA-IR) value was calculated. Results: A total of 110 schizophrenia
spectrum disorder subjects were recruited. The sample contained 68 men
(62%), with a mean age of 416 11.17 years, and 40% meeting metabolic syn-
drome criteria. Eight-one percent of subjects were Caucasian and 75% were
receiving olanzapine, clozapine, risperidone or quetiapine at the time of eval-
uation. Eight subjects with a known diabetes diagnosis were excluded from
the analysis. The T allele was present in 51% of subjects and 49% had the GG
genotype, which was in Hardy Weinberg (v2 = 0.68, P = .41). There were no
differences in demographic or laboratory values between genotype groups
and no relationship between APM1 and a metabolic syndrome diagnosis
(v2 = 1.086, P = .29). However, subjects with a T allele had lower BMIs com-
pared to the GG genotype group (P= .007). Overall, a significant interaction
between the APM1276 G>T genotypeandBMI was found, where thosewith
the T allele had higher levels of insulin resistance (HOMA-IR) at similar
BMIs compared to the GG genotype group (F = 9.94, df = 3,104, P <
.0001). After controlling for BMI differences, this interaction remained sig-
nificant (P= .0035).Conclusions: Schizophrenia subjectsare at increasedrisk
for type II diabetes and insulin resistance. New data suggests APM1
variation may play a role. We found the APM1 276T allele may increase in-
sulin resistance risk at similar BMIs compared to the GG genotype. These
results should be interpreted cautiously due to the small sample size, lack of
adiponectin levels, and the need for replication. Acknowledgements: Project
support obtained from the NIMH (K08 MH64158), the National Center for
Research Resources,General Clinical ResearchCentersProgram (M01-RR-
59 and UL1RR024986), a University of Michigan College of Pharmacy
Vahlteich Award, and Washtenaw Community Health Organization
(WCHO).
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PATIENTS WITH SCHIZOPHRENIA: THE
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Psychiatrie und Psychotherapie—Gerontopsychiatrie, Vivantes
Klinikum Hellersdorf, Berlin, Germany; 5Queen Alexandra
Hospital, Portsmouth Hospitals NHS Trust, Hants, United
Kingdom
International Congress on Schizophrenia Research
3. 3. Drug Side Effects and Physical Illness 31
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
A large, observational, multinational cross-sectional pharmacoepidemio-
logical study was initiated in 2006 in order to determine the prevalence
of diabetes and other metabolic disorders in patients with schizophrenia
receiving atypical antipsychotic drugs in Europe. Secondary objectives in-
cluded identification of risk factors for metabolic disorders. The study in-
cluded adult outpatients with schizophrenia (DSM IV TR) treated for at
least 3 months by an antipsychotic drug. In each country, patients treated
with classical or atypical antipsychotic drugs were recruited into two par-
allel strata (ratio of 1:3). The study consisted of a single visit at which a fast-
ing blood sample was taken and height, weight, waist and hip circumference
and blood pressure measured. Information was collected on socio-demo-
graphic variables, lifestyle, comorbidities and co-medications, metabolic
and cardiovascular risk factors, psychiatric history and antipsychotic
drug history. Biochemical parameters assessed included glucose, insulin,
HbA1c, triglycerides, total cholesterol, HDL cholesterol and apolipopro-
tein B. 2463 patients were included in 12 countries (Bulgaria, Czech Repub-
lic, Estonia, Germany, Greece, Italy, Latvia, Lithuania, Romania, Russian
Federation, Slovenia and Turkey). Median age of included patients was
41.0 years and 54.6% were male. Medical history revealed that 10.9% of
patients were treated for arterial hypertension, 7.1% of patients for a lipid
disorder, 0.3% for type I diabetes and 3.5% for type II diabetes. In addition,
26% of untreated patients presented biochemical evidence of dysglycemia,
67.7% of dyslipidemia and 38% had hypertension. A metabolic syndrome
was identified in 34% of the patients. No overall difference was observed in
the proportion of patients with glycemic and lipid disorders between the
two strata of antipsychotic treatment (classical or atypical). Mean weight
and weight gain, abdominal obesity and the proportion of patients with
BMI  25 kg/m2 were slightly higher in the atypical stratum compared
to the classical stratum. Hypertension was more frequent in the classical
stratum (47.3%) than in the atypical stratum (42.2%). The results observed
in this large epidemiological study emphasize the need for careful follow-up
of patients with schizophrenia treated with antipsychotic drugs to detect
metabolic disorders. The rate of patients with glycemic or lipid disorders
was very high and as such largely underdiagnosed. Funding: Sanofi-Aventis.
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BONE MINERAL DENSITY AND OSTEOPOROSIS
RISK IN OLDER PATIENTS WITH SCHIZOPHRENIA
Joo-Cheol Shim1, D. Jung2, S. Jung3, T. Min4, M. Oh1, B. Kong1,
D. L. Kelly5
1Psychiatry, Inje University, Busan, South Korea; 2Psychiatry,
Dongseo Hospital, Masan, South Korea; 3Psychiatry, Dongrae
Hospital, Busan, South Korea; 4Psychiatry, Saemyung Hospital,
Busan, South Korea; 5Psychiatry, Maryland Psychiatric Research
Center, Baltimore, MD, USA
Osteoporosis is a significant public health concern because of its morbidity
and mortality associated with fractures and its associated health care costs.
Patients with schizophrenia are at higher risk for developing osteoporosis as
compared to the general population. Aging and gender are risk factors for
developing bone loss. In our previous study, middle aged women had a sig-
nificantly greater rate of bone loss compared to men of similar ages (85.7 %
vs 50%; P< .05). In this study, we evaluated the prevalence of bone density
and gender differences in older patients (> 50 years) with a DSM-IV diag-
nosis of schizophrenia. Patients with nutritional impairments or a medical
disorder known to be risk factor for osteoporosis were excluded. Bone den-
sitometry testing was performed by dual energy x-ray absorptiometry
(DEXA) (GE Lunar 4500 scanner), in the lumbar spine (L1-L4) and in
the femoral neck, trochanter, and intertrochanteric regions of the proximal
right femur. WHO definitions were used for osteoporosis and osteopenia.
The mean age in this study (N = 312 patients (184 men, 130 women) was
56.7 6 8.1 years; duration of illness, 142.6 6 79.2 months; and chlorprom-
azine equivalent dose of antipsychotics, 589 6 518mg/day (no gender differ-
ences). Cigarette smoking was significantly higher in men compared with
women (66.9% vs, 11.3%; P< .001). The lifetime prevalence of fracture was
not significantly different in men and women (24.7% vs. 21.1%). Prevalence
of bone loss was 75.2% in men and 79.9% in women. The prevalence of
osteoporosis was significantly different between men and women patients
(P < .010); osteoporosis was higher in women as compared to men (39.5%
vs 27.2%), while the prevalence of osteopenia was higher in men (52.7% vs.
35.7%). Women had significantly lower bone density volumes in L1-L4,
neck and the trochanter region of the femur compared to men (P <
.001). T-scores, however, only in the trochanter region of the femur,
were significantly lower in women than men (P = .035). Smokers showed
significantly lower absolute bone density (0.72 6 1.22 vs. 0.78 6 0.15, P <
.0003) and t-scores (0.42 6 1.22 vs. 0.04 6 1.32, P < .003) than non-
smokers. In conclusion, bone density loss in women with schizophrenia
was more severe as compared to men, however, the prevalence of bone den-
sity loss and lifetime fractures in older men was also high, thus careful at-
tention is needed to monitor men as well as women with schizophrenia.
ID: 549015
PRELIMINARY RESULTS OF THE MEAC STUDY:
METABOLIC EFFECTS OF ANTIPSYCHOTICS IN
CHILDREN
Ginger Nicol, D. Haupt, K. Flavin, J. Schweiger, M. Hessler,
E. Hessler, M. Yingling, J. W. Newcomer
Psychiatry, Washington University School of Medicine, St. Louis,
MO, USA
The purpose of the ongoing Metabolic Effects of Antipsychotics in Chil-
dren study (MEAC) is to quantify changes in markers of adiposity and
insulin sensitivity associated with antipsychotic treatment. Antipsy-
chotic-naı¨ve children ages 7–18 with clinically significant aggression
and/or irritability (a score of > 18 on the Aberrant Behavior Checklist
(ABC) irritability subscale) who are already planning to start antipsychotic
treatment for one or more DSM-IV psychiatric disorder(s) are randomized
to 12 weeks of treatment with risperidone, olanzapine or aripiprazole fol-
lowing baseline evaluations of adiposity, insulin sensitivity and metabolic
indices. Dual energy x-ray absorptiometry (DEXA), abdominal magnetic
resonance imaging, modified frequently-sampled oral glucose tolerance
tests (mOGTT), and stable isotopomer tracer methodology during hyper-
insulinemic-euglycemic clamp conditions, as well as fasting labs and an-
thropomorphic measures, are used to assess baseline and treatment-
emergent changes in adiposity and insulin sensitivity, as well as secondary
measures, over the 12 weeks of treatment. Preliminary analyses, pooling
treatment groups into an overall study sample, indicate that 12 weeks
of initial antipsychotic treatment is associated with a statistically signifi-
cant increase in adiposity as measured by DEXA percent body fat, with
a mean increase of 2.91% 6 3.53 (mean 6 SD) corresponding to
a mean DEXA total fat increase of 2.85 kg (69.35). The primary measure
of insulin sensitivity, derived from hyperinsulinemic-euglycemic clamps,
indicated a statistically significant pooled-groups decrease in whole
body insulin sensitivity. Preliminary results also indicate that BMI percen-
tile and fasting triglyceride undergo changes similar to the patterns ob-
served in the primary measures of adiposity and insulin sensitivity.
Finally, treatment produced marked improvement in the ABC irritabil-
ity/aggression score. These preliminary results demonstrate important
effects of antipsychotic treatment on adiposity and measures of insulin sen-
sitivity within the first 12 weeks of treatment, relevant to long-term car-
diometabolic risk prediction. Clinically available surrogates for
adiposity and insulin sensitivity, BMI percentile and fasting plasma triglyc-
eride, respectively, also indicate a similar pattern of change during treat-
ment. Importantly, all three treatments produce clinically and statistically
significant improvement in mood and behavior.
ID: 548877
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ANTIPSYCHOTIC POLYPHARMACY AND RISK OF
DEATH FROM NATURAL CAUSES IN PATIENTS
WITH SCHIZOPHRENIA
Lone Baandrup1, C. Gasse2, V. D. Jensen4, B. Glenthøj1,
M. Nordentoft3, H. Lublin1, A. Fink-Jensen5, A. Lindhardt5,
P. B. Mortensen2
1Center for Neuropsychiatric Schizophrenia Research, Psychiatric
Center Glostrup, Copenhagen University Hospital, Glostrup,
Denmark; 2National Center for Register-based Research, University
of Aarhus, Aarhus, Denmark; 3Psychiatric Center Bispebjerg,
Copenhagen University Hospital, Copenhagen N, Denmark; 4The
Danish Medicines Agency, Copenhagen S, Denmark; 5Psychiatric
Center Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark
Concomitant prescription of more than one antipsychotic agent (antipsy-
chotic polypharmacy) in the treatment of schizophrenia is prevalent al-
though monotherapy is generally recommended. Mortality from natural
causes is markedly increased in schizophrenia and the role of polypharmacy
in this remains controversial. The objective of this study was to investigate if
antipsychotic polypharmacy is associated with the excess mortality from
natural causes among patients with schizophrenia. The study was designed
as a population-based nested case-control study using Danish central regis-
ters. From the study population of 27633 patients with schizophrenia or
other mainly non-affective psychoses, aged 18–53 years, we identified
193 cases who died of natural causes within a 2-year period, and 1937
age- and sex-matched controls. Current drug use was defined as at least
one prescription filled within 90 days before the date of death or the index
date. The data were analysed by conditional logistic regression. The risk of
natural death did not increase substantially with the number of concur-
rently used antipsychotic agents compared with antipsychotic monother-
apy (no antipsychotics: adjusted odds ratio 1.48 [95% confidence
interval 0.89–2.46]; two antipsychotics: 0.91 [0.61–1.36]; three or more anti-
psychotics: 1.16 [0.68–2.00]). Current use of benzodiazepine derivatives
with long elimination half-lives (more than 24 hours) was associated
with increased risk of natural death in patients with schizophrenia treated
with antipsychotics (1.78 [1.25–2.52]). We conclude that antipsychotic pol-
ypharmacy was not associated with substantially increased risk of natural
death. However, benzodiazepines, particularly those with long elimination
half-lives, should be cautiously prescribed in combination with antipsy-
chotics. The authors were supported by the National Board of Health in
Denmark, the Wørzner Foundation, and an unrestricted grant from H.
Lundbeck, Denmark.
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PREDICTORS OF CARDIOVASCULAR MORTALITY
IN HOSPITALIZED PATIENTS WITH SEVERE
MENTAL ILLNESS
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1Maryland Psychiatric Research Center, University of Maryland
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People with mental illness have an increased risk of comorbid medical con-
ditions (Sokal, et al., 2004) and premature death (Harris and Barraclough,
1998). Cardiovascular (CV) disease is the second leading cause of death in
patients with schizophrenia (Osbey et al., 2000). The present study inves-
tigated predictors of CV mortality in hospitalized people with severe mental
illness: psychosis (predominantly schizophrenia (SZ)), bipolar disorder
(BD), or other mental illness (predominantly depression and anxiety disor-
ders (OTH)). Clinical chart data was abstracted and available on 1828
patients (nSZ=1443, nBD=165, nOTH=220) from inpatient State psychiatric
hospitals between 1994 and 2000 in order to assess risk factors for cardio-
vascular (CV) mortality. Deaths were identified from the Social Security
Death Index and death records were collected for all decedents. Males
(n = 1065) and females (n = 762) between the ages of 35–65 were included.
Groups were similar in age, smoking status, and sex, however, the SZ group
had more non-whites (41%) than BD (29%) or OTH (22%). There were 60
(nmale = 30, nfemale = 30) deaths in this sample. A Cox proportional hazards
model, including age>55, race (white vs. non-white), sex, smoking status,
and diagnosis, was used for multivariate survival analysis. Increased CV
mortality was associated with age>55 (hazard ratio (HR) = 4.1, v2 =
15.76, P < 0.001), white race (HR = 2.4, v2 = 4.07, P < 0.05), and smoking
(HR = 2.0, v2 = 3.63, P = .057). Compared with patients with SZ, increase in
CV mortality was not significant in patients with bipolar disorder (HR =
1.7, v2 = 0.71, P = .399), and was marginally elevated in the OTH group
(HR = 2.7 v2=3.30, P = .069). Sex was not significantly associated with
CV mortality, P = .25. These findings are consistent with numerous studies
that suggest that older age and smoking are risk factors for heart disease
(Hennekens, 2007). Previous studies have also indicated greater CV mor-
tality risks for patients with anxiety and depressive disorders than patients
with schizophrenia (Harris and Barraclough, 1998). Racial differences in
CV mortality in patients with severe mental illness require further investi-
gation. Funded by the National Institutes of Mental Health (NIMH R03
MH069871-01; Kelly, PI) and the Advanced Centers for Intervention and
Services Research (NIMH P50 MH40279; Carpenter, PI).
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QUANTIFYING ANTIPSYCHOTIC-INDUCED EPS
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Ongoing monitoring of antipsychotic-induced extrapyramidal side effects
(EPS) is important to maximize treatment outcome and improve medication
compliance. Conventional clinical assessments of EPS appear insensitive to
differences across various atypical antipsychotics and examiner bias can re-
duce their reliability. Instrumental methods emerged as a remedy to these
problems, however, these systems have had limited clinical utility because
of their complexity and cost. We developed a novel method based on quan-
tifying handwriting movements that overcomes previous limitations of com-
plexity and cost. In our study we test the hypothesis that handwriting
movement abnormalities are associated with severity of EPS but are inde-
pendent of age, severity of psychosis, depression, or other factors that
can bias the clinical assessment of EPS. We also tested whether handwriting
movements differed across four commonly used atypical antipsychotics.
Handwriting movements from 87 psychosis patients and 45 healthy compar-
ison subjects were quantified during a loop-drawing task. Participants were
instructed to draw continuous loops 2 cm high from left to right across a dig-
itizing tablet. Samples were recorded and analyzed using commercial soft-
ware. Kinematic variables included vertical loop size and peak velocity,
relative time to peak velocity, and pen contact duration per stroke
for both primary and secondary submovements. Patients with clinically
determined EPS exhibited smaller vertical heights (P< .001), lower peak ve-
locities (P< .05), longer times to peak velocity (P< .05), and increased du-
ration of pen contact (P< .05) compared to patients without EPS. Patients
treated with aripiprazole or risperidone exhibited significantly more im-
paired handwriting movements than patients treated with quetiapine or
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olanzapine, especially for peak velocity (P < .01), whereas, clinical EPS
assessments were insensitive to these medication differences. Unlike clinical
EPS assessments, kinematic handwriting variables were independent of se-
verity of positive and negative symptoms of psychosis, depression, or demo-
graphic variables. These findings support the high specificity of our
kinematic handwriting measures to EPS. Differences between various anti-
psychotic medications suggest that handwriting kinematics may be useful in
measuring the effects of switching medication in patients with pre-existing
EPS. Research supported by NIH grant R44 MH073192.
ID: 547581
NON-PHARMACOLOGICAL INTERVENTION
FOR WEIGHT GAIN MANAGEMENT IN SEVERE
MENTAL DISORDERS: RESULTS FROM A LARGE
MULTICENTRIC STUDY
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Background: A high prevalence of metabolic abnormalities has been ob-
served in patients with severe mental disorders and schizophrenia. Obesity
interventions studies in this population are scarce. Objective: Evaluate the
effectiveness of a non-pharmacological intervention in controlling body
weight and metabolic parameters. Method: An open, multicentric, longitu-
dinal study was conducted on 57 mental health services in 34 cities in Brazil.
Patients included in this study received a 12-week 1-hour group interven-
tion. Topics such healthy nutrition, lifestyle, physical activity and self-es-
teem were discussed with patients and their relatives. Weight, high, waist
circumference and blood pressured were measured before and after the in-
tervention. A total of 656 patients participated in the intervention. All of
them were in use of some antipsychotic and/or mood stabilizers and had
some concern about weight gain. Results: 512 patients completed the inter-
vention. A significant weight loss (0.5 6 3.4kg, P < .000) and a significant
BMI reduction (0.2 6 1.4 kg/m2, P < .007) were observed. There was
a marked increase in physical activity after the intervention, at the baseline
55.2% of the patients were enrolled in some kind of exercise program, after
the intervention, 72.8% were regularly practicing physical activity. Conclu-
sion: To our knowledge, the Brazilian Wellness Program is the largest na-
tional, multicentric, naturalistic study of a non-pharmacological
intervention for severe mental disorder patients showing positive outcomes
on weight gain management, reducing diastolic blood pressure and increas-
ing physical activity. Efficacy and effectiveness studies are being conducted
to further inform the implementation of the wellness intervention as public
mental health policy.
Table. Clinical parameters at baseline and 3 months (n = 512)
Variable
Baseline
(mean 6 SD)
3 months
(mean 6 SD) Analysis P
Weight (kg) 83.2 (18.7) 82.7 (18) t = 3.549; df = 511 .000
BMI (kg/m2) 31.3 (5.6) 31.1 (5.6) t = 2.696; df = 510 .007
Waist (cm) Male 109.2 (15.2) 108.6 (14.1) t = 1.332; df = 151 .185
Waist (cm) Female 102.1 (15.5) 101.8 (13.7) t = 0.438; df = 305 .662
Systolic BP (mmHg) 119.6 (15.4) 118.6 (14.7) t = 1.653; df = 483 .099
Diastolic BP (mmHg) 79.8 (11.7) 78 (10.5) t = 3.655; df = 484 .000
BMI: body mass index; BP: blood pressure; SD: standard deviation; df:
degrees of freedom
ID: 546913
PIOGLITAZONE AS A TREATMENT FOR GLUCOSE
AND LIPID METABOLIC ABNORMALITIES IN
SCHIZOPHRENIA
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Diabetes, hyperglycemia, and hyperlipidemia more prevalent in psychiat-
ric patients and increased by treatment with antipsychotic drugs. Research
by our own and other groups have shown that some second generation
antipsychotics increase insulin resistance even in patients who do not meet
metabolic criteria for diabetes. Pioglitazone is a PPAR agonist which spe-
cifically acts by increasing insulin sensitivity, a mechanism of action dif-
ferent form other antidiabetic drugs, and has beneficial effects on
decreasing triglycerides and increasing HDL. We present preliminary
data from a double-blind placebo controlled study of pioglitazone as
a treatment for glucose and lipid abnormalities in schizophrenia and as-
sessment of its potential cognitive effects. Method: Patients with schizo-
phrenia or schizoaffective psychosis who were treated with antipsychotic
medications and had fasting glucose  100 mg/dl and fasting triglycerides
 120 mg/dl participated in a 12 week double blind study in which they
received pioglitazone or placebo. Fasting glucose, insulin, triglycerides
and other metabolic parameters were measured monthly and a glucose
tolerance test was performed at baseline and end of study. Cognitive func-
tions was assessed by RBANS, CPT, and RANDT and psychopathology
asessed by PANSS. Preliminary results from the first 29 patients showed
that by the end of treatment patients treated with pioglitazone had lower
fasting glucose and triglycerides, and higher fasting HDL than patients
treated with placebo. 46% of placebo treated patients had diabetic range
fasting glucose levels compared to 13% of pioglitazone patients. There
was no drug differences in serum insulin but pioglitazone produced an
increase in insulin sensitivity measured by the homo procedure. By the
end of treatment Pioglitazone treated patients had lower 1 and 2 hr glu-
cose glucose levels on the 75 mg GTT test than placebo patients. Piogli-
tazone patients showed a decrease in PANSS. There were no significant
drug effects on the cognitive performance.Pioglitazone may be a useful
treatment for reducing or reversing metabolic abnormalities in schizo-
phrenic patients treated with antipsychotic medication. Because pioglita-
zone increases insulin sensitivity and may prevent or delayed conversion
of impaired fasting glucose to diabetes it might be considered as a preven-
tive strategy in patients treated with some antipsychotic medications.
ID: 541974
GLUCOSE AND LIPID DISTURBANCES AFTER
1 YEAR OF ANTIPSYCHOTIC TREATMENT IN A
DRUG-NAI¨VE POPULATION
Rocio Perez-Iglesias1, I. Mata1, J. M. Pelayo-Teran1,
J. A. Amado2, M. T. Garcia-Unzueta3, A. Berja2, O. Martinez-
Garcia1, J. L. Vazquez-Barquero1, B. Crespo-Facorro1
1Psychiatry, Marques de Valdecilla University Hospital, Santander,
Spain; 2Endocrinology, Marques de Valdecilla University Hospital,
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Santander, Spain; 3Biochemistry, Marques de Valdecilla University
Hospital, Santander, Spain
The objective of this study is to examine the main metabolic side effects
induced by antipsychotic treatment in a cohort of first-episode drug-naı¨ve
subjects after the first year of treatment. A randomized, open-label, pro-
spective clinical trial was conducted. Participants were 164 consecutive
subjects included in a first episode program and never treated with anti-
psychotic medication. Patients were assigned to haloperidol, olanzapine
or risperidone. The main outcome measures were changes at one year in
fasting glucose parameters (glucose, insulin levels and insulin resistance
index) and changes in fasting lipid parameters (total cholesterol, triglycer-
ides, LDL cholesterol and HDL cholesterol). At one year follow-up 144
subjects were evaluated. There was a statistically significant increase in the
mean values of insulin levels (3.5 microU/ml; P = .004); HOMA insulin
resistance index (0.7; P = .013); total cholesterol (22.2 mg/dl; P < .001);
LDL-cholesterol (15.1mg/dl; P < .001) and triglycerides (36.6 mg/dl;
P < .001). No pathological values in fasting glucose plasma levels were
found at baseline and there were no changes after one year. Weight
gain was positively correlated with changes in insulin increase (r = .32,
P = .001); HOMA index (r = .34, P < .001) and triglyceride levels (r =
.23, P = .016) and negatively correlated with HDL changes (r = 0.25,
P = 0.007). We did not detect statistically significant differences between
treatments in any of the parameters evaluated. Fasting glycaemia and in-
sulin concentrations at baseline do not support the hypothesis that schizo-
phrenia is associated with an underlying abnormality in glucose
metabolism. To summarize, after the first year of antipsychotic treatment
we have observed an increase in insulin-resistance index and a worsening
lipid profile—but no clinically relevant illness was detected. The changes
in insulin and lipid parameters seem to be related to the magnitude of
weight gain. There were no significant differences between haloperidol,
olanzapine and risperidone concerning metabolic adverse effects after
the first year of treatment. Grants: Instituto de Salud Carlos III, FIS
00/3095 and SENY Fundatio Research Grant CI 2005-0308007, Funda-
cion Marques de Valdecilla A/02/07. No pharmaceutical company sup-
plied financial support.
ID: 541006
SELF-RATING OF PHARMACOLOGICAL
TREATMENT(SIDE-)EFFECTS INSCHIZOPHRENIA:
A COMPARISON OF INSTRUMENTS
Hugo Wolters, R. J. van den Bosch, D. Wiersma, H. Knegtering
University Medical Centre Groningen, University of Groningen,
Groningen, Netherlands
Introduction: To support clinical practice as well as clinical research, self-
rating scales have been developed to evaluate desired as well as undesired
effects of antipsychotic treatment. Psychometric properties and other char-
acteristics of four identified self-rating scales including their relationship
with subjective quality of life will be compared. Method: Four scales of
self-report of treatment effects of antipsychotics were identified through
a MEDLINE and cross-references search: the Drug Attitude Inventory
(DAI-10), the Liverpool University Neuroleptic Side Effect Rating
Scale (LUNSERS), the Subjective Wellbeing to Neuroleptics (SWN)
and the Subjects’ Reaction to Antipsychotics questionnaire (SRA). All
scales were filled out by 320 patients with schizophrenia treated with
antipsychotics together with a subjective quality of life instrument, the
WHO-QoL BREF. Results: The DAI-10 contains ten items covering
many different aspects of treatment with antipsychotics, such as compli-
ance and attitudes towards neuroleptic treatment. The scope of the LUNS-
ERS is measuring undesired effects of antipsychotics, while the SRA
incorporates desired as well as undesired treatment effects. The SWN con-
sists mainly of items on aspects of wellbeing without a direct link to anti-
psychotics. The instruments show an acceptable internal reliability
(Cronbach’s alpha’s varying between .64–93) with the exception of the
DAI-10 (Cronbach’s alpha .52), probably due to the mix of experiences.
The scales did not strongly correlate (r between .11 and .51) with each other
except for the SRA-subscale undesired experiences and the LUNSERS (r =
.68, P < .01). Correlations with quality of life were statistically significant,
with the SWN showing the strongest one (r = .78, P < .01). Conclusion:
The lack of internal reliability and the conceptual mixture of items restrict
the use of the DAI-10. Its strength lies in measuring compliance and atti-
tudes towards neuroleptic treatment. The LUNSERS maybe very useful
to screen extensively side-effects of neuroleptic treatment, with the caveat
of overestimation of the frequency of these effects. The SWN is to be rec-
ommended as an alternative for a QoL-instrument in patients (not only
with schizophrenia) using antipsychotic medication. The SRA is recom-
mended if a clinician or researcher is specifically interested in undesired
as well as desired responses attributed to the antipsychotic medication.
ID: 538965
PREDICTORS OF MORTALITY IN PATIENTS WITH
SERIOUS MENTAL ILLNESS AND CO-MORBID
DIABETES
Clayton H. Brown1,4, J. Leith2, F. B. Dickerson3, D. R. Medoff2,
L. J. Fang2, J. Kreyenbuhl2,4, R. W. Goldberg2,4, W. Potts2,
L. B. Dixon2,4
1Epidemiology and Preventive Medicine, University of Maryland
School of Medicine, Baltimore, MD, USA; 2Department of Psy-
chiatry, University of Maryland School of Medicine, Baltimore,
MD, USA; 3Sheppard Pratt Health System, Baltimore, MD, USA;
4Mental Illness Research Edcuation and Clinical Center
(MIRECC), VA Capitol Health Care Network (VISN 5),
Baltimore, MD, USA
Objective: Persons with serious mental illness (SMI) have a higher rate of
type 2 diabetes and a higher mortality rate than the general population. The
purpose of this study was to assess baseline demographic and health-related
factors in the prediction of all-cause mortality over a seven-year follow-up
period in a group of diabetes patients with serious mental illness and a group
of diabetes patients without serious mental illness. Methods: From 1999 to
2002, 300 patients with type 2 diabetes were recruited from community
mental health centers in the greater Baltimore region and nearby primary
care clinics. Of these, 100 had a diagnosis of schizophrenia, 101 a diagnosis
of major mood disorder, and 99 had no identified mental illness. Patient
deaths over an average seven-year period after baseline assessment were
identified using the Social Security Administration’s Death Master File
via the website www.rootsweb.ancestry.com. Bivariate associations be-
tween predictors and mortality were assessed in the serious mental illness
group and compared to those in the group without serious mental illness.
This was followed-up with multivariable logistic regression. Results: A total
of 21 % of persons in each group died in the follow-up period. Median age
of death was 60. Age, duration of diabetes, and hospitalization for a diabe-
tes-related condition in the 6 months prior to baseline were all predictive of
mortality. In the SMI group (but not in the Non-SMI group) decedents
were more likely to have been smokers than non-decedents (69% versus
49%, P = .021) and in the multivariable model, odds of mortality was
over two times greater among smokers than non-smokers (adjusted odds
ratio (AOR) = 2.3, 95% CI: [0.96, 5.3]). In the Non-SMI group those
who were prescribed insulin had over a four-fold greater odds of mortality
(AOR = 4.1, 95% CI: [1.3, 13.1]), however in the SMI group there was no
evidence that being prescribed insulin served as a diabetes severity marker
(AOR = 0.59, 95% CI: [0.21, 1.6]). Conclusions: Diabetes may contribute to
the excess mortality of persons with serious mental illness. To better address
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this problem, clinicians caring for persons with serious mental illness need
to be especially vigilant regarding mortality risk when the diabetes illness of
their patients requires hospitalization and as their patients age. Further-
more, it is important that smoking cessation be aggressively promoted
among persons with SMI.
ID: 550828
SUBJECTIVE EXPERIENCE MEASUREMENT IN
PATIENTS WITH SCHIZOPHRENIA/SCHIZO-
AFFECTIVE DISORDER USING THE NOVEL
ANTIPSYCHOTIC MEDICATION EXPERIENCE
SCALE (NAMES)
Donna A. Wirshing, J. Rosen, J. M. Pierre, Z. D. Erickson,
L. H. Guzik, S. J. Mena
Psychiatry, VA Greater Los Angeles Healthcare System, Los
Angeles, CA, USA
Rating scales are effective tools to assess therapeutic efficacy and patient
subjective experience. Patients suffering from Schizophrenia benefit from
treatment with psychotropic medications to reduce symptomatology, to
reduce the frequency of hospitalizations and to provide for better com-
munity reintegration. However, medication nonadherence is problematic
for the effective treatment of these patients, and patients’ negative sub-
jective responses to medications correlate with treatment noncompliance.
Therefore, assessment of the level of patient subjective experience of
a medication is an important correlate of treatment efficacy. Existing rat-
ing scales for psychotropics in Schizophrenia (eg, Drug Attitude Inven-
tory (DAI) 30, AMDP-5) were developed to assess patient report of
side effects prior to the advent of atypicals. However, these scales may
now be less useful given the application of atypicals which have different
side effect profiles. We report here a preliminary study of the validity and
reliability of the Novel Antipsychotic Medication Experience Scale
(NAMES), a new patient self-rating questionnaire. The NAMES, DAI
30, and AMDP-5 questionnaires were administered to patients meeting
inclusion criteria: 1) patients with schizophrenia/schizoaffective disorder,
between 18 and 65 years old; 2) at least 1 month of monotherapy with
clozapine, fluphenazine, haloperidol, olanzapine, quetiapine, risperidone
or ziprasidone; 3) the absence of psychiatric co-morbidity. 101 outpatients
completed the study. The results from the NAMES questionnaire are cor-
related with results from the DAI 30 and AMDP-5, with Pearson Corre-
lation Coefficients of 0.89, and .83. The NAMES Standardized Cronbach
Coefficient Alpha (SCCA) was 0.81, while the DAI 30 SCCA was 0.46,
and the AMDP-5 was .32. Subjective measures assessed by the NAMES,
show that the scale is both reliable and valid. Based upon a measure of
internal consistency, the NAMES has a higher average inter-item corre-
lation than the DAI 30 or the AMDP-5. Further analysis may indicate
that NAMES is a better measure of patient subjective experience of treat-
ment with atypicals than other rating scales because of administration
protocol.
ID: 551878
PRE-DIABETES AND DIABETES ASSESSMENT IN
VETERANS WITH SCHIZOPHRENIA
Laurel A. Copeland1,2, J. E. Zeber1,2, M. L. Parchman1,3,
V. A. Lawrence1,4, B. J. Hosek1, A. L. Miller2
1VERDICT (HSRD), South Texas Veterans Health Care System,
San Antonio, TX, USA; 2Department Psychiatry, University of
Texas Health Science Center at San Antonio, San Antonio, TX,
USA; 3Department Family and Community Medicine, University of
Texas Health Science Center at San Antonio, San Antonio, TX,
USA; 4Department Medicine, University of Texas Health Science
Center at San Antonio, San Antonio, TX, USA
In February 2004, the American Diabetes Association and American Psy-
chiatric Association issued a Consensus statement on metabolic sequelae of
antipsychotic agents, summarizing research over the previous ten years that
documented growing awareness of this connection. The Pre-diabetes in Vet-
erans with Schizophrenia study assessed monitoring of pre-diabetes and un-
diagnosed diabetes just prior to the Consensus statement, in a national
sample of 39 825 Veterans Health Administration outpatients with schizo-
phrenia, aged 50 or older, with no recorded diagnosis of diabetes and no use
of hypoglycemic medications (non-diabetic at baseline). Diagnosis of
schizophrenia was defined by one inpatient or two or more outpatient di-
agnoses over the one-year study period. The retrospective study used fiscal
year 2002 data. Blood glucose tests with same-day low-density lipoprotein
(LDL) tests were used as a proxy for fasting glucose, because patients are
required to be fasting for the LDL test. Test time of day was not available,
nor was verification of fasting status. Hemoglobin A1c tests were also
extracted, as some authors advocate their use in monitoring pre-diabetes.
Tests were categorized: 100–125 mg/dL (pre-diabetes fasting glucose), > =
126 (diabetes-indicative fasting glucose), 5.8%–6.4% (pre-diabetes A1c), >
= 6.5% (diabetes-indicative A1c). Multivariable regressions modeled receipt
of a fasting glucose test, receipt of an A1c test, test results consistent with
pre-diabetes, and test results consistent with diabetes. Patient descriptives
included average age of 60 years (SD 9.5), 60% white, 42% unmarried, with
comorbid hypertension (40%), dyslipidemia (25%), and depressive disor-
ders (22%). Approximately 27% of patients had fasting glucose tests, of
whom 42% were pre-diabetic; 9% had A1c tests, of whom 28% were
pre-diabetic per study definition. Test rates among patients on atypical
antipsychotics were slightly higher: 29% fasting glucose, 10% A1c, but
within those groups, the proportions testing pre-diabetic were identical
(42% and 28%, respectively). Both glucose and A1c testing were associated
with hypertension, dyslipidemia, and atypical antipsychotics. Among tested
patients, pre-diabetes was associated with cardiovascular disease, older age,
and being married. Dysglycemia was prevalent among schizophrenia
patients, yet glucose monitoring was uncommon. Overall, few schizophre-
nia patients were being adequately monitored for dysglycemia.
ID: 551835
AUTONOMIC SYSTEM DYSREGULATION IN
SCHIZOPHRENIA AND BIPOLAR MANIA
Brook Henry, A. Minassian, M. Paulus, M. Geyer, W. Perry
Psychiatry, UC San Diego, San Diego, CA, USA
Heart rate variability (HRV) reflects the interchange of the parasympa-
thetic and sympathetic autonomic nervous system (ANS). Severe psychiat-
ric disorders such as schizophrenia have been associated with dysfunction
of the ANS, including alterations in cardiac function and HRV. Recent
reports suggest that ANS dysregulation among psychiatric patients may
be related to responses to physical and psychological stressors. Studies con-
sistently demonstrate a correlation between psychosis and heightened anx-
iety states even when the stressful condition is relatively minor. Still, it is
unclear whether this association is due to disease-related autonomic ner-
vous system changes or a side effect of antipsychotic medication. In the
present study we examined the autonomic response of hospitalized individ-
uals with schizophrenia and bipolar-mania when exposed to a novel
environment. The patients were compared to healthy comparison subjects.
Subjects were fitted with a vest that contained an ambulatory monitoring
device that allowed us to obtain continuous recordings of cardiac, respira-
tory, and motor activity. Both schizophrenia and bipolar-manic subjects
exhibited increased heart rate, increased respiration, and decreased HRV
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during a 15 minute exposure to a novel but benign environment. Spectral
analysis of cardiac data revealed that both groups showed an increase in the
Low Frequency/High Frequency ratio of the HRV signal compared to com-
parison subjects, indicating increased sympathetic nervous system activity.
Group differences in autonomic function remained significant even after
excluding variance due to locomotion, indicating that changes in cardiac
activity and respiration were independent of differences in physical activity.
Importantly, ANS function was not significantly affected by medications.
These findings indicate that individuals with both schizophrenia and bipo-
lar-mania exhibit an increased autonomic response to a novel environment.
The data suggest that both of these disorders may be characterized by
a common deficit in the ability to adapt to challenges in the environment,
which may have a direct impact on cognitive, affective, and behavioral
function.
ID: 551807
SUBSTANCE ABUSE IS ASSOCIATED WITH
INCREASED EXTRAPYRAMIDAL SYMPTOMS
IN SCHIZOPHRENIA: A META-ANALYSIS
Ste´phane Potvin1,2, P. J. Blanchet3, E. Stip1,2
1Centre de recherche Fernand-Seguin, Montreal, QC, Canada;
2Psychiatry, University of Montreal, Montreal, QC, Canada;
3Stomatology, University of Montreal, Montreal, QC, Canada
Background: Psychoactive substances (PAS) may interact with antipsy-
chotics in the development of extrapyramidal symptoms (EPS) in schizo-
phrenia, since PAS exert impacts on the basal ganglia. Clinical data have
been gathered about the effects of PAS on EPS in schizophrenia, producing
inconsistent results. This meta-analysis sought to determine whether PAS
enhance EPS in schizophrenia patients. Methods: A search of the literature
using computerized engines was undertaken. Studies were retained in the
analysis if: (i) they included schizophrenia patients with and without sub-
stance abuse; and (ii) they comprised a measure of EPS using valid instru-
ments. Results: Fifteen studies were available identified, involving 3373
patients. The composite analysis revealed a small and positive effect size
(g = 0.246), suggesting increased EPS in substance-abusing patients.
Dual-diagnosis patients were more frequently males than single diagnosis
patients. Thus, we performed a sub-analysis of studies with no confounders
(age, sex, negative symptoms, etc.). The pooling of these 10 studies
produced a moderate and positive effect size (g = 0.405). Discussion:
Our results show that PAS negatively impact on EPS in schizophrenia, es-
pecially when potential confounding factors are controlled. As such, these
results have implications for the prevention of EPS in schizophrenia and for
the design of future studies on the topic.
ID: 551548
INFLAMMATORY MARKERS IN SCHIZOPHRENIA:
COMPARING ANTIPSYCHOTIC EFFECTS IN THE
CATIE SCHIZOPHRENIA TRIAL
Henry A. Nasrallah2, J. M. Meyer1, J. P. McEvoy3, V. G. Davis4,
D. C. Goff5, S. M. Davis4
1Psychiatry, University of California at San Diego, San Diego, CA,
USA; 2Psychiatry, University of Cincinnati College of Medicine,
Cincinnati, OH, OH, USA; 3Psychiatry, Duke University, Durham,
NC, USA; 4Psychiatry, University of North Carolina, Chapel Hill,
NC, USA; 5Psychiatry, Harvard University, Boston, MA, USA
Background: C-reactive protein (CRP), intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin are
systemic inflammatory markers (IM) that positively correlate with cardio-
vascular (CV) risk. Despite the known CV effects of atypical antipsy-
chotics, there is limited prospective data on IM changes during
treatment. Methods: IM outcomes were compared between antipsychotic
treatment groups in the CATIE Schizophrenia Trial phase 1 using subjects
with laboratory assessments at baseline and 3 months (n = 789). Results:
There were significant treatment differences in CRP, E-selectin and ICAM-
1 at 3 months, with an impact of baseline values on outcome. In overall
comparisons, olanzapine or quetiapine arms had the highest median levels
for each IM. In those with low baseline CV risk by CRP (< 1 mg/L), olan-
zapine was significantly different than perphenazine (P < .001) and risper-
idone (P = .001) after baseline adjustment. Among those with high baseline
E-selectin values, olanzapine was significantly different than perphenazine
(P = .005) and ziprasidone (P = .002), as was quetiapine vs. ziprasidone
(P = .004). Olanzapine and quetiapine also had higher 3-month ICAM-
1 levels than perphenazine in subjects with baseline ICAM-1 above the me-
dian, but the differences were not statistically significant after controlling
for multiple comparisons (P = .010 for both). The 18-month repeated
measures CRP analysis confirmed the significantly higher values for olan-
zapine in those with low baseline CRP. Conclusions: This analysis provides
further evidence for differential antipsychotic metabolic liabilities as mea-
sured by changes in systemic inflammation. CRP may emerge as a useful
target for CV risk outcomes in schizophrenia patients.
ID: 551428
MORPHOLOGICAL, CELLULAR AND
MOLECULAR CORRELATES OF ANTIPSYCHOTIC
MEDICATION EXPOSURE IN PRIMATE
NEOCORTEX
David A. Lewis1,2, K. A. Dorph-Petersen1,3, G. T. Konopaske1,4
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA;
3Centre for Psychiatric Research, Aarhus University Hospital,
Risskov, Denmark; 4McLean Hospital, Belmont, MA, USA
Schizophrenia is associated with a number of morphological, cellular and
molecular abnormalities in the cerebral cortex. Knowledge of the extent to
which prolonged treatment with antipsychotic medications contributes to
these disturbances is essential both for understanding the disease process
of schizophrenia and for gaining insight into the mechanisms underlying
the therapeutic and adverse effects of antipsychotic medications. To ad-
dress these issues, we exposed experimentally-naı¨ve, young adult, male
macaque monkeys to twice-daily oral doses of haloperidol, olanzepine
or sham treatment for approximately two years. At steady state, trough
plasma levels of haloperidol and olanzapine were in the range reported to
be therapeutic in schizophrenia. Both the haloperidol and olanzapine-
exposed groups had significantly smaller total brain weight and volume.
At the cellular level, we found lower glial cell number and higher neuron
density in the cortex, without a difference in total neuron number, in the
antipsychotic-exposed monkeys; follow-up immunocytochemical studies
revealed a significant 21% lower astrocyte number with a non-significant
13% lower oligodendrocyte number in the antipsychotic-exposed mon-
keys. Similar effects were seen in both the haloperidol and olanzapine
groups. In contrast, none of the examined GABA-related transcripts
reported to be altered in schizophrenia differed across the three groups
of monkeys. Although species differences and other factors need to be
considered, these findings suggest that certain morphological and cellular
abnormalities identified in schizophrenia might be attributable to chronic
exposure to antipsychotic medications.
ID: 551304
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SOMNOLENCE AND SEDATION IN ADOLESCENT
PATIENTS WITHSCHIZOPHRENIA TREATED WITH
ARIPIPRAZOLE IN AN ACUTE STUDY WITH LONG
TERM FOLLOW-UP
Suja J. Mathew1, R. D. McQuade2, W. H. Carson2, M. Nyilas2,
R. A. Forbes2, T. Iwamoto2, R. Mankoski3, A. Pikalov1
1Medical Affairs, Otsuka America Pharmaceutical, Inc, Rockville,
MD, USA; 2Global Clinical Development, Otsuka Pharmaceutical
Development and Commercialization Inc., Princeton, NJ, USA;
3Medical Strategy, Bristol Myers Squibb Co., Plainsboro, NJ,
USA
Background: Somnolence and sedation are relatively common side effects
of antipsychotics to which adolescents may be more sensitive. The purpose
of this study was to evaluate characteristics of somnolence and sedation in
adolescents with schizophrenia treated with aripiprazole. Methods: Data
are derived from a 6-week, double-blind, placebo controlled, randomized
clinical trial comparing two fixed doses of aripiprazole (10 and 30mg, N =
302) and a 26-week, open-label, follow-up study with flexible dosing (5-
30mg, N = 239). Somnolence and sedation were evaluated with respect
to time of onset, severity, dose-response, dose-reduction, discontinuation
rates, age, gender, and ethnicity. Results: In both the short- (ST) and
long-term (LT) studies, almost all reported cases of somnolence and se-
dation were classified as mild (ST: n = 25, 12%; LT: n = 24, 10%) or
moderate (ST: n = 8, 4%; LT: n = 9, 4%), and only one patient was
discontinued from the study due to somnolence. Most events (76%)
started early (within 2 and 4 weeks) and had resolved within the study
period. A possible dose-dependence relationship was seen, with more
events reported at the 30 mg dose. In the short-term trial, Blacks
reported substantially higher rates (35% in the 10 mg arm and 55%
in the 30 mg arm) than the overall population (12% in the 10 mg arm
and 22% in the 30 mg arm). No differences were noted in incidence strat-
ified by age or gender. In the long-term open-label study, the overall
incidence of somnolence and sedation was low (14%) and was the similar
between groups switched from aripiprazole 10 mg. 30 mg or placebo.
When sedation or somnolence occurred, most investigators took no ac-
tion or reduced the dose rather than discontinuing study drug. Conclu-
sions: Somnolence and sedation in adolescents with schizophrenia treated
with aripiprazole, if experienced, is typically mild, transient, and man-
ageable. In general, higher doses lead to an increased incidence in youn-
ger patients, and ethnicity may be a modifying factor and should be
evaluated further.
ID: 551235
PROSPECTIVE LONGITUDINAL EVALUATION OF
SERUM CREATINE KINASE LEVELS AND NEURO-
MUSCULAR DYSFUNCTION IN SCHIZOPHRENIA
PATIENTS: NEW RESULTS OF FOLLOW-UP STUDY
Ilya Reznik1, L. Volchek2, M. Reznik3, H. Y. Meltzer4,
A. Weizman1
1Laboratory of Biological Psychiatry, Felsenstein Medical
Research Center, Bat-Yam, Israel; 2Neurology Department,
Barzilay Medical Center, affiliated to Ben Gurion University,
Ashkelon, Israel; 3Psychiatry Division, Barzilay Medical Center,
affiliated to Ben Gurion University, Ashkelon, Israel; 4Division of
Psychopharmacology, Vanderbilt University Medical Center,
Nashville, TN, USA
Background: There are multiple causes of hyper-CKemia (HCK)—the
elevation of serum creatine kinase (SCK) activity above upper limits. These
increases may be related to underlying trait-like biological abnormalities in
psychosis, phasic episodes related biological abnormalities, or the effect of
drug treatment. Previously we found, that among HCKemic patients, the
majority was treated with atypical antipsychotic drug (AAPD) and some of
them had neuromuscular complaints. The purposes of this study were to
follow-up prospectively and to estimate the incidence and severity of prob-
able neuromuscular dysfunction in HCKemic schizophrenia and schizoaf-
fective patients. Methods: For this study, we selected 39 HCK-emic
patients suffering from schizophrenia or schizoaffective disorder. Eleven
patients, treated either with clozapine, olanzapine or perphenazine had
persistent/recurrent hyper-CKemia (PHCK). 25 patients had occasional
HCKemia (OHCK). Blood samples for CK determinations were col-
lected regularly up to three years of follow-up. Each year, all patients
were assessed neurologically for possible muscular and peripheral ner-
vous systems involvement. Results: During the study, SCK activity in
PHCK patients was found to be persistently elevated: 400 6 200
(mean 6 SD) in range 250-950 IU/L. Five of these patients had com-
plaints of muscular weakness, early fatigue on exercise, some muscular
pains and cramps. In two of them clinical assessment revealed mild gen-
eral muscular weakness, especially in the proximal parts of the limbs.
This pattern was diagnosed as probable mild myopathy. In majority
of OHCK patients SCK activity was reduced to the normal levels range.
Some patients remained with occasional HCK without any kind of neu-
romuscular pathology. Conclusions: The results of this first long-term
large-scale prospective comparative study indicate that among HCK-
emic schizophrenia and schizoaffective patients, only PHCK pattern
may consider to be a biochemical marker of the neuromuscular dysfunc-
tion. Meanwhile, OHCK is likely to be a benign phenomenon, has no
clinical manifestations, and does not need to be followed-up routinely.
Further investigation of neuromuscular dysfunction, its mechanisms,
pathophysiological significance and possible pharmacogenetics associa-
tions in schizophrenia patients is certainly indicated. The relationship
of HCK to mutations in neuregulin, dysbindin or reelin—genes related
both to schizophrenia and to muscle, is also of interest.
ID: 551193
METABOLIC SIDE EFFECTS OF COMBINED
ANTIPSYCHOTIC TREATMENT: RESULTS FROM
A DOUBLE BLIND TRIAL OF ADJUNCTIVE
RISPERIDONE IN CLOZAPINE TREATED PEOPLE
WITH TREATMENT-RESISTANT SCHIZOPHRENIA
Charles Michael Richardson1, S. Feldman1, D. L. Kelly1,
M. P. Ball1, D. L. Boggs1, E. Weiner1, R. C. Conley2, J. M. Gold1,
R. P. McMahon1, R. W. Buchanan1
1Maryland Psychiatric Research Center, University of Maryland
School of Medicine, Baltimore, MD, USA; 2Lilly Pharmaceuticals,
Indianapolis, IN, USA
Incomplete response to clozapine in people with treatment-resistant schizo-
phrenia poses a significant clinical challenge. The use of a second antipsy-
chotic has become widespread despite little evidence to support its efficacy
or safety. This analysis examines the safety of combined risperidone and
clozapine with respect to metabolic and prolactin-related side effects,
during a 16-week, placebo-controlled, randomized trial of adjunctive risperi-
done (4 mg/day) in clozapine partial responders. Eligible subjects were
those with DSM-IV schizophrenia or schizoaffective disorder who contin-
ued to manifest moderate illness severity (18-item BPRS total ^ 45 and
CGI Severity score ^ 4) and persistent psychosis (four BPRS psychosis
item total^ 8, with one of these items^ 4)despite adequate prior clozapine
treatment. Weight and blood pressure were measured every two weeks
and laboratory measures (fasting glucose, cholesterol, triglycerides, and
prolactin) were obtained at baseline, week 4, and endpoint. Eighty-six sub-
jects signed consent; 71 entered the 4-week evaluation phase; 65 were
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randomized and entered the double-blind treatment phase (risperidone: 30;
placebo: 35). The majority of subjects were male (risperidone group: 63.3%;
placebo group: 71.4%) and Caucasian (risperidone group: 76.7%; placebo
group: 62.9%). The risperidone group was significantly older (48.3 (7.2) ver-
sus 43.6 (9.6)). Fifty-two subjects (80%) completed all 16 weeks of treatment
(risperidone: 25/placebo: 27). Adjunctive risperidone was not associated
with weight gain or blood pressure changes compared to placebo. The ris-
peridone group had a significantly greater increase in prolactin levels com-
pared to placebo (P< .001). The presentation will include complete data on
other metabolic parameters. In summary, the addition of risperidone to clo-
zapine was associated with no significant change in weight or metabolic side
effects relative to clozapine treatment alone, although prolactin levels were
significantly elevated in the group receiving adjunctive risperidone. Sup-
ported by R01 MH45074 the Stanley Medical Research Institute and
P30 MH068580. Janssen Pharmaceuticals provided study medication.
ID: 551129
EFFECTS OF ARIPIPRAZOLE ON METABOLIC
MEASURES IN PEDIATRIC AND ADOLESCENT
PATIENTS: A POOLED ANALYSIS OF PLACEBO-
CONTROLLED TRIALS
Andrei Pikalov1, R. A. Baker2, S. Kaplita3, J. Han3, S. Mathew4,
R. Mankoski2, W. H. Carson5, R. A. Forbes5, M. Nyilas4,
T. Iwamoto6, R. Owen3
1Otsuka America Pharmaceutical Inc., Rockville, MD, USA;
2Bristol-Myers Squibb, Plainsboro, NJ, USA; 3Bristol-Myers
Squibb, Wallingford, CT, USA; 4Otsuka America Pharmaceutical
Inc., Rockville, MD, USA; 5Otsuka Pharmaceutical Development
and Commercialization Inc., Princeton, NJ, USA; 6Otsuka Phar-
maceutical Co., Ltd, Tokyo, Japan
The potential metabolic side effects of antipsychotics in children and ado-
lescents are of particular concern for not only clinicians, but also patients
and their caregivers in situations where an atypical agent may be beneficial.
In the present analysis, the metabolic effects of aripiprazole in pediatric and
adolescent patients from the aripiprazole worldwide development program
were evaluated. Metabolic measures in aripiprazole- and placebo-exposed
patients were compared with ANCOVA using LOCF. Aripiprazole pro-
duced no significant mean change (mg/dL) versus placebo in fasting plasma
glucose (aripiprazole:þ0.3, placebo:1.2; P = .38), total cholesterol (aripi-
prazole:5.8, placebo:8.5; P = .22), or fasting triglycerides (aripiprazole:
2.5, placebo: -0.9, P= .79), whilst the change in body weight was significant
(aripiprazole: þ1.6 kg, n = 381, placebo: þ0.3 kg, n = 187, P < .001).
The results inform evidence-based clinical decisions, and reinforce the
need for realistic management of weight gain and metabolic monitoring
in all children/adolescents being treated with antipsychotic medications.
ID: 551116
BONE MINERAL DENSITY IN PATIENTS WITH
PSYCHOSIS AND NON-PSYCHOTIC SIBLINGS
Machteld Marcelis1, P. Habets1, M. van Kroonenburg2,
P. Domen1, J. van Os1,3
1Department of Psychiatry and Neuropsychology, Maastricht
University Medical Center, Maastricht, Netherlands; 2Department
of Nuclear Medicine, Maastricht University Medical Center,
Maastricht, Netherlands; 3Department of Psychological Medicine,
Institute of Psychiatry, London, United Kingdom
Background: Increased rates of altered bone mineral density (BMD), like
osteopenia and osteoporosis, have been reported in schizoprenia, but the
underlying mechanism are not yet fully elucidated. Reduced BMD, as a bi-
ological marker of diminished cumulative estrogen exposure, has been sug-
gested to be a marker of increased psychosis risk. In the present family study
we tested whether decreased BMD is also an indicator of genetic liability for
the disorder. Methods: As part of an observational longitudinal study,
BMD of the spine and femur was measured with dual-energy-X-ray-
absorptiometry (DXA) in a subsample of 42 patients with schizophrenia,
54 non-psychotic siblings of these patients and 39 controls. Preliminary,
multilevel random regression, analyses were performed to assess group dif-
ferences in bone mineral density of the lumbar spine and femur (baseline
measures). Results: In female patients, bone mineral density was signifi-
cantly lower than in controls, in those not using contraceptives. This effect
was found in both the lumbar spine (b = 0.74, P < .024) and femur (b =
0.66, P < .05). Female siblings also showed (trends of) decreased bone
mineral density in the lumbar spine and femur region compared to controls.
In male patients and siblings, bone mineral density was not significantly
altered compared to controls. Conclusions: Both female patients and their
non-psychotic female siblings may have decreased bone mineral density.
This data support not only that reduced BMD, as a biological marker
of diminished cumulative estrogen exposure, may be a marker of increased
psychosis risk, but also that reduced BMD may be a marker of the genetic
liability for schizophrenia.
ID: 551025
A GUIDELINE FOR WEIGHT GAIN PREVENTION —
A PILOT STUDY
Jair Borges Barbosa1, C. Attux1, L. C. Martini1, C. M. Arau´jo1,
G. H. Kaio1, A. M. Roma1, R. F. Reis2, R. A. Bressan1
1Psychiatry, UNIFESP, Sao Paulo, Brazil; 2Endocrinology,
UNIFESP, Sao Paulo, Brazil
Introduction: Antipsychotic induced weight gain is a fair ordinary and well
known side effect. Cardiovascular disease, glucose intolerance, and type 2
Diabetes Mellitus might be the outcome of this side effect. The weight gain
is more pronounced in the first 4 months of treatment and the psychiatrist
should actively help the patient to avoid it. During the psychiatric visit
clinicians have some difficulties on evaluating and orienting these aspects,
focusing one’s attention into psychopathologic aspects. Our aim was to de-
velop a quick supportive material and a guideline to: 1) optimize the psy-
chiatric visit focusing on detecting, preventing and intervening to avoid
medication induced weight gain; 2) to structure the clinician practice sug-
gesting four levels of intervention according to the severity of problem: diet-
ing, physical activities, binge eating control and pharmacologic treatment.
Methods: Two different materials were developed; first a practical informa-
tive booklet for the patients, with healthy dieting and physical activities
recommendations. Second, a practical guideline suggesting the physician
a few questions about weight gain and appetite increase is used to establish
a dialog with the patient and promote early detection of eating problems.
The guideline provides 4 modules of intervention empowering the physician
to promote dieting and physical activity habits changes, actively treating
binge eating and increased appetite whenever necessary. Results: In our pi-
lot study 5 physicians applied our methods to 10 schizophrenic outpatients,
9 patients finished the four months period. Mean age: 35,8, 80% were male,
mean weight: 97,7 Kg, and mean BMI: 30,9 Kg/m2 at the beginning of the
study; mean weight 95,2 Kg, and mean BMI 30,2 Kg/m2 at the end. One
patient was prescribed with topiramate, due to obesity, one with metformin,
due to glucose intolerance. Discussion: This pilot study showed that the
designed material was useful in clinical practice taking less than 5 minutes.
It helped the clinician to diagnose weight changes and empowered clinicians
to actively implement measures to avoid this trend. Our future goal is test-
ing this material for the weight gain prevention in larger samples at the be-
ginning of antipsychotics use. If the major weight gain occurs during the
first 4 months, we believe this is the best period for weight gain prevention
with life style modifications, and the introduction of medications to treat
glucose intolerance or obesity.
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THE ACUTE EFFECTS OF ATYPICAL ANTIPSY-
CHOTIC DRUGS ON GLUCOSE SENSITIVITY IN AN
ANIMAL MODEL
Heidi Noel Boyda1, L. Tse1, R. M. Procyshyn2,1, A. M. Barr1,2
1Faculty of Medicine, Anesthesiology, Pharmacology and
Therapeutics, University of British Columbia, Vancouver, BC,
Canada; 2Faculty of Medicine, Psychiatry, BC Mental Health and
Addictions Research Institute, Vancouver, BC, Canada
The atypical antipsychotics are currently the drugs of choice for psychiatric
conditions including schizophrenia spectrum disorders and bipolar disor-
der. However, recent studies have shown that these compounds contribute
as risk factors for metabolic syndrome. Untoward effects induced by these
drugs, such as weight gain, hyperlipidemia, glucose intolerance and insulin
sensitivity occur within patients and rodents both acutely and on a chronic
time scale. The objective of this study is to examine these metabolic abnor-
malities through the use of a rodent model. To assess the effects of atypical
drugs on glucose sensitivity, adult female Sprague-Dawley rats were treated
with either a low or high dose of clozapine (2, 20 mg/kg) or risperidone
(0.5, 2.5 mg/kg) and compared to vehicle treated animals. Separate cohorts
of rats were subjected to an intraperitoneal glucose tolerance test (IGTT) at
1, 3 and 6 hours after antipsychotic drug treatment. For the IGTT, blood
samples were drawn every 15 min for a two hour period. Blood samples
were also stored for future measurement of drug and metabolite levels
by HPLC-UVD. The statistical analysis indicated that there was an effect
of both drug dose and time since treatment on glucose sensitivity, as mea-
sured by the IGTT. For both clozapine and risperidone, the high dose of
drug caused greater glucose resistance than the low dose and vehicle treated
animals, while the low dose drug caused greater insulin resistance than
the vehicle treated animals. This effect was greatest one hour after drug
administration and diminished over time. These data show that, at least
in an animal model, both an atypical drug with a well known metabolic
side-effect profile (clozapine) and a drug with more modest metabolic
side-effects (risperidone) can cause acute glucose resistance, and these
effects are dose-dependent. Ongoing studies will compare these findings
with additional typical and atypical antipsychotics after both acute and
chronic treatment.
ID: 550865
PERSISTENT ANTIPSYCHOTIC POLYPHARMACY
AND EXCESSIVE DOSING IN THE COMMUNITY
PSYCHIATRIC TREATMENT SETTING
Alasdair M. Barr1, S. McIsaac2, T. Wu1, R. Ko1, J. L. Johnson3,
A. H. Young2, W. G. Honer2, R. M. Procyshyn2
1Pharmacology, University of British Columbia, Vancouver, BC,
Canada; 2Psychiatry, University of British Columbia, Vancouver,
BC, Canada; 3Nursing and Health Behaviour Research Unit,
University of British Columbia, Vancouver, BC, Canada
Introduction: Clinical practice guidelines have been developed to assist
clinicians on the practical aspects of treating patients with schizophrenia,
including treatment resistant patients. Consistent among these references is
the recommendation that treatment resistant patients be trialed with clo-
zapine monotherapy before using strategies with limited or no evidence,
such as concurrent use of two antipsychotics (ie, antipsychotic polyphar-
macy). Antipsychotic polypharmacy practice may increase the risk of ad-
verse events and its benefits on mental health outcome remain largely
unsubstantiated. Methods: We investigated persistent antipsychotic poly-
pharmacy and excessive dosing in patients originally recruited for a study
that examined the relationship of tobacco use in the context of severe and
persistent mental illness. This study targeted adults who were receiving serv-
ices from a community mental health team within the Vancouver Coastal
Health Authority. BC PharmaNet (a province-wide network that that links
all British Columbian pharmacies to a central set of data systems) was used
to screen for eligible patients for this study and obtain data about prescrip-
tions filled over at least a 90 day period. Results: Of the 514 patients
recruited in the initial study, 397 patients met the inclusion criteria; 162 di-
agnosed with schizophrenia, 81 with schizoaffective disorder, 48 with major
depression, 77 with bipolar disorder, and 29 with psychosis not otherwise
specified. The highest incidence of persistent antipsychotic polypharmacy
was found in individuals diagnosed with schizoaffective disorder (32.1%),
followed by schizophrenia (30.9%), psychosis NOS (17.2%), bipolar dis-
order (15.6%) and major depression (14.6%). In the case of the atypical
antipsychotics, quetiapine was the agent associated with the greatest pro-
portion of patients treated with persistent antipsychotic polypharmacy
(46.1%) followed by risperidone (37.1%), olanzapine (32.7%), and then
clozapine (30.3%). Differences were noted between subjects treated by
monotherapy versus polypharmacy on concurrent treatment with alternate
medications. Discussion: The primary finding of this study was that 25% of
our outpatient sample was treated with persistent antipsychotic polyphar-
macy. The relationship of polypharmacy to excessive dosing remains an
important issue with respect to risk for adverse events, clinical efficacy
and economic concerns.
ID: 550830
DISCORDANT CARDIOMETABOLIC RISK OF
ATYPICAL ANTIPSYCHOTICS DESPITE SHARED
WORSENING OF BODY COMPOSITION DURING
FIRST-TIME USE IN CHILDREN AND
ADOLESCENTS
Christoph Ulrich Correll1,2, J. M. Kane1,2, V. Olshanskiy1,
B. Napolitano1, A. K. Malhotra1,2
1Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks,
NY, USA; 2Psychiatry, Albert Einstein College of Medicine, Bronx,
NY, USA
Background: Cardiometabolic effects of antipsychotics are problematic in
patients with prolonged antipsychotic exposure, but have been insuffi-
ciently studied in antipsychotic-naı¨ve and pediatric patients. Methods:
Youths (N = 272), age 4–19 (mean: 13.9 6 3.6) years, prescribed atypical
antipsychotics for the first time, underwent assessments of
weight, fasting glucose, lipids and homeostatic model of insulin resistance
(HOMA-IR) at baseline, week 4, 8 and 12. Refusing/non-adherent patients,
determined by interview and absent antipsychotic blood levels, served as
controls. Results: After 10.3 6 3.1 weeks, weight increased by 9.2 6
0.6lbs = 7.9 6 9.4% with aripiprazole (N = 41), 18.0 6 1.3lbs = 15.5 6
17.9% with olanzapine (N = 45), 12.3 6 1.2lbs = 9.9 6 12.0% with quetiapine
(N = 36), and 10.9 6 0.6lbs = 10.0 6 11.1% with risperidone (N = 135). Con-
trols (N = 15) lost weight minimally (1.5 6 1.6lbs =0.2 6 1.9%). Weight
gain>7%/>14% occurred in58.4%/17.1%ofpatientsonaripiprazole, 84.4%/
51.1% on olanzapine, 55.6%/30.6% on quetiapine, 64.4%/25.1% on risperi-
done, and 0% of controls. All metabolic parameters, except HDL-choles-
terol, increased significantly with olanzapine. With quetiapine and
risperidone, triglycerides and triglyceride/HDL-cholesterol ratio increased
significantly. With quetiapine, non-HDL cholesterol also increased signifi-
cantly. Metabolic changes were non-significant with aripiprazole and in con-
trols. New-onset dyslipidemia developed in 7.3%, 28.9%, 8.8%, and 19.4% of
youths on aripiprazole, olanzapine, quetiapine and risperidone, comparedto
6.7% of controls (P = .033). In contrast to weight gain and dyslipidemia,
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acquired insulin resistance (HOMA-IR>4.39: 2.9%–17.8%) and metabolic
syndrome (0%–6.5%) were relatively rare. Conclusions: Short-term, first-
time atypical antipsychotic use in pediatric patients produced significant
weight and triglyceride increases. Olanzapine had the most pervasive, aripi-
prazole had the most circumscript cardiometabolic liability. These results re-
quire careful clinical attention. Findings were more pronounced than
previously reported, highlighting the need to assess antipsychotic-naı¨ve sam-
ples.
ID: 554130
WEIGHT MAINTENANCE BY BOOSTER
BEHAVIORAL SESSIONS IN SCHIZOPHRENIA
SUBJECTS WHO LOST WEIGHT IN A BEHAVIORAL
PROGRAM
Rohan Ganguli1,3, J. S. Brar2
1Psychiatry, University of Toronto, Toronto, ON, Canada;
2Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
3Psychiatry, Center for Addiction and Mental Health, Toronto,
ON, Canada
Introduction: Several controlled clinical trials, involving patients with
schizophrenia, have established that almost half of the participants can ben-
efit by losing weight. However, there have been no long term follow up
studies, so far, on whether the loss is maintained. We report the preliminary
two-year follow up results on subjects who participated in an NIMH-
funded clinical trial of weight reduction in schizophrenia. The study is on-
going and hence these data are from the 23 subjects who have reached the
two-year follow up time point. Methods: Subjects in this analysis are those
who participated in a behavioral weight loss intervention and who suc-
ceeded in losing at least 3% of their initial weight. In order to evaluate
the effectiveness of every other week individual booster sessions, subjects
we re-randomized to receive individual booster sessions every other week
for two years or to usual care with follow up weights gathered yearly.
Results: There was some weight regain in both groups, but considerably
less in the booster group, as compared to the controls. The subjects in
the booster group regained 3.1 lb in the first year and an additional
1.7 lb in the second year of follow up. However, even after two years their
mean weight was still 7 pounds below their weight at entry into the behav-
ioral treatment. Controls on the other hand regained an average of 9 lb in
the first year of follow up, already exceeding their average entry weight and
then regained an additional 4.9 lb pounds in the second year of follow up.
Thus, controls were at 5.8 pounds above their weight before entering treat-
ment while subjects in boosters were 7 pounds below their weight at entry
into the study. Conclusions: From these preliminary data, we conclude that
twice monthly booster sessions appear to be effective in preventing weight
regain, following intentional weight loss, for as long as two years following
treatment. It remains to be investigated whether less active intervention,
such as monthly boosters would be as effective, and whether more active
intervention, such as weekly contact would be even more effective. These
results reinforce the proposition that obesity is a chronic disorder and
requires on-going maintenance after successful weight loss.
Table. Weight Change (lb): Initial and Over Two Year-Followup
Randomized
To
Mean
Study Entry
Weight
Mean Weight
at Start of
Followup
Mean
Weight
at 1 year
Mean
Weight
at 2 years
Booster
Treatments
228.4 217.6 220.7 222.4
Usual Care 237.7 229.1 238.1 243.0
ID: 554356
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4. 4. Electrophysiology
THE RELATIONSHIP BETWEEN GAMMA BAND
SYNCHRONY AND P300 BREAKS DOWN IN
SCHIZOPHRENIA
Judith M. Ford1, B. J. Roach1, R. E. Hoffman2,
D. H. Mathalon1
1Psychiatry, UCSF, San Francisco, CA, USA; 2Psychiatry,
Yale University, New Haven, CT, USA
Auditory P300 amplitude reduction in schizophrenia is canonical and may
be explained by poor synchronization or reduced power of the underlying
neural activity. We asked if patients have reduced synchrony and power,
and whether together with P300 amplitude, they make unique or overlap-
ping contributions to the discrimination between patients and controls. We
also asked whether people who have large P300s have higher power and
greater synchrony of neural activity, and if the relationships between
P300 and power and synchrony are different in patients and healthy con-
trols. Methods. We recorded EEG data from 22 controls and 21 patients
with schizophrenia (DSM-IV) while they performed an auditory target (P =
.10) detection task. We used wavelet analyses to estimate total power and
synchrony of delta, theta, alpha, beta, and gamma activity in a 50ms win-
dow around the peak of the P300 to the target from the single trial data. We
measured P300 amplitude from the average of the single trials, in a 50ms
window around its peak. Results and Conclusions. P300 amplitude and
delta and theta synchrony were reduced in patients; delta power and syn-
chrony better distinguished between groups than P300 amplitude. In spite
of the strong correlation between P300 amplitude and gamma synchrony in
controls (r = .79), and in spite of P300 amplitude reduction in the patients,
gamma synchrony was not reduced in the patients. Whatever is contribut-
ing to P300 amplitude reduction in the patients (eg, gray matter volume
deficits, poor clinical state, or fluctuations in attention [Ford, 1999]) is
not significantly affecting gamma synchrony. The breakdown of a lawful
relationship among neurobiological or neuropsychological variables in
schizophrenia patients is not uncommon in the field of biological psychi-
atry. It suggests that the variables are affected by independent factors and
the relationships between them are attenuated by additional pathophysio-
logical processes.
ID: 540424
VISUAL ATTENTIONAL CAPTURE IN
SCHIZOPHRENIA: AN EVENT-RELATED
POTENTIAL STUDY
Maxime Bubrovszky1,2, M. Combel1, P. Thomas1,2
1Psychiatry, University Hospital of Lille, Lille, France; 2Functional
Neurosciences and Pathology Laboratory, CNRS UMR 8160, Lille,
France
Selection of relevant information is disrupted by schizophrenia. In the vi-
sual modality, selection capacities can be studied by resistance to interfer-
ences: patients’ impairment is characterized by an abnormal persistence of
attentional capture effect when control subjects manage to ignore the same
irrelevant stimuli. We propose here to record event-related potentials
(ERP) during a visual attentional capture paradigm. We hypothesized
that electrophysiological indicator of capture will persist for patients.
We recruited 10 patients with schizophrenia (DSM IV-TR criteria) and
10 healthy controls. Subjects were instructed to detect as quickly as possible
the position of a black square which appears up or down on a screen. Dur-
ing the whole process two red circles were presented on both lateral side of
the screen. Capture was induced by lateral translation of one of the circles.
This translation occurred following randomized order for 48 of the 96 trials.
Behavioural effect was measured by difference of reaction time between the
two conditions: non-capture (square appearance) VS capture (square ap-
pearance and circle translation). Two sets of presentations were proposed.
During the first one, the translations occurred bilaterally (50/50, random-
ized order). During the second one all translations occurred unilaterally for
the right circle. ERP were recorded with 70 electrodes montage. After pre-
processing and averaging, we subtracted capture and non-capture condi-
tions. Relevant time periods and regions were defined when this subtraction
was significantly different from zero. Behavioural results are similar to
previous studies: both patients and controls are ‘‘captured’’ by bilateral
translation. For unilateral translation, patients stay captured. On contrary,
controls recover non-capture reaction time. Two time windows are selected
by electrical capture effect (maximal at frontal area). For bilateral capture,
no difference is detected. For unilateral, the later window (250 to 350 msec.)
differs between the two groups. Subtracted ERP for patients keep showing
capture effect for frontal region and are significantly higher than for
controls. Our results suggest that selectivity impairment for patients
could be linked to incapacity to ignore irrelevant stimulus. Patients persist
to engage important frontal activity to process irrelevant data. This impair-
ment could constitute a key to explore both fundamental perceptual deficits
and alteration of daily functioning.
ID: 550596
MIRROR NEURON FUNCTION IN A FIRST EPISODE
OF PSYCHOSIS POPULATION
Fiza Singh1, J. Pineda2, K. Cadenhead1
1Psychiatry, University of California at San Diego, La Jolla, CA,
USA; 2Cognitive Science, University of California at San Diego,
La Jolla, CA, USA
Schizophrenia is a chronic debilitating illness characterized by the patient’s
inability to integrate into the social milieu, although the neural basis of this
impairment is not well understood. The recent discovery of mirror-neurons
has led to conjecture that the inability of patients with schizophrenia to
express themselves, participate in and be attuned to social cues results
from an inability to simulate the mind of others, thus misinterpreting mean-
ings and goals of social interactions. Mirror neurons fire specifically in re-
sponse to viewing actions of others and facilitate anticipation of social
interaction. Their function can be measured using EEG recordings and cal-
culating mu wave suppression index (MSI) in bilateral sensorimotor corti-
ces as previously shown in autism spectrum disorders. Using this paradigm
we conducted a pilot study with 5 normal controls and 5 subjects with a first
episode (FE) of psychosis. Standard EEG disk electrodes were applied to
the scalp and data recorded while the subject sat in a quiet room and
watched videos on a computer screen. Videos consisted of a moving
hand, two bouncing balls, a ball being passed between people, a cigarette
being taken out of a case, a person pretending to smoke a cigarette, a series
of moving lights that correspond to a moving person and visual white noise.
Preliminary data suggests that at baseline controls have higher MSI in the
right hemisphere compared to FE subjects (0.1 vs. .04 log [condition/base-
line]). In addition, when viewing a moving hand, controls did not show
hemispheric effects, whereas FE subjects showed a deficit in right hemi-
spheric MSI (controls vs. FE, 0.1 vs. .01 log [condition/baseline] respec-
tively). Taken together, the data suggest that MSI, a measure of motor
mirror neuron activity, is altered at baseline and in response to viewing
of actions of others in subjects who have experienced a first episode of psy-
chosis. Interestingly, a specific deficit in the right hemisphere of the senso-
rimotor cortex is consistent with this region’s previously established role in
social cognition. The loss of function in this region may be a consequence of
the psychotic episode or may predate the episode representing a develop-
mental abnormality that confers future risk of developing psychosis. To
investigate this hypothesis further, we plan to test more FE subjects to in-
crease the power of our study and test subjects with a prodromal syndrome
who are at risk of developing psychosis.
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PERIADOLESCENT MATURATION OF DOPAMINE
ACTIONS IN THE PREFRONTAL CORTEX
Patricio O’Donnell1, K.-Y. Tseng2
1Anatomy and Neurobiology, University of Maryland School of
Medicine, Baltimore, MD, USA; 2Pharmacology and Experimental
Therapeutics, Rosalind Franklin University of Medicine and Science,
North Chicago, IL, USA
Several lines of evidence suggest that the prefrontal cortex (PFC) contin-
ues its maturation well into adolescence and beyond. Anatomical studies
from human and non-human primates reveal protracted changes in archi-
tecture and innervation. Dopamine fibers, in particular, as well as dopa-
mine (DA) receptors change their density during that late developmental
stage. In addition, markers of local circuit interneurons have also been
reported as changing during adolescence in monkeys. As the DA modu-
lation of local PFC circuitry may be critical for a number of high-order
functions and could be a primary element in schizophrenia pathophysi-
ology, we explored the changes in responses to DA of pyramidal neurons
and interneurons in the rat PFC with in vivo intracellular recordings and
whole-cell recordings from brain slices. D1 agonists enhance excitability
of pyramidal neurons, and effect more pronounced in slices from adult
rats. Co-activating D1 and NMDA receptors yielded persistent depolari-
zations resembling up states, but only in slices from adult rats. The DA
modulation of PFC interneurons also changed during adolescence. The
D2 agonist quinpirole switched from a negligible effect in slices from in-
fant (ie, PD < 35) rats to a strong increase in excitability in slices from
adult (PD > 55) rats. The data suggest that the ability of interneurons to
modulate pyramidal cell activity via feed-forward inhibition becomes re-
fined in the PFC during adolescence. A disruption in such maturation
could be responsible for the emergence of symptoms in conditions
such as schizophrenia.
ID: 550489
ABNORMAL PERIADOLESCENT MATURATION OF
INTERNEURON FUNCTION IN RATS WITH
A NEONATAL VENTRAL HIPPOCAMPAL LESION
Patricio O’Donnell1, K.-Y. Tseng2
1Anatomy and Neurobiology, University of Maryland School of
Medicine, Baltimore, MD, USA; 2Pharmacology and Experimental
Therapeutics, Rosalind Franklin University of Medicine and Science,
North Chicago, IL, USA
It is clear that a strong developmental component is important for
schizophrenia pathophysiology, and there is converging evidence
from human and animal studies that such developmental component
may affect primarily inhibitory interneurons in several cortical regions.
Such deficit is likely to cause abnormal behaviors in animals and symp-
toms in humans. The time course of interneuron development may
provide some cues to symptom onset, as there are several critical de-
velopmental stages, including a late maturation during adolescence.
Here we explored the physiological properties of neurons in the pre-
frontal cortex (PFC) of adult and preadolescent rats with a neonatal
ventral hippocampal lesion (NVHL) or sham controls. Whole-cell
recordings in slices revealed an increased excitability of PFC pyramidal
neurons and an abnormal maturation of fast-spiking interneurons. D2
agonists fail to excite interneurons, yielding a hyper-excitable and noisy
PFC. Thus, this model reveals an onset of abnormal excitation/
inhibition balance that matches the onset of symptoms in humans;
ie, during late adolescence.
ID: 550475
NEUROPHYSIOLOGICAL MARKERS OF INTER-
NEURON DYSFUNCTION IN (NON-GENETIC)
RODENT DEVELOPMENTAL MODELS OF
SCHIZOPHRENIA
Patricio O’Donnell, A. J. Gruber, M. Roesch,
G. Schoenbaum
Anatomy and Neurobiology, University of Maryland School of
Medicine, Baltimore, MD, USA
Prefrontal cortical interneurons have been reported as abnormal in brains
from schizophrenia patients in several postmortem studies. Many develop-
mental and even pharmacological rodent models show remarkable conver-
gence in altering cortical interneuron function. As high-frequency
oscillations in EEG or field recordings are known to be related to synchro-
nized activity in fast-spiking interneurons, and are affected in schizophre-
nia, it is possible that neurophysiological testing can reveal interneuron
dysfunction in rodent models. Here, we tested for field potential activity
in rats with a neonatal ventral hippocampal lesion (NVHL) during a behav-
ioral session in which they had to choose a reward site based on an odor cue.
During the interval between the odor and the response, the prefrontal cor-
tex (PFC) exhibited an increase in activity in the beta band (1330 Hz) in
control rats, but not in NVHL rats. Combined with our recordings in slices
showing that PFC interneurons fail to mature during adolescence in NVHL
rats, the results indicate that EEG measures can identify abnormal balance
of excitation/inhibition in the PFC of rodent models of schizophrenia with
an approach similar to what has been used in humans.
ID: 550449
MISMATCH NEGATIVITY IS ASSOCIATED WITH
GENETIC, CLINICAL, COGNITIVE, AND
FUNCTIONAL ABNORMALITIES OF SCHIZO-
PHRENIA PATIENTS
Gregory A. Light, T. A. Greenwood, J. Sprock, M. Pela,
A. Rissling, K. S. Cadenhead, N. R. Swerdlow, D. L. Braff
Psychiatry, University of California, San Diego, La Jolla, CA, USA
Schizophrenia patients have widespread deficits ranging from abnormali-
ties in sensory processing to impairments in cognition and daily living. Mis-
match Negativity (MMN) is an EEG waveform that is a probe of the
earliest automatic stages of sensory information processing and can be eli-
cited in the absence of directed attention. To assess the genetic architecture
of MMN, a candidate gene analysis was performed on 203 schizophrenia
patients and 119 controls from the UCSD Schizophrenia Program using the
UCSD/Consortium on the Genetics of Schizophrenia (COGS) custom 1536
SNP chip. The initial single marker analyses revealed significant associa-
tions with 25 of 94 carefully selected schizophrenia-related genes (empirical
P < .01). These genes included BDNF, GRIN3A, DISC1, CTNNA2,
NRG1, and ERBB4. Several of these genes also interact molecularly
(eg, NRG1 and ERBB4). Patients had MMN deficits (P < .01) which
were associated with impaired performance on tests of working memory
(P < .01), verbal recall (P < .01), and negative symptoms (P < .01).
MMN deficits were also associated with reduced performance on a compre-
hensive functional skills assessment battery (P< .05), and significantly (P<
0.01) lower ratings on several measures of functional status (eg, indepen-
dence in living situation, managing finances, Scale of Functioning, Global
Assessment of Functioning Scale). In contrast, MMN was not associated
with performance on other cognitive measures or positive symptoms.
MMN deficits reflect neural dysfunction associated with the core cognitive,
clinical, functional, and even genetic abnormalities of schizophrenia
patients.
ID: 550407
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PREPULSE INHIBITION AND P50 SUPPRESSION IN
YOUNG ADOLESCENTS AT RISK FOR PSYCHOSIS
Tim Ziermans, C. Kemner, M. Sprong, M. Magne´e, P. Schothorst,
H. van Engeland
Child and Adolescent Psychiatry, University Medical Center,
Utrecht, Netherlands
In schizophrenia response inhibition of repetitive auditory stimuli is
assumed to be disrupted by insufficient filtering of information. These
kind of sensory gating deficits have also shown to be present in patients
at risk for psychosis. However, the developmental course of these psycho-
physiological vulnerability markers is unclear and the timing of disease re-
lated changes remains unknown. In this study, we investigated auditory P50
suppression and prepulse inhibition (PPI) in a sample of young adolescents
(aged 12–18 years) at ultra high-risk for psychosis (UHR). P50 suppression
and PPI of the startle reflex were measured in UHR patients (n = 64) and
compared to a group of typically developing adolescents (n = 67), matched
for age, sex and IQ. PPI was significantly reduced in the total UHR group,
but did not distinguish between those making a transition to psychosis and
other patients. There were no group differences for P50 suppression. Our
results show that reduced PPI of the startle reflex is already present in
young adolescents at risk for psychosis. This suggests that PPI is a relatively
stable vulnerability marker, while changes in P50 suppression may only be
affected later during the illness course.
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CLINICAL AND COGNITIVE FEATURES OF EARLY
ONSET PSYCHOSIS: PILOT DATA FROM AN EARLY
PSYCHOSIS STUDY
Jean Starling1,2, A. Harris2,3, L. Williams2,3, C. Smith1,
M. Nagy3
1Psychological Medicine, Children’s Hospital Westmead, Sydney,
NSW, Australia; 2Discipline of Psychological Medicine, University
of Sydney, NSW, Australia; 3Brain Dynamics Centre, Sydney,
NSW, Australia
Background: Schizophrenia and other psychotic disorders are a major
cause of disability world wide. Much of this burden is due to cognitive
impairments, which predict functional outcome better than acute symp-
toms. The outcome is worse for younger patients, perhaps because they
are more likely to have neurocognitive abnormalities at presentation. Pos-
sible deficits include impaired social cognition and working memory, and
reduced gamma phase synchrony. Aims: To describe the clinical and neuro-
cognitive features of a small pilot cohort with early onset psychosis and to
identify differences in cognitive functioning in comparison with normal
children of the same age. Method: The subjects for this pilot study are four-
teen children and adolescents diagnosed with psychosis and fourteen nor-
mal controls matched for age, gender and years of education. The clinical
group have data from questionnaires on symptoms and premorbid func-
tioning (SCID, PSAS, RFS, PANSS, DASS, CDI, and YMRS). Subjects
and controls have data from the BRID battery of tests, including cognitive
and EEG measures. Results: The mean age at diagnosis was 13 (median 14),
and 64% were female. Fifty seven percent had affective psychosis, 39%
schizophrenia spectrum disorders and 14% Schizoaffective disorder or psy-
chosis NOS. The results of their performance on the BRID battery of tests
compared to controls is still being analysed and will be presented in this
poster.
ID: 550250
P3B AMPLITUDE REDUCTION IS NOT
PROGRESSIVE OVER THE COURSE OF
SCHIZOPHRENIA AFTER THE ONSET OF ILLNESS
Alp Ucok1, Y. K. Ergen2, M. Devrim Ucok2
1Psychiatry, Istanbul Medical Faculty, Istanbul, Turkey; 2Physi-
ology, Istanbul Medical Faculty, Istanbul, Turkey
P3b is an event-related potential that is elicited by attended, task-relevant
stimuli. Auditory P3b amplitude reduction is a widely replicated finding in
schizophrenia. The findings of cross-sectional studies concerning the effects
of duration of illness on P3b processes are contraversial. In this study lon-
gitudinal data of first-episode schizophrenia patients were evaluated to de-
termine whether the P3b abnormality is increased over the course of
schizophrenia, consistent with a progressive pathophysiological process.
Subject groups comprised 11 patients with schizophrenia (10 women)
and 14 age- and education-matched healthy controls (7 women). Schizo-
phrenia patients and healthy controls were tested on two occasions with
mean intertest intervals of 6.2 and 5.7 years, respectively. Schizophrenia
patients were at the post-acute phase of their first-episode during the initial
testing. All patients were receiving atypical antipsychotics during the first
and second evaluations. All patients, but one, met remission criteria in the
period between the two evaluations suggesting that our sample consisted of
patients with better outcome. P3b was elicited during an oddball paradigm
consisted of standard (1000 Hz, probability 0.8) and target stimuli (1500
Hz, probability 0.2). The differences in P3b amplitude and latency between
the two evaluations in patients and controls were assessed with the analysis
of variance repeated measures design. Groups showed the expected parie-
tocentral distribution of P3b (P = .001). P3b amplitudes were reduced in
patients compared to controls (P = .03). P3b amplitude was not different
between the two evaluations. Most importantly, groups did not differ in
P3b amplitude difference between the first and second evaluations. No dif-
ference was found for P3b latency. Our finding of P3b amplitude reduction
in schizophrenia patients is consistent with previous studies. Our results
suggested that P3b reduction is not progressive over the course of schizo-
phrenia after the onset of illness at least in a sample with better outcome
who are receiving atypical antipsychotics. To our knowledge, the present
study is the first to report on the longitudinal course of P3b in schizophrenia
to delineate illness progression.
ID: 550214
MISMATCH NEGATIVITY IN PRODROME, FIRST
EPISODE AND ESTABLISHED SCHIZOPHRENIA:
RELATIONSHIP WITH STIMULUS TYPE,
GENERATOR SOURCES, GREY MATTER LOSS,
AND FUNCTIONAL OUTCOME
Ulrich Schall1,2, P. E. Rasser1,2, R. Atkinson1,2, R. Fulham1,2,
K. Helmbold1, J. Todd1,2, S. Halpin1, P. Johnston3, P. T. Michie1,2,
P. B. Ward4, P. M. Thompson5,1, V. Carr1,2
1Centre for Brain and Mental Health Research, University of
Newcastle, Newcastle, NSW, Australia; 2Cognition and Connec-
tivity Research Panel, Schizophrenia Research Institute, Sydney,
NSW, Australia; 3Swinburn University of Technology, Melbourne,
VIC, Australia; 4Schizophrenia Research Unit, University of New
South Wales, Sydney, NSW, Australia; 5Laboratory of Neuro
Imaging, University of California, Los Angeles, CA, USA
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Mismatch negativity (MMN) is an early negative component of an event
related potential and considered a robust biological marker of schizophre-
nia. We recorded MMN in response to duration, frequency and intensity
deviance in 18 schizophrenia subjects and 18 pair-wise age- and gender-
matched healthy subjects. Patients were rank-ordered according to their
socio-occupational function levels. High-resolution structural magnetic
resonance images were acquired to generate average cerebral cortex models
using cortical pattern matching. MMN amplitude was found to be reduced
in schizophrenia patients and correlated with their reduced socio-occupa-
tional function levels. Only in patients, grey matter reduction in cortical
areas subserving auditory processing, motor organization and executive
function was correlated with reduced MMN amplitude in response to fre-
quency deviance. In a separate study, MMN generator source data were
derived from LORETA constrained source localisation performed on
current dipoles that were oriented perpendicular to the cortical surface
in realistic head models (CURRY). Generator sources were largely re-
stricted to the temporal lobes and reduced for duration deviance in young
people with a recent diagnosis of schizophrenia. Our preliminary data from
an ultra high-risk cohort of 72 referrals to a specialized mental health ser-
vice in Newcastle further suggests significantly reduced MMN to duration
deviance for those individuals who subsequently make a transition from
prodrome to schizophrenia. Our findings suggest a close association of
MMN to frequency deviance with cerebral pathology and clinical outcome
in established schizophrenia while reduced MMN to duration deviance
appears to be associated with the prodrome and first-episode phase of
the disorder. Supported by the National Health and Medical Research
Council of Australia and the Hunter Medical Research Institute.
ID: 550210
ELECTROPHYSIOLOGICAL CORRELATES OF
EMOTIONAL EXPERIENCE IN SCHIZOPHRENIA
William Powers Horan1,4, J. K. Wynn1,4, A. M. Kring2,
R. F. Simons3, S. M. Crosby1,4, P. Nori1,4, L. Mancini1,4,
C. Tripp1,4, M. F. Green1,4
1Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA,
USA; 2Psychology, UC Berkeley, Berkeley, CA, USA; 3Psychol-
ogy, University of Delaware, Newark, DE, USA; 4Psychiatry, VA
Greater Los Angeles Healthcare System, Los Angeles, CA, USA
Individuals with schizophrenia have repeatedly been found to report nor-
mal levels of pleasure when directly exposed to evocative stimuli. However,
little is known about the neural correlates and time course of emotional
experience in schizophrenia. Following a translational research approach,
this study examined performance on a well-validated affective picture view-
ing task that elicits a characteristic pattern of Event Related Potentials
(ERPs) in healthy individuals that differs between emotional versus non-
emotional images. 38 stabilized outpatients and 37 healthy were shown
a set of 60 standardized pictures of pleasant, unpleasant, and neural images
for 6000 ms each while ERP’s were recorded. Participants also provided
reports of their emotional responses to the pictures. Replicating prior re-
search, the healthy controls self-reported emotional responses that matched
the intended valences of the pictures and they demonstrated significantly
larger P300s and Late Positive Potentials (LPPs; 500–100 ms post-picture
onset) for pleasant and unpleasant pictures compared to neutral pictures.
The patients’ pattern of self-reported emotions and P300s were similar to
those found in controls. However, there was a significant group x valence
interaction for LPPs (F2,72 = 3.30, P< .05), indicating that patients showed
a smaller difference in LPPs between pleasant versus neutral pictures than
did controls. These findings support the validity of self-reports of normal
emotional responses to evocative stimuli in schizophrenia. They also sug-
gest that individuals with schizophrenia may show disturbances in affective
chronometry: while the similar mid-latency ERP’s (P300s) across groups
suggest intact attentional allocation to emotional stimuli in schizophrenia,
the difference in LPPs suggest a disruption in sustained attentional process-
ing of emotional stimuli.
ID: 550101
ELECTROPHYSIOLOGICAL CORRELATES OF
EMOTION ANTICIPATION IN SCHIZOPHRENIA
Jonathan K. Wynn1,2, W. P. Horan2,1, R. Simons4, A. Kring3,
P. Nori2, L. Mancini2, S. Crosby2, C. Tripp2, M. F. Green2
1MIRECC, VA Greater Los Angeles Healthcare System, Los
Angeles, CA, USA; 2Psychiatry and Biobehavioral Sciences, UCLA,
Los Angeles, CA, USA; 3Psychology, University of California,
Berkeley, Berkeley, CA, USA; 4Psychology, University of
Delaware, Newark, DE, USA
Schizophrenia patients report intact in-the-moment experiences of emo-
tional events. However, initial research based on self-report data suggests
that individuals with schizophrenia show disturbances during the anticipa-
tion of forthcoming emotional events, particularly those involving pleasur-
able experiences. The current study examined the electrophysiological
correlates of emotional anticipation using a cued, reaction-time contingent
emotional picture viewing task. EEG data from 38 schizophrenia outpa-
tients and 34 healthy controls were collected during an emotional anticipa-
tion task. On each trial, participants were first shown one of three visual
cues (þ, , O) for 3000 ms, which indicated whether they would subse-
quently be shown a positive, negative or neutral picture. Participants
then made a button press as quickly as possible after cue-offset, which de-
termined how long the picture was shown (ie, a fast response resulted in
a 5000 ms picture presentation ; a slow response resulted in a 500 ms picture
presentation). A 4000 ms delay interval preceded picture presentation. Two
anticipatory EEG events were analyzed: the 500 ms prior to the button
press (termed Readiness Potential, RP) and the 500 ms prior to the onset
of the picture (termed Stimulus Preceding Negativity, SPN). For the RP,
analyses revealed a significant group main effect, F1,70 = 7.40, P< .01, with
the RP for the controls being significantly larger than that for the patients (-
9.2 lV versus 5.4 lV). There were no other significant main effects or
interactions. For the SPN, analyses revealed a significant group main effect,
F1,70 = 10.57, P< .01, with the SPN for the controls significantly larger than
that for the patients (5.4 lV versus 2.9 lV). There were no other sig-
nificant main effects or interactions. The current electrophysiological find-
ings provide further support for general disturbances in emotional
anticipation in schizophrenia. Emotion anticipation is an important aspect
of adaptive approach and avoidance behavior, and anticipatory dysfunc-
tions may contribute to the hedonic and motivational deficits commonly
seen in schizophrenia.
ID: 549985
ERP’S PATTERN AND PROGNOSTIC IN
SCHIZOPHRENIA
Albert Marie Boxus1, P. Nuss2
1Psychiatry, ASM, Limoux, France; 2Psychiatry, CHU St. Antoine,
Paris, France
Objective: In a previous study*, we showed that clinical improvement with
SGA in schizophrenia is associated both cognitive change and by P300 and
P50 suppression. The aim of this study was to investigate an ERP’S pattern
associated with a good prognostic in schizophrenia all validated by PANNS
and GAF at 8 months. Methods: Fifty-five individuals (32 males and 23
females; mean age = 35.9) meeting DSM-IV criteria for schizophrenia, ad-
mitted for an acute relapse, were included in the study and observed within
eight months period from 2005/10 to 2006/07. They were treated with the
following antipsychotics (mean daily dosage) : aripiprazole (13.75 mg), ris-
pe´ridone (5.06 mg), olanzapine (14.12 mg), amisulpride (1000 mg) and
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clozapine (150 mg). Psychotropic drugs were prohibited except for benzo-
diazepines, zolpidem and anticholinergic medications. Clinical and electro-
physiological evaluations were performed before the start of treatment (T1)
and after remission (T2). Psychopathology was measured by the Positive
and Negative Syndrome Scale (PANSS). GAF was evaluated in T2.
Results: All patients are improved in T2. We separated them in 2 groups:
under and over 50% PANSS score reduction. In the ERP’S:the reaction
time P300 reduction, the increase of the amplitude of de P300 and the omis-
sions errors reduction are improved in the same way than the PANSS score
reduction and the increase of the GAF after treatment. Conclusions: Re-
action time P300 reduction, increase of the amplitude of P300 and omis-
sions errors reduction could constitute an ERP’S pattern for a good
prognostic in schizophrenia. These results need to be confirmed by a larger
scale and longer duration study. *The effect of second generation antipsy-
chotic drugs on event related potentials in schizophrenia: a preliminary
study: Albert BOXUS: Poster Nr 448 APA 2007 SAN DIEGO.
ID: 549876
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USING TMS-EVOKED POTENTIALS TO PROBE
NEURAL RESPONSE MECHANISMS IN
SCHIZOPHRENIA
Bruce I. Turetsky, P. Crutchley, M. Bhati
Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
Studies of the neuropathology of schizophrenia have implicated a failure of
appropriate neuronal inhibition and a disturbance of cortical connectivity
as two potential models of the illness. However, direct tests of these mech-
anisms in patients have been limited by the practical constraints of in vivo
clinical research, and empirical support has largely been indirect and infer-
ential. Recent developments in the use of transcranial magnetic stimulation
(TMS) as a neurophysiological probe of cortical activity have suggested
a means to test the functional integrity and responsivity of neural circuits
in a more direct manner. By combining single-pulse and paired-pulse TMS
with simultaneous multi-channel evoked potential recordings, we are able
to assess cortical reactivity and inhibitory and facilitative mechanisms
within localized brain areas. Using lagged cross-correlations of evoked ac-
tivity at different electrode sites, we can also assess neural connectivity
across brain regions. This can be all be done without requiring the subject
to attend to any sensory stimuli. This novel methodology has only been
applied to a limited extent in the study of healthy individuals, and even
less in the study of clinical populations. We will describe this methodology,
including our strategy for eliminating TMS pulse artifacts using Indepen-
dent Components Analysis. Our initial data, applying TMS over the left
prefrontal cortex, suggest the following: 1) Schizophrenia patients exhibit
abnormally sustained responses to single TMS pulses; 2) Control subjects
exhibit both cortical inhibition and facilitation following appropriate
paired-pulse stimulation; 3) Patients exhibit relatively normal cortical in-
hibition, but fail to exhibit cortical facilitation; 4) Control subjects exhibit
strongly correlated activity at homologous sites over the contralateral hemi-
sphere; 5) Patients do not show strongly correlated cross-hemisphere activ-
ity. The dual findings of sustained baseline excitation and failed prepulse
facilitation, in patients, are consistent with a model of tonically increased
glutamatergic tone in localized neuronal assemblies; this focal hyper-excit-
ability is associated with disrupted functional connectivity across brain
regions. These preliminary findings demonstrate that TMS-evoked poten-
tials hold tremendous promise as an in vivo method to investigate funda-
mental aspects of the pathophysiology of schizophrenia.
ID: 54971
SENSORIMOTOR GATING IN FIRST-EPISODE,
ANTIPSYCHOTIC-NAI¨VE SCHIZOPHRENIA
PATIENTS: A LONGITUDINAL STUDY
Bodil Aggernaes, B. Oranje, B. Glenthoj
Center for Neuropsychiatric Schizophrenia Research, University
Psychiatric Center Glostrup, Copenhagen, Denmark
Deficits in information processing appear to be core features in the patho-
physiology of schizophrenia. Prepulse inhibition of the startle response (PPI)
is an operational measure of sensorimotor gating. In clinical studies, gener-
ally no effect has been found on PPI in schizophrenia patients treated with
typical antipsychotics, whereas some studies found improved PPI in patients
treated with atypical compounds, while others did not. These inconsistencies
might be due to differences in binding characteristics of the various com-
pounds used, in particular to their affinity for the D2 dopaminergic receptor.
Alternatively, it has been suggested that PPI deficits are stable vulnerability
indicators, insensitive to medical treatment. Since most previous studies were
cross-sectional, longitudinal studies on drug-naı¨ve first-episode schizophre-
nia patients are warranted, to avoid the possible confounding of antipsy-
chotic medication and course of illness. In the present longitudinal study,
PPI of 29 antipsychotic-naı¨ve, first-episode schizophrenia patients was com-
pared to that of 30 age and sex matched healthy controls at baseline, and after
six months of treatment with the atypical antipsychotic quetiapine. Since
a gender effect was found and relatively few females were included, it was
decided to use the male data only. Consistent with literature, the patients
at baseline showed significantly less PPI than the healthy controls. At
follow-up however, PPI from the 11 patients who completed the 6 months
treatment with quetiapine, did not differ significantly from that of the
healthy controls. Since the antipsychotic-naı¨ve, first-episode schizophrenia
patients showed significantly less PPI compared to the healthy controls at
baseline, this indicates that PPI deficits are present at an early stage in
the development of schizophrenia. Furthermore, the results suggest that
Results
PANSS
score
reduction
Patients
number
GAF
score
T2
Reaction
time P300
reduction
Increase
in
Amplitude
P300 lvolt
Latency
P300
reduction
lvolt
False
alarms
reduction
Omission
reduction
errors
P50
suppression
30 to 40% 10 64.8 10.3 0.5 9 1.4 0.3 3
40 to 50% 22 69.3 2 2.5 4.3 0.3 1 2
50 to 60% 18 71.9 19.6 2.1 6.3 0.5 1.2 0
More than
60%
5 74.2 8.1 5.1 3.3 2.4 2.8 0
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PPI deficits in schizophrenia can be normalized by six months of treatment
with quetiapine.
ID: 549589
DEFICITS IN WORKING MEMORY PERFORMAN-
CES IN PEOPLE WITH CLINICAL HIGH-RISK FOR
PSYCHOSIS: ERP EVIDENCE
Su Young Lee1,2, K. R. Kim1,2, J. Y. Park2,3, H. H. Cho2,
J. S. Park1,2, H. K. Koo2, J. I. Kang2,4, E. Lee1,2, S. K. An1,2
1Psychiatry, Yonsei University College of Medicine, Seoul, South
Korea; 2Section of Affect and Neuroscience, Institute of Behavioral
Science in Medicine, Yonsei University College of Medicine, Seoul,
South Korea; 3Psychiatry, Gongju National Hospital, Gongju-si,
South Korea; 4Psychiatry, Ilsan Hospital, National Health Insur-
ance Corporation, Goyang-si, South Korea
The aim of this study was to investigate whether people with clinical high-
risk for psychosis show more rapid decline of P3 amplitudes with increasing
working memory load of verbal and spatial n-back tasks. People with clin-
ical high-risk for psychosis (CHR), schizophrenia patients (SPR) whose du-
ration of illness is less than 5 years and normal controls (NC) were recruited.
Subjects were asked to perform verbal and spatial 0/1/2-back tasks. Re-
peated measures ANOVA with PROC mixed model were performed. P3
amplitudes of 0-back were larger than those of 1- and 2-back condition
(F = 12.8, P < .001). CHR as well as SPR showed smaller amplitudes of
P3 than that of NC (F = 13.8, P < .001). The amplitudes of P3 in CHR de-
clined more rapidly than those of NC when working memory load is
increased (F = 4.6, P = .001). These findings provide the neurophysiological
evidence that the working memory deficits may be already present in pro-
dromal phase of psychosis. The associations of declined P3 amplitudes of
working memory and psychopathology, social and role functioning will
be discussed.
ID: 549427
DURATION MISMATCH NEGATIVITY IN
PRODROMAL AND FIRST-EPISODE
SCHIZOPHRENIA
Carol Jahchan1, K. S. Cadenhead2, D. L. Braff2, G. A. Light2
1Joint Doctoral Program in Clinical Psychology, San Diego State
University/University of California–San Diego, San Diego, CA,
USA; 2Psychiatry, University of California, San Diego, San Diego,
CA, USA
Background: Deficits in the automatic sensory discrimination as indexed by
mismatch negativity (MMN) are well documented in chronic schizophrenia
patients. The majority of previous studies, however, failed to detect MMN
impairments in the early stages of the illness. In fact, six out of seven studies
did not find a reduced pitch or duration MMN in patients with first-episode
schizophrenia. The only study (Brockhaus-Dumke et al., 2005) that exam-
ined MMN in the schizophrenia prodrome reported a trend for at-risk
patients to exhibit deficits on this paradigm. Methods: Nine at-risk individ-
uals (AR) and 15 patients with first-episode schizophrenia (FE), recruited
as part of the UCSD CARE (Cognitive Assessment and Risk Evaluation)
program, and 39 age-matched normal comparison subjects (NC) under-
went duration-deviant MMN testing (1000 Hz tones, standards: 50
msec, P = .90; deviants: 100 msec, P = .10) in the UCSD Schizophrenia
Program Laboratory. Results: Group differences were present in the am-
plitude of the MMN to duration deviants at fronto-central electrodes
(F2,60 = 4.60, P = .014). In contrast to previous reports showing no
MMN deficits in FE subjects, significant and large effect size (d = 0.85)
MMN reductions were observed in the FE (M = 2.03, SD = 1.64) relative
to the NC (M = 3.85; SD = 2.12) group. Consistent with Brockhaus-
Dumke et al.’s findings, the AR group’s MMN amplitudes (M = 3.32;
SD = 1.81) were intermediate between those of the NC group and the
FE group, but those differences did not reach statistical significance (d =
0.26). Conclusions: In contrast to previous studies, robust and large effect
size duration-deviant MMN deficits were observed in first-episode patients
with schizophrenia. Individuals at risk for developing schizophrenia
showed small and non-significant reductions relative to age-matched nor-
mal comparison subjects. We will assess MMN in a larger sample of at-risk
individuals and further explore the association between MMN and the de-
mographic, clinical, cognitive, and functional characteristics of the sample.
Future studies are needed to delineate the nature of MMN abnormalities
early in the course of schizophrenia and to clarify whether those deficits
reflect premorbid neuropathology or ongoing disease processes associated
with illness progression. Supported by MH60720, MH79777, NARSAD,
and the VISN-22 Mental Illness, Research, Education, and Clinical Center.
ID: 549205
A NEURAL ENSEMBLE ANALYSIS OF COGNITIVE
FAILURE
Jeremy Seamans
Psychiatry, University of British Columbia, Vancouver, BC, Canada
It is now well established that dysfunction of the prefrontal cortex (PFC) is
a key aspect of the cognitive impairments in schizophrenia. Patients exhibit
significant deficits in many aspects of cognition that rely on the PFC in-
cluding working memory, attention and executive function. Conceivably,
these deficits could occur for a number of reasons or there may be a single
underlying problem in PFC networks that affects multiple processes. As
a first step in addressing this issue we have begun to investigate the network
dynamics associated with the commission of errors on tasks of working
memory and executive function in rats. Based on multiple single-unit
recordings we found that ensembles of PFC neurons tracked each separable
cognitive component of the tasks by entering distinct and coherent activity
states. The organization and coherence of network activity states was
largely absent on trials where rats made numerous errors and the break-
down was especially evident at the choice points of the task but not
when the information was acquired or maintained over a delay. There is
also accumulating evidence that the dopamine (DA) modulation of the
PFC is crucial for optimal cognitive performance and this modulation
may be altered in schizophrenia. The PFC DA system is believed to exhibit
an inverted-U dose response curve such that too little or too much DA
becomes detrimental to performance. In order to examine the effects of arti-
ficially pushing DA levels to different parts of the curve, we injected rats
with either the catecholamine releaser amphetamine or the COMT inhibitor
Tolcapone (Tasmar). While Tolcapone improved working memory perfor-
mance, higher doses of amphetamine impaired it. Recordings of multiple
single-unit activity showed that the higher doses of amphetamine decreased
the ensemble organization making the overall network of recorded neurons
less coherent and synchronized across all task epochs. This was a different
dynamic than what was observed when untreated rats committed errors and
suggested that pushing the DA system to the ‘far end’ of the inverted -U
curve produces large-scale cortical disorganization. The next step is to de-
termine how network dynamics within the PFC change in the context of
popular animal models of schizophrenia.
ID: 548748
DURATION AND PITCH MMNS IN
SCHIZOPHRENIA AND THEIR RESPONSE TO
ACUTE NICOTINE TREATMENT
Louise Dulude1, A. Labelle2, V. *Knott2,3
1Psychology, University of Ottawa, Ottawa, ON, Canada;
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While prevalence rates of smoking are reported as high as 90% in schizo-
phrenia (SZ), the reasons for increased cigarette use in this disorder are not
well understood. Nicotine is known to enhance cognition, including early
sensory and later attention-dependent processes, which are impaired in SZ.
Mismatch negativity (MMN) is a neurophysiologic index of pre-attentive
acoustic change detection that has been found deficient in SZ and has
shown sensitivity to smoking doses of nicotine. The objective of this study
was to compare MMNs elicited by both tone duration and pitch deviants in
smokers with and without SZ and to examine the acute effects of nicotine
on MMNs in SZ. Participants included 12 stable patients with SZ and 12
non-psychiatric controls, all cigarette smokers who were smoking a mini-
mum of 15 cigarettes per day. Mid-line (Fz, Cz, Pz) event-related potential
(ERP) recordings within both a duration-MMN paradigm with 100 ms
standard tones (95%) and 50 ms deviant tones (5%) and a pitch-MMN par-
adigm with 1000 Hz standard tones (95%) and 1100 Hz deviant tones (5%)
were acquired in controls, who were assessed in one session, and patients,
who were assessed in two sessions involving, double-blind randomized ad-
ministration of placebo (0 mg) and nicotine gum (4 mg). Relative to con-
trols, MMN amplitudes of patients were significantly reduced in both
duration and pitch paradigms. Nicotine in patients did not alter pitch
MMNs but it increased the amplitude of duration MMNs to a level com-
parable to that seen in controls. These findings suggest that nicotine
modulation of aberrant central mechanisms underlying early detection
of auditory changes in SZ may be feature specific and further studies
are required to elucidate its role in relation to smoking behavior in SZ.
ID: 548055
EVENT RELATED POTENTIAL PATTERNS
REFLECTING DYSFUNCTIONAL FACIAL AFFECT
PROCESSING IN SCHIZOPHRENIA PATIENTS
Seug-Hwan Lee1,2, E. Kim2
1Psychiatry, Inje Univ. Ilsan Paik Hospital, Goyang, South Korea;
2Psychiatry, Clinical Emotion and Cognition Research Laboratory,
Goyang, South Korea
This study was designed to clarify the difference of facial affect processing
between patients with schizophrenia and normal controls. Three ERP com-
ponents were chosen as an index of three separate stages in the emotion
identification processing: P100 as a basic visual processing, N170 as a facial
structural encoding, and N250 as an facial affect decoding. Forty-two
patients who met the DSM-IV criteria for schizophrenia and 36 normal
controls were recruited. ERPs were recorded using 64 channels while par-
ticipants were presented with pictures of faces showing three different emo-
tional states such as happy, neutral, and fear. Participants were instructed
to press the button when they see the emotional face. Mean amplitude of
P100 response was not different between schizophrenia patients and normal
controls whereas the amplitudes of both N170 and N250 in patients were
significantly smaller compared to normal controls (F1,76 = 9.615, P = .003
for N170; F1,76 = 16.854, P < .001 for N250). In within group analysis, the
amplitudes of N170 and N250 of patients were significantly smaller on the
fear condition. Mean peak latency was not different across groups in nei-
ther P100 nor N250. However, the significantly shorter N170 latency was
found in schizophrenia patients compared with normal controls(F1,76 =
8.195, P = .005). This study suggests that the basic visual processing is
not different between schizophrenia patients and normal controls. But fa-
cial structural encoding and facial affect decoding are dysfunctional in
schizophrenia patients compared with normal control.
ID: 546712
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EVENT-RELATED SPECTRAL POWER DEFICITS
DURING SEMANTIC PROCESSING IN
SCHIZOPHRENIA
Michael Kiang1, M. Kutas2,3, D. L. Braff4, J. L. Hsu5, G. A. Light4
1Psychiatry and Behavioural Neurosciences, McMaster University,
Hamilton, ON, Canada; 2Cognitive Science, University of Cali-
fornia, San Diego, La Jolla, CA, USA; 3Neurosciences, University
of California, San Diego, La Jolla, CA, USA; 4Psychiatry, Uni-
versity of California, San Diego, La Jolla, CA, USA; 5Neurology,
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
Background: Schizophrenia patients exhibit abnormal electroencephalo-
graphic (EEG) N400 event-related potential (ERP) responses to semanti-
cally related materials. We investigated whether event-related EEG
spectral power changes during semantic processing are also abnormal in
schizophrenia; and if so, the extent to which they are associated with
N400 abnormalities. Methods: The EEG was recorded from 16 schizophre-
nia patients and 16 normal control participants (NCPs), as they viewed
prime words, followed after 750 ms by related (eg, METAL > STEEL)
or unrelated (DONKEY > PURSE) target words, or nonwords (DRESS
> ZORES). Participants’ task was to indicate whether or not the target was
a word, via delayed button-press. Event-related spectral perturbation
(ERSP) was calculated for primes and targets, from 0–750 ms post-stim-
ulus onset and between 1–50 Hz. Results: Across all participants, words
elicited increased power from 1–15 Hz from 50–200 ms, albeit less so in
patients relative to NCPs for related targets. Across all participants, words
elicited decreased power from 1–20 Hz from 200–750 ms. Between 600–750
ms Hz, power decreases from 1–20 Hz were larger for unrelated versus re-
lated targets, but only in NCPs; in patients, larger power decreases for re-
lated targets correlated with disorganized symptoms. Overall, ERSP
deficits did not correlate with N400 abnormalities in patients. Conclusions:
Schizophrenia patients’ abnormally attenuated early power increases for
related targets may result from deficient use of primes to predict perceptual
features of upcoming related words. In the post-N400 interval, patients
exhibited deficits in modulating power decreases to targets as a function
of relatedness to primes, reflecting the propensity of more disorganized
patients to process related targets more like unrelated ones. ERSP and
N400 ERP abnormalities in patients, however, were not associated, impli-
cating distinct pathophysiological processes.
ID: 541887
DISTINCT NEURAL GENERATORS OF SENSORY
GATING IN SCHIZOPHRENIA: BASIC
MECHANISMS AND ATTENTIONAL EFFECTS
Terrance Williams1,2, C. M. Yee1,2, K. H. Nuechterlein1,2,
K. L. Subotnik1
1Psychiatry and Biobehavioral Sciences, University of California at
Los Angeles, Los Angeles, CA, USA; 2Psychology, University of
California at Los Angeles, Los Angeles, CA, USA
Attentional and perceptual anomalies observed in schizophrenia have been
associated with underlying sensory gating deficits. Despite progress in iden-
tifying the neural generators contributing to P50 and its suppression,
a prominent measure of sensory gating, the neuroimaging methods utilized
and the results obtained have been quite varied. Through the implementa-
tion of electroencephalographic (EEG) source analysis, the current study
was designed to clarify the neural sources involved in the basic P50 suppres-
sion effect and its attentional modulation during a paired-stimulus design.
Results obtained from healthy individuals, recent-onset schizophrenia
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patients, and chronic schizophrenia patients showed involvement of a neu-
ral network, consisting of the hippocampus, thalamus, dorsolateral pre-
frontal cortex (DLPFC) and superior temporal gyrus (STG), in the
generation of P50, its suppression and modulation by attention. P50 sup-
pression in healthy participants was positively correlated with hippocampal
and, to some extent, DLPFC activity. This pattern of relationships did not
extend to schizophrenia patients, such that recent-onset patients showed
a positive correlation between DLPFC activity and the P50 suppression
ratio, and chronic patients exhibited no associations. When healthy partic-
ipants directed voluntary attention to the first stimulus of a pair, thalamic
activity was positively correlated with the P50 suppression ratio whereas no
significant correlations were detected with any of the brain structures in the
patient groups, despite improvements in P50 suppression. When healthy
individuals directed attention to the second stimulus, suppression was
disrupted and associations involving the hippocampus, DLPFC and thal-
amus were no longer evident. Similar to the baseline condition, recent-onset
patients exhibited a positive correlation between DLPFC activity and the
P50 ratio score while chronic patients showed no relationships. The current
results support hippocampal and potentially DLPFC involvement in the
basic P50 suppression effect in healthy individuals. In schizophrenia
patients, the pattern of results is consistent with the presence of hippocam-
pal abnormalities as reflected by P50 deficits beginning with the early stage
of illness, whereas DLPFC involvement appears to deteriorate over the
course of schizophrenia. Results obtained during attentional modulation
of P50 further implicate disturbances in functional connectivity in
schizophrenia.
ID: 550842
COGNITIVE-PERCEPTUAL AND INTERPERSONAL
FEATURES OF SCHIZOTYPY ALIGN WITH
DISTINCT AUDITORY ERP ABNORMALITIES
Jason Karl Johannesen1,2, B. F. O’Donnell3,4, A. Shekhar4,
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Schizotypy is conceptualized as a dimension of liability to schizophrenia,
characterized by similar but milder variants in perceptual, interpersonal,
and cognitive function. These features of schizotypy are detectable in
the general population and, at high levels, may define a latent class who
exhibit neurophysiological traits of the schizophrenia phenotype. This
study tested the hypothesis that individuals high in schizotypy express def-
icits similar to schizophrenia on event-related potential (ERP) measures of
sensory (N100) and attentional (P300) processing. Furthermore, we sought
to clarify how the Cognitive-Perceptual, Interpersonal, and Disorganiza-
tion factors of schizotypy, described by Raine and colleagues (1994), dif-
ferentially relate to these neurophysiological features. Sixty chronic
schizophrenia (SZ) and 69 healthy community volunteers, screened for
Axis I and Axis II disorders, completed the Schizotypal Personality Ques-
tionnaire (SPQ) and a two-tone auditory oddball task. ROC curves were
used to identify the cut point in each SPQ factor score distribution at which
50% of healthy subjects were classified as SZ (high schizotypy) and 50% as
normal (low schizotypy). High and low schizotypy subgroups were then
compared to the SZ sample on N100 (standard tones) and P300 (target
tones) measures by MANCOVA with age and SPQ total entered as cova-
riates. Main group comparisons replicated usual findings of N100 and P300
amplitude reductions and prolonged P300 latency in SZ. Schizotypy sub-
groups classified by Cognitive-Perceptual factor scores differed on N100
amplitude only, with high schizotypy intermediate to, and significantly dif-
ferent from, low schizotypy and SZ. Conversely, subgroups classified by
Interpersonal factor scores differed significantly in P300 amplitude, with
high schizotypy intermediate to low schizotypy and SZ. No appreciable dif-
ferences were observed between high and low schizotypy subgroups clas-
sified by either SPQ total or by Disorganization factor scores. These
results are consistent with previous evidence for auditory ERP abnormal-
ities in schizotypy, which appear to represent an intermediate point on the
continuum from normalcy to schizophrenia. Importantly, results allude
to distinct neurophysiological bases for two domains of schizotypy, with
Cognitive-Perceptual features associated with basic sensory/attentional
processing and Interpersonal features with more complex, context-relevant,
information processing deficits.
ID: 551910
COMPARING ELECTROPHYSIOLOGICAL ENDO-
PHENOTYPES IN SCHIZOPHRENIA AND BIPOLAR
DISORDER FAMILIES
Gunvant K. Thaker1,2, C. A. Tamminga2, E. Ivleva1, L. E. Hong1,
I. Wonodi1, A. Moates2
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The use of alternative phenotypes that index specific, heritable neurophys-
iological deficits associated with psychosis risk provide an approach to ex-
plore the extent of etio-pathophysiologic overlap between schizophrenia
(SZ) and bipolar disorder (BD). Several such distinct neurophysiological
deficits have been identified including abnormalities in smooth pursuit
eye movements (SPEM), pre-pulse inhibition (PPI), P50 gating, error
rate in antisaccade task, oculomotor delayed response (ODR), as well
impairments in several cognitive domains. In a set of studies we (1) exam-
ined to what extent these different physiological measures are independent
of each other. This was carried out in a Baltimore sample that included 98
families of schizophrenia and 23 families of healthy control probands.
Results suggest that SPEM, P50 gating, PPI and saccadic eye movement
measures are independent domains of neurophysiological deficits. (2) In
the same sample, measurements of SPEM and P50 gating were refined
and heritability estimates examined. SPEM measure was refined by covertly
stabilizing target image on the fovea thus isolating the predictive response.
We are in the process of analyzing data to obtain heritability estimates of
the refined SPEM measure. In the paired-click paradigm, we deconstructed
the single-trial gating response in to different frequency bands and noted
that the gating of alpha-theta band responses significantly separated SZ
probands and their 1st degree relatives from the healthy control subjects.
The heritability estimates associated with alpha-beta gating in SZ and con-
trol families ranged from 0.49–0.83, which were much higher than the tra-
ditional P50 gating measure. (3) These refined SPEM and sensory gating
measures as well as PPI and saccadic eye movement measures were exam-
ined in another family sample collected in Dallas that included families of
both SZ and BD probands. Preliminary analyses suggest that many of the
neurophysiological impairments observed in SZ families are also present in
BD families.
ID: 551896
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Deficits in neurocognition and social behavior are well-documented fea-
tures of schizophrenia. There is evidence to suggest that cognitive impair-
ment contributes to problems in social functioning, but direct correlations
between these domains are modest and inconsistent. Social cognition has
received some empirical support as a mediator between these constructs, yet
there have been few investigations to date of the underlying neural pro-
cesses associated with socially-relevant stimuli and behavior. The recent
discovery of the mirror neuron system has provided a useful starting point
for describing brain activity involved in the interpretations of other’s
actions. This study examines whether error-related negativity (ERN), an
event-related potential (ERP) that follows the execution of an error on
a task and that has been consistently found to be reduced in amplitude
among schizophrenia patients, might reflect activity involved in the pro-
cessing of error-related activity of others and whether this activity has rel-
evance for social processing and functioning. In this study, schizophrenia
patients and psychiatrically healthy controls performed the flanker task
and then observed a confederate perform the same task. Participants
also completed measures of neurocognition, social cognition, community
social functioning, and symptomatology. It was hypothesized that 1)
schizophrenia patients would show reduced ERN amplitude compared
to controls while executing and observing the task, 2) ERN activity would
be distinguishable from activity of the primary motor cortex as indexed by
the lateralized readiness potential (LRP), 3) deficits in observational ERNs
would be related to impaired social cognition and social functioning. Pre-
liminary analyses suggest the presence of a robust ERN in control subjects
and reduced differentiation of activity following errors and correct
responses in patients while performing the task. During observation, al-
though there were apparent morphological group differences and a small
differentiation between correct and error trials, no significant group differ-
ences were observed. The relationship of the observation ERN with the
LRP, social cognition, social functioning and symptoms of schizophrenia
and the implications of this research will be discussed.
ID: 551860
EXCITATORY-INHIBITORY BALANCE AND
MYELIN SIGNALING DETERMINE CRITICAL
PERIOD TIMECOURSE
Takao K. Hensch1,2, M. Fagiolini1, H. Morishita1
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Much of our adult behavior reflects the neural circuits sculpted by experi-
ence in infancy and early childhood. At no other time in life does the sur-
rounding environment so potently shape brain function. An understanding
of how this plasticity waxes and wanes with age carries an impact far be-
yond neuroscience, including education policy, therapeutic approaches to
developmental disorders or strategies for recovery from brain injury in
adulthood. Our research aimed at the interface between cell biology and
neuroscience has achieved the first direct control over critical period timing
in any system (Hensch 2005). Strikingly, manipulation of inhibitory trans-
mission in the neocortex can delay the amblyopic effects of monocular vi-
sual deprivation (by gene-targeted reduction of GABA synthesis) or
accelerate plasticity onset (by cortical infusion of a positive GABA receptor
modulator, diazepam). Remarkably, several lines of evidence now indicate
that a specific, local inhibitory circuit (parvalbumin-positive basket cells)
may drive critical period onset in mouse visual cortex. Downstream of
this GABA trigger lies an extracellular proteolytic cascade (tPA-plasmin)
which mediates the enduring structural reorganization of cortical circuits.
Ultimately, these changes become fixed to consolidate plasticity. Myelin-
related factors and Nogo receptor (NgR) signaling, a major inhibitor of
CNS regeneration following axonal injury, contribute to the inability to
recover from amblyopia in the adult primary visual cortex. Indeed, we
find the NgR 1 knockout mouse to be the first animal model which spon-
taneously recovers from amblyopia simply by reopening the deprived eye.
Microarray profiling and anatomical studies of human post-mortem tissue
now implicate the same mechanisms that regulate critical period onset (par-
valbumin cells) and closure (myelin-NgR signaling) in the visual cortex as
more broad contributors to the etiology of cognitive and psychiatric disor-
ders in adulthood. We consider the unexpected possibility that schizo-
phrenic symptoms may reflect excessive and enduring brain plasticity
due to a failure to close early critical periods.
ID: 551833
THE EFFECT OF COLD PRESSOR STRESS ON P50
GATING: IMPLICATIONS FOR SCHIZOPHRENIA
RESEARCH
Sherrie DeAnna All1,2, A. M. Hartzell1, D. Charles1, R. J. Erwin1
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Schizophrenia Research—UBHC, University of Medicine and
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The P50 auditory sensory gating deficit has received considerable attention
as a candidate endophenotype of schizophrenia and as a target of new drug
development. Furthermore, recent meta-analyses suggest that this deficit
has one of the highest effect sizes for differentiating people with schizophre-
nia from controls; however, these effects have been called into question as
reported effect sizes appear to vary. Furthermore, temporary impairments
in P50 expression and suppression can occur in practically anyone, and such
transient disruptions are thought to result from acute autonomic activa-
tion, which can create further variability in effect sizes. Most studies report
that acute stress leads to S2 suppression impairment in healthy adults.
However, some evidence suggests that S1 amplitude may also be reduced
by stress. The current study aimed to replicate and extend the one previous
study of cold pressor test (CPT) induced disruption of P50 gating in healthy
controls, using a large sample size in an attempt to identify potentially la-
tent S1 effects and to better characterize the relationship between P50
disruption and psychophysiological measures of autonomic arousal and
self-reported pain and negative affect. 40 healthy, non-smoking adults
with no history of psychiatric or neurological disease completed the exper-
iment at a small Midwestern medical school. Auditory evoked-potential,
heart rate, blood pressure, and self-report data were collected across three
experimental conditions: a resting baseline, immediately after a 3-minute
cold-pressor, and after a 25 minute recovery period. Data collection, reduc-
tion and P50 peak-picking methods will be discussed. Results of the current
study did not replicate the previously reported CPT induced changes for the
sample as a whole, a result that may have been related to methodological
differences between the two studies, which will be discussed. However,
when baseline gating was taken into account, S2 amplitudes changed sig-
nificantly across conditions. Change in P50 gating correlated significantly
with increased pain perception but no other self-report or cardiovascular
variables. These results support the need for further characterization of the
impact of stress on P50, as this relationship continues to be complicated and
unpredictable and can serve to further limit the reliability of the P50 mea-
sure in its use as an endophenotypic marker and outcome variable for ther-
apeutic interventions.
ID: 551809
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TIC NETWORKS IN SCHIZOPHRENIA
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Abnormal activation of semantic networks characterizes schizophrenia and
can be studied using the N400 event-related potential (ERP). N400 is
elicited by words that are not primed by the preceding context and pro-
vides a direct measure of the neural mechanisms underlying semantic prim-
ing. Semantic priming refers to facilitated semantic processing gained
through pre-exposure to semantic context, which can happen automati-
cally if the interval between the prime and target is very short. We pre-
dicted that, relative to healthy controls, schizophrenia patients would
have (1) overly inclusive semantic networks, reflected in a reduced (ie,
less negative) N400 to relatively unprimed words, and (2) deficits in their
use of semantic context, responding to primed words as if they were
unprimed, reflected in a an abnormally increased (ie, more negative)
N400 to primed words. EEG data were acquired from patients with
DSM-IV schizophrenia (n = 26) and age-matched healthy controls (n =
29) during performance of a picture-word verification (match vs. non-
match) choice-response task. Word targets were presented 325 ms after
a picture prime, which either matched (CAMEL’’camel’’), or did not
match the prime (‘‘InCat’’ = In Category Non-Match: CAMEL’’cow’’;
‘‘OutCat’’ = Out Category Non-Match: CAMEL’’candle’’). For each
subject, N400 was identified as the most negative peak between 300
and 500 ms following onset of unprimed words at electrode Pz. Although
primed words do not normally elicit an N400, voltage associated with
primed words was measured at the OutCat N400 peak latency. N400
was defined as the mean amplitude surrounding the N400 peak (630
ms), relative to a 100 ms pre-picture baseline, for primed and unprimed
(InCat and OutCat) words. N400 data showed that both patients and con-
trols were sensitive to the difference between primed and unprimed words,
but patients were less sensitive than controls. Similarly, N400 data showed
that both groups were sensitive to the subtler difference between classes of
unprimed words (InCat vs. OutCat), but patients were less sensitive, espe-
cially those with prominent negative symptoms. Surprisingly, there were
no correlations between N400 and the severity of thought disorder or delu-
sions in patients. Thus, abnormal activation of semantic networks in
schizophrenia may not be specifically related to the abnormalities in
thought content and process that would seem, on theoretical grounds,
to be the most dependent on semantic processes.
ID: 551753
BETA AND GAMMA CONTRIBUTIONS TO P50
SUBCOMPONENT ABNORMALITIES IN
SCHIZOPHRENIA: CLINICAL CORRELATES
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Main: Studies examining impaired sensory gating of the P50 component of
the auditory evoked potential (AEP) in schizophrenia (SZ) typically use
a bandpass of 10–100 Hz. Recent evidence suggests that using this bandpass
groups two distinct frequency bands, beta (12–20 Hz) and gamma (30–50 Hz),
together and excludes important information about beta and gamma con-
tributions, which are theoretically associated with different stages of atten-
tion. Dysfunctional attention in schizophrenia is a prominent component
and serves as a potential vulnerability marker for the disorder. Impaired
attention is associated with negative and/or disorganized clinical symp-
toms. We previously found relationships between these symptoms in
patients and abnormalities in P50 subcomponents using a 10–100 Hz fre-
quency band. This study examined the relationship between P50 subcom-
ponents and clinical measures of SZ symptomatology using separate beta
and gamma filter settings. Participants and Methods: AEP data were col-
lected on 42 healthy adults and 39 SZ patients using a 32-channel recording
array with a paired click protocol (0.5sec ISI, 10sec ITI). Amplitudes de-
rived from a spatial PCA analysis of the data were correlated with clinical
measures of schizophrenia symptomatology. Results: Temporal and spatial
PCA analyses of control data revealed a fronto temporal subcomponent in
the beta analysis and both a midline and later frontotemporal subcompo-
nent in the gamma analysis. For beta, higher suppression P50 amplitudes
were not associated with greater disorganized symptoms and exploratory
analyses indicated an inverse relationship. For gamma, lower amplitudes
were not associated with greater positive symptoms. Conclusions: This
study suggests that using either a beta or a gamma filter does not capture
the relationship between clinical measures and P50 abnormalities in schizo-
phrenia as does the traditional bandpass measure. This suggests that con-
tributions from other frequencies may be most important in indexing P50
abnormalities in schizophrenia.
ID: 551740
GAMMA BAND SYNCHRONY AS AN
ENDOPHENOTYPE FOR SCHIZOPHRENIA
Scott R. Sponheim1,2, S. Aviyente4, S. S. Kang3, J. J. Stanwyck1,
E. M. Bernat3
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The synchronous activity of cortical regions has been posited as a means by
which cognitive functions are carried out by the brain. Both the power and
phase of high frequency gamma band activity is augmented during the per-
ception of objects and appears to reflect the entrainment of neural
responses during cognitive demands. Individuals with schizophrenia
have exhibited both diminished gamma band power and synchrony during
the viewing of simple objects and contours. We have found that unaffected
individuals with genetic liability for schizophrenia exhibit diminished
gamma band power when identifying simple objects in visual noise. To
determine whether aberrant synchrony of gamma activity during the iden-
tification of objects is also associated with genetic liability for schizophre-
nia we acquired electroencephalograms (EEGs) from schizophrenia
patients, first-degree biological relatives of schizophrenia patients, and
nonpsychiatric control subjects while they viewed objects in visual noise.
Schizophrenia patients and their relatives exhibited reductions in gamma
band power during the identification of target objects. To obtain uniform
resolution phase synchrony across brain regions we applied a novel re-
duced interference complex time-frequency distribution to avoid the
trade-off between time and frequency evident in wavelet analysis. Analyses
revealed diminished phase synchrony to be associated with decremented
gamma power in schizophrenia patients. Additional analyses will test
whether first-degree biological relatives exhibit similarly diminished
gamma band phase synchrony to that of schizophrenia patients, and
whether phase anomalies are associated with susceptibility genes related
to glutamatergic and dopamanergic systems. To date, findings suggest
that deficient neural communication may underlie object identification def-
icits in schizophrenia and that such a deficit may mark genetic liability for
the disorder.
ID: 551730
ELECTROPHYSIOLOGICAL ANALYSES OF
ADOLESCENTS AT RISK FOR SCHIZOPHRENIA
Franc Donkers, N. Lucena, A. Belger
Psychiatry, University of North Carolina at Chapel Hill, Chapel
Hill, NC, USA
Background: Puberty is a critical period for the maturation of the fronto-
limbic and fronto-striate circuits critical for executive function and affective
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processing. Puberty also coincides with the emergence of the prodromal
signs of schizophrenia, possibly indicating an association between these
two processes. Methods: Event-related potentials (ERPs) and brain oscil-
latory activity in support of executive attention and affective processing
were compared in 24 healthy control (HC) subjects and 21 individuals
at genetic risk for schizophrenia (GHR) between the ages of 9 and 18 years.
Participants were matched for age, gender, ethnicity, and parental educa-
tion. Electrophysiological recordings were obtained from 32 EEG channels
while participants performed an emotional oddball task, where they iden-
tified rare visual targets while ignoring emotional and neutral distracter pic-
tures. Results: Our preliminary ERP results showed significant differences
between the high-risk and control groups in early sensory components, as
well as in late cognitive components. In addition, brain oscillatory activity
in low-frequency ranges was significantly reduced in the high-risk group.
Conclusion: Inefficient cortical information processing during puberty
may be an early indicator of altered brain function in children at risk
for schizophrenia, and may represent a vulnerability marker for illness on-
set. Longitudinal assessments will further inform about their predictive
value for illness onset in populations at high risk for psychotic illness.
ID: 551662
NEURAL RESPONSE TO IMAGES FEATURING
SYMBOLIC THREAT IN SCHIZOPHRENIA
PATIENTS: ERPS AND EVOKED AND INDUCED
EEG ACTIVITY
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Investigation of emotional experience and motivated behavior in schizo-
phrenia includes reports of both intact functioning and illness-related ab-
normalities. Many of these abnormalities involve behaviors that are
clinically relevant (eg, display of flat affect, anxiety related to fears of per-
secution), but may prove quite complex with respect to their underlying
cognitive architectures. As a basis for further study of the defensive mo-
tivational system, and more specifically, how the brain processes emotion-
ally unpleasant information within the first second of stimulus perception,
we recorded electroencephalographic (EEG) data while first-episode
schizophrenia patients and healthy comparison subjects viewed neutral
and negative images featuring symbolic representations of threat. Repre-
sentations of threat varied systematically in order to permit examination of
whether particular content categories, ranging from high (eg, attack, mu-
tilation) to low imminent threat (eg, pollution, loss), elicit group-wise dif-
ferences in electrophysiological responses that are not apparent when only
super-ordinate affect categories (ie, negative, neutral) are considered.
Event-related potentials (ERPs) previously shown to be sensitive to affec-
tive intensity of stimuli were derived. Additionally, concomitant segments
of EEG data were subjected to time-frequency transformations to measure
frequency band-specific changes in signal power and phase. Collectively,
these measures reflect large-scale neural activity in primary and secondary
visual cortex, as well as an extended network of regions that are sensitive to
the motivational salience of stimuli and interact strongly with visual cortex.
Initial analyses suggest that both patients and controls show strong mod-
ulation of ERP response amplitude, and EEG power and phase (particu-
larly in the delta/theta and alpha frequency bands) by negative content
category. Group differences appear more subtle and do not appear to
be associated exclusively with any one type of negative image content.
Relationships between ERP and EEG measures and clinical variables,
as well as possibly interacting effects of gender, will also be considered.
Finally, implications of the potential influence of affect and arousal on
more cognitively demanding tasks will be discussed.
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Joel W. Nelson1, M. K. Hall1, V. M. Goghari3,
A. W. MacDonald3, J. J. Stanwyck1, S. R. Sponheim1,2
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The basis of deficient cognitive control in schizophrenia has been charac-
terized in terms of impaired motor inhibition. Several investigations have
revealed that individuals with schizophrenia as well as their biological rel-
atives exhibit abnormal striatal activation associated with the inhibition of
motor and eye movements (Vink et al., 2006). In addition, recent work has
identified that neural activity during response inhibition is associated with
the catechol-O-methyltransferase (COMT) gene and presumably the avail-
ability of prefrontal dopamine (Kramer et al., 2007). We carried out
a study to determine whether aberrant neural responses of schizophrenia
patients and their biological relatives during motor inhibition were asso-
ciated with the Val158Met polymorphism of the COMT gene. The sample
consisted of patients with schizophrenia, their first degree relatives, and
healthy controls recruited for a family study based at the Minneapolis
VA Medical Center. We measured behavioral responses and event related
potentials (ERPs) while administering a stop-signal task. Whole blood
specimens were used to gather genetic information and to determine
the COMT genotype on subjects. Consistent with manipulation of re-
sponse demands behavioral data show an increase in response time for
GO trials as expectancy of inhibition (ie, stop signal) increases. To
date, electrophysiology data has been collected on 60 patients, 29 relatives,
and 49 controls. We expect to find aberrant N2 and P3a ERP components
in examining inhibition-related activity in schizophrenia patients and their
relatives. We also predict that the Val158Met polymorphism of the
COMT gene will associate with N2 and P3 abnormalities evident in
the patient and relative groups. If hypotheses are supported, evidence
would be consistent with the presence of anterior cingulate and prefrontal
deficits marking genetic liability for schizophrenia and a role of the
COMT gene and dopamanergic mechanisms in deficient inhibitory con-
trol in the disorder.
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NEURAL CORRELATES OF INHIBITORY MOTOR
CONTROL IN SCHIZOPHRENIA PATIENTS AND
THEIR BIOLOGICAL RELATIVES
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apolis, MN, USA; 4Psychiatry and Psychology, University of
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Several lines of research indicate that individuals with schizophrenia have
poor inhibitory control. Evidence suggests that deficient inhibition may
contribute to errant eye movements, poor episodic memory, and deficient
cognitive control in the disorder. Functional magnetic resonance imaging
studies of inhibitory control have revealed abnormal striatal and prefrontal
activation in schizophrenia patients and their biological relatives during in-
hibition of motor movements. Nonetheless, little is known about the
time-course of neural anomalies associated with poor inhibitory control
in schizophrenia. To investigate the relationship of neural events to defi-
cient inhibition in schizophrenia we carried out an event-related potential
(ERP) study using a motor response task previously used to examine
International Congress on Schizophrenia Research
52 4. 4. Electrophysiology
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
schizophrenia patients and their relatives (Vink et al. 2006). In the present
study participants completed a stop signal task that consisted of go only
blocks in which participants responded to every trial and go/stop blocks
where participants were required to inhibit their response to stop trials pre-
sented pseudo-randomly between go trials. Electrophysiological data has
been collected on 60 patients with schizophrenia, 29 first degree biological
relatives, and 49 community controls. We hypothesize that schizophrenia
patients and their relatives will exhibit impaired inhibitory control, and
that these abnormalities will be associated with the amplitude of P3a and
N2 ERP components. These components have been associated with decision
making and early response inhibition processes in other investigations and
appear to represent neural processes underlying response inhibition. A com-
parison will be made across schizophrenia, relative, and control groups con-
trasting ERP amplitudes elicited from go trials during go only blocks with
those during go/stop blocks, to investigate the effects of increased inhibitory
demand on motor control. To date, behavioral data are consistent with
slowed response inhibition associated with schizophrenia.
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This study investigates the effect of intravenous synthetic D9-tetrahydro-
cannabinol (THC) on P300 and N300 event-related potentials (ERPs) to
target and novel stimuli in a 3-stimulus auditory oddball paradigm. Can-
nabis use is implicated as a risk factor for psychotic episodes and persistent
psychosis. An acute challenge of THC leads to a state modelling of psy-
chotic symptoms; however, the precise neural mechanisms underlying
the effect of THC on behaviour and cognition are unclear. One of the
most robust neurobiological abnormalities observed in schizophrenia is
a reduction in auditory P300 amplitude. Specifically, reductions in frontal
and left temporal P300 amplitude have been associated with psychotic
symptoms. The current study used ERP methods to test a THC model
of psychosis. A randomised double-blind placebo controlled within subject
design was used to investigate the effect of 1.25 mg intravenous THC rel-
ative to placebo on ERPs in 10 healthy adults. Auditory P300 and N300
amplitudes were measured in response to target and novel stimuli in
a 3-stimulus auditory oddball task. The positive and negative syndrome
scale (PANSS) was used to assess psychiatric symptoms. Data were ana-
lysed using repeated measures analysis of variance (ANOVA). Bilateral
frontal and temporal P300 amplitude in response to targets was reduced
under THC compared to placebo conditions. A more specific right hemi-
sphere effect was seen for novelty P300 amplitude (P3a) and N300. There
were no significant effects for P3a and P3b peak latency, perhaps indicating
individual memory encoding and response strategies. Left temporal P300
effects were not found in the THC condition, indicating their possible spec-
ificity to schizophrenia. There was a trend for an increase in positive symp-
toms during the THC condition. A trend was found for reduced response
time to targets in the THC condition compared to placebo. The current
results support THC as a neuropharmacological model of schizophrenia.
It is hypothesised that THC-mediated P300 amplitude reductions underlie
working memory deficits during THC intoxication. These deficits are
thought to impair the perception of novelty, which affects context updating
and memory storage. These results may translate to psychosis, in that in-
creased endocannabinoid signalling may be responsible for reduced P300
amplitude in psychosis.
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Gamma (c) frequencies have been associated with the sensory encoding and
processing of auditory information, with auditory hallucinations (AHs) be-
ing associated with excessive c. This finding may reflect a hyperconnectivity,
which in turn could be associated with excessive processing and impaired
sensory integration. Imaging studies have implicated the superior temporal
cortex (STC), the anterior cingulate cortex (ACC) and the prefrontal cortex
(PFC) in AHs, and it appears that the abnormality in which the left PFC
influences the left STC is a result of the failure of the ACC to modulate their
interactions. Given this background, the purpose of this study was to use
gamma band oscillations (GBOs) to examine inter-regional synchrony in
hallucinating (HP) and non-hallucinating (NP) schizophrenia patients dur-
ing passive recording conditions. We were also interested in examining how
these inter-regional synchronies varied with the increasing of hallucinations.
As a number of studies have suggested that hallucinations worsen in the pres-
ence of speech and especially in the presence of unintelligible speech, the
study also examined GBOs in response to external speech presented during
background noise conditions, and during a silence condition. There were 3
groups of 12 participants: HPs, NPs and healthy controls. EEG recordings
were taken under 3 sound conditions presented randomly, and a separate
recording under silent conditions. The sound conditions consisted of fre-
quent and rare consonant-vowel syllables being presented once every ½ sec-
ond during no-noise or simultaneously with white noise or traffic noise. For
each of these 4 conditions, scalp electrical activity was recorded with a 40
channel system and artifact free activity was submitted to spectral analysis
for computation of c amplitudes, which were plotted across the scalp. Low-
resolution electromagnetic topography (LORETA) analysis was used to es-
timate current source density (CSD) and its distribution in the cortex. CSD
were also calculated for regions of interest (ROI) and these were used to com-
pute coherence values between PFC, STE and ACC regions. These ROI val-
ues were computed for the background noise conditions, as well as for the
discrete (external speech) sounds. Relative to NPs, we expect greater GBO
and greater GBO synchrony in HPs. Furthermore, we expect this pattern to
be more evident in the speech/noise conditions.
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SUBJECTIVE AND PHYSIOLOGICAL
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Background: Since Bleuler it has been widely acknowledged that disturbed
affective arousal is a primary characteristic of schizophrenia. However,
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despite a large number of studies on affective (emotional) experience, rel-
atively little research has focused on the experience of arousal in schizophre-
nia and findings are inconsistent. Moreover, it remains unclear whether
underlying physiological responsivity in schizophrenia individuals (SZ) is
in concordance with subjective experiences of arousal, and how this com-
pares to non-schizophrenic individuals. Method: Skin conductance (SC)
was assessed in 20 medicated SZ and 30 control subjects (CS) during ex-
posure to picture (n = 40), sound (40), and printed word (40) stimuli
that varied in level of arousal and valence connotation. Results: Subjective
ratings indicated a similar response pattern in SZ and CS, but SZ demon-
strated an attenuated subjective arousal experience; very calm stimuli were
experienced as less calm, and very arousing stimuli as less arousing. For
physiological findings, SZ exhibited overall reduced SC responses to all
stimuli. Despite this, SZ and CS showed a similar SC response pattern
to stimuli rated very calm and moderately arousing; lower SC responsivity
to very calm stimuli. A marked difference between groups was evident for
stimuli rated as very arousing. As expected, CS exhibited increased SC
responsivity to all stimuli rated as very arousing. SZ showed a decrease
in SC responsivity to very arousing stimuli based on normative ratings;
lowest SC responsivity to stimuli rated as very arousing that also had a nor-
mative rating of very arousing. Background: Our findings suggest a phys-
iological deficit in arousal experience in schizophrenia, which may be
particularly related to highly arousing stimuli. Other schizophrenia studies
have demonstrated deficits or attenuated responses in neurophysiological
processing of stimuli of high emotional valence (fear), and the findings pre-
sented here suggest that similar anomalies may exist for highly arousing
stimuli (stressors, threats). This dissociation between physiological and
subjective arousal experiences may contribute to the restricted affective
arousal often associated with schizophrenia.
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NIA PATIENTS
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Aberrations in attention and sensory perception have long been associated
with schizophrenia. It has been proposed that these attentional deficits may
be due to an inability to filter out extraneous sensory information, resulting
in an inability to process and integrate sensory stimuli from the environ-
ment. A deficit in this filtering process, as indexed by the P50 component
of the event-related potential (ERP), has been demonstrated in patients
with schizophrenia across different phases of the illness. Recent research
suggests that disruption in P50 suppression in patients with schizophrenia
may be associated with abnormalities in subsequent neurocognitive pro-
cesses (Boutros, Korzyukov, Jansen, Feingold, and Bell, 2004). The first
phase of the present study was designed to elucidate whether disruption
of P50 suppression influences later ERP components in patients with
schizophrenia. Ratio measures of successive components (eg, N100,
P200) were examined to determine if suppression is also diminished at these
later components. To establish whether suppression of these components
may be related to one another, the second phase of this study involved
single-trial analysis in healthy participants and patients with schizophrenia.
The third phase of this study evaluated the effects of directing voluntary
attention during a P50 paired-stimulus paradigm. The P50 ratio in schizo-
phrenia has been shown to be transiently enhanced through the manipula-
tion of attention to the first stimulus in a pair and diminished by directing
voluntary attention to the second stimulus (Yee et al., in submission). Pre-
liminary results indicate that in comparison to healthy participants, schizo-
phrenia patients showed increased ratio values at later ERP components,
paralleling results finding disruption of P50 suppression. Additionally, it
appears that directing attention to the first stimulus may not necessarily
enhance suppression at these later components in either sample, but that
voluntary attention directed to the second click resulted in reduced suppres-
sion of later ERP components, with the strongest effects observed in
healthy comparison subjects. These findings suggest that although gating
abnormalities extend beyond the P50 component, it may not be possible to
sustain attentional or top-down modulation in schizophrenia beyond a very
early stage of auditory processing, consistent with abnormalities in fronto-
temporal connectivity (Mathalon, Heinks, and Ford, 2004).
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Disturbances of global information processing as well as disturbances of
specialized networks are fundamental in schizophrenia. The aim of this
study was the comparative examination in healthy subjects and schizo-
phrenic patients of different ERP-generating networks by gradually in-
creasing the complexity of a visual stimulus. We examined 19 patients
(6f, 13m) and 15 (7f, 8m) healthy subjects, matched for age and education.
ERP were elicited by black and white patterns (21x16 squares) of increasing
complexity: i) regular checkerboard ( = simple stimulus), ii) irregular ran-
dom pattern ( = complex pattern stimulus), and iii) random pattern with
embedded letter ( = complex semantic stimulus). The number of black/white
squares was 1:1 for all stimuli. All stimuli had the same task relevance (but-
ton press). ERP were analysed for 2000ms (500ms pre-trigger) from
Fz,Cz,Pz, and from C3/C4 and P3/P4. Bandpass was 0.02 to 30 Hz, sam-
pling frequency 256 Hz. ERP were evaluated by comparisons of the curves
(Blair and Karniski) and of the area under the curves (AUC). In both
groups, all visual stimuli generated positive ERP between 300–500 ms,
larger in healthy subjects (8lV—10lV) than in patients (5lV—6lV), poten-
tials remaining positive with about 2lV till the end of analysis time(1500
ms). In healthy subjects only, the ERP of both complex stimuli differed
significantly from the simple stimulus by a distinct negative component
of about 4lV between 400–600 ms (N500). The ERP of the complex se-
mantic stimulus differed significantly from the complex pattern stimulus by
a late positive component between 900–1500 ms. Both effects were not
found in schizophrenic patients. Stimuli of same modality and task rele-
vance but different complexity generate different ERP, pronounced in
healthy subjects only. The introduction of irregularity (simple to complex
pattern stimulus) seems to generate an informational content, which seems
to activate an information-related ERP generator, leading to the N500
component. The further introduction of a semantic content seems to
activate a further neuronal processor, resulting in a prolonged positive
potential after 600 ms. Both of these effects are missed in schiophrenic
patients. This reveals a distributed disturbance of information processing
in schizophrenia, affecting multiple neuronal networks.
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Catechol-O-methyltransferase (COMT) metabolises catecholamines and
has been shown to modulate prefrontal dopamine levels. Inhibition of
COMT improves PFC-dependent task performance and a functional poly-
morphism in the COMT gene (Val158Met) has been linked with perfor-
mance on a range of cognitive tasks. COMT has therefore attracted
attention as a possible therapeutic target for treating cognitive dysfunction
in schizophrenia. More recently, evidence has emerged for a role for COMT
outside of the PFC: the Val158Met polymorphism has been associated with
hippocampal activation during emotional processing, consistent with the
high expression of COMT mRNA in this region. Therefore, we investigated
the effect of the COMT inhibitor tolcapone on CA1 Schaffer collateral and
perforant pathway field excitatory postsynaptic potentials (fEPSPs) in hip-
pocampal slices. Hippocampal slices (350 lm thickness) were prepared
from male Hooded Lister rats aged between P35–P42, transferred to an in-
terface chamber and superfused continuously with artificial cerebrospinal
fluid (aCSF). After resting for two hours, stimulating electrodes were
placed in the stratum radiatum and the stratum-lacunosum moleculare
of CA1, to evoke fEPSPs via the Schaffer collateral and perforant path-
ways, respectively. Field potentials were monitored via a recording elec-
trode placed in the stratum radiatum of CA1. Tolcapone was perfused
in aCSF once fEPSP slopes had stabilised. Between 30 and 60 minutes
post-perfusion, 20 lm tolcapone dramatically suppressed fEPSP slope in
both the Schaffer collateral and the perforant pathways (by approximately
60% after 60 minutes). Investigation of the effects of other doses of tolca-
pone, and their reversibility by dopamine receptor antagonists, are ongo-
ing. We demonstrate a striking effect of the COMT inhibitor tolcapone on
both Schaffer collateral and perforant pathway field potentials. These pre-
liminary data support emerging evidence of a role for COMT in modulating
hippocampal function, in addition to its importance in PFC. Our research is
currently investigating the extent to which tolcapone’s effects on Schaffer
collateral and perforant pathway fEPSPs is dopamine-dependent and the
dose-dependency of this effect. Such studies are critical, given the marked
non-linearity of dopamine’s effects on cortical function, and the potential
roles of COMT in both the pathophysiology and pharmacotherapy of
schizophrenia.
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ON EEG OSCILLATIONS DURING A SELF-PACED
MOTOR TASK
Judith Nottage, D. Ffytche, S. Bhattacharyya, J. Stone, A. Sumich,
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Electroencephalogram (EEG) oscillations have been shown to be altered in
schizophrenia and it has been hypothesised that deficits in synchrony may be
involved in the disease process. It has previously been reported that in a self-
paced motor task inter-trial coherence at gamma frequencies is reduced in
subjects with schizophrenia. An acute challenge ofD9-tetrahydrocannabinol
(THC) can trigger psychotic symptoms, and cannabis use is a risk factor for
development of schizophrenia. The purpose of this study was to investigate
the effect of acute THC on the synchrony and amplitude modulation of EEG
oscillations during a self-paced motor task. A randomised, double-blind,
within subject, design was used with 10 healthy adults. THC intravenous
(1.25 mg), or placebo, was administered prior to participants completing
a self-paced button pressing task. EEG was recorded using a 64 channel elec-
trode cap based on the 10–20 system. Wavelet analysis was used to determine
amplitude, spatial synchrony and inter-trial coherence of the Mu and gamma
rhythms at frontal, central and parietal electrode sites. EEG oscillations were
found to be significantly altered in the drug state compared to placebo. Ab-
errant neural oscillations may be related to the positive psychotic symptoms
and changes in consciousness produced by THC.
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GATING AND NEURONAL SYNCHRONIZATION
IN RATS—RELEVANCE TO SCHIZOPHRENIA
Mihaly Hajos
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Impaired auditory gating and abnormal neuronal synchrony are considered
as indicators of dysfunctional information processing in schizophrenic
patients, and possible underlying mechanisms of their impaired sensory
and cognitive functions. Since cannabinoid receptors and endocannabi-
noids have been linked to psychiatric disorders, including schizophrenia,
the aims of the present experiments were to evaluate the effects of canna-
binoid-1 (CB1) receptor activation on sensory gating and neuronal oscil-
lations in rats. In our experiment, auditory sensory gating has been
recorded from the hippocampus (CA3) and entorhinal cortex in anaesthe-
tized rats. Neuronal network activity was recorded from the hippocampus
(CA1, CA3), medial septum, entorhinal cortex and medial prefrontal cor-
tex. Firing rate and oscillatory activity of septal single units were monitored
simultaneously with hippocampal and cortical field potential oscillations in
anaesthetized rats. In the auditory gating experiment, event-related spectral
perturbations and inter-trial coherence analysis were applied to hippo-
pcampal and cortical recordings. In freely-moving rats, hippocampal
and cortical oscillations were monitored in home cage and in rats exposed
to novel environment. Effects of systemic administration of the selective
CB1 receptor agonist CP-55940 were evaluated on these parameters.
Thus, CP-55940 significantly disrupted auditory gating both in the hippo-
campus and entorhinal cortex via interfering with event-related network
oscillations in anaesthetized rats. Spontaneous theta field potential oscilla-
tions were disrupted in the hippocampus and entorhinal cortex, with simul-
taneous interruption of theta-band oscillations of septal neurons.
Administration of the CB1 receptor antagonist AM-251 reversed both
the agonist-induced gating deficit and the diminished oscillations. In
freely-moving rats, CP-55940 significantly reduced theta and gamma power
in the hippocampus, whereas in the entorhinal cortex only gamma power
was attenuated. However, novelty-induced theta, beta and gamma activities
were significantly diminished by CP-55940 both in the hippocampus and
entorhinal cortex. Our data indicate that activation of CB1 receptors inter-
feres with neuronal network oscillations and impairs sensory gating func-
tion in the limbic circuitry, further supporting the connection between
cannabis abuse and increased susceptibility of developing schizophrenia
spectrum disorders.
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THE STABILITY OF PREPULSE INHIBITION OF THE
STARTLE REFLEX IN SCHIZOPHRENIA: A 5 YEAR
FOLLOW-UP STUDY OF ANTIPSYCHOTIC NAI¨VE,
FIRST-EPISODE SCHIZOPHRENIA PATIENT
PRELIMINARY RESULTS
Trine Bjorg Hammer, B. Oranje, B. Glenthoj
University Psyciatric Center Glostrup, Center for Neuropsychiatric
Schizophrenia Research, Glostrup, Denmark
Deficits in information processing appear to be core features in the path-
ogenesis of schizophrenia. Prepulse inhibition of the startle response (PPI)
is an operational measure of sensorimotor gating. PPI deficits are generally
regarded as endophenotypes for schizophrenia. However, the stability of
PPI both over time, and during the course of antipsychotic treatment, is
still largely unclear. In an earlier study, we reported that neither a three
months treatment with zuclopenthixol (typical antipsychotic) nor with ris-
peridone (atypical antipsychotic) improved the PPI deficits of antipsychotic
naı¨ve, first-episode patients with schizophrenia. The current study is
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a 5 year follow-up investigation of that original study. At baseline, 25 drug-
naive first-episode schizophrenic patients and 23 healthy controls matched
for gender and age, participated in the project. Three PPI measures were
examined at baseline, after 3 month of randomized antipsychotic treatment
(risperidone or zuclopenthixol) and after 5 years follow-up. Currently, 18
patients and 16 healthy controls were reexamined at the 5 year follow-up.
Patients showed PPI deficits compared to healthy controls at baseline. At
the 5 years follow-up no significant group differences were found although
only one of the PPI measures improved significantly in the patients. The
current preliminary results support the notion that PPI deficits are funda-
mental trait markers of schizophrenia that are already present at an early
stage in the development of the disease. However, the deficits seem to di-
minish over time, most probably due to the disease process it self, or to the
effects of antipsychotic treatment.
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TIME-FREQUENCY ANALYSIS OF PREATTEN-
TIONAL COGNITION IN SCHIZOPHRENIA
PATIENTS IN TAIWAN
Jung Lung Hsu1,2, M. H. Hsieh1,3, C. M. Liu3,4, M. J. Chiu3,5,
H. G. Hwu3,4, F. S. Jaw1
1Institute of Biomedical Engineering, National Taiwan University,,
Taipei, Taiwan; 2Neurology, Shin Kong WHS Memorial Hospital,
Taipei, Taiwan; 3Department of Psychiatry, National Taiwan
University Hospital, Taipei, Taiwan, Taipei, Taiwan; 4Department
of Psychiatry, National Taiwan University College of Medicine,
Taipei, Taiwan, Taipei, Taiwan; 5Department of Neurology, Na-
tional Taiwan University Hospital, Taipei, Taiwan, Taipei, Taiwan
Disturbances of auditory information processing have repeatedly been
shown in schizophrenia. Event-related potentials are currently utilized to
study information processing under the influence of neuropsychiatric dis-
orders and are candidate endophenotypes of schizophrenia. This study tried
to focus on event-related potential components such as P50 and mismatch
negativity (MMN) between control and schizophrenia groups in Taiwan. In
addition, this study also compared the time-frequency analysis and aver-
aged event-related potentials of these event-related potentials. In 50 schizo-
phrenia patients and 50 controls EEG was recorded using an auditory
paired click paradigm for P50 and duration MMN (500msec SOA) for
MMN. Participants are seated in a comfortable recliner in a sound-atten-
uating, electrically shielded booth and instructed to relax with his/her eyes
open and to focus on a fixation point (P50 session) or the video monitor
(MMN session). The stimuli are generated by and data is recorded by Neu-
roscan STIM and ACQUIRE system. Electrodes are used at up to 36 re-
cording sites. Auditory stimuli are presented to subjects binaurally via foam
insert earphones. Written informed consent were all obtained from the
above subjects. In addition to the effect of clozapine versus other antipsy-
chotics was confirmed, the relationship of psychopathology dimensions
were also explored. In time-frequency analysis of single trial MMN, schizo-
phrenia have lower inter-trial phase coherence than controls. The induced
gamma activity did not show large difference between controls and
patients. The results support the view that deficits at sensory preattentive
information processing are essential in schizophrenia patients. These def-
icits may also play a role in the basic integrated neural network activity.
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PRELIMINARY RESULTS
Nikolaj Bak1, B. Y. Glenthøj1, E. Rostrup2, H. Larsson2,
B. Oranje1
1Center for Neuropsychiatric Schizophrenia Research (CNSR),
University of Copenhagen, Psychiatric Center Glostrup, Copenha-
gen, Denmark; 2Functional Imaging Unit, Department of Clinical
Physiology and Nuclear Medicine, Glostrup Hospital, Copenhagen,
Denmark
Reduced sensory gating appears to be among the core features in schizo-
phrenia. The sources of sensory gating however are largely unknown. The
aim of the current study is to identify these sources. To our knowledge this
is the first study in which concurrent EEG and fMRI assessment of P50
suppression was performed. Twenty healthy male volunteers were tested
with identical paradigms in two separate sessions: an EEG setting, and
an EEG concurrent with fMRI setting. Instead of the classical P50 suppres-
sion paradigm an especially constructed paradigm was used for the fMRI
environment, in which the auditory stimuli were replaced by weak electrical
stimuli. Two interstimulus intervals (ISIs) were used: 500 and 1000 ms. The
preliminary results from the 16 subjects who were analyzed in the EEG set-
ting and 9 from the fMRI setting so far showed significant P50 suppression
only in the 500 ms interval, not in the 1000 ms ISI. The contrast between the
1000 ms and 500 ms ISI revealed activation in the temporal region based on
the results from the 9 subjects who were analyzed so far in the fMRI setting.
The results indicate that the EEG data between the two settings are com-
patible. Furthermore the electrical P50 suppression paradigm gives results
that are consistent with classical auditory paradigms. The fMRI results sug-
gest that the temporal cortex is involved in P50 suppression.
ID: 551072
SOPRES (STUDY ON THE PSYCHOPATHOLOGICAL
PROGRESS OF THE PRE-PSYCHOTIC STATE) IN
TAIWAN: EVENT-RELATED POTENTIAL
FINDINGS
Ming H. Hsieh1,2, C. C. Liu2, C. M. Liu2,3, M. J. Chiu4,
H. G. Hwu2,3, F. S. Jaw1
1Institute of Biomedical Engineering, National Taiwan University,
Taipei, Taiwan; 2Department of Psychiatry, NTU Hospital, Taipei,
Taiwan; 3Department of Psychiatry, National Taiwan University
College of Medicine, Taipei, Taiwan; 4Department of Neurology,
NTU Hospital, Taipei, Taiwan
A prospective study Study On the psychopathological progress of the PRE-
psychotic State, SOPRES was initiated in Taiwan and sponsored by Taiwan
National Health Research Institute since 2006. Four psychopathological
stages (First episode psychosis; Very high risk stage; Intermediate risk
stage; Very early stage) and normal control were recruited for comparison
of P50/N100/MMN results. Ninety-six prodrome patients and fifty controls
were recruited. Participants are seated in a comfortable recliner in a sound-
attenuating, electrically shielded booth and instructed to relax with his/her
eyes open and to focus on a fixation point (P50 and N100 session) or the
video monitor (MMN session). The stimuli are generated by and data is
recorded by Neuroscan STIM and ACQUIRE system. Electrodes are
used at up to 36 recording sites. Auditory stimuli are presented to subjects
binaurally via foam insert earphones.P50 and N100 suppression were
assessed with an auditory double-click paradigm, while MMN were given
with standard (90%, 50 msec duration) and deviant (10%, 100 msec dura-
tion) tones presented in pseudorandom order and 500msec SOA. Certained
P50/N100 suppression indices and MMN differed between groups. Among
the analyzed P50 parameters, the P50 suppression ratio reached significant
differences between healthy controls and very high risk stage patients, and
between healthy controls and the first episode psychosis subgroup. The
results support the view that deficits of sensory preattentive information
processing may be essential in prodromal patients, especially those with
higher clinical risk.
ID: 551038
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EVIDENCE FOR NEURODEGENERATION?
FURTHER REDUCTION IN P300 AMPLITUDE
OBSERVED OVER 3 YEAR FOLLOW-UP IN FIRST
EPISODE SCHIZOPHRENIA
Anthony W. F. Harris1,2, K. Brown2, J. Brennan3,
L. M. Williams1,2
1Psychological Medicine, University of Sydney, Sydney, NSW,
Australia; 2Brain Dynamics Centre, Westmead Millenium Institute,
Sydney, NSW, Australia; 3Department of Child and Adolescent
Psychiatry, Sydney Children’s Hospital, Sydney, NSW, Australia
A reduction in the amplitude of the P300 waveform in the auditory oddball
paradigm in schizophrenia is a well replicated finding. However very few
studies have examined the stability of this finding over time and none in
a group of patients with their first episode of schizophrenia. This study fol-
lowed up 25 subject with their first episode of schizophrenia (male = 17,
female = 8) over a 2–3 year period as part of a larger program of research.
The subjects with schizophrenia were noted to have decreased P300 ampli-
tude at their initial recording when compared to normal controls. This re-
duction in P300 amplitude increased over the 2–3 year follow-up despite
a reduction in symptomatology. This finding was not explained by changes
in overall medication burden. This study suggests that the reduction in P300
amplitude continues to develop over the early stages of schizophrenia. This
is at odds with other work that has observed stability in the P300 compo-
nent over similar periods of time in subjects with chronic schizophrenia.
One possible explanation for this finding is that the P300 amplitude changes
reflect an ongoing pathological process that has stabilised with chronic
illness.
ID: 551016
TREATMENT RESISTANT P300 ABNORMALITIES
IN A LARGE GROUP OF ANTIPSYCHOTIC NAI¨VE,
FIRST-EPISODE PATIENTS WITH SCHIZOPHRENIA
Bob Oranje, B. Aggernaes, B. Y. Glenthoj
CNSR, University Psychiatric Center Glostrup, Glostrup, Denmark
Evidence is accumulating that cognitive deficits form core features in
schizophrenia. It has been suggested that treatment with atypical antipsy-
chotics can ameliorate these deficits. However, studies have often been
confounded by patients either being medicated or chronically ill, making
it hard to differentiate between medication effects and progress of the
disease. In addition they frequently suffer from low subject populations,
giving rise to power issues. In the present study the influence of a six
months treatment period with quetiapine (atypical antipsychotic) was in-
vestigated on psychophysiological parameters of selective attention in
a large group of first episode, antipsychotic naı¨ve schizophrenia patients
and age and gender matched healthy controls. Thirty-four antipsychotic
naı¨ve patients with first-episode schizophrenia and 40 age and sex
matched healthy controls were tested in a selective attention paradigm
at baseline and at 6 months follow-up. The patients were treated with
quetiapine during the period between baseline and follow-up, the controls
received no treatment. Both at baseline and at follow-up, the patients
showed highly significant reduced P300 amplitudes compared to the
healthy controls. No treatment effects were found. The results indicate
that deficits in P300 amplitude, and thus attention deficits, are present
at an early stage in the development of schizophrenia. Furthermore,
the results indicate that a 6 months treatment period with quetiapine
does not ameliorate these attention deficits. The results are consistent
with the concept that P300 amplitude deficits represent stable endophe-
notypes for schizophrenia.
ID: 550938
EFFECTS OF WORD FREQUENCY ON SEMANTIC
MEMORY IN SCHIZOPHRENIA
Ruth Condray1,2, S. R. Steinhauer1,2, G. J. Siegle1,2,
M. S. Keshavan1,3, D. M. Montrose1, B. Chakraborty2
1Department of Psychiatry, University of Pittsburgh School of
Medicine, Pittsburgh, PA, USA; 2Medical Research Service, VA
Pittsburgh Healthcare System, Pittsburgh, PA, USA; 3Department
of Psychiatry, Wayne State University, Detroit, MI, USA
Semantic memory deficit may represent a biological marker for schizo-
phrenia. Findings based on the N400 component of the event-related
brain potential, which reflects on-line access and integration processes,
indicate patients are compromised in discriminating the semantic features
of words, and that executive function may play a key role. Typical an-
tipsychotic medication (haloperidol) appears to improve, but not normal-
ize, patients’ N400 priming effect, which is consistent with moderating
vulnerability-trait status. This hypothesis requires examination based
on newer generation medications. In the present study, N400 was elicited
with a semantic-priming paradigm designed to engage executive processes
(slow presentation rate, resource-demanding task). N400 was recorded in
14 schizophrenia outpatients (M = 34.3 yrs) and 14 healthy controls (M =
31.4 yrs) while they performed a delayed letter probe task that was in-
cidental to the linguistic characteristics of word pairs, which varied in
semantic association (related, unrelated) and word frequency (very low
to very high). Prime-target stimulus-onset asynchrony = 1 s. At testing,
patients were receiving clinician’s-choice atypical antipsychotics; patients
and controls were group-matched for age, gender, and demographics.
The N400 priming effect differed between groups (P < .01), with only
controls showing the typical pattern of greater N400 negativity for un-
associated than associated words. N400 to word frequency also differed
between groups (P < .05); controls’ N400 became more negative with
decreasing word frequency (P < .05) while patients failed to discriminate
word frequency (P = n.s.). Cumulative findings showing N400 priming
disturbance in patients receiving both traditional (typical) and newer gen-
eration (atypical) antipsychotics are consistent with the hypothesis that
semantic memory deficit represents a moderating trait for schizophrenia.
Results also support the assumed importance of executive processes for
semantic memory function in schizophrenia, and implicate a failure to
engage brain processes associated with the access and integration of
stored information.
ID: 550924
EFFECTS OF CHRONIC EXPOSURE TO CANNABI-
NOIDS ON SENSORY GATING AND NEURAL
SYNCHRONIZATION IN HUMANS.
Patrick David Skosnik, C. R. Edwards, G. P. Krishnan,
W. P. Hetrick, B. F. O’Donnell
Psychological and Brain Sciences, Indiana University, Bloomington,
IN, USA
Recent research has shown that schizophrenia (SZ) may be associated
with abnormalities of the endogenous cannabinoid system. This line of
evidence is in accord with numerous longitudinal studies, which have dem-
onstrated increased rates of psychosis in long-term cannabis users. How-
ever, it remains unclear how chronic exposure to cannabinoids is related
to the emergence of SZ-like perceptual/cognitive features. Given that can-
nabinoid receptors (CB1) are thought to modulate neural oscillations nec-
essary for sensory and cognitive processes, it has been postulated that
a possible neurophysiological link between SZ symptomatology and can-
nabis’ neurobehavioral effects involves alterations in neural synchrony.
The current set of studies therefore assessed the effect of chronic cannabis
use on neural synchronization (using EEG) during paired-click auditory
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P50 gating and broadband (5–50 Hz) auditory steady-state responses
(ASSRs), both tasks which have been consistently shown to be aberrant
in SZ. As expected, it was found that cannabis users exhibited increased
SZ spectrum traits (schizotypy) compared to drug-naive controls, and that
overall levels of cannabis chronicity (total years of use) was positively cor-
related with schizotypy scores. In terms of auditory P50 gating, cannabis
users demonstrated abnormal gating in a pattern similar to that previously
reported in SZ. Moreover, time-frequency analyses revealed that the can-
nabis-related gating deficit observed at click S2 was accompanied by al-
tered theta and gamma oscillations. Similarly, the effect of chronic
cannabinoids on the ASSR revealed a selective decrease in spectral power
at 5 Hz (theta-range) and 40 Hz (gamma-range). Taken together, these
frequency-specific deficits in the generation and maintenance of theta
and gamma-range neural synchrony are in concurrence with recent
work in animals, demonstrating a general role of the cannabinoid system
in mediating GABAergic network oscillations. Further, these data indi-
cate that chronic cannabis use, mostly likely via CB1 downregulation/de-
sensitization, induces psychotomimetic features through dysregulation of
the GABA system.
ID: 550913
HERITABILITY OF ACOUSTIC STARTLE,
PREPULSE INHIBITION AND ONSET LATENCY
IN SCHIZOPHRENIA AND CONTROL FAMILIES
Erica Joan Duncan1,2, W. Hasenkamp1, M. P. Epstein3,
A. Green2,1, L. Wilcox1, W. Boshoven2,1, B. Lewison1,2
1Mental Health Service, Atlanta VA, Decatur, GA, USA;
2Psychiatry and Behavioral Sciences, Emory University School of
Medicine, Atlanta, GA, USA; 3Human Genetics, Emory University
School of Medicine, Atlanta, GA, USA
Background: Patients with schizophrenia have difficulty screening out ir-
relevant stimuli, and often have the experience of sensory flooding. These
‘‘gating deficits’’ may contribute to the thought disorder, cognitive frag-
mentation, and hallucinations that are so debilitating to these individuals.
The acoustic startle response is a reflex contraction of the skeletal muscles
in response to a sudden acoustic stimulus. The modulation of this reflex by
a preliminary nonstartling stimulus is termed prepulse inhibition of acous-
tic startle (PPI), a paradigm used as an operational measure of sensorimo-
tor gating. Many patients with schizophrenia have impaired PPI, and
several lines of evidence suggest that PPI may represent a heritable endo-
phenotype in this disease. The purpose of this study was to examine her-
itability of acoustic startle measures in a sample of schizophrenia and
control families. Methods: We examined baseline startle, habituation,
PPI, and onset latency of the startle response in 40 schizophrenia patients
(SCZ), 58 of their first-degree relatives (SCZ-FAM), and 100 healthy con-
trols (CONT) from 45 families. The startle session consisted of pulse alone
trials to evaluate baseline startle, and prepulseþpulse trials with interstim-
ulus intervals of 30, 60 or 120 ms between the prepulse and pulse. Herita-
bility analyses were conducted using a variance-component approach that
adjusted for age, gender, race and smoking status. We also examined differ-
ences in startle measures between subject groups. Results: We found a sig-
nificant heritability of 45% for PPI at the 60-ms interval, and 67% for
baseline startle. Onset latency heritability estimates ranged between 39%
and 90% across trial types. There was no significant heritability of star-
tle habituation. We did not find differences between CONT and either
SCZ or their families for PPI, baseline startle, or habituation. Onset
latency was longer in SCZ and SCZ-FAM than CONT. Conclusions:
PPI at the 60-ms interval, baseline startle, and onset latency were sig-
nificantly heritable in this sample of schizophrenia and control families.
No PPI impairments were detected in SCZ or SCZ-FAM compared to
CONT. Latency was longer (ie, slower) in SCZ and SCZ-FAM than in
CONT. Our data indicate that assessing family members of schizophre-
nia patients in a between group design may not be sufficient to detect
the heritability of putative endophenotypes. Supported by VA Merit Re-
view Grant (E Duncan).
ID: 550870
ALTERED D2 MODULATION OF PREFRONTAL
CORTICAL INTERNEURONS IN DEVELOPMENTAL
ANIMAL MODELS OF SCHIZOPHRENIA
Patricio O’Donnell1, C. Feleder2, K.-Y. Tseng3
1Anatomy and Neurobiology, University of Maryland School of
Medicine, Baltimore, MD, USA; 2Pharmacceutical Sciences,
Albany College of Pharmacy, Albany, NY, USA; 3Pharmacology
and Experimental Therapeutics, Rosalind Franklin University of
Medicine and Science, North Chicago, IL, USA
We have recently shown that rats with a neonatal ventral hippocampal
lesion (NVHL) exhibit an abnormal periadolescent maturation of pre-
frontal cortical interneurons. Specifically, activation of D2 dopamine
receptors becomes strongly excitatory on parvalbumin GABA interneur-
ons during adolescence in naive rats, and this maturation does not occur
in rats that wit a NVHL. Adult NVHL rats also display sensorimotor
gating deficits and other behavioral anomalies similar to those observed
with prenatal maternal infection. We tested whether an immune chal-
lenge localized to the hippocampus would cause similar deficits with in-
tra-hippocampal injections of the bacterial endotoxin LPS during
postnatal day 7–8. Adult rats with LPS, but not sham treatment
exhibited deficits in prepulse inhibition of the acoustic startle response
and increased levels on cytokines in several brain regions. Whole-cell
recordings from fast-spiking interneurons revealed that slices obtained
from sham treated animals exhibited the normal D2-mediated increase
in excitability, whereas similar recordings in slices from LPS-treated
rats failed to yield that response. Thus, the data show that activation
of immune responses in the ventral hippocampus can yield anomalies
similar to what a lesion or prenatal immune challenge may cause, sug-
gesting that the hippocampal region may be a critical target of maternal
infection.
ID: 551940
THE EFFECT OF ATTENTIONAL TASK ON
PREATTENTIVE ERP MEASURES OF SENSORY
PROCESSING IN SCHIZOPHRENIA PATIENTS
Sung-Hyouk Park1,2, D. L. Braff1, G. A. Light1
1Department of Psychiatry, University of California, San Diego,
CA, USA; 2Department of Psychiatry, Seoul National Hospital,
Seoul, South Korea
Mismatch Negativity (MMN) and P3a are considered preattentive and au-
tomatic event-related potential components because they can be elicited in
the absence of directed attention. Deficits on these measures reflect abnor-
malities in the earliest stages of sensory information processing. The degree
of automaticity of MMN and P3a measures in nonpsychiatric subjects and
schizophrenia patients, however, has been a topic of debate. The aim of the
present study was to assess the role of attentional task manipulations on
MMN and P3a in nonpsychiatric comparison subjects and schizophrenia
patients. Standard (P = .84, 1000 hz, 50 ms), duration deviant (DD, P = .08,
1000 Hz, 100 ms), and white noise deviant (WND; P = .08, white noise,
50 ms) stimuli were presented with a fixed SOA of 500 ms across 4 identical
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paradigms that varied in attentional task. During ERP recording, subjects
1) passively watched a silent video (Video), 2) performed the identical-pairs
CPT (CPT), or were instructed to press a button when they heard either the
3) DD (Auditory Target Detection-DD; ATD-DD) or 4) WND (Auditory
Target Detection-WND; ATD-WND). 20 schizophrenia patients and 20
control subjects participated. The patients had significant reductions in
both MMN (F1,33 = 5.47, P < .05) and P3a (F1,33=12.62, P < .001) across
conditions. No significant group X condition interactions were present for
MMN or P3a amplitudes or latencies. Attentional (condition) effects were
observed for both MMN (F1,33 = 90.39, P < .001) and P3a (F2,32=2.58, P =
.09) where amplitudes in Video and ATD conditions were larger than
in CPT conditions. A significant effect of condition on MMN (F2,32 =
20.36, P < .001) and P3a (F2,32 = 13.29, P < .001) latency was present
with longer latencies observed in the ATD condition. The results of the
present study indicate that there are subtle effects of attention on ERP com-
ponents that can be elicited in the absence of directed attention (ie, ‘‘pre-
attentive’’). Across all tasks and conditions, schizophrenia patients had
robust MMN and P3a deficits in response to task irrelevant stimuli.
ID: 555045
IMPACT OF NEUROCHEMICAL MANIPULATION
ON SENSORY GATING IN HEALTHY SUBJECTS
WITH LOW GATING LEVELS
Philipp A. Csomor, F. X. Vollenweider
Clinical Research, Psychiatric University Hospital Zurich, Zurich,
Switzerland
Deficient early information processing has been considered a central fea-
ture of schizophrenia spectrum disorders. A fundamental feature of infor-
mation processing is the ability gate extraneous stimuli and to attend to
salient features of the environment. Two operational measures of gating
are prepulse inhibition (PPI) and suppression of the P50 event-related po-
tential (P50 suppression). PPI refers to the attenuation of the startle re-
action elicited by an intense pulse stimulus when its presentation is
preceded by a weak prepulse. Similarly, in P50 suppression the first stim-
ulus not only produces an auditory evoked potential (AEP) but also acti-
vates gating, resulting in a suppression of the P50 AEP to the second
stimulus. Patients with schizophrenia exhibit deficits in PPI and P50 sup-
pression. Since PPI and P50 can be induced in healthy volunteers, patients
and rodents, and many findings related to the neural regulation of gating
in animal studies have been supported by studies in humans, these para-
digms represent excellent tools for translational research. These gating
measures provide a unique opportunity to characterize the neurochemical
basis of information processing and might be useful for the discovery of
novel compounds with antipsychotic properties. We have developed
a model to investigate the possible effects of antipsychotics on PPI
and P50 suppression in healthy volunteers rather than in patients. Study-
ing healthy volunteers has the potential to overcome confounding effects
of previous medication exposure in patients, the wide range in severity of
psychopathology and the generally non-random allocation of patients to
treatment regimens. We previously found that the antipsychotic clozapine
increased PPI in subjects exhibiting low baseline sensorimotor gating. In
contrast, the antipsychotic haloperidol did not increase PPI in subjects
exhibiting low baseline gating levels. Furthermore, haloperidol increased
P50 suppression in those subjects with low P50 suppression levels, and
reduced P50 gating in individuals with high P50 gating levels. The poster
summarizes the results of further psychoactive compounds, including ari-
piprazole, risperidone and amisulpride which have been tested on our
model of gating in healthy humans exhibiting low baseline gating. The
data elucidate the applicability of our translational model to serve as a use-
ful tool for the assessment of the efficacy of novel pharmacotreatment
strategies for patients with schizophrenia.
ID: 554152
MATURATION OF TASK-RELATED NEURAL
SYNCHRONY AND ITS RELEVANCE FOR THE
DEVELOPMENT AND PATHOPHYSIOLOGY OF
SCHIZOPHRENIA
Peter J. Uhlhaas1,2, F. Roux1, C. Tillmann1, E. Rodriguez3,
M. Wibral5, F. M. Leweke4, W. Singer1
1Department Neurophysiology, Max-Planck Institute for Brain
Research, Frankfurt, Germany; 2Department of Psychiatry, Johann
Wolfgang Goethe University, Frankfurt, Germany; 3Laboratorio de
Neurociencias, Pontificia Universidad Cato´lica de Chile, Santiago,
Chile; 4Department of Psychiatry, University of Cologne, Cologne,
Germany; 5MEG-Lab, Johann Wolfgang Goethe University,
Frankfurt, Germany
Schizophrenia is associated with an onset of symptoms during late adoles-
cence and early adulthood, suggesting that aberrant brain maturation dur-
ing this period may be involved in the expression of psychosis. In the current
study, we examined task-related neural synchrony during human develop-
ment as well as its impairment in patients with schizophrenia with electro-
and magnetoencephalography (EEG, MEG) to examine the developmental
role of synchronized, oscillatory activity in the pathophysiology of schizo-
phrenia. Development of neural synchrony was investigated during percep-
tual integration in healthy children, adolescents and adult participants (N =
68) between 6–21 years. Perceptual integration was assessed with Mooney
faces which consist of degraded pictures of human faces where all shades of
grey are removed. EEG-recordings were analysed for spectral power as well
as for phase-synchronisation of induced oscillations. Behavioral data
showed that improved detection rates and reaction times with age were ac-
companied by pronounced increases in spectral power and phase-syn-
chrony in the theta-, beta- and gamma-band. This development
occurred in two distinct phases the transition being characterized by
a marked reorganization of network topology and reduction of neural syn-
chrony during adolescence. Following late adolescence, we observed signif-
icant increases of spectral power and phase-synchronization in the theta-,
beta- and gamma-band during early adulthood. EEG/MEG experiments
using the same experimental paradigm show that patients with first-episode
and chronic schizophrenia are specifically impaired in indexes of neural
synchrony that undergo important changes during adolescence. Thus,
patients with schizophrenia are characterised by reduced high-frequency
gamma-band activity and decreased long-range synchronisation in the
theta- and beta-band during perceptual organisation. These data suggest
close relations between the expression and the increase of temporal
precision of synchronous, oscillatory activity, the reorganization and mat-
uration of functional networks. Specifically, we propose that the pro-
nounced changes in neural synchrony during adolescence reflect
a critical developmental period that is associated with a major rearrange-
ment of functional networks that may be related to the development of
schizophrenia during the transition from adolescence to adulthood.
ID: 552124
MULTIBLOCK AUDITORY APPROACH IN
SCHIZOPHRENIA PATIENTS
Murat Ozgoren1, A. Oniz1, S. Taslica1, A. Aktener2, B. Akdede2,
K. Alptekin2
1Department of Biophysics, Dokuz Eylul University, Faculty of
Medicine, Izmir, Turkey; 2Department of Psychiatry, Dokuz Eylul
University, Faculty of Medicine, Izmir, Turkey
The schizophrenia research area is one of the most challenging ones among
the other pathologies, as the disorder requires advanced and combined
efforts to verify onset and progress. This validates any method to tackle
this problem with parameters including cost effectiveness, clinical relative
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ease of application, test-retest etc. Accordingly, a multi-level auditory bat-
tery is being developed in our laboratory with different features. The presen-
tationwill provide theresults from thesame individualsmainly in threemajor
test divisions: (A) the modified optimal MMN, (B) the modified DL and (C)
simple auditory event related potentials. The modified MMN was applied
while watching a black and white silent movie. The stimuli consisted of du-
ration, intensity, frequency and location deviants applied in a pseudo-ran-
dom design. The modified DL paradigm consisted of consonant vowels (/ba/,
/da/, /ga/, /ka/, /pa/ and /ta/) presented through a headphone diotically or
dichotically. The simple AERP consisted of stimuli of sinusoidal waveforms
presented binaurally, where the target occurred in 20 percent of cases (1500
Hz standard, 1600 Hz target). The EEG recording was done using a 64-chan-
nel Neuroscan amplifier and the Embedded Microcontroller based Interac-
tive Stimulus Unit (EMISU). The subject group was formed of 13 patients
(age 23–54 years, mean 37.0) with schizophrenia (DSM-IV criteria) and 13
healthycontrolsubjects (age21–50years,mean34.2).Thepreliminaryresults
were as follows: (A) duration and frequency deviations to be diminished in
schizophrenia patients in respect to controls (P< .05). The MMN procedure,
effectively distinguished the four above mentioned auditory specifications in
bothpatientsandcontrols.The grandaveragewave formsbefore subtraction
point to a distinctly different wave pattern with clear responses in the con-
trols. (B) The DL pointed to Right Ear Advantage both for patients and for
controls. The error rates were higher for patients than controls (P< .05). C)
The simple P300 component was diminished in patients (P< .05). The overall
results could carry out various auditory components in a joined battery de-
sign. The cost-effectiveness, comparative ease of application, objective as-
sessment features can become useful parameters for monitoring the brain
information processing in schizophrenia as well as other cases. (Supporting
projects DEU.2006.KB.SAG.038–017).
ID: 552106
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5. 5. Eye Movement Physiology
SCHIZOPHRENIA AND BIPOLAR PATIENTS
MANIFEST A COMMON INTERMEDIATE
PHENOTYPE OF DEFICIENT SENSORIMOTOR
TRANSFORMATION
Rebekka Lencer2,1, M. H. Harris2, J. L. Reilly2, M. S. Keshavan3,
J. A. Sweeney2
1Psychiatry and Psychotherapy, University of Luebeck, Luebeck,
Germany; 2Center for Cognitive Medicine, University of Illinois at
Chicago, Chicago, IL, USA; 3Psychiatry, Harvard Medical School,
Boston, MA, USA
Background: Pursuit eye tracking deficits that are regarded as intermediate
phenotype for schizophrenia may result from distinct disturbances of neu-
rocognitive processes including visual motion processing, sensorimotor
transformation, or the utilization of predictive mechanisms. Which of these
disturbances are the primary causes of the eye tracking phenotype, and
whether they are present in other psychotic disorders is yet unclear. Meth-
ods: First-episode patients with either bipolar disorder (N = 33), major de-
pression with psychosis (N = 23) or schizophrenia (N = 73) were matched to
111 healthy subjects. Participants performed three smooth pursuit para-
digms at different target speeds (4, 8, 16, 24, 32) to evaluate sensori-
motor transformation and predictive pursuit abilities. All patients were
unmedicated at the time of testing with 108 patients being antipsychotic-
naı¨ve and 21 patients having a median life-time exposure to antipsychotics
of two weeks. Results: Pursuit initiation gain was impaired in patients with
bipolar disorder and schizophrenia (P = .014) but bipolar patients initiated
pursuit later than all other groups (P = .007). Visual motion processing dur-
ing pursuit initiation as indicated by the saccade error in a step-ramp task
was not impaired in any group. While maintenance pursuit gain with un-
predictable ramp targets was reduced in all three patient groups compared
to healthy participants (P < .001), bipolar patients exhibited more severe
impairments than did patients with schizophrenia (P < .001) or psychotic
major depression (P < .001). No difference between groups was found for
smooth pursuit of predictive pursuit. Conclusions: During initiation and
maintenanceofpursuitofunpredictabletargets,whicharedependentondirect
transformation of sensory input signals into motor commands, disturbances
weremore severe in patients withbipolar disorder than inpatients withschizo-
phreniaalthoughbothgroupswere impaired. Inpatients withpsychoticmajor
depression,sensorimotortransformationimpairmentsweredetected,butonly
during maintenance pursuit. These findings imply that psychotic disorders,
especially bipolar disorder and schizophrenia, both manifest a common inter-
mediate phenotype of impaired sensorimotor transformation abilities point-
ing to disturbances in fronto-striatal circuits. In contrast, core visual motion
processing related to extrastriate area V5 appears to be unaffected in all three
patient groups with psychosis.
ID: 549036
TAKING ANIMAL BEHAVIORAL
PHARMACOLOGY PARADIGMS INTO CLINICAL
TRIALS TO EVALUATE COGNITIVE OUTCOMES
John A. Sweeney, J. Reilly, S. Hill, M. Harris, C. Rosen,
P. J. Weiden
Psychiatry, University of Illinois, Chicago, IL, USA
Selecting cognitive tasks for schizophrenia trials has many challenges.
Investigators typically choose between well-standardized neuropsycholog-
ical tests that tap into a generalized cognitive deficit vs. tasks that evaluate
particular cognitive functions known to be regulated by specific brain cir-
cuits and transmitter systems chosen on the basis of drug mechanism of ac-
tion. This presentation will make the case for the benefits of the latter
approach using tests of sensorimotor skills, working memory, procedural
learning and voluntary inhibitory control. It will contrast findings from neu-
ropsychological and translational oculomotor testing and fMRI studies in
untreated first episode patients examined before and 6-weeks after antipsy-
chotic treatment. Data will be presented from our Pittsburgh and Chicago
studies (now 60 total patients) where similar recruitment strategies, treat-
ment and cognitive measures were used. The data shows robust pretreatment
neuropsychological deficits in schizophrenia and marginal change after
treatment, consistent with many studies. In the same patients, while the mag-
nitudes of pretreatment oculomotor and neuropsychological deficits were
similar, oculomotor measures had significantly greater sensitivity to the neu-
rocognitive impact of antipsychotic treatment. Further, unlike the profile of
modest consistent change of neuropsychological performance after treat-
ment, oculomotor findings indicated greater post-treatment changes,
some beneficial and some adverse. The neurophysiological findings are con-
sistent with behavioral pharmacology research with nonhuman primates
performing the same tasks after D2 antagonists are given. Preliminary
data with fMRI studies using oculomotor tasks show treatment effects
that are larger even than laboratory neurophysiological testing. These
data will be used to illustrate the greater sensitivity and selectivity of trans-
lational neurophysiological measures compared to neuropsychological tests
for assessing the neurocognitive effect of antipsychotic treatment. Such neu-
roscience measures may be useful cognitive outcomes in clinical trials—per-
haps especially in Phase 2 proof of concept studies. Translational outcome
measures that build on animal model platforms in which the neurophysiol-
ogy and neurochemistry of brain systems supporting task performance are
well characterized may be especially useful in this regard.
ID: 550508
IS MOTION PERCEPTION DEFICIT IN SCHIZO-
PHRENIA A CONSEQUENCE OF EYETRACKING
ABNORMALITY?
Elliot Hong1, K. A. Turano2, H. B. O’Neill1, L. Hao2, I. Wonodi1,
R. P. McMahon1, G. K. Thaker1
1Department of Psychiatry, University of Maryland, Maryland
Psychiatric Research Center, Baltimore, MD, USA; 2Wilmer Eye
Institute, Lions Vision Center, Johns Hopkins School of Medicine,
Baltimore, MD, USA
Background: Studies have shown that schizophrenia patients have motion
perception deficit, which is correlated with poor eyetracking performance.
These findings suggest that motion perception may cause eyetracking ab-
normality in schizophrenia. However, eye movement closely interacts with
motion perception. In this study, we examined how the known eyetracking
difficulties in schizophrenia patients may interact with their motion percep-
tion. Method: Two speed discrimination experiments were conducted in
a within-subject design. In Experiment 1, the stimulus duration was
150ms to minimize the chance of eyetracking occurrence. In Experiment
2, the duration was increased to 300ms, increasing the possibility of eye
movement intrusion. Regular eyetracking performance was evaluated in
a third experiment. Results: At 150ms, speed discrimination thresholds
did not differ between schizophrenia patients (n = 38) and controls (n =
33). At 300ms, patients had significantly higher thresholds than controls
(P = .03). Furthermore, frequencies of eyetracking during the 300ms stim-
ulus were significantly correlated with speed discrimination in controls (P =
.01) but not in patients, suggesting that eyetracking initiation may benefit
controls but not patients. The frequency of eyetracking during speed dis-
crimination was not significantly related to regular eyetracking perfor-
mance. Conclusions: Speed discrimination, per se, is not impaired in
schizophrenia patients. The observed abnormality appears to be a conse-
quence of impairment in generating or integrating the feedback information
from eye movements. This study introduces a novel approach to motion
perception studies, and highlights the importance of concurrently measur-
ing eye movements to understand interactions between these two systems;
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the results argue for a conceptual revision regarding motion perception ab-
normality in schizophrenia.
ID: 550203
BEHAVIORAL CHANGES FOLLOWING
DAILY PRACTICE OF SACCADE TASKS IN
SCHIZOPHRENIA
Madison Moore1, B. P. Austin2, K. A. Dyckman4, Q. Li2,
M. T. Amlung2, F. Meyer5, B. A. Clementz3, J. E. McDowell3
1Psychology, University of Georgia, Athens, GA, USA;
2Department of Psychology, Bio-Imaging Research Center,
University of Georgia, Athens, GA, USA; 3Departments of Psy-
chology and Neuroscience, Bio-Imaging Research Center, University
of Georgia, Athens, GA, USA; 4Department of Psychiatry, Mas-
sachusetts General Hospital, Charlestown, MA, USA; 5Department
of Psychology, University of Konstanz, Konstanz, Germany
It has been well documented that people with schizophrenia show impair-
ment in tasks requiring executive control such as inhibition. A simple test of
inhibition is the antisaccade task, which requires a glance towards the mir-
ror image of a peripheral cue. The goal of the current study is to determine
how practice on the antisaccade task changes performance on that task and
on related tasks known to assess executive control. Participants with schizo-
phrenia and healthy comparison subjects were assigned a single saccade
task to practice daily—either antisaccades or prosaccades (glances towards
a cue)—over a two-week period. Generalized executive control was evalu-
ated at pre- and post-test using two tasks. First, an ocular motor delayed
response (ODR) task was selected as a direct measure of changes due to
practice on a related, but distinctly different, saccade task. Second, the Wis-
consin Card Sorting Test (WCST) was selected as a means of evaluating
whether changes in executive control could be generalized beyond saccade
tasks. Preliminary results suggest that the healthy comparison group that
practiced antisaccades showed improved antisaccade performance across
the duration of the study, as well as improved performance on other exec-
utive function measures. The schizophrenia group that practiced antisac-
cades also showed an improvement in performance across executive
control measures. The schizophrenia group that practiced prosaccades,
however, showed poorer performance specifically on the ODR task by
making more anticipatory saccades. In sum, practice with saccade tasks
resulted in modest improvement in saccade task performance in both
schizophrenia and comparison groups. An exception is that the schizophre-
nia prosaccade-practice group showed more disrupted performance. This
study provides evidence that saccadic performance can be malleable within
certain parameters. The results are also are interesting for their practical
implications. If improvement on other tasks of executive control continues
to be seen in the schizophrenia antisaccade practice group, it suggests that
purposefully practicing executive control may be explored as a means of
improving activities of daily living. This research was supported in part
by a grant from the National Institute of Mental Health (MH076998)
and by the University of Georgia Honors Program’s Center for Undergrad-
uate Research Opportunities and the CURO 2008 Biomedical and Health
Sciences Research Fellowship.
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SCHIZOPHRENIA AND PSYCHOTIC BIPOLAR
DISORDER, BUT NOT PSYCHOTIC DEPRESSION,
SHARE INTERMEDIATE PHENOTYPE FOR
RESPONSE SUPPRESSION DEFICITS DURING
EARLY COURSE OF ILLNESS
Margret S. H. Harris; J. L. Reilly, C. Rosen, S. K. Keedy,
O. DeLeon, R. Marvin, P. J. Weiden, J. A. Sweeney
Department of Psychiatry, Center for Cognitive Medicine,
University of Illinois at Chicago, Chicago, IL, USA
Background: Response suppression deficits due to reduced voluntary
control of behavior have been investigated using antisaccade tasks and
are considered a promising intermediate phenotype for schizophrenia.
Disturbances in frontostriatal systems are believed to be the cause of
this deficit. Recently, multiple similarities across schizophrenia and psy-
chotic mood disorders have been demonstrated, including responsiveness
to antipsychotic medications, MRI morphometry, genetic linkage findings,
and cognitive performance deficits. Yet, few oculomotor studies have in-
vestigated the diagnostic specificity of this effect across psychotic disorders.
Methods: Unmedicated first-episode psychosis patients with schizophrenia
(N = 31), psychotic bipolar disorder (N = 21), or psychotic major depression
(N = 15) and 45 age- and IQ-matched healthy participants performed gap/
overlap antisaccade and visually-guided saccade control tasks. Results:
Both schizophrenia and psychotic bipolar patients showed similar and
higher antisaccade error rates than healthy individuals and psychotic de-
pression patients whose performance did not differ. No impairment of
the latencies of correct antisaccades was evident for any patient group.
Also, no group differences were observed for the accuracy or speed of vi-
sually-guided saccades, indicating intact sensory-motor systems across pa-
tient groups. For all groups, gap trials resulted in greater antisaccade error
rates and shorter antisaccade latencies as well as less accurate and faster
reflexive saccades compared to overlap trials. Conclusions: Results suggest
that a reduced ability to suppress context inappropriate behavior, reflected
in increased antisaccade error rates, may represent a shared intermediate
phenotype for schizophrenia and psychotic bipolar disorder. Contrary
to one of our previous studies, psychotic depression patients did not dem-
onstrate antisaccade performance impairments. These findings suggest that
both schizophrenia and psychotic bipolar disorder patient groups may ex-
perience a disruption of the prefrontal-striatal circuitry, via similar or dif-
ferent pathophysiologies, causing comparable cognitive abnormalities
across the disorders. Supported by R01 MH62134, R01 MH080066,
NARSAD.
ID: 551541
THE RELATIONSHIP BETWEEN OCULOMOTOR
MEASURES OF PREDICTIVE PURSUIT AND NEU-
ROPSYCHOLOGICAL MEASURES OF WORKING
MEMORY IN PATIENTS WITH SCHIZOPHRENIA
AND BIPOLAR DISORDER
Amanda F. Moates1, E. Ivleva1, D. Cole1, R. Gonzales1,
M. Cullum1, L. E. Hong2, G. Thaker2,1, C. Tamminga1
1Psychiatry, UT Southwestern Medical Center at Dallas, Dallas,
TX, USA; 2Maryland Psychiatric Research Center, University of
Maryland Medical School, Baltimore, MD, USA
Oculomotor deficits have been well-documented in patients with schizophre-
nia (SZ) and a subset of their unaffected relatives, likely reflecting alterations
within the prefrontal cortex (FEF) and genetic liability for the disease. Inves-
tigation of specific components of the smooth pursuit eye movement system
has shown deficits in the predictive pursuit mechanism as seen by a reduced
gain (ratio of the eye velocity to target velocity) in response to a briefly invis-
ible target. Newer techniques, such as a novel covert stabilization technique
developedbyHonget al. (2007),allowmoreprecisemeasurementof thebrain
mechanismunderlyingthispredictivemechanismbystabilizingthe target im-
age on the fovea and eliminating overt awareness on target removal. Al-
though fewer studies of eyetracking dysfunction have been conducted in
patients with bipolar disease (BD), and particularly their families, some
data have suggested deficits in affective disorders that parallel those seen
in SZ. Independently, deficits in working memory have been established in
both groups of patients and family members. The working memory system
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has been hypothesized to be the cornerstone of executive function processes,
mediatedintheprefrontalcortex,andfoundtobeimpairedinthesedisorders.
The primary goal of this research is to characterize the relationship between
deficits in these two areas across both diagnostic groups and relatives, as
working memory is thought to contribute to the predictive pursuit mecha-
nism, and both may be promising endophenotypic markers of psychosis.
Thus far 147 patients have been enrolled with diagnoses spanning the diag-
nostic categories as follows: 46 SZ, 30 schizophrenia relatives, 34 BD, 25
bipolar relatives, and 12 comparison subjects. A broad battery of neuropsy-
chologicaltestsandoculomotortaskswereperformedaspartof largergenetic
phenotyping study. Results from neuropsychological measures of working
memory(Wechsler Letter-Number SequencingandSpatial Span)will be cor-
related with predictive pursuit measures of eyetracking, specifically predic-
tiveaccelerationandpredictivegain. Data frombothatraditionalmeasureof
predictive pursuit abnormalities and from a newer novel covert stabilization
technique developed by Hong et al. will be presented.
ID: 551212
PREDICTION IN SMOOTH PURSUIT OF
SCHIZOPHRENIC PATIENTS
Andreas Sprenger1, W. Heide1,3, M. Nagel2, R. Lencer2
1Neurology, University Luebeck, Luebeck, Germany; 2Psychiatry
and Psychtherapy, University Luebeck, Luebeck, Germany;
3Neurology, City Hospital Celle, Celle, Germany
Background: The mechanisms of smooth pursuit eye movement (SPEM)
deficits in patients with schizophrenia are still under debate. Pursuit blank-
ing experiments have been used to test prediction components of pursuit
performance (eg, Becker and Fuchs, Barnes et al.). A recent pursuit blank-
ing fMRI study (Nagel et al. 2007) indicates that temporal (STG), frontal
(FEF) and cingulate brain areas (ACC) are more activated during predic-
tive pursuit in schizophrenia patients compared to healthy controls, that
seem to rely more on cerebellar mechanisms (Crus VIIIA). In a laboratory
experiment we wanted to test the oculomotor functions at different target
velocities and blanking durations in order to obtain more evidence for the
role of prediction during smooth pursuit eye movements of patients with
schizophrenia. Methods: Twenty patients and 20 age- and gender-matched
controls performed a pursuit blanking task at two target velocities (10, 15/
s) and two blanking intervals (666, 1000 ms). Eye movements were recorded
by high resolution infrared videobased oculography. Results: Patient’s
smooth pursuit velocity was significantly lower compared to healthy con-
trols. After the target was blanked off, the deceleration of eye movement
velocity started after the same time interval in both groups. However, the
deceleration velocity was significantly slower in the patient group than in
controls. The acceleration after reappearance of the target started earlier in
controls than in patients but the acceleration itself was the same in both
groups. Conclusion: When a movement has to be continued after the stim-
ulus has disappeared, patients with schizophrenia seem to rely to a higher
extent on mechanisms of prediction and velocity storage than healthy sub-
jects. Our results could explain why patients with schizophrenia are consid-
erably impaired during pursuit of randomized step-ramp but much less
during highly predictable sinusoidal stimuli.
ID: 552599
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6. 6. Epidemiology
MENSTRUAL DISORDERS IN SCHIZOPHRENIA,
POSSIBLE CAUSES AND CONSEQUENCES
Rikus Knegtering, J. Ouwehand, S. Sytema, D. Wiersma
Psychiatry, University Medical Center Groningen, Rob Giel
Research Center, BCN, University of Groningen, Groningen,
Netherlands
Menstrual Disorders (MDs) like oligomenorrhea or amenorrhea are often
found in women with schizophrenia. Although MDs are often considered
to be antipsychotic medication related, a systematic literature review did
not support this view (Ouwehand and Knegtering in preparation). The
understanding of mechanisms involved in MDs may increase our under-
standing of the pathogenesis of MDs and schizophrenia. Method: After
being treated for 6 weeks with an antipsychotic information on MDs (us-
ing the ASFQ (Knegtering et al. 2003)), medication and blood levels of
antipsychotics and hormones were evaluated in all women with schizo-
phrenia aged 17 till 40 years attending the University Medical Center
of Groningen. Results: 71 women fulfilled inclusion criteria (including
no known organic causes for MD), mean age 27 (SD7) years). 22 women
used Oral Contraceptives (OC). 43 used prolactin elevating antipsychotics
(classical antipsychotics, risperidone), 28 prolactin sparing (clozapine,
quetiapine, olanzapine, sertindole, aripiprazole). Women using prolactin
elevating antipsychotics reported more often MDs (13 out of 27 =
(48%)) than women using prolactin sparing antipsychotics (4 out of 22
= (18%)), (v2, P = .015). OC and age did not predict MD. Prolactin levels
predicted MDs (ANOVA F = 5.278, P = .025). Independent of prolactin
levels these women with schizophrenia reported more MDs in comparison
to epidemiological comparable groups (prevalence in normal population
of same age is about 1% (van der Linden et al. 2004)). Conclusion: Pro-
lactin elevation during treatment with antipsychotics for six weeks was
associated with more frequent MD. Prolactin may not be to only factor
involved. Before the introduction of antipsychotics high numbers of MD
have been reported in women with schizophrenia. More studies are war-
ranted to understand the pathophysiology of schizophrenia and MD in
women.
References
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TIME-TO-PREGNANCY AND RISK OF
SCHIZOPHRENIA IN OFFSPRING
Mark G. Opler1,3, K. Ornstein2, M. Perrin1,3, K. Kleinhaus1,3,
S. Harlap1,3, D. Malaspina1,3
1Psychiatry, New York University Medical Center, New York, NY,
USA; 2Epidemiology, Columbia University, New York, NY, USA;
3Environmental Medicine, New York University Medical Center,
New York, NY, USA
Abstract: Several studies have reported advanced paternal age as a risk
factor for schizophrenia. Given the likely role of paternal reproductive
health in this relationship, other factors associated with male fertility
should be examined. One variable that has been utilized in prior studies
of fertility, time-to-pregnancy may serve as a useful indicator. Using data
from the prospective Jerusalem Perinatal Study (JPS), a pregnancy co-
hort, data from prenatal interviews was linked to systematically collected
data on mental health outcomes in offspring. Examining those subjects
with intentionally conceived pregnancies, a modest increase in risk of
schizophrenia in offspring was measured in those with time-to-pregnancy
>6 months (OR = 1.63, 95% CI: 1.02, 2.60). When the relationship was
examined on the basis of parents’ ages at conception, it was discovered
that the risk was further increased for subjects with fathers >35 years old
and increased time-to-pregnancy (OR = 2.49, 95% CI: 1.05, 5.89). Ma-
ternal age did not appear to have the same influence on risk associated
with time-to-pregnancy in this sample. For subjects from more reli-
giously observant families, the risk associated with increased time-to-
pregnancy was statistically significant (OR = 2.09, 95% CI: 1.07, 4.1),
possibly due to reduced misclassification. These findings suggest that bi-
ological mediators related to paternal reproductive health, associated
with increased paternal age and increased time-to-pregnancy may be re-
sponsible for increasing the risk of schizophrenia. Additional research
using both epidemiologic approaches and laboratory methods are cur-
rently underway.
ID: 550801
CLINICAL AND FUNCTIONAL OUTCOME IN
SCHIZOPHRENIA AMONG A PREDOMINANTLY
TREATMENT-NAI¨VE COHORT IN RURAL
ETHIOPIA
Abebaw Fekadu1,2, D. Kebede3, T. Shibre2, A. Alem2
1Psychological Medicine, King’s College London, Institute of
Psychiatry, London, United Kingdom; 2Department of Psychiatry,
Faculty of Medicine, Addis Ababa University, Addis Ababa,
Ethiopia; 3World Health Organization, Regional Office for Africa,
Brazzaville, Congo
Background: The established view that schizophrenia has a favorable out-
come in developing compared to developed countries has been recently
challenged. However, systematic studies from developing country settings
are scarce. We present the clinical and functional outcome of schizophrenia
among a predominantly treatment-naive cohort in a rural community set-
ting in Ethiopia. Methods: Cohort was identified in a 2-stage sampling de-
sign using key informants and measurement-based assessment. After
screening 68 378 adults, ages 15–49 years, 321 cases with schizophrenia
(82.7% men and 89.6% treatment-naive) were identified and systematically
followed-up for 3.4 years. Results: Almost a third (30.8%) of cases were
continuously ill and most of the remaining cohort experienced an episodic
course. Only 5.7% of the cases enjoyed a near-continuous complete remis-
sion although 27.4% were in complete remission in the month of the final
follow-up assessment. Living in a household with 3 or more adults, later
age of onset, and taking antipsychotic medication for at least 50% of the
follow-up period independently predicted complete remission. Functioning
and other measures of health related quality of life were significantly di-
minished in cases as compared to the general population of the area at
baseline and follow up. The level of functioning observed in cases from
Butajira was also lower than that reported for cases from developed coun-
tries. Conclusion: Both the functional and clinical outcome of schizophre-
nia in this setting appears to be worse than reported elsewhere in
developing countries. Additionally, functional outcome in this setting
appears to be even worse than that reported in developed countries.
Thus our findings support the observation that the outcome of schizophre-
nia in developing countries may be heterogeneous rather than uniformly
favorable.
ID: 550785
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SCHIZOPHRENIA AMONG THE BORANA
PASTORALIST COMMUNITY IN SOUTHERN
ETHIOPIA: A RE-VISIT OF CASE ASCERTAINMENT
METHODOLOGY
Teshome Shibre Kelkile1, S. Teferra1, M. Araya1, C. Morgan2
1Department of Psychiatry, Faculty of Medicine, Addis Ababa
University, Addis Ababa, Ethiopia; 2Health Services and Population
Research Department, King’s College London, Institute of Psychi-
atry, London, United Kingdom
There are few reports on the prevalence of psychotic disorders among
isolated population groups. The major challenge is establishing a meth-
odologically sound system of case identification. In our population
based survey of the Borana pastoralist community in Ethiopia, we found
an overall prevalence of psychiatric disorders, assessed using the Com-
posite International Diagnostic Interview (CIDI), of 21.6%. However,
no case of schizophrenia was identified. We set out to investigate whether
this was because of the absence of schizophrenia or a function of the how
serious mental disorder is conceptualised in the Borana pastoralist com-
munity. We conducted 6 Focus Groups (FG) with key members of the
Borana pastoralist community, in order to investigate how serious men-
tal disorder is conceptualized. Subsequently, the FG participants were
used as Key Informants (KI) to identify cases with a possible psychotic
disorder, based on their conceptualization. Cases identified by KIs were
interviewed by a trained psychiatrist using a semi-structured interview
instrument, the Schedules for Clinical Assessment in Neuropsychiatry
(SCAN) to confirm presence of disorder. Out of 56 individuals invited
to the FGs, 49 (87.5%) participated. Participants were 25–60 years of age
and 26 (46.4%) were women. The concept of serious mental disorder
among the FG participants was informed by traditional beliefs and attri-
butions. However, there was a marked overlap between the behavioural,
emotional and biological signs identified by FG participants and those
described in modern classification systems. Following the FG, partici-
pants identified 6 individuals with schizophrenia and 13 with a psychotic
mood disorder that were subsequently confirmed through SCAN inter-
views. Concepts of serious mental disorder in the Borana pastoralist
community reflected traditional beliefs and practices. Nevertheless, indi-
viduals with a psychotic disorder were easily identified by key inform-
ants. The inability of the CIDI to identify any cases of schizophrenia
in our initial prevalence survey cannot be fully attributed to the distinct
local conceptualizations of these disorders. Studies of psychotic disor-
ders in such communities may benefit from combining structured inter-
views with the key informant method.
ID: 550758
REHOSPITALIZATION RATES OF PATIENTS
DISCHARGED WITH HALOPERIDOL OR
OLANZAPINE OR RISPERIDONE OR SULPIRIDE OR
ZIPRASIDONE OR CLOZAPINE AND ITS RELATION
TO PREVIOUS TREATMENT
Ana Paula Werneck1, H. Elkis1, J. A. Pinto2
1Department and Institute of Psychiatry, University of Sa˜o Paulo,
Sa˜o Paulo, Brazil; 2Institute of Mathematics and Statistics,
University of Sa˜o Paulo, Sa˜o Paulo, Brazil
It is well established that antipsychotics represent the mainstay of treatment
for schizophrenia. An important outcome variable for drug effectiveness
is relapse/rehospitalization prevention. Based on the previous review we
hypothesize that second generation antipsychotics are superior to conven-
tional antipsychotics for preventing relapse and rehospitalizations. Hence,
the aim of this study was to observe rehospitalization rates of patients dis-
charged on a regimen of haloperidol or olanzapine or risperidone or sul-
piride or ziprasidone or clozapine. Data were collected from charts and
hospital database. Survival curves were estimated by the product-limit
(Kaplan-Meier) formula. A total of 118 patients entered the selection
and were followed-up from discharge date (between January 2000 and De-
cember 2004) until December 2007. The percentage of patients remaining
discharged were 70% for haloperidol, 86% for olanzapine, 59% for risper-
idone, 90% for sulpiride, 75% for ziprazidone and 75% for clozapine. There
were no significant differences in readmission rates among groups (Log
Rank = 10,84, df = 5, P = .055). The results demonstrate lower rehospital-
ization rates for sulpiride and olanzapine and lower rate for risperidone,
with clozapine, haloperidol and ziprasidone in an intermediate position.
Risperidone along with haloperidol and olanzapine were the most frequent
choices for naı¨ve patients and clozapine, according to our expectations, was
started in most patients with history of use of three or more antipsychotics
previous to hospitalization. It is interesting to observe that there is a signif-
icant trend that could indicate differences among antipsychotics in rehospi-
talization rate that is not statistical different in this study due to a small
sample size.
ID: 550754
SPECIFICITY OF ASSOCIATION BETWEEN
CHILDHOOD ABUSE AND PSYCHOSIS IN
A CLINICAL FIRST-EPISODE SAMPLE
Helen Fisher1, C. Morgan1, K. Morgan1, P. Dazzan1, G. Doody2,
T. Craig1, J. Leff1, P. McGuffin1, P. Jones3, R. Murray1,
P. Fearon1
1Psychological Medicine, Institute of Psychiatry, KCL, London,
United Kingdom; 2Division of Psychiatry, University of Nottingham,
Nottingham, United Kingdom; 3Department of Psychiatry,
University of Cambridge, Cambridge, United Kingdom
Childhood adversity has been associated with increased risk of developing
psychotic symptoms in adulthood but these studies are methodologically
limited. Therefore, this study sought to explore the prevalence of childhood
abuse amongst those with and without a psychotic disorder using detailed
assessments of a large epidemiological case-control sample. Information
relating to different types of childhood maltreatment (parental neglect
and antipathy, physical and sexual abuse) was obtained using the Child-
hood Experiences of Care and Abuse Questionnaire (CECA.Q). Data
were collected on 182 first-presentation psychosis cases and 246 epidemi-
ologically-matched controls drawn from two UK centres as part of the
ÆSOP study. Initial exploration of the data demonstrated that there
was good test-retest reliability over 7 years (physical abuse: k = 0.634,
P < 0.001; sexual abuse: k = 0.590, P < .01) and convergent validity (spec-
ificity: 100% physical abuse and 98% sexual abuse) for reports of childhood
abuse from participants diagnosed with psychosis. Analysis revealed that
psychosis cases were three times more likely to report severe physical abuse
from mother that commenced prior to 12 years of age, even after adjust-
ment for other forms of adversity, gender, ethnicity, age at interview, study
centre and parental social class (OR = 3.15, 95% CI = 1.13–8.78, P = .028).
Further, there was a trend for reports of severe childhood sexual abuse to
be associated with around a two-fold increased risk for psychosis but this
failed to reach significance after adjustment for all confounders (OR = 2.09,
95% CI = 0.95–4.96, P = .065). Paternal physical, parental neglect and an-
tipathy did not significantly predict psychosis case status. These findings
provide more comprehensive evidence of the association between childhood
adversity and development of psychosis in adulthood and lend support to
the hypothesis that it is particularly intrusive early life events which are
important in the aetiology of psychotic disorders. Further analyses are
underway to explore the potentially mediating role of familial susceptibility
and candidate genes.
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DESCRIPTIVE EPIDEMIOLOGY AND COMORBID-
ITY OF SCHIZOPHRENIA VS. BIPOLAR DISORDER
IN THE NATIONAL HOSPITAL DISCHARGE
SURVEY (NHDS)
Natalya Weber1, D. N. Cowan1, S. A. Bedno1, M. A. Cavicchia1,
R. Yolken2, D. W. Niebuhr1
1Epidemiology, Walter Reed Army Institute of Research, Silver
Spring, MD, USA; 2Neurovirology, Johns Hopkins University
School of Medicine, Baltimore, MD, USA
Introduction: Medical morbidity and mortality rates in schizophrenia and
bipolar disorder patients are elevated compared to the general US popu-
lation. More than 50% of patients with schizophrenia and bipolar disorder
have been diagnosed with one or more comorbid conditions. In addition
to providing descriptive epidemiology, the purpose of this study is to iden-
tify serious medical comorbidity occurring more frequently among those
hospitalized with schizophrenia than those with bipolar disorder. Meth-
ods: Using the 1979–2003 National Hospital Discharge Survey
(NHDS), we evaluated temporal trends in the proportional morbidity
(PM) of schizophrenia and bipolar disorder, demographic characteristics
and the most frequent comorbid conditions among hospitalizations with
schizophrenia, compared to hospitalizations with bipolar disorder. The de-
mographic characteristics and comorbidity are presented for the NHDS
sample of 5 731 450 records. Results: Percent of hospitalized with schizo-
phrenia versus bipolar disorder was higher among males (PM ratio 1.5)
than females, blacks (2.7) and other (1.6) compared with whites, age group
45–64 (9.8) followed by 15–44 (9.3) and 65þ (8.0) compared with those
younger than 15, Northeast and West (1.2) followed by Midwest (1.1)
compared with South. There was a significant increase over time in the
proportion of discharges with schizophrenia and bipolar disorder and
a significant decrease in the mean length of hospital stay. Compared
with bipolar disorder discharges, those with schizophrenia have a signifi-
cantly higher proportion of comorbidity with the following system groups
of medical conditions: neoplasms (overall PM ratio 1.1), diseases of blood-
forming organs (1.2), respiratory (1.1), genitourinary (1.1) systems, as well
as diseases of the skin and subcutaneous tissue (1.2). In addition, we iden-
tified a number of serious specific medical conditions occurring at least 1.5
times more frequently among discharges with schizophrenia. Discussion:
We found that compared with bipolar disorder, those hospitalized with
schizophrenia were more likely to have some serious comorbidity both
at the system level and for certain specific conditions. These finding
may justify higher scrutiny for those conditions during clinical examina-
tion of schizophrenia patients. Closer attention to prevention, early diag-
nosis and treatment of comorbid conditions may decrease medical
morbidity and mortality and improve the prognosis of schizophrenia
patients.
ID: 550643
ADULT-ONSET SCHIZOPHRENIA IN THE US
MILITARY: PATTERNS BY SEX, RACE AND AGE
David N. Cowan1, N. S. Weber1, S. A. Bedno1, M. A. Cavicchia1,
R. Yolken2, D. W. Niebuhr1
1Epidemiology, Walter Reed Army Institute of Research, Silver
Spring, MD, USA; 2School of Medicine, Johns Hopkins University,
Baltimore, MD, USA
Background: There is substantial uncertainty about some aspects of the
epidemiology of schizophrenia, and data are sometimes conflicting.
There is limited prevalence data on US civilian population, and less
incidence data, especially for subgroups. US prevalence is approximately
1%, with conflicting data for sex, age, and racial groups. Incidence
estimates include 0.1–0.4/1000/yr (Jablensky, 1992 WHO international
estimate), and 0.08.43/1000/yr (10th–90th%) (McGrath, 2004, interna-
tional estimate). The prevalence of severe mental illnesses among
military personnel is lower than among the general population due to
self-deferral, medical screening at entry, and rapid attrition from
military. Methods: We used hospitalization data from the Defense Med-
ical Epidemiology Database for 1998–2007. Only first event hospitaliza-
tions were included. Analyses were conducted at 3-digit ICD-9 code
level. This report is a descriptive and graphical presentation of the
data to provide insight into patterns of disease. Results: During the study
period (1998–2007) there were 1,995 first-time military hospitalizations
for schizophrenia, occurring across 13 787 901 person years (PY), for an
overall incidence density (ID) 0.15/1000/PY. Over the study period the
rate of first time hospitalization for schizophrenia changed little, with
a marginally significant decrease among men (0.16 to 0.14, P = .07).
There were no changes over time by race or age. The female:male
IDR was 1.1 (P > .10). The ID ratio (IDR) among blacks (compared
to whites) was 2.4 (P < .01). Relative to those 40þ, the IDR was 14.4
(P < 0.01) for <20, decreasing to 2.4 (P < .01) for those 35–39. Among
whites rates decreased consistently with age; among blacks rates in-
creased from <20 to 20–24, then declined. At all age groups rates
were higher among blacks than whites. Among men rates declined con-
sistently with age; among women rates were flat for ages 20–24, 25–29,
and 30–34, and then declined. For younger personnel rates were higher
among men; among older they were higher among women, with rates
crossing at the 25–29 age group. Discussion: There are substantial dif-
ferences in patterns of schizophrenia by sex, race, and age. While overall
patterns provide some insight, only by reviewing data on subgroups can
these more specific patterns be discerned. These analyses clearly indicate
that there are certain groups at relatively high risk, and may provide guid-
ance in early detection of schizophrenia.
ID: 550641
SYSTEMATIC REVIEW AND META-ANALYSIS OF
POPULATION-BASED STUDIES OF PREMORBID
INTELLIGENCE AND SCHIZOPHRENIA
Golam Khandaker1, J. H. Barnett2,3, I. R. White4, P. B. Jones2,5
1Psychiatry in Learning Disability, Avon and Wiltshire Mental
Health Partnership NHS Trust, Bristol, United Kingdom;
2Department of Psychiatry, University of Cambridge, Cambridge,
United Kingdom; 3Psychiatric and Neurodevelopmental Genetics
Unit, Massachusetts General Hospital, Boston, MA, USA; 4MRC
Biostatistics Unit, University of Cambridge, Cambridge, United
Kingdom; 5Cameo (Cambridge Early Intervention in Psychosis
Service), Cambridge and Peterborough NHS Foundation Trust,
Cambridge, United Kingdom
Introduction: Previous studies have reported lower premorbid intelligence
in children and adolescents who will later develop schizophrenia. (1)
Method: We systematic reviewed the literature until August 2008, and
to the increase external validity of the research question only selected pop-
ulation-based prospective, retrospective and nested case-control studies for
meta-analysis. Included studies reported a standardised measure of intelli-
gence completed in childhood or well before any symptoms of illness. Sep-
arate meta-analysis was completed for full-scale, verbal and performance
IQ scores. Regression analysis was carried out to examine a dose-response
relationship between low IQ and risk of schizophrenia. Meta-regression
was used to examine associations between study effect sizes, mean age
of onset, and age at IQ assessment. Results: We identified 12 studies com-
prising 2654 cases and 728143 controls. Full-scale, verbal and performance
IQ all showed significant premorbid decrements (effect size 0.43–0.45) in fu-
ture cases of schizophrenia. There was no significant difference between pre-
morbid verbal and performance IQ in schizophrenia cases. A clear dose
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response effect was observed between low IQ and risk of schizophre-
nia, while risk increased by 3.7% with decrease in each IQ point
(Coef. 0.037, SE 0.0013, P < .0001). There was a significant associ-
ation between magnitude of IQ decrement and age at onset of illness (P =
.0007) and a marginal trend for greater decrement when IQ was assessed at
later ages (P = .06). Discussion: Compared with their peers, children who
will later develop schizophrenia show a consistent decrement of around
6–7IQpoints inbothverbalandnon-verbal IQ. There is alsoadose response
relationship between low IQ and risk of schizophrenia. Associations with
age of onset and age of testing, suggests a progressively widening gap
between normal and schizophrenic brain development from birth until
symptom onset.
Reference
1. Aylward E, Walker E, Bettes B. Intelligence in schizophrenia:
meta-analysis of the research. Schizophr Bull. 1984;10(3):430–459.
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SOCIAL CHARACTERISTICS OF NEIGHBORHOODS
AND THE INCIDENCE OF PSYCHOTIC DISORDERS
Wim Veling1, E. Susser2, D. March2, H. W. Hoek1,2
1Center for Early Psychosis, Parnassia Psychiatric Institute, The
Hague, Netherlands; 2Department of Epidemiology, Mailman
School of Public Health, Columbia University, New York, NY, USA
One of the most consistent findings in the epidemiology of schizophrenia
is that those who live in cities are at greater risk. It is much less clear which
risk factors drive this increased risk, because few attempts have been made
to move beyond the crude measure of urbanicity. Social factors across
different levels of organization may be involved, in particular those in-
volving availability of and access to social capital. We conducted a first
contact incidence study of psychotic disorders between 1997 and 2005 in
the city of The Hague, the Netherlands (n = 618) and investigated asso-
ciations between individual and neighborhood characteristics and the in-
cidence of psychotic disorders, using multilevel Poisson regression
analysis. First, after adjustment for individual level age, sex, marital status
and ethnic minority status, measures of neighborhood socioeconomic
level, residential mobility, population density, voter turnout at local elec-
tions and crime level were all significantly associated with the incidence of
psychotic disorders in a dose-response fashion. We calculated a cumula-
tive score of neighborhood social disadvantage, based on these five indi-
cators and divided it into tertiles (low, medium and high social
disadvantage). The individual level adjusted incidence rate ratio (IRR)
of psychotic disorders was 1.89 (95% Confidence Interval = 1.38–2.60)
for individuals living in the socially most disadvantaged neighborhoods
and was 1.35 (95% CI = 0.95–1.92) for those living in moderately disad-
vantaged neighborhoods compared to those living in the most advantaged
areas (Wald v2 [df = 2], 18.19, P < 0.0005). Second, we investigated the
effect of the ethnic composition of neighborhoods on the incidence of psy-
chotic disorders, not only among ethnic minorities, but also among native
Dutch. In neighborhoods with a very high proportion of non-Western eth-
nic minorities, the incidence rate for native Dutch was 35.4 per 100 000
(95% CI = 18.2–62.1), indirectly standardized to age, sex and neighbor-
hood socioeconomic level. In neighborhoods with a relatively low propor-
tion of ethnic minorities, the incidence rate for native Dutch was 21.1
(18.4–24.2). Among ethnic minorities, the pattern was opposite. These
results are suggestive for an ethnic density effect both in ethnic minorities
and in native Dutch. Thus, neighborhood social characteristics strongly
influence the incidence of psychotic disorders within an urban environ-
ment in interplay with individual factors.
ID: 550624
THE RATE OF TB IN INDIVIDUALS WITH
SCHIZOPHRENIA: CLUES TO INFLAMMATORY
MECHANISMS?
Marie Casey Olseth1, D. R. Hanson1,2
1Psychiatry, University of Minnesota, Minneapolis, MN, USA;
2Psychiatry, VA Medical Center, Minneapolis, MN, USA
Previously our group hypothesized that some psychotic disorders are the
result of disruption of the microvascular circulation of the brain brought
on by inflammatory processes. If inflammation is a contributing factor to
the development of psychosis, individuals with chronic inflammatory ill-
nesses, should display a higher incidence of psychosis as compared to
the general population. One such cause of chronic inflammation and acti-
vation of cytokine systems is tuberculosis (TB). TB susceptibility is genet-
ically mediated in part, based on twin and family studies in the literature.
TB infections generate circulating inflammatory agents that can have dis-
tant effects. Objective: To determine if individuals with schizophrenia have
a higher rate of tuberculosis as compared to individuals without schizo-
phrenia but who share similar contagion-risk factors. Method: An analysis
of the rates of tuberculosis in a historic (born 1860–1935) population of
psychiatric patients who had been institutionalized long term in Minnesota
State Hospitals. Complete psychiatric and medical records including autop-
sies were available. Psychiatric diagnoses were updated independently by
two clinicians according to RDC criteria. Results: The rate of TB in people
with schizophrenia was approximately 20% compared to 0.5 % in affective
illnesses and 0.5% in organic psychoses. Conclusions: The implication from
this study is that the individuals with schizophrenia have a higher incidence
of tuberculosis. There are at least two possibilities to consider. Chronic cir-
culating inflammatory processes may impact the brain leading to schizo-
phrenia. Alternatively, schizophrenia and TB susceptibility may both be
consequences of inherited perturbations of the immune system and innate
inflammatory processes triggered by unspecified environmental or epige-
netic factors.
ID: 550604
PRENATAL EXPOSURE TO TOBACCO IN PATIENTS
WITH FIRST EPISODE PSYCHOSIS
Geoffrey Smith, K. P. Good, G. W. MacEwan, L. C. Kopala,
T. S. Ehmann, A. E. Thornton, A. M. Barr, D. J. Lang,
S. W. Flynn, W. G. Honer
University of British Columbia, Vancouver, BC, Canada
Smoking during pregnancy impairs placental development and is associ-
ated with fetal undernourishment, slow fetal growth, and low birthweight.
In addition, nicotinic aceylcholine receptors are expressed early in fetal de-
velopment and animals exposed to nicotine in-utero have abnormal neuro-
nal proliferation and differentiation, and show developmental disruptions
in cholinergic and catecholaminergic systems. The neuronal consequences
of prenatal nicotine exposure in humans are not well defined but those born
to mothers who smoked during pregnancy are at increased risk for a range
of physical, behavioral, cognitive, and psychiatric problems and are more
likely to initiate smoking in adolescence. Many of these same problems are
observed in patients with psychosis, but have not been investigated in re-
lationship to maternal smoking. The goals of the present study were 1. to
determine if the mothers of first episode psychotic (FEP) patients were
more likely to have smoked during pregnancy than other women, and 2.
to determine if the known correlates of this early risk factor are observed
in FEP patients. An initial FEP sample (n = 80), a geographically distinct
FEP replication sample (n = 96), and a healthy control group (n = 58) were
recruited, and the results from a 1993 Canadian smoking survey were ac-
quired. Birth history was obtained from maternal report. FEP, control and
survey groups were compared for the proportion who were prenatally ex-
posed to nicotine. Exposed and unexposed individuals were compared for
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health-related and cognitive correlates of exposure to nicotine. The percent-
age of mothers who smoked during pregnancy was similar in the two FEP
samples (30%, 33%) and significantly greater than that of the control and
survey samples (15%, 19%). Prenatal tobacco exposure was associated with
low birthweight, poor academic achievement during childhood and ciga-
rette smoking in all three samples, and with obesity in FEP patients.
The present findings suggest that patients with psychosis are more likely
to have been prenatally exposed to nicotine than is observed in the general
population. As with the general population, prenatal exposure to nicotine is
associated with an increased risk of health-related and cognitive problems
in psychotic patients. The relatively high proportion of psychotic patients
exposed to nicotine in utero suggests that the negative correlates of this
early risk are likely to be commonly observed in patients with psychosis.
ID: 550573
GLUCOSE TOLERANCE IN NEWLY DIAGNOSED,
ANTIPSYCHOTIC-NAIVE PATIENTS WITH NON-
AFFECTIVE PSYCHOSIS
Brian W. Kirkpatrick1, E. Fernandez-Egea2, C. Garcia-Rizo3,
E. Parellada3, A. Justicia3, M. Bernardo3
1Psychiatry and Health Behavior, Medical College of Georgia,
Augusta, GA, USA; 2Psychiatry, Cambridge and Peterborough
Foundation Trust., Cambridge, United Kingdom; 3Psychiatry,
FUNDACIO PRIVADA CLINIC PER A LA RECERCA
BIOMEDICA, Barcelona, Spain
Some studies suggest patients with schizophrenia have an increased risk of
diabetes prior to antipsychotic use. Small sample sizes and the potential for
confounding by hypercortisolemia have decreased confidence in those
results. We administered a two-hour oral glucose tolerance test to 50 newly
diagnosed, antipsychotic-naı¨ve patients with nonaffective psychosis and 50
matched control subjects. The patients had significant increases in two-
hour glucose (respective means [SD] for the patient and control groups
were 111 mg/dL [35.2] and 82 mg/dL [19.3]; t = 5.15, P < .001). The prev-
alence of impaired glucose tolerance or diabetes was 16% of patients vs. 0%
of control subjects (P < .003). These differences could not be attributed to
differences in cortisol concentrations, smoking, gender, neighborhood of
residence, demographic variables, body mass index, aerobic conditioning,
ethnicity, socioeconomic status, or age. Fasting glucose and hemoglobin
A1c concentrations did not differ between the two groups. Patients with
nonaffective psychosis appear to have an increased prevalence of abnormal
glucose tolerance prior to antipsychotic treatment. These underlying
problems may contribute to the metabolic side effects of antipsychotic
medications.
ID: 550568
ALCOHOL INDUCED PSYHOTIC DISORDER AND
DELIRIUM IN THE GENERAL POPULATION
Jonna Pera¨la¨1, K. Kuoppasalmi1, S. Pirkola1,3, S. I. Saarni1,
S. Koskinen4, T. Ha¨rka¨nen4, J. Lo¨nnqvist1,3, J. Suvisaari1,2
1Department on Mental Health and Alcohol Research, National
Public Health Institute, Helsinki, Finland; 2Department of Social
Psychiatry, Tampere School of Public Health, University of Tam-
pere, Tampere, Finland; 3Department of Psychiatry, University of
Helsinki, Helsinki, Finland; 4Department of Health and Functional
Capacity, National Public Health Institute, Helsinki, Finland
Objective: We estimated the lifetime prevalence (LTP) of alcohol-induced
psychotic disorder and delirium in the general population, and compared
subjects with alcohol dependence with and without psychosis. Method: In
a nationally representative survey of 8028 persons aged 30 or over, the life-
time diagnosis of alcohol dependence was assessed in the CIDI interview
(1). In the re-assessment of psychotic disorders (2), the whole sample
was screened using CIDI, health examination and national registers.
Best-estimate DSM-IV-TR diagnoses were formed by combining SCID-I
interview and case note data. Prior hospital treatments were collected
from the National Hospital Discharge Register. Number of deaths during
eight year follow-up was obtained from the National Register of Deaths.
Results: The LTP was 0.41% (95% CI = 0.29–0.57) for alcohol-induced psy-
chotic disorder (n = 31) and 0.18% (95% CI = 0.11–0.32%) for alcohol-in-
duced delirium (n = 14). 6 subjects had had both diagnoses, and when each
individual was only counted once, the LTP for the total alcohol-induced
psychotic syndromes (AIPS) was 0.51% (95% CI = 0.38–0.70). The highest
LTP (1.77% 95% CI = 1.06–2.94) was found among men aged 45–54.
Among subjects with the diagnosis of alcohol dependence (n = 482) the
LTP for AIPS was 4.79%, and for all psychotic disorders 9.17%. Being
45–54 years, belonging to low socioeconomic groups, reporting mental
health or alcohol problems in fathers, having had high number of hospital
treatments or hospital treatments for alcohol-related disorders were asso-
ciated with AIPS among alcohol dependents. 35.9% and 7.0% of subjects
with AIPS and with alcohol dependence died in the follow-up, respectively.
The hazard ratios for mortality among subjects with AIPS were 13.0 com-
pared with the total population and 9.4 compared with other alcohol
dependents. Conclusions: Alcohol-induced psychotic disorder and delirium
are common in the general population, especially among working-aged
men. They are associated with high number of hospital treatments and
with high mortality.
References
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BDNF VAL66MET GENOTYPE, MALE GENDER
AND ADOLESCENT CANNABIS USE DETERMINE
AGE OF ONSET OF PSYCHOSIS: A STUDY IN
A LARGE SAMPLE OF PSYCHOTIC PATIENTS
Jeroen Decoster1, M. de Hert1, G. Kenis2, J. van Os2,
R. van Winkel1,2
1UPC KULeuven, campus Kortenberg, Kortenberg, Belgium;
2Department of Psychiatry and Neuropsychology, Maastricht
University Medical Centre, Maastricht, Netherlands
Several factors have been suggested to decrease age at onset of psychosis,
including male gender, cannabis and other drug use and BDNF Val66Met
genotype. The BDNF Val66Met polymorphism, of which Met-substitution
is associated with reduced intracellular trafficking and activity-dependent
BDNF secretion, was genotyped in a sample of 587 patients with psychosis.
Survival analyses with time from birth to age at first admission as indicator
for survival time were fitted as a function of several predictor variables, as
were multivariate Cox regression models. BDNF Val66Met genotype was
significantly associated with survival time (log-rank test: v2 = 4.3, P = .039),
with Met-carriers being admitted for the first time a mean of 1.2 years ear-
lier. Gender, adolescent cannabis use (<16 yrs), lifetime stimulant, cocaine
or psychedelics use were also significantly associated with survival time (log
rank test P< .05). In the multivariate Cox regression models BDNF Val66-
Met Met genotype (Hazard Ratio (HR) 1.23, P = .026), adolescent cannabis
use (HR 1.59, P = .005) and male gender (HR 1.58, P < .001) remained
significant predictors of earlier age at onset. Results did not considerably
change when analyses were restricted to patients with an age at onset below
35 years. No interaction effects were observed. These results confirm find-
ings of earlier studies suggesting an effect of BDNF Val66Met genotype,
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cannabis use before age 16 (but not later cannabis use) and male gender on
age of onset of psychosis in a mainly Caucasian population.
ID: 550516
PATERNAL AGE IS ASSOCIATED WITH
INCREASED MORTALITY RISK IN PSYCHOTIC
DISORDERS
Brian James Miller1, J. Pihlajamaa2, M. Henriksson2, H. Hannele2,
M. Huttunen2, A. Tanskanen2, M. Cannon3, J. Haukka2, J.
Suvisaari2, B. Kirkpatrick1
1Psychiatry and Health Behavior, Medical College of Georgia,
Augusta, GA, USA; 2Mental Health and Alcohol Research,
National Public Health Institute, Helsinki, Finland; 3Psychiatry,
Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin,
Ireland
Increasing paternal age is a replicated risk factor for schizophrenia in the
offspring, while schizophrenia is associated with increased mortality. A pre-
vious study of men with psychosis found that paternal age was correlated
with suicide. We examined paternal age and mortality in N = 834 patients
with psychosis born in Helsinki, Finland, between January 1, 1951 and
December 31, 1960. Subjects were followed until June 2006 (ages
46–55). Offspring of fathers who were under 20 years old were omitted
from the analyses because of small numbers. In multivariate Cox propor-
tional hazard models, after adjustment for maternal age, gender, and age of
onset of psychotic symptoms, paternal age (as a continuous variable) was
a significant predictor of suicide mortality (Hazard Rate Ratio (HRR) =
1.05, 95% CI = 1.01–1.10, P = .020). By contrast, increasing maternal
age was associated with decreased risk of suicide mortality (HRR =
0.923, 95% CI = 0.87–0.98, P = .012). In males, paternal age was associated
with increased suicide risk (HRR = 1.05, 95% CI = 1.00–1.11, P = .050), and
maternal age was associated with decreased suicide risk (HRR = 0.90, 95%
CI = 0.83–0.97, P< .01). In females, the effect of paternal age on suicide risk
was not statistically significant, although the point estimate was the same as
in males (HRR = 1.054, 95% CI = 0.97–1.15, P = .22). Paternal is associated
with a linear increase in suicides in males with psychosis. The pathway(s)
associated with this increased mortality remain to be determined. The rel-
ative contribution of biological and psychosocial factors are unclear.
ID: 550435
EVIDENCE THAT ONSET OF CLINICAL PSYCHOSIS
IS THE OUTCOME OF PROGRESSIVELY MORE
PERSISTENT SUBCLINICAL PSYCHOTIC
EXPERIENCES: IMPLICATIONS FOR EARLY
INTERVENTION
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H. U. Wittchen3,4
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Objective: It may be possible to intervene early in the prodromal phase of
psychosis. However, very little is known about the course of psychometric
risk indicators of psychosis in epidemiological samples of young people. To
examine the hypothesis that developmental expression of psychometric risk
in the form of subclinical psychotic experiences is usually transitory, but in
some instances may become abnormally persistent and progress to a clinical
psychotic state. Design: Prospective cohort study. Expression of psychosis
was assessed, using self-report and interview, four times over a period of 8.4
years. General population of adolescents, 845 individuals aged 14–17 years
at baseline, in Munich, Germany (Early Developmental Stages of Psycho-
pathology Study). A distinction was made between psychotic experiences
with impairment (clinical psychosis; defined as psychotic experiences with
Help-seeking and/or Dysfunction) and without impairment (subclinical
psychosis). Transition from subclinical psychosis at T0-T2 to clinical psy-
chosis at T3 was examined as a function of the level of prior persistence of
subclinical psychosis (present never, once, twice or thrice at T0, T1 and T2).
Results: The more subclinical psychosis persisted over the period T0-T2, the
greater the risk of transition to clinical psychosis at T3 in a dose-response
fashion (subclinical psychosis expression once over T0-T2: OR = 1.5 (CI:
0.6–3.7), post-test probability (PP) = 5%; twice: OR = 5.0 (CI: 1.6–15.9),
PP = 16%; at all three measurements: OR = 9.9 (CI: 2.5–39.8), PP =
27%. Of all clinical psychosis at T3, a third (38.3%) was preceded by sub-
clinical psychotic experiences at least once, and a fifth (19.6%) at least twice.
Conclusions: A significant proportion of psychotic disorder may be concep-
tualised as the rare poor outcome of a common developmental phenotype
characterised by persistence of psychometrically detectable subclinical psy-
chotic experiences. Early intervention efforts may target the factors that
make the common and transitory developmental expression of subclinical
psychosis persist.
ID: 550401
OBSTETRIC FACTORS, PRENATAL INFECTIONS
AND SCHIZOPHRENIA IN ADOLESCENCE AND
EARLY ADULTHOOD
Philip Nielsen, M. G. Pedersen, C. B. Pedersen, P. B. Mortensen
National Centre for Register-based Research, University of Aarhus,
Aarhus, Denmark
Several studies have reported an association between obstetric complica-
tions and schizophrenia. Especially children born small for gestational
age (SGA) have been reported to have an increased risk of schizophrenia.
No studies have however quantified whether the effect of SGA was related
to individual or familial factors. In addition, we also studied whether indi-
viduals exposed to prenatal infections have an increased risk of schizophre-
nia. Data from three population based registers, the Danish Medical
Birth Register, the Danish Psychiatric Central Register and the Danish Na-
tional Hospital Register were used. We used an historical population based
cohort design and selected all individuals born between 1979 and 1996 (n =
921 397). We identified all individuals who were listed in the Psychiatric
Register as having been first admitted to hospital from 1989 through
2006 with schizophrenia (n = 1823). We accounted for the potential con-
founding effect of parents age at child’s birth, urbanicity, parents history
of at least one psychiatric diagnosis. Individuals being small for gestational
age are more likely to develop schizophrenia, than individuals not being
small for gestational age (RR = 1.3). Results further indicate that having
an older sibling who were also small for gestational age increased the risk
for schizophrenia (RR = 2.0). Maternal infection during pregnancy in-
creased the risk by 1.4. Schizophrenia risk was associated with maternal
infections requiring hospitalization, especially infections during second tri-
mester. The association between being small for gestational age and schizo-
phrenia may be due to risk factors aggregating in families and shared by
schizophrenia and SGA, rather than an effect of SGA per se. This work
was supported by the Stanley Medical Research Institution.
ID: 550356
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ARE SELF-REPORTED AUDITORY HALLUCINA-
TIONS AMONG ADOLESCENTS VERIFIED ON
CLINICAL INTERVIEW?
Mary Cannon1,2, I. Kelleher1, A. Murtagh1, M. Blanchard1,
M. Harley1
1Department of Psychiatry, Royal College of Surgeons in Ireland,
Dublin, Ireland; 2Department of Psychiatry, Beaumont Hospital,
Dublin, Ireland
The prevalence of auditory hallucinations among adolescents ranges from 5–
30% in population-based surveys. The rate of such self-reported hallucina-
tionsvaries with developmentalage anddegree ofcertaintyrequired. Inorder
to assess the significance of these self-reported symptoms we need to know
howmanyof theseadolescentswill turnout tohavepsychotic-typesymptoms
onclinical interview.Weadministeredaself-reportquestionnairecomprising
sevenquestionsassessingpsychotic-typesymptoms(ratedas ‘yes’, ‘maybe’or
‘no’) to 334 11–13 year old school children attending primary schools in Dub-
lin.Thirty-eightpercentofthesampleanswered‘yes’or ‘maybe’toat leastone
ofthesesymptoms.Withregardtoauditoryhallucinationsspecifically:15.6%
ofthesampleanswered‘yes’and20.1%answered‘maybe’tothisquestion.We
interviewedadolescentswhoanswered‘yes’to2ormorequestions(n=22)and
a comparison group of adolescents who endorsed one or none of these symp-
toms (n=22), using the semi-structured K-SADS diagnostic interview sched-
ule administered by a trained psychologist or psychiatrist. Subjects were
interviewed within 1–2 months of completing the self-report questionnaire.
Symptoms were rated as ‘definite’ and ‘possible’ at a consensus meeting in-
volving 3 clinicians. On interview, 17 adolescents were found to experience
‘definite’ psychotic symptoms and 5 experienced ‘possible’ psychotic symp-
toms. We found that answering ‘yes’ to the auditory hallucination question
(Have you ever heard voices or sounds that no-one else can hear?) on the
screener questionnaire was highly predictive of ‘definite’ clinician-rated au-
ditory hallucinations on interview (PPV 92.3%; NPV 95.7%; Sensitivity
92.3%; Specificity95.7%)andwasalsohighlypredictiveofanyclinician-rated
‘definite’ psychotic symptom on interview: (PPV 100%; NPV 84.6%; Sensi-
tivity 76.4%; Specificity 100%). Answering ‘maybe’ to the auditory halluci-
nationsquestionwasnotpredictiveofclinician-ratedpsychoticsymptomson
interview.Ourresults indicatethatadolescentsarewillingtorevealpsychotic-
like symptoms using questionnaire methods and that the answers can be con-
firmed by clinical interview. In this age-group self-report of hearing voices is
the most useful predictor of psychotic symptoms on subsequent interview.
This research was supported by the Health Research Board (Ireland).
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STRUCTURAL BRAIN ABNORMALITIES IN
PATIENTS WITH SCHIZOPHRENIA AFTER 2ND
TRIMESTER FETAL EXPOSURE TO IL-8
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Maternal infection during pregnancy has been repeatedly associated with
increased risk for schizophrenia. Nevertheless, most viruses do not cross the
placenta; therefore the damaging effects on the fetus appear to be related to
maternal antiviral responses to infection, such as proteins linked to inflam-
mation (ie, proinflammatory cytokines). In the present cohort, fetal expo-
sure to increases in maternal levels of the proinflammatory cytokine
interleukin-8 (IL-8) was related to increased risk of schizophrenia spectrum
disorders (SSD). The purpose of the present study was to determine
whether fetal exposure to IL-8 led to structural brain abnormalities among
SSD patients. Methods: Subjects were 17 cases diagnosed with SSD and 8
controls from a birth cohort study, the Developmental Insult and Brain
Anomaly in Schizophrenia (DIBS) study. Psychiatric morbidity was deter-
mined through semi-structured interviews (DIGS) and medical records re-
view. Levels of IL-8 were ascertained from sandwich enzyme-linked
immunosorbent assays from archived prenatal sera collected during the
2nd trimester of pregnancy. Coronal T1-weighted magnetic resonance
images were acquired using a 1.5-Tesla Siemens system and 3D MP-
RAGE sequences. Volumes were determined through manually tracing
regions of interest (ROIs). ROIs were divided by intracranial volumes to
form ratios and then log-transformed. Results: Results indicated that fetal
exposure to increases in IL-8 were associated with significant increases in
ventricular cerebrospinal fluid (CSF) and significant decreases in right cau-
date, left entorhinal cortex, and right posterior cingulate volumes. In con-
trast, there were no significant effects of IL-8 on any ROIs for controls.
Conclusion: Results indicate that cases are preferentially sensitive to fetal
exposure to IL-8 compared to controls. Among cases, fetal exposure to IL-8
appears to affect dopamine-rich structures implicated in motor functioning
and memory, cognitive domains commonly disrupted among schizophrenia
patients. Fetal exposure to increases in IL-8 also was related to the most
replicated brain anomaly in schizophrenia, increases in ventricular CSF.
Overall, these findings suggest that there is likely a genetic or environmental
factor associated with schizophrenia that renders the aforementioned fetal
brain structures especially sensitive to maternal inflammatory immune
responses.
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THE DEVELOPMENTAL TRAJECTORY TO
SCHIZOPHRENIA—EVIDENCE FOR GENETIC AND
ENVIRONMENTAL INFLUENCES
Mary Catherine Clarke1, A. Tanskanen2, M. O. Huttunen2,
R. Murray3, M. Cannon1
1Psychiatry, The Royal College of Surgeons in Ireland, Dublin,
Ireland; 2Mental Health and Alcohol Research, National Public
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Childhood developmental abnormalities have frequently been described in
schizophrenia. We wished to determine whether childhood developmental
abnormality in schizophrenia is genetically mediated. We also wished to
elucidate the relationship between obstetric complications and develop-
mental deficits. The study population comprised all those born in Helsinki
between 1962 and 1969 who had developmental records archived in the Hel-
sinki City Archives. Through linking the Finnish Population Register and
the Finnish Hospital Discharge Register we identified 189 individuals who
had received a diagnosis of schizophrenia and 115 unaffected siblings who
were born between 1962 and 1969 and had developmental information
available. We also identified a control group, matched to cases and siblings
on gender and year of birth (n = 304). Prospective, standardised develop-
mental data for each subject was retrieved from the archives of ‘Well Baby’
clinics. The majority of children in Finland attend these clinics for monthly
check-ups in their first year of life. The age in months at which the following
series of motor developmental milestones were achieved significantly dif-
fered between cases, sibling high-risk and control groups: turns-over, raises
into a sitting position, raises to stand, walks supported and pincer grip.
Cases were significantly slower to reach these milestones compared to sib-
lings, who in turn were significantly slower to achieve them compared to
matched controls. Apgar scores were significantly lower among the cases
than the siblings or comparison groups. There was also an additive
effect between low apgar score and motor developmental delay such
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that exposure to both risk factors increased risk for schizophrenia to a sig-
nificantly greater extent than exposure to only one of these risk factors.
These findings support delayed motor development in the first year of
life as an endophenotype for schizophrenia, indicate that motor deficits
may be a genetic marker of vulnerability to schizophrenia and suggests
that obstetric complications may additively interact with this endopheno-
type. Funding: The Wellcome Trust, NARSAD and The Health Research
Board of Ireland.
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PSYCHIATRIC OUTCOMES AMONGST OFFSPRING
WITH PARENTAL HISTORY OF MENTAL
DISORDER
Kimberlie Dean1, H. Stevens3, P. B. Mortensen3, R. M. Murray2,
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Whilst parent-offspring associations for specific mental disorders are well
established, knowledge of the broader range of psychiatric outcomes
amongst offspring with parental history of serious mental illness (SMI)
is not. The aim of the current study was to examine the full range of po-
tential mental health outcomes occurring in a large national cohort,
amongst offspring of parents with SMI compared to the general popula-
tion. The cohort was obtained from linked Danish national registers
and consisted of all offspring born in Denmark between1980 and 1992. Off-
spring were followed from their 14th birthday for the development of
a range of psychiatric disorders (including schizophrenia, bipolar disorder,
schizoaffective disorder, affective disorder, anxiety and somatoform disor-
ders, personality disorder, substance abuse, and mental retardation) based
on outpatient and inpatient hospital data. Offspring exposure groups were
defined on the basis of parental history of mental illness and compared to
those offspring without any parental history. Poisson regression modeling
was used to obtain rate ratios for each exposure/outcome pair with account
taken of offspring gender, age and calendar year. Parental SMI (in one or
both parents) was found to be positively associated with all of the offspring
psychiatric outcomes examined. Offspring with parents (one or both) with-
out SMI but with a history of other psychiatric illness were also found to be
at increased risk of developing any of the range of psychiatric outcomes.
The strongest associations were found between history of parental illness
in both parents and offspring illnesses. Offspring of two parents with SMI
were almost 19 times more likely to develop schizophrenia for example. The
elevated risks were not confined to concordant parent-offspring associa-
tions (eg, offspring of two SMI parents were also 9 times more likely to
develop substance misuse disorders). The gender of the affected parent
had only limited impact on offspring risk of illness. The impact of parental
history of serious mental illness is not confined to elevated offspring risk of
concordant disorders. Offspring are at increased risk of a wide range of
mental disorders. This implies an important role for environmental factors
and genetic factors giving rise to broad, as well as specific vulnerabilities, in
the aetiology of familial risk.
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SCREENING FOR SUBCLINICAL PSYCHOSIS IN
THE GENERAL ADOLESCENT POPULATION
Ian Kelleher, M. Harley, A. Murtagh, M. Blanchard, M. Cannon
Psychiatry, Royal College of Surgeons in Ireland, Dublin 9, Ireland
The aim of this study was to design a psychometric instrument with good
sensitivity and specificity for the identification of subclinical psychotic
symptoms in the general adolescent population. A screening questionnaire
with seven questions designed to assess psychotic symptoms was adminis-
tered to 334 children aged 11–13 years. (1) ‘‘Some people believe that their
thoughts can be read by another person. Have other people ever read your
mind?’’; (2) ‘‘Have you ever had messages sent just to you through TV or
radio?’’; (3) ‘‘Have you ever thought that people are following or spying on
you?’’; (4) ‘‘Have you ever heard voices or sounds that no one else can
hear?’’; (5) ‘‘Have you ever felt you were under the control of some special
power?’’; (6) ‘‘Have you ever seen things that other people could not see?’’;
(7) ‘‘Have you ever felt like you had extra-special powers?’’. Answers were
scored as follows: No = 0 points; Maybe = 0.5 points; Yes = 1 point. Using
stratified random sampling we called adolescents with scores greater than
or equal to 2 on the screener for clinical interview. We also called a com-
parison sample of adolescents who scored 0 or 1 on the screener for inter-
view. In total, 44 adolescents were interviewed using the K-SADS interview
schedule by a trained clinical interviewer (psychiatrist or psychologist). The
results of these interviews were used to conduct sensitivity and specificity
analyses for the questionnaire in the identification of psychotic symptoms.
Twenty two participants reported no psychotic symptoms at interview, 17
reported ‘definite’ psychotic symptoms, and 5 reported ‘possible’ psychotic
symptoms. Symptoms were rated as ‘definite’ or ‘possible’ by a consensus
meeting after the interview. Three questions from the screening question-
naire (questions 3, 4 and 6) proved to have good predictive power for the
detection of ‘definite’ psychotic symptoms on clinical interview. Table 1
shows that endorsement of these 3 core questions provided good predictive
validity for subclinical psychotic symptoms. Our results suggest that a sim-
ple 3-item pen and paper questionnaire could be used to accurately screen
for subclinical psychotic symptoms in early adolescence.
Table. Predictive validity of three core questions for psychotic symptoms
PPV NPV Sensitivity Specificity
Endorsement of at least one question 64% 95% 94% 67%
Endorsement of at least two questions 88% 89% 93% 82%
Endorsement of all three questions 100% 82% 65% 100%
ID: 550275
UNEMPLOYMENT AND RISK OF PSYCHOSIS IN
BLACK AND MINORITY ETHNIC (BME) GROUPS
Rina Dutta, R. M. Murray, J. Boydell
Psychological Medicine and Psychiatry, Institute of Psychiatry,
London, United Kingdom
Introduction: Unemployment is closely related to both relative deprivation
and social drift of those predisposed to psychosis. Within a stress-vulner-
ability model of psychosis, unemployment would be plausible as a risk fac-
tor as well as early consequence of disease onset. However it has hardly been
studied as an epidemiological risk factor for psychosis. Some black and mi-
nority ethnic groups with high rates of psychosis also have high rates of
unemployment. The purpose of this study was to test the hypotheses
that (i) the incidence of psychosis is higher in unemployed people and
(ii) unemployed people from BME groups have a higher incidence of psy-
chosis than unemployed White people Method: All patients who presented
for the first time with an ICD-10 diagnosis of any psychotic illness, in a de-
fined area of southeast London from 1998–2004 were identified. Electoral
ward level data from 2001 census was used to calculate crude and stand-
ardised incidence rates of psychosis amongst unemployed people, by eth-
nicity (indirectly standardised to (a) the total employed population and (b)
the employed white population, stratifying for age and gender). Standar-
dised incidence ratios were calculated for each ethnic group. Results: Of
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the 178 patients with psychosis, 100 cases occurred amongst employed
people and 78 amongst the unemployed. The incidence of psychosis
was very high amongst unemployed people and extremely high amongst
Black Caribbean and Black African people. 3.4% (95% CI = 2.2–5.0%) of
unemployed Black Caribbean people become psychotic per year and
2.5% (95% CI = 1.6–3.9%) of Black African people. Standardised to
the employed population of the area, White unemployed had an almost
5-fold increased risk of psychosis (SIR 4.96; 95% CI = 2.71–8.32)
compared to a 25-fold increase for Black Caribbean (SIR 24.9; 95%
CI = 16.2–36.4) and more than 18-fold increase for Black Africans
(SIR 18.7; 95% CI = 11.9–28.1). More markedly, when standardised
to the employed White population of the area, White unemployed had
an almost 12-fold increased risk of psychosis (SIR 11.8; 95% CI =
6.4–19.7), compared to a 60-fold increase in Black Caribbeans (SIR
60.1; 95% CI = 39.3–88.1) and more than 40-fold increase in Black
Africans (SIR 40.7; 95% CI = 25.8–61.1). Conclusions: The incidence
of psychosis is higher overall in people who are unemployed. Unem-
ployed people from BME groups have a much higher incidence of psy-
chosis than White people.
ID: 550260
HEARING VOICES IN CHILDHOOD: A
PREVALENCE AND CASE-CONTROL STUDY OF
AUDITORY HALLUCINATIONS IN MIDDLE
CHILDHOOD
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Introduction: Voice hearing does occur in middle childhood, but little is
known about its prevalence, etiology and consequences. Our aim is to in-
vestigate prevalence and characteristics of auditory vocal hallucinations
(AVH) in 7-and-8-year-olds, as well as associations with pre- and perinatal
influences, early development and current behaviour problems. Methods:
AVH were assessed with the Auditory Vocal Hallucination Rating Scale in
3870 children; prospectively recorded data on pre- and perinatal complica-
tions, early development and current problem behaviour were analyzed in
children with AVH and matched controls. Results: The one-year preva-
lence of AVH was 9%. 15% of AVH children reported severe suffering
and AVH elicited more anxiety in girls. The prevalence for AVH was
higher in rural areas but AVH were more severe, more often externally
attributed and of greater functional impact in the urban environment.
There was some evidence for an association with prenatal maternal in-
fection and slower motor development in early life. Only weak associa-
tions were apparent between AVH and current problem behaviour.
Conclusions: AVH in 7/8 year olds are prevalent but of functional con-
sequence in only a minority. Nevertheless, there may be continuity with
more severe psychotic outcomes given severe suffering in a subgroup,
associations with early developmental deviance and evidence for a poorer
prognosis in an urban environment.
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We study the predictive power and associations of several schizotypal and
temperament scales with respect to familial risk and developing of schizo-
phrenic psychoses in a population-based birth cohort. Temperament and
Character Inventory, Physical Anhedonia Scale, Social Anhedonia Scale,
Perceptual Aberration Scale, Hypomanic Personality Scale, Bipolar II
Scale, and Schizoidia Scale were included in the 31-year follow-up survey
of the prospective Northern Finland 1966 Birth Cohort (N = 4,926). We
compared subjects without any previous hospitalisations (N = 4,786) to
those with previous hospital diagnoses for schizophrenia (N = 39) (concur-
rent validity) and to those who in the eight year long follow-up were hos-
pitalised due to schizophrenic psychosis (N = 12) (predictive validity). We
also compared the subjects with schizophrenic psychoses and subjects with
other psychiatric disorders (discriminant validity, N = 101 for concurrent
and N = 72 for predictive analyses). Familial risk was estimated through
parental diagnoses of psychosis in hospital discharge register data (1972
to 2005). The Perceptual Aberration Scale was the best scale for concurrent
(Effect Size, d = 1.89) and discriminant validity (d = 0.64). Subjects having
a high score in Hypomanic Personality Scale (OR 10.72; 95% CI = 2.87–
40.06) were in the highest risk for developing schizophrenic psychoses.
High harm avoidance (d = 1.14 for concurrent cases) was a dominant tem-
perament characteristic in schizophrenia when compared to controls.
Controls with familial risk differed mostly from those without familial
risk by having low physical anhedonia (d = 0.20) and high hypomania
(d = 0.18). Subjects with schizophrenic psychoses differed in most of the
scales from healthy controls and in a few from subjects with other psychi-
atric disorders. Many of the scales were useful predictors of developing
schizophrenic psychoses; however scales were not very diagnosis specific.
These scales are probably not useful as screening instruments but some
(eg, Perceptual Aberration Scale) can be used as intermediate phenotypes
when studying schizophrenia and related psychoses.
ID: 550223
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ADVANCED PATERNAL AGE IS ASSOCIATED
WITH IMPAIRED NEUROCOGNITIVE OUTCOMES
DURING INFANCY AND CHILDHOOD IN A
GENERAL POPULATION BIRTH COHORT.
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of Community Healt, Brown University, Providence, RI, USA;
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Background: Advanced paternal age (APA) is associated with an increased
risk of neurodevelopmental disorders such as autism and schizophrenia, as
well as with dyslexia and impaired intelligence. The aim of the study was to
examine the relationship between paternal age and neurocognitive measures
of children using a large birth cohort. Method: A sample of white singleton
children (n=25,131) was drawn from the US Collaborative Perinatal Project.
The outcome measures were assessed at 8 months, 4 and 7 years (Bayley
scales, Stanford Binet IQ, Graham-Ernhart test, Wechsler Intelligence Scale
for Children, Wide Range Achievement Test). The main analyses examined
the relationship between neurocognitive measures and paternal or maternal
age when adjusted for potential confounding factors. Results: Advanced
paternal age showed significant associations with poorer scores on all meas-
ures of the neurocognitive measures apart from Stanford Binet Intelligence
Scale. The findings were consistent in direction and effect size at all three
ages. In contrast, advanced maternal age was generally associated with better
scores on these same measures. Discussion: The offspring of older fathers
show subtle impairments on tests of neurocognitive ability during infancy
and childhood. In light of secular trends related to delayed fatherhood,
the mechanisms underlying these findings warrant closer scrutiny.
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Inspired in part by the pioneering work of Barbara Fish and Sarnoff Med-
nick, a number of studies have observed that obstetric complications are
associated with increased risk for schizophrenia later in life. Such factors
are also related to increased severity of certain neuropathological features
of schizophrenia, including hippocampal and cortical gray matter reduc-
tion. However, it remains to be determined whether such complications re-
sult from the schizophrenia genotype (as in G-E covariation) or interact
with genetic susceptibility to the disorder in disease expression. We con-
ducted searches of the Finnish National Hospital Discharge and Perinatal
Registers to ascertain pregnancy and birth information on 6471 offspring of
parents with schizophrenia in the country of Finland, compared with 25 884
gender matched controls born on the same day and in the same obstetric
units as the case offspring. A number of pregnancy and birth complications
were found to be elevated in the offspring with schizophrenic mothers.
However, there were no such increases among offspring of schizophrenic
fathers. These results are consistent with the view that the occurrence of
such complications is independent of genetic predisposition to schizophre-
nia, but may be influenced by maternal health risk behaviors, such as smok-
ing. In another study, we examined whether neurotrophic factors, which are
stimulated as part of a neuroprotective response to fetal distress, are dif-
ferentially expressed in cord blood samples at the time of birth following
particular obstetric stressors among individuals who developed schizophre-
nia as adults, as compared with demographically matched controls. This
study utilized a nested case-control design including 111 cases with psy-
chotic disorders (70 with schizophrenia) and 333 controls matched for gen-
der, race, and date of birth, drawn from the Philadelphia cohort of the
National Collaborative Perinatal Project. Among controls, birth asphyxia
was associated with a significant (10%) increase in BDNF in cord samples,
while among cases, asphyxia was associated with a significant (20%) de-
crease in BDNF. These findings provide serologically based prospective ev-
idence of disrupted neurotrophic signaling in response to birth asphyxia in
the molecular pathogenesis of schizophrenia and encourage search for
genes that confer heightened susceptibility via disruptions in BNDF.
ID: 550055
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Some evidence suggests newly diagnosed, antipsychotic-naı¨ve patients with
nonaffective psychosis have an increased risk of diabetes. Diabetes is asso-
ciated with abnormal circulating concentrations of the adipokines leptin
and adiponectin. We measured leptin and adinponectin in 32 fasting, newly
diagnosed, antipsychotic-naı¨ve patients with nonaffective psychosis and
control subjects (N = 53). The patients had a significant increase in leptin
concentrations (P > .001 for the variable of patients vs. control subjects)
after accounting for the variance due to age, gender, socioeconomic status,
body mass index, smoking, cortisol, and aerobic conditioning (as measured
by resting heart rate); the two groups were very similar with regard to race
and neighborhood of residence so these two variables were not included in
the multivariate analysis. Using the same variables, we found no significant
patient/control difference in adiponectin. The difference in leptin, which
could not be accounted for by a difference in body mass index, coupled
with the evidence for an increased risk of diabetes, raises the possibility
that patients with schizophrenia have increased visceral fat.
ID: 550050
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During the five decades since Dr Barbara Fish initiated her groundbreaking
research into the neurobiological antecedents of schizophrenia in children,
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an impressive volume of literature spanning epidemiology, developmental
neurology, cognitive psychology, neurophysiology and behavioural genet-
ics has brought forth novel insights into the nature of ‘‘high risk’’. Recent
research has not only vindicated the original evidence for an inherited neu-
rointegrative vulnerability and the syndrome of pandysmaturation, but has
by extension contributed to a more general understanding of schizophrenia
as a basically neurodevelopmental disorder. Yet important gaps in knowl-
edge remain. Neurobehavioural and mental disorders other than schizo-
phrenia have until recently been less incisively investigated, and the
study of gene-environment interactions and epigenetic regulation (both pre-
dicted by Dr Barbara Fish) is only now beginning to gather pace. The future
of this area of research is bright and full of hope: the working alliance be-
tween developmental and clinical neuroscience, epidemiology and genetics
is likely to unravel many of the present complexities and ultimately lead to
practical means of risk containment and reduction.
ID: 549620
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Background: Low premorbid IQ and abnormal premorbid social adjust-
ment are consistent risk factors for schizophrenia in both prospective
and cross-sectional studies. There are many potential explanations for
the correlation between premorbid functioning and schizophrenia. As
far as we know, no previous study has used the twin method to test
competing explanations for the relation. In this study we used data from
a population of twins and siblings in the Israeli Conscripts Cohort to ex-
amine the extent to which the covariation between premorbid functioning
and schizophrenia is due to genetic overlap or environmental effects. Meth-
ods: Using the Israeli Conscripts Cohort, we ascertained 7321 pairs of
same-sex monozygotic and dizygotic twins, and 251 500 pairs of same-
sex siblings with information on intellectual and behavioral functioning
at age 17. Linkage to a national psychiatric hospitalization registry iden-
tified 58 twin pairs discordant for schizophrenia, and 5 concordant twin
pairs. There were 2234 discordant siblings-pairs, and 71 concordant sib-
lings-pairs. Results: A significant phenotypic correlation (r =.15) was ob-
served between premorbid IQ and schizophrenia. Genetic factors were the
main source of this correlation. Premorbid processing speed ability had the
greatest genetic correlation with schizophrenia, followed by non-verbal rea-
soning ability. Both genetic and environmental factors contributed to the
premorbid social adjustment<–> schizophrenia relationship (r = .14 and
r = .06, respectively). Conclusions: Findings suggest that specific candi-
date genes and neurobiological processes should be tested in relation to
both premorbid functioning and schizophrenia phenotypes. Further study
of the potential mechanisms through which environmental factors confers
risk for both premorbid functioning and schizophrenia is needed.
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Research suggests that low-grade psychotic experiences in the general pop-
ulation are a common phenomenon, and previous studies indicate that per-
sons experiencing low grade psychotic experiences are at increased risk for
suffering from clinically diagnosed psychotic disorders. The aim of the cur-
rent study is to assess the predictive validity of self-reported psychotic
symptoms on risk for later psychosis, and to identify the effect of poor ed-
ucation achievements (less then 12 years of formal education) or cannabis
abuse on risk for later hospitalization, in those persons experiencing psy-
chotic symptoms. This study utilizes data from an epidemiological study of
young adults aged 25–34 conducted in the 1980#s in Israel. A random sam-
ple of 4914 subjects were screened for psychiatric symptoms using a stan-
dardized clinical interview. The interview included questions regarding
psychotic symptoms (delusions, hallucinations, thought broadcasting,
etc). Data on later psychiatric hospitalization was ascertained in 2008 using
a psychiatric hospitalization registry, enabling up to 25 years follow-up.
Similar to data from previous studies, 25% of the subjects interviewed
reported having experienced one or more psychotic symptoms during their
lifetime. Self-reported psychotic symptoms increased risk of later hospital-
ization for psychosis (OR = 3.04, 95% CI: 1.19–7.76). In terms of popula-
tion attributable risk, 34% of hospital admissions for psychotic disorders
could be attributed to the presence of psychotic symptoms at baseline. In
individuals with psychotic symptoms, poor educational achievements or
cannabis abuse did not further increase risk for later hospitalization. In
individuals aged 25–34, a quarter of the population suffers from psychotic
symptoms, and these symptoms are associated with increased risk of later
hospitalization for a psychotic disorder. These data suggest that screening
for psychotic symptoms might enable early identification and intervention,
hence decreasing hospitalizations for psychotic illness. Lower educational
attainment or a history of drug abuse did not increase risk for later hospi-
tailzation among those with psychotic symptoms.
ID: 549612
BIRTH WEIGHT AND RISK OF SCHIZOPHRENIA OR
OTHER MENTAL DISORDER: IS IT CONFINED TO
SMALL BABIES?
Kathryn Mary Francis Abel1, S. Wicks2, E. Susser3, C. Dalman2,
M. G. Pedersen4, P. B. Mortensen4, R. T. Webb1,5
1Centre for Women’s Mental Health, University of Manchester,
Manchester, United Kingdom; 2Psychiatric Epidemiology, Depart-
ment of Public Health Sciences, Karolinska Institutet, Stockholm,
Sweden; 3Department of Epidemiology, Mailman School of Public
Health, University of Columbia and New York State Psychiatric
Hospital, New York, NY, USA; 4National Centre for Register-based
Research, NCRR, University of A˚rhus, A˚rhus, Denmark; 5Health
Methodology Research Group, University of Manchester,
Manchester, United Kingdom
Studies have shown a link between low birthweight and adult mental illness,
but have focused on the WHO threshold of 2.5kg, and on schizophrenia as
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the sole outcome. Our objectives were to examine whether: (i) increased risk
for adult schizophrenia is specifically associated with birthweight <2.5kg
rather than being spread across the birthweight range; (ii) excess risk is con-
fined to schizophrenia, or also linked with other adult mental illness. We
used a population-based cohort design using data from two adjacent Scan-
dinavian countries: all singleton live births in Sweden during 1973–1985 and
in Denmark 1979–1986 (N = 1.64 million in total). These births were linked
to comprehensive national registers of inpatient psychiatric treatment, with
follow-up to December 31, 2002 in Sweden and June 30, 2005 in Denmark.
Our main outcome measures were the odds of birthweight less than 4000–
4499g in consecutive 500g strata down to 500–1499g among people admit-
ted with any psychiatric diagnosis, schizophrenia or affective disorder ver-
sus the general population. For all diagnostic groups combined, there was
a clear trend in increasing odds ratios with decreasing birthweight across
the birthweight range: 3500–3999g OR = 1.1; 3000–3499g OR = 1.2; 2500–
2999g OR = 1.5; 2000–2499g OR = 1.8; 1500–1999g OR = 2.0; 500–1499g
OR = 2.2. This pattern was mirrored in the two specific diagnostic groups.
We found no indication of specificity of effect with either schizophrenia or
affective disorder. Country of birth, year of birth and sex had a modest
combined confounding effect in the inter-country cohort. In Sweden, socio-
economic status also had little confounding effect, although maternal an-
tenatal smoking was a stronger confounder. Even when the cohort was
restricted to term births, the patterns of birthweight risk across the normal
range persisted. Our findings suggest that the association between birth-
weight and risk of mental disorder occurs across the normal birthweight
range and that there is no evidence of a threshold effect. We do not find
that risk is specific to a particular diagnosis. Findings suggest that the range
of (environmental and other) causes of poor fetal growth interact with more
specific causes of individual diagnoses (genes, postnatal experiences) to en-
able expression of a particular mental disorder. Future prevention strate-
gies might usefully target the majority at medium risk rather than a high
risk minority.
ID: 549598
PREVALENCE OF CELIAC DISEASE AND GLUTEN
SENSITIVITY IN THE CATIE STUDY POPULATION
Nicola Gerardo Cascella1, D. Kryszak2, B. Bhatti2, P. Gregory5,
D. Kelly3, J. McEvoy4, A. Fasano2, W. W. Eaton5
1Psychiatry, Johns Hopkins University, Baltimore, MD, USA;
2Medicine, University of Maryland, Baltimore, MD, USA; 3Psychia-
try, University of Maryland, Baltimore, MD, USA; 4Psychiatry, Duke
University, Durham, NC, USA; 5Mental Health, Bloomberg School of
Public Health, Johns Hopkins University, Baltimore, MD, USA
Celiac Disease (CD) and schizophrenia (SZ) share approximately overlap-
ping prevalence but epidemiologic data show higher prevalence of CD
among SZ patients. The reason for this higher co-occurrence is yet un-
known but the clinical knowledge about the presence of immunologic
markers for CD or gluten intolerance in SZ patients may have implica-
tions for treatment. We evaluated antibody prevalence to gliadin
(AGA), transglutaminase (tTG) and endomysium (EMA). AGA, tTG
and EMA was assayed in 1410 SZ patients who were part of the Clinical
Antipsychotic Trials of Intervention Effectivness (CATIE) study and 6796
controls. Psychopathology in SZ patients was assessed using the Positive
and Negative Symptoms Scale or PANSS. Chi-square test was applied to
assess for difference in the frequency of IgA AGA and tTG antibodies.
Regression analyses were conducted to predict PANSS scores from
AGA and tTG antibodies adjusting for age, gender, and race. Among
SZ patients 22% had moderate to high levels of IgA AGA compared
to 7.9% of the controls (v2 = 1234.6, df = 2, P < .001.) Moderate to
high levels of tTG antibodies were present in 4.7% of SZ patients vs.
2.4% of the controls (v2= 68.9, df =2, P< .001.) Regression analyses failed
to predict PANSS scores from AGA and tTG antibodies. Persons with
schizophrenia have higher titers of antibodies related to celiac disease
and gluten sensitivity. Our findings might have implications for the treat-
ment of SZ patients given that a gluten-free diet may contribute to the
improvement of symptoms.
ID: 549343
COMPLEX GENETIC VARIATION IN BDNF AND
COMT GENES INTERACTS WITH ADOLESCENT
CANNABIS USE IN THE DEVELOPMENT OF
PSYCHOSIS.
Ruud van Winkel1,2, G. Kenis1, J. Allardyce1, I. Myin-Germeys1,
C. Henquet1, M. De Hert2, J. van Os1
1Maastricht University Medical Centre, Maastricht, Netherlands;
2UPC KULeuven, Leuven, Belgium
Interaction between adolescent cannabis use (<16 yrs) and BDNF func-
tional haplotypic variation can be plausibly hypothesized, given the impor-
tance of both the endocannabinoid system and neurothrophins in processes
of neurodevelopment, neuroplasticity and cognition. Furthermore, gene-
environment interaction between adolescent cannabis use and COMT
Val158Met was previously suggested. 2 SNPs within the BDNF gene
were genotyped: the functional Val66Met polymorphism, of which Met-
substitution is associated with reduced intracellular trafficking and activity-
dependent BDNF secretion, and rs988748, which was reported to form
a haplotype with Val66Met. Five polymorphisms in the COMT gene
were also genotyped, four of which were recently described to form three
common functional haplotypes that better index COMT enzymatic activity
than Val158Met alone (rs6269, rs4633, rs4818, Val158Met). rs737865, a
polymorphism associated with schizophrenia in a recent meta-analysis
(Allen et al. Nature Genetics, 2008), was also genotyped. Case-only hap-
lotype analysis in 587 psychotic patients revealed a significantly higher
odds for adolescent cannabis use for the BDNF Met/rs988748_G haplotype
compared to the other BDNF haplotypes (OR 2.04, P = .033) as well as
a trend for a higher odds for the 4-SNP COMT high activity ‘LPS’ haplo-
type compared to the other COMT haplotypes (OR 1.60, P = .055). Re-
markably, the association between COMT LPS haplotype and
adolescent cannabis use was dependent of rs737865 genotype (LPS/
rs737865_T: OR 2.11, P = .016; LPS/rs737865_C: OR 1.25, P = .469),
and there was a trend towards antagonistic BDNF x COMT interaction
(b =0.83, P = .065). The associations between adolescent cannabis use
and BDNF and COMT haplotypes remained significant and similar in
magnitude after controlling for other psychotogenic drugs, and the
gene-by-gene antagonistic interaction now also reached statistical signifi-
cance (b =1.04, P = .048). No significant association was found between
BDNF or COMT haplotypes and cannabis use started after the age of 16, or
with use of any of the other substances. In conclusion, complex haplotypic
variation within BDNF and COMT interacts with adolescent cannabis use
in the development of psychosis, and these haplotypes may act through in-
dependent pathways. Therefore, these findings may serve as a ‘magnifying
glass’ in order to elucidate the pathophysiological mechanisms driving the
psychotogenic effects of cannabis.
ID: 549322
INCREASED PREVALENCE OF ANTIBODIES TO
TOXOPLASMA IN RECENT ONSET PSYCHOSIS
Faith Dickerson1, C. Stallings1, A. Origoni1, A. Sullens1, C. Copp1,
S. Khushalani1, R. Yolken2
1Stanley Research Program, Sheppard Pratt, Baltimore, MD, USA;
2Pediatrics, Johns Hopkins School of Medicine, Baltimore,
MD, USA
Background: Increased rates of infection with Toxoplasma gondii have
been found in individuals with recent onset psychosis but this issue has
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not been studied in samples in the United States. Methods: We measured
IgG class antibodies to Toxoplasma gondii in N = 127 individuals with
recent onset psychosis, N = 457 individuals with multi-episode schizophre-
nia, and N = 164 individuals with multi-episode bipolar disorder. We com-
pared serological evidence of Toxoplasma infection in these groups with
that of N = 283 control individuals without a history of psychiatric
disorder. All participants were from central Maryland in the US. Within
the recent onset group, we also determined the correlates of Toxoplasma
seropositivity. Results: There was a higher prevalence of serological evi-
dence of Toxoplasma infection in individuals with recent onset psychosis
(21.3%) than in controls (13.8%) (OR 2.06, 95% CI = 1.1–3.7, P < .020 ad-
justed for age, gender, race, and education). Within the recent onset group,
the prevalence of Toxoplasma seropositivity was highest among individuals
with a diagnosis of schizophrenia (29.6%) compared with bipolar disorder
(18%) or other diagnosis (15.2%). Within the recent onset group, Toxo-
plasma seropositivity was correlated with receipt of olanzapine (OR 3.2,
95% CI = 1.2–9.0, P < .025 adjusted for age, gender, race, education,
and diagnosis). Serological evidence of Toxoplasma infection within the
recent onset group did not differ by age, gender, or race (all P > .1).
The seroprevalence of Toxoplasma in the individuals with multi-episode
schizophrenia and multi-episode bipolar disorder did not differ signifi-
cantly from that of the controls. Conclusions: Our results add to the grow-
ing body of literature indicating that individuals with recent onset psychosis
have an increased rate of exposure to Toxoplasma gondii compared to con-
trols living in the same geographic region. Our findings support a possible
role for Toxoplasma gondii in the etiopathogenesis of schizophrenia and
provide a rationale for trials of anti-Toxoplasma medications in individuals
with schizophrenia.
ID: 549197
ENVIRONMENTAL AND FAMILIAL DETERMI-
NANTS OF ADVERSE NEUROPSYCHIATRIC OUT-
COMES IN HIGH RISK CHILDREN OF MOTHERS
WITH SCHIZOPHRENIA AND OTHER PSYCHOSES
Vera A. Morgan1,2, S. Zubrick3, C. Bower3, M. Croft1, G. Valuri1,
J. Griffith1, A. Jablensky1,2
1Neuropsychiatric Epidemiology Research Unit, University of
Western Australia, School of Psychiatry and Clinical Neurosciences,
Perth, WA, Australia; 2Centre for Clinical Research in Neuropsy-
chiatry, University of Western Australia, School of Psychiatry and
Clinical Neurosciences, Perth, WA, Australia; 3Telethon Institute
for Child Health Research, Perth, WA, Australia
This study is designed to untangle environmental and familial contribu-
tions to risk of adverse neuropsychiatric outcomes (intellectual disability;
psychiatric morbidity) in genetically high risk children of women with
psychoses. We linked the Statewide midwives register (308 022 births)
and psychiatric case register (79 599 women) to identify 3174 high risk
children born 1980–92 to mothers with schizophrenia, bipolar disorder
or unipolar depression, and a comparison group of 3129 children born
to unaffected mothers. Psychiatric status and cognitive level were deter-
mined for mothers, fathers and children, and data collected on obstetric
complications. Time-to-event data were analysed using Cox regression.
Of 6303 children, 750 had had a psychiatric illness: 18.1% of schizophre-
nia offspring, 20.1% of bipolar offspring, 16.0% of unipolar offspring
and 5.6% of comparison children. Maternal psychosis and obstetric com-
plications were independently associated with risk of psychiatric illness
in offspring. In this young cohort, 57 children had a diagnosis of psy-
chosis: 3.1% of schizophrenia offspring, 1.2% of bipolar offspring,
0.9% of unipolar offspring and 0.4% of comparison children. Maternal
schizophrenia (OR 8.0, CI 3.6–18.2) and bipolar disorder (OR 2.6, CI
1.1–6.0) were associated with risk of psychoses. The effect for obstetric
complications variables was not significant although the odds were el-
evated. There were 129 children with intellectual disability (AAMR cri-
teria). Odds of intellectual disability was increased 3-fold in case
compared to comparison children. Parental cognitive level, maternal
psychosis, paternal psychiatric illness, and labour/delivery complica-
tions were independent risk factors for intellectual disability. Case chil-
dren were more likely than comparison children to have psychiatric
illness co-occurring with intellectual disability (P < .000). In conclusion,
children of mothers with psychoses were at significantly greater risk of
neuropsychiatric outcomes compared to children of unaffected mothers.
Environmental insults and familial liability exerted independent effects
on risk of intellectual disability and of psychiatric illness across all case
groups. Risk of psychoses was differentially distributed but numbers
were small and further analysis is warranted using a dataset under con-
struction of half a million children.
ID: 548805
CHILDHOOD TRAUMA AND INCREASED STRESS-
SENSITIVITY IN PSYCHOSIS: AN EXPERIENCE
SAMPLING STUDY
Inez Myin-Germeys1,2, M. Lardinois1, T. Lataster1, J. van Os1
1Department of Psychiatry, Maastricht University, Maastricht,
Netherlands; 2school of Psychological Sciences, Manchester Uni-
versity, Manchester, United Kingdom
Background: Increasing epidemiological evidence suggests that traumatic
experiences in childhood are associated with the development of clinical
and sub-clinical psychosis in adulthood. However, the mechanism through
which trauma leads to an increased risk for psychosis remains unclear. Pre-
vious studies have demonstrated that increased sensitivity to daily life stress
is part of the underlying vulnerability for psychosis. The current study
hypothesises that early trauma increases the risk for psychosis through sen-
sitizing people for the small stresses of daily life. Method: The sample con-
sisted of three groups: patients with a diagnosis of psychotic disorder with
a recent onset (<10 years) (n = 47), their first degree relatives (n = 43) and
healthy control subjects (n = 48). The Experience Sampling Method (ESM;
a structured diary technique) was used to assess stress-reactivity in daily life
defined as (1) emotional reactivity (increase in negative affect) and (2) psy-
chotic reactivity (increase in psychosis intensity) in reaction to stress. Child-
hood trauma was assessed using the Childhood Trauma Questionnaire
(CTQ). Results: Group was significantly associated with trauma level
(F = 8.14, P < .0001), with patients reporting significantly more trauma
compared to the relatives and controls. A history of severe trauma signif-
icantly increased the emotional (B = 0.11 (SE = 0.03), P < .001) and the
psychotic (B = 0.17 (SE = 0.03), P < .001) reaction to stress in the patients.
Conclusions: The results support previous findings that patients with psy-
chosis report increased levels of childhood trauma compared to controls. In
addition, the findings suggest a mechanism of sensitization underlying the
trauma—psychosis association, since a history of childhood trauma results
in increased psychotic en emotional reactions to stress.
ID: 548793
BARBARA FISH’S LANDMARK STUDIES
AND THEIR INFLUENCE ON PARENT-BASED
HIGH-RISK STUDIES DURING THE PAST 50 YEARS
Thomas McNeil1,2
1Psychiatric Epidemiology, Lund University, Lund, Sweden;
2Psychiatry, University of Western Australia, Perth, WA, Australia
With the assistance of Barbara Fish herself, the speaker summarizes the
landmark studies of Barbara Fish beginning in the 1950’s, and discusses
their place in the zeitgeist of American psychiatry at that time, their
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influence on the ensuing multitude of parent-based high-risk studies
beginning in the 1970’s, following the NIMH and Danish studies in
the mid-1960, and their indelible foot prints observed in ongoing high-
risk studies of that type. Fish’s concept of ‘‘pandysmaturation’’ (PDM)
is for example applied to the speaker’s prospective high-risk study
data, within the framework of the now pervasive ‘‘neurodevelopmental’’
model for serious psychopathology.
ID: 548789
PATIENTS WITH FIRST EPISODE PSYCHOSIS
TAKE MORE AND STRONGER CANNABIS THAN
CONTROLS.
Marta M. Di Forti, C. Morgan, M. Valeria, S. Stilo, R. Handley,
S. Luzi, T. Marques, M. Aas, P. Corinne, R. Manuela,
A. Demjaha, B. Wiffen, A. Kolliakou, P. Dazzan, C. Pariante,
J. Powell, R. Murray
Psychological Medicine, Institute of Psychiatry, London, United
Kingdom
Background: Epidemiological studies have reported that the increased risk
of developing psychosis in cannabis users is dose related. In addition,
experimental research has shown that the active constituent of cannabis
responsible for its psychotogenic effect is Delta-9-Tetrahydrocannabinol
(THC) (Murray et al. 2007). Recent evidence has suggested an increased
in potency (% TCH) in the cannabis seized in the UK (Potter et al.
2007). Hypothesis: We predicted that first episode psychosis patients
are more likely to use higher potency cannabis and more frequently
than controls. Methods: We collected information concerning socio-demo-
graphic, clinical characteristics and cannabis use (age at first use, frequency,
length of use, type of cannabis used) from a sample of 191 first-episode
psychosis patients and 120 matched healthy volunteers. All were recruited
as part of the Genetic and Psychosis (GAP) study which studied all patients
who presented to the South London and Maudsley Trust. Results: There
was no significant difference in the life-time prevalence of cannabis use
or age at first use between cases and controls. However, cases were more
likely to be regular users (P = .05), to be current users (P = .04) and to
have smoked cannabis for longer (P = .01). Among cannabis users, 86.8%
of 1st Episode Psychosis Patients preferentially used Skunk/Sinsemilla
compared to 27.7% of Controls. Only 13.2 % of 1st Episode psychosis
Patients chose to use Resin/Hash compared to 76.3% of controls
(OR* = 7.4, 95% CI = 3.4–17.2, Adjusted for age, gender, ethnicity, level
of Education and employment status).The concentration of TCH in
these in South East London, ranges between 8.5 and 14% (Potter et
al. 2007). Controls (47%) were more likely to use Hash (Resin) whose
average TCH concentration is 3.4% (Potter et al. 2007). Conclusions:
Patients with first episode psychosis have smoked higher potency canna-
bis, for longer and with greater frequency, than healthy controls.
ID: 546713
THE SCHIZOPHRENIA PARADOX REVISITED:
LIFETIME REPRODUCTIVE OUTPUT OVER TWO
GENERATIONS IN A SWEDISH COHORT BORN
1915–1929
James Hunter MacCabe1, D. A. Leon2, R. M. Murray1, I. Koupil3
1Psychiatry, Institute of Psychiatry, King’s College London, Lon-
don, United Kingdom; 2Non-communicable Disease Epidemiology
Unit, London School of Hygiene and Tropical Medicine, London,
United Kingdom; 3Centre for Health Equity Studies, Stockholm
University, Stockholm, Sweden
Background: Schizophrenia is a highly heritable disorder of early onset,
which severely curtails reproductive output, yet it persists at a relatively
constant population prevalence over time (the schizophrenia paradox).
It has been suggested that the fitness disadvantage associated with schizo-
phrenia might be compensated by increased fitness in unaffected relatives,
otherwise the prevalence of schizophrenia would fall to zero in a few gen-
erations. Little is known about reproductive success in affective psychoses.
To study these questions with a minimum of bias requires longitudinal pop-
ulation data over several generations. Methods: We conducted a historical
cohort study using a Swedish birth cohort of 12 168 individuals born
1915–29, and followed up until 2002. By linking to data from population
registers, we identified patients with schizophrenia (n = 58) or affective
psychosis (n = 153) and their unaffected siblings, and compared their bi-
ological fitness over two generations with that of the population, adjust-
ing for a range of socio-demographic variables from throughout the
lifespan. This is the first study to use prospectively collected data across
the entire reproductive lifespan of a defined population, and to include
data on grandchildren as well as children. Results: There was strong
evidence that patients with schizophrenia had fewer children (fertility
ratio = 0.42 [95% confidence interval (CI) = 0.31–0.56]) than the healthy
population. Much of this reduction was related to low marriage rates in
schizophrenic patients. The unaffected siblings of schizophrenic patients
showed no evidence of any compensatory increase in fitness. There was
a trend towards enhanced fertility among the offspring of schizophrenia
patients, although this was not enough to compensate for the reduced
fertility in patients, so schizophrenic patients still had fewer
grandchildren overall than the healthy population (Fertility Ratio =
0.52 [95% CI = 0.33–0.80]). Patients with affective psychosis did not differ
from the general population on any fertility measure, and neither did their
siblings and offspring. Conclusions: Schizophrenia, but not affective psy-
chosis, is associated with reduced biological fitness. This persists into the
second generation, but with tentative evidence of compensatory increase
in fitness in the offspring of schizophrenic patients.
ID: 543922
EARLY EXPOSURE TO CANNABIS AND RISK
FOR PSYCHOSIS IN YOUNG ADOLESCENTS IN
TRINIDAD
Monique Konings1,2
1Department of Psychiatry and Neuropsychology, Maastricht
University, Maastricht, Netherlands; 2Department of psychiatry,
GGZ Eindhoven, Eindhoven, Netherlands
Introduction: Cannabis is worldwide the most frequently used illicit drug,
in particular among young people. Cannabis use increases the risk for psy-
chosis, but these psychotogenic effects of cannabis may be restricted to ex-
posure during early adolescence. Method In a general population based
study, 472 participants (aged 12–23 years) were randomly selected from dif-
ferent schools in Trinidad (Republic of Trinidad and Tobago). Subjects
completed questionnaires on past and current cannabis use and psychotic
symptoms (using the Community Assessment of Psychic Experiences,
a self-report questionnaire for psychotic experiences). Results Cannabis
use increased the risk to experience psychotic symptoms and this effect
was conditional upon early exposure. Exposure before but not after the
median age of 14 years predicted psychotic symptoms (respectively b:
0.71, 95% CI = 0.22; 1.19, P = .004 and b: 0.11, 95% CI = 0.57; 0.36,
P = .66). The developmental effect of cannabis use was independent of
use of other drugs or current use of cannabis. Conclusion Early onset of
cannabis use is associated with a greater risk of developing psychotic symp-
toms than later onset of use. It seems that cannabis early exposure effects
are developmental in nature and that they do not simply reflect effects of
long-term exposure associated with earlier onset of use. Thus, early adoles-
cence may be a critical period with regard to the psychotogenic effect of
cannabis. In addition, this is the first study, to our knowledge, to show psy-
chotogenic effects of early cannabis exposure in a non-western society,
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where cannabis use has a long, non-stigmatized history for medical and
recreational use.
ID: 540988
GENDER DIFFERENCES OF PERSONS WITH
SCHIZOPHRENIA IN RURAL CHINA
Mao Sheng Ran1, W. J. Mao2, C. P. Tang3, F. R. Lin3, L. Li3,
S. H. Hu2, C. L. Chan4, E. Y. Chen4, Y. Conwell5
1University of Guam, Mangilao, GU, USA; 2Chengdu Mental
Health Center, Chengdu, China; 3Xinjin Mental Hospital, Chengdu,
China; 4University of Hong Kong, Hong Kong, China; 5Department
of Psychiatry, University of Rochester, Rochester, NY, USA
The gender characteristics of persons with schizophrenia in rural commu-
nity are still unknown. The goal of this study is to explore the gender differ-
ences of persons with schizophrenia in a longitudinal study in rural China.
Methods: A 10-year follow-up investigation among a 1994 cohort (n = 510)
of patients with schizophrenia was conducted in Xinjin County, Chengdu,
China. All the patients and their informants (100%) were followed up in
2004 using Patients Follow-up Scale (PFS). Results: The results indicated
that male patients had significantly higher level of education and rates of
unmarried and divorced than females. Female patients had significantly
more family members. Male patients had significantly worse social func-
tion. The rate of homelessness was significantly higher in male than female
(Log-rank test, v2 = 4.00, P < .05). The mortality rate was significantly
higher in male {2913 per 100 000 person-years (95% CI = 2174–3652)}
than female patients {1661 per 100 000 person-years (95% CI = 1150–
2172)} (Hazard ratio 2.0, 95% CI = 1.3–3.2, P < .005). Although there
were no significant differences of suicidal attempts between male and fe-
male patients, the suicide rate was significantly higher in male {753 per
100 000 person-years (95% CI = 373–1133)} than female patients {249
per 100 000 person-years (95% CI = 50–448)} (Hazard ratio 3.1, 95%
CI = 1.2–8.0, P< .05). Conclusions: The outcome of male patients is worse
than females in rural China. Higher mortality and suicide in male than
female patients may contribute to the higher prevalence of schizophrenia
in women than in men in China. Specific intervention strategies for
improving the outcome of the illness should be developed for male and
female patients with schizophrenia. Acknowledgments: This work was
supported in part by GRIP 1 R01 TW007260–01 (M.S. Ran, PI) from
the Fogarty International Center of NIH.
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A FURTHER EXPLORATION OF THE GENDER
DIFFERENCES IN THE AGE OF ONSET OF
SCHIZOPHRENIA
Margriet van der Werf1, J. Boydell2, J. van Os1,2, R. M. Murray2,
J. Allardyce1
1Department of Psychiatry and Neuropsychology, Maastricht
University, Maastricht, Netherlands; 2Depatment of Psycological
Medicine, Institute of psychiatry, London, United Kingdom
Background: Whether the well-replicated association between male gender
and early onset of schizophrenia constitutes a biological characteristic of
the disorder (deLisi, 1992) or reflect a differential risk factor profile across
men and women modulating the timing of onset remains unclear. Methods:
All new cases who met RDC diagnostic criteria for schizophrenia, in Cam-
berwell and in Dumfries and Galloway over 20 years (1979–1998; n = 615)
were retrospectively identified. A standardised checklist and the OPCRIT
computer algorithm were used to generate diagnoses and extract premorbid
risk factors. The association of gender with age of onset was examined using
univariate and multivariate statistics. As age of onset was non-normally
distributed Mann Whitney U test was used in univariate and an amixture
analyses was used to generate age of onset groups for ordinal logistic re-
gression. Results: All risk factors were strongly associated with age of onset
in univariate analyses except winter birth and family history of other psychi-
atric disorders. Admixture analyses identified 3 age of onset classes: an early
onset (age at first presentation<42 year), a late onset (age 42–64 years) and
a very late onset schizophrenia group (after age of 64). Ordinal logistic
regressinggenderonageofonset foundahighlysignificantassociationacross
the age groups with the highest probability of effect estimate varying with
gender in the early onset group (0.69 reducing to 17.38 in the LATE and
a probability of only 13.42 in the VERY LATE onset group). The probabil-
ities of variation in effect of gender across the age groups was very much re-
duced after adjusting for being single, unemployed , premorbid social and
occupational adjustment, premorbid cannabis use, urban environment, eth-
nic minority status, family history of schizophrenia, with the probability of
change in effect of just 0.12 in the early onset group, 0.07 in the late onset
group and 0.05 in the very late onset group (the proportional odds assump-
tion was valid in both sets of analyses). Conclusion: This study supports the
assertion that the association between age of onset and gender can be largely
explained by differential exposure of other known risk factors, and is consis-
tent with previous studies which have demonstrated a strong confounding
effect of social demographic variables (Jablensky and Cole, 1997).
ID: 551904
MORE PREMORBID CANNABIS USE WITH THE VAL
ALLELE OF THE CATECHOL-O-METHYLTRANS-
FERASE GENE ASSOCIATED WITH INCREASED
RISK FOR SCHIZOPHRENIA
Marjolaine Masse1,2, A. Liu1, R. Joober1,2, S. King1,2
1McGill University, Montreal, QC, Canada; 2Douglas Mental
Health University Institute, Montreal, QC, Canada
Current thinking is that environmental influences interact with vulnerabil-
ities in some individuals to trigger the onset of certain illnesses, such as
schizophrenia. Literature on the subject supports cannabis use, and to
some extent, the COMT Val allele, as risk factors for schizophrenia.
Recently, adolescent cannabis use was found to interact with COMT geno-
type, increasing the risk for schizophrenia (Caspi et al., 2005). However, few
cases were found, greatly reducing subjects in each cell, and cannabis use was
dichotomized into use and non-use. Because the literature suggests a dose-
response relationship between cannabis use and schizophrenia, and because
onset of use has to precede the prodrome to accommodate a causal model of
cannabis, we believed greater methodological precision could increase inter-
nal validity. Prodrome onset was carefully dated, and total premorbid can-
nabis use was estimated in 72 schizophrenia patients and 63 controls.
Logistic regressions, to explain the risk of being a patient, showed a signif-
icant interaction between the Val allele (Val/Val, Val/Met) and cannabis use:
greater cannabis use increasing significantly the risk of being a patient in Val
allele carriers compared to homozygous Met allele carriers. No effect of can-
nabis use on schizophrenia was found for the Met/Met genotype. These
results support the hypothesis of a genetic vulnerability working in combi-
nation with environmental influences to increase the risk for schizophrenia.
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CANNABIS USE IN YOUNG PEOPLE AT HIGH RISK
OF DEVELOPING PSYCHOSIS
Fern Louise Day1, C. Pugh1, L. R. Valmaggia1, M. M. Byrne1,
S. Bhattacharyya1,2, P. K. McGuire1,2
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Strong evidence exists to show that cannabis use is associated with psychosis
and, as cannabis is the most widely used of illicit substances, this constitutes
a serious public health concern. The nature of the association between can-
nabis and psychosis has been the topic of much discussion and it has been
tempting to assume a causal relationship. In order to understand better the
role of cannabis in the development of psychotic symptoms and disorder, it
is important to investigate cannabis use in people who are at high risk of
developing psychosis. Information about lifetime cannabis and other sub-
stance use was obtained from 122 participants at ‘ultra high’ risk of devel-
oping psychosis. This information was used to investigate of the
relationship between cannabis use and symptom severity, level of function-
ing, and the subsequent onset of psychosis. The rate of cannabis use was
high: 78.7% of participants reported having tried it at least once. Only
18.5% of the sample was currently using cannabis, but the majority of those
that had tried it reported a past period of regular use. Lifetime or current
cannabis use was not associated with positive symptoms scores. However,
those that had used cannabis heavily, even in the past, presented with higher
scores on the PANSS positive subscale item for suspiciousness and perse-
cution (median score 3 vs 1; P = .026). No significant differences were found
in the rate of transition to psychosis between cannabis users and non-users.
However, early-onset cannabis users who also used drugs such as amphet-
amine and ecstasy tended to be more likely to become psychotic (P = .064).
The results show that heavy cannabis use is associated with greater levels of
persecutory ideation in people at high risk of developing psychosis. How-
ever, cannabis use alone does not appear to increase further the risk psy-
chosis within this population. It might be that cannabis use in the
context of other substance use, particularly stimulants, is more important.
ID: 551830
DO FIRST- AND SECOND-GENERATION
MIGRANTS HAVE A SIMILARLY ELEVATED RISK
OF DEVELOPING PSYCHOTIC DISORDERS? A
SYSTEMATIC REVIEW
Francxois Bourque, A. Malla
Psychiatry, McGill University, Montreal, QC, Canada
Background: It has been replicated that migration is a risk factor for psy-
chotic disorders such as schizophrenia. However, it is not clear yet whether
the risk increase found among first-generation immigrants persists or even
increases among second-generation migrants. This determination is crucial
to provide viable explanations for the correlation between migration and
psychotic disorders, and to provide insights into potential social causation
mechanisms. Objectives: a) to examine the magnitude of risk of developing
psychotic disorders among second-generation migrants in comparison with
first-generation migrants and reference groups; b) to explore potential
mechanisms underlying these findings. Methods: Four databases were
searched for relevant articles between 1977 and 2008. Potential studies
were screened by two independent reviewers in a two-fold process. Studies
were included if they reported numerators and denominators from a defined
area, differentiated first- and second-generation migrants, and provided
age-corrected data. Data extraction and quality analysis was performed
on included studies. Mean weighted relative risk for psychotic disorders
was computed for both first- and second-generation migrants, first using
all available effect sizes, then using only those studies reporting rates for
both migrant generations in order to reduce heterogeneity. Results: The pre-
liminary analysis of the selected studies suggest that the increased risk for
psychotic disorders observed among first-generation migrants is also present
among second-generation migrants, with a trend toward a further risk in-
crease. However, there remains significant heterogeneity across studies.
Conclusion: The persistence of an elevated risk among second-generation
migrants suggests that post-migration factors have likely more impact
than the migratory process per se or pre-migration factors, thus supporting
social causation mechanisms. Urbanicity, childhood adversity, discrimina-
tion and social defeat are among the proposed social factors of relevance to
both first- and second-generation migrants.
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CHANGES IN INCIDENCE OF PSYCHOSIS IN A LO-
CALITY OVER TIME—CLUES TO SOCIOENVIRON-
MENTAL AETIOLOGY
J. Boydell
Health Service and Population Research Department, Institute of
Psychiatry, King’s College, London, United Kingdom
Since the earliest research into psychosis, positive associations have been
repeatedly found between social adversity and incidence rates of schizo-
phrenia. It has been difficult however to completely exclude the possibility
of reverse causality. Natural experiments provide such an opportunity and
have produced some evidence that hostility towards minority groups in
Israel and Canada is linked to increased rates of psychosis. The social con-
text in which people live changes in response to political and economic
events. This can then be investigated as a natural experiment. 9/11 and sub-
sequent events in Europe including Islamophobia were such major events.
If social hostility is a factor in the aetiology of psychosis in the short term,
it would be predicted that rates of psychosis in Europe would drop
amongst people of Caribbean descent (who are overwhelmingly Christian)
and rise amongst people who identify themselves as Muslims. The Cam-
berwell Case Register has collected every incidence case of psychosis from
a geographically defined area of South East London for over four decades
up to 2004. The Black Caribbean and Black African populations who have
very high rates of schizophrenia and other psychoses, are overwhelmingly
Christian. The purpose of this study was to test whether rates fell amongst
Black Caribbean and Black African people after 2001. A binary variable
was created to distinguish cases as presenting from 1993 up to and includ-
ing 2001 or from 2002 to 2004. Poisson regression modelling was carried
out to estimate the effect of this variable on incidence and adjust for age,
gender and ethnicity if these improved the model. First the cases were strat-
ified into the two ethnic group categories and the Poisson regression mod-
elling repeated for each stratum. The analysis then proceeded to test for an
interaction between ethnicity (as the binary variable white and black ethnic
minority) and date of presentation, adjusting for age and gender. The
results for the overwhelmingly Christian Black Minority Ethnic population
show protective effects for onset post-2001 (IRR = 0.54, 95% CI = 0.33–
0.87, P = .012), age, and to a lesser extent, gender. Thus, the incidence of
psychosis in the Black Minority Ethnic population in South-East London
was significantly lower in the years 2002 to 2004 inclusive compared to the
years 1993 to 2001. This lends support to the theory of social hostility al-
though other explanations are possible.
ID: 551793
NEIGHBORHOOD SOCIAL CHARACTERISTICS
AND THE INCIDENCE OF PSYCHOTIC DISORDERS
Wim Veling1, E. Susser2, D. March2, H. W. Hoek1,2
1Center for Early Psychosis, Parnassia Psychiatric Institute, The
Hague, Netherlands; 2Department of Epidemiology, Mailman
School of Public Health, Columbia University, New York, NY, USA
One of the most consistent findings in the epidemiology of schizophrenia is
that those who live in cities are at greater risk. It is less clear which risk
factors drive this increased risk, because few attempts have been made
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to move beyond the crude measure of urbanicity. Social factors across
different levels of organization may be involved, in particular those involv-
ing availability of and access to social capital. We conducted a first contact
incidence study of psychotic disorders between 1997 and 2005 in the city of
The Hague, the Netherlands (n = 618) and investigated associations be-
tween individual and neighborhood characteristics and incidence of psy-
chotic disorders, using multilevel Poisson regression analysis. First, after
adjustment for individual level age, sex, marital status and ethnic minority
status, measures of neighborhood socioeconomic level, residential mobility,
population density, voter turnout at local elections and crime level were all
significantly associated with the incidence of psychotic disorders in a dose-
response fashion. We calculated a cumulative score of neighborhood social
disadvantage, based on these five indicators and divided it into tertiles (low,
medium and high social disadvantage). The individual level adjusted inci-
dence rate ratio (IRR) of psychotic disorders was 1.89 (95% Confidence
Interval, 1.38–2.60) for individuals living in the socially most disadvantaged
neighborhoods and was 1.35 (95% CI = 0.95–1.92) for those living in mod-
erately disadvantaged neighborhoods compared to those living in the most
advantaged areas (Wald x2 [df = 2], 18.19, P < .0005). Second, we inves-
tigated the effect of the ethnic composition of neighborhoods on the inci-
dence of psychotic disorders, not only among ethnic minorities, but also
among native Dutch. In neighborhoods with a very high proportion of
non-Western ethnic minorities, the incidence rate for native Dutch was
35.4 per 100 000 (95% CI = 18.2–62.1), indirectly standardized to age,
sex and neighborhood socioeconomic level. In neighborhoods with a rela-
tively low proportion of ethnic minorities, the incidence rate for native
Dutch was 21.1 (18.4–24.2). Among ethnic minorities, the pattern was op-
posite. These results are suggestive for an ethnic density effect both in ethnic
minorities and in native Dutch. Thus, neighborhood social characteristics
strongly influence the incidence of psychotic disorders within an urban en-
vironment in interplay with individual factors.
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EXPOSURE TO PRENATAL MATERNAL STRESS
PREDICTS DEVELOPMENT RESEMBLING THAT OF
HIGH RISK AND PRE-SCHIZOPHRENIC CHILDREN
Suzanne King1,2, D. P. Laplante1, A. Brunet1,2, D. J. Walder4,
A. Ciampi3
1Research Centre, Douglas Institute, Montreal, Quebec, QC,
Canada; 2Psychiatry, McGill University, Montreal, QC, Canada;
3Epidemiology and Biostatistics, McGill University, Montreal,
Quebec, QC, Canada; 4Psychology, Brooklyn College of the City
University of New York, Brooklyn, NY, USA
Because retrospective studies suggest that stress to the pregnant mother
increases risk for schizophrenia, our goal was to determine whether pre-
natal maternal stress explains variance in childhood characteristics seen in
pre-schizophrenic and high risk populations using a prospective ap-
proach. We have followed more than 150 children whose mothers
were pregnant during the January 1998 Quebec ice storm crisis, contact-
ing families up to 10 times since shortly after the disaster to determine if
effects could be seen on the children’s cognitive, behavioural, or physical
development. Ice storm stress was separated into objective aspects of ex-
posure (eg, days without power, financial loss) and subjective reaction
(PTSD-like symptoms rated from the Impact of Event Scale—Revised).
At the 2005 ICOSR we reported that greater prenatal maternal stress
from the ice storm was associated with poorer IQ and language at 2
years, more behavioural problems at 3 years, and greater dermatoglyphic
asymmetry. Here, we report results through age 5 years of age. Results
indicate significant effects of the severity of maternal objective stress from
the ice storm on cognitive and language development at age 5 years:
WPPSI IQ scores were significantly lower for the high stress group
than for the low stress group, especially in verbal IQ; and the high pre-
natal stress group had significantly lower Peabody Picture Vocabulary
Test scores than the low stress group. Also at 5 years, children from
the high objective stress group exhibited significantly more severe
autistic-like symptoms, whether rated by parents or teachers, than those
in the low stress group. Effects of exposure are also seen on physical
markers. The ratio of the 2nd (index) to 4th (ring) fingers (the 2D:4D
ratio) is a sexually dimorphic trait, with women having lower ratios
than men. Our results show that prenatal stress from the ice storm pre-
dicted this ratio in 5 year olds. Results also show that exposure to the ice
storm was associated with a feminization of the ratio; other studies show
that schizophrenic men and women tend to have more feminine ratios
than controls. In conclusion, we find that prenatal stress from a natural
disaster is associated with many traits seen in pre-schizophrenic or high
risk children. Supported by grants from the Stairs Memorial Fund
(McGill University), Canadian Psychiatric Research Foundation, and
Canadian Institutes of Health Research.
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THE SOCIAL DETERMINANTS OF HIGH RATES OF
PSYCHOSIS IN THE UK BLACK CARIBBEAN AND
BLACK AFRICAN POPULATIONS: A SYNTHESIS OF
FINDINGS FROM THE AESOP STUDY
C. Morgan1, J. B. Kirkbride2, G. Hutchinson3, P. Dazzan4,
K. Morgan5, G. Doody6, P. Jones2, J. Leff4, R. M. Murray4,
P. Fearon4
1Health Service and Population Research Department, Institute of
Psychiatry, King’s College, London, United Kingdom; 2University of
Cambridge, Cambridge, United Kingdom; 3University of the West
Indies, St. Augustine, Trinidad and Tobago; 4Institute of Psychiatry,
King’s College, London, United Kingdom; 5University of West-
minster, London, United Kingdom; 6University of Nottingham,
Nottingham, United Kingdom
The incidence of schizophrenia and other psychoses is elevated in migrant
and ethnic minority groups. The ÆSOP study was established to test hy-
potheses concerning social and biological factors that might explain the in-
creased incidence of these disorders in the UK Black Caribbean and Black
African populations. ÆSOP is a multi-centre incidence and case-control
study of first-episode psychosis. Cases were all individuals presenting to
specialist mental health services for a first time with a psychotic disorder
over a two-year period. Controls were a group of randomly selected, pop-
ulation-based volunteers recruited over the same time period. We collected
data on clinical presentation, ethnicity and a range of potential social and
biological risk factors. ICD-10 and DSM-IV diagnoses were determined by
consensus, blind to the subject’s ethnicity. Over the study period, 535 in-
cident cases and 391 controls were identified. Compared with the White
British population, the incidence of all psychoses was significantly higher
in both Black Caribbean (Rate Ratio (RR) 6.7) and Black African (RR 4.1)
populations. Broadly, Black Caribbean and Black African cases had more
manic and positive symptoms and fewer negative symptoms. We investi-
gated the potential contribution of social and biological factors by testing
whether the effect, or prevalence, of risk indicators was higher in the Black
populations. For indicators of childhood and adult social adversity, we
found a similarly increased odds of psychosis in all ethnic groups. However,
all indicators of social adversity (eg, separation from a parent before the age
of 16, index of adult social disadvantage) were more common in the Black
Caribbean and, to a lesser degree, Black African populations, compared
with White British. In addition, in area level analyses, we replicated the
finding that rates of schizophrenia in Black groups are highest in areas
of low ethnic density. For biological indicators (eg, minor physical anom-
alies, neurological soft-signs), there was no evidence either that effects were
higher, or the variables more common, in the Black groups. Our findings
provide strong evidence that the high rates of psychosis in the UK Black
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Caribbean and Black African populations are, in part at least, a conse-
quence of greater exposure to individual and area level social risk factors
over the life course. This further supports a role for social adversity in the
aetiology of psychosis in general.
ID: 551726
EFFECTS OF PRENATAL INFECTION ON
NEUROPSYCHOLOGICAL AND NEUROANA-
TOMIC OUTCOMES IN SCHIZOPHRENIA
Alan Stuart Brown1, L. M. Ellman1, S. Vinogradov4,
W. S. Kremen2, R. F. Deicken4, J. H. Poole4, W. Y. Tsai1,
D. M. Kern1, C. A. Schaefer3
1College of Physicians and Surgeons of Columbia University,
Columbia University/NYSPI, New York, NY, USA; 2Department of
Psychiatry, University of California, San Diego, CA, USA;
3Division of Research, Kaiser Permanente, Oakland, CA, USA;
4Department of Psychiatry, University of California, San Francisco,
CA, USA
In previous work, our research group and other investigators have identified
associations between several prospectively identified in utero infectious and
inflammatory exposures and risk of schizophrenia. In the present study, we
sought to examine whether in utero exposure to herpes simplex viruses [her-
pes simplex virus type 1 (HSV1), herpes simplex virus type 2 (HSV2), and
cytomegalovirus (CMV)], and interleukin-8 (IL-8) are related to neuropsy-
chological and neuroanatomic abnormalities that have been associated with
schizophrenia in previous studies. In the Developmental Insult and Brain
Anomaly in Schizophrenia (DIBS) study, archived maternal serum speci-
mens were assayed for each of these herpesviruses and for IL-8 among cases
of schizophrenia from a large birth cohort. Cases were assessed in adulthood
with comprehensive neuropsychological testing and magnetic resonance im-
aging in order to relate these infections and IL-8 to measures of executive
function/working memory and to neuromorphologic outcomes. In utero ex-
posure to HSV1, HSV2, and CMV were each associated with diminished per-
formance on the auditory N-back (2-back condition) and exposure to HSV1
was related to an increase in errors on the Wisconsin Card Sort Test, suggest-
ing deficits in working memory and executive function in exposed cases. Pre-
natal exposure to HSV-2 and CMV were related to diminished thalamic
volume. Elevated IL-8 in utero was associated with an increase in ventricular
cerebrospinal fluid (CSF) and decreases in volumes of the right caudate, left
entorhinal cortex, and right posterior cingulate. These findings suggest that
prenatal exposure to infection and cytokine activation disrupt the develop-
ment of neural circuitry essential to the performance of executive function
and working memory tasks among patients with schizophrenia, and impair
the genesis of neuroanatomic structures associated with this disorder. This
suggests pathogenic mechanisms by which in utero infection contributes to
risk of schizophrenia, and provides furthervalidation for a role of theseexpo-
sures in the etiology of this disorder.
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A SYSTEMATIC REVIEW OF GENE-URBANICITY
INTERACTIONS IN PSYCHOSIS
Jim van Os1,2
1Department of Psychiatry and Neuropsychology, School of Mental
Health and Neuroscience, Maastricht University Medical Centre,
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The finding that the rate of psychotic disorder is higher in children and
adolescents growing up in an urban environment is well replicated and un-
likely to be confounded entirely by gene-environment correlation due to
selective drift to urban areas in those at genetic risk for psychosis. ‘‘Urban-
icity’’ is a proxy for an as yet unidentified environmental factor (s) prevalent
in urban areas, and, if causal, may contribute to up to 20%–30% of the in-
cidence of psychotic disorder in some countries. For this reason, urbanicity
is an interesting factor to study in the context of GxE. We conducted a sys-
tematic review of the literature and identified four studies in the Nether-
lands, Germany, Israel and Denmark that attempted to examine gene-
urbanicity interactions using epidemiological designs and indirect measures
of genetic risk. All studies found evidence for gene-urbanicity interaction.
The Dutch and Danish studies reported that the increase in incidence as-
sociated with urbanicity in individuals without a family history of psychosis
was much smaller than in those with a family history. The German study
found an effect of urbanicity on psychosis rates only in individuals with
a psychometric psychosis liability. The study from Israel used cognitive im-
pairment as indicator for genetic risk and found a nearly tenfold difference
in increase in incidence associated with urbanicity between the cognitively
non-vulnerable group and the cognitively vulnerable group. Clearly, the
possibility of interaction between an environmental exposure in urban areas
and genetic risk is in need of further study, focusing on (i) the precise nature
of the urban exposure, for example growing up in an area lacking in trust
and cohesion, (ii) the psychological and neurobiological mechanism of the
environmental exposure in order to develop rational hypotheses about
gene-environment interaction, (iii) the nature of the genetic variation
involved and ultimately (iv) the mechanism of the gene-environment
interactions.
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META-ANALYSIS OF PATERNAL AGE AND
SCHIZOPHRENIA RISK IN THE OFFSPRING
Erick Messias1, B. Miller1, J. Miettunen2, J. Lo¨ho¨nen2,
A. Alara¨isa¨nen2, M. Ja¨rvelin3,4, H. Koponen5, P. Ra¨sa¨nen2,
B. Kirkpatrick1, M. Isohanni2
1Psychiatry and Health Behavior, Medical College of Georgia,
Augusta, GA, USA; 2Psychiatry, University of Oulu, Oulu, Finland;
3Epidemiology, Public Health, and Primary Care, Imperial College,
London, United Kingdom; 4Public Health and General Practice,
University of Oulu, Oulu, Finland; 5Psychiatry, University of
Kuopio, Kuopio, Finland
Advancing paternal age (APA) is a well-replicated and relatively robust
risk factor for schizophrenia in the offspring. In regards to autism risk
in the offspring, paternal age has a sexually dimorphic effect, with
a much greater impact on risk of autism in females than in males. A recent
meta-analysis of paternal age and schizophrenia risk in the offspring did
not adjust for gender and study design effects, and did not use the same
age classes across studies. We calculated pooled estimates using meta-anal-
ysis, adjusting for these factors and including data from additional studies.
Articles were identified by PubMed searches and review of references. We
attempted to contact authors of all studies published after 1992 to request
summary data stratified by gender and the same five-year paternal age
groups. Studies where greater than 80% of cases had a diagnosis of
non-affective psychosis, and who provided data in the requested format
were included. Data from the Northern Finland 1966 Birth Cohort, which
have not been previously published, were also included. A total of 8 stud-
ies met our criteria including 5 cohort and 3 case-control studies. Within
the cohort studies, males and females were considered separately. In both
cohort and case-control studies, we found a J-shaped association between
paternal age and schizophrenia risk in the offspring (reference paternal age
of 25–29). Effect sizes were similar between cohort and case-control stud-
ies. There was no evidence of sexual dimorphism for the paternal age ef-
fect. Further studies are needed to investigate mechanisms for this
association, including the increased risk in offspring of fathers under
age 25.
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Table. Risk of schizophrenia by paternal age for cohort and case-control
studies
Paternal
Cohort Studies
Case-Control
Studies
Age Cases Total Crude 95% CI Cases Controls Crude 95% CI
(years) (n) (n) RR (n) (n) OR
<20 313 49826 1.41 1.26–1.59 179 3398 1.37 1.17–1.60
20–24 2862 561986 1.15 1.09–1.20 1491 38032 0.99 0.92–1.08
25–29 4554 1025448 1.00 Reference 2420 62752 1.00 Reference
30–34 3415 754591 1.02 0.97–1.07 1812 43505 1.20 1.10–1.31
35–39 1902 366779 1.17 1.11–1.23 952 22697 1.11 1.02–1.20
40–44 927 154443 1.35 1.26–1.45 477 10121 1.24 1.12–1.38
45–49 348 55829 1.40 1.26–1.56 182 3806 1.23 1.06–1.44
50–54 136 17260 1.77 1.50–2.10 67 1160 1.48 1.16–1.90
>54 71 6858 2.33 1.85–2.94 36 322 2.87 2.03–4.06
— — — —
Total 14528 2993020 7616 185793
ID: 551689
CHILDREN OF PARENTS WITH AFFECTIVE AND
NON-AFFECTIVE PSYCHOSES: A PROSPECTIVE
STUDY OF CHILDHOOD INTERNALIZING AND
EXTERNALIZING BEHAVIOR
Jo-Ann Donatelli1, L. J. Seidman2,3, J. M. Goldstein2,4,
M. T. Tsuang5, S. L. Buka1,6
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Deaconness Medical Center, Boston, MA, USA; 3Athinoula
Martinos Center for Biomedical Imaging, Massachusetts General
Hospital and Massachusetts Institute of Technology, Charlestown,
MA, USA; 4Connors Center for Women’s Health and Gender
Biology, Harvard Medical School at Brigham and Women’s
Hospital, Boston, MA, USA; 5Psychiatry, University of California
at San Diego, Psychiatry, Center for Behavioral Genetics, San
Diego, CA, USA; 6Society, Human Development, and Health,
Harvard School of Public Health, Boston, MA, USA
It is generally accepted that children of parents with schizophrenia or other
forms of psychosis are at heightened risk for a range of behavioral prob-
lems. However, it remains unclear whether offspring of parents with differ-
ent forms of psychosis (eg, schizophrenia, other non-affective psychoses,
and affective psychoses) have distinct forms of behavioral problems (ie, in-
ternalizing and externalizing). This investigation examined behavioral
observations at ages 4 and 7 years of children of psychotic (n = 281)
and non-psychotic parents (n = 188). There were no significant differences
between groups in behavior observed at age 4. At age 7, compared to chil-
dren of unaffected parents, children of parents with psychosis had a signif-
icantly elevated risk for externalizing problems {adjusted odds ratio (aOR)
2.8 (95% CI = 1.5–5.6)}, in particular for offspring of parents with schizo-
phrenia (aOR = 4.4; 95% CI = 1.7, 12.5). This increase in risk for external-
izing problems was observed for females only (aOR = 8.1; 95% CI =
2.5–26.3). In contrast, male children were at increased risk for internalizing
problems (aOR = 3.6; 95% CI = 1.6–8.3). Additional analyses examined
rates of individual symptoms of internalizing and externalizing behavioral
problems in relation to parental psychosis. Male high-risk offspring had
higher rates of shyness and withdrawal compared to low-risk male off-
spring. Female high-risk offspring exhibited more variable mood or unsta-
ble emotional responses compared to low-risk female offspring.
Implications for treatment of parents with psychotic disorders and high-
risk children are discussed.
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MATERNAL IRON DEFICIENCY AND RISK OF
SCHIZOPHRENIA IN OFFSPRING
Alan Stuart Brown1, B. J. Insel1, C. A. Schaefer2, I. McKeague1,
E. S. Susser1
1College of Physicians and Surgeons of Columbia University,
Columbia University/NYSPI, New York, NY, USA; 2Division of
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Iron is essential for brain development and functioning. Iron deficiency in
early life leads to long-lasting neural and behavioral deficits in infants and
children, and disruptions in myelination and dopamine function. Hence, we
examined the effects of early iron deficiency on the risk of schizophrenia in
adulthood. We hypothesized that maternal iron deficiency, assessed by ma-
ternal hemoglobin concentration ascertained during pregnancy, increases
the susceptibility to schizophrenia in the offspring. The data were drawn
from a large, population-based birth cohort. Hemoglobin was prospec-
tively assayed in virtually all pregnancies. Mean hemoglobin concentration
over pregnancy was the primary exposure. Mean maternal hemoglobin 
10.0g/dl was associated with a nearly fourfold, statistically significant in-
creased rate of schizophrenia (adjusted rate ratio, 3.73; 95% CI = 1.41–
9.81, P = .008), adjusting for maternal education and ethnicity. For every
one g/dl increase in mean maternal hemoglobin, a twenty-seven percent de-
crease in the rate of schizophrenia was observed (95% CI = 0.55–0.96; P =
.024). Further analysis revealed that the effect was specific to the third tri-
mester. These novel findings suggest that maternal iron deficiency may be
a risk factor for schizophrenia in the offspring. Since iron deficiency anemia
occurs commonly in pregnancy, these findings may have important impli-
cations for prevention of schizophrenia in the population.
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CNS INFECTIONS DURING CHILDHOOD AND RISK
FOR SCHIZOPHRENIA: A CASE CONTROL STUDY
Mark Weiser1, N. Werbeloff1, D. Halperin1, A. Levine2, G. Livni3,
R. Yoffe4, M. Davidson1
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Health, Ministry of Health, Jerusalem, Israel
Some studies found a positive association between viral or bacterial CNS
infections during childhood and risk for later schizophrenia, psychotic dis-
order or mood disorder with psychotic symptoms (1,2). A large, recently
published Swedish study found a slightly increased risk for nonaffective psy-
chotic illness and schizophrenia with previous viral CNS infections, but no
increased risk with bacterial infections (2). The aim of this study was to assess
the risk for schizophrenia in early adulthood after viral or bacterial CNS in-
fection during childhood. The association between CNS infections in
childhood and hospitalization for schizophrenia was examined by identify-
ing 3500 persons who had been hospitalized as children for meningitis. Con-
trols were 6400 persons who as children had been hospitalized for gastro-
enteritis. They were followed for later hospitalization for schizophrenia
using the National Psychiatric Hospitalization Case Registry in Israel.
Cox Regression analysis was used to assess risk for later schizophrenia.
Among the 9970 individuals who were included in the study, 6371
(63.9%) were diagnosed with gastroenteritis and 3599 (36.1%) were diag-
nosed with CNS infections. Overall, no association was found between
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CNS infections during childhood and risk of later hospitalization for schizo-
phrenia. Post hoc analyses found that children hospitalized for a bacterial
CNS infection between the ages of 1–4 years were at increased risk of later
hospitalization for schizophrenia (adjusted HR = 5.27, 95% CI: 1.4–19.93)
(table). However this finding is based on 3 cases. Bacterial CNS infections at
an early age could be associated with a slightly increased risk for schizophre-
nia later in life.
ID: 551584
THE RELATIONSHIP BETWEEN
NEURODEVELOPMENTAL AND SOCIAL FACTORS
IN FIRST EPISODE PSYCHOSIS
Paul Fearon1, C. Morgan1, P. Dazzan1, T. Lloyd2, J. Leff1,
P. B. Jones3, R. M. Murray1
1Psychological Medicine, Institute of Psychiatry, London, United
Kingdom; 2Psychiatry, University of Nottingham, Nottingham,
United Kingdom; 3Psychiatry, University of Cambridge, Cambridge,
United Kingdom
Introduction: Previous work has demonstrated an association between a)
markers of neurodevelopmental impairment, and b) markers of early and
later social adversity and psychosis. We sought to explore, in an epidemi-
ological sample of first episode psychosis cases, whether there was a rela-
tionship between specific markers of neurodevelopmental impairment and
social adversity, or whether these factors comprised entirely distinct path-
ways to the disorders. Methods: All cases from the UK MRC AESOP study
with complete social and biological data (N = 213: M = 113; F = 100) were
included in this analysis. Two markers of neurodevelopmental impairment
(total Neurological Soft Sign (NSS) score and total Minor Physical Anom-
aly (MPA) score) and two markers of early (prolonged parental separation
in childhood) and later (cumulative index of long term social disadvantage
prior to onset) social disadvantage were chosen. Correlations between each
neurodevelopmental and each social item were calculated, firstly in the
whole sample, and then stratified by gender and by diagnosis. Results:
We found no evidence of any correlation between NSS scores for any social
variable, or for parental separation and any neurodevelopmental variable.
However, there was evidence of a significant and consistent positive corre-
lation between higher MPA scores and greater later social adversity (Spear-
man’s Rho 0.204; P = .003) in the whole sample. This finding held for both
men (0.214; P = .02) and women (0.208; P = .04). In terms of diagnosis, this
held true only for schizophrenia (0.22; P = .01) but not for either manic
psychosis or depressive psychosis. Conclusion: Our findings suggest a spe-
cific relationship between the presence of higher scores of MPAs and higher
levels of long term social disadvantage, in both men and women destined to
develop schizophrenia. The precise nature of this relationship, and its ap-
parent diagnostic specificity, remain to be elucidated.
ID: 551558
THE PREVALENCE OF PSYCHOTIC SYMPTOMS IN
CHILDREN AND ADOLESCENTS: A SYSTEMATIC
REVIEW
Dearbhla Connor, M. Harley, N. Devlin, M. Cannon
Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland
There is evidence that psychosis exists on a continuum in the population in
both adult and child and adolescent samples. A large number of studies have
been carried out examining the prevalence rates of psychotic symptoms in
adult populations, however studies in child and adolescent samples are more
scarce. To date, no systematic review of the literature on psychotic symp-
toms specifically in childhood and adolescence has been carried out. This
review aimed to establish prevalence rates of psychotic symptoms in children
and adolescents. A systematic review of all published literature on the prev-
alence of psychotic symptoms in children and adolescents was conducted
using electronic databases Ovid Medline, Pubmed and Psychinfo with an
agreed battery of search terms: young people, adolescents, teenagers, child,
psychotic symptoms, psychosis, paranoia, delusions, grandiosity, unusual
beliefs/ideations, bipolar, positive and negative symptoms, dissociative dis-
orders, prevalence. Reference lists of the relevant papers were examined to
identify further articles. We included both clinical and community samples
of children and adolescents. We excluded studies reporting prevalence rates
of psychotic symptoms in children and adolescents with organic illnesses and
in schizophrenic and selected samples at high risk for psychosis.126 papers
were located. Twenty nine relevant studies were identified: 14 from clinical
and 15 from community settings. Methods used to identify psychotic symp-
toms included self-report questionnaires, clinical interview, standardised in-
terview instruments and review of patient charts or a combination of
methods. Reported prevalence of psychotic symptoms for clinical samples
ranged from 0.4% to 81% across ages 2 to 19 years (outpatient samples 0.4 to
28 %, inpatient samples 1.1 to 81%). Prevalence rates in community samples
varied from 2% to 58.9% spanning ages 7 to 19 years (rates determined
by questionnaire 6% to 58.9% and at interview 9% to 50%). Differing
methodology across studies is reflected in a wide variation of rates of psy-
chotic symptoms both within and across clinical and community samples.
Research in this area would benefit from a standardised developmentally
appropriate screening instrument with high sensitivity for identifying psy-
chotic symptoms in children and adolescents. Future studies could employ
a two stage process to screen large samples of children and adolescents and
determine rates of psychotic symptoms at interview.
ID: 551476
Table. Risk for hospitalization for schizophrenia among individuals hospitalized for CNS infections in childhood (by type) compared to individuals
hospitalized for Gastroenteritis in childhood, by age groups.
Age of
Childhood
Hospitalization
Not later
hospitalized
(N = 9,898)
Later
Hospitalized
(N = 72)
Unadjusted
HR (95% CI)
Adjusted* HR
(95% CI)
<1 Gastroenteritis 3436 28 1 1
CNS infections- bacterial 224 3 1.58 (0.48–5.19) 1.57 (0.48–5.15)
CNS infections- viral 748 3 0.49 (0.15–1.6) 0.46 (0.14–1.51)
1–4 Gastroenteritis 1616 8 1 1
CNS infections- bacterial 103 3 5.26 (1.39–19.88) 5.27 (1.4–19.93)
CNS infections- viral 936 3 0.64 (0.17–2.4) 0.65 (0.17–2.46)
>4 Gastroenteritis 1271 12 1 1
CNS infections- bacterial 80 0 – –
CNS infections- viral 1484 12 0.88 (0.39–1.95) 0.72 (0.32–1.6)
*Adjusted for gender
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DO NEIGHBOURHOOD CHARACTERISTICS
AFFECT THE DURATION OF UNTREATED
PSYCHOSES?
James B. Kirkbride1, D. Lunn2, C. Morgan3, J. Lappin3,
R. Abdul-Al1, P. Dazzan3, K. Morgan3, P. Fearon3,
D. Speigelhalter2, R. M. Murray3, P. B. Jones1
1Department of Psychiatry, University of Cambridge, Cambridge,
United Kingdom; 2MRC Biostatistics Unit, University of
Cambridge, Cambridge, United Kingdom; 3Division of Psycholog-
ical Medicine, Institute of Psychiatry, London, United Kingdom
Background: Family involvement in help-seeking has been shown to be as-
sociated with a shorter duration of untreated psychoses, but it is unknown
whether factors at the neighbourhood-level also affect the duration of un-
treated psychoses [DUP]. We sought to test this hypothesis. Methods: All
cases of first-episode psychoses which occurred over a two-year period in 32
neighbourhoods of Southeast London were included in the study. DUP was
estimated for all cases. We fitted a number of multilevel Gaussian (normal)
Bayesian models, which adopted different assumptions with regard to spa-
tial variability of DUP to asses whether there was evidence of heterogeneity
in DUP by neighbourhood, having accounted for a priori individual-level
confounders. Model fit was assessed via the Deviance Information Crite-
rion. Results: 314 subjects with first episode psychoses were included in the
analysis. DUP was heavily skewed with a median of 72 days (inter-quartile
range: 22–323). The median DUP between wards varied from 19 to 631.5
days. We transformed DUP onto the log scale to normalise the outcome
variable in order to fit our Bayesian models. After adjustment for individual
differences in age, sex and ethnicity, there was no evidence of significant
variation in DUP between neighbourhoods. A Bayesian model with indi-
vidual-level predictors, but without any hierarchical effects provided the
best fit to the data. As previously reported, ethnicity minority status
and increased age were significantly associated with longer DUP. Discus-
sion: Neighbourhood factors do not appear to be associated with the du-
ration of untreated psychoses, suggesting that the predictors of DUP are
rooted in the individual and family, not at the societal level.
ID: 551448
NEUROPSYCHOLOGICAL FUNCTION AND PATH-
WAYS TO CARE: FINDINGS FROM THE AESOP
FIRST EPISODE PSYCHOSIS STUDY
Dionne Harleston1, C. Morgan1, P. Fearon1, R. Murray1,
P. Dazzan1, K. Morgan2, P. Jones4, G. Doody3, J. Zanelli1,
A. Reichenberg1
1Division of Psychological Medicine, Institute of Psychiatry, King’s
College London, London, United Kingdom; 2Westminster Univer-
sity, London, United Kingdom; 3Nottingham University, Notting-
ham, United Kingdom; 4Cambridge University, Cambridge, United
Kingdom
Numerous studies have found that patients with psychosis perform poorly
on neuropsychological tests compared with healthy controls. We sought to
investigate whether there was a relationship between cognitive function and
pathways to treatment. We also sought to investigate any differences by
demographic factors. 593 Participants, recruited as part of the three centre
AESOP study (Aetiology and ethnicity of schizophrenia- a longitudinal ep-
idemiological study of FEP) who made contact with services performed
a battery of neuropsychological tests to assess intellectual function (Na-
tional Adult Reading Test-Nart and the Wechsler Adult Intelligence scale,
Revised-WAIS-R). Participants intellectual functioning was compared
with their type of admission. Data on pre-morbid and current intellectual
function was then compared with data also gathered on clinical presenta-
tion. Any correlations in terms of socio-demographic characteristics
(namely ethnicity, age and gender) and socio-economic status were ex-
plored. Analysis was undertaken using t-tests and ANOVAs. No Signifi-
cant differences were found in pre-morbid intellectual function between
patients whose admission was compulsory versus non-compulsory. There
was however a significant relationship between current intellectual func-
tioning and pathways to care (P = .014). Patients who were voluntarily ad-
mitted had a mean full scale IQ of 91.38 compared with patients who were
compulsorily admitted who had a mean full scale IQ of 86.04. Those with
lower cognitive function were more likely to be compulsorily admitted than
being voluntarily admitted. There was additionally a trend for lower IQ and
those who had police involvement (P = .043). There was no significant re-
lationship between Criminal justice or GP referral and GP involvement.
These findings suggest poor performance on neuropsychological testing;
in this case current low intellectual functioning is associated with being
compulsorily admitted and having police involvement. These findings raise
the question of what role cognitive function actually plays in enabling peo-
ple to negotiate a positive pathway to care. There is potentially a need for
increased support and information from agencies for those with lower cog-
nitive function who may be less able to communicate with and navigate the
mental health system. Funded by the UK Medical Research Council.
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SYMPTOM CHARACTERISTICS IN AFRICAN-
AMERICAN AND EUROPEAN-AMERICAN SUB-
JECTS WITH SCHIZOPHRENIA: PRELIMINARY
RESULTS
Sarah Bergen1, A. Fanous5,7, R. Amdur5,7, S. Aggen6, A. Sanders3,
D. Levinson4, P. Gejman2, K. Kendler1,6
1Genetics/Virginia Institute for Psychiatric and Behavioral Genetics,
Virginia Commonwealth University, Richmond, VA, USA; 2Psy-
chiatry/Center for Psychiatric Genetics, Northwestern University,
Chicago, IL, USA; 3Psychiatry and Behavioral Sciences/Center for
Psychiatric Genetics, Northwestern University, Chicago, IL, USA;
4Psychiatry and Behavioral Science/Genetics of Brain Function,
Stanford University, Palo Alto, CA, USA; 5Psychiatry, Georgetown
University, Washington, DC, USA; 6Psychiatry/Virginia Institute
for Psychiatric and Behavioral Genetics, Virginia Commonwealth
University, Richmond, VA, USA; 7Washington VA Medical Center,
Washington, DC, USA
The heterogeneous presentation of schizophrenia makes symptom-level
analyses particularly important in designing studies exploring the etiol-
ogy and pathophysiology of this disorder. We used phenotypic data from
1192 African-Americans (AAs) and 1289 European-Americans (EAs)
with schizophrenia drawn from the Genetic Association Information
Network (GAIN) schizophrenia study. Factor analysis in MPlus yielded
five symptom factors in both the AA and EA cohorts: Schneiderian
symptoms, auditory hallucinations, delusions, visual hallucinations,
and negative symptoms. Additional analyses suggested that the lack
of measurement invariance in the five factor structure between the
AA and EA samples is largely due to noninvariance of the negative
factor loadings and thresholds. Demographic variables such as age of on-
set, duration of illness, and sex displayed different patterns of correla-
tions with the factors in the AA and EA samples. Earlier age of onset
predicted higher scores for all factors except the negative symptom factor
in the EA cohort which showed no significant relationship. Duration of
illness positively correlated with auditory hallucinations and negative
symptoms in both samples but visual hallucinations only in the AA sub-
jects. The only significant sex differences were higher levels of auditory
and visual hallucinations in the AA females. The extent to which these
populations differ in symptom expression may be a function of differen-
tial environmental exposures or genetic predispositions between groups.
International Congress on Schizophrenia Research
84 6. 6. Epidemiology
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
Subsequent analyses incorporating genome wide genotypic data will aid
in distinguishing these possibilities.
ID: 551416
PREVALENCE RATES AND CORRELATES OF
PSYCHOTIC-LIKE SYMPTOMS AMONG ADOLES-
CENTS REFERRED TO A CHILD AND ADOLESCENT
PSYCHIATRIC OUTPATIENT SERVICE
Nina Devlin1,2, M. Harley2,3, D. Beattie1, M. Iqbal3,
C. Fitzpatrick1,3, M. Cannon2
1School of Medicine,Catherine McAuley Research Centre,
University College Dublin, Catherine Mc Auley Research Centre,
Dublin 1, Ireland; 2Department of Psychiatry, Royal College of
Surgeons in Ireland, Smurfit Building, Beaumont Hospital, Dublin 9,
Ireland; 3Child and Adolescent Psychiatry, Mater Hospital, James
Joyce Street, Dublin 1, Ireland
During the past decade, there has been growing interest in psychotic-like
symptoms among young people. For years, such symptoms were not asked
about by child and adolescent mental health professionals as it was consid-
ered meaningless in the absence of a psychotic diagnosis. However, there is
now compelling evidence from population-based cohorts that self reported
psychotic symptoms in early adolescence are associated with a higher risk of
psychotic illness in adulthood. Prevalence studies of psychotic symptoms
among clinical child and adolescent samples are few and to date, have
shown prevalence rates of psychotic symptoms ranging from 4.5% to
33%. We wished to investigate the prevalence and correlates of psy-
chotic-like symptoms in a sample of adolescents referred to an Irish child
and adolescent mental health outpatient service. Over a one year period
consecutive referrals of 12–15 year olds to a child and adolescent mental
health service in North Dublin were asked to participate in the ‘Welcome’
Study. Subjects underwent a comprehensive assessment conducted by a psy-
chiatrist or psychologist. The interview protocol included the K-SADS PL,
Clinical Global Assessment Scale, the Clinical Global Impressions scale,
the Adolescent Wellbeing scale, the Parental Stress Scale and a psychosis
screening questionnaire. The psychosis screening questionnaire is derived
from the DIS-C: and comprises the following questions: Q1/ ‘‘Have other
people ever read your mind?’’,Q2/ ‘‘Have you had messages sent to you via
the TV/radio?’’ Q3/ ‘‘Have you ever thought people were spying on you or
following you?’’ and Q4/ Have you ever heard voices that other people can’t
hear?’’ Forty-four adolescents have participated in the study so far of whom
48.8% have responded positively to one or more of the psychosis screening
questions. Analysis of responses to individual questions was as follows: Q1
‘‘mind-reading’’16.3%; Q2 ‘‘TV/radio 0%; Q3 ‘‘spying’’ 25.6%; Q4 ‘‘voices’’
18.6%. Overall 95.4% of participants had a psychiatric diagnosis of whom
56.8% had co-morbid diagnosis and 4.5% (n = 2) were diagnosed with a psy-
chotic disorder .Of note no-one was originally referred to the service with
suspected psychosis. We conclude that the prevalence of psychotic-like
symptoms are far higher than previously thought among young adolescents
referred to a child and adolescent psychiatry service. These symptoms
should be routinely enquired about as part of the initial assessment.
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PRENATAL EXPOSURE TO RETINOL (VITAMIN A)
AND EXECUTIVE FUNCTIONING IN ADULT
OFFSPRING WITH SCHIZOPHRENIA
Poonam Nina Banerjee1, D. M. Kern1, W. S. Kremen4,
S. Vinogradov2, R. F. Deicken2, J. H. Poole2, C. A. Schaefer3,
A. S. Brown1
1New York Psychiatric Institute, Columbia University, New York,
NY, USA; 2Department of Psychiatry, University of California, San
Francisco, CA, USA; 3Division of Research, Kaiser Permanente,
Oakland, CA, USA; 4Department of Psychiatry, Center for Be-
havioral Genomics, University of California, San Diego, CA, USA
The aim of this study is to evaluate evidence for the theory that elevated
maternal retinol (vitamin A) exposure levels, particularly during the third
trimester, are associated with decreased executive functioning in adult off-
spring with schizophrenia. Prenatal exposure to excess retinol levels and
related compounds (retinoids) has been associated with toxicity to the cen-
tral nervous system as well as congenital fetal anomalies including hydro-
cephaly and spina bifida. Several studies have shown that retinoid
dysregulation may be an important factor in the etiology of schizophrenia,
since congenital anomalies similar to those caused by retinoid dysfunction
are found in patients with schizophrenia and their relatives, and numerous
schizophrenia candidate genes are regulated by retinoic acid (Goodman,
1998). In the present study, we assessed the relationship between serolog-
ically documented prenatal exposure to retinol from archived maternal
sera, and a series of measures of executive functioning, in 20 individuals
with schizophrenia from a large and well-characterized birth cohort.
The cases were derived from the Developmental Insult and Brain Anomaly
in Schizophrenia (DIBS) study. Sera were assayed for retinol by an estab-
lished protocol and cases were administered a standard neuropsychological
test battery including measures of executive function. Elevated retinol levels
among schizophrenia cases were associated more total errors on the Wis-
consin Card Sort Test (P = .01), including both perseverative errors (P = .03)
and non-perseverative errors (P = .03), and lower test scores on the Ruff
Figural Fluency test (P = .09). These findings provide compelling evidence
that retinoids, already implicated in the etiology of schizophrenia and con-
genital malformations, may also lead to executive function deficits in
patients with schizophrenia.
ID: 551282
THE RELATIONSHIP BETWEEN ETHNICITY AND
PSYCHOTIC SYMPTOMS AS MEASURED BY THE
SCAN: PILOT DATA FROM THE GENETICS AND
PSYCHOSIS (GAP) STUDY
Corinne Prescott
Psychiatry, Institute of Psychiatry, King’s College London, London,
United Kingdom
Background: The presence of underlying symptom dimensions in the psy-
chopathology of psychosis is well established, and the relationship between
ethnicity and psychotic symptoms has been demonstrated in previous stud-
ies (Janssen et al. 2003 1, Veling et al. 2007 2). Methods: The Item Group
Checklist (IGCL) of the Schedules for Clinical Assessment in Neuropsychi-
atry (SCAN) Version 2.1. was used to derive scores for 59 patients for the
SCAN. The symptoms investigated comprised the following IGCL Item
Groups: Depressive delusions and hallucinations (Item Group 13) Nonspe-
cific auditory hallucinations (IG 21) Non-affective auditory hallucinations
(IG 24) Miscellaneous delusions (IG 28) Delusions of reference (IG 29)
Delusions of persecution (IG 30) IGCL scores were dichotomised prior
to analysis into present and absent. Subjects: All 59 subjects in the present
sample were recruited to the GAP study from the inpatient services of the
South London and Maudsley NHS Foundation Trust. All met diagnostic
criteria for psychosis (ICD-10). and were recruited during the period May
2005 to June 2006. The mean age of the sample was 27.73 years (sd. 7.82)
and the group comprised 40 males and 19 females. The sample was cate-
gorised by ethnicity into Black 63%) and White/Other (37%). The Black
sample comprised Black African, Black Caribbean, and Black Other.
The White/Other sample comprised White British, Mixed, Indian, Bangla-
deshi and Caucasian. Results: Of the six groups of positive symptoms ana-
lysed, a positive rating of presence for one symptom reached significance:
There was a trend for several symptom groups to be more common in the
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black patients but these did not reach statistical significance. However, de-
pressive delusions and hallucinations (IG13) were found to be associated
with ethnicity (P = .025; Pearson’s x2(1) = 5.629), being more common
in the white/other group. Conclusion: There was a tendency for several
groups of symptoms to be rated more commonly in the black patients
but these differences were not significant. However, depressive delusions
and hallucinations were more common in the white/other patients.
ID: 551188
TIME COURSE OF ILLICIT DRUG USE AMONG FEP
PATIENTS: DATA FROM THE PICOS-VENETO
STUDY AFTER ONE YEAR OF FOLLOW-UP
Rodolfo Mazzoncini, A. Lasalvia, S. Tosato, C. Bonetto,
D. Cristofalo, K. De Santi, M. Bertani, S. Bissoli, G. Marrella,
L. Lazzarotto, M. Tansella, M. Ruggeri
Section of Psychiatry and Psychological Medicine, Department of
Medicine and Public Health, University of verona, Verona, Italy
Introduction: Substance misuse prevalence rates are higher among psy-
chotic patients than in the general population. Emerging evidences suggest
a casual role of drug exposure in developing psychosis. Of great concern
and clinical relevance is whether or not the pattern of substance use among
these subjects is changing over time and how it affects the course of illness.
This study aims to determine substance misuse prevalence rates variation
over 1 year in first episode psychotic (FEP) patients. Methods: The pre-
sented data are part of the PICOS-Veneto project, a multi-site study aiming
to characterise course and outcome of psychosis from the first contact.
Assessments were performed using standardized measures including: clin-
ical evaluation, socio-demographic characteristics and illicit drugs use.
Results: 143 FEP patients were evaluated at baseline and at 1 year follow
up. At baseline 19.6% was positive for any drug use, 18.4% cannabis, 5.0%
cocaine, 5.7% hallucinogens. At one year follow up, 9.1% was positive for
drug misuse, 9.1% cannabis, 1.4% cocaine, 0.7% hallucinogens. If com-
pared with the general population, prevalence rates, among FEP subjects,
were significantly higher at the baseline: cannabis 18.4% vs 8.0%; cocaine
5.0% vs 1.2% and hallucinogens 5.7% vs 0.3%. After one year drug use
prevalence rates are similar to those observed in the general population.
Conclusions: Substance misuse prevalence rates are significantly higher
among FEP patients than in the general population. A significant reduction
in this behaviour is observed one year after the psychosis onset. This finding
could help in understanding the meaning of the association between
psychosis and drug use.
References
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MORTALITY AND SUICIDE IN SCHIZOPHRENIA.
FINDINGS FROM THE NORTHERN FINLAND 1966
BIRTH COHORT STUDY
Antti Alara¨isa¨nen, J. Miettunen, E. Ja¨a¨skela¨inen, H. Koivumaa-
Honkanen, P. Ra¨sa¨nen, M. Isohanni
Department of Psychiatry, University of Oulu, Finland, Oulu,
Finland
Our aim was to analyze the mortality and especially suicide rate and pre-
dictors in schizophrenia and other psychotic disorders in the Northern
Finland 1966 Birth Cohort. The Northern Finland 1966 Birth Cohort
Study is based upon 12 068 pregnant women and their 12 058 live-
born children. Those who were alive at the age of 16 (n = 10 934) were
followed up to the age of 39 years. We used validated hospital diagnoses
until 1997 and information on mortality until 2005. Risk ratios (RR) were
calculated having healthy subjects as comparison group. Crude and ad-
justed hazard ratios (HR) and their 95% confidence interval (95% CI) for
suicide by school performance were computed using Cox regression which
takes the time to the event (suicide) account. RR of death for all cohort
members suffering from psychosis (n = 155) was 6.19 (95% CI: 3.96–9.49).
For schizophrenia patients (n = 100) RR was 7.07 (4.24–11.42). Due the
young age of cohort members leading cause of death was suicide. At the
end of year 2005 (age 39) 7 of 100 schizophrenia patients had commit
a suicide. Case fatality (CF, number of suicides divided by number of
subjects) was 7%. CF for females was 2.9% (1/35) and for males 9.2%
(6/65). Suicide risk was high especially for males and in early phase of
psychotic disease; two thirds of suicides in schizophrenia occurred within
three years after onset of illness. Suicide rate of schizophrenia patients
was nearly 2-fold higher six years after first discharge from psychiatric
care (P = .005) compared to hospital treated patients with non-psychotic
disorder. Among individuals with psychosis predictors of mortality were
violent criminality and male gender, while good school performance was
a predictor of suicide. For psychotic persons having good school perfor-
mance (highest 20%), the adjusted hazard ratio (HR) for suicide was 3.56
(0.97–13.05) compared with the remaining 80%. In the non-psychotic
population (97% without psychiatric hospitalization), accordingly, ad-
justed HR was 0.28 (0.07–1.16). Interaction (school performance x psy-
chiatric diagnosis) was significant (P = .01) even when adjusted with
gender, social class and age of onset of illness. This is the first study
of suicide risk in a prospectively followed population-based cohort of
individuals with schizophrenia. The suicide rate for patients with
new-onset schizophrenia followed until the age of 39 is high. Great ma-
jority of the suicides took place during the first years of the illness.
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A COMPARISON OF SYMPTOM PROFILES BE-
TWEEN DIFFERENT ETHNIC GROUPS IN A FIRST
ONSET PSYCHOSIS STUDY
Arsime Demjaha1, C. Morgan1, K. Morgan2, P. Dazzan1,
G. Hutchinson3, S. Landau1, P. Jones4, R. Murray1, P. Fearon1
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The aim of the present study was to investigate whether the symptom
profile in first onset psychosis patients from various ethnic groups
differs from that of their White British counterparts. We recruited
536 patients as part of a multi-centre, population based, incidence
study of psychosis, of which 43% were White British, 29% Black Carib-
bean, and 13% Black African. Psychopathology was assessed using the
Schedules for Clinical Assessment in Neuropsychiatry (SCAN). A Prin-
cipal Axis Factor analysis was performed on symptom scores, using Var-
imax rotation. The symptom dimension scores were then compared
between different ethnic groups employing regression analyses. Factor
analysis gave rise to a five factor solution of manic, reality distortion,
negative, depressive, and disorganisation symptom dimensions account-
ing for 47% of total variance. Regression analyses revealed significant
differences between ethnic groups. Specifically, Black Caribbean
patients experienced more reality distortion and fewer negative symp-
toms than White British (P = .045, and P = .010 respectively).
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With regards to severity, Black Africans tended to have more severe
manic and reality distortion and less severe disorganisation symptoms
when compared with White British (P = .002, P = .003, and P = .021 re-
spectively). Our results indicate that there are significant variations in
symptom profiles between Black Caribbean, Black African and White
patients with first onset psychosis. These may reflect differences in un-
derlying aetiological factors.
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DO CANNABIS AND URBANICITY INTERACT IN
CAUSING PSYCHOSIS?
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Background: Cannabis use and the urban environment are risk factors for
psychotic illness. It is unknown, however, whether these environmental
factors may interact with each other as well on psychosis risk. Method:
Prospective data on 2438 adolescents and young adults (aged 14 to 24
years) from the Early Developmental Stages of Psychopathology
(EDSP) study were analyzed. Urbanicity was defined at baseline as the
German city of Munich (4061 persons per square mile) versus the sur-
roundings of Munich (553 persons per square mile). Cannabis use and
psychotic symptoms were assessed by means of the Composite Interna-
tional Diagnostic Interview at baseline, at T2 (four years later), and again
at T3 (eight years later). Logistic regression analysis was used to investi-
gate the interaction between urbanicity and T2 cannabis use on psychosis
outcome at T3. Results: Cannabis use was associated with an increased
risk of expression of psychosis, even after exclusion of individuals with
previous experiences of psychotic symptoms at T2 and after adjustment
for age, gender, socio-economic status, use of other drugs other, and
childhood trauma (OR = 1.61, 95% confidence interval 1.03 to 2.52,
P = .036). The effect of cannabis on psychosis outcome, however, was
much stronger in those who grew up in an urban area compared to those
who grew up in a rural area (risk difference 9.6%; test for interaction v2 =
5.69, df = 1, P = .02). Neither urbanicity nor pre-existing psychotic expe-
riences predicted later cannabis use. Discussion: These results show that
environmental factors may interact with each other in causing psychosis.
The effects of cannabis on psychosis outcome seem to be particularly
detrimental for those young adults who are growing up in an urban
environment.
ID: 551108
INFECTIONS OF TOXOPLASMA GONDII AND THE
LATER DEVELOPMENT OF SCHIZOPHRENIA IN
MOTHERS
Marianne Pedersen1, H. Stevens1, B. Nørgaard-Pedersen2,
P. B. Mortensen1
1National Centre for Register-based Research, University of Aarhus,
Aarhus C, Denmark; 2Statens Serum Institut, Copenhagen,
Denmark
Several studies suggest that infectious diseases including Toxoplasma gon-
dii can influence the risk of schizophrenia. Our own previous study (1)
showed that children, who were born with high level of Toxoplasma gon-
dii-specific immunoglobulin (IgG), have a slightly increased risk of schizo-
phrenia. The elevated level of IgG in the neonatal samples in our previous
study indicates that the mother has a history of T. gondii infection. The aim
of this study is to investigate if mothers, to children born with a high level of
IgG, suffer an increased risk of schizophrenia. Children born in five coun-
ties in Denmark from 1992 to 1995 were screened for T. gondii at 5–10 days
post-partum (N = 53,881). Their mothers were followed from the day they
gave birth until first diagnosis of schizophrenia during 1992 to 2007. Pre-
liminary results indicate a general association between Toxoplasma gondii
and later psychiatric illness (RR = 1.21 (95% CI: 1.13; 1.29)). The relative
risk for schizophrenia was of similar magnitude but not statistically signif-
icant. Final analyses will be presented at the conference. Supported by the
Stanley Medical Research Institute.
Reference
1. Mortensen PB, Pedersen BN, Waltoft BL, et al. Toxoplasma gondii as
a risk factor for schizophrenia: analysis of filter paper blood samples
obtained at birth. Biol Psychiatry, 2007;61:688–693.
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PSYCHOPATHOLOGY DURING CHILDHOOD AND
ADOLESCENCE PREDICTS DELUSIONAL-LIKE
EXPERIENCES IN ADULTS: A 21 YEAR BIRTH
COHORT STUDY
James Scott1,2, J. Welham1,3, G. Martin1,2, W. Bor4, J. Najman5,
M. O’Callaghan5, G. Williams5, R. Aird6, J. McGrath1,7
1Department of Psychiatry, University of Queensland, Brisbane,
QLD, Australia; 2Child and Youth Mental Health Service, Royal
Children’s Hospital, Brisbane, QLD, Australia; 3Queensland Centre
for Mental Health Research, The Park Centre for Mental Health,
Brisbane, QLD, Australia; 4Kids in Mind, Mater Children’s Hos-
pital, Brisbane, QLD, Australia; 5School of Population Health,
University of Queensland, Brisbane, QLD, Australia; 6School of
Public Health, Queensland University of Technology, Brisbane,
QLD, Australia; 7Queensland Brain Institute, University of
Queensland, Brisbane, QLD, Australia
Community surveys have shown that many otherwise well individuals re-
port delusional-like experiences. The aim of this study was to examine the
association between psychopathology during childhood and adolescence as
predictors of subsequent delusional-like experiences in young adults. The
study was based on a birth cohort of 3617 young adults born between 1981
and 1984. Psychopathology was assessed at age 5 and 14 by mothers using
the Child Behaviour Check List (CBCL), and by the cohort members with
the Youth Self Report (YSR) at age 14 delusional-like experiences were
measured using the Peters Delusional Inventory at the 21 year follow up.
The association between childhood symptoms and later delusional-like
experiences was examined using logistic regression adjusted for gender
and age at last assessment, as well as drug use and the presence of nonaf-
fective psychotic disorder at age 21. High CBCL scores at 5 and 14 years
predicted high levels of adult delusional-like experiences; (Highest versus
other quartiles OR and 95% CI: 1.25; 1.00–1.57: 1.85; 1.482.30 respec-
tively). Those in the highest quartile of YSR scores at 14 years were nearly
four times more likely to have high levels of delusional-like experiences at
age 21 (OR and 95% CI: 3.71; 2.92–4.71). Adolescent onset psychopathol-
ogy and continuous psychopathology through both childhood and adoles-
cence strongly predict delusional-like experiences at age 21. Delusional-like
experiences and hallucinations at 14 years were significantly associated with
adult delusional-like experiences. The general pattern of associations per-
sisted when adjusted for previous drug use or the presence of nonaffective
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psychoses at age 21. Our study found that psychopathology during child-
hood and adolescence predicts adult delusional-like experiences. Under-
standing the biological and psychosocial factors that influence this
developmental trajectory may provide clues to the pathogenesis of
psychotic-like experiences.
ID: 551057
ARE NEURAL TUBE DEFECTS IN SIBLINGS A RISK
FACTOR FOR SCHIZOPHRENIA: A POPULATION-
BASED TEST OF THE ROLE OF LOW FOLATE
DURING PREGNANCY IN RELATION TO
SCHIZOPHRENIA RISK
Michael Skaarup Pedersen1, G. Davey-Smith2,
A. M. N. Andersen3, P. B. Mortensen1
1National Centre for Register-based Research, University of Aarhus,
Aarhus C, Denmark; 2Department of Social Medicine, University of
Bristol, Bristol, United Kingdom; 3Institute of Public Health, Uni-
versity of Southern Denmark, Odense, Denmark
Mothers with low folate intake and TT homozygote mothers for the meth-
yltetrahydrofolate reductase (MTHFR) gene are at increased risk for hav-
ing children with neural tube defects. Neural tube defects as well as
schizophrenia have been found to occur with increased frequency in
cohorts exposed to famine during fetal life, and a meta-analysis examining
the polymorphisms in schizophrenics and controls found the odds ratio
for TT homozygotes to be 1.48 (95% CI = 1.18–1.86). This supports
the hypothesis that folate status may be an important determinant of
schizophrenia risk. In order to test this hypothesis in a population-based
setting, we used the Danish population-based registers to examine schizo-
phrenia risk in the Danish population using the occurrence of neural tube
defects in siblings as a proxy for low folate intake or MTHFR TT homo-
zygosity in the mother. We based our data on the Danish civil registration
system. Through this system it is possible to establish links between indi-
viduals, their parents, and through the parents with their sibs for persons
born in Denmark 1952 or later. Exposure was determined by diagnosed
neural tube defects identified through the National Patient Register and
the Register of Congenital Malformations. Follow-up was made through
the Danish Psychiatric Central Register, covering all psychiatric hospitals
and since 1995 all psychiatric outpatient wards. Outcome was schizophre-
nia, ICD-8 295, ICD-10 F20, 25. We also studied the broader group of
non-affective psychoses as a potential outcome. Results will be available
at the conference.
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EARLY VIRAL INFECTIONS AS A RISK FACTOR
FOR SCHIZOPHRENIA
Preben Bo Mortensen1, C. B. Pedersen1, D. M. Hougaard2,
B. N. Petersen2, O. Mors3, A. Børglum4, E. F. Torrey5,
R. H. Yolken5
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Several studies have suggested that exposure to infections in utero or during
early childhood is a risk factor for the onset of schizophrenia later in life.
Several studies have been based on ecological data or information based
upon maternal recall, and only few cohorts exist where it is possible to fol-
low-up individuals for whom there is serological evidence of early infec-
tions. We studied the role of Herpes simplex virus 1 and 2 and
cytomegalovirus in a nationwide birth cohort in Denmark. We identified
all cases in a Danish psychiatric hospital or outpatient clinic. For each
case, we selected one control from the same cohort born on the same
day as the case and of the same gender, and alive on the data of first ad-
mission with schizophrenia for the case. We initially identified 923 schizo-
phrenia patients, but there was only sufficient biological material available
from the dried blood spot samples in the neonatal biobank for PKU screen-
ing for 602 cases and 602 controls. Those included in the study and those
who had to be excluded due to lack of biological material did not differ
significantly by established risk factors for schizophrenia including family
history of mental illness and urbanicity of place of birth. At the Stanley
Neurovirology Laboratory type specific antibodies to the gG2 glycoprotein
of viral infection were measured by enzyme immuno assay and an assay
value < 0.2 optical density unit was predefined as indicating exposure to
viral infection. There was an increased risk associated with HSV2, RR
1.51 (95% CI = 1.08–2.10). There was no general association between
CMV and schizophrenia (RR 1.10), but a significant interaction by gender
where the risk was increased in males (RR 1.49, 95% CI = 1.05–2.11), con-
trary to what was found in women (RR 0.76, 95% CI = 0.52–1.11) for
HSV1. We only found a weak and non-significant association between
HSV1 and schizophrenia (RR 1.12, 95% CI = 0.89–1.40). We did, however
find an effect in the group of individuals with foreign born mothers, ie, sec-
ond generation immigrants (RR 3.72, 95% CI = 1.30–10.61), both com-
pared to HSV1 seronegative second generation immigrants and to
seropositive and seronegative native Danes. We identified both general
and subgroup specific associations between early viral infections and
schizophrenia risk. This may indicate an interaction between early infec-
tions and other subgroup specific genetic or environmental risk factors
in the etiology of schizophrenia.
ID: 551013
CANNABIS USE AND TRUE INCIDENCE OF
PSYCHOTIC SYMPTOMS IN A POPULATION-BASED
SAMPLE
Rebecca Kuepper1, J. van Os1,3, H. U. Wittchen4,5, R. Lieb4,5,
C. Henquet1,2
1Departement of Psychiatry and Neuropsychology, South Limburg
Mental Health Research and Teaching Network, EURON,
Maastricht University Medical Center, Maastricht, Netherlands;
2Division Addiction Care, Mondriaan Zorggroep, South Limburg,
Netherlands; 3Division of Psychological Medicine, Institute of
Psychiatry, London, United Kingdom; 4Clinical Psychology and
Epidemiology Unit, Max Planck Institute of Psychiatry, Munich,
Germany; 5Institute of Clinical Psychology and Psychotherapy,
Technical University, Dresden, Germany
Research has consistently shown that adolescent cannabis use increases the
risk for later development of psychotic symptoms or schizophrenia with
a factor of two. However, it still remains equivocal whether the relationship
between cannabis use and psychosis is causal or follows the so-called self-
medication hypothesis. In the current study, prospective data from the
Early Developmental Stages of Psychopathology study (N = 2438, age
at baseline 14 to 24 years) were analyzed. Substance use and psychotic
symptoms were assessed at baseline and at follow-up at T2 (four years later)
and again at T3 (eight years later), by means of the Composite International
Diagnostic Interview. Logistic regression analyses were conducted to inves-
tigate the effect of T2 cannabis use on true incidence of psychotic symptoms
at T3, by only including individuals who were cannabis naive at baseline
and had no sign of psychotic symptoms at T2. Analyses revealed that can-
nabis use at T2 significantly increased the risk for psychotic symptoms at
T3, after adjusting for age, gender, socio-economic status, urbanicity, use of
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other drugs, and childhood trauma (OR = 1.57, 95% confidence interval
1.13 to 2.17, P = .007). The effect of T2 cannabis use on T3 psychosis out-
come remained both strong and significant when only including individuals
who were cannabis naı¨ve at baseline and had no previous psychotic expe-
riences at T2 (OR = 1.88, 95% confidence interval 1.11 to 3.16, P = .018).
Testing the reverse association (ie, the effect of psychotic symptoms at T2
on cannabis use at T3) did not reveal significant results (OR = 0.89, 95%
confidence interval 0.67 to 1.19, P = .45), speaking against self- medication
mechanisms. The data presented here confirm that adolescent cannabis use
increases the risk to develop psychotic symptoms later in life. Self-
medication mechanisms are very unlikely to explain this association.
ID: 551007
BIPOLAR DISORDER, SCHIZOAFFECTIVE
DISORDER AND SCHIZOPHRENIA OVERLAP;
A NEW COMORBIDITY INDEX
Thomas Munk Laursen, E. Agerbo, C. B. Pedersen
University of Aarhus, Aarhus, Denmark
Objective: Growing evidence of an etiologic overlap between schizophrenia,
schizoaffective disorder and bipolar disorder has become increasingly dif-
ficult to disregard. We investigated the magnitude of the overlap between
the clinical diagnoses of bipolar affective disorder, schizoaffective disorder,
and schizophrenia over a 30 year period, based on the entire Danish pop-
ulation. We introduced a new comorbidity index, measuring the magnitude
of the overlap between the three disorders, enabling us to make a new con-
tribution to the discussion of whether they are distinct or overlapping dis-
ease entities. Method: We established a register-based cohort study of more
than 2,5 million persons born in Denmark. Risks for the 3 psychiatric dis-
orders were estimated by survival analysis, using the Aalen-Johansen
method. Results: Overall, N = 12 734 were admitted with schizophrenia,
N = 4205 with bipolar disorder and N = 1881 with schizoaffective disor-
der. A female bipolar patient’s risk of also being admitted with a schiz-
oaffective disorder, before the age of 45 was approximately 103 times
higher than that of a woman at the same age in the general population.
Thus, we defined the comorbidity index between schizoaffective disorder
and bipolar disorder at age 45 to be 103. The index between schizophrenia
and schizoaffective disorder was 80 at age 45, and between schizophrenia
and bipolar disorder 20. Similar results were found for men. A strong
effect modification by age was present resulting in a higher index for
younger patients. Conclusions: The proposed comorbidity index revealed
a large overlap between the diagnostic categories of schizophrenia, schiz-
oaffective disorder, and bipolar disorder. There was a large overlap be-
tween schizophrenia and schizoaffective disorder as well as a large
overlap between bipolar disorder and schizoaffective disorder. But,
more surprisingly it was clear that a substantial overlap between bipolar
disorder and schizophrenia was present. The study supports the existence
of an overlap between bipolar disorder and schizophrenia.
ID: 551000
IS THE INCREASED RISK OF SCHIZOPHRENIA
IN IMMIGRANTS AN ARTIFACT OF SELECTIVE
MIGRATION?
Carsten B. Pedersen1, P. B. Mortensen1, E. Cantor-Graae2
1National Centre Register-based Research, Aarhus University,
Aarhus, Denmark; 2Department of Health Sciences,
Lund University, University Hospital Malmo¨, Malmo¨, Sweden
Background: Many studies have shown that foreign immigrants have an
increased risk of developing schizophrenia in their host country as com-
pared to their native counterparts. Although, the factor(s) responsible
for the increased risk remain unknown, it has been hypothesized to include
environmental factors associated with the process of migration. However, if
people migrating from one country to another have a higher liability
(genetic and/or environmental) of developing schizophrenia, then an alter-
native explanation for the increased risk associated with migration could be
that immigrants have a higher pre-existing liability of developing schizo-
phrenia, or in other words that migration per se may not increase the
risk of schizophrenia, but the increased risk associated with migration is
due to selective migration. Objective: The aim of this study was to assess
whether risk factors for schizophrenia were also risk factors for emigration.
If risk factors for schizophrenia also increase the risk of emigration, we may
have evidence that immigrants are a pre-selected group of people who have
a higher liability to develop schizophrenia as compared to the native coun-
terparts. Below we focus on the potential association of the degree of ur-
banization at place of birth on the risk of emigration from Denmark; urban
place of birth has consistently been shown to also increase the risk of de-
veloping schizophrenia. At the conference results concerning other risk fac-
tors for schizophrenia will be presented, including a history of mental illness
in a family member. Methods: We followed all people born in Denmark
1971–1991 for the first emigration from Denmark 1971–2006. Results:
Among children (0–15 yrs) the greater the degree of urbanization at place
of birth, the higher the risk of emigration from Denmark. Conclusion: The
higher the degree of urbanization of place of birth, the higher the risk of
schizophrenia and emigration from Denmark, suggesting that people
migrating from Denmark are expected to carry a higher liability to develop
schizophrenia than their native counterparts. Whatever the unknown
factor(s) responsible for the urban-rural differences in the risk of schizo-
phrenia, some of these may also be responsible for the increased risk of
schizophrenia among immigrants. Supported by the Stanley Medical Re-
search Institute.
ID: 550964
EARLY DEVELOPMENTAL RISK FACTORS FOR
VOICE-HEARING AMONG 7 AND 8 YEAR OLD
CHILDREN
Agna A. Bartels1, J. A. Jenner1, G. Van de Willige1, J. Van Os2,3,
D. Wiersma1
1University Center for Psychiatry, University Medical Center
Groningen, Groningen, Netherlands; 2Maastricht University,
Maastricht, Netherlands; 3Division of Psychological Medicine,
Institute of Psychiatry, London, United Kingdom
The accurate identification of children and adolescents who experience hal-
lucinations may allow us to target those at higher risk for psychotic illness in
adulthood. In 2002/2003 auditory vocal hallucinations (AVH) were
assessed in a population-based sample of 3870 children in the province
of Groningen, the Netherlands. Voice-hearing was assessed with the Audi-
tory Vocal Hallucination Rating Scale (AVHRS; Jenner and Van de
Willige, 2002). To investigate associations between voice-hearing and
pre- and perinatal influences, early development and current behaviour
problems, for a case-control sample data were gathered from the Infant
Health Service records, and from parental completed Child Behaviour
Checklists (CBCL). A 5-year follow-up study is currently being carried
out to investigate prevalence, persistence and characteristics of AVH in
the case-control sample of now 12 and 13 year old children, and their re-
lationship with social behaviour. At baseline, the one-year prevalence of
AVH was 9%. 15% of AVH children reported severe suffering and AVH
elicited more anxiety in girls. The prevalence for AVH was higher in rural
areas, but AVH were more severe, more often externally attributed and of
greater functional impact in the urban environment. There was some evi-
dence for an association with prenatal maternal infection (OR 2.07, 95% CI
= 1.04–4.05; P = .04) and slower motor development in early life (OR 1.22,
95% CI = 1.02–1.46; P = .03). Only weak associations were apparent be-
tween AVH and current problem behaviour. We conclude that there
may be continuity between AVH in childhood and more severe psychotic
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outcomes given the severe suffering in a subgroup, associations with early
developmental deviance and evidence for a poorer prognosis in an urban
environment.
References
1. Jenner JA, Bartels-Velthuis AA, Van de Willige G, Van Os J, and
Wiersma D. Hearing voices in childhood: a prevalence and case-control
study of auditory hallucinations in middle childhood. 2008;(submitted).
2. Jenner JA and Van de Willige G. The Auditory Vocal Hallucination
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THE ANTECEDENTS OF SCHIZOPHRENIA:
A REVIEW OF BIRTH COHORT STUDIES
Joy Lillian Welham1, M. Isohanni2, P. Jones3, J. McGrath4
1Queensland Centre for Mental Health Research, University of
Queensland, Brisbane, QLD, Australia; 2Department of Psychiatry,
University of Oulu, Oulu, Finland; 3Department of Psychiatry,
University of Cambridge, Cambridge, United Kingdom; 4Queens-
land Brain Institute, University of Queensland, Brisbane, QLD,
Australia
Background: Birth cohort studies suggest that individuals who develop
schizophrenia differ from the general population on a range of developmen-
tal indices. We summarize key findings from birth cohort studies to identify
areas of convergence and areas requiring further research. Method: We ex-
amined studies based on general population birth cohorts where data are
collected prospectively from birth or childhood, and whose outcome is
schizophrenia or related disorders. We searched various electronic data-
bases to identify such studies using the search parameters (schizo* OR
psych*) AND (birth cohort). We also examined references from relevant
articles and previous reviews. Results: We found 10 birth cohorts from
6 countries with studies adopting adult schizophrenia as an outcome.
They provide relatively consistent evidence that, as a group, children
who develop schizophrenia in adulthood have behavioural disturbances
and psychopathology, intellectual and language deficits and early motor
delays. Some studies provide evidence of changes in educational perfor-
mance and physical growth. Birth cohort studies also find evidence of
a wide range of putative risk factors for schizophrenia. Conclusions: Birth
cohort studies provide important, convergent insights into how the de-
velopmental processes of individuals with schizophrenia differ from their
peers. Some more recent studies examine developmental trajectories;
that is examining individual rather than group measures across develop-
ment—a particular strength of birth cohort designs. Larger cohorts and
new paradigms, together with modern epidemiology and biomedical sci-
ence, are illuminating the developmental pathways to schizophrenia.
ID: 550905
IMPACT OF GENETIC VULNERABILITY FOR
PSYCHOSIS, FETAL INFLAMMATION, AND
GENDER ON AGE 7 COGNITIVE AND BEHAVIORAL
FUNCTIONING
Sara Cherkerzian1, S. L. Buka2,7, J. L. Donatelli2, A. Remington3,
M. T. Tsuang4,6, J. M. Goldstein2,5
1Connors Center for Women’s Health and Gender Biology, Division
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Women’s Hospital, Harvard Medical School, Boston, MA, USA;
2Department of Community Health, Brown University, Providence,
RI, USA; 3Department of Psychiatry, Beth Israel Deaconess
Medical Center, Boston, MA, USA; 4Harvard Institute of
Psychiatric Epidemiology and Genetics, Boston, MA, USA;
5Athinoula Martinos Center for Biomedical Imaging, Massachusetts
General Hospital and Massachusetts Institute of Technology,
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Diego, CA, USA; 7Department of Society, Human Development,
and Health and of Epidemiology, Harvard School of Public Health,
Boston, MA, USA
Recent work on the etiology of schizophrenia has focused on premorbid
and prodromal endophenotypes to characterize early identifiers of risk.
This high-risk study assessed the impact of genetic vulnerability, fetal in-
flammation, and gender on age 7 offspring cognitive and behavioral out-
comes. Using data from the longitudinal New England Family Study
(NEFS) cohort, we identified 185 parents with psychosis and 126 comparable
control parents. There were 169 (87 males, 82 females) offspring among these
psychotic parents (‘High-Risk’) and 247 (125 males, 122 females) among the
controls. Fetal inflammation, parental psychosis, their interaction and gen-
der were together modeled as predictors of age 7 cognitive and behavioral
functioning in the offspring. Least-squares means, fixed effects and covari-
ance parameters were estimated using mixed linear models accounting for
intrafamilial correlation. Cognitive functioning was significantly lower
among high-risk offspring and those exposed to fetal inflammatory condi-
tions, operationalized as IQ, academic achievement, and perceptual-motor
and verbal-conceptual functions (eg, there was a 5.5 point mean IQ difference
between offspring exposed and unexposed to fetal inflammation (P< .0002);
and there was a 3.5 point mean IQ difference between the high-risk and con-
trol offspring (P< .003). The fixed-effects parameters for inflammation were
significant across all cognitive measures; genetic vulnerability was significant
for IQ (P< .01), and interactions for verbal/conceptual functioning (P< .02)
and inhibition (P < .02). Both of these interactions were found to be signif-
icant for males but not for females. Genetic vulnerability for psychosis and
fetal inflammation are independently associated with lower cognitive func-
tioning even by age 7, and together have an interactive effect on both verbal/
conceptual cognitive functioning and dysregulation of affective expression
primarily in males.
ID: 551933
EVALUATION OF PERINATAL AND PEDIATRIC
RISK FACTORS FOR THE DEVELOPMENT OF
SCHIZOPHRENIA
Raul Escamilla
Servicios Clı´nicos. Clı´nica de Esquizofrenia, Instituto Naciona de
Psiquiatrı´a, Mexico city, Mexico
Schizophrenia is a disorder that affects in a significant degree the psicoso-
cial functioning of the pacient in many areas. One of the major risks to have
this disorder is related with biological proximity; identical twins (sharing
100% of genetics) do not show a 100% concordance for schizophrenia,
which suggests that environmental or epigenetic factors that are not well
enough characterized, could have a determinant rol during neurodevelop-
ment phase on the origin of this disorder. Method. This case-control study
explored the association between perinatal risk, pediatric risk neurological
conditions (seizures on early infancy, cranial traumatism) and the risk
for schizophrenia. Case totaled 100 patients with schizophrenia diagnosis,
every case was individually matched by gender and nearly age with one
sibling without a psychiatric diagnosis in axis 1 (DSM IV criteria). Results:
Adjusted analyses showed that the risk of schizophrenia was associated
with fetal suffering/distress (x2 = 34.0, 1 gl, P < .001Fisher P < .001).
The logistic regression model was able to discriminate cases from controls
(general efficacy 86.5%, regarding Hosmer y Lemeshow model), being more
accurate to predict subjects without schizophrenia (93%). Results suggest
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that this perinatal and early childhood conditions are associated with the
risk of schizophrenia and seem to act not only independently. Conclusions:
The following complications were significantly associated with schizo-
phrenia: Cranial traumatism, seizure on early infancy, complications of
delivery (abnormal labor and delivery, fetal suffering or distress and in-
cubator use); even in a isolated way or integrated in a synergistic model.
A combination of diverse disciplines and approaches will be needed to
elucidate the mechanisms underlying these important associations in or-
der to establish preventive measures. The development and implementa-
tion of optimal strategies for recording important events during
pregnancy, delivery and early childhood is needed to identify subjects
on risk for schizophrenia.
Table. Predictors factors for schizophrenia: logistic regresio´n model
Independent risk b D. E. b Exp (b) IC 95% Exp (b) P
Cranial traumatism 3.7 0.8 39.1 8.3–183.3 <0.001
Seizure on early
infancy
3.3 1.1 27.0 3.0–240.9 0.003
Abnormal labor
and delivery
2.4 1.2 10.7 1.0–111.3 0.05
Fetal suffering
or distress
1.5 0.8 4.6 0.93–22.7 0.06
Incubator use 3.2 1.5 0.04 0.002–0.73 0.03
ID: 555523
ECT USE IN A PUBLIC HOSPITAL IN SYDNEY
Natalie Gabrielle Limet, R. R. Malesu
Psychiatry, Blacktown Hospital, Sydney, NSW, Australia
The aim of the study was to determine the use of ECT in a public hospital in
Sydney. ECT data over a 5 and a half year period at a public hospital ser-
vicing a suburb of 271 710 population (2006 census) in Western Sydney was
analysed. The data collected was: the type of ECT given (eg. bilateral / uni-
lateral etc), the indications (diagnoses), gender, age and legal status of
patients who received ECT. During this period (January 2003 to August
2008) 916 ECTs were administered of which 483 were right unilateral
and, 433 bilateral. None of the patients received bifrontal ECT. 816
ECTs were administered to females whilst only 100 ECTs were given to
males ie, F:M ratio was 8:1. This ratio of females: males was strikingly dif-
ferent from the female: male admission ratio of only 3:2. The majority (504)
of the patients who received ECT suffered from depression whilst 130 suf-
fered from schizophrenia, 274 suffered from schizoaffective disorder and 8
suffered from mania. Only a quarter (248) of ECTs were given voluntarily
while the rest (668) were given to involuntary patients who were under the
NSW Mental Health Act 2007. About 10% (90) of the patients were 65 years
or over of which 50 ECTs were given to patients over 80 years of age. The
use of ECT in this centre is much less when compared to its use in the other
centres in the same Area Health Service. Although current practices suggest
Bifrontal ECT is preferable to the other types, none of the patients were
given bifrontal ECT. In addition only half the patients received Unilateral
ECT despite unilateral ECT usually having less side effects and less memory
impairment. It has become apparent that the use of ECT in this centre needs
further evaluation and implementation of more up-to-date practices.
ID: 554143
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7. 7. Genetics, Basic
ASSOCIATION OF THE BRAIN-DERIVED NEURO-
TROPHIC FACTOR (BDNF) VAL66MET POLYMOR-
PHISM WITH HIPPOCAMPAL N-ACETYL
ASPARTATE (NAA/CHO) LEVEL AND VERBAL
MEMORY CAPACITY
Oliver Gruber1, H. Scherk1, M. Backens2, T. Schneider-Axmann1,
T. Wobrock1, A. Hasan1, W. Reith2, J. Meyer3, P. Falkai1
1Department of Psychiatry, Georg August University, Goettingen,
Germany; 2Department of Neuroradiology, Saarland University,
Homburg, Germany; 3Department of Neuro-Behavioral Genetics,
University of Trier, Trier, Germany
Background: The brain-derived neurotrophic factor (BDNF) is a key reg-
ulator of neural plasticity and has been suggested to be involved in the path-
ophysiology and pathogenesis of schizophrenia and depression, with
particular emphasis on dysfunctions of the hippocampal formation. In
the present study, we investigated the impact of the val66met polymor-
phism in the BDNF gene on hippocampal functioning, in particular on hip-
pocampal n-acetyl aspartate, a biochemical marker of neuronal integrity, as
well as on verbal memory capacity, which depends on the functional integ-
rity of the hippocampus. Methods: 192 subjects gave written informed con-
sent to participate in the study (67 schizophrenic, 45 bipolar and 33 OCD
patients, and 47 healthy subjects). Proton magnetic resonance spectroscopy
was performed in the left hippocampus according to a standardized algo-
rithm, verbal memory was assessed using the VLMT, and the subjects were
genotyped with regard to the val66met polymorphism (rs6265) of the
BDNF gene. Results: Met allele carriers showed lower relative n-acetyl as-
partate (NAA/Cho) levels (6.2%; F1,117 = 3.9, P = .05) and worse verbal
memory performance (6.6%; F1,141 = 3.8, P = .05) as compared to homo-
zygous val/val carriers. The effect on verbal memory capacity was most pro-
nounced in the schizophrenic patients (17.0%). Conclusions: These
findings provide further evidence for a crucial role of BDNF in hippocam-
pal functions, particularly in hippocampus-mediated verbal short-term
memory. Although association studies between the BDNF gene and schizo-
phrenia have been inconclusive, our results are consistent with the assump-
tion that changes in BDNF functioning may contribute to the development
of schizophrenia.
ID: 546112
A CHROMOSOME 15Q13–14 2-BASE PAIR POLY-
MORPHISM IN THE PARTIAL DUPLICATION OF
THE ALPHA 7 NICOTINIC ACETYLCHOLINE GENE
IS ASSOCIATED WITH SCHIZOPHRENIA
Melissa L. Sinkus1, S. Leonard1,2, M. J. Lee7, J. Gault3, J. Logel1,
M. Short1, A. Olincy1,6, R. G. Ross1,6, L. E. Adler1,6,
R. Freedman1,6, S. L. Christian4, J. Lyon4, D. H. Ledbetter5,
B. Sullivan1
1Psychiatry, University of Colorado at Denver, Aurora, CO, USA;
2Pharmacology, University of Colorado at Denver, Aurora, CO,
USA; 3Neurosurgery, University of Colorado at Denver, Aurora,
CO, USA; 4Genetics, University of Chicago, Chicago, IL, USA;
5Genetics, Emory University, Atlanta, GA, USA; 6Psychiatry,
Veteran’s Affairs Medical Center, Denver, CO, USA; 7University of
Appalachia College of Pharmacy, Oakwood, VA, USA
Multiple genetic linkage studies support the hypothesis that the 15q13–14
chromosomal region contributes to the etiology of schizophrenia. Among
theputative candidate genes in this area are the alpha 7 nicotinic acetylcholine
gene (CHRNA7) and a partial duplication of alpha 7 (CHRFAM7A). We
have previously reported that a large chromosomal segment including the
CHRFAM7A gene locus,but not the CHRNA7 locus, is deleted in some indi-
viduals. In addition, the CHRFAM7A gene locus also contains a polymor-
phism consisting of a 2 base pair (2-bp) deletion at position 497–498 of exon 6.
The purpose of this study was to determine whether the 2-bp polymorphism
or the segmental deletion of CHRFAM7A is associated with schizophrenia.
We have employed a PCR-based method to quantify the copy number of
CHRFAM7A and the presence of the 2-bp polymorphism in a large, mul-
ti-ethnic population of Caucasian, African-American and Hispanic descent
forassociationof this locuswithschizophrenia.Thepresence of the2-bppoly-
morphism was associated with schizophrenia (allele frequency P = .014, ge-
notype P = .055). Association of the 2-bp polymorphism with schizophrenia
was highest in the African-American population (genotype P = .018, allele
frequency P = .028). Association of the 2-bp deletion with schizophrenia
also reached statistical significance in the Caucasian population (genotype
P = .028, allele frequency P = .033). The association of the 2-bp deletion
with schizophrenia did not reach significance in the Hispanic population.
Comparison of P50 auditory gating test-to-conditioning (T/C) ratios in con-
trols revealed no significant difference in the T/C ratio in those individuals
with the 2-bp deletion (18.3 6 2.3 vs 27.4 6 6.7, P = .213). CHRFAM7A
copy number was not associated with schizophrenia or with P50 auditory gat-
ing in any of the ethnicities or in the group as a whole. The 2-bp deletion poly-
morphism is in strong linkage disequilibrium with an inversion of the entire
duplicate gene andsurrounding loci. Weconclude that thepresenceof the2 bp
deletion at the CHRFAM7A locus may therefore represent larger genomic
rearrangements that may contribute an increased risk for developing schizo-
phrenia by epistatic influences, perhaps involving CHRNA7.
ID: 550808
DIFFERENTIAL REGULATION OF THE CHRNA7
GENE IN SCHIZOPHRENIC SMOKERS
Sherry Leonard1,2, S. Mexal3, S. Stephens4, R. Berger1,
R. Freedman1,2, R. G. Ross1
1Psychiatry, University of Colorado at Denver, Aurora, CO, USA;
2Research Division, Veterans Affairs Medical Research Service,
Denver, CO, USA; 3Cenomed Biosciences, Irvine, CA, USA;
4Institute for Behavioral Genetics, Boulder, CO, USA
The a7 neuronal nicotinic receptor gene (CHRNA7) has been implicated in
the pathophysiology of schizophrenia by genetic and pharmacological stud-
ies. A mutation 1831bp upstream of exon one in the CHRNA7 gene is asso-
ciated with schizophrenia, after correction for multiple testing (Caucasians,
P= .003; African Americans, P= .001). Genotype for this SNP predicts a pos-
itive response to the a7* receptor agonist, DMXB-A. Expression of the a7*
receptor, as measured by [125I]a-bungarotoxin binding is decreased in post-
mortemhippocampus, cortexandreticularnucleus of the thalamus in schizo-
phrenic subjects compared to non-mentally ill controls. Most schizophrenic
patients are heavy smokers. Smoking changes the expression of multiple
genes and differentially regulates gene expression in schizophrenic hippo-
campus.This differential regulation is in specificpatterns; expression iseither
lower or higher in schizophrenic non-smokers, compared to control non-
smokers, and is brought to control levels or normalized in schizophrenic
smokers. Several schizophrenia candidate genes are differentially regulated
by smoking in schizophrenia, including CHRNA7. We have examined the
effects of smoking on CHRNA7 in additional subjects by qRT-PCR and
western blot, finding that smoking differentially regulates expression of
both mRNA and protein. CHRNA7 mRNA and protein levels are signifi-
cantly lower in schizophrenic non-smokers, compared to control non-
smokers (P < .05). Core promoter polymorphisms in the CHRNA7 gene,
associated with both the P50 deficit and with schizophrenia, are significantly
more abundant in the schizophrenic non-smokers with low levels of
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CHRNA7mRNA(P< .01). Inschizophrenic smokers,bothmRNAandpro-
tein and are brought to control levels. Although a7 subunit levels are ade-
quate in schizophrenic smokers, low surface expression of the a7*
receptor suggests aberrant assembly or trafficking of the receptor. We ana-
lyzed the expression of the nicotinic receptor chaperone gene, RIC3 in hip-
pocampus. RIC3 expression, though not different in schizophrenic
postmortem hippocampus was decreased in smokers.
ID: 550768
MITOCHONDRIAL VARIANTS IN SCHIZOPHRE-
NIA, BIPOLAR DISORDER, AND MAJOR
DEPRESSIVE DISORDER
Marquis P. Vawter1, B. Rollins1, M. Martin1, A. Sequeira1,
S. Watson2, A. Schatzberg3, H. Akil2, R. Myers4, E. Jones5,
D. Wallace6, W. Bunney1
1Psychiatry and Human Behavior, University of California, Irvine,
Irvine, CA, USA; 2Molecular and Behavioral Neuroscience Institute,
University of Michigan, Ann Arbor, MI, USA; 3Psychiatry, Stan-
ford University, Palo Alto, CA, USA; 4Stanford Human Genome
Center, Stanford University, Palo Alto, CA, USA; 5Neuroscience
Center, University of California, Davis, Davis, CA, USA;
6Molecular and Mitochondrial Medicine and Genetics, University of
California, Irvine, Irvine, CA, USA
An increasing number of brain studies implicate mitochondrial dysfunction
in psychiatric disorders. The present study evaluated mtDNA variants in
brain tissue including substitutions, synonymous and non-synonymous,
and rare variants, which could predispose to bipolar disorder (BD), schizo-
phrenia (SZ) and major depressive disorder (MDD). Genomic DNA from
dorsolateral prefrontal cortex (DLPFC) from a total of 77 subjects (12
with BD, 14 with SZ, 15 with MDD, and36 controls) was studied formtDNA
sequence variations using Affymetrix GeneChip Mitochondrial Resequenc-
ing Arrays 2.0. The microarray resequencing of mtDNA was 100% concor-
dant with conventional capillary electrophoresis sequencing results for 103
mtDNA variants. There was 99.997% concordance for 3 individuals that
were completely resequenced using both methods. In 45 000 sequences there
was 1 discordant base call. The mitochondrial microarray however showed
a largeNcall rate,whichmaybeimprovedbyusingsimilarPCRconditionsas
the National Institute of Standards and Technology. DLPFC from subjects
with schizophrenia had an increased rate (22% higher compared to the con-
trol rate (P = .0017)) of synonymous base substitutions in mtDNA. A novel
risk factor for BD and MDD was found in the ND4L gene at T10652C. In
addition, there was a significant increase of the mtDNA common deletion in
brain DLPFC in the ND4L T10652C carriers. Postmortem brain pH, used as
a quantitative trait, showed significant association (P = .004) with three
mtDNA SNPs (tRNA Leu, ND4, and ND5). These 3 mtDNA SNPs are eth-
nic-specific haplotype-defining polymorphisms for the super haplogroup
cluster (U, K, UK). This super-haplogroup showed a significantly increased
postmortem pH (mean 7.0 6 0.18 SD) compared to the other haplogroups
combined. Focusing on haplogroup susceptibility factors in psychiatric dis-
orders and considering mtDNA variants in brain may lead to innovative
treatments that improve mitochondrial health and brain function.
ID: 550673
A SUSCEPTIBILITY GENE FOR PSYCHIATRIC
DISORDERS INCLUDING SCHIZOPHRENIA,
BIPOLAR DISORDER AND GILLES DE LA
TOURETTE IN 13Q14
Chantal Me´rette2,1, C. Emond1, Y. C. Chagnon2,1, M. A. Roy2,1,
A. Bureau3,1, A. Fournier1, M. Maziade2,1
1Centre de recherche Universite´ Laval Robert-Giffard, Quebec, QC,
Canada; 2Department of Psychiatry, Laval University, Quebec, QC,
Canada; 3Department of Social and Preventive Medicine, Laval
University, Quebec, QC, Canada
The idea that schizophrenia (SZ) and bipolar disorder (BP) share a com-
mon genetic ethiology has emerged from the fact that several vulnerability
loci or genes may be common to the two disorders. Moreover, the nosol-
ogy of major psychoses is challenged by the findings that SZ and BP share
several neurobiological, neuropsychological and clinical phenotypic char-
acteristics. A genome-scan in a sample of 48 SZ and BP families from
Eastern Quebec was carried out with one of the main objective to test
this hypothesis. Model-based and model-free linkage analysis were per-
formed in this sample and provided a nonparametric linkage (NPL) value
of 5.21 at marker D13S1247, a score which clearly suggests that 13q14,
where lies D13S1247 locus, contains one or several genes underlying
both mood disorders and schizophrenia. Our data thus suggest a suscep-
tibility locus in 13q13-q14 that may be shared by schizophrenia and mood
disorder. That locus would be additional to another well documented and
more distal 13q locus where the G72/G30 gene is mapped. In a parallel
project on the genetic study of Gilles de la Tourette (TS), we recently com-
pleted a full genome scan in a large Eastern Quebec family (127 members)
in which 20 family members were definitely affected by Gilles de la Tour-
ette (TS) and 20 others showed tic disorders. One of the most striking fea-
tures of the results from this linkage study is that the best finding was also
obtained in 13q14 with the exact same marker (D13S1247) that yielded the
best significant evidence for linkage with SZ and BP. Indeed, in 13q14, we
observed 3 markers linked to TS with a maximum parametric lod score
(Zmax) above 1, including a Zmax of 3.01 at marker D13S1247. Moreover,
the nonparametric linkage analysis (NPL) was consistent with the para-
metric one and yielded a maximum NPL entropy score of 3.58 again
at D13S1247. Given our actual results obtained with TS, we can now ex-
pand on our previous conclusion and stipulate that 13q14 may harbor
a more general susceptibility gene for psychiatric disorders including
SZ, BP and now TS.
ID: 550663
ASSOCIATION WITH SCHIZOPHRENIA OF THE
BIPOLAR DISORDER GENE PURINERGIC
RECEPTOR P2X, LIGAND-GATED ION CHANNEL,
7 LOCATED AT 12Q24
Yvon C. Chagnon, A. Bureau, M. A. Roy, C. Merette,
M. Maziade
Laval University Robert-Giffard Research Center, Quebec, QC,
Canada
Purpose of the study: The purinergic receptor P2X, ligand-gated ion chan-
nel, 7 (P2RX7) gene is a positional candidate for bipolar disorder (BP) since
its location at 12q24 where strong linkages with BP were reported
(Morissette et al., 1999; Shink et al., 2005a,b). In fact, P2RX7
showed a strong association in French-Canadian bipolar families at the
P2RX7 non-synonymous single nucleotide polymorphism (SNP)
rs2230912 (P-value .0007), which results from an over-transmission of
the mutant G-allele to affected offspring (Barden et al. 2006). Numerous
convergences are observed between BP and schizophrenia (SZ) for
phenotypic and genetic characteristics. For instance, we observed a linkage
at 12q23.1 with a mixed phenotype (CL) including both BP and SZ
(Maziade et al. 2005). We aimed to evaluate if P2RX7 could also be
associated to SZ. Methods: We analyzed 23 SNPs located within
P2RX7, including rs2230912, in 247 unrelated SZ and 150 unrelated con-
trols. A Chi2 analysis was used to evaluate the Hardy-Weinberg equilib-
rium within SZ and controls, and to compare genotypic and allelic
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frequencies between them. We aimed to confirm some of these results in our
multigenerational families densely affected by SZ and BP using Family-
based association test (FBAT). Results: We observed differences between
genotypic frequencies at four SNPs (.0017  P  .035), and differences be-
tween allelic frequencies at 8 SNPs (.0003  P  .04), including rs2230912
previously associated to BP. Using FBAT in families, we observed no as-
sociation with BP, while a weak association between rs2230912 and our
composite phenotype CL was detected, and between a second SNP and
SZ (P = .03 for both). However, the power of our multigenerational families
to test for association is relatively low, more particularly for BP, and for
so we cannot confirm or infirm previous association reported with BP.
Conclusion: We concluded that P2RX7 is also associated to SZ in
French-Canadians.
ID: 550584
A TRANSLATIONAL APPROACH TO PRIORITIZE
CANDIDATE GENES FOR SCHIZOPHRENIA:
CONVERGENCE OF ASSOCIATION AND GENE
EXPRESSION ANALYSES
Paul D. Shilling, T. A. Greenwood, D. L. Braff, G. A. Light,
K. S. Cadenhead, M. A. Geyer, J. Sprock, N. R. Swerdlow
Department of Psychiatry, Univ of California San Diego, La Jolla,
CA, USA
Background: We have reported gene expression values in the nucleus accum-
bens (NAC) of two rat strains that exhibit differential sensitivity to the pre-
pulse inhibition-disruptive effects of the dopamine (DA) agonist,
apomorphine (APO) (Shilling et al., Biol Psych 2008). In the present study,
we used this database to prioritize a list of 29 genes that had been identified
using the custom COGS/UCSD SNP chip, based on their associations
with schizophrenia and/or at least one of the following potential endophe-
notypes for this disorder: prepulse inhibition (PPI), startle magnitude,
startle habituation, P50 S1 amplitude, or P50 suppression (Greenwood
et al. 2008). Because schizophrenia patients exhibit PPI deficits compared
to normal comparison subjects, genes associated with strain differences
in sensitivity to APO-induced PPI deficits in this animal model provide
a rationale to prioritize specific schizophrenia-associated genes for further
investigation. Methods: Affymetrix 230 2.0 chips were used to measure
gene expression in the NAC. Twenty-seven of the 29 genes identified by
association analysis in human subjects were represented on this gene
chip. Gene expression of these 27 genes in the NAC was analyzed based
on data collected from this animal model of differential PPI sensitivity
to apomorphine in Long Evans (LE) vs. Sprague Dawley (SD) rats. Sta-
tistical analysis of microarrays (SAM) was employed to identify signif-
icant between strain differences in expression using a false discovery rate
(FDR) < 5 %. Results: SAM analyses revealed that 10 of the genes as-
sociated with at least one of the potential schizophrenia endophenotypes
also exhibited significant gene expression differences in the NAC at
a FDR <5%. Interestingly, all 10 genes were upregulated in the LE
compared to SD rats. These genes include COMT, NRG1, GRIN2B
and GRID2. Gene expression/behavioral correlations will also be pre-
sented. Discussion: Specific genes that were associated with endopheno-
types for schizophrenia were also differentially expressed across strains
exhibiting differences in PPI sensitivity to a DA agonist. This conver-
gent translational approach provides a potentially powerful means to
prioritize candidate genes for investigation in future studies, and ulti-
mately might facilitate the identification of genes that contribute to
the development of schizophrenia. Supported by MH42228 and
MH68366.
ID: 550558
UNDERSTANDING NEUROCHEMISTRY OF
SCHIZOPHRENIA ENDOPHENOTYPES: GENETIC
ANIMAL MODELS OF HYPERDOPAMINERGIA
AND HYPOGLUTAMATERGIA
Raul R. Gainetdinov1,2
1Neuroscience, Italian Institute of Technology, Genoa, Italy; 2Cell
Biology, Duke University, Durham, NC, USA
There is growing understanding that abnormalities in multiple neurotrans-
mitter systems can be involved in the pathophysiology of schizophrenia.
Based on pharmacological observations, two major neurochemical hypoth-
eses have been proposed to explain schizophrenia. The dopamine hypoth-
esis suggests that either an excess of dopamine or an increased sensitivity to
the neurotransmitter is the underlying pathological mechanism. A compet-
ing notion, the hypoglutamatergic hypothesis of schizophrenia, suggests
that decreased glutamatergic transmission underlies schizophrenia, based
on the ability of NMDA receptor antagonists to recapitulate certain endo-
phenotypes of schizophrenia. In an attempt to understand the potential
contribution of various neurotransmitter systems to particular endopheno-
types of schizophrenia several genetically modified animal models have
been investigated. A mouse in which the dopamine transporter gene
(DAT-KO) has been inactivated provides a model of hyperdopaminergia.
This mouse displays hyperactivity, perseverations in cognitive tasks and de-
ficient sensorimotor gating. These behavioral deficits can be corrected by
antipsychotic drugs and as such recapitulate particular endophenotypes of
schizophrenia related to positive symptoms. A mouse, which carries a hy-
pomorphic allele of the NR1 subunit of the NMDA receptor provides
a model for a hypofunctioning glutamate system. NR1 mutant mice display
more complex set of behavioral abnormalities that include mild hyperac-
tivity, social dysfunctions, deficient sensorimotor gating and cognitive im-
pairment. These aberrant behaviors can be ameliorated more effectively by
atypical rather than typical antipsychotics and thus NR1 deficient mice
may have translational value to understand endophenotypes of schizophre-
nia related to negative symptomatology. Here I will discuss how these and
other recent genetic animal models of aberrant neurotransmission may be
instrumental to decipher the contribution of specific neurochemical abnor-
malities to certain endophenotypes of schizophrenia.
ID: 550503
ANALYSIS OF GENE EXPRESSION IN TWO LARGE
SCHIZOPHRENIA COHORTS IDENTIFIES
MULTIPLE EXPRESSION CHANGES ASSOCIATED
WITH NERVE TERMINAL FUNCTION
Jackie de Belleroche1, P. Maycox2, F. Kelly2, A. Taylor2, J. Reid2,
R. Viknaraja2, N. Jones2, M. Lennon2, C. Davies2, J. Hagan2,
C. Scorer2, C. Angelinetta1, T. Akbar1, A. Mortimer1, T. Barnes1,
S. Hirsch1
1Division of Neuroscience and Mental Health, Imperial College
London, London, United Kingdom; 2Psychiatry CEDD,
GlaxoSmithKline, Harlow, United Kingdom
Schizophrenia is a severe psychiatric disorder with a world wide prevalence
of 1%. The pathophysiology of the illness is not understood, but is thought
to have a strong genetic component with some environmental influences on
aetiology. To gain further insight into disease mechanism, we used micro-
array technology to determine the expression of over 30 000 mRNA tran-
scripts in post-mortem tissue from a brain region associated with the
pathophysiology of the disease- Brodmann Area 10 (anterior prefrontal
cortex) in 28 schizophrenic and 25 control patients. We then compared
our study (Charing Cross Hospital Prospective Collection: CCHPC)
with that of an independent prefrontal cortex dataset from the Harvard
Brain Bank (HBB). We report the first direct comparison between two
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independent studies in which 51 genes have been identified that are com-
mon between the schizophrenia cohorts and of these, 49 show the same di-
rection of disease-associated regulation. In particular, changes were
observed in gene sets associated with synaptic vesicle recycling/ transmitter
release and cytoskeletal dynamics. This strongly suggests multiple, small
but synergistic changes in gene expression that affect nerve terminal
function.
ID: 550256
ALTERATION OF MICRORNA BIOGENESIS IN
SCHIZOPHRENIA AND ITS IMPLICATIONS FOR
SYNAPTIC STRUCTURE AND FUNCTION
Murray Cairns1,2, N. J. Beveridge1,2, A. Carroll1,2, P. Tooney2,1,
E. Gardiner1,2, D. Santarelli2,3
1Schizophrenia Research Institute, Sydney, NSW, Australia;
2School of Biomedical Sciences, The University of Newcastle,
Callaghan, NSW, Australia; 3Hunter Medical Research Institute,
Newcastle, NSW, Australia
Our analysis of cortical microRNA (miRNA) expression in postmortem
tissue from the superior temporal gyrus (STG) and the dorsolateral pre-
frontal cortex (DLPFC) has shown that there is a broadly based schizo-
phrenia-associated increase. The scope of this anomaly was suggestive of
an alteration to miRNA processing and we can confirm that we have iden-
tified a corresponding increase in the expression of mRNA for the
DiGeorge Critical Region 8 (DGCR8) gene in both regions of the brain.
This gene encodes a major component of the microprocessor complex,
which is thought to be a rate-limiting step in the miRNA biogenesis path-
way. The link between altered miRNA expression and biogenesis in schizo-
phrenia was even stronger in the DLPFC, with a statistically significant,
increase in mRNA for Drosha, also part of the microprocessor, and Dicer
another RNase III synonymous with post-transcriptional gene silencing.
Quantitative real-time RT-PCR analysis supported the view that there
was a schizophrenia-associated increase in mature miRNA expression in
both cortical regions and that many of the altered miRNAs were also com-
mon to both regions. The biological significance of these findings are pro-
found as each miRNA has the capacity to regulate the expression hundreds
of target genes. This was exemplified by upregulation of the entire miR-15
family including miR-15a, miR-15b, miR16 and miR-195. This functionally
convergent group is predicted to have many target genes involved in syn-
aptic structure and function and many are also associated with schizophre-
nia. We have substantiated some of these target gene relationships through
luciferase reporter gene assays and gene expression profiling in cells trans-
fected with synthetic miRNA and miRNA inhibitors.
ID: 550221
DIFFERENTIAL NEUROBEHAVIOURAL EFFECTS
OF ACUTE AND CHRONIC CANNABINOID
TREATMENT ON HETEROZYGOUS NEUREGULIN
1 MUTANT MICE
Tim Karl1,2, B. Aurelie1,3, G. Hunt4, J. Micheau5, J. Arnold1,3
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Institute of Medical Research, Darlinghurst, Sydney, NSW,
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Australia; 5Centre de Neurosciences Inte´gratives et Cognitives,
Universite´ Bordeaux, Talence, Bordeaux, France
The human neuregulin 1 (NRG1) gene is a schizophrenia candidate gene
and mice mutant for transmembrane domain (TM) Nrg1 exhibit a marked
schizophrenia-related behavioural phenotype. Schizophrenia with its multi-
factorial aetiology has a concordance rate of 30–50% for monozygotic twins
highlighting the fact that neither environment nor genetics alone are suf-
ficient to cause schizophrenia but a combined action is likely. Cannabis
use may increase the risk of developing schizophrenia by unmasking the
disorder in genetically vulnerable individuals. Using a multi-factorial ani-
mal model strategy, we investigated the neurobehavioural phenotype of
male heterozygous TM Nrg1 mutant mice (Nrg1 HET) and their wild
type-like (WT) littermates, which were treated acutely and chronically
with either vehicle or cannabinoids [acute: 5 and 10 mg/kg delta-9-tetrahy-
drocannabinol (THC) / chronic: 0.4 mg/kg CP 55 490 (CP)]. All mice were
tested in a variety of tasks for locomotion, exploration, anxiety and senso-
rimotor gating [ie, prepulse inhibition (PPI)]. Fos B/deltaFos B as well as c-
Fos expression analyses determined neuronal correlates for the behavioural
effects of acute and chronic cannabinoid treatment. Acutely, Nrg1 HETs
were more sensitive to the locomotor suppressant actions of THC and
expressed a greater THC-induced enhancement in %PPI compared to
WT mice. Mutants were also more susceptible to the anxiogenic effects
of THC. THC selectively increased c-Fos expression in the ventrolateral
septum (LSV), the central nucleus of the amygdala and the paraventricular
nucleus of Nrg1 HETs. Chronically, Nrg1 HET mice developed more rap-
idly tolerance to CP-induced hypothermia and locomotor suppression com-
pared to WTs. Conversely, tolerance to the anxiogenic effect of CP was only
observed in WT mice. In addition, a selective increase in Fos B/deltaFos B
expression was detected in the LSV of Nrg1 HET mice following chronic
CP exposure, with no corresponding effect seen in WT mice. Acute but not
chronic CP treatment facilitated PPI in Nrg1 HET mice and decreased it in
WT mice. These data suggest that a variation in the Nrg1 gene alters the
sensitivity to the neurobehavioural effects of cannabinoids and results in
differential adaptive processes to repeated cannabinoid exposure. Overall,
our findings support the idea of an interactive relationship between neure-
gulin and the cannabinoid system.
ID: 548541
PILOT STUDY OF THE PERCEPTIONS OF GENETIC
RISK ESTIMATION AND ASSOCIATED REPRO-
DUCTIVE DECISIONS IN CHINESE
Huijie Li1,3, R. C. Chan1,2, W. G. Honer4, J. C. Austin4,5
1Neuropsychology and Applied Cognitive Neuroscience Laboratory,
Institute of Psychology, Chinese Academy of Sciences, Beijing,
China; 2Key Laboratory of Mental Health, Institute of Psychology,
Chinese Academy of Sciences, Beijing, China; 3Graduate School,
Chinese Academy of Sciences, Beijing, China; 4Department of
Psychiatry, Centre for Complex Disorders, University of British,
Vancouver, BC, Canada; 5Early Psychosis Intervention Programme,
Peace Arch Hospital, White Rock, BC, Canada
Background: Schizophrenia is a polygenic illness affecting about 1% of the
population across different countries. First-degree relatives of schizophre-
nia are more prone to be affected. However, relatively few studies have been
launched to examine the relationships between risk perception, reproduc-
tive decisions and attitudes towards predictive testing in a Chinese sample.
Aim: to investigate relationships between risk perception, reproductive
decisions and attitudes towards predictive testing, for patients with schizo-
phrenia and their first-degree nonpsychotic relatives, respectively Method:
A Chinese version of a tailor-made questionnaire (Austin et al., 2006) cap-
turing specific questions on perceptions of psychotic disorders was admin-
istered to 57 patients with schizophrenia and 25 corresponding first-degree
nonpsychotic relatives in an outpatient clinic in Shantou. Results: Only
a quarter of nonpsychotic relatives of patients with schizophrenia perceived
risk accurately and more than half of the relatives overestimated/underes-
timated the genetic risk. For the patients, only 12.3% perceived genetic risk
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accurately. 32% of the relatives and 28.1% of the patients reported that fam-
ily history had affected reproductive decisions. Majority of the relative sup-
ported prenatal genetic testing for psychosis as well as genetic testing in
general, while no more than half patients agreed with the prenatal and gen-
eral genetic testing. Conclusions: Most of the first-degree nonpsychotic rel-
atives estimated the risk inaccurately among the current Chinese sample.
Facilitating accurate risk perception through genetic counseling could sig-
nificantly impact reproductive decisions, and the appropriate impact repro-
ductive decisions, and the appropriate use of genetic tests in the future in
China.
ID: 546390
MICRORNA CHANGES IN THE PREFRONTAL AND
TEMPORAL CORTICES IN SCHIZOPHRENIA
Natalie Jane Beveridge1,2, A. P. Carroll1,2, P. A. Tooney1,2,
M. J. Cairns1,2
1Schizophrenia Research Institute, Sydney, NSW, Australia;
2School of Biomedical Sciences, University of Newcastle, Callaghan,
NSW, Australia
microRNA (miRNA) are small RNA molecules that are expressed in a de-
velopmental and tissue-specific manner, and are thought to regulate at least
a third of all human genes through the sequence-specific base pairing with
the 3#-UTR of specific target mRNAs. Expression profiling experiments
have shown that many mammalian miRNAs appear to be crucial to the
development of the brain and the nervous system. It has been suggested
that abnormalities in the miRNA system could potentially alter brain struc-
ture and function, and may contribute to the development of disorders such
as schizophrenia. Gene expression studies in our laboratory have identified
a general trend toward gene down-regulation in schizophrenia, and it is pos-
sible that this could in part be a consequence of post-transcriptional gene
silencing. To investigate this hypothesis, miRNA expression was analysed
in postmortem cortical grey matter of the superior temporal gyrus (STG)
and dorsolateral prefrontal cortex (BA9; DLPFC); from both schizophre-
nia and control subjects using a high throughput microarray platform. This
study identified a global up-regulation of miRNA expression in the STG
and DLPFC and many expression changes were validated using a custom-
designed real-time RT-PCR method. Investigation of primary and precur-
sor miRNA transcripts as well as genes involved in the miRNA biogenesis
pathway suggest that altered mature miRNA expression may be a conse-
quence of aberrant miRNA processing. Using in silico target gene analysis,
numerous schizophrenia candidate genes were found to have putative miR-
NA binding sites for these altered miRNA within their 3#-UTR (eg, BDNF,
RELN, HTR2A, DRD1, DLG4, VSNL1, GRIN3A, GRM7, CHRM1 and
PLEXNA2). A luciferase reporter gene assay was established and many
miRNA recognition elements were functionally validated. This data sug-
gests that alterations in post-transcriptional gene silencing may play a sig-
nificant role in schizophrenia-associated changes in gene expression.
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TIMING OF PRENATAL DEVELOPMENTAL
PERTURBATIONS INDUCED BY MUTANT DISC1
RESULTING IN SCHIZOPHRENIA-LIKE BEHAV-
IORAL AND PATHOLOGICAL ALTERATIONS
Yavuz Ayhan1, M. W. Vogel2, C. A. Ross1, M. V. Pletnikov1
1Psychiatry and Behavioral Sciences, Johns Hopkins University,
Baltimore, MD, USA; 2MPRC, University of Maryland,
Catonsville, MD, USA
Data from neuropathologic, neuroimaging, neuropsychological and epide-
miologic studies suggest that early neurodevelopmental alterations may
contribute to the dysfunction in schizophrenia and related disorders. We
used a genetic mouse model as an experimental system to demonstrate
the contribution of neurodevelopmental insult on adult pathology. Previ-
ously, we have generated an inducible mouse model of the human mutation
of Disrupted-In Schizophrenia 1 (mhDISC1), using a Tet-off system. The
expression of mhDISC1 is restricted to forebrain neurons. Although the
existence of mhDISC1 results in schizophrenia-like alterations, such as en-
larged ventricles, the timing for the generation of these alterations remains
incompletely understood. To evaluate the critical time points for adult
pathological alterations, we generated three groups of mice with expression
of mhDISC1 prenatally and postnatally; prenatally only; or without expres-
sion. The expression of the mhDISC1 was regulated by feeding mice with
doxycycline-containing food. Prenatal but not postnatal expression of
mhDISC1 was associated with decreased social interaction and increased
aggressiveness. Mutant mice with prenatal expression displayed enhanced
sensitivity to a NMDA antagonist, MK-801, or amphetamine. Prenatal ex-
pression was also associated with depressive features as indicated by in-
creased immobilization time and decreased latency to immobility in
Porsolt Forced Swim Test. In addition, prenatal but not postnatal expres-
sion of the mutant protein produced decreased total cortical volume, re-
duced parvalbumin immunoreactivity, and increased dendritic spine
density in granule cells of the dentate gyrus. We believe these results provide
experimental support for neurodevelopmental hypothesis of schizophrenia
and related disorders.
ID: 551899
DISC-1 PROTEINS ENCODED BY LEU607PHE
ALLELES SHOW A DIFFERENTIAL SUB-CELLULAR
LOCALISATION AND DIFFERENTIALLY
MODULATE NEUROTRANSMITTER RELEASE
Sharon L. Eastwood1, C. A. Hodgkinson2, P. J. Harrison1
1Department of Psychiatry, University of Oxford, Oxford, United
Kingdom; 2Laboratory of Neurogenetics, NIAAA, Rockville, MD,
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Like other putative schizophrenia susceptibility genes, disrupted-in-
schizophrenia 1 (DISC-1) may impact on synaptic functioning, in part
through effects on microtubules. The Leu607Phe substitution is one of
the few polymorphisms in DISC-1 which is coding, and which has been
associated to a schizophrenia spectrum phenotype. The latter property
increases the prior probability that is a functional variant, but direct evi-
dence for this is lacking. Given the links between DISC-1, microtubules,
and synapses, we have used an in vitro model system to examine whether
the polymorphism affects neurotransmitter release, microtubule dynamics,
or the sub-cellular localisation of the encoded DISC-1 protein. SH-SY5Y
cells were chosen for this study as they are human and have a neuronal
phenotype. Undifferentiated SH-SY5Y cells were transfected with con-
structs containing either V5-tagged Leu607 or Phe607 DISC-1. Twenty
four after transfection, [3H] noradrenaline neurotransmitter release from
the cells was examined using an established assay. Perfusate was collected
after basal (5mM Kþ) and stimulated (100 mM Kþ) release, the adherent
cells solubilized, and the quantities of released and non-released [3H] nor-
adrenaline determined by liquid scintillation counting. Western blots were
used to quantify tyrosinated and detyrosinated alpha-tubulin, markers of
dynamic and stable microtubules respectively. SH-SY5Y cells were also
grown on slides, transfected with V5-tagged Leu607 or Phe607 DISC-1
and anti-V5 immunofluorescence performed to characterise their sub-cel-
lular distribution. Consistent with prior observations, Leu607- and Phe607-
DISC-1 were differentially distributed, with only Leu607 DISC-1 showing
localisation to the centrosome, an organelle important in microtubule or-
ganization. Transfection of Phe607 DISC-1 decreased basal noradrenaline
release, whilst Leu607 DISC-1 had no effect. The results reveal that the
Leu607Phe polymorphism affects the subcellular localisation of DISC1
and basal neurotransmitter release by SH-SY5Y cells. The latter finding
suggests that modulation of neurotransmitter release may be added to
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the many roles that DISC-1 plays in the brain, and that may contribute to
its role in genetic pathophysiology. Ongoing studies are being conducted to
determine if the variants are associated with differences in the proportion of
stable to dynamic microtubules and with other evidence for altered micro-
tubular and synaptic functioning.
ID: 551792
HOW DISC1 MOUSE MODEL CAN HELP ADDRESS
THE COMPLEX PATHOGENESIS OF
SCHIZOPHRENIA
Mikhail Pletnikov
Psychiatry and Behavioral Sciences, Johns Hopkins University
School of Medicine, Baltimore, MD, USA
Animal models are instrumental in elucidating the neurobiology of schizo-
phrenia. Despite of significant advances, heterogeneity of etiological fac-
tors and the complex pathogenic mechanisms of this psychiatric disease
call for further development of animal models. Recent discoveries in human
genetics have provides a new framework for developing models with strong
etiological and neurobiological validity. In addition, a better elucidation of
environmental factors that contribute to the disease allows for modeling
gene-environment interactions using relevant genetic risk factors and iden-
tified environmental challenges. I will describe new findings with our mouse
models based on inducible expression of mutant human Disrupted-In-
Schizophrenia (DISC1). Two main directions in using this models will
be overviewed, ie, the timing of the effects of mutant DISC1 on neurode-
velopment and interactions of mutant DISC1 with an environmental factor
that induces strong immune response during pregnancy. For the first
project, I will evaluate the new data to indicate that majority of subtle
schizophrenia-like neurobehavioral alterations in mutant mice, such as en-
hanced sensitivity to a NMDA antagonist, MK-801, or amphetamine as
well as the decreased total cortical volume and reduced numbers of parval-
bumin-positive cells, are due to prenatal expression of mutant DISC1. For
the second project, I will discuss the new findings about possible synergistic
interactions between mutant DISC1 and prenatal poly IC treatment to
activate immune response in pregnant mouse dams. Compared to saline-
treated DISC1 mice, poly IC-challenged DISC1 mice exhibited increased
anxiety-like and depression-like responses associated with the decreased
density of dendritic spines in the dentate gyrus of the hippocampus. I
will argue that DISC1 mouse model provides new avenues for advancing
mechanistic studies of the complex pathogenesis of schizophrenia and re-
lated neurodevelopmental disorders.
ID: 551678
THE ROLE FOR THE CIRCADIAN TIMING SYSTEM
AND THE GENE CLOCK IN INFORMATION
PROCESSING
Robert Gonzalez
Psychiatry, UT Southwestern, Dallas, TX, USA
Background: The precision of the circadian timing system is in large part
dictated by endogenous molecular clocks and the expression of circadian
genes. There is recent scientific evidence that suggests an association be-
tween variations in circadian genes, bipolar disorder, and schizophrenia.
The circadian genes have been shown to be important in the processing
of somatosensory signals and in systems that affect information processing,
such as the dopaminergic system. Both neuranatomical and behavioral sim-
ilarities have been reported between circadian gene knockout mice and
patients who are diagnosed with schizophrenia. Similarities include reduced
hippocampal volume, enlarged ventricles as well as impairments in PPI and
memory. The Clock 3111 T/C SNP has been associated with variations of
activation patterns in the go no go task in bipolar depressed patients. An
increased frequency of the C allele has been reported in patients with schizo-
phrenia, particularly in disorganized and residual sub-groups. These find-
ings suggest that endogenous clocks can process sensory stimuli and play
a key role on sensory driven adaptive behavior as well as information pro-
cessing. Aim: To test the associations between Clock 3111 T/C genotype
and both clinical and neuropsychiatric measures of information processing
in subjects with psychotic illnesses. Methods: Subjects: Subjects with
a SCID-IV confirmed diagnosis of Bipolar type I with psychosis, Schizo-
phrenia, and schizoaffective disorder enrolled in a phenotyping study at the
University of Texas Southwestern Medical Center at Dallas Department of
Psychiatry’s Division of Translational Research. Genotyping: All Subjects
will be genotyped for the Clock 3111 T/C SNP (rs1801260). Measures of
Working Memory: (1) WAIS-III Digital Symbol Coding, (2) WAIS-III
Letter-Number-Sequencing, (3) WMS-III Spatial Span. Measures of Exec-
utive Functioning: (1) Wisconsin Card Sorting Test, (2) Trails B Trail Mak-
ing Test. Measures of Neuropsychiatric Functioning: (1) PPI, (2) Eye
Tracking Statistical Analyses: We will test for associations between Clock
3111 T/C genotype (T/T, T/C, C/C) and both clinical and biologic measures
of cognitive functioning. Significance: Circadian genes may serve a more
varied purpose as a component of a central integrator system and therefore
be important in information processing in psychotic illnesses.
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ASSOCIATIONS AND INTERACTIONS BETWEEN
A NETWORK OF DOPAMINERGIC GENE
POLYMORPHISMS IN SCHIZOPHRENIA: A -
FOLLOW-UP IN AN INDIAN SAMPLE
Chowdari Kodavali1, P. Semwal4, M. E. Talkowski5, J. Wood1,
S. Deshpande3, B. K. Thelma4, V. L. Nimgaonkar1,2
1Department of Psychiatry, Univ of Pittsburgh, Pittsburgh, PA,
USA; 2Department of Human Genetics, Univ of Pittsburgh, Pitts-
burgh, PA, USA; 3Department of Psychiatry, Dr. RML Hospital,
New Delhi, India; 4Department of Genetics, University of Delhi,
New Delhi, India; 5Center for Human Genetics Research, Harvard
University, Boston, MA, USA
We have earlier evaluated the hypothesis that dopaminergic polymor-
phisms are risk factors for schizophrenia (SZ) in Caucasian samples
from the USA and Bulgaria (Talkowski, et al. Hum. Mol. Genet. 2008).
The most promising associations are detected with SLC6A3 (alias
DAT), DRD3, COMT and SLC18A2 (alias VMAT2). Here we present
the follow-up analyses in the collaborative Indian trio sample (n = 601 fam-
ilies). Unscreened cord blood samples (n = 520) were collected from live
birth at Lok Nayak Hospital, New Delhi. The SZ diagnoses were based
on DSM IV criteria, similar to the US sample. Informed consent was
obtained from the probands and family members at Ram Manohar Lohia
Hospital, New Delhi. Snplex and SnapSHOT assay methods were em-
ployed for SNP genotyping. Our goals were, a) to seek replication at
SNP level based on our earlier work in the US and Bulgarian sample,
b) to understand the linkage disequilibrium (LD) patterns in the Indian
sub-population and c) to test the epistatic interactions reported. We
have evaluated a total of 41 SNPs. Suggestive associations were detected
in the same direction reported earlier at SLC18A2 (rs363338, trends test
P = .075). At DRD3 and SLC6A3, trends were noted with the opposite
alleles (respectively, rs324030, P = .084; rs403636, P = .058). We also ob-
served additional SNPs with suggestive associations at SLC18A2
(rs363399, rs10082463 and rs363285, P< .1). The LD patterns were similar
to the US and Bulgarian samples. Earlier reported epistatic SNP interac-
tions at all four genes between seven locus pairs (p  0.05), were not noted.
However, we observed other epistatic interactions, the majority being be-
tween SNPs at SLC6A3 and COMT. They need to be explored further at
a functional level. Overall, we suggest the importance of DA genes and their
interaction, as risk factors for SZ in the Indian sample.
ID: 551488
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DISC1 EXPRESSION AND FUNCTION IN THE
HIPPOCAMPUS
Kate D. Meyer1,2, J. A. Morris1,2
1Human Molecular Genetics, Department of Pediatrics, Children’s
Memorial Research Center, Chicago, IL, USA; 2Integrated
Neuroscience Program, Northwestern University, Chicago, IL, USA
Disrupted In Schizophrenia-1 (DISC1) is a highly promising schizophrenia
susceptibility gene which is involved in several processes important to neu-
rodevelopment, such as neurite outgrowth and neuronal migration. DISC1
is expressed in several brain areas implicated in schizophrenia, with partic-
ularly strong expression in the hippocampus. Immunohistochemical anal-
ysis of Disc1 expression in the mouse hippocampus reveals strong
expression in areas CA1-CA3 and the dentate gyrus throughout develop-
ment, with expression becoming more well-defined as these structures ma-
ture. We have also discovered that Disc1 is expressed by precursors
migrating toward the dentate gyrus in early development. Given that func-
tional and anatomical abnormalities in the hippocampus are consistently
observed in the schizophrenic brain, there is an intriguing possibility
that DISC1 abnormalities confer an increased risk for schizophrenia by dis-
rupting the development of the hippocampus. To investigate this possibil-
ity, we have performed functional studies in the mouse hippocampus that
indicate a role for Disc1 in its development.
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ALTERNATIVE SPLICING OF A NOVEL CASSETTE
EXON IN THE DOPAMINE TRANSPORTER IS
ASSOCIATED WITH SCHIZOPHRENIA
Vishwajit L. Nimgaonkar1, M. E. Talkowski2, M. Chen3,
L. McClain1, M. Bamne1, J. Wood1, D. Lewis1, M. Owen4,
M. O’Donovan4, G. Kirov4, L. Georgieva4, D. Toncheva5,
P. Papasaikas3, J. Lopez3
1Department of Psychiatry, University of Pittsburgh School of
Medicine, Pittsburgh, PA, USA; 2Center for Human Genetics Re-
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USA; 4Department of Psychological Medicine, Cardiff University,
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We aimed to refine previously detected, replicable associations and epistatic
interactions between intronic variations within the dopamine transporter
(SLC6A3, ‘‘DAT’’) and schizophrenia. In fine-mapping analyses, we
obtained near complete common variation information within these
regions. To date, 375 variations have been catalogued, including 164 com-
mon variants which we captured at r2 < 0.95 using 88 ‘tag’ SNPs. Signif-
icant associations with schizophrenia were replicated with several linkage
disequilibrium (LD) clusters spanning introns 3 and 4 of the gene between
two Caucasian cohorts (494 cases / 540 controls from the U.S., 659 trios
from Bulgaria). A primate-specific computational model predicted a novel
108 base pair cassette exon defined by a potential recursive splice site and
a standard 5’ splice site motif within intron 3. The predicted exon was
flanked within 600 nucleotides by schizophrenia-associated SNPs which
fell within predicted splicing regulatory signals. Alternative transcripts
have not been previously identified at DAT. We detected alternative splic-
ing of the cassette exon (E3b) in cell transfection experiments and verified
the inclusion of E3b in endogenous DAT transcripts in human substantia
nigra tissue using RT-PCR assays. Differential inclusion of E3b was ob-
served between constructs bearing schizophrenia risk alleles in this region
and a construct with non-risk alleles. Using tag SNPs to represent all plau-
sible risk alleles spanning the cassette exon and predicted regulatory
sequences, we detected a significant association between schizophrenia
and a common haplotype in both cohorts. E3b introduces multiple in-frame
stop codons into the mRNA which truncates the DAT open reading frame
and may serve as a mechanism to negatively regulate DAT production.
Exon E3b is conserved among primates and many other placental mammals
but appears to have been lost in the Glires clade. We conclude that alter-
native splicing of a novel cassette exon could alter DAT function in the
human brain and confer risk for schizophrenia.
ID: 551264
SCHIZOPHRENIA GENETICS: NUMBER OF GENES,
ENVIRONMENTAL INFLUENCES AND DISEASE
PENETRANCE UNDER EPISTATIC MODELS
Esben Agerbo1, B. E. Madsen2, C. Wiuf2
1University of Aarhus, National Centre for Register-based Research,
Aarhus, Denmark; 2Bioinformatics Research Center, University of
Aarhus, Aarhus, Denmark
Schizophrenia is a complex disease with a prevalence of about 1% in the
general population. Little is known about the genetics underlying schizo-
phrenia, the number of genes and the interplay between genes. We aim to
get insight into the genetics of schizophrenia by investigating a range of
genetic models and their fit to empirical data. In particular, we consider
additive, multiplicative and network models as well as combinations of
additive and network models. These models are evaluated by
calculating a likelihood-based score of how well they fit observed prev-
alences from pooled epidemiological studies of families where at least one
member suffers from schizophrenia. (1) Our models are functions of
number of genes, allele frequencies and environmental influence where
the disease penetrance is determined as a function of the particular ge-
netic model and environmental influence. The data are best explained by
models containing few genes in epistasis, and furthermore, models with
recessive genes are generally superior. Particularly, best fits are obtained
under a one-gene additive model combined with network models with
recessive genes, which is in keeping with recent findings on a de novo
copy number variant expressing a rare chromosomal deletion. (2) An-
other striking result is that the percentage of individuals in the general
population predisposed to schizophrenia is between 5% and 7% in the
best fit model. Compared to a prevalence of 1%, this indicates that
the environment has an important influence on the development of
schizophrenia: only one in six (five to seven) predisposed individuals
develops schizophrenia.
References
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CONVERGING EVIDENCE FOR DPYSL2 AS A RISK
FACTOR FOR SCHIZOPHRENIA
Catherine Louise Winchester1,2, L. H. O’Donovan1,2,
M. E. Bailey2, R. Hunter1,3, J. A. Pratt1,2, B. J. Morris1,2
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The genetic basis of schizophrenia is not clearly understood and no caus-
ative mutations have been definitively identified. It is highly heritable and
involves the interaction of multiple genes of small effect and their interplay
with the environment. Understanding the number of genes and their role
and interaction in the pathophysiology, susceptibility to the disease or par-
ticular clinical symptoms and antipsychotic metabolism remains a crucial
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issue in understanding the disease and developing novel drug strategies. We
identified DPYSL2 as a candidate gene for schizophrenia from a transcrip-
tome screen of the prefrontal cortex of a rodent phencyclidine (PCP) model
of schizophrenia developed in our laboratory 1,2. This PCP model produces
a pattern of metabolic hypofunction, neurochemical changes and behaviou-
ral deficits in the prefrontal cortex that closely mirror the cognitive deficits
of schizophrenia 1,2. DPYSL2 is an intriguing candidate gene as it maps to
8p21, a region of the human genome, that has been repeatedly implicated by
linkage analyses and association studies. In addtion its role in axonal for-
mation and guidance in the developing nervous system is highly consistent
with the neurodevelopmental theory of schizophrenia. To further charac-
terise the function of DPYSL2 we have validated specific siRNAs to knock-
down the expression of DPYSL2 in vitro and in vivo. In addition, we have
performed a case-control association study of DPYSL2 in DNA samples
from 500 UK patients with DSM4 schizophrenia and 500 controls using tag
SNPs selected from HapMap3 and the ABI SNPBrowser4. Genotyping of
SNPs in several haplotype blocks has been completed and association
analysis at both single SNP and haplotype levels is underway. Our initial
findings include the observation of a modest association with a 3’-UTR
SNP in DPYSL2. In conclusion, combining neurobiological and genetic
association studies provides a powerful means to understanding the con-
tribution of individual candidate genes to the pathophysiology of
schizophrenia. This work was funded by formerly Mitsubishi Pharma
Co. (currently Mitsubishi Tanabe Pharma Co.) and NHS Scotland RandD
for Mental Health Research.
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DISCOVERY AND INITIAL CHARACTERIZATION
OF A NOVEL D-AMINO ACID OXIDASE MRNA
VARIANT
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D-amino acid oxidase (DAO) degrades D-serine, the endogenous NMDA
receptor (NMDAR)co-agonist.SinceD-serine levels andNMDARfunction
may be reduced in schizophrenia DAO is a pathophysiological candidate.
This is supported by its genetic associations with and gene expression alter-
ations1,2 in schizophrenia and its potential benefit as a therapeutic target. We
previously showed regional differences in DAO cellular localization and an-
tigenicity between human cerebellum and cortex1. One potential explanation
may be the regional expression of alternative splice variants. We have de-
scribed splice variants for other schizophrenia genes3,4, of interest since
they may represent novel therapeutic targets for the disorder. This study
therefore investigated novel DAO mRNA variants in human brain. We
used exon-exon PCR and primers designed to novel human DAO sequences
deposited on the Aceview database. PCR products were purified, sequenced
and any novel variantsanalysed in silico and expressed in mammalian vectors
in vitro. A novel variant, denoted DAO_vG, was detected in human cerebel-
lum and lymphoblasts but could not be detected in cortex. Sequencing
revealed DAO_vG comprises a portion of Intron8–9 of DAO at its 5# end
continuouswithexons9,10,11andthe3#UTRoftheDAOgene.PCRexperi-
mentswithprimers flankingIntron8–9verifiedthatDAO_vGisnottheresult
of retention of the entire Intron8–9 but is likely transcribed from a novel start
site. In silico analysis revealed the presence of two single nucleotide polymor-
phisms (SNPs) in the 5’ sequence of DAO_vG and showed that one of them
alters binding of 3 transcription factors. Current studies are investigating
whether DAO_vG mRNA levels are regulated by these SNPs or are altered
in schizophrenia using lymphoblasts from Japanese schizophrenia (n = 45)
and control (n = 45) subjects. A mammalian expression vector containing
DAO_vG has been generated and ongoing studies are characterizing the
function of DAO_vG transfected into HEK293 cells. In conclusion, we re-
port a novel mRNA variant of DAO, detected in human cerebellum but not
cortex. Ongoing studies are investigating its transcriptional regulation, ex-
pression in schizophrenia and functional characterization. Supported by Ox-
ford University.
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ASSOCIATED WITH COGNITION AND
SCHIZOPHRENIA SUSCEPTIBILITY
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The TNXB is a gene of an extracellular matrix protein tenascin X (TNX)
spanning 68.2 kb on 6p21.3 in HLA-III region. TNX is important for the
proper deposition of collagen fibers in dermis and its deficiency causes an
autosomal recessive form of Ehlers-Danlos syndrome. TNX is also known
to be associated with growth of central and peripheral nerves. Recently, an
association between two SNPs of the TNXB (rs1009382 and rs204887) and
schizophrenia was observed in family trios from the UK. With moderate
significance, the results have been replicated in the Japanese but not in
the Chinese population. We have genotyped 5 SNPs of the TNXB in 51
schizophrenic patients (SP) þ 684 members of 176 European-American
families from the CBDB/NIMH ‘sibling study’. SNP genotyping was
performed on the ABI PRISM 7900HT System by using TaqMan
SNP Genotyping Assays chemistry (ABI). Single SNP and three-marker
haplotypes association analyses were calculated using the TDTPHASE
(version 2.37) based on 100 000 permutations. The FBAT was used to
test for a marker association with the clinical phenotype. Quantitative trait
analysis (ie, with cognitive phenotypes) was performed in parent-affected
child trios using QTDT (version-2.4.3). TNXB rs2071293 (C/T) and
rs185819 (Arg[T/C]His) SNPs were associated with schizophrenia.
FBAT analyses showed under-transmission of ‘‘C’’ and ‘‘T’’ alleles of
the SNPs to SP (z = 2.855; P < .005; z = 2.757; P < .004, respectively).
Two combinations of three-marker haplotypes were contributing to schizo-
phrenia as well involving those SNPs (1. rs2269429-rs204887-rs185819:
global P< .009; 2rs185819-rs204900-rs2071293: global P< .008). As single
markers the other rs2269429, rs204887, rs204900 SNPs did not show any
difference in the transmission. Healthy subject’s data suggested a significant
association of the rs185819-rs204900-rs2071293 haplotype of the TNXB
with cognitive parameters, eg, verbal (global P < .01) and visual memories
(global P< .004), memory span (global P< .015), processing speed (global
P< .04) and results of Nback (global P< .04) and card sorting (global P<
.01) tests. We have not been able to replicate previous finding in this
European-American sample. However, our data have indicated two novel
SNPs of TNXB gene in association with schizophrenia either in or out of
haplotypes. Strikingly, the haplotype involving those SNPs was also
implicating to cognitive functioning. KRM acknowledges the USA Federal
Government contract #HHSN271200700340P.
ID: 550921
International Congress on Schizophrenia Research
7. 7. Genetics, Basic 99
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
TIMING OF PRENATAL DEVELOPMENTAL
PERTURBATIONS INDUCED BY MUTANT DISC1
RESULTING IN SCHIZOPHRENIA-LIKE
BEHAVIORAL AND PATHOLOGICAL
ALTERATIONS
Yavuz Ayhan1, M. W. Vogel2, C. A. Ross1, M. V. Pletnikov1
1Psychiatry and Behavioral Sciences, Johns Hopkins University,
Baltimore, MD, USA; 2MPRC, University of Maryland,
Catonsville, MD, USA
Data from neuropathologic, neuroimaging, neuropsychological and epide-
miologic studies suggest that early neurodevelopmental alterations may
contribute to the dysfunction in schizophrenia and related disorders. We
used a genetic mouse model as an experimental system to demonstrate
the contribution of neurodevelopmental insult on adult pathology. Previ-
ously, we have generated an inducible mouse model of the human mutation
of Disrupted-In Schizophrenia 1 (mhDISC1), using a Tet-off system. The
expression of mhDISC1 is restricted to forebrain neurons. Although the
existence of mhDISC1 results in schizophrenia-like alterations, such as en-
larged ventricles, the timing for the generation of these alterations remains
incompletely understood. To evaluate the critical time points for adult
pathological alterations, we generated three groups of mice with expression
of mhDISC1 prenatally and postnatally; prenatally only; or without expres-
sion. The expression of the mhDISC1 was regulated by feeding mice with
doxycycline-containing food. Prenatal but not postnatal expression of
mhDISC1 was associated with decreased social interaction and increased
aggressiveness. Mutant mice with prenatal expression displayed enhanced
sensitivity to a NMDA antagonist, MK-801, or amphetamine. Prenatal ex-
pression was also associated with depressive features as indicated by in-
creased immobilization time and decreased latency to immobility in
Porsolt Forced Swim Test. In addition, prenatal but not postnatal expres-
sion of the mutant protein produced decreased total cortical volume, re-
duced parvalbumin immunoreactivity, and increased dendritic spine
density in granule cells of the dentate gyrus. We believe these results provide
experimental support for neurodevelopmental hypothesis of schizophrenia
and related disorders.
ID: 551930
CONVERGENT PATTERNS OF ASSOCIATION
BETWEEN PHENYLALANINE HYDROXYLASE
VARIANTS AND SCHIZOPHRENIA IN FOUR
INDEPENDENT SAMPLES
Lora L. McClain1, M. E. Talkowski2,14, T. Allen3,
L. D. Bradford4, M. Calkins5, N. Edwards6, L. Georgieva7,
R. Go8, R. Gur5, G. Kirov7, J. Kwentus9, P. Lyons10,
H. Mansour1, J. McEvoy3, M. C. O’Donovan7, J. O’Jile9,
M. J. Owen7, A. Santos11, R. Savage8, D. Toncheva12,
G. Vockley13, J. A. Wood1, B. Devlin1,2, V. L. Nimgaonkar1,
K. V. Chowdari15
1Psychiatry, University of Pittsburgh Medical Center, Pittsburgh,
PA, USA; 2Human Genetics, University of Pittsburgh, Pittsburgh,
PA, USA; 3John Umstead Hospital, Duke University Medical
Center, Durham, NC, USA; 4Psychiatry, Morehouse School of
Medicine, Morehouse, GA, USA; 5Psychiatry, University of
Pennsylvania, Philadelphia, PA, USA; 6Psychiatry, University of
Tennessee, Knoxville, TN, USA; 7Psychological Medicine, Cardiff
University School of Medicine, Wales, United Kingdom; 8Psychi-
atry, Behavioral Neurobiology and Epidemiology, University of
Alabama, Birmingham, Birmingham, AL, USA; 9Psychiatry and
Human Behavior, University of Mississippi, Jackson, MS, USA;
10Neurology, University of Virginia, Charlottesville, VA, USA;
11Psychiatry and Behavioral Sciences, Medical University of South
Carolina, Charleston, SC, USA; 12Medical Genetics, Medical
University, Sofia, Bulgaria; 13Pediatrics, University of Pittsburgh,
Pittsburgh, PA, USA; 14Center for Human Genetics Research,
Harvard University, Boston, MA, USA; 15Psychiarty, University of
Pittsburgh School of Medicine, Pittsburgh, PA, USA
Recessive mutations in the phenylalanine hydroxylase (PAH) gene predis-
pose to phenylketonuria (PKU) in conjunction with dietary exposure to
phenylalanine. Previous studies have suggested PAH variations could
confer risk for schizophrenia, but comprehensive follow-up has not
been reported. We analyzed 15 common PAH ‘‘tag’’ SNPs and three ex-
onic variations that are rare in Caucasians but common in African-Amer-
icans among four independent samples (total n = 5414). The samples
included two US Caucasian cohorts (260 trios, 230 independent cases,
474 controls), Bulgarian families (659 trios), and an African-American sam-
ple (464 families, 401 controls). Analyses of both US Caucasian samples
revealed associations with five SNPs; most notably the common allele (G)
of rs1522305 from case-control analyses (z = 2.99, P = .006). This SNP
was independently replicated in the Bulgarian cohort (z = 2.39, P = .015).
A non-significant trend was also observed among African-American families
(z= 1.39, P= .165), and combined analysis of all four samples was significant
(rs1522305: x2=23.28, 8 df, P= .003).These results for this SNP met our a pri-
ori criteria for statistical significance, namely an association that was robust
to multiple testing correction in one sample, a replicated risk allele in multiple
samples, and combined analyses that were nominally significant. Case-
control results in African-Americans detected an association with L321L
(P = .047, OR = 1.46).Our analyses suggest several associations at PAH,
with consistent evidence for rs1522305. Further analyses, including addi-
tional variations and environmental influences such as phenylalanine
exposure are warranted.
ID: 560454
ADVANCES IN STATISTICAL GENETICS:
APPLICATION TO SCHIZOPHRENIA AND
RELATED NEUROPSYCHIATRIC DISORDERS
N. Schork1, L. Lazzeroni2
1Genomic Medicine, Scripps Translational Science Institute,
LaJolla, CA, USA; 2School of Medicine, Stanford University,
Stanford, CA, USA
Background: The identification and characterization of genetic factors
contributing to common, complex neuropsychiatric diseases such as
schizophrenia has been advanced by major breakthroughs in high-
throughput, whole-genome genotyping assays and related genetic tech-
nologies. With advances in genomics, such as CNV analyses and epige-
netics, there causes a burden to ‘‘order’’ and scale these disparate
findings. The massive amounts of data these technologies generate re-
quire sophisticated data analysis methods for their reliable and compel-
ling use. Methods: Genome Wide Association Studies (GWAS) are
typically based on more 500 000 genotype assays performed on each
of many thousands of subjects. Such studies require data analysis tools
that can accommodate genetic background heterogeneity among the sub-
jects, linkage disequilibrium between genetic variations, missing data,
and the fact that many loci–both within and across different genetic
regions–may contribute to phenotype expression. Results: We describe
in a non-mathematical way, the use of novel data analysis methods
for pursing genetic background assessments on the subjects in large-scale
genetic study, as well as haplotype-based studies, that accommodate al-
lelic complexities in GWAS contexts. These methods are showcased in
actual data and brief discussion of their merits, as well as room for
International Congress on Schizophrenia Research
100 7. 7. Genetics, Basic
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
improvements, is provided. Conclusions: Advances in statistical analysis
methods, when coupled with commensurate advances in genetic/genomic
technologies and phenotyping technologies, will lead to insights into
inherited predisposition to schizophrenia and related neuropsychiatric
disorders.
ID: 555087
GENETIC ANALYSES BETWEEN BDNF AND
SNAP25 GENES AND STRUCTURAL MRI OF
EARLY-PSYCHOSIS PATIENTS
Gwyneth Zai1,2, D. Lang3, S. Shaikh2, W. G. Honer3,
J. L. Kennedy1,2
1Department of Psychiatry, Centre for Addiction and Mental
Health - Clarke Division, University of Toronto, Toronto, ON,
Canada; 2Neurogenetics Section, Centre for Addiction and Mental
Health—Clarke Division, Toronto, ON, Canada; 3Centre for
Complex Disorders, University of British Columbia, Vancouver,
BC, Canada
Background: Schizophrenia and other psychotic disorders are a heteroge-
neous group of disorders, which share similar clinical and pathophysiolog-
ical characteristics. The brain-derived neurotrophic factor (BDNF) and
synaptosome-associated protein of 25 kDa (SNAP25) genes are considered
good candidates for early psychosis due to their significant association with
schizophrenia and their importance in the postulated neurodevelopmental
model. Hypothesis: The BDNF/SNAP25 gene variant(s) will predict grey
matter abnormality in the brain of early psychosis patients when comparing
with healthy controls, as measured by magnetic resonance imaging (MRI).
Method: Two polymorphisms in the BDNF gene, BDNF(Val-66-Met) and
BDNF(HinfI), and 3 polymorphisms in the SNAP25 gene, SNAP25(DdeI),
SNAP25(MnlI), and SNAP25(TaiI), were investigated for the possibility of
association with total grey matter volume using 62 schizophrenic patients
and 28 healthy controls. We compared allelic frequencies and genotype dis-
tributions between early psychosis patients and healthy controls, and
total grey matter volume between alleles and genotypes of each of these
polymorphisms. Results: In our preliminary analysis, we detected signifi-
cant difference in total grey matter volume within early psychosis patients
between genotype distributions of BDNF(Val-66-Met) (P = .003) and
SNAP25(DdeI) (P = .015), as well as with the total sample in BDNF(HinfI)
(P = .033) and SNAP25(DdeI) (P = .009). Conclusion: Our results showed
an interesting correlation between genotypes and grey matter volume and
required further investigation with larger samples and sub-regional grey
matter volumes.
ID: 554760
MNSOD IN TARDIVE DYSKINESIA: GENE ASSO-
CIATION STUDY AND META-ANALYSIS
Clement C. Zai1, A. K. Tiwari1, V. Basile1, V. De Luca1,
D. J. Mu¨ller1, A. N. Voineskos1, G. Remington1, H. Y. Meltzer2,
J. A. Lieberman3, S. G. Potkin4, J. L. Kennedy1
1Centre for Addiction and Mental Health, Toronto, ON, Canada;
2Psychiatric Hospital at Vanderbilt University, Nashville, TN, USA;
3New York State Psychiatric Institute, Columbia University
Medical Centre, New York City, NY, USA; 4Brain Imaging Center,
Irvine Hall, Room 166, University of California, Irvine, Irvine, CA,
USA
Tardive Dyskinesia (TD) is a potentially irreversible movement side effect
that occurs in approximately 25% of patients with long-term typical an-
tipsychotic exposure (Margolese et al. 2005). The motor side effects of TD
interfere with normal voluntary movements, and causes discrimination by
others, thus these side effects greatly reduce treatment compliance and
worsen outcome. Predicting which patients will likely develop TD remains
an important issue in treatment prescription. Oxidative stress has been im-
plicated in the pathophysiology of TD. The brain is vulnerable to oxida-
tive stress for several reasons. It uses a great deal of energy. It has large
amounts of polyunsaturated fatty acids that are substrates for lipid per-
oxidation cascades. Further, certain brain regions, the basal ganglia in
particular, contain large amounts of transition metals, some of which
are involved in the formation of hydroxyl radicals via superoxide dismu-
tase (SOD). Genetic studies have suggested that the manganese superoxide
dismutase MnSOD (SOD2) Ala9 allele may be protective against TD
(Hori et al. 2000; Galecki et al. 2006), though neither Zhang et al.
(2002) nor Thelma et al. (2007) replicated the finding. We analyzed the
Ala9Val polymorphism in MnSOD for association with TD is our sample
of schizophrenia patients (N = 193 Caucasians and 30 African Americans).
We also carried out a meta-analysis of all the studies published previously.
We did not a significant association between Ala9Val and TD occurrence
or AIMS scores in our sample. We observed a significant association, with
TD-positive patients being more likely to carry the ValVal genotype (OR =
1.47; 95% CI: 1.03–2.12; P = .036). In conclusion, the Ala9Val polymor-
phism in MnSOD is involved in TD pathogenesis, though the effect may
be small.
ID: 551950
LACK OF ASSOCIATION OF THE NAD(P)H
DEHYDROGENASE, QUINONE 1(NQO1) GENE TO
TARDIVE DYSKINESIA IN CHRONIC
SCHIZOPHRENIA PATIENTS
Arun Kumar Tiwari1, C. C. Zai1, D. J. Mueller1,
G. Remington1, H. Y. Meltzer2, J. A. Lieberman3, S. G. Potkin4,
J. L. Kennedy1
1Centre for Addiction and Mental Health, Toronto, ON, Canada;
2Psychiatric Hospital at Vanderbilt University, Nashville, TN,
TN, USA; 3New York State Psychiatric Institute, Columbia
University Medical Center, New York City, NY, USA; 4Brain
Imaging Center, Irvine Hall, University of California at Irvine, CA,
CA, USA
Introduction: Tardive dyskinesia (TD) is a potentially irreversible side ef-
fect of chronic antipsychotic medication that arises in approximately 25%
of chronically treated schizophrenia patients. Oxidative stress has been one
of the proposed mechanisms influencing TD risk. NAD(P)H dehydroge-
nase, quinone 1 (NQO1; MIM# 125860) is a 35.5 kb gene consisting of
6 exons and is located on chromosome 16q22.1. It codes for a phase II de-
toxifying homodimeric flavoprotein that catalyzes two-electron reduction
of quinones to hydroquinones and is also involved in the detoxification
of superoxide radicals to hydrogen peroxide. NQO1 is expressed in the sub-
stantia nigra and carries a common functional polymorphism, Pro187Ser
(C609T), in exon 6. Individuals carrying variant TT genotype (Ser/Ser)
expressed only trace amount of NQO1 protein and exhibit only 2–4% of
the quinone reductase activity compared to the wildtype CC genotype
(Pro/Pro). Methods: We investigated the role of the NQO1 polymorphism
C609T (Pro187Ser) in a group of well-characterized schizophrenia patients
(N = 223) who have been assessed for TD. We also performed a
meta-analysis of all the previously published TD studies with the C609T
polymorphism, including data from our sample (N = 5 studies). Results:
We did not observe any allelic or genotypic association of the C609T poly-
morphism with the occurrence or severity of TD in our Caucasian and
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African American samples when analyzed independently. In the meta-anal-
ysis, 1071 schizophrenia patients were genotyped for NQO1 C609T and 396
of them were positive for the diagnosis of TD. No significant allelic or ge-
notypic association of the C609T alleles or genotypes with TD occurrence
was observed. Conclusions: The NQO1 C609T does not play a major role in
TD risk; however, additional polymorphisms should be tested before the
role of NQO1 in TD can be completely excluded.
ID: 551938
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A NEUREGULIN 1 VARIANT IS ASSOCIATED WITH
INCREASED LATERAL VENTRICLE VOLUME IN
PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA
Ignacio Mata1, R. Perez-Iglesias1, R. Roiz-Santian˜ez1,
D. Tordesillas1, A. Gonzalez-Mandly2, J. L. Vazquez-Barquero1,
B. Crespo-Facorro1
1Psychiatry, University Hospital Marques de Valdecilla, Santander,
Spain; 2Radiology, University Hospital Marques de Valdecilla,
Santander, Spain
Background: Structural brain abnormalities are already present at early
phases of psychosis and might be the consequence of neurodevelopmen-
tal deviance. Neuregulin 1 gene (NRG1) is a candidate gene for schizo-
phrenia, and its protein has different roles in nervous system
development and plasticity. A polymorphism within NRG1,
SNP8NRG243177, has been associated with brain function among
healthy and high risk subjects, and with reduced cell migration among
patients with schizophrenia. We examined whether variations in this
polymorphism influence brain volumes in first episode of schizophrenia
subjects. Methods: Ninety-five minimally-medicated patients experienc-
ing their first episode of schizophrenia underwent SNP8NRG243177 gen-
otyping and structural brain MRI. Lobar volumes of grey matter (GM),
lateral ventricles volume, and cortical cerebrospinal fluid (CSF) were
compared among the groups according to their genotype after control-
ling for total intracranial volume. Results: The SNP8NRG243177 risk T-
allele was significantly associated, in a dose-related fashion, with in-
creased lateral ventricles volume. Genotype explained 7% of the variance
of lateral ventricles volume. No significant differences in GM lobar or
cortical CSF volumes were found among subgroups. Backgrounds:
Our findings suggest that genetic variations of NRG1 gene can contrib-
ute to the enlargement of the lateral ventricles described in early phases
of schizophrenia. These results suggest novel lines of research into po-
tential mechanisms by which schizophrenia susceptibility genes might ex-
ert their effect on brain structure.
ID: 540126
GENETIC AND TRANSCRIPTIONAL VARIATION
OF AN RNA EDITING ENZYME IN
SCHIZOPHRENIA
Monsheel Sodhi1, M. Simmons1, V. Haroutunian2,
J. Meador-Woodruff1
1Psychiatry, UAB, Birmingham, AL, USA; 2Psychiatry, Mount
Sinai School of Medicine, New York, NY, USA
Evidence that RNA editing plays a role in psychiatric disorders is accu-
mulating. The linkage ‘hotspot’ for schizophrenia at locus 1q21–22
includes the ADAR1 gene(Adenosine Deaminase Acting on RNA 1),
one of three editing enzymes which convert adenosine to inosine in
RNA. This process has profound functional consequences within
ADAR substrates, which include several glutamate receptor subunits,
the GABAa3 receptor subunit and the 5-HT2C receptor. Preliminary
data indicate that RNA editing could be reduced in schizophrenia and
in addition, we have previously reported genetic association of ADAR1
with positive symptoms in schizophrenia. The current study tested the hy-
pothesis that altered expression of ADAR enzymes occurs in schizophre-
nia. ADAR transcripts were investigated in the postmortem brain of
schizophrenia cases in comparison with normal controls. The thalamus
and anterior cingulate cortex (ACC) were tested because evidence suggests
that schizophrenia patients have abnormalities in thalamo-cortical net-
works related to cognitive and sensory processing. To measure gene ex-
pression, messenger RNA (mRNA) was extracted from medial dorsal
thalamus, the ventral tier region of the thalamus and the ACC from con-
trols (n = 14, n = 11, n = 28 respectively) and schizophrenia subjects (n = 13,
n = 9, n = 37 respectively). Quantitative PCR was performed for ADAR1,
ADAR2 and ADAR3 transcripts. Data were normalized to the expression
of four housekeeping genes (glyceraldehyde 3-phosphate dehydrogenase,
beta-2-microglobulin, actin-beta, 18S). Results indicate that ADAR1 tran-
script levels are reduced in schizophrenia cases compared with controls in
the medial dorsal thalamus (P = .04)and the ACC (P = .03) but not in the
ventral thalamus. ADAR1 expression was also associated with ADAR1
genotype (P = .003) in cases and controls. No differences in ADAR2
or ADAR3 expression were detected between the groups. These results
suggest that genetic variation associated with the reduced expression of
ADAR1 is related to the pathophysiological mechanisms of schizophrenia.
These findings also suggest that generalized reductions of RNA editing in
several ADAR1 substrates could occur in schizophrenia. Extensive screen-
ing of ADAR1 is being conducted to clarify and replicate these findings.
Work funded by NARSAD (MS), NIH MH070895 (JMW), MH53327
(JMW) and MH066392 (VH).
ID: 550657
A NEW APPROACH FOR INVESTIGATING THE
ROLE OF THE DYSTROBREVIN-BINDING PROTEIN
(DTNBP1) IN PSYCHOSIS
Rachael Willhite1, T. G. van Erp1, W. Hennah4, P. M. Thompson3,
A. W. Toga3, M. Huttunen5, J. Kaprio5,6, L. Peltonen4,
J. Lonnqvist5, T. D. Cannon1,2
1Psychology, University of California, Los Angeles, Los Angeles,
CA, USA; 2Psychiatry and Biobehavioral Sciences, University of
California, Los Angeles, Los Angeles, CA, USA; 3Laboratory of
Neuroimaging and Ahmanson-Lovelace Brain Mapping Center,
University of California, Los Angeles, Los Angeles, CA, USA;
4Molecular Medicine, National Public Health Institute, Helsinki,
Finland; 5Mental Health and Alcohol Research, National Public
Health Institute, Helsinki, Finland; 6Public Health, University of
Helsinki, Helsinki, Finland
Association studies have been mixed over the role of dysbindin in
schizophrenia. Differences in findings may signal that different haplo-
types are important in varying populations. The goal of this study
was to model the role of dysbindin in psychosis, capitalizing on the
idea that different variants may contribute to risk for different people
and that dysbindin may more directly effect the endophenotype of cog-
nitive disruption than the full clinical picture of psychosis. Participants
were part of a Finnish twin cohort that has been described in detail
elsewhere. 298 twins were included in the current analyses; 127 controls
and 172 twin pairs where one twin had a diagnosis of schizophrenia,
schizoaffective disorder, or bipolar disorder with psychotic features.
Twins were tested using an extensive neurocognitive and clinical battery,
completed structural magnetic resonance imaging paradigms and pro-
vided blood samples for harvesting genetic data. Four supermarkers
were used to look at nine SNPs in the dysbindin gene, creating popu-
lation specific haplotypes. Successive backwards multiple regressions
were conducted to examine the role of haplotypes in cognitive perfor-
mance. Outcomes were standard scores in cognitive domains known
to be impaired in schizophrenia. Six ‘‘risk’’ and three ‘‘protective’’ hap-
lotypes were identified based on their effects on multiple cognitive
domains. Risk haplotypes occurred in less than 5% of the population
and a new variable was created coding for the presence of any of
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the risk haplotypes. The overall risk variable along with the three pro-
tective haplotypes, was analyzed for its effects on cognition, clinical
symptoms, brain structure and disease status. Chi-squared tests showed
patients were marginally more likely to have the risk haplotypes than
controls or healthy co-twins (P = 0.05). Mixed-models ANOVAs showed
risk haplotypes were associated with impaired cognitive performance, in-
creased CSF and sulcal volume, and marginally decreased gray matter
volume in patients and co-twins but not controls. They also predicted
higher ratings on thought disorder among patients. Protective haplo-
types predicted decreased sulcal and CSF volume across all participants
and were associated with lower ratings of hallucinations and anhedonia
in patients. These findings support the role of dysbindin in psychosis.
Multiple variants may contribute to symptom severity and disease
risk through common effects on expression of DTNBP1.
ID: 550637
CLINICAL CORRELATES OF OE NEURONS GENE
EXPRESSION IN SCHIZOPHRENIA
Nicola Gerardo Cascella, K. Ishizuka
Psychiatry, Johns Hopkins University, Baltimore, MD, USA
Over the last decade, the olfactory system and more specifically the ol-
factory epithelium (OE) has received growing attention as an alternative
model for the study of the neurodevelopmental deficits of schizophrenia.
OE is a unique tissue where some key features of neurodevelopment of
the central nervous system occur throughout life. OE and its synaptic
targets in the olfactory bulb (OB) provide an opportunity for a snapshot
of morphologic and molecular neurodevelopmental processes that are
ongoing even in late life. We have started a systematic collection of
OE tissue in patients with schizophrenia and normal controls with the
goal of studying gene expression from OE tissue and ultimately identify
biological markers specific to the disease. In this symposium we discuss
novel results on the correlation of clinical variables with UPSIT score
and neuropsychological testing as well as OE gene expression profile.
We have been able to confirm previously described association of neg-
ative symptoms with poor performance on the UPSIT in 15 patients with
schizophrenia. In a subset of 10 subjects, we found a significant corre-
lation between 5 genes, including RNA-binding protein genes, and
UPSIT score. We will discuss correlation between gene expression and
neuropsychological testing. Our results further confirm a relationship be-
tween negative symptoms of schizophrenia and poor performance on
smell identification test. They also indicate that a method to clarify
gene expression profile from OE neurons has been established and might
be a useful technique to identify genes that correlate with indicators of
psychopathology in schizophrenia.
ID: 550626
STRESS-REACTIVITY AS RISK FACTOR FOR THE
POSITIVE SYNDROME OF PSYCHOSIS: EVIDENCE
FOR A GENETIC CONTRIBUTION.
Tineke Lataster, D. Collip, M. Lardinois, J. van Os,
I. Myin-Germeys
Maastricht University, Maastricht, Netherlands
Background: Increased stress-reactivity has been reported in subjects who
are at increased risk to develop psychosis. Moreover, it has been sug-
gested that stress-reactivity may be specifically related to the develop-
ment of positive symptoms. To add evidence to the hypothesis that
stress-reactivity is an endophenotype for psychosis, the present study ex-
amined i) whether stress-reactivity clusters within families of psychotic
patients, and ii) whether stress-reactivity in the relatives co-segregates
with positive symptoms in the patients. Methods: The sample consisted
of 47 patients with a diagnosis of psychotic disorder and their siblings
(n = 47). The Experience Sampling Method (ESM—a structured diary
technique) was used to measure stress-reactivity, defined as the increase
in negative affect in reaction to stress in daily life. Positive symptoms in
the patients were measured with the Brief Psychiatric Rating Scale.
Results: Within-trait, cross-sib associations showed a significant associ-
ation between stress-reactivity in the patient and stress-reactivity in
their first-degree relative (B = 0.15 (SE = 0.04), P = .001). Additionally,
significant cross-trait, cross-sib associations were established showing
a significant association between the patient’s positive symptoms and
stress-reactivity in the first-degree relative (B = 0.30 (SE = 0.09), P =
.001). Discussion: This study provided evidence for familial transmission
of increased stress-reactivity. Furthermore, increased stress-reactivity levels
in the siblings were associated with increased positive symptom intensity in
the patients. These results thus suggest a genetic contribution to increased
stress-sensitivity, which is specifically underlying the positive dimension of
psychosis.
ID: 550461
MICRORNA GENOMIC VARIATIONS IN PSYCHI-
ATRIC DISEASES
Chunyu Liu1, J. G. Reid3, L. Cheng1, O. Alvi3, A. S. Lucas3,
L. Lewis3, O. Hall3, L. Nazareth3, D. Wheeler3, D. Muzny3,
D. Zhang1, J. A. Badner1, Y. Shen4, C. Wu4, E. S. Gershon1,2,
R. A. Gibbs3
1Psychiatry and Behavioral Neuroscience, University of Chicago,
Chicago, IL, USA; 2Human Genetics, University of Chicago,
Chicago, IL, USA; 3Human Genome Sequencing Center, Baylor
College of Medicine, Houston, TX, USA; 4Ecology and Evolution,
University of Chicago, Chicago, IL, USA
MicroRNAs (miRNAs) are short (19;25 nucleotides) single-stranded
non-coding RNAs that are generated from endogenous hairpin-shaped
transcripts, precursor miRNAs. miRNAs function as guide molecules
in post-transcriptional gene silencing by base pairing with target mRNAs,
which lead to mRNA cleavage or translational repression. With >400
members in human, miRNAs are one of the largest gene families, account-
ing for ;1% of the genome.Since miRNAs are abundant in brain and
playing important role in brain development and function, and they
can regulate the expression of many genes of neurological interest simul-
taneously, variants in miRNA genes have the potential to play a role in
complex psychiatric diseases such as schizophrenia and bipolar disorder.
We present here results on the deep resequencing of known human miR-
NA precursors and variants identification in 281 brain-significant miR-
NAs. We have sequenced the genomic DNA region of these 281
miRNAs in 282 samples including 94 HapMap (CEU, YRI, JPN and
CHB) samples and 188 Stanley Medical Research Institute (SMRI) and
NIMH Genetic Initiative Bipolar, Schizophrenia, Major depression and
control Caucasian samples. A total of 748 SNPs have been detected, of
which 103 SNPs were located in miRNA precursors. Nominally significant
associations have been detected for 33 SNPs between disease/control com-
parison and none of these associations withstood multiple testing correc-
tions. Common variant associations of the identified precursor variants in
large schizophrenia and bipolar samples will also be presented.
ID: 550421
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THE EUROPEAN NETWORK OF NETWORKS
FOR THE STUDY OF GENE-ENVIRONMENT
INTERACTION
Jim Van Os
1Department Psychiatry and Neuropsychology, Maastricht Uni-
versity, The Netherlands, Maastricht, Netherlands; 2Division of
Psychological Medicine, Institute of Psychiatry, London, United
Kingdom
The Dutch Schizophrenia Network was funded in 2005 by a large gov-
ernment grant which was matched for 50% by Industry. The model cho-
sen was that of a single large nationwide study (G.R.O.U.P.) focussing
on aetiology in the first instance, and evidence-based community psychi-
atry in the second. To date, more than 1000 families with at least one
affected member have been collected, including detailed assessment of
genetic variation, environmental exposures, cognition and structural
MRI. Data collection, including 3- and 6-year follow-up of all families,
is now extended as part of a combined effort of existing schizophrenia
networks in Europe, called the European Network of Networks for the
Study of Gene-Environment Interaction (EU-GEI). Within EU-GEI,
new paradigms have been developed for the study of gene-environment
interactions, including novel experimental psychosis paradigms, neuroi-
maging approaches and studies to assess the impact of gene-environment
interactions on transition from prodromal to clinical state, course of ill-
ness across the critical period and multiple within-sample replications of
GxE findings. In addition, novel genetic approaches towards candidate
selection are tested, including GWAS stratified by environmental expo-
sure, E-QTL, mechanism-based gene searches and impact of environmen-
tal exposures on common CNVs.
ID: 550328
DYSBINDIN AND D-AMINO-ACID-OXIDASE GENE
POLYMORPHISMS ASSOCIATED WITH POSITIVE
AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
Katrine Verena Wirgenes1,3, S. Djurovic1,2, I. Agartz1,5,
E. G. Jo¨nsson4, T. Werge6, I. Melle1,3, O. A. Andreassen1,3
1Institute of Psychiatry, University of Oslo, Oslo, Norway;
2Department of Medical Genetics, Ulleval University Hospital,
Oslo, Norway; 3Department of Psychiatry, Ulleval University
Hospital, Oslo, Norway; 4Department of Clinical Neuroscience,
HUBIN Project, Psychiatry Section, Karolinska Institute and
Hospital, Stockholm, Sweden; 5Department of Psychiatric
Research, Diakonhjemmet Hospital, Oslo, Norway; 6Research
Institute of Biological Psychiatry, H:S Sct. Hans Hospital,
Roskilde, Denmark
The purpose of the present study was to investigate whether previously
observed genotype-phenotype associations between dystrobrevin-binding
protein 1 gene (DTNBP1; dysbindin) and D-amino-acid-oxidase (DAO)
gene variants and clinical symptoms in schizophrenia patients could be
replicated in a Scandinavian patient sample. In this genotype-phenotype
association analysis, we investigated if three dysbindin single nucleotide
polymorphisms (SNPs) and three DAO SNPs were associated with
symptoms assessed with the Positive and Negative Syndrome Scale
(PANSS) in a total of 155 patients with schizophrenia spectrum disor-
ders. The PANSS items were divided into five factors; negative, disor-
ganized, positive, excited and anxiety and depression symptoms. The
main finding of the present study was an association between a dysbindin
polymorphism and negative symptoms, and between a DAO polymor-
phism and anxiety and depression. This replicates results of previous
studies. In our sample there was an additional association between
both genes and total PANSS scores and between a dysbindin SNP
and depression and anxiety. Most genetic case-control studies performed
so far have focused on the association between dysbindin and DAO and
the diagnosis of schizophrenia compared to healthy controls, although
there are some indications that clinical phenotypes across diagnoses
are associated with certain gene variants. Dysbindin and DAO, both in-
volved in glutamate receptor function, have recently been reported to be
associated with positive and negative symptoms in schizophrenia. The
present association between dysbindin and DAO SNPs and clinical
symptom characteristics further indicates involvement of glutamate
abnormalities in schizophrenia pathophysiology as suggested by previous
studies. It also indicates that dysbindin and DAO polymorphisms may
be associated with subgroups of clinical characteristics in schizophrenia.
ID: 550279
PREMORBID FUNCTION AND PRODROMAL
SYMPTOMS IN YOUNG GENETIC HIGH-RISK
RELATIVES
Debra M. Montrose1, D. Mermon1, J. Miewald1, S. Eack1,
K. Prasad1, S. Bangalore1, V. Diwadkar1,2, M. B. Abela2, C. Zajac
Benitez2, U. Rajan2, R. Rajarethinam2, M. S. Keshavan1,2
1Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA;
2Psychiatry, Wayne State University, Detroit, MI, USA
Premorbid deficits are common in schizophrenia and have been shown to
predict outcome. Similarly, negative symptoms and subthreshold and
brief-lasting intermittent psychotic symptoms are characteristic of the pro-
dromal period before the onset of schizophrenia. The relation between
premorbid functioning and prodromal symptoms in high-risk individuals
is unclear. We examined premorbid functioning using the Premorbid Ad-
justment Scale (PMAS; Cannon-Spoor et al., 1982) and prodromal symp-
toms using the Structured Interview for Prodromal Symptoms (Miller
et al., 2003). The PMAS evaluates social, sexual, academic and occupa-
tional functioning across four periods of development (childhood, early
and late adolescence and adulthood). Fifty-six young relatives, with
a first-degree family history of schizophrenia, ages 12 to 24 years were
evaluated. Cross-sectional analyses revealed that poorer social and aca-
demic function in childhood (up through age 11) correlated with a greater
degree of prodromal symptoms (Spearman r = 0.38, P = .004). In assessing
specific clusters of prodromal symptoms, negative (Spearman r = 0.38, P =
.004), disorganization (Spearman r = 0.38, P = .004) and general prodro-
mal symptoms (Spearman r = 0.26, P = .05) were significantly correlated
with childhood PMAS scores, with a trend for positive symptoms
(Spearman r = 0.23, P = .09) in adolescents and young adults (age
16.8 6 3.2 years). These analyses survived Bonferroni correction, except
positive and general symptoms. Subsequent longitudinal growth curve
analyses indicated that childhood social and academic maladjustment
was significantly predictive of greater growth in prodromal negative symp-
toms over time (b = .34, P = .001), but not positive, disorganization, or
general prodromal symptoms. These results indicate a significant relation-
ship between measures of social behavior and function and clinical meas-
ures of psychopathology. Thus, prodromal symptomatology emerging
during adolescence in genetically at-risk individuals may be preceded
by poor premorbid social and academic functioning in childhood. Premor-
bid functioning in high risk individuals is highly relevant and would be an
easy marker to target for early identification and intervention. Longitu-
dinal data will help to study the relationship between premorbid malad-
justment, prodromal symptoms and eventual conversion to psychosis in
genetically vulnerable individuals.
This work was supported by MH064023 (Keshavan).
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GENETIC RISK AND OUTCOME OF PSYCHOSIS
(GROUP), A MULTI SITE LONGITUDINAL COHORT
STUDY: OBJECTIVES, RECRUITMENT AND
ASSESSMENT METHODS AND CHARACTERISTICS
OF INCLUDED PARTICIPANTS
Lieuwe de Haan1, R. Kahn2, D. Linszen1, J. van Os3, D. Wiersma4,
R. Bruggeman4, W. Cahn2, L. Krabbendam3, I. Myin-Germeys3
1Psychiatry, AMC, Amsterdam, Netherlands; 2Psychiatry, Rudolf
Magnus Institute of Neuroscience, University Medical Center
Utrecht, Utrecht, Netherlands; 3Psychiatry, (c) Maastricht
University Medical Centre, South Limburg Mental Health Research
and Teaching Network, Maastricht, Netherlands; 4Psychiatry, (d)
University Medical Center Groningen, Department of Psychiatry,
University of Groningen, Groningen, Netherlands
Background: Studying both genes and environment in interaction is a fruit-
ful strategy to identify the variations that may give rise to the psychotic
vulnerability and variations in its course. A longitudinal study of both clin-
ical and non-clinical populations offers the opportunity to elucidate etio-
logical and pathogenetic factors. The main objective of the GROUP study
is to investigate the dynamic interaction over time between genetic and en-
vironmental factors that contribute to 1) the expression of psychosis, and 2)
the variations in course of psychosis. Methods: A naturalistic cohort study
with a 6 year follow-up of 1) patients with non-affective psychotic disorders
and 2) their siblings and parents, and (3) healthy controls performed by
a consortium of four academic psychiatric centers, with their affiliated men-
tal health care institutions in the Netherlands covering more than 7,5 mil-
lion inhabitants. Extensive assessment of demographic and diagnostic
variables, severity of psychopathology or traits, course, needs and care-con-
sumption, neuropsychological functioning, DNA. Results: Baseline assess-
ment is completed: 3737 subjects have been included: 1045 patients, mean
age 27.6, (SD 7.2), 70% with a DSM-IV diagnosis of schizophrenia, 56% in
their first psychotic episode, 1123 siblings, mean age 28.5, (SD 8.3), 828
parents mean age 53.7, (SD 6.9) and 641 healthy controls mean age
30.9, (SD 10.6). Part of this sample was used in a recently published study
on a genome-wide search for copy number variations associated with
schizophrenia (Stefansson et al. 2008) Conclusion: the Genetic Risk and
Outcome of Psychoses (GROUP)-project will provide insight in gene-envi-
ronment vulnerability and resilience factors in the development of a psy-
chotic disorder, and in the variation in the course of the disorder.
Acknowledgement: The study is supported by the ZonMW program
Geestkracht, the 30 collobarative Mental Health Organizations, and Astra-
Zeneca, Bristol-Myers Squibb, Janssen-Cilag, Lilly.
Reference
1. Stefansson et al. Recurrent microdeletions associated with schizophre-
nia, Nature. 2008;455(7210):232–236.
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ISSUES AND ADVANTAGES OF STUDYING
INTERMEDIATE PHENOTYPES IN MULTICENTER
STUDIES: THE GERMAN MOODS EXPERIENCE
Andreas Meyer-Lindenberg1, H. Walter2, M. Rietschel3,
M. No¨then4, P. Kirsch1
1Department of Psychiatry and Psychotherapy, Central Institute of
Mental Health, University of Heidelberg, J 5, 68159 Mannheim,
Germany; 2Division of Medical Psychology, Department of Psy-
chiatry, University of Bonn, 53105 Bonn, Germany; 3Division
Genetic Epidemiology in Psychiatry, Central Institute of Mental
Health, University of Heidelberg, J 5, 68159 Mannheim, Germany;
4Department of Genomics, Life and Brain Center and Institute of
Human Genetics, University of Bonn, 53105 Bonn, Germany
Intermediate phenotypes, especially using imaging genetics, have emerged
as a powerful strategy to identify neural mechanisms linked to genetic risk
for common mental disorders. In the context of large networks, studying
these phenotypes is complicated by issues of scanner and subject heteroge-
neity and quality control. We present the experience from more than 160
subjects scanned using structural and functional neuroimaging in the Ger-
man federally funded MooDs network. A reliable battery of neuroimaging
tasks and methods for stringent quality control are presented. We show that
stringent quality control is necessary to successfully combine data from dif-
ferent sites for imaging genetics. If these procedures are observed and ad-
equate statistical models are used for analysis, neural mechanisms linked to
common genetic risk variants for schizophrenia have been identified in the
context of the network with a high degree of sensitivity and reliability.
ID: 550212
DEVELOPMENTAL CRITICAL PERIOD IN GENETIC
REDOX DYSREGULATION: ANIMAL AND HUMAN
STUDIES IN SCHIZOPHRENIA
Kim Q. Do1, P. Conus2, P. Bovet2, J. H. Cabungcal1, A. Frank1,
R. Gysin1, S. Lavoie1, A. Polari1,2, P. Steullet1, T. Teichmann1,
M. Cuenod1
1Center for Psychiatric Neuroscience, Department of Psychiatry,
Lausanne University, Lausanne-Prilly, Switzerland; 2Service of
General Psychiatry, Department of Psychiatry, Lausanne
University, Lausanne-Prilly, Switzerland
Converging evidence favors an abnormal susceptibility to oxidative stress in
schizophrenia. Decreased levels of glutathione (GSH), the major cellular
antioxidant and redox regulator, was observed in cerebrospinal-fluid
and prefrontal cortex of patients. Importantly, abnormal GSH synthesis
of genetic origin was observed: Two case-control studies showed an asso-
ciation with a GAG trinucleotide repeat (TNR) polymorphism in the GSH
key synthesizing enzyme glutamate-cysteine-ligase (GCL) catalytic subunit
(GCLC) gene. The most common TNR genotype 7/7 was more frequent in
controls, whereas the rarest TNR genotype 8/8 was three times more fre-
quent in patients. The disease associated genotypes (35% of patients) cor-
related with decreased GCLC protein, GCL activity and GSH content.
Similar GSH system anomalies were observed in early psychosis patients.
Such redox dysregulation combined with environmental stressors at spe-
cific developmental stages could underlie structural and functional connec-
tivity anomalies. In pharmacological and knock-out (KO) models, GSH
deficit induces anomalies analogous to those reported in patients. (a) mor-
phology: spine density and GABA-parvalbumine immunoreactivity (PV-I)
were decreased in anterior cingulate cortex. KO mice showed delayed cor-
tical PV-I at PD10. This effect is exacerbated in mice with increased DA
from PD5-10. KO mice exhibit cortical impairment in myelin and peri-
neuronal net known to modulate PV connectivity. (b) physiology: In cul-
tured neurons, NMDA response are depressed by D2 activation. In
hippocampus, NMDA-dependent synaptic plasticity is impaired and kai-
nate induced g-oscillations are reduced in parallel to PV-I. (c) cognition:
low GSH models show increased sensitivity to stress, hyperactivity, abnor-
mal object recognition, olfactory integration and social behavior. In a clin-
ical study, GSH precursor N-acetyl cysteine (NAC) as add on therapy,
improves the negative symptoms and decreases the side effects of antipsy-
chotics. In an auditory oddball paradigm, NAC improves the mismatched
negativity, an evoked potential related to pre-attention and to NMDA
receptors function. In summary, clinical and experimental evidence
converge to demonstrate that a genetically induced dysregulation of
GSH synthesis combined with environmental insults in early development
represent a major risk factor contributing to the development of
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Rec Sante´ Que´bec, Leenaards Found.
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DRD2 VARIATION AND WEIGHT GAIN IN FIRST
EPISODE SCHIZOPHRENIA
Todd Lencz1,2, D. G. Robinson1,2, K. Xu3, B. Napolitano2,
S. Sevy1, H. Gunduz-Bruce4, J. M. Kane1,2, D. Goldman3,
A. K. Malhotra1,2
1Department of Psychiatry Research, The Zucker Hillside Hospital,
Glen Oaks, NY, USA; 2Center for Translation Psychiatry, Feinstein
Institute for Medical Research, Manhassett, NY, USA; 3Laboratory
of Neurogenetics, NIAAA, Bethesda, MD, USA; 4Department of
Psychiatry, Yale University, New Haven, CT, USA
Background: All antipsychotics act on the dopamine D2 receptor, and sec-
ond generation antipsychotics carry a substantial liability for weight gain.
The present study extends prior pharmacogenetic investigation of the D2
receptor gene (DRD2) by examining promoter region variation as a predic-
tor of short-term (6-week) weight gain in response to two first-line atypical
antipsychotics in first episode (FE) schizophrenia. Methods: Forty-four FE
patients enrolled in a randomized trial of risperidone (RIS) vs. olanzapine
(OLZ) were genotyped for a common polymorphism in the DRD2 pro-
moter region (141C Ins/Del) and had baseline and 6-week weight data
available for comparison. Carriers of the DRD2 deletion allele (n = 20)
were compared to C/C homozygotes (non-carriers, n = 24). Medication as-
signment (RIS, n = 21; OLZ, n = 23) and sex (M/F = 32/12) were also added
to the ANOVA model. Results: There were significant main effects (P <
.05) of both medication assignment (OLZ>RIS) and genotype (car-
rier>non-carrier), but no interaction of medication and genotype. Carriers
of the deletion allele gained ;6 pounds more than non-carriers by the end
of 6-weeks, regardless of medication assignment. Results did not appear to
be a function of cumulative medication dosage or baseline demographics.
Conclusions: DRD2 deletion carriers demonstrate increased liability for
antipsychotic-induced weight gain, despite previous evidence that deletion
carriers demonstrated reduced symptom response to medication. Additional
study of appropriate treatment options for these patients appears warranted.
ID: 550173
OLFACTORY DISCRIMINATION IN YOUNG
RELATIVES AT RISK FOR SCHIZOPHRENIA
Matcheri Keshavan1,2, A. Vora3, D. Montrose2, V. Diwadkar2,3,
J. Sweeney2
1Psychiatry, Beth Israel Medical Center, Boston, MA, USA;
2Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
3Psychiatry, Wayne state university, Detroit, MI, USA
Olfactory discrimination deficits are seen in schizophrenia, but it is unclear
whether they are related to familial risk and whether they are specific to the
predisposition to this illness. We examined the prevalence and clinical cor-
relates of olfactory discrimination abnormalities assessed using the Univer-
sity of Pennsylvania Smell Identification Test (UPSIT) in young relatives at
risk for schizophrenia (HR-S) and a small subset of relatives at risk for bi-
polar disorders (HR-B). UPSIT deficits in the HR-S group were correlated
with premorbid maladjustment in late adolescence, prodromal disorgani-
zation symptoms, as well as cognitive abnormalities. UPSIT scores were
reduced in HR- S and in HR-B subjects compared to the healthy controls,
and the HR-B findings survived after covarying the effects of IQ. Olfactory
discrimination deficits may reflect markers of psychopathological vulner-
ability in young relatives at risk for schizophrenia or bipolar disorder.
ID: 550142
FAMILIAL AGGREGATION OF CLINICAL,
NEUROCOGNITIVE AND CEREBRAL
STRUCTURAL FEATURES IN SIBLING PAIRS WITH
AND WITHOUT SCHIZOPHRENIA
Li-Shiun Chen1, D. M. Barch1,2, J. G. Csernansky1,3
1Psychiatry, Washington University School of Medicine, St. Louis,
MO, USA; 2Psychology, Washington University School of Medicine,
St. Louis, MO, USA; 3Psychiatry and Behavioral Sciences,
Northwestern University Feinberg School of Medicine, Chicago,
IL, USA
Clinical, neurocognitive and structural features were found to be heritable
in individuals with schizophrenia and their relatives. However, the heri-
tability of neurocognitive measures in families with and without schizo-
phrenia has not been directly compared. In this study, we examined their
genetic structure in sibling pairs with and without schizophrenia to test
the hypothesis that the familial aggregation of such measures may be al-
tered by having schizophrenia. Patients with schizophrenia and their non-
psychotic full siblings, healthy controls, and their full siblings were
recruited. Heritability was estimated for positive, negative and disorgani-
zation symptoms, working and episodic memory, executive function, at-
tention, volumes of whole brain, amygdale and hippocampus. Negative
symptoms, working memory, episodic memory and executive function,
but not positive, disorganization symptoms and attention, were found
to be significantly heritable in all sibling pairs. However, the heritability
of working memory function was significantly decreased in proband sib-
ling pairs as compared to control sibling pairs. Significant genetic corre-
lations were observed between negative symptoms and the cluster of
working memory, episodic memory and executive function. Whole brain
volume was decreased in individuals with schizophrenia and their siblings.
All structural measures were heritable and showed different change pat-
terns across sibling pair types. Most neurocognitive and structural meas-
ures were heritable in sibling pairs with and without schizophrenia.
However, schizophrenia reduced the heritability of working memory, per-
haps due to disease-related environmental or genetic factors. Evidence for
pleiotropy will inform future phenotypic studies.
Table. Heritability (h2) for Potential Endophenotypes
All Sibling
Pairs (N = 278)
Control Sibling
Pairs (N = 157)
Proband Sibling
Pairs (N = 121)
h2 S.E.
P
value h2 S.E.
P
value h2 S.E.
P
value
positive symptoms .067 .055 .11 .20 .23 .20 .00 –(a) .50
negative symptoms .32 .062 <.001 .67 .20 .0012 .19 .14 .092
disorganization
symptoms
.08 .057 .082 .35 .22 .060 .00 –(a) .50
working memory .53 .11 <.001 .85 .19 <.001 .38 .23 .052
episodic memory .57 .11 <.001 .64 .22 .0032 .43 .17 .0070
executive function .40 .096 <.001 .55 .21 .0064 .27 .12 .015
attention .039 .16 .40 .055 .31 .43 .00 –(a) .50
whole brain volume .97 .17 <.001 .79 .27 .0050 .89 .26 <.001
amygdala volume .63 .24 .0074 .37 .31 .12 .95 .33 .0037
hippocampal
volume
.93 .19 <.001 1.00 –(a) <.001 .83 .31 .0057
All models adjusted for age, gender, ascertainment bias. –(a):not estimable
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A DATABASE OF COMPREHENSIVE CLINICAL,
ENDOPHENOTYPIC AND GENETIC DATA FOR
AETIOLOGICAL STUDIES OF SCHIZOPHRENIA
Vaughan Carr1,2, C. Loughland1,2, S. Catts3, F. Henskens4,
A. Jablensky5, P. Michie1,2, B. Mowry6,7, C. Pantelis8, U. Schall1,2,
R. Scott9
1Centre for Brain and Mental Health Research, University of
Newcastle, Newcastle, NSW, Australia; 2Schizophrenia Research
Institute, Sydney, NSW, Australia; 3Department of Psychiatry,
University of Queensland, Brisbane, QLD, Australia; 4School of
Electrical Engineering and Computer Science, University of New-
castle, Newcastle, NSW, Australia; 5Centre for Clinical Research in
Neuropsychiatry, University of Western Australia, Perth, WA,
Australia; 6Queensland Centre for Mental Health Research, Uni-
versity of Queensland, Brisbane, QLD, Australia; 7Queensland In-
stitute of Medical Research, Brisbane, QLD, Australia; 8Melbourne
Neuropsychiatry Centre, University of Melbourne, Melbourne, VIC,
Australia; 9Division of Genetics, Hunter Area Pathology Service,
University of Newcastle, Newcastle, NSW, Australia
The Australian Schizophrenia Research Bank is a national database aiming
to achieve a sample of 2000 cases of schizophrenia and 2000 healthy con-
trols comprehensively assessed using a structured clinical diagnostic inter-
view and symptom ratings, together with neuropsychological evaluations,
structural MRI scans, and genetic analyses of blood samples. Recruitment
of cases and controls began in 2007. Clinical assessment includes the Di-
agnostic Interview for Psychosis, SANS, GAF and measures of childhood
adversity, schizotypal traits and personality. The neuropsychological test
battery includes Edinburgh Handedness, RBANS, WTAR, WASI, Letter
Number Sequencing, COWAT and items from the Neurological Evalua-
tion Scale. Structural MRI scans are conducted at five locations in four
states. Blood is stored for genetic analyses at most participating sites
with duplicate samples stored separately. Primary genetic analyses will
be conducted for the categorical phenotype. Secondary analyses will ex-
plore alternative phenotypes derived using empirical methods as well as pu-
tative endophenotypes based on neurocognitive and neuroimaging
variables. Preliminary data from the first 500 cases will be presented to il-
lustrate the potential of this database to link genetic findings with clinical,
neurocognitive and structural brain changes in schizophrenia.
ID: 549548
PROBABILISTIC CATEGORY LEARNING DEFICITS
EXIST IN A SUBSET OF UNAFFECTED SIBLINGS OF
PATIENTS WITH SCHIZOPHRENIA
Thomas Weickert1,2
1School of Psychiatry, University of New South Wales, Randwick,
NSW, Australia; 2Genes Cognition and Psychosis Program, Na-
tional Institute of Mental Health, Bethesda, MD, USA
While patients with schizophrenia display normal probabilistic category
learning rate in conjunction with an overall performance deficit, the extent
to which this deficit occurs in unaffected, first degree relatives of patients
with schizophrenia is unknown. A probabilistic category learning test was
administered to 128 patients with schizophrenia, 114 unaffected siblings,
and 165 healthy participants. There was no significant difference among
groups regarding learning rate; however, patients differed significantly
from siblings and healthy participants regarding overall performance. Ap-
plication of a stringent learning definition enabled further classification
into good and poor learners. There was no significant difference in learning
rate or performance between sibling and healthy good learners. There were
significant differences between the percentages of sibling and healthy poor
learners: healthy (16%), siblings (34%), patients (48%), yielding a relative
risk of 2.1, v2 (1) = 6.5, P < .01. Sibling and patient poor learners were
significantly different from healthy poor learners during early trials; how-
ever, siblings improved during latter trials to the extent that they were sig-
nificantly different from patients and indistinguishable from healthy
participants. Application of a stringent learning criteria revealed that
half of the patients with schizophrenia fail to show normal probabilistic
category learning rate and performance. One third of unaffected siblings
of patients with schizophrenia display probabilistic category learning ab-
normalities during early learning. This distinction between good and
poor learning siblings of patients with schizophrenia, who are otherwise
unaffected by illness, may be used to inform genetic studies designed to de-
tect schizophrenia risk alleles.
ID: 548710
THE EFFECT OF COMT VAL158MET POLY-
MORPHISM ON COGNITION IN EARLY ONSET
SCHIZOPHRENIA: A FAMILY-BASED STUDY
Nora S. Vyas1, L. Burke1, A. Vourdas1, D. Stahl2, J. F. Powell3,
S. Frangou1, D. A. Collier4
1Section of Neurobiology of Psychosis, Division of Psychological
Medicine, Institute of Psychiatry, King’s College London, London,
United Kingdom; 2Biostatistics and Computing, Institute of
Psychiatry, King’s College London, London, United Kingdom;
3MRC Centre for Neurodegenerative Research, Institute of
Psychiatry, King’s College London, London, United Kingdom;
4Section of Neuropsychiatric Genetics, Social Genetic and Devel-
opmental Psychiatry Centre, Institute of Psychiatry, King’s College
London, London, United Kingdom
The gene encoding catechol-O-methyltransferase (COMT), an enzyme
which regulates prefrontal cortex dopamine, contains a functional single
nucleotide polymorphism of the COMT gene (Val158Met, rs4680) which
affects performance in working-memory tasks. We sought to investigate
its effect on memory and attentional processes in early onset schizophrenia
(EOS; onset before the age of 18) using a family-based design. We con-
ducted a comprehensive neuropsychological test battery on 53 EOS pro-
bands and 117 of their unaffected first-degree relatives. They were
examined on memory (Wechsler Memory Scale-Revised; WMS-R), verbal
learning (California Verbal Learning Test; CVLT), visual information pro-
cessing (SPAN of apprehension test) and sustained attention (degraded-
stimulus continuous performance test; DS-CPT). The Structured Clinical
Interview for DSM-IV yielded four diagnostic groups: EOS; relatives
with Mood Disorders; Other Axis I diagnoses; and no diagnosis (healthy).
Analysis of co-variance was performed, with diagnosis and genotype as
fixed factors and age as covariate. Results showed that COMT Val158Met
genotype was associated with memory and attention. There was a main ef-
fect of genotype in which Met158 homozygotes showed better performance
on general memory indexes in comparison to Val158 homozygotes [P = .05],
but not heterozygotes [P = .47]. Met158 homozygozity made fewer intru-
sion errors (CVLT) than Val158 homozygotes [P = .004] and heterozygotes
[P = .01]. Similarly Met158 homozygosity was associated with a higher
learning slope compared to Val158 homozygotes [P = .03], while heterozy-
gotes were intermediate. Across trials, Met158 homozygotes produced
more correct responses (DS-CPT) compared to Val158 homozygotes [P
< .03] and heterozygotes [P< .01]. There was no effect of COMT genotype
on SPAN. After applying Bonferroni corrections, a significant genotype by
diagnosis interaction on sustained attention [P = .0004], showed that the
Val158 allele and presence of an Axis I diagnosis was associated with fewer
correct responses. Our findings implicate COMT in memory-related pro-
cesses and sustained attention but not visual processing. The findings sug-
gest that Met158 homozygosity is associated with processes involved in
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encoding new information as evidenced by the learning slope, and the ex-
ecutive control of recall (intrusion errors). The COMT polymorphism may
increase the risk of a number of Axis I diagnoses in individuals with a family
history of schizophrenia.
ID: 548050
GENETIC OVERLAP BETWEEN EXECUTIVE
FUNCTION AND SCHIZOPHRENIA—THE
MAUDSLEY TWIN STUDY
Sheena F. Owens1, F. V. Rijsdijk2, M. M. Picchioni1,
R. M. Murray1, T. Toulopoulou1
1Department of General Psychiatry, Institute of Psychiatry, King’s
College London, London, United Kingdom; 2Social, Genetic and
Developmental Psychiatry Centre, Institute of Psychiatry, King’s
College London, London, United Kingdom
Executive functioning impairment is one of the most promising putative
endophenotypes for studying the genetics of schizophrenia; however it is
not clear to what extent these deficits are genetically linked to the disorder.
The study aimed to quantify the genetic and environmental contributions to
the variability of verbal fluency and mental flexibility and to estimate the
genetic relationship between these and schizophrenia. The twin study de-
sign used bivariate genetic model fitting. A total of 335 twins participated in
this research: 27 pairs of MZ twins concordant for schizophrenia; 20 pairs
of MZ twins discordant for schizophrenia, 69 pairs of MZ twins without
schizophrenia; 14 pairs of DZ twins discordant for schizophrenia; 58 pairs
of DZ twins without schizophrenia. Verbal fluency was assessed using tests
of phonemic and semantic fluency, and mental flexibility was assessed using
Trail Making Test (TMT) indices: A, B and B-A. Regression analysis sug-
gested that genetic loading for schizophrenia was positively associated with
broader and more severe impairment in executive functioning tasks. Ge-
netic modelling indicated that genetic influences contribute substantially
to all of the executive measures, with phonemic fluency being most heritable
followed by semantic fluency and TMT B-A. Significant phenotypic cor-
relations with schizophrenia were found for all executive functioning meas-
ures. Genetic factors were the main source of the phenotypic correlations, in
particular for mental flexibility. For example, shared genetic variance
accounted for 91% of the phenotypic correlation (rph = 0.48; 95% CI =
0.38 to 0.55) between TMT-A and schizophrenia. Environmental effects,
although separately linked to neurocognition and schizophrenia, did not
generally contribute to their covariance. The strongest genetic correlation
with schizophrenia was found for mental flexibility followed by semantic
and phonemic verbal fluency. A high genetic correlation suggests that the
same genes contribute to individual differences in both executive function-
ing and to the liability to schizophrenia. Bivariate genetic model fitting sug-
gests that executive functioning is a potentially valid endophenotype
for schizophrenia. The inclusion of these phenotypes in linkage or associ-
ation analysis could improve the power to detect susceptibility genes for
schizophrenia.
ID: 548041
ENDOPHENOTYPIC STRATEGY FOR SCHIZO-
PHRENIA: AN ILLUSTRATIVE EXAMPLE WITH
NEUROLOGICAL SOFT SIGNS
Raymond Chan
Institute of Psychology, Chinese Academy of Sciences, Beijing,
China
Incontrovertible evidence for epidemiological genetic influences on schizo-
phrenia has been accumulated since the 1960’s (Rosenthal and Kety, 1968;
McGuffin, Owen, and Gottesman, 2004). However, the identification of
specific genes with large effect sizes that contribute to a susceptibility
to schizophrenia has not been successful using conventional molecular
genetic approaches. Therefore, researchers have been adopting a new di-
rection that identifies neurobiological and neurobehavioural characteris-
tics associated with schizophrenia, so-called ‘‘endophenotypes’’
(Gotttesman and Gould, 2003; Gottesman and Shields, 1972) that
may be more closely connected to the expressions of un-named genes
(Bray et al. 2008). A substantial number of studies, especially of at-
risk offspring, have suggested that neurocognitive dysfunctions are
among the most promising of the candidate endophenotypes. On the
other hand, the crucial role of neurological indicators in schizophrenia
has been recognized as among the ‘‘target features’’ that encompass the
idea that genetic and non-genetic processes lead to neurointegrative
defects later manifested in neurocognitive systems. In addition, aberrant
neurological indicators have also been suggested as potential endophe-
notypes in schizophrenia. In this presentation, we will argue with sub-
stantial evidence for the utility of quantifiable neurological soft signs as
potential endophenotypes for schizophrenia spectrum disorders. We start
by defining endophenotypes and justifying their utility. We highlight the
key criteria that must be met for an endophenotype to be useful and
assess the extent to which the manifestations of neurological soft signs
meet these criteria. Finally, recommendation for additional research is
made in order further elucidate the potential use of neurological soft
signs for schizophrenia research. Acknowledgements: The author was
supported by the Research Fund from the Institute of Psychology, Chi-
nese Academy of Sciences (KSCX2-YW-R-131), a grant from National
Science Foundation of China (30770723) and National Basic Research
Programme of China (973 Program) (2007CB512305), and the NARSAD
Young Investigator Award.
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ASSOCIATIONS BETWEEN COMT VALMET
GENOTYPE AND CLINICAL AND COGNITIVE
PHENOTYPES IN MANIC BIPOLAR PATIENTS
Arpi Minassian, J. R. Kelsoe, M. P. Paulus, M. A. Geyer,
W. Perry
Psychiatry, University of California, San Diego, San Diego,
CA, USA
The catechol-o-methyltransferase (COMT) Val158Met polymorphism has
been widely studied in relation to cognition in schizophrenia (SCZ), with
the preponderance of the literature suggesting that the Valine (Val) allele of
this gene is associated with cognitive inflexibility, eg, perseverative behav-
ior. The COMT gene has been studied relatively less in bipolar disorder
(BD) and few direct comparisons between BD and SCZ with respect to
COMT-phenotype relationships have been reported. There is some evi-
dence that COMT may confer different degrees of liability for clinical pre-
sentation and cognitive problems depending on diagnosis. The current
study examined symptom presentation, cognitive markers, and genotypes
for the COMT Val158Met polymorphism in BD patients hospitalized for
a manic episode. Manic BD subjects were genotyped and administered the
Brief Psychiatric Rating Scale (BPRS). They were tested in a sensorimotor
gating paradigm (prepulse inhibition: PPI) as well as a human open field
paradigm designed to quantify exploratory behavior, the human Behav-
ioral Pattern Monitor (BPM). Data collection is ongoing; preliminary
results indicate that manic BD Met/Met homozygotes scored higher on
BPRS ratings of mania and uncooperativeness than did patients who
were Val carriers (heterozygotes or Val homozygotes). Met homozygotes
had increased PPI in one of three PPI conditions compared to Val carriers.
In the BPM, Val homozygotes showed more perseverative exploratory be-
havior, as evidenced by more localized, restricted movements during the
latter part of the BPM session, than Met carriers (Spearman’s rho =
.81, P = .02). These initial findings suggest that, in BD, the Met allele
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may be associated with greater liability for symptoms of overactivation
and agitation and may be protective against the sensorimotor gating def-
icits that are typically seen in this population. The Val allele, as in SCZ,
may confer liability for cognitive inflexibility, perhaps because it contrib-
utes to low dopaminergic tone in frontal systems. The identification of ge-
notypic and phenotypic features that are shared by BD and SCZ versus
features that are unique to each illness has implications for the develop-
ment of novel therapeutics for these conditions, and will also contribute
to the burgeoning understanding of the overlapping and distinguishing ge-
notype-phenotype relationships in psychopathology. Supported by a NAR-
SAD Young Investigator Award and R01-MH071916.
ID: 546158
ARE INTELLIGENCE AND MEMORY GOOD
ENDOPHENOTYPES FOR SCHIZOPHRENIA?
GENETIC MODELS IN A HARVARD, IOP, AND NIH
COLLABORATION
Timothea Toulopoulou1,7, T. Goldberg2, D. R. Weinberger3,
F. Rijsdijk1, S. Faraone4, M. Tsuang5, D. Stahl1, M. Picchioni1,
P. Sham6, S. Cherney6, R. Murray1, L. Seidman7
1Institute of Psychiatry, King’s College London, London, United
Kingdom; 2Zucker Hillside Hospital, New York, NY, USA; 3Na-
tional Institute of Mental Health, Bethesda, MD, USA; 4SUNY
Upstate Medical University, New York, NY, USA; 5University of
California, San Diego, CA, USA; 6Hong Kong University, Hong
Kong, China; 7Harvard Medical School, Boston, MA, USA
Context: Impairments in verbal and visual memory, verbal learning and
intelligence are among the most promising indicators of increased risk
for schizophrenia making them candidate endophenotypes; however it is
not clear to what extent these deficits are genetically linked to the disorder.
Objective: To quantify the net genetic relationship between episodic mem-
ory, learning, intelligence and schizophrenia in a large multi-site data. De-
sign: Family and twin study. Setting: US and UK Research Institutes.
Participants: Data from 2057 individuals were pooled across three sites:
1) Harvard University,USA (2) Institute of Psychiatry,UK and (3) Na-
tional Institute of Health,USA. Of these individuals 657 were patients,
674 1st degree relatives and 726 were controls. Main outcome measur-
es:The heritabilities of memory, learning and intelligence were estimated
and the genetic relationship between each one of these and schizophrenia
quantified. Results: Genetic influences contributed to all cognitive
domains with intelligence showing the highest heritability (h2 = 0.69)
and immediate recall of verbal memory the least (h2 = 0.30). Significant
genetic correlations were found between schizophrenia and 1) immediate
(I)/delayed (D) verbal recall (I: 0.96; D: 0.94); 2) I/D verbal learning (I:
0.47; D: 0.30) and 3) I/D visual recall (I: 0.62; D: 0.68) suggesting
that schizophrenia and these measures share to some extent the same genes.
When the heritabilities of these measures were taken into account, intel-
ligence showed the biggest phenotypic correlation with schizophrenia
(.49) with shared genetic influences explaining chiefly the phenotypic
co-variance. Conclusion: Unlike molecular genetic approaches which esti-
mate the extent to which allelic variation explains endophenotypic vari-
ance, genetic modeling quantifies the net shared genetic influences
between the candidate endophenotype and the illness, giving a broader
view of the degree of genetic overlap between the two. Supporting our pre-
vious work in twins (Toulopoulou et al. 2007) intelligence appears to be the
best endophenotype for schizophrenia sharing the greatest genetic variance
with the illness. Genome wide searches using a bivariate phenotype such as
schizophrenia and intelligence should assist in the search to find quantita-
tive trait loci for schizophrenia.
ID: 546054
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GENETIC ASSOCIATIONS BETWEEN
NEUREGULIN-1 AND COGNITION IN A -
MULTIPLEX SCHIZOPHRENIA FAMILY STUDY
Jessica L. Yokley1, K. Prasad2, K. V. Chowdari2,
M. E. Talkowski2, R. C. Gur3, R. E. Gur3, L. Almasy4,
V. L. Nimgaonkar2, M. F. Pogue-Geile1
1Psychology, University of Pittsburgh, Pittsburgh, PA, USA;
2Psychiatry, University of Pittsburgh Medical Center, Pittsburgh,
PA, USA; 3Psychiatry, University of Pennyslvania School of
Medicine, Philadelphia, PA, USA; 4Southwest Foundation for
Biomedical Research, San Antonio, TX, USA
Recent work shows a potentially promising relationship between schizo-
phrenia and variation in the gene Neuregulin-1 (NRG1). A large literature
has also found strong familial relationships between schizophrenia and cog-
nitive deficits. Given the role of NRG1 in glutamate regulation, we hypoth-
esize that cognitive deficits may be related to sequence variation within
NRG1, thus providing a possible mechanism by which NRG1 could act
as a susceptibility gene for schizophrenia. This question was examined using
a multigenerational multiplex family sample (419 individuals from 40 fam-
ilies), including 58 affected participants (schizophrenia or schizoaffective
disorder, depressed type) and their 361 unaffected and 35 affected relatives.
Participants were genotyped using the SNPlex procedure for 38 NRG1 sin-
gle nucleotide polymorphisms (SNPs) that had previously been reported to
be associated with schizophrenia. In addition to diagnostic interviews, par-
ticipants were administered a previously validated computerized neurocog-
nitive battery that assessed eight cognitive domains, including: abstraction/
mental flexibility, attention, verbal/facial/spatial memory, spatial and emo-
tional processing, and sensorimotor dexterity. Pedigree-based variance
component quantitative trait analyses using the SOLAR computer pro-
gram were performed to test for genetic associations between individual
NRG1 SNPs and cognitive performance. In the full sample of affected
and unaffected individuals, each cognitive domain had at least one signif-
icant SNP association, except spatial memory. The average number of sig-
nificant associations within domains was 5.875. These associations were
spread throughout the gene, including intronic and exonic areas, as well
as upstream and downstream regions. Of the SNPs with at least one sig-
nificant association, the range of associations was between one and
four. No individual SNP was significant across all domains. When adjusted
for multiple comparisons by a very conservative Bonferroni correction (P<
.00016), two associations remained significant. These findings lend support
for several previously reported associations between NRG1 SNPs and
schizophrenia and suggest that one of the mechanisms by which NRG1
may contribute to risk for schizophrenia may be via its role in general cog-
nitive function. Future directions include multivariate analyses of cognitive
variables and SNPs.
ID: 550835
PSYCHOTIC-LIKE SYMPTOMS IN CHILDREN WITH
22Q11 DELETION SYNDROME
Eva Chow1,2, A. Ho1, S. Langlois3, A. S. Bassett1,2
1Centre for Addiction and Mental Health, Toronto, ON, Canada;
2Psychiatry, University of Toronto, Toronto, ON, Canada; 3Medical
Genetics, BC Children’s Hospital, Vancouver, BC, Canada
22q11.2 Deletion Syndrome (22qDS) is associated with a high prevelance of
Attention Deficit Hyperactivity Disorder (;40%) and anxiety disorders
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(;25%) in childhood and schizophrenia in adulthood (;25%). Previous
studies have reported the presence of psychosis or psychotic-like symptoms
in some children with 22qDS, but the rates varied. Some clinicians have
successfully managed the psychotic-like symptoms with anti-anxiety
agents. We systematically assessed 36 Canadian children with 22qDS,
and 13 of their unaffected siblings, between the ages of 8 and 12 for presence
of psychosis and recurrent psychotic-like symptoms (illusions, paranoia or
other overvalued ideas, usual thought form). We found 5 of the 36 (13.9%)
22qDS children had psychotic-like symptoms. This rate however was not
significantly different from the 15.4% rate in their siblings. Within the
22qDS group, those with psychotic-like symptoms did not differ in
mean IQ, rates of ADHD, or anxiety disorders. However, they are more
likely to be reported as ‘‘would rather be alone’’ and be ‘‘fearful’’ on
the Childhood Behavioural Checklist than 22qDS subjects without
psychotic-like symptoms. Results do not support an increased rate of psy-
chotic-like symptoms in children with 22qDS when compared to their
siblings, but those children with psychotic-like symptoms have other
symptoms that may be consistent with prodromal symptoms of
schizophrenia.
ID: 551886
PHARMACOGENETIC OPPORTUNITIES AND
CHALLENGES TO ADDRESS ANTIPSYCHOTICSIDE
EFFECTS
Christian Lavedan
Vanda Pharmaceuticals, Rockville, MD, USA
The variability in the response to antipsychotic agents is a serious chal-
lenge in the treatment of patients affected by schizophrenia. Patient re-
sponse remains unpredictable and the discontinuation rate is high.
Antipsychotics are associated, at different degrees, with a risk of various
side effects that include movement disorders such as akathisia and EPS,
metabolic disorders such as weight gain, dyslipidemia, prolactin elevation,
and QT prolongation. These adverse events present specific challenges but
also opportunities for pharmacogenetic studies. For each unwanted effect,
treatment response is a complex phenomenon resulting from a multitude
of elements that may include the severity of the disease, the individual’s
age, sex, race, concomitant illnesses and therapies, and most likely various
genetic factors. It is important to note that these genetic factors may in-
dividually contribute to only a small portion of the observed variability in
inter-individual response, which makes not only their discovery, but also
their clinical application challenging. Furthermore, while certain polymor-
phisms may play a similar role in the response of various antipsychotics,
we must also recognize that differences between drugs in receptor binding
profiles, chemical and metabolic characteristics may also lead to the dis-
covery of genetic factors unique to each drug. The field of Pharmacoge-
netics has rapidly evolved since the completion of the Human Genome
Project and is now providing opportunities to identify patients with the
greatest chance of benefiting from a particular treatment while minimizing
the risk of unwanted side effects. Candidate gene analysis and, most re-
cently, whole genome association studies have been applied to identify
DNA variants that affect drug response, and have already identified
a number of promising markers. The acceptance of predictive genetic
markers in clinical practice will necessitate the validation of their clinical
value, as well as the practical utilization of the comprehensive information
they provide. Currently, there is no standard approach to determine the
effect of multiple genetic markers in the response of a drug treatment. As
a result, it has become crucial to develop methods to combine the infor-
mation gathered from all relevant biomarkers. This will provide a clear
interpretation and therefore an easier implementation in clinical practice
of the genetic information which may otherwise be viewed as too complex
or unpractical.
ID: 551871
TEMPERAMENT AS A DISCRIMINATING MARKER
OF GENETIC LIABILITY FOR SCHIZOPHRENIA
AND BIPOLAR DISORDER
Amy M. Jimenez1, M. D. Lieberman1, C. M. Hultman2,
T. D. Cannon1,3
1Psychology, University of California at Los Angeles, Los Angeles,
CA, USA; 2Karolinska Institute, Stockholm, Sweden; 3Psychiatry
and Biobehavioral Sciences, University of California at Los Angeles,
Los Angeles, CA, USA
Socio-emotional deficits are among the most debilitating features of
both schizophrenia (SCZ) and bipolar disorder (BD). It is well known
that both disorders are highly heritable and a growing body of molec-
ular genetics research suggests there may be some overlap in genetic li-
ability for them (Ivleva et al. 2008). However, few investigations into
whether socio-emotional processing deficits may confer genetic liability
for these disorders, as well as the nature of the phenotypic overlap be-
tween them, have been conducted to date. To address this, we examined
similarities in temperament between SCZ and BD probands, their dis-
cordant co-twins, and healthy control twin pairs. Research indicates that
temperament is largely heritable, with individuals differences present
very early in life and remaining relatively stable over time (eg, Gold-
smith et al. 1997). Our aim was to examine whether certain inherited
temperaments confer increased risk for development of these disorders.
We also sought to develop a statistical model which identifies which
specific temperament dimensions discriminate between patient groups
and which (if any) are common to both. Through factor analysis we
identified two temperament factors by which to compare the groups:
schizotypy/dysthymia (Factor 1) and cyclothymia/impulsivity (Factor
2). We hypothesized that individuals with SCZ would score high on
Factor 1 and that scores of their non-affected co-twins and healthy con-
trols would decrease in step-wise fashion as genetic liability for the disorder
decreased between those groups. We predicted the same pattern of results for
BDonFactor2.Consistentwithourpredictions, individualswithSCZscored
significantly higher than healthy controls on Factor 1 (P< .05) and the scores
oftheirco-twinsfell in-betweenscoresof thosetwogroups.OnFactor2asim-
ilar trend in the datawas seen(BD>controls;P< .01,unaffectedco-twins in-
between). Unlike Factor 1, scores on Factor 2 were significantly higher for
both patient groups compared to healthy controls. Taken together, these
findings indicate that a schizotypal, depressive temperament is associated
with increased genetic liability for SCZ, and that such a temperament tends
to discriminate between SCZ and BD. On the other hand, a cyclothymic, im-
pulsive temperament is associatedwith increasedgenetic liability for BD, and
this temperament may constitute an example of phenotypic overlap between
the two disorders.
ID: 551861
A CANNABINOID-1 (CB-1) RECEPTOR GENE
VARIANT IS ASSOCIATED WITH CLOZAPINE
AND OLANZAPINE INDUCED WEIGHT GAIN IN
SCHIZOPHRENIA
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Introduction: Clozapine and olanzapine have been associated with sub-
stantial weight gain in many patients. However, an individual’s propensity
to develop weight gain largely depends on genetic factors. A possible mech-
anism may involve the endocannabinoid system which has been implicated
in the regulation of appetite signalling and food intake through the dorsal
vagal complex (DVC) of the brainstem. Animal models have shown that
olanzapine significantly decreased cannabinoid receptor binding in the
DVC (Weston-Green et al. 2008). Furthermore, the cannabinoid-1
(CB-1) receptor antagonist rimonabant has been shown to induce weight
loss. The purpose of this study has been to analyze whether variants (SNPs)
of the CB-1 receptor gene potentially modulating the endocannabinoid sys-
tem were associated with antipsychotic induced weight gain. Methods: We
have been genotyping several SNPs in a larger sample of antipsychotic in-
duced weight gain using three different samples from the US (A, B and C;
total n = 139) and one sample from Germany (D; n = 70; total n = 209),
mainly treated with clozapine and olanzapine on average for 11 weeks.
Mean weight gain was compared across the genotypic categories using
ANOVA as well as ANCOVA including baseline weight or sex as covari-
ate. Results: Mean weight gain in the sample was þ 4.01 kg (6 4.77 kg). In
the sample of Europeans (n = 123), carriers of the C/C genotype of the
promoter region SNP rs806378 gained only þ2.3 kg as compared to C/
T and T/T carriers who gained on average 4.2 kg. This association was
significant when corrected for baseline weight (P = .049). We then ex-
cluded those patients who received medications other than clozapine or
olanzapine and found a more significant association (F2,72 = 4.48, P =
.01 where homozygotes for T/T gained 6.25 kg as compared to 1.93 kg
in homozygotes for C/C carriers. The most significant finding was then
obtained when examining only patients treated with clozapine F2,61 =
7.49, P = .001. Results remained unaltered when including covariates
such as baseline weight or sex. Summary: In conclusion, our studies sug-
gest that a promoter variant of the CB-1 receptor gene is associated with
clozapine and olanzapine induced weight gain. We are currently expand-
ing our analyses with including a total of 10 tag SNPs spanning the entire
CB-1 gene. These findings may have important implications for discovery
of novel antipsychotic drug targets that do not result in weight gain side
effects.
ID: 551853
FAMILIAL AND CAS-CONSTROL ASSOCIATION
STUDIES OF POSITIONAL CANDIDATE GENES
AT 6P23-P22 FOLLOWING FURTHER LINKAGE
EVIDENCE FROM EASTERN QUE´BEC POINTS
TO MYLIP
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M. Cayer1, M. Maziade1,2
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Objectives: To test for linkage to schizophrenia (SZ) in the 6p23-p22 re-
gion while taking into account heterogeneity with the 13q13-q14 locus,
and to follow-up with an association study of single nucleotide polymor-
phisms (SNPs) across the region. Methods: A sample of 31 extended ped-
igrees informative for SZ and a sample of 247 unrelated SZ cases and
207 controls, all from the Eastern Quebec population. Parametric two-
point linkage analysis of microsatellite markers was performed on the
kindred sample, using an ordered subset analysis to take into account
heterogeneity with our former linkage finding at 13q13-q14. Pearson
v2 tests of allelic and genotypic association and score tests of haplotypic
association were performed on 279 SNPs from an expanded Illumina
HumanHap 300 SNP array and 10 candidate SNPs in the case-control
sample. A subset of these SNPs were typed in the family sample and
analyzed with family-based association tests (FBATs). Results: A max-
imum lod score of 4.03 was obtained with marker SCA1 in a sub-sample
of 16 families showing no linkage with to 13q13-q14. The strongest as-
sociation signals in the case-control sample were observed for SNPs
rs2876407 and rs2142672 near the MYLIP gene with false discovery
rate (FDR) of 0.17. Consistent association of SZ to the A/A genotype
of rs9370867, a Ser342Asn amino-acid change in the MYLIP protein,
was observed in the case-control sample (P = .02, FDR = 0.29) and
to a lesser extent in the 16-kindred sub-sample (P = .10). Association
to a 5-SNP haplotype in DTNBP1 was also observed in the full kindred
sample (FDR = 0.03). Conclusions: In our kindred sample, evidence of
linkage to 6p23-p22 is stronger in kindreds not linked to 13q13-q14 sug-
gesting genetic heterogeneity. Association to DTNBP1 may not fully ex-
plain the linkage signal, and another gene is likely involved. Our
association results do not conclusively identify that possible other gene,
but consistency of association between the case-control and family sam-
ples points to MYLIP, evidence from the latter sample stemming princi-
pally from families yielding linkage at 6p.
ID: 551852
ZNF804A, THE TOP HIT IN THE LARGEST GWAS
TO DATE, INFLUENCES PERFORMANCE IQ IN
SCHIZOPHRENIA CASES AND HEALTHY
CONTROLS
James Tynan Rhys Walters1, M. J. Owen1, G. Donohoe2,
D. Rujescu3, M. O’Donovan1
1Psychological Medicine, Cardiff University, Cardiff, United
Kingdom; 2Department of Psychiatry and Institute of Molecular
Medicine, Trinity College Dublin, Dublin, Ireland; 3Department of
Psychiatry, Ludwig-Maximilians-University, Munich, Germany
The ZNF804A locus (rs1344706) exhibited the strongest evidence for as-
sociation in the largest Genome Wide Association study to date (O’Dono-
van et al. Molecular Genetics of Schizophrenia Collaboration, 2008). The
encoded protein of ZNF804A is unknown and has no known function.
This study sets out to examine the influence of the ZNF804A SNP,
the top hit in the GWAS, on IQ tests in schizophrenia cases and healthy
controls. 251 schizophrenia cases and 1473 healthy controls were assessed
using the 11 subtests of the WAIS-R and verbal, performance and full
scale IQ scores calculated. The top hit SNP of ZNF804A from the
GWAS (rs1344706) was used to determine genotype groups (T = risk al-
lele). MANOVA using genotype and case/control status as fixed factors
was used to analyse the IQ results. Bonferonni correction was employed to
adjust for the use of the multiple IQ measures. MANOVA indicated an
effect of genotype on tests of digit symbol coding (F = 6.18, P = .002 (ad-
justed P = .028)), performance IQ (F = 6.31, P = .0018(adjusted P = .025))
and full scale IQ (F = 5.95, P = .003(adjusted P = .042)). Post hoc analysis
showed homozygous carriers of the T risk allele at rs1344706 performed
significantly better than homozygous carriers of the G allele on all 3 of
these tests. In separate case and control analysis the results hold for digit
symbol coding in cases (F = 3.12, P = .04) and controls (F = 3.63, P = .03)
and for performance IQ in cases (F = 3.73, P = .025) and controls (F = 4.0,
P = .018) all in the same direction of effect. The risk allele at the ZNF804A
locus seems to be protective for cognitive deficits in performance IQ meas-
ures in cases and controls. In the original GWAS the ZNF804A signal was
strengthened by inclusion of cases with bipolar disorder. Taken with the
results of this study this could indicate that this gene confers risk to a form
of psychosis which spares cognitive function.
ID: 551802
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NIACIN RECEPTOR VARIANTS INFLUENCE
NIACIN SKIN SENSITIVITY
Stefan Smesny1, P. Sand2, A. Ko¨hler1, C. Schneider1, M. Rudzok1,
U. Cyriax1, H. Sauer1
1Department of Psychiatry, University of Jena, Jena, Germany;
2Department of Psychiatry, University of Regensburg, Regensburg,
Germany
Introduction: Attenuated flush response to local methylnicotinate (AMN,
niacin) skin stimulation represents one of the most commonly replicated
peripheral biological parameters in schizophrenia. Skin response is medi-
ated by a pathway involving G protein-coupled nicotinic acid receptors
(GPR109A and GPR109B) at epidermal Langerhans cells,
Ca26dependent expression of prostaglandin synthetases, and formation
of vasodilatory prostaglandins acting on skin arterioles. The ‘‘precursor
deficiency hypothesis’’ posits that deficient flush response in schizophrenia
relates to an innate depletion of polyunsaturated fatty acids and disturbed
prostaglandin signalling. AMN challenge may thus serve as a surrogate
marker of phospholipid repair and remodelling processes, anti-oxidative
defense and inflammatory response. The present investigation addresses
polymorphisms of GPR109A and GPR109B niacin receptor genes and
their impact on skin phenotype to assess functionally relevant DNA var-
iants as contributing co-variate. Method: AMN (0.1M, 0.01M, 0.001M)
was applied to the skin of the volar forearm in 31 neuroleptic-naı¨ve
first-episode schizophrenia patients (SCH) and 31 healthy controls
matched for age and gender. Skin colour response was recorded at three
min intervals over 15 min using optical reflection spectroscopy. Buccal
swabs were obtained for amplification of genes encoding the high-affinity
GPR109A and the low-affinity GPR109B niacin receptor by a PCR-based
assay. Results: 20 SNPs were identified in 2 kb of genomic sequence. Two
rare missense variants of GPR109B (T173P and F198L) were detected for
the first time in SCH. Exonic SNPs modulated niacin sensitivity with at-
tenuated skin response in homocygotic carriers of rare alleles. Conclusion:
These results suggest a contributory role of GPR109 gene variants to in
niacin sensitivity, and call for further investigation of these markers’ role
in schizophrenia.
ID: 551784
MICROARRAY GENE EXPRESSION ANALYSES IN
THE HIPPOCAMPUS AND PREFRONTAL CORTEX
OF PATIENTS WITH SCHIZOPHRENIA
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Schizophrenia is a complex genetic disorder and may involve many genes.
Most microarray studies have examined changes in gene expression in
postmortem brain samples by comparing matched pairs of patients
with schizophrenia and controls. We applied a different approach. We
compared approximately 27 000 genes and ESTs in postmortem brain
samples from specific brain regions (hippocampus and prefrontal cortex)
in control subjects and patients with schizophrenia to a pooled brain sam-
ple. For each microarray experiment, fluorescence ratios of Cy5/Cy3 were
derived by comparing samples (control and schizophrenic) to the common
pooled brain reference. By comparing each sample to the pooled brain
RNA, it was possible to compare differences in ratio measurements in
gene expression profiles between control and patient brains. A roster
of cDNAs that exhibited more than 2-fold expression level changes
was generated. Three approaches were used to analyze the fluorescence
intensity data. First, the actual lists of differentially expressed genes iden-
tified in each data set was examined, and a list of genes determined to be
differentially expressed in that data set was defined. A given gene was
considered to be differentially expressed if the absolute value of the
log2 of its average fluorescence ratio was greater than 1.0. In the second
approach, all genes in each list was ranked according to the absolute value
of its fold-change measurement by comparing normal brain region to
schizophrenic brain region. Finally, overlap in the lists of differentially
expressed genes in the two brain regions (hippocampus and cortex) be-
tween normal and schizophrenic individuals was generated. In the hippo-
campus eighty seven genes/ESTs were downregulated and seventy four
genes/ESTs were upregulated in subjects with schizophrenia compared
to controls. In the schizophrenic prefrontal cortical region, nineteen
genes/ESTs were upregulated and twenty genes/ESTs were downregu-
lated. Six genes/ESTs were upregulated and eleven genes/ESTs were
downregulated in both brain regions from patients compared to controls.
Currently, studies are in progress for more detailed follow up analyses of
genes of interest.
ID: 551749
RETHINKING PSYCHOSIS
Nick Craddock
Psychological Medicine, Cardiff University, Cardiff, United
Kingdom
It has been conventional for psychiatric research, including the search for
predisposing genes, to proceed under the assumption that schizophrenia
and bipolar disorder are separate disease entities with different underlying
etiologies. These represent the traditional dichotomous classification of
the so-called ‘‘functional’’ psychoses and form the basis of modern psy-
chiatric diagnostic practice. Recently positive findings have been emerging
in molecular genetic studies of psychoses. However, the pattern of find-
ings shows increasing evidence for an overlap in genetic susceptibility
across the traditional classification categories—including association find-
ings at DISC1 and NRG1. Genome-wide association studies (GWAS)
now provide greater power to explore the relationship between mood
and psychotic illness. We have undertaken molecular genetic studies in
large samples of UK individuals with bipolar disorder and schizophrenia,
including intensive study of individual candidate genes and, most recently,
genome-wide association studies (500 000 SNPs) in 2700 mood-psychosis
cases and 3000 controls. This latter study was conducted within the con-
text of the Wellcome Trust Case Control Consortium (WTCCC), a ge-
nome-wide association study of 17 000 UK individuals for 7 common
diseases. The emerging evidence suggests the existence of relatively specific
relationships between genotype and psychopathology. For example, in
our dataset variation at GABAA receptor genes is associated with suscep-
tibility to a form of illness with mixed features of schizophrenia and bi-
polar disorder. Genome-wide significant associations at CACNA1C in
bipolar disorder and ZNF804A in schizophrenia show evidence for a con-
tribution to susceptibility across the traditional diagnostic boundaries.
The elucidation of genotype-phenotype relationships is at an early stage,
but current findings highlight the need to consider alternative approaches
to classification and conceptualization for psychiatric research rather than
continuing to rely heavily on the traditional dichotomy. As psychosis sus-
ceptibility genes are identified and characterized over the next few years,
this will have a major impact on our understanding of disease pathophys-
iology and will lead to changes in classification and the clinical practice of
psychiatry.
ID: 551721
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ASSOCIATION BETWEEN A POLYMORPHISM IN
THE DYSBINDIN GENE AND BRAIN VOLUME
MEASURES IN SCHIZOPHRENIA
Eric Alan Epping; B. C. Ho; N. C. Andreasen; T. H. Wassink
Psychiatry, The University of Iowa, Iowa City, IA, USA
Polymorhisms in the dysbindin gene (DTNBP1) have been associated with
cognition and symptoms of schizophrenia, however, little is known regard-
ing the contribution of these variants to brain morphology. In this study,
the single nucleotide polymorphism (SNP) rs1018381 (C/T) in DTNBP1
was genotyped in a sample of 241 individuals with schizophrenia spectrum
disorders and 100 healthy controls with available brain MRI data. The T
allele of this intronic SNP has evidence for association with schizophrenia
and is also contained within a schizophrenia-associated haplotype, al-
though no significant differences in genotype or allele frequencies at
rs1018381 were observed in this sample. Cortical brain gray and white
matter MRI volumes (total, frontal, temporal, parietal, and occipital)
were measured using automated methods. Analysis of covariance was
used to test the hypothesis that variation of this SNP is associated
with differences in cortical brain volumes, with volume measurement as
the independent variable and genotype as the dependent variable. Cova-
riates included gender, age, total intracranial volume, and diagnostic cat-
egory. An additional MRI scan protocol covariate was included in the
analyses as two different image acquisition protocols were used during
the time that MRI scans were obtained. Genotype and allele frequencies
were not significantly different between patient and healthy control
groups. A significant genotype by diagnosis effect was observed for frontal
gray matter (F = 3.94, P < .05). In healthy controls, T allele carriers had
larger frontal gray matter volumes compared to CC homozygotes, how-
ever, the opposite result was found in schizophrenia patients: carriers of
the T allele had smaller frontal gray matter volumes than CC homozy-
gotes. A similar trend was observed for total cortical gray matter (F =
3.46, P = .06) as well as in temporal and parietal gray matter measures.
No significant effects were observed for white matter volumes. These
results are consistent with the involvement of a variant in dysbindin con-
tributing to differences in cortical brain volumes in schizophrenia. Smaller
frontal gray matter volumes in T allele carriers at rs1018381 may indicate
that this variant is not only associated with increased schizophrenia risk,
but also has a negative impact on a brain region involved in the patho-
physiology of the disorder.
ID: 551715
NEUROCOGNITIVE IMPAIRMENTS ARE EVIDENT
AT AGE EIGHTEEN IN YOUTHS AT GENETIC RISK
FOR SCHIZOPHRENIA
Monica E. Calkins1, R. C. Gur1, J. Richard1,
K. E. Borgmann-Winter2,1, C. Kohler1, R. E. Gur1
1Psychiatry, University of Pennsylvania, Philadelphia, PA, USA;
2Psychiatry, Children’s Hospital of Philadelphia, Philadelphia, PA,
USA
Accumulating evidence suggests that neurodevelopmental abnormalities
preceding clinical manifestation of illness are present in youths at-risk
for developing psychosis. Neurocognitive abilities, especially executive, at-
tention and memory dysfunction, are implicated as candidate endopheno-
types of schizophrenia, including through evidence of impairment in adult
relatives. Impaired endophenotype performance in youths deemed at-risk
for schizophrenia bears directly on the endophenotype’s ability to serve as
a marker for early identification and treatment, but the developmental pro-
file of impairments is unclear. As one method of addressing this question,
we evaluated neurocognitive performance across the age span of 18–30
in a large sample of young relatives of schizophrenia patients. Youths
(n = 1082, age 18–30) completed a comprehensive diagnostic assessment
and the University of Pennsylvania Computerized Neurocognitive Battery
(CNB) in the context of NIMH funded multi-site genetics collaborations
(MGI, PAARTNERS, COGS) and local studies. Groups included Genetic
Risk (GR; first-degree relative with schizophrenia, n = 309); schizophrenia
(SCZ, n = 371); and community comparison subjects (CCS, n = 402); mean
age, all groups = 24 yrs. Each group was subdivided into 4 age groups: 18–
21, 22–24, 25–27, 28–30 yrs (n range for each subgroup within group = 70–
122). Collapsed across age groups, SCZ and GR showed significant (all
P’s < 0.05) impairments in accuracy of abstraction/flexibility, attention,
memory (verbal, face, spatial, working), language, spatial ability, and emo-
tion processing. Fewer differences between GR and CCS were observed in
response speed. Especially for accuracy, 18–21 yr olds exhibited the most
prominent differences between GR and CCS. However, GR across age
groups did not differ from each other except in sensorimotor speed, where
28–30 yr olds were slower than younger groups. The results suggest that
candidate neurocognitive endophenotypes reported in adult relatives are
also observable in GR adolescents by age 18–21, and are not substantially
different from those observed in young GR adults aged 22–30. Thus, they
may reflect pathophysiological abnormalities involved in schizophrenia de-
velopment, and may ultimately facilitate early identification of at-risk
youths. As our local longitudinal program grows, we will investigate neuro-
cognition in younger at-risk participants, heritability in at-risk groups, and
prediction of conversion to psychosis.
ID: 551709
THE PREVALENCE OF RISK FACTORS FOR
SCHIZOPHRENIA: IMPLICATIONS FOR STUDY
DESIGN AND PREVENTION
Daniel R. Hanson; I. I. Gottesman
Psychiatry, University of Minnesota, Minneapolis, MN, USA
Many risk factors have been postulated to be contributors (not necessarily
causes) to the development of schizophrenia including genes, birth and
pregnancy complications, season of birth, low SES, inflammatory process,
immigrant status, anoxia, parental age, and head injury to name a few.
Starting with estimates of the base rate of schizophrenia in the general pop-
ulation, mathematical methods are used to develop estimates of the pop-
ulation frequency of etiological agents (genetic and environmental) as
a function of estimates of the number of factors implicated for any one
case. The results indicate that population base rate for each risk factor
is likely to be as high as 30%– 60%. Assuming that contributing factors
are several to many for any one case, and that the contributing factors
are common in the general population, supports the concept of etiologic
heterogeneity among cases—different cases will be the product of different
combinations of common risk factors. The high rates of contributing fac-
tors in the general population will hinder research designs comparing ‘sick’
vs. ‘well’ since many ‘well’ will also have been exposed to the risk factor
under investigation. Similarly, the high rate of risk factors in the general
population will guarantee that these risk factors will be found in non-
schizophrenic psychopathologies in a manner that could be causal or co-
incidental. Sample sizes required to generate adequate power to test group
differences (null hypothesis designs) will need to be in the range of thou-
sands; odds ratios in the range of tens to hundreds. Alternate research strat-
egies that can mitigate these problems, including various forms of family
designs that capitalize on the observed nearly three fold differences in risk
for schizophrenia observed among various classes of first degree relatives of
people with schizophrenia. There is much potential in shifting emphasis
from strategies focused on many and varied and non-specific causal agents
(ie, identifying risk factors) to strategies exploring plausible final common
pathways that lead to clinical syndromes. Treatment and prevention at the
level of risk factors face many roadblocks since many of the risk factors may
not be readily modifiable—we cannot change the season in which a person
is born and cannot undo a prenatal infection. However, we may be able to
International Congress on Schizophrenia Research
114 8. 8. Genetics, Clinical
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
intervene ‘downstream’ from such events if we understand the final com-
mon pathways through which we these events operate.
ID: 551707
A COMMON NEUROCOGNITIVE ENDOPHENO-
TYPE FOR SCHIZOPHRENIA AND BIPOLAR
DISORDER
David C. Glahn1, M. A. Escamilla2, H. Nicolini4, H. Ravento´s3,
L. Almasy5
1Department of Psychiatry, Institute of Living and Yale University,
Hartford, CT, USA; 2Department of Psychiatry, University of
Texas Health Science Center San Antonio, San Antonio, TX, USA;
3Centro de Investigacio´n en Biologı´a Molecular y Celular, University
of Costa Rica, San Jose, Costa Rica; 4Grupo de Estudios Me´dicos y
Familiares Carracci, Mexico City, Mexico; 5Department of
Genetics, Southwest Foundation for Biomedical Research, San
Antonio, TX, USA
Although genetic influences on schizophrenia and bipolar disorder are well
established, localization of the genes responsible for these illnesses has
proven difficult. Given evidence that genes predisposing to psychotic ill-
nesses may be transmitted without expression of the clinical phenotype,
efforts have focused on developing endophenotypes. While several neuro-
psychological measures have been proposed to be endophenotypes for ei-
ther schizophrenia or bipolar disorder, few studies have systematically
assessed neurocognitive tests to determine which tests are sensitive to these
illnesses. Here, we will discuss two of our recent studies designed to ad-
judicate neurocognitive endophenotypes for schizophrenia and bipolar
disorder, respectively. For the schizophrenia study, 269 Latino individuals
were administered a standard neuropsychological battery. 214 of these
were members of families with at least two siblings diagnosed with schizo-
phrenia or schizoaffective disorder. The bipolar study utilized a compara-
ble design and included 708 Latino individuals from pedigrees with
a sibling pair diagnosed with bipolar I disorder or schizoaffective disorder.
Although five measures were found to uniquely model genetic liability for
schizophrenia, digit symbol coding and spatial working memory were the
most sensitive. To assess the specificity of these endophenotypes, perfor-
mance on these measures were compared to family members with bipolar
and unipolar affective disorders. These markers clearly distinguished be-
tween individuals with psychotic illnesses and those with major depression.
A group of partially overlapping neurocognitive tests was found to be sen-
sitive to genetic liability for bipolar disorder in the independent bipolar
sample, including the digit symbol coding task and measures of declarative
memory. Using two samples of extended pedigrees, one selected for schizo-
phrenia and the other for bipolar disorder, we find that neurocognitive
tests are sensitive to genetic risk for these illnesses. Furthermore, some
of these neuropsychological tests appear to be markers for both schizo-
phrenia and bipolar disorder, while others are somewhat more specific
for one illness or the other. Together these data suggest that both common
and unique biological mechanisms are involved in schizophrenia and bi-
polar disorder.
ID: 551672
miRNA EXPRESSION AND FUNCTION IN THE
BRAIN
Clark D. Jeffries
Pharmacy, University of North Carolina, Chapel Hill, NC, USA
In recent years small (about 18–22 nucleotide) RNA molecules have be-
come recognized as important regulators of gene expression. The impor-
tance of microRNAs in brain development and function is indicated by
their high level of brain expression and by their marked regional and de-
velopmental expression patterns. microRNAs are now implicated in the
regulation of neurodevelopment, synaptogenesis, and synaptic function,
as well as in stem cell proliferation and differentiation, immunologic func-
tion, latent viral infection, cell cycle control, and other gene regulation sys-
tems. In point of fact, microRNAs seem to be fine-tuning controls for the
general management of protein production. The purpose of this presenta-
tion will be to discuss the unifying concepts and pathways discovered by
microRNA researchers. This presentation will include an overview of
microRNA function. Special emphasis will be afforded to microRNA
mechanisms in neurogenesis and neural differentiation, synaptic plasticity,
and the potential role of microRNA gene regulation systems implicated in
schizophrenia.
ID: 551658
AN ASSOCIATION BETWEEN BDNF GENE
POLYMORPHISM (VAL66MET) AND COGNITIVE
IMPAIRMENTS IN SUBJECTS DIAGNOSED
WITH SCHIZOPHRENIA, AND BIPOLAR I WITH
PSYCHOTIC FEATURES
Darko Dodig, R. Gonzalez, E. Ivleva, D. Cole, A. Moates,
C. Tamminga
Psychiatry, UTSW Medical Center, Dallas, TX, USA
Background: BDNF (Brain-Derived Neurotrophic Factor) plays an im-
portant role in plasticity in the CNS.There is evidence that BDNF can
induce the transformation of early to late-phase LTP (long-term potenti-
ation), and inhibition of BDNF signaling impairs LTM (long-term mem-
ory). Recent findings suggest that BDNF single nucleotide polymorphism
is involved in pathogenesis of different psychiatric diseases including
schizophrenia. Recently, a single nucleotide polymorphism in BDNF gene
(Val66Met), has been associated with memory impairment, and suscep-
tibility to psychiatric diseases. Hypothesis and specific aim: This
preliminary study will test the associations between Val66Met genotype
and neuropsychiatric measures of information processing in subjects diag-
nosed with psychotic illnesses (BP I with psychosis, SZ, and schizoaffective
D/O). We hypothesize that the Met allele will be associated with worse
performance in measures of working memory and executive functioning;
PPI, eye tracking. Methods: Study Description: Subjects were enrolled in
an ongoing phenotyping study at the UTSW Department of Psychiatry’s
Division of Translational Research. Subjects: All subjects have a SCID
DSM-IV-TR diagnosis of SZ, BP me with psychosis, or Schizoaffective
D /O. Genotyping: All subjects included in study will be genotyped for
the Val66Met BDNF polymorphism (rs) Measures of Working Memory:
Digital Symbol Coding, Letter-Number-Sequencing, Spatial Span, Meas-
ures of Executive, Functioning: Wisconsin Card Sorting Test, Trails B
Trail Making Test, Measures of Neuropsychiatric Functioning: PPI
Eye Tracking, Statistical Analyses: We will test for associations between
BDNF genotype (Val/Val, Val/Met, Met/Met) and both clinical and bio-
logic measures of cognitive functioning. One-way ANOVA will be utilized
if the assumptions for parametric analyses are met and Kruskal-Wallis test
if not. All tests of associations will be conducted collectively among all
subjects as well as BP I and schizophrenic separately in order to ascertain
if associations identified are particular to one group or another or if the
associations are noted in both groups. Statement of significance: Although
the genetic transmission of SZ and BP D/O has been hypothesized, no
single gene or genes have been definitively implicated. A possible candi-
date gene is BDNF. Also there are some reports of connection between SZ
and BP with polymorphism BDNF gene.
ID: 551655
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GENOME-WIDE HIGH-DENSITY SNP ANALYSES
USING SPEM ENDOPHENOTYPE SUPPORTS
NRXN3 AS A CANDIDATE GENE FOR
SCHIZOPHRENIA
Ikwunga Wonodi1, L. E. Hong1, O. C. Stine2, P. Lin1, N. Krishna1,
G. K. Thaker1
1Psychiatry, Maryland Psychiatric Research Center, University of
Maryland School of Medicine, Baltimore, MD, USA; 2Epidemiol-
ogy and Preventive Medicine, Genomics Core Facility, University of
Maryland School of Medicine, Baltimore, MD, USA
Neurexins are transmembrane neuronal proteins that function as cell adhe-
sion molecules during synaptogenesis and as receptors for intracellular sig-
naling. a-Neurexins are essential for the localization and function of Ca2þ
channels and NMDA receptors. The proteins are encoded by several genes,
includingneurexin 3 gene (NRXN3), which is oneof the largesthumangenes.
Previous association and gene expression studies implicate sequence varia-
tion in NRXN3 in nicotine, alcohol, and opioid dependence, conditions with
substantial co-occurrence in schizophrenia. Using the highly heritable
smooth pursuit eye movement (SPEM) endophenotype as a between groups
variable, we performed a genome wide association study in schizophrenia
subjects with SPEM deficits compared to healthy controls with no SPEM
deficits (n = 45 in each group). NRXN3 rs12050287 (P = .05 3 10–7) and
rs8007461 (P = .07 3 10–7) were significantly associated with schizophrenia
(OR = 6.96 and 5.64, respectively). First we sought to confirm both SNPs in
a larger sample of 370 subjects (186 with schizophrenia) using schizophrenia
as a phenotype and then, the SPEM phenotype. NRXN3 rs8007461 was sig-
nificantly associated with schizophrenia (v2 = 7.99, P < .02). In addition,
there was a significant SNP by diagnosis interaction effect on SPEM
(P< .03); the NRXN3 genotype significantly affected SPEM in healthy con-
trol (P <.03) but not in schizophrenia subjects. Analyses of NRXN3
rs12050287 were not significant in the larger sample. Additional analyses
were performed in 10 neighboring SNPs and these were not significant. Fur-
thermore, we screened microarray gene expression profiles of NRXN3 tran-
scripts in a separate sample of 32 postmortem cortical specimens (16
schizophrenia and 16 non-schizophrenia controls) obtained from the human
frontal eye fields (FEF), a region associated with SPEM deficits in schizo-
phrenia. Schizophrenia patients had 1.25-fold lower expression of NRXN3
mRNA compared to non-schizophrenia controls (P = .007). Our results pro-
vide the first evidence implicating sequence variation in NRXN3 gene in the
etiopathophysiology of schizophrenia and NRXN3 mRNA expression in
frontal cortex of schizophrenia patients. These results suggest that
NRXN3 might be a candidate gene for neuropsychiatric diseases other
than substance use disorders.
ID: 551644
THE PHYSIOLOGICAL ROLE OF DOPAMINE D2
RECEPTORS UNRAVELED BY USING KNOCK-OUT
MICE
Emiliana Borrelli, M. Ramos, C. De Mei, C. Iitaka
Microbiology and Molecular Genetics, University of California
Irvine, School of Medicine, Irvine, CA, USA
Dopamine (DA) is a major neuromodulator of the central nervous system,
where it regulates very diverse physiological functions ranging from the
control of locomotion to hormone synthesis and release. Consequently,
dysfunctions of the dopaminergic system underlie major neurological
and psychiatric human disorders, such as Parkinson’s disease and schizo-
phrenia. DA elicits its control through the binding to membrane receptors,
which belong to the family of seven transmembrane domain G-protein cou-
pled receptors. Our research focuses on dopamine D2 receptors, one of the
leading actors of the dopaminergic system. Importantly, D2 receptors are
the major target of antipsychotics, this feature together with the major role
of D2 receptors in regulating dopamine synthesis and release, makes this
receptor a strong candidate gene involved in the etiology of schizophrenia.
D2 receptors in vivo have multiple roles. In fact these receptors are present
presynaptically on dopaminergic, cortical and thalamic neurons as well as
on interneurons. The presynaptic localization of D2 has been shown to
modulate release not only of dopamine, but also of other neurotransmitter
such as GABA, acetylcholine or glutamate. At the same time, D2 receptors
have also major postsynaptic functions. In addition, two isoforms of do-
pamine D2 receptors are present in the brain, D2L and D2S, both isoforms
are generated from the same gene by a mechanism of alternative splicing.
Thus, addressing the function of D2 receptors in vivo is very complex. We
have approached this study by generating genetically engineered mice in
which the expression of the dopamine D2 receptors is either abolished
or modified. The biochemical, molecular and behavioral analyses of these
mice are clarifying the physiological role of these proteins in specific D2-
mediated functions. In particular, we have been able to demonstrate that
the two isoforms, D2L and D2S, have different functions in vivo. D2L
appears to have mainly post-synaptic activities while D2S has preponderant
presynaptic release-modulating functions. More recently, we have started
in vivo studies to clearly identify the involvement of pre- versus post-syn-
aptic D2 mediated effects on animal physiology.
ID: 551620
COMT AND MTHFR GENOTYPES ARE
ASSOCIATED WITH NEUROCOGNITIVE
ABNORMALITIES DURING REAL-WORLD
COMPREHENSION IN SCHIZOPHRENIA
Tatiana Sitnikova1,2, J. L. Roffman1,2, S. L. Santangelo1,2,
G. R. Kuperberg3,1, D. C. Goff1,2
1Psychiatry, Massachusetts General Hospital, Boston, MA, USA;
2Psychiatry, Harvard Medical School, Boston, MA, USA;
3Psychology, Tufts University, Medford, MA, USA
Deficits in adaptive goal-directed behavior contribute to disability in
schizophrenia and are linked to a heritable dysfunction in the prefrontal
cortex. Execution and comprehension of behavior may be guided by com-
mon neural systems subserving real-world knowledge. In an ecologically
valid, novel paradigm that assays comprehension of goal-directed behav-
iors, we have previously described an electrophysiological correlate of ab-
normal utilization of specific knowledge critical for adaptive integration of
means in relation to behavioral goals in schizophrenia. The present study
investigated the molecular genetic basis of this abnormality by examining
how it is influenced by COMT and MTHFR genes, known to regulate pre-
frontal function, possibly starting during an individual’s development.
Event-related electrophysiological potentials (ERPs) were recorded while
16 medicated schizophrenia patients and 16 healthy controls viewed video
clips presenting congruous or incongruous target objects in real-world ac-
tivities. All incongruous objects lacked required properties to complete the
conveyed actions, but the incongruous scenes varied in comprehensibility
(eg, ‘using an electric iron in place of a knife in the context of cutting bread’
might be interpreted as ‘warming the bread up’, but, given the properties of
the engaged target object, it was harder to understand the goal of a scene ‘a
dinner fork is used in place of an electric iron in the context of ironing
pants’). This was assumed to place progressively heightened demands on
the prefrontal mechanisms mediating adaptive integration of means in re-
lation to behavioral goals. The results revealed that modulation of the P600
ERP response to target scenes (less comprehensible incongruous > more
comprehensible incongruous > congruous) was larger in controls than
patients. The amplitude of this effect in patients was larger for those
with the Met/Met genotype, relative to other genotypes of the COMT
Val108/158Met polymorphism, and the C/C genotype, relative to other gen-
otypes of the MTHFR C677T polymorphism. We conclude that in schizo-
phrenia, the COMT 108Val and MTHFR 677T alleles, both of which have
been linked to down-regulation of dopamine signaling in the prefrontal cor-
tex, may disrupt neurocognitive mechanisms crucial for flexible integration
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of objects and actions necessary for the attainment of behavioral goals.
Support: NARSAD and NIH.
ID: 551554
RARE GENE COPY NUMBER VARIATIONS ARE
ASSOCIATED WITH SPECIFIC ENDOPHENOTYPES
IN SCHIZOPHRENIA
Curtis K. Deutsch1,3, D. Malhotra4, V. Krause2, S. E. McCarthy4,
O. Krastoshevsky2, M. Coleman2, R. W. Francis1, J. A. Bodkin2,
L. Boling2, J. Cole2, A. Gibbs2, F. Johnson2, J. Lerbinger2,
N. R. Mendell5, J. Sebat4, D. L. Levy2,3
1Eunice Kennedy Shriver Center, Waltham, MA, USA; 2McLean
Hospital, Belmont, MA, USA; 3Department of Psychiatry, Harvard
Medical School, Boston, MA, USA; 4Cold Spring Harbor Labo-
ratory, Cold Spring Harbor, NY, USA; 5SUNY at Stony Brook,
Stony Brook, NY, USA
We performed genome-wide scans for copy number variations (CNVs) to
assess whether rare CNVs were associated with specific schizophrenia-
related endophenotypes. CNVs were assayed using ROMA at a 35kb-
resolution analysis of DNA copy number. Eye-tracking dysfunction
(ETD) and craniofacial dysmorphology were measured using objective,
quantitative methods. ETD assessed impairment of smooth-pursuit eye
movement, and craniofacial dysmorphology analysis focused on an
embryologically-derived measure: the junction of the frontonasal-maxillary
prominence derivatives. Because the brain and face are developmentally
linked, it is plausible that psychopathology and craniofacial dysmorphol-
ogy are causally linked. Both of these endophenotypes are statistically
over-represented among probands with schizophrenia and their first-de-
gree relatives — even among those relatives who were determined to
be psychiatrically normal. All probands in the study (N = 144) met
DSM-IV criteria for schizophrenia or schizoaffective disorder. It was pre-
dicted that rare CNVs would be associated with increased dysmorphology
since genomic disorders often feature craniofacial anomalies. We differ-
entiate here between ‘‘loss’’ CNVs (deletions), which often cause abnor-
malities in the heterozygous state, and ‘‘gain’’ CNVs (duplications), which
may maintain partial or complete genetic function. Of these probands, 35
had rare CNVs: 14 of them deletions and 21 duplications. There was
a marked excess of dysmorphology among probands with deletions
(42.9%), three times the rate among probands with duplications
(14.3%). The converse of the dysmorphology findings emerged for
ETD. Eye-tracking dysfunction was over-represented among probands
with no CNVs (58.7%) compared to those with rare CNVs (34.4%).
This pattern is consistent with previous findings of the independence
of the ETD and craniofacial dysmorphology endophenotypes among
schizophrenic probands and their relatives. ROMA methods with yet
higher resolution are also currently being applied, and these may reveal
previously undetected associations with endophenotypes. It is important
to note that the CNVs observed in this study have not yet been established
as de novo or inherited, a factor that is relevant to models of transmission
in schizophrenia. The results presented here provide the first evidence
among neuropsychiatric disorders that biologically interpretable endophe-
notypes are associated with rare CNVs.
ID: 551529
COGNITIVE AND PERSONALITY STYLES IN TWINS
DISCORDANT FOR BIPOLAR DISORDER
Manasi Sharma, E. Kravariti, F. Kane, S. Kalidindi,
A. Georgiades, P. Tymmes, R. Murray, J. Scott
Institute of Psychiatry, King’s College, London, London, United
Kingdom
Cognitive and personality styles have been implicated in the symptomatic
and euthymic phases of bipolar I disorders, but their role as genetic or en-
vironmental influences on the disorder has not been clearly delineated. The
present study employed a twin study design to examine whether specific
cognitive and personality indices represent state-dependent characteristics
or trait vulnerability markers of Bipolar I disorder. The study included 24
twin pairs discordant for Bipolar I disorder (16 MZ pairs, 8 DZ pairs), and
84 Healthy Controls (57 MZ, 27 DZ). The analysis was also carried out the
total sample of 54 Bipolar I patients and the MZ subgroup (n = 16 twin
pairs). The subjects were administered the following self-report measures:
Rosenberg self-esteem scale, Dysfunctional Attitudes Scale-24 items,
Eysenck Personality Questionnaire, BIS/BAS scale, and Positive and Neg-
ative Affect Scale. Differences in mean scores on these measures were in-
vestigated in patients, high-risk co-twins, and healthy controls across four
comparison analyses, using regression analyses for clustered observations.
Correlations between scores on these self-report measures and mood rat-
ings were also tabulated. None of the cognitive and personality style meas-
ures demonstrated any viability as endophenotypes of Bipolar I disorder.
Instead, the findings suggest that low self-esteem, higher levels of dysfunc-
tional attitudes, elevated psychoticism and neuroticism levels, high BIS ac-
tivity, and high negative affect may be inferred as disorder-related,
environmental factors. This study has implications for clinical research pur-
poses, suggesting that future studies can focus on identifying how combi-
nations of cognitive and personality patterns predispose individuals to, and
subsequently maintain, bipolar affective states. Psychotherapeutic inter-
ventions may thus target to modify these specific thinking styles, since
they do not seem to be unchangeable or genetically inherited.
ID: 551527
KCNH2 AND DOPAMINE RELATED CORTICAL
EFFICIENCY
Daniel R. Weinberger
Genes, Cognition and Psychosis, NIMH/NIH, Bethesda, MD, USA
HERG Kþ channels regulate DA neuronal excitability and HERG1a,
encoded by KCNH2, are targets for antipsychotic drugs, accounting for
the long QT syndrome side affect. In a meta-analysis of 5 independent sam-
ples constituting a total of 367 families, 1158 unrelated cases, and 1704 con-
trols, we found significant and consistent association of SNPs in a 3kb
region of KCNH2 with schizophrenia. Because of the potential role of
this gene in regulating DA activity, we explored the relationship of risk as-
sociated SNPs on cortical physiology related to DA activity in normal sub-
jects. Three of the positive SNPs from the meta-analysis were evaluated in
fMRI paradigms related to prefrontal cortical function (the N back work-
ing memory task, N = 176) and to temporal lobe function (incidental neutral
encoding memory task, N = 74). Risk associated alleles in DA related genes
have previously been associated with inefficient cortical processing during
these tasks. We observed significantly greater activation (FWE correction
P = .05) of the HF within normal risk associated allele carriers of KCNH2.
Normal subjects carrying risk associated alleles also demonstrated signif-
icantly increased activity in an allele load pattern within the DLPFC during
the N back despite the lack of a significant difference in overall task per-
formance (ie, inefficient cortical processing). These data suggest a consistent
association between risk alleles and impairments in the efficiency of infor-
mation processing within two areas of the brain implicated in the patho-
physiology of schizophrenia. The pattern of inefficient processing linked
to risk alleles suggests that DA related function may be the effector of these
physiologic associations. We will present data related to testing interactions
of KCNH2 and other DA related genes, COMT, DAARP, DRD2, and
AKT1.
ID: 551507
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GENETIC OVERLAP BETWEEN MEMORY AND
SCHIZOPHRENIA—THE MAUDSLEY TWIN STUDY.
Annelise Kristin Rodger1, S. F. Owens1, F. V. Rijsdijk2,
M. M. Picchioni1, S. Waters-Metenier1, R. M. Murray1,
T. Toulopoulou1
1Department of General Psychiatry, Institute of Psychiatry, King’s
College London, London, United Kingdom; 2Social, Genetic and
Developmental Psychiatry Centre, Institute of Psychiatry, King’s
College Londion, London, United Kingdom
Episodic memory deficits, both in the visual and verbal modalities, are
a putative endophenotypes for studying the genetics of schizophrenia;
however it is not clear to what extent these deficits are genetically linked
to the disorder. The study aimed to quantify the genetic and environ-
mental contributions to the variability of several memory domains and
to estimate the genetic relationship between these and schizophrenia.
This was a twin design using genetic model fitting. A total of 259 twins
participated in this research: 18 pairs of MZ twins concordant for
schizophrenia; 14 pairs of MZ twins discordant for schizophrenia; 56
pairs of MZ twins without schizophrenia; 9 pairs of DZ twins discor-
dant for schizophrenia; and 39 pairs of DZ twin pairs without schizo-
phrenia. Episodic memory was assessed using Wechsler Memory Scale-
R. Genetic influences contributed substantially to several of the memory
tasks; with logical memory-immediate recall and visual paired associates-
immediate recall being the most heritable. Significant phenotypic corre-
lations with schizophrenia were found for each of the memory measures.
Genetic factors were the main source of the phenotypic correlations, for
example shared genetic variance accounted for 97% of the phenotypic
correlation (rph = 0.46; 95% CI, 0.56 to 0.34) between visual paired
associates-immediate recall and schizophrenia. The strongest genetic cor-
relation with schizophrenia was found for delayed logical memory, fol-
lowed by visual paired associates and immediate logical memory.
Bivariate genetic twin modeling suggests that all three are potentially
valid endophenotypes for schizophrenia. Research into the neuroana-
tomical correlates of memory deficits may illuminate the pathophysiol-
ogy of schizophrenia. The inclusion of these phenotypes in linkage or
association analysis could improve the power to detect susceptibility
genes for schizophrenia.
ID: 551501
ASSOCIATION BETWEEN GRM3 AND GRIN2B
GENE VARIANTS AND SYMPTOMS IN
TREATMENT REFRACTORY SCHIZOPHRENIA
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1Pharmacy Practice and Psychiatry, University of Illinois at
Chicago College of Pharmacy, Chicago, IL, USA; 2Psychiatry,
University of Iowa Carver College of Medicine, Iowa City, IA, USA;
3Pharmacy Practice and Psychiatry, University of Michigan, Ann
Arbor, MI, USA
Purpose: Polymorphisms in the type-three metabotropic glutamate recep-
tor gene (GRM3) and the glutamate receptor ionotropic N-methly-D-as-
partate subunit-2B gene (GRIN2B) have been associated with the
pathogenesis of schizophrenia as well as treatment response. The purpose
of this study was to determine whether the nature of residual psychiatric
symptoms in antipsychotic non-responders is related to polymorphisms
in these two genes. Methods: Ninety-five subjects meeting DSM-IV criteria
for schizophrenia who were treatment refractory (Kane criteria n = 93 or at
least two previous agents n = 2) were enrolled in an IRB approved study
where they were eventually treated with either clozapine or olanzapine.
Prior to medication switch, residual symptoms were assessed using the
BPRS and SANS scales to examine global psychopathology and negative
symptoms, respectively. Participants were 89% Caucasian, 64% male, and
37.96 10.1 years of age. These subjects were genotyped for seven markers in
GRM3 (rs274622, rs274226, rs917071, rs6465084, rs1468412, rs1989796,
and rs1476455) and three markers in GRIN2B (rs7301328, rs1806201,
and rs1805247). Allelic and genotype associations with symptoms was
assessed using permutated (n = 1000) and Bonferroni adjusted P-values.
Results: Genotypes for GRM3 and GRIN2B markers did not deviate
from Hardy-Weinberg Equilibrium, with the exception of rs1468412
(P = 0.023), which has been previously associated with risk for schizophre-
nia. Two markers in GRM3 (rs1989796 and rs1476455) that were in
moderate linkage disequilibrium (D’ = 0.75), were associated with the pres-
ence of residual global symptoms as measured by the BPRS total score
(Bonferroni-adjusted P = .038 and 0.05 respectively) with a false discovery
rate of 0.064 for each. Participants with an rs1476455_CC genotype (n = 73)
had significantly higher BPRS scores than A-carriers (55.1 6 10.4 vs. 48.3 6
9.2; F = 7.6, P = .0071). Additionally, participants with the rs1989796_CC
genotype had significantly higher BPRS scores than T-carriers (50.1 6 5.7
vs. 55.8 6 10.5, F = 7.1, P = .0091). No evidence for significant associations
with negative symptoms was observed with markers in either gene. Conclu-
sions: These data suggest that polymorphisms in the GRM3 gene may be
associated with refractory global psychopathology but not negative symp-
toms in persons with schizophrenia.
ID: 551467
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D2 AND DAT SIGNALING TO HUMAN WORKING
MEMORY PHYSIOLOGY
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Dopamine transmission has long been implicated in the pathophysiology of
schizophrenia and of its associated working memory deficits. Dopamine sig-
naling involves several proteins, including D2 receptors (encoded by the
DRD2 gene) and dopamine transporters (DAT) which are critically impli-
cated in prefronto-striatal physiology. In these brain regions, dopamine
modulation of neuronal activity during memory tasks identifies a non-linear
inverted-U shaped function. Moreover, in vitro studies have demonstrated
that DAT and D2 proteins reciprocally regulate each other presynaptically.
In recent studies we have identified novel functional variants of DRD2 which
modify the distribution of D2 receptor isoforms in the synaptic environment
affecting the physiology of working memory performance and of its related
prefronto-striatal activity in healthy subjects and in patients with schizo-
phrenia. Therefore, we have evaluated the genetic interaction between
a DRD2 polymorphism (rs1076560) causing reduced presynaptic D2 recep-
tor expression and the DAT 3#-VNTR variant (affecting DAT expression) in
a large sample of healthy subjects undergoing BOLD—fMRI during mem-
ory tasks and structural MRI. Results indicated a significant DRD2/DAT
interaction in prefrontal cortex and striatum BOLD activity during both
working memory and encoding of recognition memory. The differential ef-
fect on BOLD activity of the DAT variant was mostly manifest in the context
of the DRD2 allele associated with lower presynaptic expression. Similar
results were also evident for gray matter content in caudate. These interac-
tions describe a non-linear relationship between compound genotypes and
brain activity or gray matter content. Complementary data from striatal pro-
tein extracts from wild-type and D2 knock-out animals (D2R-/-) indicate
that DAT and D2 proteins physically interact in vivo. Taken together,
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our results demonstrate that the interaction between genetic variants in
DRD2 and DAT critically modulates the non-linear relationship between
dopamine and neuronal activity during memory processing. These results
may have implications for modulation of prefronto-striatal pathways during
working memory in schizophrenia.
ID: 551465
PREMATURE DEATH IN ADULTS WITH 22Q11.2
DELETION SYNDROME AND SCHIZOPHRENIA
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Background: 22q11.2 Deletion Syndrome (22q11.2DS) is a common but
under-recognized microdeletion syndrome with multisystem expression
including schizophrenia in one of four adults. About 1 in 100 patients
with schizophrenia have 22q11.2DS. Little is known about longevity
in adults with the syndrome. Methods: We prospectively followed 264
subjects: 102 adults (> 17 years) with 22q11.2DS (44 M, 58 F; mean
age 33.6 SD 10.9 years) and their 162 unaffected siblings (77 M, 85
F; mean age 36.1, SD 12.2 years). 46 subjects with 22q11.2DS and 2
siblings had schizophrenia. We compared survival between groups using
Kaplan-Meier estimates. Findings: Twelve (11.8%; 4 M, 8 F) individuals
with 22q11.2DS died at median age 41.5 (range 18.1–68.6) years. No sib-
lings died (P < .0001). Seven of the deaths were in patients with schizo-
phrenia (median age 44.8, range18.1–56.2 y); only one, a suicide (age 38.2
y), could be attributed directly to the psychiatric disease. Only 50% of
patients had autopsies. Six (50%) deaths were sudden and unexpected, in
patients with schizophrenia (n = 3), major CHD (n = 2), and neither of
these diseases (n = 1). There was no evidence of coronary artery disease
or cancer, or family history of sudden death, in any of the 12 patients
who died. Survival to ages 40 and 50 years was 89.9% and 73.9%, re-
spectively. Survival curves showed non-significant findings when strati-
fied by sex (P = .48), major CHD (P = .25) or schizophrenia (P =
.60). Interpretation: Adults with 22q11.2DS have diminished life expec-
tancy and increased risk of sudden death. Further studies, including de-
tailed post mortem examinations, are needed into pathophysiological
mechanisms that may help identify preventive strategies. Some of the
premature natural deaths in schizophrenia may represent undiagnosed
individuals with 22q11.2DS.
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HIGH FREQUENCY OF RARE GENOMIC
VARIANTS IN SCHIZOPHRENIA
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Copy number variation (CNV) is a major source of genetic diversity among
individuals and is an important risk factor in susceptibility to disease.
Recent work has shown that a substantial proportion of sporadic autism
is associated with rare de novo (ie, spontaneously occurring) CNVs. Work
by our group and others have also found that rare CNVs are significantly
enriched among patients with schizophrenia. Here we examine the associ-
ation between rare CNVs and schizophrenia. We used a 2 100 000-probe
microarray platform to analyze DNA from 150 Caucasian patients who
met criteria for a DSM-IV diagnosis of schizophrenia, 90 of their first-de-
gree biological relatives and 300 controls. Important findings include the
identification of de novo and inherited rare variants, including many
that affect the integrity of genes. Interestingly, several of the CNVs iden-
tified overlap with mutations previously implicated in autism. Some of the
individual genes contained within these CNVs are involved in aspects of
CNS development, including synaptic plasticity, neuronal differentiation,
and signal transduction.
ID: 551458
GENETIC LINKAGE FOR SCHIZOPHRENIA
AND BIPOLAR DISORDER CONFIRMS SHARED
AND SPECIFIC SUSCEPTIBILITY LOCI: THE
IMPLICATIONS FOR REDEFINING PHENOTYPES
Michel Maziade, A. Fournier, M. A. Roy, Y. C. Chagnon,
C. Me´rette
Centre de recherche Universite´ Laval Robert-Giffard, Beauport, QC,
Canada
We have previously published a genome scan (Maziade et al. 2005) on 21
kindreds (Sample 1) for schizophrenia (SZ), bipolar disorder (BP) and
a Common Locus phenotype (CL) which encompasses both SZ and
BP. We performed a nonparametric linkage analysis of a second sample
of 27 kindreds (Sample 2) from the same population in the regions where
Sample 1 had given genome-wide suggestive or significant signals. In ad-
dition to the analysis in Sample 2, we assessed the overall linkage evidence
in the total sample of the 48 kindreds combining Samples 1 and 2. We
have recently reported replication results (Merette et al. 2008) in
16p13.11–p12.3 with a NPLall score of 3.70 obtained in Sample 2 at
marker D16S3060, 3.2 Mb proximal to our initial BP finding in Sample
1. The combined sample yielded a NPLall score of 3.90, maximized for
a subphenotype restricting BP to those with psychotic symptoms. We
now report strong replication results in 13q14.11 for the CL phenotype.
Sample 2 yielded a NPLpair score of 3.36 at D13S1272 (44.0 Mb), just
2.1 Mb telomeric to D13S1247 (41.9 Mb) where the initial finding had
been obtained. The analysis of the combined sample enhanced the evi-
dence with a NPLpair score reaching 5.21 at D13S1297 (42.1 Mb), suggest-
ing a strong concordance in phenotype definition and linkage peak across
samples. Thus our study raises the relevance for redefining phenotypes
given the possibility of two types of genes for major psychoses: one
that confers a general susceptibility shared by SZ and BP, while the other
a specific susceptibility to a subphenotype within BP. This research was
supported by a Canada Research Chair (#950-200810), the Canadian In-
stitute on Health Research (CIHR; #MOP-57919) and the Fonds de la
recherche en sante´ du Que´bec (FRSQ).
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SCHIZOTYPAL DEFICITS AND GENETIC
LIABILITY TO SCHIZOPHRENIA: A MULTIPLEX
FAMILY STUDY
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The development of quantitative scales that maximize sensitivity of schiz-
otypal deficits to genetic liability to schizophrenia is a crucial step in uti-
lizing schizotypal features in bivariate genetic linkage analyses to identify
schizophrenia risk genes. The 671 participants in this study included 43
European-American, multigenerational multiplex pedigrees with 103 af-
fected individuals (schizophrenia or schizoaffective disorder, depressed
type) and 480 non-psychotic, first- through fourth-degree index relatives,
and an additional 88 non-psychotic control individuals. Social-interper-
sonal, disorganized, and cognitive-perceptual symptoms of Schizotypal
Personality Disorder (SPD) were assessed in the non-psychotic relatives
and controls with a modified version of the Structured Interview for Schiz-
otypy (SIS) (Kendler et al. 1989). Genetic correlations between schizophre-
nia and the SIS subscales (Rg) were obtained using pedigree-based,
variance component analyses as implemented in the computer program,
SOLAR. Subscales were highly heritable (range 0.17–0.65). A positive ge-
netic correlation with schizophrenia was found for the majority of Social-
Interpersonal subscales (range: 0.03–0.54) and both Disorganization sub-
scales (.08 and .63), whereas all Cognitive-Perceptual subscales were neg-
atively genetically correlated with schizophrenia (range: –0.10 –0.35). The
subscales most strongly correlated with schizophrenia were Organization of
Speech/Thought, Irritability, and Suspiciousness/Guardedness (Rg = .63,
.54, and .41 respectively). Subscale genetic correlations were used to derive
weighted, aggregate SIS scale scores for each SPD symptom dimension and
across all 21 subscales. Weighted aggregation of the Social-Interpersonal
dimension resulted in a significant, positive genetic correlation with schizo-
phrenia (Rg = .46, P < .001) and a non-significant trend was found for the
Cognitive-Perceptual dimension (Rg = .27, P = .079). The Disorganization
dimension was not significantly correlated with schizophrenia (Rg = .24, P =
.248). Weighted aggregation across all subscales was also significant (Rg =
.60, P = .001). The results argue for the advantage of weighted aggregation
using genetic correlation with schizophrenia to maximize sensitivity of SPD
symptoms to schizophrenia liability. These optimal combinations of SIS
subscales should be most useful as supplementary phenotypes in linkage
analyses, although the specific weights reported in this study require
replication.
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Genetic variation in the Catechol-O-Methyltransferase (COMT) gene may
affect the susceptibility to schizophrenia and impairment on certain types of
neurocognitive tasks. The authors aimed to evaluate the effect of the asso-
ciation of COMT Val108/158 Met genotype with the response to a comput-
erized cognitive rehabilitation (CRT) in chronic schizophrenia. Method:
Inpatients with DSM-IV schizophrenia, randomly assigned to CRT
for 3 hours/wk for 12 wks were genotyped. Patients were evaluated
on neuropsychological assessments, functional skills, and clinical symp-
toms (PANSS) at baseline and at Week 12. Response definition: > = 20%
performance improvement on the Trail Making tests and WCST test at
baseline and Week 12 was used as a cut-off criterion to categorize
patients into two groups : (1) Responders (those who had normal or be-
low normal performance at baseline and increased performance at end-
point), and (2) Non-responders (those who had below-normal
performance at baseline and endpoint, and those with normal perfor-
mance at baseline, but below-normal performance at endpoint). We com-
bined Met carriers (Met/Val = 17) and Met homozygotes (Met/Met = 2)
and compared them to Val homozygotes (Val/Val n = 19). We then di-
vided our sample in four subgroups on the basis of genotype ((Val/Val)
versus (Met/Val þ Met/Met)) and (Responders versus Non-Responders).
Results: We present results on 38 subjects of a planned enrollment of
142. Significantly greater improvement was observed for the global cog-
nitive index (P = .050), Trail Making Test (P = .011) and working mem-
ory tasks (P = .049) for the (Met/Val þ Met/Met) group who were
Responders to CRT in comparison to the Val/Val group who were
Non-Responders to CRT. A significant association was observed be-
tween higher scores on the PANSS scale and genotypes Val/Val (P =
.044) for rs4680. The correlation between effect sizes of improvement
(higher global cognitive index score and lower PANSS scores) was sig-
nificant (P = .038). Conclusions: These preliminary findings support the
hypothesis that COMT polymorphism may influence cognitive function-
ing through CRT, with the caveat because of the small sample size, pos-
itive findings could be due to type I error. The presence of Met allele was
associated with significantly greater improvements in overall neurocog-
nition. As we accrue a larger sample size we may be able to determine
if the two effects (ie, improvement from CRT and COMT polymor-
phism) act at different levels.
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microRNA profiles have recently revealed consistent patterns of up- or
down-regulation in association with a number of human diseases. In
2007 we reported a statistically significant derivation of downregulation
of 14 microRNAs and upregulation of one as the outcome of a spotted
microRNA microarray testing post-mortem prefrontal samples from 29
schizophrenia patients and 15 unaffected comparison subjects. In this pre-
sentation we will describe the results of a follow-up study conducted in
a new cohort of 35 schizophrenia, 35 unaffected, and 35 bipolar subjects.
microRNA profiles were evaluated with a commercially available micro-
RNA microarray platform (Agilent). We did not replicate the originally
reported findings in this new cohort of subjects. However, when we grouped
microRNAs by their bioactive ‘‘seed’’ regions we found similar differences
in expression patterns between schizophrenia and unaffected subjects in
both cohorts. We discuss implications of these results, including that these
findings may point to a system of control agents that are dysregulated in
schizophrenia. Whether they are etiological causes or responses to dysre-
gulation elsewhere remains unknown, however.
ID: 551241
International Congress on Schizophrenia Research
120 8. 8. Genetics, Clinical
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
SEX-SPECIFIC TRANSMISSION OF PSYCHOSIS
SUGGESTS X-LINKAGE: IMPLICATIONS FOR SEX
DIFFERENCES IN MEMORY DYSFUNCTION IN
SCHIZOPHRENIA
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Recent molecular genetic studies demonstrated X-chromosome abnormal-
ities that we predict are important in understanding sex effects identified in
previous studies of schizophrenia (SCZ), with men at greater risk for chro-
nicity. Sex differences in brain abnormalities and cognitive deficits associ-
ated with memory dysfunction have also been identified, abnormalities
present in X-linked disorders. Few studies have systematically evaluated
sex-specific transmission risk and even fewer related this to sex differences
in cognitive deficits. We tested the hypothesis of sex-specific transmission of
psychoses in a recently completed high risk study, the New England Family
Studies of Schizophrenia. We hypothesized sex-specific transmission and
that it will be significantly associated with sex differences in memory deficits
in adulthood. We identified 195 parents with psychoses (non-affective (NP),
primarily SCZ, and affective (AP)) and 131 comparable control parents.
188 high risk (HR) and 147 control offspring were diagnostically assessed
(185 females; 165 males). Relative risks for psychosis and sex-specific trans-
mission were estimated using generalized estimating equations models to
account for intrafamilial correlation. Adult offspring were also cognitively
evaluated, including memory function (CVLT) and verbal fluency (FAS).
There was a significantly higher risk for psychosis in HR offspring depen-
dent on sex of parent and sex of offspring. 19% of male offspring of mothers
with psychosis developed psychosis compared to 3.1% of male offspring of
ill fathers. In contrast, 15.2% of female offspring of ill fathers developed
psychosis versus 9.5% of female offspring of ill mothers. This pattern
held for NP and AP. In case-control analyses, there was a significant in-
teraction effect of group by sex on verbal memory function (unaccounted
for by verbal fluency deficits) with male cases having significantly lower
verbal memory scores than female cases (F = 14.75, P = .0002), with effect
sizes reaching a 4.8 standard deviation (SD) sex difference between cases
versus a .8SD sex difference among controls. Results demonstrate sex-
specific (X-linked) transmission regardless of psychosis-type and that it
is associated with sex differences in memory dysfunction. Results have im-
portant implications for molecular genetic studies of SCZ and other psy-
choses suggesting the importance of one’s gender in understanding gene-
brain-behavior SCZ phenotypes.
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Serotonin (5-hydroxytryptamin; 5-HT) alternations has since long been
suspected in the pathophysiology of schizophrenia. Tryptophan hydrox-
ylase (tryptophan 5-monooxygenas; TPH) is the rate-limiting enzyme in
the biosynthesis of 5-HT, and sequence variation in intron 7 of the
TPH1 gene has consistently been associated with schizophrenia across
studies. In addition, this polymorphism is more frequent in suicide attemp-
ters and completers, than in individuals unaffected with any psychiatric
disorder. In the present study we have tried to replicate previous findings
in a combined Scandinavian case-control sample. Five single nucleotide
polymorphisms (SNPs) were genotyped in 837 individuals affected with
schizophrenia and 1473 controls. Three SNPs spanning introns 6 and
7, including the A779C/A218C polymorphisms, were associated with in-
creased schizophrenia susceptibility (odds ratio = 1.17, P = .019, corrected
for multiple testing). However there were no differences in allele frequen-
cies between affected individuals having attempted suicide at least once
and patients with no history of suicide attempts (P = .48), and heteroge-
neity between countries was evident (P = .02). A systematic review and
meta-analysis of the literature on suicidal attempts (SA) showed a large
between study heterogeneity (I2 = 0.59, P = .003, fixed model), and
gave little support for the A779C/A218C polymorphism being a SA sus-
ceptibility locus within individuals diagnosed with psychiatric disorders
(OR = 0.98, P = .84, mixed model). We conclude that the TPH1
A779C/A218C locus increases the susceptibility of schizophrenia in the
Scandinavian population, which is in agreement with previous findings
in Asian and Caucasian populations. The data at hand suggest that the
locus contributes to the liability of psychiatric disorders characterized
by elevated suicidal rates, rather than affecting suicidal behavior in indi-
viduals suffering from a disorder.
ID: 551145
TELOMERE LENGTH IN DRUG-NAI¨VE FIRST
EPISODE OF NON AFFECTIVE PSYCHOSIS
PATIENTS
Miguel Bernardo1,2, E. Fernandez-Egea1, C. M. Heaphy3,
J. K. Griffith3, E. Parellada1,2, B. Kirkpatrick4
1Servei de Psiquiatria, Institut de Neurocie`ncies, Hospital Clı´nic,
Universitat de Barcelona, Barcelona, Spain; 2Institut d’Investiga-
cions Biome`diques Augusti Pi i Sunyer (IDIBAPS)., Barcelona,
Spain; 3Department of Biochemistry and Molecular Biology, Uni-
versity of New Mexico, Albuquerque, NM, USA; 4Department of
Psychiatry and Health Behavior, Medical College of Georgia,
Augusta, GA, USA
Background: People with schizophrenia have a marked increase in mortal-
ity rate compared to the general population. Cardiovascular disease
accounts much of this increased mortality. We tested the hypothesis that
schizophrenia and related disorders are associated with a shorter telomere
length. Telomere length is correlated with metabolic and cardiovascular ab-
normalities in general population. Methods: Telomere content, which is
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a proxy for the telomere length, was measured to newly diagnosed, drug-
naı¨ve patients (n = 32) with schizophrenia and related psychotic disorders,
and control subjects (n = 32). Subjects were matched for gender, age, body
mass index and smoking status. Findings: The psychosis group had a sig-
nificantly decreased mean telomere content compared to controls (respec-
tive means [SD] 93.8% [13.2] vs. 101.5% [16.2]; P = .042). Interpretation:
Our results suggest that even prior to antipsychotic treatment, schizophre-
nia is associated with chromosome structure abnormalities that are linked
to metabolic/cardiovascular disease and an increased mortality rate.
Table. Characteristics of the Nonaffective Psychosis and Control Subjects
Psychosis
(N = 32)
Control
(N = 32)
Mean age [SD] 30.0 [10.2] 27.9 [7.2]
Male/female 21/11 21/11
Mean body mass index [SD] 23.1 [4.4] 24.0 [3.0]
Mean number cigarettes per day [SD] 7.9 [8.9] 6.2 [8.4]
Residing in the hospital’s
catchments area
21 [65.6%] 24 [75.0%]
Resting heart rate [SD] 77.4 [11.5] 74.9 [11.6]
Systolic blood pressure 120.0 [12.4] 120.5 [12.2]
For all variables, P > .30
ID: 551028
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Maureen Verna Martin1, B. Rollins1, L. Morgan1, P. A. Sequeira1,
L. E. Delisi5, W. Byerly2, H. Akil3, E. G. Jones4, S. J. Watson3,
J. Barchas5, R. M. Myers6, A. Schatzberg7, W. E. Bunney1,
M. P. Vawter1
1Psychiatry and Human Behavior, University of California, Irvine,
Irvine, CA, USA; 2Psychiatry, University of California, San
Francisco, San Francisco, CA, USA; 3Molecular and Behavioral
Neuroscience Institute, University of Michigan, Ann Arbor, MI,
USA; 4Neuroscience Center, University of California, Davis, Davis,
CA, USA; 5Psychiatry, NYU Langone Medical Center, New York
University, New York, NY, USA; 6HudsonAlpha Institute for
Biotechnology, Huntsville, AL, USA; 7Psychiatry, Stanford
University, Palo Alto, CA, USA
The purpose of this study was to correlate three features of candidate genes
for schizophrenia and their potential as biomarkers of schizophrenia. A to-
tal of 84 candidate genes were selected based upon recent meta-analysis
(Allen et al. 2008) of candidate genes and genome-wide association and
copy number variation studies implicating regions of interest in schizophre-
nia. We examined differential expression, blood and brain comparability,
and circadian effects on expression of candidate genes. First, we examined
differential expression of candidate genes in lymphoblastic cell lines in sub-
jects with schizophrenia and their non-psychotic relatives by exon array and
observed significant diagnosis effects (P < .05) on expression of APOE,
PRKAB2, CLTCL1, PIAS3, TMEM108, and HTF9C. To assess blood
and brain comparability of candidate genes, we then compared transcript
level expression of cerebellum and lymphoblastic cell lines by exon array.
From the list of 84 genes, there were 17 blood and brain correlations over
0.80, including APOE and HTF9C (r = .98 and r = .82, respectively). Be-
cause circadian rhythm effects on gene expression may confound biomarker
research, we examined the circadian rhythm of peripheral blood gene ex-
pression of these candidates in a separate sample of 4 male and 4 female
control subjects, with blood collected at 9 time points over 48 hours. There
were 5 significant circadian rhythms detected using COSOPT (P< .05) and
27 trends toward significant circadian rhythm effects (P < .10), including
trends toward circadian rhythm effects for the schizophrenia candidate
genes APOE, CLTCL2, TMEM108 and HTF9C. These results underline
the importance of controlling for circadian effects in biomarker research
and provide further information of the possible utility of these candidate
genes, particularly APOE and HTF9C, as potential biomarkers in schizo-
phrenia research.
ID: 550929
LARGE-SCALE CANDIDATE GENE ANALYSIS OF
ENDOPHENOTYPES FOR SCHIZOPHRENIA
Tiffany A. Greenwood1,2, G. A. Light1, N. R. Swerdlow1,
M. A. Geyer1,2, A. D. Radant3,4, D. L. Braff1
1Department of Psychiatry, University of California, San Diego, La
Jolla, CA, USA; 2San Diego VA Healthcare System, San Diego,
CA, USA; 3Department of Psychiatry and Behavioral Sciences,
University of Washington, Seattle, WA, USA; 4VA Puget Sound
Health Care System, Seattle, WA, USA
We developed a custom SNP chip consisting of 1536 SNPs within 94 can-
didate genes for schizophrenia and related endophenotypes based on
knowledge of relevant neurobiological systems and an extensive review
of published model organism, linkage, and association studies. We uti-
lized this SNP chip to conduct association analyses of three neurophys-
iological and three neurocognitive endophenotypes for schizophrenia in
a sample of 127 schizophrenia patients and 92 controls from the
UCSD Schizophrenia Research Program. Endophenotypes for analysis
included Prepulse Inhibition, P50 Suppression, the oculomotor Antisac-
cade Task, the Letter-Number Sequencing Test, the California Verbal
Learning Test, and the Wisconsin Card Sort Test tapping critical schizo-
phrenia-related domains. Schizophrenia diagnosis was also included as
a phenotype for analysis. Of the 1536 SNPs, 1385 remained for analysis
following elimination based on quality control thresholds for call rate,
cluster separation, and marker informativity. A total of 30 genes were
found to be associated with at least one endophenotype or schizophrenia
(empirical P < .01). Many of these genes also interact on a molecular
level, and seven genes displayed evidence for pleiotropy, revealing signif-
icant associations with two or more of the six endophenotypes. Among
these genes were ERBB4 and NRG1, providing further support for a sub-
stantial role for these genes in mediating susceptibility to schizophrenia.
The observation of extensive pleiotropy for some genes and singular asso-
ciations for others in our data suggests alternative, independent pathways
mediating schizophrenia pathogenesis. Supported by R01-MH042228 and
MH79777.
ID: 550899
UNDERSTANDING PATHOGENIC MECHANISMS
OF SCHIZOPHRENIA USING PLURIPOTENT
HUMAN STEM CELLS
Guo-li Ming, H. Song
Neurology, Johns Hopkins University, Baltimore, MD, USA
Severe psychiatric illnesses, such as schizophrenia and bipolar affective dis-
order, are chronic and generally disabling brain diseases in need of effective
treatments. Accumulative evidence supports the view that schizophrenia
is a disease of neuronal development in nature, however, the underlying
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cellular and molecular mechanisms remain large unknown. A number of
susceptibility genes have recently been identified from human genetic asso-
ciation studies. Two genes, disrupted-in-schizophrenia 1 and 2 (DISC1 and
DISC2), were identified at the breakpoint of a balanced translocation that
co-segregates with schizophrenia and major affective disorders in a large
Scottish family. Interestingly, DISC2 is only present in primates and
humans, but not in lower species. Little is known about functions of
DISC1 and DISC2 in human development due to a lack of experimental
systems. We recently made some interesting discoveries on the role of
DISC1 in regulating several essential steps of neurogenesis in vivo, including
neuronal morphogenesis, migration and positioning, axon/dendritic devel-
opment and synapse formation (Duan et al.,Cell 2007; Faulkner et al.,
PNAS 2008). We are extending these findings in animal models to human
neurons. Specifically, we have developed methodologies to culture human
embryonic stem cells (hESCs) and examine their neuronal development
both in vitro and after in utero transplantation into E13.5 mice in vivo
with immunocytochemistry, confocal and electron microscopy, FM imag-
ing and electrophysiology (Song et al., Nat. Neurosci. 2002; Ge et al., Na-
ture 2006; Ge et al., Neuron 2007). More recently, it has been possible to
reprogram human skin fibroblasts into induced-pluripotent stem (iPS) cells
that exhibit similar properties as hESCs. We were able to generate iPS cells
from human patient fibroblasts. These cells exhibit all known hESC
markers, normal karyotyping and retain the ability to differentiate into
cell lineages in three germ layers. We have recently derived fibroblasts
from several patients with schizophrenia and age-matched controls.
Such an experimental platform using hESCs and iPS cells from schizophre-
nia patients may provide a novel means to understand the molecular and-
cellular mechanisms underlying neuronal developmental defects in
schizophrenia.
ID: 550890
GENETIC VARIATIONS IN THE 6P24–21 GENOMIC
REGION THAT AFFECTS THE EYE TRACKING
ABILITY IN SCHIZOPHRENIA PATIENTS.
Nithin Krishna, I. Wonodi, E. Hong, G. Thaker
Department of Psychiatry, University of Maryland, School of
Medicine, Baltimore, MD, USA
Smooth pursuit eye movement (SPEM) is one of the most established in-
termediate phenotypes linked to schizophrenia. Two linkage studies impli-
cate chromosome 6p21–24 as a candidate locus for the oculomotor deficit;
other linkage studies that used schizophrenia diagnosis as a phenotype have
also implicated this region. This genomic region is of interest in develop-
mental dyslexia, a disorder associated with motion processing and SPEM
abnormality. In the current project we examined (i) phenotypic overlap be-
tween reading ability and the predictive pursuit gain (PPG) subcomponent
of SPEM; and, (ii) effects of select candidate genes within 6p24–21 on PPG.
We selected candidate genes based on findings of association with schizo-
phrenia (DTNBP1), dyslexia (TTRAP, KIAA0319, DCDC2), or their role
in GABA pathway (ALDH5A1). Schizophrenia (SZ) patients (n = 175) and
matched healthy control (HC) subjects (n = 171) both between the ages of
15–58 years participated in the study. Eye tracking was performed using
standard methods; PPG was measured when the moving target became
briefly invisible. We selected 13 SNPs covering the 5 genes that were inde-
pendent (not correlated) and resulting genotypes were frequent enough (ie,
> 5%) in our sample. Analyses used ANOVAs to examine the effects of the
genotypes on PPG; the p values were adjusted using the false discovery rate
(FDR) adjustment. Examination of reading ability in a small sample of
schizophrenia patients showed a significant correlation between Nelson
reading speed and PPG (r = 0.57, P < .05, n–17). The genetic analyses
showed that, there was a significant ALDH5A1 rs2328824 genotype by di-
agnosis interaction; GG (minor genotype) was associated with poor PPG
compared with AG in SZ, while AA showed significantly better PPG than
AG in HC. Variation in a dyslexia related gene, TTRAP, significantly af-
fected PPG such that the major homozygous was associated with worst
PPG. Lastly, there was a trend for DCDC2 genotype by diagnosis interac-
tion effect on PPG (P = .06 after adjusting for FDR). Our data suggest that
two genes within 6p24–21, ALDH5A1 and TTRAP are associated with
SPEM deficit. ALDH5A1 encodes an essential enzyme required for degra-
dation of gamma-aminobutyric acid (GABA). Whereas, TTRAP is a dys-
lexia related candidate gene. In our sample, preliminary data from a small
subgroup showed that patients with poor PPG perform poorly on a reading
test.
ID: 550881
GENE PROFILING OF SINGLE-CELL POPULA-
TIONS OF THE SUPERIOR TEMPORAL GYRUS
IN SCHIZOPHRENIA
Charmaine Yvonne Pietersen1, M. Lim1, R. M. McCarley2,3,
T.-U. Woo1,4
1McLean Hospital, Belmont, MA, USA; 2Department of
Psychiatry, VA Boston Healthcare System, Brockton, MA, USA;
3Department of Psychiatry, Beth Israel Deaconess Medical Center,
Boston, MA, USA; 4Department of Psychiatry, Harvard Medical
School, Boston, MA, USA
Disturbances in postnatal developmental synaptic pruning may contribute
to the onset of schizophrenia. In support of this hypothesis, recent postmor-
tem studies have revealed that deficits of glutamatergic synapses may in fact
be a prominent pathophysiologic feature of the illness. In addition, evidence
suggests that the maturation of parvalbumin (PV) inhibitory neurons, that
modulate pyramidal neuron output, may be important in regulating the
critical period for synaptic plasticity and pruning. However, the possible
molecular mechanisms that underlie the postulated disturbances of synap-
tic pruning have been largely unexplored. In a cohort of postmortem brains
from 10 schizophrenia and 10 matched normal control subjects, we used
laser capture microdissection to isolate subsets of pyramidal and inhibitory
neurons in the superior temporal gyrus (BA 42), which exhibits pronounced
gray matter reduction during the early course of schizophrenia. In pyrami-
dal neurons, preliminary data revealed 58 genes that were differentially
expressed (2 – 4 fold, P < .05) in schizophrenia. Biological networks
were generated through the use of Ingenuity Pathway Analyses (Ingenuity
Systems, www.ingenuity.com). Three main biological networks were iden-
tified: Molecular transport, nervous system development/function, and
cellular assembly/organization (significance scores: 21–26). Three down-
regulated genes were pinpointed as central to the merged network ie, neu-
regulin-4 (nrg-4), early growth response-1 (egr-1) and a calcium channel
subunit, cacna1a. This cell-type based profiling affords us the molecular
resolution to generate hypotheses as to how neuronal connectivities and
their molecular signaling control might be altered within and between cells
and could lead to novel therapeutic strategies by directly correcting neural
circuit disturbances.
ID: 551928
REFINEMENT OF GENETIC MARKERS ASSOCI-
ATED WITH CLOZAPINE-INDUCED AGRANULO-
CYTOSIS USING WHOLE GENOME AND HLA
TYPING APPROACHES
M. Athanasiou, K. A. Holick-Pierz, B. Salisbury, W. Zou, C. Reed
PGxHealth, New Haven, CT, USA
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Clozapine is a highly efficacious drug for the treatment of schizophrenia,
but its use is limited in part due to the side effect of agranulocytosis. We
have previously reported genetic variants in five genes associated with
clozapine-induced agranulocytosis (CIA) from a candidate gene study,
and replication of the association in one gene (HLA-DQB1) in an inde-
pendent cohort. We have now conducted additional studies to confirm
and refine these associations through whole genome and high resolution
HLA typing approaches. Samples from our previously collected case/con-
trol cohort (CARING, N = 87) were genotyped on the Illumina
HumanCNV370 panel to identify new genetic markers, as well as to re-
fine the association in HLA-DQB1 previously reported. Multiple signals
were detected in the major histocompatibility complex on chromosome 6
through the whole-genome analysis, including one highly significant
HLA-region marker that warrants replication. High resolution HLA typ-
ing of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 was then
conducted on subjects from the CARING cohort including clozapine-
treated controls, CIA cases and granulocytopenia cases (N = 115).
HLA typing was conducted to replicate and refine previously reported
associations by our group and others. The SNP previously identified
through our candidate gene studies as a marker of CIA (HLA-DQB1 þ
6672G>C) was found to be highly correlated with an HLA type in
HLA-DQB1. The details of all markers, as well as characteristics for
a pharmacogenetic test for CIA will be provided.
ID: 556979
ASSOCIATION OF GAD67 EXPRESSION AND CELL
CYCLE REGULATION IN HIPPOCAMPAL GABA
CELLS IN SCHIZOPHRENICS (SZS) VS BIPOLARS
(BDS)
Francine M. Benes1,2
1Psychiatry (Neuroscience), Harvard Medical School, Boston, MA,
USA; 2Program in Structural and Molecular Neuroscience, McLean
Hospital, Belmont, MA, USA
Decreased expression of GAD67 is present in the patients with both SZ
and BD and a recent network association analysis has demonstrated that
the regulation of this gene is linked to those involved in cell cycle progres-
sion via cyclin D2 (Benes et al., 2007). Laser microdissection (LMD) was
used to dissect out GABA cells in the stratum oriens of sectors CA3/2,
a key locus along the trisynaptic pathway where oscillatory rhythms
are generated. In SZs, the most significant changes involved genes in-
volved in the epigenetic regulation of the transcriptional complex that reg-
ulates progression from G1/S to G2/M. Upregulation of MBD4, HDAC1
and DAXX would put this complex in the ‘‘OFF’’ state. In BD, important
changes in the expression of genes involved in G1 arrest and progression
toward the G2 checkpoint and DNA repair were observed. BDs showed
a significant down-regulation of TGFb2, neuregulin I, four different nic-
otinic receptor subunits, cyclin D2, HDAC3, E2F, p53, CHK2, the RP-1
replication protein, two DNA polymerases (POLG2 and POLL) and two
anaphase promoting complexes (APC1 and 5). Taken together, these find-
ings suggest that there may be a failure of G1S arrest and DNA repair in
GABA cells of the SO in CA3/2 in BDs. These changes may have a neg-
ative impact on genomic and functional integrity of this discrete subpop-
ulation of GABAergic interneurons. Overall, decreased GAD67
expression in SZ and BD seems to involve fundamentally different mech-
anisms and these probably reflect unique molecular endophenotypes for
these two psychotic disorders. Supported by MH42261, MH62822,
MH068855 and MH60450.
ID: 556965
GENE VARIANTS ASSOCIATED WITH
ANTIPSYCHOTIC INDUCED WEIGHT GAIN
Daniel J. Mueller1,2, A. K. Tiwari1, O. Likhodi1, C. Zai1,
A. Lisker2, I. Puls2, A. Heinz2, J. Volavka3, S. G. Potkin4,
J. Lieberman5, H. Y. Meltzer6, J. L. Kennedy1
1Neurogenetics Section, Centre for Addiction and Mental Health,
Toronto, ON, Canada; 2Department of Psychiatry, Charite´
University Medicine (CCM), Berlin, Germany; 3Departmemt of
Psychiatry, New York School of Medicine, New York, NY, USA;
4Department of Psychiatry, University of Irvine, Irvine, CA, USA;
5Department of Psychiatry, Columbia University, New York, NY,
USA; 6Psychiatric Hospital at Vanderbilt, Nashville, TN, USA
Introduction: Clozapine and olanzapine have been associated with sub-
stantial weight gain in many patients. However, an individual’s propensity
to develop weight gain largely depends on genetic factors that will be
reviewed. A possible mechanism may involve the endocannabinoid system
which has been implicated in the regulation of appetite signalling and food
intake through the dorsal vagal complex (DVC) of the brainstem. Animal
models have shown that olanzapine significantly decreased cannabinoid
receptor binding in the DVC (Weston-Green et al. 2008). Furthermore,
the cannabinoid-1 (CB-1) receptor antagonist rimonabant has been shown
to induce weight loss. The purpose of this study has been to analyze
whether variants (SNPs) of the CB-1 receptor gene potentially modulating
the endocannabinoid system were associated with antipsychotic induced
weight gain. Methods: We have been genotyping several SNPs in a larger
sample of antipsychotic induced weight gain using three different samples
from the US (A, B and C; total n = 139) and one sample from Germany
(D; n = 70; total n = 209), mainly treated with clozapine and olanzapine on
average for 11 weeks. Mean weight gain was compared across the geno-
typic categories using ANOVA as well as ANCOVA including baseline
weight or sex as covariate. Results: Mean weight gain in the sample
was þ 4.0 kg (6 4.8 kg). In the sample of Europeans (n = 123), carriers
of the C/C genotype of the promoter region SNP rs806378 gained only 2.3
kg as compared to C/T and T/T carriers who gained on average 4.2 kg.
This association was significant when corrected for baseline weight (P =
.049). We then excluded those patients who received medications other
than clozapine or olanzapine and found a more significant association
(F2,72 = 4.48, P = .01 where homozygotes for T/T gained 6.25 kg as com-
pared to 1.90 kg in homozygotes for C/C carriers. The most significant
finding was then obtained when examining only patients treated with clo-
zapine F2,61 = 7.49, P = .001. Results remained unaltered when including
covariates such as baseline weight or sex. Summary: Our studies suggest
that a promoter variant of the CB-1 receptor gene is associated with clo-
zapine and olanzapine induced weight gain. We are currently expanding
our analyses with including a total of 10 tag SNPs spanning the entire CB-
1 gene. These findings may have important implications for discovery of
novel antipsychotic drug targets that do not result in weight gain side
effects.
ID: 555296
NEUROCOGNITIVE MEASURES IN MULTIPLEX
MULTIGENERATIONAL INVESTIGATION OF
SCHIZOPHRENIA (MGI)
Raquel E. Gur
Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
Background: Cognitive deficits are evident in schizophrenia. We reported sig-
nificant heritabilities for neurocognitive tests for multiplex, multigenerational
families affected by schizophrenia, suggesting that some variation in
traits is affected by genetic factors. How the traits vary together may
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advance the understanding of cognitive processes in schizophrenia.
Methods: The Consortium ascertained European-Americans from multi-
plex multigenerational families. The computerized neurocognitive battery
(CNB) measures accuracy and speed on abstraction and mental flexibil-
ity, attention, verbal, face, and spatial memory, emotion processing, and
sensorimotor processing. Heritability was estimated using SOLAR. Over-
all variance of the trait was divided into portions due to genetic factors
determined by pedigree relationships, environmental factors, and specific
covariates such as age and sex. Results: Heritability estimates ranged
from 0.21 for spatial memory to 0.72 for language. Mean efficiency levels
varied with age for all traits, and the square of age was significant for
abstraction and mental flexibility, attention, face memory, and emotion
processing, while sex was significant for abstraction and mental flexibil-
ity, spatial processing, face memory, verbal memory, and emotion pro-
cessing. The interaction of sex and the square of age was significant for
spatial memory and verbal memory. All genetic and environmental cor-
relations were negative. The genetic correlations between affection status
with abstraction and mental flexibility, attention, and emotion process-
ing were significantly different from zero, and the genetic correlations
between affectation status and all cognitive traits were significantly dif-
ferent from one. Environmental correlations were not statistically signif-
icantly different from zero. Conclusions: The genetic correlations of
neurocognitive traits with schizophrenia suggest that they are valid endo-
phenotypes for schizophrenia. Since these traits can also can be mea-
sured in relatives, they may provide a powerful strategy for linkage
and association studies, helping distinguish unaffected individuals who
carry alleles predisposing to schizophrenia. The quantitative nature of
these traits also provides increased power for genetic studies, potentially
differentiating levels of risk in unaffected individuals and levels of sever-
ity in affected individuals.
ID: 554994
FAMILY-BASED ASSOCIATION STUDY OF NALCN
GENE WITH SCHIZOPHRENIA
Renan Pedra Souza1,2, M. A. Romano-Silva2, J. A. Lieberman3,
H. Y. Meltzer4, M. Zhen5, G. Remington1, J. L. Kennedy1,
A. H. Wong1
1Centre for Addiction and Mental Health, Toronto, ON, Canada;
2Saude Mental, Universidade Federal de Minas Gerais, Belo
Horizonte, Brazil; 3Psychiatry, University of North Carolina,
Chapel Hill, NC, USA; 4Psychiatric Hospital, Vanderbilt Univer-
sity, Nashville, TN, USA; 5Samuel Lunenfeld Research Institute,
Mount Sinai Hospital, Toronto, ON, Canada
Schizophrenia affects about 1.0% of the population worldwide, with dev-
astating consequences for both patients and their families and is the seventh
most costly medical illness. Linkage and association studies have now im-
plicated several loci in the genome that likely harbor genes conferring risk
for schizophrenia. NALCN (sodium leak channel, non-selective) is a gene
located on chromosome 13q in a suggested linkage region for schizophre-
nia. Mouse NALCN mediates some background sodium leak in hippocam-
pal neurons and plays a role in neuronal excitability. Abnormalities in
hippocampal activity and neuronal excitability have been implicated in
schizophrenia. In this study, we examined association with schizophrenia
using family-based analysis. Twenty six NALCN polymorphisms were an-
alyzed and allelic; genotypic and haplotypic frequencies were compared
across 85 small nuclear families. We did not find any significantly altered
transmission. Our results suggest that the NALCN may not affect suscep-
tibility to schizophrenia.
ID: 554883
UPDATE ON THE PROJECT AMONG AFRICAN
AMERICANS TO EXPLORE RISKS FOR SCHIZO-
PHRENIA (PAARTNERS)
Rodney C. P. Go1, B. J. Devlin2, H. Wiener1, R. Perry1,
V. Nimgaonkar2
1Epidemiology, University of Alabama at Birmingham, Birmingham,
AL, USA; 2Psychiatry, University of Pittsburgh, Pittsburgh,
PA, USA
Background: A genetic etiology is now widely accepted for schizophrenia
(SZ). Recent reviews have identified several suggestive linkages, eg, 1q22,
6q25, 8p21–22, and 11q21, primarily in Caucasian populations. The Project
among African-Americans to Explore Risks for Schizophrenia (PAART-
NERS) is a multi-site study that seeks to identify genes that confer suscep-
tibility to schizophrenia and neurocogntive endophenotypes by linkage
mapping and targeted association analyses. Methods: PAARTNERS uti-
lizes for diagnostic assessment, the Diagnostic Interview for Genetic Stud-
ies (DIGS) and the Penn Computerized Neurocognitive Battery (CNB) to
assess cognitive abilities. Medical chart information is incorporated into the
DIGS. The Family Interview for Genetic Studies (FIGS), conducted with
family member informants, provides additional diagnostic. A Best Estimate
Final Diagnosis (BEFD) is reached by the clinicians on each participant
based on this information. Genome wide linkage analyses using the Center
for Inherited Disease Research (CIDR) Linkage IV SNP Panel genotypes,
are performed using MERLIN and SIBPAL on clinical phenotypes, while
MERLIN-regress and SOLAR are used for the normalized cognitive
domains. Results: Preliminary linkage results on 217 families with the clin-
ical phenotypes schizophrenia (S), or schizophrenia and schizoaffective dis-
order (SS), or any DSM IV diagnoses with psychoses (P) are presented.
Conclusions: Our preliminary results indicate that several linkage peaks,
especially on chromosome 11(30 cM, 68 cM), 8p, and chromosome 4
(20 cM) exhibit significant linkage. The overlapping loci identified by
this study and two other previous studies of A-A families gives us great
hope that loci affecting risk for schizophrenia in African Americans will
soon be uncovered.
ID: 554780
UBIQUITIN PROTEASOME GENE EXPRESSION AS
A BIOMARKER FOR SCHIZOPHRENIA AND BIPO-
LAR DISORDER: CONVERGENT FINDINGS FROM
TWO INDEPENDENT COHORTS
Chad A. Bousman1,2, S. J. Glatt3, G. Chana2, S. D. Chandler2,
T. May2, J. B. Lohr2, W. S. Kremen2, M. T. Tsuang2,4,
I. P. Everall2
1Public Health, UCSD/SDSU, San Diego, CA, USA; 2Psychiatry,
University of California, San Diego, San Diego, CA, USA;
3Psychiatry and Behavioral Sciences, SUNY Upstate Medical
University, Syracuse, NY, USA; 4Epidemiology and Psychiatry,
Harvard University, Boston, MA, USA
It is probable that schizophrenia (SCZ) and bipolar disorder (BPD) are eti-
ologically diverse and may be represented by different sets of genes in each
individual. Thus, we hypothesized that searching for dysregulated molec-
ular and cellular pathways and functions would be more fruitful in that
different genes could populate an identified biological pathway or function
but the pathophysiological outcome for the cell or tissue would be the same.
We conducted a blood-based transcriptomic study in two independent pop-
ulations with SCZ and BPD in San Diego (SCZ = 13; BPD = 9, control = 8)
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and Taiwan (SCZ = 11; BPD = 14, control = 16). Each diagnostic group was
compared to controls as well as subjects with a history of psychosis [PSY-
CH(þ):San Diego (n = 6), Taiwan (n = 14)] to subjects without such his-
tory [PSYCH(-): San Diego (n = 11), Taiwan (n = 14)]. For both cohorts
analyses compared diagnostic groups on the mean expression level on
a gene-by-gene basis through analyses of covariance (ANCOVAs) which
included demographic (eg, age, sex, ancestry) and clinical (eg, current psy-
chotropic medications) factors. Following ANCOVAs, the top 100 genes
in both cohorts for each diagnostic group that were significantly dysre-
gulated at P < .05 were imported into Ingenuity Pathway Analysis
(IPA) software. Results showed the ubiquitin proteasome pathway
(UPS) was listed in the top ten canonical pathways for all diagnostic
groups among both cohorts with between two and five genes populating
the pathway and a considerably low likelihood (P = 6.21e–05) of a chance
occurrence. Between both cohorts across all diagnostic groups no overlap
in biological functions or dysregulated genes populating these functions
were observed. However, comparison of the SCZ groups from both
cohorts revealed that the general biological pathway of ‘cell death’
was shared. Furthermore, comparing the PSYCH(þ) groups for each co-
hort showed that three of the ten most dysregulated general biological
pathways for both cohorts was ‘cancer’; however, specific biological func-
tions populating the ‘cancer’ pathway across cohorts did not concur. Our
findings provide convergent evidence of ubiquitin proteasome pathway
dysregulation and support for further investigation of ubiquitin protea-
some gene expression as a potential biomarker for SCZ, BPD, and/or
psychosis.
ID: 554733
UPDATEON THE CONSORTIUMON THE GENETICS
OF SCHIZOPHRENIA (COGS)
David Braff
Psychiatry, University of California San Diego, La Jolla, CA, USA
Background: Converging model organism, candidate gene and genome-
wide association (GWA) studies offer much promise in explicating theneur-
obiological significance of genes implicated in schizophrenia. Methods: The
COGS has constructed a 1536 COGS SNP Chip to interrogate 94 schizo-
phrenia-related genes of interest in schizophrenia. CIDR linkage analyses
are also forthcoming. COGS families include both parents, one proband
and one or more unaffected siblings, and 12 heritable endophenotypes
are assessed. In addition to the COGS primary endophenotypes, ‘‘second-
ary’’ endophenotypic data will be presented. For example, the oculormotor
domain antisaccade is more robustly heritable than is smooth pursuit eye
movement (SPEM). Results: 129 (of 350) families have been examined us-
ing the COGS SNP Chip. We will illustrate the distribution of SNPs that are
interrogated. The Table shows a partial representation of the striking
results. Genes such as NRG1 have significant ‘‘hits’’ on almost all of
the 12 endophenotypes, suggesting pleiotropy, and possible common
pathways that influence the expression of multiple endophenotypes. Other
genes ‘‘light up’’ singular endophenotypes suggesting alternative, perhaps
simpler pathways, leading to schizophrenia. Conclusions: The initial
analysis of the COGS SNP Chip SNPs provide a wealth of data on (1)
the heritabilities of neurophysiological and neurocognitive endopheno-
types, (2) the strong inference based SNPs reveal many (N = 194) significant
associations between heritable endophenotypes and the 94 genes in the SNP
Chip.Novel permutation and simulations will be presented on these data
analyses. These results will be discussed.
ID: 554724
NRXN3, A NOVEL RISK GENE FOR
SCHIZOPHRENIA
Ping-I Lin1,2, G. Thaker1
1Psychiatry, Maryland Psychiatric Research Center, Baltimore,
MD, USA; 2Psychiatry, National Taiwan University Hospital,
Taipei, Taiwan
In spite of numerous exciting susceptibility genetic variants disclosed by
recent studies, only few of these candidate loci have been found to be
unequivocally associated with schizophrenia across different studies.
Such inconsistent results may be attributable to genetic heterogeneity
reflected by genetic heterogeneity. Therefore, we propose to take advan-
tage of a clinical marker, smooth pursuit eye movement (SPEM), to help
circumvent the problem of genetic heterogeneity. In the current study we
have analyzed the genomic DNA of 100 subjects (ie, 51 schizophrenic
patients and 49 healthy controls, who are mostly Caucasian) using
the Affymetrix 6.0 SNP array. Four of these subjects were excluded
due to missing diagnostic data and hence 47 cases were 49 controls
were analyzed. Initially a total of 909,622 SNPs were analyzed, while
approximately 30% of these SNPs were excluded due to the concerns
about possible genotyping errors (corresponding P-values derived
from Hardy-Weinberg Equilibrium tests were less than 13107). SNPs
with a minor allele frequency < 1% were also excluded due to sparse
data in a particular genotype subgroup. Marker-by-marker association
tests were performed across the whole genome using the allelic trend
tests implemented in the software PLINK. Fifteen SNPs were hence
found to be significantly associated with risk of schizophrenia (p-value
< 13107). Eight of these 15 SNPs are located within 7 genes. All of
these 7 genes contained other SNPs nominally significantly associated
with schizophrenia (P < .05). Among these genes the NRXN3 gene
may warrant further study since it contains two SNPs, at which asso-
ciations reached the genome-wide significance. Neurexin 3 encoded by
the NRXN3 gene plays a key role in brain neuronal connectivity. In
addition, the NRXN3 gene has been found to be associated with alcohol
dependence and autism spectrum disorder. Our unpublished gene ex-
pression data also indicated that NRXN3 gene was expressed
differently between schizophrenic patients and healthy control subjects.
Taken together, NRXN3 may serve as a novel candidate gene for
schizophrenia.
ID: 552081
Table. Partial Representation of the most significant p value for each of the 12 COGS endophenotypes and 5 of the 94 candidate genes
Chr Gene PPI P50 Antisaccade DS-CPT LNS CVLT ABF FMEM SMEM SPA S-M EMO
1 NOS1AP P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.001
2 ERBB4 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.001 P < 0.01 P < 0.01
4 GRID2 P < 0.001 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01
6 GRM1 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.001 P < 0.01 P < 0.01 P < 0.01
8 NRG1 P < 0.01 P < 0.01 P < 0.01 P < 0.001 P < 0.001 P < 0.0001 P < 0.01
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ANALYSIS OF BDNF VAL66MET ALLELE-SPECIFIC
MRNA LEVELS IN SUBJECTS WITH MAJOR PSY-
CHOSIS AND SUICIDE BEHAVIOUR
Vincenzo De Luca, M. Manchia, J. Kennedy, A. Wong
Centre for Addiction and Mental Health, Toronto, ON, Canada
We investigate here the hypothesis that the BDNF Val66Met polymor-
phism is associated with suicide attempt in major psychosis. However,
the possibility that genomic imprinting in BDNF gene affects risk for sui-
cide has not been investigated before. To examine the possibility of genomic
imprinting in the BDNF gene in suicide attempt, we analyzed the parent-of-
origin effect (POE) and differential expression of the BDNF Val66Met
alleles in a sample of families with at least one subject affected by schizo-
phrenia or bipolar disorder. We performed a family-based association
study and ETDT analyses of the Val66Met polymorphism and the GT re-
peat polymorphism in 432 nuclear families, and compared allele-specific
mRNA levels in both post-mortem brain samples of suicide victims and
controls. The BDNF Val66 allele was not transmitted significantly more
often to patients with suicide attempt. There was no significant difference
between maternal and paternal transmission ratios. There was no signifi-
cant difference in the ratio of Val/Met-specific mRNA expression between
suicide victims and controls. These data do not support a role for genomic
imprinting as a modifier of the contribution of BDNF gene to risk of sus-
ceptibility to suicide in major psychosis.
ID: 551987
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9. 9. Health Economics and Services Research
REDUCING STIGMA: THE EFFECT OF AN EARLY
PSYCHOSIS EDUCATIONAL PROGRAM
Amy Nguyen-Burns1,2, K. Goddard2, S. E. Purdon2
1Educational Psychology, University of Alberta, Edmonton, AB,
Canada; 2Neuropsychology, Alberta Hospital Edmonton,
Edmonton, AB, Canada
Objective: The stigma associated with a mental illness can be an impediment
to recovery. In addition, stigma related to psychosis is more pronounced
than in other mental illnesses (Sartorius and Schulze, 2005; Jorm and
Wright, 2008). A brief educational program has been shown to be effective
in increasing knowledge and improving attitudes about mental illness (Wat-
son, 2004). The purpose of this project was to determine whether an edu-
cational intervention that focuses on psychosis delivered to high school
students increased their knowledge about signs and symptoms of early psy-
chosis and whether the same intervention reduced negative attitudes toward
people with schizophrenia. Methods: The study was a pre-post nonequiv-
alent groups quasi-experiment. One week before the educational program,
students were invited to complete a survey to assess their knowledge about
psychosis and their attitudes towards people suffering from psychosis. The
survey entailed review of a vignette about a fictitious character, ‘‘Harry’’,
who is showing signs of early schizophrenia. The students then answered
a series of questions to assess their attitudes towards ‘‘Harry’’ adapted from
Corrigan et al. (2002), and a series of questions to assess their prior expe-
rience and knowledge relating to psychosis adapted from Stuart and Arbo-
leda-Florez (2001). Upon completion of the educational program the
students completed the survey a second time. Results: Paired sample t-tests
were used to examine pre-and post-presentation differences of 24 completed
surveys. Students’ attitudes were generally more positive in the current sam-
ple relative to scores reported from similar previous investigations, but the
scores were also stable over time and gave no indication of a change after
the educational intervention. Conclusion: The educational intervention did
not produce a significant change in students’ attitudes towards people with
psychosis. This may relate to low statistical power, and a larger sample size
might detect subtle shifts related to the intervention. However, this sample
also reported more prior knowledge and more positive attitudes towards
people suffering from psychotic illnesses, perhaps resulting in a ceiling ef-
fect that is less sensitive to change. The consenting procedures in the present
study were somewhat onerous, and this may have resulted in a sample se-
lection bias towards participants with more knowledge and less negative
attitudes towards people with psychotic disorders.
ID: 535672
THE 2009 SCHIZOPHRENIA PATIENT OUTCOMES
RESEARCH TEAM (PORT) TREATMENT RECOM-
MENDATIONS: OVERVIEW AND UPDATE PROCESS
Julie Kreyenbuhl1,2, R. W. Buchanan1, L. B. Dixon1,2,
F. B. Dickerson3
1Department of Psychiatry, University of Maryland School of
Medicine, Baltimore, MD, USA; 2VA Capitol HealthCare Network
MIRECC, Baltimore, MD, USA; 3Sheppard Pratt Health System,
Baltimore, MD, USA
Background: The past decade has seen the advent of multiple sets of guide-
lines for the treatment of schizophrenia, including those developed by the
Schizophrenia Patient Outcomes Research Team (PORT). In contrast to
other guidelines, the Schizophrenia PORT treatment recommendations
are driven by the available evidence base. Expert opinion plays a limited
role. The original Schizophrenia PORT treatment recommendations
were published in 1998 and underwent revision in 2003. Over the last 5
years, there have been new developments in the pharmacological and psy-
chosocial treatment of schizophrenia, which warrant another update of the
PORT recommendations. Methods: Two Evidence Review Groups (ERGs)
comprised of over 20 faculty and trainees in psychiatry from the University
of Maryland, under the guidance of external Advisory Boards, have re-
cently conducted systematic literature searches to identify all studies of psy-
chopharmacologic and psychosocial treatments for schizophrenia
published since 2002. All studies that met pre-specified design standards
were reviewed, and pertinent data were abstracted in an online database
to facilitate the development of drafts of the updated treatment recommen-
dations along with accompanying evidence summaries. Treatments for
which the evidence is unlikely to be sufficient to warrant a treatment rec-
ommendation have also been reviewed. Results: The draft proposals will be
posted on a dedicated website and an Expert panel, comprised of the two
ERG Advisory Boards, additional clinical scientists and relevant stakehold-
ers, will provide feedback on the draft recommendations and evidence sum-
maries and will rate the quality, quantity, and consistency of the evidence. In
November 2008, we will hold a conference, at which the Expert Panel will
discuss with PORT investigators their critiques and ratings of the evidence
for each recommendation and will reach consensus on the content of the rec-
ommendations. The final updated recommendations will be published in
manuscript form and also displayed on a website for dissemination to pro-
fessionals and the public. Discussion: The proposed presentation will pro-
vide an overview of the process and the challenges of synthesizing
evidence for the 2009 Schizophrenia PORT Recommendations.
ID: 550779
THE EFFECTS OF SUBSTANCE USE ON BREAST
CANCER AND OSTEOPOROSIS SCREENING IN
WOMEN WITH SCHIZOPHRENIA: A REVIEW
OF CONTINUOUSLY COVERED MEDICAID
BENEFICIARIES
Deanna L. Kelly1, C. S. Myers2, S. Feldman1, M. T. Abrams3,
J. C. Shim4, R. P. McMahon1, S. Chen3
1Maryland Psychiatric Research Center, University of Maryland,
School of Medicine, Baltimore, MD, USA; 2National Institute on
Drug Abuse, Intramural Research Program, National Institutes of
Health, Department of Health and Human Services, Baltimore, MD,
USA; 3Center for Health Program Development and Management
(CHPDM), University of Maryland Baltimore County, Baltimore,
MD, USA; 4Department of Psychiatry, Inje University, Pusan City,
South Korea
Breast cancer (BC) and osteoporosis are major public health concerns in
women. These health risks may be significantly elevated in women with
schizophrenia, however evidence remains conflicting. Environmental fac-
tors may play a role in BC and osteoporosis risk and recent evidence sug-
gests BC mortality is increased in the general population with a substance
use disorder (SUD). SUD may also contribute to bone mineral density loss
in women with schizophrenia, however its contribution to risk has not been
examined. This study examined differential rates of BC and osteoporosis
screening in Maryland Medicaid beneficiaries. Subjects included only
non-pregnant females aged 18 to 64 with continuous (12 month) Medicaid
enrollment in FY2005. We examined administrative data from the following
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four groups of women: 1) schizophrenia and no SUD (N = 3,807), 2) schizo-
phrenia and SUD (N = 593), 3) no major psychiatric diagnosis or SUD (a
control group, N = 41,815), and 4) SUD in the absence of schizophrenia (N =
3,600). The mean age and race overall was 42.2 years and 56.9% were African
American. The unadjusted frequency of BC screening in women ages 40–64
years was 29.4% with schizophrenia, 23.3% of the control group, 19.1% of
those with schizophrenia and SUD, and 15.3% with SUD only. Logistic re-
gression models adjusting for race and Medicaid eligibility categories found
significant group effects (P < .0001) that were consistent in magnitude and
direction with these results. Screening for osteoporosis was lower across all
groups (<5% for women age 50–64) than BC screening rates, and logistic
regression modeling failed to identify significant group effects (P > 0.25).
Related sample isolation analyses found that the prevalence of non-benign
BC was 1.9% to 3.3% across the 4 groups, and osteoporosis was present in
5.0% to 7.5%. Preliminary analyses also suggest thatwomen with schizophre-
nia and SUD may be at the highest risk for bone loss and fracture. Overall,
this work indicates that Medicaid beneficiaries with schizophrenia and SUD
(dually diagnosed), or SUD alone, have lower rates of BC screening than
comparison subjects, and that the dually diagnosed group may be at slightly
heightened risk for osteoporosis. These results suggest that increased preven-
tative care efforts may be of special benefit to women with SUD and in
women who are dually diagnosed.
ID: 550336
THE 2009 SCHIZOPHRENIA PORT PSYCHOSOCIAL
TREATMENT RECOMMENDATIONS
Lisa Dixon
1Psychiatry, University of Maryland School of Medicine, Baltimore,
MD, USA; 2VA Capitol Health Care Network MIrecC, , Baltimore,
MD, USA
Background: The Patient Outcomes Research Team for Schizophrenia
(Schizophrenia PORT) project has had a major impact on the development
and dissemination of evidence-based practices for the treatment of people
with schizophrenia. In comparison to other treatment guidelines or algo-
rithms, the Schizophrenia PORT treatment recommendations are based
solely on empirical data. The original Schizophrenia PORT treatment rec-
ommendations were published in 1998, and underwent their first revision in
2003. Over the last 5 years, there have been a number of new developments
in the psychosocial treatment of schizophrenia, which warrant an update of
these treatment recommendations. Methods: Schizophrenia PORT inves-
tigators conducted extensive electronic literature searches to identify all
psychosocial treatment studies in schizophrenia published since the 2002
PORT literature review. We also reviewed studies preceding 2002 in areas
not covered by previous PORT reviews including smoking cessation, sub-
stance abuse, weight loss, and peer-based interventions. The abstracts of all
studies focusing on supported employment, family interventions, assertive
community treatment, cognitive behavioral therapy, cognitive remediation,
medication adherence, and interventions for individuals experiencing a first
psychotic episode were reviewed and abstracted. Specific intervention out-
comes were recorded including employment, hospitalization, symptoms,
quality of life, functioning, and substance abuse. If the article met pre-spec-
ified design standards, then the article was selected for review and included
in the PORT database. These articles were then used to update current
PORT psychosocial treatment recommendations and to develop draft pro-
posals for new treatment recommendations. Results: In November 2008,
the new treatment recommendations will be presented to a group of experts
in the treatment of schizophrenia, who will review the evidence for each
treatment recommendation and recommend revisions. Discussion: The
proposed presentation will discuss the final psychosocial treatment recom-
mendations for the treatment of first-episode and multi-episode people
with schizophrenia and will present areas of treatment that require further
investigation.
ID: 550118
THE 2009 SCHIZOPHRENIA PORT
PSYCHOPHARMACOLOGICAL TREATMENT
RECOMMENDATIONS
Robert W. Buchanan1,2, J. Kreyenbuhl2, D. Kelly1,2, J. Noel3,
B. Fischer1,2, D. Boggs1,2, P. Aquino2, B. Fang2, E. Peterson2,
W. Keller2
1Maryland Psychiatric Research Center, Baltimore, MD, USA;
2Psychiatry, University of Maryland School of Medicine, Baltimore,
MD, USA; 3School of Pharmacy, Baltimore, MD, USA
Background: The Patient Outcomes Research Team for Schizophrenia
(Schizophrenia PORT) project has had a major impact on the development
and dissemination of evidence-based practices for the treatment of people
with schizophrenia. In comparison to other treatment guidelines or algo-
rithms, the Schizophrenia PORT treatment recommendations are based
solely on empirical data. The original Schizophrenia PORT treatment rec-
ommendations were published in 1998, and underwent their first revision in
2003. Over the last 5 years, there have been a number of new developments
in the pharmacological treatment of schizophrenia, which warrant an up-
date of these treatment recommendations. Methods: Schizophrenia PORT
investigators conducted extensive electronic literature searches to identify
all pharmacological treatment studies in schizophrenia published since the
2002 PORT literature review. The article abstracts of all studies conducted
with first and second generation antipsychotics, antidepressants, antiepilep-
tics, benzodiazepines, and lithium and abstracts of all studies examining
specific outcomes, including agitation, cognition, first episode, metabolic
abnormalities, negative symptoms, quality of life and functional outcomes,
and substance abuse were reviewed. If the article met pre-specified design
standards, then the article was selected for review and included in the PORT
database. These articles were then used to update current PORT psycho-
pharmacological treatment recommendations and to develop draft pro-
posals for new treatment recommendations. Results: In November 2008,
the new treatment recommendations will be presented to a group of experts
in the treatment of schizophrenia, who will review the evidence for each
treatment recommendation and recommend revisions. Discussion: The
proposed presentation will discuss the final psychopharmacological treat-
ment recommendations for the treatment of first-episode and multi-episode
people with schizophrenia; the use of adjunctive medications for indications
other than positive symptoms; and the treatment of co-occurring
conditions, and will present areas of treatment that require further
investigation.
ID: 550008
STEP: PRAGMATIC RANDOMIZED PILOT TRIAL
OF INTEGRATED TREATMENT FOR FIRST
EPISODE PSYCHOSIS VS USUAL CARE IN THE
UNITED STATES
Scott W. Woods1,2, V. H. Srihari1,2, N. J. K. Breitborde1,2, J. K.
Saksa, T. H. McGlashan1,2
1Psychiatry, Yale University, New Haven, CT, USA; 2Connecticut
Mental Health Center, New Haven, CT, USA
Prospective studies of early psychosis suggest that most functional deteri-
oration occurs within the first few years after onset. The critical period hy-
pothesis holds that intensive intervention during these first few years could
lead to better functioning sustained over the long run. Randomized studies
in Europe suggest that intensive intervention for first episode patients
produces better outcomes and economic benefits that outweigh the
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increased treatment costs. These findings may not generalize automatically
to the United States (US), however, where medical care delivery is organized
very differently, where the outcomes of usual care may differ, and where the
opportunity for economic benefit may also differ. The overall objective of
Systematic Treatment for Early Psychosis (STEP) is to provide preliminary
evidence bearing on the early intervention hypothesis in the US, within
a cost-effectiveness paradigm, by conducting a randomized clinical trial
of integrated specialized services vs usual care. Insured first episode patients
are randomly assigned to receive access to STEP care in the public sector at
the Connecticut Mental Health Center, for which they would ordinarily not
be eligible because of having insurance, vs using their insurance in the pri-
vate sector as usual (usual care). Preliminary treatment utilization data
from the ongoing trial at six month follow-up show that nearly all patients
in both groups received medication but that far more patients randomized
to STEP received psychosocial treatment than those randomized to usual
care (any psychotherapy or case management, 85% vs 33%; any cognitive
behavior therapy, 77% vs 0%; any family therapy, 60% vs 0%). Preliminary
outcomes data show that 8/13 patients randomized to STEP treatment were
working or going to school at least half-time (62%), compared to 3/9
patients randomized to usual care (33%). These interim findings suggest
that a pragmatic trial of intensive treatment for first episode psychosis is
feasible in the US and underscore the question whether both treatment ef-
fect sizes and economic benefits of specialty first episode care may be more
substantial in the US than reported by previous European studies.
ID: 549955
A COST-BENEFIT ANALYSIS OF HIGHER
MEDICATION COPAYMENTS IN VETERANS
WITH SCHIZOPHRENIA
John E. Zeber1,2, L. A. Copeland1,2, A. L. Miller2,
M. Valenstein3,4, L. Luci1,5
1VERDICT (HSRD), Veterans Affairs, San Antonio, TX, USA;
2Psychiatry, UTHSCSA, San Antonio, TX, USA; 3Veterans Affairs
HSRD, Ann Arbor, MI, USA; 4Psychiatry, University of Michigan,
Ann Arbor, MI, USA; 5Medicine, UTHSCSA, San Antonio, TX,
USA
Medication non-adherence represents a significant problem for patients
with schizophrenia, substantially increasing psychiatric admission risks.
The 2002 Veterans Health Care Act raised medication copayments from
$2 to $7. From the VA’s perspective, such health policy decisions affect
both financial benefits and the potential costs associated with unintended
clinical consequences. This observational study documents the cost-offset
of copayment revenue versus subsequently higher inpatient and emergency
department (ER) costs. Pharmacy prescriptions, health services utilization,
and costs for all veterans (N = 69,986) diagnosed with schizophrenia were
analyzed 33 months Pre and Post policy change. We calculated additional
copayment revenue versus utilization costs (1999 adjusted dollars), con-
trasting veterans subject to copayment increases with a natural control
group of exempt patients. In comparison to the pre-policy period and Ex-
empt patients, total prescriptions for Copayment veterans (N = 33,431) in-
creased slightly, but psychotropic fills dropped 21%. During the same
period, psychiatric admissions and hospital days rose 4%, reversing down-
ward trends seen over the past decade. Overall, total prescriptions yielded
$17.3 million in new copayment revenue, but higher pharmacy costs of $5.5
million. Furthermore, inpatient and ER costs increased $13.3 million and
$0.6 million, respectively. Therefore, the net cost-benefit revenue change
was a negative $2.1 million, or $745 000 annualized losses. Sensitivity anal-
yses altered utilization costs and the proportion of post-policy changes due
to higher copayments, with annualized cost-benefits ranging from -$1.4 mil-
lion to -$0.1 million. This descriptive study implies that the policy change
indeed translated into greater copayment revenue. However, unanticipated
consequences included sharply reduced psychotropic fills leading to poorer
adherence and higher utilization. Recognizing complex causality assump-
tions, the VA nevertheless appeared to experience financial losses while
simultanesouly reducing veterans’ quality of life. Policy changes targeting
essential pharmacy benefits for vulnerable patients with schizophrenia
should be implemented carefully, evaluating trade-offs between immediate
financial gains and potential costs associated with clinical deterioration.
Longer term studies are needed to gauge the sustained effect over time
as veterans reconcile treatment decisions with their higher medication
expenses.
ID: 549869
THE EFFECTS OF A DOCUMENTARY FILM
ON REDUCING STIGMATISATION ABOUT
SCHIZOPHRENIA IN A SAMPLE OF UNDER-
GRADUATE PSYCHOLOGY STUDENTS
Frank Laroi, M. Van der Linden
University of Liege, Liege, Belgium
Negative public reactions concerning mental illness, and in particular
schizophrenia, may result in a number of negative consequences, including
aggravating their clinical condition and making it even more difficult for
patients to assimilate into society. The present study examined young peo-
ple’s attitudes about schizophrenia and furthermore evaluated the effect of
a documentary film (that depicts the lives of schizophrenia patients) on re-
ducing stigmatization about schizophrenia. One hundred and fifteen under-
graduate psychology students first provided information concerning their
attitudes and knowledge about schizophrenia, in addition to filling out
a questionnaire assessing their degree of acceptance of stereotypes and de-
gree of social distance towards schizophrenia patients. One week later, par-
ticipants viewed the documentary film and completed the same
questionnaire. The film significantly and positively influenced participants’
attitudes concerning schizophrenia. In particular, after having watched the
film, participants revealed less stereotypical attitudes about schizophrenia
and desired less social distance with schizophrenia patients. This change
was not related to social desirability or to age, sex or years of education.
ID: 549627
THE ROLE OF PATIENT RATED ASSESSMENTS
IN INTEGRATED CARE PATHWAYS FOR
SCHIZOPHRENIA
Robert Hunter1,2, R. C. Cameron2
1PsyRING, West Medical Building, University of Glasgow,
Glasgow, United Kingdom; 2SSOS, Gartnavel Royal Hospital,
Glasgow, United Kingdom
Introduction: The Scottish Schizophrenia Outcomes Study(SSOS) demon-
strated that patient rated assessments of mental health are an important
source of complimentary data for care planning(1). Following SSOS,
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Quality Improvement Scotland, the agency in Scotland for assuring stand-
ards of healthcare, developed a new strategy for mental health in Scot-
land(2). This recommended the introduction of routine outcome data
collection in mental health, including assessments made by patients
(PROs). This paper describes how this approach was researched and devel-
oped including: 1.the use of qualitative methods of consultation to assess
the views of patients who participated in SSOS over 3 years; 2.the work of
the Avon Development Group in Scotland (ADGS) to update the Avon
measure; 3.the use of patient rated outcomes (PROs) / needs assessment
in an Integrated Care Pathway(ICP) model of quality assurance. Methods:
A random 10% sample of the original cohort participated in 5 focus groups
consisting of patients with ICD10 F20–25 schizophrenia who had partic-
ipated in SSOS(1). Standard qualitative methods and analysis of responses
were employed. The work of ADGS will also be described. The use of ICPs
in schizophrenia will be described and an analysis of variance approach to
illustrate the quality improvement cycle for patients that utilizes outcomes
data, including self report PRO information such as Avon. Results and
Commentary: The routine collection and use of outcomes data in psychi-
atry is underdeveloped in most if not all psychiatric services. This is surpris-
ing given the challenges of patient management in schizophrenia and the
paucity of reliable outcomes and biomarkers, and the need to assess
new interventions or improve care delivered. SSOS has demonstrated
that routine data collection is possible and furthermore that patients can
contribute meaningfully to this process (using PROs) as recommended
for future trials by the FDA(3). The use of patient reported assessments
and ICPs to help improve the quality of care delivered appears a promising
approach for the future.
References
1. Hunter, et al. Psychiatric Services, 2008;in press.
2. Delivering for Mental Health. Scottish Executive Health Department,
Edinburgh, 2006. ISBN 0-7559-4835-1.
3. FDA. Guidance for industry: patient-reported outcome measures.
Health and Quality of Life Outcomes 2006;4:79.
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ATTITUDES OF PATIENTS WITH SCHIZOPHRENIA
AND DEPRESSION TOWARDS PSYCHIATRIC
RESEARCH
Monika Edlinger1, E. A. Deisenhammer2, M. Fiala2, A. Hofer1,
G. Kemmler2, R. Strauss2, C. G. Widschwendter1,
W. W. Fleischhacker1
1Biological Psychiatry, Medical University Innsbruck, Innsbruck,
Austria; 2General Psychiatry, Medical University Innsbruck,
Innsbruck, Austria
Objective: Despite considerable attention to general problems around the
availability of patients suffering from psychiatric disorders for research,
relatively little empirical work focusing on patients’ attitudes has been
done. In an attempt to replicate previous findings and extend results beyond
the group of schizophrenia patients we interviewed patients suffering from
schizophrenia and depression in a large academic centre regarding their
attitudes towards psychiatric research in a large academic centre and
a non-university psychiatric state hospital. Methods: Patients completed
the ‘‘Hamburg General Attitudes to Psychiatric Research Questionnaire’’
a newly created self-report questionnaire. Furthermore, demographic and
clinical data were collected. Illness severity was evaluated using CGI- and
GAF- Scores. Results: In general, patients in the university hospital ap-
proved of psychiatric research. Patients’ attitudes towards specific areas
of research and research methods were rather positive. There were no sig-
nificant differences between the two diagnostic groups regarding reasons
for participation or non-participation in a clinical trial. In both groups
the theoretical willingness to participate in studies was highest for studies
using a questionnaire. It was deemed highly important by all patients to
receive sufficient information about the study before taking part. Addi-
tional findings in patients treated in a non academic hospital will be avail-
able in time for the meeting. Conclusion: As our positive findings confirm
and extend those of other groups, psychiatrists should be encouraged to
approach patients to take part in clinical research.
ID: 549420
A LAYERED SERVICE AUDIT OF CLIENTS
PRESENTING TO A COMMUNITY-BASED
SERVICE FOR YOUNG PEOPLE AT INCREASED
RISK FOR PSYCHOSIS
Terry J. Lewin1,3, A. M. Conrad1, V. J. Carr1,3, U. Schall1,3,
S. Halpin1,2, K. A. Sly1
1Centre for Brain and Mental Health Research, University of
Newcastle and Hunter New England Mental Health, Newcastle,
NSW, Australia; 2Psychological Assistance Service, Hunter New
England Mental Health, Newcastle, NSW, Australia;
3Schizophrenia Research Institute, Sydney, NSW, Australia
The early detection and treatment of psychosis has been associated with
a shorter duration of untreated psychosis and better clinical outcomes.
The Psychological Assistance Service (PAS) is a community-based service
for young people at increased risk of developing a psychotic disorder, which
specialises in assessments and interventions similar to those of the Mel-
bourne PACE clinic. Recently, we commenced a layered service audit of
all presentations to PAS during the past ten-years. This project will: doc-
ument the socio-demographic and clinical characteristics of the PAS clients,
together with their estimated risk status; document patterns of service use in
the years subsequent to PAS presentation, together with any evidence of
psychosis ‘transition’; and examine relationships between baseline risk sta-
tus and service level outcomes. Preliminary findings from our service audit
will be reported, based initially on paper-based records that we have col-
lated in a database, which will be linked to regional electronic clinical and
service utilisation records. There were 2073 clients from Jan. 1997 to Dec.
2007, 22.5% were self or family referrals and 42.1% were referred by mental
health services. One-quarter (25.4%) completed a full review (ie, using the
comprehensive assessment of at risk mental states, CAARMS, or equiva-
lent). Socio-demographic, risk, referral and clinical profiles will be
reported, together with service utilisation patterns over subsequent years.
Among the first 500 clients with full reviews, 23.7% met criteria for ‘high
risk’, 16.7% were experiencing their first psychotic episode, 16.3% had an
‘existing psychosis’, and 38.9% had another disorder (typically depression).
This project provides a unique opportunity to examine service level out-
comes among clients with different patterns of risk for psychosis, and to
help to optimise future assessment and intervention strategies. We thank
the Australian Rotary Health Research Fund for their support.
ID: 549030
CONTINUITY OF CARE AFTER PSYCHIATRIC
HOSPITALIZATION
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Research, South Texas Veterans Health Care System, San Antonio,
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Together with our local community mental health center, we conducted
a demonstration project in which Medication Management Coordinators
(MMCs) contacted psychiatrically hospitalized patients assigned to one of
its clinics and followed them for six months after discharge. The program
focus was on patients with schizophrenia spectrum disorders. A
comparison group consisted of similarly diagnosed hospitalized patients
assigned to another clinic post discharge. The roles of the MMCs were
to make initial contact during the index hospitalization, to summarize
the medication history for the treating inpatient and outpatient prescribers,
to assess symptoms and record recent medication use at each clinic med-
ication visit, and to provide medication education and support. Service uti-
lization in both groups of patients was evaluated from records of the area’s
state and county psychiatric units, from the Medicaid database, and from
clinical and administrative records of the community mental health center.
Three periods were examined: 12 months prior to index hospitalization dis-
charge date, and the subsequent two six month periods. There were 326
subjects in the MMC group and 339 in the comparison group. Of the
MMC group, 208 had their initial contact with an MMC while hospitalized
and 118 were first seen at a post-discharge clinic visit. The latter group was
removed from the analyses reported here. A striking finding was the fre-
quency of patients having no medication visits to the clinics in each
time period. During the baseline period 57% of the entire group had no
recorded medication visits. During the period after the index hospitaliza-
tion this number decreased to 38%, but is unacceptably high for a group
with recently exacerbated psychoses. There was evidence that being seen
by an MMC prior to hospital discharge promoted coming in for a medica-
tion visit within 30 days. Of the patients not coming to clinic within 30 days,
71% were in the comparison group and 29% in the MMC group. The MMC
group had significantly more clinic visits, but the groups did not differ in
hospitalizations or days in the hospital during the intervention or follow-up
periods. These data illustrate lack of engagement of many patients in post-
hospital care. The MMC intervention improved clinic show rates within 30
days, but it is clear that other approaches must also be used in dealing with
the lack of engagement problem.
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THE COST OF RELAPSE FOR SCHIZOPHRENIA:
A COMPARISON OF A STATE HOSPITAL, A
PRIVATE CONTRACTED SERVICE AND A STATED
COMMUNITY ATTENDANCE
Claudiane Salles Daltio, M. B. Ferraz, J. J. Mari
Psiquiatria, UNIFESP, Sa˜o Paulo, Brazil
Objective: Relapse is an important component of the high overall cost for
Schizophrenia. The main objective of this survey is to compare the cost of
relapse in the three main settings where acute patients are admitted in the
city of Sao Paulo: a Public Hospital (PH); b) a Private Hospital partner of
the Public Health System (PHP; and c) a Psychosocial Center for Commu-
nity Care (CAPS). Methods: 30 randomly selected records of acute admis-
sions in each setting (n = 90) were selected for the year 2006. Costing of the
admissions included resources like medication, tests and consultations
(medical and other professionals), food, hosting, and service administra-
tion. Results: The total Medical-Hospital Direct Cost for relapse in schizo-
phrenia, per patient, was 8.167,58 reais ($4950) in PH; 4.605,46 reais
($2791) in CAPS and 2.397,74 reais ($1453) in PHP. The main component
of cost was related to human resources (42 a 75%) The cost of medicines
varied according to the extent of using typical or atypical antipsychotics:
typical antipsychotics were more used in the PHP and atypical in the com-
munity centers (CAPS). Conclusion: The highest cost of relapse was found
to be in the public hospital and the lower cost in the private hospital
partner. The management of the crisis in the community centers presented
a intermediary cost, but patients were more likely to be under treatment of
atypical anti-psychotics. Therefore, treating patients in the community had
an intermediary cost between Public Hospitals and Contracted Private
partners, with the benefit of treating the patient closer to his/her family,
with fewer adverse events and quality of life.
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THE FIRST THREE YEARS OF PHARMACOTHER-
APY IN PATIENTS WITH PSYCHOTIC DISORDERS:
A COMPARISON BETWEEN THE EARLY INTER-
VENTION PROGRAMME AND STANDARD CARE
SERVICE IN HONG KONG
Jennifer Yee Man Tang1, E. Chen1, C. Hui1, C. W. Law2, C. Yew1,
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Hospital, Hong Kong, China; 6Psychiatry, Kowloon Hospital, Hong
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This naturalistic study reviews the use of antipsychotics in patients with
psychotic disorders in the first three years of psychiatric treatment. This
historical-controlled study included 700 patients first presented to the local
early intervention programme (EI) from 2001 to 2003, and 700 patients first
presented to standard care service (SC) from 1998 to 2001. The data were
systematically extracted from medical records according to operationalized
definitions. In the EI group, 22.2% of cases were prescribed atypical anti-
psychotics as the initial pharmacotherapy, which increased to 59.4% and
58.7% in the first and second switches of antipsychotics respectively. Re-
spective statistics in the SC group (6.3%, 19.5% and 23.4%, all p-value
<.001) were significantly lower than the EI group. In EI, the three most
frequently prescribed antipsychotics in initial treatment were convention-
als: haloperidol (28.6%), trifluoperazine (23.7%) and sulpiride (14.5%).
First switch of antipsychotics was mainly risperidone (22.0%), olanzapine
(19.3%) and sulpiride (11.1%). Second switch of antipsychotics was mainly
to olanzapine (19.9%), risperidone (13.6%) and sulpiride (10.7%). In SC, the
three most frequently prescribed antipsychotics in the initial treatment were
haloperidol (32.1%), trifluoperazine (26.6%) and chlorpromazine (12.7%).
First switch of antipsychotics were mainly conventional antipsychotics,
which were trifluoperazine (15.3%), sulpiride (15.0%) and chlorpromazine
(11.1%). The second switch of antipsychotics was similar to the first switch:
sulpiride (16.9%), chlorpromazine (14.9%) and trifluoperazine (12.9%). In
the first three years of psychiatric treatment, the findings revealed that early
intervention programme in Hong Kong had a different practice in prescrib-
ing antipsychotics. Atypical antipsychotics were more widespread in use in
the EI group while conventional antipsychotics remained to be the major
pharmacotherapy in the SC group. This study was fully funded by Health
and Health Services Research Fund, by Food and Health Bureau, The
Government of the Hong Kong Special Administrative Region. The
reference number is 03040141.
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MANAGEMENT OF ANTIPSYCHOTIC
MEDICATION ASSOCIATED OBESITY
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The primary objective of this research proposal is to elaborate and test the
effectiveness of a program to combat the most serious side effect of anti-
psychotic medication treatment, obesity, in severely mentally ill patients.
Specifically, we wish to test the effect of the Lifestyle Balance (LB) program,
a year-long psychoeducational intervention, on knowledge about healthy
lifestyles and determine if the classes along with a prescribed diet and ex-
ercise regimen improve patients’ metabolic profiles, cardiovascular risk fac-
tor status, and mental health compared to usual psychiatric treatment. A
secondary objective of the LB program is to learn what the barriers are to
achieving weight loss in this population, and to try to create a program that
psychotic individuals will master that are easily implemented in any psychi-
atric setting and can be taught by almost any mental health staff. 120
patients with severe mental illness, identified as having gained weight result-
ing in obesity (an increase in body weight of 7% or more, or a BMI greater
than 25) while taking an antipsychotic medication, were referred for this
one year randomized research program. Each patient’s medications, mental
status, cardiovascular risk factors and metabolic status are carefully eval-
uated at baseline and then quarterly. Patients are interviewed to assess their
mental status, insight into their mental illness, and knowledge of healthy
lifestyles, diet, exercise, and nutrition. Patients were randomized to either
usual care (UC) or to the LB program. The LB program includes standard-
ized classes, meetings with a dietician, exercise sessions, field trips, and
rewards to promote healthy eating and an active lifestyle. We have enrolled
109 patients after 30 months of recruitment, 53 to LB and 56 to UC. So far,
59 of these patients have completed at least the first 6 months of the study,
45% from LB and 54% from UC. Among LB participants, 37% lost weight
by month 6, 52% maintained their weight, and 11% continued to gain
weight. Among those in UC, 16% lost weight by month 6, 46% maintained
their weight, and 38% gained weight. Weight change was defined as being
five or more pounds above or below baseline weight. To date the average
LB participant lost .13 lbs per week over the 52 weeks, while the average UC
participant gained .1 lbs/week. There was a statistically significant differ-
ence in weight between the two groups (F = 25; df 1,935; P = .01) utilizing
a random intercept model.
ID: 551919
HIGH UTILIZERS OF INPATIENT STATE HOSPITAL
SERVICES
Troy Alan Moore1, A. L. Miller1, L. Lopez2, D. Castillo1,
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High utilization of the local state hospital services by a small proportion of
the population accounts for a large proportion of inpatient services for cli-
ents of the area community mental health center (CMHC). Reduction of
inpatient hospital services requires detailed characterization of the high uti-
lizer population to design and implement interventions. The primary ob-
jective is to describe high utilizers of inpatient state hospital services in
Bexar County, Texas. State hospitalization use data was obtained for
patients assigned to the area CMHC from September 1, 2006 to January
31, 2008. ‘‘High utilizers’’ were patients with3 hospitalizations having an
admission and/or discharge date within the study period. The number of
high utilizers; number of hospitalizations/patient; average length of stay/
hospitalization; total bed days/patient; diagnosis; outpatient activity and
service level status; most recent outpatient clinical contact; and outpatient
chart availability were examined. 80/1150 hospitalized patients (7%) met
the definition of ‘‘high utilizer’’. 85% of the high utilizer population had
3–4 hospitalizations. The average length of stay/hospitalization was 37.8
days. The average total number of bed days/patient was 124. High utilizers
accounted for 19.2% of the total hospital days for the entire hospitalized
population. 74% of the population had a schizophrenia spectrum disorder.
Outpatient psychiatric clinic status was ‘‘closed’’ for 38/80 (48%) patients,
meaning they were not currently receiving any mental health services from
the CMHC. 18/42 (43%) patients with ‘‘open’’ charts were receiving ACT
services. Fifty-four high utilizers (68%) had CMHC charts available for re-
view. Of these, 18 only had a CMHC intake interview, 7 patients had only
one outpatient follow up visit, and 29 patients had multiple outpatient fol-
low up visits. Many high utilizers of inpatient state hospitalization services
in Bexar County do not engage in outpatient treatment despite being
assigned to the CMHC. Further analyses of clinical and demographic char-
acteristics that differentiate engaged versus non-engaged high utilizers are
planned.
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RISK ADJUSTMENT MODEL FOR HOSPITAL
ADMISSION IN AN EARLY PSYCHOSIS
TREATMENT SERVICE
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Background: Risk adjustment models are required in order to compare out-
comes between early psychosis treatment services (EPTS) while taking into
account case mix differences. Objectives: To develop a risk adjustment
model for comparison of EPTS programs with respect to a key outcome
measure: admission to hospital within one, two and three years of admis-
sion to the EPTS. Methods: A literature review was performed to identify
potential risk adjustment variables for hospital admission. A panel of
experts identified a set of candidate risk adjustment factors for hospital ad-
mission. Risk adjustment models were then developed and tested using data
from one cohort of early psychosis patients (n = 279) and validated using
data from a second cohort of early psychosis patients (N = 300). Eleven
potential risk adjustment variables were age, gender, ethnicity, marital sta-
tus, hospitalization prior to enrollment in EPTS, initial Global Assessment
of Functioning (GAF) and Positive and Negative Symptom severity
(PANSS) scores, co-morbid major depression, co-morbid substance abuse,
and duration of untreated psychosis (DUP). Multivariable logistic regres-
sion modeling was employed. C-statistics (a measure of model discrimina-
tion) were calculated to assess model performance. Results: In the
development data, preliminary results indicate that prior hospitalization
was the only significant predictor for hospital admissions within one
year of enrollment to the EPTS (OR = 1.88, 95%CI 1.01–3.52). Hospital
admissions after two and three years were significantly associated with
higher levels of initial positive symptoms (OR = 1.07, CI 1.02 – 1.13;
OR = 1.07, CI 1.01–1.12) respectively and prior hospitalizations (OR =
2.73, CI 1.52–4.88; OR = 3.35, CI 1.88–5.98) respectively. The performance
of the logistic modeling was good, with C-statistics ranging from 0.72 to
0.74 for the three outcomes. In the validation data, the C-statistics were
slightly lower, ranging from 0.62–0.72. Conclusions: The C-statistic values
indicate that this will be a useful method, and we are continuing our anal-
yses to assess which variables to include in the final model.
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Project GREAT (Georgia Recovery-Based Educational Approach to
Treatment) developed an educational curriculum based on the
SAMHSA-defined (2006) ten ‘‘Fundamental Components of Recovery’’.
As an initial evaluation, we examined effects of the training program on
recovery-based knowledge and recovery-consistent attitudes by compar-
ing our clinicians (n = 43) knowledge and attitudes to those of a similar
group of clinicians (n = 34) at a neighboring medical institution who did
not receive the intervention and training. Clinicians knowledge and atti-
tudes were assessed using a 26-item Recovery Knowledge Questionnaire
developed for this project, by the Recovery Knowledge Inventory (Bed-
regal, O’Connell, and Davidson 2006), by the Recovery Attitudinal Pre-
Post Survey (Cook, Jonikas, and Razzano 1995) and by the Attribution
Questionnaire–27 (AQ-27; Corrigan, Watson, Warpinsky, and Gracia
2004). Clinicians showed significant change in three of the four measures
(both knowledge and one attitude measure) but still demonstrated no
significant change in their adoption of stigmatizing attitudes toward con-
sumers as measured by the AQ-27. The clinicians receiving the educa-
tional intervention had significantly higher scores than the comparison
group for both recovery knowledge measures and more recovery-promot-
ing attitudes, although as important limitations these comparisons were
constrained by differences in baseline pre-test scores between both
groups, by sample size and by the use of self-report attitudinal scales.
While these results at least suggest the potential benefit of a Recovery-
based Educational Program, whether knowledge and attitude change
then produces meaningful behavioral change is of course another,
more fundamental question.
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A CASE-CONTROLLED STUDY ON THE OUTCOME
OF AN EARLY INTERVENTION PROGRAMME FOR
PSYCHOSIS (EASY)
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In an attempt to improve the outcome for psychotic disorders, the EASY
(Early Assessment Service for Young People with Psychosis) programme
was launched in Hong Kong in 2001. Being one of the first in Asia, it com-
prised of two major components, namely early detection and critical period
intervention. Comparison was made with a matched historical control
group under standard care where the first psychotic episode was usually
managed under in-patient care, followed by relatively sparse outpatient vis-
its with little psychosocial support. The EASY service provides specialised
multidisciplinary team to offer a comprehensive package of intervention
targeting the specific needs of patients and their carers at this stage of
the disorder. It adopts a case-management approach and assertively follows
first-episode patients for 2 years after the initial episode. Results at three
years showed that EI patients had fewer days in hospital, better functional
outcome, lower likelihood of disengagement from service, and less aggres-
sive behaviour, completed suicides or suicide attempts. No significant dif-
ference was found for relapses and the duration of untreated psychosis
(DUP) suggesting that in Hong Kong, the improved outcome was not me-
diated by these two variables. The present study suggests that early psycho-
sis programme in Hong Kong is successful in improving the 3-year outcome
of psychotic disorders. The effect appears to be attributable to improved
intervention rather than to a reduction of DUP, relapses or atypical
medication.
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THE UK MENTAL HEALTH RESEARCH NETWORK:
LARGE SCALE TRIALS FOR NON-DRUG INTER-
VENTIONS IN SCHIZOPHRENIA
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The UK Mental Health Research Network has been funded by the UK
Department of Health since 2005 to provide the clinical and scientific in-
frastructure to run large scale externally-funded trials and cohort studies. It
comprises a coordinating centre run jointly from the Institute of Psychiatry,
London, and the University of Manchester and a network of 8 research
hubs. Each research hub contains a University department and a series
of linked clinical sites and total population covered is about 50% of England
or 20 million people. Input from patient and carer groups is standard. Links
to industry, primary care and social care are important and links to other
European mental health research networks are developing. The main aims
of the network are quality assurance of study design, to accelerate start-up
of multi-centre research projects, ensure timely recruitment to target and
provide secure web-based data entry. The network hosts 130 studies in
its current portfolio totalling research costs in excess of $100 million, across
all disease areas in mental health. Three examples of large scale studies in
schizophrenia will be discussed: two multisite randomised controlled trial of
psychological interventions for psychosis, one in dual diagnosis (sample
recruited 230) and one for at risk prodromal mental states, and one cohort
study in first episode psychosis (sample recruited 680).
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INTEGRATING UHR RESEARCH AND PRACTICE
INTO THE PUBLIC HEALTH AGENDA: THE
BIRMINGHAM ED:IT PROGRAMME
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United Kingdom
The ED:IT programme has been in operation since 2000 and is a core ser-
vice of the Birmingham Early Intervention in Psychosis service; both are
embedded within a youth mental health services structure. The function
of ED:IT is to reduce DUP across the city by one of two strategies: engaging
and intervening with youth at high risk of psychosis and by a unique public
health programme across the city targeting ‘at risk’ populations, commu-
nities and key care pathways. This includes a focus on the minority ethnic
communities and their care pathways, neighbourhoods with high incidence
of psychosis and primary care. UHR youth are accessed via help seeking
pathways, including schools and colleges, counselling, drug agencies and
primary care. We illustrate the pathways approach using data from the
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UK National Evaluaton of Early Intervention Services that we lead (Na-
tional EDEN) and the EU Prediction of Psychosis (EPOS) project in which
we are co-grantholders and a collaborating site. Funding for a 5-year public
health programme to reduce DUP and UHR transitions has recently been
won from the UK Department of Health, to begin in April 2009. This brings
together the unique public health strands of ED:IT to reduce DUP across
Birmingham (pop 1.2m) from 12 to 3 months. This research programme
will be described and how it fits in with previous population based studies.
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Introduction: RCTs have limitations as a means of assessing effectiveness
and adverse impact on patients.Many therapeutic advantages and adverse
consequences are only identified post launch from observational studies
and patient feedback. While RCTs have an important role in assessing
efficacy, there is a need for complimentary studies which report patients’
experience of treatments.This approach has been utilized in other health-
care areas, and in psychiatry in the Scottish Schizophrenia Outcomes Study,
SSOS (Hunter etal 2008). Importantly the FDA has also recommended that
Patient Reported Outcome Measures should be part of the portfolio of
assessments employed in clinical trials. In this paper we report the results
of a large survey of psychiatric patients in Scotland to elicit a wide cross-
section of views from people currently treated with antipsychotic and other
medication. Method: A standard survey form was developed and distrib-
uted thru a major mental health charity, (Scottish Association for Mental
Health), including the SAMH website. The survey form was completed by
service users and returned to the research team; a number of focus groups
were also held across Scotland. Data analysis was undertaken indepen-
dently at the University of Strathclyde. The results were interpreted in
the light of clinical experience and evidence from trials such as CATIE.
Results: A total of 1012 participants completed and returned survey forms.
Of these, 76% were analyzable, with equal numbers of M and F partici-
pants; 61% aged 30–49; diagnoses: 47% depression, 22% schizophrenia,
21% anxiety disorder and 20% bipolar disorder. Only 50% of respondents
reported satisfaction with treatment experience and doctor. This report
describes respondents’ views on the usefulness and adverse effects of anti-
psychotics, comparing first and second generation; in addition participant
views on antidepressants, mood stabilizers and anxiolytics will be pre-
sented. Comment: Successful healthcare requires partnership with service
users: this is particularly important in psychiatry. This survey provides use-
ful information on the experience of medication of a large and representa-
tive sample of people with severe and enduring mental disorders in the UK.
Despite concerns about insight and subjectivity, the views of participants
using inexpensive methods are consistent with results from CATIE.
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10. 10. Neuroanatomy, Animal
ROLE OF MYELINATION GENES IN VIRALLY-
INDUCED BRAIN DISORDER IN MOUSE: A DNA
MICROARRAY AND MRI STUDY
S. Hossein Fatemi1, T. J. Reutiman1, T. D. Folsom1, S. Mori2,
D. A. Pearce3
1Psychiatry, University of Minnesota, Minneapolis, MN, USA;
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Maternal viral infection is known to increase the risk for schizophrenia in
the offspring (Fatemi et al. 2008). We sought to pursue the effects of E16
(middle 2nd trimester) infection on brain morphology and gene expression,
at postnatal days 0, 14, 35 or 56, in virally-exposed (N = 4) or sham-infected
controls (N = 4) offspring. Brains were fixed for MRI or homogenized and
subjected to DNA microarray. Morphometric analysis of brain following
infection of C57BL/6 mice at E16 revealed numerous defects. The area for
hippocampus at P35 and cerebellum at P14 were both reduced (P < .014
and P < .029, respectively). Overall brain volume was reduced at P14 (P <
.018) and ventricle volume was reduced at P0 (P < .025). Moreover, frac-
tional anisotropy (FA) revealed the following changes: decrease in white
matter thickness in the internal capsule (IC; right) at P0 (P < .033); and
increases in white matter thickness in the corpus callosum at P14 (P <
0.024) and the middle cerebellar peduncle (MCP; right) at P56 (P <
0.006) Microarray analysis of brains from exposed C57BL/6 mice
following infection at E16 showed a significant (P < .05) at least 1.5
fold up- or downregulation of genes in frontal (151 upregulated and 35
downregulated at P0; 106 upregulated and 86 downregulated at P14;
and 107 upregulated and 118 downregulated at P56), hippocampal (300
upregulated; 190 downregulated at P0; 33 upregulated and 45 downregu-
lated at P14; and 86 upregulated and 17 downregulated at P56), and cer-
ebellar (26 upregulated and 72 downregulated at P0; 204 upregulated and
15 downregulated at P14; and 449 upregulated and 204 downregulated at
P56) areas of virally-exposed mouse offspring ice. Quite interestingly, my-
elin related genes (MAG, MBP, MOBP, MOG) were significantly upregu-
lated in cerebella of P14 offspring of virally-exposed mice, explaining the
increased FA (increased white matter) in the right middle cerebellar pedun-
cle. These results implicate long-term effects of viral infection in utero on
brain development in the mouse progeny. The generous support by the Na-
tional Institute for Child Health and Human Development (5R01-
HD046589-04) to S.H.F. is greatly appreciated.
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NEURODEVELOPMENTAL DISORDERS
Tom Burne1,2, C. Foldi1, D. Eyles1,2, J. McGrath1,2
1Queensland Brain Institute, The University of Queensland,
Brisbane, QLD, Australia; 2Queensland Centre for Mental Health
Research, The Park Centre for Mental Health, Brisbane, QLD,
Australia
Epidemiological evidence suggests that advancing paternal age leads to an
increased risk of various adverse health outcomes in offspring, including
schizophrenia and autism. The biological mechanisms underlying these
associations are not known. However, because there are many more germ-
line cell divisions in the life history of a sperm relative to that of an oocyte
there may be more opportunities for copy errors in germ cells from older
fathers. Here we report data on various behavioural and neuroanatomical
parameters related to schizophrenia and autism from a mouse model of
Advanced Paternal Age (APA). Young and aged C57Bl/6J males (4 versus
18 months) were mated with 4 month old females. Adult (4 month old)
offspring were examined using a comprehensive behavioural test battery
to establish that APA induced no gross morphological or neurological ab-
normalities. Next tests incorporating animal models of anxiety (elevated
plus-maze), exploration (holeboard test), sensorimotor gating (PPI), loco-
motion (open field test), working memory (8-arm radial maze) and spatial
memory (Morris water maze) were examined. Brain anatomy in these
same animals was assessed using the 16.4 Tesla microimaging facility
(Bruker BioSpin; Centre for Magnetic Resonance, Univ. of Qld). The
adult offspring of older sires (APA group) differed significantly from
the offspring of younger sires on a range of behaviours related to explor-
atory and ‘anxious’ phenotypes. The APA group spent significantly less
time on the open arms of the elevated plus maze than the control group.
The APA group also performed significantly fewer head dips and bouts of
rearing on the elevated plus maze, had significantly more head dips in the
hole board test and showed reduced rearing behaviour in the open field.
There were no significant group differences for the other behavioural
measures. Analysis of brain structure using MRI indicated that the
male APA adult offspring had a significantly enlarged cerebral cortex
compared to control male mice. Taken together these data reveal subtle
changes in behaviour and altered brain morphology as a consequence of
APA. These findings do not map neatly onto animal models of schizophre-
nia, but are more reminiscent of animal models related to autism (anxiety,
cortical overgrowth). Future animal studies will allow us to refine the
behavioural and structural phenotype and explore genetic and epigenetic
mechanisms that may underpin these changes.
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M. Cue´nod1, K. Q. Do1
1Psychiatry–CHUV Cery, University Hospital of Lausanne, Prilly–
Lausanne, Switzerland; 2Department of Environmental Health,
University of Cincinnati, Cincinnati, OH, USA
An increased oxidative stress and alteration of the antioxidant systems
have been observed in schizophrenia. Glutathione (GSH), a major redox
regulator, is decreased in patients’ cerebrospinal fluid, prefrontal cortex
in vivo and striatum post-mortem tissue. Most importantly, there is genetic
and functional evidence for the implication of the gene of the glutamate
cysteine ligase (GCL) catalytic subunit, the key GSH-synthesizing enzyme.
We have developed animal models for a GSH deficit to study the conse-
quences of such deficit on the brain development. A GSH deficit combined
with elevated dopamine (DA) during development leads to reduced par-
valbumin (PV) expression in a subclass of GABA interneurons in rat an-
terior cingulate cortex (ACC). Similar changes are observed in post-
mortem brain tissue of schizophrenic patients. GSH dysregulation
increases vulnerability to oxidative stress, that in turn could lead to cor-
tical circuit anomalies in the schizophrenic brain. In the present study, we
use a GCL modulatory subunit (GCLM) knock-out (KO) mouse model
that presents up to 80% decreased brain GSH levels. During postnatal de-
velopment, a subgroup of animals from each genotype is exposed to ele-
vated oxidative stress induced by treatment with the DA reuptake
inhibitor GBR12909. Results reveal a significant genotype-specific delay
International Congress on Schizophrenia Research
136 10. 10. Neuroanatomy, Animal
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
in cortical PV expression at postnatal day P10 in GCLM-KO mice, as
compared to wild-type. This effect seems to be further exaggerated in ani-
mals treated with GBR12909 from P5 to P10. At P20, PV expression is no
longer significantly reduced in GCLM-KO ACC without GBR but is re-
duced if GBR is applied from P10 to P20. However, our result show that
GCLM-KO mice exhibit increased oxidative stress, cortical altered myelin
development as shown by MBP marker, and more specifically impairment
of the peri-neuronal net known to modulate PV connectivity. In addition,
we also observe a reduced PV expression in the ventro-temporal hippo-
campus of adult GCLM-KO mice, suggesting that anomalies of the PV
interneurons prevail at least in some brain regions throughout the adult-
hood. Interestingly, the power of kainate-induced gamma oscillations,
known to be dependent on proper activation of PV interneuron’s, is
also lower in hippocampal slices of adult GCLM KO mice. These results
suggest that the PV positive GABA interneurons is particularly vulnerable
to increased oxidative stress.
ID: 550998
PREFRONTAL NEURONAL ARCHITECTURE IS
DISRUPTED IN THE RAT PRENATAL STRESS
MODEL OF SCHIZOPHRENIA
Julie A. Markham; J. I. Koenig
Psychiatry, University of Maryland—Baltimore, Baltimore, MD,
USA
Although the etiology of schizophrenia remains a mystery, it is clear that
both genetic and environmental factors can confer risk for the illness.
Maternal stress, malnutrition, and viral infection during pregnancy—
events which activate the hypothalamic-pituitary-adrenal axis—increase
the risk that the offspring will later develop schizophrenia. Our labora-
tory has developed a paradigm in which maternal stress during the final
week of rat gestation alters the offspring’s HPA axis, neurodevelopment,
and behavior in ways that are consistent with the pathology observed in
schizophrenia (Koenig et al., 2005; Lee et al., 2007). In the present ex-
periment, we hypothesized that exposure to gestational stress would re-
sult in reduced dendritic spine density and dendritic tree complexity of
pyramidal neurons in layer III of the prefrontal cortex, as is observed in
post-mortem tissue from individuals who suffered from schizophrenia
(eg, Glanz and Lewis ’00). Sprague-Dawley dams were exposed to re-
peated variable stress during days 14–21 of gestation. Male and female
offspring of stressed and control dams were examined at multiple post-
natal timepoints, and brains were processed using a Golgi Cox tissue
preparation. Results support the hypothesis that prenatal stress reduces
dendritic complexity of layer III pyramidal neurons in the prefrontal cor-
tex. Interestingly, the treatment effect interacts with sex such that males,
but not females, show reduced dendritic complexity as a consequence of
prenatal stress. Thus the normal sex difference (male>female) in den-
dritic complexity is eliminated by exposure to prenatal stress. This pat-
tern of results was observed both prior to (day 20) and following (day
56) puberty. Reductions in dendritic complexity among males exposed to
prenatal stress were more striking in the basilar dendritic tree compared
to the apical. The greater vulnerability of the male prefrontal cortex to
gestational stress may be relevant to the finding that schizophrenia is
approximately 40% more prevalent among men compared to women
(Aleman et al. ’03; McGrath et al. ’04). Future experiments will test
the hypothesis that gene expression in the prefrontal cortex and cognitive
behavior supported by this region are also disrupted following prenatal
stress as they are in schizophrenia. This work was supported by NIH
grants MH067533 (J.A.M.) and RO1 MH073826 (J.I.K.).
ID: 551760
A LONGITUDINAL STUDY OF THE EMERGENCE
OF POSTNATAL NEUROANATOMICAL ABNOR-
MALITIES IN NON-HUMAN PRIMATES EXPOSED
TO IRRADIATION IN UTERO: A NEURODEVELOP-
MENTAL MODEL OF SCHIZOPHRENIA
Kristina Aldridge1,2, L. Wang2,3, M. Harms3, A. J. Moffitt1,
K. K. Pope1, J. G. Csernansky2,3, L. D. Selemon2,4
1Pathology and Anatomical Sciences, University of Missouri School
of Medicine, Columbia, MO, USA; 2Psychiatry, Northwestern
University School of Medicine, Chicago, IL, USA; 3Psychiatry,
Washington University School of Medicine, St. Louis, MO, USA;
4Neurobiology, Yale University School of Medicine, New Haven,
CT, USA
Prenatal perturbation of brain development is associated with an increased
incidence of schizophrenia. Yet symptoms of schizophrenia most often are
not expressed until adolescence or even adulthood. In this study prenatal
exposure to x-irradiation was used to disrupt neurogenesis in non-human
primates in order to model the neurodevelopmental origin of schizophre-
nia. Here we examine the temporal emergence of neuroanatomical changes
in macaques exposed prenatally to irradiation. Magnetic resonance scans
were collected at 6 months, 12 months, 3 years, and 5 years of age in mac-
aques exposed to x-irradiation (N = 5) or sham-irradiation (N = 5) during
early gestation (E30–41). Volumes of the whole brain, cortical gray matter,
striatum (caudate, putamen, nucleus accumbens), and the thalamus were
compared between cohorts at each of the four ages. Irradiated monkeys
showed reduced volume in all structures examined at all four ages. The
magnitude of reduction of whole brain volume remained relatively constant
(10–15%) with increasing age. In contrast, volumetric deficits of cortical
gray matter, thalamus, and striatal structures became disproportionately
larger with age in irradiated individuals, with thalamus (10–20%) and puta-
men (12–25%) showing the most pronounced reductions at older ages.
These results indicate that disruption of neurogenesis during early gestation
results in progressive volume loss in multiple brain structures during post-
natal ontogeny and ultimately produces a global pathology resembling that
of schizophrenia. These findings also provide biologic support for the con-
cept that small prenatal changes may produce larger effects in adulthood.
Work supported in part by MH071616, T32MH17104, and University of
Missouri Department of Pathology and Anatomical Sciences.
ID: 551677
DEVELOPMENTAL REFINEMENTS IN PRIMATE
PREFRONTAL CORTICAL CIRCUITRY
David A. Lewis, T. Hashimoto, G. Gonzalez-Burgos, D. Cruz
Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
In schizophrenia, working memory dysfunction is associated with altered
GABA transmission in the prefrontal cortex (PFC). In primate PFC, the
functional maturation of the synaptic connections of certain classes of
GABA neurons is complex. For example, the levels of pre- and post-
synaptic proteins that regulate GABA neurotransmission from chandelier
GABA neurons to the axon initial segment (AIS) of pyramidal neurons un-
dergo marked changes perinatally and during adolescence. To understand
the molecular mechanisms driving these developmental refinements, we
quantified the densities and lengths of pyramidal neuron AIS immunore-
active for ankyrin-G, BIV spectrin, or gephyrin, three proteins involved in
regulating synapse structure and receptor localization, in the PFC of rhesus
monkeys. Ankyrin-G- and BIV spectrin-labeled AIS declined in density and
length during the first 6 months postnatal, but then remained stable
through adolescence and into adulthood. In contrast, the density of gephyr-
in-labeled AIS was stable until approximately 15 months of age and then
markedly declined during adolescence. Thus, molecular determinants of the
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structural features defining GABA inputs to pyramidal neuron AIS un-
dergo distinct developmental trajectories with different types of changes
occurring perinatally and during adolescence. In concert with previous
data, our findings reveal a two-phase developmental process of GABA syn-
aptic stability and neurotransmission at chandelier cell inputs to pyramidal
neurons that might contribute to the protracted maturation of working
memory. We also evaluated developmental shifts in the expression of
GABAA receptor a1 and a2 subunits because these subunits confer differ-
ent functional properties to GABAA receptors. Expression of a1 and a2
subunits, at both mRNA and protein levels, progressively increased and
decreased, respectively, throughout postnatal development including ado-
lescence. Furthermore, as predicted by the different functional properties of
a1-containing versus a2-containing GABAA receptors, mIPSP duration
was significantly shorter in post-pubertal than in pre-pubertal animals.
Thus, the developmental shift in GABAA receptor a subunit expression
continues through adolescence, inducing a marked change in the kinetics
of GABA neurotransmission. Since levels of GABAA receptor a1 and
a2 subunits and ankyrin-G are altered in schizophrenia, disturbances in
these developmental shifts might give rise to PFC dysfunction in the illness.
ID: 551591
DIFFERENTIAL TERMINAL EXPRESSION OF
GAD67/GAD65-RELEVANCE TO SCHIZOPHRENIA
Kenneth N. Fish1, D. A. Lewis1,2
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA
The presynaptic strength of GABA neurotransmission is partially deter-
mined by the amount of terminal GABA available for release. Terminal
GABA is synthesized locally by GAD67 and GAD65 proteins whose ac-
tivities are differentially regulated. By expressing both GAD isoforms an
interneuron has more flexibility in the regulation of GABA synthesis. Re-
duced expression of GAD67 mRNA is perhaps the most replicated path-
ological disturbance in schizophrenia. Although reductions in GAD67
expression may lead to reduced GABA synthesis, resulting in weaker
GABA neurotransmission, the degree to which different classes of inter-
neurons depend on GAD67 versus GAD65 for terminal GABA synthesis
is unknown. Using an imaging methodology that allows for the quantifi-
cation of fluorescently-labeled puncta (putative axon terminals), the coloc-
alization of different labels in the same terminal, and the quantification of
fluorescence intensity in these same structures, we examined, in the monkey
prefrontal cortex, the level of GAD67 and GAD65 protein in the terminals
of three types of GABA neurons, each of which is thought to underexpress
GAD67 mRNA in schizophrenia: parvalbumin expressing chandelier
(PVch) and basket (PVb) neurons, and cannabinoid receptor expressing
basket (CB1rb) neurons. PVch interneurons were found to almost exclu-
sively contain GAD67 in their terminals. In contrast, both GAD65 and
GAD67 were easily detected in PV-immunoreactive terminals that presum-
ably belong to PVb interneurons. Interestingly, there appeared to be at least
two subpopulations of CB1rb interneurons: those that had high levels of
terminal GAD65 and almost undetectable levels of GAD67; and those
that had GAD67/GAD65 terminal ratios similar to PVb interneurons.
Thus, of the interneuron subpopulations studied, the GAD67/GAD65 ter-
minal ratio is highest in PVch, and lowest in a subpopulation of CB1rb
interneurons. The finding that the terminals of PVch, PVb, and CB1rb
interneurons contain different levels of GAD65 and GAD67 protein sug-
gests that these cells might be differentially affected by reductions in
GAD67 mRNA expression. For example, a reduction in GAD67 expres-
sion would be more likely to negatively affect the activity of PVch interneur-
ons (high GAD67/GAD65 terminal ratio) than those neurons with an
inverse ratio (eg, certain CB1rb). These findings provide crucial informa-
tion needed to formulate hypotheses about the cell type-specific consequen-
ces of the GAD67 mRNA reduction in schizophrenia.
ID: 551386
MODULATION OF PCP-ASSOCIATED METABOLIC
NETWORKS IN THE RAT BRAIN BY
ATOMOXETINE
Carmen de Groote1, R. C. Spike1, J. J. Crofts2, B. J. Morris1,
J. A. Pratt1
1PsyRING, Universities of Glasgow and Strathclyde, Glasgow,
United Kingdom; 2Mathematics, University of Strathclyde,
Glasgow, United Kingdom
Cognitive and negative deficits in schizophrenia are likely to be reflected in
abnormal metabolic patterns in neural networks. Approaches such as Prin-
cipal Component Analysis can be used to identify metabolic patterns. We
used a low dose PCP treatment regime in rats to mirror the pathophysiology
of schizophrenia and tested whether atomoxetine, a putative procognitive
drug, modulated PCP-associated alterations in metabolic networks. Rats
were treated with vehicle or PCP for 5 days (2.5 mg/kg, i.p.). Three days
later animals received vehicle or atomoxetine (0.5 mg/kg i.p.) followed
by an iv bolus of 14C-2-deoxuyglucose. Autoradiographic measurements
of 2-deoxuyglucose uptake were taken in 40 regions of interest. Principal
component analysis (PC) was used to identify spatial covariance patterns in
the four treatment groups. In the vehicle group PC1 (51.9% of total vari-
ance) high loadings were found for the retrosplenial cortex and orbital cor-
tex. PC2 (21.9% total variance) showed high loadings for the nucleus
accumbens and prefrontal cortex. In the PCP group PC1 (67.1% of total
variance) was a large scale network with high loadings for the prefrontal
cortex, cingulate cortex, sensory and psychomotor-related areas. PC2
(16.4% total variance) included the lateral lemniscus and PC3 (6.5% total
variance) consisted predominantly of hippocampal subregions. In the
atomoxetine-PCP group, PC1 (69.6% of total variance) comprised of
a smaller scale network of 9 regions with high loadings for the prefrontal
cortex and cingulate cortex. Compared to the PCP group, low loadings
were found in the frontal association cortex, ventral and lateral orbital cor-
tex, septum and subiculum. This suggests that atomoxetine modulates PCP-
associated metabolic networks. In conclusion, multivariate analysis at the
group level can be used to study the effects of cognitive modulators on met-
abolic networks in an animal model of schizophrenia.
References
1. Cochran SM, et al. Induction of metabolic hypofunction and neuro-
chemical deficits after chronic intermittent exposure to phencyclidine:
differential modulation by antipsychotic drugs. Neuropsychopharma-
cology. 2003;28(2):265–75.
2. Pratt JA, et al. Modelling prefrontal cortex deficits in schizophrenia:
implications for treatment. Br J Pharmacology. 2008;153:S465–70.
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11. 11. Neurochemistry, Animal
SCHIZOPHRENIA-LIKE BEHAVIORAL ABNOR-
MALITIES FOLLOWING PRENATAL MATERNAL
IMMUNE SYSTEM ACTIVATION ARE PREVENTED
BY PRE-TREATMENT WITH RISPERIDONE
Yael Piontkewitz, I. Weiner
Psychology, Tel-Aviv University, Tel-Aviv, Israel
There is an increased interest in the prodromal stage of schizophrenia as
an optimal stage to begin intervention with anti-psychotics. Neurodeve-
lopmental models of schizophrenia, which mimic the characteristic matu-
rational delay of the disorder, offer a valuable tool for the investigation of
preventive interventions. Here we show that adult offspring of dams ex-
posed to the viral mimic polyinosinic-polycytidilic acid (poly I:C, 4mg/kg)
on gestation day 15, display selective attention deficit as manifested in the
loss of latent inhibition (LI) and abnormally rapid reversal learning. How-
ever, treatment of the offspring with the atypical antipsychotic drug ris-
peridone (0.045 mg/kg) on postnatal days 34–47 prevented the
development of both behavioral deficits, assessed 50 and 80 days after ces-
sation of pre-treatment. A higher dose of risperidone (1.2 mg/kg) pre-
vented only rapid reversal learning. Given that maternal infection is
a known risk factor for schizophrenia, our results support the clinical find-
ings that treatment with drugs such as risperidone, during the prodromal
stage may have some protective effect at least in the short term, reducing
risk of progression to first-episode psychosis, or delaying the onset of
psychosis.
ID: 546874
RECEPTOR BINDING PROFILE OF LURASIDONE:
A NOVEL PSYCHOTROPIC AGENT UNDER
DEVELOPMENT FOR SCHIZOPHRENIA AND
BIPOLAR DISORDER
Tadashi Ishibashi1, K. Tokuda1, T. Horizawa1, M. Ogasa2,
J. Cucchiaro2, A. Loebel2
1Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; 2Dainippon
Sumitomo Pharma America, Inc., Fort Lee, NJ, USA
Background: Lurasidone is a novel psychotropic agent under development
for the treatment of schizophrenia and bipolar disorder. Lurasidone has
been reported to reverse MK-801-induced impairment in learning and
memory in the passive-avoidance test (Ishiyama et al. Eur J Pharmacol
2007;572:160–170), and Morris water maze and radial maze (Enomoto
et al. Behav Brain Res 2008;186:197–207). The reversal of MK-801-
induced cognitive impairment in these tests has been found to be more
potent than the effects of other atypical antipsychotics. We summarize
here in vitro studies designed to characterize the receptor binding profile
of lurasidone. Methods: We evaluated the receptor binding affinities of
lurasidone and several antipsychotic drugs with radioligand binding assay.
Compounds were tested under comparable assay conditions using various
receptor preparation. Results: Lurasidone was found to have high affinity
for dopamine D2 and serotonin 5-HT2A receptors. Compared with other
atypical antipsychotics, lurasidone had notably greater antagonist activity
at serotonin 5-HT7, 5-HT1A, and noradrenaline a2c receptors. Lurasidone
had minimal affinity for a1 adrenoceptors, dopamine D1 and D3 receptors,
serotonin 5-HT2C receptors, and a2A adrenoceptors; and no affinity for
histamine H1 and cholinergic M1 receptors. Conclusion: The current
results indicate that lurasidone has a binding profile that differs in several
potentially relevant respects from available antipsychotics. Consistent with
favorable effects on learning and memory in animal models, lurasidone
had no affinity for muscarinic acetylcholine and histamine H1 receptors,
but a high affinity for receptors implicated in enhancement of cognitive
function (eg, 5-HT7, 5-HT1A, a2c). Because of its serotonin 5-HT2 antag-
onist and other actions including 5-HT1A partial agonist activity, treat-
ment with lurasidone would be expected to be associated with fewer
extrapyramidal side effects than conventional antipsychotic agents. Fur-
thermore, lack of affinity for histamine H1 or 5-HT2C receptors suggests
that lurasidone may have a reduced potential for weight gain (and related
metabolic consequences) mediated by activity at these receptors. Finally,
the risk of a1 adrenergic-mediated orthostatic hypotension would appear
to be low. Confirmation of the clinical implications of the receptor binding
profile of lurasidone awaits the results of recently completed, and ongoing,
clinical trials.
ID: 550786
ALPHA-7 NICOTINIC RECEPTOR ACTIVATION
INCREASES GLUTAMATE RELEASE IN RAT
MEDIAL PREFRONTAL CORTEX IN VIVO
John Dunlop1, Q. Lin1, A. Mohan1, C. Wantuch1, S. Haydar1,
J. Ma1, R. Roncarati2, C. Ghiron2, T. A. Comery1, Z. A. Hughes1,
S. Rosenzweig-Lipson1, K. L. Marquis1, G. Terstappen2,
C. E. Beyer1
1Neuroscience Discovery Research, Wyeth Research, Princeton, NJ,
USA; 2Siena Biotech S.p.A., Siena, Italy
Alpha-7 nicotinic acetylcholine receptor (nAChR) agonists are promising
therapeutic candidates for the treatment of cognitive dysfunction associ-
ated with a variety of disorders including schizophrenia and Alzheimer’s
disease. The diverse activity of alpha7 nAChR agonists can be attributed,
at least in part, to their modulation of the release of a number of neuro-
transmitters. Among these, alpha7 nAChR agonists have been shown to
regulate release of glutamate from prefrontal cortex synaptosomes
in vitro. Since similar effects have not been studied extensively in vivo,
we have examined the effect of selective alpha-7 nicotinic receptor ago-
nists on glutamate levels in the rat medial prefrontal cortex (mPFC)
in vivo using microdialysis. An acute administration of SEN12333 (10
mg/kg i.p.) significantly (P = .035) increased glutamate levels in mPFC
to a maximum of 224% above basal levels. Interestingly, peak elevated
glutamate levels were measured > 2–3 hr after drug administration, de-
spite the fact that maximum drug levels in the brain were detected 30 min
following administration of SEN12333 (10 mg/kg i.p.). A delayed tempo-
ral profile for alpha-7 nAChR agonist stimulation of glutamate release
was also observed with the selective alpha-7 nAChR agonists SSR-
180711A and PNU-282987. An acute administration of either SSR-
180771A or PNU-282987 (3 mg/kg i.p.) significantly increased glutamate
levels in mPFC to a maximum of 128% (P = .022) and 230% (P = .018),
respectively, above basal levels. Similar to our observations with SEN-
12333, peak glutamate levels were observed 2.5–3 hr following adminis-
tration of either SSR-180711-A or PNU-282987, while peak drug levels in
brain were detected 30 min after treatment. Administration of the selective
alpha7 nAChR antagonist MLA, either systemically or by local infusion
directly to the mPFC via the microdialysis probe, completely blocked the
SEN12333-mediated increase in mPFC glutamate. The latter observation
implicates local alpha7 nAChRs in the mPFC in the regulation of gluta-
mate release. These results provide the first detailed characterization of
alpha7 nAChR regulaton of mPFC glutamate release in vivo. Modulation
of glutamate release in the mPFC may be an important property in the
potential therapeutic use of alpha-7 nAChR agonists, in particular in the
context of the glutamate hypofunction hypothesis in schizophrenia.
ID: 550748
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PREVENTION OF POST-PUBERTAL
SCHIZOPHRENIA-LIKE BEHAVIOR AND
NEUROPATHOLOGY IN THE MATERNAL
IMMUNE ACTIVATION MODEL
I. Weiner Y. Piontkewitz, Y. Assaf
Psychology, University of Tel Aviv, Tel Aviv, Israel
Schizophrenia is believed to originate in early development but is mani-
fested symptomatically after puberty. This maturational gap raises the
question of whether schizophrenia can be prevented. Studies in individuals
have suggested that preventive treatment with atypical antipsychotic drugs
(APDs) may reduce the risk of progression to psychosis, but identifying and
treating patients in the earliest disease states presents diagnostic, ethical and
methodological limitations. Neurodevelopmental animal models could
considerably aid in evaluating the plausibility of prevention. We used
the prenatal immune challenge model of schizophrenia which is based
on the association between maternal exposure to infection during preg-
nancy and increased liability to schizophrenia in the offspring. In the model,
the viral mimic polyinosinic-polycytidilic acid (PolyI:C) is used to activate
the maternal immune system. We report that: 1. Adult offspring of dams
injected with Poly I:C (4mg/kg) on gestation day 15, exhibit the hallmark
structural abnormalities associated with schizophrenia, namely, ventricular
enlargement and smaller hippocampal volume, as well as the hallmark cog-
nitive deficit of schizophrenia, namely, loss of attentional selectivity; 2Both
abnormalities are not seen at prepubertal age (35 days) thus exhibiting
a maturational progression characteristic of the clinical condition; 3Pre-
treatment with the atypical antipsychotic clozapine during prepubertal
days 34–47, prevents the emergence of both cognitive and structural abnor-
malities in the adult offspring. These findings show that at least some of the
neuropathological processes set in motion by early insults can be halted if
targeted prior to overt manifestation of behavioral abnormalities, and sup-
port the notion that treatment with atypical APDs may prevent the appear-
ance of first-episode psychosis.
ID: 550712
NEUROPLASTICITY CHANGES IN ANIMAL
MODELS OF SCHIZOPHRENIA AS TARGETS FOR
INNOVATIVE TREATMENTS
William T. O’Connor1,2, S. D. O’Shea3, A. T. Brady3,
I. E. De Souza3, M. P. Moran3, O. M. McCabe3
1Graduate Medical School, University of Limerick, Limerick,
Ireland; 2Materials and Surface Science Institute, University of
Limerick, Limerick, Ireland; 3ANRG, Conway Institute, University
College Dublin, Dublin, Ireland
According to Carlsson’s accelerator/brake hypothesis(Biological Psychia-
try, 1388, 1999) schizophrenia reflects a loss of a frontal cortical brake
on VTA dopamine. Evidence also suggests that both genetic and environ-
mental factors together combine in this imbalance. This hypothesis was
tested in the socially isolated and maternally deprived rat models of schizo-
phrenia by investigating the role of mPfc dopamine receptor activation on
VTA glutamate and GABA transmission. Thus dual probe microdialysis
was employed in the mPfc and VTA to investigate the effects of intra-
mPfc perfusion with the selective dopamine D2 receptor agonist pergolide
on dialysate VTA glutamate and GABA levels. The effect of chronic clo-
zapine (5 mg/kg i.p. daily for 10 days) on the pergolide response was also
investigated. Basal dialysate glutamate levels (lM) were similar in the ve-
hicle-treated control and isolated rat (0.435 6 0.268 (n = 7) and 0.936 6
0.720, (n = 8) respectively) while GABA levels (nM) were 14.41 6 4.47
(n = 7) in the vehicle-treated control but were reduced by 55% to 6.53 6
1.55 in the isolated rat (n = 8), P = .0066 v’s social control). Chronic clo-
zapine had no effect on basal dialysate glutamate or GABA levels in both
groups. Intra-mPfc pergolide (1 lM, 60 mins) rapidly reduced VTA gluta-
mate levels by96% (P< .001 v’s non-pergolide-treated control, ANOVA)
and VTA GABA by24% (P = .023) in the social control rat and increased
VTA GABA by þ90% in the isolated rat (P = .016 v’s control). Clozapine
counteracted the intra-mPfc pergolide-induced reduction in VTA gluta-
mate from 32% to þ9% (v’s basal) in the social control rat (P = .0103
v’s vehicle-treated group, ANOVA) while it reversed the intra-mPfc pergo-
lide-induced increase in VTA glutamate release to a decrease (ie, from
þ23% to 21%, (v’s basal) P = .0085, ANOVA) in the isolated rat. Cloza-
pine also reversed the intra-mPfc pergolide-induced increase in VTA
GABA in the isolated rat from þ99% to 9% (v’s basal) (P = .0324 v’s
vehicle-treated group, ANOVA). The findings confirm a frontal cortical
brake on the VTA in the social control rat operating via a frontal cortical
dopamine D2 receptor regulation of both corticofugal glutamate and local
interneuronal GABA release in the VTA and which is abnormal or absent
in the two animal models. Furthermore, the ability of clozapine to reverse
the pergolide effect in the social controls and normalize it in the isolated rat
suggests a role for clozapine in maintaining this brake on the VTA.
ID: 550669
CHRONIC ANTIPSYCHOTIC TREATMENT
DECREASES PHOSPHO-TRKA NERVE GROWTH
FACTOR RECEPTOR LEVELS IN THE RAT
HIPPOCAMPUS
Alvin V. Terry1, A. Pillai2
1Pharmacology and Toxicology, Medical College of Georgia,
Augusta, GA, USA; 2Psychiatry and Health Behavior, Medical
College of Georgia, Augusta, GA, USA
Neurotrophins including the prototype nerve growth factor (NGF) are well
documented to serve important roles in mammalian neurodevelopment as
well as the support and maintenance of several neuronal phenotypes in the
adult. The neurobiological effects NGF are mediated by two classes of cell
surface receptors, high affinity tyrosine kinase (TrkA) receptors and the low
affinity p75NTR receptor. Under normal conditions, NGF binding (ie, in
its processed, mature form) to TrkA promotes TrkA autophosphorylation
which activates pathways that enhance neuron survival and plasticity. In-
terestingly, there is growing evidence that neurotrophin signaling is nega-
tively altered in neuropsychiatric illnesses such as schizophrenia and
further, that neurotransmitters known to be adversely affected in schizo-
phrenia (eg, dopamine) can activate neurotrophin signaling pathways
via G protein-coupled receptors. It is unclear; however, how the primary
therapeutic agents used in schizophrenia affect neurotrophin signaling.
This is important given that all currently prescribed antipsychotics serve
as ligands (in most cases antagonists) at dopamine receptors. The objective
of the experiments described here was to evaluate the effects of chronic
treatment with commonly prescribed first and second generation antipsy-
chotics on NGF receptor levels in the rat brain, specifically the levels of
TrkA and phospho-TrkA (ie, the activated form of the receptor). Male Wis-
tar Rats 3–4 months old were treated in their drinking water with vehicle or
one of the following antipsychotics for 90 days: haloperidol 2.0, chlorprom-
azine 10.0, risperidone 2.5, olanzapine 10.0, or ziprasidone 12.0 mg/kg/day.
Subjects were given a 14 day drug-free washout period and then sacrificed.
TrkA and phospho-TrkA levels were subsequently measured in the prefron-
tal cortex and hippocampus by ELISA. The results indicated that the anti-
psychotics had little effect on TrkA levels in the prefrontal cortex or
hippocampus. In contrast, while only minor effects on phospho-TrkA levels
were observed in the prefrontal cortex, all five antipsychotics were associ-
ated with significant decreases (ie, by up to a 50%) in phospho-TrkA levels
in the hippocampus. These data indicate that chronic exposure to both first
and second generation antipsychotics may result in deleterious effects on
neurotrophin signaling in a brain region known to be important for infor-
mation processing and cognition.
ID: 550655
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GENETIC ANIMAL MODELS TARGETING THE
MOLECULAR MACHINERY OF GLUTAMATE
SYNAPTIC TRANSMISSION
Akira Sawa
Psychiatry, Johns Hopkins University, Baltimore, MD, USA
Roles for glutamate neurotransmission in the pathophysiology of schizo-
phrenia have been suggested in many lines of evidence. Possible role for D-
serine, an endogenous agonist to the NMDA-type glutamate receptor has
been supported by genetic and pharmacological studies. Here I overview
genetic animal models targeting the molecular machinery of glutamate syn-
aptic transmission in schizophrenia research, and present data with mice
that disturb D-serine metabolism in particular. PICK1 is a multifunctional
protein, and modulates serine racemase (synthesizing enzyme of D-serine),
AMPA-type glutamate receptor, and dopamine transporter DAT. In
PICK1 knockout mice, levels of D-serine are specifically impaired in the
forebrain of neonatal stages. Behavioral changes in PICK1 mice in compar-
ison with other types of mice with disturbance of D-serine-mediated neu-
rotransmission will be presented. Potentials of D-serine and enzymes/
regulators for D-serine metabolism for therapeutic strategies to schizophre-
nia will also be discussed.
ID: 550413
TYROSINE INFLUENCES ON MESOCORTICAL
DOPAMINE IN THE RAT
George Eugene Jaskiw1,2, A. Kyser1, R. Bongiovanni1
1Psychiatry Service 116A(B), Louis Stokes Cleveland VAMC,
Brecksville, OH, USA; 2Psychiatry, Case Western Reserve
University, Cleveland, OH, USA
Dysregulation of tyrosine transport in schizophrenia has been linked to
mesocortical dopamine (DA)-mediated cognitive impairment. We previ-
ously showed that tyrosine availability affected stimulated but not baseline
DA levels in the medial prefrontal cortex of the rat. We now examined the
ventral hippocampus (VHIPP), another mesocortical DA region implicated
in schizophrenia. Male (Harlan) rats had a cannula stereotaxically
implanted over the VHIPP. Two to three days later a microdialysis probe
was inserted. Data collection began on the following morning. After a stable
DA baseline was reached, a tyrosine- and phenylalanine-free neutral amino
acid mixture (NAA(-)) was administered in two equal doses one hour apart.
NAA(-) lowered tyrosine levels by approximately 50% but did not affect
tryptophan levels. Baseline levels of DA, norepinephrine or serotonin
did not change. The data indicate that just as in medial prefrontal cortex,
baseline catecholamine levels in VHIPP are not affected by a significant
lowering of tyrosine availability. Additional studies will examine stimulated
catecholamine levels.
ID: 550380
DEVELOPMENTAL VITAMIN D DEFICIENCY
(DVD) AND BRAIN DOPAMINE ONTOGENY
Darryl Eyles1,2, X. Cui1, M. Pelekanos1, J. Kesby1, T. Burne1,2,
J. McGrath1,2
1Queensland Brain Institute, Brisbane, QLD, Australia;
2Queensland Centre for Mental Health research, , Brisbane, QLD,
Australia
Developmental vitamin D (DVD) deficiency is a candidate risk factor for
schizophrenia. Our group has developed a rodent model of DVD defi-
ciency. In the adult offspring from this model we have previously described
alterations in both spontaneous and psychomimetic induced locomotion.
The aim of this series of studies was to explore the role of vitamin D in
the development of dopaminergic systems in this model. Vitamin D defi-
ciency is induced in female Sprague-Dawley rats by dietary restriction.
Females are then mated with vitamin D normal males and the pregnant
females are maintained on their respective diets during this period. At birth
all maternal animals are placed on a vitamin D normal diet. The period of
DVD-deficiency is therefore restricted to the gestational period only. Re-
sultant DVD-deficient progeny were examined either as embryos, as neo-
nates or as adults. Our findings indicate dopamine signaling is disturbed in
this model. a) the superior colliculus (the proto-basal ganglia) is the site
where the receptor for vitamin D is first expressed in foetal rat brain (Em-
bryonic day E12); b) mRNA for both Nurr-1 (a nuclear transcription reg-
ulator important in dopamine neuron development) and tyrosine
hydroxylase (a marker of dopamine cell maturity) are both reduced in
the embryonic DVD-deficient mesencephalon by E15; c) Catechol-O-
methyl transferase (a major metabolic enzyme for dopamine) was reduced
in the DVD deficient neonatal rat brain; d) the dopamine metabolic profile
in these brains reflected this enzymatic change. e) As adults, dopamine
transporter density and/or affinity were altered in DVD deficient adult fe-
male offspring whilst DA 1 receptor density, Catechol-O-methyl transfer-
ase and dopamine cell number were reduced in DVD deficient male
offspring (all P < .05 n  8). The developmental absence of vitamin D
affects dopamine neuron ontogeny. We believe that alterations in dopamine
metabolism and/or release mediate the behavioural sensitivity to psychomi-
metics displayed in this model.
ID: 550230
STRESS-INDUCED ACTIVATION OF THE VENTRAL
SUBICULUM-NUCLEUS ACCUMBENS PATHWAY
AND THE MODULATION OF DOPAMINE NEURON
ACTIVITY
Anthony A. Grace, O. Valenti, W. J. Lipski
Department of Neuroscience, University of Pittsburgh, Pittsburgh,
PA, USA
Stress has been associated with the onset and exacerbation of several psy-
chiatric disorders, including schizophrenia. Indeed, recent evidence sug-
gests that stress may play a major predisposing role in the premorbid
state of schizophrenia, potentially facilitating the conversion to psychosis.
It has been known for some time that stressors can affect the dopamine
system; specifically, exposure to acute or repeated stress will cause a sensi-
tized behavioral response to amphetamine administration, similar to that
observed in schizophrenia patients. We investigated the manner by which
stress can alter dopamine system function using single-unit recordings in
anesthetized rats. We found that, although single electrical shocks delivered
to the foot transiently inhibited dopamine neuron firing, if the shocks were
maintained there was a pronounced and sustained activation of tonic do-
pamine neuron population activity (ie, the proportion of dopamine neurons
firing spontaneously). A similar activation of tonic dopamine neuron firing
was observed following 2 hours of restraint stress. Our previous studies
showed in a developmental model of schizophrenia that increases in tonic
DA activity corresponded with activation of the ventral subiculum of the
hippocampus and contributed to the heightened behavioral response to am-
phetamine. We now report that restraint stress causes an activation of ven-
tral subicular neuron firing, as does stimulation of two stress-related
systems, the basolateral amygdala and the locus coeruleus. Moreover, in-
activation of the ventral subiculum reversed both footshock- and restraint-
induced increases in tonic DA neuron firing. Therefore, both in an animal
developmental model of schizophrenia and with stress, the dopamine sys-
tem is rendered in a hyper-responsive state secondary to activation of the
ventral subiculum. Such a condition may underlie the ability of stressors
to exacerbate or lead to relapse in schizophrenia. Moreover, a heightened
response to stress during the premorbid state may contribute to the
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hippocampal damage and interneuron loss proposed to trigger the conver-
sion to schizophrenia in late adolescence/early adulthood.
ID: 550195
CANNABINOID EFFECTS ON CANNABINOID
AND SEROTONIN RECEPTOR DENSITY AND
DOPAMINE RECEPTOR FUNCTIONALITY IN THE
RAT BRAIN
Katerina Zavitsanou1,2, V. S. Dalton1,2, V. Nguyen1
1Radiopharmaceutical Research Institute (RRI), Australian
Nuclear Science and Technology Organisation (ANSTO), Sydney,
NSW, Australia; 2Schizophrenia Research Institute, Sydney, NSW,
Australia
Cannabinoids have been shown to interact with neurotransmitter systems
implicated in psychosis such as serotonin and dopamine. However, the ex-
act mechanisms of such interactions are not fully understood especially dur-
ing adolescence a critical period for both the development of psychosis and
for initiation to substance abuse. In the present study, we measured can-
nabinoid CB1, serotonin 5HT1A and 5HT2A receptor density and dopa-
mine D2 receptor functionality in the brain of male rats treated with the
synthetic cannabinoid HU210 (25,50 or 100ug/kg, ip) for 14 days or re-
ceived a vehicle for 13 days and an acute dose of HU210 on day 14.
CB1, 5HT1A and 5HT2A receptor density was measured on brain sections
using [3H] CP55,940 [3H]8-OH-DPAT and [3H] ketanserin respectively,
whereas D2 receptor functionality was examined by measuring activation
of GTP-binding proteins by the D2 agonist (R(-)-Propylnorapomorphi-
ne,(NPA). A significant dose dependent reduction in CB1 receptor density
was seen in cortical, basal ganglia and limbic brain regions examined after
chronic administration of HU210 with overall decreases in binding of 70.3–
89.2%, 56.3–85.2% and 41.6–68.6% (p,0.01) in 100, 50, 25 lg/kg treatment
groups respectively when compared with controls. 5HT1A receptor density
was significantly increased in hippocampal regions CA1 (28%, P = .028),
CA2 (31%, P = .024) and dentate gyrus (20%, P = .001) of rats treated
with the 100ug/kg of HU210 for 14 days compared to vehicle treated con-
trols. In addition, 5HT2A receptor density was significantly decreased in
the caudate nucleus of rats treated with the 100ug/kg of HU210 for 14
days compared to vehicle treated controls (34%, P = .023). Stimulation
of GTP binding proteins by NPA was significantly increased in the caudate
nucleus (12.3%, P = .01) and cortical layers I–III (19.6%, P < .001) and V–
VI (24.3%, P< .001) of rats in the same treatment group compared to con-
trols. Interestingly, the acute dose of HU210 resulted in a significant in-
crease in NPA stimulation of GTP binding in the caudate nucleus only
(17.4%, P < .001).The present results may have implications for under-
standing the mechanisms by which cannabis may trigger psychosis in vul-
nerable individuals and for treating cannabis dependent individuals.
ID: 550133
HIPPOCAMPAL HYPERACTIVITY DUE TO
INTERNEURON LOSS ACCOUNTS FOR DOPAMINE
HYPER-RESPONSIVITY AND DIMINISHED
OSCILLATORY ACTIVITY IN MAM MODEL OF
SCHIZOPHRENIA
Anthony A. Grace1, D. J. Lodge1, M. M. Behrens2
1Department of Neuroscience, University of Pittsburgh, Pittsburgh,
PA, USA; 2Department of Medicine, University of California San
Diego, La Jolla, CA, USA
Recent imaging data suggest that the psychosis in schizophrenia is corre-
lated with an increase in baseline activity within the hippocampal complex.
We have recently shown that in a rat developmental disruption model of
schizophrenia, there is hyperactivity within the ventral subiculum of the
hippocampus. Moreover, this hyperactivity causes an increase in the
number of dopamine neurons firing spontaneously, thereby increasing
the amplitude of a phasic burst response to stimuli. As a result, stimuli
would produce an overactivation of dopamine neuron activity and path-
ologically high levels of dopamine release within the limbic striatum. In-
activation of the ventral subiculum in these animals both restores the
dopamine neuron population activity to normal, and eliminates the be-
havioral hyper-responsivity to amphetamine administration. We now find
that there is a selective loss of parvalbumin interneuron staining within
the ventral subiculum, and moreover this correlates with a loss of evoked
rhythmic activity. Rats administered the mitotoxin methylazoxymethanol
acetate (MAM) during gestational day 17 exhibit anatomical, behavioral,
and pharmacological responses consistent with an animal model of
schizophrenia. When examined as adults, these rats demonstrated a signif-
icant loss of parvalbumin-containing interneurons within the ventral (but
not dorsal) subiculum of the hippocampus and the medial prefrontal cor-
tex. This reduction occurs in parallel with a significant reduction in theta
and beta/gamma band responses evoked by a conditioned tone. More-
over, in a latent inhibition paradigm, the deficit in evoked oscillatory ac-
tivity in the ventral hippocampus and prefrontal cortex is associated with
behavioral impairment in the MAM-treated rats compared to controls.
These data suggest that a deficit in GABAergic signaling within the hip-
pocampal-prefrontal cortical system leads to hippocampal hyperactivity
and overdrive of the dopamine system, as well as an impairment in cog-
nitive task performance due to loss of oscillatory activity. Moreover, it
suggests that a more effective therapeutic approach to the treatment of
schizophrenia may reside in restoring normal activity states within the
hippocampus.
ID: 549996
INDUCIBLE EXPRESSION OF HUMAN MUTANT
DISC1 IN THE MOUSE IS ASSOCIATED WITH
A NEUROCHEMICAL SHIFT RELEVANT TO THE
KYNURENINE PATHWAY
Christine Lyn Miller1, Y. Ayhan2, M. Pletnikov2
1Pediatrics, Johns Hopkins University, Baltimore, USA;
2Department of Psychiatry and Behavioral Sciences, Johns Hopkins
University, Baltimore, MD, USA
Kynurenine pathway dysfunction has been implicated in the pathogenesis
of schizophrenia by several research laboratories around the world. Here
we present data for extracts of mutant human DISC1 (mhDISC1) trans-
genic mouse brains, analyzed by reverse-phase HPLC coupled to UV de-
tection. All analyses were conducted while blinded to mouse category.
Consistent with a report of tryptophan increases in postmortem brain sam-
ples of schizophrenic humans, tryptophan concentrations were found to be
significantly elevated in mhDISC1 transgenic mice, 1.77-fold in the cerebel-
lum (P = .01, power = 0.86) and 1.54-fold in anterior cortical regions (P =
.001, power = 0.90) as compared to matched controls. The kynurenine con-
centrations trended towards an elevation in the cerebellum (1.47-fold that
of controls, P = .09, power = 0.18) but were not significantly elevated in
anterior cortical regions of the mhDISC1 transgenics (1.37-fold that of con-
trols, P = .32, power = 0.11). These results represent preliminary evidence
that the downstream effects of the mutant DISC1 protein include a shift in
the regulation of tryptophan concentrations of relevance to changes seen in
schizophrenia, but will require additional transgenic animals to confirm
whether or not a difference exists for kynurenine. The mechanism of the
elevation in tryptophan is unknown, but would be expected to involve
gene-expression differences in enzymes or receptors involved in kynurenine
pathway regulation.
ID: 549841
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DISSOCIABLE EFFECTS OF D-AMPHETAMINE
IN LATENT INHIBITION AND LOCOMOTOR
ACTIVITY IN D2 RECEPTOR KNOCKOUT MICE
Paula M. Moran1, C. Bay-Richter1, C. M. O’Tuathaigh2,
G. O’Sullivan2, D. M. Heery3, J. L. Waddington2
1School of Psychology, University of Nottingham, Nottingham,
United Kingdom; 2Molecular and cellular Therapeutics, royal col-
lege of Surgeons in Ireland, Dublin, Ireland; 3School of Pharmacy,
University of Nottingham, Nottingham, United Kingdom
The purpose of this study was to investigate the role of the dopamine D2
receptor subtype (D2) in latent inhibition (LI), d-amphetamine-induced
disruption of LI and locomotor hyperactivity. These effects of amphet-
amine are reversed by antipsychotic drugs which also enhance LI, and
as such are commonly used as animal models to test novel antipsychotic
drug activity. LI is a model of information filtering abnormalities seen
in schizophrenia and refers to the process whereby prior exposure of a stim-
ulus without consequence impairs subsequent learning of an association to
that stimulus. A role for D2 in LI has been suggested by pharmacological
studies, however, none of the available DA ligands are receptor subtype
specific making it difficult to attribute effects to specific receptor subtypes.
We investigated the relative importance of D2 in d-amphetamine-induced
disruption of LI and locomotor hyperactivity models using congenic D2
knockout mice (D2KO) backcrossed onto the C57/Bl6 strain. In a standard
LI procedure, learning was measured as suppression of drinking upon pre-
sentation of an 85dB tone that had previously been paired with footshock in
water restricted mice. There were two experimental groups. One group was
pre-exposed to the tone 60 times prior to two pairings with a 1sec, 0.38mA
footshock (pre-exposed/PE), while one group was exposed to the same con-
ditions but did not receive tone pre-exposure (non-pre-exposed/NPE). Test-
ing was carried out using a 3 day procedure. d-Amphetamine (2.5mg/kg
i.p.) was given on days 1 and 2, mice were tested drug free on day 3. LI
is reduced learning in PE compared to the NPE group. Locomotor activity
was measured in photocell cages over 30 mins, 30 mins following injection.
D2KO mice showed clear enhancement of LI. This effect directly parallels
antipsychotic drug effects in LI and confirms the importance of the D2 re-
ceptor in the enhancement of LI. d-amphetamine (2.5 mg/kg, i.p.) abolished
LI similarly in both WT and D2KO mice suggesting that the D2 receptor is
not important in d-amphetamine disruption of LI. In contrast, d-amphet-
amine induced hyperactivity in WT but not D2KO mice suggesting that the
D2 receptor is important for d-amphetamine induced hyperactivity. These
data suggest that while d-amphetamine disruption of LI and induction of
locomotor hyperactivity are both reliably reversed by antipsychotic drugs,
the mechanism may be different with respect to the role of the dopamine D2
receptor.
ID: 549630
INTERLEUKIN-6 MEDIATES THE INCREASE
IN NADPH-OXIDASE IN THE KETAMINE MODEL
OF SCHIZOPHRENIA.
M. Margarita Behrens, S. S. Ali, J. Lucero, G. Shekhtman,
L. L. Dugan
Geriatrics Division, Department of Medicine, UCSD, La Jolla,
CA, USA
Acute exposure to N-methyl-D-aspartate receptor (NMDA-R) antago-
nists, such as ketamine, produces psychosis in humans, and exacerbates
symptoms in schizophrenic patients. We recently showed that ketamine,
when applied on two-consecutive days in mice, induces the activation of
the superoxide-producing enzyme NADPH-oxidase in brain. The superox-
ide produced leads to a loss of the inhibitory characteristics of a subset of
fast-spiking inhibitory interneurons, those expressing the calcium binding
protein parvalbumin (PV). This effect was observed only when animals
were treated with ketamine on two consecutive days, but absent when
brains were analyzed after a single exposure to the NMDA-R antagonist.
These results suggest that the first exposure to the NMDA-R antagonist
primes the brain such that the deleterious effects only appear upon a second
exposure. In search for the neurochemical changes responsible for the in-
duction and activation of NADPH-oxidase upon ketamine exposure we
have found that neuronal production of interleukin-6 (IL-6) is necessary
and sufficient for ketamine-mediated activation of NADPH-oxidase in
brain. Removal of IL-6 in neuronal cultures by anti-IL-6 blocking antibod-
ies, or in vivo by use of IL-6-deficient mice, prevented the increase in super-
oxide by ketamine and rescued the interneurons. Accumulating evidence
suggest that schizophrenia patients suffer from diminished antioxidant
defenses, and a recent clinical trial showed that enhancing these defenses
may ameliorate symptoms of the disease. Our results showing that ket-
amine-induced IL-6 is responsible for the activation and induction of
NADPH-oxidase in brain suggest that reducing brain levels of this cytokine
may protect the GABAergic phenotype of fast-spiking PV-interneurons
and thus attenuate the pro-psychotic effects of ketamine.
ID: 549001
PERINATAL ASPHYXIA REDUCES DENTATE
GRANULE CELLS AND EXACERBATES
METHAMPHETAMINE-INDUCED
HYPERLOCOMOTION IN ADULTHOOD
Tomoyasu Wakuda1, H. Matsuzaki5, K. Suzuki4, Y. Iwata1,
K. Iwata4, S. Yamamoto4, K. J. Tsuchiya4, G. Sugihara4, S. Suda1,
T. Ueki2, K. Nakamura1, D. Nakahara3, N. Mori1, N. Takei4,6
1Department of Psychiatry, Hamamatsu University School of
Medicine, Hamamatsu, Japan; 2Department of Neuroscience,
Hamamatsu University School of Medicine, Hamamatsu, Japan;
3Department of Psychology, Hamamatsu University School of
Medicine, Hamamatsu, Japan; 4Research Center for Child Mental
Development, Hamamatsu University School of Medicine, Hama-
matsu, Japan; 5Research Center for Child Mental Development,
Graduate School of Medicine, Osaka University, Osaka, Japan;
6The Institute of Psychiatry, London, United Kingdom
Obstetric complications (OCs) are considered to be a risk factor for schizo-
phrenia. One of the mechanisms underlying the association is postulated to
be a hypoxic process in the brain in the offspring around the time of birth.
To clarify such a mechanism and understand pathophysiological changes in
the brain caused by hypoxia, we used an animal model of perinatal as-
phyxia, in which rat pups were artificially exposed to anoxia for 15 min
at birth. At 6-week (corresponding to adolescence) and 12-week (corre-
sponding to adulthood) -old, we assessed behaviors of the pups on tests
including examination of methamphetamine-induced locomotion (ie, eval-
uation of any sensitivity in the dopaminergic system). In addition, the hip-
pocampus, a hypoxia-vulnerable brain area and postulated to be a key
brain region in relation to schizophrenia, was histopathologically scruti-
nized by means of stereology. At 12 weeks of age, but not at 6 weeks of
age, we found an elevation in methamphetamine-induced locomotor activ-
ity. This elevation was confirmed to be associated with an increase of do-
pamine release in the nucleus accumbens, indicating that exposure to
asphyxia at birth is associated with the later development of dopaminergic
dysfunction in matured rat brain. At the same age (12 weeks after birth), but
not at 6 weeks of age again, there was a reduction of the number of dentate
granule cells in the hippocampus, structural and functional abnormalities
of which have previously been reported in individuals with schizophrenia,
in the rodents exposed to asphyxia. These findings suggest that perinatal
asphyxia may lead to disturbed regulation of the dopaminergic system,
which become manifest after brain maturation, and it is also related to
an aplastic process in the hippocampus. Our findings may provide a
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biological basis for understanding the elusive association previously
reported between a history of OCs and the risk of the development of
schizophrenia.
ID: 548798
THE UTILITY OF ANIMAL MODELS TO EXPLORE
THE NEURODEVELOPMENTAL FEATURES OF
SCHIZOPHRENIA
John Joseph McGrath1,2, T. H. Burne1,2, D. W. Eyles1,2
1Queensland Centre for Mental Health Research, University of
Queensland, Wacol, QLD, Australia; 2Queensland Brain Institute,
University of Queensland, Brisbane, QLD, Australia
The pioneering studies of Barbara Fish provided us with a deeper appre-
ciation of the altered developmental trajectories that precedes the onset of
schizophrenia. Complementing the clues emerging from observational ep-
idemiology, experimental work based on animal models has provided us
with clues to the neurobiological correlates of normal and abnormal brain
development. This talk will provide a concise summary of the utility of an-
imal models related to schizophrenia. In particular, this presentation will
examine if animal models can be used to explore the underlying neurobi-
ological correlates of developmentally-specific surface-level phenotypes.
For example, some animal models have behavioural phenotypes (eg, psy-
chomimetic-induced hyperlocomotion) that only emerge in adulthood,
while other models display features from neonatal and juvenile stages.
Could these models reflect the developmental onset and offset of various
intermediate phenotypes of interest to schizophrenia research? We argue
that the antecedents of schizophrenia identified by studies such as those
of Barbara Fish can help inspire new generations of experimental research
based on animal models.
ID: 548539
THE DIFFERENTIAL EFFECT OF CLOZAPINE
COMPARED TO OTHER ANTIPSYCHOTIC DRUGS
ON CORTICAL AND STRIATAL EGF-ERK CELL
SIGNALING: A NOVEL ANTIPSYCHOTIC DRUG
MECHANISM?
Avril Pereira1,2, G. Fink1,2, S. Sundram1,3
1Molecular Psychopharmacology, Mental Health Research Institute
of Victoria, Parkville, VIC, Australia; 2Centre for Neuroscience,
The University of Melbourne, Parkville, VIC, Australia; 3Northern
Psychiatry Research Centre, The Northern Hospital, Epping, VIC,
Australia
Antipsychotic drugs (APD) have limited and variable efficacy in treating
positive psychotic symptoms. The atypical APD clozapine appears demon-
strably effective in a proportion of these treatment resistant cases. The
mechanism through which clozapine exerts this quality is unknown but
likely to involve interactions with multiple G-protein coupled receptors
(GPCRs) and related signal transduction pathways. A potential candidate
is the mitogen activated protein kinase-extracellular signal regulated kinase
(MAPK-ERK) cascade that links GPCR and ErbB growth factor signaling
systems, thereby regulating synaptic plasticity and connectivity, processes
impaired in schizophrenia. We previously reported that clozapine and other
APD in vitro acutely inhibited ERK activation but only clozapine stimu-
lated ERK with sustained treatment. This stimulation was mediated by the
epidermal growth factor (EGF) receptor (ErbB1) rather than by Gi/o/q
coupled receptors and PKA/C signaling systems typically associated
with these agents. Here we extend our findings in vivo, to investigate if clo-
zapine, haloperidol, quetiapine and aripiprazole differentially modulate the
EGF-ERK1/2 pathway in prefrontal cortex (PFC) and striatum of C57Bl/6
mice following acute treatment. Phosphorylation of the predominant neu-
ronal ERK isoforms, ERK1/2 was measured by immunoelectrophoresis.
ERK1/2 phosphorylation was inhibited by clozapine at 20 and 60 min fol-
lowed by subsequent activation at 8 hrs and normalization of the pERK1
response at 24 hrs. This in vivo clozapine induced ERK activation was sig-
nificantly reduced by the EGF receptor inhibitor, AG1478, in both brain
regions (PFC clozapine 8 hrs: 144.7 6 7.4% vs clozapine þ AG1478 8 hrs:
46.7 6 10.7%, P< .001). Differential patterns of activation were noted with
the other APD tested, in particular, haloperidol significantly stimulated
pERK1 in striatum for up to 8 hrs. In contrast, aripiprazole triggered bi-
phasic ERK phosphorylation, with pERK1/2 levels decreased in the PFC at
20 min, increased by 60 min, decreased by 4 hrs and stabilized thereafter
with no striatal changes noted, indicating regional ERK specificity. These
in vivo data suggest that clozapine action may be uniquely linked to the
EGF signaling system which has been implicated in schizophrenia. There-
fore clozapine recruitment of ErbB1 signaling to activate ERK1/2 may war-
rant investigation as a novel therapeutic target for treatment resistant
patients.
ID: 550994
MATERNAL INFECTION AND CYTOKINES IN
SCHIZOPHRENIA AND AUTISM
Paul H. Patterson
Biology Divison, California Institute of Technology, Pasadena, CA,
USA
Maternal infection is associated with increased risk of schizophrenia in the
offspring. In a mouse model, infection with influenza virus at mid-gestation
leads to behavioral abnormalities in the adult offspring that are consistent
with abnormalities seen in schizophrenia, have post-pubertal onset, and are
corrected by anti-psychotic drugs. The cause of these abnormalities is ma-
ternal immune activation (MIA), as evoking an anti-viral-like immune re-
sponse in uninfected, pregnant mice with the dsRNA, polyI:C, mimics the
effects of infection on the offspring. Since infection and polyI:C induce
cytokines, we asked whether these proteins mediate the effects of MIA
on the fetal brain. Injection of IL-6 in normal pregnant mice causes behav-
ioral deficits in the offspring, while co-injection of anti-IL-6 antibody (but
not anti-IFN) with polyI:C in pregnant mice strongly attenuates the effects
of MIA on the behavior of the offspring. Moreover, the offspring of
polyI:C-treated IL-6 knockout mice do not display behavioral abnormal-
ities. In addition, maternal co-injection of anti-IL-6 with poly(I:C) blocks
the transcriptional changes seen in the brains of adult offspring. That is,
90% of the changes in the adult forebrain of MIA offspring are prevented
by co-administration of anti-IL-6 with maternal poly(I:C). The MIA model
has face and construct validity for schizophrenia, and is useful for exploring
the mechanism of how MIA alters fetal brain development and subsequent
changes in behavior and gene expression. Supported by the NIMH and the
Simons, Autism Speaks, Binational Science, McGrath, and Weston Havens
Foundations.
ID: 551881
MATERNAL INFECTION AND CYTOKINES IN
SCHIZOPHRENIA AND AUTISM
P. Patterson, A. P. and B. F. Biaggini
Biology, California Institute of Technology, Pasadena, CA, USA
Maternal infection is associated with increased risk of schizophrenia in the
offspring. In a mouse model, infection with influenza virus at mid-gestation
leads to behavioral abnormalities in the adult offspring that are consistent
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with abnormalities seen in schizophrenia, have post-pubertal onset, and are
corrected by anti-psychotic drugs. The cause of these abnormalities is
maternal immune activation (MIA), as evoking an anti-viral-like immune
response in uninfected, pregnant mice with the dsRNA, polyI:C, mimics the
effects of infection on the offspring. Since infection and polyI:C induce
cytokines, we asked whether these proteins mediate the effects of MIA
on the fetal brain. Injection of IL-6 in normal pregnant mice causes behav-
ioral deficits in the offspring, while co-injection of anti-IL-6 antibody (but
not anti-IFN) with polyI:C in pregnant mice strongly attenuates the effects
of MIA on the behavior of the offspring. Moreover, the offspring of
polyI:C-treated IL-6 knockout mice do not display behavioral abnormal-
ities. In addition, maternal co-injection of anti-IL-6 with poly(I:C) blocks
the transcriptional changes seen in the brains of adult offspring. That is,
90% of the changes in the adult forebrain of MIA offspring are prevented
by co-administration of anti-IL-6 with maternal poly(I:C). The MIA model
has face and construct validity for schizophrenia, and is useful for exploring
the mechanism of how MIA alters fetal brain development and subsequent
changes in behavior and gene expression. Supported by the NIMH and the
Simons, Autism Speaks, Binational Science, McGrath, and Weston Havens
Foundations.
ID: 551594
PHARMACOLOGICAL INTERVENTION ON
A MOVING TARGET: ANIMAL MODELS WITH
DEVELOPMENTAL RELEVANCE TO
SCHIZOPHRENIA
Neil Mark Richtand1,2, R. Ahlbrand1, P. Horn2,4, K. Stanford1,
R. Tambyraja1, R. K. McNamara1, G. A. Gudelsky3
1Department of Psychiatry, University of Cincinnati College of
Medicine, Cincinnati, OH, USA; 2Psychiatry Service, Department
of Veterans Affairs Medical Center, Cincinnati, OH, USA; 3James
L. Winkle College of Pharmacy, University of Cincinnati,
Cincinnati, OH, USA; 4Department of Mathematical Sciences,
University of Cincinnati, Cincinnati, OH, USA
Introduction: The ideal pharmacological characteristics of effective inter-
vention for individuals exhibiting prodromal symptoms at high risk for
first-episode psychosis are not currently known. Data from human studies
suggest antidepressant and antipsychotic medications are effective in
improving clinical outcome in prodromal adolescents. Enrollment and re-
tention challenges in psychosis prevention trials, however, impede screen-
ing diverse interventions. Use of relevant animal models could help
circumvent these barriers. Methods: In order to test observations from
human studies in a pre-clinical model, we evaluated the effect of atypical
antipsychotic medications, and the selective serotonin reuptake inhibitor
antidepressant medication fluoxetine, in preventing behavioral abnormal-
ities (locomotor response to amphetamine and MK-801) following prena-
tal immune activation, a developmental model with relevance to
schizophrenia. Results: Significant developmental changes were observed
over time in relevant pharmacological intervention targets using this
model. Prominent alteration in locomotor response to the NMDA-sub-
type glutamate receptor antagonist MK-801, suggesting glutamatergic
dysregulation, was observed early in development. In contrast, altered be-
havioral response to the dopamine-releasing agent amphetamine did not
appear until later in development. Treatment with the atypical antipsy-
chotic medications risperidone, paliperidone, and aripiprazole during
peri-pubertal development each resulted in long-standing corrective im-
pact on altered locomotor responsiveness to amphetamine. Of interest, ev-
idence suggests this may be mediated through serotonergic effects.
Treatment with the selective serotonin reuptake inhibitor antidepressant
medication fluoxetine during peri-pubertal development also resulted in
a protective adaptation to subsequent amphetamine exposure persisting
into early adulthood. Conclusions: These data support the observations
in human studies of protective effects of atypical antipsychotic and selec-
tive serotonin reuptake inhibitor antidepressant medications for psychosis
prevention. In combination, these findings also suggest developmental ad-
aptation to serotonergic intervention may provide a useful pharmacolog-
ical target for psychosis prevention. Finally, these results highlight the
utility of translational research with relevant animal models in the psycho-
sis prevention field.
ID: 551385
MODELLING THE NEGATIVE SYMPTOMS OF
SCHIZOPHRENIA IN THE SUBCHRONIC
PHENCYCLIDINE-TREATED RAT
Trisha Anne Jenkins1, M. K. Harte2, C. E. McKibben1,
J. J. Elliott1, G. P. Reynolds1
1Department of Psychiatry, Queen’s University, Belfast, United
Kingdom; 2School of Pharmacy, University of Bradford, Bradford,
United Kingdom
In schizophrenia, negative symptoms include alogia, anhedonia, flat af-
fect, avolition and social withdrawal. The development of animal models
for these symptoms have proven difficult; some are exclusively ‘human’
characteristics and thus unsuited, while other behaviours have been mod-
elled but cannot be associated with concurrent brain neurochemical
changes. Persistent blockade of NMDA receptor function by repeated
phencyclidine (PCP) dosing produces pathophysiological changes that
model the cognitive deficits observed in schizophrenia. In this study we
evaluate the validity of the sub-chronic PCP rat in modeling behaviours
associated with the negative symptoms of schizophrenia. Male Lister-
hooded rats administered PCP for 7days followed by a 7day drug free
period were evaluated for two behaviours: social interaction and anhedo-
nia. Social behaviour of PCP-injected (2mg/kg bidaily) or saline-injected
rats paired with novel saline-injected peers was examined, analysing con-
tact (anogenital sniffing, crawling, and play behaviours), and non-contact
(following and proximal sniffing) interaction. In a second study, PCP-ad-
ministered rats (2 or 5 mg/kg bidaily) and saline-injected controls were
assessed for sucrose preference in a two-bottle choice test as a model
of anhedonia. Chronic PCP-injected rats exhibited significantly more
non-contact interaction than their saline-injected peers after treatment.
PCP did not produce a decrease in social interaction but profoundly af-
fected social behaviour, that is, the PCP rats followed or chased their
partners much more than did their saline-injected peers. In the two-choice
bottle test of anhedonia, PCP administration produced no difference in
sucrose intake compared to controls, nor a difference in water intake
or total volume of liquid consumed at either time point. These results sug-
gest that sub-chronic PCP is not a valid model for the negative symptoms
of schizophrenia, despite the enduring schizophrenia-like deficits in
GABAergic neurons and cognitive dysfunction induced by this repeated
PCP administration.
ID: 551337
A NEW CELL MODEL TO STUDY THE
MECHANISMS OF GENE-ENVIRONMENT
INTERACTIONS RELEVANT TO SCHIZOPHRENIA
Jun Nomura, Y. Ayhan, A. Sawa, C. A. Ross, M. V. Pletnikov
Psychiatry and Behavioral Sciences, Johns Hopkins University,
Baltimore, MD, USA
The pathogenesis of schizophrenia and related neurodevelopmental psychi-
atric disorders is likely to involve interactions between genetic vulnerability
and environmental factors. Among non-genetic factors, prenatal microbial
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infections and ensuing maternal immune response have been associated
with the increased incidence of mental diseases. The scarcity of experimen-
tal models has impeded mechanistic studies of gene-environment interac-
tions (GEI). We have been characterizing a GEI cell model based on
neuronal expression of mutant human Disrupted-In-Schizophrenia-1
(hDISC1) and applications of pro-inflammatory factors to mimic neuroim-
mune activation due to maternal virus infections during pregnancy. The
main goal of the study is to evaluate the neuronal effects of pro-inflamma-
tory soluble factors, expression of which we have found altered in our mice
prenatally treated with polyriboinosinic-polyribocytidilic acid (poly IC) to
pregnant dams. We evaluated the effects of IL-6 on neurite outgrowth in
cortical primary neurons. Consistent with previous results (Pletnikov,
2008), compared to control untreated cortical neurons, untreated cortical
primary neurons that express mutant hDISC1 had significantly attenuated
neurite outgrowth. Application of 100U/ml of IL-6 did not affect signifi-
cantly neurite otgrowth in mtant or control neurons. In contrast, adding
1000U/ml of the cytokine led to a significantly greater decrease in neurite
outgrowth in primary mutant hDISC1 neurons compared to control cells.
These preliminary data seem to indicate greater susceptibility of maturing
mutant neurons to adverse effects of pro-inflammatory factors. Investiga-
tions are in progress to evaluate the effects of other soluble factors and/or
direct applications of poly IC itself (to activate TLR-3 receptors) on neurite
outgrowth, synaptogenesis and spine density in cortical or hippocampal
primary neuronal or mixed neuron-astrocytes-microglia cultures. We be-
lieve that our model of the cellular effects of GEI will facilitate identifica-
tion of the specific molecular pathways affected by the genetic mutation
combined with soluble inflammatory molecules. These models have the po-
tential to advance our understanding of the pathogenesis of schizophrenia
and related neurodevelopmental disorders.
ID: 551151
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BRAIN GLUTAMATE PREDICTS COGNITIVE
FUNCTION IN SCHIZOPHRENIA BUT NOT IN
HEALTHY CONTROLS: A PROTON ECHO PLANAR
SPECTROSCOPIC IMAGING (PEPSI) STUDY AT 4
TESLA
Juan Ricardo Bustillo1,2, S. Posse3, H. Chen4, C. Gasparovic3,4,
J. Lauriello1
1Psychiatry, University of New Mexico, Albuquerque, NM, USA;
2Neuroscience, University of New Mexico, Albuquerque, NM,
USA; 3Neurology, University of New Mexico, Albuquerque, NM,
USA; 4Mind Research Network, Albuquerque, NM, USA
Glutamatergic dysfunction related to NMDA hypofunction has been pos-
tulated in schizophrenia (SZ). We examined the relationship between glu-
tamatergic metabolism and congnition in SZ. Thirty SZ patients and 28
healthy volunteers (HV) were studied .Two-dimensional spatial mapping
was performed using short TE (15 ms)PEPSI with a 4 T MedSpec scanner.
Water-suppressed and non-supressed data (8.5 and 1 min, respectively)
were acquired with 1 cm3 spatial resolution from a supra-ventricular axial
slice parallel to AC-PC. For spectral fitting with LC model, a simulated
basis set was used. Automated spectral quality control and selection as
follows: FWHM<0.06, SNR>5, CRLB<20 {NAAþNAAG (NAAc),
Ins, Cre, Cho, Glu þGlutamine (Glx). This permitted excellent fits in
about 130 voxels per subject. T1, T2 and partial volume correction (for
CSF, gray and white matter) were performed to obtain milimolal concen-
trations. A broad neuropsychological battery (18 tests) was completed by
both subject groups as well as standard clinical and functional measures by
the SZ patients. ‘‘Pure’’ gray (GM) and white matter (WM; regression
method) Glx was not different between SZ and HV. However global cog-
nition (factor 1, accounting for 70% of the neuropsychological variance)
was directly correlated with WM Glx in the SZ group (r(29) = 0.6, P =
.0005) but not in the HV (r(26) = 0.04, P = .83). Furthermore, factor 1
only correlated with two clinical measures: SANS total score (r(29) =
0.4, P = .03) and Employment impairment (r(29) = 0.4, P = .04).
Path analyses suggested that Glx and factor 1 share variance as they relate
to SANS total. Still, the path goes from factor 1 to SANS total and from
SANS total to Employment. Other metabolites differed between the
groups, depending on age (same results with duration of illness):
‘‘pure’’ GM NAAc was lower in young (<30 yr) SZ compared to young
HVs(F1,20 = 4.9, P = .04). In older SZ ‘‘pure’’ GM Ins was increased com-
pared to the older HVs(F1,34 = 11.4, P = .002). Low range (but normal)
glutamate levels may interact with NMDA hypofunction to render some
SZ’s into a functional hypoglutamatergic state with cognitive impairment.
Low cortical GM NAAc (with normal cortical volume) in young SZ’s,
may be evidence of early reduction of dendritic spines. Latter normaliza-
tion of cortical NAA in older SZ’s (with reduced cortical volume) may
reflect increased neuronal packing. Elevation in cortical Ins at latter
age suggests glial activation.
ID: 550029
TEMPORALLY COHERENT BRAIN NETWORKS
ESTIMATED USING ICA MAY BE INTERMEDIATE
PSYCHOSIS PHENOTYPES
Godfrey D. Pearlson1, V. D. Calhoun1,2, S. Meda1
1Psychiatry, Yale University/Institute of Living, Hartford/New
Haven, CT, USA; 2MIND Institute, University of New Mexico,
Albuquerque, NM, USA
Because task-based fMRI studies can be confounded by variable effort and
task performance1,2, we have utilized 1). a simple auditory oddball dis-
crimination task (AOD)3 where accuracy does not differ between groups,
and 2). resting state studies (RSS)1, requiring only that subjects stay awake
with eyes open. We conducted such fMRI experiments with 25 chronic
schizophrenia and 12 psychotic bipolar patients and in 18 and 12 of their
first-degree relatives respectively, plus 31 healthy controls, to determine if
imaging markers could differentiate these groups. We employed two sep-
arate analytic approaches: classic SPM and independent component anal-
ysis (ICA) designed to identify distinct brain networks exhibiting
temporally coherent activity. The SPM analysis showed relatively few dif-
ferences between patient groups, or between patients and their relatives,
although all differed from healthy controls. The ICA analysis was able
to identify temporal lobe and ‘‘default’’ mode networks from all partici-
pants and distinguished between groups with high sensitivity and specific-
ity. Patterns for both AOD and RSS showed a similar pattern of
significantly more low frequency power in controls and significantly
more high frequency power in patients (P < .05 FDR corrected for mul-
tiple comparisons). These data support the hypothesis that the use of co-
herent brain networks such as the temporal lobe and default modes, may
provide a more reliable measure of disease than conventionally employed
fMRI activity. ICA-derived brain networks show promise as a hemody-
namic independent phenotypes of schizophrenia and psychotic bipolar dis-
order. Supported in part by the following grants: MH077945, MH074797
and a MERIT Award MH43775 (Pearlson), EB 000840 and EB 005846
(Calhoun).
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SDF-1 AMONG DRUG NAIVE FIRST PSYCHOTIC
EPISODE PATIENTS
Emilio Fernandez-Egea1, A. Bruna2, C. Garcia-Rizo1,
M. Bernardo1, B. Kirkpatrick3
1Hospital Clinic Schizophrenia Program—Psychiatry Department,
Hospital Clinic, Barcelona, Spain; 2Cancer Research Institute,
Cancer Research—University of Cambridge, Cambridge, United
Kingdom; 3Department of Psychiatry and Health Behavior, Medical
College of Georgia, Augusta, GA, USA
Background: Although it is usually considered primarily a psychotic dis-
order, schizophrenia is associated with widespread anatomical and meta-
bolic abnormalities, including risk of type 2 diabetes, and possibly early
arteriosclerosis. We hypothesized that SDF1, a chemokine central to adult
stem cell trafficking, would be decreased in newly diagnosed, antipsy-
chotic-naı¨ve patients with schizophrenia and related disorders. Material
and methods: Patients with schizophrenia and related disorders (n = 24)
were matched to healthy control subjects (n = 24) on age, gender, body
mass index (BMI), and smoking (average number of cigarettes per day);
all were European Caucasians. The severity of psychotic symptoms was
defined as the sum of the Positive and Negative Syndromes Scale (PANSS)
item scores for hallucinations, delusions, and disorganization. Results:
SDF1 blood concentrations were lower among psychotic patients, in
both direct t-student comparison (1750.0 ng/mL [SD = 306.6] vs. 1926.7
[280.9]; P = .043) and in a multiple regression analysis in which age, gender,
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diagnosis, BMI, socioeconomic status and smoking were the independent
variables. SDF-1 levels also correlated with the degree of psychosis (r =
0.54, P = .007). Conclusions: These results suggest that the physiological
abnormalities associated with schizophrenia include poor function of the
adult stem cell system. Poor reparative processes in the brain may contrib-
ute to the widespread central nervous system dysfunction found in schizo-
phrenia.
ID: 550713
IMMUNE PATHOLOGY OF SCHIZOPHRENIA: THE
ROLE OF GLIA CELLS
M. Rothermundt
Psychiatry, University of Muenster, Muenster, Germany
Recent research has supported a potential role of immune pathology in the
etiopathogenesis of schizophrenia. Specific and unspecific evidence has
been obtained. In the CNS various viruses (eg, HERV, BDV) were iden-
tified in the brains of schizophrenic patients. Pro-inflammatory cytokines
were found to be associated with the stage of disease. Microglial cells were
reported to be activated in a subgroup of schizophrenic patients in post
mortem as well as imaging studies. Until recently, astrocytes were regarded
as mere supporters of neurons regulating the environmental milieu. New
research, however, has demonstrated that astrocytes play a major role in
the immune regulation of the CNS and modulate neuronal proliferation
and differentiation. Since neuronal remodelling appears to be a relevant
pathogenic factor in schizophrenia the role of astrocytes needs to be eval-
uated. S100B, a calcium binding astrocyte-specific cytokine, presents
a marker of astrocytic activation.
Recent studies showed increased S100B levels in medicated acutely psy-
chotic patients with schizophrenia and drug naı¨ve schizophrenics. A pos-
itive correlation between negative symptoms and S100B was described.
In a longitudinal approach over 24 weeks a continuously increased
S100B concentration was associated with persistency of negative symp-
toms and deceleration of therapeutic response. In schizophrenic patients
increased S100B concentrations are associated with increased myo-inosi-
tol, another astrocytic marker measured by MRSpectroscopy. In this
presentation new data regarding the relationship between astrocyte acti-
vation and cognitive performance is shown. S100B serum concentration,
memory performance, and psychopathology were assessed in 40 first-ep-
isode and 35 chronic schizophrenia patients upon admission and after
four weeks of treatment. Chronic schizophrenia patients with robust
high S100B were impaired in cognitive performance compared to chronic
schizophrenic patients with low S100B levels and first-episode patients
(low S100B). The findings support the hypothesis that astrocyte activa-
tion might contribute to the development of cognitive dysfunction in
schizophrenia.
ID: 550672
CORTISOL REACTIVITY IN DAILY LIFE:
A MECHANISM UNDERLYING PSYCHOSIS
Inez Myin-Germeys1,3, M. Lardinois1, T. Lataster1, N. Nicolson1,
J. Sulon2, J van Os1
1Department of Psychiatry, Maastricht University, Maastricht,
Netherlands; 2Veterinary Department, University de Liege, Liege,
Belgium; 3School of Psychological Sciences, Manchester University,
Manchester, United Kingdom
Background: The tendency to react psychotically to stress might be an es-
sential feature of psychosis, present both in patients suffering from a psy-
chotic disorder, as well as in first-degree relatives of these patients (Myin-
Germeys et al. 2005). The present study used a momentary assessment
strategy to unravel the underlying biological mechanisms of this increased
stress-sensitivity. In a sample of first-degree relatives, it was investigated
whether 1) vulnerability for psychosis is associated with changes in
hypothalamic-pituitary-axis responsivity, one of the major mediating sys-
tems involved in stress responses, and 2) whether altered hpa-responsivity
is associated with increases in sub-clinical psychosis in reaction to daily
life stress. Method: The sample consisted of siblings of patients with a psy-
chotic disorder (n = 57) and healthy control subjects (n = 66). The Ex-
perience Sampling Method (ESM; a structured diary technique) was used
to assess stress and momentary psychotic symptoms in the reality of daily
life as well as to sample cortisol in saliva at similar moments. Results:
Multilevel analyses revealed significant differences between the two
groups in basal cortisol level (B = 0.24 (SE = 0.07); P = .001) and cortisol
reaction to stress (B = 0.02 (SE = 0.01); P = .05), with larger cortisol
reactivity in relatives compared to controls. Furthermore, deviations
from the normal daily cortisol curve significantly predicted increases
in sub-clinical psychotic experiences (B = 0.01, (SE = 0.01); P = .030)
and this effect was significantly stronger in the siblings compared to
the controls (B = 0.04, (SE = 0.01); P = .002). Discussion: These results
demonstrate that momentary assessment strategies might be helpful to in-
crease our understanding of underlying biological mechanisms relevant to
psychosis. The data support the hypothesis that vulnerability for psychosis
is associated with HPA hyper-responsivity. In addition, the data suggest
that HPA hyper-responsivity might be a biological substrate underlying
the increase in psychotic symptoms after a stressor, possibly through
its association with excessive dopaminergic responses.
Reference
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SUSCEPTIBILITY TO METABOLIC AND OXIDATIVE
STRESSES IN LYMPHOBLASTS FROM PATIENTS
WITH SCHIZOPHRENIA: SYSTEMATIC COMPARI-
SON OFPERIPHERALCELLSAND NEURONS FROM
THE SAME SUBJECTS
Akira Sawa, S. Lin
psychiatry, JHU, Baltimore, MD, USA
In order to address molecular pathogenesis of mental disorders, examina-
tion of patient tissues and cells in comparison with control subjects is cru-
cial. Autopsied brains are useful to examine molecular profiles, but cannot
be utilized for functional assays. Use of blood cells has limitation, because
it is uncertain how peripheral cells represent characteristics of neurons.
Here we present our new study on possible susceptibility to metabolic
and oxidative stresses in lymphoblasts from patients with schizophrenia,
which is compared with olfactory neurons obtained from the same set of
subjects. Our results in this functional study will be compared with pre-
vious studies of molecular profiling with autopsied brains as well as some
studies with fibroblasts that have been reported by others. We propose our
hypothesis that the major side effects of obesity and type 2 diabetes elicited
by administration of atypical neuroleptics is, at least in part, a manifesta-
tion of intrinsic susceptibility of schizophrenics to metabolic and oxidative
stresses. Consistency and difference of molecular and functional character-
istics between blood cells and neurons from the same subjects will be
discussed.
ID: 550419
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STRESS AND THE HYPOTHALAMIC-PITUITARY-
ADRENAL AXIS ACTIVITY IN FIRST EPISODE
PSYCHOSIS
Valeria Mondelli, M. Aas, A. D’Albenzio, M. Di Forti, M. Di
Nicola, R. Handley, N. Hepgul, T. Marques, H. Taylor,
A. S. David, P. Dazzan, R. M. Murray, C. M. Pariante
Psychological Medicine, Institute of Psychiatry, King’s College
London, London, United Kingdom
Background: Hypothalamic-pituitary-adrenal (HPA) axis is the main bio-
logical system involved in the stress response. The aim of our study was to
evaluate objective and subjective stress together with HPA axis activity in
first-episode psychosis patients and healthy controls. Methods: We
recruited 40 first-episode psychosis patients (mean 6 SEM age: 29.4 6
1.2 yrs; gender: 35% females) and 30 controls (mean age: 27.4 6 1.0 yrs;
gender: 23.3% females) as part of the large Genetic And Psychosis
(GAP) study, carried out in South London. Information about childhood
trauma, recent stressful events and perceived stress were collected using val-
idated schedules. Salivary cortisol was obtained at awakening, at 15, 30,
and 60 minutes after awakening, and at 12 pm, and 8 pm. We calculated
the Areas Under the Curve to investigate the cortisol levels during the day
and the cortisol response to awakening. An independent t-test and was used
to analyze differences in the stress variables and cortisol secretion. Corre-
lation analyses were run to investigate the association between stress var-
iables and cortisol secretion. Results: First-episode psychosis patients
reported more childhood trauma, recent stressful events, and higher per-
ceived stress compared with controls (P < .001). Patients showed no sig-
nificant difference in cortisol levels during the day compared with
controls (P = .2). However, patients showed a significantly lower cortisol
awakening response than controls (P = .034). A positive correlation was
found between number of recent stressors or perceived stress and cortisol
during the day in controls (r = .377, P = .04 and r = .321, P = .08). In con-
trast, a negative correlation between number of recent stressors or perceived
stress and cortisol during the day was found in patients (r = .413, P = .01
and r = .356, P = .04). Conclusions: Our data show that first episode psy-
chosis patients have higher number of stressful events but similar cortisol
levels during the day when compared with healthy controls. First episode
psychosis patients have an impaired HPA axis response to stress as shown
by the blunted cortisol response to awakening and by the negative corre-
lation between measures of recent stress and cortisol secretion during the
day. Acknowledgement: This research is funded by NARSAD Mental
Health Research Association, British Academy, and NIHR Biomedical
Research Centre Institute of Psychiatry (Kings’ College London).
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INFLAMMATION MARKERS IN DRUG-NAI¨VE
FIRST EPISODE OF NON AFFECTIVE PSYCHOSIS
PATIENTS.
Clemente Garcia1,2, E. Fernandez-Egea2,3, B. Miller4,
E. Parellada1,2, L. Nguyen4, M. Bernardo1,2, B. Kirkpatrick4
1Psychiatry, Hospital Clinic, Barcelona, Spain; 2Institute of
Biomedical Research Agusti Pi i Sunyer (IDIBAPS), Hospital
Clinic, Barcelona, Spain; 3Psychiatry, University of Cambridge,
Cambridge, United Kingdom; 4Psychiatry and Health Behavior,
Medical College of Georgia, Augusta, GA, USA
A subclinical inflammatory status has been described in schizophrenia, al-
though this relationship might be confounded by antipsychotic treatment,
which is associated with weight gain and an increased risk of diabetes. Stud-
ies of antipsychotic-naı¨ve patients found an abnormal pulse pressure and an
increased risk of diabetes, which are associated with inflammation. We hy-
pothesized that an increase in pro-inflammatory molecules would be pres-
ent in schizophrenia and related disorders prior to antipsychotic treatment.
We measured fasting blood concentrations of interleukin 6 (IL6) and C-re-
active protein (CRP) in newly diagnosed, antipsychotic-naı¨ve patients with
nonaffective psychosis. Patients were categorized into deficit (N = 23) and
nondeficit (N = 41) groups. In a logistic regression model controlling for
age, gender, body mass index, smoking, and socioeconomic status, deficit
patients had significantly higher IL6 concentrations than did nondeficit
patients. In a linear regression model controlling for the same potential con-
founders, there was no difference in CRP between deficit and nondeficit
groups. These findings provide further evidence that patients with nonaf-
fective psychosis have metabolic abnormalities prior to antipsychotic treat-
ment, which may interact with antipsychotics to increase the risk of diabetes
and cardiovascular disease. Our findings also provide further evidence that
deficit and nondeficit schizophrenia have differing etiopathophysiology.
ID: 551042
IMPAIRED CORTICAL KYNURENINE PATHWAY
METABOLISM IN SCHIZOPHRENIA: FOCUS ON
KYNURENINE 3-MONOOXYGENASE
Robert Schwarcz, K. V. Sathyasaikumar, E. Stachowski,
I. Wonodi, R. C. Roberts, G. Thaker
University of Maryland School of Medicine, Baltimore, MD, USA
The levels of kynurenic acid (KYNA), a metabolite of the kynurenine path-
way of tryptophan degradation, are elevated in the prefrontal cortex of
individuals with schizophrenia (SZ) (Biol. Psych., 50: 521, 2001), and
this increase is unrelated to antipsychotic medication. Endogenous, ie,
nanomolar, concentrations of KYNA, a preferential antagonist of a7 nic-
otinic acetylcholine and NMDA receptors, reduce the extracellular levels of
glutamate and dopamine in the frontal cortex of experimental animals.
Therefore, it is conceivable that increased brain levels of KYNA may
play a role in the pathophysiology of SZ. We now determined the activity
of the enzyme kynurenine 3-monooxygenase (KMO), which appears to
control the tissue levels of KYNA, in the prefrontal cortex of patients
and well-matched controls (n = 15 each), obtained from the Maryland Brain
Collection. Compared to controls, KMO activity was reduced (36% and
38% in Brodmann areas 9 and 10, respectively; P < .05 each) in SZ sam-
ples. In separate post-mortem samples, we screened microarray expression
profiles of several kynurenine pathway genes in 32 frontal cortical tissues
(16 from SZ patients) from Brodmann area 6, a cortical area related to eye
movement deficits in patients and their relatives, and examined mRNA ex-
pression of KMO by RT-qPCR. KMO expression was significantly reduced
in SZ (P < .01). Taken together, our data demonstrate a distinct, and pos-
sibly endophenotype-specific, impairment in cortical KP metabolism in SZ.
Our results raise the possibility that the normalization of cortical KP me-
tabolism may constitute a useful new treatment strategy in SZ.
ID: 551863
INFLAMATORY MARKERS IN A PSYCHOTIC
CHILDREN CLINICAL IMPLICATIONS FOR
PROGNOSIS
Tatiana Falcone, D. Janigro, K. Franco, A. Viguera
Psychiatry and Psychology P57, Cleveland Clinic, Cleveland,
OH, USA
Human and animal studies have suggested an underlying inflammatory
mechanism for a variety of neurological disorders, including schizophrenia.
To date, all available reports have focused on adult patients with chronic
schizophrenia. Knowledge of how inflammation affects the development
of schizophrenia remains limited but several studies have identified
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inflammatory markers in all stages of disease: acute psychosis, chronic
schizophrenia and residual schizophrenia. No studies have evaluated a pos-
sible link between inflammation and psychosis in children or adolescents.
The purpose of this study is to assess inflammatory markers in a group of
psychotic children and adolescents age 12– 18 years old and correlate these
findings with clinical variables. To date, 30 patients and 30 healthy controls
have been included in the study. Four different groups have created immu-
nological animal models of schizophrenia. Their findings, which examine
cytokine levels, mimic those we observed in our preliminary studies of chil-
dren and adolescents with psychosis. Psychotic patients were diagnosed by
a consensus of 2 child psychiatrist. Diagnosis included Psychosis NOS,
Schizophrenia, schizophreniform disorder, and schizoaffective disorder fol-
lowing DSM-IV TR criteria. To participate in the study, a patient must
have one of 3 core psychotic symptoms (hallucinations, delusions or pecu-
liar fantasies) at admission. To measure the severity of symptoms the stan-
dardized SAPS for positive symptoms, the SANS for negative symptoms,
and the Brief Psychiatric Rating Scale-Children version has been used. The
CGI-Schizophrenia was also used to assess improvement. The level of 4
outcome laboratory measures were taken; These include serum
S100Beta, an IL1 beta, IL 6 and TNF alpha as well as routine standard
of care laboratory exams for children with first episode psychosis. There
are two primary findings in this study. The first is that the initial episode
of psychosis in children is associated with changes in immune cells consis-
tent with inflammation. Although both lymphocyte and monocytes abso-
lute levels were increased in psychotic children, this was not simply
a consequence of hospitalization or psychiatric illness since these values
were less elevated in non-psychotic psychiatric inpatients. The second im-
portant outcome is a link between psychiatric illness, inflammation, and
BBB disruption, demonstrated by elevation of cytokines and S100b, a pe-
ripheral marker of BBB function.
ID: 551691
SSAT GENE EXPRESSION CHANGES IN SCHIZO-
PHRENIA AND ITS IMPLICATION WITH SUICIDE
P. Adolfo Sequeira1, M. P. Vawter1, L. Morgan1, J. Li6, S. Evans2,
P. Choudary3, D. Walsh1, J. Barchas5, A. F. Schatzberg4,
R. Myers7, S. J. Watson2, H. Akil2, E. G. Jones3, W. E. Bunney1
1Psychiatry and Human Behavior, University of California, Irvine,
Irvine, CA, USA; 2Molecular and Behavioral Neuroscience Institute,
University of Michigan, Ann Arbor, MI, USA; 3Center for Neu-
roscience, University of California, Davis, Davis, CA, USA;
4Department of Psychiatry and Behavioral Sciences, Stanford
University, Palo Alto, CA, USA; 5Department of Psychiatry,
Cornell University, New York, NY, USA; 6Human Genetics,
University of Michigan, Ann Arbor, MI, USA; 7HudsonAlpha
Institute, HudsonAlpha Institute for Biotechnology, Huntsville,
AL, USA
Schizophrenia patients have high rates of suicide. However, only a subset
of schizophrenia patients ever attempt or commit suicide. In the past half
decade, there have been a number of studies utilizing microarray technol-
ogy to conduct genome wide screenings of gene expression changes in post-
mortem brain tissue leading to potential candidate genes for suicide that
have not been investigated in the schizophrenia context. The purpose of
this study was to investigate if spermidine/spermine N1-acetyltransferase
(SSAT) gene expression, a previously confirmed gene for suicide1, plays
a role in either schizophrenia or suicide in schizophrenia. We used Affy-
metrix HG-U133 Plus2, Illumina HumanRef-8 Expression BeadChip, as
well as RT-PCR expression data to compare SSAT levels in schizophrenic
patients who committed suicide (S-Schz (N = 4)), non-suicide schizophrenic
patients (NS-Schz (N = 10)) and controls (N = 44) in the dorsolateral pre-
frontal cortex (DLPFC). Brain tissue was obtained through the University
of California, Irvine Brain Bank following approval by the Institutional
Review Board. Analysis was performed correcting in an ANOVA model
for demographic variables (age, gender) and quality control parameters
(pH and RNA degradation) using PARTEK. SSAT was differentially
expressed in both platforms when comparing all schizophrenia subjects
to controls and when comparing those schizophrenia subjects who com-
mitted suicide (S-Schz) to controls. However, SSAT expression was not
significantly different between non-suicides schizophrenia patients (NS-
Schz) and controls. We confirmed the schizophrenia and suicide specific
results using RT-PCR SYBRGreen expression levels data. In summary,
SSAT gene expression is altered in the DLPFC of schizophrenic patients
when compared to controls and more specifically in schizophrenic patients
who committed suicide. This confirms the previously reported implication
of SSAT in suicide and points out to a possible biomarker or therapeutic
target for suicide across diagnostics. SSAT is the rate-limiting enzyme in
the catabolism of polyamines and this study extends the implication of the
polyamine system in suicide in schizophrenic patients.
Reference
1. Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y,
Casero RA Jr, Rouleau G, Benkelfat C, Turecki G. Implication of
SSAT by gene expression and genetic variation in suicide and major
depression. Arch Gen Psychiatry. 2006;63(1):35–48.
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CATION CHLORIDE COTRANSPORTERS: EXPRES-
SION PATTERNS IN DEVELOPMENT AND
SCHIZOPHRENIA
Thomas Michael Hyde, S. V. Mathew, T. Ali, B. K. Lipska,
A. J. Law, O. E. Metitiri, D. R. Weinberger, J. E. Kleinman
Clinical Brain Disorders Branch, GCAP, IRP, NIMH, NIH,
Bethesda, MD, USA
The biophysical effects of GABA in the brain are dependent upon the rel-
ative expression of the cation-chloride cotransporters KCC2 and NKCC1
by GABA-receptive neurons. While early in development GABA has an
excitatory post-synaptic effect due to high levels of NKCC1, GABA tran-
sitions to an inhibitory neurotransmitter due to increasing levels of KCC2
expression. To assess the expression pattern of these two cation-chloride
cotransporters from the second trimester of fetal development through late
adulthood, assays were conducted on human frontal cortical tissue using
qRT-PCR. Across the second trimester of human fetal development, in
frontal cortex, KCC2 mRNA levels rise rapidly while the NKCC1:KCC2
ratios fall. Levels of KCC2 and NKCC1 mRNA continue to rise during
childhood and adolescence, leveling off in early adulthood. The ratio of
their expression in the DLPFC is relatively constant after birth. Examining
multiple brain regions in the adult human brain, KCC2 expression is high-
est in gray matter, consistent with a neuron-specific pattern of KCC2 ex-
pression. NKCC1 expression is highest in cerebellum. Contrasting adult
patients with schizophrenia to age-matched normal control subjects,
KCC2 expression is significantly lower in the hippocampal formation of
patients with schizophrenia, but not in the DLPFC. There were no differ-
ences in NKCC1 expression in either brain region. To address the effects of
neuroleptic treatment on co-transporters, rats treated with three dose regi-
mens of haloperidol or clozapine for 28 days were compared to saline con-
trols. There were no differences in the expression of either KCC2 or
NKCC1 mRNA, in homogenates taken from sections at the level of the
hippocampus. This suggests that the difference in hippocampal KCC2 ex-
pression in human patient groups is less likely to be a neuroleptic effect.
EGR4 is a transcription factor that increases the expression of KCC2.
Schizophrenic subjects had significantly lower levels of EGR4 expression
in the hippocampal formation compared to controls. Finally, patients with
schizophrenia carrying a GAD1 schizophrenia-associated risk allele had
significantly lower KCC2 expression, suggesting that the decreased level
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of hippocampal KCC2 expression might in part be mediated by decreased
GABA neurotransmission in the hippocampus. Alterations in KCC2 ex-
pression associated with schizophrenia may be one of the molecular mech-
anisms underlying hippocampal dysfunction in this disorder.
ID: 551540
A PRIMATE AND BRAIN SPECIFIC ISOFORM OF
KCNH2 IS AN ETIOLOGIC AND PATHOPHYSIO-
LOGIC COMPONENT OF SCHIZOPHRENIA
Daniel R. Weinberger
Genes, Cognition and Psychosis, NIMH/NIH, Bethesda, MD, USA
Organized neuronal firing is critical for cortical information processing and
is disrupted in schizophrenia. Using 5’ RACE in human brain, we identified
a primate-specific isoform (3.1) of the potassium channel KCNH2 that
modulates neuronal firing patterns. Isoform 3.1 mRNA levels are compa-
rable to KCNH2-1A in prefrontal cortex and hippocampus but over 1000-
fold lower in heart. Postmortem expression analysis in brains of patients
with schizophrenia of multiple ethnicities shows a consistent 2.5-fold in-
crease in Isoform 3.1 relative to KCNH2-1A in schizophrenic hippocam-
pus. A meta-analysis of 5 independent samples constituting a total of 367
families, 1158 unrelated cases, and 1704 controls shows statistically signif-
icant association of SNPs in KCNH2 with schizophrenia. Risk-associated
SNPs also predict increased isoform 3.1 mRNA expression in postmortem
human hippocampus. Protein immunoblotting studies confirm expression
in brain and in transfected tissue culture. Structurally, Isoform 3.1 lacks
most of the PAS domain critical for slow channel deactivation. Electro-
physiological characterization in primary cortical neurons reveals that
overexpression of Isoform 3.1 results in a rapidly deactivating Kþ current
and a high-frequency, non-adapting firing pattern. These results identify
a novel KCNH2 channel and strongly support its role in cortical physiol-
ogy, and psychosis, providing a potential new target for psychotherapeutic
drugs.
ID: 551477
CHARACTERIZATION AND GENETIC
ASSOCIATION OF NOVEL SPLICE VARIANTS OF
DISRUPTED-IN-SCHIZOPHRENIA-1 (DISC1) IN
HUMAN BRAIN
Barbara K. Lipska, K. Nakata
CBDB, NIMH, Bethesda, MD, USA
Disrupted-In-Schizophrenia-1 (DISC1) is a promising susceptibility gene
for major mental illness, but the mechanism by which the DISC1 gene
confers risk for the clinical associations is unknown. Previous studies
identified several alternatively spliced DISC1 transcripts. In this study,
we searched for novel DISC1 transcripts in adult and fetal human brain
and tested whether the expression of novel transcripts is altered in brains
of patients with schizophrenia as compared to controls, and associated
with the genetic variation within the DISC1 gene. A large number of
novel alternatively spliced transcripts were identified, including a group
that lack exon 3 (delta3), a group that lack exons 7 and 8 (delta7delta8),
and a variant that has an insertion of exon 3 within a known isoform Es
(Esv1), all of which would presumably encode truncated DISC1 proteins.
We also identified a group of transcripts resulting from intergenic splic-
ing between TSNAX and DISC1. The short isoforms, delta7delta8, Esv1,
and delta3 were more abundantly expressed during human fetal devel-
opment than during the postnatal ages and were expressed at signifi-
cantly higher levels in the hippocampus of patients with
schizophrenia. Importantly, there were significant effects of schizophre-
nia risk-associated DISC1 single-nucleotide polymorphisms [two non-
synonymous SNPs rs821616 (Cys/Ser) and rs6675281 (Leu/Phe) and
rs821597] on expression levels of delta3 and delta7delta8. Moreover,
the same allele at rs6675281 that predicted higher expression in the hip-
pocampus was associated with higher expression of delta7delta8 in lym-
phoblasts in an independent sample. Our present data suggest
a molecular mechanism of genetic risk associated with DISC1 involving
alterations in gene processing.
ID: 551455
3-HYDROXYKYNURENINE AND COGNITIVE IM-
PAIRMENT IN FIRST-EPISODE NEUROLEPTIC-
NAIVE PATIENTS WITH SCHIZOPHRENIA
Jeffrey Yao1,2, R. Condray1,2, R. D. Reddy1,2, M. S. Keshavan2,3,
D. M. Montrose2, W. R. Matson4, J. McEvoy5,
R. Kaddurah-Daouk5
1Medical Research Service, VA Pittsburgh Healthcare System,
Pittsburgh, PA, USA; 2Department of Psychiatry, University of
Pittsburgh School of Medicine, Pittsburgh, PA, USA; 3Department
of Psychiatry, Wayne State University, Detroit, MI, USA; 4Medical
Research Service, Bedford VA Medical Center, Bedford, MA, USA;
5Department of Psychiatry, Duke University Medical Center,
Durham, NC, USA
One branch of tryptophan catabolic cascade is kynurenine (Kyn) pathway,
which produces neurotoxic (3-hydroxykynurenine and quinolinic acid) as
well as neuroinhibitory (kynurenic acid) compounds. Kynurenic acid acts
as a competitive antagonist of the glycine site of N-methyl-D-asparate
receptors at high concentrations and as a noncompetitive antagonist of
the a-7-nicotinic acetylcholine receptor at low concentrations. Evidence
that Kyn pathway may have a functional role in cognitive deficits has
implications for the cognitive impairments associated with schizophrenia.
Using high-pressure liquid chromatography coupled with a coulometric
multi-electrode array system, we examined 13 tryptophan metabolites
measured from the plasma of first-episode neuroleptic-naı¨ve patients
with schizophrenia (n = 25) collected at baseline and 4 weeks after treat-
ment with clinician’s-choice antipsychotics. Associations between these
metabolites and clinical symptoms measured using standard rating scales
(BPRS, SAPS, SANS, GAS, CGI) are the focus of this presentation.
Highly significant correlations were obtained between baseline level of
3-hydroxykynurenine (3-OHKyn) and baseline total symptom score
(BPRS-18), as well as between this metabolite at baseline and magnitude
of change (or improvement) in BPRS-18 at 4 weeks follow-up (P < .01).
The direction of these associations indicates that increases in baseline
3-OHKyn were related to lower levels of overall symptomatology at base-
line (less severe clinical presentation), but reduced magnitude of clinical
improvement at follow-up. Moreover, level of 3-OHKyn at baseline
was associated with the magnitude of change in symptoms of clinical
thought disorder, such as disorganized speech and bizarre thought content
and psychosis, including hallucinations and delusions, at 4-weeks follow-
up. Direction of these latter relationships indicates that increased levels of
3-OHKyn at baseline were associated with decreased improvement in cog-
nition-related symptoms at 4 weeks. In conclusion, the pattern of relation-
ships between cognitive distortions at follow-up and 3-OHKyn appears
in contrast to the pattern observed between overall symptomatology at
baseline and 3-OHKyn. If replicable, findings suggest that tryptophan
metabolism at baseline may predict clinical presentation, including
cognition-related positive symptoms, following short-term treatment
with antipsychotic medications. Supported in part by VA Merit Review
and MH58141 grants.
ID: 551398
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HPA-AXIS ACTIVITY; A PREDICTOR OF TRANSI-
TION TO PSYCHOSES IN ULTRA HIGH-RISK
PATIENTS?
Dorte Nordholm, M. Nordentoft
Psychiatric Centre Bispebjerg, Copenhagen University, Faculty of
Health Sciences, Copenhagen, Denmark
This study is a part of the NEURAPRO-E (North America, EURope, Aus-
tralia PROdrome) study, which is a multicenter controlled trial of Omega-
3-fatty acids and cognitive behavioural case management (CBCM) for
symptomatic patients at ultra high risk (UHR) for early progression to
schizophrenia and other psychotic disorders. In this study we identify
UHR patients and offer them 3 month of CBCM and either Eicosapenta-
noic, an omega-3 essential fatty acid or placebo. We plan to investigate
whether intervention with EPA combined with CBCM can reduce the tran-
sition rate in prodromal patients, McGorry et al. (2008) An average one-
year transmission rate of 36,7 % in UHR subjects who did not receive
antipsychotic medicine is reported, using a combination of various studies;
Ruhrmann et al. (2003). Different kinds of treatments/intervention offered
can delay, if not prevent the onset of psychosis. But still we treat many
patients who might never develop psychosis. It would be interesting if
we could identify further predictors, ex. biological predictors. Previous
studies have identified an increased pituitary volume before the onset of
psychosis, Garner et al. (2005). In our study we would like to examine
weather it is possible using a HPA axis activity as predictor of transition
in UHR subjects. The rational for this approach will be explored.
ID: 551253
DISTURBED SKIN BARRIER FUNCTION IN
SCHIZOPHRENIA: RECONSIDERING THE
LINK BETWEEN MENTAL ILLNESS AND SKIN
PHYSIOLOGY
Stefan Smesny1, C. Schmelzer2, A. Hinder2, A. Ko¨hler1,
C. Schneider1, M. Rudzok1, U. Cyriax1, R. Neubert2, H. Sauer1,
J. W. Fluhr3
1Department of Psychiatry, University of Jena, Jena, Germany;
2Institute of Pharmacy, University of Halle-Wittenberg, Halle
(Saale), Germany; 3Center of Experimental and Applied Cutaneous
Physiology, Department of Dermatology, Charite´, Berlin, Germany
Introduction: Associations between mental disorders and skin physiology
have been studied for more than five decades. This ongoing interest might
be caused by the obvious suitability of the skin for diverse diagnostic test-
ing. Having used a variety of approaches (measurements of skin conduc-
tance, skin temperature, dermatoglyphics, skin blood perfusion; several
skin stimulation tests), research strongly indicates links between diverse
skin physiology parameters and functioning of the central nervous system.
Only the diagnostic value is still a matter of debate. Non-invasive biophys-
ical techniques allow the quantitative assessment of skin barrier function as
a comprehensive parameter. This is of interest, as the skin barrier is strongly
related to the cell regeneration rate in basal layers of the skin and the me-
tabolism of skin lipids. Both, the cell regeneration cycle and lipid metab-
olism are disturbed in schizophrenia. Method: We investigated 31
neuroleptic naı¨ve first-episode schizophrenia patients (SCH) and 31 healthy
age and gender matched control volunteers. Skin barrier function was
assessed measuring transepidermal water loss, stratum corneum hydration
and skin surface pH values in vivo. Skin lipid profiles were measured using
a Hexan/Ethanol (2:1) wash out technique and combined HPTL/gas-chro-
matography. Results: Our data show decreased skin hydration level in SCH
patients and dependent on the gender an alteration of skin surface pH val-
ues. Analysis of skin lipids is still ongoing. Conclusion: Disturbance of skin
barrier function is not previously reported in schizophrenia. Dermatologic
studies are suggestive for links between skin barrier dysfunction and mental
stress, deficiency of polyunsaturated fatty acids, eicosanoid metabolism
and sex hormone levels. The present alterations in SCH are discussed in
the context of current schizophrenia models.
ID: 551953
THE ROLE OF DOPAMINE AND NOREPINEPHRINE
IN THE PATHOPHYSIOLOGY OF MOOD
DISORDERS
Charles Nemeroff
Department of Psychiatry and Behavioral Sciences, Emory
University School of Medicine, Atlanta, GA, USA
Evidence from preclinical and clinical investigations supports a role for dys-
regulation of multiple neurotransmitter systems in the pathophysiology of
schizophrenia and mood disorders. The dopamine hypothesis, proposed in
the 1970s, implicated elevations of dopaminergic neurotransmission in the
pathogenesis of schizophrenia and appeared to explain the efficacy of typ-
ical antipsychotics. The development of atypical antipsychotics, which pos-
sess a binding profile distinct from typical antipsychotics but offer broadly
equivalent efficacy in schizophrenia, supported evidence from other sources
implicating serotonin (5-HT) receptors in pathogenesis. More recently,
other neurotransmitters have been implicated in the development of schizo-
phrenia, including glutamate and neurotensin. It is increasingly clear that
schizophrenia results from pathologic alterations of several, interacting
neurotransmitter systems. As in schizophrenia, mood disorders, including
major depressive disorder, bipolar disorder, and the mood disorders asso-
ciated with schizophrenia, may be explained by monoaminergic neuronal
dysfunction. Evidence for the involvement of norepinephrine in depression
derives from observations including reductions in norepinephrine release
and altered adrenoceptor sensitivity in depressed patients, and is supported
by the efficacy of norepinephrine reuptake inhibitors in these patients. The
involvement of dopaminergic systems in depression is suggested by imag-
ing, postmortem, and biological fluid analyses which have identified
reduced receptor binding in the amygdaloid complex and reduced trans-
porter binding in the striatum of depressed patients. In summary, emerging
evidence implicates the involvement of multiple, interacting neurotransmit-
ter systems in the etiology of schizophrenia and mood disorders and pro-
vides further insights into the mechanism of action of agents with efficacy in
these disorders.
ID: 555406
THE CONCEPT OF ATYPICALITY—NEUROPHAR-
MACOLOGICAL UNDERPINNINGS AS REVEALED
BY MOLECULAR IMAGING
Lars Farde
AstraZeneca R and D, Sodertalje, Sweden
Growing understanding of the mechanism of action of antipsychotic drugs
has implications for the treatment of schizophrenia and mood disorders.
The modern pharmacological treatment of schizophrenia began in the
1950s with discovery of the phenothiazine derivative, chlorpromazine. Sim-
ilar compounds (so-called ‘typical antipsychotics’) were subsequently devel-
oped, but all conferred pronounced adverse effects on the extrapyramidal
system. Development of the atypical antipsychotics (eg, risperidone, olan-
zapine, quetiapine, ziprasidone, and aripiprazole) offered reduced extrapy-
ramidal effects, considered related to their receptor binding profile. While
typical antipsychotics act primarily via D2 receptors in schizophrenia, atyp-
ical antipsychotics additionally bind to serotonin (5-HT) receptors and, via
this pathway, elevate dopamine levels indirectly. Ongoing investigations
indicate that disordered dopamine neurotransmission is not solely
responsible for the pathogenesis of schizophrenia, and further investigation
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of antipsychotics may characterize actions via additional neurotransmitter
systems. Novel agents with non-dopamine-related mechanisms of action
are also under investigation, with promising results. Continued investiga-
tion into the mechanism of action of agents in the antipsychotic drug class
has identified the existence of active metabolites, including paliperidone
(from risperidone), N-desmethylclozapine (from clozapine), and norquetia-
pine (from quetiapine). These metabolites may contribute to the clinical
efficacy of the parent compound by offering distinct binding characteristics.
For example, the major active metabolite of quetiapine in man, norquetia-
pine (N-desalkyl quetiapine), is similar to quetiapine in its 5-HT2A receptor
and D2 receptor binding profile, but is dissimilar in displaying high levels of
norepinephrine transporter (NET) occupancy, even at low plasma concen-
trations. As NET inhibition is a known mechanism of action for conven-
tional antidepressants, norquetiapine may explain the antidepressant and
mood stabilizing effects of quetiapine that are observed in clinical trials of
schizophrenia, bipolar disorder, and major depressive disorder. In conclu-
sion, antipsychotic agents display differences in receptor binding profile
that appear to translate into differences in efficacy profile which are rele-
vant in the treatment of schizophrenia and mood disorders.
ID: 555117
A TRANSLATIONAL PERSPECTIVE ON
QUETIAPINE—BEYOND AN ATYPICAL
Svante Nyberg
AstraZeneca R and D, Sodertalje, Sweden
Quetiapine fumarate is approved in the USA and other countries for the
treatment of schizophrenia, bipolar mania, and bipolar depression, includ-
ing bipolar maintenance. Additional clinical studies have also shown effi-
cacy for quetiapine in major depressive disorder and generalized anxiety
disorder. This broad spectrum of efficacy was not predicted based on initial
assessments of preclinical pharmacology, and additional preclinical re-
search has been undertaken to find a potential explanation for these effects.
In vitro receptor binding studies show that quetiapine has a major active
human metabolite, norquetiapine (N-desalkylquetiapine), which has differ-
ent receptor binding properties than the parent compound. Research by
both AstraZeneca and others (Jensen et al. 2008) has shown that norque-
tiapine has moderate to high affinity for central neuroreceptors including
D2 dopamine and 5-HT2A receptors as well as the norepinephrine
transporter (NET). Occupancy at the NET is a characteristic not demon-
strated for other atypical antipsychotics. In collaboration with the Karo-
linska Institute, a radioligand for the NET has been developed,
(S,S)[18F]FMeNER-D2, enabling positron emission tomography studies
in both non-human primates and humans. These have confirmed in vitro
receptor binding profiles, demonstrating dose-dependent occupancy of
D2 and 5-HT2A receptors by quetiapine and norquetiapine, while norque-
tiapine additionally induces high occupancy at the NET even at low plasma
concentrations. In order to understand receptor binding profiles in more
detail and explore their potential clinical relevance, theoretical models of
receptor occupancy are in development. Modeling studies suggest that neu-
rotransmitter systems may be engaged along different timescales depending
on the dose and formulation of quetiapine.
Reference
1. Jensen NH, et al. N-desalkylquetiapine, a potent norepinephrine reup-
take inhibitor and partial 5-HT1A agonist, as a putative mediator of
quetiapine’s antidepressant activity. Neuropsychopharmacology.
2008;33:2303–2312.
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NEUROBIOLOGY—NET INHIBITION AND THE
EFFECTS OF ANTIPSYCHOTIC DRUGS
Torgny H. Svensson
Department of Physiology and Pharmacology, Karolinska Institutet,
Stockholm, Sweden
The dopamine hypothesis of schizophrenia implicates impaired prefrontal
dopamine functioning coupled with a hyperactive or hyperreactive subcor-
tical dopamine projection to limbic areas of the brain. Dopamine in the
prefrontal cortex is profoundly involved with control of cognition. Rodent
studies support the notion that atypical antipsychotics increase dopamine
output in the prefrontal cortex, eg, via 5-HT2 receptor antagonism. Further
studies suggest that inhibition of the norepinephrine transporter (NET)
may augment the efficacy of classical D2 antagonists to increase the avail-
ability of dopamine in the prefrontal cortex. By enhancing the efficacy of
typical and atypical antipsychotics, adjunctive NET inhibition may reduce
the D2 receptor occupancy required for an antipsychotic effect, with poten-
tial for less extrapyramidal effects, cognitive and motivational impairment,
and weight gain. As selective NET inhibition also exerts an antidepressant
effect, an enhanced therapeutic effect on negative symptoms may addition-
ally be achieved. The glutamate hypothesis of schizophrenia and cognitive
impairment implicates dysfunctional NMDA receptor subtypes in the pre-
frontal cortex. In line with animal studies supporting this hypothesis,
NMDA antagonists are known to exacerbate psychotic symptoms and cog-
nitive impairment in schizophrenic patients, as well as inducing these symp-
toms in healthy volunteers. Atypical antipsychotics share a common
property of augmenting NMDA-evoked responses in pyramidal cells of
the prefrontal cortex, implying facilitation of NMDA receptor-mediated
transmission. In analogy with atypical antipsychotics, selective NET inhib-
itors also facilitate prefrontal NMDA receptor-mediated transmission and,
in addition, enhance the effects of atypical antipsychotics in this regard. In
short, similar to most atypical antipsychotics, selective NET inhibition
facilitates both prefrontal dopaminergic and NMDA receptor-mediated
transmission, which provides a neurobiological rationale for a cognitive en-
hancing action. Consequently, the combination of quetiapine and its active
metabolite norquetiapine (N-desalkylquetiapine), which is a NET inhibi-
tor, would be expected to generate an improved effect in schizophrenia,
particularly on depressive symptoms and cognitive deficits.
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13. 13. Neuroimaging, Neurochemical
EXTRASTRIATAL AND STRIATAL D2 RECEPTOR
BINDING IN A LONGITUDINAL STUDY OF
ANTIPSYCHOTIC-NAI¨VE FIRST-EPISODE
SCHIZOPHRENIC PATIENTS: RELATION TO
POSITIVE AND NEGATIVE SYMPTOMS
Birte Yding Glenthoj1, H. Rasmussen1, C. Svarer2, L. Pinborg2, C.
Videbaek2, W. Baare4, L. Friberg3
1Center for Neuropsychiatric Schizophrenia Research, Glostrup,
Copenhagen University Hospital, Glostrup, Denmark;
2Neurobiology Research Unit, Rigshospitalet, Copenhagen
University Hospital, Copenhagen, Denmark; 3Department for
Nuclear Medicine, Bispebjerg, Copenhagen University Hospital,
Copenhagen, Denmark; 4Danish Research Center for Magnetic
Resonance Imaging, Hvidovre, Copenhagen University Hospital,
Copenhagen, Denmark
Background: Whereas the literature strongly supports that positive psy-
chotic symptoms can be dampened by striatal D2 blockade, the relation
between striatal and extrastriatal D2 receptors and negative symptoms—
and between extrastriatal D2 receptors and positive symptoms is weaker.
We have studies regional baseline D2 binding potentials (BP) as markers
for treatment outcome—and the relation between striatal and extrastriatal
D2 occupancies and psychopathology after 3 months of treatment in a lon-
gitudinal study of 23 antipsychotic-naı¨ve first-episode schizophrenia
patients. Methods: Twenty-three neuroleptic-naı¨ve schizophrenic patients
were examined with psychopatho-logical ratings and single-photon emis-
sion computerized tomography (SPECT) using the D2-receptor ligand
[123I]epidepride before and after 3 months of treatment with either the
atypical an-tipsychotic drug, risperidone, or the typical antipsychotic com-
pound zuclopenthixol. Results: We found a highly significant correlation
between frontal D2 BP in the antipsychotic-naı¨ve state and treatment out-
come with regard to the effect of antipsychotic medication on positive
symp-toms. After 3 months of treatment the effect on positive symptoms
was not, however, correlated with extrastriatal but only with striatal D2
occupancy. In contrast, high frontal D2 occupancy was correlated with
more negative symptoms. Discussion: In agreement with our previous re-
port of a relation between frontal D2 BP and positive symptoms (1), high
frontal D2 BP seem to be a marker predicting the effects of antipsychotic
medication on these symptoms. The results do not, however, support that
the effect of antipsychotics on positive symptoms is mediated via blockade
of frontal receptors. Instead, they support an association between high
frontal blockade and negative symptoms—and in agreement with the liter-
ature also between striatal blockade and effect on positive symptoms. Op-
timal antipsychotic effect seems to depend on a delicate balance between
striatal and extrastriatal D2 blockade in the individual patent.
ID: 549577
DOPAMINE D2 AND D3 RECEPTOR OCCUPANCY
OF CARIPRAZINE IN SCHIZOPHRENIC PATIENTS
David B. Keator1, Specialist1, J. Mukherjee1, A. Preda1,
D. Highum1, A. Lakatos1, A. Gage2, S. G. Potkin1
1Department of Psychiatry and Human Behavior, University of
California, Irvine, Irvine, CA, USA; 2Forest Reseach Institute,
Jersey City, NJ, USA
Background: Cariprazine is a novel dopamine D3/D2 receptor functional
antagonist, that may have antipsychotic properties based on in vitro
and animal pharmacological studies. The D3 dopamine receptor is a possi-
ble pharmacological target in part because of its high density in the ventral
striatum and its ability to improve cognition in animal models. The addi-
tion of significant D3 antagonism to cariprazine’s D2 antagonism is hypoth-
esized to offer reduced potential for extrapyramidal symptoms, cognitive
enhancement, and improvement in negative symptoms. This study was
designed to determine the D3/D2 occupancy at various doses of cariprazine.
Methods: To determine the D2 and D3 occupancy of cariprazine we con-
ducted an open-label, fixed-dose, 2-week trial with up to 4 PET scans
obtained at baseline, during dosing, end of dosing period and at the fol-
low-up visit in 8 male subjects with a DSM-IV diagnosis of schizophrenia.
F-18 Fallypride was the radiotracer used because of its high D3/D2 receptor
affinity. Subjects received daily dosing of cariprazine for 2 days followed by
a higher dose for 12 additional days. The oral doses ranged from 0.5 mg to
3.0 mg QD. Results: D3/D2 receptor occupancy in the caudate and putamen
was greater than 50% following 14 days of cariprazine 1.5 mg QD, and at
least 90% for cariprazine 3mg QD. Conclusions: Cariprazine at doses of 1.5
to 3 mg has D3/D2 receptor occupancy within the antipsychotic range pre-
dicted by other atypical antipsychotic medications.
ID: 550746
LONGITUDINAL INVESTIGATION OF 3T 1H-MRS
AND PSYCHOTIC SYMPTOMS IN UNMEDICATED
FIRST EPISODE PSYCHOSIS
Philip Tibbo1,3, D. Bernier1, P. Seres2, C. Hanstock2,
A. Nguyen-Burns3, S. Purdon3
1Psychiatry, Dalhousie University, Halifax, NS, Canada; 2In Vivo
NMR Center, Department of Biomedical Engineering, University of
Alberta, Edmonton, NS, Canada; 3Bebensee Schizophrenia
Research Unit, Department of Psychiatry, University of Alberta,
Edmonton, NS, Canada
This prospective study used 1H-MRS at 3 Tesla to investigate
NAAþNAAG, CrþPCr, Choline compounds (Cho) and glutamate in
the medial prefrontal region of unmedicated young adults with first episode
psychosis (FEP). Concentration levels were examined in association with
measures of current severity of symptoms. Sixteen patients (22.3 þ 3.2 years
of age) with FEP and without mitigation from substance abuse were assessed
at baseline (while non-medicated), at 2–6 months and at 12 months after
initiation of randomized monotherapy with either olanzapine, risperidone
or quetiapine. Sixteen matched healthy controls (HC) were also recruited
(21.71 þ 3.3 years of age). Mixed ANOVAs were computed to assess be-
tween-group differences in neurochemical levels at baseline and at fol-
low-up scans (averaging repeated follow-up scans for each participant).
A marginally significant discrepancy was found between the FEP and
HC groups in concentration levels of NAAþNAAG referenced to internal
water. Follow-up tests revealed a significant difference solely at follow-up
time [t30 = 2.1, P = .047), indicating lower levels in the FEP group. Non-
parametric bivariate correlations revealed a significant and negative asso-
ciation between baseline Cho levels and scores on the positive scale of
the PANSS (r=.66, P= .006, n= 16). Greater severity of positive symptoms
was associated with lower levels of prefrontal Cho. This association was rep-
licated in repeated measures with a subsample of patients assessed after two
to six months of medication (r=.83, P= .042, n= 6), but it was not observed
at the 12-month follow-up (r = .07, P = .911, n = 5). Reduced frontal
NAAþNAAG concentration levels have been previously reported in groups
of patients with chronic schizophrenia. We report similar findings in young
adults with first episode psychosis, but solely after medication was initiated
for a few months. The negative association between prefrontal Cho levels
and severity of positive symptoms, which was found at baseline and repli-
cated in the early but not later follow-up assessment, might be indicative of
a disturbed regional phospholipid turnover in the early stages of the illness,
in gradation with the severity of positive symptoms. This research was sup-
ported by a CIHR grant.
ID: 550706
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GLUTAMATE/GLUTAMINE AND GABA LEVELS IN
HIPPOCAMPUS IN SCHIZOPHRENIA: A 3T H-MRS
STUDY
Ana Despina Stan1,2, P. Mihalakos2, S. Morris4, C. Choi3,
C. Tamminga2
1WPIC/UPMC, Pittsburgh, PA, USA; 2Psychiatry, UT South-
western, Dallas, TX, USA; 3Advanced Imaging Research Center,
UT Southwestern, Dallas, TX, USA; 4Medical School, UT
Southwestern, Dallas, TX, USA
Schizophrenia (SZ) is a debilitating disease with long recognized phenom-
enology, but only partially understood pathophysiology. The diversity of
etiological factors and the variability of clinical presentation diversity
leaves an open question as to what brain regions and what neurotrans-
mitter systems are defective in schizophrenia. There is reliable evidence for
hippocampus involvement: neuroimaging and postmortem studies have
consistently documented hippocampal alterations is schizophrenia. Based
upon pharmacological challenge and postmortem chemistry, glutamate
transmission decrease appears to be one of the prevailing mechanistic
explanations of the disease. Using 3T H-MRS, we measured glutamate,
glutamine, NAA and GABA levels in a cohort of 15 subjects with schizo-
phrenia (SZ) in comparison with their matched normal controls (NC).
Data was collected from a single voxel of 50/15/15 mm that was placed
over the left hippocampus. Experiments were carried out on a whole-body
Philips 3T scanner (Philips Medical Systems). A standard birdcage head
RF coil was used for transmission and signal reception. MP-RAGE (mag-
netization prepared rapid gradient echo) images were used for voxel po-
sitioning. The data were corrected for field drift using the NAA singlet
during the post-acquisition processing. LCModel software was used for
spectral fitting of the data. Triple refocusing was used for Gln-Glu mea-
sure. An additional 180 pulse that refocused resonances between 1.7 and
3.3 ppm was applied within PRESS. The three subecho times were opti-
mized for simultaneous detection of Gln and Glu signals. The total echo
time was 193 ms, which gave a minimum signal of the NAA aspartate
moiety at ;2.45 ppm where a small Gln peak is generated. The Glu
peak at ;2.35 ppm was suppressed to enhance the selectivity of a neigh-
boring Gln signal. GABA was measured using scalar difference editing
(MEGA). All reported values were normalized to creatine. We found
no difference between the groups with respect to glutamine (NC =
0.51 6 0.05; SZ = 0.51 6 0.05; P = .98), glutamate (NC = 1.61 6 0.05;
SZ = 1.53 6 0.05; P = .35), or GABA (NC = 0.22 6 0.01; SZ =
0.20 6 0.01; P = .31) concentrations. We did found a significant decrease
in NAA in the schizophrenia group (NC = 1.57 6 0.04; SZ = 1.38 6 0.04;
P = .0035). In our opinion, the NAA decrease represents most probably
a treatment effect.
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DECREASED FRONTAL 5-HT2A RECEPTOR
BINDING IN ANTIPSYCHOTIC-NAIVE FIRST
EPISODE SCHIZOPHRENIA PATIENTS
Hans Rasmussen1, D. Erritzoe2, B. Ebdrup1, B. Aggernaes1,
B. Oranje1, J. Madsen2, R. Andersen1, J. Kalbitzer2, L. Pinborg2,
W. Baare´3, C. Svarer2, H. Lublin1, G. M. Knudsen2, B. Glenthoj1
1CNSR, Psychiatric Centre Glostrup, Glostrup, Denmark;
2NRU, Rigshospitalet, Copenhagen, Denmark; 3DRCMR, Hvidovre
Hospital, Hvidovre, Denmark
The purpose of this study was to assess in vivo brain 5-HT2A receptor bind-
ing in a large sample (n = 30) of first episode, antipsychotic-naı¨ve schizo-
phrenic patients and age and gender matched healthy controls and relate
the binding with psychopathology. In vivo brain 5-HT2A receptor binding
was measured using [F-18]altanserin Positron Emission Tomography
(PET) in a bolus infusion approach. The binding potential of specific tracer
binding was used as the outcome parameter. Psychopathology was assessed
using the Positive and Negative Symptom Rating Scale (PANSS). Schizo-
phrenic patients had significantly lower frontal cortical 5-HT2A binding
(t =2.16, df = 61, P< .05) as compared to controls. There was a significant
negative correlation (r = .571, P = .007) between frontal 5-HT2A binding
and positive psychotic symptoms in the male patients. Our results suggest
that frontal 5-HT2A receptors are involved in the early stages of schizo-
phrenia.
ID: 549656
POSITRON EMISSIONTOMOGRAPHY IMAGING OF
AMPHETAMINE-INDUCED DOPAMINE RELEASE
IN THE HUMAN CORTEX: A COMPARATIVE
EVALUATION OF THE HIGH AFFINITY DOPAMINE
D2/3 RADIOTRACERS [
11C]FLB 457 AND
[11C]FALLYPRIDE
W. Gordon Frankle1,2, R. Narendran2,1, N. S. Mason1,
E. A. Rabiner3, R. N. Gunn3, G. E. Searle3, S. Vora1, M. Litschge1,
S. Kendro2, T. B. Cooper4, C. A. Mathis2, M. Laruelle3,5
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Radiology, University of Pittsburgh, Pittsburgh, PA, USA;
3Clinical Imaging Center, GlaxoSmithKline, London, United
Kingdom; 4Psychiatry, Columbia University, New York, NY, USA;
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The use of PET and SPECT endogenous competition binding techniques
has contributed to the understanding of the role of dopamine in schizo-
phrenia. An important limitation of these imaging studies is the fact that
measurements of acute changes in synaptic dopamine have been restricted
to the striatum. The ligands previously used, such as [11C]raclopride and
[123I]IBZM, do not provide sufficient signal to noise ratio to quantify D2
receptors in extrastriatal areas, such as cortex, where the concentration of
D2 receptors is much lower than in the striatum. Given the importance of
cortical DA function in cognition and the cognitive deficits observed in
schizophrenia, a method to measure cortical dopamine function in humans
would be highly desirable. The goal of this study was to compare the abil-
ity of two high affinity DA D2 radioligands [
11C]FLB 457 and [11C]fall-
ypride to measure amphetamine-induced changes in DA transmission in
the human cortex. D2 receptor availability was measured in the cortical
regions of interest with PET in 12 healthy volunteers under control
and post amphetamine conditions (0.5 mg kg-1, oral), using both
[11C]FLB 457 and [11C]fallypride (four scans per subject). Kinetic model-
ing with an arterial input function was used to derive the binding potential
(BPND) in eight cortical regions. Under control conditions, [
11C]FLB 457
BPND was 30 to 70% higher compared to [
11C]fallypride BPND in cortical
regions. Amphetamine induced DA release led to a significant decrease in
[11C]FLB 457 BPND in six out the eight cortical regions evaluated. In con-
trast, no significant decrease in [11C]fallypride BPND was detected in cor-
tex following amphetamine. The difference between [11C]FLB 457 and
[11C]fallypride ability to detect changes in cortical D2 receptor availability
following amphetamine is related to the higher signal to noise ratio pro-
vided by [11C]FLB 457. These findings suggest that [11C]FLB 457 is supe-
rior to [11C]fallypride for measurement of changes in synaptic dopamine in
cortical regions, including the dorsolateral prefrontal cortex, a region hy-
pothesized to be a key node in the cognitive impairments observed in
schizophrenia.
ID: 549619
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ASSESSMENT OF HUMAN BRAIN GLUTAMATE
USING A HYPEROSMOLAR PROBE AND 1H-MRS
Handan Gunduz-Bruce1, A. J. Peixoto2, J. Moussai1,
Z. Bhagwagar1, J. Q. Watzl3, D. L. Rothman3, J. H. Krystal1,
G. F. Mason3
1Psychiatry, Yale University, West Haven, CT, USA; 2Medicine,
Yale University, New Haven, CT, USA; 3Diagnostic Radiology,
Yale University, New Haven, CT, USA
Converging evidence suggests that glutamatergic abnormalities play a role
in the pathogenesis of schizophrenia, but validation of these abnormalities
in vivo remains to be determined. Thus, we developed a novel method to
assess the change in glutamate concentrations in response to a hyperosmolar
probe using 1H-MRS based on preclinical data that have shown that in
addition to being the most abundant neurotransmitter, glutamate is
a major osmolyte, which accumulates in brain tissue with sustained
hyperosmolality. Methods: To induce sustained hyperosmolality, first we
developed a water restriction paradigm (WRP). WRP was safe and effec-
tive. Healthy controls (N = 8) completed 1H-MRS scans before and after
WRP on a 4T Bruker system to examine the link between sustained hyper-
osmolality and cortical glutamate concentrations. We have also obtained
preliminary data from patients (N = 2) using WRP and MRS. Occipital 1H
MRS was performed with a spin-echo acquisition (TE/TR = 68 ms/2500 ms)
with ISIS and outer volume suppression, using a surface coil with outer
volume suppression. GABA measurements were obtained from J-edited
difference spectra. Results: The WRP was effective in inducing sustained
hyperosmolality [F4,32 = 2.8, P = .04] and there was no significant group
effect [F1,7 = 2.1, P = .18] suggesting that it was effective in both groups.
A significant increase in glutamate concentrations was found in healthy
controls using both water (t = 3.5, df = 7, P = .01) and creatine (t = 3.4,
df = 7, P = .01) referencing. Consistent with the animal literature, in healthy
controls, sustained hyperosmolality was associated with increased cortical
glutamate concentrations (r = .69, P = .05). In healthy controls, the other
measured molecules (NAA, GABA, glutamine, myoinositol, and choline)
did not show significant changes (all P > .05). Patients did not show sig-
nificant changes in the concentrations of any of the molecules measured (all
P > .05). Discussion: We have shown that sustained hyperosmolality is as-
sociated with increased cortical glutamate concentrations in healthy
humans, as predicted from the preclinical literature. Our preliminary find-
ings in the patients suggest that schizophrenia may involve abnormal reg-
ulation of the glutamatergic system in relation to water metabolism.
ID: 550872
A COMBINED FMRI AND 1H-MRS STUDY OF THE
ACC AND THE HIPPOCAMPUS IN PATIENTS WITH
SCHIZOPHRENIA AND MATCHED HEALTHY
VOLUNTEERS
Adrienne C. Lahti1, M. Reid1,3, L. Stoeckel1,2, D. White1,
J. den Hollander4, S. Akella3, K. Avsar2,1
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Our previous imaging studies in schizophrenia have revealed that limbic
brain networks, such as the anterior cingulate cortex (ACC) and the hip-
pocampus (HIP), are related to psychosis. In this study we use fMRI to-
gether with proton magnetic resonance spectroscopy (1H-MRS) to
contrast the physiological and biochemical properties of the ACC and
HIP in patients with schizophrenia (SZ) and matched healthy volunteers
(HV). We hypothesized that greater BOLD response to cognitive tasks
known to activate the ACC (Stroop) and the HIP (episodic memory) as
well as greater N-acetyl-aspartate (NAA) and GLU metabolite measure-
ments in these regions would be seen in HV vs. SZ. All scans were acquired
with a Siemens 3T scanner. fMRI: BOLD data were acquired with single-
shot gradient echo planar imaging (TR = 2.1sec, TE = 40msec, Flip angle = 70
degrees, slice thickness = 2.5mm, 1mm gap, FOV = 240mm) during a Stroop
and an episodic memory task. An event-related design was used with 3 runs
of 88 trials each for the Stroop and 2 runs of 60 word presentations for the
memory task. The preprocessed fMRI data were analyzed using SPM5. The
mean percent signal change was found for the cluster of maximum activa-
tion in the ROIs for which the contrasts of incongruent > congruent
(Stroop) and encode (episodic memory) were significant as calculated by
MarsBar. 1H-MRS: Water-suppressed spectra were acquired with a point
resolved pulse sequence (PRESS) (TR = 2000ms, TE = 80ms, 2000 HZ spec-
tral width) from voxels prescribed in the left HIP and the bilateral dorsal
ACC. Combined fMRI and 1H-MRS scans were acquired in HV (n = 9) and
SZ (n = 8). Significant activation in dorsal ACC/medial PFC (Stroop) was
seen in HV (MNI: -2, 16, 42; t = 8.15) and SZ (6, 26, 44; t = 4.17) and in left
HIP (Memory encode) in HV (20, 32, 10; t = 4.02) and SZ (34, 34,
2; t = 2.02). There was a trend level (P = .07) decrease in the NAA/Cr ratio
in SZ vs. HV in the ACC. In the ACC, there was a positive correlation (r =
0.53, P = .16) between percent signal change (Stroop) and NAA/Cr ratio in
SZ but not in HV. The data suggest that, in SZ, there is a loss of neuronal
integrity in the ACC. In addition, the combined fMRI/1H-MRS data in
that region suggest that, in SZ, there is a tighter relationship between func-
tional activity and neuronal integrity. These data show the feasibility of
combining fMRI and 1H-MRS to investigate the function and the bio-
chemistry of the ACC and the HIP.
ID: 551490
D2/D3 RECEPTOR BINDING IN STRIATAL AND
EXTRASTRIATAL REGIONS IN SCHIZOPHRENIA
STUDIED WITH PET AND [18F]FALLYPRIDE
Lawrence S. Kegeles1,2, M. Slifstein1, X. Xu1, E. Hackett1,
R. Gil1, B. Alvarez1, E. Meyers1, N. Urban1, M. Laruelle3,
A. Abi-Dargham1,2
1Psychiatry, Columbia University, New York, NY, USA; 2Radiol-
ogy, Columbia University, New York, NY, USA; 3Schizophrenia
and Cognitive Disorder Discovery Performance Unit,
GlaxoSmithKline, Harlow, United Kingdom
Background: Alterations in dopamine (DA) D2/D3 receptor binding have
been reported in schizophrenia, showing a modest elevation in baseline
radioligand binding in striatum. New radioligands now allow the assess-
ment of these receptors in extrastriatal regions, and several studies have
been reported with variable findings. We used [18F]fallypride PET imaging
to evaluate these receptors in both striatal and extrastriatal regions in
schizophrenia. Methods: Twenty-one patients with schizophrenia and 22
group-matched healthy controls were scanned with [18F]fallypride and
an HRþ camera. Each scan was acquired over 240 min in 3 sessions of
50, 60 and 40 min with breaks. Arterial blood was collected for metabo-
lite-corrected plasma input function. Regions of interest were drawn on
each subject’s MRI and transferred to the coregistered PET. Regional
data were analyzed by kinetic modeling using reference tissue and 2 tissue
compartment models. Binding potential outcome measures BPND, BPP,
and BPF were compared with 2-tailed t tests. Results: Mean regional
BPND values were nonsignificantly elevated in striatum in schizophrenia
as in prior literature, although no striatal or extrastriatal region showed
significantly altered BPND. For example, mean regional BPND values
in patients and controls respectively were 20.2 6 4.0 and 19.5 6 2.9 in whole
striatum, 18.7 6 3.9 and 18.3 6 3.1 in dorsal caudate, 1.8 6 0.4 and 2.0 6 0.4
in amygdala, and 2.2 6 0.5 and 2.1 6 0.3 in thalamus (P > .05 in all cases).
While BPP regional values were significantly lower in patients in several
regions, both plasma free fraction of radioligand and nondisplaceable dis-
tribution volume assessed in the cerebellum were lower in the patient group,
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resulting in absence of significant regional differences in BPND or BPF in
any brain region. Discussion: In this study, we did not find significant alter-
ations in D2/D3 receptor expression levels in schizophrenia. These results
are consistent with some but not all previous studies of extrastriatal D2/D3
receptors. Assessing DA function in extrastriatal regions, such as with stim-
ulated release or DA depletion paradigms, may be a more productive ap-
proach to understanding the role of these regions in the pathophysiology of
the illness, as previously shown for the striatum. Acknowledgment: This
work was supported by NIMH 1 P50 MH066171.
ID: 551379
THALAMIC GLUTAMATE AND THE TRANSITION
TO PSYCHOSIS
James M. Stone, H. Tsagaraki, F. Day, I. Valli, D. J. Lythgoe,
R. L. O’Gorman, M. A. McLean, G. J. Barker, P. K. McGuire
Institute of Psychiatry, London, United Kingdom
The thalamus is central to the NMDA receptor dysfunction hypothesis of
schizophrenia. Functional impairment of thalamic NMDA receptors is
thought to give rise to a disinhibition of thalamocortical projection neu-
rons, potentially leading to cortical dysfunction, excitotoxicity and grey
matter loss. Reduced thalamic glutamate prior to the development of psy-
chosis is one mechanism by which this might occur. We tested the hypoth-
eses that subjects at ultra high risk of psychosis (UHR) have reduced
thalamic glutamate and that this reduction correlates with reductions in
cortical grey matter volume. 27 healthy controls and 27 UHR subjects
were recruited. All subjects underwent magnetic resonance spectroscopy
(MRS) and structural SPGR MRI scanning on a 3T Signa GE MRI scan-
ner. The MRS acquisition employed a PRESS sequence with a 30ms TE,
with a 2 x 2 x 1.5cm voxel placed on the left thalamus. SPGR images were
segmented into grey matter, white matter and CSF using SPM. MRS data
were analysed using LCModel, with water-scaled values being corrected for
voxel CSF content. Voxel-based morphometry (VBM) analysis relating
thalamic glutamate levels to cortical grey matter changes were preformed
using XBAMM. 10 of the healthy controls and 8 UHR subjects were
rescanned after 1 year or after transition to psychosis. Thalamic glutamate
was significantly reduced in UHR subjects (n = 26; P = .017) and directly
correlated with grey matter reductions in the left prefrontal, insular and tem-
poral cortical regions most robustly affected in schizophrenia (n = 26; P =
.007). Transition to psychosis in 2 subjects was associated with a further de-
crease in thalamic glutamate levels (reduction of 30%, n = 2, SD = 15%),
whereas other ARMS subjects and controls showed a small increase in tha-
lamic glutamate levels between the two time points (increase of 6%, n = 6, SD
= 23%; and increase of 7%, n = 10, SD = 25%, respectively). These results
indicate that central glutamate dysfunction predates the onset of schizophre-
nia and may underlie the neuroanatomical abnormalities associated with the
disorder. The findings suggest that enhancement of thalamic glutamate func-
tion represents a potential therapeutic target for novel compounds, partic-
ularly in the early phase of psychosis.
ID: 551363
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Cognitive impairments like attention deficits are core symptoms of people
with schizophrenia, which may be related to nicotinic receptor deficits. Cor-
respondingly smoking prevalence in schizophrenia is increased possibly for
self-medication reasons. Complementary co-therapies of novel nicotinic
ligands are being developed to add to antipsychotic therapy in order to treat
the cognitive impairment of schizophrenia. Therefore we assessed the un-
derlying functional mechanisms of cholinergic attention modulation (1) by
functional Magnet Resonance Imaging (fMRI) in healthy subjects while
performing the Attention Network Task (ANT) under pharmacological
treatment with mecamylamine, a non selective nicotinic antagonist, pla-
cebo, or Scopolamine a muscarinic antagonist. The ANT operationalises
Alertness, Orienting and Executive Control, the three attentional networks
as described by Posner and Petersen (2). Twelve healthy, male, right handed
nonsmokers were assessed with fMRI in intervals of at least one week in
a single blind, double dum:my, cross-over- design three times. Prior to each
scanning session they received in a randomized order either Mecamylamine
or Scopolamine plus placebo or exclusively Placebo. The functional brain
activation was assessed during the ANT as operationalised for the fMRI
environment by Fan et al. (3). During the placebo trial the orienting
and executive control network activations were in line with Posner and
Petersens hypothesis (2), resulting in bilateral activations in predominantly
frontal and subcortical areas in the orienting trial and in bilateral activa-
tions in the anterior cingulum, the precuneus and occipital areas of the left
hemisphere in the executive control trial. In both conditions both antago-
nists effectively disrupted these activation patterns with more extensive
disruptions by the nicotinic antagonist. This selective modulation has impli-
cations on cognitive enhancements in schizophrenia. Supported by the
Deutsche Forschungsgemeinschaft (KFO 112).
References
1. Green, et al. 2005.
2. Posner and Petersen. 1990.
3. Fan, et al. 2002.
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INDUCES STRIATAL DOPAMINE RELEASE IN
HUMANS: AN [11C]RACLOPRIDE PET STUDY
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The use of cannabis increases the risk for developing schizophrenia and
worsens its clinical outcome. In schizophrenia, enhanced striatal dopamine
function has been consistently demonstrated. Further, in animal models,
cannabinoid substances such as D9-tetrahydrocannabinol (THC), the
main psychoactive component in cannabis, stimulate striatal dopamine
neurotransmission by activating cannabinoid CB1 receptors. However, it
is not known whether THC affects the human striatal dopamine system.
Therefore, as a first step to unravel the role of the endogenous cannabinoid
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system in schizophrenia, the purpose of the present study was to investigate
whether THC can induce dopamine release in the striatum of healthy
human subjects. Seven male subjects were included in this double-blind,
randomized, placebo-controlled, cross-over study. They underwent two
PET scans after inhalation of either 8 mg THC or placebo using a Vol-
cano vaporizer. Scanning sessions were separated by two weeks and all
subjects were incidental cannabis users. Dopamine release in striatal
subregions was assessed by determining changes in binding potential
(BPND) of the dopamine D2/D3 receptor ligand [11C]raclopride. In ad-
dition, behavioral and subjective effects of THC were assessed using the
Brief Psychiatric Rating Scale (BPRS) and Visual Analogue Scales. Ve-
nous blood samples were withdrawn to determine THC plasma concen-
trations. [11C]raclopride BPND was significantly reduced in ventral
striatum and precommissural dorsal putamen, but not in other striatal
subregions, after inhalation of THC compared with placebo (see table).
This is consistent with increased dopamine release in these striatal subre-
gions after THC administration. In addition, THC induced well-known
significant behavioral, subjective and physiological effects. Plasma concen-
trations of THC showed a maximum of 143 6 91 ng/ml five minutes after
inhalation, decreasing rapidly thereafter. These findings indicate that the
endogenous cannabinoid system is involved in regulating striatal dopa-
mine release. This allows new directions in research on the effects of
THC in schizophrenia.
Table.
Region BPND Placebo BPND THC Difference (%) P-values
Ventral striatum 1.40 6 0.24 1.35 6 0.24 3.43 6 3.70 0.029 *
Precommissural dorsal
caudate
2.18 6 0.25 2.12 6 0.13 2.09 6 6.44 0.355
Precommissural dorsal
putamen
2.75 6 0.24 2.64 6 0.16 3.88 6 4.07 0.042 *
Postcommissural caudate 1.62 6 0.19 1.55 6 0.15 4.12 6 7.14 0.157
Postcommissural putamen 2.74 6 0.29 2.69 6 0.20 1.50 6 4.42 0.329
Striatum 2.28 6 0.22 2.21 6 0.12 2.57 6 4.42 0.153
ID: 557778
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Glutamate (Glu) has been implicated in the pathophysiology of schizo-
phrenia. Its receptor blockers can induce schizophrenia-like symptoms.
There is evidence of a complex interaction between dopamine (DA)
and Glu neurotransmission in schizophrenia; but, little is known about
the role of Glu in a dense DA innervated region like the associative-
striatum. Proton magnetic resonance spectroscopy (1H-MRS) is a non-
invasive neuroimaging technique for measuring in vivo metabolite
concentration such Glu and creatine (Cr). The aim of this study was to
compare the Glu levels in patients with schizophrenia, before and after
antipsychotic treatment (Risperidone), with appropriate controls in the
associative-striatum (anterodorsal caudate) and in a negligible DA region
(cerebellar cortex). Fourteen patients with schizophrenia (age: 24.9 6 5.9,
7-males) and nineteen healthy controls (age: 26.6 6 5.9, 13-males) were
included. The patients were during an acute psychotic episode (PANSS =
87.8 6 19.8); drug free for at least one month; and able to consent the
procedures involved. They were treated with Risperidone for 6-weeks
and the doses (3.43 6 1.45 mg/day) were adjusted based on clinical judg-
ment (PANSS-post treatment = 56.2 6 12.6). Concomitant medications
were not allowed during the study. Patients underwent two 1H-MRS stud-
ies, one before treatment and other after 6-weeks of daily Risperidone
treatment. Controls underwent one 1H-MRS study. 1H-MRS were per-
formed on a 3.0-T GE scanner using a PRESS pulse sequence with
TR = 1500 ms, TE = 35 ms, 128 repetitions in 4ml voxels (2x2x1 cm) lo-
calized on the anterodorsal caudate and cerebellar cortex. All metabolite
concentrations were normalized by the relative concentration of Cr. Our
results indicate that the increase of Glu in the associative-striatum in
schizophrenia is related to the illness and does not change after 6-weeks
of antipsychotic treatment. Moreover, the lack of change in the cerebellum
suggests that the increase of Glu in schizophrenia is not ubiquitous within
the brain and may be associated with DA target regions. The results might
tie with the glutamatergic hypothesis of schizophrenia; which propose
a disinhibition of dopamine and glutamate subcortical activity due to
hypofunction of the cortical NMDA-receptor.
ID: 554585
[11C]GSK931145: A NEW PET LIGAND FOR GLYCINE
TRANSPORTER1
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1Neurosciences CEDD, GlaxoSmithKline, London, United
Kingdom; 2GSK Clinical Imaging Centre, GlaxoSmithKline,
London, United Kingdom; 3IAT, , Barcelona, Spain; 4CLinical
Pharmacology Unit, IMIM, Barcelona, Spain; 5Neurosciences
CEDD, GlaxoSmithKline, RTP, NC, USA; 6WW Safety Assessment,
GlaxoSmithKline, Ware, United Kingdom; 7CPMS, GlaxoSmithKline,
Verona, Italy; 8Columbia University, New York, NY, USA;
9Neurosciences CEDD, GlaxoSmithKline, Barcelona, Spain
Introduction: NMDA receptors possess recognition sites for the two oblig-
atory co-agonists glutamate and glycine. Enhancing glycine levels at the
NMDA site may reverse impaired NMDA function in schizophrenia
and glycine transporter1 (GlyT-1) inhibitors are under investigation for
its treatment. The development of a GlyT-1 PET radioligand would allow
for quantification of GlyT-1 density, determination of drug-induced recep-
tor occupancy and allow researchers to examine the role of GlyT-1 in
healthy volunteers and patients with schizophrenia. In this study,
[11C]GSK931145 was evaluated as a PET ligand for GlyT1 in animals
and translated to humans. Methods: Animals (pig, n = 2 and baboon,
n = 2) were scanned following i.v. administration of [11C]GSK931145 at
baseline and following pre-treatment with pharmacological doses of selec-
tive GlyT-1 inhibitors (GSK565710 or GSK931145). Dynamic data were
quantified using a two tissue compartment model to derive estimates of
the distribution volume (VT). Two further primates were scanned for
the purpose of obtaining dosimetry estimates. [11C]GSK931145 was
then transitioned to humans and healthy volunteers (n = 6) were studied
following tracer injection. Further (n = 4) healthy volunteers underwent
whole body PET-CT scans to confirm preclinical dosimetry estimates.
Results: In both pig and baboon [11C]GSK931145 demonstrated a hetero-
geneous uptake with regional distribution volumes consistent with known
GlyT1 distribution: brainstem ; thalamus > cerebellum > cortex. The ki-
netics were reversible and brain uptake was reduced to homogenous levels
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following blockade (pig: VND = 1.81, baboon: VND = 1.53 6 0.19) and
allowing estimation of binding potentials (Table). In humans, the tracer
demonstrated reversible kinetics and maintained binding ratios,
although a reduced uptake, as compared to preclinical species was
observed. Dosimetry data in baboons (ED: 4.5lSv/MBq) was confirmed
in humans (ED: 4.1lSv/MBq) with the liver being the dose limiting
organ. Conclusion: [11C]GSK931145 is a novel PET ligand for imaging
of GlyT-1 which may be used to support clinical development of GlyT-1
inhibitors and to investigate the role of GlyT-1 in the pathogenesis of
schizophrenia.
Table. [11C]GSK931145 Binding Potentials in different brain regions
BPND Brainstem Thalamus Cerebellum Cortex
Pig 1.94(0.16) 1.96 (0.36) 0.97 (0.01) 0.52 (0.01)
Baboon 2.80 (0.59) 2.55 (0.04) 2.28 (0.28) 1.37 (0.10)
Values are mean (SD)
ID: 552010
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AN AGFCTIVATION LIKELIHOOD ESTIMATION
META-ANALYSIS OF FACIAL EMOTION
PROCESSING IN SCHIZOPHRENIA
Raymond Chan1, H. Li1, G. M. McAlonan2, Q. Gong3
1Institute of Psychology, Chinese Academy of Sciences, Beijing,
China; 2Department of Psychiatry, The University of Hong Kong,
Hong Kong Special Administrative Region, China; 3Department of
Radiology, Sichuan University, Chengdu, China
Background: Although there is a consensus of behavioural findings that
patients with schizophrenia have certain deficits in perceiving and express-
ing facial emotional expression, interpretation of imaging findings is com-
plicated by the range of experimental design and differences in the clinical
characteristics of the patient samples recruited may contribute to inconsis-
tencies in the results. Aim: The current study adopted a relatively recent
voxel-wise technique, activation likelihood estimation (ALE) to consolidate
the existing evidence of the neural basis of facial emotional perception in
schizophrenia. Method: Fifteen articles meeting inclusion criteria were
recruited for the meta-analysis. 7 articles reported coordinates from
patients with schizophrenia alone, 12 articles reported coordinates from pa-
tient-control contrasts were included. The ALE analyses were conducted in
the Talairach space. Results: The healthy controls activated six distinct
brain regions. These regions included large portions of the bilateral fusi-
form gyri (Brodmann areas [BA] 19, 37), and amygdala, right inferior fron-
tal gyrus (BA47), parahippocampal gyrus (BA28) and cerebellum and the
left insula (BA 13). Compared to the controls alone analysis, analysis of
schizophrenia samples alone generated more extensive activation of left
insula, and also included the right insula and more ventral portions of
BA 28 (corresponding to the uncus). Healthy subjects activated prefrontal
areas more than patients, in particular medial regions of BA 6, 8, 9 and 10.
Patients with schizophrenia activated multiple widespread regions which
were relatively limited in extent compared to the cluster sizes generated
by previous analyses. Apart from small clusters in dorsolateral prefrontal
lobe, the clusters reported were mostly in posterior brain regions: medial
aspects of the left fusiform gyrus (BA 20), right inferior occipital gyrus
(BA 18), bilateral parahippocampal gyri (BA 35), right posterior cingulate
(BA 29, 30), ventral striatum, mid-brain and bilateral cerebellum.
Conclusions: ALE meta-analyses showed that when processing facial
expressions of emotions, patients with schizophrenia activated some similar
regions as controls, namely the bilateral amygdala, bilateral fusiform gyri
and insula. However, the extent of activation in these regions was general
much more limited in the schizophrenia samples.
ID: 538250
HIPPOCAMPAL HYPERACTIVITY IS ASSOCIATED
WITH POSITIVE SYMPTOMS
Dolores Malaspina1,2, C. Corcoran2, S. Schobel2, S. Small2,
D. Kimhy2, N. Lewandowski2
1Psychiatry, NYU, New York, NY, USA; 2Psychiatry, Columbia
University, New York, NY, USA
Our studies show that overactivity of the hippocampus is associated with
positive symptoms in schizophrenia. We previously demonstrated the
presence of medial temporal lobe hyperperfusion in separate subgroups
of schizophrenia patients who had distinct regions of hypoperfusion
(Malaspina 2005). In a new study focused on the hippocampus, we con-
firmed resting hippocampal hypermetabolism, showing it was restricted
to outflow tracks in CA1 and the subiculum. This activation was associated
with positive symptoms of the disease. We propose that hippocampal hy-
perfunction could be a primary defect that drives dysfunction in other cor-
tical and subcortical areas. Among hippocampal outflow sites, we found
strong associations of CA1 activity to OFC cerebral blood volume (F =
5.0; P = .015). CA1 activity was not related to DLPFC activity. OFC itself
stimulates a broad range of downstream areas, including subcortical dopa-
mine, and subcortical emotion and cognitive processing regions. Blocking
dopamine with antipsychotic medications may decrease psychotic symp-
toms, but not ameliorate other cognitive and emotional effects that are
also driven by the hippocampal dysfunction. CA1 particularly interacts
with the amygdala. Increased CA1 and subiculum hippocampal activity
is proposed to be a principal driver of psychosis in schizophrenia.
ID: 550739
INDEPENDENT COMPONENTS ANALYSIS
OF WORKING MEMORY NETWORKS IN
SCHIZOPHRENIA
Kristen M. Haut, A. W. MacDonald
Psychology, University of Minnesota, Minneapolis, MN, USA
Functional activity during performance of neurocognitive tasks differs
between patients with schizophrenia and normal controls. One of the
most consistent cognitive deficit findings suggests that patients show
impairments in the executive functions involved in working memory
(Reichenberg and Harvey, 2007). In addition, abnormal functional connec-
tivity within or between neural networks in the brain has been suggested to
contribute to the symptoms of schizophrenia and may also be related to the
cognitive functioning of patients. Functional activation within these net-
works has been shown to discriminate between patients with schizophrenia
and controls (Calhoun, Maciejewski, Pearlson, and Kiehl, 2007). This study
examines differences in functional networks during working memory per-
formance in both patients and controls. Methods: Independent compo-
nents analysis (ICA) was used to identify networks associated with
working memory activity in patients with schizophrenia and normal con-
trols. The networks most strongly associated with task were identified by
correlating the time course within individual components with the time
course of the task. The two groups were then compared in order to identify
any group differences in the maximum and average task/component corre-
lation. Results: Correlations between task and activity within the compo-
nent with the highest task association ranged from .21–.87 (mean = .546,
SD = 0.178) in patients with schizophrenia and from .27–.87 (mean = .594,
SD = 0.138) in controls. While patients with schizophrenia tended to have
a slightly lower task/component correlation and a greater variability of
task/component correlation, there was not a significant difference between
groups (P = .389, effect size = .297). Conclusions: These results suggest that
patients with schizophrenia activate a working memory network associated
with task to the similar degree as controls. Thus, differentiating groups us-
ing functional activity during working memory performance likely relies on
overall strength of activation and/or overall pattern of activation.
References
1. Calhoun VD, Maciejewski PK, Pearlson GD, Kiehl KA Temporal lobe
and ‘‘default’’ hemodynamic brain modes discriminate between schizo-
phrenia and bipolar disorder. Hum Brain Mapp. 2007.
2. Reichenberg A, Harvey PD. Neuropsychological impairments in
schizophrenia: Integration of performance-based and brain imaging
findings. Psychological Bulletin, 2007;133(5):833–858.
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Schizophrenia (SZ) patients have difficulty processing dynamic visual stim-
uli (eg, motion). SZ is also characterized by social dysfunction such as im-
paired Theory of Mind (ToM). Biological motion (BM) refers to
movements generated by living beings. The visual system rapidly extracts
socially-relevant information from BM and a deficit in BM perception may
lead to detrimental consequences for social information processing. Our
past work indicates that BM perception deficit in SZ is associated with re-
duced social functioning. The present study aimed to identify the neural
underpinnings of impaired BM perception in SZ and to further specify
the relationship between BM perception and social deficits. We measured
brain activation using event-related fMRI in SZ and healthy controls (CO)
during a BM perception task which required participants to decide whether
a point-light stimulus display looked like a human or not. Three types of
stimuli were presented (BM, scrambled, and partially scrambled motion).
Clinical symptom ratings and ToM tests were also administered. Signal de-
tection analyses showed a reduced sensitivity in SZ compared with CO on
BM detection, which was due to higher false-alarm rates (‘biological’ re-
sponse to scrambled motion) rather than lower hit rates (‘biological’ re-
sponse to BM). The fMRI results from CO indicated that the posterior
superior temporal sulcus (STSp) is strongly activated by BM, but not by
scrambled motion. Interestingly, strong STSp activation was also observed
for scrambled or partially scrambled motion when the participant perceived
it as BM. STSp activation in SZ was not selective to BM, resulting in rel-
atively greater activation to scrambled motion compared to CO. Further-
more, this abnormal STSp activation was associated with ToM deficits and
positive symptoms. In CO, STSp activation in relation to BM perception
interacted with observer’s response regardless of the stimulus, highlighting
the influence of top-down processing on perceptual experience. SZ’s in-
creased false-alarm rates and accompanying elevated STSp activation to
non-BM indicate that BM perception deficit is due to misperception of
non-BM as biological rather than a failure to perceive BM. Overall, these
results suggest an intricate interaction among subjective perceptual experi-
ence, STS activation, psychotic symptom, and social deficits. This study
was supported by NARSAD.
ID: 550653
NEUROINFLAMMATION IN SCHIZOPHRENIA:
A POSITRON EMISSION TOMOGRAPHY STUDY
Janine Doorduin1, E. F. de Vries1, A. T. Willemsen1,
R. A. Dierckx1 H. C. Klein1,2
1Nuclear Medicine and Molecular Imaging, University Medical
Center Groningen, University of Groningen, Groningen,
Netherlands; 2University Center of Psychiatry, University Medical
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Schizophrenia is a chronic and disabling brain disease with unknown
etiology. It has been suggested that neuroinflammation plays a role in
the pathophysiology of schizophrenia. Neuroinflammation is characterized
by activated microglia cells that show an increase in the expression of the
peripheral benzodiazepine receptor (PBR). The isoquinoline (R)-PK11195
[(R)-N-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-car-
boxamide)] is a PBR ligand and can, after labeling with carbon-11, be used
for imaging of neuroinflammation with positron emission tomography
(PET). Neuroinflammation was hypothesized to be more profound during
psychosis and therefore 7 schizophrenic patients were included that had
a score of at least 5 on the positive item of the PANSS, or a score of 4
on two items. The patients were compared to 8 age-matched healthy con-
trols. A dynamic PET scan of 60 minutes was acquired after a bolus injec-
tion of 404 6 49 MBq of [11C]-(R)-PK11195. During the PET scan, whole
blood activity was monitored using an automated sampling system. In ad-
dition, blood samples were taken 20, 45 and 60 minutes after tracer injection
to correct for metabolites. All subjects underwent a T1-weighted MRI scan.
The T1-weighted MRI image was co-registered with the PET image of the
same subject and both the MRI and PET images were normalized to a T1-
template in SPM2Automated regions of interest were used to generate time-
activity curves of the PET image, which were fitted to a two-tissue compart-
ment model to calculate the binding potential (BP) per region of interest.
The whole brain BP was non-significantly higher in patients (1.81 6 0.61) as
compared to the healthy controls (1.36 6 0.39). A statistically significant
higher BP of [11C]-(R)-PK11195 was found in the hippocampus (2.07 6
0.42 vs. 1.37 6 0.30; P = .004), midbrain (2.63 6 0.40 vs. 1.68 6 0.60;
P = .009) and pons (2.85 6 1.42 vs. 1.54 6 0.32; P = .014) of patients as
compared to healthy volunteers. In the basal ganglia an almost significant
increase in BP was found in patients as compared to healthy volunteers
(1.82 6 0.59 vs. 1.39 6 0.28; P = .054). No abnormalities were found on
the MRI images. In a small group of patients, the present study showed
that neuroinflammation may play an important role in schizophrenia,
especially during psychosis. This neuroinflammation may precede brain
atrophy. This study was funded by the Stanley Medical Research Institute.
ID: 550619
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SCHIZOPHRENIA: AN FMRI STUDY
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Numerous neuroimaging studies suggested that working memory (WM)
dysfunction is a core component of schizophrenia. However, the extreme
heterogeneity among patients hindered to yield a consistent WM dysfunc-
tion model. The aim of the present study was to compare the brain activa-
tion patterns of deficit schizophrenia (DS) and nondeficit schizophrenia
(NDS) under parametric increasing WM load, and investigate the relation-
ship of WM-dysfunction, cerebral activation, and diagnostic specificity. We
used functional magnetic resonance imaging (fMRI) and a parametric n-
back WM task (n = 0, 1, 2) to examine 10 DS patients, 10 matched
NDS patients and 10 healthy controls. In all three groups, we found increas-
ing reaction times (RT) and decreasing accuracy with increasing load.
Schizophrenic patients performed worse and slower than controls, while
only the differences between DS and controls on the 2-back task achieved
significant. Compared with controls, patients with schizophrenia showed
more activation in frontoparietal network and subcortical regions, whereas
the 2 schizophrenia subtypes differed in the activity or recruitment with in-
creasing load. At each WM load level, NDS patients showed more activa-
tion in prefrontal cortex than that of controls, which recruited ventrolateral
prefrontal cortex (VLPFC) to a significantly greater degree. However, DS
patients showed more activation in dorsolateral prefrontal regions (DL
PFC) than that of controls at load 1 and significant hypofrontality at
load 2In addition, the DS patients showed more activation in inferior pa-
rietal cortex than that of controls at each WM load level. The results in-
dicated that peak activation of the WM-system is reached at a lower
processing load in schizophrenic patients than in healthy controls. Com-
pared with controls, NDS patients used greater prefrontal resources (ie,
hyperfrontality) and achieved lower but relatively normal accuracy (ie,
physiological inefficiency), which reflect a compromised neural strategy
for handling information mediated by the prefrontal cortex. However,
DS patients failed to sustain the prefrontal network and achieved significant
lower accuracy, even with the compensative recruitment of inferior parietal
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cortex. The present study provided further support for that deficit schizo-
phrenia may have characteristic impairment of prefrontal lobe. This re-
search was supported by grants from NSFC (30700236) and RFDP
(20070533067).
ID: 550593
TASK RELATED ACTIVATION DEFICITS IN
SCHIZOPHRENIA ARE DUE TO AN AROUSAL-
COGNITION DECOUPLING: AN EEG-FMRI STUDY
Jack Rene Foucher1,2, D. Luck2, C. Marrer3,4, H. Ozenberger4,
I. Offerlin-Meyer1
1Psychiatry, HUS, Strasbourg, France; 2Physiology—U666, ULP/
INSERM, Strasbourg, France; 3Biophysic, ULP, Strasbourg,
France; 4LINC, CNRS, Strasbourg, France
Introduction: Because cognition is correlated to social and occupational
status, it is a target to therapeutic interventions. Among the latter,
many of the procognitive drugs target arousal systems. This study attempts
to test for the rational of arousal targeted intervention to improve cogni-
tion. Are most hypoactive regions sensitive to arousal? If it is the case, then
are hypoactive regions also merely hypo-aroused or is it that cortical
arousal is no more properly converted in cognitive activity, ie, not correctly
coupled?. Methods: Seventeen right-handed patients and the same number
of controls took part in the study. Participants performed a Sternberg-like
visual working memory paradigm during the EEG-fMRI acquisition. Be-
cause the low frequencies in the EEG (5-9.5 Hz) are well correlated with
cortical arousal, this measure allows to map cortical regions sensitive to
it. All main effects maps had a threshold of P < .001, and masked group
difference at P< .01 (ext. 800 mm3 in both). The overlap between the hypo-
active and arousal sensitive regions was evaluated by a mutual information
measure and its statistic by bootstrapping. The arousal-cognitive coupling
was evaluated by the slope of the regression line between the arousal effect
and the task effect for the voxels belonging to the same region. Results:
Quite all the voxels that were hypoactive in the patient group were sensitive
to arousal (MI = 0.03, P < 10-5). All correspond to a prefronto-parietal
network. Although there were less than expected arousal sensitive voxels
that were not hypoactive in patients, these still correspond to a substantial
group covering the posterior visual regions. Patients’ hypoactive regions
did not show a reduction of their arousal sensitivity, neither could we ob-
served a global reduction of arousal using behavioral or EEG measures.
Conversely, the arousal-cognition coupling index was largely decreased
in the hypoactive areas (P = .005). Conclusion: Arousal targeted procog-
nitive drugs might well help in reducing patients cognitive deficit since all
task-related hypoactive regions are arousal sensitive. However, they would
do so just by optimizing arousal which is not different from controls in this
stabilized treated group. Nevertheless it would not target the core of the
problem, ie, the conversion of arousal triggered activity increase in a coher-
ent cognitive activity. Such arousal modulating or potentiating interven-
tions remain to be invented.
ID: 550565
REPRODUCIBILITY OF FMRI ACTIVATIONS IN
PATIENTS WITH SCHIZOPHRENIA
Olivier Maı¨za1,2, P. Y. Herve2, A. Razafimandimby2,
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Longitudinal functional Magnetic Resonance Imaging (fMRI) studies
of schizophrenic patients might be of great interest in evaluating brain
response to therapeutic interventions. However, it is crucial to assess
the reliability of fMRI paradigms. Indeed, it has been suggested that
schizophrenic patients present unreliable activations (Manoach et al.,
2001). The aim of this study was to evaluate reproducibility of fMRI acti-
vations in schizophrenic patients. Ten right-handed (RH) patients (DSM
IV) and 10 RH controls were scanned 21 months apart during a story lis-
tening paradigm. This paradigm involved 2 conditions (French narrative
versus Rest and French narrative versus Tamil). The former text was easier
to understand while the second needed more integrated language processes.
Task performances were evaluated through a post session comprehension
questionnaire.Two indices of reproducibility were used: the intersession
overlap percentage of activation maps and the intersession relative stan-
dard deviation (RSD) computed on a voxel-wise basis. Individual RSD
maps were entered in a SPM analysis comparing patients and controls.
In both conditions, patients had lower comprehension scores than con-
trols. Regarding the Text versus Rest condition, patients and controls
did not differ significantly neither for the overlap percentage (65.37 6
8.28 vs 60.50 6 7.04) nor for the RSD, and task performances did not im-
pact on reproducibility. Concerning the Text minus Tamil condition,
patients had a significantly lower overlap percentage (30.65 % 6
15.81%) than controls (47.00 % 6 11.59 %, P = .005) and, in comparison
with controls, patients intersession variability assessed with the RSD was
significantly higher (P < .001, uncorrected) in 3 left hemispheric regions:
the posterior part of the middle temporal gyrus, the pars triangularis of the
inferior frontal gyrus and the medial part of the superior fontal gyrus.
However, when controlling for task performances, these differences
were no longer significant. In patients with schizophrenia, activations
were as reliable as in healthy subjects for a task targeting automatic cog-
nitive processes. When more integrated cognitive processes were involved,
the reproducibility of activations was decreased in patients probably due to
worse task performances. Hence, longitudinal fMRI studies might be
suited for patients with schizophrenia but the effect of task performances
should be carefully assessed.
ID: 550527
AN FMRI STUDY OF PREDICTIVE MOTOR MODELS
IN SCHIZOPHRENIA
Sukhi S. Shergill1,2, D. Joyce2, P. Bays2, D. Wolpert2, C. D. Frith2
1Psychiatry, Institute of psychiatry Kings College London, London,
United Kingdom; 2institute of neurology university college london,
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Introduction: Patients with schizophrenia with positive symptoms can mis-
attribute their own actions to an external source; this labelling of an action
as ones own is hypothesized to depend on a match between the predicted
and actual sensory consequences of the action. Previously, we have shown
that there are sensory prediction deficits in patients with schizophrenia2
and we now examine the underlying neural basis of this phenomenon using
functional magnetic resonance imaging (fMRI). Methods: A fMRI study of
20 patients with schizophrenia, and a matched group of controls, examined
while performing a sensorimotor force matching task on a 3T scanner. Data
were analysed using SPM5 with analyses of main effect of group and task and
an interaction between these factors. Activation was assessed for correlation
with the positive symptoms of psychosis. Results: Performance was matched
between the groups, as assessed by equivalent force generated and perceived
during the task. The fMRI results demonstrated a significant interaction be-
tween group and task evident in the right postcentral gyrus (Brodman Area 3;
Talairach coordinates 57, 12, 48). This sensory region demonstrated acti-
vation in the control subjects only when a force was being applied to their left
index finger; but in patients also showed activation when a force was antic-
ipated, on the basis of a predictive motor model, but no force was actually
being applied to this finger. There were no correlations with composite scores
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on positive symptom scales. Discussion: The results show that self-generated
forces showed less attenuation within the post central gyrus in the patient
group, suggesting a dysfunction in their ability to predict the sensory conse-
quences of their actions. Although most of the patients were treated with an-
tipsychotic medication, the absence of any difference between patients and
healthy volunteers in the force levels applied during the experiment suggests
that there is no systematic effect of medication upon motor performance;
indeed there was no significant correlation between the chlorpromazine
doseequivalentsofmedicationandthe degreeof functional attenuationdem-
onstrated by patients. The present study provides support for the presence of
a dysfunctional sensory predictive mechanism based in the sensory cortex in
schizophrenia.
ID: 550457
OPPOSITE NEURAL EFFECTS OF THE MAIN
PSYCHOACTIVE INGREDIENTS OF CANNABIS ON
THE NEURAL SUBSTRATE FOR PSYCHOSIS
Sagnik Bhattacharyya, P. Fusar-Poli, S. Borgwardt,
R. Martin-Santos, J. A. Crippa, Z. Atakan, C. O. Carroll, P. Allen,
C. Nosarti, P. K. McGuire
Section of Neuroimaging, Division of Psychological Medicine and
Psychiatry, Institute of Psychiatry, London, United Kingdom
The cannabis plant has many psychoactive ingredients. Delta-9-THC, the
main psychoactive ingredient of cannabis, impairs memory and induces
anxiety and psychotic symptoms acutely and increases the risk of psychotic
disorders in regular cannabis users. There is increasing interest in the ther-
apeutic potential of Cannabidiol (CBD), the second most abundant com-
ponent of Cannabis. CBD does not impair memory, may have anxiolytic
and possibly antipsychotic effects. Hence, we compared directly the acute
neural effects of these two active ingredients of cannabis, by combining
pharmacological challenge with fMRI in 15 healthy volunteers with min-
imal exposure to cannabis and other illicit drugs. Using a double-blind, re-
peated measures, within subject design and oral challenge with 10mg of
delta-9-THC, 600mg of CBD or placebo, we examined whether delta-9-
THC and CBD have opposing effects on the neural substrates of verbal
memory and whether they also have opposing effects on the neural sub-
strates of psychotic symptoms induced by delta-9-THC. Delta-9-THC in-
duced psychotic symptoms acutely but there was no change in psychotic
symptoms with CBD. During the memory task, delta-9-THC and CBD
had opposing effects on activation in the anterior cingulate and the striatum
bilaterally. While delta-9-THC attenuated striatal activation, CBD in-
creased activation in the striatum bilaterally. Effect of delta-9-THC on
striatal activation was inversely correlated with the psychotic symptoms in-
duced by it concomitantly. Thus, the modulation of striatal activation by
delta-9-THC may underlie the psychotogenic effects of cannabis. Opposing
effects of CBD on striatum and anterior cingulate, key neural substrates for
psychotic symptoms may suggest possible therapeutic role of CBD in coun-
tering the adverse psychological effects of cannabis and more specifically
cannabis-induced or cannabis use related psychotic disorders. Funding:
Psychiatry Research Trust, UK.
ID: 550414
OBJECT-LOCATION SOURCE RECOGNITION IN
WORKING MEMORY: AN FMRI STUDY
Christian Thoresen1,3, J. Jensen1,2, N. P. Sigvartsen2, I. Bolstad2,
O. A. Andreassen1,2, T. Endestad3
1Division of Psychiatry, Ulleval University Hospital, Oslo, Norway;
2Institute of Psychiatry, University of Oslo, Oslo, Norway; 3Institute
of Psychology, University of Oslo, Oslo, Norway
Source monitoring is suggested to be an important aspect of the episodic
memory system, integrating different contextual information related to the
specific memory. The purpose of the study was to investigate a previous
studied network implicating the posterior precuneus, left ventro-lateral
frontal cortex and left dorsal inferior frontal cortex in an event related
source monitoring working memory fMRI paradigm. Lundstrom et al.
(2005) suggested a two step process in this system were the left ventro-
lateral frontal cortex is associated with the search of relevant information
and working in tandem with the posterior precuneus for regeneration of
rich contextual information. Secondly, areas in the dorsal inferior frontal
cortex were suggested to be important for selection of correct information.
fMRI BOLD data were acquired on a 3 T General Electric Signa HDx scan-
ner. Twenty healthy subjects completed a working memory source moni-
toring paradigm. In each trial subjects were instructed to remember several
neutral pictures and their location. Memory test (recognition) of object by
location was collected immediately after encoding of each trial. Memory
load were varied between three to five units in eight possible different loca-
tions. Preliminary results showed that all conditions of load activated the
areas of interest. Posterior precuneus and the ventro-lateral frontal cortex
were activated bilaterally whereas the dorsal inferior frontal cortex was ac-
tivated on the left side only. Using a linear contrast on memory load a trend
towards increasing activation in posterior precuneus and right ventro-lat-
eral frontal cortex with load was obtained, while the left dorsal inferior
frontal cortex showed a declining activation with increasing memory
load. The previously suggested network by Lundstrom et al. (2005)
was activated in a source monitoring working memory task. Future studies
will be conducted where the modulation of this network in a source
monitoring working memory task in patients with schizophrenia will be
investigated.
ID: 550408
NEURAL CHANGES ASSOCIATED WITH
SUCCESSFUL RELATIONAL LEARNING IN
SCHIZOPHRENIA
Laura M. Rowland1, E. A. Spieker1, K. Buchanan1,
P. B. Barker2,3, H. H. Holcomb1
1Psychiatry, MPRC, University of Maryland School of Medicine,
Baltimore, MD, USA; 2Radiology and Radiological Science, Johns
Hopkins University School of Medicine, Baltimore, MD, USA;
3F.M. Kirby Research Center for Functional Brain Imaging,
Kennedy Krieger Institute, Baltimore, MD, USA
Relational learning and memory, processes dependent upon medial tem-
poral lobe (MTL) function, may be particularly vulnerable in schizo-
phrenia. This study investigated neural changes with fMRI before
and following training on a relational learning paradigm, transverse pat-
terning (TP), in schizophrenia volunteers (SV) and healthy volunteers
(HV). Diffusion tensor imaging (DTI) was also used to investigate the
integrity of the fornix, a major hippocampal white matter tract. Proton
magnetic resonance spectroscopy (1H-MRS) was acquired from the
hippocampus to assess neurochemistry. Seventeen SV and 15 HV partic-
ipated in this study. MR scanning was conducted on a 3T Philips MR
scanner at the Kirby Imaging Center, Kennedy Krieger Institutes.
The imaging protocol consisted of hippocampal single-voxel 1H-
MRS, and DTI; fMRI scans were acquired during initial TP learning
and following training. The fMRI results reveal different patterns of
neural activity between groups despite similar performance. For HV,
MTL activity was present during the initial stages of TP learning, but
was not present following training. After training HV parietal lobe
activity was prominent. In contrast, SV exhibited no MTL activity
but instead engaged the anterior cingulate and cuneus during initial
TP learning, and visual cortical regions following training. Fornix
fiber tracking results revealed reduced fractional anisotropy (FA) in
SV compared to HV, and 1H-MRS revealed a trend toward elevated
International Congress on Schizophrenia Research
14. 14. Neuroimaging, Functional 163
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
hippocampal glutamateþglutamine in SV compared to HV. HV engaged
the MTL and parietal regions, which are part of a neural network com-
monly associated with relational learning. These experience dependent
activation patterns support the hypothesis that the MTL is important
for encoding information, but additional brain regions are used for
memory retrieval. These results also show that successful relational
learning in SV is accomplished through alternative brain networks
that include frontal and visual circuits. The reduced fornix FA in SV
suggests compromised connections to/from the hippocampus, and al-
tered glutamateþglutamine in SZ suggests compromised hippocampal
function. The DTI and MRS changes may help to explain why MTL
activity, commonly observed during relational learning in HV, is not
observed in SV.
ID: 550369
SEX DIFFERENCES IN THE PROCESSING OF
POSITIVE AND NEGATIVE AFFECT IN
SCHIZOPHRENIA: AN FMRI AND ERP STUDY
Adrianna Mendrek1,2, A. Mancini-Marı¨e1,2, J. Jime´nez1,2,
M. Rinaldi2, M. Germain2, E. Stip1,2, P. Lalonde1,2, F. Guillem1,2,
M. Lavoie1,2
1Psychiatry, Universite de Montreal, Montreal, QC, Canada;
2Centre de recherche Fernand-Seguin, Louis-H Lafontaine Hospital,
Montreal, QC, Canada
Introduction: We have demonstrated recently disturbed normal sexual
dimorphism in cerebral function of schizophrenia patients during expo-
sure to aversive pictures (Mendrek et al., 2007), as well as during emo-
tional memory processing (Guillem et al., 2008). The present study was
designed to extend these preliminary findings by including appropriate
control groups, studying both negative and positive affect, and combing
functional magnetic resonance imaging (fMRI) with event-related
potentials (ERP). Methods: The fMRI (BOLD 3T) and ERP (56 EEG
electrodes) data were collected on separate days during presentation
of unpleasant-high arousal, unpleasant-low arousal, pleasant-high
arousal and pleasant low arousal pictures. The data of schizophrenia
men (SZ-M) and schizophrenia women (SZ-W) were compared to
healthy control men (HC-M) and healthy control women (HC-W).
Results: fMRI: there were no differences between sexes during exposure
to pleasant stimuli either in patients or in controls, though overall HC-M
and HC-W exhibited more activations in the inferior frontal, parietal
and temporal cortex, as well as the thalamus and amygdala. In contrast,
during exposure to negative pictures both HC-M and SZ-W activated
occipital, orbitofrontal and middle frontal cortex, cerebellum and cau-
date, while HC-W and SZ-M showed significant activations only in the
occipital region. ERP: both SZ-M and SZ-W presented significantly re-
duced late positive component (LPC) at the anterior and central regions
relative to controls. However, while the SZ-W showed smaller LPC am-
plitude and were less reactive to emotional valence than to the arousal
content of the image, the SZ-M showed the opposite pattern with smaller
LPC amplitude and less reactivity to the arousal content than to the emo-
tional valence of the images. Conclusion: Present results reveal disturbed
sexual dimorphism in cerebral function associated with emotion process-
ing in schizophrenia and suggest that affect might be mediated by dif-
ferent neural mechanisms in men and women patients. Moreover, the
data point to the importance of considering sex of tested participants
in neurophysiological investigations of cognitive, perceptual and emo-
tional processing. Acknowledgements/Funding: Canadian Institute of
Health Research (CIHR), Fonds de recherche en Sante´ Quebec
(FRSQ), participants.
ID: 550343
DOPAMINE EFFECTS ON REWARD ANTICIPATION
AND REVERSAL LEARNING IN SCHIZOPHRENIA
Andreas Heinz1, J. Wrase1, B. Schott2,1, M. Rapp1, A. Beck1,
F. Schlagenhauf1
1Department of Psychiatry and Psychotherapy, Charite´—University
Medicine Berlin, Berlin, Germany; 2Department of Neurology II and
Center for Advanced Imaging, Otto von Guericke University,
Magdeburg, Magdeburg, Germany
In those diagnosed with schizophrenia, dopamine dysfunction may inter-
fere with an error feedback signal that encodes surprising reward or pre-
sentation of reward-indicating, conditioned stimuli. Functional brain
imaging shows that unmedicated schizophrenics display reduced activation
of the ventral striatum during reward anticipation, ie, after presentation of
a conditioned stimulus that predicts reward. Furthermore, reduced activa-
tion of the ventral striatum interferes with behavioral adjustment after un-
expected outcomes. In healthy controls, learning of a probabilistic reversal
task is driven by the connectivity between the substantia nigra and dorsal
striatum, which may reflect dopaminergic input. To further explore the in-
teraction between dopaminergic neurotransmission, reward anticipation
and reversal learning, we used a multimodal imaging approach that com-
bines positron emission tomography and functional magnetic resonance
imaging. The radioligand 18-F-DOPA was used to measure dopamine syn-
thesis capacity in the brainstem, dorsal and ventral striatum. The results
were correlated with functional activation elicited by a probabilistic rever-
sal task and a reward anticipation task in unmedicated schizophrenic
patients and healthy controls. The schizophrenic group’s dopaminergic
dysfunction diminishes the group’s ability to learn quickly and precisely.
They are, however, able to compensate for those neural errors by engaging
alternative circuits.
ID: 550316
FUNCTIONAL MAGNETIC RESONANCE IMAGING
OF INNER SPEECH IN SCHIZOPHRENIA
Claudia Simons1, D. Tracy2, L. Krabbendam1, S. Shergill2
1Department of Psychiatry and Neuropsychology, Maastricht
University, Maastricht, Netherlands; 2Division of Psychological
Medicine, Institute of Psychiatry, London, United Kingdom
Auditory verbal hallucinations have been linked to defective monitoring of
one’s own verbal thoughts. Previous studies have shown that patients with
auditory verbal hallucinations show attenuated activation of brain regions
during the monitoring of inner speech. Fifteen patients with schizophrenia
and 12 healthy controls were studied using functional magnetic resonance
imaging while listening to sentences or imagining sentences. Significant
interactions between group (controls vs. patients) and task (listening vs. in-
ner speech) were seen for the left superior temporal gyrus, left posterior
cingulate, right sub-gyral of the temporal lobe, and bilateral cingulate gy-
rus. Attenuated activation of the left superior temporal gyrus in schizophre-
nia patients during the processing of self-generated speech may indicate
deficits in self-monitoring.
ID: 550300
M100 PHASE-LOCKING IN SCHIZOPHRENIA:
ASSOCIATIONS WITH SYMPTOMS AND
MEDICATION
James Christopher Edgar1,2, B. I. Turetsky3, T. P. Roberts1,
A. Smith2, M. Huang4, J. M. Canive2,5, G. A. Miller5,6
1Radiology, The Children’s Hospital of Philadelphia/University of
Pennsylvania, Philadelphia, PA, USA; 2Center for Functional Brain
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Imaging, New Mexico VA Healthcare System, Albuquerque, NM,
USA; 3Department of Psychiatry, The University of Pennsylvania,
Philadelphia, PA, USA; 4Radiology, University of California, San
Diego, CA, USA; 5Psychiatry, University of New Mexico, Albu-
querque, NM, USA; 6Psychology and Psychiatry and Beckman
Institute Biomedical Imaging Center, University of Illinois at
Urbana-Champaign, Urbana, IL, USA
Electroencephalographic (EEG) and magnetoencephalographic (MEG)
studies have observed an abnormally small 100 ms auditory evoked re-
sponse (N100/M100) in patients with schizophrenia (Sz), which could be
the result of decreased low-frequency phase locking (PL). Associations be-
tween low-frequency PL, medication status, and patient symptoms are
largely unexamined and may shed light on mechanisms contributing to
the abnormal response and options for treating it. The present study exam-
ined whether left or right superior temporal gyrus (STG) PL differs as
a function of medication or patient symptoms. Dense-array MEG from
45 controls and 45 patients with Sz administered a standard paired-click
task produced left- and right-hemisphere 100 ms STG PL measures.
Patients on typical antipsychotics (haldol and prolixin) showed less STG
theta-band PL than controls and patients on atypical antipsychotics (ari-
priprazole, olanzapine, risperidone, quetiapine). Quadratic associations in-
dicated that the more patients’ STG theta-band PL values diverged from
the mean PL value observed in controls, the more impaired was the patient
(higher PANSS/SANS scores). As MEG primarily reflects the activity of
cortical pyramidal cells, PL abnormalities may be the result of problems
timing the interaction of these cell types (perhaps dysfunction of glutama-
tergic input to inhibitory interneurons as well as dysfunction of GABAA-
receptor mediated hyperpolarization). Findings indicate that several
atypical antipsychotics may normalize STG theta-band activity and that
normalization of theta-band PL would be a promising target of treatment
in patients.
ID: 550276
VELOCITY RELATED MECHANISMS OF SMOOTH
PURSUIT EYE MOVEMENTS (SPEM) IN SCHIZO-
PHRENIC PATIENTS. AN EVENT RELATED FMRI
STUDY
Matthias Nagel1, A. Sprenger2, F. Binkofski2, R. Lencer1
1Department of Psychiatry and Psychotherapie, University Luebeck,
Luebeck, Germany; 2Neurology, University Luebeck, Luebeck,
Germany
In about 50% of schizophrenic patients the SPEM velocity is reduced com-
pared to healthy subjects. In this study we wanted to find out velocity-
related regions which show different activations in the patient group. Meth-
ods: We included 19 schizophrenic patients and 20 healthy subjects (all
right handed males). Medication was: Quetiapine (7), Amisulpride (5),
Olanzapine (4), Ziprasidone (2), Aripiprazole (1). Exclusion criteria
were: medication with Risperidone, Clozapine, Lithium, Benzodiaze-
pines and Carbamazepine. We presented ramps with different SPEM-
velocities (5, 10, 15, 20/s) in a range of 40 from right to left. An event
related design was used to analyze the fMRI data with spm2. Eye move-
ments were registered in the scanner environment. Velocity of the targets
were correlated with the BOLD (MRT: 3 Tesla, 38 x 3 mm, 158 Volumes
*4 sessions, TR 2.62) Results / Discussion: In both groups the frontal eye
fields the intraparietal sulcus, V1 and V5 were activated. Comparing the
patients with the healthy subjects revealed lesser activation in the Puta-
men and the supplementary eye field (SEF) of the patient group. Since
the SEF is related oculomotor prediction and learning, reduction of SEF
activation seems to be in line with previous findings of frontal dysfunc-
tion in the patients. Reduced activation in the Putamen seems to repre-
sent a deficit in the feedback loop from the FEF -> Putamen ->
Thalamus -> FEF.
ID: 550274
FDG-PET AND MRI IMAGING OF THE EFFECTS OF
TYPICAL AND ATYPICAL NEUROLEPTICS ON THE
THALAMUS AND STRIATUMI IN SCHIZOPHRENIA
Monte Stuart Buchsbaum, N. Dusi, J. Entis, W. Byne,
M. Haznedar, E. Kemether, R. Newmark, K. Chu, J. Ianuzzi,
E. Hazlett, E. Teague
Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
Twenty-two never-previously medicated psychotic adolescents received an
anatomical MRI and FDG-PET scans at baseline and after 8–9 weeks of
a randomized double-blind trial of either olanzapine or haloperidol and 15
adult patients with schizophrenia received an MRI and FDG-PET scans
after 6 weeks of a randomized double-blind trial of either sertindole or hal-
operidol. Adults were then crossed to the other treatment and scanned
again at week 12. Caudate nucleus, putamen and globus pallidus were
traced on the MRI. Younger adolescents (13–15) treated with haloperidol
had a significant increase in the relative metabolic rate of both the caudate
nucleus and putamen at dorsal levels while treatment with olanzapine gen-
erally decreased metabolic rates. The difference between the two medica-
tions was most marked anteriorly. Similarly, in the adult sample we
found that the metabolic rates of the caudate nucleus and the putamen
were significantly higher with haloperidol than with sertindole.
ID: 550232
DIFFERENTIATING VOLITION FROM HEDONIA
USING A MONITARY REWARD TASK DURING
FMRI
Arielle D. Stanford1, G. Lai2, B. Luber1, J. Moeller1,
S. Baboumian4, J. Hirsch2, D. Malaspina3, S. H. Lisanby1
1Psychiatry, NYSPI, Columbia University, New York, NY, USA;
2Neuroscience, Columbia University, New York, NY, USA;
3Psychiatry, NYU School of Medicine, New York, NY, USA;
4Barnard College, New York, NY, USA
Reward paradigms are useful in understanding volition and hedonia. Few
studies have examined both motivational aspects of reward circuitry or
have compared fMRI activity to reports of motivation and hedonia. Study-
ing this circuitry in relation to self report measures may provide insight into
the relationship between these states and psychopathology. Seven healthy
subjects performed a monetary reward task during event related fMRI.
Subjects responded to one of two cues that signified increasing score for
a correct and fast response after a variable delay. After a second delay, sub-
jects received feedback on their accuracy. All subjects also completed self
report measures of volition and hedonia: the TEPS, MEI and Chapman
Questionnaire. fMRI data were analyzed using GLM in FSL. Cues acti-
vated visual cortex, supplemental motor area (SMA), anterior cingulate,
primary motor and sensory cortex (SMC; thresholded at Z > 1.6, cluster
P < .05). Activity in the nucleus accumbens (NuAc) was modulated by re-
ward magnitude. During the first delay prior to responding, activity was
found in the insula, striatum, cingulate, pre-SMA, and SMC. Activity in
the SMA, striatum and anterior cingulate was modulated by reward mag-
nitude. SMC, thalamus, inferior frontal lobe, orbital frontal cortex, stria-
tum, anterior cingulate, and inferior parietal lobe were active during
response. Self reports of social motivation correlated with reaction time
on the no reward condition (r = .67, P = .045) and mental motivation
correlated with social pleasure (r = .71, P = .03). The TEPS correlated
with activity during the cue in the putamen (r = .80, P = .03), NuAc
(r = .93, P < .003) and SMA (r = .85, P < .02). Task activated circuitry
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related to regions of motor planning, action and reward anticipation. Re-
ward magnitude modulated activity of the NuAc during the cue and activity
in regions of motor planning before response, suggesting reward modulates
volitional action and reward anticipation. Lower reports of hedonia were
associated with greater activity in regions modulated by reward magnitude
and self reported motivation was reflected in faster reaction time. This
study is one of the first to explore and link motivation as a state and be-
havior and their circuitry. Such work may be the first step towards under-
standing avolition and anhedonia in psychiatric disorders like
schizophrenia, where normal consummatory hedonia does not overcome
inaction and anticipatory anhedonia. Irving Center NIH CTSA Pilot
Award.
ID: 550012
ALTERED HIPPOCAMPAL NEURONAL ACTIVITY
AND PERFUSION IN SCHIZOPHRENIA
Binu Thomas1, P. Mihalakos1, J. Uh1, H. Kirane1, A. Wagner2,
H. Lu1, C. Tamminga1
1Psychiatry, The University of Texas Southwestern Medical Center,
Dallas, TX, USA; 2Psychology, Stanford University, Stanford, CA,
USA
Alterations in the function of hippocampus (hipp.) and medial temporal lobe
(MTL) have been described in schizophrenia (SZ). The hipp. shows elevated
basal perfusion and decreases in task-stimulated activations in SZ, especially
in the anterior hipp. Aim: We will examine predictions of the metaplasticity
and SZ model that hipp. subfield activations and perfusion will differ in the
three populations, NV, SZ-on and SZ-off, especially in DG and CA3. The
model of pathophysiology we have proposed in MTL invokes distinct activa-
tions in hipp. subfields and distinct correlates between the subfields and SZ
symptoms. We will carry out high resolution (hi-res) imaging for perfusion
with VASO and activation with fMRI BOLD (the latter using MTL encoding
andrelational memory tasks). Vascular SpaceOccupancy (VASO)willbeused
to assess hi-res rCBV (measure of perfusion) focused on hippocampal sub-
fields during rest. Then, using fMRI BOLD with high resolution, we will de-
scribe hipp. subfield activations in SZ alone (SZ-off) and in SZ treated (SZ-on)
bothcontrastedwithNV’s.Withrespect toperfusion,wepredicta reduction in
DG perfusion and an increase in CA3 perfusion. We predict a reduction in
task-associated activation in DG and CA3. In the SZ-off, we predict a direct
correlationbetweenpsychosis andCA3 perfusionanda lossof thatcorrelation
in the SZ-on. Methods: High resolution fMRI images (1.5x1.5x1.5 mm3) and
T2w images (0.5x0.5 mm2 in-plane resolution, 2mm thick slices) have been
acquired so far on 1 NV, 2 SZ-ON and 2 SZ-OFF. BOLD images were cor-
egistered to the T2w image; subfields DG, CA1, CA3 and subiculum were
drawn on the T2w image, fMRI analysis was performed and % BOLD signal
change extracted.Results and conclusion: This early data analysis was focused
on providing high-res. subfield rCBV results for CA3 in the three groups and
an initial look (noting the low subject number) at a correlation between rCBV
and BOLD activation. In CA3 we see an increase in rCBV in the SZ-OFF 1.69
(0.69) compared with NV 1.38 and SZ-ON 1.49(0.50), however this CA3 in-
crease in the SZ-OFF was only apparent in the anterior CA3 and did not ob-
tain in the posteriorCA3. The outcomescorrespondtoour predictions in these
subjects. Subfield high-res. fMRI BOLD results were correlated with rCBV
data; while numbers are clearly too low to demonstrate a correlation, the di-
rection of the association in both the patient groups is inverse.
ID: 549965
SCHIZOPHRENICS LEARN A VISUAL MATCH-TO-
SAMPLE TASK BY USING THE PREFRONTAL
CORTEX FOLLOWING INFORMATIVE ERROR
FEEDBACK
Henry H. Holcomb1,2, L. M. Rowland1, J. A. Griego1
1MPRC, University of Maryland School of Medicine, Baltimore,
MD, USA; 2Psychiatry, Johns Hopkins University, Baltimore,
MD, USA
Neither healthy volunteers (NV) nor research participants diagnosed with
schizophrenia (SZ) can quickly learn a difficult perceptual matching task
without informative feedback. But in the presence of feedback both groups
improve quickly in their accuracy. This report examines how these two di-
agnostic groups successfully adapt to informative feedback. The brain ac-
tivity characteristics of each group, before and after feedback, are also
presented. Those findings demonstrate how each group responds to the
task initially, before learning, and subsequently, after learning. This
fMRI study lasted about sixty minutes and consisted of three consecutive
twenty minute stages. Each stage provided forty-eight match-to-sample tri-
als that required the subject to judge whether the height of the first rectangle
was identical to the height of a second rectangle. Feedback, only provided
during the second stage of the study, consisted of an icon that indicated the
subject’s trial accuracy. Subjects who improved by 7% or more during
stage-2 were classified as learners. 12 out of 21 NV, and 10 out of 18
SZ met ‘‘learner’’ criteria. Correct trials in all stages were classified in
one of two ways, correct-following-correct (CC) or correct-following-incor-
rect (IC). IC and CC trials were assessed in each stage. IC versus CC con-
trasts were also generated for each group at each stage. IC-minus-CC
contrasts were significantly different between stages and between groups.
NV IC-minus-CC contrasts: Stage-one contrasts revealed significant
changes in orbital frontal cortex,dorsal medial frontal cortex, parietal cor-
tex, ventral striatum, caudate, and globus pallidus. Stage-two (feedback)
contrasts revealed significant changes in amygdala, hippocampus, ventral
striatum, globus pallidus, putamen, dorsal medal frontal cortex and pari-
etal cortex. Stage-two (uniquely) contained significant habenular activity
for IC and CC trials. Stage-three contrasts revealed significant changes
in amygdala, hippocampus, globus pallidus, and putamen. SZ IC-minus-
CC contrasts: Stage-two contrasts provided significant change clusters in
the left dorsolateral prefrontal cortex. No other significant changes were
observed. Healthy volunteers engage an extensive subcortical system
when confronted with this implicit learning task. Parietal, orbital and me-
dial frontal systems also participate. These findings emphasize the SZ
group’s ability to ‘‘solve’’ a difficult perceptual problem through cortical
systems.
ID: 549802
SCHIZOPHRENICS LEARN A VISUAL MATCH-TO-
SAMPLE TASK BY USING THE PREFRONTAL
CORTEX FOLLOWING INFORMATIVE ERROR
FEEDBACK
Henry H. Holcomb1,2, L. M. Rowland1, J. A. Griego1
1MPRC, University of Maryland School of Medicine, Baltimore,
MD, USA; 2Psychiatry, Johns Hopkins University, Baltimore, MD,
USA
Neither healthy volunteers (NV) nor research participants diagnosed with
schizophrenia (SZ) can quickly learn a difficult perceptual matching task
without informative feedback. But in the presence of feedback both groups
improve quickly in their accuracy. This report examines how these two di-
agnostic groups successfully adapt to informative feedback. The brain ac-
tivity characteristics of each group, before and after feedback, are also
presented. Those findings demonstrate how each group responds to the
task initially, before learning, and subsequently, after learning. This
fMRI study lasted about sixty minutes and consisted of three consecutive
twenty minute stages. Each stage provided forty-eight match-to-sample tri-
als that required the subject to judge whether the height of the first rectangle
was identical to the height of a second rectangle. Feedback, only provided
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during the second stage of the study, consisted of an icon that indicated the
subject’s trial accuracy. Subjects who improved by 7% or more during
stage-2 were classified as learners. 12 out of 21 NV, and 10 out of 18
SZ met ‘‘learner’’ criteria. Correct trials in all stages were classified in
one of two ways, correct-following-correct (CC) or correct-following-incor-
rect (IC). IC and CC trials were assessed in each stage. IC versus CC con-
trasts were also generated for each group at each stage. IC-minus-CC
contrasts were significantly different between stages and between groups.
NV IC-minus-CC contrasts: Stage-one contrasts revealed significant
changes in orbital frontal cortex, dorsal medial frontal cortex, parietal cor-
tex, ventral striatum, caudate, and globus pallidus. Stage-two (feedback)
contrasts revealed significant changes in amygdala, hippocampus, ventral
striatum, globus pallidus, putamen, dorsal medal frontal cortex and pari-
etal cortex. Stage-two (uniquely) contained significant habenular activity
for IC and CC trials. Stage-three contrasts revealed significant changes
in amygdala, hippocampus, globus pallidus, and putamen. SZ IC-minus-
CC contrasts: Stage-two contrasts provided significant change clusters in
the left dorsolateral prefrontal cortex. No other significant changes were
observed. Healthy volunteers engage an extensive subcortical system
when confronted with this implicit learning task. Parietal, orbital and me-
dial frontal systems also participate. These findings emphasize the SZ
group’s ability to ‘‘solve’’ a difficult perceptual problem through cortical
systems.
ID: 549802
NEURAL BASIS OF HUMOUR APPRECIATION AND
UNDERSTANDING OTHERS’ INTENTIONS IN
SCHIZOPHRENIA: AN FMRI STUDY
Daniel Tai-yin Tsoi1, K. H. Lee1, G. Pluck1, T. F. Farrow1,
I. D. Wilkinson2, P. W. Woodruff1
1Academic Clinical Psychiatry, University of Sheffield, Sheffield,
United Kingdom; 2Academic Unit of Radiology, University of
Sheffield, Sheffield, United Kingdom
Individuals with schizophrenia have social cognition deficits which affect
their ability to recognise humour and understand others’ intentions. It
remains unclear how humour appreciation interacts with understanding
of others’ intentions in patients. Using fMRI, we compared the neural
response for the interaction of these two processes between patients
with schizophrenia and healthy controls. We hypothesised that the lateral
prefrontal cortex of patients with schizophrenia would be underactivated
compared to that of healthy controls. Nineteen right-handed individuals
with DSM-IV diagnosis of schizophrenia (mean age = 37.4 6 10.7) and 22
right-handed healthy controls (mean age = 36.8 6 10.4) underwent fMRI
scans (Philips Intera 3T system; TR = 3 sec; 576 time points; 32x4mm
transverse slices). Subjects in the scanner viewed two separate runs of
15-second silent coloured video clips (36 clips per run). These previously
validated clips, which were arranged in a 2x2 factorial block design, in-
cluded probes of understanding others’ intentions (necessary or not nec-
essary) and humour (present or absent). After each clip, participants
indicated whether the clip was funny or not. The imaging data were pre-
processed and analysed using Statistical Parametric Mapping (SPM5)
(second level random effect analysis; P < .001 uncorrected; extent thresh-
old over 35 voxels). Results for the interaction between humour appreci-
ation and understanding of others’ intentions showed that patients with
schizophrenia had less activation than the controls in the left dorsolateral
prefrontal cortex (DLPFC) [Brodmann’s area 9]. This finding indicated
that, in patients, there were significant increases of activation in the
DLPFC when only one of the two processes occurred (ie, humour present
without the need to understand others’ intentions and humour absent but
understanding of others’ intentions was necessary). The activation was
not significantly increased when both phenomena were present together
(ie, humour present and understanding of others’ intentions were needed).
On the contrary, in controls, the activation at the DLPFC was signifi-
cantly increased only when both processes were present together, but
not when either humour appreciation or intentions understanding ocurred
on their own. Though preliminary, these findings suggest that the left
DLPFC may be involved in the integration of emotion and cognition
and its dysfunction may contribute to the social cognition deficits in
schizophrenia.
ID: 549789
STRUCTURE AND FUNCTION IN SCHIZOPHRENIA
PATIENTS, NON-PSYCHOTIC RELATIVES, AND
COMMUNITY CONTROLS
Vina M. Goghari, S. R. Sponheim, A. W. MacDonald
Psychology, University of Minnesota, Minneapolis, MN, USA
Diffuse structural and functional brain abnormalities are commonly found
in schizophrenia patients and have recently reported in patients’ first-degree
non-psychotic relatives. Previously, we reported structural abnormalities in
the cingulate and temporal cortices and functional abnormalities in the pre-
frontal cortex in the non-psychotic relatives of patients compared to con-
trols. The goal of the present study was to recruit a new sample of
schizophrenia patients, non-psychotic relatives, and community controls
to investigate in tandem, structural and functional correlates of the schizo-
phrenia diathesis at varying genetic loads. To date, imaging data has been
collected on 26 patients, 20 relatives, and 30 controls. Functional imaging
was conducted during a context-processing task that required the active sup-
pression of a prepotent tendency to complete a weaker task-relevant re-
sponse. Analysis of behavioral data demonstrated all groups had more
difficulty overriding a prepotent response evidenced by longer mean reaction
times on these trials compared to prepotent response trials. Schizophrenia
patients demonstrated more difficulty inhibiting prepotent responses com-
pared to non-psychotic relatives and controls, whereas, there was no differ-
ence between non-psychotic relatives and controls. Neuroimaging data
will be analyzed to determine the neural correlates of context-processing
difficulties in schizophrenia patients. In relatives, we will analyze whether
the neural correlates found to be aberrant in schizophrenia patients are
also disrupted and whether any compensatory neural mechanisms exist
that enable normative performance. Multiple indicators of brain structure,
such as cortical thickness, surface area, and volume will be examined. Lastly,
we will investigate whether there is any correspondence between the location
of abnormalities in form and function.
ID: 549783
THE NEURAL BASIS OF SELF-INHIBITION IN
THEORY OF MIND IN PSYCHOSIS PRONENESS: AN
FMRI STUDY
Lisette Van der Meer1, N. A. Groenewold1, W. A. Nolen2,
A. Aleman1
1BCN Neuroimaging Center, University Medical Center Groningen,
Groningen, Netherlands; 2Department of Psychiatry, University
Medical Center Groningen, Groningen, Netherlands
Previous research on the functional and neural basis of perspective taking
has shown that the prefrontal cortex and the temporo-parietal junction
play a role in this so called Theory of Mind (TOM) capacity. This
TOM capacity can be subdivided into two perspective taking components:
(1) self-perspective inhibition and (2) other-perspective taking (Samson
et al., 2005, Brain). In this study, we looked at differences between psy-
chosis prone subjects (PP) and healthy control subjects (HC) in networks
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processing TOM, using functional MRI. The task consisted of short
movie clips differing in demands regarding self-perspective inhibition
and other-perspective taking. Conditions with a similar demand in
other-perspective taking, but a differing demand in self-perspective inhi-
bition were compared. In HC we found activation of the left inferior pre-
frontal cortex for self-perspective taking, which has also been implicated
in simple response inhibition (eg, Rubia et al., 2001, Schizophrenia Re-
search). Furthermore, we found activation of the middle temporal gyrus
when conditions similar in other-perspective taking demand were com-
pared to a baseline condition. This confirms the subdivision of TOM
into self-perspective inhibition and other-perspective taking. We did
not find behavioural differences between groups, however PP showed
stronger activation in left IFG, DLPFC, MTG and SFG in PP in self-per-
spective taking. Thus, in order to perform as well as HC, PP excessively
addressed these self-perspective taking networks. Finally, we found deaci-
tivation in the PCC and mPFC in false belief reasoning versus baseline,
which was stronger in HC than in PP. Possibly the IFG inhibits self-
perspective by deactivating the mPFC and increasing TPJ activation,
implying that less deactivation in mPFC reflects more difficulty in this
inhibition process. The results suggest that PP—in order to equal the
behavioural performance of the HC—have to compensate by excessively
activating TOM networks. This paradigm could reveal interesting results
in psychotic patients lacking insight in illness. These patients may have
difficulty inhibiting their own perspective resulting in more difficulties
in taking someone else’s perspective. Being unable to observe themselves
through the eyes of others and critically reviewing their own behaviour,
might result in problems in adapting their own self-image to reality,
namely that they suffer from a psychotic disorder.
ID: 549593
CORRELATION BETWEEN PREPULSE INHIBITION
AND CORTICAL PERFUSION DURING AN AT-
TENTIONAL TEST IN SCHIZOPHRENIA
Vicente Molina1, C. Montes2, P. Tamayo3, R. Villa1, J. Pe´rez1,
J. Matı´as1, D. Gonza´lez1
1Pscyhiatry, Hospital Universitario, Salamanca, Spain; 2Medical
Physics, Hospital Universitario, Salamanca, Spain; 3Nuclear
Medicine, Hospital Universitario, Salamanca, Spain
Background: Processes underlying cortical hypoactivation in schizophrenia
are poorly understood but some evidence suggests that a deficient sensory
filtering is associated to with the condition. This filtering deficit can be stud-
ied by using measures of prepulse inhibition (PPI) of the startle reflex. Ob-
jective: To evaluate the contribution of sensory filtering deficits to cortical
hypoperfusion during an attention test in schizophrenia. Method: PPI
measurements of the startle reflex and perfusion during the performance
of a Stroop test (assessed with single-photon emission tomography) were
obtained in 10 acutely treated schizophrenia patients (6 with recent onset,
RO) and 16 control subjects. These measurements were compared between
patients and controls and the correlation between PPI and perfusion was
evaluated within each group using Statistical Parametric Mapping. Results:
In comparison with normal subjects, the patients exhibited lower PPI, al-
though the difference was not statistically significant. Perfusion was signif-
icantly lower in the prefrontal and premotor regions of the patients. In the
patient group, there was a statistically significant correlation between PPI
and perfusion in the parietal, premotor and cingulate regions. When the
associations were analyzed in the RO alone, a positive correlation was
also found between prefrontal perfusion and PPI, and anterior hippocam-
pal perfusion was inversely related to PPI. Conclusions: These results sup-
port the notion that deficient sensory-motor filtering is associated with
decreased cortical task-related activation in schizophrenia.
ID: 549591
DECODING COMPLEX BEHAVIOR BY MEANS OF
RAPID CEREBRAL HEMODYNAMIC MODULA-
TION IN HEALTHY SUBJECTS AND PATIENTS
WITH SCHIZOPHRENIA
Daniel Schuepbach, D. Hell
Psychiatric University Hospital Zurich, University of Zurich,
Zurich, Switzerland
Rapid cerebral hemodynamic modulation substantially correlates with
non-routine spatial planning. This finding contrasts missing or erroneously
reported brain behavior relationships with functional imaging techniques
during planning. In the following investigation, we did not only expand
the above findings to a minute analysis of routine and non-routine spatial
planning in schizophrenia, but we applied this novel measure to the Wis-
consin Card Sorting Test (WCST). Healthy subjects and patients with
chronic schizophrenia performed a spatial planning task and the WCST
while rapid cerebral hemodynamic modulation was measures by means
of functional transcranial Doppler sonography. Uni- and multivariate anal-
yses of variance and correlation analyses were applied. Slowing during set
shifting of WCST showed a shared variance of 80.5% (P = .0004) with early
modulation of cerebral hemodynamics in a normal sample. Healthy sub-
jects rapidly adjusted cerebral hemodynamic modulation to the respective
phases of the planning task (P < .01), whereas patients failed to do so.
Rapid cerebral hemodynamic modulation is a major correlate of complex
behavior, and there is evidence of impairment in schizophrenia. Pathophys-
iological mechanisms and a review of relevant functional imaging literature
are included in this presentation.
ID: 549579
ELEVATED FUNCTIONAL CONNECTIVITY IN
A CORTICOSTRIATAL LOOP AND THE MECHA-
NISM OF AUDITORY/VERBAL HALLUCINATIONS
IN PATIENTS WITH SCHIZOPHRENIA
Ralph Edward Hoffman1, T. Fernandez1, B. Pittman1,
M. Hampson1,2
1Psychiatry, Yale University School of Medicine, New Haven, CT,
USA; 2Diagnostic Radiology, Yale University School of Medicine,
New Haven, CT, USA
The pathophysiology of auditory/verbal hallucinations (AVHs) in patients
with schizophrenia is poorly understood. We tested the hypothesis that el-
evated functional connectivity linking the superior temporal gyrus (STG) to
sites in the left inferior frontal gurus (IFG) leads to emergence of AVHs.
Functional connectivity estimates were extracted from correlations between
‘‘steady-state’’ time-course of fMRI-generated BOLD signal across brain
regions. Thirty-two patients with schizophrenia and active AVHs, 23 sim-
ilarly diagnosed patients without AVHs, and 22 healthy controls were stud-
ied. Groups were well-matched in terms of age, gender, education. The two
patient groups were well-matched in terms of positive symptoms, chronicity
and antipsychotic medication dosage. Functional connectivity was calcu-
lated relative to a bilateral superior temporal gyrus (STG) reference region
shown to be involved in the genesis of AVHs in a prior fMRI study. As
predicted, ROI analysis revealed significantly greater functional connectiv-
ity referenced to STG in subregions of the left IFG among hallucinators
compared to nonhallucinating patients. This finding emerged in the context
of reduced functional connectivity linking the STG reference region to
other, diverse cortical regions—as well as increased functional connectivity
linking the STG reference region to a large subcortical region—when both
patient groups were compared to healthy controls using a voxel-based anal-
ysis following FDR correction. This subcortical region consisted of the
thalamus, the dorsal striatum, and midbrain monoamine centers. A fol-
low-up region-of-interest analysis identified a functional loop of heightened
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functional connectivity linking IFG, STG, and the dorsal striatum in hal-
lucinators. Eliminating from the analysis those patients with frequent
AVHs during scanning demonstrated that functional connectivity eleva-
tions in hallucinators were not a consequence of waxing/waning co-activa-
tion coincident with AVHs, but instead reflected a sustained vulnerability
factor. These findings suggest that AVHs arise from relatively heightened
functional connectivity linking sites in IFG and STG that produce language
representations possibly triggered by the striatum. Parallel elevations in
functional connectivity linking STG to thalamic and/or midbrain dopamine
centers may gate resulting, spurious language representations into con-
sciousness as hallucinated speech. Research supported by NIMH
R01MH067073.
ID: 549435
ALTERED STRUCTURAL AND FUNCTIONAL
CONNECTIVITY OF COGNITIVE CONTROL NET-
WORKS IN SCHIZOPHRENIA
Ralf Schlo¨sser1, K. Koch1, G. Wagner1, C. Schultz1, M. Ro¨bel1,
C. Schachtzabel1, J. R. Reichenbach2, H. Sauer1
1Psychiatry, FSU Jena, Jena, Germany; 2Medical Physics Group,
FSU Jena, Jena, Germany
Disruption of executive cognitive control has been implicated in the path-
ophysiology of schizophrenia. Our findings from a series of fMRI studies
in schizophrenia patients are suggesting altered cortico-cortical and fron-
to-striatal networks (Schlo¨sser et al. 2003, 2008; Koch et al. 2007, 2008)
and a correlation between frontal DTI fractional anisotropy (FA) reduc-
tion and fMRI activation (Schlo¨sser et al. 2007). However, the relation-
ship between white matter structural integrity and functional connectivity
parameters within these networks remains largely unknown. In the cur-
rent study thirteen patients with schizophrenia and 13 controls were stud-
ied with DTI and fMRI while performing a short-term memory task
associated with increasing overlearning of stimulus material. Functional
connectivity was investigated by analyses of psychophysiological interac-
tions (PPI). DTI analyses were based on voxel-based and ROI-based sta-
tistics. Results revealed significant (P < .05, FDR) task-related
modulation of functional connectivity between the left DLPFC and a net-
work including the right DLPFC, left VLPFC, parietal cortex, left and
right cerebellum. A significant correlation between task-dependent pre-
frontal interhemispheric functional interaction (PPI-analysis) and FA
of the corpus callosum (DTI) could be found in schizophrenic patients.
The findings are demonstrating structure-function relationships with
regard to interhemispheric and frontal-subcortical circuitry. The com-
bined analysis of DTI and BOLD fMR provides complementary informa-
tion supporting the notion of schizophrenia as a cortical-subcortical
connectivity disorder.
References
1. Schlo¨sser, et al. Altered effective connectivity during working memory
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TEMPORAL MODELING DEMONSTRATES
PRESERVED OVER LEARNING PROCESSES IN
SCHIZOPHRENIA: AN FMRI STUDY
Kathrin Koch1, G. Wagner1, I. Nenadic1, C. Schachtzabel1,
M. Roebel1, C. Schultz1, M. Axer1, J. R. Reichenbach2, H. Sauer1,
R. G. Schlo¨sser1
1Department of Psychiatry, University of Jena, Jena, Germany;
2Department of Radiology, University of Jena, Jena, Germany
Working memory impairment is a central component of the cognitive dys-
function seen in schizophrenia. However, whether this impairment must be
regarded as a trait marker of the disorder or can be positively modified by
practice has scarcely been investigated. Therefore, the present study aimed
to quantify and model the neural substrates of continuous overlearning of
short-term memory information to investigate patients ability to profit
from practice. Thirteen schizophrenic patients and 13 healthy volunteers
were studied with fMRI while performing a Sternberg overlearning para-
digm. Because previous findings in healthy subjects demonstrated that
short-term practice, in the context of working memory, was associated
with exponential activation decreases, the practice-associated changes
were modelled according to an exponential signal decay. We found that
short-term learning was associated with significant individual perfor-
mance improvements and exponential signal decreases in a fronto-parieto-
cerebellar network both in schizophrenic patients and healthy volunteers.
Patients exhibited stronger signal decreases relative to controls in anterior
cingulate (BA 32), middle and superior temporal (BA 37, BA 22), superior
frontal (BA 8/9, BA 6) and posterior parietal regions (BA 40). A relative
hyperactivation in the patient group was observable only at the beginning
of the learning process when task demands were high and decreased with
continued practice. Our data indicate a gradual reduction of recruited neu-
ronal resources and a practice-associated activation normalization in
patients with schizophrenia. Inefficient working memory function and as-
sociated activation abnormalities in schizophrenia do not seem to consti-
tute stable characteristics of the disorder but might be modified by adequate
practice and experience.
ID: 549272
ASSESSING INTRA-AMYGDALA ACTIVITY TO
AFFECTIVE FACES IN SCHIZOPHRENIA OFF-
SPRING: IMPLICATIONS FOR DISORDERED
BEHAVIOR DURING ADOLESCENCE
Tracy Barbour1, E. R. Murphy2, P. Pruitt1, S. B. Eickhoff3,
M. S. Keshavan1,4, U. Rajan1, R. Rajarathinem1, C. Zajac-
Benitez1, V. A. Diwadkar1,5
1Psychiatry, Wayne State University SOM, Detroit, MI, USA;
2Psychology, Georgetown University, Washington, DC, USA;
3Neurowissenschaften und Biophysik Medizin, Forschungszentrum
Juelich, Juelich, Germany; 4Psychiatry, Beth Israel Deaconness
Medical Center, HMS, Boston, MA, USA; 5Psychiatry, University
of Pittsburgh SOM, Pittsburgh, PA, USA
Abnormal affective processing in structures such as the amygdala may un-
derlie disordered affective function in offspring of schizophrenia patients
(Scz-Off; Phillips and Seidman, 2008). The amygdala contributes to the
processing of affect, and its critical sub-nuclei (Centro-medial: CM; Baso-
lateral: BL; Superficial: SF) play different roles in relaying affective
information to other cortical and sub-cortical centers. Abnormal response
of regions such as the CM that project to autonomous centers in the brain
(McDonald, 2003) may result in blunted behavioral responses to rewarding
(positive) stimuli in Scz-Off. To assess this we used fMRI, to estimate intra-
amygdala activity (Eickhoff et al., 2007) to negative, neutral and positive
affect in adolescent (age:10–20 yrs) controls (HC) and Scz-Off. Twenty one
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HC (8 females; mean age:14.7 yrs) and 14 Scz-Off (5 females; mean age:14.7
yrs) performed a jittered event-related affective working memory task
(Bruker MedSpec 4Tesla; 345 EPI scans; TR = 2s; 24 slices;
3.8x3.8x4mm). Subjects viewed faces (Ekman and Oster, 1979) in sequence
to assess if the emotion conveyed on the current face matched that on the
preceding one. fMRI data were processed and analyzed used SPM2Regions
of interest (ROI) were created by overlaying maximum probability maps of
amygdala nuclei (Eickhoff et al., 2005) with amygdala masks (Tzourio-
Mazoyer et al., 2002). BOLD percent signal change to different affective
valences were computed for ROIs from unsmoothed fMRI images (to pre-
serve relative localization of signal). Data for each emotion were analyzed
in separate repeated measures ANCOVA’s. A significant group x region x
hemisphere interaction was observed for both positive, F2,62 = 4.26, P< .02,
MSe=.05, and neutral faces, F2,62 = 5.64, P < .01, MSe = .04. Further pair-
wise tests revealed, hypo-activity in the left CM in Scz-Off relative to HC to
positive stimuli, t33 = 2.37, P < .02. The CM integrates signals from other
nuclei (Pitkanen et al., 1997), and recent studies indicate the value of the
amygdala in modulating responses to rewarding stimuli (Baxter and Mur-
ray, 2002). Though preliminary, our data suggesting hypo-activity of the
CM sub-region to positive stimuli in Scz-Off, may reflect reduced sensitivity
to reward eliciting stimuli. This in turn may blunt the salience of positive
social cues, impairing social cognition and interaction in Scz-Off. These
intriguing links between amygdala activity and behavior will need further
investigation.
ID: 549140
THE EFFECT OF NEUREGULIN1 ON NEURAL
CORRELATES OF EPISODIC MEMORY ENCODING
Axel Krug1, V. Markov1, S. Krach1, A. Jansen1, K. Zerres2,
T. Eggermann2, T. Sto¨cker3, N. J. Shah3, M. M. No¨then4,
M. Rietschel5, T. Kircher1
1Psychiatry and Psychotherapy, RWTH Aachen University,
Aachen, Germany; 2Institute of Human Genetics, RWTH Aachen
University, Aachen, Germany; 3Institute of Neuroscience and
Biophysics 3 -Medicine, Research Center Ju¨lich, Ju¨lich, Germany;
4Genomics, Life and Brain Center, Bonn, Germany; 5Genetic
Epidemiology in Psychiatry, Central Institute of Mental Health,
Mannheim, Germany
Neuregulin 1 (NRG1) has been found associated with schizophrenia. Im-
paired performance in episodic memory tasks is an often replicated finding
in this disorder. In functional neuroimaging studies, this dysfunction has
been linked to signal changes in prefrontal and medial temporal areas
and could possibly constitute an endophenotype. Therefore, it is of interest
whether genes associated with the disorder, such as NRG1, modulate ep-
isodic memory performance and the neural correlates of memory encoding.
85 healthy individuals performed an episodic memory encoding task while
brain activation was measured with functional MRI. All subjects were gen-
otyped for the single nucleotide polymorphism (SNP) in the NRG1 gene,
SNP8NRG221533 (rs35753505). The effect of genotype on brain activation
was assessed with fMRI during an episodic memory encoding task. While
there were no differences in performance, brain activation in the right cin-
gulate gyrus (BA 24) and the bilateral middle frontal gyrus (BA 9) was pos-
itively correlated with the number of risk alleles in NRG1. NRG1 genotype
does modulate brain activation during episodic memory in key areas for
memory encoding. The results suggest that subjects with risk alleles
show hyperactivations in areas associated with elaborate encoding strate-
gies in order to improve task performance.
ID: 549025
GENETIC VARIATION IN THE SCHIZOPHRENIA-
RISK GENE NEUREGULIN 1 CORRELATES WITH
BRAIN ACTIVATION AND IMPAIRED SPEECH
PRODUCTION IN A VERBAL FLUENCY TASK IN
HEALTHY INDIVIDUALS
Tilo Kircher1, A. Krug1, V. Markov1, C. Whitney1, S. Krach1,
K. Zerres2, T. Eggermann2, T. Sto¨cker3, N. J. Shah3,
M. M. No¨then4, M. Rietschel5
1Psychiatry and Psychotherapy, RWTH Aachen University,
Aachen, Germany; 2Institute of Human Genetics, RWTH Aachen
University, Aachen, Germany; 3Institute of Neuroscience and
Biophysics 3 -Medicine, Research Center Ju¨lich, Ju¨lich, Germany;
4Genomics, Life and Brain Center, Bonn, Germany; 5Genetic
Epidemiology in Psychiatry, Central Institute of Mental Health,
Mannheim, Germany
Impaired performance in verbal fluency tasks is key finding in schizophre-
nia. In functional neuroimaging studies, this dysfunction has been linked to
signal changes in prefrontal and temporal areas. Since schizophrenia has
a high heritability, it is of interest whether susceptibility genes for the dis-
order, such as NRG1, modulate verbal fluency performance and its neural
correlates. 429 healthy individuals performed a semantic and a lexical ver-
bal fluency task. A subsample of 85 subjects performed an overt semantic
verbal fluency task while brain activation was measured with functional
MRI. NRG1 (SNP8NRG221533; rs35753505) status was determined
and correlated with verbal fluency performance and brain activation.
For the behavioral measure, there was a linear effect of NRG1 status
on semantic but not on lexical verbal fluency. Performance decreased
with number of risk-alleles. In the fMRI experiment, decreased activation
in the left inferior frontal and the right middle temporal gyri as well as the
anterior cingulate gyrus was correlated with the number of risk-alleles in the
semantic verbal fluency task. NRG1 genotype does influence language pro-
duction on a semantic level in conjunction with the underlying neural sys-
tems. These findings are in line with results of studies in schizophrenia and
may explain some of the cognitive and brain activation variation found in
the disorder. More generally, NRG1 might be one of several genes that in-
fluence semantic language capacities.
ID: 549020
GENETIC VARIATION IN THE SCHIZOPHRENIA-
RISK GENE NEUREGULIN1 CORRELATES WITH
DIFFERENCES IN FRONTAL BRAIN ACTIVATION
IN A WORKING MEMORY TASK IN HEALTHY
INDIVIDUALS
Axel Krug1, V. Markov1, T. Eggermann2, S. Krach1, K. Zerres2,
T. Sto¨cker3, N. J. Shah3, F. Schneider1, M. M. No¨then4,
J. Treutlein5, M. Rietschel5, T. Kircher1
1Psychiatry and Psychotherapy, RWTH Aachen University,
Aachen, Germany; 2Institute of Human Genetics, RWTH Aachen
University, Aachen, Germany; 3Institute of Neuroscience and
Biophysics 3 -Medicine, Research Center Ju¨lich, Ju¨lich, Germany;
4Genomics, Life and Brain Center, Bonn, Germany; 5Genetic
Epidemiology in Psychiatry, Central Institute of Mental Health,
Mannheim, Germany
Working memory dysfunctions are a prominent feature in schizophrenia.
These impairments have been linked to alterations in prefrontal brain ac-
tivation with studies reporting hypo- and hyperactivations. Since schizo-
phrenia has a high heritability, it is of interest whether susceptibility
genes modulate working memory and its neural correlates. The aim of
the present study was to test the influence of the NRG1 schizophrenia sus-
ceptibility gene on working memory and its neural correlates in healthy sub-
jects. 429 healthy individuals performed a verbal and a spatial working
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memory task. A subsample of 85 subjects performed a 2-back version of the
Continuous Performance Test (CPT) in a functional MRI study. The
NRG1 SNP8NRG221533 (rs35753505) carrier status was determined
and correlated with working memory performance and brain activation.
There were no effects of genetic status on behavioural performance in
the working memory tasks in the 429 subjects and in the fMRI task (n
= 85). A linear effect of NRG1 SNP8NRG221533 carrier status on neuronal
activation emerged in the fMRI experiment. Hyperactivation of the supe-
rior frontal gyrus (BA 10) was correlated with the number of risk-alleles.
NRG1 carrier status did not have an influence on working memory perfor-
mance on the behavioural level. The fMRI data however suggest that per-
formance measures between groups did not differ due to a compensational
activation of BA 10 in risk-allele carriers. Our results are in line with func-
tional imaging studies in patients with schizophrenia, which also showed
a differential activation in lateral prefrontal areas.
ID: 549019
THE DIFFERENCE IN CEREBRAL ACTIVITY
BETWEEN AUDITORY VERBAL HALLUCINA-
TIONS AND INNER SPEECH
Iris Else Sommer1, J.-D. Blom2, R. S. Kahn1
1neuroscience, University Medical Center Utrecht, Utrecht,
Netherlands; 2Parnassia PsychoMedical Center, The Hague,
Netherlands
The pathophysiology of Auditory Verbal Hallucinations (AVH) is largely
unknown. Several functional imaging studies have measured cerebral acti-
vation during AVH, but sample sizes were relatively small (1–8 subjects)
and findings inconsistent. In this study cerebral activation was measured
using fMRI in 24 psychotic patients while they experienced AVH in the
scanner and, in another session, while they silently generated words. All
patients were right handed and diagnosed with schizophrenia, schizo-affec-
tive disorder or psychosis NOS. Group analysis for AVH revealed activa-
tion in the right homologue of Broca’s area, bilateral insula, bilateral
supramarginal gyri and right superior temporal gyrus. Broca’s area and
left superior temporal gyrus were not activated. Group analysis for
word generation in these patients yielded activation in Broca’s and Wer-
nicke’s area and to a lesser degree their right-sided homologues, bilateral
insula and anterior cingulate gyri. Lateralization of activity during AVH
was not correlated with language lateralization, but rather with the degree
to which the content of the AVH had a negative emotional valence. The
main difference between cerebral activity during AVH and activity during
normal inner speech appears to be the lateralization. The predominant en-
gagement of the right inferior frontal area during AVH may be related to
the typical low semantic complexity and negative emotional content of
AVH.
ID: 548933
NEURAL CORRELATES OF THE SUBJECTIVE
EXPERIENCE OF REWARD IN SCHIZOPHRENIA
James A. Waltz1, J. B. Schweitzer2, J. M. Gold1, E. J. Rose3,
P. K. Kurup3, B. J. Salmeron3, T. J. Ross3, S. M. McClure4,
E. A. Stein3
1Department of Psychiatry, Univ of Maryland School of Medicine,
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3Neuroimaging Research Branch, National Institute on Drug Abuse,
Baltimore, MD, USA; 4Department of Psychology, Stanford
University, Stanford, CA, USA
In many experimental studies of emotion in schizophrenia (SZ), patients
have reported finding pleasant stimuli as rewarding as controls. Nonethe-
less, patients generally show a diminished capacity to initiate and sustain
goal-directed behavior, motivated by potential rewards. The relative inabil-
ity of rewards to drive behavior in SZ suggests that responses to rewards, at
the physiological level, may be abnormal, and possibly disconnected from
the reported experience of them. In healthy volunteers, the subjective ex-
perience of a food reinforcer has been been linked to neural responses in
ventral prefrontal cortex (PFC). We hypothesized that, relative to controls,
SZ patients would show a reduced correspondence between subjective rat-
ings of reinforcer pleasantness, and neural responses in ventral PFC. In
a 3-T MRI scanner, we administered 18 patients and 18 matched controls
600-ll boluses of the juice of their choice (apple, grape, or fruit punch; juice
was delivered at a rate of 1 ml/s). Subjects were administered 78 total squirts
(46.8 ml), separated by intervals of approximately 20 seconds, over the
course of 3 runs of 26 squirts each. Between runs of the fMRI experiment,
subjects were prompted to rate, on a visual analog scale, their enjoyment of
the juice. For each individual subject, we identified reward-evoked BOLD
signal changes, using juice delivery times as regressors. Neural responses
corresponding to individual ratings of juice pleasantness within a group
were then assessed using voxel-wise whole-brain analyses (regression anal-
yses performed with AFNI). We corrected for multiple comparisons based
on cluster size (a minimum cluster size of 424 ml extent, for a voxel-wise
threshold of P < .002, was determined by a Monte Carlo simulation).
Patients and controls did not differ in their average ratings of juice pleas-
antness [t34=1.25; P > 0.10]. Regression analyses revealed that, within the
group of control subjects, BOLD activity in both mesial and lateral areas of
PFC tracked subjective ratings of rewards. No such correspondences be-
tween MRI responses and subjective ratings were observed in patients.
These results support previous findings in healthy volunteers, and suggest
that patients with schizophrenia do not show the same correspondence be-
tween PFC physiology and the subjective experience of rewards. These find-
ings may contribute to our understanding of hedonic deficits in SZ, and
inform our treatment of negative symptoms.
ID: 548832
DISORDERED FUNCTIONAL MATURATION OF
THE AMYGDALA DURING ADOLESCENCE:
FMRI STUDIES OF AFFECTIVE JUDGMENT IN
SCHIZOPHRENIA OFFSPRING
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R. Rajarathinem1, C. Zajac-Benitez1, V. A. Diwadkar1,2
1Psychiatry and Behavioral Neurosciences, Wayne State University
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Beth Israel Deaconness, Harvard Medical School, Boston, MA,
USA
Adolescent offspring of schizophrenia patients (Scz-Off) are an important
group in whom to assess impaired functional brain development associated
with affective function (Phillips and Seidman, 2008). Maturation of affec-
tive processing and of brain regions such as the amygdala is particularly
dynamic during adolescence (Herba and Phillips, 2004). Further, Scz-Off
show increased incidence of behavioral impairments related to dysfunction
and dysmaturation of limbic regions. We assessed developmental trends in
fMRI-estimated amygdala function in a group of controls (HC) and Scz-
Off using a continuous affective judgment task. In particular, we were in-
terested in whether amygdala response to negative stimuli attenuates with
age in HC but not Scz-Off. Fourteen Scz-Off (5 females, mean age = 14.7
yrs) and 20 HC (8 females, mean age = 14.9 yrs) were assessed. During
fMRI, faces (Ekman and Oster, 1979) and distorted faces (control stimuli)
were presented (3s/face) in sequence. Subjects judged if the affect depicted
on a face was identical to that on the previous face (irrespective of identity).
Stimuli were presented in a jittered event-related design. fMRI was
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conducted on a Bruker MedSpec 4T system (345 EPI scans; TR = 2s; 24
slices; 3.8x3.8x4mm). Analyses were performed in SPM2. Stimuli were
modeled as 3s events; Contrast images (faces>distorted; negative valen-
ce>distorted) were submitted to intra group regression to assess age-related
effects on valence-related activation. Analyses were restricted to the amyg-
dala (Maldjian et al., 2003). In HC, a significant inverse correlation was
observed between age and amygdala response to all faces (t18 = 4.57,
pFWE < .05, x = 32, y = 1, z = 22). This effect was largely modulated
by an age-related decrease in amygdala response to negatively valenced
faces (t18 = 3.05, pFWE < .05, x = 30, y = 3, z = 20). Age-related asso-
ciations were absent in Scz-Off (P > .1). To account for differences in sam-
ple size, HC analyses were replicated in a sub-sample of HC that were age-
and gender-matched to the Scz-Off subjects (t12 = 3.60, pFWE<.05, x = 26,
y =8, z =10). Positive correlations were absent. HC trends are consistent
with previously published data (Kilgore et al., 2001) and may reflect
increased age-related modulation of the amygdala by cortical regions. Such
age-related modulation may be absent in Scz-Off, suggesting a cortico-
sub-cortical mechanism underlying behavioral disorders in these subjects.
ID: 548739
PET IMAGING OF CANNABINOID RECEPTORS IN
SCHIZOPHRENIA
Dean F. Wong1,2, H. Kuwabara1, A. Horti1, A. Kumar1, J. Brasic1,
W. Ye1, M. Alexander1, V. Raymont1, J. Galecki1, M. Charlotte1,
N. Cascella2
1Division of Nuclear Medicine, Russell H. Morgan Department of
Radiology, Johns Hopkins University, Baltimore, MD, USA;
2Psychiatry, Johns Hopkins University, Baltimore, MD, USA
The CB1 cannabinoid receptor is of considerable interest in schizophrenia
(SZ) (as well as Alzheimer’s, obesity and drug abuse). Here, we present data
from the first human study with [11C]OMAR in SZ. We previously showed
OMAR has specific binding in regions consistent with the known distribu-
tion of CB1. PET were carried out on 7 controls (HC; mean age = 29) and
two 45 year old subjects with DSM-IV criteria for SZ with no history of
cannabis abuse or drug dependence. Dynamic PET scans of 90 min after
IV injection of high specific activity OMAR (6 -8 Ci/micro mole; mean dose
of 19 mCi) with radial arterial blood sampling and HPLC metabolite anal-
ysis. Each subject had an SPGR MRI for definition of volumes of interest.
Total distribution volume (VT) was estimated in brain regions by the Logan
plasma reference graphical analysis (PRGA) and a 2 tissue compartment
model with constraint with 5 parameters (TTCM-5C). The brain time-ac-
tivity curves of OMAR peaked at approximately 20 minutes post injection
(% SUV ranged from 136 to 207% in putamen) and decreased gradually
thereafter to reach a SUV between 80 and 117% at 90 min. The average
parent ligand in plasma was 41% at 60 minutes by HPLC. The average
VT for brain regions in HC ranged between 1.0 and 1.7 in multiple cortical
and subcortical regions. The highest binding was observed in cingulate,
globus pallidus and putamen, all CB1 rich areas. The first of the two SZ
subjects had increases in VT ranging from 3.7 to 13.1% above the mean
and from 4% to 13% above the upper 95% confidence limit of the HC group.
The greatest differences were seen in the frontal cortex, cingulate and
globus pallidus. The other subject with SZ was within the confidence limits.
Interestingly enough the subject with elevated CB1 receptors had a higher
BPRS total score (32 vs. 22), with a greater score on the psychosis subscale;
7 vs. 3; anxiety subscale; 8 vs 4; and hostility subscale 5 vs 3, and was gen-
erally considered to be clinically more affected. OMAR has characteristics
for studying in human brain including neuropsychiatric disorders such as
SZ. It has reversible kinetics during the 90 minute PET .These early findings
of elevations in multiple brain regions of CB1 receptors in subjects with
more severe SZ symptoms will be expanded to a series of at least 6 patients.
These studies could have important implications for the role of CB1 in the
pathophysiology of SZ and possible novel treatments.
ID: 548716
CORTICAL ACTIVITY DURING VISUAL-
PERCEPTUAL BINDING IN SCHIZOPHRENIA AS
REVEALED BY FMRI
Steven Michael Silverstein1,2, S. Berten1,2, B. Essex2, I. Kovacs3,
T. Susmaras4, D. Little4
1University Behavioral HealthCare, University of Medicine and
Dentistry of New Jersey, Piscataway, NJ, USA; 2Psychiatry,
University of Illinois at Chicago, Chicago, IL, USA; 3Cognitive
Science, Budapest University of Technology and Economics,
Budapest, Hungary; 4Neurology and Rehabilitation, University
of Illinois at Chicago, Chicago, IL, USA
Background: Behavioral and electrophysiological studies of schizophre-
nia have consistently demonstrated impairments in the integration of vi-
sual features into unified perceptual representations. Specific brain
regions involved in this dysfunction, however, remain to be clarified.
The purpose of this study was to examine, using fMRI, the relative in-
volvement of visual cortex areas involved in form perception, and parietal
and frontal regions involved in attention, in the visual integration impair-
ment in schizophrenia. Methods: Fourteen patients with schizophrenia
and 14 healthy controls were compared on behavioral performance
and data acquired via fMRI while completing a contour integration
task that had previously been used to identify a visual integration deficit
in schizophrenia. Results: Schizophrenia patients demonstrated poorer
visual integration than controls. Analyses of peak signal change indicated
that while the groups were equivalent in area V1, the schizophrenia group
demonstrated reduced signal in areas V2-V4, which are the earliest
regions sensitive to global configurations of stimuli. Moreover, whereas
the control group demonstrated greater recruitment of prefrontal and pa-
rietal areas during perception of integrated forms compared to random
stimuli, the schizophrenia group demonstrated greater recruitment of
frontal regions during perception of random stimuli. The groups differed
on brain regions involved in form perception even when they were
matched on accuracy levels. Conclusions: The visual integration distur-
bance in schizophrenia may involve both deficient basic visual processes
(beginning at least as early as occipital region V2), as well as reduced feed-
back from visual attention regions that normally serves to amplify rele-
vant visual representations relative to irrelevant information.
ID: 548683
THE NEURAL BASIS OF RESPONSE SELECTION
IN SCHIZOPHRENIA: A POTENTIAL
ENDOPHENOTYPE
Neil Woodward1, B. Waldie2, B. Rogers3, P. Tibbo2, P. Seres2,
S. Purdon2
1Psychiatry, Vanderbilt University, Nashville, TN, USA;
2Edmonton Early Psychosis Intervention Clinic and Bebensee
Schizophrenia Research Unit, University of Alberta Hospital,
Edmonton, AB, Canada; 3Vanderbilt University Institute of Imaging
Sciences, Vanderbilt University, Nashville, TN, USA
The search for genes conferring liability for schizophrenia may be aided by
the identification of endophenotypes. Response selection is a heritable
cognitive function that is impaired in patients with schizophrenia and
their unaffected siblings. The abnormalities in cerebral function that pre-
sumably underlie the deficit in patients and unaffected siblings remain to
be elucidated. We employed fMRI to examine cerebral neurophysiology
during performance of a 4-choice reaction time (CRT) task in 25 patients
with schizophrenia (15 medication free first episode (FEP) and 10 chronic
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patients), 32 controls, and 12 unaffected siblings of individuals with
schizophrenia. CRT was impaired in both medication free FEP and
chronic patients with schizophrenia, and unaffected siblings. FEP
patients, chronic patients, and unaffected siblings demonstrated greater
BOLD response in the right dorsolateral prefrontal cortex (dlPFC) during
CRT task blocks. Functional connectivity analysis revealed marked
reductions in connectivity between the right dlPFC and multiple brain
regions in both patient groups and, to a lesser degree, unaffected siblings.
The magnitude of connectivity between right dlPFC and inferior parietal
lobule correlated with task performance in the combined patient/unaf-
fected siblings group, but not controls suggesting that the network of
brain regions recruited to perform the task differed as a function of genetic
liability for schizophrenia. Altered activity and connectivity of the right
dlPFC appears to be related to genetic vulnerability for schizophrenia and
may represent a potential endophenotype of the disorder. Consequently,
genes linked to behavioral performance and cerebral activity, including
regional connectivity, associated with response selection may be related
to schizophrenia vulnerability.
ID: 548421
FUNCTIONAL NEURAL CORRELATES OF
PHYSICAL ANHEDONIA IN NON-CLINICAL
INDIVIDUALS AND IN PATIENTS WITH
SCHIZOPHRENIA
Philippe-Olivier Harvey1,3, J. Armony1,2, A. K. Malla1,2,
M. Lepage1,2
1Douglas Mental Health University Institute, Montreal, QC,
Canada; 2Department of Psychiatry, McGill University, Montreal,
QC, Canada; 3Department of Neurology and Neurosurgery, McGill
University, Montreal, QC, Canada
The persistent nature of negative symptoms in schizophrenia has led to
the investigation of neural abnormalities underlying such symptoms. In-
ter-individual variability in anhedonia severity is likely to be multi-deter-
mined. It may be explained by basic neural abnormalities present prior to
the onset of the illness, as well as by other factors that have emerged fol-
lowing illness onset. In the current study, we proposed to better charac-
terize the brain abnormalities associated with anhedonia in
schizophrenia. Anhedonia potentially affects emotional processing and
fMRI is a well-suited technique to explore the relation between emotional
processing and neural activity as a function of anhedonia severity. In an
event-related functional MRI study, we used an emotional picture view-
ing task to identify in 26 non-clinical individuals and 30 people with
schizophrenia the brain regions whose activity significantly correlated
with physical anhedonia severity during hedonic processing. A conjunc-
tion analysis identified the neural correlates of anhedonia common to
both groups. An interaction analysis identified the neural correlates of
anhedonia specific to schizophrenia. We found anhedonia severity to
be inversely correlated with the activity of visual attention-related corti-
cal regions in both groups. The orbitofrontal cortex, insula, and puta-
men/ventral striatum activity was negatively correlated with
anhedonia severity in people with schizophrenia only. The data first sug-
gest that basic neural abnormalities associated with trait anhedonia and
potentially representing a neural marker of vulnerability for schizophre-
nia involve a poor modulation of perceptual and attentional brain
regions during the processing of hedonic information. Alternatively,
the orbitofrontal/anhedonia link found in schizophrenia could reflect
the specific impairment of indirect factors, such as reward anticipation
deficits, that influence the measurement of anhedonia severity through
self-report questionnaires.
ID: 548006
A MULTIMODAL IMAGING STUDY OF THEORY OF
MIND FUNCTIONING IN A JAPANESE SAMPLE OF
SCHIZOPHRENIA PATIENTS
Katja Koelkebeck1,2, K. Hirao2, T. Saze2, J. Miyata2, R. Kawada2,
P. Ohrmann1, J. Bauer1, A. Pedersen1, V. Arolt1, T. Murai2
1Department of Psychiatry, University of Muenster, School of
Medicine, Muenster, Germany; 2Department of Neuropsychiatry,
Kyoto University, Graduate School of Medicine, Kyoto, Japan
There is empirical evidence from functional imaging studies that during
performance of Theory of Mind (ToM)-tasks (ability to infer other’s
thoughts and intentions) schizophrenia patients activate certain brain areas
less than healthy controls. In the rare Diffusion Tensor Imaging (DTI) stud-
ies published so far, white matter analyses focusing on the superior tempo-
ral junction and the basal temporal regions have shown a reduction of white
fibers. In our study we implemented a sophisticated ToM-paradigm first
used by Abell et al. (2000; Research group Uta Frith, UC London) in a func-
tional Magnetic Resonance Imaging (fMRI) design and combined these
analyses with DTI in a sample of schizophrenia patients. We hypothesized,
that a reduced activation pattern during ToM-task performance should be
related to a reduction of white matter integrity of ToM-relevant brain areas.
This is an innovate approach that has not been performed for ToM-tasks
yet. 11 schizophrenia patients and 12 healthy controls have been assessed
with the functional MRI-paradigm (3T), comprising short video anima-
tions with geometrical, moving shapes acting in social, sometimes ToM-re-
lated patterns. DTI was additionally applied to assess white matter
integrity. Also, psychopathology, neuropsychological data and behavioral
ToM-data were obtained. First analyses of the fMRI data indicate differ-
ential activation patterns in schizophrenia patients compared to controls in
cortical areas that have been related to the proposed ToM neuronal net-
work. Interestingly, while performing ToM-tasks, certain brain areas,
eg, the ACC and the temporal lobes, were more activated in schizophrenia
patients than in healthy controls. First results of white matter tract inves-
tigations revealed lower FA-values in the left arcuate fasciculus and right
deep white matter of the temporal lobes in schizophrenia patients. Our
functional MRI results of the ToM-paradigm imply a compensatory stron-
ger activation of ToM-related areas in schizophrenia patients, whereas for-
mer studies reported reduced activations in these ToM related brain areas.
Lower FA-values indicate disturbed white matter integrity in the temporal
lobes. Further analyses of our data in combination with clinical perfor-
mance and neuropsychological results might help to amplify our under-
standing of the neurobiological basis of social cognition deficits. The
study was supported by a research fellowship of the Japan Society for
the Promotion of Science (JSPS).
ID: 546817
AUDITORY-VERBAL HALLUCINATIONS AND
MENTAL IMAGERY COMPETE FOR SHARED
NEURAL RESOURCES: AN FMRI STUDY
Ans Vercammen1, J. A. Jenner2, J. A. Den Boer2, C. J. Slooff3,
H. C. Klein4, R. Knegtering2, R. Bruggeman2, D. Wiersma2,
A. Aleman1
1BCN NeuroImaging Center, University Medical Center Groningen,
Groningen, Netherlands; 2Department of Psychiatry, University
Medical Center Groningen, Groningen, Netherlands; 3Mental
Health Care Center Drenthe, Assen, Netherlands; 4Mental Health
Care Center Groningen, Groningen, Netherlands
Auditory-verbal hallucinations (AVH) are a cardinal feature of schizophre-
nia. Cognitive models have suggested that AVH are related to abnormal
mental imagery processes. Specifically, it has been hypothesized that the
production of inner speech, and its subsequent misattribution to an external
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source may give rise to AVH. Using a behaviorally controlled auditory
mental imagery task in an fMRI setting, Aleman et al. (2005, Cereb Cortex)
showed that secondary auditory processing areas, namely posterior supe-
rior temporal sulcus, as well as speech production areas (inferior frontal
gyrus), were activated during imagery in healthy subjects. Interestingly,
similar areas are found to be activated when schizophrenia patients observe
AVH (Shergill et al., 2000, Arch Gen Psychiatry). We hypothesized that if
auditory imagery processes and AVH compete for the same neural resour-
ces, differential activation patterns will be observed during an auditory im-
agery task. Specifically, we expected an attenuation of the neural response
in hallucinating patients. Functional MR images were obtained from 25
right-handed males subjects (8 patients with AVH, 8 patients without
AVH and 9 healthy controls, group-matched for age and education level),
who performed a metrical stress evaluation task, which requires the forma-
tion of an auditory mental image of a visually presented word, in order to
generate the correct stress pattern. Active task blocks were interspersed
with 30 second rest periods. Whole brain EPI images were acquired on
a 3T Phillips System. Compared to healthy controls, hallucinating patients
showed increased activation in the left middle and superior temporal gyrus,
the left middle cingulate gyrus and the left postcentral gyrus during audi-
tory imagery compared to baseline. Alternatively, reduced activation was
observed in the right superior temporal gyrus. When compared to non-hal-
lucinating patients, right middle cingulate gyrus was more activated. Right
superior temporal gyrus, which has previously been found to activate dur-
ing AVH, showed reduced responsivity to auditory imagery in hallucinating
schizophrenia patients. Alternatively, patients showed increased activation
in left temporal areas, possibly as a compensatory mechanism. This finding
is interpreted as resulting from competition for shared neural resources, and
implicates auditory imagery processes in the genesis and/or maintenance of
AVH.
ID: 543930
CEREBRAL ACTIVATION ON FMRI DURING
PROCEDURAL LEARNING IN UNMEDICATED
FIRST EPISODE PSYCHOSIS
Scot E. Purdon1, B. Waldie1, N. D. Woodward1,4, K. Goddard1,
P. Seres1,2, P. G. Tibbo1,3
1Bebensee Schizophrenia Research Unit—Department of Psychia-
try, University of Alberta, Edmonton, AB, Canada; 2In Vivo NMR
Research Center—Department of Biomedical Engineering,
University of Alberta, Edmonton, AB, Canada; 3Department of
Psychiatry, Dalhousie University, Halifax, NS, Canada;
4Department of Psychiatry, Vanderbilt University, Nashville,
TN, USA
Using fMRI, we have previously identified abnormal activity in the cerebral
cortex and basal ganglia during procedural learning in individuals with
chronic schizophrenia and in unaffected siblings, suggesting dysfunction
of distributed cortical-subcortical circuitry with potential relevance to an
endophenotype of schizophrenia. To assess this further we examined un-
medicated patients experiencing a first episode of psychosis. Method: Sev-
enteen unmedicated individuals suffering their first episode of psychosis
(FEP) were recruited from the Edmonton Early Psychosis Intervention
Clinic (EEPIC). They were 22 years of age (mean = 21.94 years, SD =
3.99), ill for 5 months (mean duration of illness = 0.38 years, SD =
0.27), and had minimal prior exposure to neuroleptic treatment (mean prior
exposure = 17.87 days, SD = 25.38; four were neuroleptic naı¨ve). An age-
and gender-matched healthy control (HC) sample was recruited through
campus advertising. The HC sample was also 22 years of age (mean
age = 22.12, SD = 3.19). All subjects completed an embedded series Serial
Reaction Time (SRT) task while undergoing fMRI on a 1.5T scanner
Results: The FEP and HC groups exhibited comparable procedural learn-
ing, but the FEP group exhibited less left hemisphere cortical activity in the
DLPFC (BA 46 and 9), the premotor cortex (BA 6) and the superior tem-
poral gyrus (BA 22). The HC group also exhibited significant activation of
bilateral anterior cingulate cortex that was not apparent in the FEP group.
Sub-cortically, significant activation of the basal ganglia was evident during
procedural learning in both the FEP and HC groups. Conclusions: Cortical
but not subcortical pathology was apparent in this unmedicated first ep-
isode sample. Previously we reported similar cortical anomalies in unaf-
fected siblings of patients. We also reported cortical and subcortical
anomalies in medicated individuals with chronic schizophrenia. fMRI
appears sensitive to (1) a cortical anomaly of the left hemisphere that
may represent an endophenotype marker for schizophrenia, and (2) a sub-
cortical anomaly that may result from prolonged illness and/or pharma-
cotherapy. Delineation of an endophenotype marker for schizophrenia
would facilitate premorbid identification and early intervention. Recog-
nition of anomalies caused by prolonged illness or treatment is essential to
the development of safe and effective treatments for schizophrenia.
ID: 540726
EFFECTS OF EYE GAZE DIRECTION ON
AMYGDALA ACTIVATION TO THREAT RELATED
EXPRESSIONS IN SCHIZOPHRENIA
Amy Pinkham, J. Loughead, K. Ruparel, E. Overton, R. Gur,
R. Gur
Department of Psychiatry, Neuropsychiatry Section, University of
Pennsylvania, Philadelphia, PA, USA
Emotion recognition deficits are well documented in schizophrenia and
are associated with abnormal amygdala functioning. This is pronounced
for threat related emotions, and previous work has demonstrated that the
threat relatedness of stimuli modulates amygdala activity in healthy con-
trols with lesser effects in individuals with schizophrenia. We sought to
examine whether eye gaze direction of threat related faces, a factor shown
to modulate amygdala activation in healthy controls, would evoke dif-
ferential amygdala responses in schizophrenia. Neural activity was mea-
sured using BOLD fMRI in 21 healthy controls and 22 schizophrenia
patients during emotion recognition. Faces displaying anger, fear or
no emotion were presented. Half were shown with direct gaze so that
they appeared to be looking straight at the participant, and half were
averted by 8 so that they appeared to be looking slightly away from
the participant. Analysis of performance revealed a gaze by emotion in-
teraction such that both patients and controls were more accurate for
direct gaze anger than averted gaze anger and for averted relative to di-
rect gaze fear. Analyses of neural activation demonstrated that patients
showed reduced activation in a network of neural regions associated with
face processing including left amygdala and bilateral fusiform gyrus.
Examination of percent signal change in the left amygdala revealed a sig-
nificant 3-way interaction of group, emotion, and gaze. Controls showed
greater activation for direct anger than averted anger, and comparable
levels of activation for averted anger and direct and averted fear.
Patients, however, showed a reverse pattern with greater amygdala acti-
vation to averted anger and direct fear than their opposite gaze counter-
parts. These results demonstrate that patients with schizophrenia show
modulation of amygdala activation in an opposite pattern to that of con-
trols and to their pattern of behavioral performance, with poorest per-
formance in conditions inducing greatest amygdala activation. The
results are consistent with previous work suggesting that increased amyg-
dala activation in patients may interfere with the top-down cognitive pro-
cesses necessary for accurate emotion recognition. They also suggest
that the increased ambiguity of averted anger and direct fear may be
perceived by patients as more threatening than direct anger and averted
fear expressions. Support provided by NIMH grants R01-MH060722
and T32-MH019112.
ID: 550829
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INFLUENCE OF EMOTIONAL PROCESSING ON
WORKING MEMORY IN SCHIZOPHRENIA
Karla Becerril, D. M. Barch
Psychology, Washington University in Saint Louis, Saint Louis,
MO, USA
Schizophrenic patients seem to be equally sensitive to the emotional content
of stimuli than controls. But how do they further process this information
while they perform a cognitive task? We compared the influence of emotion
on working memory in patients and healthy controls using behavioral
measures and fMRI. 38 patients and 32 controls performed a nonverbal
2back working memory task while being scanned. To manipulate the emo-
tional content in the task, faces displaying happy, neutral or fearful expres-
sions were presented in blocks so that positive, neutral and negative
conditions were created. Repeated measure ANOVAs indicated that
patients, but not controls, were significantly more accurate in the negative
as compared to neutral condition. Neither group showed a difference in
accuracy between positive and neutral conditions. In both groups, RTs
in the negative condition were significantly longer than in the neutral or
happy conditions. A number of brain regions, including the basal ganglia,
lingual and fusiform gyri, hippocampus, superior temporal cortex, as well
as regions in the DLPFC and cerebellum showed a significant interaction
between condition and group in whole brain analyses, with patients tending
to have greater activation in the negative condition, and controls in the neu-
tral condition. A ROI analysis of areas involved in signaling stimulus sa-
lience showed that amygdalar activation was significantly higher in the
negative condition in patients, but did not significantly differ among con-
ditions in controls. The lenticular and caudate nuclei were more active in
the neutral than emotional conditions in controls, but more active in the
negative than neutral or positive conditions in patients. Regions thought
to be associated with emotion regulation (such as DLPFC and hippocam-
pus) demonstrated significantly greater activity in the neutral than negative
and positive conditions in controls. Patients, however, demonstrated signif-
icantly greater activation in the negative condition in anterior DLPFC
regions and hippocampus, and no difference in activation among condi-
tions in more posterior DLPFC regions. These results suggest that patients
experience an enhanced influence of negative emotion on cognition, which
potentially increases the engagement of areas involved in emotion regula-
tion. In the context of a working memory task, this enhanced influence
of negative emotion may facilitate encoding of the stimuli and thus
more accurate performance.
ID: 551888
ABNORMAL CORTICAL-THALAMIC-
CEREBELLAR RECRUITMENT DURING SUCCESS-
FUL MEMORY RETRIEVAL IN SCHIZOPHRENIA
Jo Cara Pendergrass1, A. P. Weiss2, S. H. Heckers1
1Psychiatry, Vanderbilt University Medical Center, Nashville,
TN, USA; 2Psychiatry, Massachusetts General Hospital, Boston,
MA, USA
Declarative memory deficits are a prominent feature of schizophrenia. Pre-
vious studies have demonstrated that patients with schizophrenia engage
less in conscious recollection of details and rely more on a sense of famil-
iarity for retrieval of information. In the present study, we employed a slow
event-related fMRI design using a Remember-Know paradigm to study the
neural basis of episodic and semantic memory in schizophrenia. Eighteen
male schizophrenia and 15 matched healthy control participants learned
108 words and then were presented with a randomized list of the original
and 28 novel words while undergoing functional neuroimaging. Partici-
pants initially decided whether words were previously learned or new
and then indicated whether they remembered details of the encoding expe-
rience (Remember = R) or if they simply recognized the word (Know = K).
Behavioral performance (overall hit rate) was assessed during the old/new
and R/K judgments. We used a mixed-effect model in SPM5 to compare
brain activation (P< .05, corrected) during correct recognition (hits versus
misses) and episodic memory (hit-R versus hit-K) between groups. Schizo-
phrenia patients were less accurate when remembering the previously
learned words (overall hit rate), but this difference was not significant.
We did not find evidence for selective impairments of episodic or semantic
memory in our sample of schizophrenia patients: all groups had similar hit-
R rates (0.46 in controls; 0.42 in schizophrenia patients) and hit-K rates
(0.27 in controls; 0.21 in schizophrenia patients). In the context of equiv-
alent recognition performance, the control group exhibited significantly
greater activation compared to schizophrenia patients in five brain regions:
cerebellum, thalamus/caudate, precuneus, left medial frontal gyrus, and bi-
lateral superior frontal gyri. The schizophrenia group did not exhibit any
areas of significantly greater activation compared to the control group, and
there were no group differences when comparing hit-R and hit-K events. In
contrast to previous behavioral studies, the current slow event-related
fMRI study could not confirm selective episodic memory deficits in schizo-
phrenia. However, we found compelling evidence for impaired recruitment
of a cortico-thalamic-cerebellar network during successful memory re-
trieval in schizophrenia. This provides the opportunity to explore further
the neural basis of memory function in schizophrenia.
ID: 551885
EVALUATION OF MEDIAL TEMPORAL LOBE
STRUCTURES IN SCHIZOPHRENIA USING BOLD
FMRI DURING NOVELTY DETECTION WITH
MULTIPLE STIMULI
Harshal Kirane, M. Collins, S. Dantu, P. Mihalakos, B. Thomas,
C. Tamminga
Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA
Alterations of declarative memory in schizophrenia implicate aberrant
mechanisms of processing within medial temporal lobe (MTL) structures,
namely, the hippocampus, entorhinal cortex, perirhinal cortex, and para-
hippocampal cortex. Examination of differential activation along the ros-
trocaudal axis affords multiple regions of interest (ROI) for evaluation.
Using 3T T2* high-resolution blood-oxygen-level-dependent (BOLD)
functional magnetic resonance imaging (fMRI), we employed a block de-
sign of categorically related stimuli to contrast neural responses of normal
and schizophrenic subjects. Statistical parametric mapping (SPM2) and
ROI analysis, with manual generation of ROIs for the aforementioned
regions, is ongoing. Preliminary analysis of the normal control group using
SPM2 confirms a posterior localization of activation with novel scene stim-
uli, an anterior localization with novel faces, and combined A-P involve-
ment with novel word stimuli, whereas the schizophrenia group
demonstrates significant variation of activation. Moreover, a subject’s de-
viation from normal activation correlates with their degree of psychosis.
These results evidence a modular architecture for the MTL structures in-
volved in encoding memory and suggests the MTL is one of the sites of
dysfunction associated with psychosis in schizophrenia.
ID: 551884
ABERRANT FUNCTIONAL CONNECTIVITY IS
ASSOCIATED WITH HALLUCINATIONS DURING
SOURCE MONITORING
Paul Daniel Metzak1,2, E. Ngan1, T. S. Woodward1,2
1Psychiatry, University of British Columbia, Vancouver, BC,
Canada; 2BC Mental Health and Addictions Reasearch Institute,
Provincial Health Services Authority, Vancouver, BC, Canada
Previous research suggests that the dysfunctional cognitive operations
underpinning hallucinations in schizophrenia overlap with those leading
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to inner/outer (ie, self/other) confusions in source memory. Specifically,
associations are observed between internal-to-external source misattri-
butions (ie, externalizations) and hallucinations. In the current study
we investigated the neural underpinnings of this association using func-
tional magnetic resonance imaging (fMRI). 10 hallucinating and 14 non-
hallucinating patients with schizophrenia alternated between saying and
hearing words prior to scanning. During scanning, each of these words
was displayed visually, and subjects were required to indicate, by key-
press, whether they had previously said or heard the words. A control
condition was included that involved task monitoring. For this, subjects
alternated between reading and providing a semantic associate to words
prior to scanning. During scanning, each of these words was displayed
visually, and subjects were required to indicate, by keypress, whether
they had previously read or associated the words. Constrained principal
component analysis for fMRI (CPCA for fMRI) was used to identify
connected neural networks that differed between hallucinating and non-
hallucinating patients. The importance of each component in each peri-
stimulus scan and in each condition of interest was computed, and
these values were compared across patient groups in a mixed-model
repeated measures ANOVA in SPSS. A component involving the right
hippocampus and superior temporal cortex followed a different time-
course for hallucinating compared to nonhallucinating patients, and
the difference between the patient groups also depended on whether
they were carrying out the source monitoring or task monitoring (con-
trol) condition. These results suggest that the association between exter-
nalizations and hallucinations in schizophrenia may result from
differences in functionally connected networks involving the right hip-
pocampus and superior temporal cortex. These findings concur with
previous research describing significant activation of the right temporal
cortex in schizophrenia patients during hallucinations, and while making
external misattributions.
ID: 551879
DELUSIONS OF REFERENCE AND ABNORMALI-
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Certain classes of delusions- including delusions of reference and perse-
cutory delusions may be characterized by abnormalities in social cogni-
tion- such as the misinterpretation of ambiguous but potentially self-
relevant stimuli or a misunderstanding of the intentions of others.
Both these processes require metacognitive evaluations of external so-
cially relevant stimuli. A growing body of research has begun to examine
the neural systems underlying the appraisal of the self and others and
implicates a number of regions including the medial prefrontal cortex,
anterior and posterior cingulate cortex and precuneus (collectively
known as the cortical midline structures- CMS), and a number of sub-
cortical areas including striatal, limbic and paralimbic regions. We hy-
pothesized that patients with delusions of reference would show
abnormal neural activity in processing socially relevant information-
particularly when they are required to make metacognitive evaluations
about others. In the current fMRI study schizophrenia patients with
prominent delusions of reference (N = 13) and healthy controls (N =
15) were presented with trait adjectives and were asked to make yes/
no judgments in three different conditions: a self referential evaluation
(SE), where participants had to judge whether the trait words were
true of them, a significant other-evaluation (OE), where participants
had to judge whether the traits were descriptive of a significant other,
and a non-referential semantic positivity evaluation. We hypothesized
that both referential conditions (SE and OE) would evoke activity along
the CMS, and that patients with delusions would show differential activ-
ity in processing information about significant others. As predicted, both
referential conditions showed robust activity along the CMS in both
groups. As per our second hypothesis, the significant other versus self
evaluation contrast revealed that deluded patients showed greater activ-
ity in the amygdala and other limbic structures, while controls showed
greater activity in the mPFC and cortical structures relative to the
patients. We hypothesize that these differences in neural activity-
particularly increased activity in the limbic system (which is intimately
connected to the CMS) in the patient group during the metacognitive
evaluation of other people might play a role in the misinterpretation
of external social stimuli, thus leading to delusional ideation.
ID: 551869
ABNORMAL NEURAL SYNCHRONY OF CORTICAL
SOURCE SIGNALS DURING SPATIAL WORKING
MEMORY TASK IN SCHIZOPHRENIA PATIENTS
Seung Suk Kang1,2, E. M. Bernat1, S. Aviyente3, M. V. Chafee5,
C. Im4, A. W. MacDonald1,5, S. R. Sponheim1,2
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Seoul, South Korea; 5Neuroscience, University of Minnesota,
Minneapolis, MN, USA
Schizophrenic symptoms have been known to be associated with func-
tional integration deficits in neural dynamics. It has been posited that
the gamma frequency band power reflects functional integration in local
neural circuits involved in specific cognitive functions. On the other
hand, the synchronous neural activity across distant cortical regions
has received much attention as an index of long-range functional integra-
tion, in which distant neurons coordinate to generate various complex
cognitive functions. It has been found that schizophrenia patients exhibit
both diminished gamma band power and synchrony while they perceive
complex visual objects. We have found that schizophrenia patients ex-
hibit reduced gamma band power modulation associated with spatial
working memory (SWM) task performance over dorsolateral prefrontal
cortex (DLPFC) and posterior parietal cortex (PPC). To investigate ab-
errant neural synchrony of gamma activity between these cortical
regions, we acquired 248 sensor magnetoencephalography (MEG) signals
from schizophrenia patients and nonpsychiatric control subjects while
they perform SWM task. Cortical source time series signals of these
regions were generated by consecutive inverse problem solving with in-
dividual structural magnetic resonance image (MRI) and minimum norm
algorithm, which were applied for every time points of the MEG sensor
signals. With the cortical source signals, we computed phase synchrony
estimates between cortical regions involved in SWM for 5 frequency
bands (delta, theta, alpha, beta, and gamma). To yield uniform resolution
of phase synchrony across brain regions we applied a novel reduced in-
terference distribution method to avoid the trade-off between time and
frequency evident in wavelet analysis. Analyses revealed that schizophre-
nia patients failed to exhibit gamma synchrony modulation between left
DLPFC and right PPC and between left DLPFC and right inferior
frontal cortex according to SWM load. These results will be discussed
regarding the role of gamma synchrony in SWM deficits and schizo-
phrenic symptoms.
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DEVELOPMENT OF RESTING STATE NETWORKS
FROM BIRTH TO AGE 2 YEARS
John H. Gilmore1, Q. Zhu2, W. Gao2, Y. Chen2, C. H. Toh2,
M. Styner1, G. Gerig3, J. K. Smith2, B. Biswal2, W. Lin2
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3Scientific Computing and Imagaing, University of Utah, Salt Lake
City, UT, USA
People with schizophrenia have evidence of abnormal resting state net-
works. To better understand the development of these networks in humans,
we used resting functional MRI to depict brain regions exhibiting temporal
synchronization, also known as resting brain functional connectivity (rfc),
to determine the temporal and spatial patterns of rfc in healthy children
between 2wks and 2yrs old. Resting brain functional connectivity was per-
formed on 85 children: 38 neonates (2–4 wks), 26 1yr olds and 21 2yr olds.
All subjects were imaged while asleep; no sedation was employed. Six
regions-of-interest (ROIs) were chosen, including the primary motor, sen-
sory, and visual cortices in each hemisphere. Mean signal of each ROI was
used to perform correlation analysis pixel-by-pixel throughout the entire
brain, identifying regions with high temporal correlation. Functional con-
nectivity was observed in all subjects in the sensorimotor and visual areas.
The percent brain volume exhibiting rfc and the strength of rfc increased
from 2wks to 2yrs. The growth trajectories of the percent brain volume of
rfc appear to differ between the sensorimotor and visual areas while the z-
score is similar. The percent brain volume of rfc in the sensorimotor area is
significantly larger than that in the visual area for 2wks (P = .008) and 1yr
(P = .017) olds but not for the 2yr olds. These findings suggest that rfc in the
sensorimotor precedes the visual area from 2wks to 1yr but becomes com-
parable at 2yrs. In contrast, the comparable z-score values between the sen-
sorimotor and visual areas for all age groups suggest a disassociation
between percent brain volume and the strength of cortical rfc. Ongoing
studies of the development of the default network will also be presented.
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ALTERED PREFRONTAL-PARIETAL PHYSIOLOGY
DURING OLD-NEW ITEM RECOGNITION IN
SCHIZOPHRENIA: A MULTIMODAL NEUROI-
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Prefrontal-parietal networks are essential to many cognitive processes, in-
cluding the ability to differentiate new from previously presented items.
Given the well-documented recognition memory performance decrement
in patients with schizophrenia (compared to healthy individuals), we hy-
pothesized that these patients might demonstrate task-related abnormali-
ties in prefrontal and parietal physiology as measured by both functional
magnetic resonance imaging (fMRI) and magnetoelectroencephalography
(MEG). A total of 18 medicated outpatients with schizophrenia and 18 age-
matched healthy control subjects participated. Subjects underwent an old-
new item recognition paradigm during scanning with both fMRI (using
a 1.5 T Siemens Avanto whole-body clinical scanner) and MEG (using
a dc-SQUID Neruomag Vectorview system). During encoding blocks, par-
ticipants saw and heard 26 words and identified the gender of the recorded
voice using a keypad button. Immediately following encoding, participants
were presented with 52 words (26 previously presented and 26 new) and
were asked to specify whether each word was new, or previously presented
by a male or female voice. While controls exhibited strong, bilateral acti-
vation of prefrontal and posterior parietal regions during successful iden-
tification of old versus new items, patients showed markedly attenuated
activation of the right prefrontal and parietal cortices. However, among
the patient group, those with better performance activated more strongly
these right-sided regions, and unlike in controls, old-new effect-related
activations in frontal and parietal regions were tightly correlated. As
seen with the finer temporal resolution of MEG, control subjects—but
not patients—exhibited a sequential pattern of old> new electrical activity
in the left posterior parietal cortex and then right prefrontal cortex; how-
ever, patients uniquely exhibited old > new activity in right temporal cor-
tex, a region not usually implicated in old-new item recognition processing
in healthy subjects. Collectively, these findings point to markedly different
distributions of regional specialization necessary to complete the old-new
item recognition task in patients versus controls. Inefficient utilization of
prefrontal-parietal networks, with compensatory activation in temporal
regions, may thus contribute to deficient old-new item recognition in
schizophrenia.
ID: 551767
DISTINGUISHING EFFECTS OF SCHIZOPHRENIA
AND IQ DECLINE ON BOLD FMRI ACTIVATION
Steven Graham1, J. Jiang1, V. C. Manning1, H. M. Chan1,
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P. J. McKenna3
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Many previous fMRI studies examining functional brain differences in
schizophrenia are confounded by differences in intelligence score (IQ) be-
tween patients and healthy controls. Patients’ IQ is often below 100,
whereas those of age and education matched controls are usually much
higher. Using a variation of the Wisconsin Card Sorting Test (WCST),
a standard neuropsychological test (modified for use in fMRI), we inves-
tigated brain activation in a group of high functioning schizophrenia
patients and two groups of healthy controls that were matched either in
terms of their current IQ or premorbid IQ. The results have significant
implications for any researchers trying to distinguish which BOLD
fMRI differences relate to IQ decline or schizophrenia itself. 12 patients
with diagnosis of schizophrenia were matched to 12 healthy controls on
the basis of premorbid (WTAR) IQ, and to another 12 on current
(WASI) IQ estimates. Age, education, sex, and SES were matched between
groups. All subjects then performed the modified WCST during fMRI.
BOLD fMRI (TR = 3s; FA = 90; matrix = 64 x6 4; FOV = 192 x 192;
780 volumes of 32, 3 mm slices acquired parallel to AC-PC plane) was per-
formed on a 1.5 T Siemens Symphony MRI scanner. Motion correction, 8
mm FWHM smoothing, and Talairach transformation was performed
prior to random effects general linear modeling using FIR deconvolution
(BrainVoyager QX v1.10, Brain Innovation, Holland). Voxels above
threshold (corrected P< .05) were considered significant. Significant group
differences were found in several regions, including dorsolateral prefrontal
cortex (DLPFC) and posterior parietal cortex. In these regions, hypoactiv-
ity was found for low IQ relative to high IQ subjects. Previous fMRI studies
have noted DLPFC hypoactivity for schizophrenics (in whom IQ is lower)
relative to healthy controls (with higher IQ). The present study therefore
raises the possibility that DLPFC hypoactivity, which was previously as-
cribed to schizophrenia, may instead simply reflect reduced intellectual
function in these patients. Caution is therefore needed when interpreting
fMRI studies with patients in whom IQ may be affected. To avoid potential
confounds, stricter IQ matching is required.
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THE DEVELOPMENT OF AN AUTOMATED TOOL
FOR THE DETECTION OF FMRI ACTIVITY PAT-
TERN ASSOCIATED WITH SCHIZOPHRENIA
Jong H. Yoon1, D. Nguyen2, M. H. Minzenberg1, S. Ursu1,
J. D. Ragland1, C. S. Carter1
1Psychiatry, Univ. Cal. Davis, Sacramento, CA, USA;
2Biostatistics, UC Davis, Davis, CA, USA
Background: The development of objective, laboratory based diagnostic
tools would significantly augment our ability to accurately identify individ-
uals suffering from or at high risk of developing schizophrenia. Here we
report on our efforts to use automated multivariate pattern analysis to dif-
ferentiate fMRI activation patterns from individuals with schizophrenia
from healthy subjects. Method: 25 patients with first episode schizophrenia
and 24 demographically matched healthy control subjects underwent fMRI
scanning while they completed the AXCPT. A non-linear neural network
based pattern classifier analyzed DLPFC seeded functional connectivity
maps of the contrast between B Cue (high cognitive control) and A Cue
(low cognitive control) conditions. Training and testing was conducted us-
ing a jack-knife or n-1 cross-validation procedure in which the subject’s
data to be tested (classified) was excluded from the training set in an iter-
ative manner. Results: The pattern classifier achieved overall diagnostic ac-
curacy of 75.5%, identifying 72% of patients and 79% of controls correctly.
Conclusion: Automated diagnosis based on fMRI activation pattern anal-
ysis achieved fairly high accuracy, suggesting that this procedure is a viable
method to assist in the assessment and diagnosis of individuals with or
thought to be at risk for schizophrenia.
ID: 551750
PRACTICE-INDUCED CHANGES IN NEURAL CIR-
CUITRIES SUPPORTING SACCADE PERFOR-
MANCE IN SCHIZOPHRENIA: AN FMRI STUDY
Benjamin Piya Austin1, K. A. Dyckman2, M. T. Amlung1, Q. Li1,
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Decreased prefrontal cortex (PFC) function is hypothesized as a key deficit
in people with schizophrenia. PFC circuitry supports higher level executive
control processes such as inhibition. A simple test of inhibition is provided
by an antisaccade task, which requires a glance to the mirror image of a pe-
ripheral cue. People with schizophrenia make more antisaccade errors to-
wards the cue and have lower PFC activity than healthy participants. The
extent to which PFC activity may be enhanced to possibly improve exec-
utive control in schizophrenia is uncertain. Recent studies from our labo-
ratory showed that in healthy people daily antisaccade practice improves
antisaccade performance, while daily prosaccade practice disrupts antisac-
cade performance. These behavioral changes are accompanied by quantifi-
able changes in brain activation. The current study was designed to
determine whether neural pathways supporting antisaccade performance
in schizophrenia are modified across time. People with schizophrenia
and healthy comparison subjects took part in a 2-week trial. Testing eval-
uated anti- and pro-saccade performance in a 3-Tesla fMRI environment at
3 time points, each separated by a week; 1) Pre-Test, 2) Mid-Test, and 3)
Post-Test. Subjects were assigned to a practice group (either antisaccades or
prosaccades) and between fMRI testing sessions completed daily practice
sessions on the assigned task. The behavioral results were similar to pre-
vious studies; at Pre-Test, participants with schizophrenia had normal pro-
saccade performance, but made more antisaccade errors. The imaging
results across groups illustrated typical saccadic circuitry including: supple-
mentary eye fields (SEF), frontal eye fields (FEF), posterior parietal cortex
(PPC), visual cortex, cingulate gyrus and caudate, with thalamus and pre-
frontal cortex (PFC) observed in the antisaccade task. The schizophrenia
group, however, showed brain activation patterns that differed from com-
parison subjects. For instance, signal associated with task performance was
modified differentially over the three time points. Group differences were
observed in SEF, FEF, PPC, and PFC. This study may have implications
for understanding the malleability of activity in PFC and its associated cir-
cuitry in people with schizophrenia. This research was supported by a grant
from the National Institute of Mental Health (MH076998).
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PERCEIVED REALITY AND LOUDNESS OF AUDI-
TORY VERBAL HALLUCINATIONS IS ASSOCIATED
WITH REDUCED CONNECTIVITY BETWEEN
THALAMUS AND AUDITORY CORTEX: AN FMRI
STUDY IN SCHIZOPHRENIA PATIENTS
Andre Aleman1, E. Liemburg1, H. Knegtering2, R. Bruggeman2,
J. A. Jenner2, B. Curcic-Blake1, A. Vercammen1
1BCN NeuroImaging Center, Department of Neuroscience,
University Medical Center Groningen, Groningen, Netherlands;
2Psychiatry, University Medical Center Groningen, Groningen,
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Auditory hallucinations (AVH‘s) are a prominent and often disabling symp-
tom of schizophrenia, that may interfere with social functioning. There may
be considerable differences between patients in terms of severity of AVH‘s,
however. The neural correlates of phenomenal aspects such as loudness and
perceived reality of hallucinations has not been studied as yet. In this study
we investigated whether perceived reality and loudness of auditory verbal
hallucinations would be associated with abnormal functional connectivity
between thalamus and auditory cortex, which are key nodes in the auditory
system. Eighteen schizophrenia patients with active hallucinations in the
week prior to scanning underwent a resting state fMRI scan (TR = 2.3 s;
200 volumes). All patients filled out the Auditory Hallucinations Rating
Scale (AHRS). Regions of interest were delineated with help of a brain atlas,
and included the thalamus and auditory cortex. The Pearson‘s correlation
coefficient was calculated between both areas for each hemisphere seper-
ately, and converted to Z-scores. The frequency, reality and loudness items
of the AHRS were correlated with the Z-scores using the nonparametric
Spearman‘s rho. The results revealed that Z-scores of right thalamus—right
auditory cortex connection were negatively correlated with the reality (q =
0.585; P< .011) and loudness (q =0.617; P< .008) item. Thus, our find-
ings show that decreased connectivity between right thalamus and auditory
cortex are associated with more realistic and louder voices. We hypothesize
that a disconnection between these regions can lead to reduced bottom-up
control of the thalamus over spurious auditory activation.
ID: 551734
ELEVATED ACTIVITY WITHIN THE POSTERIOR
CINGULATE CORTEX IN SCHIZOPHRENIA
DURING SELF-REFLECTION
Daphne Jane Holt1, B. S. Cassidy1, S. M. Lee3, J. D. Gabrieli2,
D. C. Goff1, J. M. Moran2
1Psychiatry, Massachusetts General Hospital, Charlestown, MA,
USA; 2Brain and Cognitive Sciences, Massachusetts Institute of
Technology, Cambridge, MA, USA; 3Psychology, Yale University,
New Haven, CT, USA
Background: Schizophrenia is characterized by abnormalities in social cog-
nition and self-reflection. Functional neuroimaging studies in healthy
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subjects have found that social cognitive processes that require reflection on
the self or familiar others lead to activation of medial prefrontal and pos-
terior cingulate cortices. Results of previous studies in healthy participants
have suggested a role for the posterior cingulate cortex in episodic memory
processes, and involvement of the medial prefrontal cortex in semantic
aspects of self-reflection. However, it is not known whether one or both
parts of this network function abnormally during self-reflective processes
in schizophrenia. Methods: We measured activity within this network in 17
patients with schizophrenia and 18 demographically-matched control sub-
jects. Participants underwent functional MRI scanning while adjectives rep-
resenting desirable or undesirable personality traits (eg, ‘‘honest,’’ ‘‘lazy’’)
were presented. During scanning, participants were asked to judge whether
each word described themselves. In additional blocks, participants were
asked to judge whether an adjective described a familiar other (the partic-
ipant’s mother), and whether an adjective represented a good or bad quality
(a valence judgment). Activation elicited by the two social reflection tasks
was compared to activation elicited by the valence judgment task within the
medial prefrontal and parietal cortices within and between subject groups.
Results: The control and schizophrenia groups did not differ in their pat-
tern of response types during scanning. Also, both the control and schizo-
phrenia group exhibited activation of the medial prefrontal cortex during
social reflection. However, during both social tasks, the patients with
schizophrenia exhibited significantly greater activation within the right pos-
terior cingulate cortex than the healthy control subjects. Conclusion:
Greater engagement of the posterior cingulate cortex in schizophrenia dur-
ing social reflection may reflect an increased reliance on (or inefficient pro-
cessing of) episodic, autobiographical memory. Follow-up studies will
determine whether dysfunction of the posterior cingulate cortex in schizo-
phrenia is associated with impairment in social cognition and real-world
functioning.
ID: 551722
ABNORMAL BRAIN ACTIVATION DURING A -
VISUAL DISCRIMINATION FMRI TASK IN
INDIVIDUALS WITH SCHIZOPHRENIA AND
THEIR FIRST-DEGREE RELATIVES
David Matthew White1, K. Avsar1,2, L. Stoeckel1,2,
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1st degree relatives of individuals with schizophrenia (F) exhibit cogni-
tive abnormalities similar to those found in individuals with schizophre-
nia (SZ). Previous PET studies have shown that SZ exhibit abnormal
cingulate activation during matched-performance on auditory discrim-
ination tasks, but it is unclear whether F might also show similar pat-
terns. This study investigated brain activation found in SZ during a
matched-performance visual discrimination task and examined whether
these patterns represent a marker of cognitive dysfunction that is also
found in F. fMRI was used to compare 10 SZ, 5 F, and 8 controls
(C) who engaged in a matched-performance visual discrimination
task. The fMRI session consisted of 8 runs (20 trials/run; 12 task con-
ditions and 8 control presentations). The task condition consisted of 1 of
6 discrepancy levels. A correct response was a decision of equivalence or
nonequivalence between the two blocks. The control condition consisted
of a block that was offset to the left or right of the screen. A correct re-
sponse was selection of the offset side of the block. Preprocessed fMRI
data were analyzed in SPM5 by using a whole-brain approach in a mixed-
effects design. The task> control contrast during the decision period was
greater in SZ compared to controls in the bilateral superior Medial Fron-
tal Gyrus (MFG), right Superior Temporal Gyrus (STG), right inferior
frontal gyrus/operculum, left middle frontal gyrus, and left insula. C
showed similar activation in MFG and STG during the time period pre-
ceding the decision compared to SZ. F showed greater activation during
the decision period in left postcentral gyrus, left precuneus, and left cau-
date compared to C. C showed significantly greater activation in left cau-
date and right MFG during the time period preceding the decision.
Compared to C, SZ and F have different patterns of brain activation
during a visual discrimination task, despite similar performance on
the task. Assuming the pattern of activation found in C reflects an
efficient decision-making strategy; hypoactivation during the period pre-
ceding the decision may indicate a less efficient strategy for decision-
making in SZ and F. The widespread activation during the decision
period in SZ, but not F, compared to C reflects the greater magnitude
of dysfunction in this group. The abnormal pattern of brain activation
during the decision period may be a viable candidate as an Imaging
Marker of cognitive dysfunction for SZ.
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SEMANTIC MEMORY RETRIEVAL BRAIN
ABNORMALITIES IN SCHIZOPHRENIA: STATE
VS. TRAIT?
Michal Assaf1,2, K. Jagannathan1, M. Moult1, R. Lorenzoni1,
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The neural basis of Formal Thought Disorder (FTD) in psychoses is un-
known. An influential hypothesis is that FTD results from impaired se-
mantic memory processing. Using a functional MRI (fMRI) semantic
object retrieval task (SORT), we previously showed that chronic, stable
schizophrenia patients have impaired activation in semantic brain areas
when compared to healthy controls (HC). Furthermore, we found a cor-
relation between the rostral anterior cingulate cortex (ACC) activation
and patients’ FTD severity (Assaf et al. Biol Psychiatry, 59: 452–9). How-
ever, it is not yet known if these findings are related to state vs. trait of the
disease. In the current study we used the SORT to explore the neural cor-
relates of semantic memory retrieval in chronic schizophrenia patients
who were either stable (S-SZ; n = 13) or in a matched group of acute re-
lapsing phase (RL-SZ; n = 14) compared to matched HC (n = 17). SORT
requires participants to determine whether word pairs describing object
features combine to retrieve an object. One-way ANOVA demonstrated
a group difference in reaction time, such that HC were significantly faster
than S-SZ, who were faster than RL-SZ. Functionally, an ANCOVA
(controlling for full scale estimated pre-morbid IQ) demonstrated signif-
icant group differences in several brain areas, including: bilateral inferior
parietal lobule (IPL), dorsolateral prefrontal cortex, posterior cingulate
cortex and ACC, and left middle temporal cortex, such that HC had
greater activation than all schizophrenia patients (P < .01). Of these areas,
only the IPL showed a significant difference between the two schizophre-
nia groups, such that S-SZ showed greater activation (ie, were less abnor-
mal) than RL-SZ. These results suggest that while some brain
abnormalities are related to the general trait of the illness, IPL activation
depends on illness phase. The relationship of our findings to patients’
symptoms will be discussed. This work was partially supported by The
Patrick and Catherine Weldon Donaghue Medical Research Foundation
(PI: Assaf) and NIMH grants: RO1 MH-60504, R01 MH43775 and RO1
MH-52886 (PI: Pearlson).
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FRONTO-TEMPORAL HYPOACTIVATION DURING
PERFORMANCE OF A VIRTUAL WATER MAZE
TASK IN SCHIZOPHRENIA
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In the current study, we applied fMRI BOLD methods to investigate differ-
ences in brain activation in a group of schizophrenic patients compared to
a group of healthy control subjects during completion of a hippocampal-
dependent virtual water maze task. We focused on frontal and medial tem-
poral lobe (MTL) structures because previous studies have identified mem-
ory processing deficits as part of the core cognitive symptoms of
schizophrenia. These deficits could be mediated by NMDA receptor hypo-
function in fronto-temporal areas (Tsai and Coyle 2002). NMDA receptors
in the hippocampus and associated MTL structures are essential for spatial
learning and memory and that pharmacological blockade of NMDA recep-
tors impairs spatial navigation. Imaging data was acquired on a 3.0 Tesla
Varian MRI scanner. Fourteen schizophrenic patients (mean age 40.3
years; 3 females, 11 males) and fourteen age and gender matched controls
were included in the study. The water maze task consisted of 3 conditions:
encoding, retrieval, and motor. During encoding, subjects swam to a visible
platform that was always in the same spatial location and were instructed to
remember the location of the platform. During retrieval, the platform was
hidden and subject had to navigate to the correct location. The motor con-
dition tested the ability of subjects to navigate in the maze. Imaging data
was motion corrected and analyzed in SPM 5 (height threshold P < .005,
extent k=20 voxels). Contrasts were created using the motor condition as
a control condition. Our preliminary results showed lower activation in the
hippocampus, and dorsal and posterior cingulate cortex during the encod-
ing task. During the retrieval of spatial information, the decrease in acti-
vation was more widespread in schizophrenic patients, and included the
cerebellum, superior and inferior frontal gyri, middle temporal gyrus,
dorsal cingulate cortex, and posterior parahippocampal gyrus. These
findings suggest that memory deficits in schizophrenic patients could be
related to hippocampal deficits during encoding of information. Further
it suggests that spatial learning and recall in schizophrenia are associated
with dysfunctional fronto-temporal networks, rather than abnormalities in
a single region.
Reference
1. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu
Rev Pharmacol Toxicol. 2002;42:165–179.
ID: 551694
IMPAIRED METACOGNITIVE EVALUATIONS
AND HYPOACTIVITY OF THE NEURAL CIR-
CUITRY OF SELF-OTHER AWARENESS IN EARLY
SCHIZOPHRENIA
Benjamin Kalmin Brent1,2, E. Murphy3, M. S. Keshavan1,3,
M. Benton3, V. Diwadkar3, R. Rajarethinam3
1Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA,
USA; 2Public Psychiatry, Massachusetts Mental Health Center,
Jamaica Plain, MA, USA; 3Psychiatry, Wayne State University,
Detroit, MI, USA
Background: The neural correlates of deficits in metacognitive evalua-
tions (MEs) of self and others in schizophrenia are incompletely under-
stood. In healthy controls (HCs), self-other awareness activates the
medial prefrontal cortex, the posterior superior temporal sulcus (STS),
and the temporal poles bilaterally. We used functional magnetic reso-
nance imaging (fMRI) to evaluate differences in brain activity during
an ME task involving self-other awareness in patients in the early phase
of schizophrenia (EPS) and HCs. Methods: Eleven EPS subjects (diag-
noses based SCID interviews/DSM IV criteria for schizophrenia) (7
males; mean age 26.6 6 8.0) and 10 HCs (4 males; mean age 29.6 6
8.4) were recruited at Wayne State University. fMRI scanning was
obtained using a full body Brucker MedSped 4.0 T scanner and imaging
data was processed with statistical parametric mapping (SPM2) software.
The fMRI task required participants to provide yes/no responses to
adjectives in three separate descriptor-referential conditions: self-evalu-
ation, other evaluation, and non-referential semantic positivity-evalua-
tion. Single sample group t-tests were performed for each condition in
both groups, followed by second level between-group analyses. The
threshold p value was set to <0.005 and a voxel threshold = 50. Results:
The EPS group showed a significant decrease in activation of the poste-
rior left STS (FDR corrected P < .049) and a trendworthy decrease in
activation of the right middle frontal gyrus (FDR corrected P < .073)
during MEs of others compared to HCs. There were no significant group
differences in areas of activation during self-evaluative processes. Con-
clusion: To our knowledge, this is the first study of the neural correlates
of MEs regarding the self and others in EPS. Hypoactivity of the left STS
may provide the neural basis for disturbances in MEs of others associated
with failures of source monitoring and theory of mind (ToM) found in
patients with EPS. Deficits in MEs regarding others may mediate key
symptoms of psychosis (eg, delusions and auditory hallucinations) and
lead to misattributions regarding others’ intentions that contribute to
the functional disability of schizophrenia. Larger, prospective follow
up studies are required to further assess the relationships between de-
creased activation of neural circuits associated with awareness of others,
specific forms of metacognition (eg, ToM and source monitoring), and
the clinical/functional course of schizophrenia.
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DEVELOPMENTAL CHANGES IN FUNCTIONAL
ACTIVATION DURING WORKING MEMORY IN
ULTRA-HIGH RISK SUBJECTS AND HEALTHY
CONTROLS
Katherine Helen Karlsgodt1,2, J. H. Sanz5, T. G. van Erp1,
C. E. Bearden3,4, T. D. Cannon1,3
1Psychology, UCLA, Los Angeles, CA, USA; 2Semel Institute,
UCLA, Los Angeles, CA, USA; 3Psychiatry and Biobehavioral
Sciences, UCLA, Los Angeles, CA, USA; 4Brain Research Institute,
UCLA, Los Angeles, CA, USA; 5Behavioral Psychology, Kennedy
Krieger Institute, Los Angeles, CA, USA
Across adolescence and young adulthood ongoing neurodevelopmental
changes occur, including processes such as synaptic pruning and myeli-
nation, as the brain begins to settle into an adult-like architecture. Func-
tional and structural imaging studies indicate that there are observable
changes in both functional activation and grey matter density throughout
adolescence. This period of change represents a time of special vulnera-
bility for patients with schizophrenia; onset of the disorder occurs during
this period and is thought to be associated with either a disruption in this
developmental process or the exertion of a normal developmental process
on an already compromised system. Further, this period is of particular
interest in subjects at ultra-high risk for schizophrenia, as understanding
any dynamic developmental differences may offer a unique opportunity
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to identify points of intervention. Previous studies of brain development
indicate that patients with schizophrenia and controls may have different
trajectories of grey matter change over time, but this has not yet been
assessed using functional imaging. To assess these issues of neurodeve-
lopmental changes in the prodrome, we performed a cross-sectional anal-
ysis of ultra-high risk (UHR) and healthy control subjects ranging in age
from 12 to 26 years. A verbal Sternberg-style working memory task was
used as a functional probe of the working memory circuitry, which is
known to be compromised in schizophrenia. Subjects performed this
task while undergoing functional magnetic resonance imaging (fMRI)
scans. Using polynomial regression we assessed the differences between
the relationship of functional activation in the working memory circuitry
and age in UHR and control groups. The function defining the relation-
ship between age and neural activation in the UHR group differed from
that in controls, and may indicate a different developmental trajectory
in these subjects. This finding may have implications for our understand-
ing of functional neuroanatomic changes that occur leading up to the
onset of psychosis.
ID: 551652
SPECIFIC DEFICITS DURING MEMORY
FORMATION AS A MARKER OF SHORT-TERM
CLINICAL OUTCOME IN FIRST EPISODE
PSYCHOSIS: BEHAVIOURAL FMRI RESULTS
Michael Bodnar1,2, A. Achim4, A. K. Malla1,3, M. Lepage1,3
1Prevention and Early Intervention Program for Psychoses, Douglas
Mental Health University Institute, Montreal, QC, Canada;
2Neurology and Neurosurgery, McGill University, Montreal, QC,
Canada; 3Psychiatry, McGill University, Montreal, QC, Canada;
4Centre de Recherche Universite Laval Robert-Giffard, Universite
Laval, Quebec, QC, Canada
Background: Memory is one of the cognitive functions most affected in
schizophrenia with deficits observed from the first episode of psychosis
(FEP). Both short-term and long-term outcome have been related to var-
ious memory deficits. However, no previous study has examined specific
aspects of memory formation in relation to short-term clinical outcome in
FEP patients. Methods: To examine specific memory processes in FEP in
relation to clinical outcome. Behavioural fMRI data were collected in 55
FEP patients (32 poor outcome and 23 good outcome—based on six--
month clinical outcome) and in 32 matched healthy controls. Partici-
pants completed 2 fMRI encoding sessions each comprised of 56
different pairs—28 semantically unrelated items and 28 semantically
related items. They were cued to use one of two specific encoding
strategies—associative (ie, to compare the 2 images and answer which
of the two would be bigger in real life) or deep item-oriented (ie, to judge
whether one of the images represented a living entity). Recognition, not
accompanied by a fMRI session, was a yes/no answer for identifying
a previous pair with 112 pairs presented in each of two sessions. Results:
In general, compared to healthy controls, the FEP patients show a poor-
er recognition performance for arbitrary pairs relative to the semanti-
cally related pairs; supporting our previous finding with a smaller
sized sample. More particular to the patients, there was a significant
triple interaction (encoding strategy x semantic relatedness x group;
F = 13.18, P = .001). More specifically, the poor outcome group per-
formed worse than the good outcome group when using the associative
encoding strategy for semantically related pairs only. Conclusions: This
selective deficit that affects memory performance in FEP may confer
greater vulnerability to not only psychotic disorders but also to a poorer
outcome after six months of treatment. These findings may have ther-
apeutic implications.
ID: 551642
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WITH SCHIZOPHRENIA: AN FMRI STUDY
Ming Wei Wan1, H. Strachan2, D. Downey3, A. Wieck2,
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Bowlby suggested that parenting behaviour is likely to have biological
roots which produce unique, powerful emotions experienced by mothers
with new infants. We and others have previously reported that, when
healthy new mothers see their infants, an extensive brain circuit is acti-
vated, which integrates affective and cognitive information to direct ma-
ternal behaviour. We have also described a range of deficits in the
capacity of new mothers with schizophrenia to respond to infants.
This study begins to explore the relationship between maternal brain
responses and behaviour in schizophrenia. In this study we aimed to
use fMRI to examine the neural correlates of maternal responsiveness
in new healthy mothers and compare them to new mothers with schizo-
phrenia and present preliminary findings. 11 healthy and 7 new mothers
with schizophrenia (matched on age, education and infant age) undertook
an 8min fMRI task. Participants viewed alternating 30sec blocks of pre-
recorded video showing their own infant, an unfamiliar (age matched)
infant interspersed with neutral video (moving traffic). Whole brain
images were acquired on a 1.5T Philips Intera scanner using a TR of
2.55s. Data were analysed using SPM5. We replicated our findings in
healthy mothers: compared to neutral stimuli, new mothers showed wide-
spread visual activation (eg, BA19) when viewing infants. Ill mothers
viewing own baby vs neutral show decreases in orbitofrontal cortex
(OFC) (BA47) and frontal pole (BA10) activation relative to controls.
Viewing other baby vs neutral, ill mothers had a decrease in activation
in anterior cingulate (AC) and an increase in middle temporal gyrus
(BA21) relative to controls. Finally, when viewing just their own babies,
healthy mothers showed increased activity in AC (BA32), left amygdala,
right frontal pole (BA10), right putamen and hippocampus compared to
ill mothers. These findings suggest a blunted response to emotionally sa-
lient stimuli in ill mothers which may be related to their poor parenting
outcomes. Further studies aim to relate these effects to behavioural def-
icits in maternal responsiveness observed in mothers with schizophrenia.
ID: 551604
IMPACT OF PHARMACOTHERAPY ON
HIPPOCAMPAL VOLUME AND FUNCTION IN
SCHZIOPHRENIA
Mujeeb Uddin Shad, B. Thomas, P. Mihalakos, M. Faryal,
C. A. Tamminga
Psychiatry, UT Southwestern at Dallas, Dallas, TX, USA
Neuroimaging studies have reported deficits in hippocampal volume and
function in schizophrenia patients. Structural analyses, such as region of
interest (ROI), and functional imaging paradigms, such as novelty detec-
tion (ND), have been employed frequently to assess hippocampal volume
and function, respectively. However, too few studies have investigated re-
lationship between hippocampal volume and function. We have hypothe-
sized that ND-induced hippocampal activation with novel stimuli will
correlate with hippocampal volume. This is an ongoing study to examine
correlation between hippocampal volume and function in schizophrenia
subjects with (on-meds) and without (off-meds) antipsychotic medications.
These preliminary data are based on a partial sample in 14 right-handed
schizophrenia subjects with DSM-IV TR diagnosed schizophrenia or
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schizoaffective disorder and seven right-handed normal controls (NC; av-
erage age = 34.7 6 12.6; M/F = 2/5). Seven out of 14 schizophrenia subjects
are off-meds (average age = 36.7 6 10.1; M/F = 5/2) and seven are on-meds
(average age = 39.7 6 8.5; M/F = 6/1). Psychopathology is assessed with
Positive and Negative Syndrome Scale (PANSS) and cognitive function
with the Repeatable Battery to Assess Neuropsychological Status
(RBANS). Structural and functional MRI scans are obtained on a 1.5 T
GE system. Morphometric measurements are conducted on BRAINS 2
by a trained rater blind to clinical information and all hippocampal vol-
umes are adjusted for total brain volume (TBV). Our preliminary findings
show a larger right (t = 4.36; df = 12; P = .0009) and left hippocampal vol-
ume (t = 2.40; df = 12; P = .03) in NC as compared to off-meds schizophrenia
subjects. However, only the right hippocampal is larger in NC as compared
to on-meds schizophrenia subjects (t = 3.22; df = 15; P = .005). No signif-
icant differences in right or left hippocampal volumes are found between
on- and off-meds schizophrenia subjects. Likewise no significant associa-
tions are found between any TBV-adjusted hippocampal volumes and
PANSS or RBANS scores. Caution is required in the interpretation of these
preliminary findings as they are based on a small sample. Findings from
a larger sample will be reported later along with the analysis of relationship
between hippocampal volume and function.
ID: 551603
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Decreased prefrontal, but increased cerebellar activity has been associated
with cognitive deficits and negative symptoms in patients with schizophre-
nia. Here, we tested our hypothesis that theta burst stimulation (TBS) to the
left dorsolateral prefrontal cortex (DLPFC) or to the medial cerebellum
would produce a cognitive enhancing effect in patients. In a factorial, be-
tween-group design, 36 patients with chronic schizophrenia were assigned
to receive either 600 TBS pulses of left DLPFC facilitation (intermittent
TBS), cerebellar suppression (continuous TBS) or sham TBS at an intensity
of 80% resting motor threshold. Patients were scanned twice using the iden-
tical letter fluency task (which has been associated with prefrontal and cer-
ebellar activation), immediately before and after TBS. Functional data were
acquired using a 3T system, and were analysed using SPM2 (random-
effects, P < .001, uncorrected). Patients’ verbal responses during scanning
were recorded and scored off-line to produce total numbers of correct
responses, omission errors, clustering and switching. Following left
DLPFC TBS facilitation, there was significant increase of activation in
right DLPFC (BA 46), along with caudate nucleus, left medial prefrontal
cortex (BA 10) and left premotor area (BA 6). The increased right DLPFC
activation was associated with decreased number of omission errors (r =
.76, P = .005) and increased total number of clustering (r = .77, P
=.004). In the cerebellar TBS suppression group, areas activated more fol-
lowing TBS included left inferior frontal gyrus (Broca’s area) and inferior
parietal lobule (BA 40), bilateral superior temporal gyri (BA 22), pulvinar
of the thalamus, and anterior cerebellum (lobule III). The increased ante-
rior cerebellum activation following TBS was positively correlated with in-
creased number of switching (r = .78, P = .003). The sham group activated
right DLPFC (BA 46), but this activation was not related to performance
measures. In this study, we investigated the acute effect of TBS protocols on
DLPFC and cerebellar activity during fMRI. The results support evidence
that high frequency TMS produced increases activation in task-specific
brain areas in healthy volunteer studies. Hence, this study provides a scien-
tific justification for the design of further TBS experiments and clinical eval-
uation in patients with schizophrenia.
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BRAIN ACTIVATION CHANGES ON FMRI
FOLLOWING COMPUTERIZED COGNITIVE
TRAINING
B. E. Wexler, T. Constable, M. Bell
Psychiatry, Yale University, New Haven, CT, USA
Cognitive remediation in schizophrenia can be achieved through neural
‘‘restoration’’– restoring normal activity in brain regions that are active
during a task in healthy subjects, but are under- or over-active in patients
prior to treatment. It can also be achieved through neural ‘‘compensation’’–
changes in activity in brain regions in patients that increase (rather than
decrease) the differences between patients and healthy subjects. In this on-
going study, we asses the relative contribution of these two processes by
performing fMRI scans before and after 100 hours of computerized cog-
nitive remediation exercises. There are three subject groups: schizophrenia
patients receiving cognitive remediation, and patient and healthy subject
control groups. During both fMRI sessions, subjects perform three differ-
ent cognitive activation tasks: N-back with letter stimuli, color-word
Stroop, and Go-No go response inhibition. The use of three different tasks
allows further assessment of the nature of the underlying neuropathology as
well as its response to treatment. In our work to date, at baseline, patients
and healthy subjects show highly similar general patterns of activation dur-
ing all three tasks, indicating that the patients were successfully engaged in
the tasks. There are also significant differences between patients and con-
trols on all three tasks, the location of which differ among the tasks. These
data suggest that schizophrenia is characterized by impaired recruitment of
task-specific neural systems. Patients show changes after treatment (P <
.05) on all tasks, and these changes are in areas that do not show significant
change on re-testing in healthy controls. Nearly all changes are in areas in
which patients differ from healthy subjects pre-treatment, and serve to de-
crease these differences, thus suggesting neural ‘‘restoration.’’ The changes
are primarily in different anatomic locations on the three tasks, providing
preliminary evidence for system-level plasticity in the response to treat-
ment. If borne out in larger samples, these data will provide light on mech-
anisms of cognitive remediation, and guide further development of this new
and important treatment approach.
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DOES IV THC INCREASE THE AVAILABILITY OF
DOPAMINE IN THE STRIATUM?
Emma Barkus1, P. Morrison1, J. Dickson2, P. Ell1, L. Pilowsky1,
S. Kapur1, R. Murray1
1Institute of Psychiatry, London, United Kingdom; 2Neuroimaging,
Kings College Hospital, London, United Kingdom
Background: For centuries people have used cannabis to produce altered
state of consciousness. A wealth of evidence suggests that, in some individ-
uals, cannabis can induce an acute schizophrenia-like psychosis. Of the 66
individual cannabinoid molecules found in herbal cannabis,D9-tetrahydro-
cannabinol (THC) has been identified as the component underlying the psy-
chotomimetic effects. Despite the indirect evidence that psychotic
symptoms are attributed to alterations in the levels of the neurotransmitter
dopamine (DA), to date there is little evidence that administration of THC
in humans leads to an increase in DA levels. Furthermore it is unknown if
excess striatal dopamine underlies the psychotomimetic properties of THC.
Method: Under randomised, double-blind, placebo-controlled conditions
we used IBZM-single photon emission tomography (SPET) to measure
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striatal dopamine D2/D3 receptor availability, prior to, and following
a challenge with intravenous THC (2.5mg). Ten male healthy volunteer
completed two IBZM-SPET scanning sessions. Receptor availability was
calculated using a region-of-interest approach, using a reference region
to control for non-specific binding. Psychotic symptoms were rated using
the PANSS scale. Results: Administration of THC increased positive psy-
chotic symptoms (z = 2.5, P = .01). Differences in striatal dopamine re-
lease under placebo versus THC sessions were compared. Initial analysis
suggests that THC increases DA release in the striatum. Conclusion:
The administration of THC does lead to the experiencing of psychotic
symptoms in otherwise healthy males and preliminary analysis suggests
it also increases DA release in the striatum. The relationship between
THC-psychosis and THC-DA release will be discussed further.
ID: 551525
MODAFINIL EFFECTS ON PREFRONTAL
CORTEX DURING COGNITIVE CONTROL IN
SCHIZOPHRENIA: A PHARMACO-FMRI STUDY
Michael Minzenberg, A. J. Watrous, J. H. Yoon, J. Nunez del
Prado, S. Ursu, J. D. Ragland, C. S. Carter
Psychiatry, University of California Davis, Sacramento, CA, USA
Background: Schizophrenia is characterized by dysfunction of prefrontal-
dependent cognition. This prominently includes impairments in cognitive
control and its basis in a cortical network centered on the dorsolateral PFC
(DLPFC) and anterior cingulate cortex (ACC). These PFC areas are also
strongly modulated by catecholamines, and there is evidence that pro-cat-
echolaminergic agents improve PFC-dependent cognitive performance in
animal models and in humans. We sought to test whether the novel agent
modafinil exerts a remediating effect on PFC-dependent cognitive dysfunc-
tion in schizophrenia. Methods: To date, 12 adults with clinically-stable
chronic schizophrenia participated in a double-blind, placebo-controlled
crossover study of a single oral dose of modafinil 200 mg. Subjects were
scanned 3–4 hours after dosing, and performed the Preparing to Overcome
Prepotency (POP) task during slow event-related fMRI with GLM-based
analysis of BOLD contrast. In the POP task, color cues are presented which
signal congruent (Green Cues) versus incongruent (Red Cues) stimulus-re-
sponse mappings to subsequent targets (left or right-pointing arrows). Cue-
Target delay period activity is elicited in DLPFC as a measure of context
processing, whereas Post-Target period activity is elicited as a measure of
conflict monitoring in the ACC. Both regional BOLD responses are stron-
ger after Red Cues. Results: To date, the patients show higher delay-period
DLPFC and ACC activity on modafinil compared to placebo, particularly
for Red Cue-related activity, with improved performance. Conclusions: A
single dose of modafinil is associated with improved DLPFC activity during
context processing. Additional studies are underway to evaluate the relative
effects of single-dose versus sustained modafinil treatment.
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ANHEDONIA AND SUBJECTIVE EMOTIONAL
EXPERIENCE IN SCHIZOPHRENIA: AN FMRI
STUDY
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Emotional disturbances such as anhedonia and flat affect are well-known
clinical features of schizophrenia (SCZ), but self-report data suggests that
emotional experience is intact in SCZ. We explored this disconnect among
different components of emotion in SCZ by using fMRI to examine brain
activity in response to affect-eliciting stimuli and its relationship to clinical
measures of anhedonia. 40 SCZ and 32 demographically matched controls
(CON) made arousal and valence ratings to pictures, words, and faces that
varied in both arousal and valence. Behaviorally, the pattern by which the
ratings were modulated by the emotional content of the stimulus was the
same in SCZ and CON. fMRI analysis revealed that the pattern of func-
tional activity varied with the valence and arousal characteristics of the
stimuli in largely the same way in SCZ and CON. Contrast analyses sen-
sitive to the valence and arousal characteristics of the stimuli revealed no
differences between groups in a whole-brain analysis, or in an ROI analysis
of the amygdala. An ROI analysis of the basal ganglia, however, revealed
a group difference in which SCZ showed reduced activity to positive stimuli
as compared with controls. This suggests a possible role of abnormal basal
ganglia activity in anhedonia in SCZ. To examine the relationship between
emotional experience and individual differences in clinical measures of an-
hedonia, we correlated the behavioral ratings and the fMRI data with
SANS global anhedonia and Chapman physical and social anhedonia
scores. While SCZ showed greater anhedonia overall, greater anhedonia
was associated with less-valenced (ie, more neutral) ratings of the emotional
stimuli in both groups. Furthermore, in both groups, greater anhedonia
was associated with reduced amygdala activity to positive stimuli as com-
pared to negative and neutral stimuli. The basal ganglia, however, showed
opposite patterns between the two groups. In CON, greater anhedonia was
associated with less activation to positive versus neutral and negative stim-
uli. In contrast, SCZ showed greater anhedonia in association with greater
activation to positive versus neutral and negative stimuli. Together, these
results suggest that subjective emotional experience and its associated brain
activity are largely intact in SCZ, with the exception of activity in the basal
ganglia, which shows blunted responses to positive stimuli and an abnormal
association with symptoms of anhedonia.
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PREFRONTAL BRAIN SYSTEMS IN
SCHIZOPHRENIA AND PUTATIVE INTERACTING
DOPAMINERGIC GENE MECHANISMS
Hao-Yang Y. Tan, Q. Chen, K. K. Nicodemus, R. E. Straub,
B. Kolachana, A. Meyer-Lindenberg, Y. Sei, V. S. Mattay,
J. H. Callicott, D. R. Weinberger
Clinical Brain Disorders Branch, National Institute of Mental
Health, Bethesda, MD, USA
Schizophrenia has complex genetic heritability. It is also likely to be genet-
ically heterogeneous. To the extent that genes are associated with symptom
constellations of schizophrenia, they do so by affecting the development and
function of brain cells and neural systems that mediate the expression of such
diverse behavioral, cognitive and perceptual phenomena. While precise
mechanisms of human brain dysfunction remain to be well understood, do-
paminergic brain processes have been well implicated in the cognitive dys-
function and symptomatic treatment response in schizophrenia, and is an
important foothold to elucidate disease mechanisms. Here, we will review
recent findings of aberrant neural correlates of prefrontal brain systems en-
gaged by disease-associated working memory processes, particularly execu-
tive processes tapping rapid updating of information in working memory
(Tan et al. Am J Psychiat2006). We will extend observations of dysfunctional
brain network physiology to explore its underlyingdopaminergicgene mech-
anisms using ‘imaging genetics’, an emerging field that attempts to integrate
the basic biology of putativegenetic mechanisms of disease with intermediate
brain-based neuroimaging phenotypes from the live functioning human
brain. In this regard, we will review recent imaging genetics findings of pre-
frontal-striatal working memory updating and executive processes mediated
by dopamine-associated signal-to-noise processing (Tan et al. J Neurosci
2007). Further, we will examine genetic variation in pathways of interacting
dopaminergic and glutamatergic systems implicated in schizophrenia (eg
COMT and GRM3), and their modulation of prefrontal brain physiology
(Tan et al. PNAS 2007); we will also examine recent suggestions that down-
stream dopamine-associated intra-cellular signaling molecules (eg AKT1)
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are implicated (Tan et al. J Clin Invest 2008). In conclusion, these findings
suggest that emerging developments in imaging genetics to examine multi-
gene pathways could potentially provide a viable platform to understand
human genetic mechanisms of cognitive brain processes relevant to neuro-
psychiatric diseases such as schizophrenia.
ID: 551454
FUNCTIONAL NEUROIMAGING FOLLOWING
COGNITIVE REMEDIATION IN SCHIZOPHRENIA
Margaret E. Balfour, D. Moore, B. Thomas, C. Tamminga
Psychiatry, UT Southwestern, Dallas, TX, USA
Cognition has become a focus of treatment development in schizophrenia
(SCZ), due to the adverse effect that cognitive dysfunction has on psycho-
social outcome in the illness. However, despite promising preclinical data,
pharmacological interventions have not yielded improvements in cognition.
Therefore, it has been hypothesized that the implementation of pharmaco-
logical treatments may require a behavioral component in order to become
manifest. Cognitive remediation (CR) is a behavioral intervention that
appears increasingly promising in improving both cognitive function
and psychosocial outcomes in individuals with SCZ. Moreover, it holds
considerable face validity, given current knowledge of brain plasticity
mechanisms and their reliance on repetition to change function. However,
few studies have investigated the effect of CR on brain function. Cognitive
deficits in SCZ have been correlated with changes in rCBF in multiple brain
areas, and it is hypothesized that CR may normalize these deficits. We de-
veloped a four-cell intervention designed to test two treatments (atomox-
etine and cognitive remediation) alone and together in people with stable
SCZ and demonstrable cognitive dysfunction. We have carried out an in-
terim analysis with an N = 6 in each of four groups (atomoxeti-
ne[A]þcontrol[Con]; Aþcognitive remediation[CR]; placebo[P]þ Con;
PþCR) , to look both at symptom and cognition outcomes and at potential
biomarker outcomes represented by changes in functional imaging charac-
teristics. Here we report the outcomes of CR vs Con in individuals with SCZ
who have participated in CR three times weekly (60–90 min) for 12 weeks
using CACR-developed software. These volunteers participated in MR im-
aging before and after the intervention, while performing the N-Back task
with fMRI BOLD assessment. Voxel-wise analysis using SPM software
allowed us to contrast the group of individuals with active cognitive reme-
diation vs similarly treated computer control individuals. In the CR minus
Con contast (1-back minus 0-back), there was a significant increase in fMRI
BOLD signal following CR in the regions corresponding to the tertiary vi-
sual cortex; whereas, in the Con minus CR contrast(1-back minus 0-back),
the regions where CR diminished activations was in the prefrontal cortex,
particularly in the middle frontal gyrus. These results suggest that CR
increases the use of sensory regions of the brain while enhancing processing
efficiency of association areas.
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TEMPORAL BRAIN ACTIVATION DURING IRONY
COMPREHENSION
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M. Erb2, R. Saur2,1, M. M. Hensler1, B. Wild1, W. Grodd2
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A failure to decode ironic meanings during language comprehension in
schizophrenia has been documented by a number of recent studies. Recent
work assumed a similar deficit in subjects with schizotypal personality traits
(Langdon and Coultheart, 2004). Most authors suggested a theory of mind
deficit is crucial for irony comprehension deficits in schizophrenia, however
the underlying pathophysiology and neurobiology is unknown and recent
research accents a possible role of language comprehension abnormalities.
The aim of this work was to detect fMRI brain activation changes associ-
ated with schizotypal personality traits during irony comprehension. We
hypothesised that either a frontomedial (theory of mind) or lateral temporal
(language abnormalities) activation deficit is associated with schizotypy. 15
female right-handed subjects (age 20–53 years) completed personality test-
ing as well as functional magnetic resonance imaging and neuropsychology.
Subjects were recruited from the general population. No subject had life-
time history of relevant psychiatric disorder or treatment, however subjects
differed in their score on the German version of the Schizotypal Personality
Questionaire (SPQ). During the fMRI-scans, subjects silently read 44 short
text vignettes which ended in either an ironic or literal statement. Imaging
was performed using a 3 T Siemens scanner. The influence of schizotypy on
brain activation was investigated by using a SPM5 regression analysis with
the SPQ total score and SPQ cognitive-perceptual factor as regressors.
There was no effect of schizotypy on behavioral data. However, during
reading of ironic sentences, brain activation in the temporal lobe of
both hemispheres showed a significant negative association with the
SPQ total score and SPQ cognitive perceptual factor. Significant positive
correlation with the SPQ total score was present in the left inferior frontal
gyrus. We conclude attenuated temporal lobe activation is associated with
brain activation during pragmatic language comprehension in schizotypy.
Structural and functional abnormalities in the middle temporal gyrus, a key
region of language comprehension, have been shown in previous research in
both schizophrenia and schizotypy. Recently, Sievers (Sievers and Davis,
2004) suggested a temporal deficit is compensated in the lateral prefrontal
cortex in schizotypy, but not schizophrenia. The brain activation pattern in
our study could support this model.
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THE EFFECTS OF HALOPERIDOL AND
ARIPIPRAZOLE ON AUDIO-VISUAL MATCHING
IN HEALTHY VOLUNTEERS: AN FMRI STUDY
Rowena Handley, S. Reinders, T. Marques, C. Pariante,
P. McGuire, P. Dazzan
Institute of Psychiatry, Kings College London, London, United
Kingdom
Deficits in the integration of information from different sensory modalities
are present in excess in patients with schizophrenia. The contribution of
antipsychotic medication to such deficits, independent of the pathophysi-
ology of the disorder, remains poorly understood. This study investigates
the functional impact of antipsychotics in healthy volunteers. Haloperidol
(3mg) and Aripiprazole (10mg) were administered to 10 healthy Caucasian,
right handed males (age: 21, SD:3) in a repeated measures, counterbalanced
placebo controlled design. Volunteers had no past psychiatric history and
abstained from smoking and recreational drug use for at least 3 months
prior to the study. Images were acquired on a 1.5T scanner whilst a compu-
terised version of the audio-visual integration sub-test of the Neurological
Evaluation Scale (Buchanan and Heinrichs, 1989) was administered. In this
task volunteers listened to an auditory paced tone sequence (varying in
length), then selected either the visual representation of the auditory se-
quence from three different options, or selected the ‘forced choice’. Ran-
dom effects analysis was performed in SPM5. Haloperidol significantly
reduced overall activation in the left superior and right middle temporal
gyri and left cerebellum compared with placebo, and in the right superior
temporal gyrus and left cerebellum compared with Aripiprazole. In the ex-
perimental relative to control condition, activation was greater after Ari-
piprazole in the right insula compared with Haloperidol and in the
cerebellum bilaterally, compared with placebo. Reduced activation in
the right inferior frontal gyrus was observed in the experimental relative
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to rest condition, in the Haloperidol group compared with placebo. In ac-
cordance with the literature in individuals with psychosis, compared with
placebo and Aripiprazole, Haloperidol was associated with reduced activa-
tion in regions known to be involved in audio-visual matching (frontal, tem-
poral, cerebellar, insula). Although structural abnormalities in these areas
have been identified in patients, evidence for the contribution of antipsy-
chotics to sensory integration deficits are mixed. These findings indicate
that sensory integration functioning is altered by even a single dose of an-
tipsychotic medication. This implicates a role for antipsychotics in sensory
integration deficits observed in treated patients with Schizophrenia.
ID: 551396
HIGH-FREQUENCY OSCILLATIONS DURING
PERCEPTUAL ORGANISATION IN CHRONIC AND
FIRST-EPISODE SCHIZOPHRENIA PATIENTS
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Recent evidence suggests that patients with schizophrenia are characterized
by reduced synchronous, oscillatory activity in the beta- and gamma-band
range that may index a core dysfunction in the coordination of distributed
neural activity. However, it is currently unclear to what extent high-fre-
quency oscillations (>60Hz) contribute to impaired neural synchronization
as research has so far focussed on gamma-band oscillations between 30–60
Hz. Secondly, it is not known whether deficits in high-frequency oscillations
are already present at the onset of the disorder and to what extent reduc-
tions may be related to the confounding influence of medication.
To address these issues, we employed magnetoencephalography (MEG),
a method particular suited for the examination of low-amplitude, high-
frequency oscillations, during perceptual organisation in a sample of
chronic patients with schizophrenia (N = 13), a sample of first-episode,
never-medicated patients (N = 10), and in a group of healthy controls
(N = 25). Perceptual organisation was examined with Mooney Faces.
MEG signals were analysed for spectral changes in oscillatory activity in
the frequency range of 25–200Hz. Compared to healthy controls, both
groups of schizophrenia patients showed a highly significant reduction
in high-frequency gamma-band activity (60–120Hz) over parieto-occipital
sensors. Furthermore, we observed a relative increase of gamma-band
power in the lower frequency range (25–45Hz) on fronto-temporal channels
in schizophrenia patients compared to controls. Chronic patients were
characterized by a pronounced deficit in gamma-band activity and percep-
tual organisation relative to first-episode patients. To identify the neural
generators of gamma-band activity, we used a beamforming technique
and performed source localization in the frequency range of maximum
power in the gamma band. The analysis of high-frequency gamma-band
activity in source space revealed reduced power in the lateral occipital com-
plex (LOC) in chronic schizophrenia patients compared to controls, sug-
gesting that dysfunctional processing in LOC might underlie the
observed deficits in perceptual organisation. These results suggest that
schizophrenia is associated with a widespread reduction in high-frequency
oscillations that indicate local network abnormalities. These dysfunctions
are independent of medication status and already present at onset, suggest-
ing a possible progressive deficit during the course of the disorder.
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BRAIN ACTIVITY RELATE TO EMOTIONAL
WORDS IN SCHIZOPHRENIA
Maria Jose Escarti1,4, J. Sanjuan2,4, J. Lull3, L. Marti-Bonmati3,
E. J. Aguilar1,4, G. Garcia-Marti3,4
1Psychiatry, Clinic Hospital, Valencia, Spain; 2Psychiatry, Faculty
of Medicine, Valencia, Spain; 3Radiology, Quiron Hospital,
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Valencia, Spain
Auditory hallucinations are a core feature in schizophrenia. Affective pro-
cessing deficits have been implicated in the pathogenesis of this symptom.
Nowadays, functional neuroimaging techniques are used to study the neu-
robiological mechanisms of the emotional response in such patients. We
apply an emotional auditory paradigm to evaluate cerebral activation using
fMRI in 26 healthy volunteers and 32 psychotic patients (20 with chronic
hallucinations and 12 without hallucinations). The aim is compare differ-
ences in brain activation with listening to emotional words between three
groups of study. A different and more extensive pattern of brain activation
in patients compared to healthy control subjects was discovered. In partic-
ular, a differential activation due to emotional words processing was ob-
served in patients in the frontal areas, globus pallidus, precentral,
hipocampus/parahipocampus and cerebellum. Differences in activation
were found between hallucinators and non-hallucinators, particularly in
middle temporal sulcus, hippocampus and parahipocampus and vermis.
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CATECHOL-O-METHYLTRANSFERASE (COMT)
GENE MODULATES THE NEURAL BASIS FOR THE
ACUTE EFFECTS OF CANNABIS ON LEARNING
AND PSYCHOSIS
Sagnik Bhattacharyya1, D. Prata1,2, P. Fusar-Poli1, S. Borgwardt1,
R. Martin-Santos1, P. Allen1, S. Malhi1, Z. Atakan1, D. Collier2,
P. K. McGuire1
1Section of Neuroimaging, Division of Psychological Medicine and
Psychiatry, Institute of Psychiatry, London, United Kingdom;
2SGDP Centre, Institute of Psychiatry, London, United Kingdom
Recent evidence suggests that variation in the Catechol-o-methyltransfer-
ase (COMT) gene modulates the effects of cannabis use on memory(1) and
long-term risk of developing schizophrenia(2). However, whether the acute
effects of cannabis on brain function and behaviour in man depend on their
COMT status has not been formally investigated. We investigated this by
combining functional MRI and pharmacological challenge with delta-9-tet-
rahydrocannabinol (delta-9-THC), the main psychoactive ingredient of
cannabis, in individuals with known COMT genotype as part of an ongoing
study. 20 healthy males (10 Val homozygotes and 10 Met carriers) were
studied twice, following oral administration of 10mg of delta-9-THC or pla-
cebo 1 hour prior to scanning, in a double-blind design. MR images were
acquired while subjects performed a verbal learning task. During the encod-
ing condition, relative to placebo, delta-9-THC augmented activation in the
parahippocampal gyrus such that the normal linear decrement in activation
across successive encoding blocks was no longer evident. During the recall
condition, relative to placebo, delta-9-THC attenuated activation in the
ventral striatum which was directly correlated with the severity of psychotic
symptoms it induced. In both regions, the effect of delta-9-THC on activa-
tion was greater in Val homozygotes than in Met carriers. There was also
a trend for Val homozygotes to experience more severe psychotic symptoms
following delta-9-THC than Met carriers. Evidence that delta-9-THC influ-
ences function in these regions provides a plausible mechanism for the in-
creased risk of schizophrenia in regular cannabis users, as the medial
temporal cortex and striatum are critically implicated in the pathophysiol-
ogy of the disorder. The influence of COMT genotype on the neural
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response to delta-9-THC in these regions is consistent with the modulatory
effect of COMT genotype on the risk of developing schizophrenia following
regular cannabis use and provides preliminary evidence for the biological
plausibility of this hypothesis. Funding: This study was funded by the
Psychiatry Research Trust, UK and a Joint MRC/Priory Clinical Research
Fellowship to Sagnik Bhattacharyya.
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Abstract: Cognitive abnormalities, particularly of working memory (WM),
are important features of schizophrenia. WM functions appear to be me-
diated by neural networks involving the dorsolateral prefrontal cortex
(DLPFC) and have shown hypoactivity in schizophrenia. The aim of
this study is to determine brain activation changes in the DLPFC during
stimulation with a neurocognitive task before and after computerized cog-
nitive remediation therapy (CRT). Methods: Patients with DSM IV diag-
nosis of schizophrenia are randomized to a 12 week trial of CRT using
COGPACK software or to a 12-week control condition. Patients in the
CRT group complete a total of 36 one-hour sessions. Patients receive at
baseline and endpoint an fMRI scan while performing a WM task (N-
back test); a neuropsychological test battery (MATRICS); and functional
and symptom assessments. Results: We present preliminary results of this
ongoing study. Patients in the CRT group showed significantly more im-
provement in WM than patients in the control group. All patients in the
CRT group who received an fMRI scan showed improvement in accuracy
on the verbal letter 2-back task after CRT. The signal difference between 2-
back and 0-back in DLPFC was significantly higher in the post-CRT scans
as compared to the pre-CRT scans. Conclusion: Results indicate an in-
crease in activity in WM related brain areas after 12 weeks of CRT support-
ing an adaptive cortical effect of CRT. This study offers an opportunity to
examine the underlying neurophysiological effects of neurocognitve treat-
ments of WM deficits.
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AUDITORY CORTEX HYPER-RESPONSIVITY
DURING AUDITORY STREAMING IN SCHIZO-
PHRENIA: CORRELATED INCREASES IN FMRI
ACTIVITY AND EVOKED GAMMA OSCILLATIONS
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Fundamental physiological abnormalities in sensory cortical processing
may contribute to reality distortion and cognitive impairment in schizo-
phrenia (SZ). To probe sensory processing abnormalities, we examined
fMRI activity and related it to EEG gamma oscillations as SZ patients
and healthy controls (HC) performed an auditory perceptual integration
task. Subjects performed identical tasks in separate EEG and fMRI ses-
sions. Subjects passively attended to 42-sec blocks of tones separated
by18-sec blocks of white noise (fMRI baseline). Tone blocks consisted
of 50msec pure tone stimuli of different pitches, organized in triplets
(ABA_ABA.), with tones separated by 50msec and triplets separated
by 100 msec. Tone A was always 1000Hz; tone B varied across blocks
(500, 950, 1100, or 2000 Hz). In blocks where B and A are close together
(small pitch step), a single ‘galloping’ rhythm is heard; in blocks with a large
pitch step, a perceptual shift (streaming) occurs where the initial galloping
rhythm separates after several seconds into two distinct rhythms (A..A..
and B.B.). 3T fMRI BOLD data were preprocessed and analyzed
with standard techniques. BOLD responses in auditory cortex (Superior
Temporal Gyrus, STG) to streaming and galloping blocks were evaluated
for differences between conditions and groups. An across-subject correla-
tion analysis examined the relationship of BOLD amplitude to EEG
gamma oscillatory power (see companion abstract by Leitman et al. for
EEG methods and results). Both groups showed fMRI activation of bilat-
eral auditory temporal cortex extending throughout the STG, which was
greater for streaming than galloping blocks. Consistent with EEG results,
SZ showed greater STG BOLD activation than HC in both streaming and
galloping conditions, as well as a greater difference between conditions.
Both groups showed a positive correlation between gamma power and au-
ditory cortex BOLD activation. To our knowledge, this is the first study
using fMRI to examine auditory streaming in SZ, as well as the first study
to directly relate evoked gamma oscillations to fMRI BOLD activation in
a cohort of patients with SZ. We suggest that that the observed enhance-
ment of both BOLD signal and gamma oscillations reflect the same basic
underlying abnormality in neuronal processing, perhaps a deficit in inhibi-
tion or habituation mechanisms thought to underlie streaming phenomena.
Supported by NIMH P50 MH64045.
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Studies correlating cognitive performance with brain activity have found
atypical patterns of brain-behavior organization among individuals with
schizophrenia. Most studies, however, have used composite performance
measures to correlate with brain activity. We used a probability model
of a Serial Item Recognition Paradigm (SIRP) to identify cognitive com-
ponents of memory retrieval to correlate with brain function. Eighty-nine
patients with schizophrenia or schizoaffective disorder and 93 healthy indi-
viduals received a SIRP task during a multisite functional magnetic reso-
nance imaging (fMRI) study. The SIRP included an encode period, when
participants learned a memory set composed of one, three, or five digits,
and a recognition probe period. Four stochastic models fit to SIRP re-
sponse times were compared. Voxel-wise regression models that included
group, site, and probability model parameters were used to test for group
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differences in correlation patterns. The best fitting probability model as-
sumed exhaustive serial memory scanning followed by self-terminating fa-
miliarity matching with one intercept parameter to represent SIRP
encoding and response processes. Patients displayed significantly longer re-
sponse times with increasing memory load and differed on the memory
scanning, familiarity matching, and intercept parameters of the best fitting
probability model. Group differences in the correlation of the memory
scanning parameter with linear brain response to increasing memory
load during the probe period were found in the left inferior frontal gyrus,
left middle frontal gyrus and in the left, dorsal, anterior cingulate gyrus. The
pattern of findings indicated that greater scanning capacity was associated
with greater neural capacity among healthy subjects, but that greater scan-
ning capacity required a larger brain response to increasing memory load
among schizophrenia patients. Group differences in the correlation of the
model’s familiarity matching parameter with BOLD response to memory
load were found in multiple dorsal mid-sagittal regions. Group differences
in the model’s intercept parameter were observed in the superior left frontal
gyrus and left angular gyrus during the encoding phase and in mid-line cer-
ebellum, mid-brain, and inferior medial frontal cortex in the probe period.
Poorer performing schizophrenia patients experienced either inefficient or
deficient neural activation depending on which component of item recog-
nition was assessed.
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Social cognition has been proposed to mediate the influence of cognitive
impairment to social functioning in patients with schizophrenia. Despite
impairment in social cognition, patients with schizophrenia show behav-
ioral improvements required for social adjustment through group environ-
ment and group therapy provided by day hospital programs. In this study
we examined how therapeutic factors of group milieu, such as group cohe-
sion and group pressure affect the brain function of patients with schizo-
phrenia in decision making process. Thirteen patients with schizophrenia
attending day hospital programs in two university hospitals, one general
hospital, one community mental health center and one psychiatric clinic,
and 15 healthy controls from the same group in work places or graduate
schools participated in this study. Participants were shown 3 photographs
of their group members or strangers along with each of their response to
a prior survey and then immediately asked to decide on the more frequently
used meaning of 50 homographs while being scanned by a 3T MRI scanner.
Patients with schizophrenia showed significantly lower Working Alliance
Inventory scores, but no significant difference in the conformity rates to
group opinion in the homograph meaning decision task than healthy par-
ticipants. While healthy participants did not show significant difference in
the response time between strangers and group condition, patients with
schizophrenia responded significantly faster to group opinion than strang-
ers’ opinion. Greater activity to group condition as compared to stranger
condition was observed in the parahippocampal gyrus in healthy partici-
pants. In addition to the parahippocampal gyrus, patient with schizophre-
nia showed greater activities to group condition in the insular gyrus,
fusiform gyrus, precuneus, and the superior frontal gyrus. These findings
demonstrate that patients with schizophrenia being treated in group milieu
are more influenced by their own group in their decision making and that
this process may involve the recruitment of neural networks related to emo-
tional processing and mentalizing. This study also suggests possible neural
mechanism behind group therapy in patients with schizophrenia.
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Performance of motor tasks is known to be impaired in schizophrenia but
learning of motor skills has often found to be preserved; this study examined
functional imaging correlates of this dissociation. Forty-three chronic
schizophrenic patients and 34 normal controls underwent fMRI while per-
forming easy and hard versions of a motor sequence skill acquisition task.
Activation associated with performance of the task was measured in com-
parison to a baseline non-motor task. We also measured changes in activa-
tion as a function of repetition of the task and consequent improvement in
performance. Normal subjects showed significant activation in a number of
motor-related brain regions associated with performance of the task, includ-
ing the cerebellum, basal ganglia, bilateral precentral gyrus and supplemen-
tary motor area. The schizophrenic patients showed reduced activation in
these and other areas activated during task performance. These differences
were not a function of neuroleptic dosage or presence of extrapyramidal side-
effects. In the normal subjects repetition of the task was associated with pro-
gressive de-activation in the precentral gyrus and supramarginal gyrus, plus,
in the hard version of the task, the basal ganglia and extensive areas of the
prefrontalcortex.The schizophrenic patients showed few areas ofdifferences
from the controlsassociatedwith repeatedperformance of the task (although
in the hard version of the task they showed significantly less de-activation in
the right dorsolateral PFC). These findings support previous findings that
patients with schizophrenia show reduced brain activation during motor
task performance. The lack of differences between patients and controls as-
sociated with improved performance over time may reflect the finding of pre-
served procedural learning in the disorder. Supported by the Instituto de
Salud Carlos III (FI05/00322, PI05/2693, CP07/00048), Centro de Investiga-
cio´n Biome´dica en Red de Salud Mental (CIBERSAM), and Marie Curie
European Reintegration Grant (MERG-CT-2004-511069).
ID: 551315
MODULATION OF FUNCTIONAL CONNECTIVITY
OF THE DEFAULT MODE NETWORK BY
ANTIPSYCHOTIC DRUGS
Anna Murphy1, Y. Kong2, S. Mckie1, S. Williams2, J. W. Deakin1
1Neuroscience and Psychiatry Department, University of
Manchester, Manchester, United Kingdom; 2Imaging Science and
Biomedical Engineering, University of Manchester, Manchester,
United Kingdom
Hallucinations and delusions have been conceptualised as errors in social
cognition. Neural substrates for these functions are suggested to lie in the
medial frontal regions, the posterior parietal cortex (PCC) and lateral pa-
rietal cortices. These regions comprise the so called ‘‘default mode’’ (DM)
of the brain, which is active at rest but deactivates during cognitive tasks.
Abnormalities in this network are implicated in the pathogenesis of schizo-
phrenia. The aim was to analyse the effects of antipsychotic drugs on the
DM network in healthy volunteers to understand their mechanism of action
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without confounding effects of disease state on the DM network. 36 male
subjects were randomised to receive a single oral dose of 5 mg aripiprazole
(ARI), 1mg risperidone (RSP) or placebo (PBO) before having a 5 min rest-
ing state scan. Group independent component analysis was carried out on
the resting state data using the fMRI toolbox GIFT. The DM component
was identified as that which correlated most significantly with a predefined
mask of the DM network. The DM components from all 36 subjects were
analysed for group effects in SPM5. A preliminary functional connectivity
analysis was carried out for 20 subjects. Time series were extracted from the
medial frontal gyrus (MdFG) and PCC as identified from the DM compo-
nent and used as linear regressors in SPM to give functional connectivity
maps of the DM network. MdFG and PCC were less active after ARI and
RSP treatment compared to PBO. Reductions in anterior MdFG were sig-
nificantly more pronounced after ARI than RSP whereas RSP reduced ac-
tivity in the left inferior temporal gyrus compared to ARI. Both drugs
reduced the connectivity of the DM compared to placebo. In the connec-
tivity maps seeded from the MdFG, connections to the PCC and angular
gyrus were attenuated by both drugs whereas only RSP attenuated connec-
tions seeded from the PCC. Despite their contrasting pharmacological
mechanisms (partial D2 agonism vs antagonism) both drugs reduced acti-
vation and functional connectivity of key areas of the DM network. This
supports the idea that aberrant social cognition in schizophrenia is reflected
in altered DM processing, which can be targeted by antipsychotic drugs.
Their different pharmacologies may be reflected in the different emphasis
on the DM network. However, modulating connections from the prefrontal
cortex may be a primary antipsychotic action as both drugs attenuated an-
terior to posterior connections.
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It has been suggested that auditory hallucinations (AVH’s) may be caused
by increased connectivity between auditory and language areas (Hofmann
e.a., 2007). In contrast, other authors have hypothesized that AVH’s may
originate from disconnectivity of these areas (Silbersweig e.a., 1998). Rest-
ing state connectivity is a suitable way to test both hypotheses. Right-
handed, male patients with schizophrenia with AVH’s (VH; n = 9), without
AVH’s (NVH; n = 7) and healthy controls (HC; n = 10) participated in a rest-
ing state fMRI study. Independent Component Analysis (ICA) was used to
extract so-called independent components, which are brain regions that
have a similar temporal pattern. Components of the thalamus, superior
temporal gyrus (STG) and Broca’s area were selected, and correlations
of the time courses were calculated between each two brain regions for
all groups. Correlation coefficients were converted to Z-scores and statis-
tically compared between groups with the Kruskal-Wallis test. A Mann
Whitney U test was used for post-hoc comparisons. Results are listed in
the table below. There was a significant difference in correlations of
STG and thalamus time courses. The difference between NVH and HC
time courses was significant, and nearly significant for VH vs HC. The
Kruskal-Wallis of STG—Broca and thalamus—Broca almost reached sig-
nificance. For both connections, differences between VH and HC, and VH
and NVH were almost significant. According to the these results, connec-
tivity between thalamus and STG was larger in healthy controls than in
patients with and without AVH’s. On the other hand, in contrast to healthy
controls and non-hallucinating subjects, hallucinating patients might be
characterized by an absence of connectivity between these areas. Thus,
our results suggest that changes in connectivity may underlie some aspects
of AVH’s.
Table.
Connection VH NVHVH
Kruskal
Wallis
VH vs
HC
VH vs
NVH
NVH vs
HC
STG—thalamus 0.36 0.40 0.74P < .046*P < .079P < .962P < .012*
STG—Broca -0.0510.21 0.17P < .084 P < .053P < .088P < .758
thalamus—Broca0.068 0.19 0.21P < .068 P < .065P < .043P = 1.00
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The ability to accurately perceive affective facial expressions is a crucial com-
ponent of interpersonal communication. Schizophrenia is associated with
difficulties in the recognition of facial affect, which contribute to social dys-
functionof the patientsandthesedifficultiesare more pronounced for threat-
related, emotionally salient expressions such as fear. ‘‘Positive symptoms’’ of
schizophrenia (ie, hallucinations and delusions) are thought to be associated
with aberrant assignment of salience to external objects and internal repre-
sentations. The aim of the present study was to identify brain regions asso-
ciated with amelioration of hallucinations and delusions in a group of
patients with schizophrenia during processing of emotionally salient stimuli.
Factor analytic studies of schizophrenia symptoms have shown that hallu-
cinations and delusions, irrespective of content, comprise a distinct syn-
drome of schizophrenia symptoms, the reality distortion syndrome, which
may suggest a common underlying pathological process involving a shared
network of brain regions. We used functional Magnetic Resonance Imaging
to measure cerebral blood oxygenation changes during an implicit emotional
task in 11 patients with schizophrenia, who were scanned at two different
stages of their illness 6–8 weeks apart. We found that reality distortion syn-
drome reduction in the patients was associated with increases in activation of
the affective division of anterior cingulate cortex and bilateral middle frontal
gyri. Our findings may indicate that changes in the activation of the affective
division of anterior cingulate and lateral prefrontal cortices may represent
neural markers of psychotic symptoms’ improvement.
ID: 551232
REDUCED FUNCTIONAL CONNECTIVITY IN AN
FMRI IMPLICIT SEQUENCE LEARNING TASK:
FURTHER EVIDENCE FOR FRONTOSTRIATAL
DYSFUNCTION IN SCHIZOPHRENIA
Anya Pedersen1, J. Bauer1, K. Koelkebeck1, H. Kugel2,
T. Suslow1, V. Arolt1, P. Ohrmann1
1Department of Psychiatry, University of Muenster, Muenster,
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Several studies have reported impaired implicit sequence learning indicative
of a frontostriatal dysfunction in schizophrenia patients. Using 3 Tesla
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functional MRI we examined functional connectivity of neural correlates
associated with implicit learning on a serial reaction-time task (SRT) in
nineteen schizophrenia patients and twenty-one matched healthy control
participants. In the SRT paradigm the degree of implicit learning depends
on participants’ profiting from a hidden stimulus sequence measured as
a faster responding on sequential compared to random blocks. Whole-brain
analyses as well as time series analyses for predefined regions of interest
were performed. Schizophrenia patients revealed significantly decreased
functional connectivity between bilateral putamen and prefrontal regions
(Brodmann areas 46 and 9) compared to controls for sequential blocks and
to a lesser extent for random blocks. In controls, but not in patients, ac-
tivation in bilateral putamen, left insula, and right frontal middle gyrus
was significantly correlated with the degree of implicit sequence learning.
Our results provide further evidence of frontostriatal dysfunction in schizo-
phrenia patients.
ID: 551220
PROBABILISTIC REASONING IN PSYCHOSIS: FIRST
RESULTS OF A GERMAN MULTI-CENTER
PROJECT ON THE NEURAL CORRELATES OF
A COGNITIVE BEHAVIORAL THERAPY
Katharina Pauly1, I. Lengsfeld2, S. Loos3, A. Rotarska-Jagiela4,
F. Musso5, A. Ciaramidaro6, T. Kellermann1, K. Schnell7,
H. Kockler4, J. Brinkmeyer5, M. Schwalm6, M. Sauder7,
R. Thienel1, S. Klingberg2, H. Walter7, G. Wiedemann6,
G. Winterer5, K. Vogeley4, B. Mu¨ller3, A. Rapp2, T. Kircher1
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University, Aachen, Germany; 2Department of Psychiatry and
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Germany
Under conditions of uncertainty patients with psychosis frequently make
a decision or form a conclusion based on comparatively few evidence
(‘jumping to conclusion’). The corresponding neural correlates and even
more so potential effects of psychotherapy have only been investigated
for very small sample sizes. In the German Psychosis Psychotherapy
Network, 80 patients with psychosis and 80 matched healthy subjects
will be investigated in the fMRI scanner using a decision making
paradigm—before and after 9 month of Cognitive Behavioral Therapy
or Supportive Therapy. The fMRI data of 40 patients with chronic psycho-
sis and 40 healthy subjects have been collected at six University Hospitals in
this ongoing study, so far. During scanning, participants were asked to per-
form a ‘‘balls in the bottle’’ decision task investigating the potential ‘‘jump-
ing to conclusions’’ phenomenon. Red and blue beads were presented in
a block design. Subjects had to decide by button press from which of
two jars they had been drawn (with either 60 red and 40 blue balls in
one jar or vice versa in the other jar). Measurements took place before
and after 9 months of either Cognitive Behavioral Therapy or Supportive
Therapy. SPM5 analyses investigated differences in brain activation be-
tween patients and healthy subjects as well as brain activation changes after
psychotherapy. We found a widespread activation pattern of ventromedial,
ventrolateral and dorsolateral prefrontal areas, the anterior cingulate and
the parietal cortex in healthy subjects. Decreased brain activation in
patients with positive symptoms was mainly found in dorsolateral prefron-
tal areas and the inferior parietal cortex. Preliminary results of patients who
completed psychotherapy yielded an increase in brain activation in a small
medial prefrontal cluster as well as a substantial brain activation increase in
the precuneus and other parietal areas. Therefore, decision making under
uncertainty resulted in decreased brain activation in psychotic patients in
key areas of the decision making process. An increase of activation in pa-
rietal areas (mainly the precuneus) and the medial prefrontal cortex after 9
month of psychotherapy might reflect the correlates of newly learnt coping
strategies in patients with psychosis. So far, our data suggest that—in con-
trast to older beliefs—Cognitive Behavioral Therapy could be a valuable
element of the common routine care of patients with psychotic disorders.
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HYPOFRONTALITY IS A FEATURE OF CHRONIC,
BUT NOT FIRST-EPISODE SCHIZOPHRENIA
Amalia Guerrero1,2, J. J. Gomar1,2, R. Salvador1,2, S. Sarro´1,2,
P. J. McKenna1,2, E. Pomarol-Clotet1,2
1Benito Menni CASM, Sant Boi del Llobregat, Spain;
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Reduced activation in the dorsolateral prefrontal cortex (DLPFC) and
other frontal regions has been found in many, but not all, functional im-
aging studies of schizophrenia. We used fMRI to image groups of schizo-
phrenic patients: chronic schizophrenic patients and first episode patients
with non-affective functional psychosis during performance of the n-back
task. Both groups were matched with age- and sex-matched controls. The
chronic schizophrenic patients showed reduced activation in a network of
cortical regions similar to those identified in a meta-analsysis of studies us-
ing the n-back task1: bilateral rostral frontal cortex, bilateral DLPFC, bi-
lateral mid-ventrolateral PFC, bilateral and medial posterior parietal
cortex, bilateral motor cortex, and dorsal cingulate/medial premotor cortex
including the supplementary motor area (BA 32,6). In contrast the first-
episode patients showed no areas of reduced activation compared to
age- and sex-matched controls. The results suggest that reduced task-re-
lated prefrontal activation or hypofrontality is a function of chronic schizo-
phrenia but not acute schizophrenia, in accordance with the findings of
a recent meta-analysis2. Supported by the Instituto de Salud Carlos III
(PI05/2693, FI05/00322, CP07/00048), Centro de Investigacio´n Biome´dica
en Red de Salud Mental (CIBERSAM), and Marie Curie European Rein-
tegration Grant (MERGCT-2004-511069).
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CE., Velligan DI. Beyond hypofrontality: a quantitative meta-analysis
of functional neuroimaging studies of working memory in schizophre-
nia. Human Brain Mapping 2005;25:60–9.
2. Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, McKen-
na PJ. Hypofrontality in schizophrenia: a meta-analysis of functional
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THE DYSEXECUTIVE HYPOTHESIS OF THOUGHT
DISORDER: A NEUROPSYCHOLOGICAL AND
FMRI STUDY
Bibiana Sans-Sansa1,2, E. Pomarol-Clotet1,2, J. Ortiz-Gil1,2,
S. Sarro´1,2, R. Duen˜as1, R. Salvador1,2, P. J. McKenna1,2
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This study examined whether the symptom of formal thought disorder
(FTD) in schizophrenia is associated with underlying frontal/executive
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dysfunction, as assessed neuropsychologically and by functional imag-
ing. Thirty-two intellectually preserved schizophrenic patients with
FTD, 36 without FTD and 23 matched normal controls were examined
on a battery of tests assessing executive function, memory, language and
visual/visuo-spatial function. 14 patients with FTD, 19 without FTD and
22 controls also underwent fMRI during performance of a working
memory task (the n-back task). The patients with FTD differed from
patients without FTD on a composite measure of executive function,
the Behavioural Assessment of the Dysexecutive Syndrome (BADS,
P = .02), but not on a working memory task, letter-number sequencing.
The patients with and without FTD also differed significantly from those
without FTD on one of four long-term memory measures (verbal recall),
the Token Test but none of 7 visual/visuospatial tests. As a group, the
schizophrenic patients showed significantly reduced activation in pre-
frontal and other regions compared to controls during performance
of the n-back task. However, there were no differences between patients
with and without FTD in any prefrontal subregions, but significant dif-
ferences were found in the left temporal cortex and fusiform gyrus. The
results provide qualified support for the hypothesis of a neuropsycholog-
ical deficit in executive function associated with the symptom of FTD.
However, prefrontal cortical functional brain abnormality does not
differ between patients with and without FTD, at least when a
working memory task is used. Supported by the Instituto de Salud
Carlos III (CM07/00016, PI05/2693, CA06/0129, CP07/00048), Centro
de Investigacio´n Biome´dica en Red de Salud Mental (CIBERSAM).
ID: 551185
FUNCTIONAL MAPPING OF EFFECTS IN BRAIN OF
SUSCEPTIBILITY GENES SHARED BY SCHIZO-
PHRENIA AND BIPOLAR DISORDER
Daniel R. Weinberger
Genes, Cognition and Psychosis, NIMH/NIH, Bethesda, MD, USA
While risk for schizophrenia and bipolar disorder show overlap in families
and several recent genetic associations are common to both diagnoses, the
molecular basis of the clinical differences is unknown. We have explored
with functional and structural neuroimaging associations with several can-
didate susceptibility genes common to both disorders to identify pathways
to the clinical phenomenology. fMRI during N back working memory and
during emotional face matching and VBM have been explored in a large
sample of normal subjects genotyped for SNPs genes that have been asso-
ciated both with schizophrenia and bipolar disorder, including DISC1,
NRG1, ErbB4, COMT, AKT1, GRM3, GRM7, all of which have been
implicated in both schizophrenia and bipolar disorder, but with variable
consistency. Conjunction analyses also were performed looking for com-
mon effects. Our results show that risk alleles in each of these genes con-
verge on a pattern of inefficient prefrontal function during executive
cognition, but show less consistent effects on amygdale/hippocampal pro-
cessing of negative emotion. DAOA, GRM3, NRG1 and COMT show
strong effects on hippocampal/amygdala processing. Our results suggest
overlapping but dissociable effects of genetic variation in genes related
to schizophrenia and bipolar disorder that may clarify the figurative
Ven Diagram of overlapping risk factors associated with these disorders.
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THE NEURAL CORRELATES OF SEVERE COGNI-
TIVE IMPAIRMENT IN SCHIZOPHRENIA
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J. J. Gomar1,2, A. Aguilera-Martı´nez1, R. Salvador1,2, S. Sarro´1,2,
C. Junque´3, P. J. McKenna1,2
1Unitat de Recerca, Benito Menni CASM, Sant Boi del Llobregat,
Spain; 2CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain;
3Departament de Psiquiatria i Psicobiologı´a Clı´nica, Universitat de
Barcelona, Barcelona, Spain
This study aimed to identify structural and/or functional brain correlates
of severe cognitive impairment in schizophrenia (‘schizophrenic demen-
tia’). We carried out structural MRI and voxel-based morphometry in
25 cognitively impaired and 22 cognitively preserved schizophrenic
patients plus 37 healthy controls. Presence of cognitive impairment
was defined on the basis of performance below the 1st percentile on either
the Rivermead Behavioural Memory Test (RBMT) or the Behavioural
Assessment of Dysexecutive Syndrome (BADS), or below the 5th percen-
tile on both. A subset of 15 cognitively impaired patients, 15 cognitively
preserved patients, and 29 controls, also underwent fMRI during perfor-
mance of a working memory (n-back) task. No differences were found
between cognitively intact and cognitively impaired patients in lateral ven-
tricular volume or whole brain volume. Voxel-based morphometry
revealed no clusters of significant difference in grey matter volume. How-
ever, during performance of the n-back task, cognitively impaired patients
showed hypoactivation compared to cognitively intact patients in the an-
terior cingulate, superior ventromedial frontal cortex, dorsolateral pre-
fontral cortex, bilateral insula, thalami, and left basal ganglia. Other
areas of activation included L >R precentral and parietal cortex and pre-
cuneus. These findings replicate and extend those of an earlier, small scale
study1 and indicate that cognitively impaired schizophrenic patients show
no more structural brain abnormality than in the disorder as a whole, but
that their brain function is more compromised. Supported by the Instituto
de Salud Carlos III (CA06/0129, PI05/2693, CM07/00016, FI05/00322,
CP07/00048), Centro de Investigacio´n Biome´dica en Red de Salud
Mental (CIBERSAM), and Marie Curie European Reintegration Grant
(MERG-CT-2004-511069).
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DEFAULT MODE NETWORK DYSFUNCTION:
A POTENTIALLY SIGNIFICANT ABNORMALITY IN
SCHIZOPHRENIA
Peter McKenna1,2, R. Salvador1,2, P. Fernandez-Corcuera1,2,
N. Moro1, S. Sarro´1,2, J. Goikolea2,3, B. Sans-Sansa1,2,
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Recent studies have implicated the default mode network—medial cortical
and other brain regions which are active at rest but which de-activate during
performance of a wide range of cognitive tasks—in schizophrenia. We car-
ried out fMRI during performance of the n-back working memory task in
32 chronic schizophrenic patients, 18 manic patients and 16 bipolar de-
pressed patients, plus normal controls. The schizophrenic patients showed
apparent hyperfrontality in the medial prefrontal/anterior cingulate cortex,
similar to that found in other studies using working memory tasks(1).
However, further analysis revealed that, rather than being due to intrinsic
hyperactivation, this represented failure of de-activation, in an area corre-
sponding to the anterior midline node of the default mode network. The
manic and depressed patients showed smaller and less robust clusters of
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failure to de-activate in the same area. Our findings suggest that some of the
‘hyperfrontality’ found in recent fMRI studies of schizophrenia is artefac-
tual and in reality reflects failure of de-activation in the default mode net-
work. This failure is marked in schizophrenia but is evident to a lesser extent
in bipolar manic and depressed patients. Failure to de-activate the default
mode network during performance of cognitive tasks could provide a novel
way of accounting for cognitive impairment in schizophrenia. Additionally,
the default mode network is currently believed to play an important role in
maintaining one’s sense of self and so offers intriguing new ways for relating
symptoms to brain dysfunction.
Reference
1. Glahn DC, Ragland JD, Abramoff A, et aI. Beyond hypofrontality:
a quantitative meta-analysis of functional neuroimaging studies of
working memory in schizophrenia. Human Brain Mapping
2005;25:60–69.
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SCHIZOPHRENIA AS A HEREDITARY
‘DISCONNECTION’ SYNDROME: EVIDENCE FROM
DIFFUSION TENSOR IMAGING (DTI), AND
DYNAMIC CAUSAL MODELLING OF FMRI DATA
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Ireland
A single observed cortical abnormality, which is both sufficient and neces-
sary, for the development of schizophrenia has not been identified, leading
to proposals that schizophrenia is a disorder of connectivity (eg, Friston
and Frith, Clin Neurosci, 1995). Schizophrenia appears highly heritable,
and changes in connectivity may represent an endophenotype. We sought
to test this hypothesis by combining measures of structural and functional
connectivity, in families multiply affected by psychosis. 20 patients with
DSM-IV schizophrenia, 20 of their unaffected first degree relatives and
20 healthy controls, underwent DTI and fMRI scans. Measures of struc-
tural connectivity from DTI (Fractional Anisotropy- FA) were compared
in a voxel based analysis. In addition an fMRI scan of the n-back (0-,1-,2-,3-
back) working memory paradigm, facilitated group level comparisons of
BOLD activation, as well as effective connectivity measurements using Dy-
namic Causal Modeling (DCM) in SPM-5. Subjects were generally well
matched for demographic variables, with no differences identified in com-
parison to the control group. DTI: Reductions in FA were identified in pro-
bands, within the genu, left sup. longitudinal fasciculus, and posterior
regions of the inf. longitudinal fasciculus bilaterally. Relatives showed
trend level FA reductions within these clusters (P = .079). fMRI: Reduced
cortical activation was identified in schizophrenia probands and their unaf-
fected relatives in bilateral inferior frontal gyri, left frontal pole, left dor-
solateral prefrontal cortex (DLPFC) and bilateral inferior parietal lobule,
that was not related to impaired task performance (at 2-, 3-back) in
probands. DCM: Intrinsic connectivity values were assessed
between DLPFC, inferior prefrontal cortex (VLPFC), and posterior pari-
etal lobule (PPL), in a fully connected model. Impaired intrinsic connectiv-
ity was identified in schizophrenia probands between prefrontal and PPL
regions, both within and between hemispheres. A significant positive cor-
relation was observed between a summary measure of the intrinsic connec-
tivity paths and FA values extracted from clusters showing FA reductions
in the proband vs control comparison (r = 0.331, P = .014). In summary,
correlated structural and functional connectivity impairments are apparent
in schizophrenia probands, and also (at trend level) in their unaffected rela-
tives, suggesting that genetic mediation of connectivity abnormalities may
underlie psychosis.
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A LANGUAGE INDEPENDENT N-BACK TASK FOR
NEUROIMAGING STUDIES IN SCHIZOPHRENIA IN
A MULTI-LINGUAL SETTING—A VALIDATION
STUDY
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The N-back task is widely used in neuroimaging investigations to study
the neurocognitive processes involved in working memory and executive
functions. Variants of this task have been used to explore frontal lobe
dysfunction in schizophrenia. The promise of gaining better insights
into the etiopathology of schizophrenia by linking specific genotypes
to prefrontal functions has renewed interest in paradigms like the N-
back task suited for imaging executive functions. N-Back tasks adapted
for neuroimaging have generally used monitoring the identity or location
of letters, numbers or abstract shapes. The letter and number based tasks
presume the ability to read and are often difficult to administer in schizo-
phrenia patients from varied educational backgrounds as encountered in
developing countries. Moreover the letter based tasks are language spe-
cific and pose difficulties in settings involving subjects who are linguis-
tically heterogeneous. In view of these methodological issues, we aimed
to develop and validate a N-back task for fMRI which would be inde-
pendent of language and suitable for use in a schizophrenia imaging-
genomics project in a multi-linguistic population such as that in South
India. Simple characters chosen from the CJK Ideographs subset of
the Arial Unicode MS font type were used as stimuli in a block design
2-back task which included a zero-back baseline condition. An echo
planar imaging sequence was used in a 3T Philips MR scanner to acquire
the fMRI time series which were then processed and analysed using
SPM5. The prefrontal cortical hemodynamic responses elicited by the
above N-back task in a sample of 20 healthy subjects demonstrates
the validity of the above task as a test of executive function which
can be utilized in imaging genomics studies of schizophrenia in a multi-
lingual setting. Funding: Department of Biotechnology, Government of
India (BT/PR/8363/MED/14/1252/2006—JPJ).
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DYSFUNCTION IN EARLY ONSET SCHIZOPHRE-
NIA: AN FMRI STUDY
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A dysfunctional prefrontal cortex is suggested to be a part of the neural
underpinnings of working memory deficit in general as well as in individuals
with schizophrenia. Several studies have shown prefrontal dysfunction in
adult onset schizophrenia and the current study aimed to examine whether
this region is dysfunctional in early onset schizophrenia as well. fMRI
BOLD data were acquired at 1.5T (Siemens, Sonata). The working memory
task consisted of 2-back and 0-back blocks. Twelve adolescents with schizo-
phrenia symptoms and eleven healthy controls between 13–17 years were
included. The two groups were matched on age and gender. Preliminary
analysis showed stronger activations bilaterally in the dorsolateral prefron-
tal cortex (DLPFC) in the patient group compared to the healthy controls.
The behavioral data yielded no significant difference in performance in
working memory between the groups. These preliminary results indicate
that neural dysfunction in DLPFC is present in adolescents with schizo-
phrenia. The data suggests a hyperactive DLPFC in the patients performing
at the same level as healthy controls. Thus, these findings on early onset
schizophrenia are in line with recent studies on adult onset schizophrenia
displaying a non-efficient activation pattern.
ID: 550986
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INDIVIDUALS AT ULTRA-HIGH RISK FOR
PSYCHOSIS
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Language processing abnormalities are a hallmark feature of schizophre-
nia. Yet, no study to date has investigated underlying neural networks as-
sociated with discourse processing in adolescents at ultra-high risk (UHR)
for developing psychosis, in order to determine whether abnormalities in
language systems may predate illness onset. Forty UHR youth and 24 de-
mographically matched healthy controls underwent functional neuroimag-
ing (fMRI) while performing a naturalistic discourse processing task. fMRI
data were acquired on a Siemens 3T scanner. We assessed differences in
blood oxygenation level-dependent (BOLD) activity between task condi-
tions (Topic Maintenance vs. Reasoning) and between groups (ie, UHR
vs. controls, UHR subjects who subsequently developed psychosis vs. those
who did not). Furthermore, we examined the association of regional brain
activity with symptom severity and social outcome at 12–24 month follow-
up. Across groups, whole-brain analyses revealed activation in a large bi-
lateral network of regions typically associated with language processing,
including the left inferior temporal lobe, inferior frontal gyrus, and anterior
cingulate, as well as their right hemisphere homologues (corrected cluster P
< .01). Further, increased activity in the superior temporal gyrus (IT;
BA38), caudate, left inferior frontal gyrus (LIFG; BA44/45and47) and an-
terior cingulate (BA24and32) distinguished those who subsequently devel-
oped psychosis. Within the UHR sample, the severity of positive formal
thought disorder at follow-up was positively correlated with signal change
in the LIFG, superior frontal gyrus, and IT, whereas social outcome was
inversely correlated with signal change in these regions. Our results suggest
that language networks may be disrupted in youth at ultra-high risk for
developing psychosis. In particular, subsequent conversion to psychosis
was associated with increased activity in brain regions involved in language
processing. These findings are consistent with a neural inefficiency hypoth-
esis in those at greatest risk for psychosis, and additionally suggest that
baseline activation differences are predictive of symptomatic and functional
outcome. These results highlight the need to further investigate the neural
systems involved in conversion to psychosis, and how language disruption
changes over time in at-risk adolescents.
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RESPONSE DURING A LEARNING TASK IN
SCHIZOPHRENIA
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The effects ofanticholinergic (ACH) burden on cognition in schizophrenia are
well established. It has been found that that high ACH burden is linked to
impairment in verbal learning and memory in patients with schizophrenia
(Tracy et al. 2001; Minzenberg et al. 2004). Functional abnormalities in the
prefrontal cortex during learning and memory have repeatedly been reported
inpatientswithschizophrenia.Eylerandcolleagues(2008), forexample, found
that brain response wassignificantly loweramong schizophrenia patients than
healthy individuals in the inferior frontalgyrus (IFG)during awordpair learn-
ing task. The relationship between ACH burden and functional abnormalities
during learning remains unexamined however. Our aim was to examine the
relationship between ACH burden and brain response in a priori regions pre-
viously shown to respond abnormally during learning in schizophrenia. Spe-
cifically, we examined the relationship ofanticholinergicity to functional brain
response in three clusters within the IFG during a verbal learning task among
26 outpatients with schizophrenia/schizoaffective disorder. Brain response
during novel wordpair learning comparedtofixationwas measuredwith func-
tional magnetic resonance imaging. Mean brain response was calculated for
each individual across all voxels within three clusters in the IFG that had been
identified as under-responsive in patients compared with healthy individuals.
Subsequently, the mean brain response in each cluster was correlated with se-
rum anticholinergicity (pmoles/ml of atropine equivalents) from a recent
blood draw. We found a negative relationship between functional brain acti-
vation and anticholinergicity in one of the clusters in the left IFG (r=.45; P=
.05) and a negative, but non-significant, correlation in the right hemisphere
cluster (r = .42, P = .07). Patients with high ACH burden demonstrated
the most abnormal brain response patterns (greater deactivation) illustrating
the inability toengage the IFG to levels seen inhealthy controls whenperform-
ing the same verbal paired-associates task. Further studies are needed to rep-
licate these findings and to investigate the specificity of these relationships to
schizophrenia.
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NORMAL SENSORIMOTOR RESERVE IN SCHIZO-
PHRENIA: AN FMRI STUDY
Adrian Preda1, H. J. Lee1, J. A. Turner1, V. D. Calhoun2,3,
S. G. Potkin1
1Psychiatry and Human Behavior, UC Irvine, Orange, CA, USA;
2Electrical and Computer Engineering, University of New Mexico,
Albuquerque, NM, USA; 3Psychiatry, Yale University, New Haven,
CT, USA
While there is a wealth of literature establishing abnormalities in schizo-
phrenia (SCZ), little is known about the reserve of normal tissue or function
in SCZ. To define normal sensorimotor reserve we investigated the
activation of the primary motor and sensorimotor cortex in stable SCZ
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patients and healthy controls (HC) during a unilateral finger-tapping task
in response to a flashing checker board. A total of 86 HC and 85 SCZ
patients aged 19–65 from eight different sites were enrolled. All contribut-
ing sites were part of a multi-site functional MRI (fMRI) study (Functional
Imaging Biomedical Informatics Research Network—fBIRN). Voxel-wise
fMRI analysis was carried out using the fBIRN Image Processing Stream
(FIPS), an fBIRN multi-site fMRI analysis package based on FSL. Percent
signal changes (PSC) in predefined regions of interest (ROI) and a weighted
laterality quotient (WLQ) were calculated. Our voxel-based analysis
showed similar activations and no significant differences between the
HC and SCZ subjects. All results were thresholded at z > 2.23, with a clus-
ter-wise significance of P < .05. In the ROI analyses, neither the effect of
diagnosis nor the interaction of hemisphere and diagnosis were significant.
As predicted based on the task unilaterality, the PS change in the motor
cortex and the weighted laterality quotient were greater in the left hemi-
sphere for both SCZ and HC; however, there were no significant between
groups differences. Combined data from the 3T scanner sites showed stron-
ger mean PS changes than the 1.5T sites. Power analyses indicate that based
on these data, with 171 subjects, we were sufficiently powered to detect a dif-
ference in PS change of 0.12 between SCZ and HC. Our tapping task, con-
tingent on the checkerboard flashing, rather than being fast rhythmic
movements, was designed to be performable equivalently by schizophrenics
and controls and to result in strong activation levels. The overall results of
our multi-site fMRI study showed similar activation in primary motor and
sensorimotor cortex activation in SCZ patients and HC during this task,
providing a basis for tasks aimed to show equivalent function in SCZ
and normal controls. Future studies can build on these results to further
investigate motor system dysfunction in SCZ.
ID: 550897
FUNCTIONAL CONNECTIVITY ABNORMALITIES
ASSOCIATED WITH ABNORMAL BEHAVIOR IN
SCHIZOPHRENIA
Kelvin O. Lim1, J. Camchong1,2, C. Bell1, B. A. Mueller1,
A. W. MacDonald2,1
1Psychiatry, University of Minnesota, Minneapolis, MN, USA;
2Psychology, University of Minnesota, Minneapolis, MN, USA
Functional connectivity abnormalities have been previously reported in
schizophrenia (SZ) patients. These abnormalities may underlie behavioral
problems associated with schizophrenia. The present study examines the re-
lationship between functional connectivity abnormalities and behavior in
schizophrenia. In order to investigate this, the relationship between intrinsic
fluctuations of the default mode network (DMN) during rest and behavioral
measures such as clinical symptoms and cognitive performance was exam-
ined. Twenty nine chronic SZ patients (11 females, age: M = 41.3, SD = 9.28)
and 29 healthy participants (11 females, age: M = 41.1, SD = 10.6) were
recruited. SZ patients were assessed with scales for the assessment of neg-
ative and positive symptoms (SANS and SAPS). All participants were
assessed with D-KEFS Tower and Grooved pegboard tests. Participants un-
derwent a 6 min rs-fMRI scan during which they were instructed to stay still
with their eyes closed and remain awake. Independent components analysis
was used to identify (1) the group DMN and (2) each individual’s contrib-
uting time-course to the group DMN. Voxel-wise whole-brain multiple
regressions with corresponding DMN time-courses were conducted for
each individual. An unpaired t-test was conducted on resulting maps to
look for differences in DMN connectivity between groups. In addition, vox-
el-wise correlations were conducted to investigate the relationship between
individually identified DMN and behavioral measures. Between-group
results revealed altered connectivity in medial frontal and anterior cingulate
gyri within the DMN of SZ patients. In addition, DMN connectivity was
significantly associated with both the negative and positive symptoms of
SZ patients. SZ patients also showed positive correlations (1) between D-
KEFS Tower test and activity in anterior cingulate, precuneus, cuneus,
and dorsolateral prefrontal cortex and (2) between the Grooved pegboard
test scores and activity in right cerebellum, visual cortex, and left motor cor-
tex (P< .05, corrected). Results suggest that schizophrenia is associated with
functional connectivity abnormalities in the DMN. In addition, resting-
state connectivity in schizophrenia was associated with clinical symptoms
as well as cognitive performance. Results from this preliminary study
provide support for the hypothesis that altered functional connectivity is
associated with behavioral problems in schizophrenia. Supported in part
by NIH MH-060662.
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BEHAVIORAL AND NEURAL CORRELATES
OF POOR SACCADIC CONTROL IN
UNDERGRADUATES
Michael T. Amlung1, Q. Li1, B. P. Austin1, J. Camchong2,
J. E. McDowell3
1Department of Psychology, Bio-Imaging Research Center, Uni-
versity of Georgia, Athens, GA, USA; 2Departments of Psychiatry
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3Departments of Psychology and Neuroscience, Bio-Imaging
Research Center, University of Georgia, Athens, GA, USA
Correct antisaccade (AS) performance requires inhibition of a reflexive
glance to a newly appearing visual cue and generation of a saccade to
its mirror image location. Patients with schizophrenia make an increased
proportion of AS errors which are associated with dysfunction in prefrontal
cortex (PFC) circuitry. It is uncertain whether this relationship is specific to
schizophrenia, or if decreased PFC activity is associated with increased AS
errors in non-clinical samples. Undergraduate students (N = 350) partici-
pated in an eye movement study involving AS and prosaccade (PS: requires
a glance towards a peripheral cue) tasks. Good and poor performers (as
identified by scores in the upper or lower 33% of the distribution on
two different days of testing) performed AS and PS tasks while fMR images
were acquired. Poor performers made significantly more errors on the AS
task, but did not significantly differ in saccade latencies compared to their
good performer counterparts. In both groups, saccade tasks were associ-
ated with activation in the well-defined circuitry: frontal and supplementary
eye fields, posterior parietal cortex, thalamus and basal ganglia. Addition-
ally, AS performance was associated with activation in bilateral PFC. Al-
though region of interest analyses showed few between-group differences,
the poor performing group showed evidence of decreased activation in PFC
and supplementary eye fields that also was related to behavior. In the poor
performing group there was an inverse relationship between antisaccades
errors and PFC activity such that more errors were associated with lesser
PFC activity. Despite an increased proportion of errors on the AS task,
poor performers as a group seem to successfully activate the neural circuitry
supporting saccades. There also was evidence, however, that as the demand
for cognitive control increases, the poor performers were unable to recruit
additional neural resources to offset increased task difficulty. Overall, these
data suggest that healthy people who show compromised inhibitory control
may be more likely to show evidence of disregulation of PFC circuitry un-
der conditions of increased task demand.
ID: 550883
NEURAL BASIS OF REWARD PROCESSING IN
SCHIZOPHRENIA
Ivy Fei Tso1,2, E. R. Stern2, C. S. Sripada2, R. C. Welsh3,
S. F. Taylor2
1Department of Psychology, University of Michigan, Ann Arbor,
MI, USA; 2Department of Psychiatry, University of Michigan, Ann
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International Congress on Schizophrenia Research
14. 14. Neuroimaging, Functional 193
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
Introduction: Anhedonia, amotivation, and apathy are core negative symp-
toms of schizophrenia. It has been speculated that these symptoms reflect
abnormalities of brain reward systems. Several paradigms have recently
emerged to probe these systems, which are quite distinct form regions in-
volved in traditional cognitive functions. For example, ventral medial cor-
tex is associated with processing rewards, but little data exist as to brain
activation patterns in schizophrenia when processing reward. Method:
To address this question, we examined reward processing with a monetary
incentive paradigm in 12 (4 female; age = 36.3 6 11.2) stable outpatients
with schizophrenia and 11 (2 female; age = 36.5 6 10.8) demographically
matched healthy controls using event-related fMRI. Subjects were pre-
sented with cues indicating whether a correct response in a two-choice re-
action time task (modified from an Erikson Flanker task) would result in
a gain of money (10c or 50c gain trials), avoidance of a loss of money (10c or
50c loss trials), or no change in money (neutral trials). Responses were fol-
lowed immediately by feedback. Loss and neutral trials followed by a cor-
rect response were later labelled as no-gain trials. Subjects underwent fMRI
BOLD imaging, with standard pre-processing and statistical analysis with
the general linear model. Results: Both schiz patients and controls showed
high accuracy on the task (schiz: 93.6 6 9.8%; control: 98.2 6 2.0%, n.s.).
There was no significant group difference in reaction time (schiz: 1011 6
172ms; control: 933 6 130 ms, n.s.). During the outcome phase of gain
vs. no-gain trials, while controls showed activation in rostral anterior cin-
gulate/ventral medial prefrontal cortex (rACC/vmPFC) (3, 24, 3; Z =
4.14, k = 8), no significant signal was observed in schiz patients. Two-sam-
ple t-test showed that schiz patients demonstrated lower activity than con-
trols on gain vs. no-gain trials in rACC/vmPFC (9, 33, 33; Z = 4.61; k = 9)
(9, 27, 21; Z = 4.55, k = 10). Discussion: Patients with schizophrenia failed to
show expected activation in rACC and vmPFC, brain regions associated
with the outcome phase of reward processing. While this pilot study is lim-
ited by small sample size and the use of medicated patients, further inves-
tigation of these regions in schizophrenia during reward processing is
warranted.
ID: 550882
GENE DISCOVERY THROUGH IMAGING
GENETICS: IDENTIFICATION OF TWO NOVEL
GENES ASSOCIATED WITH SCHIZOPHRENIA
Steven G. Potkin1, J. A. Turner1, J. A. Fallon1, A. Lakatos1,
D. B. Keator1, G. Guffanti2, F. Macciardi2
1Psychiatry, University of California, Irvine, Irvine, CA, USA;
2Science and Biomedical Technology, University of Milan, Milan,
Italy
Background: Genome-wide association scans (GWAS) allow the identifica-
tion of genes whose relationship with the disease phenotype has not even
been hypothesized. GWAS offer enormous promise in identifying genetic
variation involved with illness and its response to treatment by allowing
all areas of the genome to be considered. Methods: We combined a ge-
nome-wide screening strategy with neuroimaging measures as the quantita-
tive phenotype and identified the Single Nucleotide Polymorphisms (SNPs)
related to these genes as consistently associated with the phenotypic varia-
tion. Genotyping was performed with the Illumina Infinium Human1 chip
and HumanCNV370 Duo Bead Chip yielding 105,950 autosomic SNPs.
Samples successfully genotyped in less than 90% of markers on either array
were excluded from analysis. The quantitative phenotype was BOLD acti-
vation in the left dorsal lateral prefrontal cortex measured during a working
memory task. We determined the impact of genetic variation on the DLPFC
activation using permutation testing to control for false positives. The dis-
covery sample consisted of 28 chronic schizophrenic patients. The differen-
tial distribution of SNPs associated with these two genes in cases and
controls was then corroborated in a larger, independent sample of patients
with schizophrenia (n = 82) and healthy controls (n = 91) matched for gender
and age. This was part of a larger cohort collected by the Functional Imaging
Biomedical Informatics Research consortium (FBIRN). Results: Twenty-
seven SNPs in one gene on chromosome 3 and 19 on chromosome 6
were significantly associated with activation in the DLPFC by permutation
testing. Thirteen of the 17 chromosome 3 SNPs tested and 6 of the 18 chro-
mosome 6 SNPs tested were significantly associated with a diagnosis of
schizophrenia in the Corroborative sample, substantiating a role of these
two genes in schizophrenia. Conclusions: We introduce the use of fMRI ac-
tivation as a quantitative phenotype in conjunction with genome-wide as-
sociation as a gene discovery tool. With this tool, we have both discovered
and verified the association of two genes with schizophrenia. Up until now
these genes have not been linked to any neuropsychiatric illness, although
both genes have a role in prenatal brain development and functioning of the
prefrontal system relevant to schizophrenia deficits.
ID: 550876
ALLELIC VARIATION IN KCNH2 IS ASSOCIATED
WITH DORSOLATERAL PREFRONTAL CORTEX
ACTIVATION DURING WORKING MEMORY
Joseph H. Callicott, M. J. Prust, S. J. Huffaker, H. Y. Tan,
B. Kolachana, M. F. Egan, D. R. Weinberger
CBDB, GCAP, NIMH, DIRP, NIH, Bethesda, MD, USA
The coordination of cortical microcircuits for organized neuronal firing is
essential for higher order information processing in human beings and
may be disrupted in schizophrenia. Recently, single nucleotide polymor-
phisms (SNPs) in KCNH2, a voltage-gated potassium channel that regulates
neuronal firing and is highly expressed in human prefrontal cortex, have
shown association to schizophrenia across 5 independent samples (Huffaker
et al., in submission). Here we explore the effects of a SNP identified as show-
ing association with schizophrenia and with hippocampal function. Using
the N-back paradigm, we used fMRI to assay BOLD activity in 150
right-handed Caucasian healthy volunteers across genotype (M33; N = 62
GG, N = 65 GA, N = 23 AA) Performance and demographic measures
did not differ across genotype groups. Using SPM2, we conducted a corre-
lation of KCNH2 genotype with task-dependent activation at 2-back. We
found that subjects with the risk allele at M33 (A) exhibited increased acti-
vation of the left dorsolateral prefrontal cortex (DLPFC) (-30 30 41; P<.05
small volume correction) relative to subjects with the non-risk major allele, in
spite of equivalent accuracy and response time. This inefficient DLPFC re-
sponse in healthy subjects at 2-back suggests that individuals with the A allele
at M33 required increased cortical resources for WM processing relative to
individuals with the non-risk allele. These results in healthy individuals map
faithfully onto the intermediate phenotype of prefrontal inefficiency ob-
served in unaffected relatives of schizophrenic probands (Callicott et al.,
2003) and a PFC region reported to show moderate heritability for this
task in twins (Blokland et al., in press) . Additional analyses revealed that
this activation difference was independent of the DLPFC efficiency effects
of COMT Val158Met (Egan et al. 2001). Whether an interaction exists be-
tween KCNH2 allelic variation and other genes associated with this pheno-
type and schizophrenia awaits further study.
ID: 551934
INVESTIGATING DIFFERENTIAL CORRELATIONS
BETWEEN FMRI AND LANGUAGE-ASSOCIATED
GENES USING PARALLEL ICA, IN HEALTHY
CONTROLS AND SCHIZOPHRENIA PATIENTS
Shashwath Meda1, N. Powers5, J. R. Gruen5, V. D. Calhoun2,3,
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Electrical and Computer Engineering, University of New Mexico,
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We utilized task-related imaging findings from an fMRI auditory oddball
(AOD) task as a potential intermediate phenotype (endophenotype) to in-
vestigate genomic factors derived from multiple single nucleotide polymor-
phisms (SNP’s) from risk genes for language between groups of SZ patients
and controls. We studied 33 controls and 20 SZ patients (matched on age,
ethnicity and sex). All subjects performed an AOD task, which consists of
detecting an infrequent sound within a series of frequent sounds. Each sub-
ject was characterized on 22 different SNP markers spanning different risk
genes previously associated with various language disorders. We used a re-
cently developed technique named parallel independent component analy-
sis (paraICA) to identify simultaneously independent components of each
modality and the relationships between them. Data were preprocessed us-
ing SPM2, which involved realignment, normalization and smoothing with
a 12 mm3 kernel. First-level statistics were run to derive contrast images for
subjects responding to AOD that were then carried over as input to the
paraICA algorithm. Six independent fMRI and genetic components
(each) were estimated using the minimum description length criteria. We
found 4 fMRI components significantly correlated with four distinct
gene components. The fMRI components, along with their significant ge-
netic profile (dominant SNP) correlations were as follows: 1) Cuneus- SFG-
R STG-Post-central gyrus-Thalamus and rs2304503 (ROBO1), rs1087266
(DCDC2) [r = .47; P = .0004], 2) STG-MTG-MFG-Precentral gyrus and
rs1087266 (DCDC2) [r = .42; P = .001], 3) SFG-Posterior Cingulate and
rs807724 (DCDC2), 4) Default Mode Network-Cingulate-STG-IFG-IPL
and rs6795556 (ROBO1), rs6935076 (KIAA0319). Many of the above
regions (including DLPFC, cingulate, STG, IPL, IFG) are identified as ab-
normal in SZ. The above described fMRI regions are all spatially indepen-
dent; eg, STG regions appearing in component 1 and component 4 are
different sub-regions that cytoarchitecturally fall within the same Brod-
mann area. Importantly, gene-fMRI combination 4 (t = 2.80; P = .007)
listed above showed a significant difference between controls and patients,
based on their correlated loading coefficients. Our findings suggest that ge-
nomic SNP factors can be investigated by using endophenotypic imaging
findings in a multivariate format and that language-related genes may play
a role in SZ.
ID: 555108
NEURAL CORRELATES OF VERBAL FLUENCY
TASKS IN KETAMINE-INDUCED MODEL
PSYCHOSES: A FMRI STUDY
Arne Nagels1, S. Krach2, A. Kirner3, T. Kircher4
1Psychiatry and Psychotherapy, RWTH Aachen, University
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Hospital, Aachen, Germany; 4Psychiatry and Psychotherapy,
RWTH Aachen, University Hospital, Aachen, Germany
The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been im-
plicated in the pathophysiology of schizophrenia. In healthy individuals,
a subanaesthetic dose of the non-competitive NMDA antagonist ketamine
reproduces positive, negative and disorganized symptoms of schizophrenia,
including speech disturbances and thought disorder. 19 healthy, right-
handed, native German-speaking male individuals performed an overt
verbal fluency task while brain activation was measured with functional
magnetic resonance imaging (fMRI). A within-subject, placebo controlled,
counterbalanced design was assessed for all subjects. Overall performance
was impaired under the ketamine condition. In contrast to the placebo con-
dition increased brain activation was found in frontal regions (Brodmann
area 9/10) and in the right anterior pole of the temporal lobe (Brodmann
area 38). The increased activation in frontal and temporal regions can be
linked to the cognitive impairments observed in schizophrenia as these
regions show differential activation when compared to healthy individuals.
The regions that were found to be differentially activated are key regions
in speech production and working memory. These results offer further
support for a role of glutamatergic dysfunction in the symptoms of
schizophrenia.
ID: 554802
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Merilyne C. Waldo1,2, J. R. Tregellas1,2, D. Singel2, R. S. Astur3,4,
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Research Center, Institute of Living, Hartford, CT, USA;
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The ability to complete complex tasks including learning and memory is
known to be impaired in individuals with schizophrenia. Both anatomic
and functional deficits have been identified using a variety of techniques.
In this study we compare brain functioning and behavioral processing in 13
schizophrenic patients and 15 controls using a virtual water maze adapted
from classic animal studies. Patients performed as well as the controls when
the virtual platform was visible, but more poorly during the hidden trials (P
<.001). Imaging studies were performed using a GE 3.0 T MR scanner.
fMRI data was acquired using EPI T2* BOLD (Blood Oxygen Level De-
pendent) contrast technique. BOLD echo-planar data (TR = 2000,TE = 30,
642 matrix, 240 mm2 FOV, 28 axial slices angled parallel to the planum
sphenoidale, 4mm thick, 0 mm gap) were motion corrected, normalized
to standard space, spatially smoothed with an 8 FWHM kernel and eval-
uated using the GLM in a random effects analysis in SPM2 (Wellcome De-
partment of Imaging Neuroscience, London). A network of brain regions
were involved in completing the test. The most active areas in controls were
the cerebellum, R parietal areas, frontal eye fields, the anterior insula and
inferior frontal gyrus, the DLPFC, and the basal ganglia and striatum
(FDR = 0.001). In some regions, schizophrenics demonstrated significantly
less activation than controls, including the cerebellum, the occipital and
parietal visual areas, the medial thalamus, the left DLPFC (FDR =
0.01). A region of interest analysis of the hippocampus also demonstrated
significantly less activation in schizophrenics, particularly in the very pos-
terior part of the hippocampus. This area is of special interest since it has
been shown to demonstrate the greatest growth potential following inten-
sive training in normal controls (Maguire et al. 2000), suggesting that it may
be a focus for cognitive training.
Reference
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Introduction: A novel method of combining functional and anatomical
connectivity estimates has been recently described [1], to quantify the rela-
tionship between two distinct features of brain connectivity. Anatomical
Connectivity is measured using DTI analysis of the integrity of white matter
tracts, while Functional Connectivity represents the strength of correlations
in the resting fMRI fluctuation. These two measures are related in healthy
subjects. In this study we analyzed the relationship between anatomical and
functional connectivity in schizophrenia patients. Data Analysis: 19 healthy
control and 19 age matched schizophrenia subjects were scanned on a 3T
Allegra Siemens scanner. Resting state time courses of gray matter voxels
were correlated to create a resting state connectivity matrix. After standard
deterministic fiber tracking the connectivity between each two white matter
voxels was estimated by integrating multifiber paths and propagated into
grey matter. Results: While overall measures of anatomical and resting cor-
relation did not differ significantly between the control and schizophrenia
populations, we found a strong and significant (P < .02) difference in the
correlation between functional and anatomical connectivity maps when
comparing schizophrenia patients and healthy controls. In the schizophre-
nia patients the maps agreed less, ie, their functional connectivity measures
were less in agreement with the anatomical connectivity map than in
healthy controls. Between- group differences were most prominent for con-
nections originating in the Anterior Cingulate, Cuneus, and Precuneus. The
differences between control and schizophrenia group were further con-
firmed by the correlation between the coherence score in schizophrenia sub-
jects and the Thought Disorder Index. Conclusion: Significant differences
exist in the brain connectivity of schizophrenia patients. The multimodal
approach in which a functional and anatomical measure of connectivity
are combined together provides a more powerful measure of connectivity
deficit than each measure taken alone.
Reference
1. Skudlarski P. et al. Measuring Brain Connectivity: Diffusion Tensor
Imaging Validates Resting State Temporal Correlations, Neuroimage
[in press].
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The ability to have voluntary executive/cognitive control of behavior con-
tinues to develop through adolescence as important brain maturational
processes are still taking place. Core to cognitive control of behavior is
working memory (WM), the ability to retain information on-line in order
to guide goal directed behavior in a planned manner. The purpose of the
following studies was to characterize the developmental trajectory of work-
ing memory through adolescence to adulthood with behavioral studies and
neuroimaging studies using functional Magnetic Resonance Imaging
(fMRI). Studies were performed using the oculomotor delayed response
task (ODR) (memory-guided saccade task) where subjects are instructed
to make a planned eye movement directed to the location retained in work-
ing memory of a cue presented previous to a delay period. This is a well-
characterized method that has been widely used in single cell non-human
primate studies to delineate the neural circuitry underlying WM. Behav-
ioral results indicated that working memory accuracy as well as reaction
time continued to improve through adolescence indicating protracted de-
velopment of WM. Subjects also performed event related fMRI studies
while performing WM tasks. The first study presented short and long delay
period to assess developmental differences in WM maintenance. With age
fronto-caudal areas were recruited which supported saccade precision while
posterior parietal cortex was recruited to support extended delay periods.
The second study manipulated both encoding and maintenance durations.
We found the prefrontal cortex became better specialized into adulthood
supporting both encoding and maintenance aspects of working memory.
Diffusion Tensor Imaging (DTI) studies, were also performed to assess in-
direct measures of myelination that may underlie improvements in working
memory. Results indicated that white matter regions adjacent to prefrontal
cortex (BA9) as well as orbitofrontal and striatal regions continue to mature
through adolescence. Together these studies indicate a protracted develop-
ment of working memory through adolescence that is subserved by contin-
ued specialization of a widely-distributed brain circuitry that supports
optimal encoding and precision of WM, which may reflect a stage of par-
ticular vulnerabilities to developmental abnormalities including schizo-
phrenia. Supported by MH067924.
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Mingxiong Huang1,2, R. R. Lee1,2, K. Gaa2, T. Song2,
D. L. Harrington1,2, C. Loh1,3, R. J. Theilmann2, J. C. Edgar4,
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Cognitive impairments related to somatosensory functions are common in
people with schizophrenia, including reduced speed and/or accuracy of so-
matosensory information-processing. However, the somatosensory system
has been largely ignored in functional imaging research of schizophrenia.
The present study used magnetoencephalography (MEG) to identify the
neural networks that support selective-attention to somatosensory stimuli
in healthy adults and abnormalities in these networks in schizophrenia. A
median-nerve oddball task was used to probe for selective-attention to
somatosensory stimuli during MEG recordings, and an advanced high-
resolution MEG source-imaging method was used to analyze the MEG
data. In healthy subjects, selective-attention-related activations were seen
in a sensorimotor network involving primary somatosensory area (S1), sec-
ondary somatosensory area (S2), primary motor area (M1), pre-motor area
(PrM), and paracentral lobule (PCL). In addition, the frontal-parietal-tem-
poral ‘‘attention network’’ which contains dorsal- and ventral-lateral pre-
frontal cortex (DLPFC and VLPFC), orbitofrontal cortex, anterior
cingulate cortex (ACC), superior parietal lobule (SPL), inferior parietal
lobule (IPL)/supramarginal gyrus (SMG), and the temporal lobe areas,
was also activated. Individuals with schizophrenia showed early hyper-acti-
vations related to selective-attention in S1 and M1, but hypo-activation in
S1, S2, M1, PrM, and SPL at later latency in the sensorimotor network.
Within the attention-network, hypo-activations were found in DLPFC, me-
dial aspect of orbitofrontal cortex, and dorsal aspect of ACC at a variety of
latencies, but hyper-activations were seen in SMG/IPL, frontal pole, and
ventral aspect of ACC in individuals with schizophrenia. These findings
link attention-related somatosensory deficits to dysfunction in both the sen-
sorimotor and the frontal-parietal-temporal networks in schizophrenia.
ID: 554268
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REWARD AND SUBJECTIVE WELL-BEING IN
SCHIZOPHRENIA: AN FMRI STUDY
James K. Gilleen, S. Shergill, S. Kapur
Institute of Psychiatry, London, United Kingdom
Patient subjective well-being is a major determinant of treatment compli-
ance. Comparisons of conventional and atypical medication, as well as neu-
roimaging studies have suggested that the subjective experience of patients
may be related to the mesolimbic dopamine system crucial in processing
reward information. Negative subjective changes have been shown to be
related to altered reward processing, and striatal dopamine function. As
dopamine may be associated with subjective experience and is the major
neurochemical component in reward; and reward systems have been shown
to be impaired following dopaminergic medication, negative subjective ex-
perience may be due to impairment of the reward system. The primary aim
of the study was to examine whether the relationship between dopamine
and subjective well-being is attributable to dysfunctional reward process-
ing. It was hypothesised that patients low in subjective well-being will have
decreased activation in anticipation of reward in the ventral reward system.
Twenty patients with schizophrenia were administered a Monetary Incen-
tive Delay task, previously used by Knutson et al. (2001), while undergoing
fMRI brain imaging on a 3T scanner. Positive, neutral and negative stimuli
predicted valence of subsequent reward on each trial, while reaction time to
hit a target determined trial outcome. Reward was obtained in reward tri-
als, and loss avoided on losing trials on 66% of trials irrespective of subject
performance abilities as determined by an automated adaptive timing al-
gorithm which adjusted target speed. Functional images were preprocessed
and modeled with SPM5. Analysis contrasted brain activation during an-
ticipation of reward in positive trials (financial gain) with anticipation of
outcome on neutral trials (zero gain). BOLD activation was significantly
greater in the left inferior frontal lobe and caudate nuclei in response to
positive reward. It was also of interest to establish whether there were differ-
ences in activation between subsets of patients with low and high subjective
well-being. Preliminary analyses suggest that patients with high subjective
well-being (N = 5) have greater activation in ventral medial temporal and
inferior frontal structures compared to patients low subjective well-being
(N = 5) during anticipation of rewarding outcomes. Activation in ventral
structures may directly be associated with subjective well-being or alterna-
tively via inhibition of primary reward areas such as the striatum.
ID: 552306
HYPER-RESPONSIVITY TO STRESS IN THE HPA
AXIS DURING EARLY PSYCHOSIS
Belinda Garner1, P. D. McGorry1,2, L. J. Phillips3, S. J. Wood4,
C. Pantelis4, R. Parslow1, S. Bendall1, K. Thompson1,
A. R. Yung1,2
1Psychiatry, ORYGEN Research Centre, Melbourne, VIC,
Australia; 2ORYGEN Youth Health, NorthWestern Mental Health,
Melbourne, VIC, Australia; 3School of Behavioural Sciences,
University of Melbourne, Melbourne, VIC, Australia; 4Melbourne
Neuropsychiatry Centre, University of Melbourne, Melbourne, VIC,
Australia
A series of studies have been conducted in Melbourne, Australia investigat-
ing hypothalamic-pituitary-adrenal (HPA) axis function in young people at
ultra high risk (UHR) of psychosis, young people experiencing a first psy-
chotic episode (FEP) and healthy controls. Our findings suggest the acute
phase of psychosis is associated with hyperactivity of the HPA axis, indi-
cated by enlarged pituitary volume and impaired glucocorticoid receptor
functioning. Recent preliminary findings suggest a subset of FEP patients
with a history of childhood trauma exhibit enhanced negative feedback of
the HPA axis, similar to the biological abnormalities seen in PTSD. The
hippocampus is highly sensitive to the neurotoxic effects of gluococorti-
coids. We have conducted a longitudinal study in drug-naı¨ve FEP patients
investigating the relationship between HPA axis function and metabolic
changes in hippocampal and prefrontal brain regions during the initial
three months of treatment. These studies will be described in detail and fu-
ture directions for research will be suggested.
ID: 552032
DELUSIONAL IDEATION MAY BE ASSOCIATED
WITH ABERRATIONS IN CONFLICT PROCESSING
William Speechley, E. Ngan
Psychiatry, The University of British Columbia, Vancouver, BC,
Canada
Introduction: To better understand delusional ideation we must identify
which core processes are malfunctioning to allow the formation and main-
tenance of delusions. Dual-stream decision-making models propose two
interacting processes; a fast, intuitive system (Stream 1) and a slower,
more logical process (Stream 2). When the two streams diverge, healthy
individuals may experience conflict, which we suggest biases decision-mak-
ing towards Stream 2 and increases the likelihood of a judgment in keeping
with the available evidence. In schizophrenia, a failure in this conflict-
modulation system may allow erroneous intuitive interpretations to endure
unchallenged. Study 1: Patients with schizophrenia and healthy controls
judged the logical validity of two-part conditional statements that were
either congruent or incongruent with respect to agreement between their
logical validity (Stream 2) and the believability of their concluding senten-
ces (an automatic, Stream 1 judgment). Performance deficits in the patient
group were significantly worse for the incongruent condition, which was
designed to generate conflict between the two streams. Study 2: A simplified
version of our conditional reasoning paradigm was performed by subjects
while undergoing functional magnetic resonance imaging. For the incon-
gruent condition, healthy controls exhibited significantly greater activation
in the dorsal anterior cingulate cortex (BA32) and dorsolateral prefrontal
cortex (BA46) than for the congruent condition. This significant pattern of
activation was absent in patients with schizophrenia. Conclusions: The
behavioural data provides support for our suggestion that dual-stream con-
flict may pose a particular difficulty for patients with schizophrenia. The
fMRI results indicate that, in schizophrenia, attenuated activation of
regions associated with conflict detection and logical reasoning may under-
lie the increased likelihood to make erroneous decisions when there is a con-
flict between intuition and reason.
ID: 552016
THE EFFECT OF CANNABIDIOL (CBD), A CANNA-
BIS SATIVA CONSTITUENT, ON NEURAL CORRE-
LATES OF ANXIETY: A REGIONAL CEREBRAL
BLOOD FLOW STUDY
Jose´ Alexandre Crippa1, G. Derenusson1, A. W. Zuardi1,
L. Wichert-Ana1, F. Duran1, T. B. Ferrari1, R. Martin-Santos2,
P. K. McGuire3, G. F. Busatto4, J. E. Hallak1
1Neuropsychiatry and Medical Psychology, Sao Paulo University,
Ribeirao Preto, Brazil; 2Neuropsychopharmacology Group,
IMIM-Hospital del Mar and Department of Psychiaty, Institute of
Neurosciences, Hospital Clinic, IDIBAPS, CIBER-SAM,
Barcelona, Spain; 3Department of Psychological Medicine, Section
of Neuroimaging, Institute of Psychiatry, University of London,
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London, United Kingdom; 4Department of Psychiatry, Faculty of
Medicine, University of Sa˜o Paulo, Sao Paulo, Brazil
Cannabis use is common in patients with psychiatric disorders such as
schizophrenia, bipolar and anxiety disorders. Anecdotal reports suggest
that some patients take this drug to alleviate both anxiety and psychotic
symptoms. Animal and human studies have shown that cannabidiol
(CBD), a major compound of the cannabis plant, may possess anxiolytic
and antipsychotic properties, but how these effects are mediated centrally is
not fully understood. Regional cerebral blood flow (rCBF) was measured at
rest using 99mTc-ECD SPECT in ten subjects with high levels of trait anx-
iety, randomly divided in two groups of 5 individuals. Each subject was
studied on two occasions, one week apart. In the first session, subjects
were given an oral dose of CBD (400mg) or placebo, in a double-blind pro-
cedure. SPECT images were acquired 90 minutes after drug ingestion. The
VAMS scale was applied to assess subjective states. In the second session,
the same procedure was performed using the drug that had not been ad-
ministered in the previous session. Within-subject between-condition
rCBF comparisons were performed using SPM. CBD significantly de-
creased subjective anxiety without increasing sedation, while placebo did
not induce significant changes. Assessment of brain regions where anxio-
lytic effects of CBD were predicted a priori revealed decreases in ECD up-
take in the CBD relative to placebo condition: revealed one voxel cluster of
significance (P < .001, uncorrected) located in the left parahippocampal
gyrus and hippocampus, extending to the inferior temporal gyrus
(BA20). Significantly increased (P < .001, uncorrected), ECD uptake in
the CBD relative to the placebo condition was also evident in one region
located in the right posterior cingulate gyrus (BA23/31). Considering the
CBD condition, the SPM showing negative correlations with Anxiety
VAMS factor revealed two clusters (>20 voxels) which achieved statistical
significance level (P< .001, uncorrected for multiple comparisons): one lo-
cated in the left whereas the other was located in the right amygdala. These
results suggest that CBD has anxiolytic properties and that these effects are
mediated by an action on limbic and paralimbic brain areas and may help to
reconcile apparently conflicting findings obtained with cannabis sativa in
relation to its use in patients with anxiety and other psychiatric disorders
such as schizophrenia.
ID: 551942
NEUROFUNCTIONAL EFFECTS OF DELTA-9-THC
AND CANNABIDIOL ON EMOTIONAL
FUNCTIONING
Paolo Fusar-Poli
Psychobehavioural Sciences, University of Pavia, Pavia, Italy
Context: Cannabis use can both increase and reduce anxiety in humans.
The neurophysiological substrates of these effects are unknown. Objective:
To investigate the effects of two main psychoactive constituents of Canna-
bis Sativa, (delta-9-tetrahydrocannabinol [delta-9 THC] and cannabidiol
[CBD]) on regional brain function during emotional processing. Design:
Subjects were studied on three separate occasions using an event-related
fMRI paradigm while viewing faces that implicitly elicited different levels
of anxiety. Each scanning session was preceded by the ingestion of either
10mg of delta-9-THC, 600mg of CBD, or a placebo, in a double-blind,
randomised, placebo controlled design. Patients and other participants:
Fifteen healthy English-native right-handed men who had used cannabis
fifteen times or less in their life. Main outcome measures: Regional brain
activation (BOLD response), electrodermal activity (Skin Conductance
Response, SCR) and objective and subjective ratings of anxiety. Results:
delta-9THC increased anxiety, as well as levels of intoxication, sedation
and psychotic symptoms, whereas there was a trend for a reduction in anx-
iety following administration of CBD. The number of SCR fluctuations
during the processing of intensely fearful faces increased following admin-
istration of delta-9THC but decreased following administration of CBD.
CBD attenuated the BOLD signal in the amygdala and the anterior and
posterior cingulate cortex while subjects were processing intensely fearful
faces, and its suppression of the amygdalar and posterior cingulate
responses was correlated with the concurrent reduction in SCR fluctua-
tions. Delta-9-THC mainly modulated activation in frontal and parietal
areas. Conclusions: delta-9-THC and CBD had clearly distinct effects
on the neural, eclectrodermal and symptomatic response to fearful faces.
The effects of CBD on activation in limbic and paralimbic regions may con-
tribute to its ability to reduce autonomic arousal and subjective anxiety,
whereas the anxiogenic effects of delta-9-THC may be related to effects
in other brain regions.
ID: 551935
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15. 15. Neuroimaging, Structural
WHITE MATTER MARKERS FOR PSYCHOSIS IN
A PROSPECTIVE ULTRA HIGH RISK COHORT.
Oswald Jan Nicolaas Bloemen, M. B. de Koning, N. Schmitz,
D. H. Nieman, H. E. Becker, P. M. Dingemans,
D. H. Linszen, T. A. van Amelsvoort
Psychiatry, Academic Medical Centre, Amsterdam, Netherlands
First episode schizophrenia patients have regionally reduced fractional an-
isotropy (FA), however, to a lesser extent than chronic patients1. Subjects at
Ultra High Risk (UHR) for developing psychosis have volumetric white
matter reductions, although to a lesser extent than first episode schizophre-
nia patients2. No one has yet investigated FA in UHR subjects. Hence we
investigated a prospective cohort of UHR subjects and compared whole
brain FA of those who would later develop psychosis (UHR-P) to those
who would not (UHR-NP). We recruited 37 subjects who fulfilled UHR
criteria3. 3 Tesla MRI scans and PANSS ratings were obtained at baseline.
Subjects were assessed at 9, 18 and 24 months for development of frank psy-
chosis. Subsequently UHR-P and UHR-NP FA and white matter densities
were compared and FA was correlated to PANSS ratings. UHR-P subjects
had significantly lower FA than UHR-NP subjects lateral to the right puta-
men and of left superior temporal lobe. FA in the right superior temporal
lobe negatively correlated with positive symptoms at baseline. Further,
UHR-P had higher FA in the right medial temporal lobe. UHR-P had a cor-
responding white matter density reduction lateral of the right putamen, but
this did not survive correction for multiple comparisons. Concluding, UHR
subjects that develop psychosis have differences at baseline in white matter
integrity compared to UHR subjects who do not develop psychosis. These
differences implicate the striatal and superior temporal regions, areas known
to be involved in schizophrenia. Further, FA in the superior temporal region
negatively correlates with positive symptom severity at baseline. This study
was funded by grant QLGU-CT-2001-01081 of the European Commission.
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GRAY AND WHITE MATTER VOLUMETRIC
INTERMEDIATE PHENOTYPES ACROSS THE
PSYCHOSIS SPECTRUM
Elena I. Ivleva, B. Thomas, A. Moates, D. Cole, B. Witte,
C. Tamminga
Psychiatry, UTSW Medical Center, Dallas, TX, USA
In this study we attempted to contrast gray matter (GM) and white matter
(WM) intermediate phenotypes across the psychosis spectrum to character-
ize effects of psychosis on brain structure. 62 subjects: 19 schizophrenic
patients (SZP), 16 schizoaffective patients (SADP), 17 patients with psy-
chotic bipolar I disorder (BDP) and 10 healthy controls (HC) were in-
cluded. MRI was performed on a 3T Magnetom Trio scanner following
the ADNI protocol. T-1-weighted MPRAGE sequences were used for stan-
dardized VBM analysis (MATLAB7.0, SPM5). Socio-demographic char-
acteristics were comparable between the study groups. Although GAF
and total BPRS scores did not differ between the groups, SZP had higher
psychosis BPRS scores (d = 0.8) and BDP had higher affective BPRS scores
(d = 1). SZP and SADP performed worse on the Social Functioning Scale
compared to BDP and HC. SZP and SADP showed diffuse loss of GM with
similar regions in superior temporal and middle frontal gyri, caudate and
thalamus; BDP showed decreased GM volumes in caudate bilaterally, com-
pared to HC. WM comparisons showed that SZP and SADP had lower
volumes in anterior cerebellum, brain stem and postcentral gyrus; while
BDP showed diffusely reduced WM in left (L) anterior cerebellum, superior
temporal and middle frontal gyri; in the right (R) cerebellar tonsil, superior
frontal and subcallosal gyri; and bilaterally in posterior cerebellum, com-
pared to HC. The psychosis groups (SZP, SADP and BDP) did not differ
significantly in either GM or WM volumes. BPRS psychosis scores directly
correlated with GM volumes in L inferior temporal lobe and R medial fron-
tal gyrus in SZP; in R superior frontal gyrus in SADP, and in middle and
superior frontal, middle occipital and superior temporal gyrus in BDP.
Patients treated with atypical and typical antypsychotics (AP) (n = 8)
had higher GM volume in medial frontal gyrus compared to AP-free indi-
viduals (n = 11). In this preliminary analysis, the greatest volumetric GM
and WM differences were found between HC and psychosis groups across
the SZ/BD boundary. SZ and SAD cases were structurally similar and
showed diffuse decrease in GM, while BDP showed no significant GM
loss but diffuse WM reduction. Across the psychosis spectrum the groups
did not significantly differ in either GM or WM volumes. This may suggest
gross effect of psychosis on brain structure independent of categorical di-
agnosis. Severity of psychosis and AP treatment showed effect on GM vol-
ume in all psychosis groups.
ID: 550805
RELATIONSHIP OF THOUGHT DISORDER IN
SCHIZOPHRENIA WITH BRAIN STRUCTURE AND
WITH WHITE MATTER INTEGRITY: ANALYSIS OF
DATA COLLECTED BY THE MIND RESEARCH
NETWORK(MRN) JOINT STUDY OFFIRSTEPISODE
AND CHRONIC SCHIZOPHRENIA
Peter Milev1, S. C. Schulz1, S. Lee1, K. O. Lim1,
A. MacDonald III1, S. Sponheim1, T. White1, B. C. Ho3,
R. L. Gollub2, J. Bockholt4, V. Calhoun4, N. C. Andreasen3
1Psychiatry, University of Minnesota, Minneapolis, MN, USA;
2Psychiatry, Harvard University, Boston, MA, USA; 3Psychiatry,
University of Iowa, Iowa City, IA, USA; 4Psychiatry, University of
New Mexico, Albuquerque, NM, USA
The purpose of this study is to explore the relationship between the severity
of thought disorder (TD) in schizophrenia and brain structure and connec-
tivity. TD has been not been studied as extensively as negative symptoms
and psychotic symptoms in relation to longitudinal course, psychosocial
outcome and underlying neuroanatomical abnormalities. The persistence
thought disorder after the resolution of the first psychotic episode(s) is a
strong predictor of poor response to behavioral and pharmacological treat-
ment and of poor psychosocial outcome, and is related to poor performance
on tests of visual perceptual organization (Uhlhaas and Silverstein 2005).
A better understanding of thought disorder in precise neuroanatomical
terms will enhance our knowledge of the basic neuroscience of schizophre-
nia and will generate ideas for the development of new treatments. This
study is based on data collected by the MIND Research Network
(MRN) Joint Study of First Episode and Chronic Schizophrenia that in-
cluded investigative teams from four imaging centers and collected brain
MRI data on 153 subjects with schizophrenia and 160 healthy controls.
TD was studied with The Scale for the Assessment of Positive Symptoms
(Andreasen 1984). Anatomical and diffusion tensor imaging MRI scans
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were collected using either a 1.5T Siemens Scanner (University of Iowa,
University of New Mexico, Harvard University-MGH) or a 3.0T Siemens
Trio scanner (University of Minnesota). Structural data were analyzed
using FreeSurfer, an automated set of software tools for study of cortical
and sub-cortical anatomy (Fischl and Dale, 2000) and by voxel-based
morphometry with SPM5 (Wellcome Department of Cognitive Neurol-
ogy). DTI data were processed using GTRACT software (Cheng et al.,
2006). DTI data and the anatomical data were co-registered to allow
identification of the white matter compartment. Results will be presented
examining: 1) the relationship between severity of TD with poor psycho-
social functioning and with poor performance on cognitive tests of visual
perceptual organization; 2) the relationship between severity of TD and
brain anatomy, particularly, with gray matter volume in brain regions
involved in visual perceptual organization: striate cortex, lateral occipital
complex, fusiform gyrus, posterior parietal regions; 3) the correlation
between severity of TD and DTI measures of white matter structural
connectivity.
ID: 550752
MULTIMODAL IMAGING STUDY OF THE
THALAMUS IN FIRST-EPISODE PSYCHOSIS
Fidel Vila-Rodriguez1, W. Su1, D. J. Lang2, B. Khorram1,
W. G. MacEwan1, W. G. Honer1
1Psychiatry, University of Briitish Columbia, Vancouver, BC, Canada;
2Radiology, University of British Columbia, Vancouver, BC, Canada
The thalamus (Th) is a central node of pathophysiology in schizophrenia.
Structural and neurochemical abnormalities are seen using different imag-
ing techniques such as morphometric assessment, tissue segmentation, and
1H MRS. However, no integration of these imaging methods into a single
sample set has been attempted to date. To investigate structural abnormal-
ities in first-episode psychosis (FEP) patients we conducted a longitudinal
multimodal structural magnetic resonance (MR) assessment of the Th in
FEP at two time points. Preliminary baseline findings from structural
MRI and MRS scans are reported here. Methods: 29 FEP (mean age
20.7 years; 15 male) and 18 age and gender-matched volunteers (mean
age 20.8; 13 male) were recruited as part of larger longitudinal study.
FEP patients with less than 8 weeks of total lifetime exposure to antipsy-
chotic treatment were included. 1.5mm thick axial SPGR images were
obtained on a GE 1.5 T MRI scanner. Manual tracing of thalamus was
performed, and thalamus mask was used to apply a geometric subdivision
of the thalamus so that thalami would be parceled out along the coronal
plane into 40:40:20 subdivisions, and along the sagittal plane by 50% sub-
divisions. Single-voxel (1HMRS) was used to measure concentrations of
NAA in the left Th. Spectra from 3.24mL voxels, centered in the left thal-
amus, were acquired using a PRESS sequence. NAA peaks determined
from LCModel were corrected for T1 and T2 relaxations, and CSF content.
Statistical analyses were performed using SPSS 11.0. and Superanova.
Results: At baseline, ANCOVA (ICV covariate) analysis showed no signif-
icant differences in total right or left thalamic volume (F1,44 = 0.031, P = .86;
F1,44 = 0.094, P = . 76). ANCOVA (ICV covariate) for Anterior, Medio-
dorsal, and Pulvinar nuclei on both sides did not show any statistical sig-
nificant difference. Finally, ANCOVA (age covariate) for the left thalamus
1H MRS voxel, showed a statistically significant reduction in Th absolute
NAA in SCZ (F1,43 = 5.14, P = .028). Additionally, there was a statistically
significant diagnostic x age interaction (F1,43 = 4.04, P = .05). Conclusions:
Although there were no differences in total thalamic volumes or particular
nuclei, there was a reduced NAA content in left Th at baseline. Current
results highlight the relevance to integrate different imaging modalities,
and point towards a different effect on structure vs. biochemical content
in early stages of schizophrenia.
ID: 550686
MULTIPLE-STRUCTURE ANALYSIS OF
LONGITUDINAL SHAPE CHANGE IN
SCHIZOPHRENIA
Lei Wang1, M. I. Miller2, J. G. Csernansky1
1Department of Psychiatry and Behavioral Sciences, Northwestern
University Feinberg School of Medicine, Chicago, IL, USA; 2Center
for Imaging Science, Johns Hopkins University, Baltimore, MD, USA
Objective: Progressive decreases in cortical gray matter volume have been
reported in individuals with schizophrenia. However, recent longitudinal
neuroimaging studies of progressive change in subcortical structures
have not yielded consistent findings. In a previous study of individual struc-
tures, we reported that brain structures that receive direct, excitatory con-
nections from the cortex may be more likely to show progressive changes, as
compared to brain structures that receive indirect, inhibitory connections
from the cortex. In this study, we combined shape information from the
above individual structures to examine the longitudinal change in the net-
work of subcortical structures. Methods: Two high-resolution, T1-
weighted magnetic resonance images were collected two years apart in
55 schizophrenia and 62 control subjects. Large-deformation high-dimen-
sional brain mapping was used to generate surfaces for the thalamus, cau-
date nucleus, nucleus accumbens, globus pallidus, putamen, hippocampus
and amygdala at baseline and follow-up. Deformation maps were com-
puted for each structure with respect to the population mean to form vector
fields at the structural boundary. These vector fields were combined across
all structures in each hemisphere. Baseline shape was computed as eigen-
vectors from principal components analysis on these vector fields, which
have support across all structures. Follow-up shape was expressed in terms
of the baseline eigenvectors. Repeated-measures ANOVA on the first ten
eigenvectors was used to test for longitudinal changes in shape. Results: The
schizophrenia subjects exhibited a longitudinal shape change that was sig-
nificantly different from the controls (shape-by-group interaction: Wilks’
Lambda F = 3.1, df = 10,106, P = .0017). Visual inspection of the pattern
of progressive changes confirmed the previously-reported variable patterns
of between-group differences, and these differences spanned across the thal-
amus, caudate nucleus, nucleus accumbens and hippocampus. The other
structures either showed similar changes in both groups (amygdala and
putamen) or no progressive changes (globus pallidus). Conclusions: These
results suggest that there is ongoing volume loss in subcortical brain struc-
tures in schizophrenia, and that this volume loss may be accentuated in
structures that have more direct connections with the cortex. Further re-
search is underway to investigate long-term changes in neural networks
in schizophrenia.
ID: 550685
ABNORMAL FRONTAL CORTICAL ASYMMETRY
PREDICTS NONRESPONSE TO ANTIPSYCHOTICS
IN FIRST-EPISODE SCHIZOPHRENIA
Philip Szeszko1,2, K. L. Narr3, O. R. Phillips3, J. McCormack2,
S. Sevy2, J. M. Kane1,2, R. M. Bilder4,5, D. Robinson1,2
1Center for Translational Psychiatry, Feinstein Institute for Medical
Research, Manhasset, NY, USA; 2Psychiatry Research, Zucker
Hillside Hospital, Glen Oaks, NY, USA; 3Laboratory of
Neuroimaging, Department of Neurology, Geffen School of
Medicine at UCLA, Los Angeles, CA, USA; 4Departments of
Psychology and Psychiatry and Biobehavioral Sciences, Geffen
School of Medicine at UCLA, Los Angeles, CA, USA; 5Jane and
Terry Semel Institute for Neuroscience and Human Behavior,
David Geffen School of Medicine, Los Angeles, CA, USA
The identification of predictors of response to antipsychotic medications
in patients with schizophrenia is an important goal for imaging research.
The lack of controlled treatment trials from which to recruit patients for
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imaging studies to investigate relationships with treatment response/out-
come has limited studies in this area. In this study we tested the hypothesis
that abnormalities in the normal, healthy pattern of cortical asymmetry
would be associated with nonresponse to antipsychotic medication in
patients experiencing a first-episode of schizophrenia. Magnetic resonance
(MR) imaging exams consisted of 124 coronal images (slice thickness = 1.5
mm) acquired using a 3D Fast SPGR with IR Prep at 1.5T. Thirty-nine
(30M/9F) patients experiencing a first-episode of schizophrenia who
were enrolled in a treatment trial comparing the efficacy of risperidone
(dosage range = 1 to 6mg) versus olanzapine (dosage range = 2.5 to
20mg) received MR imaging exams either prior to or close to the onset
of treatment and had a median of 0 days (range = 0 to 14 days) cumulative
lifetime exposure to antipsychotics. Twenty-five patients were classified as
responders and 14 patients were classified as nonresponders. Cortical pat-
tern matching methods were used to spatially associate homologous corti-
cal locations across the two hemispheres. Regional hemispheric shape
asymmetries were mapped by computing radial distances from the origin
(the anterior commissure point at midline) to thousands of spatially equiv-
alent points on the left and right hemispheric surface. An asymmetry index
was then computed at each hemispheric location within subjects and com-
pared across responders and non-responders at high spatial resolution. Sta-
tistical maps, obtained by comparing asymmetry measures at thousands of
homologous locations across the hemispheric surface, showed significantly
(P < .05; uncorrected) greater asymmetry in the frontal lobes among the
responders, but not nonresponders. In addition, significant differences
(P < .05; uncorrected) in cortical asymmetry were observed when respond-
ers were compared directly to non-responders. These preliminary findings
suggest that a pattern of abnormal cortical asymmetry may be useful in
identifying a subgroup of patients with first-episode schizophrenia who
are nonresponsive to atypical antipsychotics at standard dosages.
ID: 550399
NEUROLOGICAL SOFT SIGNS IN
SCHIZOPHRENIA—STATE-RELATED OR A TRAIT?
Johannes Schro¨der, P. Thomann, S. Bachmann
Section of Geriatric Psychiatry, Heidelberg University, Heidelberg,
Germany
Although minor motor and sensory deficits, or neurological soft signs
(NSS), are among the best established neurobiological findings in schizo-
phrenia, the question whether NSS are rather state or trait related is not yet
resolved. We therefore investigated NSS (i) in the clinical course of first
episode schizophrenia, (ii) in subjects with an increased genetic liability
of disease, and (iii) by using magnetic resonance imaging (MRI) with re-
spect to their potential cerebral correlates. NSS in first episode patients
were significantly elevated relative to healthy subjects and subjects with
an increased genetic liability at both examinations performed one year
apart. Whereas NSS remained stable in healthy subjects (time 1: mean =
4.8, SD = 3.3; time 2: mean = 4.6, SD = 3.9), they significantly decreased
in patients (time 1: mean = 15.7, SD = 7.1; time 2: mean = 10.1, SD = 7.9).
This effect was more pronounced in patients with a favourable versus
a chronic course and mainly accounted for by motor signs. Interestingly,
NSS scores obtained in the former were in the same range as those of high-
risk subjects. Follow-up NSS scores were predicted by NSS levels at t1 and
treatment compliance. Voxel based morphometry of MRI scans obtained in
103 first episode patients yielded significant associations of NSS-total-
scores with reduced gray matter densities in the pre- and postcentral gyrus,
middle and inferior frontal gyrus, lingual gyrus, caudate nucleus, thalamus
and cerebellum. Preliminary analyses of follow-up MRI scans taken in
a subsample after 1 year confirmed a progression of the respective changes
in the frontal and temporal cortices but not in the thalamus or the cerebel-
lum. Our findings demonstrate that NSS refer to both, state and trait char-
acteristics of schizophrenia. The variation of NSS in the clinical course is
clearly state dependent, while their association with genetic liability and
non-progressive cerebral changes refers to a trait. From a clinical perspec-
tive, NSS may serve as a marker of both, the disease process and genetic
liability.
ID: 550354
CANNABIS SMOKING AND WHITE MATTER IN
HEALTHY VOLUNTEERS
Matt Allin, O. Khan, M. Walshe, D. Kontis, C. Nosarti,
G. Barker, L. Rifkin, R. M. Murray
Psychological Medicine, Kings College London Institute of
Psychiatry, London, United Kingdom
Introduction: Cannabis smoking has been implicated in the aetiology of
psychosis, a condition that is associated with alterations of white matter
connectivity. We used Diffusion Tensor Imaging (DTI) to examine associ-
ations between cannabis and white matter in healthy volunteers. Methods:
DTI data were acquired in 45 healthy volunteers, at mean age 18.5 years
(SD 0.97), using a 1.5T GE MRI scanner. 30 individuals had used cannabis
at some point during their lives; 15 had been lifelong abstainers. There were
no significant group differences in age, socioeconomic status or gender dis-
tribution. We used group-mapping techniques implemented by locally-writ-
ten software (XBAM) to compare those with and without a history of
cannabis use. Results: The cannabis-using group had 2 clusters of reduced
fractional anisotropy relative to the abstinent group (P = .005). Coordinates
of the centres of mass of these clusters were: 34, 48, 10 (left occipito-
frontal and superior longitudinal fasciculi); and 20,46, 36 (right posterior
corona radiata) respectively. Conclusions: Cannabis use is associated with
reduced white matter integrity in healthy volunteers. Alterations of white
matter connectivity may underlie the propensity of cannabis to cause
psychosis.
ID: 550262
DIAGNOSTIC SPECIFICITY AND VALIDITY OF
BRAIN MORPHOLOGICAL ABNORMALITIES IN
SCHIZOPHRENIA SPECTRUM DISORDERS
Roberto Roiz-Santia´n˜ez1 D. Tordesillas-Gutie´rrez1,
R. Pe´rez-Iglesias1, I. Mata1, V. Ortı´z Garcı´a de la Foz1,
E. Marco de Lucas2, A. Gutie´rrez2, B. Crespo-Facorro1
1Psychiatry, University of Cantabria, University Hospital Marque´s
de Valdecilla, Santander, Spain; 2Neuroradiology, University
Hospital Marque´s de Valdecilla, Santander, Spain
We aimed to investigate the specificity and validity of the brain structural
abnormalities found in a putative broad sample of first episode patients
with non affective psychosis. 142 first episode patients with schizophrenia
spectrum disorders (schizophrenia:82, schizophreniform disorder:36, other
psychosis-schizoaffective and brief psychotic disorder-:24) and 83 healthy
volunteers were included in the study. MR images were acquired on a 1.5-T
GE Signa scanner and processed using the software BRAINS2. Sociodemo-
graphic and clinical variables were also assessed. We examined the volumes
of whole brain, whole brain gray matter cortical CSF and lateral ventricles,
gray matter volumes of cortical and volumes of subcortical regions. Re-
peated-measure analyses of covariance were used with group (schizophre-
nia, schizophreniform, other psychosis, control) as the between-subjects
factor, hemisphere as the within-subjects factor, and age as a covariate.
Post-hoc comparisons were performed using the Bonferroni adjustment
for multiple comparisons. Relative volume was used in the analyses. There
were significant differences between groups in relative brain tissue (F = 4.62,
P = .004), relative external CSF (F = 4.27, P = .006), relative thalamus (F =
2.84, P = .039), and relative lateral ventricle volumes (F = 3.54, P = .015).
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Post-hoc analyses revealed that total tissue volume was smaller in patients
with schizophrenia and shizophreniform disorder compared with controls
(P = .006, P = .36 respectively). External CSF volume was bigger in patients
with schizophrenia and schizophreniform disorder compared with controls
(P = .017 and P = .23 respectively). Thalamus volume was smaller in
patients with schizophrenia compared with controls (P = .039). Compare
with controls, schizophrenia patients showed greater ventricular volume
(P = .026) and schizophreniform disorder patients showed a trend level in-
crease (P = .073). In conclusion, 1.- brain structural abnormalities are al-
ready present at early phases of the psychotic illness; 2.- these brain
abnormalities seem to be specifically associated with the diagnoses of
schizophrenia and schizophreniform disorder. Thus, structural brain
anomalies might demarcate boundaries between nonaffective psychoses
and provide valid quantitative phenotypes for genetic research. Funding:
Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499,
PI060507, SENY Fundacio´ CI 2005-0308007, Fundacio´n Marque´s de Val-
decilla API07/011.
ID: 550251
OLANZAPINE AND HALOPERIDOL EFFECTS ON
HIPPOCAMPUS STRUCTURE IN FIRST-EPISODE
PSYCHOSIS
Daniel Mamah1, M. P. Harms1, L. Wang2,
D. M. Barch1,3, M. Styner4, J. Lieberman5
1Psychiatry, Washington University School of Medicine, St. Louis,
MO, USA; 2Psychiatry, Northwestern University, Chicago, IL,
USA; 3Psychology, Washington University, St. Louis, MO, USA;
4Neurodevelopment Disorders Research Center, University of North
Carolina, Charlotte, NC, USA; 5Psychiatry, Columbia University,
New York, NY, USA
Structural brain abnormalities occurring early in the development of
schizophrenia have been extensively described. In a previous longitudinal
study of first-episode psychosis (Lieberman et al. 2005, Arch Gen Psychi-
atry), patients treated with the ‘typical’ antipsychotic haloperidol showed
significant decreases in temporal lobe gray matter after 24 and 52 weeks,
which were not observed in patients treated with the ‘atypical’ antipsychotic
olanzapine. This implied possible haloperidol-associated toxicity or greater
therapeutic effect of olanzapine. In a follow-up study of the majority of
these patients, we tested the hypothesis that similar structural changes
will be present in the hippocampus (which is located within the temporal
lobe) as were found in temporal lobe gray matter. MRI scans of 145 patients
with first-episode psychosis (predominantly from schizophrenia) and 50
healthy controls were obtained from 14 academic medical centers (United
States 11, Canada 1, Netherlands 1, and England 1). Patients had been ran-
domly allocated to treatment with either olanzapine (5-20 mg/d; n = 73) or
haloperidol (2–20 mg/d; n = 72). Large-deformation high-dimensional brain
mapping (HDBM-LD) was used to evaluate both volume and shape of the
hippocampus at baseline and periodically for up to 104 weeks. At baseline,
gender-adjusted mean hippocampal volumes of patients with first-episode
psychosis were significantly smaller than that of controls (left: 2767 mm3 vs.
2986 mm3, P = .016; right: 3419 mm3 vs. 3684 mm3, P = .018). Hippocam-
pal shape analysis using MANOVA of reduced measures of surface vari-
ability (ie, principal components) resulted in even more significant
differences between probands and controls (left: Wilks lambda = 0.92,
P < .0001; right Wilks lambda = 0.70, P < .0001). At baseline, there
were no differences in either hippocampal volume or shape between sub-
jects allocated to the two treatment groups, consistent with the prior study
of the temporal cortex. We are currently analyzing longitudinal changes in
hippocampal volume and shape at weeks 12, 24, 52 and 104, to determine if
there is differential structural change across diagnosis and treatment.
ID: 550107
EFFECTS OF ANTIPSYCHOTICS ON BRAIN
STRUCTURE AT THE FIRST PSYCHOTIC EPISODE
AND 6 YEARS LATER
Paola Dazzan1, K. D. Morgan1, S. Reinders1, C. Morgan1,
P. Fearon1, J. Zanelli1, J. Suckling2, P. B. Jones2, P. K. McGuire1,
R. M. Murray1, J. Lappin1
1Division of Psychiatry, Institute of Psychiatry, London, United
Kingdom; 2Department of Psychiatry, University of Cambridge,
Cambridge, United Kingdom
The mechanisms underlying the different actions of antipsychotics on brain
remain poorly understood. We aimed to establish whether antipsychotics
affect brain anatomy, after short and long term treatment. We investigated
global brain volumes of 84 patients at their first psychotic episode (32 fe-
male; mean age 27.1 6 9 years; 47 with DSM IV Schizophrenia, 37 with
Other psychoses) and followed them up 6 years later. Dual echo MRI
data were acquired at 1.5T. Differences in grey matter between groups
were estimated at each intracerebral voxel after registration of images in
standard space. At the time of the first psychotic episode, 32 patients
were taking typical antipsychotics, 30 were taking atypicals, and 22 were
drug-free. There were no differences in global grey and white matter, and
CSF volumes, between patients exposed to either typical or atypical antipsy-
chotics and the drug-free patients. Over the 6 years follow up, the average
time spent on treatment, mostly with atypicals, was 3 years. 47 patients had
a second MRI scan at follow up. Length of time spent on atypicals was neg-
atively correlated with white matter volume at follow up (0.049), and pos-
itively correlated with follow up CSF volume (0.08), but only in patients with
schizophrenia or schizoaffective disorders. Long term exposure to atypical
antipsychotic drugs may affect white matter and CSF volumes.
ID: 550003
CAN WHOLE BRAIN VOXEL-BASED
MORPHOMETRY STUDIES APPLIED TO DTI DATA
LOCALIZE WHITE MATTER CHANGES IN
SCHIZOPHRENIA?
Eric D. Melonakos1, M. E. Shenton1,2, Y. Rathi1, S. Bouix1,
M. Kubicki1,2
1Psychiatry Neuroimaging Laboratory, Department of Psychiatry,
Brigham and Women’s Hospital, Harvard Medical School, Boston,
MA, USA; 2Department of Psychiatry, VA Boston Healthcare
System, Harvard Medical School, Boston, MA, USA
Voxel-Based Morphometry (VBM) is a whole brain, voxel-wise analysis
method that attempts to compare Diffusion Tensor Imaging (DTI) data
across subjects and between populations. A number of schizophrenia stud-
ies have utilized this method to localize differences in Fractional Anisot-
ropy (FA), a measure of white matter integrity, between patients and
normal controls. Using this method, FA differences are seen over the entire
brain at once and, using a statistical threshold, local differences in white
matter integrity are documented, thus providing a hypothesis-free route
for studying schizophrenia. The number of publications using this method
has grown, although it is unclear how reproducible this method is since
there have been no meta-analysis of VBM studies in schizophrenia to
date. Here, we analyze and combine results from 20 studies published to
date in order to evaluate the reproducibility of this method in DTI analysis.
Using 3D Slicer, we plotted coordinates of each region reported in every
VBM DTI study published thus far in schizophrenia onto a Montreal
Neurological Institute (MNI) atlas (points listed in Talairach atlas space
were converted into MNI space beforehand). Only statistically significant
coordinates representing reduced FA in schizophrenic patients were
plotted. For the papers with no points listed, coordinates were approxi-
mated by comparing the images in the papers to the Talairach atlas using
the Talairach Applet and Sleuth v.1.1. These points were subsequently
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converted into MNI space. The coordinates representing reduced FA in
patients with schizophrenia were scattered across the brain. The genu of
corpus callosum, the splenium of corpus callosum, the right anterior corona
radiata, and the right posterior thalamic radiation (including the optic ra-
diation) were the most consistently reported regions; each was reported in
30% of the papers we studied. Other instances of reduced FA were repli-
cated at an even lower rate. When compared on the same atlas, findings
from different papers were shown to be scattered across the brain and
largely inconsistent, with only a small number of regions being reported
individually in 30% of the papers reviewed. Differences in registration
and segmentation methods, followed by other factors such as statistical
threshold, subject age, medication, and/or other factors all likely contribute
to the inconsistent findings across studies. Such factors need further con-
sideration in future studies.
ID: 549968
CAUDATE AND HIPPOCAMPAL VOLUME
REDUCTIONS IN ANTIPSYCHOTIC-NAI¨VE
SCHIZOPHRENIC PATIENTS: LIFETIME ABUSE
SIDE-DIAGNOSIS MATTERS
Bjorn Hylsebeck Ebdrup1, W. F. Baare´2, H. Lublin1,
B. Y. Glenthoj1
1Psychiatric University Centre Glostrup, (1) Centre for
Neuropsychiatric Schizophrenia Research, CNSR, Glostrup,
Denmark; 2MR Department, Hvidovre University Hospital, (2)
Danish Research Centre for Magnetic Resonance, DRCMR,
Hvidovre, Denmark
Two recent meta-analyses indicate only hippocampal volume reduction and
ventricular enlargement to be consistently present in first episode schizo-
phrenia, Vita et al. Schizophr.Res (2006), Steen et al. Br.J.Psychiatry
(2006). Studies in antipsychotic-naı¨ve first episode schizophrenia patients
have generally focused on the basal ganglia. These studies tend to find re-
duced absolute volume caudate nucleus volumes, however, only few studies
reach significance, likely due to small sample sizes. This study aimed to con-
firm the presence of reduced hippocampal volumes and enlarged ventricles
in 38 antipsychotic-naı¨ve first episode schizophrenic patients as compared
to 43 matched healthy controls by means of VBM using a high-dimensional
non-linear inter-subject warping. Moreover, reduction in the caudate nu-
cleus was hypothesized. The possible effect of lifetime abuse was examined
by categorizing patients into two subgroups; without (n = 29) and with (n =
9) lifetime (but not current) substance abuse side-diagnosis. Patients were
diagnosed with SCAN interviews (DSM-IV). Clinical measures included
PANSS and Duration of Untreated Illness (DUI). Subjects underwent
a high-resolution 3D T1-weighted MRI-scan on a 3 Tesla scanner. Images
were analysed using SPM5 and spatial normalized with DARTEL. Small
volume correction was performed for hippocampus, caudate nucleus and
the lateral ventricles, using FDR (0.05) to control for multiple comparisons.
As hypothesized, patients as compared to healthy controls had significant
bilateral reduced hippocampal and caudate volumes. The hippocampal
reductions, however, were solely driven by the subgroup of patients with
lifetime substance abuse side-diagnosis, while the caudate reductions
were most prominent in the patients with no history of abuse. Ventricles
were not enlarged. Differences in global gray or white matter or CSF
were absent. Exploratory analyses revealed an association between left hip-
pocampal volume reduction and longer DUI. Our results support the pres-
ence of hippocampal and caudate reductions in first episode antipsychotic-
naı¨ve schizophrenic patients. The hippocampal reductions, however, seem
to be influenced by lifetime abuse and not specific to schizophrenia per se.
The latter agrees with the fact that hippocampal changes are observed in
various neuropsychiatric disorders, including substance abuse. Caudate
volume reductions, on the other hand, might be specific for schizophrenia
at the onset of the disorder.
ID: 549948
BRODMANN AREA ANALYSIS OF WHITE MATTER
ANISOTROPY AND AGE IN SCHIZOPHRENIA
Jason Schneiderman1,2, J. Zhang3, C. R. Goodman3,
R. E. Newmark3, Y. Torosjan3, E. L. Canfield3, V. Mitropoulou3,
C. Tang4, A. Hajianpour4, K. L. Davis3, J. Gorman3,
J. Friedman3, M. S. Buchsbaum3
1Psychiatry, Brigham and Women’s Hospital, Boston, MA, USA;
2Psychiatry, Harvard Medical School, Boston, MA, USA;
3Psychiatry, Mount Sinai School of Medicine, New York, NY, USA;
4Radiology, Mount Sinai School of Medicine, New York, NY, USA
Background: In Diffusion Tensor Imaging (DTI) healthy organized mye-
linated axon bundles have high anisotropy. Bundles where the fibers are
crossing, oriented in different directions, or in which the myelin or axons
are unhealthy have low anisotropy. This study investigates the changes in
white matter anisotropy by Brodmann Area in schizophrenia and between
first break and chronic disease states. Methods:97 adults with schizophre-
nia and 93 normal adults were scanned on a 3T MRI system. Each subject
received a structural (MP-RAGE) sequence and a diffusion tensor se-
quence. Average Fractional Anisotropy (FA) values determined for white
matter in each Brodmann Area in each hemisphere and T-tests were per-
formed between groups. To determine the effect of duration of illness anal-
ysis of covarience were performed on the anisotropy values controlled for
age for the white matter in each Brodmann region between the acute and
chronic subgroups Results: Fractional anisotropy (FA) in white matter was
decreased in patients with schizophrenia broadly across the entire brain, but
to a greater extent in white matter underneath frontal, temporal and cin-
gulate cortical areas. Both normals and patients with schizophrenia showed
a decrease in anisotropy with age but patients with schizophrenia showed
a significantly greater rate of decrease in FA in Brodmann area 10 bilat-
erally, 11 in the left hemisphere and 34 in the right hemisphere. When
the effect of age was removed, patients ill more than three years showed
lower anisotropy in frontal motor and cingulate white matter in compar-
ison to acute patients ill three years or less. Conclusions: In schizophrenia
deficits in language, memory, auditory hallucinations, social behavior, de-
cision making, emotional processing and motor functioning are associated
with the regions in which differences in anisotropy was seen. White matter
deficits in several regions of the brain change progressively between the first
break and the chronic state of the disease.
ID: 549866
ABNORMALITIES IN TENSOR MORPHOLOGY IN
PATIENTS WITH SCHIZOPHRENIA: A DTI STUDY
OF THE CORPUS CALLOSUM
Thomas Whitford1,2, M. Kubicki1, R. King1,
U. Khan1, D. Markant1, J. Alvarado1,
R. W. McCarley3, M. E. Shenton1,3
1Psychiatry Neuroimaging Laboratory, Department of Psychiatry,
Brigham and Women’s Hosptial, Harvard Medical School, Boston,
MA, USA; 2Melbourne Neuropsychiatry Centre, Department of
Psychiatry, University of Melbourne, Melbourne, VIC, Australia;
3Clinical Neuroscience Laboratory, Department of Psychiatry, VA
Boston Healthcare System, Harvard Medical School, Brockton,
MA, USA
This study uses diffusion tensor imaging (DTI) to provide a detailed char-
acterization of the diffusion properties of the corpus callosum in young
healthy adults, in order to better infer the microstructural features
of the commisural fibers. Additionally, in keeping with the prevailing
‘connectivity’ models of psychosis, this study also investigates abnormali-
ties in the diffusion properties of the corpus in patients with chronic schizo-
phrenia. 19 patients with chronic schizophrenia and 19 healthy controls,
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matched on age, handedness, and parental socioeconomic status, partici-
pated in this study. Diffusion-weighted images were acquired with 51
non-collinear gradients on a 3T GE magnet (1.7 x 1.7 x 1.7mm voxels),
and converted into DT images. The DT images underwent whole-brain
tractography, followed by an automatic clustering procedure, and clusters
constituting the corpus fibers were parcellated into 6 segments (frontal, pre-
motor, sensorimotor, parietal, visual and temporal) on the basis of the 3-
dimensional fiber projections. The diffusion properties of the corpus were
quantified via three scalar indices (fractional anisotropy (FA), trace and
mode), which were calculated and compared both between segments and
between clinical groups. FA and mode exhibited a similar and distinctive
‘U-shaped’ pattern of change from the genu to the splenium. The visual and
temporal fibers exhibited the highest anisotropy and most cylindrical mode,
while the premotor and sensorimotor fibers exhibited lower anisotropy and
a comparatively ‘disk-shaped’ mode. Trace was relatively stable between
corpus segments. Relative to the healthy controls, the schizophrenia
patients exhibited reduced FA in the frontal and temporal corpus segments.
It seems likely that the high FA and cylindrical mode exhibited in the visual
and temporal segments indicate that these fibers are either: a) more mye-
linated, b) more densely packed, c) more structurally coherent, and/or d)
experience less fiber crossings relative to other corpus fibers. The fact that
schizophrenia patients exhibited FA abnormalities in frontal and temporal
corpus suggests an anatomical basis for the aberrant inter-hemispheric
communication that has consistently been reported in patients with the dis-
ease. Furthermore, to the extent that DTI abnormalities have been shown
to influence axonal transmission velocities, these results provide support for
theories which emphasize neural timing abnormalities in the etiology of the
disease.
ID: 549641
ANATOMICAL ABNORMALITIES OF THE
HIPPOCAMPUS IN PATIENTS WITH
SCHIZOPHRENIA
Tiziano Colibazzi1, R. Bansal1, J. P. Sanchez1, R. Whiteman1,
C. Corcoran1, B. Wexler2, P. S. Bradley1
1Child Psychiatry, Columbia University, New York, NY, USA;
2Psychiatry, Yale University, New Haven, CT, USA
Although overall volumetric reductions of the hippocampus have been
reported in schizophrenia, findings have been inconsistent, revealing either
abnormalities in the head of the hippocampus or in its tail. The purpose of
this study is to clarify the pattern of anatomical abnormalities in the hip-
pocampus using surface analytic techniques in a larger sample. We studied
65 patients with schizophrenia and 60 healthy controls. Surface morphol-
ogies of the hippocampus were compared across diagnostic groups while
covarying for age, age2 and gender. We computed the signed Euclidean
distances from each point of the surface of the hippocampus of every
subject to the corresponding point on the hippocampus of a reference sub-
ject. We first used a rigid body similarity transformation to register each
participant’s brain with a template brain. Subsequently, we used these es-
timated parameters to register the manually defined hippocampus into the
template space. The transformed hippocampus of each subject was then
rigidly coregistered to the reference hippocampus and then warped onto
this reference structure using a non-rigid high-dimensional warping algo-
rithm. After identifying corresponding points on the surface of the hippo-
campus of each subject and of the reference hippocampus, we unwarped
each subject’s hippocampus in order to compute the distances. We detected
localized volumetric abnormalities in the right and, to a smaller extent, in
the left hippocampus. In the right hippocampus, volumetric reductions
were located in the lateral aspect of the head (anterior CA1) and in the
tail. An area of volumetric increase was also seen in the ventral aspect
of the head. In the left hippocampus, volumetric reductions were present
in the tail only. The anterior hippocampus is implicated in emotional, de-
fensive and autonomic responses by virtue of its connections with the
mOFC, the amygdala, the accumbens and the hypothalamus. The posterior
hippocampus, functionally linked to sensory and parietal areas as well as to
the PFC, is implicated in spatial learning, spatial memory and working
memory. Our study extends findings from prior imaging research and it
suggests that the involvement of both anterior and posterior hippocampus
could be the structural correlate of the disruption of fronto-limbic and
dorso-parietal circuitry in schizophrenia.
ID: 549494
EVIDENCE OF CEREBRAL WHITE MATTER
CHANGES ON COMBINED STRUCTURAL MRI AND
DIFFUSION TENSOR IMAGING IN FIRST EPISODE
SCHIZOPHRENIA
Kang Sim1, W. Y. Chan1, Ik Yung Lau1, M. Y. Chia1,
G. L. Yang2, D. Loh1, Y. Y. Sitoh3, W. Nowinski2
1Adult Psychiatry, Institute of Mental Health, Singapore,
Singapore; 2Biomedical Imaging Laboratory, Singapore Biomedical
Imaging Consortium, Agency for Science, Technology and Research,
Singapore, Singapore; 3Neuroradiology, National Neuroscience
Institute, Singapore, Singapore
Previous studies have revealed volumetric abnormalities of white matter in
patients with schizophrenia but the corresponding white matter dysconnec-
tivities are less studied in tandem. The aim of this study is to examine white
matter integrity in the region of white matter volume deficit in patients with
first-episode schizophrenia (FES). A cross-sectional, case-control design
was adopted and we used empirically-defined region of known white matter
volume deficit to interrogate diffusion tensors. The participants included
103 subjects comprising of 39 patients with FES and 64 age-, sex-, and
handedness-matched healthy controls. The neurocognitive domains
assessed included intelligence, attention, executive functioning, verbal
and spatial working memory. The main outcomes were gray and white-
matter partial volumes, fractional anisotropy, trace and geometric diffusion
indices. Structural voxel-wise analyses revealed that patients with first ep-
isode schizophrenia had lower gray matter volumes in bilateral hippocampi
(P < .01) and lower white matter volume in the right temporal-occipital
region (P< .005) corresponding to the inferior longitudinal fasciculus. Fur-
ther analyses of diffusion anisotropy in the right temporal-occipital region
revealed lower planar anisotropy, cp, and higher linear anisotropy, cl (P =
.012) in patients with first episode schizophrenia. However, no differences
were found for fractional anisotropy and trace in the implicated white mat-
ter region between the two groups. Patients performed poorer in digit span,
spatial working memory and executive functioning, compared to healthy
controls. To the best of our knowledge, this is the first study to employ
geometric diffusion measures in interrogating the nature of diffusion tensor
in schizophrenia. We confirmed previous findings of white matter volume
deficit in the region of inferior longitudinal fasciculus. The presence of
changes in geometric diffusion indices in the implicated white matter region
suggests that pathophysiological processes which underlie cerebral white
matter volume reduction may not be reflected by changes in fractional an-
isotropy. Further research is needed to better understand the nature of these
white matter changes and its progression in schizophrenia over time.
ID: 549454
PROGRESSIVE WHITE MATTER ABNORMALITIES
IN SCHIZOPHRENIA: A MULTI-SITE DIFFUSION
TENSOR IMAGING STUDY
Tonya White1,2, V. A. Magnotta3, H. J. Bockholt4, S. Williams4,
R. L. Gollub5,6, B. A. Mueller1, B. C. Ho7, R. Jung4, V. P. Clark4,9,
J. Lauriello8, J. R. Bustillo8, S. C. Schulz1, N. C. Andreasen7,
V. D. Calhoun4,9, K. O. Lim1,2
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5Psychiatry, Massachusetts General Hospital, Boston, MA, USA;
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Diffusion tensor imaging (DTI) is a magnetic resonance imaging method
that measures the spatial profile of the self diffusion of water molecules in
tissue. DTI is sensitive to disruptions in white matter microstructure and
may reflect aberrant connectivity between brain regions. The existing
DTI studies examining patients with schizophrenia tend to have relatively
small numbers and have disparate patterns of white matter abnormalities.
One approach to increasing the number of subjects in clinical studies is to
use multiple acquisition sites. While dramatically increasing the number of
subjects, multi-center studies have added methodological issues related to
site differences in scanning equipment and subject demographics. This
study presents DTI results from a large multicenter study that involved
the Massachusetts General Hospital and the Universities of Iowa, Minne-
sota, and New Mexico. The participants included 114 patients with schizo-
phrenia (31 first-episode (FE) and 83 chronic patients) and 138 controls (43
matched to the first-episode and 95 matched to the chronic patients). The
mean ages for the chronic and FE patient groups were 36.4 (SD 11.0) and
25.2 (SD 6.7), respectively. The mean ages for the control groups were 34.0
(SD 11.3) and 25.6 (SD 6.6), respectively. Positive, negative, and disorga-
nized symptom scores measured using the SANS and SAPS were similar
between the patient and FE groups. There was a significant effect of
site, and thus site was used as a covariate in the analyses. Patients with
chronic schizophrenia had lower fractional anisotropy (FA) in the whole
brain, and in the frontal, parietal, occipital, and temporal lobes, but did
not have lower FA in the brainstem or the cerebellum. FA was not signif-
icantly different between the FE patients and in all brain measures. How-
ever, comparing the chronic and FE patients, only the frontal lobe had
significantly lower FA There is a trend for the FE patients to show FA in-
termediate between the control and chronic groups. Our findings suggest
progressive alterations in white matter microstructure in cortical regions in
patients with schizophrenia.
ID: 549443
ABNORMALITIES IN HIPPOCAMPUS VOLUME
AND SHAPE IN NONPSYCHOTIC, ADOLESCENT/
YOUNG ADULT BIOLOGICAL RELATIVES OF
SCHIZOPHRENIA PROBANDS
Beng-Choon Ho1, L. Fuhrmeister1, M. A. Ingalhalikar2,
R. Pierson1, V. Magnotta3
1Psychiatry, University of Iowa, Iowa City, IA, USA; 2Engineering,
University of Iowa, Iowa City, IA, USA; 3Radiology, University of
Iowa, Iowa City, IA, USA
Biological relatives of schizophrenia probands are more likely to have sim-
ilar but subtler neuroanatomic, electrophysiologic, neurocognitive and be-
havioral deficits as schizophrenia probands. Most family studies to-date
have examined older relatives. Studying adolescent or young adult relatives
who are still at-risk has the potential to increase our understanding of the
neurodevelopmental etiology of schizophrenia, and to discover biomarkers
that may aid in early identification of the disorder. In this study, we utilized
an artificial neural network segmentation algorithm to automatically define
and reliably measure MRI hippocampus volumes. We compared 46 non-
psychotic first- or second-degree relatives of schizophrenia probands
against 46 healthy volunteers (HNV) without family history of schizophre-
nia (Mean age = 20.4 years; Range = 13 to 28 years). Relatives had signif-
icantly smaller left hippocampus volumes than HNV (F = 4.53, P = .04). On
examining hippocampus volume-age relationships, we found hippocampus
volume normally decreases with age during late adolescence into early
adulthood. In contrast, relatives did not show these age-expected changes
which may be indicative of aberrant hippocampal neurodevelopment. We
further assessed how obstetrics complications (a trigger for aberrant neuro-
development in utero) may contribute to hippocampus volume deficits.
Relatives with a history of obstetrics complications (N = 28) had signifi-
cantly smaller left and right hippocampi than relatives without obstetrics
complications (F 4.31, P .04). In both relatives sub-groups, hippocam-
pus volume-age relationships again differed from the age-expected reduc-
tions in HNV (Left: Pearson partial correlations = 0.26, 0.07 and 0.16
for HNV, relatives with and without obstetrics complications respectively;
Right: r = 017, 0.04 and 0.22 respectively). We further analyzed hippo-
campal shape using spherical harmonics functions. Relatives had deform-
ities in the heads of bilateral hippocampi corresponding to inward
displacements compared to HNV. Schizophrenia likely involves different
aberrant neurodevelopmental processes. Some neurodevelopmental anom-
alies occur during early brain maturation while others may manifest closer
to illness onset in adolescence/early adulthood.
ID: 549200
IS THERE ROOM FOR THE ‘LITTLE BRAIN’ IN
PSYCHOSIS? AN MRI STUDY EXAMINING
CEREBELLAR VOLUME AND NEUROLOGICAL
FUNCTION IN FIRST EPISODE PSYCHOSIS
Monica Anna Charalambides1,2, J. M. Lappin1,2, K. D. Morgan1,2,
C. Morgan2,3, P. Fearon4,2, E. Okon-Rocha2, P. B. Jones5,
R. M. Murray1,2, P. Dazzan1,2
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Psychiatry, Institute of Psychiatry, London, United Kingdom;
4Psychosis, Institute of Psychiatry, London, United Kingdom;
5Psychiatry, University of Cambridge, Cambridge, United Kingdom
The role of the cerebellum in psychosis has been suggested to be important
in contemporary research. This study examined the relationship between
cerebellar volume and neurological soft signs in first episode psychosis
(FEP) patients compared to healthy controls. Cerebellar volume and neu-
rological soft signs were also compared between schizophrenia and other
psychoses. Data were collected from 80 FEP patients (male:female 49:31;
mean age 27.7 years 6 8.1) and 43 healthy controls (male:female 21:22;
mean age 31.0 years 6 9.3) from the London arm of the ÆSOP study. Scans
were acquired with a General Electric Signa 1.5-T system and whole
cerebellum volume was obtained using stereologically unbiased volume es-
timation. An expanded version of the Neurological Evaluation Scale was
used, comprising the following subscales; Primary, Sensory Integration,
Motor Coordination, and Motor Sequencing. All comparisons were ad-
justed for age, gender, and ethnicity. FEP patients had a significantly small-
er cerebellum volume than healthy controls (P = .02). In addition,
schizophrenia patients had a significantly smaller cerebellum volume
than other psychoses patients (P = .049). FEP patients had a higher total
NSS score than controls (P = .001), but there was no difference in NSS
scores between diagnostic subgroups. There was no relationship between
cerebellar volume and NSS global scores or classical motor cerebellar signs
in either patients or controls. Similarly, there was no such relationship in
either the schizophrenia or other psychoses subgroups. Inclusion of pre-
morbid IQ as an additional covariate did not affect results. This study sug-
gests that cerebellar volume is reduced in FEP patients compared to
controls, and that this is more marked in schizophrenia compared to other
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psychoses. In addition, NSS were greater in subjects compared to controls.
However, despite the presumed importance of the cerebellum in neurolog-
ical function, no functional link with global volume was found in this study.
This may reflect the fact that global cerebellar volume is a very gross mea-
sure of cerebellar structure; thus a more detailed analysis into cerebellar
sub-regions is necessary.
ID: 549029
VOXEL-BASED MORPHOMETRY OF PATIENTS
WITH SCHIZOPHRENIA AND BIPOLAR
I DISORDER
Jun-Seok Lee1,2, G. G. Brown1,2, I. Strigo2, M. Caligiuri1,2,
M. J. Meloy1,2, J. B. Lohr1,2
1Psychiatry, VA San Diego Healthcare System, San Diego, CA,
USA; 2Psychiatry Department, University of California at San
Diego, San Diego, CA, USA
The issue of similarities and differences in neuroanatomical structure be-
tween schizophrenia (SZ) and bipolar I disorder (BP), and how each group
differs from healthy individuals is a long-standing question in psychiatry.
Recently, voxel-based morphometry (VBM) has been increasingly applied
in elucidating structural brain changes associated with these functional psy-
chotic disorders. However, VBM studies in SZ and BP have reported in-
consistent results. Potential causes of these inconsistencies include
differences in the samples studied, especially differences in age, gender, du-
ration of illness, or subtypes of BP. The aim of the study was to compare
gray matter volumes in a cross-sectional VBM design including subjects
with chronic SZ, chronic BP and healthy control (HC) subjects matched
for age, gender and duration of illness. Seventeen subjects with SZ, 15 sub-
jects with BP, and 21 HC subjects without psychiatric illness were studied.
Study inclusion criteria were 1) age: 25–70; 2) duration of illness: over 3
years; and 3) DSM-IV bipolar I disorder or schizophrenia. Groups were
well matched on age, gender, and illness duration. Scans were performed
with a 1.5-Tesla Siemens Magnetom Vision scanner using an MPRAGE
protocol (TR = 24 ms, TE = 5 ms, 1.0 mm thickness, voxel size = 1.0 3
1.0 3 1.0 mm). Data preprocessing and statistical analysis were performed
using the VBM5 toolbox, which utilizes the new unified segmentation ap-
proach to optimize VBM and is implemented in SPM5. Preprocessed
images were compared between diagnostic groups using an ANCOVA
model controlling for the possible effects of age and gender. Significance
was set at a p value of P < .001, uncorrected, with a minimum cluster
size of 200 voxels. Then, a cluster-level threshold of P < .05, corrected
for multiple comparisons, was applied. Compared with HC group, SZ
and BP groups showed evidence of reduced right middle frontal region
and right superior and middle temporal regions. However, reductions in
bilateral thalamic regions and right hippocampus, amygdala and putamen
were specific to SZ group. The results suggest similarities and differences in
affected gray matter volumes in patients with SZ and BP, even when the two
groups are matched on age, gender, and illness duration. These similarities
and differences of structural abnormalities may be important factors in the
common and differential manifestations of these two functional psychotic
disorders.
ID: 548907
PARACINGULATE ASYMMETRY IN
SCHIZOPHRENIA
Christiana M. Leonard1, S. D. Towler1, S. Welcome3,
C. Chiarello3, J. M. Kuldau2
1McKnight Brain Institute, University of Florida, Gainesville, FL,
USA; 2Veterans Administration Research Service, , Gainesville, FL,
USA; 3Psychology, University of California, Riverside, CA, USA
Structural correlates of hemispheric dominance for language are found in
medial frontal cortex and superior temporal lobe. The paracingulate sulcus,
a shallow sulcus that courses dorsal to the cingulate sulcus is more frequent
on the left (Ide et al., 1999; Paus et al., 1996) in normal adults but not in
schizophrenia (Le Provost et al., 2003; Yucel et al., 2002). Interestingly,
a dorsal paracingulate sulcus was not identified by Ono et al., 1990). In-
stead, a large ‘‘double parallel’’ sulcus originating inferior to the genu of
the corpus callosum ran parallel to the cingulate in about 25% of both
the left and right hemispheres. In the present study of 46 adults (37 M,
9 F) with chronic schizophrenia (S), 37 (34 M, 3 F) controls (C) matched
on age and SES, and 200 normal young adults (YA) (100 M, 100 F), we
replicated Ono’s finding of symmetry for the double parallel sulcus. Raters,
blind to hemisphere, sex, and diagnosis, then used Yucel’s criteria to rate
the size of the dorsal paracingulate sulcus. This sulcus was significantly
larger on the left in all samples (S: t45 = 2.4, P < .02; C: t38 = 3.0, P <
.005; YA: t199 = 5.23, P < .0001) and this asymmetry was not affected sig-
nificantly by sex, writing hand, diagnosis, or cognitive status. As this sam-
ple of schizophrenics also has normal leftward planar asymmetry it appears
there must be particular conditions associated with disrupted brain asym-
metry in schizophrenia. Supported by a Veterans Administration Research
Service Merit Review Grant (JK) and NIH DC 006957 (CC).
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Table. Percent of of each sample demonstrating rightward asymmetry,
symmetry and leftward asymmetry of the paracingulate sulcus.
L<R L = R L>R
S (n = 46) 20 30 50
C (n = 39) 13 37 50
YA (n = 200) 26 22 52
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The progression of white matter deficits and their relationship with age in
schizophrenia is not well understood. Fronto-temporal white matter tracts
represent an important susceptibility network in schizophrenia. Diffusion
tensor imaging (DTI) is a powerful tool that can measure white matter tract
integrity. Moreover, diffusion tensor tractography allows such measure-
ments to be carried out along white matter tracts. The present study exam-
ines three frontotemporal tracts in schizophrenia patients and healthy
controls across the adult lifespan using diffusion tensor tractography. 30
individuals with schizophrenia or schizoaffective disorder and 22 healthy
controls ranging from 25–78 years were matched on parental socioeco-
nomic status, gender, and age, and all subjects were right-handed. Diffusion
gradients were applied in 23 non collinear directions, with two b = 0 images,
whole brain coverage, repeated three times, on a 1.5 T GE system. Follow-
ing co-registration, whole brain seeding and tractography, the uncinate fas-
ciculus (UF), inferior occipito-frontal fasciculus (IOFF), and cingulum
bundle (CB) were segmented. Fractional anisotropy, trace, radial, and axial
diffusivity were calculated. Using Pearson correlation coefficients, left side
fronto-temporal tract FA for each of UF and IFOF and CB were signif-
icantly negatively correlated with age in schizophrenia (r =.376, P = .019,
r = .498, P = .006 and r = .341, P = .05 respectively) and in healthy con-
trols (r = .428, P = .004, r = .398, P = .012, and r = .375, P = .04 re-
spectively). While there were no differences between the late life groups, the
early adult life schizophrenia group showed decreased FA in left UF (P =
.035), right CB (P = .028), decreased axial diffusivity in left CB (P = .029)
and increased radial diffusivity in right IOFF (P = .031) when compared to
the early adult life control group. There is growing evidence that abnormal-
ities of white matter integrity are progressive in schizophrenia, rather than
occurring entirely prior to the first episode of psychosis. Our DTI tractog-
raphy study across the adult lifespan in schizophrenia presents evidence
that there are differences in white matter integrity in schizophrenia com-
pared to controls, and that these differences are primarily detectable in
the first half of adult life. Damage to fronto-temporal white matter tracts
may be progressive in the first half of adult life but not in late life in schizo-
phrenia compared to controls.
ID: 548671
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J. Zanelli1, K. D. Orr2, G. Hutchinson3, P. K. McGuire1, P. Jones4,
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Introduction: An excess of neurological signs is present in psychosis, par-
ticularly in primary and motor coordination signs. It remains unclear
whether these signs progress over the course of the illness, and it has never
been investigated whether any progression is associated with changes in
brain structure. Methods: We evaluated 49 individuals (mean age 27 years
68; 59% males; 45% DSM IV schizophrenia) at the time of the first psy-
chotic episode and 6 years later. We investigated neurological function us-
ing the Neurological Evaluation Scale, and grey matter volume using
Magnetic Resonance Imaging, with a 1.5 T GE scanner. We estimated
grey matter volume with automated segmentation methods. Results: Rates
of primary and motor coordination signs remained stable over the follow
up period, as did motor sequencing signs. In contrast, sensory integration
signs increased over the follow up period (P = .007). Higher rates of primary
signs (at baseline) and higher rates of motor coordination signs (at follow
up) were correlated with more grey matter loss over follow up (P = .05 and P
= .07 respectively). Conclusions: Primary and motor coordination deficits
may represent trait markers of psychosis and their presence may be predic-
tive of a more progressive illness course. Further work will investigate
whether these signs are also associated with regional brain changes.
ID: 548642
REGIONAL BRAIN CORTICAL THICKNESS DIF-
FERENTIATE SCHIZOPHRENIA FROM BIPOLAR
DISORDER AND HEALTHY CONTROLS
Cecilie Bhandari Hartberg1, L. M. Rimol1,2, R. Nesva˚g3,
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Schizophrenia and bipolar disorder are currently classified as separate ill-
nesses. Clinical and genetic studies suggest similarities between the disor-
ders, while neuroimaging studies of the cerebral cortex have not
consistently shown structural similarities. Previous studies have shown re-
gional alterations in prefrontal cortex areas in bipolar disorder (1) and pre-
frontal and temporal cortex areas in schizophrenia (2), as compared to
healthy controls, suggesting overlapping but dissimilar patterns of regional
cortical alterations. In the present study, we measured cortical thickness in
subjects with schizophrenia and bipolar disorder and in healthy adults en-
rolled in the Thematic Organized Psychosis Research Study (TOP) and
assessed for differences across the three groups. Subjects included patients
with schizophrenia (n = 112), bipolar disorders (n = 84) and healthy subjects
(n = 101) were included. Patients were diagnosed according to DSM-IV and
all participants underwent MR scanning. The FreeSurfer software was used
for all automated image processing and to obtain estimates of cortical
thickness. All analyses were corrected for age. Results were presented as
continuous surface maps depicting statistical significant differences in cor-
tical thickness between the subject groups. To adjust for multiple compar-
isons the level of significance was set at a False Discovery Rate of 0.05. In
schizophrenia thinner cortices were found in several localized frontal areas
and the superior temporal area in both hemispheres, as compared to
healthy controls. In bipolar disorder no significant differences were found
compared to healthy controls. Thinner cortices were found in the left su-
perior temporal gyrus in schizophrenia compared to bipolar disorder. In
frontal brain areas, cortical thickness in bipolar disorder did not signifi-
cantly deviate from either schizophrenia or healthy controls, which suggest
morphological similarities with both groups. A thinner cortex in the left
superior temporal gyrus may differentiate patients with schizophrenia
from patients with bipolar disorder.
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AN MRI REGIONAL BRAIN VOLUMETRIC
ANALYSIS IN ANTIPSYCHOTIC-NAI¨VE FIRST
EPISODE PSYCHOSIS SUBJECTS BEFORE AND
AFTER ATYPICAL ANTIPSYCHOTIC TREATMENT
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Fronto-striatal neural pathways represent a priority for research in first-
episode psychosis (FEP), as altered regulation of cortical and sub-
cortical dopamine pathways have been implicated in the etiology of
psychosis. In the current study we examined total brain, frontal and
basal ganglia white and grey matter volumes in a cohort of antipsy-
chotic-naı¨ve FEP subjects and healthy volunteers. Twenty-five FEP
and 31 healthy subjects were recruited. A total of 23 FEP subjects
and 28 healthy volunteers completed all follow-up assessments. Subjects
were scanned on a Philips 3T Achieva MRI Scanner at baseline, 4 weeks
and 8 weeks after start of low-dose atypical antipsychotics; MR segmen-
tation was automated. Symptom severity was assessed at each time point
using the Positive and Negative Symptoms Scale (PANSS). Follow-up
comparisons were performed on baseline and 8-week follow-up meas-
ures. At 8-weeks 21 of 23 FEP subjects were being treated with atypical
antipsychotics (19 received risperidone, 2 received quetiapine). Mean to-
tal baseline PANSS scores were 47.3, and 32.4 at 8-week follow-up.
Baseline frontal white and grey matter volumes were not significantly
different between FEP subjects and controls (all P-values > 0.050).
At follow-up FEP subjects experienced significant increases bilaterally
in frontal grey matter volume after treatment with atypical antipsy-
chotics (Left: P = 0.009. Right: P = 0.02). No significant changes in white
matter volume were observed. In basal ganglia, FEP subjects had sig-
nificantly larger left nucleus accumbens volumes compared to healthy
volunteers at baseline (P = .0008). No differences in left or right caudate,
putamen or globus pallidus were observed between groups at baseline
(all P-values > 0.40). Striatal volumes remained stable at follow-up
and no changes were observed in FEP subjects or healthy volunteers.
Antipsychotic-naı¨ve FEP subjects displayed differences in regional
brain grey and white matter volumes compared to healthy controls,
with both left and right frontal grey volume increased after atypical an-
tipsychotic treatment. In contrast, striatal volumes were unchanged by
exposure to low-dose atypical antipsychotic exposure, despite baseline
abnormalities of left nucleus accumbens in FEP subjects. The findings
provide further evidence for the importance of fronto-striatal brain regions
in early psychosis.
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We examined the relationship between cortical parameters (thickness, sur-
face area and grey matter volume) and cognitive measures in a group of
patients with first episode psychosis (FE) compared to healthy controls.
37 patients (25 males; mean age 26.76) and 38 controls (22 males; mean
age 24.98) were imaged on a 1.5T GE Signa MRI scanner. Patients had
received medication for less than 12 weeks. A T1-weighted axial dataset
was obtained using an IR-SPGR echo sequence with a 24 cm field of
view and 256 x 256 matrix size to provide a resolution of 1.2 x 1.2 x 1.2
mm3. A total of 124 contiguous slices were acquired (TR = 15ms; TE =
5.4ms; flip angle = 15o). Images were processed using FreeSurfer software
(version 4.0.1) that allows the measurement of cortical parameters using
automated segmentation and surface topographical analysis. Premorbid
IQ, current IQ, executive functions (working memory span, set shifting,
planning, working memory manipulation) and episodic recall memory
were measured. Associations between cortical parameters and cognitive
measures were examined using linear mixed models. There were no signif-
icant differences in age, gender or handedness between patients and con-
trols, but patients performed worse on all cognitive tests and showed
smaller temporal area. The association of frontal area with premorbid
IQ (z = 2.28, P = .023), current IQ (z = 3.11, P = .002) and set-shifting
(z = 2.49, P = .013) was different in patients and controls. In patients,
but not in controls, frontal area was associated with current IQ (z =
3.52, P < .001) and set-shifting (z = 3.03, P = .002). Patients also had
a different association of frontal volume with premorbid IQ (z = 2.39,
P = .017) and current IQ (z = 3.08, P = .002) from controls, although there
were no differences in regional associations by diagnostic group. No asso-
ciations were present between temporal cortical parameters and cognition
or between side and cortical or cognitive measures. The most salient find-
ings of our study were the differences in cortical area between patients and
controls and the association between area of frontal cortex, current IQ and
set shifting in patients, suggesting that in FE better cognitive performance is
accompanied by larger frontal cortical area. By contrast, cortical thickness
was not related to cognition. This pattern of cortical abnormalities is dif-
ferent from that observed in progressive neurodegenerative disorders and
points to a developmental abnormality.
ID: 548428
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Annabella Di Giorgio1,2, G. Caforio1, G. Blasi1,
A. Papazacharias1, R. Romano1, L. Fazio1, L. Lo Bianco1,
M. Nardini1, G. Pero2, T. Popolizio3, A. Bertolino1,3
1Psychiatric Neuroscience Group, Department of Psychiatry and
Neurology, University of Bari, Bari, Italy; 2Department of
Neuroscience, University of Catania, Catania, Italy; 3Section of
Neuroradiology, IRCCS Casa Sollievo della Sofferenza,
S.G. Rotondo (FG), Italy
Cathecol-O-Methyltransferase (COMT) Val158Met is thought to modulate
dopamine regulated neuronal plasticity in prefrontal cortex and in hippo-
campus in healthy subjects, and to weakly increase risk for developing
schizophrenia. Recently we have demonstrated an association of COMT
Val158Met with the phenotype of hippocampal physiology during memory
encoding in schizophrenia. Aim of the present study was to investigate if
this polymorphism is also associated with hippocampal gray matter (GM)
volume in schizophrenia. 28 controls and 26 patients with schizophrenia
(DSM-IV criteria) matched by COMT Val158Met genotype and by a series
of socio-demographic variables were recruited. All patients were on stable
antipsychotic treatment. Structural images were acquired on a GE 3T scan-
ner using a gradient echo fast SPGR sequence with 124 sagittal slices of 1.3
mm thickness. Voxel Based Morphometry analysis and second level
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random effects analysis (Factorial ANCOVA) were performed within
SPM5 (all P < .005). A region of interest approach centered on the HF
(WFU PiclAtlas) was used. We found a main effect of genotype, with
Met/Met subjects showing reduced GM volume in left HF compared to
Val homozygote; a main effect of diagnosis, with healthy subjects showing
greater GM volume than patients in left anterior HF; and a gene-by- di-
agnosis interaction, in that the effect of diagnosis on HF GM was evident
only in Met/Met subjects. As suggested by the lack of correlation with
chlorpromazine equivalents, these differences were not because of pharma-
cological treatment. Collectively, our data indicate that COMT genetic var-
iation may differentially contribute to modulate the phenotype of
hippocampal morphometry in patients with schizophrenia.
ID: 548367
WHITE MATTER DISRUPTION IN INDIVIDUALS
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RISK DETERMIEND BY SPECIFIC GENETIC
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There is strong evidence of white matter abnormalities and altered connec-
tivity in schizophrenia and bipolar disorder, but there is a lack of studies
examining diagnostic specificity, disruptions in high risk groups or the re-
lationship to specific susceptibility genes. In a series of linked experiments,
we used MRI and diffusion tensor MRI to assess white matter integrity in
patients with bipolar I disorder, schizophrenia, subjects at high risk of
psychosis and healthy controls. We also examined white matter associa-
tions with risk-associated variants in Neuregulin I and ErbB4. Fractional
anisotropy (FA) was compared between the groups using voxel-based
morphometry, automated region of interest analysis and probabilistic
tractography. Patients with both disorders showed reduced FA in fronto-
thalamic and frontotemporal connections compared with controls and
these deficits were related to risk associated genetic variants, including
NRG1 and ErbB4. Reduced white matter density and integrity is common
to both schizophrenia and BD and those at high risk for genetic reasons.
The white matter disruptions appear to be determined by shared genetic
risk factors.
ID: 546715
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RELATIONSHIP WITH CLINICAL SYMPTOMS
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Background: Thinning of the neocortex has previously been demonstrated
in individuals with schizophrenia. In this study, we used principal compo-
nents analysis (PCA) to examine the pattern of cortical thinning in schizo-
phrenia subjects compared to healthy individuals. We hypothesized that
cortical thinning would be more prominent in fronto-temporal regions.
Method: 42 healthy participants and 42 subjects with schizophrenia
were recruited from a ongoing longitudinal study of psychopathology, cog-
nition and brain structure. Groups were matched for age, gender, race, ed-
ucation, handedness, and parental SES. Positive, Negative, and
Disorganized symptoms domains were assessed using the SAPS and
SANS. Structural data were processed using FreeSurfer 3.0.5 with user su-
pervision. Cortical parcellations were obtained. PCA with Varimax rota-
tion on cortical thickness was conducted for each hemisphere. One-way
ANOVAs were performed on the principal component scores for group
analysis. Pearson correlations were calculated between the PCA scores
and clinical symptoms. Results: Across both groups of subjects, a left hemi-
sphere PCA yielded 6 components that explained;70% of variance. Based
on variable loadings, the LH components are described as: Lateral-medial
Parietal/Occipital, Superior Medial Frontal, Dorsal Medial Frontal, Lat-
eral Temporal, Ventolateral Frontal, and Anterior Temporal. A RH
PCA yielded 6 components that explained ;70% of variance. These are
described as: Dorsolateral Parietal/Temporal, Dorsolateral-medial Pre-
frontal, Dorsomedial Parietal/Occipital, Cingulate Cortex, Ventral Tempo-
ral, and Ventromedial Occipital. The RH Dorsolateral Parietal/Temporal
component revealed a trend-level difference (F = 6.01, P = .016), while other
components did not show group differences. This factor was negatively cor-
related with negative symptoms in the schizophrenia group (r = .355, P =
.021). Conclusions: Individuals with schizophrenia in this study exhibit
a pattern of cortical thinning in parietal/temporal regions. Thinning in
this region was correlated with more severe negative symptoms in the
schizophrenia subjects. These findings lend support to the hypothesis
that temporal and parietal heteromodal cortices play an important role
in the pathogenesis of schizophrenia, and perhaps, in particular, the
expression of negative symptoms. Support: MH071616 and MH056584.
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FRONTO-TEMPORAL DISCONNECTIVITY
REVEALED BY TRACTOGRAPHY IN
FIRST-EPISODE PSYCHOSIS
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Mental Health University Institute, Verdun, QC, Canada
Background: Changes in fronto-temporal anatomical connectivity have
been proposed to be a central feature of pathophysiology in schizophrenia,
with early occurrence. However, it remains unclear whether these changes
exist early in the disease process during a first-episode of psychosis (FEP).
Our study investigated whether baseline measures of white matter integrity,
as assessed by diffusion tensor imaging (DTI) are related to symptom se-
verity. Methods: Fifty-one FEP patients and 30 healthy controls completed
DTI scans at baseline. FEP patients completed clinical assessments evalu-
ated with SAPS and SANS. White matter integrity was assessed using frac-
tionation anisotropy (FA) and total volumes. A probabilistic DTI-based
tractography algorithm was used to generate tracts connecting frontal
and temporal regions. Analyses focused on the uncinate fasciculus
(UNC), the superior longitudinal fasciculus (SLF) and the cingulum.
For the cingulum two separate segments were defined: the upper part along
the cingulate gyrus (CGC: cingulum cingulate gyrus part) and the lower
segment along the ventral side of the hippocampus (CGH: cingulum hip-
pocampal part). Relationships between symptoms severity and structural
values in areas showing between-group differences were also examined.
Results: Volumetric measurements indicated no significant between-group
differences in the three tracts. In contrast, lower FA values in FEP were
observed for the UNC and the SLF, but not for both parts of the cingulum,
relative to controls. With respect to symptoms, FA values for the UNC
were inversely correlated with negative symptoms and positively correlated
with positive symptoms. For the SLF, significant correlations emerged be-
tween FA values and negative, but not positive, symptoms. Conclusion:
The FA decrease, associated with preserved volumes, in the UNC and
the SLF suggests anatomical abnormalities of fronto-temporal connectivity
in FEP, possibly resulting from disordered fiber networks or decreased
neuropil density. These results also provide evidence that these early ana-
tomical abnormalities are highly predictive of negative symptoms, and may
constitute a predominant pathophysiological marker of psychosis.
ID: 550824
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NO DIFFERENCES IN THE PREVALENCE OF
CAVUM SEPTUM PELLUCIDUM AND ADHESIO
INTERTHALAMICA BETWEEN FIRST-EPISODE
PSYCHOTIC PATIENTS AND HEALTHY
CONTROLS: A POPULATION-BASED STUDY
Clarissa Trzesniak1, M. Schaufelberger2, P. R. Menezes3,
M. Scazufca3, F. Duran2, D. Arau´jo1, C. Chaves1, A. Filho1,
M. C. Freitas-Ferrari1, R. Murray4, P. McGuire4, J. Hallak1,
J. A. Crippa1, G. F. Busatto2
1Neuropsychiatry and Medical Psychology, University of Sa˜o Paulo,
Ribeira˜o Preto, Brazil; 2Psychiatry, University of Sa˜o Paulo, Sa˜o
Paulo, Brazil; 3Preventive Medicine, University of Sa˜o Paulo, Sa˜o
Paulo, Brazil; 4Psychiatry, University of London, London, United
Kingdom
Early neurodevelopmental alterations are considered one of the possible
etiologic hypotheses for psychosis. Two of these abnormalities are the cav-
um septum pellucidum (CSP) and the absence of adhesio interthalamica
(AI). Several magnetic resonance imaging (MRI) studies have investigated
CSP and AI in psychosis, with conflicting findings. Differences in the prev-
alence of large CSP were seen in eight of 16 researches; and five of ten stud-
ies related higher incidence of non-AI in patients. Such discrepancies could
be partly explained by differences in imaging techniques, CSP/AI definition
criteria among the reports, and heterogeneity in the selection of the sample.
For minimizing these contradictory results, recent works have employed
more quantitative methods to analyze CSP e AI. However, there is no study
that has carefully selected the subjects, particularly using a population-
based sample. The objective of the present research was to evaluate, by
using MRI, the CSP and the non-AI in first-episode psychotic patients,
including a population-based sample in order to examine these alterations.
The sample was composed by 122 first-episode psychotic subjects, who
established contact with mental health services in the city of Sa˜o Paulo be-
tween 2002 and 2005. For obtaining a population-based sample of controls,
94 next-door neighbors of each patient were invited to participate, matched
on socio-demographic characteristics of cases. We investigated prevalence
of small and large CSP (ie,  6 mm in length) and the volume of the cavity,
as well as the incidence of non-AI. No significant differences were found
between patients and controls in any of the measures of CSP and AI. Like-
wise, there was no association between these structures and neuropsycho-
logical tests. However, the absence of AI was higher among men when all
the subjects were pooled together. This increased prevalence of non-AI in
men is in agreement with the literature, given that sexual dimorphism seems
to be related to abnormalities in this structure. On the other hand, the lack
of differences between patients and controls in both CSP and AI data sug-
gests that these abnormalities may not be neurodevelopmental markers of
psychosis and cast doubt over the notion that they play a major role in the
neurobiology of such disorders. Further, it emphasizes the importance of
the strict selection of the sample, since bias in subject’s recruitment could
interfere in the results of case-control studies.
ID: 551903
STRUCTURAL CORRELATION OF THALAMIC
ZONES WITH PREFRONTAL CORTEX IN
SCHIZOPHRENIA
Michael P. Harms1, L. Wang3, C. Ng1, D. M. Barch1,2,
J. G. Csernansky3
1Department of Psychiatry, Washington Univ. School of Medicine,
St. Louis, MO, USA; 2Department of Psychology, Washington
University, St. Louis, MO, USA; 3Department of Psychiatry and
Behavioral Sciences, Northwestern University Feinberg School of
Medicine, Chicago, IL, USA
Abnormalities of the functional and anatomical relationships between the
thalamus and dorsolateral prefrontal cortex (DLPFC) may be an important
aspect of the pathophysiology of schizophrenia. However, relatively little is
known about the patterns of structural correlation between the thalamus
and DLPFC, particularly in regards to their sub-regions. Using high-res-
olution magnetic resonance images, we examined the correlation of sub-
regions (ie, ‘‘zones’’) of the thalamic surface with gray matter volume of
the three major gyri of the DLPFC—the superior (SFG), middle
(MFG), and inferior (IFG) prefrontal gyri—in a group of 36 individuals
with schizophrenia and 44 control subjects. Thalamic zones corresponding
to the anterior, dorsal medial, pulvinar, and ‘‘remainder’’ portions of the
thalamic surface were defined on a template thalamus, and automatically
mapped onto the corresponding surface nodes of the thalamus of each sub-
ject using high-dimensional brain mapping. The product of the surface area
of a zone with the average surface deformation of that zone (relative to a
template) yielded a measure of volume change associated with each zone.
The IFG, MFG, and SFG were delineated manually on the white matter
surface of each subject, and gray matter volumes obtained for each gyrus by
labeled cortical depth mapping. Left and right values for each thalamic
zone and prefrontal gyrus were summed. MFG volume was positively cor-
related with the dorsal medial and remainder thalamic zones in the schizo-
phrenia subjects (both Pearson’s r > 0.49, P < .003), but not the control
subjects (|r| < 0.09), such that the strength of these correlations differed
significantly between the schizophrenia and control groups (P < .03 in
a comparison of correlations using Fisher’s z transformation). SFG volume
was correlated with the anterior thalamic zone, but to a similar degree in
both the schizophrenia and control subjects (r = .46 and 0.36, respectively).
IFG volume was not correlated with any of the thalamic zones for either
subject group. Notably, the correlation of the dorsal medial zone with
MFG in schizophrenia subjects was stronger than with either of the other
two prefrontal gyri (P < .05, using a one-tailed test for comparing corre-
lated correlation coefficients). These results suggest that in schizophrenia,
disease-related processes may affect the dorsal medial thalamus and middle
prefrontal cortex in tandem, perhaps due to shared genetic and/or environ-
mental influences.
ID: 551900
SEX DIFFERENCES IN CORPUS CALLOSUM
FRACTIONAL ANISOTROPY IN SCHIZOPHRENIA
PATIENTS: A PILOT TRACTOGRAPHY STUDY
USING DIFFUSION TENSOR IMAGING
Adham Mancini-Marie1, J. Cohen-Adad2, J. Jimenez1,
C. Corcoran4, P. Rainville3, E. Stip1, S. Potvin1, A. Mendrek1
1Department of Psychiatry, Fernand-Seguin Research Center, L-H
Lafontaine Hospital, University of Montreal, Montreal, QC,
Canada; 2Department of Physiology, Faculty of Medicine,
University of Montreal, Montreal, QC, Canada; 3Department of
Stomatology, Faculty of Dental Medicine, University of Montreal,
Montreal, QC, Canada; 4Center of Prevention and Evaluation, New
York State Psychiatric Institute, Columbia University, New York,
NY, USA
The relative size of the corpus callosum (CC) is 5% larger in normal women
compared to men. Studies in schizophrenia have shown that specifically the
middle section of the corpus callosum (MCC) is larger in women compared
to men. Very few studies attempted to investigate if volumetric findings are
substantiated with intact white matter integrity. The aim of this study is to
investigate white matter tract integrity in the MCC in patients with schizo-
phrenia compared to healthy controls using fiber tracking and fractional
anisotropy (FA) analyses. We scanned 17 men and 13 women with schizo-
phrenia and controls matched for age and sex using Diffusion Tensor Im-
aging (DTI). Here we present the results in 2 women and 2 men with
schizophrenia compared to healthy controls (2 women and 2 men). DTI
analyses were performed using MedINRIA software (http://www.sop.
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inria.fr/asclepios/software/MedINRIA/) to perform fiber-of-interest analy-
ses using the ‘‘DTI Track module’’ of MedINRIA. White matter fiber tracts
of MCC was created in 3D based on similarities between neighboring voxels
in shape (quantitative diffusion anisotropy measures) and orientation (prin-
cipal eigenvector map) of the diffusion ellipsoid. Our findings show that
patients in general had lower FA, lower number of fibers and lower bundle
volume compared to controls (mean volume = 4098 m3; mean number of
fibers = 373.5; mean FA = .62). Men in both groups had higher scores on the
3 items analysed except for FA which was only higher in healthy men com-
pare to healthy women. Our results in the schizophrenia group are in ac-
cordance with previous findings on reversed normal sexual dimorphism in
these patients. Nevertheless, results for healthy controls are not in accor-
dance with volumetric findings of the CC, and suggest that DTI approaches
could lead to differential results compared to other structural methods.
These results should be interpreted with caution considering the small sam-
ple size and until a complete analyses is performed on all scanned subjects.
ID: 551877
MAPPING OF CORTICAL AREA 46 LAMINAR
BOUNDARIES IN MRI VOLUMES: A METHOD
DEVELOPED TO STUDY THE PRENATALLY
IRRADIATED MACAQUE
Can Ceritoglu1, L. Wang2, M. Trachtenberg1, L. D. Selemon3,
J. G. Csernansky2, M. I. Miller1, J. T. Ratnanather1
1Center for Imaging Science, Johns Hopkins University, Baltimore,
MD, USA; 2Department of Psychiatry and Behavioral Sciences,
Northwestern University Feinberg School of Medicine, Chicago, IL,
USA; 3Department of Neurobiology, Yale University School of
Medicine, New Haven, CT, USA
We have previously developed a multistep registration process to transfer
cytoarchitectonic boundaries from high resolution photographic images of
histological sections to ante-mortem magnetic resonance (MR) subvolumes
of the same brain. Here we extend this methodology to transfer laminar
boundaries from area 46, as identified in the histological sections, to the
MR subvolumes. This process capitalizes on the strengths of both techni-
ques as postmortem analysis of Nissl-stained sections allows precise local-
ization of layer boundaries while volumetric analysis in the MR subvolume
permits determination of the layer volumes that are not shrunken or dis-
torted by postmortem fixation and processing. The motivation of this work
is to develop a methodology that can be used to specifically identify the
laminar pattern of cortical pathology in prenatally irradiated monkeys.
We acquired MR in vivo volumetric scans of nine adult macaque brains
with a resolution of 0.625 x 0.7 x 0.625 mm/voxel. A series of celloidin-em-
bedded, 40lm thick Nissl-stained sections (approximately stereotactic)
through the frontal lobe was generated from these same animals postmor-
tem. High resolution digital photographic images (0.005534x0.005534
mm2/pixel) were acquired without any external reference point for each his-
tological section. In the registration process, the MR scans were first reor-
iented to AC-PC orientation. Then the histological sections were used to
manually segment the boundaries of area 46 and the boundaries between
layer I/II and IV/V. Each histological section and its proximal MR section
were landmarked to reconstruct a 3D histological image based on low di-
mensional affine transformations of the landmarks. LDDMM (large defor-
mation diffeomorphic metric mapping) landmark matching was used to
further align the reconstructed 3D histological volume to the 3D MR image
subvolume, to overcome the difference in brain slicing orientation.
LDDMM image matching was used to complete the registration. Volumet-
ric analysis of layers in the MR subvolumes will be undertaken to determine
whether cortical pathology in area 46 is restricted to infragranular or supr-
granular layers in the prenatally irradiated monkey. The combined use of
in vivo neuroimaging analysis and postmortem cytoarchitectonic delinea-
tion of layer boundaries may have a wider application to study of neuro-
psychiatric diseases such as schizophrenia and affective disorders. Grants:
P50 MH071616, P41 RR15241, R01 MH59329.
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HERITABILITY OF CORTICAL THICKNESS
CHANGE OVER TIME IN SCHIZOPHRENIA
PATIENTS AND THEIR DISCORDANT CO-TWINS
Rachel Brans, N. van Haren, C. van Baal, H. Schnack, R. Kahn,
H. H. Pol
University Medical Centre Utrecht, Department of Psychiatry
A.01.126, Rudolf Magnus Institute of Neuroscience, Heidelberglaan
100, 3584 CX Utrecht, The Netherlands, Utrecht, Netherlands
Introduction: Structural brain abnormalities have consistently been found
in schizophrenia, with increased familial risk for schizophrenia having been
related to these abnormalities.1 Some brain volume changes are progressive
over the course of the illness.2 Here we demonstrate that genes involved in
the etiology of schizophrenia contribute to progressive brain volume loss
observed in the patients and in their co-twins.3 This study is currently being
extended with cortical thickness measurements. Methods: Two 1.5 T MRI
brain scans were obtained from monozygotic (MZ) and dizygotic (DZ)
twins discordant for schizophrenia (23 MZ and 23 DZ subjects) and
matched healthy comparison twin pairs (29 MZ and 27 DZ subjects)
with a scan interval of 5 years. Brain volumes were measured of the whole
brain, gray and white matter of the cerebrum, cortical lobes, and lateral and
third ventricles. Cortical thickness is estimated based on the algorithm
designed at the McConnell Brain Imaging Centre of the Montreal Neuro-
logical Institute. Brain structure changes and disease and familial related
effects in schizophrenia were analyzed using repeated measures analysis
of co-variance and structural equation modeling with Mx software. Results:
Significant additive genetic influences were revealed on the correlations be-
tween schizophrenia liability and whole brain, frontal and temporal lobe
volume change. First analyses of cortical thickness show a difference in
the extent of cortical thickness change in the sensorimotor cortex bilaterally
and left orbitofrontal cortex in the discordant twin-pairs as compared to the
healthy comparison twin-pairs. This change may be attributable to familial
(possibly genetic) factors. Moreover, additional areas of more extensive
change were found in frontal cortex bilaterally, which could be attributed
to disease-related factors. Conclusions: The progressive brain volume loss
found in patients with schizophrenia and their unaffected co-twins is at least
partly attributable to genetic factors related to the illness. Influence of dis-
ease-related factors on cortical thickness change in some areas is also sug-
gested.This research was supported by Grant No. 908-02-123 (HEH) from
the Netherlands Organization for Health Research and Development
ZonMw.
References
1. Hulshoff Pol H.E. et al. Biol Psychiatry. 2004;55(2):126–30.
2. van Haren NEM. et al. Biol Psychiatry. 2008;63(1):106–13.
3. Brans RGH. et al. Arch Gen Psychiatry. In press.
ID: 551814
LATERAL VENTRICLE VOLUMES AS A NEURAL
MARKER OF SHORT-TERM CLINICAL OUTCOME
IN FIRST EPISODE SCHIZOPHRENIA
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Background: Abnormalities in brain morphology have been consistently
described in schizophrenia with increased ventricular volumes being related
to poor long-term clinical outcome. Very few studies have focused on short-
term clinical outcome. In this study, we explored whether or not baseline
lateral ventricle volumes are related to short-term clinical outcome. Meth-
ods: Ventricle volumes were manually segmented in 50 first episode schizo-
phrenia (FES) patients with baseline MRI images. The patients were
separated into 37 poor outcome and 13 good outcome patients. Good out-
come was defined as a rating of 2 or less (mild) on all global subscales of the
SAPS and SANS, except ‘‘attention’’, using six month clinical data.
Results: At baseline, there were no significant differences in ventricular vol-
umes between outcome groups. See Table 1 for results. Conclusions: De-
spite a numerical difference between the groups, this non-significant result
suggests that ventricle volumes measured at baseline may not be related to
short-term clinical outcome.
Table. Lateral ventricle volumes in poor outcome and good outcome FES
[mean (SD)].
Poor Outcome Good Outcome p-value
Left Ventricle 11021 (5941) 9927 (3778) 0.54
Right Ventricle 10732 (7305) 9630 (3053) 0.60
ID: 551795
CORTICAL GYRATION INTERACTS WITH TIME
AND GENDER IN OFFSPRING OF SCHIZOPHRENIA
SUBJECTS
Konasale Prasad1, D. Goradia1, S. Eack1, J. Nutche1, T. Magge1,
M. Keshavan1,2
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Psychiatry, Harvard Medical School, Boston, MA, USA
Background: Genetic factors may contribute to the etiology of schizophre-
nia (SZ) by affecting the neurodevelopment. A systematic study of adoles-
cent offspring of SZ subjects (HR) before they manifest the illness could
clarify neurodevelopmental antecedents associated with increased genetic
risk. The cortical gyration indices may be such antecedents. We examined
cortical surface area, curvature and thickness at baseline and one year
among HR and matched healthy subjects (HS). Methods: Structural mag-
netic resonance scans were acquired on a series of HR (n = 31) and HS (n =
33). Of these, 15 HS and 16 HR underwent follow up scans after one year.
Images were processed using BRAINS2. Lobewise cortical surface areas,
thickness and curvatures were obtained from all these scans. We used
MANCOVA models by including age, total brain surface area and gender
as covariates to examine the differences between the groups at baseline and
one year follow up. Results: Total brain surface area did not differ signif-
icantly between the two groups. Separate MANCOVA models that in-
cluded lobar surface area, curvatures and thickness at the gyri and sulci
controlling for age, sex and total brain surface area were each significant.
Bilateral parietal gyral surface was reduced and sulcal curvatures were in-
creased in HR compared to HS. HR showed reduced right parietal cortical
thickness relative to HS. We observed a significant gender by study group
interaction at the bilateral frontal sulcal mean curvatures such that male
HR showed reduced right and left frontal sulcal curvature compared to
male HS, and female HR showed increased right and left frontal sulcal cur-
vature and right occipital gyral curvature compared to female HS. Re-
peated measures MANCOVA models showed that the right frontal
gyral surface increased among HS whereas it decreased among HR over
one year follow up. Similar patterns were observed at the occipital and pa-
rietal regions. Discussion: The main finding is that the HR show systematic
differences in the parieto-occipital regions before the onset of the illness.
This heteromodal association area is implicated in the integration of
multimodal sensory inputs. Gender and risk status interaction at the frontal
and occipital regions suggest that gender may have a pathoplastic effect.
Frontal, occipital and parietal regions appear to follow different
neurodevelopmental trajectories among HR compared to HS. Correlation
with psychopathology and soft signs are being examined.
ID: 551780
SYMPTOM INSIGHT AT THE FIRST ONSET OF
PSYCHOSIS: NEUROCOGNITIVE CORRELATES AT
BASELINE AND FOLLOW-UP
Kevin Morgan1,2, P. Dazzan2, C. Morgan2, J. Lappin2,
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The capacity to correctly identify and attribute psychotic symptoms as
pathological (symptom relabelling) may be the component of insight
most closely associated with neurocognition. We compared the neurocog-
nitive profile of first onset psychosis patients with no symptom relabelling
ability to those with at least some symptom relabelling ability in 204
patients (124 males; mean age 29 SD 10; 90 schizophrenia) recruited
from London, Nottingham and Bristol as part of the AESOP first-onset
psychosis study. Patients were rated on the Schedules for Clinical Assess-
ment in Neuropsychiatry (SCAN, 2.0), David’s insight schedule and a neu-
ropsychological test battery rating IQ, working memory, attention and
verbal fluency. Structural MRI scans were acquired from a sub-sample
of the patients at baseline (n = 82) and six years later (n = 41) using
a Dual Echo sequence acquired with a 1.5T scanner. Brain volumes
were measured with a voxel-based automated analysis. ANCOVA showed
that at baseline patients with no symptom relabelling scored significantly
lower than patients with at least some relabelling ability on NART (P <
.01), FSIQ (P < .01), verbal fluency (P < .05), Trails A (P < .05) and au-
ditory working memory, (P = .001). Baseline MRI analysis showed total
grey tissue volume in patients with no symptom relabelling ability group
was 6.7% lower than in patients with at least symptom some relabelling
ability (P = .01). Significant regional reductions in grey tissue volume
were also identified in the no symptom relabelling ability group at: 1)
left insula, 2) right putamen, 3) left superior temporal gyrus, 4) bilateral
posterior cingulate gyrus and 5) right pre-cuneus (P = .002). ANCOVA
at six years follow-up showed no significant differences between patients
with no baseline symptom relabelling ability and those with some baseline
symptom relabelling ability in 1) global grey and white matter volume
changes over the follow-up period and 2) global grey matter and global
white matter volumes at time of follow-up scan. Our findings suggest a neu-
rocognitive contribution to poor symptom relabelling ability during the
first episode of psychosis, and implicate brain regions (eg, cingulate gyrus)
which may be part of a mid-line cortical system involved in the self-ap-
praisal of psychotic symptoms. The study however, found no evidence
to suggest symptom relabelling ability at the first onset of psychosis is pre-
dictive of global brain matter changes over a six-year period.
ID: 551738
ANATOMICAL CORRELATES OF THOUGHT
DISORDER IN SCHIZOPHRENIA: A FREESURFER
STUDY
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Background and Objectives: Neuroimaging has delineated differences be-
tween subjects with schizophrenia and healthy controls, but correlating
symptoms to structural changes has been difficult. We sought to describe
relationships between thought disorder and cortical measures using an au-
tomated brain parcellation technique. We hypothesized we would find de-
creased cortical gray matter in the left superior temporal gyrus, an area
previously associated with thought disorder. Methods: T1-weighted mag-
netic resonance images were obtained from 52 subjects with schizophrenia
and were parcellated automatically using FreeSurfer software. Thought dis-
order was measured using the Scales for Assessment of Positive Symptoms
(SAPS) and Negative Symptoms (SANS). 33 regions were examined bilat-
erally to test relationships between gray matter decreases and severity of
thought disorder. Results: We did not find significant correlations between
structural measures of the left superior temporal gyrus and thought disor-
der. We then examined other variables in an exploratory fashion. Regions
clustered in the inferior frontal, temporal, and temporo-occipital areas
showed inverse correlations at the P < .05 level between gray matter thick-
ness and thought disorder severity. The right parahippocampal gyrus, left
lateral occipital cortex, and the right isthmus of the cingulate correlated
negatively with symptoms in more than one structural measure. We con-
firmed a previously reported association between thought disorder and the
inferior frontal gyri. Conclusions: Despite failing to replicate previous find-
ings associating the left superior temporal gyrus with thought disorder, we
did observe a number of inverse relationships between reduced cortical gray
matter and thought disorder. The large number of variables tested in-
creased the chances that correlations would achieve numerical significance
in the absence of true relationships. Nevertheless, unambiguous trends to-
wards inverse correlations between severity of thought disorder and cortical
thickness emerged. Many of the affected areas, while not reaching statistical
significance individually, nevertheless clustered together, especially in the
temporal lobes and around the cingulate cortex. It is especially intriguing
that two of the regions that were found to be affected bilaterally in this
study (the lingual gyrus and the isthmus of the cingulate) are contiguous
structures. Further studies will need to confirm these findings.
ID: 551735
REGIONAL PREFRONTAL CORTICAL GRAY
MATTER VOLUMES IN ADOLESCENTS AND
YOUNG ADULTS AT FAMILIAL RISK FOR
SCHIZOPHRENIA
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Regional prefrontal cortical (PFC) gray matter (GM) reductions have been
identified in magnetic resonance imaging (MRI) and postmortem studies of
schizophrenia, and likely reflect a combination of genetic risk and disease
effects, as well as age-related changes in the disorder’s lifelong neurodeve-
lopmental course. This is the first region-of-interest MRI study of PFC GM
subregions in young biological relatives of schizophrenia patients. We hy-
pothesized that reduced dorsolateral and ventromedial PFC GM would
mark genetic risk for schizophrenia in adolescence (using family history
as a proxy for genetic risk), and that ventromedial PFC GM deficits would
also be associated with subpsychotic symptoms. Twenty-seven ‘‘familial
high-risk’’ (FHR) adolescent relatives of schizophrenia patients and
forty-eight ‘‘familial low-risk’’ (FLR) adolescents without a family history
of psychosis underwent MRI scanning at 1.5 Tesla. The PFC was parcel-
lated into polar, dorsolateral, ventrolateral, ventromedial and orbital sub-
regions. The Chapman scales measured subpsychotic symptoms. General
linear models examined PFC volume associations with familial risk and
subpsychotic symptoms. For subregions that differed between risk groups,
exploratory age regressions tested differences in slope and intercept be-
tween groups. Statistical significance level was .05. FHR adolescents
had significantly reduced GM volume compared with FLR adolescents
in ventromedial and polar PFC. Ventromedial GM was significantly neg-
atively correlated with psychosis proneness scores within the FHR group.
The intercepts of the regressions of age on polar and ventromedial GM were
significantly lower in FHR than FLR adolescents. The slopes of the age
regressions on polar PFC were similar, such that GM declined similarly
with age in the two groups. The slopes of the age regressions on ventrome-
dial PFC were different between groups at a trend level, such that FHR
subjects did not show the GM decline with age seen within the FLR group.
Ventromedial and polar PFC GM volume deficits may be markers of ge-
netic risk for schizophrenia in young biological relatives. Ventromedial GM
reduction may also mark the presence of subpsychotic symptoms in these
relatives. Our findings suggest future avenues of research into age-related
changes in neuroanatomical markers for schizophrenia: those that mark
genetic vulnerability and those that may differentiate young relatives
who develop psychosis.
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CHANGES IN GRAY MATTER VOLUME IN ROS-
TRAL MIDDLE FRONTAL GYRUS OF CHRONIC
SCHIZOPHRENIA SUBJECTS
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M. Chiu1, P. Pelavin1, R. W. McCarley3, M. E. Shenton1,3
1Psychiatry, Brigham and Women’s Hospital, Boston, MA, USA;
2Psychiatry and Human Behavior, University of California, Irvine,
CA, USA; 3Psychiatry, Harvard Medical School, Brockton, MA,
USA
Background: In this study we used structural MRI to determine volume
differences in the mid-rostral middle frontal gyrus (MR-MFG) among
chronic schizophrenia subjects and normal control subjects. MR-MFG
is thought to be anatomically related to the Dorsolateral-prefrontal cortex
(DLPFC), a functional site of working memory, which is one of the
domains of cognitive feature and dysfunctional in schizophrenia. fMRI
studies have shown reduced activation in this brain region in schizophrenia
subjects performing working memory tasks, but the exact localization
remains to be defined. Methods: 20 patients with chronic schizophrenia
and 20 healthy controls, matched on age, handedness, and parental socio-
economic status, participated in this study. The acquisition of structural
MRI was done on a 3-Tesla whole body MRI Echospeed system GE scan-
ner. The images were processed using FreeSurfer tools (http://surfer.
nmr.mgh.harvard.edu) and automated parcellation of brain regions was
generated. Rostral MFG was then further delineated anteriorly and poste-
riorly using objective neuroanatomical landmarks. Gray matter volumes of
MR-MFG were then compared between the schizophrenia and the normal
subjects group and correlated with working memory tests. Results: MR-
MFG was reduced in gray matter volume in patients with schizophrenia
as compared with controls. Additionally, in the schizophrenia group
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MR-MFG volume reduction in the right hemisphere correlated with poorer
performance on the Wisconsin Card Sorting test, a measure of working
memory. Discussion: These results support the theory that working mem-
ory abnormalities observed in schizophrenia are related to volume changes
in MR-MFG and that MR-MFG is the anatomical site of DLPFC.
ID: 551569
DIFFUSION TENSOR IMAGING STUDIES OF
SCHIZOPHRENIA PATIENTS, FIRST-DEGREE
RELATIVES AND HEALTHY MZ TWINS
Jazmin Camchong, K. O. Lim2, S. R. Sponheim1,2,
A. W. MacDonald1,2
1Psychology, University of Minnesota, Minneapolis, MN, USA;
2Psychiatry, University of Minnesota, Minneapolis, MN, USA
Diffusion tensor imaging (DTI) provides anatomical connectivity informa-
tion by examining the directional organization of white matter microstruc-
ture. Previous studies have suggested that anatomical connectivity and its
abnormalities may be heritable traits. To further examine this hypothesis,
two studies were conducted in which anatomical connectivity was com-
pared (a) between monozygotic (MZ) twin pairs and random pairs and
(b) between schizophrenia patients, their first-degree relatives and a healthy
control group. Analyses focused on anterior regions of the brain following
previous findings of anatomical connectivity abnormalities associated with
schizophrenia. For Study 1, eighteen MZ twin pairs (11 female pairs, age: M
= 25.44, SD = 5.69) were recruited. For Study 2, fourteen schizophrenia
patients (4 females, age: M = 41.86, SD = 10.43), 12 of their first-degree
relatives (6 females, age: M = 50.25, SD = 5.64), and 16 healthy controls
(7 females, age: M = 37.31, SD = 11.09) were recruited. The primary
DTI variable was fractional anisotropy (FA), which reflects the degree
of white matter directional organization. The regions of interest in the fron-
tal lobe included cingulum bundle and genu of corpus callosum. For study
1, voxel-wise correlations in the whole brain as well as in the ROI were con-
ducted between (1) members of a MZ twin pair and (2) randomly generated
pairs. For study 2, voxel-wise analysis of variance within the ROI was con-
ducted to examine regional group differences. In Study 1, FA values were
more strongly correlated between MZ twin pairs than between randomly
generated pairs both in the whole brain as well as in the ROI. In Study 2,
analysis of variance revealed significant overall group differences in the
ROI (P < .05, corrected). Post-hoc analysis revealed lowest FA values
in schizophrenia patients, and intermediate FA values in the relative group
when compared to the control group (P< .05, corrected). The present study
suggested that medial prefrontal cortex anatomical connectivity was mod-
erately heritable, an important criterion in the development of an endophe-
notype. In addition, parametric abnormalities in white matter directional
organization in this region suggested that altered anatomical connectivity
may correspond to the level of genetic risk for schizophrenia.
ID: 551520
AMYGDALA VOLUME IN POOR OUTCOME
FIRST-EPISODE SCHIZOPHRENIA: A MAGNETIC
RESONANCE IMAGING STUDY
Audrey Benoit1,3, M. Bodnar1,3, Y. Czechowska1, A. Malla2,3,
R. Joober2,3, M. Lepage1,3
1Brain Imaging Group, Douglas Mental Health University Insitute,
Montreal, QC, Canada; 2Prevention and Early Intervention
Program for Psychoses, Douglas Mental Health University
Institute, Montreal, QC, Canada; 3Psychiatry, McGill University,
Montreal, QC, Canada
Outcome from schizophrenia is heterogeneous. Of those that experience
a poor outcome following a first-episode, a sub-group of patients can
be identified that display persistent negative symptoms. Emotional dys-
functions are thought to be central to negative symptoms which may sug-
gest the involvement of the amygdala. We investigated the association
between amygdala volume and persistent negative symptoms (PNS) in
the context of poor-outcome first-episode schizophrenia (FES) patients.
Twenty subjects with FES underwent structural magnetic resonance imag-
ing. They were separated into good (7) and poor (13) outcome groups
based on six month clinical data as proposed by Andreasen et al.
(2005). The poor outcome group was further sub-divided into patients pre-
senting PNS (8) and patients who did not (5) according to a recently pro-
posed definition by Buchanan (2007). Amygdala volumes were obtained
through manual segmentation. Good and poor outcome groups did not
differ in amygdala volume on either the right or left side. However, within
the poor outcome group, the PNS sub-group showed a trend for larger left
and right amygdala volumes compared to the non-PNS sub-group (left
amygdala: t11 = 1.87, P = .088; right amygdala: t11 = 1.88, P = .087).
From this small sample of FES patients, amygdala volume does not appear
to have good predictive value for 6 month clinical outcome. However, it
appears the amygdala is better for characterizing a sub-group of patients
that will experience PNS. These preliminary results encourage the explo-
ration of the amygdala and its possible role in negative symptoms that fail
to remit.
ID: 551435
DURATION OF UNTREATED PSYCHOSIS PRE-
DICTS POOR OUTCOMES BUT THIS IS NOT CAUSED
BY GLOBAL BRAIN VOLUME CHANGES
Julia M. Lappin1, K. D. Morgan2, A. A. Reinders1,
C. M. Morgan1, J. Suckling3, P. Fearon1, P. Jones3,
R. M. Murray1, P. K. McGuire1, P. Dazzan1
1Division of Psychological Medicine, Kings College London Institute
of Psychiatry, London, United Kingdom; 2Psychology, University of
Westminster, London, United Kingdom; 3Psychiatry, University of
Cambridge, Cambridge, United Kingdom
Background: Despite good evidence that longer duration of untreated
psychosis (DUP) is associated with poorer outcome, it is not known
whether DUP causes poor outcome and, if so, how. One theory is that
long periods of untreated psychosis cause a deleterious impact on function
through a ‘toxic’ effect on the brain: if one assumes that brain structure and
function are linked, this model predicts that brain structural measures will
be associated with length of DUP. This theory was tested here. Methods: 44
(28 male:16 female; 26 schizophrenia:18 other psychosis) subjects from an
original cohort of 89 first episode psychosis patients, were re-scanned using
Magnetic Resonance Imaging. Changes in tissue volume between baseline
and follow-up were calculated, correcting for baseline whole brain volume.
Results: Mean follow-up interval was 6.8 (6 1.2) years. Median values:
DUP = 6 weeks; duration of untreated illness (DUI) = 24 weeks. Grey
matter volume decreased (t = 4.72; P = .001) and cerebrospinal fluid
volume increased (t = 3.48; P = .001) over the follow-up period. Both
longer DUP and DUI were significantly associated with a range of poorer
outcomes at follow-up: greater global disability; higher likelihood of being
psychotic; and of having had a continuous illness course. DUP and DUI
were not significantly related to any tissue volume change in the entire
sample or in the schizophrenia only subgroup. Discussion: The finding
that longer DUP/DUI is associated with poorer clinical and functional
outcome was replicated; however there was no evidence that this relation-
ship was caused by changes in brain volume over time. If a toxic effect of
DUP/DUI exists, it is not detectable in change in global brain tissue
volumes over time.
ID: 551362
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NEUROANATOMICAL CHANGE DURING
COGNITIVE REHABILITATION: RESULTS FROM
A TWO-YEAR TRIAL OF COGNITIVE
ENHANCEMENT THERAPY
Matcheri Keshavan1,2, S. Eack2, K. Prasad2, D. Montrose2,
D. Greenwald2, S. Hogarty2
1Beth Israel Medical Center, Boston, MA, USA; 2Psychiatry,
University of Pittsburgh, Pittsburgh, PA, USA
Background: Cognitive rehabilitation has proven to be a promising method
for addressing the social and non-social cognitive deficits experienced by
individuals with schizophrenia. While the beneficial effects on cognition
documented by a variety of approaches has a presumed neurobiologic
basis, few studies have examined changes in neurobiology as a result of
cognitive rehabilitation. We conducted a preliminary examination of neu-
roanatomical changes in gray matter in a sample of early course outpatients
participating in a two-year randomized-controlled trial of Cognitive En-
hancement Therapy (CET; www.CognitiveEnhancementTherapy.com).
Methods: Outpatients in the early course of schizophrenia or schizoaffec-
tive disorder were randomly assigned and treated in a two-year trial with
CET (n = 30) or an active Enriched Supportive Therapy (EST) control (n =
23), and assessed annual using structural magnetic resonance imaging and
a comprehensive cognitive battery. CET is an integrated approach to the
remediation of social and non-social cognitive deficits in schizophrenia that
utilizes computer-assisted cognitive training and group-based secondary
socialization techniques. EST focuses on illness management and stress re-
duction through an individualized psychotherapeutic approach. Results:
Initial voxel-based morphometry analyses of gray matter change during
the two-year trial indicated significant differential patterns of density
change between treatment groups in a left hemispheric social-cognitive net-
work cluster including the amygdala, fusiform, and parahippocampal gy-
rus. Subsequent volumetric analyses revealed that while individuals
receiving EST showed a loss of gray matter volume in this social-cognitive
network over the two years of study, patients receiving CET exhibit a pres-
ervation, and at times, significant increases in gray matter volume in these
regions. Mediator analyses revealed that CET effects on social cognition
could be indirectly accounted for, in part, by differential gray matter
changes in the left amygdala/fusiform/parahippocampal gyrus social cog-
nition network. Conclusions: CET is an effective approach for the
remediation of social and non-social cognitive deficits in schizophrenia
that may achieve its efficacy through acting on social cognition brain
networks.
ID: 551352
PROGRESSIVE GM AND WM ABNORMALITIES IN
CHILDHOOD-ONSET SCHIZOPHRENIA(COS)
Nitin Gogtay
Child Psychiatry Branch, National Institute of Mental Health,
Bethesda, MD, USA
Structural neuroimaging studies in COS show profound parieto-frontal
cortical GM loss during adolescence, where the pattern appears exaggera-
tion of the normal GM maturation. Long term follow up shows that the
GM loss slows with age and gets circumscribed to prefrontal and superior
temporal cortices (n = 84,197 scans vs controls n = 86, 220 scans; age range
8–28yrs), mimicking a pattern seen in adult onset schizophrenia. Longitu-
dinal analyses on healthy COS siblings (n = 85,170 scans) also show pre-
frontal and temporal GM deficits in early ages which normalize by age.
Similar patterns of ‘early deficits followed by their relative normalization
in COS, and complete normalization in siblings’ could suggest that the GM
trajectory itself could be a trait marker. Candidate gene analyses support
these observations. For example, preliminary analyses comparing GM de-
velopment in 59 COS subjects (160 scans), 36 healthy siblings(80 scans) and
183 healthy controls (221 scans) showed that subjects with GAD1 risk allele
had accelerated GM loss across the three groups over most cortex. How-
ever, Group*Risk*Age interaction showed COS and healthy siblings with-
out risk allele had slower rate of GM loss compared to those with the risk
allele (a difference not seen in controls) suggesting a role for epistatic fac-
tors. Sub regional cerebellar maps in 85 COS subjects (206 scans), 78
healthy siblings, and 95 matched healthy controls (225 scans) show signif-
icant ‘sub regional’ decline in volume with age, while the vermal regiosn
showed fixed deficits. The volume loss is shared by healthy COS siblings
in the posterior inferior cerebellar regions (compared to the same set of con-
trols) suggesting the trait nature of these changes at sub regional level. Fi-
nally, it is important to understand the progressive nature GM changes in
the context of underlying white matter (WM) development. Our recent 3-D
maps of local WM growth rates in 12 COS patients and 12 healthy controls
matched for age, gender and scan interval, over a 5-year period, show up to
2.2% slower WM growth per year in COS (P = .02, all P-values corrected).
The deficits appear early in the frontal regions and later in the parietal
regions suggesting a progressive abnormality that follows the normal front
to back WM developmental pattern. In addition to highlighting significant
WM growth deficits in COS, these findings also suggest that the cortical
GM loss in schizophrenia is unlikely to be the result of WM encroachment.
ID: 551328
INTERNAL CAPSULE ANISOTROPY AND TRAC-
TOGRAPHY IN THE SCHIZOPHRENIA SPECTRUM
Igor Nenadic1,2, E. A. Hazlett2, J. Friedman2, M. M. Haznedar2,
K. W. Chu2, J. J. Entis2, N. Dusi2, C. R. Goodman2,
R. Newmark2, A. Robson2, J. Zhang2, M. S. Buchsbaum2
1Psychiatry and Psychotherapy, Friedrich-Schiller-University of
Jena, Jena, Germany; 2Psychiatry, Mount Sinai School of Medicine,
New York, NY, USA
Volume reductions of the thalamus (esp. mediodorsal nucleus) and prefron-
tal cortex have been demonstrated, and more recently also the internal cap-
sule. Here we used diffusion tensor imaging and tractography to assess the
anterior limb of the internal capsule, which provides the connections be-
tween the two brain regions. We obtained structural 3T MP-RAGE ana-
tomical and diffusion tensor MR images on 111 patients with schizophrenia
(mean age = 36.8 years, 79 men, 32 women), 29 patients with schizotypal
personality disorder (mean age = 36.6 years, 17 men, 12 women), and 222
healthy controls (mean age = 31.3 years, 114 men, 108 women). Placement
of anatomical images in standard AC-PC position, coregistration of DT
images to the anatomical images, computation of anisotropy and of tract
angles was done with FSL. We manually traced the axial slice of the ante-
rior limb of the internal capsule at the dorsoventral level of the dorsoventral
midpoint of the thalamus on the structural MRI. We oriented the tracing
of the 3D vectors from the internal capsule toward the prefrontal cortex.
Beginning with the anterior limb of the internal capsule region of interest,
we counted the number of tracts which arrived through a 20x20mm vertical
frame positioned 25% of the distance between the anterior tip of the internal
capsule and the anterior most point on the brain, a distance typically of 40–
60mm and approximately centered on the anterior thalamic radiations. Sig-
nificantly more tracts arrived through the frame on the left side of the brain
than on the right in all groups. Patients with schizophrenia had the greatest
asymmetry (17 fewer on the right), patients with schizotypal personality
second greatest asymmetry (10 fewer on the right) and normal controls
the least asymmetry (7 fewer on the right; hemisphere3group interaction)
and this was most marked in female patients. When voxels over the 0.3 an-
isotropy threshold were counted, patients with schizophrenia had fewer
voxels than healthy controls. Taken together, this data is consistent with
a deficit in the fronto-thalamic circuit in schizophrenia.
ID: 551300
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WHITE MATTER ABNORMALITIES IN FIRST
EPISODE OF PSYCHOSIS: A DTI STUDY
Diana Tordesillas-Gutierrez1, R. Pe´rez-Iglesias1, G. J. Barker2,
R. Roiz-Santian˜ez1, P. K. McGuire3, E. Marco de Lucas4,
J. L. Va´zquez-Barquero1, B. Crespo-Facorro1
1Psychiatry, Hospital Universitario Marque´s de Valdecilla,
University of Cantabria, Santander, Spain; 2Center for
Neuroimaging Sciences, Institute of Psychiatry, London,
United Kingdom; 3Section of Neuroimaging, Institute of Psychiatry,
London, United Kingdom; 4Neuroradiology, Hospital Universitario
Marque´s de Valdecilla, Santander, Spain
Schizophrenia has been presented as a disconnectivity disorder. There is
some evidence in the literature of white matter (WM) abnormalities in
chronic psychotic patients. We aimed in this study to see whether there
are differences in white matter integrity between patients recently diagnosed
with a First Episode of Psychosis (FEP) and healthy volunteers. In order to
assess WM integrity fractional anisotropy (FA) was measured using Dif-
fusion Tensor Imaging (DTI). FA is a measure of anisotropic diffusion
of water molecules in tissue and reflects the directional coherence of the
fiber tracts thus white matter organization. Sixty-two patients with a First
Episode of Psychosis (FEP) (31 M, 30 .8 6 9.5 yo) and fifty-six matched
control subjects (34 M, 30.1 6 8.1 yo) underwent a DWI-MRI study. Sub-
jects were right-handed and not drug or alcohol dependent. Imaging acqui-
sition was performed on a 1.5T GE: EPI (25 directions, b = 1000s/mm2).
Image Analysis: Voxel-based analyses of fractional anisotropy were done
using in-house software with group mapping utilizing SPM2, and non-
parametric statistical analyses in XBAMv3.4 (voxel significance P =
.025; cluster significance P = .0001). Reduced fractional anisotropy was
found in FEP when compared with the healthy control group on the Corpus
callosum (Genu bilaterally and left body but not splenium), left external
and posterior limb of the internal capsule, left superior longitudinal fascicle
and left inferior fronto-occipital fasciculus. FA was also reduced Forceps
Minor. There was not found any region where FA was greater in FEP than
the control group. Our results show that reduction in white matter orga-
nization is already present in the onset of the illness, mostly in the left hemi-
sphere. Abnormal connectivity can play a role in the pathophysiology of
schizophrenia.
ID: 551144
AUDITORY CORTICAL VOLUME AND LOUDNESS
OF AUDITORY HALLUCINATIONS IN
SCHIZOPHRENIA
Michael Hunter1, T. F. Farrow1, M. Hogan1, M. Q. Khan1,
H. Linnington1, J. Mitchell1, N. Mir1, I. D. Wilkinson2,
P. W. Woodruff1
1Academic Clinical Psychiatry, University of Sheffield, Sheffield,
United Kingdom; 2Academic Unit of Radiology, University of
Sheffield, Sheffield, United Kingdom
We aimed to investigate the relationship between anatomy of the auditory
cortex and perceived loudness of auditory hallucinations in people with
schizophrenia. Nineteen patients with schizophrenia (mean 6 SD age =
40.7 6 10.5 years) and marked auditory hallucinations participated
(mean Scale for the Assessment of Positive Symptoms global hallucination
severity rating = 3.7 6 0.7). On the day of scanning, each completed a visual
analogue scale to describe the loudness of their auditory hallucinations
(ranging from ‘absent’ to ‘as loud as the loudest shouting’). Structural
images were acquired on a 1.5 T Eclipse system (T1-weighted RF-FAST
sequence; 190 slices; 1 x 1 x 1 mm voxels). Temporal lobe volumes-of-
interest were measured using stereology implemented in Analyze 8.1
(Mayo Foundation, Minnesota). We measured left and right Heschl’s gyrus
(HG) and planum temporale (PT) volumes. Between-hemisphere differen-
ces in volumes were assessed using paired t-tests. Within the group, we ran
bivariate correlations between measured volumes-of-interest and loudness
ratings. Heschl’s gyrus was significantly larger on the left than the right
(13.7 6 3.5 ml versus 11.8 6 2.8 ml; t = 3.6; P = .002). There was no sig-
nificant difference between left and right PT volumes (13.6 6 2.8 ml and
13.8 6 2.8 ml, respectively; t = 0.4; P = .670). The volume of left HG
was positively correlated with hallucination loudness (r = 0.5; P =
0.035). Previous work has shown auditory hallucinations to be associated
with smaller auditory cortical structures, including the superior temporal
gyrus (Barta et al., Am J Psychiatry 1990; 147: 1457–1462). Our data sug-
gest that within a group with auditory hallucinations, some relative pres-
ervation of Heschl’s gyrus is associated with louder hallucinations. This is
compatible with the idea that auditory hallucinations are abnormal percep-
tions, experienced as perceptions because their mechanism implicates cor-
tex involved in normal perception.
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RELATIONSHIP BETWEEN ANTIOXIDANT STATUS
AND BRAIN VOLUMES IN CHILDREN AND
ADOLESCENTS WITH FIRST EPISODE PSYCHOSIS
David Fraguas1,2, S. Reig3, M. Desco3,
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Experimental Medicine, Hospital General Universitario Gregorio
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Medicine, University of Ca´diz, Ca´diz, Spain; 5Department of Child
and Adolescent Psychiatry and Psychology, Institut Clinic of
Neurosciences (Institut d’Investigacions Biome`diques August Pi
Sunyer), Hospital Clı´nic Universitari of Barcelona, Barcelona,
Spain; 6Section of Child and Adolescent Psychiatry and Psychology,
Hospital Infantil Universitario Nin˜o Jesu´s, Madrid, Spain; 7Stanley
Institute International Mood Disorders Research Center, Hospital
Santiago Apo´stol, Vitoria, Spain; 8Child and Adolescent Mental
Health Unit, Department of Psychiatry and Psychology, Hospital
Universitario Marque´s de Valdecilla, Santander, Spain
Background: Brain volume abnormalities and oxidative cell damage have
been reported to be pathological characteristics of schizophrenia patients.
This study aims to assess a potential relationship between these two char-
acteristics in child and adolescent patients with first-episode psychosis.
Method: 26 child and adolescent patients with first-episode early-onset
schizophrenia, 14 with first-episode early-onset psychotic bipolar disorder,
and 78 age- and gender-matched healthy controls were assessed. Magnetic
resonance imaging (MRI) scans were used for volumetric measurements of
five cerebral regions: gray matter of the frontal, parietal, and temporal
lobes, sulcal cerebrospinal fluid (CSF), and lateral ventricles. Oxidative
cell damage was traced by means of a systemic increase in lipid hydroper-
oxides. (LOOH). Results:Lateral ventricle volumes were significantly
higher in schizophrenia patients than in controls. LOOH was significantly
higher in bipolar patients than in controls. Brain volumes and oxidative cell
damage were not significantly different between schizophrenia and bipolar
patients. In schizophrenia patients, a significant positive relationship was
found between oxidative cell damage (LOOH levels) and the abnormal en-
largement of the lateral ventricles, after controlling for total intracranial
volume, age, gender, daily smoking status, intelligence quotient (IQ), psy-
chopathology, and time since onset of psychotic symptoms. No association
was found between brain volume and oxidative cell damage in bipolar
patients or control subjects. Conclusions: Our results suggest that, in
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patients with first-episode early-onset schizophrenia, enlargement of the
lateral ventricles is associated with chronic oxidative cell damage.
ID: 551091
AGE-RELATED CHANGES IN CORTICAL
THICKNESS IN PATIENTS WITH SCHIZOPHRENIA:
A 5-YEAR LONGITUDINAL MRI STUDY ACROSS
THE COURSE OF ILLNESS
Neeltje van Haren1, H. Schnack1, M. van den Heuvel1, W. Cahn1,
C. Lepage2, A. Evans2, H. H. Pol1, R. Kahn1
1Department of Psychiatry, Rudolf Magnus Institute of
Neuroscience, Utrecht, Netherlands; 2McConnell Brain Imaging
Centre, Montre´al Neurological Institute, Montre´al, QC, Canada
Schizophrenia is characterized by excessive reductions in cerebral gray mat-
ter volume. Also, patients with schizophrenia show decreases in cortical
thickness (CortT) as compared to healthy subjects. However, it is unre-
solved whether these changes are static or progress over time. Moreover,
In case of excessive change in patients with schizophrenia it is investigated
whether these changes are influenced by age. Two Magnetic Resonance
Imaging T1 brain scans were obtained with an interval of 5 years from
96 schizophrenia patients and 113 healthy controls (age 16–57 years).
In-house software was used to segment cerebral gray (GM) and white mat-
ter (WM). These segments were used as input for an advanced neural net
classifier. A surface deformation algorithm was applied that first fits the
white matter surface and then expands outward to find the gray matter-
cerebrospinal fluid intersection (software Montreal Neurological Institute:
CLASP). For each subject, CortT change is calculated for every vertex.
Group difference in CortT change is calculated by using regression anal-
yses with age and gender as covariates. The statistics were corrected for
multiple comparisons by applying a false discovery rate of alfa = 0.05. Re-
gression analysis in the form of a locally-weighted running-line smoother
will be used to obtain the dependence of volume changes on age. Software
for these analyses has been developed in house. For each group fits with
different degrees of freedom (df) will be calculated for each vertex to find
the one that described the data best. Excessive decreases in CortT in
patients relative to controls were found predominantly in the frontal
and temporal cortices ranging from 0.08 to 0.16 mm at vertices with the
highest F-values. Parietal and occipital cortices were relatively spared. Ex-
cessive cortical thinning seemed more pronounced in the left hemisphere,
particularly in the left frontal cortical areas. These findings are in line with
earlier longitudinal volumetric and voxelbased morphometry studies sug-
gesting progressive changes in schizophrenia patients in particularly frontal
and temporal areas in the brain. We expect to find differences in age-related
cortical thickness change between patients with schizophrenia and compar-
ison subjects which would be suggestive for abnormal maturation of the
brain in adult schizophrenia.
ID: 551081
OBSTETRIC COMPLICATIONS, GENETIC
VARIATION AND HIPPOCAMPAL VOLUMES IN
SCHIZOPHRENIA
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We retrospectively studied the effect of severe obstetric complications
(OCs) on hippocampal volumes in schizophrenia patients and healthy con-
trol subjects, and examined to what extent such effects depends on allele
variation in hypoxia-related genes. Fifty-four adult subjects with schizo-
phrenia and 54 healthy control subjects were MR scanned, genotyped
and assessed for OCs. Hippocampal and intracranial volumes were quan-
tified by automated processing of MR images with the FreeSurfer software.
Genomic DNA was extracted from whole blood samples. Forty-nine single
nucleotide polymorphisms (SNPs) spanning five hypoxia-regulated genes
(GRM3, BDNF, DTNBP1, NRG1 and PRODH) were genotyped with
the Illumina BeadStation 500GX and the 1536-plex Illumina Golden
Gate assay. Presence of OCs was determined from birth records, and
scored blindly according to the McNeil-Sjo¨stro¨m scale. Severe OCs was
defined as presence of at least one grade 5 complication. The effects of in-
tracranial volume, age and disease on hippocampal volume were accounted
for in the statistical analysis. As previously demonstrated hippocampal vol-
umes were smaller in affected individuals than in healthy controls (P =
.003). Surprisingly, individuals who had experienced severe OCs had larger
hippocampal volumes than individuals who had not (P = .04), and this effect
was independent of disease status (pdisease*OC = 0.37). None of the exam-
ined SNPs was associated to hippocampal volumes. However we noted that
enlarged volumes of the right hippocampus in individuals who had expe-
rienced severe OCs were strongly associated with two GRM3 SNPs located
in intron 1 (pSNP*OC = 0.0002). In this group, the nine carriers of the
minor alleles had a clearly larger volume of the right hippocampus than
subjects without OCs, whereas the 17 non-carriers had volumes similar
to subjects without OCs. The volume of the left hippocampus showed a sim-
ilar, but weaker association (pSNP*OC = 0.04). As a result, a combination
of severe OCs and these GRM3 alleles related to a significantly disturbed
hippocampal laterality (P = .001). Although the interaction between
GRM3 and severe OCs was highly significant, and withstands Bonferroni
correction, the finding must be viewed as preliminary due to limited sample
size. The present study suggests that there might be an interaction effect
between severe OCs and genetic variation on hippocampal size, but find-
ings need further replication.
ID: 551079
IS THE THALAMUS SMALLER IN PATIENTS
WITH SCHIZOPHRENIA? A VOXEL—BASED
MORPHOMETRY STUDY
Julio Sanjuan1,4, G. Garcia-Marti2,4, L. Marti-Bonmati2,
O. Brotons3,4, E. J. Aguilar3,4
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Clinic Hospital, Valencia, Spain; 4CIBERSAM, Spanish Ministry
of Health, Valencia, Spain
Background: Previous studies have suggested a reduction of the thalamus in
patients with schizophrenia (1) This reduction could be related specifically
with auditory hallucinations (2). The aim of the present work is to repli-
cated this findings in a larger clinically homogenous sample. Methods
and Materials: 33 patients with DSM-IV schizophrenia with auditory hal-
lucinations and 38 healthy paired subjects (same age, ethnic group [Cauca-
sian], educational level [secondary school] and handedness [all right
handed]) entered the study. All underwent a clinical evaluation and Mag-
netic Resonance imaging (1.5T) examination. Images were acquired with
a spoiled gradient-echo pulse sequence. Data were processed according
to VBM optimized protocol and statistically analyzed with the Statistical
Parametric Mapping software (SPM5). Results: No significant gray
matter (GM) differences were found in the thalamus when comparing
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schizophrenic patients with auditory hallucinations and control subjects
(P < .05 with False Discovery Rate correction). Conclusions: We were un-
able to find thalamic morphometrical changes in patients with schizophre-
nia and auditory hallucinations compare with control subjects. So our
results do not support previous findings
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PROGRESSIVE GRAY MATTER REDUCTION OF
THE SUPERIOR TEMPORAL GYRUS DURING
TRANSITION TO PSYCHOSIS
Christos Pantelis1, T. Takahashi1,4, S. J. Wood1, A. R. Yung2,
B. Soulsby1, M. Suzuki4, L. J. Phillips3, D. Velakoulis1,
P. D. McGorry2
1Melbourne Neuropsychiatry Centre, Department of Psychiatry,
The University of Melbourne, Melbourne, VIC, Australia;
2ORYGEN Research Centre, The University of Melbourne,
Melbourne, VIC, Australia; 3Department of Psychology, The
University of Melbourne, Melbourne, VIC, Australia; 4Department
of Neuropsychiatry, Toyama University, Toyama, Japan
Longitudinal magnetic resonance imaging studies have shown progressive
gray matter reduction in superior temporal gyrus (STG) during the earliest
phases of schizophrenia. It is unknown whether these progressive processes
predate the onset of psychosis. We examined gray matter reduction of the
superior temporal gyrus over time in individuals at risk for psychosis
(UHR) and first-episode psychosis (FEP) patients. Subjects included: 35
UHR individuals (12 later developed psychosis [UHRP] and 23 did not
[UHRNP]), 23 first-episode psychosis (FEP) patients, and 22 controls. Vol-
umes of STG subregions (planum polare, Heschl’s gyrus, planum tempo-
rale [PT], and rostral and caudal regions) were measured at baseline and
follow-up (mean, 1.8 years) scans. Cross-sectional comparisons: only
FEP had significantly smaller PT and caudal STG than other groups at
baseline, while male UHRP subjects had smaller PT compared to controls
at follow-up. Longitudinal comparisons: UHRP and FEP patients showed
significant gray matter reduction (2–6%/year) in the planum polare, planum
temporale, and caudal region compared with controls and/or UHRNP.
FEP patients also exhibited progressive gray matter loss in left Heschl’s
gyrus (3.0%/year) and rostral region (3.8%/year), which were correlated
with severity of delusions at follow-up. These data indicate that a progres-
sive process in the STG precedes the first expression of florid psychosis.
These findings provide further evidence for progressive structural changes
in temporal lobe regions at the earliest stages of psychotic illness (Pantelis
et al. Schizophr Bull, 2005), and have implications for early intervention
during or before the first episode of psychosis.
ID: 551051
NEURAL PLASTICITY AND STRUCTURAL BRAIN
CHANGE IN SCHIZOPHRENIA: ARE WE ASKING
THE RIGHT QUESTIONS?
Philip B. Ward
Psychiatry, University of New South Wales, Liverpool BC, NSW,
Australia
There is growing evidence that structural brain change can be detected in
healthy volunteers following short-term changes in physical and/or cogni-
tive activity. Colcombe et al. (2006) showed that significant increases in
brain volume could be detected in healthy elderly volunteers following
six months of aerobic exercise training, including the anterior cingulate,
right inferior frontal gyrus and the left superior temporal gyrus. Draganski
et al. (2006) studied medical students who showed significant increases in
gray matter in posterior and lateral parietal regions whilst studying highly
abstract information, and a more pronounced increase in the posterior hip-
pocampus three months after their exams. Ilg et al. (2008) showed that
increased gray matter following practice in mirror reading was associated
with decreased activation in in the right superior parietal cortex and in-
creased activation in the right dorsolateral occipital cortex that was linked
to increased task-related gray matter increases in young healthy volunteers.
Boyke et al. (2008) found gray-matter changes in the middle temporal area
of the visual cortex in healthy elderly subjects and young healthy volun-
teers who learned a juggling task. Additional transient increases in gray
matter in the left hippocampus and bilateral nucleus accumbens were
found in elderly volunteers who learned to juggle. Taken together, these
data suggest alternative explanations for longitudinal structural and func-
tional brain changes described during the transition to psychosis or ob-
served in longitudinal studies of patients with established schizophrenia.
Such studies involve patients whose physical or cognitive activity has
changed over the time intervals between repeat scans, and the results
obtained may reflect changes in inter-scan activity rather than changes
in diagnostic status (reflecting changes in psychopathology) or treatment
effects as are currently posited to explain the structural and functional
changes reported in studies of first episode psychosis or schizophrenia.
It is possible that treatment-related changes in metabolic status may
also impact on physical fitness in patients with first-episode psychosis
or schizophrenia, leading to further variance in observed structural func-
tional brain changes.
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ENDOPHENOTYPES FOR SCHIZOPHRENIA AND
BIPOLAR DISORDER DETERMINED USING BRAIN
IMAGING
Andrew Mark McIntosh, J. Hall, S. M. Lawrie
Department of Psychiatry, Edinburgh Universty, Edinburgh, United
Kingdom
Structural and functional brain abnormalities have been identified in both
schizophrenia and bipolar disorder and some of these findings may be rel-
evant to their predominantly genetic aetiology. Using structural and func-
tional imaging, individuals with schizophrenia, bipolar disorder, their
relatives and those at high risk for genetic reasons will be compared
with a view to identifying heritable endophenotypes. Secondly, the neural
correlates of specific susceptibility-associated genes for both schizophrenia
and bipolar disorder will be identified by comparing those with and without
the risk genotypes. Our results show that schizophrenia and bipolar disor-
der are characterised by largely shared structural findings and largely
separate functional findings. These findings are also related to susceptibility
variants in the genes encoding NRG1 and G72. These findings suggest that
strategies targeted to the identification of specific and overlapping endo-
phenotypes may be a fruitful means of understanding the genetic mecha-
nisms underlying these disorders.
ID: 551032
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PROGRESSIVE BRAIN CHANGES IN EARLY-ONSET
PSYCHOSIS
Celso Arango1,2, M. Parellada1, S. Reig1, C. Moreno1, J. Janssen1,
M. Mayoral1, M. Giraldez1, D. Moreno1, M. Desco1,2
1Hospital General Universitario Gregorio Maran˜on, Madrid, Spain;
2Centro de Investigacio´n Biome´dica en Red de Salud Mental,
CIBERSAM, Madrid, Spain
Progressive loss of cortical gray matter volume and increase in ventricular
volume have been reported in patients with childhood-onset schizophrenia
(COS) during adolescence. In addition, some studies show that, although
less exaggerated, progressive changes are also present in non-schizophrenia
early-onset psychosis. However, the previous studies were conducted in
patients with early-onset schizophrenia or psychosis with a mean duration
of illness of several years. In a multicenter, longitudinal, follow-up study of
first-episode early-onset psychosis, we aimed to assess whether progressive
changes were present in this less biased population and if the baseline or
progressive changes were predictors of diagnosis or prognosis. Magnetic
resonance imaging studies were obtained at baseline and 2 years later in
66 children and adolescents (mean age 15.5 6 1.8) with a first psychotic
episode and 93 healthy controls matched for age, gender, and years of ed-
ucation. Length of illness was 2.1 6 1.7 months at the time of the MRI scan.
The diagnosis was assessed with the K-SADS, both at baseline and at
follow-up (2 patients had schizophrenia, 12 bipolar disorder, and 27 other
psychoses). Whole-brain volumes and gray matter (GM) and cerebrospinal
fluid (CSF) volumes of the frontal, parietal, temporal, and occipital lobes
were measured at baseline and at 2-year follow-up. In the frontal lobe, the
rate of GM volume loss was significantly higher in male patients (3.1% and
2.2%, respectively, at left and right) than in controls (1.4% and 0.9%, re-
spectively, at left and right). In the left frontal lobe, male patients showed
a significantly higher rate of CSF volume increase than controls (3.1% vs.
0.9%). These differences in volume change rates were observed in male and
female patients, with significant time x group interactions. An exploratory
analysis revealed that schizophrenia and non-schizophrenia psychotic dis-
orders showed similar volume change patterns relative to controls. Change
in clinical status did not correlate with longitudinal brain changes.
Our results support progression of frontal lobe changes in males with
childhood- and adolescent-onset psychosis.
ID: 551030
GREY MATTER VOLUME CORRELATES OF
ACTIVITIES OF DAILYLIVING INSCHIZOPHRENIA
Sudheer Tumkur Lankappa1, C. J. Kaylor-Hughes1,
A. Hope-Urwin1, R. J. Fung3, T. F. Farrow1, J. Woodhead1,
M. L. Brook1, I. D. Wilkinson2, S. A. Spence1
1Academic Clinical Psychiatry, University of Sheffield, Sheffield,
United Kingdom; 2Academic Radiology, University of Sheffield,
Sheffield, United Kingdom; 3Mental Health Unit, Rotherham
General Hospital, Rotherham, United Kingdom
Schizophrenia is often associated with impairments of occupational and so-
cial functioning which may impact the individual’s ability to live in the com-
munity. While many researchers have studied the association between lab-
based neuropsychological performance and regional brain volumes in
schizophrenia there has been less investigation of the relationship between
regional brain volumes and ‘real life’, purposeful activities. In a prospective
cohort study we acquired structural MRI scans to investigate the relation-
ship between daily functioning, as assessed by the Instrumental Activities of
Daily Living (IADL) scale (Lawton and Brody, 1969) and regional grey mat-
ter volumes. The IADL scale assesses performance in 8 domains comprising
the ability to use a telephone, grocery shopping, preparing meals, doing laun-
dry, getting to places beyond walking distance, doing housework, taking
medications and managing money. 53 patients satisfying DSM IV diagnoses
of schizophrenia or schizoaffective disorder were recruited, and underwent
comprehensive neuropsychological assessment. Patients were 33 6 7 years
old, had an illness duration of 8.5 6 6 years and a premorbid IQ of 105 6
8. All patients completed the IADL scale with a member of the team by rating
their present ability to perform specified tasks. Within a week of initial as-
sessment, a high resolution 3D T1- weighted dataset was acquired in the sag-
ittal plane, using a magnetization prepared rapid acquisition gradient echo
(MP- RAGE) technique (TR = 10.5ms; TE = 4.8ms) at 3T. Imaging data
obtained from scanning were processed using VBM in SPM2. IADL scores
were entered into a simple regression analysis with whole brain grey matter
segmented maps.Patients scored 1362.6 out of 16 on the IADL scale. Simple
regression with IADL scores showed a correlation with reduced grey matter
density in right dorsolateral prefrontal cortex (DLPFC; BA9), bilateral in-
ferior prefrontal cortex (BA47), P = .001 uncorrected. These prefrontal
regions have been implicated in such process as self monitoring, response
reversal and suppression. Hence they may be involved in behavioural
modulation in everyday life. Funded by MRC (UK), Career Establishment
Grant to SAS.
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CORTICAL THICKNESS IN SCHIZOPHRENIA
Heleen Boos1, A. Evans2, N. van Haren1, H. Schnack1, M. Van den
Heuvel1, W. Cahn1, H. H. Pol1, C. LePage2, R. Kahn1
1Rudolf Magnus Institute of Neuroscience, The Netherlands,
Department of Psychiatry, Utrecht, Netherlands; 2McConnell Brain
Imaging Centre, Montreal Neurological Institute, Montreal, ON,
Canada
Introduction: Schizophrenia is characterized by excessive reductions in ce-
rebral gray matter volume. Interestingly, in first-degree relatives the same
abnormalities are found although less pronounced. Few studies have exam-
ined cortical thickness (CorT) in patients with schizophrenia but these in-
clude relatively small samples. Methods: Magnetic Resonance Imaging
(MRI) brain scans were obtained from 159 patients and 158 healthy con-
trols (age 16–57 years). In-house software was used to segment cerebral
gray (GM) and white matter (WM) [1]. These segments were used as input
for an advanced neural net classifier. A surface deformation algorithm was
applied that first fits the white matter surface and then expands outward to
find the gray matter-cerebrospinal fluid intersection (software Montreal
Neurological Institute: CLASP [2]). For each subject, CorT is calculated
for every vertex. Group difference in CorT was calculated by using regres-
sion analyses with age and gender as covariates. The statistics were cor-
rected for multiple comparisons by applying a false discovery rate of
alpha = 0.05. In a second independent sample we obtained Magnetic Res-
onance Imaging brain scans from 175 schizophrenia patients, 185 of their
siblings and 125 healthy control subjects (age 17–56 years). The analyses of
this second study will be done with Structural equation modeling. Results:
Application of false discovery rate correction lead to significance thresholds
of F = 14.8 (left hemisphere) and F = 10.6 (right hemisphere). In patients
excessive decreases in CorT relative to controls were found, predominantly
in left and right frontal, temporal and cingular cortices. Interestingly, left
Wernicke area showed cortical thinning in patients. Increases were found in
bilateral occipital cortex, left precentral and postcentral gyrus, and right
parietal cortex. Conclusions: These findings show cortical thinning, pre-
dominantly in left and right frontal, temporal and cingular cortices of
schizophrenia patients relative to controls. We hypothesize that siblings
of patients with schizophrenia also show cortical thinning in the frontal
and temporal cortices although less pronounced.
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ASSOCIATION BETWEEN DURATION OF
UNTREATED PSYCHOSIS, OUTCOME AND BRAIN
MORPHOLOGY IN SCHIZOPHRENIA WITHIN THE
NORTHERN FINLAND 1966 BIRTH COHORT
Matti Sakari Penttila¨1, M. Haapea1, J. Veijola1, J. Miettunen1,
P. Tanskanen1, H. Koponen1,2, M. Isohanni1, E. Ja¨a¨skela¨inen1
1Department of Psychiatry, University of Oulu, Oulu, Finland;
2Department of Psychiatry, University of Kuopio, Kuopio, Finland
Long duration of untreated psychosis (DUP) has been reported to associate
with poor outcome in schizophrenia, possibly reflecting a neurodegenerative
process after the onset of overt psychosis. Hypothetically these neurodegen-
erative processes may be cause or consequence of changes in brain structures.
Our aim was to define differences in clinical and social outcome and volumes
of gray and white matter, intracranial cerebrospinal fluid (CSF), regional
gray matter in temporal, frontal, limbic, parietal and occipital cortices
and subcortical gray matter between schizophrenia subjects with long and
short DUP. Subjects with psychosis from the Northern Finland 1966 Birth
Cohort were invited to MRI scan of the brain conducted in 1999-2001
(average follow-up ten years). DUP (mean;38 weeks, median;20 weeks)
was assessed from medical records. It was categorized as short (under 6
months, n = 28) and long (over 6 months, n = 20). DUP was also assessed
as logarithmic transformation. MRI-data and DUP was available for 48
and outcome for 52 subjects with DSM-III-R schizophrenia. Outcome
was measured with PANSS, SOFAS and working ability. Covariates used
in adjustment were onset age, intracranial volume and current use of anti-
psychotic medication. Longer DUP was correlated with smaller volume of
left (P= .041) and right limbic area (P= .003). Logarithmic transformation of
DUP was significantly correlated with volumes of right central (P= .013) and
right limbic area (P = .036). DUP did not correlate with total gray or white
matter or CSF. In group of long DUP symptomatic outcome was somewhat
poorer, although not statistically significantly (total PANSS mean 55.3 vs
61.7 P = .21; positive 13.5 vs 15.0 P = .27, negative 16.6 vs 18.7 P = .45).
SOFAS and working ability did not differ between two groups. At least
some brain abnormalities were associated with long DUP in schizophrenia.
There was trend linking long DUP and poor symptomatic outcome. This
study provides new detailed information on developmental pathways of
schizophrenia utilising longitudinal birth cohort design.
ID: 550984
CORTICAL THINNING IN THE POSTERIOR
CINGULATE GYRUS: AN ENDOPHENOTYPE FOR
SCHIZOPHRENIA?
Petra Habets1, I. Weltens1, J. van Os1,2, R. Goebel3,4, M. Marcelis1
1Department of Psychiatry and Neuropsychology, Maastricht
University, Maastricht, Netherlands; 2Division of Psychological
Medicine, Institute of Psychiatry, London, United Kingdom;
3Department of Cognitive Neuroscience, Maastricht University,
Maastricht, Netherlands; 4F.C. Donders Centre for Cognitive
Neuroimaging, Nijmegen, Netherlands
Background: Studies investigating cortical thickness in schizophrenia using
genetically sensitive samples are still scarce. The evidence to date suggests
that decreased cortical thickness of the posterior cingulate and temporal
gyrus may be influenced by genetic factors, which is based on regions
of interest analyses. The present family study examined whether decreased
cortical thickness can be found as an indicator of genetic liability for the
disorder, using a whole brain analyses approach. Methods: T1-weighted
MRI scans were acquired on a 3 Tesla scanner from 92 patients with
schizophrenia, 98 non-psychotic siblings and 91 controls. BrainVoyager
QX was used to measure cortical thickness using the Laplace method.
Group differences were assessed with whole brain, vertex-based, analyses
(ANCOVA), performed in surface space after cortex based alignment of
segmented cortices, and adjusted for potential confounders. Results: Anal-
ysis showed significant clusters of cortical thinning in patients compared to
controls in the left and right superior parietal lobe, the right postcentral
gyrus, the left collateral sulcus, the left middle occipital gyrus, the left
extrastriate cortex, the left lateral occipitotemporal gyrus and the right
posterior cingulate gyrus; increases were found in the left precentral gyrus.
Siblings showed thinner cortex compared to the controls in the right col-
lateral sulcus and the right posterior cingulate gyrus; increases were found
in the right inferior frontal gyrus, the left lateral sulcus, the right postcen-
tral sulcus, the left middle temporal gyrus and the left cingulate sulcus.
Patients had thinner cortices than their siblings in the left and right supe-
rior frontal gyrus, the left postcentral gyrus and sulcus, the right precuneus,
the right intraparietal sulcus, the left inferior temporal sulcus, the right
collateral sulcus, the left lateral occipitotemporal gyrus, the left middle oc-
cipital gyrus, the left medial occipitotemporal gyrus and the left cuneus.
Conclusions: Psychotic patients and their non-psychotic siblings were
found to have widespread cortical thickness alterations compared to con-
trols, as evinced by decreases and increases in several brain regions. De-
creased cortical thickness in the right posterior cingulate gyrus was present
in both patients with psychosis and their siblings. Thus, decreased cortical
thickness in the right posterior cingulate gyrus may be influenced by genes
that are associated with schizophrenia.
ID: 550977
POST ONSET PROGRESSION OF BRAIN
ABNORMALITIES IN FIRST EPISODE PSYCHOSIS:
WHO, WHERE, WHEN, AND HOW MUCH
Robert McCarley1, M. E. Shenton1,2, D. F. Salisbury3,
M. Nakamura4, M. S. Koo5, M. Niznikiewicz1
1Psychiatry, VAMC/Harvard, Brockton, MA, USA; 2Psychiatry,
Brigham and Women’s Hospital/Harvard, Boston, MA, USA;
3Psychiatry, McLean/Harvard, Boston, MA, USA; 4Psychiatry,
Yokahama City University, Yokohama, Japan; 5Psychiatry,
MyungJi Hospital/Kwandong University, Kyunggi-Do, South Korea
This study presents new, never-presented data and newly re-analyzed data
relevant to determining the ‘‘who, where, when, and how much’’ of post-
onset brain abnormality progression. We used a naturalistic design of
tracking individuals with first episode schizophrenic psychosis (FESZ)
or affective psychosis (FEAFF, almost all manic) and using structural
MRI and mismatch negativity (MMN) ERPs to document brain changes
between first hospitalization and 1.5 years later (total Ns of 40) and 3 years
later (total Ns of 26). Highly reliable manual Region of Interest (ROI) anal-
yses were used on the 1.5 T scans. All changes were significant at P’s< 0.05.
We first describe the ‘‘who’’, ‘‘where’’, and ‘‘how much’’ of progression at
1.5 years after first hospitalization. FESZ have a progressive loss of neo-
cortical gray matter (GM, 1.7%), most pronounced in temporal and frontal
lobes (2.5%), and associated with a worse outcome on positive symptom
measures. FESZ showed a complementary progressive increase in lateral
ventricular (10.4%) and sulcal CSF (7.2%) associated with a worse outcome
on negative symptoms measures. In middle and inferior temporal gyri there
was no progression, but superior temporal gyrus (STG) FESZ showed post-
onset GM reduction in left posterior STG and Heschl Gyrus (HG), a pro-
gression associated with more cognitive disorganization and thought dis-
order. Moreover, there was a conjoint progression of reduced HG GM
and MMN amplitude. FESZ also showed progressive GM reduction in
the posterior cingulate cortex (CC, 2.0%) and anterior CC subdivisions
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of subgenual (4.2%), cognitive (4.9%), and affective (6.1%). In marked con-
trast, FEAFF showed post-onset progression of GM loss only in subgenual
CC (5.6%) but not in any STG subregion. The present data suggest pro-
tective effects of antipsychotics on GM reduction in FESZ (P = .085),
with mood stabilizers acting to increase GM; however, the GM increase
observed in FEAFF (3.6%) was not associated with changes in clinical out-
come. At the 3 years retest interval FESZ show continued reduction in neo-
cortical GM and increase in sulcal CSF. The ‘‘when’’ of changes differed by
region, FESZ STG reductions being most rapid. In summary, FESZ show
certain ROI ‘‘hot spots’’ of greater GM reduction that are associated with
worse clinical outcome and worse MMN measures. Of note, almost all ROI
with progressive changes in FESZ also showed abnormalities at initial scan,
suggesting the possibility of progression in the prodromal period.
ID: 550856
THE EFFECTS OF ANTIPSYCHOTIC MEDICATION
ON CORTICAL THICKNESS IN PATIENTS WITH
SCHIZOPHRENIA; A FIVE-YEAR LONGITUDINAL
MRI STUDY
W. Cahn1, N. E. van Haren1, H. G. Schnack1, H. E. Hulshoff Pol1,
C. Lepage2, A. C. Evans2, R. S. Kahn1
1Psychiatry, Rudolf Magnus Institute of Neuroscience, Utrecht,
Netherlands; 2McConnell Brain Imaging Centre, Montre´al
Neurological Institute, Montre´al, QC, Canada
In schizophrenia overall gray matter volume reduces over the course of the
illness. Progressive gray matter volume reduction is not only related to the
disease process, but also to the cumulative amount of antipsychotic med-
ication (Cahn et al. 2002, van Haren et al. 2008). Nevertheless, it is unclear
whether (the type of) antipsychotic medication influences some cortical
areas more than others. This five-year longitudinal study included 96
patients with schizophrenia and 113 healthy controls Magnetic Resonance
Imaging was performed at inclusion (T0) and after five years (T5). Every
patient was monitored carefully for the amount and type of medication pre-
scribed between base line and follow-up. Antipsychotic medication (intake
per year during the scan interval of typical and atypical antipsychotics in
haloperidol equivalents, clozapine in mgs) was calculated. For each subject
cortical thickness (CortT) change over time was computed using in-house
software(Schnacketal.2001)andCLASP(Kimetal.2005).Groupdifference
in CortT change was calculated by using regression analyses with age and
gender as covariates. The statistics were corrected for multiple comparisons
by applying a false discovery rate of alpha = 0.05. Spearman’s rank correla-
tionswereperformedon thesignificantcorticalareas toexaminetheeffectsof
antipsychotic medication. Excessive decreases over time in CortT in patients
relative to controls were found predominantly in the frontal and temporal
cortices.Cumulativetypicalantipsychoticmedicationcorrelatedwithchange
over time in CortT in the left post central area (rho=.36, P= .008), atypical
antipsychoticmedicationwithchangeinCortTintherightparacentral lobule
(rho = .32, P = .008) and clozapine with the cortical areas of the right medial
superiorfrontal (rho= .36,P= .005), right lateralmiddle frontal (rho= .41,P=
.002) and right cingulate (rho = .41, P= .001). These findings suggest that the
progressive cortical changes in patients with schizophrenia are also affected
by antipsychotic medication and that different types of medication might af-
fect different cortical brain areas.
References
1. Cahn, et al. Arch Gen Psychiatry. 2002;59:1002–10.
2. Van Haren, et al. Biol.Psychiatry. 2008;63:230–237.
3. Schnack, et al. Neuroimage. 2001;13:230–7.
4. Kim, et al. Neuroimage. 2005;27:210–221.
ID: 550833
THALAMUS VOLUME AND COGNITIVE
FUNCTION IN FIRST-EPISODE PSYCHOSIS
PATIENTS AND HEALTHY CONTROLS
Tiago Reis Marques, U. Ettinger, C. Nosarti, K. Morgan,
C. Morgan, P. Fearon, R. Murray, P. Dazzan
Psychological Medicine, Institute of Psychiatry, London,
United Kingdom
Introduction: Thalamus abnormalities have been implicated in the path-
ophysiology of Schizophrenia, placing it in the centre of dysfunctional
neural connectivity. This structure is also suppose to be involved in a num-
ber of different cognitive functions but, until present moment, only few
studies have investigated the relation between thalamic volume and cog-
nitive functioning in patients with First Episode Psychosis. Methods: 70
first episode psychosis patients (35 males, 25 females; mean age: 28.48
67.3) and 50 healthy controls (33 males, 17 females; mean age: 29.2 6
7.47) were scanned using a 1.5 Tesla scanner. Thalamus volumes were cal-
culated using stereological principles with the software MEASURE.
Patients and healthy controls completed a comprehensive battery of neu-
ropsychological tests, assessing executive functioning, verbal memory,
general intellectual ability and IQ. Results: Analyses of (Co)variance
(ANCOVA) were conducted, with age and whole brain volume as cova-
riate’s on the thalamic volume. Thalamic volume was then correlated with
neuropsychological scores. First episode psychosis patients display signif-
icantly reduced thalamic volume compared to controls (F1,90 = 9.493), P =
.03). No significant correlation was found between thalamic volume and
cognitive performance, in either of the cognitive dimension assessed. Con-
clusion: In our study we demonstrated significant thalamic volumes differ-
ences in patients with first-episode psychosis relative to healthy controls,
suggesting a potential abnormal thalamic circuitry. These data suggest no
relation between thalamic volume and cognitive performance in first-ep-
isode psychosis.
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A COMPARISON OF CAUDATE VOLUME AND
COGNITIVE FUNCTION BETWEEN FIRST-EPISODE
PSYCHOSIS PATIENTS AND HEALTHY CONTROLS
Heather Taylor1, A. Ricciardi1, K. Morgan2, C. Morgan1,
P. Fearon1, C. Nosarti1, P. Jones1, R. Murray1, P. Dazzan1
1Psychological Medicine, Institute of Psychiatry, King’s College
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Westminster, London, United Kingdom
The caudate volume is a structure often implicated in the pathogenesis of
schizophrenia. This structure also regulates a number of cognitive func-
tions. However, only few studies have investigated the correlation of cog-
nitive functioning with caudate volume in patients with psychosis. The
aim of this study was to investigate the comparison of caudate volume
in first episode psychosis patients between healthy controls and to further
examine the relationship between caudate volume and cognitive function-
ing. 95 first episode psychosis patients (60 males, 35 females; mean age
(27.49) 67.8; 47 schizophrenia, 29 Affective disorders, 18 Other) and
91 healthy controls (54 Males, 37 females; mean age (30.2) 68.72)
were scanned using a 1.5 Tesla scanner. The software MEASURE was
used to estimate caudate volume. Executive functioning, verbal memory,
general intellectual ability and IQ were examined in a neuropsychological
test battery. Analyses of (Co)variance (ANCOVA) were conducted with
whole brain volume and age and as covariate’s on the caudate volume,
diagnosis and pharmacological data. Caudate volume was then correlated
with neuropsychological scores. The results showed that patients had
larger caudate volume than healthy controls, albeit only at trend level
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(P = .069). Within the patient group, there was a positive correlation be-
tween caudate volume and performance on the Ravens task (P = .008) and
the trail making task (P = .006). These data suggest that a smaller caudate
volume in schizophrenia is associated with a poorer performance in tests
of general intellectual ability and executive function. It would be interest-
ing, next to investigate this data longitudinally with information collected
at a follow up.
ID: 564775
FRACTIONAL ANISOTROPY AND MOVEMENT
DISORDER IN SCHIZOPHRENIA
Stephen C. Olson1, T. White1, J. Vuchetich1, K. O. Lim1,
B. C. Ho2, J. Lauriello3, N. C. Andreasen2, V. A. Magnotta4,
H. J. Bockholt5, V. Calhoun5,6, R. L. Gollub7, S. C. Schulz1
1Psychiatry, University of Minnesota, Minneapolis, MN, USA;
2Psychiatry, University of Iowa, Iowa City, IA, USA; 3Psychiatry,
University of New Mexico, Albuquerque, NM, USA; 4Radiology,
University of Iowa, Iowa City, IA, USA; 5The Mind Research
Network, Albuquerque, NM, USA; 6Electrical and Computer
Engineering, University of New Mexico, Albuquerque, NM, USA;
7Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Diffusion tensor imaging (DTI) studies in patients with schizophrenia gen-
erally demonstrate decreased fractional anisotropy (FA) in white matter
(WM) in patients compared to controls, which is thought to reflect im-
paired WM connectivity. To date, there are no studies addressing the re-
lationship between WM changes with neurologic movement disorders,
which can be manifestations of schizophrenia, or a side effect of antipsy-
chotic medication experienced by some patients. We examined the relation-
ship of FA indices to measures of parkinsonism, akathisia, and dyskinesia
in a large sample of patients with chronic (CSZ) and first episode (FEP)
schizophrenia to test the hypothesis that patients with lower FA have higher
rates of movement disorders. Patients with CSZ (n = 83) and FEP (n = 31)
were recruited from either the University of Minnesota, University of New
Mexico, Massachusetts General Hospital, or the University of Iowa, sites
participating in the Mind Clinical Imaging Consortium project. Due to dif-
ferences in scanning hardware and procedures, FA measures were z-trans-
formed within each site before combining the measures for group analyses.
Abnormal movements were rated using the Simpson-Angus (SA), Barnes
Akathisia (BA), and Abnormal Involuntary Movement Scale (AIMS) rat-
ing scales for parkinsonism, akathisia, and dyskinesia, respectively. Results
showed no significant correlations between the whole brain FA measures
and any of the movement ratings, either in the group as a whole, or in CSZ
alone. As expected, FEP patients, who were all on atypical antipsychotics,
had low rates of movement symptoms. Spearman rank order correlations
with regional FA brain measures suggested higher SA ratings were associ-
ated with lower FA in the left cerebellum (P = .012, CSZ; P = .004, CSZ and
FEP combined), but not measures of FA in the frontal, temporal, parietal,
or occipital lobes. Tardive dyskinesia was identified in only 4 of the 83 SCZ
patients and was associated with age and cumulative dose-years of treat-
ment, but FA measures did not differ between affected and unaffected
patients. Further analyses of the data will be presented. These results suggest
a possible association between parkinsonian symptoms and cerebellar FA,
but future studies controlling for antipsychotic dosing and samples enriched
for patients with dyskinesia will be needed to clarify possible relationships
between WM connectivity and movement disorders in schizophrenia.
ID: 554803
INTERLEUKIN-1BETA GENE MODULATES
PREFRONTAL AND TEMPORAL BRAIN
STRUCTURE IN SCHIZOPHRENIA
Raka Maitra1, R. Schloesser1, A. Rosa2, S. Papiol2, C. Gaser1,
C. Schachtzabel1, M. Axer1, M. Roebel1, C. Schultz1, G. Wagner1,
K. Koch1, J. R. Reichenbach3, H. Sauer1, L. Fananas2, I. Nenadic1
1Department of Psychiatry and Psychotherapy, Friedrich-Schiller
University of Jena, Jena, Germany; 2Unitat d’Antropologia,
Department Biologia Animal, University of Barcelona, Barcelona,
Spain; 3Department of Medical Physics, IDIR,
Friedrich-Schiller-University of Jena, Jena, Germany
Introduction: Interleukin-1beta (IL-1b, chromosome 2q13) has a key role
in differentiation of dopaminergic neurons and dendrite growth in devel-
oping cortical neurons. Previous studies by our group and others have
shown that IL1b genotype a) is associated with schizophrenia and b)
modulates activity in the dorsolateral prefrontal cortex. Here we investi-
gated the effect of the risk allele (511 T) on brain structure using vox-
el-based morphometry. Methods: 61 patients with DSM IV
schizophrenia (mean age 31.8 yrs; SD 11.53 yrs) and 54 healthy subjects
(mean age 29 yrs; SD 9.87 yrs) were genotyped for a functional single nu-
cleotide polymorphism of IL-1B (rs16944) and grouped into risk-allele car-
riers (A2 homozygotes and A1/A2 heterozygotes) vs. A1 homozygotes.
Grey matter volume was analyzed using optimised voxel based morphom-
etry on T1-weighted high-resolution anatomical images (TR = 15ms, TE =
5ms, flip angle = 300, FOV = 256mm, matrix = 256X256, sagittal slices =
192, slice thickness = 1 mm, voxel dimension 1X1X1 mm3). Results: Main
effect of diagnosis showed grey matter (GM) volume loss in bilateral
DLPFC, bilateral caudate, bilateral insula, left fusiform gyrus (P <
.001, uncorr.). In healthy controls, risk allele carriers showed grey matter
reduction in the left insula. In schizophrenia patients, risk allele carriers
showed grey matter increase in the left inferior temporal cortex. We found
a significant (P < .01, uncorr.) effect of group X genotype interaction in
bilateral superior lateral prefrontal cortex, superior temporal gyrus, ante-
rior temporal pole, and left posterior temporal cortex. Only the left fusiform
gyrus showed increased grey matter in patients who are A1 homozygous
compared to the other groups. Conclusions: This study demonstrates
effects of IL-1b in prefrontal and temporal cortical areas, which have
been associated with cognitive deficits in schizophrenia. Given the role
of IL-1b in early development, this might reflect higher vulnerability of
A2 risk allele carriers for brain structural deficits in these areas.
ID: 554460
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16. 16. Neuropathology, Histology
THE NEUREGULIN-1ISOFORMS ALPHA AND BETA
ARE DIFFERENTLY EXPRESSED IN THE PRE-
FRONTAL CORTEX IN SCHIZOPHRENIA AND
AFFECTIVE DISORDER
Hans-Gert Bernstein1, U. Lendeckel2, I. Bertram1,
H. Dobrowolny1, J. Steiner1, G. Keilhoff3, B. Bogerts1
1Psychiatry, University of Magdeburg, Magdeburg, Germany;
2Biochemistry, University of Greifswald, Magdeburg, Germany;
3Cell Biology, University of Magdeburg, Magdeburg, Germany
Neuregulin-1 proteins play important roles in neuronal migration, differ-
entiation and signal mediation, as well as in the survival of oligodendro-
cytes. The NRG-1 gene codes for 15 different isoforms. At least five
different haplotypes of the NRG-1 gene may be associated with schizophre-
nia. An abnormal expression pattern of NRG-1 mRNA was found in the
prefrontal cortex of schizophrenic patients and patients suffering from de-
pression. Here we investigated in postmortem brains the expression of the
two NRG-1 isoforms alpha and beta, which differ with regard to their
EGF-like domains, in schizophrenia and depression. NRG-1alpha was
immunohistochemically visualized on brain sections of 22 schizophrenics,
12 patients with affective disorders and 22 matched controls, NRG-1beta in
brains of 7 schizophrenics, 6 patients with affective disorders and 8 matched
controls. The number of NRG-1alpha immunoreactive neurons per hemi-
sphere was counted using a computer assisted analysis system. NRG-1beta
immunopositive cells were counted in den DLPFC and ACC by using a light
microscope. Normal anatomical distribution showed for NRG-1alpha only
few immunopositive interneurons located in the prefrontal gray and white
matter, whereas for NRG-1beta a widespread immunoreactivity in pyrami-
dal cells and interneurons was observed. In schizophrenia stereologic anal-
ysis revealed a significant reduction of NRG-1alpha cells in the white as
well as in the gray cortical matter. In patients with unipolar depression
the density of NRG-1alpha immunoreactive neurons was also significantly
reduced in the prefrontal gray matter. In contrast to the 1alpha-isoform,
NRG-1beta immunopositive interneurons and pyramidal cells in DLPFC
and ACC were significantly increased in schizophrenics in comparison to
controls. Interneurons of the DLPFC differed significantly between cases of
affective disorders and schizophrenics.The diminished expression of NRG-
1alpha in interstitial white matter neurons supports a neurodevelopmental
component to schizophrenia (disturbed migration). With regard to NRG-
1beta we suppose that the increase of the immunopositive neurons in schiz-
ophrenics leads to a hypofunction of NMDA-receptors via enhanced
binding of this NRG-1 isoform to its receptor, ErbB4 (Hahn et al.
2006). However the increased expression of NRG-1beta could also be
due to the chronic administration of antipsychotics.
ID: 540132
ENDOCANNABINOID SYNTHESIZING AND
METABOLIZING ENZYMES IN THE PREFRONTAL
CORTEX IN SCHIZOPHRENIA
David Volk1, S. Eggan1, D. Lewis1,2
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA
Cannabis use in schizophrenia is increasingly recognized as a major public
health concern. For example, cannabis use worsens prefrontal cortex
(PFC)-related cognitive impairments in subjects with schizophrenia. Inter-
esting, cognitive deficits in schizophrenia are linked to reduced GABA sig-
naling in the PFC, and activation of the cannabinoid 1 receptor (CB1R)
reduces the release of GABA. Thus, cannabis use may worsen cognitive
deficits in schizophrenia by exogenously activating the CB1R which further
impairs PFC GABA signaling. Direct investigations of the endogenous
cannabinoid (eCB) system may help clarify the biological basis for the neg-
ative effects of cannabis use in schizophrenia. For example, lower CB1R
mRNA and protein levels have been reported in the PFC in schizophrenia.
However, do lower CB1R levels reflect an overall deficiency in eCB signal-
ing in the disease, or are CB1R levels downregulated in response to exces-
sive eCB signaling? Discriminating between these possibilities requires
knowledge of the eCB ligands that bind to the CB1R. For example, the
eCB 2-arachidonoylglycerol (2-AG) is synthesized by diacylglycerol lipase
(DAGL) and is degraded by monoglyceride lipase (MGL). Inhibiting
DAGL lowers 2-AG levels and enhances GABA signaling; conversely,
inhibiting MGL raises 2-AG levels and further suppresses GABA signaling.
While it is not possible to directly measure 2-AG levels in postmortem
human brain tissue, determining the levels of DAGL and/or MGL may
help elucidate the status of 2-AG signaling in schizophrenia. Therefore, us-
ing postmortem brain tissue from a cohort of 23 schizophrenia subjects with
decreased CB1R mRNA levels compared to matched control subjects, we
are using quantitative PCR (qPCR) to quantify relative mRNA levels for
DAGL and MGL in the PFC. The comparative threshold cycle (Ct)
method is used in which transcript levels are expressed as normalized values
to the geometric mean of 3 control genes. The specificity and efficiency of
the qPCR amplification of DAGL and MGL mRNA in human brain have
been confirmed in pilot experiments. Final data collection is ongoing with
experimenters blinded to diagnosis. We predict that DAGL mRNA levels
are reduced and MGL mRNA levels are increased in the PFC in schizo-
phrenia. These findings, in concert with lower CB1R levels, would suggest
an overall decrease in 2-AG signaling which may have a compensatory
effect for impaired GABA signaling in schizophrenia.
ID: 550361
QUETIAPINE ALLEVIATES THE CUPRIZONE-
INDUCED WHITE MATTER PATHOLOGY IN THE
BRAIN OF C57BL/6 MOUSE
Yanbo Zhang1,3, H. Xu4, J. Wengao5, L. Xiao6, J. He3, X. Bi1,3,
Y. Wang1,3, J. Kong2, X.-M. Li1,3
1Psychiatry, University of Manitoba, Winnipeg, MB, Canada;
2Human Anatomy and Cell Science, University of Manitoba,
Winnipeg, MB, Canada; 3Psychiatry, University of Saskatchewan,
Saskatoon, SK, Canada; 4Anatomy, Southern Illinois University,
Carbondale, IL, USA; 5Neuropharmacology, Wenzhou Medical
College, Wenzhou, China; 6Histology and Embryology, Third
Military Medical University, Chongqing, China
Recent human studies employing new magnetic resonance imaging techni-
ques and micro-array analyses feature schizophrenia as a brain disease with
alterations in white matter (WM), which is mainly composed of oligoden-
drocytes (OLs) and their processes wrapping around neuronal axons. To
examine the putative role of OLs in the pathophysiology and treatment
of schizophrenia, animal studies are essential. In the present study,
C57BL/6 mice were given 0.2% cuprizone (CPZ) in their diet for five weeks
during which they drank distilled water without or with quetiapine (QTP,
10 mg/kg). The mice fed with normal chow were used as controls. CPZ is
a copper chelator and has been reported to induce consistent demyelination
in the brain of C57BL/6 mouse by specifically damaging OLs. QTP is an
atypical antipsychotic widely used in the treatment of schizophrenia and
other psychotic disorders. In accordance with previous studies, CPZ-
exposed mice showed pervasive myelin breakdown and demyelination.
The amount of myelin basic protein (MBP) in the cerebral cortex was de-
creased by CPZ-exposure as shown in Western-blot analysis. In addition,
the demyelinated sites were teemed with activated microglia and astrocytes
but a few myelin forming OLs. Moreover, the activity of copper-zinc
superoxide dismutase decreased in the cerebral cortex of CPZ-exposed
mice. However, all of these pathological changes in WM were either
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prevented or alleviated in CPZ-exposed mice co-administered with QTP.
These results suggest that the CPZ-exposed C57BL/6 mouse is a potential
animal model to study possible roles of OLs in the pathogenesis and treat-
ment of schizophrenia.
ID: 550211
GAD67 PROTEIN LEVELS AT THE AXON
TERMINAL IN THE DORSOLATERAL
PREFRONTAL CORTEX OF SUBJECTS WITH
SCHIZOPHRENIA
Allison A. Curley1, K. N. Fish2, D. A. Lewis1,2
1Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA;
2Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
Impaired GABA neurotransmission in the dorsolateral prefrontal cortex
(DLPFC) may contribute to the cognitive deficits of schizophrenia. The
presynaptic strength of GABA neurotransmission is partially determined
by the amount of GABA in the axon terminal available for release. Termi-
nal GABA is synthesized locally by the 67- and 65-kDa isoforms of gluta-
mic acid decarboxylase (GAD67 and GAD65). In the DLPFC of subjects
with schizophrenia, a reduction in GAD67, but not GAD65, mRNA has
been widely-replicated. This deficit appears to be present in the subclass of
GABA neurons that contain the calcium-binding protein parvalbumin
(PV). However, it is unknown if the deficit in GAD67 mRNA is accompa-
nied by a comparable decrease in GAD67 protein in PV terminals. To an-
swer this question, we have developed a novel fluorescence intensity/
morphological segmentation protocol, that in combination with immuno-
cytochemistry, spinning disk confocal microscopy, and stereological sam-
pling, permits the unbiased assessment of both the relative density of axon
terminals and relative protein levels per terminal. We are utilizing this
approach in a cohort of 20 matched pairs of schizophrenia and control sub-
jects, all with RNA integrity number > 7 and postmortem interval < 20
hours. The latter is associated with good preservation of GAD67 and
GAD65 protein, as determined by Western blot. Blind to diagnosis, we
are quantifying GAD67 protein levels in puncta (putative axon terminals)
triple-labeled for GAD67, GAD65, and PV in layers 3 and 4 of DLPFC
area 9. A reduction in the levels of GAD67 protein in GAD65/PV terminals,
but no change in the density of triple-labeled terminals, in subjects with
schizophrenia would parallel the mRNA data and support the hypothesis
of reduced GABA synthesis and neurotransmission in PV-containing
GABA neurons in schizophrenia.
ID: 549927
DECREASED COX ACTIVITY IN THE PUTAMEN
IN SCHIZOPHRENIA.
Rosalinda C. Roberts1, S. Somerville2, J. K. Roche1,
R. R. Conley2,3
1Psychiatry, University of Alabama, Birmingham, Birmingham, AL,
USA; 2Maryland Psychiatric Research Center, University of
Maryland, Baltimore, Baltimore, MD, USA; 3Neuroscience, Lilly
Technology Center, Indianapolis, IN, USA
Schizophrenia (SZ) is a very heterogeneous disease with a spectrum of
symptoms, risk factors and probably etiology. The striatum, a brain region
involved in motor, cognitive and emotional skills, is abnormal in patients
with SZ. Abnormalities in mitochondria, the energy producing organelles
of the cell, have been observed in subjects with SZ in the striatum and else-
where. Mitochondrial function can be assessed by measuring the activity of
cytochrome oxidase (COX), a component of complex IV of the electron
transport chain. In the present study, COX histochemistry was performed
in postmortem striatal tissue from subjects with SZ and normal controls
(NCs), and in rats treated chronically (4 months) with the antipsychotic
drugs (APD) clozapine or haloperidol. Postmortem human brain tissue
was obtained with family permission from the Maryland Brain Collection.
SZ cases (n = 12) and NCs (n = 6) were matched using age, sex, post mortem
interval (PMI), and race as criteria. SZ cases were divided into two sub-
groups: on APD and off APD (n = 6 per group). The mean ages were:
NCs, 56.8 6 15.8y; SZ on APD 54.2 6 17.0y; SZ off APD, 47.3 6 21.3y.
The mean PMIs were NCs, 12 6 6.7h; SZ on APD, 9.0 6 8.1h; SZ off
APD, 15.7 6 4.9h). There was significantly (P< .001) less COX (a decrease
of 20%) in the putamen of the combined SZ group (0.341 6 0.01) vs. NCs
(0.4236 0.01). Both subgroups with SZ had lower (P< .001) putamen COX
values (SZ on APD, 0.340 6 0.01; SZ off APD, 0.342 6 0.01) than that of
NCs (0.423 6 0.01). In the caudate, there were no differences in COX levels
in the two group (NCs, 0.405 6 0.01; SZ, 0.396 6 0.02) or three group anal-
yses (NCs, 0.405 6 0.01; SZ on APDs, 0.395 6 0.009; SZ off APDs, 0.397 6
0.01. In rats, COX activity was not decreased by either haloperidol (0.453 6
0.004) or clozapine (0.416 6 0.002) compared to that of controls (0.398 6
0.004). The similar decrease in COX activity in the putamen of SZ on and
off APD, together with the rat data suggests that the decrease in COX ac-
tivity in the putamen of SZs does not seem to be caused by APDs. The data
suggest mitochondrial abnormalities in the putamen in SZ.
ID: 549892
EXPRESSION OF CORTICAL GABAA RECEPTOR
SUBUNIT TRANSCRIPTS IN SCHIZOPHRENIA:
ALTERED INHIBITORY NEUROTRANSMISSION
IN SPECIFIC CORTICAL CIRCUITS
Monica Beneyto1, A. Abbott2, T. Hashimoto1,3, D. A. Lewis1,2
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA;
3Psychiatry, Kanazawa University, Kanazawa, Japan
Disturbances in working memory and prefrontal cortex (PFC) function in
schizophrenia may reflect abnormalities in the intrinsic circuitry of this re-
gion. Previous studies have described alterations in presynaptic markers in
certain classes of PFC GABA neurons in schizophrenia. At the postsynap-
tic site, the effects of GABA are mediated by GABAA receptors whose sub-
unit composition and subcellular location are specific to different local
cortical circuits. To determine the postsynaptic circuit specificity of altered
GABA neurotransmission in schizophrenia, we examined the expression of
GABAA receptor a1, a2, a3, and a5 subunits and their assembly partners b2
and b3. We used in situ hybridization in DLPFC samples from 23 matched
pairs of schizophrenia and control subjects. For each subunit, we deter-
mined the overall level and laminar pattern of mRNA expression. In a par-
allel study, the potential effects of antipsychotic medications on GABAA
receptor subunit expression were assessed in male macaque monkeys chron-
ically exposed to haloperidol, olanzapine, or placebo. Each GABAA a sub-
unit had a distinct laminar pattern of expression that was similar in control
and schizophrenia subjects. In schizophrenia, mean GABAA a1 mRNA ex-
pression was 16% lower in layers 3–5, a2 mRNA was 14% higher in layer 2,
and a5 was 15% lower in layer 4 relative to matched controls. In contrast, a3
mRNA expression did not differ from controls. Absence of alterations in
the antipsychotic-exposed monkeys suggested that the abnormal expression
of those transcripts in schizophrenia was not due to medication effects.
Blinded quantification of GABAA b2 and b3 mRNA expression is in prog-
ress. Our results suggest that GABA neurotransmission in the DLPFC of
subjects with schizophrenia is altered at the postsynaptic level in a receptor
subunit- and layer-specific manner. Given the predisposition for receptors
containing these different subunits to be preferentially located at synaptic
contacts from axon terminals of specific classes of GABA neurons and at
specific locations on pyramidal neurons, our results suggest that altered
GABA neurotransmission in schizophrenia is circuit-specific and affects
the firing of pyramidal neurons in different ways. Supporting
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ARRESTED NEUROPLASTICITY?: ALTERED
AGEING EFFECTS REVEAL A DYNAMIC
NEUROPATHOLOGY OF SCHIZOPHRENIA
Steven A. Chance1, P. Harrison3, T. Crow2
1Oxford University, Oxford, United Kingdom; 2SANE/POWIC,
Psychiatry, Warneford Hospital, Oxford, United Kingdom;
3Psychiatry, Warneford Hospital, Oxford, United Kingdom
Recent hypotheses concerning synaptic deficits in schizophrenia do not ex-
plain why the degree of abnormality is not more catastrophic. It indicates
that the problem may be relatively discrete and lie with a particular com-
ponent of the repertoire of neuroplastic mechanisms. Here we demonstrate
that normal age-associated changes in association cortex neuron spacing
are not found in schizophrenia. These age-associated changes are reported
in an adult population (age range 29–90yrs) and are not found in primary
sensory cortex, indicating that they are selective to the more plastic regions
of association cortex involved in cognition. The deviation of patients from
the normal ageing curve of controls was found to correlate with age of onset
(linear regression, P< .01). On the basis of these findings a meta-analysis of
the neuropathology literature (56 studies of neuron density) was conducted
and revealed a negative correlation between the mean age of the subjects
and the size of the cell density change in schizophrenia (r2 =0.46, P< .01).
The contrast between patients and controls depends on when in adulthood
the cell density is measured. Additional meta-analysis of post-mortem brain
weight (1367 subjects) indicated accelerating brain size reduction with age
in patients. The literature on neuron number in the cortex implicates cell
loss as the cause. The neurodevelopmental hypothesis proposed that ‘‘a
fixed ‘lesion’ early in life interacts with normal brain maturational events
that occur much later’’ (Weinberger, 1987), however the findings presented
are consistent with abnormal maturation. Healthy maturation involves an
expansion and later reduction of neuropil (tissue between cells). In schizo-
phrenia the neurons are more closely packed to begin with but show little
change in adulthood. An arrest of plasticity may confer vulnerability to cell
loss and brain volume reduction when adult neuroplastic demands are not
met. The inference is that the size of the plasticity deficit is linked to the
timing of the arrest and the age of illness onset.
ID: 551873
CANNABINOID 1 (CB1) RECEPTOR PROTEIN
EXPRESSION IN THE PREFRONTAL CORTEX
OF SUBJECTS WITH SCHIZOPHRENIA OR
MAJOR DEPRESSION
Stephen M. Eggan1, S. R. Stoyack2, D. A. Lewis1,2
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA
Cannabis use causes impairments in cognitive processes, such as working
memory, that are also present in schizophrenia. Working memory impair-
ments in schizophrenia are associated with reduced GABA signaling in the
dorsolateral prefrontal cortex (DLPFC). The cannabinoid 1 receptor
(CB1R) is highly expressed in the DLPFC, is contained in the axon termi-
nals of a subpopulation of perisomatic-targeting GABA neurons, and when
activated, inhibits the release of GABA. These data suggest that altered
signaling via the CB1R may be involved in the pathophysiology of schizo-
phrenia. Indeed, we recently demonstrated that the expression of CB1R
mRNA and protein was significantly reduced bilaterally in DLPFC area
9 in a cohort of 23 pairs of subjects with schizophrenia and matched control
subjects. In this study, we determined whether the reduction in CB1R pro-
tein levels 1) is also present in DLPFC area 46 in the same subjects with
schizophrenia, 2) is present in area 46 in a new subject cohort, and 3) is
specific to schizophrenia or also present in subjects with major depression
(MDD). We used immunocytochemical techniques to examine the levels
and laminar distribution of CB1R protein in area 46 in 12 pairs of subjects
from the previously studied cohort and from a new cohort of 14 matched
triads of schizophrenia, MDD, and control subjects. In the 12 pair cohort,
optical density analysis revealed that the levels of CB1R immunoreactivity
in area 46 were significantly reduced by 19% in schizophrenia subjects. The
within-pair percent changes in CB1R immunoreactivity in area 46 signifi-
cantly correlated with those previously observed in area 9 of the same sub-
jects with schizophrenia. In the cohort of 14 triads, CB1R immunoreactivity
was reduced by 20% and 23% in subjects with schizophrenia compared to
matched control and MDD subjects, respectively. Levels of CB1R immu-
noreactivity did not differ between MDD and comparison groups. Laminar
analysis revealed that CB1R immunoreactivity was decreased across all cor-
tical layers in subjects with schizophrenia. These results demonstrate that
reductions in CB1R protein are 1) common in schizophrenia, 2) conserved
across DLPFC regions in schizophrenia, and 3) not present in subjects with
MDD. Thus, altered inhibition from CB1-containing GABA neurons may
be a critical component of the disease process underlying DLPFC dysfunc-
tion in schizophrenia.
ID: 551825
A DISC1 MOUSE MODEL OF GENE-ENVIRONMENT
INTERACTIONS IN THE PATHOGENESIS OF
SCHIZOPHRENIA
Bagrat Abazyan1, Y. Ayhan1, M. W. Vogel2, C. A. Ross1,
M. V. Pletnikov1
1Department of Psychiatry, John Hopkins Hospital, Baltimore,
MD, USA; 2MPRC, University of Maryland, Baltimore, MD, USA
Interplay between genetic and environmental factors likely plays a major
role in development of schizophrenia and related psychiatric conditions.
However, mechanistic studies of potential interactions have been difficult
due to the paucity of experimental models directly relevant to human ep-
idemiological data. Recent discoveries of candidate genes and a better un-
derstanding of the nature of immune response of the body to aversive
environmental factors have facilitated the development of novel in vitro
and in vivo models. We have developed a mouse model of inducible expres-
sion of mutant human Disrupted-in-Schizophrenia-1, DISC1, a predicted
truncated protein product of the chromosomal translocation previously
shown to segregate with psychiatric illness. We use this model to elucidate
the mechanism of interactions between mutant DISC1 and prenatal im-
mune activation with a synthetic analog of double-stranded RNA (poly
IC) that induces immune activation in pregnant dams similar to that asso-
ciated with viral infections during pregnancy. We found that prenatal im-
mune challenge significantly up-regulated pro-inflammatory cytokines in
the serum of pregnant mice and embryonic brains, indicating immune ac-
tivation in mutant DISC1 mice. Compared to saline-treated DISC1 mice,
poly IC-challenged DISC1 mice exhibited increased anxiety in elevated plus
maze, dark-light box emergency test, and open field, decreased exploration
of social and non-social targets and depression-like phenotype in Porsolt
test, suggesting the synergistic effects of immune activation and mutant
DISC1 in the adult offspring. Poly IC treatment increased the volumes
of the lateral ventricles in control mice and did not significantly affect
the already enlarged lateral ventricles in mutant DISC1 mice. Our prelim-
inary data showed that prenatal stimulation decreased the density of den-
dritic spines in the dentate gyrus of the hippocampus in mutant DISC1 mice
without altering the spine density in control animals. The present results
suggest significant interactions between mutant DISC1 and environmental
challenge during neurodevelopment and lend additional support to the use
International Congress on Schizophrenia Research
16. 16. Neuropathology, Histology 225
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
of our model for elucidating the molecular pathways that mediate gene-
environment interactions in schizophrenia and related mental disorders.
ID: 551818
CEREBROVASCULAR DISEASE, MYELIN, AND
COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA
Andrew J. Dwork1,3, B. Ilievski1,3, B. Mancevski1, I. Trencevska2,
V. Ortakov3, T. Serafimova3, G. B. Rosoklija1,4, J. Keilp1
1College of Physicians and Surgeons of Columbia University and
New York State Psychiatric Institute, New York, NY, USA; 2New
York State Psychiatric Institute, New York, NY, USA; 3School of
Medicine, University Ss. Cyril and Methodius, Skopje, Macedonia;
4Macedonian Academy of Arts and Sciences, Skopje, Macedonia
Introduction: Severe cognitive dysfunction is common in elderly individuals
with schizophrenia. The neuropathological basis of this decline is unknown.
We previously reported evidence for reduced tolerance to Alzheimer-type
pathology in chronically institutionalized patients with schizophrenia; how-
ever, many instances of severe cognitive decline remained unexplained. We
now explore the possibility that cognitive decline in schizophrenia might be
related to white matter deficits resulting from cerebrovascular disease or
from schizophrenia itself. Methods: Semiquantitative evaluations of Ver-
hoeff myelin stain were performed on white matter from the dorsal half of
onefrontal lobeatthelevelof therostralpoleofthelateralventricle inautopsy
brainsof81elderly individualswithschizophreniawhodiedinstatehospitals,
and 21 individuals without psychiatric disease or dementia. Cognitive func-
tion in the schizophrenia subjects was quantified with the Scales of Cognitive
Impairment Rated From Institutional Records for the beginning and end of
the illness, and for intervening 10 year intervals. Hypertensive, atheroscle-
rotic, or amyloidotic vascular disease was diagnosed by neuropathological
examination. Results: Two-way ANOVA yielded, as expected, a significant
effect of vascular disease on myelin integrity (P = .02). Schizophrenia (P =
0.29) and the interaction of vascular disease and schizophrenia (P = .81)
did not affect the histological integrity ofmyelin in this region.Over the entire
course of illness, schizophrenia subjects with vascular disease had nearly 50%
greatercognitivedeclinethanschizophreniasubjectswithoutvasculardisease
(P = .003), whose cognitive decline was nonetheless many times greater than
reported for normal aging. The cognitive decrement associated with vascular
disease in schizophrenia was itself much greater than the effects of normal
aging. Curiously, in both the schizophrenia and nonpsychiatric groups,
the effect of vascular disease on myelin was greater in females, while the effect
of vascular disease on cognitive change was similar for male and female
schizophrenia subjects. Conclusion: These findings suggest that in schizophre-
nia, there is a heightened susceptibility to the cognitive effects of
cerebrovascular disease. Acknowledgements MH60877, MH64168,
NARSAD, Stanley Medical Research Institute, Lieber Center for
Schizophrenia Research at Columbia University.
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HOW TO RUN A BRAIN BANK FOR PSYCHIATRIC
DISORDERS—DO WE NEED AN INTERNATIONAL
CONCENSUS?
Rivka Ravid
1Netherlands Institute of Neurosciences, Amsterdam, Netherlands;
2Brain Bank, Netherlands Institute of Neurosciences, Amsterdam,
Netherlands
Current developments in research of psychiatric disorders are partly due to
the progress and growth in the field of brain tissue/Bio (BTB) banking. We
have recently proposed a new standardized version of golden standards for
brain banking (Ravid 2008a,b; these include organization, methodology of
collecting, handling and storing specimens for high quality and modern re-
search, the standard operating procedures (SOP’s),legal /ethical /social/
moral issues and the Code of Conduct. Psychiatric brain banks are impor-
tant as they form a bridge between donors, their relatives, clinicians, neuro-
pathologists , scientists and the pharmaceutical companies, looking for
targets and developing drugs. We have developed parameters for quality
control and matching of samples to correct for the enormous variability in
patient material; these include age, gender, clinical history, medication, ag-
onal state / pH, seasonal and annual variation, post mortem-delay,
handling methods, fixation time and storage time. As the aetiology and
pathophysiology of psychiatric disorders are still unknown, we have
also identified several brain regions as regions of interest for assessments,
specifically the area of the prefrontal cortex, which was followed by devel-
oping new dissection protocols for post-mortem brain at rapid autopsy.
The availability of autopsy material from patients with psychiatric disor-
ders is very limited while the interest from the international scientific com-
munity is ever-growing. To solve this problem we introduced an intense
collaboration with psychiatric departments and research institutions to im-
plement a post-mortem research program including genetic research and
search for gene-expression profiles. The global decline in autopsy rates
is a worrying situation which makes well operating and efficient brain
banks even more vital. The legislative /ethical framework needed to run
brain banks is still a matter of debate and will determine the future and
the continuity of research on psychiatric disorders. We are preparing an
Inter-national consensus for protocols and procedures of sample acquisi-
tion in psychiatric disorders which will hopefully facilitate a breakthrough
in research.
References
1. Ravid, R. Standard operating procedures, ethical and legal regulations
in BTB (brain/tissue/bio) banking: what is still missing? Cell Tissue
Bank. 2008a;9(2):121–37.
2. Ravid R, and Grinberg-Tenenholz L. How to run a brain bank-
revisted. Cell Tissue Bank. 2008b;9(3):149–50.
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VA/VL THALAMIC CELL NUMBER IN
SCHIZOPHRENIA AND MOOD DISORDERS
Keith A. Young, W. Bonkale, S. Sachsenmaier, P. Hicks
Neuropsychiatry Research Program, CTVHCS/Texas AandM
HSC, Temple, TX, USA
The thalamus has been found to be a site of anatomical disturbance in
schizophrenia and mood disorders. We have previously reported increased
volume and neuron number in the mediodorsal and anteroventral/antero-
medial nuclei of the thalamus in major depression, with no change in the
number of neurons in schizophrenia in these nuclei in subjects of moderate
age (average age = 45; Young et al., 2004 Am J. Psychiatry 161: 1270–1277).
In the present post-mortem investigation of specimens from the Stanley
Foundation Brain Collection diagnosed with schizophrenia, major depres-
sion and bipolar disorder, we performed stereological study of the ven-
troanterior/ventrolateral nucleus (VA/VL), a large nuclear group which
projects primarily to the cingulate, premotor and motor cortex. We ob-
served in subjects with major depression that volume and neuron number
of the VA/VL was nearly double that of controls, while schizophrenia sub-
jects had a normal complement of neurons and a normal volume. Bipolar
subjects were observed to have an intermediate volume and neuron number
which was not statistically different from controls. We also observed that
prior treatment with antidepressants was associated with a reduced volume
(but no change in neuron number) of the AV/AM, a finding previously
reported for whole thalamic volume (Young et al., 2008, British Journal
of Psychiatry 192, 285–289). The present finding supports a robust alter-
ation in neuron number in major depression in several thalamic nuclei
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that project to the anterior portions of the cortex in middle-aged subjects,
with no major changes in this region in schizophrenia.
ID: 551595
SIMILARITIES AND DIFFERENCES IN SCHIZO-
PHRENIA OR BIPOLAR DISORDER: EVIDENCE
FROM POSTMORTEM INVESTIGATIONS
Sabina Berretta
1Department of Psychiatry, McLean Hospital, Belmont, MA, USA;
2Harvard Medical School, Boston, MA, USA
In postmortem studies, microscopic, cytochemical, molecular and genetic
approaches are demonstrating both similarities and differences between
schizophrenia (SZ) and bipolar disorder (BD). These two disorders affect
largely overlapping brain regions, neural circuits and neurotransmitter sys-
tems.However, there is also evidence fordivergent pathophysiologicalmech-
anisms. This talk will review neuropathological investigations comparing SZ
to BD and will give particular focus to recent findings in the amygdala and
entorhinal cortex. In the amygdala of SZ subjects, but not BDs, fibers
expressing dopamine transporter are reduced, while tyrosine hydroxylase-
positive fibers were normal. These findings suggest that dopamine uptake
may be impaired in SZ, potentially causing a state of hyperdopaminergia.
Lack of similar changes in BD may contribute to pharmacological differen-
ces between these disorders. Marked increases of glial cells expressing extra-
cellular matrix proteoglicans were also detected in the amygdala of SZ
subjects. These changes suggest that a disruption of glial cell functions
and extracellular matrix properties may contribute to the pathophysiology
of amygdala in SZ. Dopamine transporter and extracellular matrix changes
were not detected in BD. However, the amygdala of these subjects is mark-
edly altered, as indicated by substantial neuron number reductions in specific
amygdala nuclei in BD. These abnormalities are postulated to contribute to
the impairment of emotion processing encountered in BD. Distinct sets of
abnormalities also affect the superficial layers of the entorhinal cortex in
SZ and BD subjects. Glial and extracellular matrix abnormalities affect spe-
cifically layer II only in SZ. Decreases of neurons expressing parvalbumin in
layer II and III were found only in BD. Thus, processing and outflow of cor-
tical inputs directed to the hippocampus may be altered in both diseases, al-
though the mechanisms, and likely pathophysiological outcome, are disease-
specific. In conclusion, disease-specific patterns of anomalies in SZ and BD
suggest that distinct pathophysiological mechanisms may underlie disrup-
tion of amygdala and entorhinal cortex functions in the two disorders. Clin-
ical,geneticandpharmacological similaritiesanddifferencesbetweenSZand
BD may reflect an overlap/mismatch pattern of affected brain regions, neuro-
transmitter, cellular and molecular systems. Funded by NIH MH066280,
MH066955 and MH083222.
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EXTRACELLULAR MATRIX-GLIAL ABNORMALI-
TIES IN THE AMYGDALA AND ENTORHINAL
CORTEX OF SUBJECTS DIAGNOSED WITH
SCHIZOPHRENIA
Sabina Berretta1,2, H. Pantazopoulos1
1Department of Psychiatry, McLean Hospital, Belmont, MA, USA;
2Harvard Medical School, Boston, MA, USA
Chondroitin sulfate proteoglycans (CSPGs), a main component of the
brain extracellular matrix (ECM), regulate neuronal functions throughout
development and adulthood. CSPGs functions, such as neuronal migra-
tion, synaptic regulation and interactions with the GABAergic, glutamater-
gic and dopaminergic systems bear direct relevance to the pathophysiology
of schizophrenia. Furthermore, CSPGs are one of the main components of
perineuronal nets (PNNs), ECM aggregates enveloping neuronal soma and
dendrites and known to play a crucial role in the regulation of neuronal
functions in adults. With the present postmortem study, we tested the hy-
pothesis that SZ may be associated with CSPG abnormalities in the amyg-
dala and entorhinal cortex (ECx). We have recently shown that astrocytes
are the main cell types expressing detectable levels of CSPG in the normal
human amygdala. To assess the involvement of glial cells in CSPG abnor-
malities, we measured numerical densities of CSPG-positive glial cells. To
test whether increases of CSPG-positive glial cells are associated with
CSPG changes within the ECM, we measured numerical densities of
PNNs. Our subject cohort consisted of 15 normal controls, 11 SZ and
11 BD subjects. CSPG-positive glial cells were massively increased in the
deep nuclei of the amygdala (419–1162 %) and in ECx layer II of subjects
with SZ (567-1560 %). These changes were not accompanied by astrocyto-
sis, suggesting CSPG-specific glial abnormalities. PNNs were instead re-
duced in LN and layer II of ECx-L in absence of altered PVB-positive
neuron numbers, a finding consistent with CSPG anomalies within the
ECM, rather than loss of PNN-associated neurons. CSPG changes were
negligible in subjects with bipolar disorder. These results point to substan-
tial, specific, and thus far unsuspected anomalies affecting CSPG expres-
sion in glial cells and ECM perineuronal aggregates in SZ, but not BD. The
large effect size of changes in schizophrenia points to a pivotal role for
ECM-glial interactions in the pathogenesis of this disease. A disruption
of these interactions, unsuspected thus far, may represent a unifying factor
contributing to disturbances of neuronal migration, synaptic connectivity,
and neurotransmission in schizophrenia. Lack of CSPG abnormalities in
bipolar disorder points to a distinctive aspect of the pathophysiology of
schizophrenia in key medial temporal lobe regions. Funded by NIH
MH066280, MH066955 and MH083222.
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17. 17. Neuropathology, Biochemistry
EARLY-STAGE SCHIZOPHRENIA AND NORMAL
AGING SHARE COMMON MOLECULAR PROFILES
Elizabeth Anne Thomas1, B. Tang1, W. Chang1, C. Lanigan3,
B. Dean2, J. Sutcliffe1
1Molecular Biology, MB-10, The Scripps Research Institute, La
Jolla, CA, USA; 2Rebecca L. Cooper Research Laboratories,
Mental Health Research Institute, Melbourne, VIC, Australia;
3Molecular and Integrative Neurosciences, The Scripps Research
Institute, La Jolla, CA, USA
Kraepelin described schizophrenia as a chronic deteriorating psychiatric
disorder characterized by rapid cognitive disintegration, calling it ‘‘demen-
tia praecox’’ (premature dementia). To investigate the aging process in
schizophrenia, we examined genome-wide expression datasets from human
frontal cortex of normal and schizophrenic individuals ranging from 19 to
81 years of age. We found that changes in gene expression that are corre-
lated with aging in normal subjects differ dramatically from those observed
with aging in schizophrenic subjects. Only 2.5% of genes were correlated
with age in both cohorts. Real-time PCR analysis confirmed expression dif-
ferences for the top correlated genes in young (19–26 yrs) vs. older (42–80
yrs) age control groups, changes that were not observed in schizophrenic
subjects. Surprisingly, we also found a significant overlap (29–34%) be-
tween those genes whose expression was correlated with aging in normal
subjects and those significantly altered in subjects with early-stage schizo-
phrenia (within 5 years from initial diagnosis). Furthermore, Gene Ontol-
ogy terms associated with normal aging were similar to those related to
early-stage schizophrenia. These data demonstrate that the molecular basis
for aging differs in schizophrenic and normal subjects. In particular, normal
aging and early-stage schizophrenia share common molecular signatures,
suggesting that onset of schizophrenia anticipates the normal aging process.
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THE RELATIONSHIP BETWEEN GENE EXPRES-
SION OF NMDA RECEPTOR SUBUNITS AND
A NEUREGULIN-1 SNP IN THE CEREBELLUM OF
SCHIZOPHRENIA PATIENTS
Andrea Schmitt1,2, M. Zink2, E. Parlapani1, J. Treutlein2,
T. Schulze2, M. Rietschel2, P. Falkai1, F. A. Henn3,2
1Department of Psychiatry, University of Goettingen, Goettingen,
Germany; 2Central Institute of Mental Health, University of
Heidelberg, Mannheim, Germany; 3Life Sciences, Brookhaven
National Laboratory, New York, NY, USA
Schizophrenia patients show cognitive and subtle motor deficits which may
be related to disturbances of the prefronto-thalamo-cerebellar neuronal cir-
cuit. The volume of the cerebellar vermis has been shown to be reduced in
schizophrenia, but the underlying neurobiological processes remain to be
elusive and may involve alterations of the glutamatergic system. To deter-
mine if N-methyl-D-aspartate (NMDA) receptor alterations are present in
the cerebellum in schizophrenia, we measured NMDA receptor binding and
gene expression of the NMDA receptor subunits in a post-mortem study of
elderly patients with schizophrenia and non-affected subjects. Furthermore
we assessed influence of genetic variation in the candidate gene neuregulin1
(NRG-1) on the expression of NMDA receptor subunits in an exploratory
study. Cerebellar post-mortem samples from 10 schizophrenia patients
were compared with 9 healthy subjects. We investigated NMDA receptor
binding by receptor autoradiography and gene expression of the NMDA
receptor subunits NR1, NR2A, NR2B, NR2C and NR2D by in-situ hy-
bridization. For the genetic study, we genotyped the NRG-1 polymorphism
SNP8NRG221533. Additionally, we treated rats with the antipsychotics
haloperidol or clozapine and assessed cerebellar NMDA receptor binding
and gene expression of subunits to examine effects of antipsychotic treat-
ment. Gene expression of the NR2D subunit was increased in the right cer-
ebellum of schizophrenic patients compared to controls. Individuals
carrying at least one C allele of SNP8NRG221533 showed decreased ex-
pression of the NR2C subunit in the right cerebellum, compared to indi-
viduals homozygous for the T allele. Correlation with medication
parameters and the animal model revealed no treatment effects. Increased
NR2D expression results in an hyperexcitable NMDA receptor suggesting
an adaptive effect due to receptor hypofunction. The decreased NR2C ex-
pression in NRG-1 risk variant may cause an additional deficit in NMDA
receptor function. This supports the hypothesis of an abnormal glutama-
tergic neurotransmission in the right cerebellum in the pathophysiology of
schizophrenia. However, due to the small sample size, results should be con-
firmed in a larger study group.
ID: 550326
EPIGENETIC MECHANISMS FOR
TRANSCRIPTIONAL DYSREGULATION IN
SCHIZOPHRENIA
Bin Tang, E. Thomas
Molecular Biology, The Scripps Research Institute, La Jolla,
CA, USA
DNA modifications and chromatin remodeling represent important mech-
anisms in the regulation of gene expression. Recently, increased evidence
has indicated that epigenetic factors, specifically resulting in decreased
gene expression, could represent a pathogenic mechanism in schizophrenia.
Previously published studies have reported increased methylation of DNA
at promoter sites of certain genes as marker for epigenetic regulation of
gene expression. DNA methylation is intricately associated to patterns
of histone remodeling, such as histone methylation and histone deacetyla-
tion, however these have not been widely studied in relation to schizophre-
nia. Recent microarray analyses, including our own, have revealed many
altered gene expression patterns in postmortem brain samples from schizo-
phrenic subjects. The most dramatic expression changes were decreases in
gene expression. In addition to glutamate decarboxylase 1 (GAD1), one of
the most abnormally expressed genes in schizophrenia, the mRNAs encod-
ing myelin basic protein (MBP), UDP glycosyltransferase 8 (UGT8), and
translocase of outer mitochondrial membrane 70 homolog A (TOMM70A)
were also down-regulated. Using Chromatin Immunoprecipitation (CHIP)
assay, with antibodies directed against histone H3 and total H3, we find
that histones associated with the promoters of GAD1, MBP, UGT8 and
TUMM70A were hypoacetylated in brain of subjects with schizophrenia.
This effect coincides with the observed decreases in expression of these four
genes. These findings indicate that the acetylation status of histones repre-
sents an important epigenetic mechanism for gene expression regulation in
schizophrenia.
ID: 549932
MODULATION OF NEURONAL MARKERS OF
SYNAPTIC PLASTICITY BY THE MGLUR5 PAM,
CDPPB, IN THE HIPPOCAMPUS AND PREFRONTAL
CORTEX OF RATS
Sophie Parmentier-Batteur1, R. B. Flick1, J. S. Lam1, J. A. Clark2,
M. A. Jacobson1, P. H. Hutson1
1Schizophrenia Research, Merck Research Laboratories, West
Point, PA, USA; 2Integrative Systems Neuroscience, Merck
Research Laboratories, West Point, PA, USA
The hypoglutamatergic hypothesis of schizophrenia has led to the develop-
ment of novel therapeutic strategies modulating NMDA receptor function.
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One of these strategies targets the activation of the metabotropic glutamate
receptor 5 (mGluR5) using positive allosteric modulators (PAMs). CDPPB
was the first discovered brain penetrant selective mGluR5 PAMs (O’Brien
et al., Mol. Pharm., 2003 and JPET, 2004) and displayed antipsychotic like
activity in rats (Kinney et al., JPET, 2005). However, CDDPB has also re-
cently been shown to improve cognitive performance in Y maze, passive
avoidance, object recognition and set shifting assays (Balshun et al.
2006, Uslaner et al., 2009). Although the molecular mechanisms of how
CDPPB exerts these pro-cognitive activities still remain to be defined. In
this study, we examined the effects of CDPPB in rats at behaviorally effec-
tive doses on markers of synaptic plasticity including NMDA receptor NR1
subunit phosphorylation, ERK phopshorylation, PSD95, synaptophysin,
AMPA receptor GluR1, and Cam KII expression in hippocampus and pre-
frontal cortex (PFC) using western blot analysis. Consistent with enhance-
ment of NMDA glutamate-mediated signal transduction mechanisms by
mGluR5 activation, CDPPB increased phosphorylation of ERK to similar
levels in the PFC and hippocampus whereas phosphorylation levels of NR1
was increased earlier and reached higher levels in PFC as compared with
hippocampus. These data suggest that activation of mGluR5 receptors with
CDPPB can regulate both PFC and hippocampal NMDA receptors and
other proteins involved in neuronal plasticity.
ID: 549918
DECREASED GYRIFICATION-INDEX (GI) IN THE
CEREBELLAR VERMIS OF SCHIZOPHRENIA
PATIENTS AND AN ANIMAL MODEL OF
SCHIZOPHRENIA
Eleni Parlapani1, A. Schmitt1, W. Schulenberg1, H. G. Bernstein2,
B. Bogerts2, P. Falkai1
1Psychiatry and Psychotherapy, University of Goettingen,
Goettingen, Germany; 2Psychiatry, University of Magdeburg,
Magdeburg, Germany
An increased gyrification index (GI) has been demonstrated in the frontal
lobe of patients with schizophrenia. This hypergyria may serve as a neuro-
developmental or endophenotypic marker in this disease. Schizophrenia
patients show subtle motor symptoms and cognitive deficits possibly re-
lated to the dysfunction of a fronto-thalamo-cerebellar network including
the cerebellum. Additionally, the cerebellar vermis showed volume reduc-
tions in schizophrenia. Alterations in gyrification of the cerebellum may
indicate neurodevelopmental disturbances of migration and brain folding.
Hence, in a post-mortem study we investigated the GI in cerebellar subre-
gions of schizophrenia patients and GI in the cerebellum of a probable an-
imal model of schizophrenia, the reeler mouse. Using a stereologic
workstation, consisting of a light microscope (Olympus), motorized spec-
imen, PC and stereology software (Stereoinvestigator, MBF Bioscience) we
determined the GI (inner contour of the gyri/outer contour of the cerebel-
lum) according to the methods of Vogeley et al. (2000) and Zilles et al.
(1998). We investigated 4 coronal sections (20lm) of the medial cerebellum
in 9 schizophrenia patients and 10 healthy controls as well as 6 sagittal sec-
tions of the cerebellum of 11 homozygous, 23 heterozygous reeler mice and
17 wildtype mice. In the vermis of schizophrenia patients, the GI was re-
duced compared to controls (method of Vogeley et al.: P = .015, method of
Zilles et al.: P = .020). In contrast, in both hemispheres of the cerebellum, no
differences have been detected. In the cerebellum of homozygous reeler
mice compared to heterozygous reeler mice and wildtype mice, GI was de-
creased (P< .001). The decreased GI in the vermis of schizophrenia patients
points to neurodevelopmental disturbances since the GI is mainly deter-
mined during the perinatal period. However, the underlying neurobiolog-
ical processes remain to be determined. Reelin is a protein involved in
migration of neurons during development and the heterozygous reeler
mouse may represent an animal model of behavioral disturbances in schizo-
phrenia, while the homozygous mutation is lethal during the postnatal pe-
riod. Decreased expression of reelin may lead to gyrification disturbances,
which has been shown in our study in homozygous reeler mice. The further
role of reelin in gyrification disturbances of the vermis in schizophrenia
patients should be investigated.
ID: 549872
HISTONE MODIFICATIONS (H3K9K14AC AND
H3K9ME2) IN SCHIZOPHRENIA; EVIDENCE FOR
AN EXCESS OF RESTRICTIVE CHROMATIN
Rajiv P. Sharma, D. Gavin, C. Rosen, D. Grayson
Psychiatry, University of Illinois at Chicago, Chicago, IL, USA
Objective: To survey chromatin assemblies in a population of schizophrenia
and bipolar subjects and identify unique histone modifications that are ab-
errantly expressed. Measures of H3K9K14ac (acetylated histones), and
H3K9me2 (dimethylated histones) representing facilitative and restrictive
chromatin respectively, were measured in clinical subjects along with an
epigenetically regulated schizophrenia candidate gene GAD1. Method:
Fresh mononuclear cells were extracted from blood samples of normals
and clinical patients recruited at the UICMC. Primary cell cultures were
established using standard in-vitro procedures. Histone protein and
mRNA measurements were performed to investigate a) baseline differen-
ces; b) response of cultured cells to HDAC inhibitors; c) response to clinical
treatment across four weeks with the HDAC inhibitor valproic acid.
Histone protein modifications were measured by Western blot, and
GAD1 mRNA expression was measured using quantitative RT-PCR.
Results: a) Schizophrenia subjects have significantly lower levels of
H3K9K14ac histones compared to normals subjects as measured in fresh
mononuclear cells (schizophrenia (n = 23), normals (n = 21); P < .04). b)
Levels of H3K9me2 histones are significantly elevated in fresh mononu-
clear cells in patients with schizophrenia (P< .02). c) primary mononuclear
cultures from schizophrenia subjects manifest significantly blunted acety-
lation of histones when incubated for 24 hrs with the HDAC inhibitor Tri-
chostatin-A (P < .01). c) similarly, clinical levels of valproic acid applied
over four weeks in clinically treated subjects are far less effective in mod-
ifying histones in schizophrenia patients when compared to bipolar patients
(P < .04). Conclusions: Chromatin is the DNA-protein platform required
for the focusing and assembly of regulatory proteins especially on the pro-
moter sequence of a given gene. Our results suggest that schizophrenia is
associated with an excess of restrictive type chromatin. These results sup-
port the investigation into the relationship of chromatin modifications to
gender, metabolism, chronicity, medication use, and selective augmenta-
tion with an HDAC inhibitor.
ID: 549769
SELECTIVE REDUCTION OF OLIGODENDRO-
CYTES IN THE POSTERIOR HIPPOCAMPUS OF
SCHIZOPHRENIC PATIENTS AND A MURINE
MODEL OF SCHIZOPHRENIA WITH A SELECTIVE
PARIETAL LOBE LESION
Peter Gaston Falkai1, A. Schmitt1, C. Steyskal2, C. Schmitz3,
B. Bogerts4, H. G. Bernstein4, D. Sargin5, I. Hassouna5,
H. Ehrenreich5
1Psychiatry and Psychotherapy, University of Goettingen,
Goettingen, Germany; 2Psychiatry and Psychotherapy, University of
Saarland, Homburg/Saar, Germany; 3School for Mental Health and
Neuroscience, Maastricht University, Maastricht, Netherlands;
4Psychiatry, Psychosomatics and Psychotherapy, University of
Magdeburg, Magdeburg, Germany; 5Division of Clinical
Neuroscience, Max-Planck-Institute for Experimental Medicine,
Goettingen, Germany
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The bilateral volume reduction of the hippocampus is one of the best rep-
licated findings in schizophrenia and is correlated with disturbed verbal
memory functions being one of the best predictors for the unfavourable
outcome in schizophrenia. Nevertheless, there is very limited knowledge
concerning the underlying pathophysiological processes. In this respect
we investigated numbers and densities of neurons, oligodendrocytes and
astrocytes in the posterior hippocampal subregions in post-mortem brains
from 10 patients with schizophrenia and 10 matched controls using design-
based stereology performed on Nissl-stained sections. Compared to the
controls, the patients with schizophrenia showed a significant decrease
in the mean number of oligodendrocytes in the left and right CA4. This
is the first finding of reduced numbers of oligodendrocytes in CA4 of
the posterior part of the hippocampus in schizophrenia. Our results are
in line with earlier findings in the literature concerning decreased numbers
of oligodendrocytes in the prefrontal cortex in schizophrenia. To gain
mechanistic insight into the pathophysiological processes involved we per-
formed an experimental study aiming at modelling degenerative aspects of
schizophrenia. Applying a small cryolesion onto the right parietal cortex of
juvenile mice, we induced late-onset global brain atrophy with memory
impairments, reminiscent of cognitive decline and progressive brain matter
loss in schizophrenia. Whereas the total number of neurons and astrocytes
in cingulate cortex and hippocampus remained unaltered and pointed to
a non-gliotic neurodegeneration (as seen in schizophrenia), we found re-
duced expression of the myelin protein CNPase (cyclic nucleotide phospho-
diesterase) together with a reduction of oligodendrocytes. Remarkably,
early intervention with recombinant human erythropoietin (EPO), a hema-
topoietic growth factor with multifaceted neuroprotective properties, pre-
vented these neurodegenerative changes. In summary, the outlined human
post-mortem study reveals a selective reduction of oligodendrocytes in the
posterior hippocampus in schizophrenia. The animal study nicely demon-
strates that a small parietal cortical lesion in juvenile mice can induce a selec-
tive loss of oligodendrocytes in a non-gliotic degenerative process as it
potentially underlies the pathophysiology of schizophrenia.
This project was supported by a grant by the European commission
(BrainNet Europe II, LSHM-CT-2004-503039).
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IDENTIFICATION OF A MUSCARINIC RECEPTOR
DEFICIT SCHIZOPHRENIA
Brian Dean1,5, T. F. Cowie4, S. Kanellakis4, S. Sundram3,7,
C. Pantelis3,6, E. Scarr1,2
1Rebecca L. Cooper Research Laboratories, Mental Health
Research Institute, Parkville, VIC, Australia; 2Centre for
Neuroscience, University of Melbourne, Parkville, VIC, Australia;
3Psychiatry, The University of Melbourne, Parkville, VIC,
Australia; 4Pathology, The University of Melbourne, Parkville,
VIC, Australia; 5Psychological Medicine, Monash University,
Clayton, VIC, Australia; 6Melbourne Neuropsychiatry Centre,
University of Melbourne, Parkville, VIC, Australia; 7Northern
Psychiatry Research Centre, The Northern Hospital, Epping,
VIC, Australia
We have shown decreased cortical muscarinic M1 receptors (CHRM1) in
schizophrenia and wished to determine the extent of this deficit in subjects
with the disorder. We have now gone on to determine levels of [3H]piren-
zepine binding in Brodmann’s area 9 from controls (n = 74) and subjects
with schizophrenia (n = 80) and CHRM1 genotype in DNA from their
CNS tissue. The data from this study showed that there was no relationship
between levels of [3H]pirenzepine binding and CHRM1 genotype. How-
ever, [3H]pirenzepine binding was significantly decreased in subjects
with the schizophrenia compared to controls (Mean 6 SEM: 133.9 6
7.25 vs. 182.76 4.50 fmol/mg ETE; P< .0001). Moreover, a Kernel Density
Analyses showed that the control data was consistent with a single popu-
lation in which the data was binomially distributed. By contrast the data
from the subjects with schizophrenia was consistent with two-populations,
one (n = 22) had very low levels of pirenzepine binding (Mean 6 SEM:
44.3 6 6.88) and another (n = 58) had levels of radioligand binding
(Mean 6 SEM: 167.8 6 4.52 fmol/mg ETE) similar to that observed in con-
trols. From these data we conclude that subjects with a marked reduction in
cortical CHRM1 receptors (76%) may represent a discrete endophenotype
within the syndrome of schizophrenia
ID: 549569
PHOSPHOLIPID CONCENTRATIONS IN
DORSOLATERAL PREFRONTAL GREY AND
WHITE MATTER IN SCHIZOPHRENIA AND
BIPOLAR DISORDER
Clare Beasley1, S. M. Innis2, W. G. Honer1
1Psychiatry, University of British Columbia, Vancouver, BC,
Canada; 2Pediatrics, University of British Columbia, Vancouver,
BC, Canada
The ‘membrane hypothesis of schizophrenia’ proposes that brain phospho-
lipid metabolism is altered in this disorder. While lower levels of membrane
lipid components, including phospholipids and fatty acids, have been
reported in schizophrenia, most studies have examined peripheral markers
rather than brain tissue. However, previous post-mortem studies have iden-
tified lower phosphatidyl ethanolamine (PE) levels in the cholesterol ester
fraction of the frontal cortex and lower phosphatidyl choline (PC) levels in
the caudate and thalamus in this disorder. Although membrane alterations
have also been proposed in bipolar disorder, brain phospholipid levels have
not yet been assessed in this disorder. Lipid content is known to differ be-
tween white and grey matter, mainly due to higher levels of myelin in the
former. Considering recent reports of white matter alterations in schizo-
phrenia and bipolar disorder, our aim was to quantify phospholipid levels
in grey and white matter in these disorders in order to assess region and
disease specificity of membrane alterations. Samples of grey and underlying
white matter were obtained from the dorsolateral prefrontal region (Brod-
mann area 9), courtesy of the Stanley Medical Research Institute brain col-
lection (35 schizophrenia, 34 bipolar disorder, 35 control). Groups were
matched for age and post-mortem interval. Lipids were quantified using
high-pressure liquid chromatography. PE and PC peaks were measured
and concentrations compared between groups using repeated measures
analysis of variance. We observed a significant effect of region, with PE
and PC levels higher in white matter than in grey matter. Overall, there
was a significant effect of diagnosis (F = 3.297, P = .041), with contrasts
indicating that phospholipid levels were altered in both the schizophrenia
(P = .025) and bipolar disorder (P = .033) groups. We observed no signif-
icant region by diagnosis, or lipid by diagnosis effect. In white matter both PE
and PC levels were lower by 3% in the schizophrenia group and by 5% in the
bipolar disorder group. In grey matter both PE and PC levels were lower by
7% in the schizophrenia group and by 5% in the bipolar disorder group. The
results are consistent with a small but significant reduction in phospholipid
levels in both grey and white matter in schizophrenia and bipolar disorder,
suggestive of a global membrane abnormality.
This work was supported by SMRI, CIHR and MSFHR.
ID: 550820
CANNABIS AND PREFRONTAL CORTICAL
CIRCUITRY IN SCHIZOPHRENIA
David A. Lewis1,2, S. M. Eggan1
1Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
2Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA
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Cannabis use during adolescence is associated with an increased risk of
schizophrenia, and cannabis exposure causes impairments in a number
of cognitive processes, such as working memory, that are also exhibited
by individuals with schizophrenia. Working memory impairments in schizo-
phrenia are associated with both reduced GABA neurotransmission in the
dorsolateral prefrontal cortex (DLPFC) and altered gamma oscillations.
The effects of cannabis are mediated by the cannabinoid CB1 receptor
(CB1R), which is highly expressed in the DLPFC, is present in high density
on the axon terminals of a subset of GABA neurons, and when activated,
suppresses the release of GABA and alters gamma oscillations. Thus, un-
derstanding the normal role of the CB1R receptor in regulating GABA neu-
rotransmission in the DLPFC, and the status of this receptor in
schizophrenia, is essential. In this presentation, we will review recent and
unpublished findings demonstrating 1) the distribution and development
of the CB1R in primate DLPFC, 2) lower CB1R mRNA and protein levels
in the DLPFC of subjects with schizophrenia, 3) the replication of these
findings in another subject cohort and their presence in another prefrontal
region, 4) the absence of altered CB1R levels in major depression, and 5)
improvement in working memory and gamma oscillations in schizophrenia
with a novel compound that augments GABA neurotransmission at
GABAA receptors post-synaptic to GABA axon terminals bearing
CB1Rs. Together, these findings providea potential mechanistic basis for the
observations of cannabis exposure and adverse outcomes in schizophrenia.
ID: 551844
ANALYSIS OF POSTYSYNAPTIC DENSITY
PROTEINS AND THEIR LOCALIZATION IN
SCHIZOPHRENIA
Adam Funk1, R. E. McCullumsmith1, J. C. Hammond1,
V. Haroutunian2, J. H. Meador-Woodruff1
1University of Alabama Birmingham, Birmingham, AL, USA;
2Mt. Sinai School of Medicine, New York City, NY, USA
Converging evidence implicates NMDA receptor dysfunction in schizo-
phrenia. Chronic blockade of NMDA receptors with PCP alters the expres-
sion levels of NMDA receptors and changes the stoichiometry of NMDA
receptor subunits. Treatment with NMDA receptor modulators such as
glycine or D-serine reduced negative symptoms, and several postmortem
studies have found altered expression of NMDA receptor subunits and
binding sites in schizophrenia. Recent work found increased expression
of the alternatively spliced NR1C2’ NMDA receptor subunit, which is as-
sociated with increased transit of the NMDA receptor from ER to the post-
synaptic density. These data suggest that the deficits in schizophrenia may
not simply be a problem of increased or decreased receptor expression, but
an alteration in the intracellular localization of the NMDA receptor. Spe-
cifically, we hypothesize that there is decreased trafficking and localization
of NMDA receptors to the postsynaptic density, contributing to altered
glutamatergic transmission in schizophrenia. To identify any alterations
in the composition of the postsynaptic density (PSD), we are using an
anti-PSD95 antibody bound to agarose beads to enrich a fraction specific
for PSD from human postmortem tissue. SynGAP, a RasGTPase that di-
rectly binds to PSD95 via MUPP1 (a multi-PDZ domain containing scaf-
folding protein) and localizes to the PSD, is co-enriched in our PSD
fraction. This technique will be used to quantify the fraction of PSD com-
ponents that are trafficked to the PSD in schizophrenia. In addition to our
PSD studies, we have performed Western blot analysis on proteins that cre-
ate a complex within the postsynaptic density that is critical for scaffolding
and proper orientation of activating proteins. Scaffolding proteins PSD95
and MUPP1 form a complex with SynGAP which has functional relevance
to NMDA receptor mediated glutamatergic neurotransmission. We found
a significant reduction of PSD95 in anterior cingulate cortex (ACC), with
no changes in other areas. SynGAP showed no change in any of the areas
analyzed. Data for the expression of MUPP1 in schizophrenia will be pre-
sented. The ACC is reported to process some executive functions such as:
error and expectation awareness, conflict monitoring, reward anticipation
and reward based learning, which are abnormal in schizophrenia. This find-
ing supports the hypothesis of dysregulated NMDA receptor stabilization
at the PSD.
ID: 551713
BRAIN REGIONAL EXPRESSION PATTERN OF THE
VOLTAGE-GATED POTASSIUM CHANNEL, KV3.2
IN SCHIZOPHRENIA
Masaya Yanagi1, M. Bose2, B. W. Potts1, A. D. Stan1,
K. L. Lewis-Amezcua1, S. Ghose1, R. H. Joho2, C. A. Tamminga1
1Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA;
2Neuroscience, UT Southwestern Medical Center, Dallas, TX, USA
Accumulating evidence suggests that individuals with schizophrenia exhibit
a reduction in stimulus-mediated gamma oscillations in brain. Gamma
oscillations are fast frequency bands of electroencephalography (EEG)
rhythms at 30–100Hz. Fast-spiking GABA-containing interneurons are
presumed to participate in the generation of these gamma oscillations. Par-
valbumin-containing GABA interneurons, which comprise only a subset of
GABA interneurons, have fast-spiking properties, and are thought to have
a primary role in gamma oscillations. Altered expression of GABA related
proteins has been found in schizophrenia tissue, in particular, proteins
which are related to these parvalbumin-positive GABA-containing inter-
neurons in schizophrenia prefrontal cortex. Kv3 channels are voltage-gated
Kþ channels involved in the rapid repolarization of the action potential,
and four Kv3 genes (Kv3.1-Kv3.4) are found in both rodents and humans.
Kv3.1 and Kv3.2 channels are expressed prominently in GABA neurons in
the cortex of rodents where they facilitate fast-spiking of the neurons. Fur-
thermore, the Kv3.1 channel specifically is reported to play a role in the
generation and maintenance of gamma oscillations. These convergent lines
of evidence suggest that Kv3.1 and Kv3.2 channels could contribute to mech-
anisms involved in some of the manifestations of schizophrenia. Thus, we
determined the expression and distribution of Kv3.1 and Kv3.2 channel pro-
teins in human postmortem brain and compared the expression between
schizophrenia and control tissue. We examined the expressions of Kv3.1
and Kv3.2 proteins using Western blots in dorsolateral-prefrontal, cingulate,
orbito-frontal, parietal, and occipital cortices, and in cerebellum, caudate nu-
cleus, nucleus accumbens, thalamus, and hippocampus from normal control
tissue. Immunoreactivity of Kv3.2 was strongly seen in these regions, al-
though that of Kv3.1was not strong enough to detect reliably in any of
the regions. We quantified the immunoreactivity of Kv3.2 in 12 cases with
schizophrenia and 12 controls in these ten regions. No differences emerged
in Kv3.2 expression levels between schizophrenia and controls except a small
yet significant difference in nucleus accumbens. Our results suggest that the
expression levels of the Kv3.2 protein do not distinguish schizophrenia from
normal brain tissue, and that alterations in the concentration of these proteins
do not account for alterations in neo- or sub-cortical function.
ID: 551674
GABA-RELATED MRNA EXPRESSION IN THE
DORSOLATERAL PREFRONTAL CORTEX (DLPFC)
OF SUBJECTS WITH BIPOLAR OR MAJOR
DEPRESSIVE DISORDER
Harvey M. Morris1, D. A. Lewis1,2
1Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA;
2Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
In schizophrenia, disturbances in cognitive functions, such as working
memory, are associated with alterations in the inhibitory circuitry of
the DLPFC. These alterations seem to be specific to certain subpopulations
of GABA-containing interneurons. For example, transcripts that encode
for somatostatin (SST) and parvalbumin (PV), each expressed in separate
subpopulations of interneurons, are robustly reduced; in contrast,
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calretinin (CR) mRNA, expressed in a third subpopulation of interneurons,
is not altered in schizophrenia. In addition, the magnitude of the reductions
in SST and PV mRNAs were greater than for the mRNA encoding the
67-kilodalton isoform of glutamic acid decarboxylase (GAD67), the en-
zyme principally responsible for GABA synthesis, and little to no change
was detected for the mRNA encoding the 65-kilodalton isoform of GAD
(GAD65). Assessing the expression of these GABA-related transcripts in
other psychiatric populations is necessary to determine if this pattern of
transcript alterations is specific to schizophrenia. Bipolar (BPD), but
not major depressive (MDD), disorder appears to share some genetic risks
with schizophrenia, although many individuals with each of these disorders
have similar environmental consequences associated with a severe and per-
sistent psychiatric illness. Therefore, we utilized qPCR to examine the ex-
pression of GAD67, GAD65, PV, SST, and CR mRNAs in DLPFC area 9
from 19 matched triads of subjects with BPD, MDD and control subjects.
Each qPCR run included 3 subjects from a triad and amplified the 5 tran-
scripts of interest and 3 internal control transcripts in quadruplicate.
ANCOVA and subsequent multiple comparisons correction revealed a sig-
nificant (F2,49 = 10.73; corrected P < .0007) effect of diagnosis for PV
mRNA expression. Post-hoc analysis demonstrated that BPD subjects
had a 16% reduction in PV mRNA expression compared to control subjects
and an 18% reduction compared to MDD subjects. In contrast, expression
levels for the other four transcripts were very similar across the 3 groups of
subjects. These results suggest that altered PV expression in the DLPFC
might be common to both schizophrenia and BPD, but the profile of
GABA-related gene expression alterations is diagnosis-specific. Further-
more, the lack of alterations in MDD subjects suggests that the findings
in schizophrenia and BPD may reflect the disease process and are not a
common consequence of severe psychiatric illness.
ID: 551669
ABNORMALITIES OF EXCITATORY AMINO
ACID TRANSPORTER-1 GLYCOSYLATION IN
SCHIZOPHRENIA
Robert McCullumsmith1, D. Bauer1, V. Haroutunian2,
J. Meador-Woodruff1
1Psychiatry, UAB, Birmingham, AL, USA; 2Psychiatry,
Mount Sinai School of Medicine, New York, NY, USA
Several studies have demonstrated cortical abnormalities in glutamate neu-
rotransmission in schizophrenia. The excitatory amino acid transporters
(EAATs) facilitate the vast majority of synaptic glutamate clearance and
thus are critical to normal glutamatergic signaling. Genetic and gene ex-
pression studies have recently implicated the glial glutamate transporter
EAAT1 in schizophrenia. We have previously described increased
mRNA expression and decreased protein expression of EAAT1 in prefron-
tal cortex in schizophrenia. EAAT1 function can be modified at additional
levels beyond transcript and protein expression, including post-transla-
tional modifications such as glycosylation, which is required for EAAT1
trafficking and multimerization. We hypothesize that EAAT1 glycosyla-
tion is altered in prefrontal cortex in schizophrenia. In this study, we
digested postmortem brain homogenates from subjects with schizophrenia
and controls with the deglycosylating enzymes endoglycosidase H and
PNGase F and measured shifts in molecular weight using Western blot
analysis. We found an increase in the PNGase F induced molecular weight
shift in the anterior cingulate cortex in patients with schizophrenia versus
controls, but no changes in endoglycosidase H induced shifts. We found no
difference in shifts in controls or subjects with schizophrenia in the dorsal
lateral prefrontal cortex following treatment with either glycosidase. These
data suggest that EAAT1 N-linked glycosylation may be selectively altered
in the anterior cingulate cortex in schizophrenia. To further investigate
these differences at the level of specific glycosyl residues, we immunopre-
cipitated EAAT1 for two types of analysis: mass spectrometry and lectin-
based carbohydrate detection. We have successfully detected mannose and
glucosamine residues in our EAAT1 immunoprecipitates using biotinylated
lectins, including concanavalin A, wheat germ agglutinin, and lens culinaris
agglutinin. Data from these lectin studies probing for alterations in specific
glycosyl residues in subjects with schizophrenia and controls will be pre-
sented. Our results suggest an increase in EAAT1 glycosylation in schizophre-
nia which may impact EAAT1 trafficking and multimerization, leading to
alterations in EAAT1 surface expression and activity. These data represent
an important new lead for understanding abnormalities of the glutamate
cycle in schizophrenia.
ID: 551624
CHARACTERIZATION OF A UNIQUE, DEVELOP-
MENTALLY REGULATED SPLICE VARIANT OF
HUMAN NRG1 TYPE IV. IMPLICATIONS FOR
SCHIZOPHRENIA
Amanda Jayne Law
1Department Psychiatry, University of Oxford, Oxford, United
Kingdom; 2CBDB, NIMH, Bethesda, MD, USA
Genetic studies implicate NRG1 in risk for schizophrenia and a clinically-
associated polymorphism (rs6994992) represents a cis regulatory element
associated with transcription of NRG1, type IV in the adult human brain
(Law et al. 2006; Tan et al. 2007). Type IV is 3.5 fold higher in the human
fetal brain compared to the adult however its role in neurodevelopment and
its relationship to schizophrenia risk are unknown. We have cloned and
characterized NRG1, type IV transcripts in the human fetal brain and re-
veal a complex pattern of alternative splicing. Of particular interest is the
identification of a novel splice isoform (termed NFIV1) whose expression is
restricted to a critical period of human neurodevelopment and regulated by
rs6994992. The NRG1, type IV family was cloned from cDNA libraries of
fetal human brain. Utilizing real time QRT-PCR we then measured quan-
titative expression traits of NFIV1 in a cohort of human fetal brains (N = 45;
14–20 weeks gestation) and individuals across the lifespan (n = 195 Age range
0–80 years). All individuals were genotyped for rs6994992. To assess the bi-
ological function of NFIV1 we developed Myc-tagged constructs for trans-
fection of rat primary hippocampal neurons. Translation characteristics,
subcellular localization and dendritic spine development were examined.
NFIV1 is a unique NRG1 transcript characterized by the absence of exon
E24 which codes for the a-secretase cleavage domain and a premature
stop codon in the cytoplasmic domain. Expression of NFIV1 in the human
brain emerges in the second trimester were it was highly expressed and
remains so until approximately 12 months postnatal. NFIV1 was not iden-
tified in adult brain. Risk genotypes at rs6994992 predict lower expression of
NFIV1 during development. Fusion protein studies reveal that the NFIV1
transcript is translated into a truncated protein which is resistant to biochem-
ical processing mediated via a-secretase and shows a diffuse cytoplasmic and
dendritic localization with intense nuclear expression. NFIV1 expression af-
fected the maturation and growth of dendritic spines in rat primary hippo-
campal neurons. Our results demonstrate a role for NRG1, type IV in human
brain development and demonstrate a complex pattern of splicing during crit-
ical developmental periods which has implications for type IV’s involvement
in genetic risk for schizophrenia.
References
1. Law, et al. Proc Natl Acad Sci USA. 2006;103(17):6747–52.
2. Tan, et al. J Biol Chem. 2007;282(33):24343–51.
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The glial enzyme D-amino acid oxidase (DAO) metabolizes D-serine, a
co-agonist of the NMDA receptor. We and others have demonstrated
an increase in the expression and activity of DAO in schizophrenia, which
may reduce brain D-serine concentrations, and thence contribute towards
NMDAR hypofunction in the disorder. This hypothesis, however, requires
that DAO has access to D-serine from the synapse (via the D-serine trans-
porter), and that the increased DAO is not counter-balanced by an eleva-
tion in serine racemase (SRR), the D-serine synthesizing enzyme. We have
been using rat C6 glioma cells as a model system to investigate the effect of
increased DAO expression on SRR and D-serine uptake. We have estab-
lished that C6 cells normally express SRR, DAO, and the D-serine trans-
porter ASCT2, and have over-expressed DAO protein in the cells using
recombinant DAO transfections; this was confirmed using western blotting
normalized to beta-actin (control cells: 1.22 þ 0.1 vs over-expressing cells :
2.1 þ 0.1, P< .01, n = 6, paired t-test). The over-expression of DAO did not
alter levels of SRR (control cells: 0.97 þ 0.2 vs over-expressing cells:
1.01 þ 0.16, n = 6, P = .184). The kinetics of extra-cellular D-serine uptake
into C6 cells were examined by measuring the incorporation of radioactivity
one hour after the addition of [3H]-D-serine to the culture medium. DAO
over-expression did not alter the uptake of [3H]-D-serine (control cells:
30 þ 1 vs over-expressing cells: 32 þ 2 pmol/min/mg protein, n = 6, P =
.241). We quantified ASCT2 mRNA using RT-PCR and its expression,
normalized to GAPDH mRNA, was also unaffected (control cells:
0.56 þ 0.04; over-expressing = 0.53 þ 0.04, n = 6, P = .311). These data
show that a two-fold elevation of DAO expression in C6 cells does not af-
fect the levels of the D-serine synthetic enzyme SRR, nor D-serine uptake
nor ASCT2 expression. If a similar absence of compensatory changes per-
tains in the brain in vivo, it supports the possibility that the increased DAO
expression and activity seen in schizophrenia may indeed impact upon
D-serine availability. In ongoing work in this cell model, we are measuring
intracellular D-serine concentrations, and studying the consequences of
lowering DAO by RNAi and of manipulating SRR expression. Integrative
studies of this kind will clarify the likely functional implications of increased
DAO in schizophrenia, and help to evaluate DAO and other D-serine
related molecules as therapeutic candidates.
ID: 551449
GROUP I AND II METABOTROPIC GLUTAMATE
RECEPTORS IN THE HUMAN PREFRONTAL
AND TEMPORAL CORTEX: DIFFERENCES IN
SCHIZOPHRENIA
Subroto Ghose, K. Gleason, B. Potts, K. Amezcua, C. Tamminga
UTSW, Dallas, TX, USA
Schizophrenia is a chronic brain disease of unknown etiology. There have
been several hypotheses proposed for explaining schizophrenia pathophys-
iology, the most recent of which proposes a disruption of glutamatergic
neurotransmission. It is based on the ability of N-methyl-D-aspartate
(NMDA) receptor antagonists, such as phencyclidine (PCP) and ketamine,
to produce a syndrome that is clinically indistinguishable from schizophre-
nia. The group I (mGluR 1 and 5) and group II (mGluR 2 and 3) have been
implicated in this illness. The group II mGluR agonists attenuate neuro-
chemical and behavioral effects of PCP, similar to actions of atypical an-
tipsychotic medications. A recent Phase 2 clinical trial with an mGluR2/3
agonist, LY 2140023, demonstrates antipsychotic activity in patients with
schizophrenia. Animal and human post mortem studies suggest that
mGluR 1 and 5 may also be important in the pathophysiology of schizo-
phrenia. This study was designed to distinguish the expression of mGluR1,
2, 3 and 5 receptor proteins in schizophrenia using human post mortem
brain tissue. Receptor-specific antibodies were used in immunoblotting
experiments to determine differences in expression levels of each mGluR
in the prefrontal (PFC) and temporal (TC) in 15 matched cases of schizo-
phrenia and normal controls. Six month chronic antipsychotic treatment in
rodents was conducted to examine the potential effect of antipsychotic
drugs on protein expression. We find a significant reduction of mGluR3,
but not mGluR1, 2 or 5, in the PFC in schizophrenia. Chronic antipsychotic
treatment in rodents did not influence mGluR3 levels. There were no sig-
nificant differences in any of the mGluRs in the TC. These data suggest that
reduced signaling at the mGluR3 receptor in the PFC may be important in
the pathophysiology of schizophrenia. Further, these data implicate the
mGluR3 receptor in the antipsychotic action of mGluR2/3 agonists.
ID: 551420
ISOLATION AND ANALYSIS OF ENDOSOMES IN
SCHIZOPHRENIA
John Hammond1, R. E. McCullumsmith1, A. J. Funk1,
V. Haroutunian2, J. H. Meador-Woodruff1
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Accumulating evidence suggests that glutamate receptor dysfunction in
schizophrenia is not a problem of too much or too little receptor expression,
but instead a problem of receptor trafficking. Trafficking of receptors is con-
trolled, in part, by phosphorylation of specific residues on the AMPA re-
ceptor subunits. Phosphorylation may lead to stabilization of a receptor
at the synapse or internalization of the receptor in endosomes. Turnover
of receptors via endosomes is a critical event for regulation of neuronal
transmission at the synapse. We postulate that alterations in endosome con-
tent may underlie neuropathological alterations in schizophrenia. We hy-
pothesize that there is an increase in AMPA receptor containing early
endosomes in schizophrenia, suggesting increased turnover of AMPA recep-
tors in this illness. The aim of this study is to isolate the early endosomes
from postmortem human brain tissue and to use a modified subcellular frac-
tionation technique to probe for alterations in endosome content and
AMPA receptor subunit expression. Tissue homogenates were pre-cleared
of non-specific binding via incubation with magnetic beads. Using this pre-
cleared tissue homogenate, we targeted endosomes for immunoisolation us-
ing a magnetic bead-antibody complex (specific binding) or using magnetic
beads only (negative control). Captured material was removed from the
beads and analyzed by Western blot analysis. The early endosome marker,
Early Endosome Antigen 1 (EEA1) was detected in the pre-clear pellet (non-
specific binding) and in the immunoisolation (specific binding) lanes, but not
in the negative control lane. As confirmation of endosomal isolation, elec-
tron microscopy (EM) imaging was used. By double-blind evaluation, we
observed a 6.15 fold enrichment of endosomes in the immunoisolation (spe-
cific binding) sample compared to the pre-clear (non-specific) pellet sample.
Data on expression of EEA1 and AMPA receptor subunits in endosome
fraction for subjects with schizophrenia and a comparison group will be pre-
sented. Overall protein expression of EEA1, Rab4, and Rab7 in anterior
cingulate cortex and dorsolateral prefrontal cortex will be presented. In sum-
mary, we have developed a modified immunoisolation protocol to isolate
early endosomes from postmortem tissue. This technique will permit us
to test the hypothesis that there is an alteration in trafficking of AMPA glu-
tamate receptor subunits in the endosomal compartment in schizophrenia.
ID: 551407
ROLE OF c-Cbl (AN E3 UBIQUITIN LIGASE) IN BDNF/
TRKB SIGNALING IN SCHIZOPHRENIA AND
BIPOLAR DISORDER
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Brain derived neurotrophic factor (BDNF) through its receptor, TrkB
plays a crucial role in neuroplasticity (ie, growth and branching of den-
drites, remodeling of synaptic contacts and neurogenesis). TrkB dysregu-
lation has been associated with several pathophysiological conditions
including neurodegenerative diseases and psychiatric disorders such as
schizophrenia and depression. Understanding the mechanisms regulating
TrkB may provide new strategies for the prevention and treatment of
the pathologies associated with TrkB dysregulation. The present study
has explored the role of ubiquitination in the regulation of TrkB signaling
in schizophrenia. We have identified an E3 ubiquitin ligase, c-Cbl that asso-
ciates with TrkB in the postmortem brain samples from schizophrenia and
bipolar disorder subjects. c-Cbl gene expression was analyzed in dorsolat-
eral prefrontal cortex samples from the Stanley Array Collection. Quanti-
tative real-time PCR analysis of RNA in 100 individuals (35 with
schizophrenia, 31 with bipolar disorder, and 34 psychiatrically normal con-
trols) showed significantly increased expression of c-Cbl in both schizo-
phrenia and bipolar disorder. Our study also showed that the binding of
c-Cbl to TrkB leads to the ubiquitination and downregulation of TrkB
in mouse cortical neurons. Our results suggest that ubiquitination of
TrkB may be involved in the downregulation of BDNF signaling in schizo-
phrenia and bipolar disorder. The identification of a specific E3 ubiquitin
ligase molecule represents a potential mechanism to control the levels of
TrkB function in psychiatric disorders.
ID: 551321
DECREASED PROTEIN EXPRESSION AND
ALTERATION OF N-GLYCOSYLATION OF THE
GLUR2 AMPA RECEPTOR SUBUNIT IN
SCHIZOPHRENIA
Janusz Tucholski1, S. Patel1, D. Bauer1, V. Haroutunian2,
J. H. Meador-Woodruff1
1Psychiatry and Beh Neurobiology, University of Alabama at
Birmingham, Birmingham, AL, USA; 2Psychiatry, Mount Sinai
School of Medicine, New York, NY, USA
Abnormalities in glutamate neurotransmission have been proposed to un-
derlie some aspects of schizophrenia. We and others have demonstrated sig-
nificant abnormalities in schizophrenia of ionotropic glutamate receptor
transcripts that are region- and receptor subunit-specific. For example,
we have demonstrated that transcript levels for some AMPA receptor sub-
units (GluR2, GluR3 and GluR4) are decreased in dorsolateral prefrontal
cortex (DLPFC) in schizophrenia. Further, we have reported alterations in
expression of AMPA receptor-associated proteins that regulate AMPA re-
ceptor trafficking and expression at the plasma membrane. We have found
decreased PICK2 mRNA and elevated stargazin mRNA in DLPFC in
schizophrenia. Interestingly, both of these proteins play a critical role in
AMPA receptor trafficking: PICK1 regulates GluR2 recycling at the post-
synaptic cell membrane by favoring retention of internalized GluR2 in recy-
cling pools, while stargazin promotes AMPA receptor trafficking through
an early biosynthetic pathway. Abnormalities of PICK1 and stargazin ex-
pression may thus result in abnormal AMPA receptors trafficking and/or
postranslational modification (N-glycosylation) in schizophrenia. N-glyco-
sylation takes place early in AMPA receptor biosynthesis, and is postulated
to regulate trafficking, proteolysis and to modulate AMPA receptor func-
tion at the synapse. In this study, we investigated total protein expression, as
well as N-glycosylation state of the GluR2 AMPA receptor subunit. Total
protein levels and N-glycosylation of GluR2 were determined in DFPLC
and anterior cingulate cortex (ACC) in schizophrenia and a comparison
group by western blotting analysis. N-glycosylation was assessed in brain
samples following digestion with endoglycosidase H (Endo H), which
removes immature high mannose sugars, and with peptide-N-glycosidase
F (PNGase F), which removes all N-linked sugars. We discovered that
GluR2 protein levels were decreased in schizophrenia and that a GluR2 pro-
tein pool was significantly less sensitive to Endo H-driven deglycosylation in
schizophrenia. These data suggest that GluR2 may be differentially glyco-
sylated in schizophrenia and controls. In the future, we plan to expand the
current study and determine protein levels for all four of the AMPA receptor
subunits and their N-glycosylation status in DLPFC and ACC in this illness.
ID: 551313
PHARMACOLOGICAL MODULATION OF
CANNABINOID SYSTEM DIFFERENTLY
AFFECTS SCHIZOPHRENIA-LIKE SYMPTOMS IN
ANIMAL MODELS
Daniela Vigano’, C. Guidali, T. Rubino, D. Parolaro
DBSF and Neuroscience Center, University of Insubria, Busto
Arsizio, Italy
Evidences suggest an involvement of the endogenous cannabinoid system in
the pathophysiology of schizophrenia. We demonstrated that chronic phen-
cyclidine (PCP) treatment, a model of cognitive symptoms of schizophrenia,
altered the cannabinoid system in the rat prefrontal cortex. Moreover, we
demonstrated that prolonged delta-9-tetraydrocannabinol exposure wors-
ened behavioural and biochemical effects induced by PCP (Vigano` et al.,
2008). This study put forward the hypothesis of potential antipsychotic
properties of cannabinoid receptor antagonists. On this basis, we evaluated
behavioural and biochemical responses induced by chronic administration
of low dose of AM251 (0.5mg/kg), a CB1 receptor antagonist, in rats co-ex-
posed to chronic PCP (2.5mg/kg). Chronic AM251 co-treatment improved
the PCP-altered recognition memory in a novel object recognition task and
reduced the immobility induced by PCP in the forced swim test. Addition-
ally, the behavioural improvement induced by the CB1 receptor antagonist
was accompanied by the counteraction of the reduction in CB1 receptor
functionality produced by PCP. These results suggest a potential beneficial
role of AM251 for cognitive and negative schizophrenia-like symptoms in-
duced by PCP. Moreover, to better understand the role of endocannabinoid
ligands in all the behavioural aspects induce by PCP, we studied the effects of
direct and indirect cannabinoid agonists in positive schizophrenia-like
symptoms. To this aim, rats received an acute administration of the CB1
receptor agonist delta9-THC (0.5mg/kg) and the anandamide uptake inhib-
itor AM404 (3mg/kg) before acute PCP (3.5mg/kg). Both these compounds
counteracted PCP-induced psychotic-like symptoms, inhibiting the increase
of the locomotor activity and ataxia, and reducing stereotypies. The relative
involvement of cannabinoid or vanilloid receptors in the protective effects of
AM404 was assessed through the pre-treatment with the cannabinoid an-
tagonist AM251 (0.5mg/kg) or vanilloid antagonist capsazepine (10mg/
kg). AM251 reversed the protective effect of AM404 on locomotion whereas
capsazepine better reversed AM404 protective effects on stereotypies and
ataxia suggesting a dual role of CB1 and TRPV1 receptors in modulating
beneficial effect of cannabinoids. In conclusion, CB1 receptor agonists and
antagonists seem to be promising candidates for novel approaches in the
treatment of different symptoms of schizophrenic disorders depending on
the frequency use.
ID: 551254
ALTERED EXPRESSION OF DENDRITIC
SPINE-RELATED GENE PRODUCTS IN THE
DORSOLATERAL PREFRONTAL CORTEX OF
SUBJECTS WITH SCHIZOPHRENIA
Masayuki Ide, D. A. Lewis
Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
International Congress on Schizophrenia Research
234 17. 17. Neuropathology, Biochemistry
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
Spine density on the basilar dendrites of deep layer 3 pyramidal neurons is
decreased in the dorsolateral prefrontal cortex (DLPFC) of subjects with
schizophrenia. The mRNA expression of CDC42, which promotes spine
formation, is decreased in the DLPFC in schizophrenia, and CDC42
mRNA levels correlated with spine density. However, CDC42 mRNA
was decreased in deep layer 3, as well as in layer 6 where spine density
was not altered. To determine the molecular mechanisms contributing to
laminar-specific spine deficits in schizophrenia, we used real-time qPCR
to measure mRNA levels of two downstream targets of CDC42,
CDC42EP3 and CDC42EP4, which are preferentially expressed in layers
2 and 3, in the DLPFC from two cohorts of matched pairs of schizophrenia
and control subjects (cohort 1 = 12 pairs; cohort 2 = 19 pairs). We also mea-
sured the mRNA levels for interacting gene products [septins (SEPT2, 3, 5,
6, 7, 8 and 11), PUM2, ANLN] and other spine-specific gene products (spi-
nophilin, PSD95, synaptopodin). ANCOVA analyses (including age, sex,
PMI, RNA integrity number, pH, storage time and cohort as covariates)
showed significant increases in CDC42EP3 (26.6%, 15.3%, P = .002),
PUM2 (16.5%, 8.7%, P = .005) and SEPT11 (20.6%, 19.8%, P = .02),
and a significant decrease in SEPT7 (8.6%, -6.0%, P = .02) mRNA expres-
sion in schizophrenia. Although SEPT7 is a spine neck component and its
mRNA levels significantly correlate with CDC42 mRNA, and in situ hy-
bridization confirmed decreased SEPT7 mRNA in schizophrenia (8%,
P = .03), the decrease was found in both layer 3 (9%, P = .046) and layer
6 (13%, P = .005). However, PUM2 could control spine formation
through regulating dendritic translation of spine related genes possibly in-
cluding CDC42EP3 or septins. Thus, the altered expression of PUM2,
SEPT11 and/or CDC42EP3 might contribute to the reductions in spine
density predominantly in layer 3. In situ hybridization studies are in process
to determine the laminar-specificity of these findings. Molecules regulating
the downstream signaling of CDC42 could be novel molecular targets for
therapeutic interventions in the illness.
ID: 551150
SIMILAR INFLAMMATORY PROFILE IN BIPOLAR
DISORDER AND SCHIZOPHRENIA: SELECTIVE
INCREASE IN SOLUBLE TUMOR NECROSIS
FACTOR RECEPTOR I AND VON WILLEBRAND
FACTOR
Sigrun Hope1,2, I. Melle1,3, P. Aukrust4, N. E. Steen1,5,
A. B. Birkenaes1, S. Lorentzen5,1, I. Agartz1,6, T. Ueland4,
O. A. Andreassen1,3
1University of Oslo, TOP Study Group,Institute of Psychiatry, Oslo,
Norway; 2Department of Psychiatry, Østfold Hospital, Eidsberg,
Norway; 3Department of Psychiatry, Ulleval University Hospital,
Oslo, Norway; 4Research Institute of Internal Medicine,
Rikshospitalet University Hospital, Oslo, Norway; 5Department of
Psychiatry, Aker University Hospital, Oslo, Norway; 6Department
of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
Alterations in the inflammatory system have been associated with schizo-
phrenia and mood disorders. Bipolar disorder has been less studied, and the
literature is inconsistent with regard to the specific underlying mechanisms.
This study aim was to investigate inflammatory parameters in a represen-
tative sample of bipolar disorder and schizophrenia compared to healthy
controls. Plasma levels of soluble tumor necrosis factor receptor 1
(sTNFR1), Interleukin 1 receptor type 1 (ILR1), Interleukin 6 (IL6),
high-sensitivity CRP (hs-CRP) and von Willebrand factor (vWf) was mea-
sured with ELISA techniques in a catchment area based sample of consec-
utively referred patients with severe mental disorders (n = 443; comprising
bipolar spectrum disorder (n = 169) and schizophrenia spectrum (n = 274),
and healthy volunteers (n = 261)). Plasma levels of sTNFR1 and vWf were
highly statistically significantly increased in both bipolar disorder and
schizophrenia compared to controls, but with no major differences between
the two diagnostic groups. Controlling for age, gender and ethnical differ-
ences did not affect the results. There was a trend towards statistically sig-
nificant elevation of hs-CRP between the two diagnostic groups and the
controls. There were no differences in other inflammation factors between
the groups. This study indicate specific alterations of endothel related
inflammation processes in severe mental disorders.
ID: 551024
THE OLFACTORY EPITHELIAL BIOPSY APPROACH
FOR THE STUDY OF NEURODEVELOPMENTAL
DYSREGULATION IN SCHIZOPHRENIA
Chang-Gyu Hahn1,2, K. E. Borgmann-Winter1
1Psychiatry, University of Pennsylvania, Philadelphia, PA, USA;
2Monell Chemical Senses Center, Philadelphia, PA, USA
The olfactory neuroepithelium (OE) is the only neural tissue that is readily
obtainable from living human subjects and thus can provide a unique op-
portunity to examine neurons of patients with neuropsychiatric illnesses.
The OE biopsy tissues can be examined under in vivo, ex vivo and in vitro
conditions for biochemical, molecular and electrophysiological character-
istics in the subjects’ neural tissues. Particularly relevant to the pathophys-
iologic study of schizophrenia is a neurodevelopmental characteristic of the
OE; neuronal regeneration continues throughout life. Human OE may dif-
fer from the rodent counterpart in molecular processes underlying neuro-
genesis. In the rodent OE, two distinct cell types in the basal cell layer,
horizontal basal cells (HBC) and globose basal cells (GBC) play critical
roles in neurogenesis. Subsequent maturation of rodent olfactory neurons
(ORNs) occurs in layers of immature and mature ORNs in laminar orga-
nization. The basal cell layer of human OE does not contain HBCs, plu-
ripotent cells and laminar organization of ORNs does not exist in the
human OE. In vitro organotypic cultures of the OE can be a powerful
tool to study neurodevelopmental dysregualtion in schizophrenia. We
and others have shown that organotypic cultures of human OE can produce
BrdU labeled cells expressing neuronal markers and that neuronal differ-
entiation can partly occur in vitro. In addition, OE cells propagated in dis-
sociated cultures express functionally active D2, 5HT1A, 5HT2A and
NMDA receptors, which permit an opportunity to examine dysregulations
in neurotransmitter receptor functions in patients’ neuronal cells. Cellular
heterogeneity and individual variability in the cellular composition of OE
tissues pose a special challenge in relating the data from OE cells to the
person’s characteristics. The OE consists of neuroepithelium as well as
respiratory epithelium and each biopsy tissue varies in proportions of
neuronal and non-neuronal cell types. Similarly, in vitro OE cultures con-
tain neuronal, non-neuronal cells and some in transition and their compo-
sitions appear to vary between individuals and even different passages of
the same cell line. As powerful as the OE biopsy approach may be concep-
tually, it will be important to develop research paradigms to capture stable
measures despite the issues of cellular heterogeneity and individual variability.
ID: 550916
THE TOPICAL NIACIN SKIN TEST IN EARLY
PSYCHOSIS AND HEALTHY CONTROLS:
IDENTIFYING MEANINGFUL SUBTYPES.
Melissa Jenni Kerr1, S. M. Cotton1, T. M. Proffitt1,
M. A. McConchie1, C. Markulev1, H. P. Yuen1, S. J. Wood2,3,
S. Smesny4, P. D. McGorry1, G. Berger1
1ORYGEN Research Centre, Department of Psychiatry,
Melbourne, VIC, Australia; 2Melbourne Neuropsychiatry Centre,
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Niacin sensitivity is strongly related to prostaglandin D2, a derivate of
arachidonic acid, a bioactive lipid. These lipids have been implicated in
the etiology and pathophysiology of psychosis. Studies have demonstrated
that a subgroup of psychotic patients show an attenuated response to top-
ical niacin application when compared with controls (CTL). The aim of this
study was to compare a group of first episode psychosis (FEP) patients with
CTLs on the niacin skin test (NST). A unique two-step cluster analysis of
the NST scores was also conducted to identify subgroups. The topical NST
was administered to 92 FEP patients and 42 CTLs. The test was scored
using a semi-quantitative descriptive scale incorporating oedema and ery-
thema at four different concentrations across four time points. Repeated
measures ANOVA across the FEP and CTL cohorts revealed significant
main effects for group, F1,132 = 36.40, P < .001, time, F1.88, 247.48 =
403.15, P < .001, and the group x time interaction, F1.88,247.48 = 9.08, P
< .001. Three clusters were derived from the analysis of the NST matrix:
The first two clusters appear to comprise patients who were more similar to
controls (Cluster 1 equal distribution FEP and CTL, Cluster 2 predomi-
nantly CTLs) and Cluster 3 was primarily FEP patients. There was a sig-
nificant difference between the three clusters with respect to total niacin
sensitivity score, F2,89 = 165.53, P < .001. Post hoc analyses indicated
that FEP patients in Cluster 2 exhibited the highest mean niacin sensitivity
score. When examining psychopathology across the three clusters (patients
only), there were significant differences on Affective Flattening/Blunting,
F2,89 = 5.0, P = .009, and Anhedonia/Asociality, F2, 89 = 3.9, P = .022,
with Cluster 2 having lower mean scores. A novel cluster analysis of the
NST data matrix revealed very interesting findings. First, there is a sub-
group of FEP patients who, like CTLs, are niacin sensitive and thus do
not appear to have disturbed lipid biology during their first illness presen-
tation. Second, there is a subgroup of niacin insensitive FEP patients who
also exhibit significantly greater levels of negative symptoms. This may in-
dicate that the niacin sensitive FEP patients have a less schizophrenia-like
illness presentation and better outcomes—a hypothesis worthy of further
exploration. Our data supports the use of the NST to subtype FEP.
ID: 550879
NEUREGULIN 1 IN SYNAPTIC PLASTICITY AND
SCHIZOPHRENIA
Lin Mei
Neurology, Medical College of Georgia, Augusta, GA, USA
Schizophrenia is a mental disorder that affects 1% of population. It is char-
acterized by abnormal neuronal activity in the brain including hypogluta-
matergic function. Molecular pathogenic mechanisms of schizophrenia,
however, remain unclear. Recent genetic studies have identified several sus-
ceptibility genes including neuregulin 1 (NRG1) and its receptor ErbB4.
NRG1 is a family of polypeptides important role in neural development.
NRG1 and ErbB4 are expressed in adult brain in addition to the developing
nervous system. We showed that ErbB4 is concentrated at the postsynaptic
density of excitatory synapses in adult brains and NRG1 suppresses long-
term potentiation (LTP) in the hippocampal CA1 region, a cellular model of
learning and memory (Neuron 26:443, 2000). Recently, we found that
NRG1 stimulates activity-dependent release of GABA, a major inhibitory
neurotransmitter, in the prefrontal cortex (PFC) (Neuron 54:599, 2007).
This effect requires ErbB4, but not pathways of dopamine, glutamate, ace-
tylcholine, norepinephrine and serotonin. These results indicate that NRG1
plays a role in synaptic plasticity in developed brain in addition to neural
development. More recently, we found that PI3 kinase is required for
NRG1 regulation of GABA release. This is intriguing because PI3 kinase
activation is mediated by CYT-1 ErbB4, an isoform whose expression is
higher in schizophrenic PFC. In light of earlier observations that mRNAs
of type I and IV NRG1 and NRG1 signaling are increased in schizophrenic
PFC, we propose that the gain-of-function of NRG1 signaling contributes
to hypoglutamatergic function in the schizophrenic brain. In support of this
hypothesis were recent results that NRG1 reduces whereas a neutralizing
peptide increases firing frequencies of pyramidal neurons in the PFC. We
have also investigate which interneurons are target of NRG1 by analyzing
conditional mutant mice. Ablation of ErbB4 in parvalbumin-positive neu-
rons in the brain blocks the NRG1 regulation on GABA release and pyra-
midal neuron firing in the PFC. The mutant mice appeared to be hyperactive
in open field exploration with impaired prepulse inhibition. Together, these
observations demonstrate an important role of NRG1 and ErbB4 in synap-
tic plasticity, and provide intriguing leads to pathogenic mechanisms of
schizophrenia. Supported by grants from NIMH, NINDS, and NARSAD.
ID: 553068
BRAIN-DERIVED NEUROTROPHIC FACTOR
(BDNF) SPLICE VARIANT AND ENDOGENOUS
ANTISENSE TRANSCRIPT EXPRESSION IN
PREFRONTAL CORTEX IN SCHIZOPHRENIA
Kayvon Salimi1, R. M. Hamer2, L. A. Glantz1, S. Vadlamudi1,
G. Rajkowska5, C. A. Stockmeier5, L. F. Jarskog3,4
1Psychiatry, University of North Carolina at Chapel Hill, Chapel
Hill, NC, USA; 2Biostatistics, University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA; 3Psychiatry, Columbia
University College of Physicians and Surgeons, New York, NY,
USA; 4Lieber Center for Schizophrenia Research and Treatment,
New York State Psychiatric Institute, New York, NY, USA;
5Psychiatry and Human Behavior, Univeristy of Mississippi Medical
Center, Jackson, MS, USA
Altered brain-derived neurotrophic factor (BDNF) signaling has been im-
plicated in the pathophysiology of schizophrenia. Several prior studies have
reported reduced expression of BDNF mRNA and protein in prefrontal
cortex (PFC) in schizophrenia. We aimed to characterize the expression
of BDNF splice variant and endogenous BDNF antisense (opposite strand)
transcripts in schizophrenia PFC to provide insights into the mechanisms of
altered BDNF expression. Relative quantities (RQ) of total BDNF mRNA
(BDNFT), BDNF1 and BDNF4 splice variant mRNAs, and BDNF oppo-
site strand (BDNFOS) mRNA were measured by qPCR and BDNF protein
was measured by Western blot in postmortem PFC from individuals with
schizophrenia and matched controls. Samples with RNA integrity number
(RIN) less than 7.0 were excluded prior to conducting qPCR. Groups did
not differ on mean postmortem interval (PMI), pH, RIN, or age. qPCR
revealed no difference in BDNF1, BDNF4 or BDNFT RQ between schizo-
phrenia and control groups (BDNF1 RQ: þ14%, P = .5; BDNF4 RQ:
15%, P = .2; BDNFT RQ: 14%, P = .3). The schizophrenia group
had higher mean BDNFOS RQ compared to the control group (þ15%,
P = .02). In secondary analyses, BDNF1 RQ, BDNF4 RQ, and BDNFT
RQ each correlated modestly with PMI (Pearson r -0.28 to 0.32, P < .05)
and more strongly with age (Pearson r = 0.35 to 0.6, P < .01) and RIN
(Pearson r 0.6 to 0.7, P< .0001). BDNFOS RQ did not correlate with PMI,
age, or RIN and remained higher in the schizophrenia group after covary-
ing for PMI, pH, RIN, and age. Data on BDNF protein will also be pre-
sented. In summary, BDNF mRNA expression and BDNF splice variant 1
and 4 mRNA expression were not altered in PFC in schizophrenia. How-
ever, BDNF antisense mRNA was increased in PFC in schizophrenia. This
could represent a post-transcriptional mechanism by which BDNF signal-
ing is altered in the setting of normal total BDNF mRNA levels. Further
pathophysiological implications of these data and factors that may have
contributed to not replicating lower total BDNF mRNA in schizophrenia
will be discussed. This study is supported by Center Grant NCRR,
RR17701 (GR and CAS), and NIH RO1 grant R24-MH068855 (the Har-
vard Brain Tissue Resource Center), and the Foundation of Hope, NC
(LFJ and KS).
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18. 18. Cognitive Neuroscience
AVOIDANT PERSONALITY DISORDER SYMPTOMS
IN FIRST-DEGREE RELATIVES OF
SCHIZOPHRENICS PREDICT PERFORMANCE ON
NEUROCOGNITIVE MEASURES: THE UCLA
FAMILY STUDY
David Leslie Fogelson1, K. H. Nuechterlein1, R. A. Asarnow1,
K. L. Subotnik1, K. S. Kendler2, M. Neale2, K. C. Jacobson3,
C. A. Sugar4
1Department of Psychiatry and Biobehavioral Sciences, University
of California Los Angeles, Los Angeles, CA, USA; 2Virginia
Institute of Psychiatric and Behavior Genetics and Department of
Psychiatry, Virginia Commonwealth University, Richmond, VA,
USA; 3Department of Psychiatry, University of Chicago, Chicago,
IL, USA; 4Department of Biostatistics, School of Public Health,
University of California Los Angeles, Los Angeles, CA, USA
Whether avoidant personality disorder (APD) symptoms (Sxs) are related to
putative neurocognitive (neurocog) endophenotypes of schizophrenia (Sz) is
unknown. We report the relationship between APD Sxs and performance on
neurocog measures in the first-degree relatives (1st Rels) of probands with Sz.
367 1st Rels of probands with Sz and 245 Rels of community controls (CC)
were interviewed for the presence of APD Sxs as well as Sxs of paranoid
(PD)and schizotypal (SPD) personality disorders. All Rels were also admin-
istered neurocog measures. Relationships between neurocog measures and
total APD Sxs were analyzed in SAS Proc Mixed using mixed effects regression
models with a random effect for family using a variance components structure.
Models were fit separately in theRels of the Sz andCC probands. Inadditionwe
fitmodels witha groupbySx interaction inthecombinedsample to formally test
fordifferencesintherelationshipofneurocognitionandAPDSxsbetweenSzand
CCrelatives.NorelationshipswerefoundinCCsalone.APDdimensionalscores
predictedperformanceonthespanofapprehension(Span),3-7ContinuousPer-
formanceTest, and Trail Making Test in Rels, and the group by Sxs interactions
were significant in the combined models, confirming a stronger relationship in
relatives of SZ versus CC probands. In secondary models. APD dimensional
scores predicted performance on the Span and Trails even after adjustment
for PD dimensional scores in the Rels. APD dimensional scores predicted per-
formance on the Span after adjustment for SPD dimensional scores. However,
the group by Sx interaction term was significant or trending toward significance
in all the combined sample models even after adjustments for PD and SPD di-
mensional scores. Given the substantial correlation between dimensional scores
for APD and SPD Sxs, and the assumption that these personality disorders are
not independent, we conclude APD dimensional scores and SPD dimensional
scores are useful predictors of performance on these neurocog measures that are
not fullyseparable.These findings indicate thatAPDdimensional scorespredict
poorer neurocog performance in the Rels of SZ probands, often more strongly
than in the Rels of CCs. The relationships between dimensional scores of APD
SxsandprobableneurocogendophenotypesforSZsupports thehypothesis that
APD is a useful SZ spectrum phenotype for SZ research.
ID: 536960
VISUAL LEARNING AND MEMORY IN THE
RODENT: NOVELOBJECTRECOGNITION AND THE
MORRIS WATER MAZE—PROS AND CONS
Andrew J. Grottick
In Vivo Pharmacology, CNS, Arena Pharmaceuticals Inc.,
San Diego, CA, USA
Visual learning and memory was identified by the MATRICS process as
one of seven key domains of cognitive function impaired in schizophrenia.
Visual learning and memory impairments have been identified in schizo-
phrenic patients, and some evidence suggests that such deficits may predate
illness onset in high risk individuals. In humans, MATRICS selected the
Brief Visual Memory Test-Revised (BVMT-R) to assess visual learning
and memory. This paper based task assesses the subjects ability to recall
and recognize six geometric figures which are presented for short (10s) peri-
ods of time. As such there are both spatial and non-spatial aspects to the
task. An important second step to conceptualizing cognitive function in
schizophrenia is to consider the precise nature of animal models and tests
which should form the focus of future research, and importantly how well,
or indeed whether these can map onto the cognitive domains identified by
MATRICS. In the rodent, a large number of tasks exist which assess visual
learning and memory. This talk will focus on two commonly used rodent
tasks: A visuospatial maze-based task (Morris water maze), and a nonspa-
tial test of recognition memory (Novel object recognition). The focus of this
discussion will be both practical and theoretical issues associated with their
use, and their applicability to cognitive research in schizophrenia.
ID: 550760
PRECLINICAL ASSESSMENT OF VIGILANCE IN
RATS AND MICE: TRANSLATIONAL VALIDITY
FOR THE CONTINUOUS PERFORMANCE TEST
Jared William Young
Psychiatry, University of California, San Diego, La Jolla, CA, USA
Cognitive disruption in schizophrenia correlates closely with functional
outcome. Thus the need to develop cognitive therapeutics for this disease
has never been greater. The Measurement And Treatment Research to Im-
prove Cognition in Schizophrenia (MATRICS), identified impaired atten-
tion/vigilance as one of the core deficits experienced by schizophrenia
patients. Vigilance is commonly assessed in humans using the continuous
performance test (CPT), which requires a response to signal events and an
inhibition of response to non-signal events. Signal detection theory (SDT) is
used to evaluate performance in the CPT. In fact MATRICS chose the
CPT-identical pairs to assess attention/vigilance in their cognitive test bat-
tery. Few rat or mouse paradigms follow these task parameters however.
Two tasks available which fulfill these criteria are the rat sustained atten-
tion task and the recently developed mouse 5-choice CPT, based on the 5-
choice serial reaction task. These tasks have been assessed for translational
validity as tests of vigilance and are now being used to develop animal mod-
els of impaired vigilance with relevance to schizophrenia. The sustained at-
tention task has been available for over a decade in rats and recent studies
have been performed with relevance to schizophrenia. The effects of anti-
psychotic treatment on normal animals have been investigated, as have pu-
tative pro-cognitive drugs. Moreover, the effects of antipychotics have also
been investigated in an animal model of schizophrenia. The more recent 5-
choice CPT has received only limited investigation to date, although numer-
ous studies in different laboratories are now being conducted. This task
utilizes 5-hole chambers. The use of holes as opposed to levers makes
this task ideal to assess vigilance in mice. To date, poorer performance
of DBA2/J mice relative to C57BL/6J mice has been demonstrated. More-
over, reduced expression of the dopamine D4 receptor in mice resulted in
poorer vigilance, consistent with that of schizophrenia patients with re-
duced prefrontal D4 receptor expression. Two rodent vigilance tasks
with translational validity to the CPT exist. Studies continue to explore
the neurobiological contribution to performance in these tasks, as well
as develop animal models of schizophrenia with face, predictive and con-
struct validity. Once fully developed, these models and tasks can be used in
the drug discovery process to investigate future putative therapeutics.
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DISTINCT NEURAL SIGNATURES OF RESPONSE
MONITORING DEFICITS IN SCHIZOPHRENIA
AND AUTISM: A NEUROCOGNITIVE
ENDOPHENOTYPE?
Dara Manoach1,2, K. A. Dyckman1, Y. Agam1, M. Isom1,
R. M. Joseph3, D. C. Goff1
1Psychiatry, MGH, Charlestown, MA, USA; 2Athinoula A.
Martinos Center for Biomedical Imaging, Harvard Medical School,
Boston, MA, USA; 3Anatomy and Neurobiology, Boston University
School of Medicine, Boston, MA, USA
Adaptive, flexible behavior depends on intact ‘response monitoring’, which
involves evaluating whether the consequences of a behavior are consistent
with its intent and, if an error occurred, instituting adjustments to optimize
outcomes. Schizophrenia and autism spectrum disorder (ASD) are neuro-
developmental disorders that are characterized by rigid, stereotyped, and
perseverative behavior. In the present study we investigated the contribu-
tion of anterior cingulate cortex (ACC) structure and function to response
monitoring using event-related functional MRI (fMRI) and diffusion ten-
sor imaging (DTI) in 12 ASD participants, 18 schizophrenia patients, and
15 demographically-matched healthy controls. We compared ACC activa-
tion following correct and erroneous antisaccade responses with fMRI and
examined the microstructural integrity of the white matter underlying ACC
as indexed by fractional anisotropy (FA). Both experimental groups made
more antisaccade errors than controls. Schizophrenia patients performed
correct antisaccade trials more slowly than controls, while ASD partici-
pants performed faster. With regard to ACC activation, both experimental
groups showed reduced discrimination between error and correct trials, but
the basis of this reduction differed by group. In schizophrenia, the reduc-
tion reflected a blunted ACC response to errors, while in ASD it reflected
a hyperactive response to correct trials, which correlated with Autism Di-
agnostic Interview-Revised ratings of restricted, repetitive behavior. Rela-
tive to controls, both groups showed significantly reduced FA in ACC
white matter. These findings demonstrate functional and structural ACC
abnormalities that may contribute to behavioral rigidity in both ASD
and schizophrenia. However, the behavioral and neural abnormalities dif-
fered by group. Given recent evidence of genetic mediation of response
monitoring by common polymorphisms, these findings suggest that neuro-
imaging-based indices of deficient response monitoring are promising can-
didate endophenotypes that are clinically-relevant and can distinguish
between neurodevelopmental disorders.
ID: 550741
INTERACTION BETWEEN WORKING MEMORY
LOAD AND GESTURE IMITATION ABILITY IN
SCHIZOPHRENIA
Natasha Matthews1, B. J. Gold2, R. Sekuler2, S. Park1
1Psychology, Vanderbilt University, Nashville, TN, USA;
2Volen Center for Complex Systems, Brandeis University,
Waltham, MA, USA
In Imitation one person observes and reproduces the behavior of another
person. Imitation plays a key role in skill acquisition, and the development
of fundamental social skills such as understanding the goals, intentions and
desires of other people. Recent evidence suggests that individuals with
schizophrenia (SZ) are impaired in their ability to imitate manual, facial,
and vocal gestures. This impairment may be linked to well established dif-
ficulties in generating internal representation in working memory (WM). In
the present study we used a novel technique to investigate the relationship
between WM and imitation ability. Individuals with SZ and demograph-
ically matched CO subjects imitated, both online and from memory, a series
of manual sequences each consisting of two gestures. Imitation was per-
formed while wearing an electronic data glove that transduced the move-
ment of the subject’s fingers as the gesture was reproduced. This allowed
precise analysis of the velocity and accuracy of the finger movements. In the
online task subjects imitated each sequence concurrently with the stimulus
display; in the memory task subjects imitated each sequence after a 2 sec
delay. In both conditions each sequence was displayed 8 times, so that ges-
ture learning could be investigated. Clinical symptoms were also assessed.
The results revealed a significant interaction between diagnostic status and
imitation condition, with SZ producing more errors relative to CO in the
memory condition compared to the online condition. This suggests that
adding a WM requirement interacts with imitation ability in the disorder.
Imitation learning did not differ significantly between groups. However this
may have been due to the relatively few errors produced overall. There was
also a significant interaction between group and memory condition in pre-
motor planning, the time taken to make the first gesture in a sequence, with
SZ requiring significantly longer time to begin the first gesture compared to
CO in the memory condition, but not the online condition. Significant cor-
relations were found between negative symptoms in SZ and both the
number of errors produced and planning time in the memory condition.
Taken together, these results suggest that imitation ability in SZ is partic-
ularly sensitive to WM load.
ID: 550691
CORRELATION OF PREPULSE INHIBITION WITH
WISCONSIN CARD SORTING TEST PERFORMANCE
IN PATIENTS WITH SCHIZOPHRENIA AND
CONTROLS: EFFECTS OF SMOKING STATUS
Rachel A. Rabin1, A. A. Woznica1, K. A. Sacco2, T. P. George1,2
1Schizophrenia and Addictions, Centre for Addiction and Mental
Health, Toronto, ON, Canada; 2Psychiatry, Yale University
School of Medicine, New Haven, CT, USA
Background: In patients with schizophrenia, cigarette smoking rates are
high and smoking appears to alter two important neurocognitive deficits
associated with the illness: information processing as measured by pre-
pulse inhibition (PPI) of the acoustic startle response and frontal lobe
function as assessed by the Wisconsin Card Sorting Test (WCST). Ob-
jective: The goal of this study was to evaluate the relationship between
PPI and prefrontal cortical functioning in individuals with schizophrenia
and controls and examine how smoking influences this relationship. De-
sign: The study included four groups: (i) schizophrenia smokers (SS; n =
15), (ii) schizophrenia nonsmokers (SNS; n = 11), (iii) non-psychiatric
control smoker (CS; n = 14) and (iv) non-psychiatric control nonsmokers
(CNS; n = 10). All subjects were assessed identically on PPI and WCST.
Results: Baseline differences amongst the four groups were observed for
PPI on the Diagnosis x Smoking Status x PPI Interval interaction [F11,140
= 4.89, P < .01]. SNS demonstrated the poorest PPI function, while SS
showed comparably high levels of PPI to CNS at the 120 msec pre-pulse
to pulse interval. Significant differences also existed between the four
groups on categories completed [F3,47=3.78, P = .015] and perseverative
errors [F3,47=3.65, P = .017] outcomes on the WCST, with non-psychiatric
controls outperforming individuals with schizophrenia irrespective of
smoking status. Categories completed on the WCST and PPI at the
120 msec prepulse condition significantly correlated in SS (r = .61,
P < .01). In contrast, there were no significant correlations between
PPI and any WCST outcomes in SNS, CS or CNS (all P’s >0.20). Dis-
cussion: Selected executive function outcomes of WCST (eg, categories
completed) are strongly correlated with PPI in smokers with schizophre-
nia, but not in non-smoking patients, and controls, suggesting that the
association between sensorimotor gating and prefrontal executive func-
tioning is enhanced by acute cigarette smoking. Our preliminary findings
may contribute to understanding the vulnerability of patients with schizo-
phrenia to nicotine dependence, and may lead to the development of tar-
geted treatments for this co-morbidity. Nicotine receptor-stimulating
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drugs are a promising alternative to cigarettes, as they will help alleviate
cognitive deficits ie, target executive functioning and PPI deficits, without
the adverse health consequences implicated with regular tobacco use.
ID: 550662
MODELLING WORKING MEMORY IN THE RAT:
A MISGUIDED EFFORT?
Verity J. Brown
School of Psychology, University of St. Andrews, St. Andrews,
United Kingdom
The lack of effective treatments for the cognitive symptoms of schizophre-
nia is a prime driver in the search for predictive ‘‘animal models’’. The goal
is to find measures of complex cognitions—such as working memory—that
have clear ‘‘translational’’ utility. The result is a wide variety of behavioural
protocols for the rat and mouse. Nevertheless, there remains a fundamental
dissatisfaction with these ‘models’ and, more significantly, no break-
throughs in treatment. Cognition is a covert operation and must be inferred
from carefully measured and well-characterised behavioural analysis. For-
tunately, even the most complex behaviour is the product of an assembly of
a subset of more basic cognitions acting in concert. We assume that, in psy-
chiatric disorders such as schizophrenia, complex deficits arise from funda-
mental cognitive impairments. Identifying what these fundamental
cognitive impairments are has provided a route ‘backwards’, from the clin-
ical manifestation (the psychiatric symptomatology) to the core cognitive
impairments. For example, the MATRICS initiative has described
‘domains’ of core cognitive functions that are compromised in schizophre-
nia. The focus therefore is now on the possibility of translating these ‘down-
wards’, back to preclinical research. Here, I propose that translation should
not be seen as a movement (in either direction) along a path that leads from
the preclinical to the clinical. Rather, there are parallel paths: one is con-
cerned with the neurobiology underlying the symptoms of psychiatric ill-
ness (in humans) while the other is concerned with the neurobiology of
rodent cognition. ‘Translation’ is required to ensure that these pathways
intersect so that progress towards understanding on either pathway facil-
itates progress on the other. Thus, we can abandon talk of ‘animal models
of human cognition’ and study instead ‘animal cognitions that are trans-
lated’. This approach obviates the requirement for the rat to be a model
of the human. Instead, the emphasis is to ensure that the appropriate overt
behaviours (predictive of functional capacity and clinical outcome) are
measured. Examples of behavioural protocols that fulfill these require-
ments will be reviewed, with particular emphasis on understanding working
memory.
ID: 550634
REASONING AND PROBLEM SOLVING—THE
ATTENTIONAL SET SHIFTING TASK
Hugh M. Marston
Pharmacology, Schering-Plough Corporation, Newhouse,
United Kingdom
Cognitive inflexibility in schizophrenia is treatment-resistant and predictive
of poor outcome. Within the framework of MATRICS, deficits in cognitive
flexibility map onto both the problem solving and speed of processing
domains, both of which are believed to be dependent upon frontal-lobe
function. Evidence for this includes the observation, for example, that tasks
that are sensitive to frontal-lobe damage, such as the Wisconsin Card Sort
test, are also impaired in schizophrenic patients. Therefore developing a bet-
ter understanding of the inter-relationship between the neuroanatomical,
and neurochemical substrates, the psychological processes, and pharmaco-
logical agents may offer new insight into how theses domains could be bet-
ter manipulated in the clinic. Recent studies have examined the effect of
asenapine, a novel psychopharmacologic agent being developed for schizo-
phrenia and bipolar disorder, on the performance of rats with ibotenic acid-
induced lesion of the medial prefrontal cortex (mPFC) in an intradimen-
sional / extradimensional (ID/ED) test of cognitive flexibility. The effect
of subcutaneously administered asenapine on ID/ED performance of con-
trols or mPFC lesioned rats was examined using a within-subjects, re-
peated-measures design. In a second experiment, lesioned and control
rats were tested with or without asenapine in a modified version of the
task, with multiple set-shifts, before brains were processed for Fos-immu-
noreactivity in the mPFC. The mPFC lesion-induced deficit in the ID/ED
task was stable with repeated testing over more than two months. Asena-
pine (75lg/kg, P < .05) completely restored the performance of lesioned
rats. A second experiment replicated these results and demonstrated that
it is possible to measure set-shifting multiple times within a test session.
Asenapine (75lg/kg) was associated with differential activation of the neu-
rons in the anterior mPFC of lesioned animals, but was without effect in
controls. These data show that asenapine can ameliorate mPFC lesion-in-
duced impairment in attentional set-shifting, probably by a greater activa-
tion of the spared neurons in the anterior mPFC. As such this gives an
insight into the various substrates that mediate this aspect of cognition.
Further, with the amelioration by aspenapine, we now have the potential
to translate and validated these hypotheses.
ID: 550614
VALIDATION OF SOCIAL COGNITION TESTS FOR
SCHIZOPHRENIA PATIENTS IN INDIAN SETTING
Urvakhsh Meherwan Mehta1, J. Thirthalli1, C. Naveen Kumar1,
K. Rao2, B. N. Gangadhar1
1Psychiatry, National Institute of Mental Health and Neurosciences,
Bangalore, India; 2Mental Helalth and Social Psychology, National
Institute of Mental Health and Neurosciences, Bangalore, India
There are no standardized tools in India to test social cognition. This paper
describes validation of tools for two social cognition constructs in schizo-
phrenia: theory of mind and attributional bias. Theory of mind (ToM) tests
that we validated included, (a) two first order TOM tasks [Sally-Anne
(Baron-Cohen et al. 1985) and Smarties task (Perner et al. 1987)], (b)
two second order TOM tasks [Ice cream van (Perner and Wimmer,
1985) and Missing cookies story (Stone et al. 1998)], (c) two metaphor-irony
tasks (Drury et al. 1998 and Herold et al. 2002) and (d) the faux pas rec-
ognition test (Stone et al. 1998). We also validated The Internal, Personal,
and Situational Attributions Questionnaire (IPSAQ) (Kinderman and Ben-
tall, 1996). We generated Indian equivalents of these tests and modified the
questions slightly. Eighteen mental health professionals rated the tests on
likert scale (1 = strongly disagree; 5 = strongly agree) as to whether the mod-
ified tasks tested the same construct as in the original and whether they were
culturally appropriate in India. Tests which received a score of <4 (not
aggreable) from >25% of experts were revised based on their comments.
After revision, all tests were administered on 9 schizophrenia patients
and 9 healthy individuals to assess discriminant validity. Both first-order
and second-order TOM tasks, both metaphor-irony tasks, the stories
1–6, 8–11, 13–18, and 20 of faux pas recognition test and IPSAQ were
agreed upon by >75% of the experts and met our criteria for content val-
idity. Significantly greater proportion of patients had first and second order
TOM deficits and irony detection deficits. They also identified less number
of faux pas situations and had greater scores on externalizing bias on
IPSAQ. Indian modification of social cognition tasks has content validity
and discriminant validity. Schizophrenia patients have poorer social cog-
nition than healthy controls.
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Table. Comparison of cases and controls: The figures are in percent of
subjects with deficits (*) or mean (SD) scores (**)
Variable
Cases
(n = 9)
Controls
(n = 9)
v2/ Mann-
Whitney-U P
TOM first order* 4 (44%) 0 (0%) 5.14 0.02
TOM second order* 9 (100%) 3 (33%) 9 0.003
Metaphor* 1 (11%) 0 (0%) 1.1 0.30
Irony* 9 (100%) 1 (11%) 14.4 0.002
IPSAQ Externalizing bias** 4.7 (4.9) 0.4 (2.4) 20.5 0.07
IPSAQ Personalizing bias** 0.72 (0.2) 0.79 (0.3) 32.0 0.49
Total faux pas
identified correctly**
5.3 (2.6) 8.2 (1.4) 14.5 0.02
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IMPOVERISHED PROSODY PRODUCTION IN
SCHIZOTYPAL PERSONALITY DISORDER
Chandlee Dickey1, L. Panych3, M. Shenton2, M. Niznikiewicz1,
M. Voglmaier4, C. Murphy1, R. Zacks1, D. Terry2, R. McCarley1
1Psychiatry, Harvard Medical School, VA Boston Healthcare
Services, Brockton, MA, USA; 2Psychiatry, Brigham and Women’s
Hospital, Boston, MA, USA; 3Radiology, Brigham and Women’s
Hospital, Boston, MA, USA; 4Psychiatry, Cambridge Health
Alliance, Cambridge, MA, USA
Background: Schizotypal personality disorder (SPD) is epidemiologically
and phenotypically related to schizophrenia and is considered part of
the schizophrenia spectrum disorders. Social cognition deficits have been
more fully studied in schizophrenia despite five out of the nine diagnostic
criteria for SPD being in the social domain. One important aspect of social
reciprocity and social interactions is the ability to speak with prosody. Re-
search studies have shown schizophrenia subjects to have decreased pitch
variation in their speech. The goal of this study is to examine pitch variation
and its clinical implications in SPD subjects. Methods: Nineteen neurolep-
tic-naı¨ve SPD subjects were compared with 23 healthy control subjects in
terms of the amount of pitch variation (standard deviation of pitch) ana-
lyzed acoustically. In a separate analysis, trained raters also listened to sub-
jects’ speech and rated how much the raters would like to hear more from
the subjects along a 7-point Likert scale. Pause proportion, the amount of
time free of utterances, was also calculated. Verbal fluency was measured
with the Word Generation Task. Subjects also completed the Alexithymia
questionnaire as a measure of their insight into their difficulties verbally
communicating their emotions. Results: As predicted SPD subjects had
less pitch variation in their speech compared with controls. Less pitch var-
iability correlated with raters not wanting to hear more from them. Not
only did SPD subjects have less pitch variability, but they also had
more pauses compared with controls. SPD subjects also generated fewer
phonemic and semantic words in one minute compared with controls on
the Word Generation Task. SPD subjects scored higher on our measure
of alexithymia (more alexithymia). Conclusions: We believe these data sug-
gest that SPD subjects compared with controls, have deficits in prosody
production. Poor executive functioning may be compounding the difficul-
ties as SPD subjects also had poor word generation. These deficits have
clinical repercussions as raters did not want to hear more from them.
SPD subjects do, however, have insight into their difficulties—they are
aware that they are not communicating their emotions well. Taken together
these data suggest that research directed toward enhancing the pitch var-
iation and decreasing pause proportion, may be important toward helping
schizophrenia spectrum subjects navigate the social world.
ID: 550550
WORKING MEMORY MAINTENANCE AND
MANIPULATION DEFICITS IN SCHIZOPHRENIA
Scot Kristian Hill1, G. B. Griffin1, T. K. Miura2, J. A. Sweeney1
1Psychiatry, University of Illinois at Chicago, Chicago, IL, USA;
2Psychology Department, Loyola University Chicago, Chicago,
IL, USA
Encoding and maintenance of information as well as internal manipulation
of information are key components of working memory systems. Given the
broad pattern of cognitive deficits associated with schizophrenia, manipu-
lation deficits are believed to be more pronounced than encoding/mainte-
nance impairments. However, these two working memory processes have
rarely been directly compared. We evaluated chronic schizophrenia patients
(n = 25) on stable medication regimens and healthy comparison participants
(n = 22) matched on age, education, parental SES, sex, race, and estimated
intelligence. Participants were administered a modified verbal span task
with four levels of difficulty. Maintenance was assessed using single item
verification probes (Was X the 3rd letter?). Maintenance plus manipulation
was assessed via double item verification probes which required more com-
plex serial search strategies comparing relative temporal sequence (ie, Was
X before Y?). Both groups showed reduced accuracy and increased reaction
time for manipulation compared to maintenance processing. Between-sub-
ject effect sizes (Cohen’s d) indicated medium-large effect sizes for mainte-
nance probes, whereas the magnitude of patient deficit was small-medium
for manipulation probes. When participants were retested at 4-weeks,
maintenance deficits increased due to greater practice effects in the healthy
group, especially at lower working memory loads. The magnitude of im-
pairment for working memory manipulation was more consistent over
time. These findings are consistent with meta-analytic findings of impaired
encoding and/or early maintenance of information in working memory in
schizophrenia. Additionally, the findings suggest that deficits of encoding
information in working memory may be greater than deficits in manipula-
tion of information stored in working memory systems.
ID: 550549
fMRI AND BEHAVIOURAL STUDIES OF NORMAL
AND ABNORMAL LEARNING IN PSYCHOSIS.
Graham Keith Murray
Psychiatry, University of Cambridge, Cambridge, United Kingdom
In a number of recent learning studies from CAMEO, the Cambridge early
onset psychosis service, we have shown that in moderately symptomatic
psychosis patients, whilst there are very subtle behavioural abnormalities
in learning reward and causal associations, the crude learning of simple re-
ward and causal associations is nevertheless broadly intact. Interestingly, in
a recent fMRI study of probabilistic reward learning, we showed that this
broadly intact learning is accompanied by remarkably abnormal patterns
of brain activation as measured by concurrent fMRI BOLD signal change.
How can we reconcile these seemingly inconsistent findings of abnormal
brain activity, unusual patterns of thought and behaviour on mental state
examination, yet comparatively normal behaviour on computerised tests of
learning? One possibility that has been previously advanced is that fMRI is
a more sensitive investigative tool, which can reveal abnormalities that
computerised cognitive testing cannot. A more interesting possibility is
that although patients’ primary brain systems of learning reward associa-
tions may be dysfunctional (for example, meso-limbic dopamine systems
and fronto-striatal systems), patients may engage in recruitment of com-
pensatory, secondary, intact neural systems to attain reasonable perfor-
mance on cognitive learning tasks. Arguments to support this possibility
stem from studies of experimental animals, such as genetically engineered
dopamine deficient (DD) mice. Although in the DD state, such mice are not
motivated to engage in goal directed behaviours, nevertheless DD mice are
able to learn about rewards. Although there is extensive evidence for a role
for dopamine in reward learning, such experiments show that, perhaps
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through compensatory pathways, learning can still occur, even in the ab-
sence of dopamine. I will argue that in an analogous fashion, in spite of
remarkably dysregulated mesolimbic, mesostriatal and mesocortical sys-
tems in psychosis patients, compensatory neural systems are engaged in or-
der to attain successful behavioural performance on computerised cognitive
testing. The implications of this will be discussed further in the presentation.
ID: 550499
MIND IN MOTION—PSYCHOPATHOLOGY IN
PATIENTS WITH SCHIZOPHRENIA IS REFLECTED
IN NONVERBAL BEHAVIOR MEASURED BY
MOTION ENERGY ANALYSIS (MEA)
Zeno Kupper, F. Ramseyer, H. Hoffmann, W. Tschacher
University Hospital of Psychiatry, University of Bern, Bern,
Switzerland
Motor behavior is prominently affected in schizophrenia. Alterations of
nonverbal behavior have been regarded as diagnostically salient and as crit-
ically important for functional outcome, eg, in the case of negative symp-
toms. Nonverbal signs of the disorder can be understood as alterations in
complex, organized patterns of functioning, expressing mind in motion. Al-
though nonverbal behavior is both theoretically and clinically important,
empirical research on nonverbal behavior in schizophrenia has been mostly
confined to rating-based approaches. Traditional objective measures of
nonverbal behavior (eg, marker-based movement tracking) are costly,
time consuming and scarcely functional outside laboratory settings. Mo-
tion energy analysis (MEA) refers to a method by which objective measures
of body movement can be extracted from ordinary video recordings. In this
study brief videotaped role play scenes with 30 stabilized outpatients were
analyzed. Each patient interacted in 14 short scenes with an investigator
who portrayed an interpersonal partner. Correlations between movement
parameters (percentage of time in movement, movement speed) and psy-
chopathology ratings from independent PANSS interviews were calculated.
As predicted, both reduced movement activity and slowness of movement
were correlated with negative symptoms and with specific general symp-
toms, eg, depression and motor retardation. Positive symptoms were
generally not related to movement parameters with the exception of suspi-
ciousness being correlated with reduced head movements. Overall, there
was a close and theoretically meaningful association between the objective
MEA movement parameters and the symptom profiles. Furthermore, there
were clear signs of contagion in the interactions, ie, in patients with lower
movement rates investigators also showed reduced movement. Lower
movement synchrony between patients and investigators was associated
with psychopathology, even after controlling for patients’ levels of move-
ment. MEA measures of nonverbal behavior in schizophrenia patients seem
to be strongly and specifically linked to psychopathological symptoms. The
MEA method allows for quantifying nonverbal behavior from a wide range
of video recordings. MEA based studies of ‘mind in motion’ may provide
new insights into links between the phenomenological level of psychopa-
thology and its expression on an objective behavioral level.
ID: 550465
ATYPICAL ANTIPSYCHOTICS IMPROVE EMOTION
RECOGNITION DEFICITS IN SCHIZOPHRENIA:A
LONGITUDINAL STUDY
Rishikesh V. Behere, R. Arasappa, N. N. Reddy,
G. Venkatasubramanian, B. N. Gangadhar
Department of Psychiatry, National Institute of Mental Health and
Neurosciences, Bangalore, India
Facial Emotion Recognition Deficits [FERD] have been demonstrated in
schizophrenia (Kohler et al. 2003). However effect of antipsychotic treat-
ment on FERD in never-treated schizophrenia is yet to be explored. Sub-
jects included 25 antipsychotic naı¨ve schizophrenia patients [DSM-IV] and
30 age-,sex-,education- matched healthy controls. Psychopathology and
FERD were assessed with SAPS and SANS and the Tool for Recognition
of Emotions in Neuropsychiatric DisorderS [TRENDS] (Behere et al;
Award Paper 2008) respectively. TRENDS a culturally appropriate emo-
tion recognition tool with optimal validity, consists of staticanddynamic
visual stimuli of seven basic facial expression (neutral, happy, sad, fear,
anger, surprise, and disgust). The patient group was then started on
Risperidone 4mg and Trihexyphenidyl 2mg per day and reassessed after
a mean duration of 38.2 6 17.1days. At baseline patients made significantly
more errors in emotion recognition (P< .001) than controls specifically for
emotions of fear and disgust (P < .001). SANS score showed significant
negative correlation with Emotion Recognition Accuracy [ERA]
total score (P = .001). On follow up, patients showed significant improve-
ment in SAPS and SANS scores. On paired samples‘t’ test there was sig-
nificant improvement in ERA total score (P = .02), specifically for disgust
sub-score (P = .002). Improvement in ERA scores was significant even af-
ter controlling for potential confounding effects of reduction in SANS
scores. This longitudinal study for the first time demonstrates beneficial
effect of neuroleptics on FERD in antipsychotic naı¨ve schizophrenia
patients. This effect is independent of improvement in psychopathology.
Specific improvement in disgust sub scores suggests potential effects of
antipsychotics on dopaminergic dysfunction. Acknowledgement: This
study was financially supported by Indian Council of Medical Research
(ICMR).
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MAINTENANCE OF RESPONSE IN TRIALS OF
OLANZAPINE VERSUS OTHER ATYPICALS FOR
TREATMENT OF SCHIZOPHRENIA
Virginia Stauffer1, H. Ascher-Svanum1, L. Liu1, T. Ball2,
R. Conley1
1Eli Lilly and Company, Indianapolis, IN, USA; 2i3 Statprobe,
Ann Arbor, MI, USA
Objective: Compare time maintaining response in patients with schizophre-
nia treated with olanzapine or another atypical antipsychotic. Methods:
We conducted post-hoc analyses on data from five long-term (24–28
weeks), double-blind, randomized trials of olanzapine versus risperidone
(1 study), ziprasidone (2 studies), quetiapine (1 study), and aripiprazole
(1 study). Loss of response was defined as an increase in PANSS Total
score of 20% along with a Clinical Global Impression-Severity Index
score (CGI-S) of 3 in patients who had achieved response at Week 8.
For each study individually, between-group comparisons were made for
cumulative days spent in response, where response was defined as
20% decrease in PANSS1-7 Total score. Results: Time maintaining re-
sponse was statistically significantly longer for olanzapine compared to ris-
peridone (P < .001, quetiapine (P = .003), and ziprasidone (P = .008 and
P = .03). The mean percentage of cumulative days spent in response was
statistically significantly greater for olanzapine compared to ziprasidone
(P < .001 and P = .035). Conclusion: Evaluating drug efficacy over
time is important for treatment of long-term illnesses such as schizophre-
nia. In these analyses, patients randomized to olanzapine maintained
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response for a longer period of time than patients randomized to risper-
idone, ziprasidone, or quetiapine and spent more time in response than
patients randomized ziprasidone.
ID: 550436
CAUSALITY PERCEPTION AND INTERSENSORY
INTEGRATION IN SCHIZOPHRENIA
Wolfgang Tschacher, Z. Kupper
University of Bern, Bern, Switzerland
Patients with schizophrenia spectrum disorders often maintain deviating
views on cause-effect relationships, especially when positive and disorgani-
zation symptoms are manifest. Altered perceived causality is prominent in
delusional ideation, in ideas of reference, and in the afflicted mentalizing
ability or ‘Theory of Mind’ (ToM) of patients. In the present study, per-
ception of causality was investigated as a pre-attentional cognitive capabil-
ity, which was considered analogous to processes of cognitive coordination
such as perceptual grouping and gestalt perception. Thirty-one patients (24
men and 7 women, mean age 27.7 y) and the same number of healthy con-
trol subjects matched to patients with respect to age and sex were included.
A visual neuropsychological paradigm was developed in which two iden-
tical discs move, from opposite sides of a monitor, steadily toward and then
past one another. Their coincidence generates an ambiguous, bistable per-
cept (discs are subjectively perceived as either ‘streaming through’ or
‘bouncing off’ one another). The bouncing perception, ie, perceived causal-
ity, is enhanced when auditory stimuli were presented at the time of coin-
cidence. Thus, the experimental setup also afforded intersensory
integration of visual and auditory stimulation. Psychopathology was
assessed in the patient group using the Positive and Negative Syndrome
Scale (PANSS) and a personality test in controls. It was found that positive
symptoms were associated with increased perceived causality, disorganiza-
tion with attenuated perceived causality. Multiple regression analysis indi-
cated that psychopathology explained 46 percent of the variance of
causality perception. At the same time, perceived causality was unrelated
to personality traits. Patients were not significantly different from controls,
and timing of the auditory stimulus had similar influences on causality per-
ception in the patients and control groups, pointing to insignificant differ-
ences in intersensory integration. Perceived causality may be interpreted as
a basic constituent underlying higher cognition such as ToM and social cog-
nition, which appears to be specifically sensitive to symptom states. Con-
clusions for cognitive remediation therapy may be drawn based on the
results. In addition, it is suggested that the present paradigm has value
as a language-free, implicit marker of ToM-related cognition.
ID: 550412
CAN VISUAL ORGANIZATION IMPAIRMENT LEAD
TO ATTENTIONAL DISENGAGMENT DEFICIT IN
SCHIZOPHRENIA?
Mitsouko van Assche, A. Giersch
INSERM Unit 666, Clinique Psychiatrique, Hopital Civil,
Strasbourg, France
Patients with schizophrenia are impaired at organizing visual elements.
This capacity involves both automatic perceptual grouping, allowing the
binding of elementary features, and top-down control, that is necessary
to avoid excessive binding and to allow flexibility during visual exploration.
Previous studies have suggested a lack of top-down control, but preserved
ability to focus on targets defined by automatic grouping processes in
patients (Giersch and Rhein, 2008). Here we explore to what extent lack
of top-down control and impaired executive functions reduce flexibility
during visual exploration. 26 stabilized patients and matched controls
were submitted to 1) a perceptual search task, where an horizontal array
with an alternance of squares and circles was presented in each trial,
with only two adjacent figures being identical (Beck and Palmer, 2002).
Subjects had to identify whether these two targets were circles or squares.
Targets were either linked by a connector (within-group target pair) or lo-
cated between two connectors (between-group target pair), this, at an equal
frequency (50% of within-group target pairs block), or within perceptual
groups preferentially (75% of within-group target pairs block). 2) a modified
Stroop task, requiring to inhibit the automatic reading response of colour
names to select their colour ink. Patients were globally impaired to identify
targets located between perceptual groups, but were able to focalize effi-
ciently on within-group targets when those were more frequent (75% of
within-group target pairs block). Moreover, patients displaying increased
interference effects in the Stroop task showed disproportionate difficulties
to locate targets that were positioned between perceptual groups, especially
when the task incited them to focalize on within-group pairs (75% of within-
group target pairs block). These results suggest that preserved automatic
mechanisms, together with a lack of top-down control and deficient exec-
utive functions, may lead to adverse effects in schizophrenia, reminding of
a disengagement deficit. This may in turn lead to decreased flexibility dur-
ing visual exploration. Hence, restoring flexibility of perceptual organiza-
tion appears crucial when considering remediation therapies.
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REPETITION PRIMING OF FACIAL EXPRESSION IN
SCHIZOPHRENIA: COGNITIVE AND NEUROI-
MAGING FINDINGS
Barbara Lyn Schwartz1,2, D. Shook3, C. Vaidya3,4, S. I. Deutsch1,2
1Mental Health Service, Veterans Affairs Medical Center,
Washington, DC, USA; 2Department of Psychiatry, Georgetown
University, Washington, DC, USA; 3Department of Psychology,
Georgetown University, Washington, DC, USA; 4Children’s
Research Institute, Children’s National Medical Center,
Washington, DC, USA
Research has shown that people with schizophrenia have difficulty making
explicit judgments about the intentions and feelings of others. In particular,
they have difficulty identifying and labeling negative facial affects. Often,
however, we do not make conscious decisions about another’s facial expres-
sion. The processing of expressions, especially threatening ones, is auto-
matic and occurs implicitly without conscious awareness. Here, we
examined repetition priming in an indirect memory test to explore implicit
processing of emotional expressions in schizophrenia. Repetition priming
refers to enhanced processing of a stimulus (faster reaction times, increased
accuracy) following prior exposure to the identical stimulus. Our aims were
first, to determine whether or not priming for facial expressions was im-
paired in schizophrenia, and second, to test whether there were differences
in patterns of brain activation involved in priming between patients and
controls. In the first study, adults with schizophrenia and controls viewed
alternating blocks of faces with neutral and fearful expressions and iden-
tified each face as male or female. Immediately after each block of expres-
sions, the identical faces were repeated and, again, faces were identified as
male or female. Repetition priming was observed for neutral and fearful
expressions, as evidenced by faster reaction times to make judgments for
repeated versus novel expressions. Priming did not differ as a function
of emotional expression. Of greater significance, the magnitude of priming
did not differ for the groups. Implicit memory for facial expressions was
preserved in schizophrenia; however, as expected, explicit recognition
of previously viewed expressions was impaired. We then used fMRI to
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determine if activation patterns for repetition priming differed for patients
and controls. We again observed priming for neutral and fearful expres-
sions, and there was no difference in priming between the groups. In con-
trast, brain activation did differ for patients and controls. Priming for
neutral faces was associated with activity in the orbitofrontal area and fu-
siform face area for controls but not for patients. These findings point to
abnormal brain mechanisms associated with implicit processing of faces in
schizophrenia. Despite normal priming, patients with schizophrenia engage
different neural pathways to process facial affect, even when processing
occurs implicitly without explicit awareness.
ID: 550314
TOLCAPONE IMPROVES EFFICIENCY IN CORTI-
CAL AREAS UNDERLYING WORKING MEMORY
IN PATIENTS WITH SCHIZOPHRENIA
Jose Antonio Apud, R. Rasetti, B. Stankevich, K. Skjei;
S. Magalona, V. S. Mattay, D. R. Weinberger
CBDB, NIMH, Bethesda, MD, USA
Converging evidence suggests that decreased prefrontal dopamine (DA)
cortical function may underlie some of the cognitive impairments seen
in patients with schizophrenia. Catecholamine-O-methyltransferase
(COMT), one of the main catabolic pathways for prefrontal cortex
(PFC) DA, impacts the regulation of prefrontal DA flux, and COMT var-
iants possessing different levels of activity have been associated with vari-
able prefrontal efficiency. Subjects with the VA/ Val allele (higher enzyme
activity and low PFC DA) show less prefrontal cortical efficiency than sub-
jects with the Met/Met allele (lower enzyme activity and high PFC DA). A
specific pharmacological approach to modulate cortical DA activity con-
sists in the use of Tolcapone (TOL), a potent COMT inhibitor which pen-
etrates the blood-brain barrier and improves prefrontal efficiency in normal
volunteers. In this study, we assessed the ability of TOL to improve cortical
efficiency in patients with schizophrenia. Performance analysis using
ANOVA with drug and task load as co-factors showed significant decrease
in accuracy with increased task load, but no effect of the drug was found in
accuracy or reaction time. ANCOVA analysis of neuroimaging data
revealed significant task load-related brain activation in the PFC and pa-
rietal cortex. During the 2-back task, a paired t-test revealed a significant
main effect of TOL with greater cortical activation in brain regions under-
lying working memory function, particularly the PFC and the parietal cor-
tex, during the placebo condition relative to TOL with no differences in
accuracy or reaction time across the two drug conditions (all P-value >
0.05). No significant main effect of drug was observed in either the 1-
back or 3-back. These results suggest that TOL improves the efficiency
of information processing during working memory in the PFC and parietal
cortex in patients with schizophrenia probably through a dopamine medi-
ated enhancement in neurophysiological signal to noise ratio during the
working memory task. TOL’s ability to improve cortical focusing suggests
that it could have several useful neuropsychiatric applications, such as im-
proving cognitive deficits associated with schizophrenia.
ID: 550296
CLINICAL VARIABLES AS PREDICTORS OF
COGNITIVE FUNCTIONING IN FIRST EPISODE
OF PSYCHOSIS
Rosa Ayesa-Arriola, J. Rodriguez-Sanchez, R. Perez-Iglesias,
I. Mata, B. Crespo-Facorro
Universitary Hospital Marque´s de Valdecilla, Santander, Spain
Patients with first-episode schizophrenia (FES) seem to have similar neuro-
cognitive deficits to chronic patients. However, little is known about the
influence clinical variables on neurocognitive changes in course of illness.
The present study analyzes if baseline clinical variables would predict neu-
rocognitive evolution in first episode psychosis patients. 104 first episode
psychotic patients and 21 healthy subjects were assessed twice, at baseline
and 1-year follow-up. The neurocognitive battery consisted of: Rey Audi-
tory Verbal Learning Test = RAVLT; Rey Complex Figure Test = RCFT;
Backward Digits = BD; Digit Symbol = DS; Trail Making Test- B = TMT-
B; Fluency test =FAS; Brief Attention Test =BTA = ; Finger Tapping =FT;
Grooved Pegboard = GP. A composite neurocognitive score was obtained.
Clinical symptoms were assessed by means of the Scale for the Assessment
of Positive symptoms (SAPS) and Scale for the Assessment of Negative
symptoms (SANS). Analyses were carried out using the SPSS 15. We car-
ried out a multiple regression analysis to predict neurocognitive function-
ing. As independent variables, we included clinical variables. Patients that
presented more positive symptoms at baseline have better neurocognitive
improvements at 1 year (r = 0.217; P = .029). Neurocognitive improvements
were not mediated by the severity of negative symptoms at baseline. Un-
expectedly, the severity of baseline positive symptoms would predict neuro-
cognitive changes at short time in schizophrenia.
ID: 550277
IMPAIRMENTS OF FACIAL EMOTIONAL PERCEP-
TION IN PEOPLE WITH CLINICAL HIGH-RISK
FOR PSYCHOSIS
Suk Kyoon An1,2, S. Y. Lee1,2, K. R. Kim1,2, J. S. Park1,2,
H. K. Koo2, J. I. Kang2,3, E. Lee1,2
1Psychiatry, Yonsei University College of Medicine, Seoul, South
Korea; 2Section of Affect and Neuroscience, Institute of Behavioral
Science in Medicine, Yonsei University College of Medicine, Seoul,
South Korea; 3Psychiatry, Ilsan Hospital, National Health
Insurance Corporation, Goyang-si, South Korea
The purpose of this study was to investigate whether people with clinical
high-risk for psychosis show impairments of facial emotion perception,
which is well-known findings in schizophrenia. Participants were people
with clinical high-risk for psychosis (CHR), schizophrenia patients
(SPR) whose duration if illness is less than 5 years and normal controls
(NC). Participants were requested to perform facial emotion recognition
tests. The facial emotional stimuli were selected from Ekman’s pictures
of facial affect (Ekman, 1976) and Matsumoto and Ekman’s Japanese
and Caucasian Facial Expression of Emotion (JACFEE) and Neutral Faces
(JACNeuF). The recognition rates of fear and sadness in Ekman’s pictures
in CHR were significantly lower than those in NC (F = 4.11, P = .028 for
sad, F = 6.51, P = .005 for fear). The recognition rates of fear and sadness of
JACFEE in CHR significantly lower than those in NC (F = 8.17, P = .002
for sad, F = 4.44, P = .022 for fear). These findings suggest that impairments
of facial emotion recognition may be already present in prodromal phase of
psychosis. The implications with psychopathologies, social and role func-
tioning in CHR and SPR will be discussed.
ID: 550202
VISUAL AND COGNITIVE PROCESSING OF FACE
INFORMATION IN SCHIZOPHRENIA: DETECTION,
DISCRIMINATION AND WORKING MEMORY
Yue Chen1, D. Norton1, R. McBain1, D. Ongur1, S. Heckers2
1Psychiatry, Harvard Medical School/McLean Hospital, Belmont,
MA, USA; 2Psychiatry, Vanderbilt University, Nashville, TN, USA
Face recognition involves several physiological and psychological pro-
cesses, including those in visual, cognitive and affective domains. Studies
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have found that schizophrenia patients have deficient recognition of facial
emotion, yet visual and cognitive processing of facial information in this
population has not been systematically examined. In this study, we exam-
ined visual detection, perceptual discrimination and working memory of
faces as well as non-face visual objects in patients. Visual detection was
measured by the accuracy when detecting the presence of a briefly displayed
sketched face image which contained only the basic configural information
of a face. Perceptual discrimination was measured by the discriminability
scores for individual identities from face photograph images of which the
degree of similarity was systematically varied via morphing. Working mem-
ory was measured by the discriminability scores when two comparison face
images were separated by 3 or 10 seconds. All measurements were acquired
using a psychophysical method (two-alternative forced choice). Relative to
controls, patients showed significantly reduced accuracy in visual detection
of faces (P = .003). Patients exhibited moderately degraded performance in
perceptual discrimination of faces (P = .065). Furthermore, patients showed
significantly impaired performance in working memory of faces (P < .001
for both 3 and 10 sec conditions). Performance in face recognition in
patients, while degraded, was not correlated with that in recognition of
non-face visual objects. This pattern of results indicates that visual and cog-
nitive processing of facial information in schizophrenia requires greater sig-
nal strength and is thus inefficient.
ID: 550164
THE VALUE OF MEASURING NEUROCOGNITIVE
HOMOLOGUES IN ANIMAL MODELS OF
‘‘PATHOGENESIS’’ IN SCHIZOPHRENIA
Holly Moore
Psychiatry and Integrative Neuroscience, Columbia University and
the New York State Psychiatric Institute, New York, NY, USA
In the development of ‘‘animal models of schizophrenia’’, we strive to
model pathogenic mechanisms leading to both the neuropathology and
psychopathology of the disorder. In this presentation, we will argue that
a continuing evaluation of the many approaches there are to building
such models is necessary if the goal is to arrive at animal models with
the validity and reliability necessary to help us understand the pathogenesis
of the disorder and to screen potential therapeutic strategies. This presen-
tation will briefly review approaches to building models based on ‘‘etio-
logic’’ (early risk-factor) data versus those based on understanding the
‘‘proximal’’ neuropathophysiology of cognitive and behavioral abnormal-
ities. This will be followed by a discussion, with examples, of how these
approaches can intersect. The presentation will highlight the need for stud-
ies in schizophrenia patients in which the neurocognitive processes hypoth-
esized to be abnormal are tested with paradigms that have verifiable
construct validity and, thus, can be translated to paradigms in animal mod-
els. Although not all of the behavioral and cognitive phenomenology of
schizophrenia is easily (or even best) conceptualized as an abnormality
in a neurocognitive or neurobehavioral construct that has a homologue
in rodents, we argue that significant progress can be made by identifying
such constructs and utilizing paradigms that measure them in experimental
animals. Such paradigms can then be used in animal models designed to
examine the effect of risk factors and hypothesized pathogenic mechanisms,
or novel treatments, on neurocognitive and neurobehavioral constructs re-
liably affected in schizophrenia.
ID: 550149
ASSESSING SOCIAL-COGNITIVE DEFICITS IN
SCHIZOPHRENIA WITH THE MAYER-SALOVEY-
CARUSO EMOTIONAL INTELLIGENCE TEST
Shaun M. Eack1,2, C. G. Greeno1,2, M. F. Pogue-Geile3,
C. E. Newhill1, G. E. Hogarty2, M. S. Keshavan2
1School of Social Work, University of Pittsburgh, Pittsburgh, PA,
USA; 2Western Psychiatric Institute and Clinic, University of
Pittsburgh, Pittsburgh, PA, USA; 3Psychology, University of
Pittsburgh, Pittsburgh, PA, USA
Background: The emotion management subscale of the Mayer-Salovey-
Caruso Emotional Intelligence Test (MSCEIT) has recently been
recommended by the MATRICS committee as the sole measure of social
cognition for trials of cognitive enhancement in schizophrenia, yet the psy-
chometric properties of this subscale and the larger instrument in schizo-
phrenia patients have not been thoroughly examined. This research sought
to conduct a comprehensive psychometric investigation of the MSCEIT for
assessing social cognition in schizophrenia. Methods: A total of 64 outpa-
tients with schizophrenia were assessed using the MSCEIT. Scale reliability
and validity parameters were estimated through internal consistency
analyses; comparisons of patient performance with norms from healthy
samples; examinations of convergence with measures of cognition, func-
tional outcome, and psychopathology; and a series of exploratory factor
analyses. Results: The MSCEIT demonstrated adequate internal consis-
tency among its branch and total scales, and patient test performance
was significantly below normative levels. Estimates of discriminant and
concurrent validity indicated that the MSCEIT diverged from measures
of neurocognitive functioning and psychopathology, but was only modestly
related with objective measures of functional outcome. Convergent validity
estimates suggested that, contrary to expectations, the MSCEIT did not
correlate with a behavioral measure of social cognition. Finally, explor-
atory factor analyses suggested the possibility of a shift in the latent struc-
ture of emotional intelligence in schizophrenia, compared to studies with
healthy individuals. Conclusions: These findings support the use of the
MSCEIT as a reliable and potentially valid measure of social cognition
in schizophrenia, but also point to the need for further psychometric inves-
tigation of the instrument and additional measurement efforts to assess
broader social-cognitive domains that may exhibit stronger relations
with functional outcome.
ID: 550121
CNTRICS: WHY IT STARTED AND WHERE IT IS
GOING
Cameron S. Carter
Psychiatry, U.C. Davis, Sacramento, CA, USA
One of the greatest challenges facing Medicine in the 21st century is the
development of procognitive agents or other interventions to enhance cog-
nition and improve functional outcome in schizophrenia. The tools and
constructs of cognitive neuroscience provide a potentially powerful trans-
lational bridge between our rapidly growing knowledge about brain func-
tion and the application of this knowledge in both early and late phases of
treatment development. These tools include computer-administered tasks
that measure specific cognitive systems (such as attention, working mem-
ory, long-term memory, cognitive control) as well as the component cog-
nitive processes that comprise these more overarching systems. The
advantages of using these tools include the ability to identify and use ho-
mologous animal and human models in the drug discovery and testing pro-
cess and the ability to incorporate noninvasive functional imaging measures
into clinical trial contexts at several different phases of the drug develop-
ment process. However, despite these advantages a number of barriers exist
to their translation from basic science tools to tools for drug discovery. We
discuss the development and implementation the Cognitive Neuroscience
Treatment to Improve Cognition in Schizophrenia (CNTRICS) initiative,
designed to identify and overcome these barriers. Three meetings over a pe-
riod of 18 months brought together leaders in basic and clinical cognitive
neuroscience, psychometrics and drug development in an unprecedented
format. The result was a series of recommendations related to the cognitive
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systems to be targeted for treatment development for impaired cognition in
schizophrenia, a set of guidelines for establishing the reliability and prac-
ticability of administration of tasks, and a set of recommended tasks for
further development as measures of treatment effects on cognition in
schizophrenia. We will also discuss the proposed next phase of CNTRICS,
including a focus on the development of appropriate animal homologues of
targeted cognitive constructs as well as biomarker development.
ID: 550053
CNTRICS: DATA AND PRODUCTS FROM THE
‘‘CONSTRUCTS’’, ‘‘PSYCHOMETRICS’’ AND
‘‘TASKS’’ MEETINGS
Deanna Marie Barch
1Psychology, Psychiatry, Washington University, Saint Louis, MO,
USA; 2Radiology, Washington University, St. Louis, MO, USA
The purpose of this talk is to provide an overview of the data and delib-
erations generated as part of the first three meetings of the CNTRICS ini-
tiative. The first CNTRICS meeting focused on identifying cognitive
constructs that: 1) had been well validated in the human and animal cog-
nitive neuroscience; and 2) were relevant to understanding cognitive func-
tion in schizophrenia. In preparation for this meeting, CNTRICS
conducted two on-line surveys. The first asked members of relevant re-
search fields help generate and rank criteria for evaluating potential cog-
nitive constructs. The second asked respondents to rank a number of
potential constructs on these criteria, as input for the discussion at the first
conference. The first conference had basic science experts present overviews
on the cognitive and neural mechanisms involved in each of six domains:
1) working memory; 2) executive control; 3) attention: 4) long term learning
and memory; and 5) perception; and 6) social cognition. Following these
overview talks, smaller groups ‘‘broke-out’’ to identify 12 cognitive con-
structs from these 6 domains that were felt to have sufficient cognitive
and neural construct validity for further consideration. The second
CNTRICS meeting focused on identifying the translational challenges fac-
ing research aimed at developed paradigms from basic cognitive neurosci-
ence Prior to the meeting a web based survey asked a wide range of experts
in the field to provide rankings on the key issues and challenges related to
measurement development that helped focus the discussion. In addition,
this survey helped to establish benchmark values for various psychometric
properties deemed critical in the task development processing (eg, test-
retest reliability, maximum practice effects, etc.). The third meeting focused
on identifying promising cognitive tasks to measure each of the constructs
selected in the first CNTRICS meeting. Prior to the meeting a web based
survey sought nominations for specific tasks for targeted measurement of
the constructs identified at Meeting 1 together with documentation of their
construct validity, amenability for use in imaging studies, relationship to
animal models, psychometric properties, sensitivity to drug effects and
existing data in schizophrenia. Breakout groups at the meeting ranked tasks
according to specific criteria, recommending 1-2 tasks for further develop-
ment for each construct.
ID: 550032
DO EARLY CHANGES IN TRIGLYCERIDES PRE-
DICT LATER CHANGES DURING OLANZAPINE
TREATMENT?
Robert Conley, V. P. Hoffmann, M. Case, V. L. Stauffer,
J. Jacobson
Eli Lilly and Company, Indianapolis, IN, USA
Purpose: To characterize changes in fasting serum triglycerides during
olanzapine treatment and determine whether changes in triglyceride con-
centrations early in treatment predict clinically significant changes at 6
months. Methods: Fasting triglyceride data were from three 6-month, ac-
tive-comparator studies of treatment for schizophrenia or schizoaffective
disorder. Minimum age was 18 years for all trials. Maximum age was
75, 60, and 55 years for trials A, B, and C respectively. Analyses included
only patients with fasting triglyceride data at all protocol-specified time
points. In trials A, B, and C respectively, 277, 202, and 281 patients
were randomized to olanzapine; 128, 48, and 134 patients met analysis
criterion. Patients were categorized according to change from baseline in
triglycerides at Weeks 5–13 and Weeks 22–30. Cut-off points of 20, 30,
40, and 50 mg/dL change in triglycerides from baseline were used for Weeks
5–13. Positive and negative predictive values (PPV, NPV) were calculated
for all cut-off points. Results: Mean baseline fasting triglyceride concentra-
tions (standard deviation [SD]) were 133.5 mg/dL (98.1), 210.4 mg/dL
(214.8), and 147.1 mg/dL (96.8), respectively for trials A, B, and C.
Mean changes from baseline at endpoint (SD) were 41.0 mg/dL (115.7),
9.1 mg/dL (124.4), and 37.2 mg/dL (97.1) for trials A, B, and C. In all trials,
the largest change was seen in the first 12 weeks of treatment. Given a <20
mg/dL early change in triglycerides, probability of a50-mg/dL change at 6
months ranged from 12% to 17%. NPVs ranged from 83.3% to 87.7%. PPVs
ranged from 40.0% to 46.2%. Conclusions: Early assessment of fasting
triglyceride concentrations can help identify patients who may be at poten-
tial risk for clinically significant changes with longer treatment. While NPV
values are informative, potential risk of triglyceride increase is still present.
Clinicians should continue to monitor serum triglycerides.
ID: 549884
USING EYE-MOVEMENTS TO ASSESS ITEM-
SPECIFIC AND RELATIONAL LONG TERM
MEMORY IN SCHIZOPHRENIA
J. Daniel Ragland1, D. E. Hannula2, C. S. Carter1, J. Yoon1,
M. Minzenberg1, M. Solomon1, S. Ursu1, C. Ranganath2
1Psychiatry and Behavioral Sciences, University of California at
Davis, Sacramento, CA, USA; 2Psychology, University of
California at Davis, Davis, CA, USA
Episodic long-term memory is among the most severely impaired cognitive
domains in schizophrenia, and is also one of the strongest predictors of
long-term functional outcome among schizophrenia patients. However,
the field has yet to arrive at a precise understanding of the cognitive
and neural mechanisms of these memory impairments. Here, we used direct
(behavioral performance) and indirect (eye movement monitoring) meas-
ures to test the hypothesis that memory deficits observed in schizophrenia
are a consequence of a specific impairment in the encoding of inter-item
relationships, with encoding of item-specific information largely intact.
During study trials, participants viewed several rendered scenes. An orient-
ing question directed attention to a critical item in each scene thereby en-
couraging participants to process information about the item itself (ie, its
precise physical form) or its relationship to other items in the scene. At test,
participants were shown repeated (unchanged) scenes, manipulated scenes,
and novel scenes. In manipulated scenes, a critical item was either replaced
with a different exemplar (item manipulation) or moved to a different lo-
cation (relational manipulation). Participants were asked to indicate
whether the scene was unchanged, old with an item manipulation, old
with a relational manipulation, or new. Each response was followed by
a confidence rating. Eye movements, monitored throughout the test block,
provided an indirect measure of memory for scene repetition (novel vs. re-
peated scenes), relational memory (original vs. relational manipulation
scenes), and item-specific memory (original vs. item manipulation scenes).
Preliminary results show that performance on the orienting question was
high in both groups, which indicates that all of the participants were
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engaged in the task and had attended to the critical region of each scene. In
addition, relative to the matched comparison group, schizophrenia patients
performed more poorly on the test of relational memory and failed to show
some of the normal changes in viewing that are evident in scan paths of
neurologically-intact participants when scenes have been manipulated. Fur-
ther analyses will investigate the relationship between relational memory as
expressed in eye movements and overt reports.
ID: 549870
SWITCHING ANTIPSYCHOTIC DRUGS ENHANCES
IMPROVEMENT IN PATIENTS WHO SHOW LACK
OF AN EARLY RESPONSE TO THEIR INITIAL
ANTIPSYCHOTIC THERAPY
Sara Kollack-Walker1, V. L. Stauffer1, L. Chen1,
H. Ascher-Svanum1, W. Zhou1, S. Kapur2, J. Kane3, B. J. Kinon1
1Eli Lilly, Indianapolis, IN, USA; 2Institute of Psychiatry, King’s
College of London, London, United Kingdom; 3Zucker Hillside
Hospital, Glen Oaks, NY, USA
Objective: To examine the utility of switching to an alternative antipsy-
chotic drug for patients who fail to show an early response to their initial
antipsychotic therapy. Methods: This randomized, double-blind, flexible-
dose, 12-week study enrolled 630 patients diagnosed with schizophrenia or
schizoaffective disorder. All patients were initially assigned to risperidone
(RIS) therapy (2-6 mg/day) for 2 weeks. Early responders (20% improve-
ment PANSS total score from baseline to 2 weeks) continued on RIS (N =
144), whereas early non-responders to RIS were randomized at Week 2 (1:1)
double-blind to continue on RIS (N = 192) or switch to olanzapine (OLZ)
(10-20 mg/day; N = 186) for 10 additional weeks of therapy. These two early
non-responder groups were compared on efficacy and safety parameters.
Given observed heterogeneity in response, post-hoc analyses were con-
ducted for patients who were at least moderately ill (58%) at Week 2
and repeated for those who were not (42%). Results: Early non-response
to RIS was observed in 72.4% of patients. Early non-responders had sig-
nificantly less improvement in PANSS total score throughout the 12-week
study (P < .001) compared to early responders. Switching RIS early non-
responders to OLZ resulted in significant symptom improvement in
PANSS total score (P = .020) and MADRS (P = .020) at endpoint (up
to 10 weeks). Among the early non-responders, OLZ-treated patients
had numerically greater weight gain (P = .143), significantly greater increase
in triglycerides (P = .005), but a greater decrease in prolactin (P < .001).
Among early non-responders who were still at least moderately ill at
Week 2, OLZ-treated patients experienced significantly greater improve-
ment in PANSS total, positive, negative and general psychopathology
scores (P < .05) and in the MADRS (P < .001), with separation between
the OLZ and RIS groups evident by 4 weeks after switching. Treatment
differences were not observed among early non-responders who were
less than moderately ill at randomization (Week 2). Conclusion: Switching
RIS early non-responders to OLZ at Week 2 is an effective strategy that
facilitates further symptom improvement but is also accompanied by
changes in safety parameters, thus warranting individual benefit-risk con-
siderations. Among early non-responders to RIS who continue to be at least
moderately ill at Week 2, switching to OLZ is associated with greater symp-
tomatic improvement.
ID: 549817
IDENTIFYING SALIENT FEATURES OF VISUAL
PROCESSES FOR EMOTION IDENTIFICATION IN
SCHIZOPHRENIA WITH THE BUBBLE TECHNIQUE
Junghee Lee1, F. Gossselin2, S. Crosby1, J. Wynn1, M. Green1
1Neuropsychiatric Institute, UCLA, Los Angeles, CA, USA;
2Psychology, Universite´ de Montre´al, Montreal, QC, Canada
By identifying facial expression of emotion, people can rapidly infer the
feelings and thoughts of others. Emotional facial expression communicates
socially relevant information needed for adaptive behavior. Schizophrenia
patients exhibit difficulties recognizing emotions from facial expression,
and this deficit is linked to poor social functioning. It is not known which
aspects of visual information processing lead to inadequate recognition of
facial emotional expression in schizophrenia. In this study, we used a novel
‘Bubble technique’ (Gosselin and Schyns, 2001) that has not previously
been applied to schizophrenia to determine the salient visual information
involved in recognizing facial emotional expression. Seventeen schizophre-
nia patients and 17 healthy controls (matched for age and gender) received
the Bubbles task in which they categorized whether emotional expression of
the face stimulus was happy or fear. The Bubble technique creates facial
stimuli by sampling features of facial information at random spatial loca-
tion at five non-overlapping spatial frequency bands, resulting in a final
stimulus of face that is partially occluded by ‘bubbles’. Online titration
of sampling density of bubbles ensured 75 % overall accuracy for each sub-
ject. Multiple linear regression analyses between sample space (spatial lo-
cation and spatial frequency bands) and accuracy revealed salient features
of face stimuli for recognizing emotional expression. To correctly recognize
a happy face, healthy controls used both eye and mouth regions, whereas
schizophrenia patients relied primarily on mouth regions. To recognize
fear, both groups utilized eye and mouth regions. However, schizophrenia
patients relied more on higher spatial frequency for fear identification,
whereas healthy controls utilized lower spatial frequency. By revealing
how schizophrenia patients use different regions and different spatial fre-
quencies of visual information to recognize emotion, these findings 1) sug-
gest aspects of basic visual processing that can contribute to identification
errors, and 2) suggest possible rehabilitation approaches to improve of
facial emotion identification in schizophrenia.
ID: 549807
IDENTIFICATION OF SYMPTOMS THAT PREDICT
ANTIPSYCHOTIC RESPONSE IN THE TREATMENT
OF SCHIZOPHRENIA
Lei Chen, S. Ruberg, V. L. Stauffer, H. Ascher-Svanum,
S. Kollack-Walker, R. Conley, B. J. Kinon
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: Early non-response to antipsychotics is a robust predictor of
subsequent non-response to continued treatment with the same antipsy-
chotic. This analysis pursued simple decision rules using one and two
PANSS item groups to predict early response/non-response to antipsy-
chotics in the treatment of moderate-to-severely ill schizophrenia patients
with at least moderate positive symptoms. Methods: Data was pooled from
6 randomized double-blind trials of atypical antipsychotics in the treatment
of schizophrenia (N = 1494). Response was defined as a 30% reduction in
PANSS total score at 8 weeks. Predictors of response included change from
baseline in PANSS items at Week 2. Classification and regression tree
(CART) analysis was used to define a decision tree creating a predictive
model for response/non-response. Results: Analysis of individual positive
symptoms indicated a composite measure of positive symptoms worked
best. The first node of the decision tree used a 2-point decrease in at least
2 of the 5 positive symptoms from baseline to Week 2. If this response cri-
terion was not met, the second node used a 2-point decrease in the excite-
ment item. Using this algorithm, most patients (92%) were classified as
responders/non-responders with high positive (79%) and negative (75%)
predictive value. Conclusion: Using items selected from the 30-item
PANSS, a simple decision tree was found to be predictive of response/
non-response based on 2 week change on 6 individual PANSS items.
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Findings could lead to the development of a brief evaluation tool to help
guide treatment decisions early in the course of antipsychotic drug therapy.
ID: 549730
ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
ACTIVATION PREVENTS SCHIZOPHRENIA-
RELEVANT BEHAVIORAL AND MOLECULAR
CHANGES INDUCED BY REPEATED PCP
TREATMENT IN MICE
Morten Skott Thomsen1,2, D. Z. Christensen4,
H. H. Hansen2, J. Redrobe3, J. D. Mikkelsen2,5
1Neuroscience and pharmacology, University of Copenhagen,
Copenhagen N, Denmark; 2Translational Neurobiology,
NeuroSearch A/S, Ballerup, Denmark; 3Department of Behavioral
Pharmacology, NeuroSearch A/S, Ballerup, Denmark; 4Department
of Psychiatry, University of Goettingen, Goettingen, Germany;
5Neurobiology Research Unit, Copenhagen University Hospital,
Copenhagen, Denmark
Aim: To study the differential effect of phencyclidine (PCP) and the selec-
tive alpha 7 nicotinic acetylcholine receptor (nAChR) agonist SSR180711
on working memory/attention as well as their effect on the expression of
genes relevant to schizophrenia. Special focus was put on the ability of
SSR180711 to prevent changes produced by PCP. Methods: A modified
Y-maze test was used to asses working memory/attentional performance
in mice treated repeatedly with PCP and/or SSR180711, and in situ hybrid-
ization was used to correlate these data to gene expression in the prefrontal
cortex (PFC). We examined the expression of parvalbumin and synapto-
physin, which are altered in schizophrenic patients, as well as the activ-
ity-regulated cytoskeleton-associated protein (Arc), which is important
for synaptic plasticity. Results: Repeated PCP treatment (10 mg/kg/day
for 10 days) induced impairments in working memory and attention, as
measured in the modified Y-maze. This behavioral impairment was accom-
panied by a decreased expression of parvalbumin and synaptophysin
mRNA in the PFC, which corresponds to the changes seen in patients
with schizophrenia. In addition, PCP was found to increase basal
mRNA expression of the activity-regulated cytoskeleton-associated protein
(Arc) in the PFC. Activation of the alpha 7 nAChR by acute administration
of the alpha 7 nAChR agonist SSR180711 (3 mg/kg) reversed the behav-
ioral impairment produced by PCP. Importantly, repeated co-administra-
tion of SSR180711 and PCP prevented both the behavioral impairment
induced by PCP and the changes in parvalbumin, synaptophysin, and
Arc mRNA expression in the PFC. Conclusion: The alpha 7 nAChR ag-
onist SSR180711 is the first compound shown to prevent the deleterious
effects induced by repeated PCP treatment. The preventive effect of alpha
7 nAChR agonism in this PCP model suggests an involvement of the alpha
7 nAChR not only in the symptomatic relief, but also the pathophysiology,
of cognitive deficits in schizophrenia.
ID: 549623
THE USE OF FORMULAIC EXPRESSIONS IN
SCHIZOPHRENIA: A BASIS FOR IDENTIFYING
NEURAL SUBSTRATES
Christina Garidis1,6, D. V. L. Sidtis1,2, V. Tartter3,
T. Rogers1,2, J. J. Sidtis2,4, D. C. Javitt2,5
1Speech and Language Pathology, NYU, NY, NY, USA; 2Brain and
Behavior Lab, Nathan Kline Institute, Orangeburg, NY, USA;
3Psychology, City College of New York, CUNY, NY, NY, USA;
4Department of Psychiatry, NYU School of Medicine, NY, NY,
USA; 5Cognitive Neuroscience and Schizophrenia Program, Nathan
Kline Institute, Orangeburg, NY, USA; 6Brain and Behavior Lab;
Cognitive Neuroscience and Schizophrenia Program, Nathan Kline
Institute, Orangeburg, NY, USA
Background: Among various speech and language disturbances that have
been reported in schizophrenia (SZ), pragmatics of language are considered
the most affected. Within this sphere, certain types of nonliteral language
comprehension measures (eg, proverbs, idioms, indirect request) have been
investigated in SZ, which have bearing on the ability to relate socially and
emotionally. These are formulaic expressions (FEs), which are produced
spontaneously in social conversational contexts and have emotional and
attitudinal charge. They have linguistic and functional properties indicating
that they are a special class of utterances. In healthy individuals, FEs make
up over 25% of everyday speech. Studies of brain damaged individuals have
shown that FEs are processed mainly by the right hemisphere (RH) and the
basal ganglia. This study was the first to examine the production of FEs in
social and conversational settings by patients with SZ. Methods: We mea-
sured FE production in 6 patients (5 schizophrenic/1 schizoaffective), and 8
healthy controls. Instruments included an audio-recorded structured con-
versation, and formal tasks used to measure FE knowledge/production.
Results: A comparison of the production of FEs in patients diagnosed
with SZ and in controls indicated that the SZ group was comparable to
the controls in their use of FEs on formal tasks, indicating that they have
knowledge of these expressions. However, patients’ spontaneous production
ofFEs in a conversational setting was significantly diminished in comparison
to controls (P < .01), as was their performance on responsive formulas in
social settings (P < .05). A significant correlation was observed between
the lack of vocal inflections item on the SANS and the proportion of FE pro-
duction. Conclusions: These results indicate that in SZ the ability to use two
modes of language, holistic and analytic, is disturbed. Patients’ performance
was comparable to individuals with basal ganglia and RH damage. FE pro-
duction is a well-characterized and quantifiable measure of language com-
munication, which may contribute to the remediation of social cognitive
deficits in SZ. A future goal is to correlate these results with a physiological
or imaging measure in order to identify possible neural substrates involved in
diminished use of formulaic language.
ID: 549453
ROLE OF FRONTO-STRIATAL SYSTEMS IN
LEARNING AND EXECUTIVE MECHANISMS
RELEVANT TO SCHIZOPHRENIA
Trevor William Robbins
Expt. Psychology, University of Cambridge, Cambridge,
United Kingdom
The purpose is to review and re-examine the role of aberrant associative
learning mechanisms in fronto-striatal pathways in explaining both positive
symptoms and certain cognitive deficits in schizophrenia. The effects of the
NMDA antagonist ketamine on associative learning in a functional imag-
ing paradigm utilizing the BOLD response are described in normal volun-
teers and in schizophrenic patients, using a human causal learning
paradigm (collaboration with P. Corlett and PC Fletcher). These responses
will be compared with deficits in discrimination learning and set-shifting
affected by the atypical stimulant modafinil, using the id/ed paradigm
from the CANTAB battery which is related to the Wisconsin Card Sorting
Test (collaboration with D Turner and BJ Sahakian). The utility of the id/ed
test will also be examined from recent large-scale studies in schizophrenia
(collaborations with G Murray, and EM Joyce). Ketamine impaired pre-
dictive learning in volunteers and patients with schizophrenia, effects that
were associated with BOLD activations in certain regions, including the
midbrain, nucleus accumbens and dorso-lateral prefrontal cortex (DL-
PFC). The extent of the activation in DL-PFC predicted effects of higher
doses of ketamine to induce delusions outside the scanner. Modafinil im-
proved discrimination learning in the intra-/extra-dimensional set-shifting
paradigm from the CANTAB battery, (in accordance with similar data
in a related animal model of schizophrenia based on NMDA receptor
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antagonism). Results from the two parallel investigations illustrate that as-
sociative learning may be associated with positive symptoms in schizophre-
nia such as delusions, and also with impairments in executive function, such
as set formation and shifting. These deficits are sensitive to pharmacological
modification by both ketamine and modafinil. To explain these data, one
hypothesis links positive symptoms to aberrant learning mechanisms within
sub-cortical circuitry that impacts at the cortical level, and cognitive impair-
ments to additional deficits in related cortico-striatal networks at the cor-
tical level. The availability of longitudinal data for the id/ed test in a large
sample of first episode cases also enables investigation of the contribution
of basic deficits at the initial simple discrimination learning phase to the
executive impairments in set-shifting, (as well as test-retest reliability of
such deficits), over the course of the disorder
ID: 549326
LESSONS LEARNED FROM THE IMPLEMENTA-
TION OF A CLINICAL TRIAL USING THE
MATRICS-FDA-NIMH GUIDANCE
W. Rein and N. Peters
Sanofi-Aventis Research and Developement, Malvern, PA, USA
Sanofi-Aventis is currently conducting a large (;700 patients), multi-site
(;70), multi-country (US and Canada) study in patients with cognitive im-
pairment diagnosed with schizophrenia, the CONNECT study. We have ex-
perienced both opportunities and challenges using the study methodology
for this novel therapeutic approach. The study is a 24-week, multicenter,
double blind, randomized, parallel-group, dose ranging study of the efficacy
and safety of three oral doses of AVE1625, a CB1-receptor antagonist, and
placebo on top of an established treatment of either olanzapine, risperidone,
paliperidone, quetiapine or aripiprazole monotherapy. The primary end-
point is the MATRICS Consensus Cognitive Battery; the co primary end-
point for functional capacity is the UCSD Performance-Based Skills
Assessment University, 2. S-a acknowledges the many positive opportunities
this experience has provided our company, both scientifically and profes-
sionally. These opportunities include guidance from the FDA regarding
requirements for trial design and endpoints, expertise in the use of the
MCCB and UPSA2 and the establishment of relationships with many
experts in this therapeutic area. S-a’s involvement in the MATRICS-CT Sci-
entific Board as a pharmaceutical partner has also been a unique and reward-
ing experience. Challenges occurred in the following areas: limited number
countries in which to perform the study, protocol design, need for increased
financial resources and patient retention. The following actions are part of
the lessons learned: Increase the number of sites and length of enrollment, use
shorter treatment period, consider inclusion of schizoaffective diagnosis, in-
clude use of all SGAs, allow some form of combination antipsychotic ther-
apy, reconsider age limit of diagnosis, use abbreviated assessments such as
the UPSA Brief, consider all English speaking countries from the beginning
(in the absence of translations), plan for 2 day visits for ‘heavy’ assessments
weeks and consider using an inpatient setting if patients are there only for
lack of outpatient placement. In conclusion, sanofi-aventis sees this as a pos-
itive endeavor that has provided the company with many ‘Lessons Learned’
which will be beneficial in future clinical trials. Additionally, the translations
of the MCCB and development of the co primary functional outcome meas-
ures will be of importance for the upcoming studies. The company also rec-
ognizes the many experts who have helped us along the way.
ID: 549063
THE mGluR5 POSITIVE ALLOSTERIC MODULATOR,
CDPPB, HAS ANTIPSYCHOTIC EFFECTS,
IMPROVES MEMORY, AND INCREASES HEDONIA:
RELEVANCE TO SCHIZOPHRENIA.
Jason Martin Uslaner, N. O. Surles, J. D. Vardigan, S. L. Huszar,
P. H. Hutson
Schizophrenia, Merck, West Point, PA, USA
Schizophrenia ismarkedbyaclusterofbehavioralandpsychologicaldeficits,
generallyclassifiedinto3subgroups:positivesymptoms,negativesymptoms,
and cognitive deficits. Unfortunately, no currently prescribed medication ef-
fectively improves all of these symptom domains. Because accumulating ev-
idencesuggests that NMDAreceptor hypofunction underlies at least some of
the behavioral manifestations of schizophrenia and mGluR5 receptor acti-
vation is thought to positively regulate NMDA receptor function, we exam-
inedthe influenceanmGluR5positiveallostericmodulator (PAM),CDPPB,
on behavioral assays relevant to schizophrenia. CDPPB (30 mg/kg ip) atten-
uated both amphetamine (1.5 mg/kg sc) and MK-801 (0.23 mg/kg sc) induced
psychomotor activity, assays sensitive to compounds with antipsychotic po-
tential.Furthermore, CDPPB(3and10mpkip)reversedanMK-801(0.3mg/
kg ip) induced deficit innovel object recognition andpassiveavoidance learn-
ing, indicating that mGluR5 PAMs have pro-cognitive effects. Finally, we
report that CDPPB (3 mpk ip) alleviated an MK-801 (0.3 mg/kg ip) induced
deficit inhedonicvaluation,acorefeatureofnegativesymptoms,asmeasured
by the sucrose preference test. These results suggest that mGluR5 PAMs may
have a novel therapeutic profile in that they might improve all of the symp-
toms domains present in schizophrenia.
ID: 549042
SEMANTIC PRIMING ABNORMALITIES AS
PUTATIVE ENDOPHENOTYPE OF PSYCHOSIS:
AN EVENT-RELATED POTENTIAL STUDY
Stefanie Pfeifer1, N. Schiller2, J. van Os1,3, W. Riedel4,
L. Krabbendam1
1Psychiatry and Neuropsychology, Maastricht University,
Maastricht, Netherlands; 2Social Sciences and Cognitive
Psychology, Leiden University, Leiden, Netherlands; 3Psychological
medicine, Institute of Psychiatry, London, United Kingdom;
4Neuropsychology and Psychopharmacology, Maastricht
University, Maastricht, Netherlands
Background: Several studies have indicated that patients with psychosis
show an abnormal, faster and further spread of activation through the se-
mantic network (eg, Moritz et al., 2001). This has been shown in direct and
indirect semantic priming paradigms. The aim of the present study was to
investigate whether the direct and indirect semantic priming effect is a puta-
tive endophenotypic marker which is also found in first-degree relatives (sib-
lings) of patients. The study used Event-Related potentials, ie, the language
specific N400 component, as an indicator of the underlying neural correlates
of abnormal semantic priming. Method: Thirteen patients with non-affec-
tive psychosis, 14 siblings and 16 controls participated in a lexical decision
task with three conditions (directly related, indirectly related and unrelated)
and two different stimulus onset asynchronies (SOAs), 250 ms and 500 ms, to
disentangle the effect of strength of semantic associations and to control for
time differences of stimulus presentation, tapping automatic (short SOA,
hereafter SOA250) and more controlled (long SOA, hereafter SOA500) pro-
cesses. Results: For SOA250, control participants showed a N400 direct
priming effect, but no difference in the N400 component between the indi-
rect and unrelated condition. The N400 priming effect was present in all con-
ditions with SOA500, the indirect condition in-between the other two
conditions. In patients, the N400 priming effect was similar in the indirect
and the direct condition for both SOAs, and was pronounced for SOA500 in
both conditions. For SOA250, siblings showed similar results as patients (no
difference between the direct and indirect condition compared to the unre-
lated condition), indicating abnormal semantic priming processes. For
SOA500, siblings showed similar results as controls (ie, N400 priming effect
for both conditions with the indirect condition in-between). Conclusion: Ab-
normal spreading of activation in the semantic network is present in patients
with psychosis. Siblings also showed abnormal spreading of activation at the
level of automatic processing, which dissolve and become normal in more
controlled processes. Semantic priming abnormalities can be considered
a possible risk marker for psychosis.
ID: 549035
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THE CONTRIBUTION OF INTEGRATING
DISCONFIRMATORY EVIDENCE AND JUMPING
TO CONCLUSIONS TO DELUSIONS IN
SCHIZOPHRENIA
Todd Stephen Woodward1,2, W. J. Speechley1, S. Moritz3,
T. Lecomte4, E. Ngan1
1Department of Psychiatry, University of British Columbia,
Vancouver, BC, Canada; 2Department of Research, BC Mental
Health and Addictions Research Institute, Vancouver, BC, Canada;
3Klinik fu¨r Psychiatrie und Psychotherapie, Universita¨tsklinikum
Hamburg-Eppendorf, Hamburg, Germany; 4De´partement de
Psychologie, Universite´ de Montre´al, Montre´al, QC, Canada
Previous research has consistently demonstrated a bias against disconfirma-
tory evidence (BADE) and a jumping to conclusions (JTC) bias in schizophre-
nia, with some studies reporting this effect to be more pronounced in patients
currently experiencing delusions compared to those with remitted delusions.
We report evidence for correspondences between cognition and delusions in
three studies using novel versions of the BADE and JTC tasks.
Study 1. In the first study, participants were administered a version of the
BADE test, consisting of 30 delusion-neutral scenarios, for which three in-
creasingly disambiguating sentences were sequentially presented. Partici-
pants rated the plausibility of four interpretive statements that were
initially rated for plausibility based on a single scenario-descriptive sen-
tence, and were then re-rated against two subsequently presented sentences
that were either confirmatory or disconfirmatory in nature. A measure of
integration of disconfirmatory evidence discriminated between the delu-
sional schizoprenia patient group and all other groups, including non-de-
lusional schizophrenia patients, bipolar, and healthy control groups. No
group differences were observed for other measures derived from the
test, such as initial ratings prior to the introduction of disconfirmatory
evidence.
Study 2. In the second study, a JTC task was used, for which participants
rated the likelihood that a fisherman was catching a series of white and/or
black fish from two lakes with differing proportions of white and black fish
(lake A or lake B). Probability ratings in favour of the more likely lake were
higher for delusional schizophrenia patients compared to non-delusional
schizophrenia, bipolar, and healthy control groups. No group differences
were observed for ratings of the non-preferred lake.
Study 3. In a third study, individuals with schizophrenia spectrum disorders
completed a version of the JTC task involving fishing from lakes at two
timepoints 12 weeks apart. The results revealed significant negative corre-
lations between change in the number of fish requested before a decision
was made, and change in delusion scores over time. These studies provide
evidence for two independent cognitive processes underlying delusions,
a BADE and JTC, with JTC additionally demonstrating sensitivity to
changes in the severity of delusions in schizophrenia.
ID: 548989
IMPAIRED CAPACITY BUT PRESERVED
PRECISION OF VISUAL SHORT-TERM MEMORY
IN SCHIZOPHRENIA
Britta Hahn1, W. Zhang2, B. M. Robinson1,
E. S. Kappenman2, V. M. Beck2, S. J. Luck2, J. M. Gold1
1Department of Psychiatry, University of Maryland School of
Medicine, Baltimore, MD, USA; 2Center for Mind and Brain,
University of California, Davis, CA, USA
Deficits in short-term memory are consistently reported in patients with
schizophrenia, such that fewer items are remembered in delayed match
to sample paradigms. The impairment is more prominent with larger
set sizes, suggesting reduced memory capacity. However, capacity limita-
tions cannot explain persisting memory deficits at set sizes as small as one
item. The underlying problem may instead be that memory representations
are imprecise. ‘‘Noisy’’ representations would cause recall impairment at
any set size, and would also explain findings that deficits diminish when com-
parisons between sample and test items do not depend on a differentiated
level of encoding. In the present study, 22 patients with a diagnosis of schizo-
phrenia and 19 matched controls performed a visual short-term memory task
designed to independently measure memory capacity (K) and precision
(Zhang and Luck 2008, Nature 453:233). A sample array of 3 or 4 colored
squares was presented for 500 ms. After a 1 or 4 s delay, one of the previous
square locations was cued. The task was to match the color remembered at
this location as accurately as possible on a color wheel displaying the entire
spectrum. A maximum likelihood algorithm was used to derive separate esti-
mates of the number of representations that can be stored (K), and the pre-
cision of representations (average distance from true value) when the item
was present in memory. Three-factor ANOVA with group as between-
and set size and delay as within-subject factors revealed a main effect of
group on K (P = .03) but not precision (P > 0.9), reflecting significantly
reduced memory capacity in schizophrenic participants but no indication
for noisier memory representations. The reduced K in patients tended to be
more prominent with the larger set size, as reflected by a trend-level inter-
action of group with set size (P = .07). In contrast, the impairment did not
differ with delay length (P > 0.4), consistent with previous reports of nor-
mal memory decay rates. The results provide evidence against the hypoth-
esis that short-term memory impairment in schizophrenia is caused by
deficits in the precision of memory representations, at least for simple color
stimuli. Capacity reduction may limit the number of represented items;
however, the quality of these representations seems unimpaired. Alterna-
tive explanations for capacity-independent impairment in memory tasks
include transient lapses in attention or task set maintenance. Supported
by NIMH MH065034.
ID: 548429
GLOBAL COGNITIVE MEASURES AS PRIMARY
OUTCOMES IN TREATMENT TRIALS
Richard Keefe1, S. Mohamed2, C. Siu3, R. Rosenheck2, K. Fox6,
D. A. Lowe4, G. Garibaldi5, L. Santarelli5, S. Murray4
1Duke University Medical Center, Durham, NC, USA; 2Psychiatry,
Yale Medical School, West Haven, CT, USA; 3Data Power (DP),
Inc., Ringoes, NJ, USA; 4Memory Pharmaceuticals, Montvale, NJ,
USA; 5Roche Pharmaceuticals, Nutley, NJ, USA; 6NeuroCog
Trials, Inc., Durham, NC, USA
Results from large trials of patients with schizophrenia suggest that the
amount of cognitive improvement associated with second-generation anti-
psychotic treatment in chronic schizophrenia and first episode psychosis is
minimal, and may not exceed the amount of improvement that would be
expected from placebo or practice effects. Clearly, additional pharmaco-
logic and behavioral treatments are needed to improve cognition in schizo-
phrenia. Numerous large-scale trials are underway to investigate treatment
effects on cognitive impairment in patients with schizophrenia. While the
MATRICS recommendations to FDA suggested a single composite score
as the primary outcome measure for these trials, they allowed that
some trials may target more specific cognitive outcomes. General cognitive
functions measured by composite scores are more highly correlated with
real-world functioning, yet refined cognitive tests may measure abnormal
brain processes in schizophrenia with greater precision. This presentation
will discuss several recent unpublished schizophrenia cognition trials that
have used composite scores or general cognitive functions as a primary out-
come measure, and will compare these global cognitive measures to more
specific domain scores. For example, in one yet unpublished study using the
MATRICS Consensus Cognitive Battery (MCCB), preliminary data from
90 patients suggest that these general composite scores have slightly greater
test-retest reliability (ICC = 0.88) than domain scores (ICCs ranging from
0.85 to 0.64), and greater sensitivity to impairment (T-score = 28.1 6 SD =
11.5 for patients compared to 50.0610.0 for controls) than individual
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domain scores, which ranged from T = 34.1 for processing speed to T = 39.5
for reasoning and problem solving. In addition, recently analyzed data
from 794 patients treated with different antipsychotic medications in the
CATIE trial suggest that improvements in Quality of Life are more highly
correlated with improvements in overall composite scores (beta = 0.32, df
= 54,853, P < .0001) than are any of the five individual domain scores
(beta ranging from 0.09 to 0.16). This series of results suggests that while spe-
cific cognitive measures may have utility for early phase studies, currently
existing measures of general cognitive functions have proven reliability for
multisite clinical trials and clinical relevance for real-world functioning,
and should continue to serve as the standard for later phase studies.
ID: 548358
LARGE VERBAL ABILITY CONTRIBUTION TO
MSCEIT SCORES OF SOCIAL COGNITION IN
SCHIZOPHRENIA
Bruce E. Wexler1, W. Zito1,2, T. C. Greig1, M. D. Bell1,2
1Psychiatry, Yale University School of Medicine, New Haven, CT,
USA; 2Psychology, VA CT Medical Center, West Haven, CT, USA
The Emotion (EM) and Social Management Tasks (SM) tasks from the
MSCEIT are included in the MATRICS battery to assess social cognition.
Unlike other subtests of the MATRICS, which have ample support from
previous literature, these two tasks have not had much prior use in schizo-
phrenia research. Both tasks require verbal comprehension and memory for
written narrative. These prerequisite neurocognitive abilities may reduce
the validity of these tasks as measures of social cognition. Given the prom-
inence of language function deficits, it is important to consider their poten-
tial contributions to performance when using the EM and SM tasks to
evaluate social cognition in schizophrenia. Method: 45 stable outpatients
with schizophrenia completed a battery of neurocognitive and social cog-
nitive assessments, which included the MATRICS battery. Pearson corre-
lations were computed for scores from the MSCEIT tasks and measures of
verbal ability (HVLT Total, WAIS Digit Span, WAIS Vocabulary, WMS
Logical Memory I (LM-I), WAIS Letter-Number Sequencing); and also
with other social cognitive tasks (Bell Lysaker Emotion Recognition
Test (BLERT), Hinting Task, Social Attribution Test—Multiple Choice
(SAT-MC)). Results: The MSCEIT social cognition tasks correlate sub-
stantially with WMS LM-I (EM: r = .63; SM: r = .63; P’s < .001) and
WAIS Vocabulary (EM: r = .51; SM: r = .54; P’s < .001). MSCEIT tasks
do not correlate significantly with Hinting Task nor SAT-MC, although we
found smaller associations with the BLERT (EM: r = .37; SM r = .31; P’s<
.05). However, when partial correlations were computed to remove vari-
ance associated with WMS LM-I from r(BLERT, EM) and from r(BLERT,
SM), those relationships were no longer significant (EM: r = .20; SM: r =
.12). To appreciate the magnitude of the effect, all six verbal tasks were
regressed on EM and again on SM. Verbal tasks significantly predicted
37% (P < .01) and 51% (P < .001) of the variance, respectively. In com-
parison, the verbal tasks failed to significantly predict Hinting Tasks or
SAT-MC scores and predicted 32% of the variance on the BLERT (P <
.05). Conclusions: Findings indicate that EM and SM may be more closely
related to verbal ability, particularly story recall, than they are to social
cognition. Given these results, when using EM and SM in schizophrenia
research, the effects of compromised verbal abilities must be considered be-
fore making inferences about social cognition.
ID: 548117
A REVERSE TRANSLATIONAL APPROACH TO
CHARACTERIZING EXPLORATORY BEHAVIOR
AND MOTOR ACTIVITY IN SCHIZOPHRENIA AND
BIPOLAR-MANIA
William Perry, A. Minassian, J. Young, B. Henry, M. A. Geyer
Psychiatry, University of California, San Diego, La Jolla, CA, USA
Schizophrenia and bipolar-mania are recognized as separate disorders but
share many commonalties and are considered by some to be the same dis-
order on a continuum. Exploration is a behavior that is fundamental to
survival and is dysregulated in neuropsychiatric disorders such as schizo-
phrenia and bipolar-mania. Exploratory behavior in rodents has been stud-
ied for decades but surprisingly little work has examined this critical
function in humans. In the present study we characterize exploratory be-
havior as a potential endophenotype that may help distinguish between
schizophrenia and bipolar mania and offers promise as a useful transla-
tional paradigm. We developed a novel human open field paradigm, the
Behavioral Pattern Monitor (BPM), to quantify exploratory behavior of
individuals with schizophrenia and bipolar-mania and to identify distinc-
tive phenotypes of these illnesses. We also studied several putative mouse
models to determine their consistency with the results of our human studies.
We found that schizophrenia subjects demonstrated a pattern of explor-
atory behavior that was distinct from patients with bipolar-mania. Namely,
Bipolar-manic subjects exhibited significantly higher motor activity and ob-
ject exploration while schizophrenia patients did not show the expected ha-
bituation of motor activity. Furthermore, measures from the human BPM
classified schizophrenia and bipolar-mania subjects with better sensitivity
and specificity than did symptom scores. When testing the mouse models,
genetic or selective pharmacological inhibition of the dopamine transporter
matched the bipolar-mania phenotype better than the ‘‘gold standard’’
model of mania (amphetamine). These findings serve to validate the human
open field paradigm and to distinguish defining characteristics that differ-
entiate schizophrenia and bipolar-mania. This cross-species study of explo-
ration has allowed us to challenge an accepted animal model and develop
more accurate human and animal models, which are essential to identify
neurobiological underpinnings of neuropsychiatric disorders. Supported
by an NIH award R01-MH071916.
ID: 546403
THE SOCIAL ATTRIBUTION TEST IN SCHIZO-
PHRENIA: COMPARISON WITH HEALTHY
CONTROLS AND RELATIONSHIP TO
NEUROCOGNITIVE AND SOCIAL COGNITIVE
MEASURES
Tamasine Greig1, W. Zito1,2, B. Wexler1, J. Fiszdon1,2,
M. D. Bell1,2
1Psychiatry, Yale University School of Medicine, New Haven,
CT, USA; 2Psychology, VA CT Medical Center, West Haven,
CT, CT, USA
Impairments in social cognitive processes including attribution failures are
a possible source of poor community functioning in schizophrenia and
a possible target for interventions. However, there are few procedures avail-
able for the study of attributions, particularly measures that are not heavily
dependent on verbal ability. In a study of adolescents and adults with
Aspergers Syndrome (AS) and high functioning autism, Klin (2000) created
a scoring procedure for attributions using Heider and Simmel’s 1944 silent
cartoon animation in which geometric shapes enact a social plot. Subject
narratives were coded in terms of the participants’ abilities to attribute so-
cial meaning to the geometric cartoon. Results revealed marked deficits in
both clinical groups, and these were unrelated to verbal IQ or metalinguistic
skills. Based on these findings, a multiple choice version of this task was
developed (SAT-MC) and used for the first time in the current study to
assess adults with schizophrenia (n = 25). This clinical sample was compared
with adults attending community college who were screened for psychiatric
illness (Community Controls (CC) n = 85). Correlations between SAT-MC
scores and neurocognitive and social cognitive measures were also per-
formed. Results revealed significantly poorer performance for the schizo-
phrenia sample (sz mean (sd) = 9.8 (5.07); CC = 15.3 (2.9) P< .001). As with
findings in the AS sample, SAT-MC scores were not significantly related to
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WAIS Vocabulary, WMS Logical Memory I or WMS Logical Memory II.
Correlations with the MATRICS indices (not including social cognition)
were also not significant. However, correlations with other social cognition
measures (Bell Lysaker Emotion Recognition Test (BLERT), Hinting
Task, Social Management and Emotion Management (from MATRICS)
revealed significant associations with the BLERT (r = .42, P < .001)
and with the Hinting Task (r = .24, P < .05), but not the MATRICS meas-
ures. These results support the use of the SAT-MC for further explorations
of social attribution deficits in schizophrenia and may serve as a potential
link for understanding similarities and differences in the social deficits of
autism and schizophrenia.
Reference
1. Klin A. Attributing social meaning to ambiguous visual stimuli in high-
er-functioning autism and aspergers syndrome: the social attribution
test. J. Child Psychol. Psychiat. 2000;7:831–846.
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EMOTION RECOGNITION PERFORMANCE
AMONG ADOLESCENTS AT GENETIC HIGH RISK
FOR SCHIZOPHRENIA.
Diana Mermon1, S. Eack1, D. Montrose1, J. Miewald1, M. Keshavan1,2
1Neurobiology Psych, University of Pittsburgh, Pittsburgh, PA,
USA; 2Department of Psychiatry, Wayne State University, Detroit,
MI, USA
Background: Studies have shown that people with schizophrenia and their
non-psychotic relatives have deficits in emotion recognition, a measure of
social cognition. There are few published data on emotion recognition in
adolescents at risk for schizophrenia. The relation of such deficits to cog-
nitive and psychopathological measures is also unclear. Methods: Partici-
pants, recruited through the Pittsburgh Risk Evaluation Program, include
70 first- and second-degree adolescent relatives of individuals with schizo-
phrenia (HR) and 63 healthy comparison (HC) subjects. Subjects were
assessed using the Penn Emotion Recognition Test, a timed test which
requires subjects to assign emotion (Happy, Sad, Anger, Fear, No emotion)
to 40 faces. Results: HR individuals were significantly more likely to over-
attribute emotions to neutral faces (P = .017), with such individuals fre-
quently misinterpreting neutral faces as negative. In addition, at-risk indi-
viduals had significantly greater reaction times when completing emotion
recognition tasks, regardless of valence (P = .002). Impairments in neuro-
cognition were largely independent of social-cognitive performance (range
of r = .06 to .19), and emotion recognition impairments persisted after
adjusting deficits in neurocognitive function. Further, social-cognitive
impairments in the interpretation of neutral faces were significantly asso-
ciated with greater positive (r =.36, P = .002) and general prodromal psy-
chopathology (r = .36, P = .002), whereas neurocognitive impairments
were only associated with disorganization (r = .46, P < .0001). Conclu-
sions: HR children appear to have deficits in emotion recognition, similar to
that of patients with schizophrenia, and perhaps independent of non-social
cognitive deficits. It is unclear whether these deficits represent an additional
risk factor for developing a psychotic disorder. Specific, targeted training
may be helpful in reducing the impact of poor social cognition in at-risk
individuals. Longitudinal studies are needed to ascertain the long-term im-
pact of social cognition deficiencies.
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TRANSLATING SCIENCE INTO ACTIVE INGRE-
DIENTS: OPTIMIZING COGNITIVE TRAINING
APPROACHES IN SCHIZOPHRENIA
Sophia Vinogradov1, M. Merzenich4, A. Medalia3, B. Wexler2
1Psychiatry, University of California, San Francisco, San Francisco,
CA, USA; 2Psychiatry, Yale University, New Haven, CT, USA;
3Psychiatry, Columbia University, New York, NY, USA; 4Physiology,
University of California, San Francisco, San Francisco, CA, USA
One of the greatest challenges for 21st century biomedicine is to develop an
effective treatment for the cognitive dysfunction of schizophrenia. Cogni-
tive remediation trials have demonstrated some efficacy, but recent meta-
analytic work reveals a glass ceiling of low to medium effect sizes across
a wide variety of methods. How can we break through this glass ceiling
and optimize the benefits of cognitive training in schizophrenia? How
do we translate science into ‘‘active ingredients’’ for successful behavioral
approaches to cognitive enhancement? We will start our analysis with an
examination of the basic neuroscience evidence on the ‘‘active ingredients’’
that promote widespread neuroplasticity in cortex and in subcortical neuro-
modulatory systems during successful learning. What are the implications
of these basic science findings? How can they be successfully translated into
human interventions? Next, we will move to the level of the clinical encoun-
ter, by exploring the science behind the ‘‘active ingredient’’ of participant
engagement and motivation. How does participant motivation relate to
outcome? How do findings from educational psychology inform the design
of maximally engaging cognitive training programs for persons with schizo-
phrenia? Finally, we will turn to the human laboratory as we investigate the
science behind the ‘‘active ingredient’’ of training-induced brain plasticity.
We will present fMRI, MEG, and serum biomarker evidence of neural
changes associated with intensive computerized cognitive training. What
do these findings tell us about the underlying mechanisms of cognitive im-
provement in patients with schizophrenia? How can we optimally harness
these mechanisms in the design of cognitive training exercises? At all levels
of analysis, our vision will be to create optimally effective restorative cog-
nitive training approaches for people with schizophrenia.
ID: 542178
EMOTION CATEGORIZATION PERCEPTION IN
SCHIZOPHRENIA: EFFECT OF SOCIAL CONTEXT
DURING CONVERSATIONS
Jia Huang1,2, R. C. Chan1,3, X. Lu4, Z. Tong4
1Psychology, Sun Yat-Sen University, Guangzhou, China; 2Faculty
of Life Sciences, Sun Yat-Sen University, Guangzhou, China;
3Institute of Psychology, Chinese Academy of Science, Beijing,
China; 4Guangzhou Brain Hospital, Guangzhou, China
Increasing evidence suggests that context plays an important role in the
cognitive activities of schizophrenia and their context processing is im-
paired, it would be necessary to examine the impact of social dyadic in-
teraction to the emotional perception. The purpose of the current study
was to investigate the response patterns of patients with schizophrenia
within a continuum of facial expression in different scenarios of social con-
text. In particular, it aimed to investigate whether the boundaries between
happy and angry emotions of schizophrenia would be influenced by the
social context and whether there is any difference in the emotion catego-
rization boundary between schizophrenia and healthy control. Eighteen
patients with schizophrenia and sixteen healthy controls were
administered a forced-choice emotion identification task in which they
were required to attend to a series of conversations with different social
context. Stimuli were linear morphed facial expressions between emotion
‘happy’ and ‘angry’. For each type of social context, measures of response
slope and the location of the boundary shift point between ‘happy’ and
‘angry’ were calculated. The schizophrenia group demonstrated no signif-
icant difference in the boundaries of emotion categorization perception of
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four types of conversations in different social context. Compared with
healthy control, the schizophrenia group demonstrated a steeper slope
at the shift point regardless of the conversation type. The results might
suggest that the categorization of emotion perception in patients
with schizophrenia was less discriminative during the conversations
with different social context. However, when the signal strength increased
from the left pole to the right one independent of the social context,these
patients were more alert to angry facial expression.
Table. Slope and mean signal threshold difference in two groups
Question
type
Mean Slope (std) Mean signal threshold (std)
Schizophrenia
(n = 18)
Healthy
control
(n = 16) t
Schizophrenia
(n = 18)
Healthy
control
(n = 16) t
blame 1.641 (0.261) 0.825 (0.126) 3.98* 6.176 (0.286) 5.847 (0.143) 1.46
Control
mask
1.803 (0.294) 0.766 (0.093) 4.76** 6.386 (0.314) 6.104 (0.106) 1.2
inquiry 1.919 (0.268) 0.749 (0.062) 6.02** 6.415 (0.282) 6.335 (0.071) 0.38
praise 1.899 (0.226) 0.800 (0.116) 6.12** 6.411 (0.238) 6.56 (0.132) 0.77
*P < .05; **P < .01
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A NOVEL SCHIZOPHRENIA MODEL ESTABLISHED
BY SUBCUTANEOUSLY INJECTING A CYTOKINE
TO A CYNOMOLGUS MONKEY NEONATE
Hiroyuki Nawa1, T. Someya2, M. Sakai2
1Molecular Neurobiology, Brain Research Institute, Niigata
University, Niigata, Japan; 2Psychiatry, Niigata University,
Graduate School of Medicine and Dentistry, Niigata, Japan
Inflammatory cytokines are implicated in the developmental hypothesis of
schizophrenia, as human fetuses and neonates are exposed to high concen-
trations of these factors in response to infection, inflammation and brain
injury. Our previous postmortem studies also support the biological impor-
tance of the cytokines (EGF, IL-1, and NRG) to its neuropathology. Based
on these findings, we have established rodent models for schizophrenia by
subcutaneously administering these cytokines to mouse and rat neonates.
For example, the rodent model with EGF exhibits various behavioral ab-
normalities in acoustic startle response, prepulse inhibition, latent learning,
social interaction, and sensitivity to psychostimulants, most of which can be
ameliorated by subchronic treatment with atypical antipsychotics. In con-
trast, its gross learning ability and brain structures appeared to be normal.
Because of the given behavioral differences between rodents and human,
however, it is difficult to fully evaluate validity and implication of this
model in schizophrenia pathology. To address this issue, we attempted
to establish a primate model, subcutaneously administering EGF to a cyn-
omolgus monkey neonate (2 week postnatal) in 2002. The monkey has
grown without any apparent physical abnormality. After adolescence, how-
ever, the monkey exhibits various behavioral abnormalities, including bi-
pedal hyper-locomotion, stereotypic movement, vocalization, cautious
stance, and self-injury. The self-injury is always initiated with cautious
stance and touching eyes with hands, potentially reflecting visual halluci-
nation. Some of the behavioral deficits are attenuated by subchronic treat-
ment with risperidone. The behavioral abnormalities of this primate model
are more distinguished in comparison with those induced by amphetamine
or phencyclidine. Although the replication of this study is required, the
present observation suggests the possibility that endogenous EGF circulat-
ing in the periphery has significant impact on behavioral development of
prenatal and perinatal primates including human. Note; The monkey
experiments were performed in Shin Nippon Biomedical Laboratories,
Ltd (Kagoshima, JAPAN) in accordance with the Guiding Principles for
the Care and Use of Laboratory Animals approved by the Japanese Phys-
iological Society.
ID: 537649
BRIDGING THE GAP BETWEEN SCHIZO-
PHRENIA AND PSYCHOTIC MOOD DISORDERS:
RELATING NEUROCOGNITIVE DEFICITS TO
PSYCHOPATHOLOGY
Matthew James Smith1, D. M. Barch2,3, J. G. Csernansky1
1Psychiatry and Behavioral Sciences, Northwestern University,
Chicago, IL, USA; 2Psychology, Washington University, St. Louis,
MO, USA; 3Psychiatry, Washington University, St. Louis, MO, USA
Background: The neurobiological relationship between schizophrenia and
psychotic mood disorders (PMD) is not well understood. Neurocognitive
deficits have been described in both types of disorders and have been pro-
posed to reflect underlying neurobiological dysfunction. Examining the re-
lationship between neurocognitive function and psychopathology could
help illuminate the neurobiological relationship between schizophrenia
and psychotic mood disorders. Methods: Participants included 72 individ-
uals with DSM-IV schizophrenia, 25 individuals with a psychotic mood
disorder, and 72 community controls. Standardized scores and correlations
between four domains of neurocognition and psychopathology were exam-
ined. Results: Individuals with schizophrenia and psychotic mood disorders
scored similarly on several dimensions of neurocognitive function and psy-
chopathology. The relationships between neurocognitive function and psy-
chopathology were similar in the two groups. Conclusions: Individuals with
schizophrenia and psychotic mood disorders were similar in terms of both
the level of impairment in neurocognitive function and psychopathology, as
well as in the relationship between the two dimensions of illness. These
results suggest that schizophrenia and psychotic mood disorders such as
schizoaffective disorder and bipolar disorder with psychotic features are
on a neurobiological continuum.
Table. Correlations between Neurocognition and Psychopathology
Among SCZ and PMD
SCZ
(n = 72)
PMD
(n = 25) Fisher’s z
Working Memory and Negative
Symptoms
0.262* 0.383þ 0.55
Working Memory and Disorganized
Symptoms
0.355** 0.179 0.68
Episodic Memory and Negative
Symptoms
0.275* 0.489* 1.03
Episodic Memory and Disorganized
Symptoms
0.370** 0.062 1.33
Executive Function and Negative
Symptoms
0.305** 0.238 0.30
Executive Function and Disorganized
Symptoms
0.284* 0.177 0.46
IQ and Disorganized Symptoms 0.231* 0.091 0.59
**P < .01, *P < .05, þP < .06 denote significance within group; Fisher’s z
signifies statistical difference between groups.
ID: 537431
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METACOGNITION ACTIVATES A CONSISTENT
NETWORK DURING DIFFERENT TASKS
Richard James Drake1, K. Kala1, S. McKie1, R. Elliott1,
D. Koren2, S. W. Lewis1
1Psychiatry Research Group, University of Manchester,
Manchester, United Kingdom; 2Department of Psychology,
University of Haifa, Haifa, Israel
Metacognition (which can be said to involve monitoring the quality—eg,
accuracy—of object-level knowledge and using this to guide behaviour)
correlates with insight more strongly than any other neuropsychological
test during first episodes of schizophrenia; and recent studies in samples
with and without schizophrenia suggest that it is a critical determinant
of real-world competence. This study investigated the neural activation
produced by metacognitive processes during various cognitive tasks in
those without illness, as a precursor to studying sufferers. We hypothesized
that meta-level monitoring and control of different object-level cognitive
tasks would activate the same specific network. 12 right-handed males
without psychiatric illness performed three tasks during fMRI imaging
in a 1.5T scanner, using a randomized, repeated block design. One task
was a based on set shifting, another word recognition, the third judging
line length. Each task had two forms: one with a heavy metacognitive
load; and a control with minimal metacognitive load. For each task the
response during blocks of control versions of tasks was contrasted with
that for metacognitive blocks, using version as a cofactor in ANOVAs
for each task. Activation of a consistent, almost entirely bilateral network
of clusters was specifically demonstrated by each task contrast: BA8/9/32;
middle frontal gyrus; inferior frontal gyrus/insula; inferior parietal lobule;
and posterior cerebellum. Contrasting metacognitive and control condi-
tions across all tasks gave a similar result. This form of the construct
of metacognition appears meaningful, recruiting consistent processes in
different tasks. Activation suggested, for instance, action monitoring,
online assessment and calculation; and decision making. Comparison
with schizophrenia sufferers is likely to be instructive and may illuminate
insight’s processes.
ID: 550826
HIGH NAILFOLD PLEXUS VISIBILITY IN
SCHIZOPHRENIA IS ASSOCIATED WITH
A DISTINCT NEUROPSYCHOLOGICAL PROFILE
AND LESS VENTRICULOMEGALY
John P. Vuchetich, S. K. Miranowski, B. A. Mueller, K. O. Lim
Psychiatry, University of Minnesota Medical School, Minneapolis,
MN, USA
High nailfold plexus visibility (High NPV) has been demonstrated to iden-
tify a subtype of schizophrenia characterized by more negative symptoms
and lower occupational and social functioning. High NPV has been pro-
posed as a schizophrenia endophenotype. We have been further character-
izing the High NPV phenotype in preparation for family and genetic
studies, using clinical, neuropsychological, and brain imaging measures.
Despite the apparent negative functional consequences of this trait, the
one previous brain imaging study of High NPV in schizophrenia unexpect-
edly found that patients with elevated NPV had less ventriculomegaly than
their fellow patients. In this preliminary analysis of 30 patients along with
their controls, we confirmed that High NPV schizophrenia patients have
more negative symptoms on the SANS (d = .41). We have previously shown
that this trait is independent of the Deficit Syndrome, and this finding is
strengthened by controlling for deficit status (d = 1.07, P = .03). However,
the High NPV patients also show higher educational achievement than their
fellow patients (t25 = 8.14, P< .01) and score significantly better on several
neuropsychological tests, including frontally mediated tasks such as the
Delayed Response Test, Verbal Fluency, and the RBANS Visual Construc-
tive Index. Furthermore, the High NPV patients exhibited less ventriculo-
megaly based on structural MRI (t25 = 4.56, P = .04). This replicates the
earlier finding of Curtis et al. Given that most of our findings show better
cognitive functioning and more normative brain structure in the High NPV
patients, it is surprising that such patients have generally been found to have
a poorer social and occupational outcome. Much of this may stem from
their elevated level of negative symptomatology. We have also observed
evidence of worse white matter tract disruption based on DTI brain imaging
in earlier pilot work with High NPV patients. We will be analyzing DTI
data in the next steps of the current study.
ID: 551907
BEHAVIORAL DIFFERENCES IN RECOMBINANT
INBRED MOUSE STRAINS SELECTED FOR
GENETICALLY-INFLUENCED VARIATION IN
CORTEX AND THALAMUS VOLUME
Hongxin Dong1, N. Hicklin2, C. Yuede3, T. Taylor4, J. Cheverud5,
J. G. Csernansky1
1Psychiatry and Behavioral Sciences, Northwestern University
Feinberg School of Medicine, Chicago, IL, USA; 2Neurology,
Washington University School of Medicine, St Louis, MO, USA;
3Psychiatry, Washington University School of Medicine, St Louis,
MO, USA; 4Anatomy and Neurobiology, Washington University
School of Medicine, St Louis, MO, USA; 5Behavioral Neuroscience,
University of Missouri, St Louis, MO, USA
In previous studies, we have shown that patients with schizophrenia have
correlated reductions of gray matter in the cerebral cortex and thalamus. In
the present study, we tested the hypothesis that these associated neuroan-
atomical phenotypes may be impacted by shared genetic influences. Using
BXD recombinant inbred (RI) mice, we found significant QTLs that re-
lated to cortex and thalamus volumes (Dong et al. 2007). To determine
the behavioral consequences of this complex neuroanatomical phenotype,
we selected 10 BXD strains known to exhibit either large (BXD strains 1, 5,
12, 15 and 22) or small (BXD strains 2, 6, 24a, 29 and 33) cortex and tha-
lamic volumes and tested them on a number of behavioral paradigms re-
lated to cortical and thalamic functions as well as schizophrenia. Our
results shown the significant differences between strains in terms of an anx-
iety measure, the elevated plus maze (P < .05); a sensory motor battery
(P < .05); and a measure of higher-order attentional processes, attentional
set shifting (P < .05). Those strains associated with a larger cortex and
thalamus displayed significantly more time in the open arms of the plus
maze, finer sensory motor skills, and greater ability to shift attention be-
tween relevant dimensions. These results support our hypothesis and pre-
vious findings that these behavioral paradigms are dependent on cortex
and thalamus function. Moreover, to the behavioral variation observed
in the strains with a smaller cortex and thalamus may be relevant to
the dysfunctions characteristic to schizophrenia and other neuropsychiat-
ric disorders. Further, we then applied immunohistological techniques us-
ing calcium-binding parvalbumin and calbindin in order to characterize
strain differences in interneuron number in the mediodorsal thalamic nu-
cleus and the cingulate cortex. While parvalbumin staining analysis did not
show any significant differences (P > 0.05), the number of calbindin-pos-
itive neurons showed a trend favoring an increased number of such inter-
neurons in the strains with larger cortex and thalamus volumes (P = .054).
Together, these results illustrate the value of recombinant inbred strains of
mice as model systems to investigate the genetic basis for neurobiological
abnormalities that have been associated with schizophrenia.
ID: 551810
International Congress on Schizophrenia Research
18. 18. Cognitive Neuroscience 253
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
FEAR EXTINCTION STUDIES IN CALCYON
TRANSGENIC MICE POINT TO EFFECTS
ON PREFRONTAL CORTEX MATURATION AND
FUNCTION
Clare Bergson1, A. Vazdarjanova2
1Pharmacology and Toxicology, Medical College of Georgia,
Augusta, GA, USA; 2Synapses and Cognitive Neuroscience,
Medical College of Georgia, Augusta, GA, USA
Calcyon is a neuronal protein that regulates clathrin mediated endocytosis
of AMPA receptors in brain presumably via interaction with clathrin light
chain. The calcyon gene is present only in mammals, and postmortem stud-
ies suggest that both the protein and mRNA are significantly elevated in
schizophrenics. However, whether calcyon up-regulation relates to etiology
of schizophrenia or is merely a bi-product of the disease process is un-
known. Thus, we created CalOE transgenic mice that express the human
calcyon gene in forebrain in order to learn whether up-regulation of calcyon
is sufficient to alter behavior. Initial studies revealed an impact on behav-
ioral control as the CalOE mice are hyperactive and exhibit reduced anxiety
or impaired restraint. Here, we examined whether up-regulation of calcyon
impairs hippocampal synaptic plasticity and/or cognitive flexibility. We
trained CalOE and control littermates to associate a spatial context with
an aversive event. Then we tested how quickly they learn that the emotional
valence of the context has changed by exposing them to the training context
without footshock (extinction). Although both groups learned the initial
association equally well, CalOE mice were impaired in extinction. Remark-
ably, the extinction deficits were reversed by shutting off high levels of cal-
cyon during adolescence with a dose of doxycycline that silences calcyon
transgene expression in the hippocampus, cortex and amygdala. These find-
ings suggest that calcyon over-expression in the forebrain leads to cognitive
deficits associated with switching the emotional valence of fear-associated
stimuli. The data are also consistent with reduced cognitive flexibility po-
tentially due to alterations in prefrontal cortex maturation. As such, they
suggest that CalOE mice would be useful for modeling and manipulating
this drug refractory aspect of schizophrenia.
ID: 551797
TRANSLATING THE BASIC SCIENCE OF LEARN-
ING-INDUCED NEUROPLASTICITY INTO HUMAN
INTERVENTIONS
Michael Merzenich
1UCSF, San Francisco, CA, USA; 2Posit Science Corp, San
Francisco, CA, USA
A large body of animal and human experiments have now richly documented
the neurological basis of ‘‘adult (post-critical period) neuroplasticity’’. Other
studies have documented the neurological bases of perceptual, cognitive and
motor deficits that limit the performance abilities of a variety of psychiatri-
cally- and neurologically-impaired child and adult patient populations. We
have combined these lines of investigation by creating animal models that
exhibit deficits that arise in developmental and acquired-adult disabilities
or ‘disease’, then engaged animals in intensive forms of ‘cognitive training’
designed to ameliorate or reverse those neurological deficits. Combined
with human studies, these experiments have now shown that most aspects
of negative change paralleling the emergent expressions of psychiatric or neu-
rological illness are reversible. We have used this science to develop specific
training strategies targeting developmental (in language, reading and cogni-
tion) and acquired adult impairments and disease (schizophrenia, normal and
pathological aging, TBI, acquired motor deficits). We shall briefly summarize
the basic principles guiding this novel approach, and illustrate and contrast it
with more conventional ‘cognitive therapy’ training strategies.
ID: 551782
EARLY VISUAL PROCESSING DEFICITS AS
A PRECURSOR TO EMOTION RECOGNITION
DEFICITS IN SCHIZOPHRENIA; AN EVENT-
RELATED POTENTIAL STUDY
Ilana Y. Abeles1,3, E. C. Dias1, N. Weiskopf1, D. C. Javitt1,2,
P. D. Butler1,2
1Schizophrenia Research Center, Nathan Kline Institute, Orange-
burg, NY, USA; 2Department of Psychiatry, New York University
School of Medicine, New York, NY, USA; 3Program in Cognitive
Neuroscience, City University of New York, New York, NY, USA
The purpose of this study was to investigate contributions of early visual
processing deficits to emotion recognition dysfunction in patients with
schizophrenia (SCZ). SCZ show deficits in early visual processing, as evi-
denced by preferential magnocellular (M) system dysfunction. SCZ also
show deficits in face emotion recognition, but have been shown to have
intact experience of emotion, indicating that emotion recognition deficits
are not a result of emotion processing problems per se. Thus, we examined
the contribution of physical aspects of faces to emotion processing deficits
in SCZ. Ekman and Friesen faces (fear, happy, sad, neutral) were presented
(500 ms) at 3 contrasts (4%, 12%, and 96%). The lower contrast images bias
processing towards the M pathway. Behavioral performance and event-re-
lated potentials (ERPs) (72 channel BioSemi system) were obtained in sep-
arate sessions. In the ERP study, attention to task was monitored by an
implicit task: participants pressed a button to a target picture of a flower
that was shown 20% of the time. In the behavior task, SCZ showed im-
paired emotion recognition at each contrast. Controls performed well
(80% correct) at even the lowest contrast (4%), whereas SCZ only reached
55% correct at this contrast. ERPs showed decreased P1 amplitude at each
contrast in SCZ compared to controls. In addition, SCZ needed 96% con-
trast to obtain or approach control levels at 4% contrast in both behavioral
performance and P1 amplitude. In conclusion, the relatively intact behavioral
performance by controls at 4% contrast indicates that they are able to rec-
ognize emotions using only M-biased information, whereas patients have dif-
ficulty using the M-pathway for emotion recognition. Decreased P1
amplitude suggests impaired early visual processing in response to face emo-
tion stimuli in SCZ. These results support the hypothesis that impaired ability
to use physical attributes of face emotion stimuli (ie, contrast) contributes to
emotion processing deficits in SCZ and builds upon previous studies showing
contrast sensitivity deficits to more basic stimuli in SCZ. Supported by
NIMH RO1 MH66374, R37 MH49334 and K02 MH01439.
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A META-ANALYTIC REVIEW OF OLFACTORY
FUNCTION IN SCHIZOPHRENIA
Paul Joseph Moberg1,2, D. Marchetto1, Z. Liapis4,1, V. Kamath3,1,
K. Borgmann-Winter1, B. Turetsky1,2
1Psychiatry, University of Pennsylvania, Philadelphia, PA, USA;
2Otorhinolaryngology: Head and Neck Surgery, University of
Pennsylvania, Philadelphia, PA, USA; 3Psychology, University of
Central Florida, Orlando, FL, USA; 4Psychology, Hanover College,
Hanover, IN, USA
The study of olfactory deficits in patients with schizophrenia has been
a topic of increasing interest. A previous meta-analysis of this literature
by our group revealed large effect sizes across various olfactory tasks
that appeared to be relatively unaffected by potential moderator variables.
These data suggested that olfactory dysfunction may be a central feature of
this disorder and may reflect aberrant neurodevelopment in these sensory
brain regions. As this literature has grown exponentially since our original
1999 study, the aim of the current meta-analysis was to expand the prior
study through the inclusion of a greater number of studies, examination of
different olfactory test types, and expanding the potential moderator
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variable analyses. A thorough review of the literature concerning olfactory
function in schizophrenia was conducted and relevant studies were
extracted using a Quality of Reporting of Meta-analysis standard. Review
and application of exclusionary criteria yielded 111 studies out of 56 pub-
lications available for meta-analysis. All analyses were subsequently con-
ducted using the Comprehensive Meta-Analysis—2.0 software package.
Using a random effects model, results revealed that the overall effect
size (d) for olfactory processing tasks across all studies was -0.81 [95%
CI = -0.69 < d<-0.93], which fell in the range of a ‘‘large’’ effect using
Cohen’s 1988 criteria. Homogeneity analysis revealed significant heteroge-
neity among study effect sizes that supported the examination of possible
moderator variables (QB[110]=539.98, P < .001). In order to understand
the variability among effect sizes, psychophysical, clinical and demographic
variables that might explain this heterogeneity were examined. These anal-
yses revealed significant contributions to the magnitude of the olfactory
deficit by psychophysical task type (ie, odor identification v. threshold,
v. memory, v. hedonics), presentation type (ie, birhinal v. unirhinal), age
of onset, duration of illness, medication type, and sex. Overall, the findings
from the current meta-analytic review suggest a large magnitude deficit in
olfactory function that appears to vary by the domain of olfactory function
assessed. In addition, various moderator variables appear to have a signif-
icant positive or negative impact on these deficits and warrant consider-
ation in future prospective studies. Funded in part by NIMH grants
MH-63381 (Dr. Moberg), MH-59852 (Dr. Turetsky), and an Independent
Investigator Award from the NARSAD/Hofmann Trust (Dr. Moberg).
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LEARNING-RELATED PATTERNS OF
HIPPOCAMPAL FUNCTIONAL CONNECTIVITY IN
SCHIZOPHRENIA
Michele Korostil1,2, S. Kapur1,3, M. Tassopoulos2, M. Menon1,
A. R. McIntosh2
1Schizophrenia Program, Ctr for Addicition and Mental Health,
Univ of Toronto, Toronto, ON, Canada; 2Rotman Research Inst,
Baycrest—Univ of Toronto, Toronto, ON, Canada; 3Section on
Schizophrenia, Imaging and Therapeutics, Institute of Psychiatry,
Kings College, London, United Kingdom
We explored the brain-behaviour relationship of practice-related learning
in schizophrenia in an fMRI experiment using an associative language par-
adigm developed by Breitenstein and Knecht (J Neuro Methods, 2002). The
paradigm measures the acquisition of a novel lexicon by pairing pseudo-
words with object drawings. Six subjects with a diagnosis of schizophrenia,
stabilized on atypical antipsychotics, were matched with eight healthy con-
trol subjects. All participants were tested in two sessions: the first to accli-
mate to the fMRI scanning environment and practice the task, and the
second to learn the novel language in the scanner. Both groups showed
equal rates of learning. Imaging data were acquired in 5 successive runs.
The data were analyzed using multivariate partial least squares (PLS) anal-
ysis to capture the full spatiotemporal pattern as subjects learned. Both
groups showed linear decreases in dorsal medial prefrontal and occipitopar-
ietal cortices. Increases were noted in retrosplenial, anterior temporal cor-
tices, and medial fusiform gyrus. Hippocampal engagement occurred early
in the session for controls, but much later in patients despite roughly equiv-
alent behavioural performance. Given the theoretical interest in the hippo-
campus, we examined its functional connectivity across sessions for each
group. Consistent with the activation differences, the functional connec-
tions in controls were most stable in early in learning with strong interac-
tions of the hippocampus with left inferior frontal, anterior temporal and
medial occipitoparietal cortices. Hippocampal functional connectivity in
patients was unstable early in learning, gradually becoming more robust
by the end of the scanning session. The pattern of connectivity included
similar areas as in the controls, with the notable exception of left anterior
temporal cortex. Moreover, the region with the strongest hippocampal
functional connection was the left anterior prefrontal cortex. These results
are consistent with general observations of distinct patterns of functional
connectivity in schizophrenia, but also highlight that these neuroatypical
connections can support learning profiles similar to those observed in controls.
ID: 551710
IMPAIRMENT IN LONG-TERM RETENTION OF
PREFERENCE CONDITIONING IN SCHIZOPHRENIA
Ellen Herbener
Psychiatry and Psychology, University of Illinois at Chicago,
Chicago, IL, USA
Background: Schizophrenia illness is characterized by significant impair-
ments in long-term episodic memory, which are associated with hippocam-
pal abnormalities. The current study assessed long-term memory for
preference conditioning, which is believed to be more strongly based in
the basolateral amygdala, in order to determine whether abnormalities
in biological systems supporting long-term memory are specific to the hip-
pocampus, or shared across brain regions involved in different types of
memory. Methods: 17 schizophrenia (SC) and 16 healthy (HC) subjects,
matched on age, sex, and years of education participated in the study.
All subjects completed an implicit preference conditioning task which as-
sociated different patterns with different frequencies of reward. Subjects
were then tested for their preference for the patterns both immediately after
training, and following a 24 hour delay. Results. Both SC and HC subjects
demonstrated a preference for the more frequently rewarded pattern im-
mediately after training. Following a 24 hour delay, HC subjects continued
to prefer the more rewarded pattern in contrast to the less rewarded pat-
tern, but SC subjects did not maintain this differentiation. Conclusions:
These data suggest a significant deficit in the ability to maintain stimu-
lus-reward relationships in memory over long delay periods (24 hours)
in individuals with schizophrenia. This data is consistent with prior re-
search indicating normal response to emotional stimuli during learning,
but impaired long-term memory for the stimuli, and suggest that there
may be a common abnormality in biological systems supporting consoli-
dation of long-term memory across multiple types of memory in individ-
uals with schizophrenia.
ID: 551698
DISTINGUISHING EFFECTS OF SCHIZOPHRENIA
AND IQ DECLINE FROM BEHAVIOURAL
PERFORMANCE DURING EXECUTIVE
FUNCTIONING
Jiaying Jiang1, V. C. Manning1, H. M. Chan1, S. M. Rievan1,
Z. Koh1, T. M. Oh1, P. J. McKenna2, S. Graham1
1Psychology, National University of Singapore, Singapore,
Singapore; 2Psychiatry, Benito Menni Hospital, Barcelona, Spain
Neuropsychological studies have consistently identified deficits in
attentional set-shifting on tasks such as the Wisconsin Card Sorting Test
(WCST), suggesting impaired ability to inhibit previously learned responses
and shift attention to relevant stimulus. However, it is not understood if this
is due to deficits in motivation, attention, memory or executive function.
Findings are often also confounded by differences in intelligence score
(IQ) between schizophrenia and control subjects. We investigated set-
shifting behaviour in high functioning schizophrenia patients and two
groups of healthy volunteers matched on pre-morbid IQ (assessed by
WTAR) and current IQ (assessed by WASI) respectively. The 12 schizo-
phrenia patients were matched to the current IQ controls (n = 12) on
age, education, gender and current IQ and to the pre-morbid IQ group
(n = 12) on education, gender and pre-morbid IQ. All participants per-
formed a computerised WCST modified to permit separation of response
selection and feedback evaluation. In general, the current IQ-matched
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controls responded significantly more slowly and more poorly (achieved
fewer shifts overall and made more errors per shift; P < .001) compared
to the pre-morbid IQ group. Schizophrenia patients did not differ signifi-
cantly in their reaction times, number of shifts or number of errors per shift
to either control group (their means on the various tasks generally fell be-
tween the two groups). However, we did find a difference for the response
selection trial associated with initial positive feedback (‘‘update’’). Here
schizophrenia patients performed significantly more slowly than pre-mor-
bid IQ controls (P < .05) but showed a similar mean to the current IQ con-
trols. This apparent difficulty did not carry over to the subsequent
(‘‘maintenance’’) trials associated with continuing positive feedback. The
results suggest that despite a decline in intellectual function, in general
schizophrenia patients do not appear to be as disadvantaged on executive
function performance measures as healthy controls with the same current
IQ. One aspect of cognitive set shifting behavior that does appear dispro-
portionately troublesome for patients with schizophrenia is the process of
updating to the new cognitive set. We recommend that where possible,
attempts should be made to match for both current as well pre-morbid in-
tellectual functioning in order to interpret patients’ performance more fully.
ID: 551648
DECISION MAKING IN FIRST EPISODE
SCHIZOPHRENIA AND DRUG-USE DISORDERS:
ARE DEFICITS DUE TO A PREFERENCE FOR
SHORT-SIGHTED DECISIONS OR FAILURE TO
EFFECTIVELY LEARN THE TASK?
Clifford M. Cassidy, M. Lepage, A. Malla
Psychiatry, McGill University, Montreal, QC, Canada
Background: Evaluations of emotion-based decision making in early
schizophrenia using the Iowa Gambling Task (IGT) have yielded inconsis-
tent results. This study aims to investigate whether this may be due to the
confounding effect of co-morbid drug use which has been shown to be as-
sociated with poor IGT performance. Methods: The IGT was administered
to 53 first-episode schizophrenia-spectrum psychosis patients and 21 con-
trols; 31 patients and 5 controls met criteria for a lifetime SCID substance
use diagnosis. Performance on the IGT was measured as the number of
choices from the two advantageous decks minus the number of choices
from the two disadvantageous decks. Results: Using a two-way ANOVA
we found no significant effect of patient or drug use status on IGT perfor-
mance and no interaction between the two although there was a trend to-
wards poorer performance amongst patients (P = .18) and those with
a history of drug use (P = .18). To investigate this further we considered
whether poor performance in these groups was due to a preference for mak-
ing short-sighted decisions or a failure to learn the task and hence make
more random decisions. We postulate that selecting cards back and forth
at a high rate between decks to be indicative of random card selection.
There was a strong inverse correlation between performance on the task
and the number of such deck switches (r = .51, P < .001). This was
more pronounced over time as subjects who learned the task persisted
in selecting from advantageous decks. A two-way ANOVA showed subjects
with substance-use diagnosis had a greater tendency to switch decks (F1,73 =
3.9, P = .053) while there was no significant main effect of patient status on
deck switching. IGT performance was re-examined in a two-way ANOVA
controlling for deck switching with the intent to isolate the effect of delib-
erate short-sighted decision making. This showed patients had poorer per-
formance than controls (F1,73 = 4.8, P = .032) while there was no main effect
of drug use diagnosis. Conclusion: Although overall performance on the
IGT was not significantly affected by patient or drug use status, our results
suggest that subjects with a drug-use diagnosis may be less likely to effec-
tively learn the task while first episode schizophrenia patients may have
a greater preference for making short-sighted decisions.
ID: 551641
SOCIAL COGNITION TRAINING PRODUCES
CHANGES IN NEURAL MECHANISMS SUPPORT-
ING EMOTION RECOGNITION
Christine I’Lee Hooker1, M. D’Esposito2, S. Vinogradov3
1Psychology Department, Harvard University, Cambridge, MA,
USA; 2Helen Wills Neuroscience Institute, University of California,
Berkeley, CA, USA; 3Psychiatry Department, University of
California, San Francisco, CA, USA
Schizophrenia patients have well-documented impairments in facial affect
recognition and these impairments contribute to problems in social and oc-
cupational functioning. Ability to identify emotions in others depends on
an appropriate level of activity in the amygdala. Recent neuroimaging re-
search has shown that emotion recognition deficits in schizophrenia
patients may be due to dysfunctional amygdala activity when processing
emotional information from faces. Here, we investigated whether neuro-
plasticity-based targeted cognitive training (TCT) which incorporated in-
tensive training on facial affect recognition would improve behavioral
performance and restore proper amygdala function during a facial affect
recognition task. 21 schizophrenia patients and 18 healthy control subjects
were scanned in high field (4Tesla) fMRI while completing a facial affect
recognition task in which subjects were shown positive (happy, flirty,
dreamy, and happy-surprised), and negative (sad, angry, fear, disgust) fa-
cial expressions and were asked to identify the facial expression in a forced-
choice paradigm. In the control condition, using a similar forced-choice
paradigm, subjects were asked to identify the color of objects. After the
baseline scan, schizophrenia patients were randomly assigned to 40 hours
of TCT (N = 12) or 40 hours of an active control condition (N = 9) which
consisted of playing computer games (CG). We found that, before training,
TCT subjects did not show amygdala activity to either positive or negative
facial expressions as compared to objects, nor was amygdala activity cor-
related with emotion recognition performance. However, after training,
TCT subjects showed significant behavioral improvement in emotion rec-
ognition performance. In addition, among the TCT group, there was a sig-
nificant positive correlation between emotion recognition performance and
individual amygdala activity when identifying emotions versus objects. The
CG group, on the other hand, did not show behavioral improvement and
amygdala activity was not related to performance. These data suggest that
intensive TCT which includes facial affect recognition training may engage
the amygdala in the process of facial affect recognition, and thus restore the
appropriate neural circuitry to facilitate emotion recognition performance.
ID: 551639
LOGITUDINAL CHANGES OF N-ACETYL-ASPAR-
TATE AND COGNITIVE FUNCTION IN EARLY
ONSET PSYCHOSIS
Marta Rapado-Castro, M. Mayoral, A. Zabala, C. Bailo´n, S. Reig,
M. Desco, M. Parellada, D. Moreno, C. Arango
Unidad de Adolescentes, Dpto. Psiquiatrı´a, Hospital General
U. Gregorio Maranon, Madrid, Spain
Background: Early-onset psychosis (EOP) is a rare and severe condition
which has been associated with a number of developmental disturbances.
Low concentrations of N-Acetyl-Aspartate (NAA) are interpreted as a bi-
ological marker of changes in neural integrity. Studies using Proton Mag-
netic Resonance Spectroscopy (H-MRS) have shown reduced NAA levels
in the Dorsolateral Prefrontal Cortex (DLPC) in both chronic and first-
episode psychotic patients. This reduction of frontal NAA levels has
been related to the presence of cognitive deficits in adult onset schizophre-
nia and has also been described as a good outcome predictor for psychosis.
Methods: A sample of 54 first-episode psychotic patients (mean age 17.74)
and a matched control sample were longitudinally assessed using a compre-
hensive neuropsychological battery. This battery included those measures
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considered to be related to DLPC functioning (attention, working memory
and executive function). The single voxel proton spectra were obtained in
a 1.5 T Philips Gyroscan ACS from the DLPC area with and without water
suppression at baseline and 2 years follow up. Results: There were signif-
icant differences in NAA levels between patients and controls at two years
follow-up (t = 1,15; P = .250) but not at baseline (t = 2,55; P = .013). Lon-
gitudinal changes in NAA levels were significant in the group of controls
(F = 1,79; P = .189) but were not in the group of patients (F = 1,79; P = .189).
Patients had significantly less NAA levels at follow-up. Cognitive function
in patients improved over time (F = 22,59 0 = 0.000) but NAA levels did not
explain changes in cognition. Conclusions: The pattern of NAA/water con-
centrations described for the group of patients at the early course of the
illness remained stable during the first two years. Controls presented a spe-
cific increase in the left DLPFC NAA/water ratio at two years follow-up.
This result replicates previous findings in our group which are congruent
with the neurodevelopmental hypothesis of early onset psychosis. Our
results indicate that changes in cognitive DLPC function are not related
to NAA levels.
ID: 551571
SCHIZOPHRENIA PATIENTS SHOW DEFICITS IN
INTRA-STIMULUS SHIFTS OF ATTENTION TO
DIFFERENT LEVELS OF GLOBAL-LOCAL STIMULI
Michael J. Coleman1, L. Cestnick2, O. Krastoshevsky1,
V. Krause1, Z. Huang3, N. R. Mendell3, D. L. Levy1
1Psychology Research Laboratory, McLean Hospital, Belmont,
MA, USA; 2Department of Psychiatry, Harvard Medical School,
Boston, MA, USA; 3Department of Applied Math and Statistics,
State University of New York at Stony Brook, Stony Brook,
NY, USA
Abnormalities of attention suggesting left hemisphere dysfunction have
been well documented in schizophrenia. Schizophrenia patients show a local
processing deficit on the global-local task, which has been interpreted as
evidence of a left lateralized attention deficit. The global-local task is a mea-
sure of attention and perceptual organization that utilizes visual stimuli
comprised of large letters (global level) made up of smaller letters (local
level). Subjects identify target letters appearing at either the global or local
level of the stimulus. In this study, we used a version of the global-local task
specifically designed to examine lateralized hemispheric processing and at-
tention shifting in schizophrenia patients and normal controls. Global-local
stimuli were presented in couplets (consecutive pairs). Reaction time for the
second target in a couplet was compared under conditions in which the tar-
get remained at the same level (global-global, local-local) and when the tar-
get changed levels (global-local, local-global). Schizophrenia patients were
significantly slower shifting attention from the global to the local level, con-
firming previous findings of a left-lateralized local processing deficit in
schizophrenia patients and suggesting that schizophrenia patients have def-
icits disengaging attention from global to local levels of hierarchically or-
ganized stimuli.
ID: 551567
SERUM BRAIN DERIVED NEUROTROPHIC FAC-
TOR (BDNF) IN PATIENTS AT ULTRA-HIGH-RISK
FOR PSYCHOSIS
Rachel L. Loewy1, M. Fisher1, B. Stuart1, C. Holland1, S. Mellon2,
O. Wolkowitz1, S. Vinogradov1
1Psychiatry, UCSF, San Francisco, CA, USA; 2Obstetrics and
Gynecology, UCSF, San Francisco, CA, USA
Brain-derived neurotrophic factor (BDNF) is the most widely distributed
neurotrophin in the central nervous system and plays a critical role in brain
development, function, neuronal survival, and neuroplasticity. In vivo se-
rum BDNF levels in schizophrenia patients are generally reduced compared
to healthy subjects, and may be reduced even prior to the onset of psychosis,
thereby marking risk for schizophrenia. In this ongoing study, we assess
serum BDNF in a sample of patients diagnosed as being at ultra-high-
risk for psychosis (N = 8; mean age = 18.5), compared to an age-matched
sample of first-episode schizophrenia subjects (N = 10), healthy controls
(N = 16), and a group of chronic schizophrenia patients (N = 54). Clinical
assessments, MATRICS-based neurocognitive assessments and blood
draws were conducted at study entry for all subjects. All three patient
groups demonstrated lower levels of serum BDNF compared to the healthy
controls (F3,78 = 4.20, P = .008). Within the total group of patients, lower
BDNF was associated with increased symptom severity and lower func-
tional status, as measured by the Global Assessment of Functioning
(GAF) scale (P = .006). Within the UHR group, lower BDNF levels
were significantly correlated with more severe negative symptoms (P <
.05), worse disorganized symptoms (P< .05) and poorer social functioning
(P < .01). These preliminary results suggest that reduced BDNF may pre-
cede the onset of schizophrenia and may be related to some of the first clin-
ical signs of prodromal psychosis- negative symptoms and poor
functioning. Future analyses will assess whether reduced serum BDNF pre-
dicts conversion to full psychosis in the UHR group.
ID: 551564
REWARD ASSOCIATIONS ARE INFLUENCED BY
MODULATION OF HABENULAR OUTPUT
Carolyn Danna, P. D. Shepard, G. I. Elmer
Psychiatry, UMB, Catonsville, MD, USA
Dopamine neuronal activity increases in response to novel rewards or to
stimuli that predict their occurrence while transient decreases in activity
accompany the absence of an expected reward. Recent developments in
the field of reward processing indicate that the habenula is a source of in-
hibitory input. The habenula communicates with the both the ventral teg-
mental area and substantial nigra compacta through its sole output
pathway, the fasciculus retroflexus (FR). In order to better understand
how reward learning is regulated, we electrolytically lesioned the FR, elim-
inating communication between these brain regions. We also stimulated
this same region to create a false habenular signal. The effect of disrupting
habenula output on reward association learning was assessed using an
autoshaping paradigm. Sucrose rewards were delivered on a variable inter-
val schedule; presentation of a CSþ cue was predictive of reward delivery
while the CS cue was not. The acquisition of stimulus-reward associations
was quantified by the comparing the number of approaches to the positive
(CSþ) and negative (CS) cues. Once the paradigm had been firmly estab-
lished, the two cues were reversed, so that the cue that once signaled reward
no longer predicted reward and vise versa. FR lesions created prior to
acquisition of the task significantly increased the number of approaches
to the CSþ during the acquisition. It also slowed extinction of responding
to the new CS when the cues were reversed. The lesion did not affect the
amount of pellet dispenser exploration or reward consumption during any
portion of the trial. Another group of animals was lesioned between acqui-
sition and reversal to specifically investigate the effects of lesion on reversal.
FR lesion after acquisition of the task did not potentiate approach behavior
to the new CSþ cue, in contrast, it diminished approach behavior. The af-
fective valence of stimulation of the FR is assessed using conditioned place
preference (CPP). Stimulating during CPP did not appear to cause aversion
in the subjects. In summary, a FR lesion prior to but not after exposure to
the autoshaping paradigm significantly potentiates approach behavior to
a newly acquired reward association and delays the reversal of responding
to the new rewarded cue. These data are consistent with the notion that the
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habenula provides a modulatory input to ventral midbrain dopamine neu-
rons and participates in the reinforcement learning.
ID: 551559
DOES NEUROCOGNITION PREDICT SOCIAL AND
OCCUPATIONAL FUNCTIONING IN FIRST-EPI-
SODE PSYCHOSIS?
Srividya Iyer1,2, L. Bechard-Evans1,2, M. Lepage1,2, A. Malla1,2
1Prevention and Early Intervention Program for Psychoses, Douglas
Mental Health University Institute, Montreal, QC, Canada;
2Psychiatry, McGill University, Montreal, QC, Canada
Much research has examined neurocognition and functional outcome in
chronic schizophrenia. Findings show that neurocognition predicts func-
tioning but this association is weaker upon accounting for symptoms.
Few studies have examined the influence of neurocognition on outcome
in first-episode psychosis. Our aim was to investigate whether neurocogni-
tion predicts social and occupational functioning at entry and one year after
specialized early intervention in a schizophrenia-spectrum FEP sample.
Method: Neuropsychological assessments were done at baseline and scores
were converted into z-scores based on 51 healthy controls. Scores for six
domains (Verbal Memory, Processing Speed, Working Memory, Verbal
Fluency, Attention, and Reasoning) were computed as the mean of z-scores
for tasks comprising these domains. A global neurocognitive score was
computed by averaging scores for the six domains. Functioning was
assessed with the Social and Occupational Functioning Assessment Scale
(SOFAS) at baseline (N = 151) and one year (N = 66). Symptoms were
assessed using the Scales for the Assessment of Positive and Negative Symp-
toms (SAPS and SANS). Results: Patients (N = 151; mean age 22.8; 71.5 %
male) were significantly more impaired on all cognitive domains compared
to healthy controls (F’s = 4.19–38.69; P < .05). At baseline, all six domains
(r’s = 0.21–0.33; P < .05) and the global neurocognitive score were signif-
icantly correlated with SOFAS total (r = 0.33; P< .01). Regression analyses
were conducted to examine the contribution of cognition (the global score
was used to avoid colinearity) and symptoms to SOFAS. Cognition
accounted for 9% of the variance in functioning at baseline. When
SAPS and SANS were also included, only SANS was significant and
accounted for 15% of variance. The global and individual domains were
not significantly correlated with SOFAS at one year. Discussion: At base-
line, cognition explained 9% of the variance in social and occupational
functioning but this effect disappeared upon accounting for negative symp-
toms. Further, cognition was not associated with functioning at one year.
While our findings are somewhat contrary to the literature, the effect of
cognition on functional outcome in these studies is modest, explaining
only 3–6% of variance after controlling for symptoms. Factors such as so-
cial support, negative symptoms, and intensive case management may
buffer the effects of cognitive deficits on functioning, particularly early
in the illness course.
ID: 551555
RELATIONSHIPS BETWEEN TEST AND FACTOR
SCORES, AND PSYCHOMETRIC PROPERTIES: THE
MATRICS CONSENSUS COGNITIVE BATTERY
(MCCB) AND THE INTEGNEURO COMPUTERIZED
BATTERY IN SCHIZOPHRENIA
Igor Malinovsky1,2, J. Jaeger4, A. M. Donovan-Lepore5,
S. Wilkniss6, A. Savitz7, D. N. Hawthorne1,2, S. R. Raines4,
S. J. Carson1, Z. Khan1,2, K. Biondo1,2, S. L. Dove-Williams1,
P. Pandya1, D. Hartley1, S. C. Marcello1, S. Zurkin4, S. Furlong4,
G. Dent4, S. M. Silverstein1,3
1University Behavioral HealthCare, University of Medicine and
Dentistry of New Jersey, Piscataway, NJ, USA; 2Graduate School
of Applied and Professional Psychology, Rutgers, the State
University of New Jersey, Piscataway, NJ, USA; 3 University of
Medicine and Dentistry of New Jersey, Robert Wood Johnson
Medical School, Piscataway, NJ, USA; 4AstraZeneca
Pharmaceutical Company, Wilmington, DE, USA; 5Zucker Hillside
Hospital, Glen Oaks, NY, USA; 6Thresholds Psychiatric
Rehabilitation Centers, Chicago, IL, USA; 7Weill Medical College
of Cornell, New York Presbyterian Hospital, White Plains,
NY, USA
Cognitive impairment is prevalent in schizophrenia, and is related to
poorer functional and treatment outcomes. Cognitive assessment is there-
fore now a routine aspect of clinical trials of new medications for schizo-
phrenia. The current gold-standard for cognitive assessment in clinical
trials for schizophrenia is the MATRICS Consensus Cognitive Battery
(MCCB), which was developed based on expert consensus, and incorpo-
rates paper-and-pencil tests (and one computerized measure) with an
established history in the field of neuropsychology. Recently, however, in-
terest has increased in using computerized batteries for clinical trials, due
to their ease of administration and smaller error variance that is associated
with standardized pre-recorded instruction sets, and automated scoring
procedures. In this study, we tested 155 people with schizophrenia and
75 healthy control subjects on both the MCCB and IntegNeuro (a
touch-screen based computerized battery with previously demonstrated
high levels of reliability and validity) to determine comparability between
test scores. In addition, we assessed test-retest reliability over a one-month
interval for both batteries, and determined correlations between cognitive
test scores and scores on functional outcome measures. Results indicate
comparability across the two batteries, with the strongest levels of agree-
ment observed between total battery composite scores (r > .80) and in ca-
nonical correlation analyses that included all critical single test scores from
each battery (rc>.90). Correlations between single test scores, and between
cognitive domain composite scores were lower than for full-battery com-
parisons, but were within the range observed in prior validation studies of
other widely used cognitive test batteries for schizophrenia. The batteries
demonstrated essentially equivalent sensitivity in discriminating between
patients and controls, and adequate test-retest reliability. Correlations be-
tween cognitive test scores and functional outcome measures were equiv-
alent between the two batteries, and low in nearly all cases, suggesting that
cognitive indices are not proxy measures of real-world functioning.
Principal components analyses of the batteries will be reported, as will
comparability of these results across batteries. Advantages and disadvan-
tages of computerized vs. paper-and-pencil neurocognitive tests for
schizophrenia, as revealed by these batteries will also be discussed.
ID: 551552
THE ROLE OF VISUAL PERCEPTION DEFICITS
IN WORKING MEMORY IMPAIRMENT IN
SCHIZOPHRENIA
Olga Krastoshevsky1, M. J. Coleman1, V. Krause1,
N. R. Mendell2, D. L. Levy1
1Psychology Research Laboratory, McLean Hospital, Belmont,
MA, USA; 2Department of Applied Math and Statistics, State
University of New York at Stony Brook, Stony Brook, NY, USA
Deficits in the visual working memory system have been consistently
reported in schizophrenia patients. Here we assess the role of visual percep-
tion in subjects’ performance on object working memory. 37 patients with
schizophrenia and 24 nonpsychiatric control subjects were tested on a visual
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object recognition working memory task across three delay periods: 200
msec, 3 sec, and 10 sec. Both schizophrenia and control subjects showed
a significant decline in performance on the 3 and 10 sec delay intervals com-
pared with the 200 msec delay interval. Performance on the 3 sec delay pe-
riod did not differ significantly from that in the 10 sec condition in either
group. Schizophrenia patients performed significantly less accurately than
controls in all three delay intervals. After co-varying the effect of perception
(200 msec delay) on performance in the two longer delay periods (3 sec and
10 sec), schizophrenia and control subjects no longer showed a significant
difference in accuracy on the 3 sec delay, but the groups remained signif-
icantly different for the 10 sec delay interval. After removing the effect of
accuracy during the perceptual task, controls did not differ on the 3 sec and
10 sec delays, but SZ patients showed a weak trend to perform worse on the
10 sec delay than on the 3 sec delay. Once the perception component was
removed, schizophrenia patients demonstrated intact working memory (3
sec delay). In contrast, although the 10 sec delay period imposes a higher
memory load on both groups, it impacted performance only in the patients.
These results suggest that an impairment in perception seems to be a major
contributor to what appears to be a deficit in the visual object working
memory system in schizophrenia patients.
ID: 551545
PHARMACOLOGICAL TREATMENTS OF
COGNITION: ONE DRUG FOR ALL DOMAINS?
Mark A. Geyer, J. Young
Psychiatry, UCSD, La Jolla, CA, USA
The NIMH-funded MATRICS Program (Measurement and Treatment
Research to Improve Cognition in Schizophrenia) developed a broad con-
sensus regarding the nature of the cognitive impairments in schizophrenia
and how they might best be assessed and treated. MATRICS identified
seven domains of cognition of specific relevance for schizophrenia and de-
veloped a battery of tests that combines individual assessments of specific
domains with a global score of performance across all domains. The sub-
sequent discussions of the CNTRICS (Cognitive Neuroscience measures of
Treatment Response of Impaired Cognition in Schizophrenia) program fo-
cused on neuroscience- and brain-based translational approaches to the un-
derstanding of cognition, with a focus on specific constructs within the field
of cognition that are impacted in schizophrenia. The fields of neuroscience
and physiological psychology provide extensive evidence that specific cog-
nitive functions are subserved by specific neural circuits. Indeed, much of
the neuropsychological literature addressing tests for various cognitive
constructs utilizes circuit-based differentiations as tests of the validity of
the tests as measuring the specific construct of interest. Similarly, extensive
evidence from animal research indicates that different cognitive functions
are impacted differentially by pharmacological manipulations. This presen-
tation will provide examples of pharmacologically specific effects of drug
treatments on some domains of cognition as distinct from other domains.
The possibility that specific treatments for specific cognitive deficits can be
predicted from animal model studies will be discussed. The further possi-
bility that cross-species paradigms can be developed to assess domain-spe-
cific effects of pharmacological treatments will also be addressed.
ID: 551532
ABNORMAL OSCILLATORY ACTIVITY IN
SCHIZOPHRENIA PATIENTS DURING AN AUDI-
TORY STREAMING TASK
David I. Leitman, J. Rosner, D. H. Wolf, R. C. Gur, R. E. Gur,
B. I. Turetsky
Brain Behavior Laboratory, University of Pennsylvania School of
Medicine, Philadelphia, PA, USA
Patients with Schizophrenia have well documented deficits in basic audio-
sensory processing. Such dysfunction could contribute to how sequential
sounds are integrated in to a coherent percept. In everyday life one is bom-
barded with a cacophony of sounds from multiple sources, and it is the job
of our auditory apparatus to segment these sounds based on the spectral
similarity and temporal coincidence. This ability to isolate and perceive au-
ditory streams can be investigated in ‘‘auditory streaming’’ experiments: In
our streaming experiment subjects were presented with tones organized in
triplets (ABA_ABA.), with individual tones separated by 50 msec and
triplets separated by 100 msec. Tone A was always 1000Hz. There were
two conditions, depending upon the pitch of tone B. In the first condition,
tone B was either 950Hz or 1100Hz and the sequence was perceived as a sin-
gle stream of galloping triplets. In the second condition, tone B was either
500Hz or 2000Hz. In this latter condition subjects typically perceived that
low and high tones separated into two alternate streams much like coun-
terpoint in music (Sussman, et al., 1999). We examined total and evoked
gamma oscillations to these two conditions to 24 controls and 22 schizo-
phrenia patients. We found that patients with schizophrenia had signifi-
cantly higher total gamma power than healthy subjects across both
conditions. Control subjects exhibited increased total gamma power during
the ‘single stream’ condition vs. the ‘dual stream’ condition, but patients
failed to show this modulation with condition. Furthermore, while controls
displayed a sequential decrease in gamma power to each tone of the ABA
triplet during ‘single stream’ stimulation, patients displayed the opposite
pattern of increasing evoked gamma activity following each subsequent
stimulus. These findings together suggest increased gamma activity in
patients disrupts the stimulus-evoked modulation of gamma responses
that is necessary for integrated auditory perception.
ID: 551516
NEUROCOGNITIVE DEFICITS ARE ASSOCIATED
WITH PSYCHOTIC-LIKE EXPERIENCES AFTER
CANNABIS.
Emma Barkus1, L. Smith1, M. Diforti2, R. Murray2
1Institute of Psychiatry, London, United Kingdom; 2Psychiatry,
Institute of Psychiatry, London, United Kingdom
Background: The relationship between cannabis and psychotic disorders is
still under debate. It is clear however that in some individuals even recre-
ational use of cannabis can lead to a transient period where some symptoms
of psychosis are experienced. There is extensive anecdotal evidence for in-
dividual differences in the experiences which people have after smoking
cannabis. Previous work has shown that schizotypy may mediate the expe-
riences which people have when smoking cannabis (Barkus et al., 2006; Bar-
kus and Lewis, 2008). Specifically, those who score higher on schizotypy are
more likely to experience psychotic-like immediate effects and report more
after effects from cannabis use. Given that altered cognitive performance
has been associated with both schizotypal trait and cannabis use, it is pos-
sible that cognition may have a role in mediating the experiences which peo-
ple have when they use cannabis. We hypothesised that individuals who
reported psychotic-like experiences after cannabis use would have impaired
cognitive performance across multiple domains of cognition. Method: We
tested fifty participants (mean age 23 years) who had been selected on the
basis of their scores on the psychotic-dysphoric subscale on the Cannabis
Experiences Questionnaire (Barkus et al., 2006). They were tested on meas-
ures of working memory, spatial working memory, executive functioning
and learning. Groups were well matched on other recreational drug use and
patterns of cannabis use. Results: Those who reported psychotic-like expe-
riences after cannabis reported higher scores on neuroticism and emotional
reactivity (t = 2.479, P < 0.05 and t = 2.739, P < .05 respectively), these
effects were independent of gender. Those who had psychotic-like experi-
ences had more between search errors on the spatial working memory task
and longer latencies on a working memory task; while there were no differ-
ences on attention and Trails A and B. Conclusion: In the absence of differ-
ences in patterns of cannabis use, individuals who have psychotic-like
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experiences after cannabis do demonstrate some cognitive deficits, partic-
ular in working memory. These cognitive deficits occur in the absence of
differences in patterns of cannabis use.
ID: 551498
THE TEMPORAL STABILITY OF THE BEADS TASK
Katrina McMullen1, L. Martin2, T. Rushe3, E. J. Barkus4
1Clinical Neuroscience, Centre for Neuroimaging Sciences, Institute
of Psychiatry, London, United Kingdom; 2School of Psychological
Sciences, University of Manchester, Manchester, United Kingdom;
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Background: Cognitive accounts of delusions implicate reasoning biases in
the formation and maintenance of delusions. People with delusions display
a jumping to conclusions bias (JTC): a tendency to reach a decision on little
evidence and high confidence. The bias is found in the actively deluded,
delusion prone and first degree relatives of schizophrenia patients. It has
been associated with formation as well as the maintenance of delusional
beliefs. The beads task is a commonly used measure of the JTC bias. In
its simplest form, two jars of beads are presented in opposing ratios of
two colours eg, 85:15 red to blue beads in one jar and the reverse in the
other jar. Participant’s are then shown a sequence of beads and are asked
when they have seen enough beads to decide which jar the beads are being
drawn from. The aim of this study was to assess the temporal stability of the
beads task administered on two separate occasions without intervention.
Method: The beads task was administered on two separate occasions to 30
healthy (13 male, 17 female and mean age 23.90 years) volunteers in a paired
study design. There were a number of different ratios and number of jars
used in the trials. Results: There was no difference found between the num-
ber of beads to reach a decision for the two administrations of the task in-
dicating that the beads task has a good temporal stability (t -1.987, df = 29,
P = .06). There was no significant correlation between performance over
time and personality characteristics such as schizotypy and delusional
proneness. Conclusions: This finding demonstrates the strength of the
beads task in producing similar scores in the same individuals over time.
There were no associations between change in performance over time
and psychosis-like traits suggesting test retest regardless of trait psychosis
proneness.
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Although a great deal of recent work has focused on cognitive enhancing
medications in schizophrenia, and on their underlying neurobiological
mechanisms, very little work has focused on the underlying neurobiology
of behavioral cognitive treatments. This is somewhat surprising, given that
behavioral treatments such as cognitive remediation have demonstrated ef-
ficacy, and could potentially be a critical component of the therapeutic
armementarium in schizophrenia. We report longitudinal MEG, fMRI,
and serum biomarker data obtained in clinically stable adult outpatients
with schizophrenia who were randomly assigned to participate either in
50 hours of ‘‘neuroplasticity-based’’ computerized cognitive training or
50 hours of a computer games control condition. In this innovative
form of behavioral cognitive enhancing treatment, participants engage
in a heavy schedule of computerized training that places implicit, increasing
demands on auditory perception and accurate aural speech reception.
This psychophysical training is embedded within a suite of increasingly
complex auditory and verbal working memory/verbal learning exercises.
A fundamental goal of this treatment is to increase the accuracy, the tem-
porally-detailed resolution, and the power of aural speech inputs feeding
working and long-term memory processes. We present the following evi-
dence of neurobiological effects as a function of training, obtained in
the active condition but not the control subjects: 1) MEG data indicating
improved efficiency in early auditory processing; 2) fMRI data showing
‘‘normalization’’ of brain activation patterns during a verbal memory
task; 3) significant increases in serum BDNF and d-serine levels. Taken to-
gether, these data indicate that 50 hours of ‘‘neuroplasticity-based’’ cogni-
tive training drives neurobiological changes consistent with restoration and
enhancement of key neurocognitive processes.
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People with schizophrenia consistently show recognition memory impair-
ment but we currently know little about potential faulty processes that con-
tribute to this problem. Recognition memory accuracy relies on how well
someone remembers encoded items but also on how well he classifies never
presented items as new. Sometimes, new items act as lures because they
share similarities with encoded items. When someone is unable to differen-
tiate the lures from the encoded item, he tends to classify the lure as an old
item and commits a false recognition. People with schizophrenia have been
shown to exhibit heightened sensitivity to false recognition as compared to
healthy people. Lures were however essentially induced at a conceptual (ie,
semantic) level. In our on-going project, we tested false recognition induced
at a perceptual level in conditions simulating real-life situations potentially
causing such false recognition. This idea was motivated by the fact that
people with schizophrenia are known to exhibit several visual impairments
and that might exacerbate their proneness to false recognition. To date,
participants include 10 first episode of non-affective psychosis (FEP)
patients and 11 healthy controls. There were two blocks of a classic yes/
no memory recognition task. Overall, 240 photos of common objects
were presented sequentially during the encoding phase. In the recognition
phase, 120 of the encoded objects were presented randomly with 120 lures.
The lures were objects never presented before. They were exemplars of the
encoded objects with which they share up to two dimensions: 1) 30 were of
identical position and color, 2) 30 were of identical position, 3) 30 were of
identical color, and 4) 30 were in different position and color. Preliminary
behavioural results indicate that FEP participants were more prone to false
recognition than healthy controls only for the less similar lure. In conditions
of strong lures induced by a similarity of object’s position and/or color, the
two groups performed similarly. The false recognition proneness of FEP
participants thus emerged only when evidence against false recognition
cumulated, likely because they were unable to take advantage of this
combination of evidence as healthy controls did.
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RELATIONSHIP OF CONTEXT MAINTENANCE TO
POSITIVE SYMPTOMS AND CREATIVITY
Joscelyn Elizabeth Fisher1, G. A. Miller2, W. Heller2,
C. R. Cortes1, M. A. Tagamets1
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Urbana-Champaign, IL, USA
Making unusual associations relative to current context is associated with
both ‘‘creativity’’ and positive symptoms in schizophrenia spectrum disor-
ders, but creativity and these disorders are not necessarily related to each
other. The following studies investigate this divergence. It was hypothesized
that a combination of reduced context maintenance (right frontal activa-
tion of remote associates) with reduced evaluation (frontal executive
function) leads to positive symptoms, whereas reduced context mainte-
nance coupled with intact context evaluation manifests as creativity. Study
1: Healthy individuals completed neuropsychological, creativity, and schiz-
otypy measures, and a recognition memory paradigm that indexes context
maintenance. Two groups were created according to lure accuracy on the
memory paradigm. Those with high accuracy had higher scores on frontal
lobe measures and lower scores on Magical Ideation and Unusual Percep-
tual Experiences, indicating stronger executive function and less psychopa-
thology. Groups did not differ on the Remote Associates Test (RAT), an
index of ‘‘creativity’’. However, the RAT was negatively correlated with
Odd Beliefs within the high accuracy group indicating that ‘‘creativity’’
was associated with low psychopathology in individuals who could differ-
entiate between presented words and lures. In contrast, the RAT was pos-
itively correlated with Odd Beliefs within the low lure-accuracy group,
indicating that creativity is positively associated with psychopathology
in individuals who do not evaluate or monitor associations well. As pre-
dicted, individuals with weaker executive function and recognition memory
accuracy showed a relationship between ‘‘creativity’’ and positive symp-
toms. Study 2: Lure accuracy does not differ between patients with schizo-
phrenia and controls. Perhaps this finding differs according to frontal
measures and positive symptoms as in the low-accuracy group in Study
1. Preliminary analyses indicate that lure accuracy is negatively correlated
with Magical Ideation, and neuropsychological measures of right hemi-
sphere function in patients with schizophrenia. As data collection contin-
ues, we will investigate the associated symptoms and neural mechanisms
(using ERP and fMRI) of context maintenance and evaluation and deter-
mine how they are related to the manifestation of either creativity or
positive symptoms.
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In cognitive insight studies, an association between delusions and a ten-
dency to show increased confidence in one’s beliefs and judgments
(‘‘Self-Certainty’’) has been reported in chronic psychotic patients and
for healthy people who report delusion proneness. Individuals who are de-
lusion prone also show more willingness to acknowledge fallibility and in-
corrigibleness (‘‘Self-Reflectiveness)’’ than those who show low delusion
proneness. Chronic psychotic patients without delusions report lower
Self-Reflectiveness than deluded patients. A direct assessment of the cog-
nitive insight/delusions link early in the disease process after a first episode
of psychosis (FEP) has not yet been done. In our study, sixty-two individ-
uals with a FEP (48 non-delusional, 14 delusional at the time of evaluation)
were administered a clinical examination and delusional severity was
assessed with the Positive and Negative Syndrome Scale. Cognitive insight
was measured with the Beck Cognitive Insight Scale (BCIS). Delusion
groups differed on depression and anxiety (t60 = 0.21, P = 0.04; t60 =
0.45, P < .01). As the present study’s goal was to evaluate the unique re-
lationship of cognitive insight to delusion groups, these scores were entered
as covariates. Delusional FEP individuals showed a trend for lower Self-
Reflectivity, F1, 55 = 3.64, P = .06 than non-delusional FEP individuals.
BCIS Self-Certainty scores did not significantly discriminate between de-
lusional and nondelusional FEP individuals, F1, 55 = 1.03, P = .32. In an
exploratory correlational analysis between delusions scores and BCIS in-
dices, no significant associations emerged (all rs < 0.22, ps > 0.09). These
data suggest that the cognitive system involved in Self-Reflectiveness is
functioning suboptimally in FEP individuals with active delusions. Taken
together, a psychopathological model of cognitive insight may consider
whether (1) diminished Self-Reflectiveness may be a vulnerability factor
for psychosis, (2) the association between low Self-Reflectiveness and
the absence of delusions in chronic psychosis may be a confound of the
effects of illness chronicity or lengthy antipsychotic exposure, (3) delusions
may contribute to overconfidence in later phases of the illness.
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Schizophrenia is associated with sensory processing difficulties. Deficits in
the ability to discriminate simple features of auditory stimuli such as pitch
and duration are extensively documented. Ability to detect tone location
has been studied to a lesser degree and has been primarily assessed using
cues derived from interaural delays, rather than free field sound. Such
assessments provide limited information about the severity of impairment
because they can only accurately assess differences in perceived location
relative to the midline. The present study compared performance between
individuals with schizophrenia (n = 16) and healthy controls (n = 12) on
spatial location and discrimination tasks using low frequency tones.
Free field sound was generated by seven speakers concavely arranged
with 30 degrees separation. In the location task, a tone was randomly pre-
sented from one speaker and subjects indicated which speaker the tone
came from. In the discrimination task, two tones were sequentially pre-
sented from the same or different speakers. Subjects reported whether
both originated from the same speaker or not. In the location task, repeated
measures analysis of variance revealed significant main effects for group
status (individuals with schizophrenia vs. controls) and speaker location.
Both groups were more accurate at detecting location when tones were clos-
est to the midline. Although individuals with schizophrenia were less accu-
rate than controls across all speakers, significant differences were observed
at the midline and 30 degrees to the right of the midline. Comparable results
were found for the discrimination task. Individuals with schizophrenia had
more difficulty distinguishing between tones originating from different
speakers, especially for pairs crossing the midline. In peripheral stimuli
pairs, individuals with schizophrenia generally performed worse than con-
trols when there was a smaller degree of separation between the speakers
and overall performance was worse in the right than left hemisphere. The
results provide insight into the degree of impairment in auditory processing
of sound location information in schizophrenia.
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TRANSFER GENERALIZATION IN SCHIZOPHRE-
NIA: SPECIFICITY AND CO-FAMILIALITY
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Schizophrenia is associated with hippocampal pathology. Schizophrenia
patients show impairments in transitive inference, a component of rela-
tional memory organization dependent on an intact hippocampus. Transfer
generalization is another component of relational memory organization
that is thought to tap hippocampal functioning. In this study we examine
whether 1) schizophrenics show deficits on a transfer generalization task, 2)
transfer generalization deficits are specific to schizophrenia or also occur in
bipolar disorder, and 3) transfer generalization deficits are co-familial (ie,
also occur in well relatives of schizophrenia patients). In the transfer gen-
eralization task, subjects learn which member of a pair of stimuli hides
a smiley face based on one attribute, shape or color. All groups learned
to criterion and performed equivalently when tested on the learned pairs.
Transfer generalization requires subjects to identify the relevant attribute
(shape or color) in new pairs of stimuli based on the relevant attribute of the
learned stimuli. There were no group differences in accuracy on the shape
pairs. On the color pairs, schizophrenia and bipolar patients performed sig-
nificantly worse than controls. Relatives of schizophrenics performed equiv-
alently to control subjects and significantly better than schizophrenia
patients. The performance of bipolar patients fell between that of schizo-
phrenics andrelatives of schizophrenics, anddid not differ from either group.
The greater salience of the shape stimuli may have facilitated compensation
for impairments in hippocampal functioning that became evident when
the less salient color stimuli were used. These results indicate that transfer
generalizationdeficitsareassociatedwithbothschizophreniaandbipolardis-
order, but are not co-familial. Transfer generalization paradigms provide
a potentially useful behavioral probe of hippocampal function.
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Studies of visual backward masking have frequently revealed an elevated
masking threshold in schizophrenia. This finding has frequently been inter-
preted as indicating a low-level visual deficit. However, more recent models
suggest that masking may also involve late and higher-level integrative pro-
cesses. In a previous behavioural study, we found that access to conscious
report of masked stimuli was impaired in schizophrenia, while fast bottom-
up processing of the same stimuli, as assessed by subliminal priming, was
preserved. [1] These findings suggested a high-level origin of the masking
deficit in schizophrenia but left open for further research its exact relation
to previously identified bottom-up visual processing abnormalities. In the
present work, we tried to investigate the neural mechanisms of this deficit in
perceiving visual masked stimuli, based on a previous ERP study in normal
subjects. [2] We measured high density event-related-potentials and source
localization in a group of 16 patients with schizophrenia compared to
a group of 16 normal controls during two different conditions of masking
aimed at differentiating top-down from bottom-up processing. We found
that abnormal early and late neural events observed in patients during ‘‘top
down’’ condition were most normalized for the ‘‘bottom up’’ condition.
These results are discussed in the context of previous research in visual
masking and cognitive deficits described in schizophrenia.
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Drugs commonly prescribed for schizophrenia and other psychotic illnesses
have been shown to increase patients’ risk of developing diabetes including
increasedthirst, frequenturination,appetiteandrapidweightgain.Although
there are a vast array of studies which have demonstrated the psychological
and physical health benefits of regular aerobic exercise for adolescents and
adults, studies have not researched in the question of why patients with
schizophrenia do not adhere to sporting activities. Understanding the mean-
ingbehindaperson’spostureorbodymovementcomeseasily to manypeople
and helps guide how we react to others socially. This understanding is re-
quired for team sports but also important in individual sports where learning
comes through observing and understanding the moves. But people with
schizophrenia, even those who have mild to moderate symptoms and take
medications, are not fluent in understanding body language (Paradiso and
Andreasen 2006). Motor, cognitive and social deficits may thus be the lim-
itingfactor forpatients toenjoyandtoadhere toregularaerobicexercise.Our
projectwastouse innovatingtools—developedandvalidated infundamental
research protocols—for the quantification of those motor and cognitive def-
icits observed at an individual level in patients with schizophrenia. From
these results, a psycho education program was initiated in order to sensitive
patients to their functional deficits and to choose with them that sporting ac-
tivity that would best fit their capacities but also their taste. A series of motor
and cognitive tests were used to quantify motor and cognitive disorders in
early onset and chronic patients with schizophrenia. The focus was set on:
motor efficiency, motor coordination, motor synchrony; focused, divided
and sustained attention; understanding; mental imagery; motivation. A se-
lection of personality tests was also used to better orient the patients toward
sports that would suit them best. The experimental session lasted 60 min. The
most relevant tests that provided the means to help guide patients in their
choice of sporting activities will be presented. We will also present the first
results obtained for the psycho education program that seemed to help over
half the patients to better understand the importance of sports for their
health. This program may also provide the means to help the patients’ family
to feel more involved in the social rehabilitation of their sibling.
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Drugs commonly prescribed for schizophrenia and other psychotic illnesses
have been shown to increase patients’ risk of developing diabetes including
increased thirst, frequent urination, appetite and rapid weight gain. Al-
though there are a vast array of studies which have demonstrated the psy-
chological and physical health benefits of regular aerobic exercise for
adolescents and adults, studies have not researched in the question of
why patients with schizophrenia do not adhere to sporting activities. Under-
standing the meaning behind a person’s posture or body movement comes
easily to many people and helps guide how we react to others socially. This
understanding is required for team sports but also important in individual
sports where learning comes through observing and understanding the
moves. But people with schizophrenia, even those who have mild to mod-
erate symptoms and take medications, are not fluent in understanding body
language (Paradiso and Andreasen 2006). Motor, cognitive and social def-
icits may thus be the limiting factor for patients to enjoy and to adhere to
regular aerobic exercise. Our project was to use innovating tools—devel-
oped and validated in fundamental research protocols—for the quantifica-
tion of those motor and cognitive deficits observed at an individual level in
patients with schizophrenia. From these results, a psycho education pro-
gram was initiated in order to sensitive patients to their functional deficits
and to choose with them that sporting activity that would best fit their
capacities but also their taste. A series of motor and cognitive tests were
used to quantify motor and cognitive disorders in early onset and chronic
patients with schizophrenia. The focus was set on: motor efficiency, motor
coordination, motor synchrony; focused, divided and sustained attention;
understanding; mental imagery; motivation. A selection of personality tests
was also used to better orient the patients toward sports that would suit them
best. The experimental session lasted 60 min. The most relevant tests that
provided the means to help guide patients in their choice of sporting activ-
ities will be presented. We will also present the first results obtained for the
psycho education program that seemed to help over half the patients to bet-
ter understand the importance of sports for their health. This program may
also provide the means to help the patients’ family to feel more involved in
the social rehabilitation of their sibling.
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Background: Schizophrenia is associated with high rates of cigarette smok-
ing and deficits in sensorimotor gating, as measured by prepulse inhibition
(PPI) of the startle response. However, the relationship between PPI deficits
and smoking status is not clear. The goal of this study was to identify how
smoking status modifies PPI deficits in schizophrenia.
Methods: We studied PPI as a function of smoking status and schizophre-
nia diagnosis in four groups using a cross-sectional design: Smokers with
schizophrenia (SS; n = 14), non-smokers with schizophrenia (SNS; n = 15),
control smokers (CS; n = 11), and control non-smokers (CNS; n = 10). PPI
in smokers was recorded under conditions of smoking satiation, and smok-
ing status was verified biochemically using expired breath carbon monoxide
and plasma cotinine levels. Results: At all prepulse to pulse intervals
(PPTPI’s; 30, 60 and 120 msec), SNS had decreased (;40–50%; P <
.01) PPI compared to CNS. However, when SS were compared to CS under
conditions of smoking satiation, SS had comparable levels of PPI to CS,
and significantly higher levels of PPI than SNS. We also observed signif-
icant Diagnosis x Smoking Status interactions on PPI at all PPTPI
conditions (all P’s <0.05). Conclusions: Our findings suggest that PPI def-
icits are present in nonsmokers with schizophrenia and are significantly
modified by smoking status. Smoking in schizophrenia is associated
with an elevation of PPI to the levels present in non-psychiatric control
smokers. These findings have significant implications for understanding
vulnerability to tobacco dependence in schizophrenia, which can lead to
the development of more effective treatments for PPI deficits in this
population.
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The ability to empathize, ie, to communicate and understand intentions and
feelings, and perceive the emotional states of others as well as in oneself is
a vital skill. Empathy has various definitions, however, according to most
models three core components can be derived: emotion recognition, 2) af-
fective responsiveness, and 3) emotional perspective taking (Decety and
Jackson, 2004). In a preceding behavioral study we showed that patients
with schizophrenia demonstrate deficits in all three empathy components,
thus suggesting a dysfunctional neural network for empathic behavior. The
aim of the study was to gather more information on the neural dysfunctions
underlying the observed empathy deficit. Thus, we measured patients suf-
fering from schizophrenia and matched controls with a 3T MRI scanner (36
slices, TR = 2200 ms, TE = 30 ms, slice thickness 3 mm, gap 0.3 mm) and
applied three paradigms tapping each core component of empathy sepa-
rately. Data analysis indicates a significant empathic deficit in patients,
reflected in their worse performance in all three domains. This deficit
was only partly reflected in the self-report empathy questionnaires. Com-
paring the different tasks, emotional perspective taking was the most dif-
ficult task for all subjects. Preliminary analyses of the functional data reveal
task specific as well as general neural dysfunctions in brain regions asso-
ciated with empathy and emotion processing in schizophrenia patients.
The data indicate that the observed deficits in perceiving and processing
of emotional stimuli leading to a severe impairment in empathic abilities
that is also represented on a neural level. Hence, our data suggest that
patients with schizophrenia suffer from a more general dysfunction of emo-
tional competencies that can also be characterized within the underlying
neural networks. Moreover, our results implicate the necessity to develop
specific training programs to improve empathic abilities in schizophrenia
patients addressing each competency independently in behavioral
therapies, thereby offering a possibility to improve socio-occupational
life. The study was supported by the Interdisciplinary Center for Clinical
Research (IZKF TVN 70) of the Medical Faculty RWTH Aachen Univer-
sity. BD was also supported by the International Research and Training
Group (IRTG 1328, DFG).
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Impairment in working memory processes, including the maintenance of
information to guide future responses, is a commonly reported neurocog-
nitive deficit in schizophrenia that implicates dysfunction of prefrontal
cortex circuitry. The diagnostic specificity of this neurocognitive deficit
to schizophrenia vs. affective psychoses is not known and is of interest
given the common risk genes and neurobiological abnormalities observed
across these disorders. We investigated working memory maintenance in
schizophrenia and affective psychosis patients using an oculomotor delayed
response task—a widely used spatial working memory paradigm translated
into the clinic from laboratory studies with nonhuman primates. In this task
subjects were required to maintain spatial location information in working
memory over a delay period and then execute a saccadic eye movement
guided only by the mental representation of that remembered location.
Thirty-three patients with schizophrenia, 19 patients with psychotic bipolar
disorder, 19 patients with psychotic depression and 42 healthy individuals
were studied. Patients were early in their course of illness and untreated at
the time of testing. Groups were matched on age and estimated IQ. Schizo-
phrenia and affective psychoses patients demonstrated comparably reduced
accuracy of their initial eye movement to remembered locations relative to
healthy individuals. After the opportunity to correct for the error of their
initial movement, only schizophrenia and psychotic bipolar disorder
patients remained impaired in the spatial accuracy of their response. All
patient groups demonstrated normal accuracy of eye movements made
to visible targets. This indicates that the schizophrenia and psychotic
bipolar disorder patients’ impairments were attributable to deficient use
of maintained mental representations of location information to guide
responses and not the execution of precise eye movements. Deficits in
maintaining information in working memory to accurately guide future
behavioral responses appears to be a common trait in schizophrenia and
bipolar disorder, but may be less pronounced in patients with psychotic
depression. These working memory maintenance impairments which are
suggestive of dysfunction of prefrontal system circuitry appear to be
most pronounced in schizophrenia and psychotic bipolar disorder.
Supported by R01 MH62134, R01 MH080066, NARSAD.
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The purpose of this study was to investigate the effects of atypical antipsy-
chotic medications on implicit memory performance in first-break psy-
chotic patients. Atypical antipsychotic medications, such as risperidone,
olanzapine and quetiapine, have become the first-line treatment for schizo-
phrenia. Compared to the typicals, these newer medications have multire-
ceptor profiles and produce fewer extrapyramidal motor symptoms due to
their lower affinity for dopamine D2 receptors in the striatum. Probabilistic
classification learning measures implicit memory and activates the striatum.
A probabilistic classification learning task was administered to 19 controls,
32 first-break psychotic patients being treated with atypical antipsychotics
and 15 non-medicated first-break psychotic patients. Participants were
placed in front of a computer screen and asked to predict the weather
(rain or shine)associated with various shapes. Groups were matched on
age and education. Given the low affinity of atypical antipsychotics for
striatal dopamine D2 receptors, it was hypothesized that controls would
perform better than both patient groups but that performance differences
between medicated and non-medicated patients would be neglible. Interest-
ingly, controls performed significantly better than both patient groups, as
predicted, but non-medicated patients performed significantly better than
medicated patients. Participants were administered 100 trials of the prob-
abilistic classification task and results were analyzed and compared in 5
blocks of 20 trials. All groups showed gradual improvement and demon-
strated learning over blocks with the control group means ranging from
13.89– 17.26, non-medicated patient group means ranging from 12.4–
14.6 and the medicated patient group means ranging from 10.72–12.38.
There was a highly significant group effect, F2,63 = 17.23, P = .000. These
results suggest that, although atypical antipsychotics seem to cause fewer
extrapyramidal motor symptoms, they still may affect striatal functioning.
It will also be important to compare levels of psychopathology between the
patient groups.
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SCHIZOPHRENIA PATIENTS SHOW ALTERED
PROCESSING OF RISK INFORMATION IN THREE
DECISION-MAKING TASKS
Kristen J. Prentice1,2, J. M. Gold1, S. M. August1, B. A. Fischer1,
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We examined decision-making in schizophrenia patients (SZs) and nonpa-
tient controls (NCs) on three tasks in which subjects could win and lose real
money, each with a different risk/reward framework: the Iowa Gambling
Task (IGT); a modified gambling task (MGT); and the Balloon Analog
Risk Task (BART). We focused on how subjects’ choices were influenced
by information about the frequency and magnitude of potential wins and
losses. In the IGT, subjects choose cards from 4 decks where variable fre-
quency and magnitude of wins and losses creates 2 decks with a net gain and
2 with a net loss. In the MGT, 5 decks have equal expected value but dif-
ferent variances of potential win/loss outcomes (low variance is less risky,
high variance is more risky). In the BART, subjects accumulate 2 cents with
each pump of a balloon, but if it pops before they stop to collect their win-
nings, then they win nothing. Thus, each pump increases potential winnings
by 2 cents, but also risks losing all of that trial’s money. Across the tasks,
SZs (N = 53) processed risk/reward information differently than NCs (N =
31). Patients did not show a normal preference for IGT decks with a net
gain over those with a net loss, despite a normal preference for infrequent
(vs. frequent) losses in general. In the MGT, SZs were less risk-averse than
NCs, as they were less likely to avoid the riskiest deck (40% chance of a win,
60% chance of a loss). Patients were also, however, less likely than NCs to
choose the safest deck (100% and 0%). In the BART, SZs made significantly
fewer balloon pumps than NCs, reliably opting to collect their winnings
earlier and, as a result, consistently experienced fewer pops but also
won less money. Patients’ conservatism suggests they were less driven
than NCs to win more, opting instead to avoid winning nothing. These
tasks provide convergent evidence of an altered ability in SZs to integrate
multiple pieces of information needed to generate optimal choices. In the
IGT, SZs showed a diminished ability to pair loss frequency with magni-
tude information needed to generate a normal preference for advantageous
decks. In the MGT, SZs appeared less sensitive than NCs to the outcome
variability underlying the decks’ relative riskiness, thus appearing less risk-
averse. And in the BART, SZs’ apparent risk-aversion and under-appreci-
ation of the magnitude of potential rewards led them to choose small but
certain wins over larger, less certain wins, leaving them at a disadvantage.
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LARGER TIME VARIABILITY FOR BASIC
DECISION PROCESSES IN SCHIZOPHRENIA
Thomas Karantinos1, C. Theleritis1, I. Evdokimidis2,
I. Apostolopoulos2, N. C. Stefanis1, I. Hatzimanolis1,
N. Smyrnis1,2
1Psychiatry Department, National and Kapodistrian University of
Athens, Athens, Greece; 2Department of Neurology, National and
Kapodistrian University of Athens, Athens, Greece
Slower mean Reaction Time (RT), known as psychomotor slowing and an
increased error rate, is well documented in patients with schizophrenia per-
forming the antisaccade task. Fewer studies have shown increased variabil-
ity of RT in these patients suggesting a basic difference in the distribution of
RT. In this study, several antisaccade indices including median RT and its
variability were measured for the antisaccade task performed by 45 patients
and 2006 control subjects. Then average cumulative RT distributions were
derived for each group for both correct antisaccades and error prosaccades
and the RT distribution for each group was modeled using a decision signal
rising linearly to a threshold signaling the beginning of the eye movement.
There was a noticeable increase in the median RT for patients performing
correct antisaccades while the median RT did not differ significantly be-
tween the two groups when performing error prosaccades. More over
the patients RTs were much more variable from trial to trial leading to a dif-
ference in the average RT distribution of the patient group both for correct
antisaccades and error prosaccades. The model application led to the con-
clusion that this difference in the distribution of RT for patients could be
attributed to a basic difference in information processing leading to the de-
cision to move the eyes. The same conclusion was reached in our previous
study for visually triggered saccades performed by these patients and favors
the hypothesis that a fundamental deficit of larger time variability in basic
decision processes might be present in schizophrenia independent of the
specific task used.
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COGNITIVE CORRELATES OF ANHEDONIA IN
FIRST-DEGREE RELATIVES OF PATIENTS WITH
SCHIZOPHRENIA
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There is growing evidence that anhedonia serves as a useful phenotype with
respect to the genetic etiology of schizophrenia. Anhedonia has been asso-
ciated with increased vulnerability to schizophrenia spectrum disorders and
with poor outcome in individuals affected by these disorders. First-degree
biological relatives of schizophrenia patients also exhibit increased anhedo-
nia, particularly those relatives who carry the form of the COMT gene pos-
ited as related to low levels of dopamine in the prefrontal cortex. Although
both anhedonia and cognition seem to be abnormal in first-degree relatives,
it is unclear whether these symptoms are related to a common biological
substrate. Anhedonic individuals from the general population and college
samples have been shown to exhibit impaired visual-spatial working mem-
ory. Anhedonia has also been associated with a decrease in left visual-field
bias in college students, and reduced right hemisphere white matter in peo-
ple with schizophrenia. More recently anhedonia in patients with schizo-
phrenia has been associated with aspects of episodic memory that may
be lateralized in the brain. To explore the possibility that anhedonia and
select cognitive deficits derive from a shared substrate, this study examined
whether episodic and working memory functions thought to be lateralized
in the brain were associated with anhedonia in individuals with genetic li-
ability for schizophrenia. Biological relatives of schizophrenia patients and
nonpsychiatric control subjects completed.verbal and nonverbal working
memory and episodic memory tests. Subjects also completed questionnaires
assessing physical and social anhedonia as well as interviews that assessed
DSM Axis-I diagnoses and cluster A personality characteristics. Analyses
will be carried out to determine whether performance on select memory
tests correlates with scores on social and physical anhedonia scales in bi-
ological relatives. We hypothesize that relatives with higher anhedonia
scores will exhibit a more lateralized pattern of performance and may
also show decreased performance on nonverbal memory tests compared
to controls. Such a pattern of results would support a theory that anhedonia
and cognitive endophenotypes may both relate to right hemisphere function
in individuals with genetic liability for schizophrenia.
ID: 551136
DIFFICULT COMPARISON OF EVENT ONSETS
INDEPENDENT OF INTER-HEMISPHERIC
TRANSFER
Laurence Lalanne-Tongio1, J. R. Foucher1, M. Elliott2,
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Patients with schizophrenia show a disturbed sense of continuity. For Hus-
serl, sense of time continuity is underpinned by integration of past, present
and future events. The sense of present time results from the continuous
integration of successive events in a time window. Inside this window
(30 to 50 ms in controls), all events are considered as simultaneous, and
events must be separated by a delay of 30 to 50 ms to be distinguished
from each other. In previous studies, we suggested that this time window
is enlarged in schizophrenia (Foucher et al. 2007 Schizophrenia Res,
Giersch et al. in press Schizophrenia Bull). To test this assumption, two
bars had been presented left and right from the centre of the screen and
subjects decided if bars appeared simultaneously or asynchronously. Given
that synchronization of neurons coding the events may underlie the percep-
tion of present time (Elliott et al. 2006, J Cogn Neurosci), and given that
inter-hemispheric transfer might be impaired in patients, we checked
whether the difficulty of the patients was due to presentation of stimuli
in different hemifields. In the present study, continuous eyetracking en-
sured that stimuli were presented in the same or in different hemifields.
SOAs varied between 0 and 96 ms. Our results confirm that patients
have a difficulty to consciously detect an asynchrony between stimuli
and show an inter-hemispheric cost of similar amplitude in patients and
controls. However, patients are very sensitive to the apparition of the first
stimulus, even if it precedes the second one by only 8 ms. Analysis based on
response-compatibility effects in different conditions (the first and second
stimulus in the same or opposite hemifields) shows that patients correctly
followed instructions. Sensitivity to short-duration stimulus was correlated
with impaired asynchrony detection. Patients would have a difficulty to
consider separated stimuli together, and thus to compare them. Given
that the effect of inter-hemispheric processing is similar in both groups, im-
paired mechanisms probably require more indirect pathways than inter-
hemispheric connexions, like antero-posterior connexions and top-down
mechanisms. Difficulty to code separated events in time may originate
impairments in cognitive functions that entail the smooth sequencing of
different events, like language to motor action.
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PRESERVED BINDING IN VISUAL PERCEPTION
AND ATTENTION NORMALIZES WORKING
MEMORY IN PATIENTS WITH SCHIZOPHRENIA
Anne Giersch1,2, D. Luck1, C. Huron2
1U666, INSERM, Strasbourg, France; 2of Psychiatry, University
Hospital, Strasbourg, France
Patients with schizophrenia are impaired at binding visual elements, but the
impact of this impairment on working memory is still discussed. Here we
base the work on results showing that patients display impaired top-down
control in visual perception, but still benefit from binding by proximity, and
are able to focalize on object groups (Giersch and Rhein, J Abn Psychol
2008). Evaluation of both perception and memory performance allows
to explore whether preserved abilities help patients to memorize pairs of
objects and to which amount impaired top-down control impedes memory.
28 stabilized patients and matched controls were submitted to a memory
task after each of three different visual perception blocks run in random
order. During these blocks, subjects had to find two identical figures dis-
played among seven different objects. Proximity was manipulated and tar-
gets were located in the same pair or belonged to two different groups.
According to the proportion of target types (within the same pair or belong-
ing to different groups), the block incited subjects to focalize on either
within or between-group pairs of objects. Each block was followed by
a memory task designed with the same figures and the same proximity ma-
nipulation. After the encoding phase of 2500 ms and an ISI of 1000 ms, one
of the 5 figures presented at encoding was displayed with a question mark
on one side of the figure. Subjects had to recognize which figure had been
displayed in the location of the question mark. At encoding, the two figures
had been within a pair of objects (within-group trials) or in different pairs
(between-group trials) in equal proportion. This design allowed to attribute
a change in performance across memory blocks to the attentional incentive
during the visual perception task. There was no effect of visual perception
on memory in controls. In patients however, memory accuracy was corre-
lated with the ability to focus on within-group pairs in visual perception.
Memory for within-group trials was normalized for patients able to focus
attention, except when the visual perception task incited to prioritize be-
tween-group pairs. Preserved grouping coupled with attentional prioritiza-
tion can thus help memorization in patients. This effect is fragile, however,
possibly related with weak binding in memory and high sensitivity to dis-
tractors. The results give original indications regarding the kind of mech-
anisms which should be cared for during cognitive remediation.
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STIMULATION ON PROBABILISTIC CATEGORY
LEARNING IN PATIENTS WITH SCHIZOPHRENIA
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Schizophrenia has been characterized, in part, by debilitating cognitive
impairments which, in general, are more informative indicators of the bi-
ological basis of the illness than measures of psychotic symptoms. The most
reliable cognitive deficits, common to the majority of patients, are those
related to prefrontal cortex dysfunction. Probabilistic category learning
is one such cognitive process shown to rely on frontal-striatal activation
in healthy adults that generally elicits a deficit in patients with schizophre-
nia relative to healthy adults that is suggestive of prefrontal cortex dysfunc-
tion. Weak anodal transcranial Direct Current Stimulation (tDCS) of the
dorsolateral prefrontal cortex has been shown to improve probabilistic cat-
egory learning in healthy adults. The aim of the current study was to eval-
uate the therapeutic efficacy of weak anodal tDCS of the dorsolateral
prefrontal cortex to reverse probabilistic category learning deficits in
patients with schizophrenia. Using a single-blind, cross-over, counter-bal-
anced, within-subject design, anodal tDCS at an intensity of 2.0 mA or
sham stimulation was administered continuously for 20 minutes to the
left dorsolateral prefrontal cortex of patients with schizophrenia while
they performed 150 trials of the ‘‘weather prediction’’ probabilistic category
learning test. Each individual participated in three testing sessions on dif-
ferent days over the course of one week, an initial baseline session without
stimulation followed by randomized presentation of one active and one
sham tDCS session. Preliminary results indicate that the patients showed
an increase in percent correct, a reduction of omissions and a reduction in
reaction times during active stimulation relative to no stimulation at base-
line and sham conditions. These results suggest that tDCS may provide
a therapeutic benefit by improving cognitive function in patients with
schizophrenia.
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DRUG USE IS NOT ASSOCIATED WITH GREATER
COGNITIVE IMPAIRMENT IN FIRST-EPISODE
PSYCHOSIS PATIENTS.
Kim Donoghue1, R. Mazzoncini2, J. Hart2, J. Zanelli2,
A. Reichenberg2, C. Morgan2, P. Fearon2, P. Dazzan2,
R. M. Murray2, P. B. Jones3, G. A. Doody1
1Division of Psychiatry, University of Nottingham, Nottingham,
United Kingdom; 2Institute of Psychiatry, Kings College London,
London, United Kingdom; 3Department of Psychiatry, University of
Cambridge, Cambridge, United Kingdom
Cognitive impairment is a core feature of schizophrenia. Due to the detri-
mental effects of drug use on cognitive function in healthy individuals, there
is concern that schizophrenia plus the misuse of drugs may result in a mor-
e pronounced deficit in cognitive function. The aim of this study is to
investigate the association between drug use and cognitive function in those
with a first-episode psychotic disorder and community matched controls. A
comprehensive battery of neuropsychological tests were administered to
four groups of participants; 108 with an ICD-10 diagnosis of a psychotic
disorder (Psych), 94 participants with an ICD-10 diagnosis of a psychotic
disorder plus drug use (Psychþ), 85 community matched controls (Cont)
and 27 community matched controls plus drug use (Contþ). Both of the
psychosis groups performed worse than Cont group on tests of working
memory, visual and verbal memory, executive function and visual attention
and psychomotor speed. None of the comparisons between the Cont group
and Psych or Psychþ groups were significant. There were no differences
between drug users and non-drug users for those with a psychotic disorder.
When comparing drug users and non-drug users within the controls, the
Contþ group performed significantly worse than the Cont group on
a task of working memory. Analyses were repeated for only those partic-
ipants with a diagnosis of schizophrenia or schizoaffective disorder, similar
results were obtained. Individuals with a diagnosis of a psychotic disorder
show a wide spread impairment in cognitive function compared to controls
that do not use illicit drugs. However, those with a psychotic disorder tend
to perform at an equal level to community matched controls that use drugs.
It appears that concurrent drug use in those with a psychotic disorder does
not result in greater impairment in cognitive function at the first-episode.
Longitudinal studies are required to further investigate the effects of sub-
stance use on cognitive function in individuals with a psychotic disorder.
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ANTITHETICAL ASYMMETRY IN SCHIZOPHRENIA
AND BIPOLAR AFFECTIVE DISORDER: A LINE
BISECTION STUDY
Naren P. Rao, R. Arasappa, N. N. Reddy,
G. Venkatasubramanian, Bangalore, N. Gangadhar
Psychiatry, National Institute of Mental Health and Neurosciences,
Bangalore, India
Evolutionary theories link pathogenesis of psychoses with anomalous
brain asymmetry (DeLisi et al., 1997). Aberrant lateralization is linked
to schizophrenia with elevated rates of lefthandedness and reversal of nor-
mal cerebral asymmetries. Moreover, a paternally transmitted imprinted
gene-LRRTM1 is associated with handedness and schizophrenia.Line bi-
section task is a valid test to assess behavioral manifestations of cerebral
asymmetry (Morton, 2003).Reports suggest rightward bias in schizophrenia
in contrast to normal leftward pseudoneglect. However, lateralization is yet
to be explored in bipolar affective disorder (BPAD).We, for first time, re-
port concurrent analyses of asymmetry in schizophrenia and BPAD using
line bisection task.Study group consisted of 30 schizophrenia and 31BPAD
patients and 103 healthy controls. A 2-hand line bisection task with estab-
lished methodology was used.Task consisted of 20 horizontal black lines of
width 70 to 160 mm randomly placed to the right or left side of paper. Sub-
jects were asked to bisect each line at center first from right hand and then
from left, on separate sheets. Raters with good interrater reliability
(ICC>0.8) measured deviation from center. Study groups did not differ
significantly on age, sex and handedness (P > 0.06). Task performance
was compared using analysis of covariance (age, sex and education as cova-
riates).Patients (schizophrenia and bipolar) had significantly greater errors
in identifying center than controls (P < .001). On further analysis between
schizophrenia and BPAD, there was a significant rightward deviation in
schizophrenia (P = .04) and trend towards leftward deviation in BPAD
(P = .10). There was a significant interaction between diagnosis and direc-
tion of deviation (P = .01). Our findings suggest the accentuation of normal
pseudoneglect in BPAD and attenuation in schizophrenia. That is, schizo-
phrenia patients showed a tendency towards symmetry, supporting im-
paired laterality and right hemisphere involvement (Mitchell and Crow,
2005). Thus, from an evolutionary perspective, schizophrenia and BPAD
may lie along a continuum.
References
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asymmetry and language processing in schizophrenia. Schizophr Bull,
1997;23:255–71.
2. Mitchell RL, Crow TJ. Right hemisphere language functions and
schizophrenia:the forgotten hemisphere? Brain, 2005;128:963–78.
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NEUROCOGNITIVE DEFICITS ARE ASSOCIATED
WITH PSYCHOTIC-LIKE EXPERIENCES AFTER
CANNABIS.
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Background: The relationship between cannabis and psychotic disorders is
still under debate. It is clear however that in some individuals even recre-
ational use of cannabis can lead to a transient period where some symptoms
of psychosis are experienced. There is extensive anecdotal evidence for in-
dividual differences in the experiences which people have after smoking
cannabis. Previous work has shown that schizotypy may mediate the expe-
riences which people have when smoking cannabis (Barkus et al., 2006; Bar-
kus and Lewis, 2008). Specifically, those who score higher on schizotypy are
more likely to experience psychotic-like immediate effects and report more
after effects from cannabis use. Given that altered cognitive performance
has been associated with both schizotypal trait and cannabis use, it is pos-
sible that cognition may have a role in mediating the experiences which peo-
ple have when they use cannabis. We hypothesised that individuals who
reported psychotic-like experiences after cannabis use would have impaired
cognitive performance across multiple domains of cognition. Method: We
tested fifty participants (mean age 23 years) who had been selected on the
basis of their scores on the psychotic-dysphoric subscale on the Cannabis
Experiences Questionnaire (Barkus et al., 2006). They were tested on meas-
ures of working memory, spatial working memory, executive functioning
and learning. Groups were well matched on other recreational drug use and
patterns of cannabis use. Results: Those who reported psychotic-like expe-
riences after cannabis reported higher scores on neuroticism and emotional
reactivity (t = 2.479, P < 0.05 and t = 2.739, P < .05 respectively), these
effects were independent of gender. Those who had psychotic-like experi-
ences had more between search errors on the spatial working memory
task and longer latencies on a working memory task; while there were
no differences on attention and Trails A and B. Conclusion: In the absence
of differences in patterns of cannabis use, individuals who have
psychotic-like experiences after cannabis do demonstrate some cognitive
deficits, particular in working memory. These cognitive deficits occur in
the absence of differences in patterns of cannabis use.
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THEORY OF MIND AND NEUROCOGNITION IN
FIRST-EPISODE SCHIZOPHRENIA
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This study aims to investigate the extent, impact and specificity of ‘theory of
mind’ (ToM) impairment in first-episode schizophrenia. Numerous studies
have demonstrated that people with chronic schizophrenia are impaired in
their abilities to accurately infer other people’s thoughts and hence to take
appropriate account of other people’s mental states in social interactions.
Such impairments are significant and impact upon the patients’ real-world
social functioning. In order to examine whether such impairments represent
a trait marker of schizophrenia, 22 first-episode schizophrenia patients were
recruited from two early psychosis intervention services in New South
Wales, Australia. Fourteen patients were diagnosed with schizophrenia,
two with schizoaffective disorder, and six with schizophreniform disorder.
Nineteen age and gender-matched healthy controls were also recruited from
the general community. All participants completed a battery of three ToM
tasks, as well as neurocognitive tests of IQ, attention, memory, and exec-
utive function (planning, set-shifting and semantic fluency). Symptom se-
verity, socio-occupational functioning and quality of life were also assessed
in the patients. Significant group differences were found for most tasks. A
composite ToM score, semantic fluency and verbal memory showed the
largest effect sizes (d’s = 2.32, 2.39, 2.03). While neurocognitive meas-
ures correlated with ToM scores, logistic regression analysis revealed that
the best (independent) predictors of group membership were the ToM and
semantic fluency scores. Both of these measures correlated significantly
with levels of negative, but not positive, symptoms, while it was the seman-
tic fluency score which better predicted socio-occupational functioning and
quality of life in the patients. In conclusion, the study findings indicate that
selective ToM impairments are evident in first-episode schizophrenia, con-
sistent with the proposal that such impairments are domain-specific and
represent a trait marker of schizophrenia.
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ACUTE AND CHRONIC PCP-INDUCED COGNITIVE
PERFORMANCE DEFICITS IN THE 5-CHOICE
SERIAL REACTION TEST: INFLUENCE OF
CLOZAPINE
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Cognitive deficits are a core feature of schizophrenia that respond mini-
mally to existing drugs. Improved translational models with greater predic-
tive validity are required to identify treatments that are most likely to be
clinically effective. We have shown that repeated PCP treatment to rats
reproduces dysfunctional prefrontal cortex activity (hypofrontality)
(Cochran et. al. 2003 Neuropsychopharmacology 28: 265–75; Pratt et al.
2008 Brit. J. Pharmacol, 153 Suppl 1:S465–70.). Since hypofrontality cor-
relates with cognitive performance in schizophrenia, the aim of this study
was to determine if PCP elicits deficits in a cognitive task that recruits the
prefrontal cortex. We selected the 5-choice serial reaction time task (5-
CSRTT) since this test measures aspects of attentional function related
to the Continuous Performance Task in humans. To increase the transla-
tional validity of this approach we employed analysis taken from signal de-
tection theory (SDT). Long Evans rats were trained to criteria in the 5-
CSRTT. PCP (2.6 mg/kg i.p.) was administered according to our chronic
intermittent treatment regime (Cochran et. al. 2003) in the presence or ab-
sence of clozapine (20mg/kg/day). A range of attentional performance and
inhibitory control measures were recorded. In addition, SDT analysis of
perceptual sensitivity and discriminability measures were employed. Meas-
urements were made in the presence and absence of PCP intermittently over
the treatment period. There was a marked increase in anticipatory respond-
ing 30min following PCP injections (F1,34 = 5.34 P < .05) that was main-
tained throughout the four-week treatment protocol. Clozapine did not
reduce the PCP-induced increases in anticipatory responding although
there was a modest ability to restore sustained PCP-induced deficits in per-
ceptual sensitivity; a measure of discriminative accuracy impaired in schizo-
phrenia. Taken together, these results support the view that performance
deficits in the 5-CSRTT induced by PCP may be of relevance to schizophre-
nia. The modest ability of clozapine to restore these deficits is in line with
the minimal effects of the drug in restoring cognitive processes in the clinic
and its inability to restore hypofrontality. In conclusion, PCP-induced def-
icits in the 5-CSRTT may be a useful model for identifying new agents that
may be clinically effective in schizophrenia.
Supported by former Mitsubishi Pharma Co. (currently Mitsubishi Tanabe
Pharma Co.)
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EMOTIONAL-SOCIAL INTELLIGENCE IN
PATIENTS WITH SCHIZOPHRENIA AND THEIR
HEALTHY SIBLINGS
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Background: Emotional intelligence is concerned with understanding one-
self and others, relating to people, and adapting to and coping with the
immediate surroundings to be more successful in dealing with environmen-
tal demands. Higher scores on emotional intelligence tests have been asso-
ciated with various indicators of social adaptation. Aims: The aim of this
study is to investigate emotional intelligence in patients suffering from a first
psychotic episode in order to identify social cognitive markers for develop-
ing a non-affective psychosis. Method: 32 patients, 32 siblings and 32
healthy volunteers completed the Bar-On Emotional Quotient Inventory
(EQ-i. The EQ-i is a self-report measure of emotionally and socially intel-
ligent behavior, which provides an estimate of one’s underlying emotional
and social intelligence. The Hinting Task(a theory of mind task) and a short
version of the Wechsler Adult Intelligence Scale were also measured.
Results: The groups differ significantly on total EQ-I scores (F = 35.8,
P < .001) and all of the subscales. Post hoc tests revealed that the patients
had lower scores than both other groups. The siblings had significantly
lower scores than the control subjects. The difference remains significant
when the EQ-I scores are corrected for IQ and theory of mind (F =
13.9, P < .001). Discussion: The differences in emotional intelligence be-
tween the groups may provide an explanation for the deficits in social func-
tioning of patients with schizophrenia.
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2Department of Neurology, Psychiatry and Sensory Sciences,
Faculty of Health Sciences, University of Copenhagen, Copenhagen,
Denmark; 3Center of Neuropsychiatric Schizophrenia Research,
Psychiatric University Centre Glostrup, Glostrup, Denmark
In schizophrenia, cognitive impairment is believed to be one of the overall
decisive factors for a patients’ community functioning. Healthy subjects re-
ceiving the NMDA antagonist phencyclidine (PCP) have been reported to
experience a schizophrenia-like psychotic state. Concordantly, injection of
PCP in laboratory animals has been shown to induce abnormalities similar
to those observed in patients with schizophrenia.
The purpose of this study was to evaluate sub-chronic and early postnatal
treatment of PCP in rats as preclinical models of schizophrenia. Briefly, for
the sub-chronic paradigm Lister Hooded rats were treated with PCP,
5 mg/kg, BID for 7 days and tested 8 days after the last dose. For the early
postnatal treatment regime, PCP (20 mg/kg) was administered on postnatal
days (PNDs) 7, 9, and 11 and rats were tested in adulthood (ie, after PND
56). Rats were tested in an attentional set-shifting task addressing cognitive
deficits, specifically deficits in executive functioning. The test requires sub-
jects to respond to various extra dimensional-intra dimensional (EDID)
shifts in accordance with changing rules. Data analyses were performed us-
ing a general linear model followed by Tukey post-hoc analyses.
The data showed that rats treated with PCP, ie, both models, were selec-
tively impaired in performing the extra dimensional shift compared to a con-
trol groups (P< .05). In order to further validate the preclinical models, we
tried to reverse the PCP induced deficits with two drugs, which were chosen
due to their potential as clinically relevant drugs in the treatment of cog-
nitive deficits associated with schizophrenia. Sertindole, a 2nd generation
antipsychotic, which has shown to reverse cognitive deficits significantly
more than haloperidol and the AMPAkine (ie, potentiator of alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor function)
CX516. Both sertindole and CX516 showed significant (P < .05) effects
in their ability to reverse the PCP induced deficits to the levels of the control
group. Taken together, these data suggest that sub-chronic and early
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postnatal treatment of PCP, demonstrates a phenotypes, which in some
aspects resembles the symptoms observed in patients with schizophrenia.
Both models also seem to have some predictive value. However, this cannot
be fully concluded until the effect of the tested drugs on the cognitive do-
main has been firmly established in clinical trials.
ID: 550956
COGNITIVE EFFECTS OF 6-MONTH QUETIAPINE
TREATMENT IN ANTIPSYCHOTIC-NAI¨VE
FIRST-EPISODE SCHIZOPHRENIC PATIENTS
Rune Andersen1,2, A. Gade2, B. Fagerlund3, B. Oranje1,
B. Y. Glenthoj1
1Center for Neuropsychiatric Schizophrenia Research, University
Psychiatric Center Glostrup, Glostrup, Denmark; 2Department of
Psychology, Copenhagen University, Copenhagen, Denmark;
3Center for Child and Adolescent Psychiatry, Bispebjerg University
Hospital, Copenhagen, Denmark
Studies have found that atypical antipsychotics improve some cognitive
deficits in schizophrenia, although it is unclear whether improvements
are due to ameliorated cognitive functions, placebo effects, or retest-effects.
Very few treatment studies have included both first-episode antipsychotic-
naı¨ve schizophrenic and matched healthy controls, and may therefore be
confounded by prior medication and retest effects on neuropsychological
tasks. Effects of quetiapine on cognition were investigated in a group of
first-episode antipsychotic- naı¨ve patients with schizophrenia (n = 24). A
comprehensive battery of neuropsychological tests was administered at
baseline and after 6 months of treatment with quetiapine (mean dose
519.6 mg/day; S.D. = 297.4). In order to control for retest effects, a matched
and untreated healthy control group was also tested at baseline and after 6
months. At baseline, patients performed significantly worse than controls
on measures of intelligence, attentional set shifting, sustained attention,
spatial working memory, spatial memory span, processing- and psychomo-
tor speed, verbal and figural fluency, and verbal memory. While patients
seemed to improve at follow-up on a number of these measures (within-
group tests), they were found to improve significantly only on measures
of attentional set shifting and speed of processing when controlled for retest
effects (between group tests). The results suggest that cognitive changes af-
ter treatment with quetiapine may mainly be due to retest effects. However,
certain cognitive measures are also improved beyond retest effects, which
supports some efficacy of quetiapine on cognition. The results emphasize
the importance of controlling for retest effects, by including baseline-and
follow-up assessments of healthy controls, in order to distinguish retest
effects from cognitive amelioration.
ID: 550949
PRENATAL STRESS DIFFERENTIALLY IMPACTS
THE SOCIAL AND ANXIETY-RELATED
BEHAVIORS OF ADULT MALES AND FEMALES
Kalynn M. Schulz, J. N. Pearson, E. W. Neeley, R. Berger,
S. Leonard, K. E. Stevens
Psychiatry, University of Colorado Denver, Aurora, CO, USA
Schizophrenia is a disease with etiological links to the prenatal period. In
particular, stress during the second trimester of pregnancy is associated
with increased incidence of schizophrenia in offspring. The current study
sought to better characterize the effects of prenatal stress on behaviors
associated with the negative symptoms of schizophrenia such as social
withdrawal. In addition, given that anxiety disorders are common in
schizophrenia, we sought to characterize the effects of prenatal stress
on adult anxiety-related behavior. Both the severity of negative symptoms
and comorbidity with anxiety disorders differ between male and female
schizophrenia patients. The negative symptoms tend to be more severe
in men than women, but women are more likely to exhibit an anxiety
disorder, suggesting that the neurodevelopmental underpinnings of this
disease differentially effect the expression of symptoms across gender.
Given these gender differences found in schizophrenia, we tested the hy-
pothesis that prenatal stress will cause sex-specific changes in adult social
interactions and anxiety-related behaviors. This hypothesis predicts that
prenatal stress will impair social interactions of adult males more so than
adult females, and will increase anxiety behavior in adult females more so
than in males. Sprague-Dawley rats experienced random stress 2–3 times
daily during the last week of gestation (P14–21). At weaning, the offspring
of the stressed and nonstressed dams were assigned to same-sex treatment
groups (male vs. female, stressed vs. nonstressed; n = 10; overall N = 40).
In adulthood, animals were tested for anxiety-related behavior in an el-
evated zero maze and social behavior in an open field with a same-sex
same-treatment partner. Prenatal stress significantly decreased the
amount of time spent in the open areas of the zero maze in females
[F1,18 = 4.45, P < .05], but not males [F1,18 = 0.32, P > 0.05], indicating
that prenatal stress increased anxiety only in females. In contrast, prenatal
stress decreased the amount of time males sniffed partners, and slightly
increased the duration of sniffing in females [sex x treatment interaction
F1,36 = 4.32, P < .05], indicating that prenatal stress decreased social inter-
actions in males but not females. These data suggest that prenatal stress
differentially impacts males and females to bring forth sex-specific adult
behaviors similar to those observed in schizophrenia.
ID: 550934
COGNITIVE REMEDIATION THERAPY FOR
SCHIZOPHRENIA IN MALAYSIA
Muhammad Najib Mohamad Alwi1,2, A. W. Harris1, P. Boyce1,
M. R. Salleh2
1Discipline of Psychological Medicine, University of Sydney,
Sydney, NSW, Australia; 2Department of Psychiatry, School of
Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia
Cognitive Remediation Therapy (CRT) was introduced in Malaysia in
2006. The effectiveness of computerised cognitive remediation using the
principles of Neuropsychological Educational Approach to Remediation
(NEAR) was studied in a randomized controlled trial involving five treat-
ment centres throughout Malaysia. The main difference in this treatment
model was the use of a web-based assessment for neurocognition and minor
adjustments that had to be done to accommodate for lack of resources in
a developing country. This study investigated whether a 20 session inter-
vention with CRT was more efficacious than wait list in reducing cognitive
deficits and improving psychosocial functioning. It was also designed to
investigate whether or not there would be any additional benefit of adding
four booster sessions following completion of CRT. In the first phase,
schizophrenia patients with cognitive deficits were recruited and randomly
allocated into either CRT group (n = 30) or Waitlist (n = 30). They were
assessed at baseline and post-treatment using measures of cognitive func-
tioning, psychosocial functioning and psychopathology. In the second
phase, patients including those from the waitlist were randomly allocated
into standard treatment (n = 20) or booster group (n = 20). In the booster
group, after receiving 20 sessions of CRT an additional four sessions were
given after a two weeks gap. The same measurements were repeated 5 weeks
post standard treatment. Patients receiving CRT demonstrated significant
improvements in both verbal and visual memory and a trend towards im-
provement in processing speed and attention. There was also significant
improvement in psychosocial functioning and a positive trend in psycho-
pathology. However, booster sessions did not contribute to any additional
benefit. In conclusion, CRT is effective for Malaysian patients with schizo-
phrenia, although adding booster sessions did not give additional
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advantage to patients. This may reflect the brief period between CRT and
booster sessions. Thus, CRT is a promising treatment option for schizo-
phrenia patients with cognitive deficits in Malaysia. This further supports
the role of CRT in the treatment of schizophrenia.
ID: 550930
RESPONSE INHIBITION AND RESPONSE
MONITORING OF SACCADES IN A STOP SIGNAL
TASK IN SCHIZOPHRENIA AND BIPOLAR
DISORDER
Katharine Natasha Thakkar1, J. D. Schall1, L. Boucher1,
G. D. Logan1, S. Park1,2
1Psychology, Vanderbilt University, Nashville, TN, USA;
2Psychiatry, Vanderbilt University, Nashville, TN, USA
Objective: The goal of this study was to investigate response inhibition and
response monitoring in individuals with schizophrenia (SZ) and bipolar dis-
order (BP) using a saccadic stop signal task, which assesses the ability to
stop a planned action. Research from nonhuman primates have identified
specific neural correlates of both the stopping and monitoring of behavior
during this task. Methods: SZ patients, BP patients and demographically-
matched control participants performed a saccadic stop signal task. On no-
stop signal (NSS) trials, a peripheral target appeared, and subjects were
instructed to look towards it. On stop signal (SS) trials, the fixation point
was re-illuminated after a variable delay (stop signal delay; SSD) following
the initial target, and subjects were instructed to withhold the saccade. Suc-
cessfully inhibited trials were labeled as cancelled, and trials in which they
failed to inhibit were labeled noncancelled. As SSD increases, successful
inhibition becomes more difficult. The probability of failing to cancel at
each SSD describes the inhibition function. The duration of the inhibitory
process (stop signal reaction time; SSRT) was determined according to
a race model. Response monitoring was indexed by the magnitude and di-
rection of RT adjustments as a function of performance in the prior trial.
Results: Preliminary results suggest that SSRT is increased in SZ, but not in
BP, compared to healthy controls. Longer SSRT was associated with in-
creased positive symptoms. Across groups, the greatest RT slowing fol-
lowed cancelled trials, with less slowing following noncancelled trials.
SZ patients showed enhanced RT adjustments based on trial history. Com-
pared to both BP patients and healthy controls, SZ patients showed greater
RT slowing after successfully cancelled stop-signal trials. Conclusions:
Results suggest that SZ but not BP, patients require more time to inhibit
a planned response, compared to controls, and the time needed to cancel
a response is associated with increased positive symptoms. This deficit
exists despite greater RT adjustments, which were enhanced compared
to both healthy and BP participants. Results speak to the nature of inhib-
itory deficits in SZ, and provide evidence for potentially enhanced response
monitoring, compared to healthy controls and a psychiatric control group.
(Supported by F32-EY016679, P30-EY08126, Ingram Chair in Neurosci-
ence, MH073028).
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NEUROPLASTICITY-BASED COGNITIVE TRAIN-
ING IMPROVES REALITY MONITORING IN
SCHIZOPHRENIA PATIENTS: BEHAVIORAL AND
FMRI ASSESSMENTS
Karuna Subramaniam1, T. Luks2, S. Aldebot1, A. Hearst1,
A. Thangavel1, M. Fisher1, C. Garrett1, G. V. Simpson2,
S. Nagarajan2, S. Vinogradov1
1Psychiatry, UCSF, San Francisco, CA, USA; 2Radiology, UCSF,
San Francisco, CA, USA
Prior research indicates that schizophrenia patients (SCZs) are impaired at
identifying themselves as the source of self-generated information (reality
monitoring). They also show relatively decreased activation within the dor-
sal medial prefrontal cortex (dMPFC) compared to healthy comparison
subjects (HCs) when engaged in this process (Vinogradov et al., 1997;
2006). In the present study, we investigated whether this deficit is amenable
to a behavioral intervention. Twenty four SCZs and 12 HCs underwent an
fMRI source-memory task at baseline. Twelve SCZs were then randomly
assigned to 80 hours of computerized targeted cognitive training (TCT) that
focused on auditory and visual processing, facial affect recognition, and
mentalizing tasks. The other twelve SCZs were assigned to a control con-
dition of 80 hours of computer games (CGs). All subjects repeated the task
after the 16-week intervention. Prior to scanning, subjects were presented
with sentences, where the final target word was either supplied by the ex-
perimenter, or left blank for subjects to generate themselves. During scan-
ning, subjects were presented with target words, and decided whether they
were experimenter-presented or self-generated. BOLD fMRI activity was
measured on a 3T GE scanner (EPI; TR = 1sec, 14 slices) before and after
the intervention. Images were analyzed using SPM2. At baseline, patients
were significantly more impaired on each category within the source-mem-
ory task, relative to controls. Whole-brain analyses focused on brain
regions showing greater activation for correctly remembered self-generated
versus externally presented items (a self-referential effect). Across 12 HCs at
baseline, the largest region that demonstrated this self-referential effect was
dMPFC. In contrast, at baseline, all SCZs showed deactivation in bilateral
frontal regions. Paired t-tests indicate that after 16 weeks of computer
games compared to baseline, CG subjects showed increased activation in
bilateral occipital gyri during self-referential processing. In contrast, after
16 weeks of TCT exercises compared to baseline, TCT subjects showed in-
creased activation in dMPFC during self-referential processing. These
fMRI results indicate a possible ‘‘restorative’’ effect of targeted training
in schizophrenia subjects, not observed in computer games control subjects,
whereby behavioral performance on a self-referential source memory task is
improved and brain activation patterns are ‘‘normalized.’’
ID: 550910
RELIABILITY OF REPEATED ASSESSMENT OF
ATTENTIONAL PERFORMANCE IN INDIVIDUALS
AT RISK FOR PSYCHOSIS AND IN THE FIRST
EPISODE OF SCHIZOPHRENIA
Tejal Kaur, K. M. Shafer, K. S. Cadenhead
Department of Psychiatry, University of California, San Diego,
La Jolla, CA, USA
As attentional deficits, particularly the CPT-IP paradigm, have been
implicated as an endophenotypic marker suggesting predisposition towards
psychosis, this study aims to examine the reliability of repeated CPT-IP
assessment in young adults at risk for schizophrenia. Subjects at risk for
psychosis (AR N = 51), patients in their first episode of schizophrenia
(FE N = 21), and normal comparison subjects (NC N = 36) were assessed
for attentional performance on the d’ measure of the CPT-IP at baseline
and follow-up ranging from six months to one year. The reliability of
CPT-IP over the subjects’ initial and follow up visit was examined to assess
whether the paradigm is a stable measure of attentional deficits. A repeated
measures ANOVA displayed a significant overall group effect (F2,105 = 7.2,
P = .001) with post hoc tests revealing that first episode subjects displayed
significant attentional impairments in comparison to the AR and NC sam-
ples. However, the AR sample did not differ significantly from the NC sam-
ple. While all groups improved in performance over time (F1,105 = 19.4, P<
.000), there were no group by time interaction effects. Paired samples t-test
correlations revealed all CPT conditions were stable across groups in the
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AR and NC samples, while only the Numbers Slow condition and Shapes
Fast condition were stable in the FE sample. On longitudinal assessment,
the CPT-IP appears stable within control and at risk populations on all
measures of d’, however some variability is observed in the first episode
sample, perhaps indicative of the neurodevelopmental processes and dy-
namic changes in the early stages of illness. The reliability of particular
measures of the CPT-IP across all groups confirms the validity of the
CPT-IP paradigm as an endophenotypic marker for schizophrenia which,
combined with clinical and genetic risk factors, may improve our ability to
predict which individuals are at greatest risk for developing psychosis.
This work was supported by the National Institute of Mental Health Cog-
nitive Assessment and Risk Evaluation (CARE, MH60720).
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FUNCTIONAL ASSOCIATIONS OF DECLARATIVE
MEMORY DEFICITS IN SCHIZOPHRENIA
Perry Mihalakos1, B. Thomas1, H. Kirane1, A. Wagner2,
C. Tamminga1
1Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA;
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Schizophrenia (SCZ) is broadly defined by psychosis and diverse cognitive
abnormalities, with declarative memory deficits among the most noted. In
healthy persons, declarative memory reliably encapsulates representations
of facts and events which subsequently enable novel inferences and general-
izations about the world and self. This study employs the acquired equiv-
alence task (AE) and conjunctive memory task (CM) to analyze declarative
memory in schizophrenic subjects on- or off-antipsychotic drugs (APDs)
(SZ-on vs. SZ-off) and healthy volunteers (NV). The AE was used as a per-
formance measure and fMRI paradigm to localize BOLD-activations as-
sociated with deficits in ‘generalization’; likewise, we are using the CM
to dissociate mnemonic processes required for ‘inference-making’ from sim-
ple declarative recall. Results (NV N = 20, SZ-on N = 40, SZ-off N = 16)
from the AE are nearly complete, showing SZ-on and SZ-off to have intact
memory for trained-item recall (NV 9863%; SZ-on 9963%; SZ-off 9763%;
P = .82). However, there is a selective medication effect on ‘generalization’
performance (t-test, SZ-off 5963%, NV 9163%, P = .001); in contrast to SZ-
off, when tested on-medication, ‘generalization’ performance improved sig-
nificantly (t-test, SZ-on 7564% vs. SZ-off 5963%, P = .04). A preliminary
SPM group analysis shows that NV (N = 7) activated hippocampus proper
during the ‘generalization’ trials as contrasted with the trained-item trials,
whereas SZ-on (N = 10) failed to show any activation in hippocampus. Vox-
el-level subtraction of the SZ-on from the NV shows a significant activation
decrement in SZ-on within the hippocampus, albeit analyzed at a P = .05
level. A complementary trend is emerging from preliminary CM data (NV
N = 11, SZ-on N = 13, SZ-off N = 2) showing that SZ-on performs similarly
to NV on trained sets of face-house pairs but worse than NV on unlearned
(related via ‘inference’ only) face-face pairs (P = .056, d’ = .81). We hypoth-
esize that whole-brain group analysis of the CM will also reveal task-related
hypofunction in the medial temporal lobe (MTL) in SZ , with further alter-
ations in the basal ganglia and prefrontal cortex. Results already demon-
strate MTL-hypofunction to be associated with selective impairment of
declarative memory in schizophrenia, specifically during trials requiring
generalization or inference-making. APD treatment may partially remedi-
ate, but not fully repair, memory performance in these contexts.
ID: 551929
SCHIZOPHRENIA: MEASURING BRAIN
PLASTICITY
Michael Miran1,2, E. R. Miran1
1Michael D. Miran Ph.D Psychologist PC, Rochester, NY, USA;
2Rochester Institute of Technology, Rochester, NY, USA
The brain is plastic and can respond to interventions. The data in this pre-
sentation demonstrates that specific interventions change (improve) brain
function and ecologically valid/functional behaviors. Brain function was
measured via on-line EEG during a series of cognitive training interven-
tions. These interventions included the Orientation Remediation Module
(ORM) (NYU Rusk Institute), auditory stimulation, and relaxation train-
ing. A computer software program, the ORM, measured reduction in the
high variability of reaction time scores and in decreased attention/concen-
tration scores, as well as improved reasoning and planning scores. High
variability is indicative of brain states that are not stable, synchronized
and functioning coherently. Ecologically valid/functional behavior was
measured on behavioral observation scales. The behavior was rated as pres-
ent or absent (1 = present and 0 = absent). Treatment staff and observers
measured the behavior pretreatment and at intervals during treatment. The
results of a pilot study using on-line EEG demonstrated that subjects who
are actively hallucinating were able to move their brain activity from a slow
wave state to a normal alpha rhythm. This study showed that working on
the ORM changes brain function to a normal alpha rhythm; which is
reflected in lower reactions time in general and reduced variability in
responding. Training subjects on the ORM and other interventions leads
to improved ecologically valid behaviors as measured by rating of func-
tional behaviors. In conclusion the brain functions as a homeostatic system
with activating and inhibiting networks. Change (improvement) in brain
function and ecologically valid behaviors occur through a process. The pro-
cess can use a variety of interventions. This change in reciprocal activating
and inhibiting systems produced a change from slow wave to alpha rhythms
on EEG, reduce errors and variability on reaction time and reasoning cog-
nitive tasks, and improved ecologically valid/functional behaviors. Net-
works of the brain that are involved with hallucinatory activity were
inhibited by the intervention, while networks of the brain that are involved
in a normal alpha state and frontal lobe activity were activated.
ID: 563719
A UNITARY MODEL FOR THE MOTOR ORIGIN OF
SCHIZOPHRENIA AND BIPOLAR DISORDER
Jacques van Hoof
Research, GGZ Oost-Brabant, Oss, Netherlands
The core problem in brain research of schizophrenia and bipolar disorders
is the lack of an adequate physiological model. An attempt was made to
bridge the gap between biological and psychological phenomenon’s (van
Hoof, 2003). In this model, it is assumed that the relevant problems are
the manifestation of an imbalance between two mechanisms in the brain:
the first is motor power or drive and the second is steering or guidance. Both
mechanisms are used to control movements. The core of this model’s thesis
is that during the normal phylo- and ontogenesis of the human brain both
of these mechanisms are implemented in a repetitive way from the ‘‘how to
do’’ motor domain into the ‘‘what to do’’ intentional (limbic) domain
through cortical- subcortical circuits. The first, striatal mechanism (parallel
information processing) is necessary to initiate and calibrate movements
and intentions, such as intimidation or affiliation. This intentional drive
mechanism is organized primarily by a circuit located in the ventral part
of the brain. The second, cerebellar (serial information processing) mech-
anism is necessary for guidance. The intentional variant of the representa-
tional guidance mechanism is organized primarily in a circuit located in the
dorsal part of the brain. The repetitive application of both mechanisms
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during brain development allow the creation of unique human capacities;
viz. the ability to create (meta) representations, language and consciousness,
but also an increased capacity to deal with conflicting demands and emo-
tions. This development is the neuronal correlate for the process called men-
talization. Evidence is accumulating that the principally genetically based
reliance on one or both types of mechanisms has a bimodal distribution. A
genetically based insufficient development of one of both mechanisms and
an exaggerated reliance on the other mechanism cause an imbalance. The
repetitive implementation of these mechanisms will increase this imbalance
and create a situation where comparatively small stressors produce a tipping
of the scale manifesting itself as schizophrenia or a bipolar disorder. This
model has a greater explanatory power than current alternatives and there-
fore it will provide a useful framework for further research.
ID: 555590
MYRIADS OF SEX HORMONAL EFFECTS ON
BRAIN, PERSONALITY AND THEIR MODULATING
EFFECTS ON SCHIZOPTYPY.
Ag Alias
1Chester Mental Health Center, Chester, IL, USA; 2Biochemistry,
Amrita Institute of Medical Sciences, Kochi, India
Sheldon believed that the masculine and feminine components of the phy-
sique are two ‘‘most important constitutional factors in determining per-
sonality.’’ Rees wrote, ‘‘the work of [several authors-six cited] suggests
that schizophrenics with [frail] body build tend to have [an early onset,
more withdrawn], apathy and scattered thinking, whereas, schizophrenics
of [sturdier] built tend to have [later onset and better] preservation of per-
sonality and better affective responses.’’ This implies that testosterone de-
ficiency worsens the psychopathology in (only male) schizophrenics. More
recently, five studies in a total of 145 male schizophrenics in Delhi (2000,
2004), Japan (2002), Iran (2006), South Korea (2007) and Kerala, India
(2007), all essentially showing a negative correlation between negative
symptoms and testosterone levels, and none so far refuting it. Contrariwise,
Manfred Bleuler and coworkers found that women with signs of virilism
tended to have poor prognosis, with severe deterioration. And Jayashree
Kulkarni’s group demonstrated effective adjuvant role for estradiol in fe-
male schizophrenics. Further, more recently, as well as over 50 years ago
dehydroepiandrosterone has been shown to cause modest reversal of neg-
ative symptoms. 5alpha-reduced androgen and progesterone metabolites
have neuroprotective, and probably cognitive enhancing effects, whereas,
testosterone, but not its 5alpha-reduced dihydrotestosterone enhanced
‘‘spatial working memory’’ in another animal model. Further, in Alz-
heimer’s disease brain, the level of allopregnanolone, an eventual 5al-
pha-reduced progesterone metabolite, is decreased proportionately to
neuropathological changes. And allopregnanolone can reverse transgenic
mouse model of Alzheimer’s disease. Thus, sex hormones can at least mod-
ulate the course and severity of schizophrenia.
ID: 555063
DIFFERENTIAL EFFECTS OF DIFFICULTY ON
LEARNING STRATEGY AND ON MONITORING
OF KNOWLEDGE IN PATIENTS WITH
SCHIZOPHRENIA
Elisabeth Bacon1, M. Izaute2
1U 666, INSERM, Strasbourg, BP 426, France; 2LAPSCO, CNRS-
University, Clermont-Ferrand, France
This study was aimed at further investigating the strategic control of study
time and the metamemory processes and accuracy of schizophrenia patients
during the encoding of episodic information. Metamemory refers to the
ability to monitor and control how well information is processed depending
on the loads and needs of the task at hand. Metamemory functions are im-
paired in schizophrenia at both the times of memory acquisition and re-
trieval (Danion and al., 2001; Bacon and al., 2007). The difficulty of to-
be-learned material was varied (associated versus non associated word
pairs). The participants controlled themselves their learning time allocation
and had to judge how efficient they were. 23 patients and 23 control subjects
participated in the study. Both memory control and memory monitoring
were assessed using study time allocation and Judgments Of Learning
(JOL), respectively. Patients used the same strategies as normal participants
with respect to difficulty, and they spent more time to learn the difficult
than the easy pairs. However, their learning strategy was less adapted
and their memory performance was worse. In the meantime, Their Judg-
ments Of Learning about their future performances in an eventual cued
recall task, expressed question by question, remained sensitive to the
difficulty of the material. The patients’ JOL did not differ from the
controls for the easy items, but they were lower for the difficult items,
for both the eventual correct and the incorrect recalls. Moreover, the global
patients’ predictive accuracy of their JOLs (the Gamma correlation) was
accurate and not different from the controls. This reveals that in some
circumstances, even if their cognitive behavior and awareness differs in
some respects from healthy subjects, schizophrenia patients may display
intact ability to take into account the intrinsic characteristics of the
to-be-learned material to adapt their learning strategies so as to improve
performance, and may have a relatively preserved awareness of their
own efficiency in a learning task.
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INVESTIGATING THOUGHT DISORDER IN
SCHIZOPHRENIA: EVIDENCE FOR
PATHOLOGICAL SPREADING OF ACTIVATION
Ziad Safadi1,2, A. Henik2, M. Malik1, M. Hipolito1
1Psychiatry and Behavioral Sciences, Howard University,
Washington, DC, USA; 2Psychology, Ben Gurion University, Beer
Sheva, Israel
Background: Previous research has yielded evidence for enhanced semantic
priming in formal thought-disordered schizophrenia patients, a result that
fits well with the hypothesis of disinhibited processes of spreading activa-
tion in this population. Methods: The present study tested this hypothesis
by using semantic and identical priming in two different experiments and
manipulating the SOA (Stimulus Onset Asynchrony, 240ms vs. 740ms)
within block. Assuming that performance in this paradigm relies on a bal-
ance between activation and inhibition processes in healthy participants, we
compared formal thought-disordered schizophrenia patients, n = 33 non-
thought disordered schizophrenia patients, n = 35 and healthy controls
n = 34. Results: For thought-disordered schizophrenia patients, we found
a large positive semantic and identical priming effect (129 ms and 154 ms
respectively) only in short SOA. SOA and type of priming did not modulate
the priming effects in the control groups. Conclusions: This result yields
further evidence for the lack of inhibitory processes in thought-disordered
patients. Hyper priming in the Thought Disorder group may be an outcome
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of withdrawing of activation from the initially activated prime stimuli after
a short time.
ID: 552006
DO CURRENT PRECLINICAL MODELS ACCU-
RATELY ASSESS THE CONSTRUCTS OF CONTROL
OF ATTENTION AND RULE GENERATION AND
SELECTION IDENTIFIED BY CNTRICS?
Sheree Logue, M. P. Kelly, R. Graf, C. Kelley, T. A. Comery
Neuroscience, Wyeth Research, Princeton, NJ, USA
The need for comparable animal models was an important consideration to
CNTRICS (Cognitive Neuroscience Treatment Research to Improve Cog-
nition in Schizophrenia) during the identification and development of the
cognitive systems and tasks to be used to drive the discovery of novel treat-
ments cognitive impairment associated with for impaired cognition in
schizophrenia. In order to determine if animal models are indeed compa-
rable to those tasks being used and/or developed by CNTRICS it is essential
to understand the relationship between the underlying cognitive constructs
of the preclinical and clinical tasks. Similar to what has been done for the
tests used in humans, the animal models need to be individually decon-
structed and the underlying cognitive constructs be compared with the
higher cognitive functions delineated by CENTRICS to determine the de-
gree of congruence. This presentation will focus on constructs established
by CNTRICS for attention and executive control addressing specifically
control of attention and rule generation and selection. There are a variety
of preclinical models used to study attention and executive function/control
in rodents and this presentation will include the Sarter Sustained Attention
Task, the 5-choice serial reaction time test and the attention set-shift (ID/
ED) test. Our own data from these tasks along with literature data will be
used deconstruct these tasks to identify similarities and critical differences
between these preclinical tasks and between tasks identified by CNTRICS
for assessing control of attention and rule generation and selection.
ID: 551976
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19. 19. Clinical Neuropsychology
RELATIONSHIP OF COGNITIVE TRAINING
ACHIEVEMENT TO NEUROCOGNITIVE
IMPROVEMENT IN SCHIZOPHRENIA
Morris David Bell,1,2, W. Zito1,2, T. C. Greig1, B. W. Wexler1
1 Psychiatry, Yale University School of Medicine, West Haven, CT,
USA; 2Rehabilitation Research and Development, Department of
Veterans Affairs, West Haven, CT, USA
Cognitive training has been shown to improve neurocognition in a number
of studies using a variety of training methods. Neurocognitive Enhance-
ment Therapy (NET) has been found to improve working memory and ex-
ecutive function in two published RCT’s. It is a ‘‘bottom-up’’ approach that
relies on intensive practice and a hierarchy of training tasks. In the RCT’s it
was imbedded in a rehabilitation program that included skills groups and
work activity. The current study attempted to determine the link between
achievement in the cognitive training and neuropsychological outcomes in
order to isolate the effects of the cognitive training and to directly associate
cognitive performance during training to improvements in neurocognition.
Method: 72 stable outpatients with schizophrenia or schizoaffective disor-
der recruited from an urban CMHC were randomly assigned to a 12 month
vocational program (VOC, n = 34) or NET þ VOC (n = 38). NET included
26 computer-based cognitive training exercises, a social skills group and
a work feedback group. Participants completed a comprehensive neuropsy-
chological test battery before and after treatment. Subjects either graduated
from a task (met a criterion of performance), reached a plateau and moved
to another task, or never attempted the task. Number of graduations was
used as the sole measure of achievement and entered as a mediator to ex-
plain previously reported differences between conditions in a MANCOVA
of working memory tasks and a MANCOVA of executive function tasks.
Results: The mean number of graduations was 8.66 (sd = 7.7) and the me-
dian was 8 with a range of 0 to 26. A significant difference on Working
Memory was found for condition (F = 3.16, P < .05) with NETþVOC
showing greater improvement over 12 months than VOC only. However,
when Total Graduations was used as a mediator, there was no longer a dif-
ference between condition (F = .383, P< .68). Similarly, conditions differed
significantly on improvement in Executive Function (F = 3.49,P< .02) with
NETþVOC showing greater improvement than VOC only. When Total
Graduations was used as a mediator, the difference was no longer signif-
icant (F = 2.45, P < .07). Conclusions: Findings support the direct contri-
bution that achievement in cognitive training makes to improving
neurocognitive outcomes. It suggests that whatever other non-specific fea-
tures may be involved, mastering cognitive tasks in NET has meaningful
cognitive benefits.
ID: 538046
THE NEGATIVE SUBSYMPTOM APATHY AND ITS
RELATION TO EXECUTIVE FUNCTIONING IN
FIRST EPISODE PSYCHOSIS
Ann Faerden1, A. Vaskinn1, A. Finset3, I. Agartz4,5,
E. A. Barrett2,6, S. Friis1,5, C. Simonsen1, R. Nesvag4,
O. A. Andreassen1,5, I. Melle1,5
1Psychiatry, Ulleva˚l University Hospital, Oslo, Norway;
2Psychiatry, Aker University Hospital, Oslo, Norway; 3Institute
of behavioural sciences in medicine, Univsersity of Oslo, Oslo,
Norway; 4Psychiatry, Diakonhjemmet Hospital, Oslo, Norway;
5Institute of Psychiatry, University of Oslo, Oslo, Norway;
6Department of Psychology, University of Oslo, Oslo, Norway
Background: Investigation of the relationship between the different nega-
tive sub symptoms and neurocognition is one approach in the effort to un-
derstand more of the underlying nature of the negative symptom complex in
psychosis. Apathy, one of the negative sub symptoms, is also common in
other brain disorders such as Alzheimer- and Parkinson disease, where the
association with neurocognition is well studied. Here apathy has been
found to be repeatedly associated with executive dysfunction. The only
study of apathy and its relationship to neurocognitive function in patients
with psychosis also found the same specific relationship, but the study was
of small sample size and in a chronic patient population. Objective: The aim
of the present study was to investigate the association between apathy and
neurocognitive functioning in patients with first episode psychosis (FEP)
and compare this with a group of healthy controls (HC). Material and
Method Seventy-one FEP patients and 62 HC were assessed with an exten-
sive neuropsychological test battery. Level of apathy was assessed with the
abridged Apathy Evaluation Scale (AES-C-Apathy). Results: The FEP
patients were significantly more apathetic than the HC (mean 27.2
(SDþ6.8) vs. 18.0 (SDþ4.4); t =9.04;P< .01). The FEP group performed
worse than HC on all neuropsychological tests, with an effect size ranging
from moderate to large. For FEP; apathy was only found to be significantly
correlated with Semantic fluency (r = .37,P< .01), Phonetic fluency (r = .25,
P< .05) and Letter Number Span (r = .26,P =< .05); the first two are verbal
fluency tests and represent the initiation part of executive functioning,
whereas the latter test represent working memory, another aspect of exec-
utive functioning. Confounding variables such as co-occuring depression,
positive symptoms or use of antipsychotic medication did not significantly
influence the results. For the HC there was a trend toward a statistical sig-
nificant relationship only between Semantic fluency (r = .18, P = .16) and
apathy, and no other neuropsychological tests. Conclusion: Apathy in FEP
was found to have the same relationship to executive functioning, and spe-
cifically Semantic fluency, as that reported in patients with other brain dis-
orders. This points to a common underlying nature of apathy across
disorders that can add to the understanding of the puzzle of the underlying
nature of the negative symptom complex.
ID: 550767
DOES MORNING CORTISOL INFLUENCE COGNI-
TIVE FUNCTION IN FIRST EPISODE PSYCHOSIS?
Monica Aas, V. Mondelli, T. Toulopoulou, A. Reichenberg,
M. DiForti, T. Marques, C. Joseph, B. Wiffen, R. Handley,
H. Taylor, N. Hepgul, A. David, R. Murray, P. Dazzan,
C. M. Pariante
Psychological Medicine, Kings College London; Institute of
Psychiatry, London, United Kingdom
Background: Hyperactivity of the HPA axis can be found in a variety of
psychiatric disorders, including first episode psychosis. High level of morn-
ing cortisol indicates a stable long-lasting HPA axis hyperactivity. Further-
more, general cognitive decline, executive and memory abnormalities have
been observed in animals given glucocorticoids and in stress related disor-
ders. Method: We recruited 15 patients with first episode psychosis and 21
controls as part of the Genetic and Psychosis study carried out in South
London. Patients and controls underwent neuropsychological assessment
to measure general cognitive performance from WAIS-III (Information,
Block Design, Digit Symbol Coding and Matrix Reasoning) executive func-
tion from the Trails (Trail A and Trail B) and immediate and delayed mem-
ory from WMS-III (Logical Memory and Visual Reproduction). Salivary
cortisol was collected on two consecutive days, just after awakening. The
saliva was centrifuged at 3000 rev/min for 5 minutes and frozen at 20C.
The patients and controls were divided in two groups based on the cortisol
median of the controls (9.40 nmol/l). 8 patients and 10 controls were in low
range cortisol group and 7 patients and 11 controls were in the high range
cortisol group. Results: The mean age of the patient group was 28 6 8 yrs,
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and 35% of these subjects were females. The mean age of the controls was of
27 6 5 yrs, and 28% of these subjects were females. For all tests presented
the patients scored significantly worse than the controls (P < .05). For ex-
ecutive and memory tasks patients with high cortisol did worse than the
patients with low cortisol, while the opposite or no effect was found in
the controls. Specifically, the P values for the statistical interaction, cova-
riate for age, were: Trail A, P = .005; Trail B, P = .014; Logical Memory
Delayed Recall, P = .020; Logical Memory Immediate Thematic Score, P =
.020; Logical Memory Delayed Thematic Score,P = .031; Visual Reproduc-
tion Percentage Retention, P = .005; Visual Reproduction Immediate Re-
call, P = .046; and Visual Reproduction Delayed Recall, P = .010. No effect
of stress was found for general cognition from the WAIS-III. Conclusions:
The present data show that patients with first episode psychosis may be
particular vulnerable to an increased HPA axis, shown by significant
stress effect on performance on executive tasks, such the Trails and imme-
diate and delayed memory from WMS-III Logical Memory and Visual
Reproduction.
ID: 550735
A DATA-DRIVEN METHOD TO ILLUSTRATE
MECHANISMS UNDERLYING VERBAL RECALL
AND ITS APPLICATION TO SCHIZOPHRENIA
RESEARCH
Julia Longenecker, P. Kohn, S. Liu, B. Zoltick, D. Weinberger,
B. Elvevaag
CBDB, NIH, Bethesda, MD, USA
The California Verbal Learning Test (CVLT) is a widely used neuropsy-
chological tool for evaluating verbal memory recall strategies. A list of 16
words comprised of four semantic categories is presented orally and freely
recalled. Performance metrics include number of words recalled in the ini-
tial trial and final trial, improvement between the initial and final trials,
and overall recall in all five trials. In general people who recall the most
words employ a semantic clustering technique, whereas those with poor
recall tend to rely on serial techniques. Limitations to previous analysis
approaches include the rigidity of the predetermined serial and semantic
divisions and the assumption that the two strategies have an inverse re-
lationship. In order to be agnostic about the possible orthogonalization of
recall mechanisms and strategies, we adopted a data-driven approach of
computing transition probabilities (the probability that one item on a list
will follow another during recall) across all learning trials as a function of
word presentation order and recall. Out of approximately 450 patients
with schizophrenia and 700 healthy unrelated volunteers, we selected
the 50 highest and 50 lowest performers in each group and applied the
probability measures. Performance was defined as total words recalled
over the 5 trials in the CVLT. Parsing CVLT with respect to learning trial
revealed that strategies interact and change over time, with serial-based
strategy the first step for high and low performers. The high performing
healthy volunteers utilized serial strategies in trial one, but adopted se-
mantic strategies for the remaining trials. The pattern of healthy low per-
formers did not change across trials, suggesting that it is the combination
of strategies more than use of a semantic strategy that leads to good per-
formance in verbal recall. High performing patients changed strategies af-
ter relying on serial order in trial one, while low performing patients
recalled only the words for which they employed serial strategies. This
agnostic approach may aid in examination of verbal memory recall strat-
egy in people suffering from memory disorders and may be especially use-
ful in patients with schizophrenia for whom episodic memory deficits are
a hallmark feature. Greater knowledge of how cognitive deficits and strat-
egy choice interact may help identify the neural mechanisms underlying
these specific strategies.
ID: 550732
COGNITIVE DYSFUNCTION IN EARLY PSYCHOSIS
OF SCHIZOPHRENIA, BIPOLAR DISORDER, AND
PSYCHOTIC DEPRESSION BEFORE AND AFTER
ANTIPSYCHOTIC TREATMENT
John A. Sweeney, J. L. Reilly, R. W. Marvin, C. Rosen,
O. A. De Leon, P. J. Weiden, S. K. Hill
Psychiatry, University of Illinois, Chicago, IL, USA
Neuropsychological dysfunction is associated with affective and nonaffec-
tive psychosis, but the potential for distinct profiles of cognitive dysfunction
and differential rates of improvement with treatment are not well studied.
This study was designed to compare the severity and profile of cognitive
dysfunction in first episode affective and nonaffective psychotic disorder
patients before and after antipsychotic treatment. Untreated first-episode
psychotic patients (30 schizophrenia, 22 bipolar with psychosis, and 21 psy-
chotic depression) completed tests of reasoning and flexibility, attention,
verbal memory, face memory, working memory, and processing speed.
Patients completing 6-weeks of antipsychotic treatment were retested at
that time. A group of healthy individuals (n = 41) matched on age, educa-
tion, and parental SES were studied in parallel. At baseline, schizophrenia
patients displayed significant deficits relative to controls in all cognitive
domains. The two psychotic affective groups were also impaired overall
relative to controls, but generally performed intermediate between the
schizophrenia patients and controls. There was no difference in the profile
of neuropsychological deficits across the three psychotic patient groups.
Following 6-weeks of treatment, no patient group improved more than
practice effects seen in healthy individuals, and improvement in the affec-
tive psychosis groups was no greater than that observed in schizophrenia.
These findings with first episode psychosis patients document generalized
neuropsychological deficits in psychotic affective disorders that were sim-
ilar in profile but less severe than the deficits observed in schizophrenia.
Recovery of cognitive function after clinical stabilization was no greater
in mood disorder patients than in schizophrenia, suggesting that, as in
schizophrenia, neuropsychological deficits may be trait-like deficits with
persistent functional implications.
ID: 550687
ABNORMAL MODULATION OF PROSODY
PRODUCTION IN SCHIZOPHRENIA
Sohee Park,1,2, T. J. Crow2,3, M. L. Doop1,2, M. Kar Ray2,3,
C. Mackay3, A. Luk2
1Psychology, Vanderbilt University, Nashville, TN, USA;
2P.O.W.I.C., University of Oxford, Oxford, United Kingdom;
3Psychiatry, University of Oxford, Oxford, United Kingdom
Abnormal perception of prosody has been shown reliably in schizophrenia
patients but the production of prosodic speech in schizophrenia has not
been extensively studied. Production of appropriate prosody in speech is
central to effective verbal communication and social interactions. Emo-
tional prosody in speech can be evaluated by examining the range of fun-
damental frequency (Fo), which corresponds to pitch. The goal of this study
was to investigate prosody regulation during a structured interview in indi-
viduals with schizophrenia and healthy controls. All participants were
interviewed with the same set of neutral and emotional questions. The inter-
views were recorded and digitized for acoustic analyses using Praat soft-
ware. Minimum and maximum Fo were extracted from two neutral and
two emotional speech samples to derive pitch ranges. Results indicate
that there was no significant difference between the two groups in the min-
imum Fo but schizophrenic patients have significantly reduced range
of pitch compared with healthy participants. Moreover there was an
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interaction between diagnosis and pitch range such that healthy partici-
pants, but not schizophrenic patients, increased range during emotional
speech compared with neutral speech. Thus, healthy participants modulate
their tone of voice appropriately in affective context. In contrast, schizo-
phrenia patients seem unable to connect the content of their speech (seman-
tics) with prosody. Negative symptoms score was inversely correlated with
pitch range in the patients. These results suggest that in addition to prosody
perception, prosody production is also impaired in schizophrenia and this
deficit is associated with negative symptoms. Impairment in prosody pro-
duction may be due to deficits in emotion expression. On the other hand, it
is also possible that difficulties in modulating the tone of voice in affective
context is due to an inability to coordinate the left and the right hemisphere
language systems in real time in everyday interactions. These possibilities
remain to be tested.
ID: 550541
INTELLECTUAL AND COGNITIVE DYSFUNC-
TIONS IN CHILDREN WHO PRESENT PSYCHOTIC-
LIKE EXPERIENCES AND OTHER ANTECEDENTS
OF SCHIZOPHRENIA
Kristin R. Laurens1,3, A. Cullen1, H. Dickson1, S. Hodgins1,
R. Morris2, R. M. Murray3
1Department of Forensic Mental Health Science, Institute of
Psychiatry, King’s College London, London, United Kingdom;
2Department of Psychology, Institute of Psychiatry, King’s
College London, London, United Kingdom; 3Department of
Psychological Medicine and Psychiatry, Institute of Psychiatry,
King’s College London, London, United Kingdom
We have proposed that children who present psychotic-like experiences as
part of a triad of antecedents of schizophrenia (including also a speech and/
or motor developmental delay or abnormality, and a social, emotional, or
behavioural problem) may experience elevated risk for the development of
schizophrenia (Laurens et al. 2007). While only longitudinal follow-up will
establish the degree to which the triad of antecedents predicts later schizo-
phrenia, the present study examined whether children experiencing the triad
also present intellectual and cognitive deficits that characterise first-episode
patients with schizophrenia and ‘‘high-risk’’ (prodromal) youth. Question-
naire data from 5 158 children aged 9–12 years and 1 133 of their primary
caregivers demonstrated that 9% of children (12% of boys, 6% of girls) pres-
ent the triad of antecedents. Fifty-eight children (21 presenting the anteced-
ent triad and 37 control children without the antecedents) subsequently
completed standardised assessments of IQ (WASI), scholastic achievement
(reading, spelling, numerical operations; WIAT), memory (verbal, visual,
and working memory; WRAML2) and executive function (verbal fluency,
and inhibition; D-KEFS). Children presenting the antecedent triad expe-
rienced moderate deficits in cognitive function (mean effect size 0.65,
range 0.56 to 0.77) relative to control children, with significant perfor-
mance decrements observed in all domains (excepting a non-significant
trend in visual memory performance). Children who present antecedents
of schizophrenia demonstrate moderate intellectual and cognitive impair-
ments that are comparable to those observed in prodromal youth (mean
effect size ;0.8), but less marked than deficits apparent in first-episode
patients (mean effect sizes;1.1–1.8). Children experiencing the antecedents
of schizophrenia might represent a ‘‘high-risk’’ population who may benefit
from preventive interventions for schizophrenia. Acknowledgements:
NIHR Career Development Fellowship, NARSAD Young Investigator
Award, BMA Margaret Temple Award, BIAL Foundation.
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A VERBAL MEMORY-BASED APPROACH TO
REDUCING THE HETEROGENEITY OF
SCHIZOPHRENIA
Narmeen Ammari, R. W. Heinrichs, A. A. Miles
Psychology, York University, Toronto, ON, Canada
Schizophrenia is a heterogeneous condition involving widespread variabil-
ity in symptoms, neurocognitive function, and functional outcome. It has
been argued that verbal memory performance is a valuable dimension
along which to organize patients. Verbal memory impairment constitutes
a significant cognitive defect in many, but not all, patients with the illness.
Research has shown that patients with verbal memory impairment expe-
rience more psychotic symptoms and a poorer quality of life than unim-
paired patients. However, a major limitation of this research is that it does
not address the question of whether verbal memory impairment reflects
a broadly based impairment or whether it occurs disproportionately to
other cognitive impairments. Accordingly, this study aimed to: 1) identify
patients with specific verbal memory impairment that is disproportionate
to their general cognitive abilities, and 2) assess the cognitive, clinical and
functional status profiles of this specifically impaired group. The Califor-
nia Verbal Learning Test (CVLT-II) provided an index of verbal memory
acquisition, whereas the Wechsler Adult Intelligence Scale (WAIS-III)
Vocabulary subtest provided an estimate of general verbal abilities. Dis-
proportionate impairment was defined as a Z-score CVLT-WAIS differ-
ential of at least 1.0. On the basis of these two measures, patients were
partitioned into three groups: patients with a verbal memory impairment
that is disproportionate to their general verbal abilities, patients with
a verbal memory impairment that is proportionate to their general verbal
abilities, and patients with intact verbal memory and average verbal cog-
nitive abilities. Demographic, clinical, cognitive, and functional data were
obtained from 157 patients with schizophrenia or schizoaffective disorder
and from 74 healthy adults. Results show that when general verbal abil-
ities are held constant, the clinical and functional profiles of memory-
impaired patients are indistinguishable from their memory-unimpaired
counterparts. Although specific verbal memory impairment distinguishes
a subgroup of patients with schizophrenia, they do not have distinct clin-
ical or functional profiles when compared to other patients. These find-
ings suggest that key indicators of clinical severity and functional status
are premorbid, illness-resistant abilities; and thus have implications for
the development of treatments aimed at improving functional outcome
via cognitively-enhancing medications.
ID: 550484
COGNITIVE CONTROL DEFICITS IN PRODROMAL
PSYCHOSIS
Tara A. Niendam, R. Walter, M. J. Minzenberg, J. H. Yoon,
J. D. Ragland, S. Ursu, M. Solomon, C. S. Carter
Psychiatry and Behavioral Sciences, University of California, Davis,
Sacramento, CA, USA
Although impairment in cognition related to DLPFC functioning is con-
sistently documented in schizophrenia, it remains unclear how such fron-
tally-mediated deficits in cognitive control manifest during the
developmental period prior to psychosis onset. This study investigates
the profile of performance on a measure of cognitive control in individuals
identified as ultra-high-risk (UHR) for psychosis, first-episode schizophre-
nia individuals, and demographically matched controls. It was hypothe-
sized that UHR individuals would show impairment in accuracy on the
AX-CPT, a computerized measure of cognitive control, that is intermediate
between healthy control (HC) and first episode (FE) participants. Specif-
ically, it was predicted that UHR and FE participants would demonstrate
a pattern of impaired context processing, as indicated by increased rates
of BX errors relative to AY errors. Eighteen UHR, 22 FE, and 22 HC
International Congress on Schizophrenia Research
276 19. 19. Clinical Neuropsychology
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
participants were identified from referrals to the UC Davis Early Detection
and Preventive Treatment (EDAPT) clinic, using the Structured Interview
for Prodromal Syndromes (SIPS) and Structured Clinical Interview for
DSM-IV (SCID-I/P). Participants completed a cognitive test battery in-
cluding the AX-CPT. While no differences in accuracy were observed
across groups on the AY condition, UHR and FE participants demon-
strated equivalent impairment in accuracy on BX trials when compared
to controls, suggesting that both groups demonstrate a generalized deficit
in cognitive control. Consistent with previous findings in UHR samples,
current results suggest that UHR individuals show deficits in sustained at-
tention and response inhibition when compared to demographically
matched controls, in a manner that is similar to individuals in the first
episode of schizophrenia.
ID: 550477
SIMULATING FUTURE EVENTS IN PSYCHOSIS
Vyv Huddy1, G. P. Brown2, T. Boyd3
1Department of Psychology, Institute of Psychiatry, London, United
Kingdom; 2Department of Psychology, Royal Holloway, University
of London, London, United Kingdom; 3Department of Rehabilitation
Psychology, Camden and Islington Mental Health Trust, London,
United Kingdom
Mental simulation is an effective means of predicting events and planning
future behaviour. The ability to generate detailed simulations of future
events facilitates effective coping. Simulation is also likely to utilise exec-
utive functioning, which is a neuropsychological domain known to be im-
paired in psychosis. We sought to firstly establish the integrity of simulation
processes in psychosis, secondly to establish how simulation was affected by
a threat theme and thirdly to determine how the ability to simulate future
events might relate to other established measures of reasoning. There were
two groups of participants: people with psychosis (N = 21) and healthy com-
parison participants (N = 21). All participants completed a simulation task,
which required participants to give a step-by-step account of how various
scenarios might come about. The scenarios either had threat or neutral
themes. Following simulation, participants rated each scenario on how
likely and worrying it appeared. Analysis included independent ratings
of the quality of the responses, yielding a goodness of simulation (GOS)
score. In addition, a cognitive measure of data gathering and a self-rated
measure of thinking style were applied. People with psychosis showed lower
GOS overall, less data gathering and reduced self-rated rational thinking.
GOS scores were also lower in threat themed scenarios—an effect that was
equivalent in both groups. In addition, GOS was negatively correlated with
worry about the threat themed scenarios. Furthermore, in both groups
GOS scores were positively associated with both data gathering and a ra-
tional thinking style. These data indicate that the simulation task can be
used to successfully index simulation processes in psychosis. More specif-
ically, it suggests that improved simulation of threatening events promotes
successful coping, as higher quality simulations of threat scenarios were as-
sociated with less worry. Taken together, these findings suggest that sim-
ulation might provide a useful way of understanding how basic cognitive
processes relate to functional measures of outcome in psychosis.
ID: 550433
ATTENTIONAL SET-SHIFTING ABILITY AND
REVERSAL LEARNING OVER THE FIRST THREE
YEARS OF PSYCHOTIC ILLNESS: CHANGES OVER
TIME AND RELATIONSHIP WITH IQ AND
CLINICAL MEASURES
Verity C. Leeson1,2, T. W. Robbins3, T. R. Barnes1, E. Matheson1,
I. Harrison1, E. M. Joyce2
1Psychological Medicine, Imperial College London, London, United
Kingdom; 2Institute of Neurology, University College London,
London, United Kingdom; 3Department of Experimental
Psychology, University of Cambridge, Cambridge, United Kingdom
The Intradimensional/Extradimensional (ID/ED) task offers a differenti-
ated assessment of the processes involved in the Wisconsin Card Sort
Task. Studies of patients with schizophrenia have consistently revealed def-
icits at the set-shifting, extra-dimensional shift (EDS) stage with some also
reporting difficulties at earlier stages. Cross sectional studies examining
length of illness and a one-year follow up study additionally suggest
that performance on this task may deteriorate over the course of illness.
Two-hundred and sixty-two first-episode psychosis patients and 76 healthy
controls, matched for age and premorbid IQ, were assessed using the ID/
ED task and the Wechsler Adult Intelligence Scale. Significantly more
patients failed at the EDS stage suggesting that shifting attention from
a previously reinforced dimension presented the greatest difficulty. How-
ever, patients additionally made more errors prior to successful rule acqui-
sition at all stages indicative of more subtle difficulties in rule acquisition
and reversal learning. As passing the EDS stage predicted WAIS IQ, a sub-
group of patients and controls with equivalent current IQ were compared.
The difference in pass rate was no longer significant but patients showed
selectively greater errors at all reversal stages indicating that, whereas set
shifting is inextricably linked with IQ, inhibition of a prepotent response
may be independent. Further, errors on reversal learning were correlated
with disorganisation symptoms, particularly positive formal thought disor-
der. A subset of 104 patients and 25 controls were followed up on two fur-
ther occasions over three years and a small improvement was observed in
patients by third assessment, although they continued to substantially
underperform compared to controls. There was consistency in terms of
passing the test over the three assessments, with passing the previous assess-
ment predicting passing the next. Examining the three-year follow-up data,
significantly more patients who failed at the EDS stage had residual neg-
ative symptoms. In conclusion, rule acquisition, set shifting and reversal
learning are impaired from first presentation to services in patients with
psychosis. However, contrary to what has been previously suggested, we
did not find evidence of further deterioration over the first three years
of illness.
ID: 550378
GENDER DIFFERENCES IN NEUROPSYCHOLOGI-
CAL PERFORMANCE IN PATIENTS WITH FIRST
EPISODE OF PSYCHOSIS
Jolanta Zanelli1, A. Reichenberg1, K. Morgan1,5, P. Fearon1,
C. Zanelli1, P. Dazzan1, C. Morgan1,2, P. Jones3, G. Doody4,
R. M. Murray1
1Psychological Medicine and Psychiatry, Institute of Psychiatry,
King’s College, London, London, United Kingdom; 2Health Service
and Population Research, Institute of Psychiatry, King’s College,
London, London, United Kingdom; 3Psychiatry, University of
Cambridge, Cambridge, United Kingdom; 4Psychiatry, University of
Nottingham, Nottingham, United Kingdom; 5Psychology, Univer-
sity of Westminster, London, United Kingdom
Although there are several studies examining neuropsychological per-
formance in first episode of psychosis, the issue of gender differences in
neurocognitive function among psychotic patients has been addressed by
few studies, and the results are inconsistent. We examined gender differen-
ces in neuropsychological performance in an epidemiological sample of
first episode psychosis patients: schizophrenia (M = 42, F = 23), bipolar/
manic (M = 15, F = 22), and depressive psychosis (M = 16, F = 23),
and compared performance with a representative sample of healthy
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controls (M = 77, F = 98). Data was collected on 18 neuropsychological
measures assessing six cognitive domains: (1) memory (verbal and visual),
(2) WAIS-R academic verbal abilities, (3) attention, concentration and
mental speed, (4) executive functions and working memory, (5) language,
and (6) visual constructual/perceptual abilities. Premorbid intelligence
(NART), current full-scale IQ, performance IQ and verbal IQ were also
assessed. There was strong evidence for disorder-specific gender differences
in neuropsychological functioning. In the schizophrenia group, women per-
formed better than men on the majority of neuropsychological measures.
By contrast, women with psychotic depressive disorder performed worse
than men. Differences in neuropsychological performance between men
and women with bipolar/manic disorder were restricted to verbal memory
and language. In our epidemiological study, gender appeared to modify
the characteristics of cognitive impairment of patients with first episode
psychosis.
ID: 550321
AWARENESS OF NEURO-COGNITIVE ABILITY IN
PEOPLE WITH SCHIZOPHRENIA VERSUS
HEALTHY CONTROLS
Julie Ann Thysen1, B. Freilich2, A. Medalia3
1Department of Psychiatry, James J. Peters VA Medical Center/
Mount Sinai School of Medicine, Bronx, NY, USA; 2Department
of Psychiatry, Montefiore Medical Center, Bronx, NY, USA;
3Department of Psychiatry, Columbia University Medical Center,
New York, NY, USA
Objective: The objective of this study was to compare self-report of cogni-
tive deficit in neuropsychologically impaired schizophrenia patients with
self report of cognitive deficit in normal controls who do not have neuro-
psychological deficit. Method: Seventy-one patients with schizophrenia
were administered the MIC-SR along with the PANSS, BACS, and ILS.
The MIC-SR is a scale that measures self reported frequencies of cognitive
problems in everyday life. Forty-six healthy controls were also administered
the MIC-SR as well as a cognitive battery. All healthy controls obtained z
scores above 1.35 on neuropsychological measures and therefore were
considered cognitively intact. Results: Patients with schizophrenia reported
significantly more cognitive problems as occurring‘‘Almost Daily’’ than did
healthy controls. Subsequent analysis showed that those schizophrenia
patients who evidenced more depression, but not those with more objective
neuropsychological deficit, were more likely to endorse cognitive problems
as occurring ‘‘Almost Daily’’. All the schizophrenia patients had cognitive
impairment yet they were most likely to respond that a cognitive problem
‘‘Never’’ occurred, whereas the healthy controls who were not cognitively
impaired most often responded that they experienced cognitive problems
‘‘Once a Week or Less.’’ Schizophrenia patients who reported that cognitive
problems ‘‘Never’’ occurred had less depression, but not less objective neu-
ropsychological performance than other schizophrenia patients. About one
quarter of the cognitively impaired patients with schizophrenia showed no
awareness of cognitive deficit on the MIC-SR. The Total Score on the MIC-
SR did not prove useful in differentiating healthy controls from patients.
Conclusions: These findings suggest that clinicians must use self report ju-
diciously as an indicator of actual cognitive impairment. Many cognitively
impaired schizophrenia patients reported having no cognitive problems,
and as a group they reported having no more cognitive problems than
did the cognitively intact healthy controls. However, the response patterns
of schizophrenia patients and healthy controls differed significantly. The
MIC-SR captures a range of awareness of cognitive difficulty in schizophre-
nia patients, and those with depression were most likely to report cognitive
problems. The data indicates that many patients would benefit from
psycho-education about the impact of schizophrenia on neuro-cognition.
ID: 550299
THE ROLE OF IMPULSIVITY IN SUICIDAL AND
NON-SUICIDAL SELF-HARM AMONG PEOPLE
WITH SCHIZOPHRENIA
Graham Pluck, N. P. Lekka, S. Sarkar, O. Sharif, R. W. Parks,
P. Bath, K. H. Lee, P. W. Woodruff
Academic Clinical Psychiatry, University of Sheffield, Sheffield,
United Kingdom
High rates of self-harm, including suicide are well known to be associated
with schizophrenia. Previous research has identified trait impulsivity, such
as that measured by the Barrat Impulsivity Scale (BIS-11) as being linked to
self-harm in a range of psychiatric disorders. In addition, raised levels of
cognitive-motor impulsivity, such as measured with the Go/No-Go reac-
tion time task appear to be linked to past self-harm. We wished to examine
the association of both trait and cognitive-motor impulsivity to past self-
harm behaviour among people with schizophrenia. We hypothesized that
impulsivity, measured either as a trait or as cognitive-motor performance,
would be related to self-report of past suicidal and non-suicidal self-harm
behaviour. To test these hypotheses, a sample of 88 patients with a DSMIV
diagnosis of schizophrenia was recruited. The mean age of the sample was
39.8 (SD = 11.4, range 18–63) and 74 (84%) were male. Patients were asked
to complete the self-report BIS-11 and the Deliberate Self-harm Inventory,
which assesses lifetime frequency of a range of self-injurious, but non-sui-
cidal behaviours. In addition, details of the lifetime history of suicide
attempts were recorded. The patients also performed a computerized
Go/No-Go task to assess cognitive-motor impulsivity. The sample were di-
vided into groups on the presence or absence of past self-harm to compare
levels of trait and cognitive motor impulsivity using independent groups t-
tests. Forty seven of the 88 patients (53.4%) reported at least one suicide
attempt in the past, and 41 (46.6%) reported at least one occasion when
they had deliberately self-harmed without suicidal intent. Comparing
patients with or without an attempted suicide history, there was a trend
for higher trait impulsivity scores in the attempted suicide group, though
this did not reach significance (P = .058). There was no relationship be-
tween impulsive errors on the Go/No-Go task (P = .58) between the two
groups. However, those with a history of non-suicidal self-harm produced
significantly more impulsive errors on the Go/No-Go task (P = .018) and
reported significantly higher trait impulsivity scores on the BIS-11 (P =
.001), than those without a non-suicidal self-harm history. Our findings
provide evidence to support the conclusion that impulsivity in schizophre-
nia is primarily a risk for self-harm behaviour which is not motivated by
intent to die.
ID: 550255
SELF MONITORING DEFICITS AND AUDITORY
VERBAL HALLUCINATIONS: IS THERE ANY
EVIDENCE?
Paul Allen
Psychological Medicine, Institute of Psychiatry, London, United
Kingdom
A range of psychological theories have been proposed to account for the
experience of auditory hallucinations in patients with psychosis One of the
most influential cognitive models proposes that auditory verbal hallucina-
tions (AVH) result from an impairment in the ability to monitor one’s own
inner speech leading to the misidentification of verbal thoughts or memories
as alien voices. However, data from tasks used to examine verbal self mon-
itoring (VSM) has provided mixed results. Evidence from studies of patients
with schizophrenia, individuals in the prodromal phase of the illness and
non-clinical will de presented and discussed. Overall the available data sug-
gest that cognitive impairments other than self-monitoring, such as difficul-
ties with appraising degraded stimuli may contributed to the observed
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misidentification bias. The specificity of such a bias to AVH is also question-
able as most studies report that patients with delusions tend to make external
misidentification errors when listening to their own distorted speech.
ID: 550253
SUICIDE ATTEMPTS AND NEUROCOGNITIVE
FUNCTIONING IN SCHIZOPHRENIA SPECTRUM
DISORDERS
Elizabeth Ann Barrett1,2, K. Sundet2, C. Simonsen2,3, I. Agartz4,5,
S. Lorentzen1,4, L. Mehlum6, E. Mork1,6, O. A. Andreassen3,4,
I. Melle3,4
1Department of Mental Health, Aker University Hospital, Oslo,
Norway; 2Department of Psychology, University of Oslo, Oslo,
Norway; 3Department of Psychiatry, Ulleval University Hospital,
Oslo, Norway; 4Institute of Psychiatry, University of Oslo, Oslo,
Norway; 5Department of Research and Development, Diakonh-
jemmet Hospital, Oslo, Norway; 6National Centre for Suicide Re-
search and Prevention, University of Oslo, Oslo, Norway
Studies of the relationship between schizophrenia, suicidality and neurocog-
nition are few and have yielded inconsistent results. This study aimed to in-
vestigate whether patients with schizophrenia spectrum disorder who had
attempted suicide showed better general neurocognitive functioning, better
executive functioning and were more impulsive compared to non-attemp-
ters. The study included 174 patients, 58% men, mean age 32 years (SD =
10). Diagnoses were set according to SCID-I for DSM-IV (79% schizophre-
nia, 15% schizoaffective disorder and 6% schizophreniform disorder).
Patients were classified as suicide-attempters (31%) if they reported one
or more suicide attempts. Age at illness onset, duration of illness, number
of psychotic- and depressive episodes, use of medication, years of education,
and drug- and alcohol use the last 6 months was recorded. The Positive and
Negative syndrome scale (PANSS) was used to rate psychotic symptoms and
depression. Premorbid functioning was assessed with the Premorbid Adjust-
ment Scale (PAS). The neurocognitive test battery comprised measures of
motor functioning (Grooved Pegboard), psychomotoric tempo (Digit Sym-
bol), attention (Digit Span), verbal memory (CVLT-II), and intelligence
(WASI). Executive functioning and impulsivity was measured by subtests
from the D-KEFS. There were no statistically significant differences be-
tween suicide attempters and non-attempters on neurocognitive variables.
Significantly more suicide attempters were found amongst female patients
(42%) compared to male patients (22%) (P = .008, v2), and amongst patients
with schizoaffective disorder (54%) compared to the patients with schizo-
phrenia/schizophreniform disorder (26%) (P = .01, v2). Suicide attempters
had significantly lower age at illness onset (P = .032), more depressive epi-
sodes (P < .000) (both Mann-Whitney U Test), longer duration of illness
(P = .014, Independent-Samples T-Test), and had a significantly smaller
decline in premorbid social functioning (P = .011, Independent-Samples
T-Test). A series of multiple hierarchical regression analyses showed no
confounding effects of clinical and demographical variables. There were
no differences in general neurocognitive functioning, executive function-
ing or impulsivity between suicide-attempters and non-attempters with
schizophrenia spectrum disorders.
ID: 550228
COGNITIVE IMPAIRMENT IN DUAL DIAGNOSIS:
THE ADDITIVE EFFECT OF ALCOHOLISM AND
SCHIZOPHRENIA
Victoria Manning1,3, S. Graham1, M. Goddop3, S. Betteridge2,
S. Wanigaratne3, D. Best4
1Psychology, National University of Singapore, Singapore,
Singapore; 2Neuropsychology, The Wolfson Neurorehabilitation
Centre, London, United Kingdom; 3Psychological Medicine,
National Addiction Centre, Maudsley Hospital/Institute
of Psychiatry, London, United Kingdom; 4Psychiatry, University
of Birmingham, Birmingham, United Kingdom
Patients with dual diagnosis constitute one of the biggest challenges faced
by mental health services. Their ‘revolving-door’ pattern of service use and
poor clinical outcomes incur a considerable economic burden. Cognitive
impairment is common among patients with schizophrenia and patients
with alcohol use disorders. Outcomes may therefore be further compro-
mised if cognitive impairment is compounded by the co-occurrence of
the two disorders. However, little is known about the severity and nature
of cognitive impairment and the possible ‘additive effect’ among patients
with both disorders. A detailed neuropsychological battery including tests
of pre-morbid, current IQ, motor speed, attention, verbal and visual mem-
ory and executive functioning was administered to 30 inpatients with
schizophrenia and 30 inpatients with schizophrenia and alcohol use disor-
der. The mean age was 36.4 (68.5) years and participants averaged 11.5
years education. Patient population profiles of cognitive impairment
were examined using Z-scores based on the performance of 30 matched con-
trols. Both clinical populations exhibited generalised impairment across the
battery. Greater impairment was observed on almost all measures among
the dually diagnosed, with significant differences in mental flexibility
(working memory and cognitive set-shifting), delayed verbal memory
and planning (all P < .01). Logistic regression with diagnosis (schizophre-
nia or dual diagnosis) as the dependent variable, and executive functioning
score, memory score, pre-morbid IQ, age of onset of schizophrenia, and
severity of psychiatric symptoms (HADS and BPRS) as co-variates
revealed the finding that executive functioning and psychiatric severity
(BPRS) were the best predictors of dual diagnosis status (v= 11.0, P <
.01). The current findings provide support for an ‘additive effect’ of the
two disorders on cognitive impairment. The implication of this finding
is that greater (positive) symptom severity and cognitive deficits may affect
response to treatment and subsequent outcomes. Patients may benefit from
learning compensatory techniques or from CRT as executive deficits may
increase risk of relapse. An understanding of the cognitive profiles of the
dually diagnosed can inform the adaptation of treatment delivery. Psycho-
logical interventions can then be tailored to enhance cognitive strengths,
accommodate deficits, promote further recovery and ultimately improve
clinical outcome.
ID: 550197
DISTURBANCES IN OBSERVABLE BEHAVIOURS
IN PATIENTS WITH FIRST-RANK (PASSIVITY)
SYMPTOMS
Flavie Waters, A. Jablensky
Centre for Clinical Research in Neuropsychiatry, University of
Western Australia, Perth, WA, Australia
First-rank (passivity) symptoms (FRS) refer to experiences where there is
a subjective disturbance in the voluntary control of actions and mental acts.
Theoretical models propose that FRS result from deficits in internal motor
representations and from a failure in representing the self. One question
that arises is whether these cognitive disturbances are associated with impair-
ments in observable behaviours linked to interactive and communicative
skills. In this study, we examined the relationship between FRS and observ-
able behaviours in a large sample of patients with first-episode psychosis.
We also examined the stability of this performance after 2-years. A second-
ary aim of the study was to observe the course of symptom profiles relating
to FRS over a 2-year period. As part of the WHO study on the Determi-
nants of Outcome of Severe Mental Disorders, a large prospective cohort of
non-medicated patients with first-episode psychosis was assessed with the
Psychological Impairment Rating Schedule (WHO-PIRS), a validated in-
strument which allows detailed recording of patients’ behaviours. 227
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patients, in whom the presence/absence of FRS could be evaluated with
certainty, completed the PIRS. Results show that patients with FRS had
significant impairments in behaviours linked to interactive and communi-
cative skills compared to patients without these symptoms; furthermore,
these impairments persisted 2 years after the initial assessment. The results
also showed that the symptom profile of patients relating to FRS was re-
markably stable over time. In conclusion, deficits in behavioural interactive
skills were found in patients with FRS, consistent with theoretical accounts
proposing that FRS represent disturbances in internal cognitive motor rep-
resentations and in processes underlying self/other differentiations. The
results also suggest that the presence of FRS may have enduring consequen-
ces on the quality of patients’ interpersonal communications, and interac-
tions with the social environment. These findings have implications for
interventions in FRS, which need to target behavioural impairments and
social skills training. Flavie Waters is recipient of an Australian National
Health and Medical Research Council (NHMRC) Research Fellowship (nu
404117).
ID: 550051
SELECTIVE ENHANCEMENT OF VISUOSPATIAL
IMAGERY AND ITS DISSOCIATION FROM
WORKING MEMORY IN SCHIZOPHRENIA
Kathleen Patricia Collins1, N. Matthews1, K. Thakkar1, S. Park1,2
1Psychology, Vanderbilt University, Nashville, TN, USA;
2Psychiatry, Vanderbilt University, Nashville, TN, USA
Working memory (WM) deficit in schizophrenia (SZ) is a fundamental
characteristic of the disorder and may be a result of difficulty generating
and manipulating internal representations. However, previous research
has shown that SZ patients have more vivid mental imagery (MI). WM
and MI both rely on generation and manipulation of internal representa-
tions. WM and MI are associated in healthy populations, but very little is
known about the relationship between WM and MI in SZ. Schizophrenic
(SZ), bipolar (BP), and demographically matched healthy (CO) partici-
pants performed a spatial delayed response WM task and a letter MI
task. In the WM task, a target was presented briefly, and after a 10 s delay
the participant selected the remembered location of the target. In the MI
task, participants were asked to imagine the position of a series of block
letters on a grid and decide whether a marker on the grid overlapped
with the imagined letter. In the perceptual control task, the same task
was performed with the letter shown on the grid. SZ were less accurate
and slower compared to CO on the WM task, but they were faster than
CO on the MI task. Importantly, within the MI task the RT advantage
for SZ was only observed for the imagery and not for the perceptual control
condition, suggesting a selective advantage for the MI component. BP and
CO did not differ on the WM task, but BP were faster than CO on both the
MI and the perceptual control task. Thus, BP participants showed intact
WM and enhanced MI. These results indicate that the generation and ma-
nipulation of MI is intact or enhanced in SZ even though they show WM
deficits. The selective MI enhancement may be unique to SZ and not char-
acteristic of other psychiatric conditions such as BP. In SZ there is disso-
ciation between MI and WM whereas the two cognitive processes appear to
be linked in CO and BP. A comprehensive theory of WM should account
for this dissociation in SZ between manipulation of internal representations
required for performance on WM and MI tasks. This work was supported
by MH073028.
ID: 549911
NEUROCOGNITION IN EARLY PSYCHOSIS: FROM
PRODROME TO FIRST EPISODE AND BEYOND
Larry J. Seidman1, A. J. Giuliano1, K. A. Woodberry1,
S. V. Faraone2, R. I. Mesholam-Gately1
1Psychiatry, Harvard Medical School; Massachusetts Mental
Health Center at Beth Israel Deaconess Medical Center, Boston,
MA, USA; 2Medical Genetics Research;Child and Adolescent
Psychiatry Research, SUNY Upstate Medical University, Syracuse,
NY, USA
Background: Compromised neurocognition is a core feature of schizophre-
nia and well characterized. However, it is still unclear when most of the
neurocognitive impairment occurs and when deterioration occurs. In order
to answer this question, we carried out two meta-analyses, on premorbid IQ
and on neuropsychological functioning in first episode (FE) schizophrenia
and compared these with existing meta-analyses. Methods: In the meta-
analysis of IQ in the premorbid phase in persons who later develop schizo-
phrenia, we analyzed 18 studies meeting study criteria (Woodberry, Giu-
liano, Seidman, 2008, Am J Psychiatry). In a subsequent meta-analysis
(submitted), we analyzed 43 separate samples of 2204 FE patients with
a mean age of 25.3 (3.5) and 2775 largely age- and gender-matched control
subjects across ten neurocognitive domains. Results: Overall, schizophrenia
samples demonstrated a reliable medium-sized impairment in premorbid
IQ (d = 0.54) in Woodberry et al. (2008). The IQ effect size in FE schizo-
phrenia was d = 0.91, which was virtually comparable to that observed in
Heinrichs and Zakzanis, 1998 (d = 0.96) in chronic schizophrenia. More-
over, the effect sizes of most neuropsychological domains were just as im-
paired as in chronic patients with schizophrenia with a mean effect size
deficit of about 1.0. Conclusion: Substantially larger impairments in IQ
at the FE compared to the premorbid period strongly suggest maximal de-
terioration occurs between those phases. Moreover, neuropsychological
impairment, at least in group samples, suggests that impairment is roughly
as severe in the first episode as in chronic phases. Further research during
the premorbid, prodromal and very early stages of psychosis is required to
detect when the decline specifically occurs. Research designed to categorize
heterogeneity of courses is important to address which patients decline and
which improve over the long term. Data linking brain structure, function
and cognition is essential to understand the neural bases of neurocognitive
impairment.
Reference
1. Woodberry K, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophre-
nia: A meta-analytic review. Am J Psychiatry. 2008;165:579–87.
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OLFACTORY IDENTIFICATION AND
PREFERENCE IN SCHIZOPHRENIA AND
BIPOLAR DISORDER
Amanda Gayle Albritton1, N. Matthews1, S. Park1,2
1Psychology, Vanderbilt University, Nashville, TN, USA;
2Psychiatry, Vanderbilt University, Nashville, TN, USA
Brain regions reported to be abnormal in schizophrenia (SZ) overlap with the
neural circuits that support olfactory functioning including the orbitofrontal
and entorhinal areas. Olfactory identification deficits have been reported in
individuals with SZ regardless of medication status. This deficit has also been
reported in healthy schizotypal individuals and relatives of individuals with
schizophrenia. However, it is unclear whether the olfactory identification
deficit is specific to SZ or present in psychotic disorders in general. The
major aim of this study was to compare olfactory identification and pref-
erence in SZ and bipolar disorder (BPD). In addition, we examined the rela-
tionships among olfactory functioning, clinical symptoms and social
functioning. Individuals with SZ or BPD and demographically matched
healthy participants (CO) were given the University of Pennsylvania Smell
Identification Test (UPSIT). After identifying each odor, participants were
asked to indicate how much they liked or disliked the odor on a 5-point
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rating scale. The severity of symptoms, social functioning and general in-
tellectual functioning were also assessed. SZ patients made significantly
more errors on the UPSIT than did CO. The error rates of BP patients
were in the intermediate range between those of SZ and CO. SZ and
BPD did not differ from CO on ratings of olfactory preference. Across par-
ticipants there was a significant correlation between olfactory identification
performance and social functioning. There were no significant correlations
between clinical symptoms ratings and olfactory errors or preference
scores. These results support previous evidence of an olfactory identifica-
tion deficit in SZ and further provide evidence that this ability may also be
impaired in BPD, although to a lesser degree. This finding suggests that
olfactory identification deficit may not be specific to schizophrenia. In-
stead, such deficit may also be present albeit in a milder form in bipolar
disorder. Regardless of diagnosis, olfactory identification deficits may be
linked to a decrease in social functioning. This study was supported by
the MH073028 and NARSAD.
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POOR INSIGHT IN PSYCHOSIS: COGNITIVE
DEFICIT OR BIAS?
Anthony David, N. Bedford
Institute of Psychiatry, King’s College London, London, United
Kingdom
Introduction: A recurrent theme in cognitive neuropsychiatry is whether
psychopathological symptoms are best explained as deficits (following
the neurological model) or biases (a social-psychological model). Taking
lack of insight as a phenomenon which may be studied in this way, evidence
for a deficit account comes from studies correlating neuropsychological
impairments on standard tests with lack of insight in schizophrenia
patients. An alternative view is that patients choose certain explanations
over others to explain unusual experiences or their predicament. Such
explanations may seem implausible or may betray the lack of acknowledge-
ment of information—ie, they are biased—but are not evidence of a fixed
disability or a limitation to cognitive processes. Methods: We conducted
a meta-analysis of neuropsychological studies in relation to insight and psy-
chosis and also conducted a number of novel cognitive studies in a group of
schizophrenia patients selected on the basis of good or poor insight. These
included semi-qualitative methods to explore the acceptance of traits (in-
cluding those associated with mental illness) and the use of vignettes to ex-
plore attitudes to self- disclosure of evidence of mental disorder. Results: In
favour of the deficit account, we showed that though there are reliable
effects in relation to IQ, executive functioning and insight, effect sizes
are modest. We postulated that trait acceptance would be biased towards
individual judgement of the desirability of such traits but this was not found
to be influential in the poor insight group. Second, using vignettes we found
that self-disclosure of mental illness traits in both sets of patients was influ-
enced by pragmatic factors and preservation of the participants ‘image’.
Discussion: Our results suggest that both deficits and biases may contribute
to poor insight in schizophrenia and that assessment of both is necessary for
a full account of psychopathology.
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EXECUTIVE FUNCTION AND NEGATIVE
SYMPTOMS IN EARLY-ONSET SCHIZOPHRENIA-
SPECTRUM DISORDERS.
Aina Holme´n1,4, M. Juuhl-Langseth2, R. Thormodsen3,
I. Melle4,5, B. R. Rund1,3
1Department of Psychology, University of Oslo, Oslo, Norway;
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The literature on adult schizophrenia show that one of the most severe neu-
ropsychological impairments are apparent in executive functioning, evident
also on a background of a generalized cognitive deficit. This executive func-
tion deficit has in some studies been associated with more negative symp-
toms, adding to the risk of a poor functional outcome. Accordingly,
cognitive deficits have been found prevalent in early-onset schizophrenia,
but are investigated to a much lesser extent. We wanted to examine the re-
lationship between executive functions and negative symptoms in the ad-
olescent group. 31 adolescents (12–18 years) with schizophrenia spectrum
disorders are included at the time of their first contact with the mental
health service. Diagnoses are based on the DSM-IV criteria. Symptom level
is assessed using the PANSS and the Global Assessment Scale. Neuropsy-
chological functioning is assessed with the MATRICS battery, WSCT and
Stroop. Eighty-three healthy adolescent controls have also been included in
the study. Results show that adolescents with schizophrenia performed
poorer than healthy controls on executive functioning (P = .005).
We found, however, no significant correlation between the patients’ nega-
tive symptoms and executive functioning, suggesting that executive dys-
function is more independent of negative symptomatology in early-onset
schizophrenia.
ID: 549712
DIFFERENTIAL EFFECTS OF EMOTION ON
EPISODIC MEMORY SYSTEMS AS A BASIS FOR
MOOD CONGRUENT VS. MOOD INCONGRUENT
DELUSION FORMATION
Ayana Gibbs, A. David
Psychological Medicine and Psychiatry, Institute of Psychiatry,
King’s College London, London, United Kingdom
A phenomenological distinction has been made between delusions that
arise out of underlying affective disturbance (mood congruent delusions)
and delusions arising in the absence of affective disturbance (mood incon-
gruent delusions) (1). Yet the role of emotion in delusion formation and
maintenance has only recently begun to be investigated. Emotional arousal
may contribute to memory errors and distortions that may play a role in the
formation and maintenance of delusional beliefs. We hypothesised that this
would be more likely to be the case in mood congruent (MC) versus mood
incongruent delusions (MI). We used the Deese-Roediger-McDermott
(DRM) (2) paradigm to investigate the effect of emotional arousal on false
memory formation in 24 patients with delusions (13 MI, 11 MC) and 31
healthy volunteers. Participants studied 15 DRM word lists (5 positive,
5 negative and 5 neutral) followed by an old/new recognition memory
test comprising 30 presented target words, 30 non presented ‘‘lures’’ and
60 novel words. We calculated recognition rates and signal detection meas-
ures (discrimination d’ and response bias C) The MC patient group dem-
onstrated higher false recognition rates for negative words (lures and novel)
and poorer discrimination for negative words than the MI group. There
were no effects in relation to positive items. The results indicate differential
effects of emotional arousal on memory errors in patients with MC versus
MI delusions, in support of our hypothesis. This provides further insight
into emotional memory and constructive memory processes in psychosis
and is relevant for potential therapeutic approaches.
References
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THE PROCESS OF BINDING IN SCHIZOPHRENIA:
EXAMINATION OF ASSOCIATIONS WITH
TEMPORAL AND SPATIAL CONTEXT IN
WORKING MEMORY
Andre´e-Anne. Lefe`bvre1,2, C. Cellard1,2, S. Tremblay1,2,
A. M. Achim1, R. Bruneau-Bhe´rer1,2, M. A. Roy1,2
1Centre de Recherche Universite´ Laval Robert-Giffard, Que´bec, QC,
Canada; 2E´cole de Psychologie, Universite´ Laval, Que´bec, QC,
Canada
It is well established that schizophrenic (SZ) patients have difficulties in
binding target information with their contextual features in order to create
a unified episodic representation in memory but the nature of this deficit
remains unclear. The present study proposes a systematic examination of
memory for target information and its association with either spatial or
temporal context in working memory. Performance of SZ patients (n =
25) was compared to that of matched healthy controls on a probe-recall
task modified to capture both target information and associations. We ob-
served a memory deficit in SZ patients compared with healthy controls that
encompassed the capacity to remember items per se and the association
with their temporal as well as spatial context. Our results confirm the
patient’s difficulty to bind items and locations in WM, and extend this bind-
ing deficit to the capacity to associate items to their temporal context. Con-
sequently, the binding deficit observed in previous studies using tasks with
a spatial component cannot be exclusively attributed to an impairment in
dealing with spatial information.
ID: 549633
PSYCHOMETRIC PROPERTIES OF A NORWEGIAN
VERSION OF THE MATRICS CONSENSUS
COGNITIVE BATTERY (MCCB)
Kjetil Sundet1, A. K. Torgalsbøen1, I. Melle2,3, O. Andreassen2,3,
B. R. Rund1,4
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Introduction: In the making of MCCB, tests rated high on (a) test-retest
reliability, (b) utility as repeated measures, (c) sensitivity to functional out-
come, and (d) tolerability and practicality, were chosen. The battery seeks
to be the preferred method for assessing neurocognition in research on psy-
chosis patients, especially when treatment issues are in question. The
MCCB has recently been translated into Norwegian and is being used in
several ongoing research projects, paralleling studies initiated by the The-
matic Organized Psychosis (TOP) group using another set of neuropsycho-
logical tests within largely the same cognitive domains. In this paper we
question reliability and validity issues of the Norwegian MCCB in compar-
ison to the TOP battery. Method: Healthy subjects (n = 66, age: 35, IQ: 114)
and outpatients with a psychotic spectrum disorder (n = 20, age: 28, IQ: 114)
from the TOP study were recruited for retesting with the MCCB. The TOP
battery consists of measures of speed (Grooved Pegboard, Digit Symbol,
Semantic Fluency, Color-Word Interference), attention (Digit Span), learn-
ing and memory (CVLT-II, LM I and II, RCFT), reasoning and problem
solving (WASI), and social function (SFS). Predefined correlations between
tests from the MCCB and the TOP batteries within the same cognitive
domains were computed, and test profiles for patients and controls within
each test battery were compared. Results: Correlations between a priori de-
fined same-function tests were generally high (r > .50, P < .001) indicating
high test-retest stability. Patients scored systematically below controls on
each battery irrespective of using published norms or control group means
as reference, indicating diagnostic validity for each battery. On one test
(Animal naming) Norwegian subjects outperformed the US normative
sample. Otherwise the US norms suited the Norwegian group well. Corre-
lations and group differences were generally smaller than expected due to
high IQ-level in both groups. Conclusion: The Norwegian version of the
MCCB documents adequate psychometric properties. Further research
is needed to confirm the conclusion also for subjects with less cognitive
reserve.
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DECONSTRUCTING EXECUTIVE FUNCTIONS IN
SCHIZOPHRENIA
Gauri N. Savla1,2, E. W. Twamley1, D. C. Delis1,3, D. V. Jeste1,4,
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Deficits in executive functions may be among the strongest predictors of
everyday functioning difficulties among people with schizophrenia. Yet,
there is considerable debate over whether executive functions comprise
a unitary construct or multiple constructs, and whether they are uniquely
impaired above and beyond general cognitive deficits. The aim of the cur-
rent study was to clarify the construct of executive functions in schizophre-
nia, and to examine the performances on ten executive functioning tasks as
measured by the Delis-Kaplan Executive Functioning System (D-KEFS)
among 81 adults with schizophrenia or schizoaffective disorder (SCs)
relative to 81 demographically-matched neuropsychiatrically healthy
comparison subjects (HCs). SCs, on average, had consistently worse
performance than did HCs on all executive functioning tasks. Overall
differences between performances on multi-level executive tasks, ie, those
demanding two or more cognitive processes at the same time (eg,
switching), and basic cognitive tasks (eg, motor speed) were greater among
SCs than among HCs. Exploratory factor analysis of the ten D-KEFS
tasks among the SCs revealed a two-factor solution, ie, abstraction and cog-
nitive flexibility. A latent profile analysis of the D-KEFS performances
among the SCs yielded three distinct executive functioning profiles, with
most patients being characterized as mildly impaired or average, and about
10% being classified as high-average-to-superior. Within-group ipsative
comparisons indicated that SCs in the mildly-impaired group did worse
on abstraction tasks and better on switching, while those in the high average
group, while generally doing better on all tasks, showed the opposite pat-
tern of results, ie, they did relatively worse on switching tasks and better on
abstraction tasks. Findings from the current study support the idea that
executive functions are not a single, unitary construct in schizophrenia,
but may comprise at least two distinct, but related constructs, ie, abstrac-
tion and cognitive flexibility. While in general, patients with schizophrenia
did worse than demographically-matched healthy comparison subjects,
similar to deficits in other cognitive domains, the presence and degree of
executive functioning impairments varied considerably. Among the execu-
tive functions, abstraction seemed to be more impaired than cognitive flex-
ibility in schizophrenia; if replicated, this distinction may be relevant to
treatment planning.
ID: 549560
International Congress on Schizophrenia Research
282 19. 19. Clinical Neuropsychology
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
A 10-WEEK, DOUBLE-BLIND, PLACEBO
CONTROLLED, CROSS-OVER TRIAL OF
ADJUNCTIVE MODAFINIL FOR
NEUROCOGNITIVE IMPAIRMENTS IN
SCHIZOPHRENIA
Karine Le´tourneau1,2, M. F. Demers1,3, M. Simard1,2, C. E´mond3,
M. A. Roy1,3
1Centre de Recherche Universite´ Laval Robert-Giffard, Que´bec, QC,
Canada; 2E´cole de Psychologie, Universite´ Laval, Que´bec, QC,
Canada; 3Clinique Notre-Dame des Victoires, Centre Hospitalier
Robert Giffard, Que´bec, QC, Canada
Although some open-label studies suggest that modafinil could be an effec-
tive cognitive enhancer in schizophrenia, results from controlled studies are
contradictory and the scope of the cognitive domains that they assessed was
limited. Therefore, the aim of the present study is to assess the effects of
modafinil on neurocognition in participants suffering from a schizophrenia
spectrum disorder. Twenty subjects treated with a second-generation anti-
psychotic and showing attentional impairments completed this 10 week
double-blind, placebo-controlled cross-over study. The participants were
assessed on four occasions with neuropsychological tests typically assessing
information processing speed, visual selective attention, sustained atten-
tion, inhibition, cognitive flexibility, verbal and visual short term memory,
as well as lexical and semantic verbal fluency. Clinical scales were also used
to characterise changes on psychotic symptoms, side effects, clinical global
improvement, and global functioning. Tirthy-one participants took part to
the initial assessment, 28 were randomized in the two experimental condi-
tions, and 20 out of them completed the entire assessments. In regard to the
neuropsychological respects, modafinil, in comparison to the placebo, sig-
nificantly improved the semantic verbal fluency, verbal short term memory,
and the ability to detect visual targets among non-verbal distractors. How-
ever, modafinil increased the commission errors in a task typically used to
assess sustained attention. Clinically, modafinil significantly improved sub-
jective memory, as well as fatigue. In conclusion, modafinil do not seems to
lead to specific improvements in processing speed, but rather, to facilitate
response initiation in various neurocognitive domains. Furthermore, it
improves some side effects which are frequently reported by patients
and constitute challenge for clinicians. Therefore, modafinil remains an al-
ternative as a potential neurocognitive enhancer in schizophrenia spectrum
disorders although further neurocognitive and clinical studies are needed.
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PATTERNS OF COGNITIVE DYSFUNCTION IN
SCHIZOPHRENIA: RESULTS FROM THE MATRICS
PSYCHOMETRIC AND STANDARDIZATION
STUDY (PASS)
Robert S. Kern1,2, J. Gold3, D. Dickinson9, M. Green1,2,
K. Nuechterlein1,4, L. Baade5, R. Keefe6, R. Mesholam-Gately7,
L. Seidman7,8, S. Marder1,2
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MIRECC, Los Angeles, CA, USA; 3Department of Psychiatry,
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Baltimore, MD, USA; 4Department of Psychology, UCLA, Los
Angeles, CA, USA; 5University of Kansas School of Medicine,
Wichita, KS, USA; 6Department of Psychiatry and Behavioral
Sciences, Duke University, Durham, NC, USA; 7Massachusetts
Mental Health Center, Public Psychiatry Division of the Beth Israel
Deaconess Medical Center Department of Psychiatry, Harvard
Medical School, Boston, MA, USA; 8Massachusetts General
Hospital, Boston, MA, USA; 9Department of Veterans Affairs
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An aim of the MATRICS initiative was to address an obstacle to drug de-
velopment in the treatment of cognitive deficits in schizophrenia, namely
the absence of a consensus-based measurement of cognition for clinical tri-
als. Following a careful process of evaluation, the MATRICS Consensus
Cognitive Battery (MCCB) became available in April, 2006. The
MATRICS Psychometric and Standardization Study (PASS) collected
data on the MCCB from 176 persons with schizophrenia or schizoaffective
disorder from five participating sites (Duke University, Harvard Univer-
sity, University of Kansas, Maryland Psychiatric Research Center, and
UCLA). To obtain norms on the MCCB, 300 community residents strat-
ified by age, sex, and education, were tested at the same sites. This sympo-
sium will be the first to present findings on: (a) the profile pattern of patients
vs. community residents on the seven neurocognitive domains assessed by
the MCCB, and (b) the neurocognitive domains which best discriminate
patients vs. community residents. For profile pattern, the data were ana-
lyzed using MANOVA with two groups (patients vs. community residents)
and seven neurocognitive domains (attention/vigilance, working memory,
verbal learning, visual learning, speed of processing, reasoning and prob-
lem-solving ability, and social cognition). Discriminant function analyses
were used to evaluate how well each neurocognitive domain discriminated
patients vs. community residents. Patients performed significantly worse
than community residents on all seven neurocognitive domains with level
of impairment ranging from 0.9 sds (reasoning and problem-solving ability)
to 1.5 sds (speed of processing). The combination of speed of processing,
social cognition, and verbal learning best discriminated patients from com-
munity residents, correctly classifying 74.1% of patients, 88.1% of commu-
nity residents, and 83.0% of the overall sample. These findings provide
support that the MCCB is sensitive at detecting patient vs. healthy adult
differences across multiple domains of neurocognition.
ID: 549398
CLINICAL APPLICATIONS OF THE NEUROLOGI-
CAL EXAMINATION IN SCHIZOPHRENIA
Richard D. Sanders
1Psychiatry, Dayton VA, Dayton, OH, USA; 2Psychiatry, Wright
State University, Dayton, OH, USA
Many neurologic signs are readily elicited and prevalent in schizophrenia,
so they may have potential for routine clinical use. This presentation will
cover research pertaining to several applications of ‘‘soft signs’’ in the
management of schizophrenia: (1) screening for conditions causing a sec-
ondary (organic) psychosis, (2) enhancing differential diagnosis among pri-
mary (functional) psychotic disorders, (3) predicting onset and outcome, (4)
selecting among treatment options; and increasing the yield of special di-
agnostic measures, including (5) neuroimaging and (6) neuropsychological
testing. Some of these applications (screening for relevant neuropathology,
selecting among treatment options, and clinically relevant relationships
with neuroimaging) have received very little direct investigation in schizo-
phrenia. Results in other areas are inconsistent, probably due to differences
in item selection, differences in the ways that individual neurological signs
are grouped for statistical analysis, differences among groups in the admin-
istration of these tests and rating of performance, and inter-rater reliability.
These issues of methodology will also be reviewed.
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AGE AND GENDER EFFECTS ON SCHIZOTYPY
AND COGNITIVE FUNCTION
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1Neuroscience and Psychiatry Unit, University of Manchester,
Manchester, United Kingdom; 2School of Psychological Sciences,
University Of Manchester, Manchester, United Kingdom; 3Centre
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Kingdom; 4School of Psychology, University of Ulster at Magee,
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Deficits in neurocognition are one of the hallmarks of schizophrenia, a find-
ing present prior to the onset of illness, in those with psychosis and psycho-
sis prone individuals. Initial symptoms of psychotic disorders emerge
during adolescence when adult levels of neurocognition come online. Inves-
tigating neurocognition and psychosis proneness at different stages of de-
velopment may help to determine which cognitive alterations are indicative
of the emergence of symptoms. Adolescents and young adults in the age
range 16–25 took part in an online survey where they completed the
SPQ (Raine, 1991) and three cognitive tasks examining spatial working
memory, sustained attention and spatial cognition. From an initial sample
of 1178 participants, 98 were invited back for follow up questionnaires and
a battery of cognitive tasks measuring executive function, verbal fluency,
working memory, attention and IQ. In the initial sample, age was associ-
ated with a decline in levels of schizotypy in females only (P < .001). Cog-
nitive performance was influenced in an age and gender dependent manner.
High levels of negative schizotypy were associated with impaired perfor-
mance on the spatial working memory task in young females only (P <
.05). Higher levels of positive schizotypy were associated with impaired per-
formance on the sustained attention task in older males only (P< .05). Pre-
liminary analysis of the sub-sample of 98 participants indicates high levels
of schizotypy were associated with cognitive biases in a variety of other
domains. During the critical risk period of late adolescence and early adult-
hood, levels of schizotypy decrease in females only. Gender differences are
also noted in the relationship between schizotypy and neurocognitive per-
formance. These findings may be indicative of different developmental tra-
jectories in males and females. The results may also raise issues with the
measurement of schizotypy in younger samples, as well as the inclusion
of mixed samples which are used extensively in the literature. Further test-
ing on a subset of participants is being carried out to investigate other
effects of schizotypy on cognition in the age range 16–25.
Reference
1. Raine A. The SPQ-A Scale for the Assessment of Schizotypal Person-
ality Based on DSM-III-R Criteria. Schizophrenia Bulletin. 1991;
17(4):555–564.
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HOW TO ENHANCE INTRINSIC MOTIVATION
WITHIN THE SETTING OF A COGNITIVE
REMEDIATION PROGRAM
Jimmy Choi, A. Medalia
Psychiatry, Columbia University Medical Center, New York, NY,
USA
Amotivation is a telling hallmark of negative symptomatology and it impacts
nearly every facet of behavior, including inclination to attempt the difficult
cognitive tasks involved in cognitive remediation (Medalia and Freilich,
2008). Experiences of external reward and reinforcement are diminished
in schizophrenia (Gold et al. 2008), so therapeutics which target intrinsic
motivation for cognitive tasks may enhance task engagement, and subse-
quently, remediation outcome. We examined whether outpatients could at-
tain benefits from an intrinsic motivation approach which (a) presents
materials in a meaningful game-like context, (b) personalizes elements of
the learning materials into themes of high interest value, and (c) offers
choices so patients can increase their control over the learning process.
We directly compared one method that incorporated the motivational par-
adigm into an arithmetic learning program against another method that care-
fully manipulated out the motivational variables in the same learning
program. Subjects were randomly assigned to one of the two conditions
for 10 thirty-minute sessions. Outcome measures were attention, motivation,
self competency, arithmetic, and symptom severity. Results showed the mo-
tivational group (a) acquired more arithmetic skill, (b) possessed greater in-
trinsic motivation for the task, (c) reported greater feelings of self competency
post-treatment, and (d) demonstrated better attentional resource allocation.
Also, baseline perceptions of self competency accounted for 43% of the var-
iance on post-test arithmetic scores. Results demonstrate that incorporating
intrinsic motivation techniques into a difficult cognitive task promotes
greater learning of the material, higher levels of intrinsic motivation to at-
tempt the demanding task, and greater feelings of self efficacy and achieve-
ment. Research supported by NIMH grant 1 R03 MH071733-01A2.
Table.
Measures
Treatment
(n = 20)
Control
(n = 22) ANOVA
Intrinsic Motivation
Inventory (0–147)
Pre Post
57.60 (17.47)
97.32 (15.45) *
61.14 (16.83)
72.06 (14.02)
.03
Perceived Competency
Scale (4–28) Pre Post
10.21 (3.02)
18.43 (3.89) *
11.29 (4.92)
14.02 (3.93)
.05
Arithmetic Test Total
Correct (0–60) Pre Post
31.32 (7.27)
52.31 (6.34) *
34.92 (9.05)
44.88 (8.56)
.04
CPT-IP False Positives
Pre Post
9.95 (3.43)
6.01 (4.37) *
8.47 (4.38)
9.97 (5.55)
.05
ID: 548962
SEARCHING FOR ANHEDONIA IN
SCHIZOPHRENIA
Fabien Tremeau1,2, D. Antonius2, J. T. Cacioppo3, R. Ziwich1,
P. D. Butler1,2, D. C. Javitt1,2
1Nathan Kline Institute, Orangeburg, NY, USA; 2Psychiatry,
New York University, New York, NY, USA; 3Psychology,
University of Chicago, Chicago, IL, USA
Evocative studies have shown that subjects with schizophrenia (SCH) re-
port the same level of pleasure from positive stimuli as non-patient control
subjects (NCS): they do not show a global anhedonia. However, two ques-
tions remain: do SCH show a domain-specific pleasure deficit, and are SCH
with negative symptoms anhedonic? Seventy-two patients with a SCID diag-
nosis of schizophrenia (including 23 SCH with primary negative symptoms)
and 36 NCS participated in the study. The stimuli were 48 photographs of
low or high intensity from the International Affective Pictures System, and
48 sounds from the International Affective Digitized Sounds. After each
stimulus, participants rated the degree of pleasantness, unpleasantness
and arousal that they experienced. From this battery, specific stimuli
were identified to measure three hedonic domains: 1) food (three pictures),
2) erotica (one picture, two sounds), and 3) social pleasure (12 pictures).
Compared to NCS, SCH with or without negative symptoms gave similar
pleasantness and arousal ratings, and higher unpleasantness ratings for
each hedonic domain. Pleasantness ratings were not significantly correlated
with SANS scores. For positive pictures, a significant interaction was found
for group by intensity by sociality; SCH without negative symptoms rated
social positive stimuli of moderate intensity as more pleasant than NCS did,
whereas SCH with negative symptoms did not differ from NCS. To con-
clude, SCH with or without negative symptoms were not anhedonic when
representations of food, sex and social interaction were used. However, they
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reported a higher degree of unpleasantness to these positive stimuli, leading
to more affective ambivalence. SCH with negative symptoms did not show
impaired reactivity to positive social stimuli of moderate intensity, which
are the stimuli that people encounter most often in their daily life, suggest-
ing that lack of social motivation is not secondary to affective deficits in
schizophrenia.
ID: 548853
WHAT DIFFERENCES AND SIMILARITIES
BETWEEN SCHIZOPHRENIA AND BIPOLAR
DISORDER ARE SHOWN IN NEUROCOGNITIVE
FUNCTIONS?
Yu Sang Lee1, J. Chae2, J. Yoo1, W. Lee1, Y. Lee1
1Department of Psychiatry, Yongin Mental Hospital, Yongin-City,
South Korea; 2Department of Psychiatry, The Catholic University of
Korea, Seoul, South Korea
Introductions: Considering recent progresses of genetics, neuroimaging and
psychopharmacologic studies for schizophrenia and bipolar disorders
(BPD), Kraepelinian dichotomy needs to be taken into account. We exam-
ined neurocognitive functions tests for patients with schizophrenia, BPD
and normal controls. Methods: We compared the neurocognitive functions
of 19 patients with schizophrenia and 22 patients with euthymic BPD to
those of 17 healthy controls. The following domains of the neurocognitive
functions were tested in 3 groups: auditory attention (digit span), sustained
attention (Degraded Stimulus Continuous Performance Test), verbal mem-
ory (Korean-California Verbal Memory Learning Test: K-CVLT), working
memory (N-Back Working Memory Task) and executive function (Wiscon-
sin Card Sorting Test: WCST and Chicago Word Fluency Test: CWFT).
Multivariate of analyses of variance (MANOVAs) was performed for sta-
tistical comparisons of neuropsychological functioning among three
groups. Results: There were significant overall differences among the three
groups for the cognitive domains in the statistical comparisons. Bonferroni-
adjusted post hoc comparisons showed that the neurocognitive functions of
schizophrenia group were significantly (P < .01) worse than normal con-
trols groups and BPD group also were significantly (P < .01) worse than
normal controls on almost every cognitive domains except 0-back task and
CPT False Alarm. In the comparison of performance of digit span and K-
CVLT, the order was schizophrenia<BPD<normal controls. Both patient
groups performed significantly worse than normal controls especially on
the N-back working memory task and CWFT. Conclusions: Attention
and memory are thought to differentiate schizophrenia from BPD. Both
similarities and differences were present in neurocognitive functions of
both schizophrenia and BPD. It might mean that schizophrenia and
BPD are neither wholly mutually exclusive nor wholly continuous.
ID: 548558
THE ENDURING INFLUENCE OF D. SHAKOW’S
NEUROPSYCHOLOGICAL INVESTIGATIONS ON
SCHIZOPHRENIA RESEARCH
Loring Ingraham
Professional Psychology, George Washington University,
Washington, DC, USA
David Shakow (1901–1981) investigated a range of cognitive and perfor-
mance measures of schizophrenia patients at Worcester State Hospital
and later at the NIMH, initially focusing on reaction time and efforts to
precisely characterize the deficits (and capabilities) of schizophrenia
patients. The variables that he delineated in his schizophrenia research
have in recent decades proven fruitful in family and developmental studies
of schizophrenia. Contemporary schizophrenia research literature bears wit-
ness to his enduring influence. While the term he coined for schizophrenia-
related deficit, segmental set, is not frequently used in contemporary pub-
lications, Shakow’s papers describing his empirical work with schizophrenia
patients remain frequently cited. The consortium on the genetics of schizo-
phrenia describing neurocognitive endophenotypes for use in investigations
of the genetics of schizophrenia cited Shakow’s 1962 Archives paper on seg-
mental set as support for inclusion of attentional measures; in the last decade
there have been eighteen journal citations to that single paper. The phenom-
enon of reaction time crossover that Shakow explored continues to engage
researchers, and has been expanded to the investigation of crossover effects
in schizotypy, reflecting contemporary interest in schizophrenia spectrum
conditions. Perhaps one of the most counterintuitive of Shakow’s empirical
findings is his description of normalizing trends observed in schizophrenia,
such that individuals with schizophrenia can at times perform in the normal
range on neuropsychological tests. The investigation of the correlates of nor-
mal neuropsychological function in schizophrenia is an active research area,
with some reports replicating Shakow’s findings of normal neuropsycholog-
ical functioning among some schizophrenia patients. More broadly influen-
tial in schizophrenia research than any specific variable or domain was
Shakow’s insistence on methodological rigor and the importance of reliabil-
ity and validity in measurement. In a 1966 paper, Shakow summed up his
approach thus: (Bull. Men. Clinic, (1966) 30:15–60) ‘‘Above all I want to
stress the guiding principle I learned from the Worcester studies.It can
be summed up in just three words: Standards, standards, standards.’’
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TEMPORAL EXPERIENCE OF PLEASURE IN
INDIVIDUALS WITH SCHIZOTYPAL
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Background: Hedonic experience is one of the core features being studied in
schizophrenia research. The Temporal Experience of Pleasure Scale (TEPS)
has recently been devised to capture two distinct constructs of anticipatory
and consummatory pleasure. Aim: The current study aimed to evaluate the
feasibility of administering the Chinese version of the TEPS using a rigorous
2-stage factor analysis approach to validate the Chinese version, ie, per-
forming the exploratory factor analysis and confirmatory factor analysis
in two independent samples to examine the latent structure of the
TEPS. Method: 2275 healthy college students were recruited from local
universities in mainland China. They were randomly split into two subsam-
ples. The first subsample was submitted to an exploratory factor analysis in
order to identify a factor structure for the TEPS in a Chinese sample. The
second subsample was used as a validation sample for the identified struc-
ture from the EFA and CFA was adopted. All the data preparation and
EFA analyses were performed using SPSS 15.0 and the CFAs were
performed with LISREL 8.70. The Beran-Stine-Bentler bootstrapping
procedure was performed with EQS6.1. Results: The EFA suggested
a four-factor model instead of Kring’s two-factor model. However, the con-
structs of the four-factor models were highly correlated in such a way that
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two consummatory factors (abstract and concrete) contributed to a second
order latent factor (known as consummatory factor). Similarly, the two an-
ticipatory factors (abstract and concrete) also contributed to a second order
latent factor (known as anticipatory factor). Therefore, the CFA was
performed with a four-factor model and a four-factor 2nd order model,
in parallel with the original two-factor model of the TEPS. Conclusions:
The 2nd order model showed a better fit to the subsample and this finding
was confirmed in the second subsample based on the validation CFA in the
Chinese non-clinical sample.
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THE CHINESE SETTING: A PRELIMINARY PSY-
CHOMETRIC STUDY
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Background: Impaired social functioning is one of the most crucial features
of schizophrenia. However, most of the current clinical ratings maybe too
brief to capture this complex construct. Aims: The current study aimed to
report the preliminary psychometric properties of a Chinese version of
a new questionnaire capturing different domains of social functioning in
psychosis. Methods: The Social Functioning Scale for Psychosis Scale
(SFSPS) was administered to 220 university students, 69 university students
with schizotypal personality features, and 43 patients with schizophrenia.
All the participants also completed the validated Chinese versions of the
Schizotypal Personality Questionnaire, Beck Depression Scale, Beck Anx-
iety Scale, General Health Questionnaire, and Dysexecutive Questionnaire.
Results: Principal component analysis of the university students with and
without schizotypal personality features yielded a 5-factor model compris-
ing Interacting, School, Family, Living Skills and Intimacy. These factors
also demonstrated adequate internal consistency (Cronbach alpha ranges
from 0.6 to 0.76) and test-retest reliability (r ranges from 0.4 to 0.75) sup-
porting the construct validity and reliability of the assessment. Significant
differences were found in Family (P < .05), Living Skills (P < .0005), and
Intimacy (P < .0005) factor scores between participants with and without
schizotypal personality features, and patients with schizophrenia. Trends of
significance were also demonstrated in Interacting (P = .064 and School
(P = .061). Conclusions: The results provide the preliminary psychometric
adequacy of the translated SFSPS in the Chinese setting.
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ARE PSYCHOTIC PSYCHOPATHOLOGY AND
NEUROCOGNITION ORTHOGONAL? A SYSTEM-
ATIC REVIEW OF THEIR ASSOCIATIONS
Maria de Gracia Dominguez Barrera1, W. Viechtbauer2,
C. Simons1, J. Van Os1,3, L. Krabbendam1
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Objective: A systematic review (58 studies, 5009 individuals) is presented of
associations between psychopathological dimensions of psychosis and
measures of neurocognitive impairment in subjects with a lifetime history
of non-affective psychosis. Results: Results showed that negative and dis-
organized dimensions were significantly but modestly associated with cog-
nitive deficits (correlations ranging from 0.29 to 0.12). In contrast,
positive and depressive dimensions of psychopathology were not associated
with neurocognitive measures. The patterns of association for the four psy-
chosis dimensions were stable across neurocognitive domains and indepen-
dent of age, gender and chronicity of illness. In addition, significantly
higher correlations were found for the negative dimension in relation to
verbal fluency (P-value: .005), and for the disorganized dimension in
relation to reasoning and problem solving (P-value: .004) and attention/
vigilance (P-value: .03). Conclusions: Psychotic psychopathology and neu-
rocognition are not entirely orthogonal, as heterogeneity in non-affective
psychosis is weakly but meaningfully associated with measures of neuro-
cognition, suggesting differential latent cerebral mechanisms underlying
the cluster of disorganized and negative symptoms versus positive and
affective ones.
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Gudrun Sartory1, S. Bal1, S. Loos1,2, B. Mueller2,
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Lack of insight represents a core symptom of schizophrenia and accounts to
a large degree for the lack of adherence to treatment, frequently encoun-
tered in this group of patients. Previous studies in chronic schizophrenia
found either deficits of executive function or of declarative memory to be
related to lack of insight. In the present study, 27 patients with predominant-
ly positive symptoms were administered a battery of neuropsychological tests
and the SUMD (Scale to Assess Unawareness of Mental Disorder).
Symptom ratings and scores of test performance were entered into regres-
sion analysis with insight scores as dependent variable. Results revealed
deficits in declarative memory to be significantly related to lack of insight.
The results are consistent with findings of lack of insight in amnestic
disorders.
ID: 542335
COGNITIVE ASSESSMENT IN PATIENTS WITH
FIRST EPISODE PSYCHOSIS USING SPANISH
BACS (BRIEF ASSESSMENT IN COGNITION IN
SCHIZOPHRENIA)
Nuria Segarra1, M. Bernardo1, A. Justicia1, E. Fernadez- Egea1,
F. Gutierrez1, M. Allas2, F. Contreras2, G. Safont3, J. Gascon3,
J. Menchon2, R. Keefe4
1Schizophrenia Program, Hospital Clinic Barcelona, Barcelona,
Spain; 2Psychiatry, Bellvitge University Hospital, Barcelona, Spain;
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3Psychiatry, Hospital Mutua of Terrassa, Barcelona, Spain;
4Psychiatry, University of Duke, Durkham, FL, USA
Neurocognitive impairment is a core feature of schizophrenia and is closely
associated with functional outcome. The importance of the cognitive assess-
ment nowadays is broadly accepted, and it is becoming increasingly neces-
sary to have available a cognitive tool that is easy to use and validated
internationality. In first psychosis episode patients the cognitive assessment
it would be a predictor of daily life functioning. We evaluate 14 first episode
psychosis with 36 healthy controls with the Spanish BACS. Spanish BACS
cognitive measures discriminated between patients and controls in almost
all the BACS domains. These preliminary results indicate that Spanish
BACS is a good neuropsychological tool in patients with first episode
psychosis.
ID: 541809
FURTHER CLARIFICATION OF THE NATURE OF
PROSPECTIVE MEMORY IMPAIRMENT IN
SCHIZOPHRENIA
Ya Wang1,2, R. Chan1,3, X. Hong4, Z. Ma5, T. Yang6, L. Guo2,
X. Yu7, Z. Li5, Y. Yuan7, Q. Gong8, D. Shum9
1Neuropsychology and Applied Cognitive Neuroscience Laboratory,
Institute of Psychology, Chinese Academy of Sciences, Beijing,
China; 2School of Life Sciences, Sun Yat-Sen University,
Guangzhou, China; 3Key Laboratory of Mental Health, Institute of
Psychology, Chinese Academy of Sciences, Beijing, China; 4Mental
Health Center, Shantou University, Shantou, China; 5Beijing
Anding Hospital, Beijing, China; 6Department of Psychology, Sun
Yat-Sen University, Guangzhou, China; 7Institute ofMental Health,
Peking University, Beijing, China; 8Huaxi MR Research Centre,
Department of Radiology,West ChinaHospital /West China School
of Medicine, Sichuan University, Chengdu, China; 9School of
Psychology and Applied Cognitive Neuroscience Research Centre,
Griffith University, Brisbane, QLD, Australia
Memory impairment is a core deficit in schizophrenia, previous studies
have focused on retrospective memory, and several studies have found pro-
spective memory deficit in schizophrenia, the nature of this deficit is yet to
be fully known. Prospective memory refers to the ability to execute
a delayed intention, and it includes the following stages: intention forma-
tion; intention maintenance; cue detection and intention retrieval; intention
execution. The present study aimed to further clarify the nature of prospec-
tive memory impairment in schizophrenia. Fifty-four patients with schizo-
phrenia and 54 age, education, IQ and executive function matched healthy
controls participated the study, they completed time-, event-, and activity-
based prospective memory tasks and a set of neurocognitive tests, ie, work-
ing memory tests (Chinese Letter-Number Span, N-back), verbal and visual
memory tests. Patients with schizophrenia performed worse in all time-
(P< .001), event- (P< .01) and activity-based (P< .001) prospective mem-
ory tasks than healthy controls. Correlation analysis found that prospective
memory correlated significantly with other cognitive functions. Patients
still performed poorer even after controlling other cognitive functions
(working memory, verbal memory, visual memory and executive func-
tions). Results also found patients with schizophrenia did not perform
poorer in recalling task requirements after finishing the prospective mem-
ory tasks, so the intention formation and intention maintenance stages
maybe relatively intact in schizophrenia, and patients were mainly impaired
in cue detection and intention retrieval stage. Prospective memory is a pri-
mary not secondary deficit in schizophrenia. Prospective memory deficit
mainly occur in cue detection and intention retrieval stage.
ID: 541548
EARLY STIMULANT EXPOSURE IS RELATED TO
THE SEVERITY OF PSYCHOSIS
Bonnie Lichlyter1,3, S. Purdon2,3, P. Tibbo1,3
1Department of Psychiatry, Univeristy of Alberta, Edmonton, AB,
Canada; 2Capital Health, Alberta Hospital Edmonton, Edmonton,
AB, Canada; 3Bebensee Schizophrenia Research Unit, University of
Alberta, Edmonton, AB, Canada
Stimulant abuse has been a growing concern and increased use of potent
drugs like methamphetamine over the last decade have lead to a host of
social problems, including increased presentations of drug-induced psychi-
atric disorders. Stimulants like methamphetamine can lead to a persistent
psychotic disorder not unlike schizophrenia, however there has been a pau-
city of research investigating why some users develop these symptoms and
others do not. As part of a larger study examining biological correlates in
drug-induced psychosis, 35 abstinent stimulant users aged 18–35 were
recruited from the community and subjected to a semi-structured interview
to assess prior drug exposure and to quantify psychiatric symptoms with
Positive and Negative Syndromes Scale (PANSS). Age at first use of the
stimulant drug was inversely related to the PANSS Positive Syndrome
Score (Pearson correlation = 0.300; P = .040). Also, subjects with
more than five years duration of chronic use exhibited greater severity
of symptoms on the PANSS Positive Syndrome Score (t = 2.469, P =
.019) and the PANSS General Syndrome Score (t = 3.029, P = .005).
The method of drug administration, duration of abstinence, latency
from first use to regular use, and prior solicitation of treatment were
not related to PANSS Positive, Negative, or General Syndrome Scores. Se-
verity of psychosis appears to be related to earlier and longer exposure to
stimulants, consistent with a ‘‘threshold’’ effect of stimulant use on the de-
velopment of psychotic symptoms. The association may also suggest a crit-
ical developmental period that is most susceptible to the deleterious effects
of stimulant exposure. The identification of a biological correlate to this
vulnerability may offer insight into pathogenesis while also offering an im-
portant tool for the differential diagnosis of substance induced psychosis.
These biological factors, including those that are purported to be contrib-
utory to schizophrenia are being examined in this cohort and will be
reported on at a later date.
ID: 541124
IDENTIFICATION OF PLEASANT, NEUTRAL, AND
UNPLEASANT ODORS IN SCHIZOPHRENIA
Vidyulata Kamath1,2, B. I. Turetsky2,3, P. J. Moberg2,3
1Department of Psychology, University of Central Florida, Orlando,
FL, USA; 2Neuropsychiatry Division, Department of Psychiatry,
University of Pennsylvania School of Medicine, Philadelphia, PA,
USA; 3Department of Otorhinolaryngology: Head and Neck Sur-
gery, University of Pennsylvania School of Medicine, Philadelphia,
PA, USA
Recent work on odor hedonics in schizophrenia has indicated that patients
display abnormalities in hedonic judgments of odors in comparison to
healthy comparison participants. In the current study, identification accu-
racy for pleasant, neutral, and unpleasant odors in individuals with schizo-
phrenia and healthy controls was examined. Thirty-three schizophrenia
patients (63% male) and thirty-one healthy volunteers (65% male) were
recruited. The groups were well-matched on age, sex, and smoking status.
Participants were administered the University of Pennsylvania Smell Iden-
tification Test, which was subsequently divided into 16 pleasant, 15 neutral,
and 9 unpleasant items. Raw scores were rescaled to standard equivalents
based on means and standard deviations of the control group to ensure
comparability across valence types. Analysis of identification z-scores
for pleasant, neutral, and unpleasant odors revealed a significant diagnosis
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by valence interaction. Post-hoc contrasts revealed that the schizophrenia
participants made significantly more identification errors on pleasant and
neutral odors compared to the control group. Conversely, accuracy did not
differ significantly between the schizophrenia and control groups for un-
pleasant odors. No effect was seen for sex. Analysis of odor identification
performance by valence category within patients revealed that significantly
more identification errors were made in response to both pleasant and neu-
tral odors relative to unpleasant odors. No differences between identifica-
tion of pleasant and neutral odors was observed. The findings from the
current investigation suggest that odor identification accuracy in patients
is influenced by odor valence. Specifically, males and females with schizo-
phrenia displayed significantly reduced identification accuracy for pleasant
and neutral smells while showing intact identification for unpleasant smells.
This pattern of results parallels a growing body of literature indicating that
patients display aberrant pleasantness ratings for pleasant smells with rat-
ings for unpleasant smells comparable to healthy controls. These findings
highlight the need for additional research on the influence of odor valence
on olfactory identification performance in individuals with schizophrenia.
This study was funded in part by NIH Grants MH-63381 to PJM, MH-
59852 to BIT, and an Independent Investigator Award from NARSAD
to PJM. The authors thank the Hofmann Trust for their support.
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COMPARISON OF CURRENT AND ESTIMATED
PREMORBID IQ AT FIRST-EPISODE: UTILITY IN
PREDICTING CLINICAL AND COGNITIVE
FUNCTIONING DURING THE FIRST THREE
YEARS OF PSYCHOTIC ILLNESS
Eileen Maria Joyce1,2, V. C. Leeson2, P. Sharma2, M. Harrison2,
I. Harrison2, M. A. Ron1, T. R. Barnes2
1UCL Institute of Neurology, London, United Kingdom;
2Psychological Medicine, Imperial College, London,
United Kingdom
Longitudinal studies suggest that IQ is attenuated and may also decline
premorbidly in individuals who later go on to develop schizophrenia. Com-
parison of concurrently obtained measures of current IQ and estimated pre-
morbid IQ, derived from irregular word reading tasks, have also shown this
pattern and suggest that patients can be subgrouped into those with con-
sistently low, deteriorated or preserved IQ. Previous studies have demon-
strated these subgroups to have differing neuropsychological profiles,
although none to date have followed-up these subgroups longitudinally
to establish whether they demonstrated differing cognitive or clinical tra-
jectories. One hundred and twenty-nine individuals with first episode psy-
chosis were subgrouped based on comparison of current and estimated
premorbid IQ scores, with 44% demonstrating evidence of a ten point
or greater deterioration, 23% showing consistently low IQ, 23% of pre-
served IQ with a further 8% demonstrating current full scale IQ that
was greater than reading IQ by at least ten points. Comparison of these
patient groups and 120 healthy controls revealed equivalent patterns in
the low and deteriorated groups, namely impairment compared to controls
on all neuropsychological tests and greater negative and disorganisation
symptoms than the other patient groups. The preserved IQ group under-
performed compared to controls on WAIS-III digit symbol and working
memory suggesting that processing speed difficulties are present even in
those without evidence of attenuated or deteriorated IQ and may underpin
working memory dysfunction. The small subgroup with higher current IQ
were unique in that they did not evince poorer digit symbol performance
than controls although they were impaired on learning and memory meas-
ures; a deficit observed in all four patient groups. Fifty-one patients and 27
controls were assessed on two further occasions and the subgroups derived
from baseline scores were compared. Analyses revealed that the patient
groups did not differ in terms of cognitive or clinical trajectory over the
first three year of illness. Indeed, controls and patients showed a very sim-
ilar pattern of change in performance on neuropsychological tasks, despite
differences in overall level of achievement. The results suggest that grouping
patients based on premorbid-current IQ differences has limited utility and
that current IQ measures may be more informative.
ID: 551902
THE NATURE AND FRACTIONATION OF INSIGHT
IN SCHIZOPHRENIA: A CORE SET OF PREDICTIVE
FACTORS
James K. Gilleen, K. Greenwood, A. David
Psychological Medicine, Institute of Psychiatry, London, United
Kingdom
Patients with schizophrenia commonly lack insight into their psychotic
symptoms, and cognitive and behavioural impairments. In turn, low insight
has been shown to be associated with poor adherence to treatment, clinical
outcome, mood and also increase the level carer-burden. It is, therefore, of
clinical interest to delineate the nature of insight and in so doing reveal ther-
apeutic targets for reducing low insight, and improve patient quality of life.
As insight has been shown to fractionate by domain, such as insight into
cognition, behavioural functioning and symptomatology, the present study
aimed to contrast awareness into these different dimensions and examine
whether there was a common constellation of factors which predicted
awareness irrespective of domain or alternatively whether each domain
of awareness was associated with specific predictors. Thirty-one schizo-
phrenia patients with low levels of insight underwent clinical interview, as-
sessment on standard insight scales and a battery of psychological tests.
Results suggested that there existed a core set of variables which together
were associated with insight per se. Thus greater insight across all domains
of interest was associated with lower positive, and manic-excitement symp-
tomatology factor scores (Brief Psychiatric Rating Scale; Lukoff et al.
1986), better memory, and greater self-reflectivity and lower self-certainty
scores (Beck Cognitive Insight Scale; Beck et al. 2004). Over and above
these core factors, correct attribution of symptoms to mental disorder
was additionally predicted by executive test performance; while awareness
of mental disorder was associated with capacity to ‘set-shift’; and higher
awareness of behavioural impairments was associated with low mood.
Post-hoc analyses suggest that a key mechanism in poor insight may be
that deficits in attention and working memory impact negatively on the capac-
ity for awareness via their effects on reducing the capacity for self-reflectivity.
In conclusion, the cognitive capacities of attention and memory are sug-
gested to underpin the ability to reflect on changes to mental and functional
status. If this is impaired, low self-reflectivity and high self-certainty could
develop which, when coupled with the presence of psychiatric symptoms,
precludes good insight. Reducing positive symptoms, improving attention,
increasing the capacity to self-reflect, and lowering self-certainty are there-
fore key targets for improving awareness.
ID: 551817
PREDICTORS OF REMISSION IN SCHIZOPHRENIA
Prakash Masand1, C. O’Gorman2, F. Mandel2
1Psychiatry, Duke University Medical School, Durham, NC, USA;
2Pfizer Inc, New York, NY, USA
Background: Development of remission criteria for schizophrenia has been
hindered by the heterogeneity of the disorder and limitations of currently
available treatments. The first consensus-based definition of remission pro-
posed by the Remission Working Group in Schizophrenia (Andreasen et al.
2005) provided a conceptual model incorporating criteria that were easy to
assess in different phases of the disorder. This new definition linked remis-
sion to symptoms as defined in the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) and used established rating
scales to measure these symptoms. The objective of these analyses was to
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determine whether remission could be predicted by improvement defined by
rating scales such as the PANSS or BPRS at early time points during treat-
ment. Methods: A search of the ziprasidone clinical trials database identi-
fied10 ziprasidone studies, all  1 year, including acute core studies and
their open-label extensions, as well as 1 year trials. As many as 600 subjects
were included in analyses that identified potential symptomatic, syndromal,
functional predictors of functional remission in schizophrenia. Several cri-
teria for response were examined as predictors of remission, and PANSS
and BPRS scores at weeks 1, 3, and 4 were used to predict remission at
end point. Remission was also defined using the working group definition:
PANSS (P1, P2, P3, N1, N4, N6, G5, and G9)  3 for  6 consecutive
months and BPRS (items 4, 7, 8, 11, 12, 15, and 16) 3 for 6 consecutive
months. ROC curves were generated for each of these predictors (at each
time point) for each of these definitions at end point, and area under the
ROC curve (AUC) was calculated. Results: In the combined ziprasidone
arms, BPRS scores at weeks 1, 3, and 4 successfully predicted PANSS re-
mission (P< .01); and BPRS remission (P< .0001) at study end point (44–
196 weeks). PANSS scores (at weeks 1, 3, and 4) successfully predicted
PANSS remission (P < .01); and BPRS remission (P = .02 at week 3
only) at study end point. AUC ranged from 0.59 to 0.93. Conclusion:
BPRS and PANSS remission criteria at study end points were accurately
predicted by BPRS or PANSS total scores at weeks 1, 3, and 4.
Reference
1. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Am J Psychiatry.
2005;162:441–9.
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COGNITIVE GAINS FROM NEUROCOGNITIVE
ENHANCEMENT THERAPY SUSTAINED AT 2-
YEAR FOLLOW-UP
Christian R. Miner, W. Zito, T. Greig, B. Wexler, M. Bell
Psychiatry, Yale University School of Medicine, New Haven,
CT, USA
Background: Previous work from our lab evaluated outcomes of a 1-year
program of Neurocognitive Enhancement Therapy(NET) for persons with
schizophrenia or schizoaffective disorder. In a component control design,
NET plus a supported employment program, modified with transitional
funds (NETþVOC) was compared with VOC alone. At the conclusion
of 1 year of treatment, participants randomly assigned to NETþVOC
had significantly greater improvement on measures of executive function-
ing and working memory than those in the VOC only condition (Greig et al.
2007). We now report results of follow-up assessments at 2 years, 12 months
after the end of active treatment. Methods: N = 72 participants were admin-
istered neurocognitive assessments at baseline and again at 1 and 2 years
post-baseline. Measures include tests of executive function, working mem-
ory, visual and verbal memory, and social cognition. Intent to treat analyses
were conducted by the longitudinal method of Generalized Estimating
Equations. Each cognitive measure served as an outcome, regressed on
Group, Time and Group x Time: all models were evaluated by omnibus
Wald v2 test (3df) with Bonferroni-corrected criterion alpha = .0038 for
13 outcomes. Subsequent tests of significance for each regression coefficient
b are considered protected. Secondary analyses focused on the degree of
achievement in NET treatment and its relation to outcome. Results:
With no differences by condition at baseline, participants in both
conditions improved over time on story telling (WMS-LMI: b = 1.01,
P < .001; WMS-LMII: b = 0.66, P < .005) and executive functioning
(WCST errors: b = 1.90,P< .10) [All Wald v2 s> 20.95,P’s< .0001]. Further,
NET participants showed significantly greater improvements on measures of
executive functioning (WCST-CL: b = 2.59, P < .10); visual memory
(WMS-VR1: b = 0.87, P < .05; WMS-VRII: b = .52, P < .10) and social
cognition (Hinting: b = 1.03,P< .005) [All Wald v2 s> 17.40,P’s< .001]. A
moderator effect of achievement in NET training was found to predict con-
dition effects for WCST, WMS-VRI, WMS-VRII, and Hinting Task. For
example, with each‘‘graduation’’ from one task to another, experimental
participants increase their subsequent performance on WMS-VR1 by
b = .18 scale score points (z = 3.17, P < .002). Discussion: Some neurocog-
nitive gains seen immediately following a 1-year program of NET are
sustained at 2-year follow-up in the context of ongoing vocational
placement and coaching.
ID: 551805
FUNCTIONAL DISABILITY IN SCHIZOPHRENIA
AND BIPOLAR DISORDER: CLINICAL AND
NEUROCOGNITIVE CORRELATES
Katherine E. Burdick1,2, N. Gunawardane1, P. DeRosse1,
N. Chitkara1, T. Lencz1,2, A. K. Malhotra1,2
1Psychiatry Research, Zucker Hillside Hospital-NSLIJHS, Glen
Oaks, NY, USA; 2Psychiatry, Albert Einstein College of Medicine,
Bronx, NY, USA
Schizophrenia is a debilitating illness, characterized by positive and nega-
tive symptoms, as well as significant cognitive impairment. Converging
data suggest that persistent low-level psychosis, negative symptoms, and
neurocognitive impairment during remission are directly related to poor
functional outcome in schizophrenia (SZ). Less is known about the rela-
tionship between these illness features and everyday functioning in patients
with bipolar disorder (BPD). The relative impact of persisting symptoms
and neurocognitive impairment upon functional capacity is of extreme clin-
ical importance and critical to our efforts toward improving psychosocial
outcome in both SZ and BPD. We evaluated a large cohort of remitted SZ
patients (n = 69) and a sample of euthymic BPD patients with a history of
psychosis during mania (n = 31) on a comprehensive neurocognitive battery
and on several measures of functional capacity (social, occupational, and
independent living) and compared their performance with a demographi-
cally-matched healthy control sample. We further assessed the contribu-
tions of subsyndromal symptoms and cognitive performance on
functional outcome in each group using logistic regression. Results indicate
that SZ patients were significantly impaired on nearly all major cognitive
domains, including premorbid IQ, attention, processing speed, verbal mem-
ory, and executive functions as compared with healthy controls (0.41 to
1.53 SDs below average). BPD patients were comparably impaired on
measures of processing speed (0.56 SDs below average) and verbal mem-
ory (0.52 SDs below average) but otherwise demonstrated intact cogni-
tion in all other domains. The pattern of the influence of cognitive
impairment and symptomatology on functional assessments differed by di-
agnostic group; however, cognition was a significant predictor of functional
outcome in both patient groups. These data support previous reports that
cognitive impairment is a strong correlate of functional disability in stable
SZ patients and extends these findings to demonstrate a similar relationship
in euthymic BPD patients. Furthermore, while some clinical symptoms
overlap between these major psychiatric disorders, the relative contribution
of affective symptoms and psychosis to functional capacity differs by diag-
nostic categorization. These results are derived from an ongoing study;
thus, a larger sample will be available for presentation by ICOSR 2009.
ID: 551800
EXECUTIVE FUNCTIONING AND FUNCTIONAL
CAPACITY IN SCHIZOPHRENIA
Cynthia Z. Burton1, L. Vella3, E. W. Twamley1,2
1Psychiatry, University of California, San Diego, San Diego, CA,
USA; 2Psychology Service, VA San Diego Healthcare System,
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San Diego, CA, USA; 3Psychology, SDSU/UCSD Joint Doctoral
Program in Clinical Psychology, San Diego, CA, USA
Executive dysfunction is common in schizophrenia and adversely affects
everyday functioning. The relationship between different aspects of execu-
tive function and functional capacity, however, remains unclear. This study
aimed to examine multiple types of executive functioning in a schizophrenia
sample. We used the Delis-Kaplan Executive Functioning System (D-
KEFS), a comprehensive battery measuring set-switching abilities (Trail-
Making, Verbal Fluency, Design Fluency, and Color-Word Interference)
and abstraction abilities (Sorting, Twenty Questions, Word Context,
Tower, and Proverbs). No published studies have yet characterized D-
KEFS performance in individuals with schizophrenia. It was hypothesized
that executive functioning would be associated with functional capacity. 73
outpatients diagnosed with schizophrenia or schizoaffective disorder par-
ticipated in the study. Participants completed a baseline neuropsycholog-
ical, functional, and clinical battery that included the D-KEFS, the UCSD
Performance-Based Skills Assessment (UPSA), the Positive and Negative
Syndrome Scale (PANSS), and the Hamilton Depression Rating Scale
(HAM-D). Less than a third of participants were impaired on set-switching
tasks (age-corrected scale score 6 on contrast scores comparing switching
to the same task without the switching component); 32% were impaired on
Trails, 11% on Verbal Fluency, 7% on Design Fluency, and 4% on Color-
Word. On subtests of abstraction, 19% were impaired on Sorting, 23% on
Twenty Questions, 36% on Word Context, 33% on Tower, and 29% on
Proverbs. Overall, more participants were impaired on a mean switching
score (40%) than were impaired on a mean abstraction score (32%). Func-
tional capacity, as measured by the UPSA, was significantly correlated with
positive symptoms (r =.377; P = .002), negative symptoms (r =.244; P =
.045), and the mean abstraction score (r = .428; P < .001). Using partial
correlations to control for positive symptoms, functional capacity was still
significantly related to abstraction ability (r = .437; P < .001). Similar
results were observed when controlling for negative symptoms (r = .408;
P = .001). UPSA performance was not related to the mean switching score
(r = .067; P = .586). These results indicate that although a minority of
schizophrenia outpatients are impaired on various D-KEFS tests of exec-
utive function, abstraction ability is related to everyday functioning ability
beyond what can be explained by positive or negative symptomatology.
ID: 551788
NEUROCOGNITIVE AND COPING CORRELATES
OF SPEECH DISORDER IN SCHIZOTYPY
Kyle Minor, B. Iglesias, G. M. Najolia, A. S. Cohen
Psychology, Louisiana State University, Baton Rouge, LA, USA
Speech disorder is a cardinal symptom of schizophrenia. There is evidence
to suggest that difficulties in basic neurocognitive abilities are related to SD
in patients with schizophrenia. Moreover, increases in SD are associated
with impairments in ‘real world’ functioning. There is reason to believe
that speech disturbances (SD) are also important in understanding schiz-
otypy, defined in terms of a putative genetic risk for schizophrenia without
full phenotypic expression. The aim of this project was to investigate the
relationship between speech disorder, neurocognition, and coping style,
a ‘real world’ measure of functioning, in individuals with schizotypy.
We also wanted to examine whether specific schizotypal symptoms were
associated with neurocognition and coping. In this study, data from 83
psychometrically-identified individuals with schizotypy and 22 healthy con-
trols was examined. Speech samples were produced by all participants dur-
ing separate laboratory controlled pleasant and stressful conditions. SD
was rated using a validated measure of assessing speech disorder. Compar-
ing groups, we found a significant increase in the use of avoidant coping and
a trend level increase in SD for the schizotypy group. There were no sig-
nificant differences when comparing these groups on overall cognitive func-
tioning; however, the schizotypy group had significantly higher scores on
the immediate memory scale. Within the schizotypy group, avoidant coping
was correlated with a significant increase in SD in the stressful, but not
pleasant, condition. Surprisingly, increased SD rates were associated
with better performance on immediate and delayed memory. When inves-
tigating specific schizotypy symptoms, overall cognitive performance and
attention scores were correlated with increased negative symptoms, and
avoidant coping was correlated with increased positive and disorganized
symptoms. In sum, we found that avoidant coping strategies are signifi-
cantly related to increases in SD when stress was induced, and that cognitive
functioning was not, as we predicted, inversely correlated with speech dis-
order. These findings demonstrate that individuals with schizotypy who
produce high levels of SD in stressful situations also tend to implement
more unhealthy coping strategies. However, we were unable to find
a link between cognitive performance and SD, which may suggest that
the neurocognitive underpinnings of speech disorder may differ in schizo-
typy and schizophrenia.
ID: 551785
BASELINE CHARACTERISTICS ASSOCIATED
WITH SUICIDE AMONG 18 154 PATIENTS WITH
SCHIZOPHRENIA IN A LARGE SIMPLE TRIAL OF
ZIPRASIDONE AND OLANZAPINE
John M. Kane1, S. M. Eng2, J. L. Geier2, C. M. Kremer2,
E. Pappadopulos2, X. Yikang2, W. W. Fleischhacker3
1Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA;
2Pfizer Inc, NewYork, NY,USA; 3Psychiatry, Innsbruck University
Clinics, Innsbruck, Austria
Background: Patients with schizophrenia are at increased suicide risk rel-
ative to the general population. Understanding characteristics of patients
with schizophrenia who have committed suicide is of critical importance to
the identification of patients at risk and the development of preventive
interventions. Objective: To determine baseline factors associated with
completed suicide among patients with schizophrenia in routine clinical
treatment enrolled in a randomized, open-label, post-approval large sim-
ple trial across 18 countries. Methods: 18 154 subjects were randomized to
ziprasidone or olanzapine and followed for 1 year. A baseline question-
naire collected demographic data, medical/psychiatric history, and con-
comitant medication use; follow-up questionnaires elicited data on
hospitalization, vital status, randomized study medication status, and
concomitant antipsychotic medication(s). Completed suicide was a sec-
ondary end point adjudicated by a blinded end point committee according
to a prespecified algorithm Results. 35 completed suicides were observed
over the 1 year study period, yielding an incidence of 1.9 per 1000 patients.
Subjects who committed suicide had a similar demographic profile to
those who did not. Patients who committed suicide had a shorter duration
of illness and were more likely to be older adults. In univariate analyses,
clinical impression score, frequency of psychiatric hospitalizations, and his-
tory of suicide attempts was greater for patients committing suicide, as was
frequency of baseline use of concomitant antipsychotics, antidepressants, and
hypnotics, sedatives, or anxiolytics. Multivariate logistic regression modeling
yielded 2 variables associated with risk of completed suicide: history of suicide
attempts and baseline use of hypnotics, sedatives, or anxiolytics. Due to their
clinical importance, age, sex, age at diagnosis, and prior psychiatric hospital-
ization were also kept in the final model. Conclusions: In this real-world co-
hort of 18 154 people with schizophrenia, 1-year incidence of completed
suicide was 1.9 per 1000 patients. Completed suicide was associated with
older age at the time of diagnosis, history of psychiatric hospitalization,
prior suicide attempts, and baseline use of hypnotics, sedatives, or anxio-
lytics. These findings suggest that patients with a shorter duration of illness,
history of suicide attempts, and comorbid mood/anxiety symptoms are at
increased risk for suicide.
ID: 551743
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EXECUTIVE FUNCTIONS AND RETRIEVAL CON-
TEXT SPECIFICITY IN HABITUAL PROSPECTIVE
MEMORY PERFORMANCE IN SCHIZOPHRENIA
Janice L. Ritch1,2, D. I. Velligan1, D. Tucker2,3
1Psychiatry, The University of Texas Health Science Center in
San Antonio, San Antonio, TX, USA; 2Austin Neuropsychology,
Austin, TX, USA; 3Psychology, University of Texas at Austin,
Austin, TX, USA
Habitual prospective memory (PM) is the mechanism by which one is able
to remember to perform some intended future action on a regular interval
(eg, taking medication). Such tasks are hypothesized to have heavy reliance
on executive functions (EF). Previous research with non-impaired popula-
tions indicates that retrieval context specificity benefits task performance.
The present study examined the role of retrieval context specificity and EF
in a habitual PM task in schizophrenia. Participants and Methods: Forty-
four outpatients diagnosed with schizophrenia were administered the Wis-
consin Card Sorting Test and received instructions to complete a 5-day ha-
bitual PM task with either a general or specific retrieval context. Group
effects for specificity of retrieval context and level of EF on habitual
PM task performance were examined. Results: One-way between subjects
ANOVAs were calculated to examine the effects of instruction set (general
vs. specific) and level of EF (fair vs. poor) on task performance. Analyses
yielded no significant main effect for instruction set (F1,42 = .009; P = .923),
but a significant main effect for level of EF (F1,39 = 5.213; P = .028). Spe-
cifically, participants with fair EF outperformed those with poor EF. The
sample was divided to explore the effect of task specificity on performance
by level of EF. There continued to be no benefit of context specificity for
participants with poor EF (F1,24= .000;P = 1.00); however, there was a trend
for participants with fair EF to demonstrate a benefit in performance when
provided with a specific retrieval context (F1,13 = 4.129; P = .063). Conclu-
sions: Findings indicate that participants with better EF completed more
days of the task compared to participants with poorer EF regardless of re-
trieval context specificity. However, further analyses indicated a trend for
patients with better EF to demonstrate improved performance with in-
creased task specificity as has been shown with non-impaired populations.
Findings support the hypothesis that EF is an important aspect in the per-
formance of habitual PM tasks. However, a minimum level of EF may be
necessary for individuals to benefit from additional information which fur-
ther specify the retrieval context.
ID: 551724
TREATMENT DELAY AND COURSE OF ILLNESS
IN AFRICAN AMERICAN PATIENTS WITH FIRST
EPISODE PSYCHOSIS DURING A TWO-YEAR
FOLLOW-UP
Huijun Li1, D. Montrose2, G. Haas2, L. Seidman1, M. Keshavan2
1Psychiatry, Harvard Medical School, Boston, MA, USA;
2Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
Delays in treatment of psychotic illnesses adversely impact their prognoses.
Cross cultural studies on duration of untreated psychosis (DUP) have indi-
cated ethnic differences in the length of delay. However, the findings are in-
consistent. Few studies have examined course of illness over time in African
Americanpatients. The purpose of this study was to examineDUP in African
American (AA) and White patients and the course of illness in the two groups
of patients during two years of time. Two hundred thirty seven patients with
a first episode of psychosis, recruited at the Western Psychiatric Institute and
Clinic, Pittsburgh, were included in this study at baseline. There were 159
White and 78 AA patients, 153 males and 84 females, with a mean age of
24. ANCOVA was used to examine DUP with gender and patient years
of education as covariates. Similarly, separate race by time ANCOVAs
with positive and negative symptoms were conducted to examine longitudi-
nal clinical outcome. The AA patients had significantly longer DUP than
that of White patients (P = .001). No significant differences in positive
and negative symptoms between the two groups were observed at baseline.
However, there was significant race by time interaction effects for positive
(P = .002) and negative symptoms (P = .001) respectively during follow-ups
up to two years. AA patients showed significantly more persistent positive
and negative symptoms than White patients. African American patients had
significantly longer DUP. African Americans may interpret the illness dif-
ferently, influencing their help-seeking behavior. The longitudinal outcome
of AA patients was also not as promising as White patients. Negative expe-
riences with mental health services, lack of insurance and family support,
lack of compliance to treatment, and lack of culturally sensitive professionals
may account for the poor outcome of AA patients. The clinical implications
of the findings and directions for future research will be presented. This study
was supported by a Center for Neuroscience in Mental Disorders grant: MH
45156 (David Lewis, MD, PI).
ID: 551714
USING ACOUSTIC ANALYSIS OF NATURAL
SPEECH TO UNDERSTAND THE NEUROCOGNI-
TIVE, CLINICAL AND FUNCTIONAL CORRELATES
OF DIMINISHED EXPRESSIVITY IN SCHIZOTYPY
Alex S. Cohen, G. M. Najolia, K. S. Minor
Psychology, Louisiana State University, Baton Rouge, LA, USA
Diminished expressivity is a cardinal negative symptom of schizophrenia-
spectrum disorders, but surprisingly little is known about its underlying
neuropathology and clinical and functional concomitants. The present
study employed acoustic-analysis of natural speech during a labora-
tory condition to understand diminished expressivity in individuals
with schizotypy—individuals with the putative genetic loading for
schizophrenia pathology that do not meet full diagnostic threshold.
We examined a) the severity of diminished expressivity across the hetero-
geneous manifestations of schizotypy b) whether schizotypic individuals
with diminished expressivity show a distinct neurocognitive profile, and
c) the extent to which diminished expressivity is associated with real world
impairments in coping and quality of life. Data for a relatively large group
of individuals with psychometrically-identified schizotypy and controls
were examined here. As a group, individuals with schizoypy and controls
did not differ in overall expressivity, although expressivity was dramatically
reduced in individuals with negative schizotypy. Interestingly, individuals
with more pronounced positive and disorganization symptoms showed ab-
normally high levels of expressivity. Within the schizotypy group, dimin-
ished expressivity was significantly associated with dysfunctions on tests
tapping right hemispheric functions. There was virtually no association be-
tween left-hemispheric tests and diminished expressivity suggesting that the
neurocognitive dysfunction is not generalized in nature. Finally, diminished
expressivity was associated with poorer quality of life, notably in social
domains, and greater use of unhealthy coping strategies. These findings
highlight the deleterious effects of diminished expressivity in schizotypy
and raise questions about the specificity of the right hemisphere in this
symptom. The use of acoustic analysis of speech as a sensitive means of
measuring diminished expressivity is also supported here.
ID: 551693
LACK OF EARLY IMPROVEMENT
DEMONSTRATES STRONG NEGATIVE
PREDICTIVE VALUE FOR LATER TREATMENT
RESPONSE WITH ATYPICAL ANTIPSYCHOTICS
IN PATIENTS WITH SCHIZOPHRENIA
Cedric O’Gorman1, J. Kane2, S. Kapur3, S. Kolluri1,
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1Pfizer Inc, New York, NY, USA; 2Psychiatry, The Zucker Hillside
Hospital, New York, NY, USA; 3Institute of Psychiatry, King’s
College, London, United Kingdom
Background: Prediction of antipsychotic treatment response based on pa-
tient outcomes within the first 2 weeks of treatment would facilitate the
decision to continue treatment or switch to an alternative agent. Methods:
Data were pooled from 2 similarly designed, flexible-dose, randomized,
comparative trials of inpatients with an acute exacerbation of schizophre-
nia or schizoaffective disorder. In the 8-week study (ziprasidone vs risper-
idone), patients were required to have a PANSS total score  60, and
a score of  4 on  2 core items of the PANSS. In the 6-week study
(ziprasidone vs olanzapine), patients were required to have a CGI-S score
 4, and a score of  4 on  1 item of the PANSS positive symptom
items. Ziprasidone and risperidone were titrated to a flexible dose range
of 80–160 mg/d (mean dose: 114.2 mg/d) and 6–10 mg/d (mean dose: 7.4
mg/d), respectively. In the 6-week trial, ziprasidone and olanzapine were
titrated to a flexible dose range of 80–160 mg/d (mean dose: 129 mg/d)
and 5–15 mg/d (mean dose: 11.3 mg/d), respectively. Week 1 improve-
ment, week 2 improvement, and week 6 response based on the PANSS
or BPRS total score were defined as  10%,  20%, and  40% reduc-
tions from baseline, respectively. Baseline characteristics for week 1 and
week 2 improvers and nonimprovers were compared descriptively. Sensi-
tivity and specificity, positive predictive value (PPV), negative predictive
value (NPV), and predictive power (PP) were calculated. Results: Early
improvers and early nonimprovers were comparable with regard to their
baseline characteristics. Improvement at week 1 correctly identified 71 of
107 (66.36%, sensitivity) week 6 responders, while nonimprovement at
week 1 correctly identified 159 of 262 (60.69%, specificity) week 6 non-
responders. Of the 174 week 1 improvers, 71 (40.80%, PPV), were
week 6 responders. Of the 195 week 1 nonimprovers, 159 (81.54%,
NPV) were week 6 nonresponders. The PP of the week 1 result was
65.4%. Similar results were obtained using week 1 and week 6 PANSS
scores (sensitivity 66.35%, specificity 65.03%, PPV 42.59%, NPV
83.17%, PP 65.4%). The use of week 2 and week 6 BPRS scores yielded:
sensitivity 80.43%, specificity 69.16%, PPV 52.86%, NPV 89.16%, and
PP 72.5%. Conclusion: These results indicate that early assessment of
symptom change is predictive of later treatment outcome, which may
have important clinical implications in the treatment of patients with
schizophrenia.
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PROPERTIES OF THE DOT PATTERN EXPECTANCY
TASK FOR CLINICAL USE
Jessica Ann Hurdelbrink Jones1, S. R. Sponheim2,3,
A. W. MacDonald1,3
1Psychology, University of Minnesota, Minneapolis, MN, USA;
2Psychology, Minneapolis Veteran Affairs Medical Center,
Minneapolis, MN, USA; 3Psychiatry, University of Minnesota,
Minneapolis, MN, USA
The Dot Pattern Expectancy (DPX) task was created to efficiently assess
context processing deficits in patients with schizophrenia. Three studies to-
gether investigated the characteristics of the DPX that may qualify it for
clinical use in assessing cognition in schizophrenia. To answer questions
regarding the psychometric properties of the task, performance on this
task was studied in samples of healthy undergraduates (n = 214), healthy
community adults (n’s = 38 and 48), and schizophrenia patients (n = 47).
Acceptable internal consistency and retest reliability, as evidenced by sig-
nificant similarity in performance across runs (d’-context intra-class corre-
lation = .77) and lack of practice effects (F46,1 = .03, P = .88,g2 = .001), were
found for both longer versions of the DPX and a suggested brief version
(DPX-brf), which may be practical for clinical purposes. Alpha values
ranged from .81.97 for AX trials and from .81.90 for BX trials. Perfor-
mance on the DPX was studied in the sample of schizophrenia patients to
address the task’s ability to detect specific deficits. The DPX task revealed
a deficit in context processing in patients with schizophrenia (d’-context
g2 = .249); the DPXbrf was also sensitive to this deficit (d’-context g2 =
.251). The combination of adequate psychometric properties, shorter du-
ration and ability to elucidate a specific deficit in context processing sug-
gested this task may be useful for assessing this construct in both clinical
and research settings.
ID: 551619
NEUROCOGNITIVE PREDICTORS OF FUTURE
RECOVERY IN SCHIZOPHRENIA: A 20-YEAR
FOLLOW-UP
Aaron Bonner-Jackson, L. Grossman, M. Harrow, C. Rosen
Psychiatry, University of Illinois College of Medicine, Chicago,
IL, USA
Objective: Previous research has indicated that patients with schizophrenia
demonstrate deficits in cognition, though little is known about whether or
how these deficits change across the lifespan. Furthermore, the question
remains as to whether cognitive deficits in schizophrenia are related to
global outcome and recovery. The current prospective longitudinal re-
search is unique in that it affords comparison of potential changes in cog-
nitive functioning over time and the relationship between cognitive deficits
and outcome, for patients with schizophrenia as well as other psychotic dis-
orders. Method: As part of The Chicago Follow-up Study, we prospectively
assessed 187 patients seven times (once at index hospitalization, and then 6
times over 20 years) to provide longitudinal data about cognitive deficits
and recovery. Patients were assessed on standardized research instruments
evaluating cognitive functioning, symptoms, work disability, psychosocial
functioning, treatment, and recovery. Results: 1) At all 7 assessments,
patients with schizophrenia showed poorer processing speed than patients
with other psychotic disorders or nonpsychotic disorders. 2) All patient
groups showed improvement in cognitive functioning between index hos-
pitalization and the first follow-up 2 years later (P’s< .001). 3) Contrary to
previous hypotheses, schizophrenia patients did not show cognitive declines
as they grew older (P > .60). 4) There was a strong association between
better cognitive function and recovery for patients with schizophrenia,
as well as for patients with other psychotic disorders and non-psychotic
depression. 5) Schizophrenia patients demonstrated significant associations
between better cognition at 2-year follow-up and recovery at each successive
follow-up (P’s< .005), whereas these relationships were also present, but not
as robust, in other patient groups. Conclusions: Current data support the
presence of cognitive impairment in schizophrenia, as well as the associa-
tion between cognitive impairment and global recovery in all patient
groups. Our findings suggest that cognition in schizophrenia is related
to current level of recovery and may be predictive of likelihood of future
recovery.
ID: 551556
THE CONSISTENCY BETWEEN CLINICALLY
RATED ANHEDONIA AND OLFACTORY VALENCE
JUDGMENT IN PATIENTS WITH DEFICIT
SYNDROME SCHIZOPHRENIA
Gregory Paul Strauss1,2, L. A. Duke2, S. A. Ross2, D. N. Allen2
1Psychiatry, University ofMaryland School ofMedicine, Baltimore,
MD, USA; 2Psychology, University of Nevada Las Vegas, Las
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Previous research on emotion and schizophrenia reveals a consistent pat-
tern of contradictory findings, whereby individuals with schizophrenia
report experiencing significantly less pleasure than non-patients when emo-
tional experience is measured using self-report questionnaires and
clinical interviews (ie, anhedonia), yet appear surprisingly normal when
rating evocative stimuli in laboratory-based paradigms. Few studies, how-
ever, have examined whether this discrepancy holds when patients with
the most severe affective deficits, such as those with primary and enduring
negative symptoms (ie, deficit syndrome schizophrenia), are compared to
patients with less pronounced affective disturbance. The current study ex-
amined the consistency of affective disturbance as evaluated by clinical
rating and a laboratory-based measure of olfactory valence judgment
in 22 healthy controls (CN) and 41 patients with schizophrenia. Patients
were sub-grouped into deficit (DS: n = 15) and non-deficit (ND: n = 26)
syndrome subtypes using the Schedule for the Deficit Syndrome. Valence
ratings for pleasant and unpleasant odors were assessed for items on the
Brief Smell Identification Test (B-SIT). Results indicated that DS patients
received significantly higher anhedonia ratings than ND patients, and that
although schizophrenia patients as a whole did not differ from CN in their
subjective valence ratings of pleasant odors, differences did exist among
DS and ND sub-types. Specifically, DS patients rated pleasant odors as
being significantly less pleasant than ND patients and CN, who did not
significantly differ from each other. No differences were found between
DS and ND groups when rating unpleasant odors. Furthermore, DS
patients rated a significantly higher proportion of pleasant smells as fall-
ing within the unpleasant range of the valence scale than ND patients and
CN, indicating that they may experience some pleasant stimuli as aversive.
Findings suggest that among individuals with schizophrenia, patients
meeting criteria for the DS uniquely rated olfactory valence in a way
that was consistent with their self-reported positive mood as measured
by clinical rating scales.
ID: 551542
SEX SPECIFIC ASSOCIATIONS BETWEEN
OLFACTORY PROCESSING AND SCHIZOTYPY
IN HEALTHY VOLUNTEERS
Naina Mathur, P. M. Moran
School of Psychology, University of Nottingham, Nottingham,
United Kingdom
A number of studies have shown that people with schizophrenia and their
relatives have impaired olfactory identification. This suggests that it may
prove to be a useful vulnerability marker for schizophrenia. The evidence
for olfactory abnormalities in schizotypy is less clear, with some studies in-
dicating deficits in olfactory threshold in males and some indicating no ab-
normalities. Variability in findings may be attributable to variations in the
sensitivity of psychometric measures of schizotypy and the specific aspect of
olfactory function being tested, identification, threshold or discrimination.
We examined olfactory ability in healthy volunteers using an olfactory test
that addresses different aspects of olfactory ability and a schizoptypy mea-
sure that measures distinct schizotypal subscales. The ‘‘sniffin sticks’’ test of
nasal chemosensory performance based on pen-like odour dispensing devi-
ces was used. It includes three tests of olfactory function, 1) odour threshold
(using n-butanol concentrations), 2) odour discrimination (16 pairs of
odours, triple forced choice) and 3) odour identification (16 common
odours, multiple forced choice from 4 verbal items per odour). Schizotypy
was measured using the O-LIFE which provides measures relevant to pos-
itive (unusual experiences, UNEX) negative (introvertive anhedonia,
INTAN) and cognitive (cognitive disorganisation, COGDIS) symptoms.
Healthy Volunteers (26 M, 50 F, mean age 21yrs) were used. The results
indicate that UNEX is positively associated with odour identification in
females but negatively in males. COGDIS is positively associated with
odour identification and discrimination in females only. No association
with INTAN was found for any olfactory measure. There were no sex dif-
ferences in identification, threshold or discrimination ability. These data
support the suggestion of a negative association between olfactory ability
and schizotypy in males. They further suggest that these associations are
specific to positive aspects of schizotypy, males and the odour identification
aspect of olfactory ability.
Table. Association between olfactory scales and O-LIFE
OLFACTORY/
O-LIFE SCALE THRESHOLD DISCRIMINATION IDENTIFICATION
FEMALE UNEX 0.12 0.08 0.28*
FEMALE COGDIS 0.16 0.32* 0.25
MALE UNEX 0.15 0.18 0.29*
MALE COGDIS 0.01 0.04 0.09
*P < .05, spearman’s rho
ID: 551538
RANKING NEUROCOGNITIVE DOMAINS BY
LEVEL OF IMPAIRMENT IN FIRST-EPISODE
PSYCHOSIS: DOES PREMORBID ADJUSTMENT
MATTER?
Laura Be´chard-Evans, S. Iyer, M. Lepage, A. K. Malla
Psychiatry, Douglas Mental Health Institute, Montreal,
QC, Canada
Background: There is evidence that impairments in a simple processing
speed test, the Digit Symbol Coding Test (DST), are larger than the
ones in other cognitive domains in schizophrenia. It is not clear whether
these differences between domains can be identified during the first epi-
sode and if poor premorbid adjustment is associated differentially with
severity of impairments in cognitive domains. Method: Patients (N =
129) with first-episode schizophrenia-spectrum psychosis completed
a full neuropsychological battery at baseline. All test scores were con-
verted into z-scores based on a sample of 52 healthy controls. Five cog-
nitive domains were computed using the mean z-scores for relevant tasks
(ie, Verbal Memory, Processing Speed, Working Memory, Attention, Ex-
ecutive Functions). Performance on the DST was examined independently.
To test for group differences on all cognitive domains and the DST,
ANCOVA models were conducted with group (patient vs.control) as
the between-group factor and gender and education as covariates. Based
on the Premorbid adjustment scale, patients were classified into three
groups (ie, deteriorating, stable-good and stable-poor). Results: The pa-
tient sample (mean age 22.9; 72% male; education 11 years; median
DUP 18.7 weeks) was significantly more impaired compared to healthy
controls on all domains and on the DST after adjusting for gender and
education. Impairments were most pronounced in the Verbal Memory do-
main (ES = 1.54) followed closely by the DST task (ES = 1.45) and the
processing speed domain (ES = 1.25). All three premorbid groups were
impaired on all domains. Patients in the stable-poor group showed the
largest impairment across most cognitive domains, followed by the dete-
riorating and stable-good groups. Conclusion: As early as the first episode,
generalized cognitive impairments are present with more pronounced def-
icits in verbal memory and processing speed. Although significantly im-
paired in first-episode psychosis, impairment on the DST task was not
much higher than impairment in other processing speed tasks. We found
that the more neurodevelopmentally impaired sub-group (ie, stable poor)
may be distinguishable from other sub-groups on the basis of severity and
not type of cognitive impairments.
ID: 551519
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STRIATAL AND EXTRASTRIATAL DOPAMINE
D2/3 RECEPTOR BINDING POTENTIALS AND
OCCUPANCY IN FIRST-EPISODE SCHIZOPHRENIA:
CORRELATIONS WITH COGNITIVE DEFICITS
Birgitte Fagerlund1,4, L. Pinborg2, C. Svarer2, W. Baare´3,
B. Y. Glenthøj4
1Bispebjerg Center for Child and Adolescent Psychiatry, Copen-
hagen University Hospital, Copenhagen, Denmark; 2Neurobiologi-
cal Research Unit, Copenhagen University Rigshospitalet,
Copenhagen, Denmark; 3MR department, Copenhagen University
Hospital Hvidovre, Copenhagen, Denmark; 4Center for Neuropsy-
chiatric Schizophrenia Research, Psychiatric Center Glostrup,
Copenhagen University Hospital, Copenhagen, Denmark
Introduction: Studies of in vivo dopamine receptor activity and density in
schizophrenia have mostly focused on high-density striatal areas. The pur-
pose of the current study was to examine D2/3 dopamine receptor binding
potentials (BP) and occupancy (OCC) in both striatal and extrastriatal
ROIs. The primary objective was to examine whether BP when drug-naı¨ve
predicted the effects of antipsychotics on cognition. The secondary objec-
tive was to examine whether OCC was related to the change in cognition
after treatment with antipsychotics. Methods: Twenty-one drug-naive
schizophrenic patients were scanned with Single-Photon Emission Comput-
erized Tomography (SPECT) using the D2/3-receptor ligand [123I] epidepr-
ide. The regions of interest (ROIs) were the frontal cortex, the temporal
cortex, the thalamus, caudate nucleus, and putamen. BPs were assessed
when patients were drug-naı¨ve, and OCC after 12 weeks of antipsychotic
treatment. Cognitive functions including verbal memory, attention, execu-
tive functions, processing speed and pre-morbid intelligence were assessed
within days of the SPECT scans. The level of significance (0.05) was divided
by the number of regions, and significant results considered according to
this level (0.01). Results: Baseline BP did not predict the efficacy of anti-
psychotics on most measures of cognition, except for one measure of verbal
learning, where faster learning was positively correlated with baseline BP in
the temporal cortex. Frontal and temporal D2/3 occupancy after 12 weeks
of antipsychotic treatment was significantly positively correlated with im-
proved measures of planning efficiency but also negatively correlated with
improved measures of attention. Discussion: The results suggest involve-
ment of extrastriatal D2/3 BP and OCC in aspects of cognitive functions,
and suggest differential levels of optimal D2/3 occupancy for attention and
planning.
ID: 551453
PLANNING SKILLS, COGNITIVE REMEDIATION
THERAPY AND WORK PERFORMANCE AMONG
PEOPLE WITH SCHIZOPHRENIA
Christopher Rice, C. Reeder, T. Wykes
Institute of Psychiatry, London, United Kingdom
Introduction: Cognitive problems are commonly observed in people having
schizophrenia. A growing body of evidence indicates that such problems are
linked to poor social functioning, including poor work performance. The
aim of this study is to investigate these relationships and to explore the po-
tential impact that receiving cognitive remediation therapy may have on
work performance. This investigation expanded on previous findings by
exploring the influence of metacognition. Metacognition allows the person
to reflect upon and regulate their own thinking. This may be important, for
example, when generating and implementing strategies, problem solving,
evaluating plans, etc. Methods: 57 participants aged 18 to 65 who satisfied
DSM-IV criteria for schizophrenia or schizoaffective disorder. They were in
sheltered, voluntary or open/competitive employment and receiving dedi-
cated employment support. Participants were excluded if they had a history
of brain injury, organic brain disorder, learning difficulty or current pri-
mary substances abuse. Work performance was assessed using the Work
Behaviour Inventory (WBI). Cognitive assessments encompassing execu-
tive functions, working memory, memory, IQ and metacognition were
also administered. Positive and negative symptoms were also rated. Path
analysis was employed to explore relationships between differing domains
of cognition, metacognition, symptoms and work performance before re-
ceiving cognitive remediation therapy and three months after therapy com-
pletion. Metacognition and symptoms were included in all our models as
hypothesised predictors of work behaviour. Results: At baseline planning
skills predicted work performance, v2 = 10.3, df = 8,P = .25. The same model
also predicted work performance 3 months after therapy completion, v2 =
6.7, df = 8, P = .57. Both models have good goodness of fit (P > .20). The
data will be further analysed to assess the relationship between change in
planning skills and work performance. Discussion: Poor planning skills ap-
pear to impact on work performance and are potentially a target for reme-
diation in this regard. One possible explanation could be that the two tests
that fed in to the latent variable of planning captured cognitive processes
critical for dealing with real-life scenarios at work. Both tests (the Key
Search Test and the Zoo Map Test) are designed to have ecological validity,
being part of the Behavioural Assessment of the Dysexecutive Syndrome
(BADS) battery.
ID: 551445
THE AFFECTIVE PATHWAY TO PSYCHOSIS:
EVIDENCE FROM A LARGE, EPIDEMIOLOGICAL
SAMPLE
Manuela Heins1,2, L. Krabbendam1, J. Van Os1,
I. Myin-Germeys1
1Social Psychiatry, University of Maastricht, Maastricht,
Netherlands; 2University College Maastricht, University of
Maastricht, Maastricht, Netherlands
Objectives: It has been argued that an affective pathway is underlying the
development of positive symptoms of psychosis (Myin-Germeys et al.
2007). This affective pathway is characterized by an increased sensitivity
to stress, possibly resulting from a sensitization process from previous expo-
sures to life events or childhood trauma. This affective pathway model has
mainly been developed in smaller samples using momentary assessment
technology. The current paper aims to validate this model in a large, epi-
demiological sample. Method A large sample of 312 patients diagnosed
with a non-affective psychotic disorder, partly pertaining to the same fam-
ilies, was assessed with the Positive and Negative Syndrome Scale (PANSS)
and the Youth Trauma Questionnaire. Stress-reactivity was assessed using
the Eysenck Neuroticism scale. Results Multilevel regression analyses
revealed that neuroticism was significantly associated with positive symp-
toms (B = 0.36, P = .00), whereas no significant association with negative
symptoms was found (B = 0.07, P = .44). In addition, a history of childhood
trauma was significantly associated with positive (B = 0.10,P = .00), but not
negative symptoms of psychosis (B = 0.00, P = .87). The association be-
tween childhood trauma and the positive symptoms of psychosis was par-
tially mediated by levels of neuroticism. Conclusion: The current results
provide further evidence for an affective pathway to psychosis, character-
ized by increased levels of neuroticism or stress-reactivity and higher levels
of childhood trauma, which is specifically associated with the positive
symptoms of psychosis.
Reference
1. Myin-Germeys I, van Os J. Stress-reactivity in psychosis: evidence for
an affective pathway to psychoses. Clinical Psychology Review.
2007;27:409–424.
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EXPLORING THE DYNAMIC ASSESSMENT
PARADIGM AND ITS USEFULNESS AT ASSESSING
LEARNING POTENTIAL OF SCHIZOPHRENIA
PATIENTS
Yan Yin Ho1, R. Ho2, S. Graham1
1Psychology, National University of Singpoare, Singapore,
Singapore; 2Psychological Medicine, National University Hospital,
Singapore, Singapore
Clinicians hoping to improve the quality of life of schizophrenia patients
constantly face the situation of scarce rehabilitation resources. Dynamic
assessment (DA) proponents suggest using DA to measure patients’ learn-
ing potential to prioritize the allocation of rehabilitation resources to
patients. DA measures cognitive functions through an active teaching pro-
cess aimed at quantifying and also qualifying learning potential of a person
during the acquisition of new cognitive skills. A general DA paradigm con-
sists of a pretest—training—posttest scenario. The training is the quintes-
sential part of DA whereby it allows examiners to evaluate the examinee’s
learning potential, specific deficient functions, and possible mediational
strategies that may be utilized by the examinee. While proponents of
DA argue that the training in the assessment paradigm is the reason
that brings about the improved performance, critics suggest that practice
effect may be the reason behind the improvement. Validation of the training
paradigm in DA is needed before it can be utilized to measure learning po-
tential in clinical settings. This study examines whether the improvement in
performance detected in DA sessions is due to the training or practice effect.
Patients diagnosed with schizophrenia are recruited and divided into four
groups. All four groups are administered the Wisconsin Card Sorting Test
(WCST) twice. One group is taught how to perform on the WCST in be-
tween the two test sessions while other groups of patients either undergo
a control task intervention or is administered WCST without training.
The last group of patients acts as a control group. Preliminary result sug-
gests the efficacy of DA on the assessment of learning potential has impli-
cations on the utility of rehabilitation resources. The assessment of learning
potential by DA means can streamline the referral process of admitting
patients into rehabilitation programs, making the programs more cost ef-
fective by pre-selecting patients based on their readiness for rehabilitation.
ID: 551403
AUTOBIOGRAPHICAL MEMORY DEFICITS IN
CHRONIC SCHIZOPHRENIA
Johannes Schro¨der, U. Seidl, H. Lamparter, P. Toro
Section Geriatric Psychiatry, Heidelberg, Germany
Autobiographic memory is important for the constitution of self identity and
is generally differentiated into a semantic and a episodic domain which refer
to life facts and vivid recall of personal episodes, respectively. In an ongoing
study, we investigate autobiographical memory functioning in patients with
chronic schizophrenia. Up to now, 33 nursing home residents with chronic
schizophrenia (mean age: 47, SD: 9.9 years), 32 patienst with major depres-
sion (mean age: 55.0, SD: 0.9 years) and 71 otherwise healthy controls (mean
age: 55.0, SD: 1.0 years) were included. Patients with schizophrenia were
recruited among nursing home residents (duration of nursing home place-
ment:10, SD:9 years), the comparison subjects were participants of the lon-
gitudinal study of aging (ILSE). Semantic and episodic memories from five
lifetime periods were explored by using the Bielefeld Autobiographical Mem-
ory Inventory. Executive functioning and logical memory were assessed on
the Trail Making Test and the Wechsler Memory Scale, respectively. Rela-
tive to both, healthy and depressive comparison subjects, patients with
schizophrenia were significantly impaired in autobiographical memory, pre-
dominantly regarding episodic memory, relatively sparing semantic aspects.
While the comparison subjects scored higher for the most recent lifetime pe-
riod, this recency effect did not apply for the schizophrenic patients. Within
the latter, these effects were not associated with psychopathological symp-
toms, duration of illness, immediate or delayed recall (Wechsler Memory
Scale), nor executive functioning. Taken together, our findings demonstrate
autobiographical memory deficits in patients with chronic schizophrenia.
These deficits primarily involve episodic memories and may thus diminish
quality of life and social functioning in chronic schizophrenia. Acknowledge-
ment: The study was supported by the D.-Hopp-Foundation.
Table. Episodic memory performance in healthy subjects, patients with
depression and patients with chronic schizophrenia within 5 lifetime
periods: Results of an Analysis of Variance
Mean
(Standard
Deviation)
preschool
period
elementary
school
period
secondary
school
period
young
adulthood
last five
years
Healthy
Subjects
5.4 (4.4) 7.8 (4.3) 8.0 (4.2) 9.6 (3.0) 9.3 (3.5)
Depression 6.4 (4.3) 8.7 (3.5) 9.6 (2.3) 9.3 (3.1) 10.4 (1.6)
Schizophrenia 5.1 (4.7) 6.0 (4.7) 5.1 (4.8) 6.3 (4.6) 5.6 (5.1)
Main Effect ‘‘Diagnosis’’: F = 14.19 (P < .01) Main Effect‘‘Lifetime
Period’’: F = 12.62 (P < .01) Interaction‘‘Diagnosis*Lifetime Period’’:
F = 2.24 (P < .05)
ID: 551349
ADDITION OF COGNITIVE RETRAINING TO IM-
PROVE GLOBAL FUNCTIONING IN SCHIZOPHRE-
NIA—A RANDOMIZED CONTROLLED STUDY
Shantala Hegde
Neuropsychology Unit, Department of Mental Health and Social
Psychology, National Institute of Mental Health and Neuro
Sciences, Bangalore, India
Purpose: To examine the effectiveness of addition of cognitive retraining to
psychoeducation and drug therapy (TAU) on neuropsychological func-
tions, psychopathology and global functioning in first episode schizophre-
nia patients and the effectiveness of the intervention on psychological
health, perception of level of family distress and attitude towards mental
illness in caregivers of the schizophrenia patients. Method: 45 first episode
schizophrenia patients and their caregivers were randomly allotted to ex-
perimental and control group. Patients were assessed on battery of neuro-
psychological tests, Positive Negative Syndrome Scale and WHO Disability
Assessment Schedule. Caregivers of patients were assessed on General
Health Questionnaire, Scale for Assessment of Family Distress and Orien-
tation to Mental Illness. Patients and caregivers were assessed at baseline.
Post assessment was after completion of 2-months from baseline assessment
and follow-up assessment was after completion of 6 months from baseline
assessment. The effectiveness of addition of cognitive retraining was exam-
ined using generalized linear mixed model ANCOVA and ANOVA.
Results: TAU led to significant improvement in neuropsychological func-
tioning, psychopathology and improvement in global functioning.Addition
of cognitive retraining led to improvement in neuropsychological functions,
a significant decrease in negative symptoms and a qualitative change in oc-
cupational functioning. In caregivers, psychoeducation led to significant im-
provement in psychological health, reduction in perception of family distress
and decrease in unfavorable attitude towards mental illness. Conclusions:
Addition of cognitive retraining along with psychoeducation and drug treat-
ment led to improvement in cognitive domains of attention, executive func-
tions, verbal learning and memory and visual memory as well as a significant
decrease in negative symptoms in the initial phase of the illness. Effect sizes
were large, although the sample size was small. Future studies with large sam-
ple size will prove the effectiveness of cognitive retraining further. Cognitive
retraining should be part of total treatment package for schizophrenia.
ID: 551296
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AN EXAMINATION OF VERBAL AND SPATIAL
MEMORY ERRORS IN RELATION TO CLINICAL
SYMPTOMS OF PATIENTS WITH RECENT-ONSET
SCHIZOPHRENIA
Caroline Cellard2,3, A. A. Lefebvre2,3, M. A. Roy2, L. Laplante1,
A. M. Achim2, H. Marcaurelle2, R. H. Bouchard2, S. Tremblay2,3
1E´cole de psychologie, Universite´ Laval, Quebec City, QC, Canada;
2Centre de recherche Universite´ Laval Robert-Giffard, Quebec City,
QC, Canada; 3Groupe de recherche en psychologie cognitive,
Universite´ Laval, Quebec City, QC, Canada
Deficits in serial recall in patients with schizophrenia (SZ) are considered as
a key feature of the clinical manifestations of the disease. In order to further
examine the role of memory deficits in SZ, the pattern of errors in verbal
and spatial serial recall tasks committed by SZ patients was compared to
that of healthy controls. The evaluation of the relationship between these
memory errors and the clinical symptoms assessed with the PANSS and the
SAPS was also computed. Twenty-seven outpatients with recent-onset SZ
and 27 matched healthy controls had to remember sequences of items (digits
or localizations) in a serial recall task. The results indicate that the number of
omissions and transpositions can differentiate between patients suffering
from SZ and healthy controls. The pattern of correlation for transpositions
(positive association with general psychopathology and delusion subscales)
was the same whether to-be-remembered information was verbal or spatial.
Commission errors (intrusion, transposition) in verbal memory were associ-
ated with the negative subscale. The relationships between the observed mem-
ory errors for symptomatology are similar across the spatial and verbal
domains. The failure to associate a to-be-remembered item and its temporal
position (transposition) can be regarded as a form of confusion consistent
with delusions observed in SZ (see also Woodward et al. 2006). The exam-
ination of error patterns, especially transposition errors, rather than the mere
analysis of overall memory performance, should be considered for a better
understanding of the disease and for a more targeted treatment.
ID: 551230
FACIAL EMOTION PERCEPTION IN
SCHIZOPHRENIA: A META-ANALYTIC REVIEW
Kristin Healey, E. A. Martin, J. B. Walker, P. J. Moberg,
C. G. Kohler
Neuropsychiatry Section, University of Pennsylvania, Philadelphia,
PA, USA
Objective: Many studies have reported on facial emotion perception deficits
in schizophrenia and clinical relevance. Potential factors that influence
findings, ie, task design, demographic and clinical characteristics, and treat-
ment status remain better understood. Methods: 86 studies reporting on
schizophrenia patients and controls published between 1970–2007 were iden-
tified through a computerized search of public databases. A Quality of Report-
ing of Meta-analysis standard was followed, data were analyzed using
Comprehensive Meta-Analysis version 2.0. Differences in perception scores
between studies were standardized by calculating Cohen’s d. Cochran Q-sta-
tistics assessed homogeneity of effect sizes. Results: 86 studies on emotion iden-
tification and differentiation employing photographic images were identified.
Analysis revealed a large deficit in emotion perception (N = 3822, d =
0.91,95% CI = 0.97 < d < 0.84), irrespective of task type, that was het-
erogeneous (QB = 295.7, P< .001). Effect sizes for schizophrenia (N = 71, d =
0.98) and the schizophrenia/schizoaffective diagnosis (N = 15, d = 0.85)
were large and homogeneous. Greater age in patients (N = 81) (Z =
5.25, P < .001) and controls (N = 84) (Z = 2.98, P < .01) related to im-
pairment. Percentage of male controls (N = 80) were negatively related to effect
sizes (Z = 3.53, P< .001). Hospital status revealed heterogeneity (QB = 19.65,
P < .001), inpatients were more impaired than outpatients (QB = 16.01,
P < .001) and mixed group (QB = 10.57, P < .01). Later age of onset
(N = 16) related to greater impairment (Z = 2.79, P < .01). Studies that
employed the Scheduled Assessment of Negative (N = 20, Z = 4.13, P <
.001) and Positive Symptoms (N = 18 studies, Z = 4.48, P < .001) related
higher symptoms to greater deficit. Medication studies were classified as med-
icated (N = 57), unmedicated (N = 2), mixed (N = 20) showing heterogeneity
(QB = 11.76, P < .01). Unmedicated patients were most impaired, followed
by medicated and mixed groups. Effect sizes were heterogeneous (QB =
9.35, P < .01) for first-generation (N = 25), second-generation (N = 7) and
mixed groups (N = 22). FGA were more impaired than SGA (QB1 = 9.00,
P < .01) and mixed (QB1 = 4.12, P < .05) groups. No effects were found
for duration of illness, past number of hospitalizations, education and ethnic-
ity. Conclusion: Emotion perception represents a robust impairment in
schizophrenia moderated by certain clinical and demographic factors.
Results may inform design of future studies that evaluate emotion percep-
tion in schizophrenia.
ID: 551166
THE PERCEPTION OF EMOTIONAL PROSODY AND
AWARENESS OF ILLNESS IN SCHIZOPHRENIA
Marjolijn Hoekert1, A. Vercammen1, H. Knegtering2,
R. Bruggeman2; A. Aleman1
1BCN Neuroimaging Center, University Medical Center Groningen,
University of Groningen, Groningen, Netherlands; 2University
Medical Center Groningen, University of Groningen, Department of
Psychiatry, Groningen, Netherlands
Being able to understand not only what someone says, but also how it is
said, is very important in social communication. People with schizophrenia
have been found to be impaired in this ability, ie, they may have difficulties
in understanding the emotional cues given in the intonation of spoken
language. Problems in social functioning form one the most devastating
symptoms in schizophrenia. Another problematic manifestation of schizo-
phrenia is poor awareness on having psychotic symptoms (APA, 1987). We
hypothesized that there would be a relationship between emotion process-
ing and awareness of psychotic symptoms. An association between insight
and facial emotion identification has been found (Goodman, 2005). The
aim of the present study was to examine the relation between awareness
of illness and the ability to perceive emotional prosody in schizophrenia
patients. 32 patients (17 females, mean age 36 (SD 12.3)) with a DSM-
IV diagnosis of schizophrenia or schizoaffective disorder were included.
Most of them were diagnosed with the paranoid subtype of schizophrenia.
The Positive and Negative Syndrome Scale (PANSS; Kay, 1987) was ad-
ministered and all patients completed an emotional prosody task, consist-
ing of 24 sentences with neutral content spoken with an emotional
intonation (anger, fear or neutral) by actors. This task was developed using
stimuli derived from Vingerhoets (2003). Scores on PANSS item G12 (Lack
of judgment and insight), and accuracy scores on the emotional prosody
task were analyzed. A higher score on G12 was related to more errors
in the detection of the emotional intonation from sentences over all emo-
tions (Kruskal- Wallis v2 = 5.72, P < .05). The detection of anger and fear
was more impaired in patients who show reduced awareness of their symp-
toms as compared to patients who show good awareness of their illness.
These differences did not reach significance (K-W v2 = 1.4, P = .2 and
K-W v2 = 2.8, P = .09 respectively). Results from our study show that
patients with poor symptoms awareness are less able to detect the emotion
from intonations in speech. This finding is in line with the suggestion that
there is an overlap in mechanisms related to emotion processing and to in-
sight generation (Goodman, 2005).
References
1. APA, Diagnostic and statistical manual of mental disorders
DSM-III-R, 1987.
2. Goodman C. Comprehensive Psychiatry. 2005.
3. Vingerhoets G. Neuropsychology. 2003.
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HIPPOCAMPAL MEMORY FUNCTION OVER
INITIAL TREATMENT PERIOD IN FIRST-EPISODE
PSYCHOSIS: THE ROLE OF STRESS AND HPA AXIS
FUNCTIONING
Felicity Butselaar1,2, B. Garner1, S. J. Wood3, G. Savage4,
C. Markulev1, T. Proffitt1, Y. Yun1, C. Phassouliotis1, L. Phillips1,
P. McGorry1
1Department of Psychiatry, The University of Melbourne, ORY-
GEN Research Centre, Melbourne, VIC, Australia; 2School of
Psychological, Psychiatry and Psychological Medicine, Monash
University, Melbourne, VIC, Australia; 3Melbourne Neuroscience
Centre, The University of Melbourne, Melbourne, VIC, Australia;
4Macquarie Centre for Cognitive Science, Macquarie University,
Sydney, NSW, Australia
Hippocampal dysfunction and structural abnormalities are commonly
found in Schizophrenia. They are evident in the first episode of illness
and have shown strong associations with functional outcome. However,
the biological origins and stability of these deficits over the illness course
remain unclear. One plausible hypothesis involves increased stress levels
and dysfunction of the central cerebral region responsible for its regulation,
the Hypothalamic-Pituitary-Adrenal (HPA) axis. Hippocampal function,
particularly the ability to remember new associations, is highly sensitive
to the neurotoxic effects of sustained increased cortisol levels. The aim
of the current study was to test the stability of hippocampal function in
drug-naı¨ve first-episode psychosis (FEP) patients over the first three
months of treatment, and test possible relationships with biological meas-
ures of stress and HPA dysfunction. The performance of FEP patients and
normal controls (NC) were compared using a novel memory task that in-
cluded standard list learning and paired associated learning (PAL). At base-
line, FEP patients (n = 26) were significantly more impaired on a list
learning task than NC (n = 24) (P = .023), as well as on a hippocampal
PAL task (P = .027). Further, FEP patients showed greater impairment
on paired associates considered to be more abstract, which have been pos-
tulated to require greater hippocampal involvement. 12 FEP patients re-
peated the assessment after 3 months of treatment with an alternate
form of the task, and showed a significant improvement in list learning per-
formance that was not seen in NC (n = 18) (time X group interaction
P = .019). Conversely, FEP patients continued to be impaired on PAL
(P < .001) and there was no effect of or interaction with time (P =
.447). These findings suggest that hippocampal dysfunction is stable
over the first 3 months of treatment in first episode psychosis. Future anal-
ysis to determine possible associations between these findings and biolog-
ical measures of stress and HPA axis activity (post-dexamethasone cortisol
levels and glucocorticoid receptor function) will be incorporated as a part of
this presentation.
ID: 551121
NEUROCOGNITIVE DYSFUNCTION IN BIPOLAR
AND SCHIZOPHRENIA SPECTRUM DISORDERS:
THE ROLE OF HISTORY OF PSYCHOSIS
Carmen Simonsen1,2, K. Sundet2, A. Vaskinn4, A. B. Birkenaes1,3,
J. A. Engh1,3, A. Faerden1,3, H. Jonsdottir1,3, P. A. Ringen1,3,
S. Opjordsmoen1,3, I. Melle1,3, S. Friis1,3, O. A. Andreassen1,3
1Division of Psychiatry, Ulleval University Hospital, Oslo, Norway;
2Department of Psychology, University of Oslo, Oslo, Norway;
3Institute of Psychiatry, University of Oslo, Oslo, Norway;
4Department of Psychiatry, Aker University Hospital, Oslo, Norway
Objectives: Neurocognitive dysfunction in bipolar disorder is less severe
than in schizophrenia spectrum disorders. However, as lifetime history
of psychosis has been related to neurocognitive deficits, we investigated
whether bipolar disorder with a history of psychosis is neurocognitively
closer to schizophrenia spectrum disorders than to bipolar disorder without
a history of psychosis. Methods: From a large ongoing study on severe
mental disorder (TOP), a sample of schizophrenia (n = 102), schizoaffective
disorder (n = 27), bipolar disorder with history of psychosis (n = 75) and
bipolar disorder without history of psychosis (n = 61) and healthy controls
(n = 280) were included. Neurocognitive function was measured with an
extensive neuropsychological test battery. Results: The three groups
with a history of psychosis (schizophrenia, schizoaffective disorder and bi-
polar with a history of psychosis) did not differ from each other and per-
formed poorer than the healthy controls across neurocognitive measures.
The bipolar group without a history of psychosis was not reduced com-
pared to healthy controls on any measures and performed better than
the three groups with a history of psychosis on a number of neurocognitive
measures. Conclusions: Our findings suggest that bipolar disorder with
a history of psychosis is neurocognitively more similar to schizophrenia
spectrum disorders than to bipolar disorder without a history of psychosis.
This suggests that neurocognitive dysfunction in bipolar and schizophrenia
spectrum disorders depends on history of psychosis rather than diagnostic
group belonging.
ID: 551096
NEUROCOGNITIVE FUNCTIONS AND SYMPTOMS
IN SCHIZOPHRENIA: AN ANALYSIS OF FAMILIAL
LIABILITY
Anne-Kathrin Fett1, J. van Os1,2, I. Myin-Germeys1,3,
L. Krabbendam1
1Department of Psychiatry and Neuropsychology, South Limburg
Mental Health Research and Teaching Network, EURON,
Maastricht University, Maastricht, Netherlands; 2Division of
Psychological Medicine, Institute of Psychiatry, London, United
Kingdom; 3School of Psychological Sciences, University of
Manchester, Manchester, United Kingdom
Associations between symptoms of psychosis and neurocognition seem
most robust for the negative symptom cluster, although several studies
have reported associations between specific neurocognitive deficits and
positive symptoms. However, the aetiology of any association remains un-
clear. This study uses a genetically sensitive design to investigate whether
any association between cognitive functioning and symptoms is due to a ge-
netic aetiology. Subjects were recruited in the context of the GROUP study,
site Maastricht. 235 patients with a DSM-IV diagnosis of non-affective psy-
chosis, 118 of their siblings and 230 healthy controls completed a cognitive
battery including measures of IQ (WAIS-III), verbal memory (WLT), sus-
tained attention (CPT) and mentalising (Hinting task). Positive and nega-
tive symptoms were assessed with the Positive and Negative Syndrome
Scale. Cross-trait cross-sib analyses were conducted between all possible
patient-sibling pairs (120) to investigate associations between symptomatic
expression of psychosis in patients and cognitive performance in siblings.
Analyses revealed significant group differences on all cognitive measures
(all P < .01). Patients performed worst, their siblings performed interme-
diate and controls performed best. In patients, cognitive deficits were
strongly and significantly related with negative symptoms. Positive symp-
toms were significantly associated with lower IQ, but not with other cog-
nitive test parameters. Within-trait cross-sib associations were significant
for verbal memory (b = 0.16, P = .01), IQ (b = 0.34, P = .00), and sustained
attention (b = 0.23, P = .00), but not for mentalising (b = 0.07, P = .29).
Cross-trait cross-sib analyses showed a significant association between
IQ in siblings and positive symptoms in patients, which remained equally
large and significant after adjustment for the corresponding traits in the
patient and sib (b = 0.19, P = .05). All other cross-trait cross-sib associ-
ations were small and non-significant. The findings indicate that in patients
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cognitive deficits are primarily associated with negative symptoms. With
the exception of the mentalising task, performance on cognitive tasks shows
substantial familial clustering, indicative of genetic factors contributing to
cognitive functioning. However, the lack of any familial covariation sug-
gests that the overlap with negative symptoms is due to individual rather
than shared factors.
ID: 551093
CORRECTING FOR THE PSYCHOMETRIC
CONFOUND ON NEUROPSYCHOLOGICAL TASKS:
BEYOND TRUE-SCORE VARIANCE
Angus William MacDonald1,2, S. S. Kang1
1Psychology, University of Minnesota, Minneapolis, MN, USA;
2Psychiatry, University of Minnesota, Minneapolis, MN, USA
The most prominent feature of behavioral experiments in schizophrenia
patients is a pattern of impaired performance across a wide variety of tasks
known as the generalized deficit. Tasks that measure this generalized deficit
show larger or smaller effect sizes depending on those tasks’ discriminating
power, irrespective of the cognitive domains that they measure. This has
come to be known as the psychometric confound. The current project tested
several means of correcting for the psychometric confound that is caused by
differential discriminating power using classical psychometric theory and
a simulation study method. Method: Simulations mimicked task perfor-
mance on free response and binary forced-choice tasks of different length
(2–100 items), difficulty (1–99% correct), variability and internal consis-
tency. The advantage of the simulation method was that the size of the gen-
eralized deficit and specific deficits could be assigned and varied in each
case. We examined the extent to which various weightings of task character-
istics accurately corrected for a generalized deficit and recovered specific
deficits in a large group simulation (n = 10 000 per group). Weightings
were cross-validated in a second set of simulations (n = 40 per group).
Results: True-score variance (the product of variance and reliability)
was a poor proxy for discriminating power. Instead, there were independent
effects on discriminating power from all the parameters that had been var-
ied (length, difficulty, variance and reliability) as well as multiple interac-
tions between these parameters. This multi-parameter approach was able to
account for 97% of variance in discriminating power across tasks in the
original samples and 79% of variance in discriminating power in the
cross-validation sample for free-responses tasks. For forced-choice tasks,
these psychometric parameters accounted for 84% of variance in task dis-
criminating power in the original sample and 84% of variance in the cross-
validation sample. Conclusion: The results suggest that the psychometric
confound may be ‘‘corrected’’ post-hoc, based on the psychometric charac-
teristics of a task within the context of classical psychometric theory, but not
simply by using true-score variance. A spreadsheet that allows investigators
to use these equations to correct for discriminating power is now available
on the web.
ID: 551090
THE ROUGH RIDE OF EXPERIMENTAL
PARADIGMS: FROM HYPOTHESIS TESTING IN
UNDERGRADUATES TO CLINICAL APPLICATION
Angus William MacDonald
1Psychology, University of Minnesota, Minneapolis, MN, USA;
2Psychiatry, University of Minnesota, Minneapolis, MN, USA
Experimental psychology and cognitive neuroscience are dedicated to
untangling the many mechanisms that underlie thought. There is a strong
appeal to applying the technologies developed for this purpose to address
clinical questions. Direct transfers of tests developed to understand norma-
tive cognitive and brain functioning in undergraduates face the following
limitations: such tasks are too long to be practical in clinical applications;
they often suffer from ceiling effects; and, they do not allow for the inter-
pretation of a deficit on the function of interest in patient groups. This talk
will use a case study approach to describe the (many) failures and (a few)
successes our laboratories have experienced when using basic cognitive
tasks to address clinical questions. These scenarios include multiple, differ-
ent versions of cognitive control and decision-making paradigms that have
had to be scuttled in early phases because they were not sensitive to indi-
vidual differences, did not measure the original construct in patient pop-
ulations, or proved unworkable for other, unforeseen reasons. The talk
will also describe on-going initiatives to prepare successful tasks for the
higher standards required to measure change over time.
ID: 551077
ASSOCIATION BETWEEN WAIS-III PERFORMANCE
AND SCHIZOTYPY IN HEALTHY VOLUNTEERS
Jenny Rouse, P. M. Moran
School of Psychology, University of Nottingham, Nottingham,
United Kingdom
Evidence suggests that schizophrenia is associated with generalised def-
icits in intelligence measured using general scales such as the Wechsler
Adult Intelligence Scales (WAIS-III) and that these deficits are associated
specifically with negative and cognitive symptoms (Dickinson et al. 2004).
It is not known whether this generalised profile extends to schizotypy. We
therefore investigated a potential association between different dimen-
sions of schizotypy corresponding to positive (Unusual Experiences) neg-
ative (Introvertive Anhedonia) or cognitive (Cognitive Disorganisation)
symptoms in addition to total schizotypy scores and the full WAIS-III
in healthy volunteers. 28 undergraduate/graduate students (19 F, 9 M,
mean age 23.3 yrs) completed the short form O-LIFE (Oxford-Liverpool
Inventory of Feelings and Experiences) schizotypy scale and the complete
WAIS-III. Adopting the continuum model, bi-variate correlations were
performed between the full scale score and three subscales (Unusual
Experiences, Cognitive Disorganisation, Introverted Anhedonia) scores
on the O-LIFE and the scaled subtest scores and four indices (Verbal
Comprehension, Perceptual Organisation, Working Memory and Pro-
cessing Speed) of the WAIS-III. There were no significant correlations
between O-LIFE measures and overall intelligence, as measured by
full Scale IQ (Total O-LIFE and IQ, r =  .113). A significant correlation
was found between the Matrix Reasoning subtest and total O-LIFE score
(r = .383 P < .05). Letter-Number Sequencing subtest was associated
with Cognitive Disorganization (r = .387 P < .05), Impulsive Non-
Conformity (r = .414 P < .05) and Total O-LIFE score (r = .441,
P < .01). The Working Memory Index showed a negative correlation
with Cognitive Disorganisation (r = .438 P < .05). These results
show that schizotypy is only weakly negatively associated with overall
IQ in healthy volunteers. When subscales are examined schizotypy is neg-
atively correlated with Matrix Reasoning and Letter-Number sequencing.
When schizotypy subscales are examined, cognitive disorganisation is as-
sociated with reduced performance on both letter number sequencing and
the Working memory Index subscales. This reduced performance is less
generalised than that found in studies using the WAIS-III in patient stud-
ies. However, the letter-number sequencing and working memory associ-
ation recapitulates findings of deficits in patients in abstract reasoning,
attention and working memory.
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ACTION PLANNING IN ADOLESCENT ONSET
PSYCHOSIS
Maria Luisa Barrigo´n1,2, J. A. Becerra-Garcı´a2, M. Ferrı´n2,3,
J. M. Moreno2, M. D. Salcedo2, M. Ruiz-Veguilla2
1Unidad de Investigacio´n de Neuropsiquiatrı´a del Desarrollo,
Hospital de Santa Ana, Motril, Spain; 2Unidad de Investigacio´n de
Neuropsiquiatrı´a del Desarrollo, Complejo Hospitalario de Jae´n,
Jae´n, Spain; 3Department of Child and Adolescent Psychiatry,
Institute of Psychiatry, London, United Kingdom
Cognitive deficits are core features on psychotic disorders. Executive func-
tion is one of the most affected cognitive domain on psychosis. An impor-
tant aspect of executive functioning involves the ability to form and carry
out complex plans, such us action planning. To date few studies have fo-
cused on planning performance in early onset psychosis. Objective: This
study aimed to investigate action planning in 19 patient with adolescent
onset psychosis compared to 20 healthy controls using an ecological plan-
ning subtask derived from the Behavioural Assessment of the Dysexecutive
Syndrome (BADS) test battery, the ‘‘Zoo Map Test’’. Method: A total of
19 Patient (P) aged 18.11 6 1.56, and 20 Healthy Controls (HC) aged
17.70 6 2.27, completed the two versions of the ‘‘Zoo Map Test’’. In
the first version consists of a ‘‘high demand’’ version of the subtask.
The participants must plan in advance the order in which they will visit
designated locations in a zoo. The second, is a ‘‘low demand’’ version,
the participant is simply required to follow a concrete externally imposed
strategy to reach the locations to visit. In this study, scoring was based on
the: a) sequencing score, b) total number of errors, c) thinking times (time
being taken to plan the action) and d) drawing time (time to execute this
plan). Results: The adolescent psychotic group presented more drawing
time in both version, high (P:148.53 6 37.36 vs HC:119.60 6 41.26; U =
107.5, P < .005) and low (P: 97.63 6 32.04 vs HC: 64.95 6 30.50; U =
64.5, P < .005) demand. Only in the low demand version , the patients
presented more total number errors. (P:1.47 6 1.61 vs HC:0.25 6 0.44;
U = 90.0, P < .005) Conclusions: These results suggest that adolescent psy-
chotic group presents with more problems for executing complex plans,
while planning was less affected. Execution was equally affected in both
highly and low external imposed strategies.
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THE ORYGEN CLINICAL NEUROPSYCHOLOGY
UNIT: IDENTIFYING AND MANAGING
COGNITIVE DYSFUNCTION IN YOUTH
EXPERIENCING EARLY PSYCHOSIS
Tina-Marie Proffitt, K. A. Allott, P. D. McGorry, W. J. Brewer
Psychiatry, University of Melbourne, ORYGEN Research Centre,
Parkville, VIC, Australia
Objective: To describe the referral population and service characteristics of
the first 200þ referrals to the ORYGEN Neuropsychology Unit (ONU),
and the benefits of a neuropsychological approach to case formulation and
treatment planning in at-risk and first-episode populations. Methods: We
discuss key findings from a clinical audit conducted to 1) quantify service
delivery key performance indicators and 2) further characterise the refer-
rals from the Early Psychosis Prevention and Intervention Centre (EPPIC)
and other clinics within ORYGEN Youth Health, to the ONU. Results:
Of the referrals (n = 216, 65% male, mean age = 19 years) made to the
ONU, ;70% were from EPPIC. The cognitive ‘profiles’ of cases from
the early psychosis, ultra-high risk, and mood and anxiety clinics were in-
dicative of significant impairments in multiple cognitive domains at, or
prior to illness onset. The degree of impairment was similar between
the broad clinic groups, although there were some differences in the pat-
tern of impairment across the assessed domains. Comorbidity was very
prevalent eg, ;44% had threshold or subthreshold personality disorder
diagnoses and;55% had problematic substance use. Around 60% of refer-
rals had experienced trauma (either directly or observed). Neurodevelop-
mental ‘insults’ were also very common eg,;70% had premorbid learning,
intellectual or behavioural problems. Neuropsychological case formula-
tion, however, revealed that rate-limiting factors for functional recovery
(eg, social, vocational) were often not solely cognitive, but included dys-
functional schema/heuristics, substance misuse and reduced opportunity,
amongst others. Conclusions: Cognitive impairment is common and at
times severe, in at-risk and first-episode populations. Our data provides
some support for 1) a paradigm shift away from crystallised DSM-type
diagnostic labels and towards phenomenological and phenotypic charac-
terisation, 2) the allocation of funds for the implementation of psycholog-
ical interventions eg, cognitive therapies in these patient groups. Specialist
neuropsychological consultation involves evaluating the specific character-
istics that contribute an individuals’ unique trajectory into mental illness,
and providing a comprehensive formulation that outlines their potential
capacity and current cognitive capabilities, with particular regard to
what this means functionally in the context of history and current circum-
stances.
ID: 550933
IMPAIRED MOTOR CONTROL IN ADOLESCENTS
AT HIGH RISK FOR SCHIZOPHRENIA
Theo Manschreck1, L. J. Seidman1, S. V. Faraone1,
M. T. Tsuang2,1, B. A. Maher1
1Psychiatry, Harvard Medical School, Boston, MA, USA;
2Psychiatry, Institute of Behavior Genomics, University
of California, San Diego, San Diego, CA, USA
We present evidence from the Harvard Adolescent High Risk Study
designed to determine the association between motor control and lateral-
ization performance and risk for schizophrenia. A frequent observation in
high-risk studies has been that a significant number of individuals who are
at risk for or who have developed schizophrenic disorder have experienced
motor symptoms or impairment of motor control, especially fine motor co-
ordination, prior to the onset of psychosis. Prior work has suggested that
motor control, specifically coordination and precision of movement as
measured with a line drawing task, is associated with an earlier age of di-
agnosis, and with higher scores on psychometrically estimated schizotypy in
normal young adults. In contrast to many earlier studies, this investigation
employed quantitative measures of motor behavior and a sample of youn-
ger high risk subjects. The study sample was composed of three groups,
biological children and siblings of schizophrenia patient probands, biolog-
ical children and siblings of affective psychosis patient probands and bio-
logical children and siblings of community control subject probands. All
high risk and community control participants were between the ages of
13 and 25. Subjects were assessed psychiatrically and with an extensive bat-
tery of neuropsychological measures. We used the line drawing measure
and standard assessments of handedness to estimate motor control and lat-
eralization. We hypothesized that participants at risk for schizophrenia
would exhibit deviant performance distinct from that of controls. The
results of this investigation add plausibility to the notion that increased vul-
nerability to schizophrenia, reflected in a greater degree of motor abnor-
mality, could be associated with earlier recognition and diagnosis of the
manifest psychotic disorder. The refinement of a profile of measures to de-
tect high levels of vulnerability to schizophrenia may have value in the de-
velopment of preventive interventions that might delay and/or mitigate the
disorder.
ID: 550887
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COGNITIVE AND CLINICAL DYSFUNCTION IN
CHINESE ADULT, NONPSYCHOTIC RELATIVES OF
SCHIZOPHRENIA PATIENTS PREDICTS DEFICITS
IN A WIDE RANGE OF NEUROPSYCHOLOGICAL,
SOCIAL AND CLINICAL FUNCTIONS: FINDINGS
FROM THE CHANGSHA STUDY
William S. Stone1, X. Hsi4,5, L. Tan2, S. Zhu1, L. Li2,
M. T. Tsuang3
1Psychiatry, Beth Israel Deaconess Medical Center / Harvard
Medical School, Boston, MA, USA; 2Mental Health Institute,
Second Xiangya Hospital of Central South University, Changsha,
China; 3Psychiatry, University of California, San Diego, San Diego,
CA, USA; 4MIT Medical, Massachusetts Institute of Technology,
Cambridge, MA, USA; 5Psychiatry, Cambridge Health Alliance /
Harvard Medical School, Cambridge, MA, USA
Introduction: This study reports initial findings from a collaborative in-
ternational study that seeks to identify vulnerability syndromes in rela-
tives of schizophrenia patients, based on multidimensional measures of
function. Methods: The Changsha study uses diagnostic (DIGS), neuro-
psychological, clinical and physical measures of function to assess adult
(ages 18–59), non-psychotic, first-degree biological relatives of patients
with schizophrenia. Phase I of the study involves the identification of:
1) neuropsychological deficits in declarative memory, sustained concen-
tration and executive function; and/or 2) negative symptoms, in subjects
assessed at the Mental Health Institute, Second Xiangya Hospital of
Central South University, Changsha (Hunan, China). Additional meas-
ures of cognitive function are also administered, as are self-report meas-
ures of social function, and medical measures that emphasize cardiac,
hepatic, lipid and glycemic control. Relatives are classified as affected
(‘schizotaxic’) on the basis of diagnostic criteria in neuropsychological
and negative symptom domains (ie, at least 1 standard deviation below
expected mean values in selected cognitive measures, and/or at least 6
scores rated 3 or higher on the SANS), and are compared statistically
with relatives who do not meet criteria, and with healthy control subjects
(n = 30). Current analyses focus on data collected from the first 110 sub-
jects to complete the protocol. Results: Based on diagnostic criteria de-
scribed above, 45/110 relatives were classified as schizotaxic, and 65 were
not. Age and education levels were used as covariates in analyses of cog-
nitive, clinical and medical function (ANOVAs, with post-hoc compari-
sons). Among the major findings: 1) Non-schizotaxic relatives generally
did not differ statistically from controls; 2) Schizotaxic relatives were im-
paired on a wide range of independent (ie, non-criterion related) cognitive,
clinical and social measures compared to both other groups; and 3) Most
physical measures, including glucose tolerance, did not differ between
groups. Conclusions: Deficits in selected cognitive and clinical domains
predict a wide range of additional independent cognitive and clinical def-
icits in a subset of non-psychotic, adult relatives of schizophrenia
patients. These deficits are similar to those seen in schizophrenia, and
may reflect identifiable areas of vulnerability that may eventually serve
as useful treatment targets.
ID: 550860
USING A TWO-STEP CLUSTER ANALYSIS TO
IDENTIFY NEUROPSYCHOLOGICAL SUBGROUPS
IN SCHIZOPHRENIA
Sharron E. Dawes1, B. W. Palmer1,2, D. V. Jeste1,3
1Psychiatry, UCSD, San Diego, CA, USA; 2Psychiatry, VMRF,
San Diego, CA, USA; 3Psychiatry, VAMedical Center, San Diego,
CA, USA
One of the barriers to identifying the neurobiologic underpinnings of
schizophrenia is the presence of substantial inter-person heterogeneity. Al-
though clustering of neuropsychological data in people with schizophrenia
has been done before, no one has looked at the pattern of performance
rather than the magnitude effects of performance. In an effort to identify
more homogenous neurocognitive subgroups, the present study involved
application of a two step clustering procedure to neuropsychological
data from 148 middle-aged and older (age > 40 years; mean [and SD]
52 [7] years) people with schizophrenia. Participants completed an ex-
panded neuropsychological battery, as well as standard ratings of psycho-
pathology (Positive and Negative Syndrome Scale; Hamilton Depression
Rating Scale) as part of participation our Center research on mid-to-late
life schizophrenia. The 23 individual cognitive test scores were factor an-
alyzed to reduce the number of variables to 6 [verbal (Verb) and visual (Vis)
abilities, working memory (WM), auditory and visual memory (Mem)
speed/attention (SA) and executive functioning (EF). These 6 factor scores
were then submitted to a two step clustering procedure: (1) Hierarchical
cluster analysis (HCA) was conducted to determine the number of clusters,
(2) K-Means analysis (KMA) utilized to define final cluster membership.
The HCA indicated that a 5-cluster solution provided the best fit to the
data. Membership of the clusters derived from KMA, was fairly evenly
distributed (11%–27%), with the profiles demonstrating reasonable
independence; these included: Cluster 1: Strength-Verb, Vis, PS,
Weakness- Mem and EF; 2: Strength-PS, Weakness-EF; 3: Strength-PS,
Weakness- Mem; 4: Strength-Verb, Weakness- EF and PS; 5: Strength-
Vis Weakness- Mem and EF. There were no significant differences among
the clusters in terms of age, other demographic characteristics, or severity of
psychopathology. Replication of these findings is needed, but these findings
suggest this method may be useful in identifying subgroups of schizophre-
nia patients with greater within-group homogeneity in the pattern of im-
pairment. The relationship of such subgroupings to brain structure or
function, course of illness, and independent functioning warrant further
study.
ID: 550859
NEUROCOGNITIVE PREDICTORS OF CLINICAL
AND FUNCTIONAL OUTCOME IN THE MEDIUM-
TERM IN FIRST EPISODE PSYCHOSIS
Suzanne Lucia Barrett1, C. C. Mulholland1, S. J. Cooper1,
R. McCaul1, R. A. Anderson1, A. Turkington1, T. M. Rushe2
1Psychiatry, Queens University Belfast, Belfast, United Kingdom;
2Psychology, University ofManchester,Manchester, United Kingdom
Objective: Verbal fluency at illness onset was the strongest neurocognitive
predictor of global functioning at one-year in patients participating in the
Northern Ireland First Episode Psychosis Study (Barrett et al. 2007). The
following analyses aimed to replicate this finding using outcome data gath-
ered at three years, and to examine predictors of employment status at this
time point. Methods: Sixty-two patients (M/F = 59/23; age = 34 6 10.4;
51.6% = SCZ) were included in the analyses. The following neurocognitive
predictor variables were included in regression models: attention, working
memory, verbal and visual memory, executive functioning, verbal fluency,
language and callosal function. Age of onset, symptoms at onset and gender
were subsequently assessed as possible additional predictor variables. Out-
come was measured using the GAF, PANSS, BDI and employment status
at three years. Results: Two factors accounted for 30% of the variance in
GAF at three-year follow-up: verbal fluency (b = 0.48, P < .001) and base-
line positive symptoms (b =0.32, P< .01). Verbal fluency (b =0.31, P<
.01), attention (b =0.25, P< .05) and baseline positive symptoms (b = 0.4,
P< .001) accounted for 27% of the variance in negative symptoms at three-
years. Attention (b = 0.41, P < .001), age of onset (b = 0.25, P < .05),
positive symptoms (b = .36, P < .01) and depressive symptoms (b = 0.29,
P< .05) at onset predicted depressive symptoms at three years (29% of var-
iance). Verbal fluency also predicted employment status at three years
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(Wald = 4.8, P < .05), but this was rendered non-significant once baseline
employment status was included in the model. Conclusions: Reduced ver-
bal fluency at illness onset is a strong predictor of global functioning and
the severity of negative symptoms in both the short and medium-term.
Attention is an additional neurocognitive domain that predicts negative
and depressive symptoms at three-years in first episode psychosis patients.
Reference
1. Barrett SL, et al. Verbal Fluency is a Strong Predictor of Short-Term
Outcome in First Episode Psychosis. Schizophrenia Bulletin. 2007;
33(2):582.
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THE COGNITIVE PROFILE OF THE 22Q11.2 DELE-
TION: A UK SAMPLE
Clare Elizabeth Harvey Jacobson1,2, J. Shearer2, E. Kravariti3
1Neuropsychology, The National Hospital for Neurology and
Neurosurgery, London, United Kingdom; 2Psychology, Great
Ormond Street Hospital, London, United Kingdom; 3Neuroscience,
Institute of Psychiatry, London, United Kingdom
Background: The 22q11.2 deletion is the most frequent microdeletion syn-
drome. Learning difficulties (LD) are frequently reported with marked var-
iability both within cognitive domains and between subjects. Comorbid
psychiatric disorder is common and by early adulthood up to 30% develop
a schizophrenia-like psychosis (Murphy et al. 1999; Feinstein et al. 2002;
Gothelf et al. 2004a; 2007b). A review of the literature presents the
main findings and methodological limitations. Aim: The aim of the study
is to explore the cognitive profile in children with the 22q11.2 deletion at
Great Ormond Street Hospital in the UK. Method: Thirty one children
with the 22q11.2 deletion were examined on standardized tests of intelli-
gence, memory, literacy and numeracy. Results: The mean Full Scale IQ
(FSIQ) was 65, in the Mild LD range. Verbal IQ was significantly higher
than Performance IQ, with the discrepancy clinically significant in half the
sample. Memory function was higher than FSIQ, with no significant differ-
ences between verbal and visual memory. Memory was significantly higher
for simple than complex verbal information. Verbal rote learning was
a strength. Basic reading was significantly higher than mathematics, espe-
cially in those with FSIQ below 70. All other results remained significant in
children with an FSIQ above 70 and when controlling for age, gender and
cardiac surgery. Conclusions: Children with the 22q11.2 deletion in this
sample have LD with a specific but heterogeneous cognitive profile.
Heterogeneity is contributed to by many factors including presence of
schizophrenia, genotype, nature of microdeletion, developmental effects
and cardiac defects. Implications for schizophrenia research are reviewed.
This study replicates the findings of previous research, apart from the
weakness of visual memory compared with verbal memory.
ID: 560094
NEUROTROPHIC FACTORS AND SCHIZOPHRE-
NIA: RELATION TO COGNITION
Berna Binnur Akdede, K. Alptekin, M. Oguz, S. Aykan, H. Ulas
Psychiatry, Medical School of dokuz Eylul University, Izmir,
Turkey
Gial cell line-derived neurotrophic factor (GDNF) and Brain derived neu-
ritrophic factor (BDNF) may play an important role in various neurode-
velopmental processes which are assumed to be abnormal in schizophrenia.
The objective of this study was to determine the relationship between pe-
ripheral BDNF and GDNF serum and gene expression levels and cognition
in schizophrenia. Thirty five patients diagnosed with schizophrenia accord-
ing to DSM-IV (APA, 1994) and 17 healthy volunteers were included in the
study. The patients were recruited from inpatient and outpatient depart-
ments of Psychiatry of Dokuz Eylu¨l University Hospital. Patient and con-
trol groups were comparable for gender and years of education but not for
age. Total RNA extracted from lymphocytes of individuals was amplified
by RT-PCR. Quantitative real time PCR using SYBR Green I was used to
quantify the expression of BDNF and GDNF genes. Relative expressions
of BDNF and GDNF were normalized with beta-actin as housekeeping
gene. The DeltaDeltaCt method was used for the analysis of relative expres-
sion. Serum BDNF and GDNF levels were measured by sandwich ELISA.
Neuropsychological tests were administered to evaluate attention, execu-
tive functions, verbal and visual learning and memory, working memory,
verbal fluency and motor function. The relationship between peripheral
BDNF and GDNF serum and gene expression levels and measures of cog-
nitive tests were examined with Pearson correlation test. Serum BDNF level
was related to a measure of verbal learning and GDNF gene expressions
levels were corelated to measures of verbal learning and memory, executive
function and motor function in healthy subjects. Patient group revealed
a neagtive correlation between Serum BDNF level and a measure of motor
function (r = 0.35) and no other correlations were found between serum
and gene expression levels of BDNF-GDNF and measures of neuropsycho-
logical tests in patiens with schizophrenia. There are few studies indicating
a possible relation between BDNF and cognitive functions particularly
learning-memory and executive functions in healthy subjects. The number
of studies investigating the relationship between cognition and neutrophic
factors in schizophrenia are a few and their results are conflicting. This
study examined this relationship using a wide cognitive battery and did
not find a significant relationship.
ID: 554815
VERBAL AND VISUAL THEORY OF MIND IN
A SCHIZOPHRENIC AND BIPOLAR POPULATION
Katherine Steffen Filip, A. G. Albritton, S. Park
Psychology, Vanderbilt University, Nashville, TN, USA
Theory of mind (ToM) is described as the mental capacity to assign emo-
tions, thoughts, or feelings to others. It has been hypothesized that this trait
plays an integral role in social functioning and interpersonal relations. This
study inquired into the existence of a deficit in ToM in schizophrenic (SZ)
and bipolar populations (BPD), and whether this deficit is related to the level
of social functioning, symptom severity, and/or intellect. The tests used in-
cluded a verbal task, the Hinting Task, and a visual task, the Eyes Test, both
originally established for autistic adult populations. This study aims to not
only investigate group differences, but also to inquire into the possible stra-
tegic differences in ToM. SZ, BPD, and demographically matched healthy
participants (CO) were giventhe Intelligence Quotient (IQ), SocialFunction-
ing Scale (SFS), the Hinting Task, the Eyes Test and a symptoms rating scale.
In the Eyes Test, the participants completed a computer task in which they
were asked to choose the appropriate emotion to describe the eyes presented
from a list of four adjectives; all term definitions are provided. The Hinting
Task is administered as an interviewwhere ten scenes are described where one
of the actors is hinting at an action. The subject is asked what the actor is
hinting at based on the description. These scores were compared to a series
ofempathy, social functioning,and intelligence tests scores. SZ showed a def-
icit when compared to the CO, while BPD was not significantly different
from either group. Eyes test scores over all groups were positively correlated
with the Social Functioning Scale, as well as with IQ scores. The symptoms
rating scale showed negative trend between positive symptoms and Eyes Test
Score in SZ. Overall Hinting Task scores are not significantly correlated with
the Eyes Test scores. Hinting Task is only positively correlated to the Verbal
IQ and one subscale of SFS. There was a trend toward group differences in
the Hinting Task, but BPD did not differ significantly from CO or SZ. This
suggests that there is the possibility of a socially related deficit in ToM with
International Congress on Schizophrenia Research
19. 19. Clinical Neuropsychology 301
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
respect to SZ and also that the hinting task is not a very sensitive measure of
ToM.
ID: 554745
PROCEDURAL LEARNING IN SCHIZOPHRENIA
AND IN PATIENTS WITH AND WITHOUT TARDIVE
DYSKINESIA
Jesu´s Gomar1,2, E. Pomarol-Clotet1,2, S. Sarro´1,2, R. Salvador1,2,
C. Myers3, P. McKenna1,2
1Research Unit, Benito Menni C.A.S.M, Sant Boi de Llobregat,
Spain; 2CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain;
3Department of Psychology, Rutgers University, Newark, NJ, USA
This study re-examined the conflicting findings concerning whether proce-
dural learning remains normal in schizophrenia, despite impairment in
other areas of long-term memory. Forty-three patients with schizophrenia
and 21 normal controls were administered motor, perceptual and cognitive
procedural learning tasks: the pursuit rotor, mirror reading and probabi-
listic learning (weather prediction). All patients had a current WIAS III IQ
of 80. Since procedural learning has been found to be impaired in basal
ganglia disorders like Huntindon’s disease and Parkinson’s disease, the
patients were also rated for presence of tardive dyskinesia. The schizo-
phrenic patients showed comparable learning to the controls on the pursuit
rotor and mirror reading. They showed impaired learning on the probabi-
listic learning task, but here the difference disappeared when subgroups
matched for current IQ were examined. Patients with tardive dyskinesia
showed a significantly lower level of performance on the pursuit rotor
than those without. This study therefore finds that patients with schizo-
phrenia show preserved learning on some, but not all procedural learning
tasks. When procedural learning impairment is found, current IQ dif-
ferences between patients and controls may be an important determining
factor. Tardive dyskinesia is associated with impaired performance, but
not learning on a motor skill task, the pursuit rotor. Acknowledgement:
Supported by the Instituto de Salud Carlos III, Centro de Investigacio´n
Biome´dica en Red de Salud Mental, CIBERSAM.
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NEUROCOGNITIVE CHANGES FOLLOWING AN-
TIDEPRESSANT OR ANTIPSYCHOTIC TREAT-
MENT IN THE SCHIZOPHRENIA PRODROME
Christopher R. Bowie1, C. W. Smith2, D. McLaughlin2,
A. Auther2, B. Cornblatt2
1Queen’s University, Kingston, ON, Canada; 2Psychiatry Research,
Hillside Hospital, Glen Oaks, NY, USA
Cognitive impairment is ubiquitous in schizophrenia. The severity of impair-
ment after the onset of psychosis is such that small, yet statistically signifi-
cant, improvements in cognition following treatment may not be clinically
meaningful. Cognitive dysfunction is detectable in the prodromal phase of
schizophrenia. Although the profile of impairments is similar to chronic
schizophrenia, the attenuated magnitude in the prodrome offers promise
for remediation. In a naturalistic treatment design, 49 individuals considered
at clinical high risk for schizophrenia were treated with an antidepressant
(AD; n = 14), second-generation antipsychotic (SGAP; n = 14), or no med-
ication (Control; n = 21). All subjects were assessed pre-intervention and 12
weeks after initiating treatment with a symptom interview and cognitive tests
measuring sustained attention, processing speed, working memory, verbal
learning, verbal fluency, and executive functioning. Subjects did not differ
at baseline on demographic or symptom variables. Repeated measures anal-
ysis of variance tests were conducted to examine changes over time by treat-
ment group. Bivariate correlations were used to examine the relationships
among baseline symptoms and demographics with change in neurocogni-
tion. Chi-square analyses were conducted to examine the proportion of sub-
jects who improved to a clinically significant degree (ie, z-score change of
0.5) by group. Significant visit by group interactions were found for verbal
learning, working memory, and sustained attention. Pairwise comparisons
revealed a significantly greater improvement for the AD group compared to
the SGAP group on verbal learning, but a greater improvement for the
SGAP group compared to the AD group on working memory. The control
group of high risk patients showed significantly greater improvement on sus-
tained attention than the SGAP group, which declined by a mean of nearly
0.5 SD. Clinically meaningful neurocognitive improvement was observed in
a large minority of patients. For the entire sample, severity of disorganized
symptoms at baseline was associated with change in processing speed, while
severity of negative symptoms was associated with change in sustained at-
tention. These data provide preliminary evidence for differential treatment
effects on specific neurocognitive domains in the schizophrenia prodrome.
ID: 554362
CAN WE HARNESS COMPUTERIZED COGNITIVE
BIAS MODIFICATION TO TREAT ANXIETY IN
SCHIZOPHRENIA? A FIRST STEP HIGHLIGHTING
THE ROLE OF MENTAL IMAGERY
Craig Steel1, T. Wykes2, A. Ruddle3, G. Smith4, D. Shah5,
E. A. Holmes5
1Psychology, University of Reading, Reading, United Kingdom;
2Psychology, Institute of Psychiatry, London, United Kingdom;
3Clinical Health Psychology, University College London, London,
United Kingdom; 4Psychology, University of Surrey, Guildford,
United Kingdom; 5Psychiatry, University of Oxford, Oxford, United
Kingdom
A new wave of computerised therapy is under development which, rather
than simulating talking therapies, uses bias modification techniques to sys-
tematically target the core psychological process underlying anxiety. Such
interventions are being aimed at anxiety disorders, but have not yet been
adapted for co-morbid anxiety in psychosis. The cognitive bias modifica-
tion (CBM) paradigm delivers repeated exposure to stimuli in order to train
individuals to resolve ambiguous information in a positive, rather than anx-
iety provoking, manner. The current study is the first to report data from
a modified form of CBM which targets co-morbid symptoms of anxiety
within individuals diagnosed with schizophrenia. Our version of CBM in-
volved exposure to one hundred vignettes presented over headphones. Par-
ticipants were instructed to actively simulate the described scenarios via
visual imagery. Twenty-one participants completed both a single session
of CBM and a single control condition session in counter-balanced order.
Within the whole sample, there was no significant improvement on inter-
pretation bias of CBM or state anxiety, relative to the control condition.
However, in line with previous research, those participants who engage in
higher levels of visual imagery exhibited larger changes in interpretation
bias. We discuss the implications and challenges for harnessing computer-
ised CBM therapy developments for co-morbid anxiety in schizophrenia.
ID: 554349
PREFRONTAL COGNITIVE DYSFUNCTION IS AS-
SOCIATED WITH SMOKING CESSATION FAILURE
WITH NICOTINE PATCH AND BUPROPION
TREATMENT IN SMOKERS WITH SCHIZOPHRENIA
Taryn Gabrielle Moss1,2, K. A. Sacco4,5, T. M. Allen4,
A. H. Weinberger4,5, J. C. Vessicchio4,5, T. P. George1,3
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1Schizophrenia, Centre for Addiction and Mental Health, Toronto,
ON, Canada; 2Department of Psychology, The University of
Toronto, Toronto, ON, Canada; 3Department of Psychiatry, The
University of Toronto, Toronto, ON, Canada; 4Program for
Research in Smokers with Mental Illness (PRISM), Connecticut
Mental Health Center, New Haven, CT, USA; 5Department of
Psychiatry, Yale University School of Medicine, New Haven,
CT, USA
Patients with schizophrenia have higher rates of smoking (58–88%) than in
the general population (;22%), and endure frequent cessation failure.
These patients also exhibit numerous neurocognitive deficits, some of
which may be ameliorated by cigarette smoking. The neurocognitive ben-
efits derived from nicotine may, in turn, contribute to elevated rates of
smoking and smoking persistence in schizophrenia. The purpose of the
present study is to examine the relationship between neurocognitive func-
tion and smoking cessation in schizophrenia. Treatment-seeking schizo-
phrenic smokers (N = 58) participated in a 10-week placebo-controlled
trial of sustained-release (SR) bupropion plus transdermal nicotine patch.
Neuropsychological performance was evaluated in a subset of patients (n =
30), prior to pharmacological treatment, on a standardized battery includ-
ing Wisconsin Card Sorting Test (WCST), Visuospatial Working Memory
(VSWM) task, Continuous Performance Test (CPT), Iowa Gambling Test
(IGT), California Verbal Learning Test (CVLT), Digit Span of the WAIS-
III, and Trail Making Test (TMT) Parts A and B. Subjects were compared
as a function of endpoint smoking status (Quit versus Not Quit, assessed
by end of trial 7-day point prevalence abstinence, confirmed by CO level
<10 ppm) on demographic traits, smoking, and clinical outcomes. While
there were no significant baseline differences between quitters and non-
quitters, non-quitters exhibited significantly greater deficits in perfor-
mance on TMT-B (P = .01) and on Digit Span backwards (P = .04) com-
pared to quitters. No associations were found between quit status and
performance on other neuropsychological measures. Our findings extend
results of previous studies (Dolan et al. 2004), which suggest deficits in
working memory and executive function are associated with smoking ces-
sation failure in schizophrenia. Specifically, cognitive deficits in frontal
executive function and working memory associated with smoking cessa-
tion failure in this population. This suggests that targeting prefrontal def-
icits through pharmacological or behavioral interventions might improve
smoking cessation treatment outcomes among individuals with schizo-
phrenia. This is important for the development of tailored smoking ces-
sation treatments in this population. This work was supported in part by
NIDA grants RO1-DA-15757 and RO1-DA-13672 and KO2_DA-13672
(to TGP).
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AUTISM SPECTRUM DISORDER SYMPTOMS IN
FIRST EPISODE AND ULTRA HIGH RISK PATIENTS
Emily Kristina Olsen1,2, M. Solomon1,3, M. Minzenberg1,2,
J. D. Ragland1,2, S. Ursu1,2, J. Yoon1,2, T. A. Niendam1,2
1Psychiatry, UC Davis, Sacramento, CA, USA; 2Imaging Research
Center, UC Davis, Sacramento, CA, USA; 3MIND Institute, UC
Davis, Sacramento, CA, USA
Individuals with autism and schizophrenia spectrum disorders exhibit sim-
ilar social, language, and sensory/motor behaviors. There have been no
studies comparing specific differences in these domains in ultra high
risk, first episode psychosis, and autism spectrum disorder patients.
Four groups of 15 patients aged 12–18 diagnosed using gold standard meas-
ures as being ultra high risk (UHR), first episode (EPP), autism spectrum
disorder (ASD) or typically developing (TYP) were ascertained from a clin-
ically referred sample. Parents completed common autism research meas-
ures including the Social Communication Questionnaire, Social
Responsiveness Scale, the Children’s Communication Checklist-2, and
Short Sensory Profile. Based on SCQ, 7 % of each UHR and EPP cohorts
exhibited symptoms consistent with an ASD diagnosis. On the CCC-2,
UHR and EPP exhibited deficits in the areas of articulation and phonology,
coherence, nonverbal communication, increased scripted language, and
language context violations. UHR resembled ASD in their tendency to
talk repetitively about topics without regard for listener interest, while
EPP resembled ASD in relational aspects of communication. On the
SRS, EPP and UHR demonstrated impairments in reciprocal social behav-
ior with similarities to ASD in reduced social motivation and increased au-
tistic mannerisms. EPP exhibited unique resemblance to ASD in lack of
social awareness and conversational skills. On measures of sensory issues,
EPP and UHR differed from TYP in nearly all domains, yet shared many of
the deficits exhibited by ASD: increased sensitivity to taste/smell, greater
auditory filtering, and increased sensory seeking behaviors. Thus, prelim-
inary findings suggest that ASD exhibit worse language, social, and sen-
sory/motor symptoms than other groups. UHR and EPP show
symptoms that are generally not different, however are of intermediate se-
verity to TYP and ASD. Notable exceptions are that EPP, unlike UHR,
show reduced quality of social awareness and communication of compara-
ble severity to ASD; that UHR, unlike EPP, show inappropriate social ini-
tiations comparable to ASD; and that EPP and UHR are very similar to
ASD with respect to some elements of sensory/motor atypicalities. This
work has implications for understanding developmental precursors to psy-
chosis, risk prediction, comparative neurobiology, and intervention.
ID: 551939
EFFECT OF ETHNICITY ON NEUROLOGIC
PERFORMANCE AMONG FAMILY MEMBERS
OF SCHIZOPHRENIC PATIENTS
Richard D. Sanders1,2, J. Woods3, V. Nimgaonkar3
1Psychiatry, Wright State University, Dayton, OH, USA; 2Mental
Health, Dayton VA, Dayton, OH, USA; 3Psychiatry, Western
Psychiatric Institute and Clinic, Pittsburgh, PA, USA
Neurologic exam abnormalities (NEA) are prevalent among patients with
schizophrenia. Some studies of NEA find ethnic differences in performance,
which may be relevant to understanding individual differences in NEA and
for understanding inconsistencies among studies. Using a refined and dis-
tilled version of the Neurological Evaluation Scale (Buchanan and Hein-
richs 1989), we found significant heritability estimates for certain
individual NEA among extended multiply affected European-American
(EA) families (Sanders et al. 2006). To evaluate the NEA in relation to eth-
nic factors, we compared individuals of African-American (AA) and EA
ethnicity. EA samples formed part of a multi-generational, multiply af-
fected family sample ascertained through schizophrenic probands (Sanders
et al. 2006). We evaluated relatives who did not have schizophrenia or schiz-
oaffective disorder, to avoid potentially confounding illness-related factors.
Comparison of 108 AA and 212 EA relatives revealed significant differen-
ces with regard to the fist ring test (FR), audiovisual integration (AV), rapid
alternating movements (RAM) and repetitive motor movements (RM),
a global score comprised of FR, RAM and alternating fist-palm. Subse-
quent multivariate analyses suggested that ethnicity was a significant pre-
dictor in models including sex, age, ethnicity, psychiatric diagnosis, medical
conditions and degree of relationship to proband (P = .005 or better, FR
(right-errors), RAM (right-time), RAM (left-time). Separate analyses re-
stricted to first degree relatives were significant with regard to RAM
(right-time), RAM (left-time) and RM. The results were partly attributable
to different speed-accuracy trade-offs: AA family members executed the
tasks more quickly and less accurately than EA family members. If repli-
cated and extended to probands and to the general population, these results
would have implications for interpreting performance across ethnic groups.
ID: 551926
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20. 20. Functional and Psychosocial Outcome
A RELIABLE RATING SCALE FOR WARD INTER-
ACTION STYLE
Rick Stewart
Psychology, Colorado Mental Health Institute–Pueblo, Pueblo,
CO, USA
The purpose of the study was to create a simple, reliable ward atmosphere
rating scale. The design of the studywas the creation of a rating scale and then
assessing inter-rater agreement. Based on the Staff-Resident Interaction
Chronograph, a briefer rating scale for ward staff-patient interaction style
was created. The new rating scale consistently has inter-rater reliabilities over
0.80 with ten minutes training time. Both staff and patients have been used as
raters. Norms have been developed for formal groups, wards, and 1:1 inter-
actions. This includes interactions per hour per staff member, interactions
per hour per patient, and style of interaction (ratio of positive to negative
to neutral). Judgments have suggested cutoffs for high, medium and low
rates. By linking this with published data for the Staff-Resident Interaction
Chronograph, there can be a very rough estimate of cut scores for the amount
and style of interaction that relates to outcome, although this measure has
not been tested for correlation with outcome. The tool has three columns and
three rows. The three rows are‘‘positive, neutral and negative’’ staff interac-
tions, withthe observer generatinga hashmark(slash,‘‘/’’) upon an occurrence
of each staff interaction. The columns are for‘‘definitions,’’ ‘‘hash marks’’
and‘‘write comments for further discussion.’’ The ‘‘definitions’’ has multiple
sub-sections within each main section, allowing further subtyping of ratings
in the future. By recording the total observation time, average number of
staff in the area during rating time, and average number of patients in the
area during rating time, then rates per hour can be assessed. The rater
observes an individual staff member, or an area such as a section of a day
hall. The column‘‘write comments for further discussion’’ is useful for gen-
erating group discussion on how to improve interaction.‘‘I noticed you said
. what about saying (different category). instead?’’ Possible target rates
include positives to neutral interactions at 2:1, no negative interactions, in-
teraction rates at 15 per hour per patient, 100 per hour per staff, 250 per hour
per ward. People at a variety of training levels (high school to doctoral, staff
and patients) can reliably use the tool. The conclusion is that it is possible to
create a simple reliable ward rating tool.
ID: 533934
INCREASING COHESION AND QUALITY OF LIFE
AMONG RESIDENTS LIVING IN A BOARD AND
CARE ENVIRONMENT
Irwin S. Rosenfarb1, S. Borghei1, A. A. Mullane1, J. Ventura2
1California School of Professional Psychology, Alliant International
University, San Diego, CA, USA; 2Psychiatry, UCLA, Los Angeles,
CA, USA
Since the desinstitionalization of patients from psychiatric hospitals in the
1960s, most individuals with schizophrenia reside in community supported
housing facilities. These community placements, however, are often ill-
equipped to deal with residents’ needs and have been described as ‘‘impov-
erished’’ (Hansson et al. 2002). Yet, research attempting to improve sup-
ported housing conditions for individuals with schizophrenia has been
virtually nonexistent. The purpose of the present pilot investigation was
to develop and implement a 9-month psychoeducational treatment pro-
gram, based upon a family treatment model, aimed at improving the rela-
tionship among residents living in community housing facilities. Six
residents living in a community board-and-care placement in San Diego
participated in the study. Preliminary results indicate that residents who
were highly negative in their attitudes toward the facility (as assessed by
their level of expressed emotion) improved significantly in their perceptions
of cohesion among residents (t = 3.50, P< .05) and improved marginally in
their overall quality of life (t = 2.43, P = .06). These preliminary results sug-
gest that psychoeducational interventions can be successfully implemented
in a board-and-care facility and may lead to significant improvements in
both perceptions of cohesion among residents and residents’ quality of life.
ID: 550802
RELATIONSHIPS AMONG NEUROCOGNITION,
THEORY OF MIND, SOCIAL COMPETENCE, AND
FUNCTIONAL OUTCOME IN SCHIZOPHRENIA
Shannon M. Couture1, E. L. Granholm2,4, S. Fish3
1Psychology, University of Maryland College Park, College Park,
MD, USA; 2Psychiatry, University of California at San Diego, San
Diego, CA, USA; 3Psychology, University of California at San
Diego, San Diego, CA, USA; 4VA San Diego Health Care System,
San Diego, CA, USA
Improving models of the relationships among variables that influence func-
tioning will inform interventions targeting functional goals. This study ex-
amined how two constructs previously identified as important for
functioning, neurocognition and social cognition, relate to functional ca-
pacity and functioning in a path analysis framework. 130 participants
(M/F = 76/54; mean age = 46.4, SD = 11.0) with schizophrenia or schizo-
affective disorder were evaluated. Neurocognition was indexed as a global
composite of processing speed, working memory, verbal and visual learning
and memory, and executive functioning. The Hinting Task was used to as-
sess social cognition (Theory of Mind), the Maryland Assessment of Social
Competence was used to assess functional capacity (performance-based so-
cial problem-solving roleplays), and a composite score for self-reported
functioning was used from the Independent Living Skills Survey. The
full model included neurocognition as a predictor of both social cognition
and functional capacity; social cognition as a mediator between neurocog-
nition and functional capacity; and functional capacity as a predictor
of functioning. The model fit the data well (v2(df = 2) = 1.725, P = .422;
CFI = 1.0, RMSEA < .001), and accounted for 7.8% of the variance in
functioning, 21.2% of the variance in functional capacity, and neurocogni-
tion accounted for 24.5% of the variance in social cognition. Social cogni-
tion served as a partial mediator between neurocognition and functional
capacity. Examination of nested models (removing the direct effect of neu-
rocognition on functional capacity, removing social cognition, or removing
functioning) all resulted in poorer fit. In addition, adding the direct effect of
neurocognition on functioning decreased model fit. These results support
recent models of the relationships among these variables (eg, Green et al.
2000), and also suggest that theory of mind, in addition to social perception
and emotion recognition, has a mediational role between neurocognition
and functioning. Findings provide further evidence that neurocognition
and social cognition are promising treatment targets for improving func-
tioning in schizophrenia. However, it is clear that functional capacity dem-
onstrates a strong relationship with predictor variables, and thus may be
a vital measure to include in treatment studies targeting neurocognition
and/or social cognition given that functioning is likely impacted by a myriad
of other variables.
ID: 550777
DAILY LIFE CHANGES IN PSYCHOTIC SYMPTOM
DIMENSIONS, APPRAISALS AND AFFECT DURING
COGNITIVE BEHAVIOUR THERAPY
Emmanuelle Peters1, I. Myin-Germeys2, T. Lataster2, S. Williams1,
K. Greenwood1, E. Kuipers1, P. Garety1
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1PO 77, Psychology, Institute of Psychiatry, London, United
Kingdom; 2Psychiatry, Maastricht University, Maastricht,
Netherlands
Background: Experience Sampling Method (ESM) is a structured diary
technique permitting ‘on-line’ measurement of daily psychotic experiences.
It is ideally suited to detect the subtle changes in symptom dimensions and
appraisals that are expected to occur with Cognitive Behaviour Therapy
(CBT). Methods: This study assessed changes over time in appraisals of
symptoms, characteristics of key symptoms, and affect. Twelve psychotic
outpatients undergoing CBT participated, providing 1 273 datapoints in
total. Individuals were signalled by a bleeping wrist watch to complete
an ESM booklet at 10 random times of day for 6 consecutive days.
They repeated this procedure at 5 time-points over a period of 15 months
(baseline (at referral to the clinic); pre-therapy (after 6 months on the wait-
ing list); mid-therapy (3 months into therapy); end of therapy (6 months
post pre-therapy); follow-up (3 months after end of therapy)). Results:
For hallucinations, significant changes compared to baseline were demon-
strated from mid-therapy, and maintained at follow-up, in interference,
controllability, beliefs about power of voices, insight, and ‘decentring’(‘‘my
problems are something to do with the way my mind works’’). Intensity of
voices was reduced at the end of therapy but was not maintained at follow-
up, while voice-related distress did not reduce until follow-up. For delu-
sions, significant changes were demonstrated from mid-therapy, and main-
tained at follow-up, in intensity, distress, interference, and preoccupation.
Conviction was reduced at the end of therapy but was not maintained at
follow-up, while insight did not increase until follow-up. Psychotic apprais-
als for both hallucinations and delusions reduced dramatically prior to, and
during therapy, but these changes were not maintained. General negative
affect, but not positive affect, was improved by therapy. Conclusions: This
study demonstrates that ESM is a useful methodology to capture ‘on-line’
changes in psychotic phenomenology over the course of therapy. The pat-
tern of results obtained in this small sample suggests that CBT has a signif-
icant impact on specific symptom dimensions and appraisals, while others
such as delusional conviction and voice intensity are not affected.
ID: 550751
STRESS REACTIVITY, STRESS APPRAISAL AND
COPING RESPONSES IN SCHIZOPHRENIA
Zainab Delawalla, D. Barch
Department of Psychology, Washington University, Saint Louis,
MO, USA
To date, research on the role of stress in schizophrenia has documented that
individuals with schizophrenia experience more stress, although they do not
necessarily report more stressful life events. Studies show that individuals
with schizophrenia have an altered neuroendocrine stress response. There is
also some evidence that individuals with schizophrenia are more likely to
use ineffective coping strategies to alleviate stress. However, there has been
no systematic investigation about how life events, appraisals of these
events, perceived stress, HPA-axis stress response and coping strategies in-
teract to increase the subjective experience of stress in individuals with
schizophrenia. A better understanding of the mechanisms by which an
event is experienced as a stressor in individuals with schizophrenia could
further our understanding of the role of stress in triggering relapse of psy-
chotic episodes. Results of this research may also provide a basis for the
development of interventions targeted at stress management to prevent
or delay stress-related relapse. Data will be presented on how individuals
with schizophrenia differ from controls in their appraisal of and coping to-
wards laboratory induced stress. We will also present similarities and differ-
ences in reported life stress (life events and daily hassles) as well as coping
strategies and coping resources used to manage life stress.
ID: 550727
PERSPECTIVES ON THE ADHERENCE CHAL-
LENGE: REPORT FROM AN NIMH-SPONSORED
MEETING ON ADHERENCE METHODOLOGY
William Riley
National Institute of Mental Health, Bethesda, MD, USA
The National Institute of Mental Health (NIMH) has a long history of
supporting research on the problem of poor treatment adherence, the con-
tributing factors to poor adherence, and interventions to improve adher-
ence in those being treated for mental disorders, particularly
schizophrenia. Although this support has produced a number of impor-
tant findings and efficacious adherence enhancing interventions (AEIs),
advances have been hindered by a number of methodological challenges,
including poor translation of existing knowledge into clinical practice. In
September 2007, NIMH convened a panel of treatment adherence
researchers to discuss and articulate potential solutions for dealing with
methodological adherence research challenges. The group discussed three
primary methodological areas: participants, measures and interventions.
When selecting patients for adherence-enhancing interventions (AEIs),
a stepped-care approach was considered that draws from the universal,
selective, and indicated prevention model and emphasizes the appropriate
matching of interventions to the selected population. Suggestions were
also made to reduce potential selection biases in patient recruitment
and retention. The panel addressed the pros and cons of various methods
that can be used to measure adherence, and concluded that it is appropri-
ate to use multiple measures whenever possible. Finally, the panel identi-
fied a broad range of intervention approaches and conditions applicable to
schizophrenia and other mental disorder treatments that are likely to be
most effective at reducing barriers to adherence and reinforcing adherent
behavior. Increased emphasis on patient-centered approaches and on eco-
logical models that address not only the patient but also the broader en-
vironmental context of adherent behaviors were considered important
directions for improving adherence to the treatment of schizophrenia
and other mental disorders.
ID: 550724
FUNCTIONAL CAPACITY AND INTERVIEW-
BASED MEASURES: RAND PANEL JUDGMENTS
Nina. R. Schooler1,2, M. F. Green3,4, R. S. Kern3,4, B. H. Deng5
1Department of Psychiatry and Behavioral Sciences, SUNY
Downstate Medical Center, Brooklyn, NY, USA; 2VISN 5 MIR-
ECC, Washington DC VAMedical Center, Washington, DC, USA;
3Semel Institute for Neuroscience and Human Behavior, University
of California—Los Angeles, Los Angeles, CA, USA; 4VISN 22
MIRECC, VA Greater Los Angeles Healthcare System, Los
Angeles, CA, USA; 5Department of Psychology, Claremont
Graduate University, Los Angeles, CA, USA
The ultimate goal of cognition enhancers for schizophrenia is to improve
community functioning. However, changes in community functioning in
schizophrenia may require long periods of time and depend on environ-
mental factors such as the local economic situation that are beyond the
scope of a clinical trial. Intermediate measures (ie, functional capacity
or interview-based) are designed for use during the more limited time
frames of clinical trials for cognitive enhancers. We convened a RAND
panel to evaluate intermediate measures in order to select measures for
a study of the relationship of intermediate measures to cognitive perfor-
mance and functional outcome in the community. By review of the
literature and contact with experts in the field, we identified nine perfor-
mance-based measures and six interview-based measures of cognition. The
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RAND panel included 11 members with expertise in cognition, clinical
trials, community adaptation, neuroscience, biostatistics and other rele-
vant disciplines. The panel met in February 2008 and their ratings
form the basis of this presentation. Data for the performance-based meas-
ures were submitted to a formal RAND panel review involving advance
ratings on specific criteria, in-person discussion and final rankings. The in-
terview-based measures were not as well-suited for formal evaluation; the
panelists reviewed measures in terms of criteria and provided consensus
judgments. Based on the RAND panel ratings, five measures (three per-
formance-based and two interview-based) were selected for inclusion in
a reliability and validation study. They are: Independent Living Scales
(ILS); Test of Adaptive Behavior in Schizophrenia (TABS); UCSD Per-
formance-based Skills Assessment (UPSA) for performance-based; the
Cognitive Assessment Interview (CAI) and the Clinical Global Impres-
sions Scale for Cognition, for interview-based. These measures are all
designed for administration in a clinical setting and have detailed training
procedures available. They are all conceptually intermediate between lab-
oratory measures of cognition and community functioning. The RAND
panel process for decision making provided an effective method for reduc-
ing a number of potential candidate measures to a more limited number
that can be subjected to rigorous evaluation.
ID: 550715
COMPARISON OF NEUROLOGICAL SOFT SIGNS
BETWEEN UNTREATED AND ANTIPSYCHOTIC-
TREATED SCHIZOPHRENIA PATIENTS
Venkatesh Basappa Krishnamurthy1, J. Thirthalli2,
K. V. Kengeri2, V. Ganesan2, S. K. Dattathreya3,
G. N. Bangalore2, A. Udupi4
1Psychiatry and Behavioural Sciences, Wayne State University,
Detroit, MI, USA; 2Psychiatry, National Institute of Mental Health
and Neuro Sciences, Bangalore, India; 3Biostatics, National
Institute of Mental Health and Neuro Sciences, Bangalore, India;
4Psychiatry, Manasa Nursing Home, Thirthahalli, India
The relationship between neurological soft signs (NSS) and antipsychotic
in schizophrenia is sparsely studied. The purpose of this study was to com-
pare the NSS in patients treated with antipsychotics and those who had
remained untreated in a rural community of South India. The sample for
the study comes from a project, in which community-living schizophrenia
patients in Thirthahalli (an administrative block in South India with a pop-
ulation of 143 000) were identified and followed up. Of the initially iden-
tified 151 patients, 55 were not receiving any antipsychotics and 96 were
receiving antipsychotics (85% were receiving atypical antipsychotics). A
trained psychiatrist assessed their psychopathology using the Positive
And Negative Syndrome Scale (PANSS; Kay et al. 1987). He also assessed
the NSS using Neurological Evaluation Scale (NES; Buchanan and Hein-
richs, 1989) in all the 96 patients on antipsychotics and 33 of the 55
patients not on antipsychotics (the rest 22 were too symptomatic to co-
operate for a valid administration of NES). The table shows the compar-
ison of the two groups. The treated group had significantly lesser scores
(fewer soft signs) on two components of NES: complex motor sequencing
and sensory integration signs. They also had lesser psychopathology
scores. Pearson’s correlation showed that the higher the NES component
scores, the higher was the PANSS negative syndrome score in both groups.
The association among higher NSS, greater psychopathology and un-
treated state could be a natural selection or a chance association, limiting
interpretation on causality. Nearly all medicated patients received atypical
antipsychotics. This leads to a speculation that NSS may be reversible if
treated with these medications. This remains to be tested in a prospective
design.
Table. Shows the difference between treated and untreated patients. Second
and third columns represent mean (SD) except in case of sex
Variable
Treated
patients
(n = 96)
Untreated
patients
(n = 33) t/v2 P
Age in years 41.6 (11.4) 40.2 (9.8) 0.62 0.52
Sex (Males:Females) 49:47 18:15 0.12 0.72
Duration of illness 11.4 (8.7) 9.7 (6.3) 1.01 0.31
Years of education 6.5 (4.8) 6.3 (4.4) 0.12 0.91
PANSS positive syndrome score 10.7 (5.8) 19.2 (8.8) 5.3 <0.01
PANSS negative syndrome score 17.6 (6.6) 27.1 (7.3) 6.94 <0.01
NES Motor coordination 2.01 (2.7) 2.51 (2.7) 0.91 0.36
NES complex motor sequencing 8.8 (3.9) 10.5 (2.8) 2.69 <0.01
NES sensory integration 5.4 (2.7) 7.0 (3.3) 2.65 <0.01
NES Primitive reflex 3.8 (2.5) 3.8 (2.9) 0.049 0.96
ID: 550579
EXAMINING THE RELATIONSHIP BETWEEN
NEGATIVE SYMPTOMS AND SOCIAL SKILL IN
SCHIZOPHRENIA: A PILOT STUDY OF THE NEW
NIMH-MATRICS NEGATIVE SYMPTOM RATING
SCALE
Katiah Llerena, S. G. Lin, C. Forbes, A. Wilson, J. J. Blanchard,
M. E. Bennett
University of Maryland, College Park, MD, USA
An NIMH consensus development conference on negative symptoms
(Kirkpatrick et al. 2006) recommended the development of a new neg-
ative symptom assessment instrument that addresses conceptual and psy-
chometric limitations of existing instruments. The NIMH-MATRICS
negative symptom workgroup has developed a new instrument, the Neg-
ative Symptom Rating Scale (NSRS), which represents a substantial step
forward in the assessment of this critical symptom domain. As part of
ongoing efforts to examine the reliability and validity of this new mea-
sure, the current study examined how the NSRS is related to social skill.
Prior studies have shown that negative symptoms are associated with
behavioral skills deficits in schizophrenia and we sought to replicate
these findings with the NSRS. Further, we sought to examine which neg-
ative symptoms were most strongly associated with skills deficits and if
these associations were independent of other psychotic or affective symp-
toms. Forty individuals diagnosed with schizophrenia or schizoaffective
disorder will complete assessments of current symptoms, social function-
ing in the community, and social skill. Social skill will be assessed with
a role-play-based social skills assessment, the Maryland Assessment of
Social Competence (MASC). Other symptoms will be assessed with
the BPRS and the Calgary Depression Scale. Functioning in the com-
munity will be measured with the Birchwood Social Functioning Scale.
Results will provide additional information regarding the performance of
the NSRS in schizophrenia and inform the further development of this
instrument.
ID: 550519
FUNCTIONAL SIGNIFICANCE OF AFFECT
RECOGNITION DEFICITS IN SCHIZOPHRENIA
Joanna Fiszdon1,2, J. K. Johannesen1,2
1Psychology, VA Connecticut Healthcare System, West Haven, CT,
USA; 2Psychiatry, Yale University School ofMedicine, NewHaven,
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Affect recognition (AR) is a core component of social information process-
ing, thus may be critical to understanding social behavior as well as func-
tioning in broader aspects of daily living. Deficits in AR are well
documented in schizophrenia (Sz), and have been associated with poorer
independent functioning. However, studies also show variability in the de-
gree of AR impairments, with some noting subgroups of patients with near-
normal AR performance. Variability in the expression of AR deficits in Sz
has previously been linked to differences in course, symptomatology, diag-
nostic subtype, and neurocognition. In the current study, we sought to eval-
uate the functional significance of AR deficits by comparing subgroups of
Sz patients with normal-range AR performance to those with impaired AR
performance on proxy and interviewer-rated measures of real-world func-
tioning. Sz outpatients were classified as normal-range (n = 17) and im-
paired (n = 31) using logistic regression, in which BLERT scores were
entered as a predictor of diagnosis against a normative sample of healthy
control subjects (n = 56). The derived Sz subgroups were then compared on
proxy (UCSD, UPSA, SSPA, MMAA) and interviewer-rated (QLS, ILSS)
measures of functioning. Differences in demographics, symptom severity,
and neurocognitive test performance were also evaluated. Because the nor-
mal-range AR subgroup scored significantly higher than the impaired sub-
group on a number of cognitive variables, a neurocognitive composite score
was computed for use as a covariate in primary analyses. Comparison on
proxy measures indicated superior MMAA performance in the normal sub-
group, but comparable UPSA and SSPA performance between groups.
Covariate analyses indicated that the difference in MMAA was fully me-
diated by differences in neurocognitive ability. Group comparisons on
interviewer-rated measures indicated significantly higher QLS in the normal-
range AR subgroup, but comparable ILSS. Significant differences in QLS
remained after entering the neurocognitive composite as a covariate. These
results support three main conclusions. First, AR, like many other domains
of psychopathology studied in Sz, is preserved in select subgroups. Second,
there is a positive relationship between AR performance and functional
outcome measures. Third, neurocognition appears to mediate the rela-
tionship between AR and proxy, but not interviewer-rated, measures of
functioning.
ID: 550456
NEGATIVE SYMPTOMS AND MOTIVATIONAL
DEFICITS AS PREDICTORS OF DISABILITY
Elizabeth Henderson DeOreo1, P. D. Harvey1, F. R. Leifker1,
C. R. Bowie2
1Psychiatry and Behavioral Health, Emory University Department
of Psychiatry and Behavioral Health, Atlanta, GA, USA;
2Psychiatry, Mt. Sinai School of Medicine, New York City,
NY, USA
In schizophrenia, severity of cognitive impairments and performance on
measures of functional capacity are clear predictors of real world disabil-
ity. Various symptomatic factors serve to mediate the relationships be-
tween capacity and real world outcomes. Specifically, deficits in
motivation and other negative symptoms may have greater impact on out-
comes than ability variables alone. Two hundred and forty three older
patients with schizophrenia were assessed with a neuropsychological
(NP) battery, the Positive and Negative Syndrome scale (PANSS), rated
by their case managers for real world social and community activities, and
were assessed for social competence and functional abilities using the fol-
lowing scales: The Social Skills Performance Assessment (SSPA), Every-
day Living Skills (UCSD) Performance-Based skills assessment (UPSA).
Scores on the SSPA and PANSS negative subscale were accounted for var-
iance in social outcomes (R-squared = .17), but NP impairments were not
an independent predictor. When SSPA scores were forced in the equation
first, PANSS negative symptoms still accounted for variance in real-world
social outcomes; when the order of entry was reversed, the SSPA did not
enter the equation. In contrast, community activities were well predicted
by these variables: r-squared = .26. SSPA scores, UPSA scores, and NP
impairments all entered the equation across combinations of entry order,
but negative symptoms accounted for no variance unless they were entered
into the equation first and then only accounted for 3% variance. Negative
symptoms appear to have a substantial influence on social outcomes that
exceeds that of social abilities. In contrast, community activities are not
greatly influenced by the severity of negative symptoms. Efforts to treat
real world disability will have to be aimed at the determinants of these
outcomes; improving cognitive or social abilities may only influence
real-world social outcomes if negative symptoms are reduced as well.
NIMH grant MH63116
ID: 550417
A SYSTEMATIC REVIEW OF THE CORRELATIONS
BETWEEN FUNCTIONAL CAPACITY, COGNITIVE
IMPAIRMENT, AND FUNCTIONAL DISABILITY:
IMPLICATIONS FOR TREATMENT STUDIES
Philip D. Harvey
Psychiatry, Emory University School of Medicine, Atlanta,
GA, USA
Background: Impairment on neuropsychological (NP) tests has been found
to be correlated with the presence and severity of real-world functional dis-
ability in schizophrenia. A new feature of this research has been the devel-
opment of performance-based measures of living skills, referred to as
functional capacity (FC). As these measures seem to be more proximal
to real-world disability, they may be more strongly correlated with real-
world outcomes than NP impairments. Methods: For a different study,
the existing English language literature was reviewed to identify all studies
involving formal ratings of real-world disability in schizophrenia. We then
selected the most widely used functional outcomes measures (n = 11) and all
studies using these measures were examined to see if they also collected in-
formation on NP performance and FC. Results: We found a total of 25
studies using those 11 scales that collected NP performance, 9 studies
that had measures of functional capacity, and 5 studies that had both.
The averaged correlation between composite NP performance and real-
world outcomes was r = .41, while the correlation between NP performance
and FC was r = .63 and the FC to real world outcomes correlation averaged
r = .46. In the studies where both NP and FC performance were examined,
FC was in all cases more strongly correlated with real-world disability then
was NP impairment and in some cases accounted for all of the variance in
the correlation between NP impairment and real-world outcomes. Implica-
tions. Direct assessment of FC appears to give a stronger signal than NP
performance for predicting real-world disability. Further, there is minimal
evidence regarding associations between neuroscience measures and real-
world outcomes. Later research will need to evaluate these relationships
and determine if neuorscience measures add to the prediction of disabiity
and improve treatment development efforts as a result.
ID: 550327
VALIDATING MEASURES OF REAL-WORLD
OUTCOME: THE RESULTS OF THE VALERO
EXPERT POLL AND RAND PANEL
Philip D. Harvey1, R. K. Heaton2, T. L. Patterson2
1Psychiatry, Emory University School of Medicine, Atlanta, GA,
USA; 2Psychiatry, UCSD Medical Center, La Jolla, CA, USA
Background: Recent studies have shown that there is considerable discrep-
ancy between self-reported real-world outcomes and several other aspects
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of the functional outcomes construct, including informant reports, perfor-
mance on neuropsychological tests, and measures of functional capacity.
It is not clear whether these discrepancies originate from the psychometric
instruments used to examine real-world outcomes or from the perspective
of different informants. The VALERO (Validation of Everyday Real
World Outcomes) was designed to directly compare different psychometric
instruments across different informants. Methods: The first step of the
study was an expert poll, where experts (n = 75) on real-world outcomes
were asked to provide their opinions about the best measures for assess-
ment of real-world outcomes. After these nominations were received, 11
outcome measures, examining social functioning, independent living, or
combinations of these outcome domains, were identified as most highly
regarded. All published data on these 11 scales was collected and provided
to 9 members of a RAND panel. Panelists were asked to rate the scales on
reliability, convergence with other elements of outcome, sensitivity to
change, practicality, usefulness for multiple raters, independence from
symptoms, and comprehensiveness. Results: Scales were selected on the
basis of highest ratings for social, functional, and hybrid scales. The
two highest rated hybrid scales were the Quality of Life Scale (QLS)
and the Specific Levels of Functioning (SLOF); the two highest rated so-
cial functioning scales were the Social Behavior Schedule and the Social
Functioning Scale; and the two highest rated functional scales were the
Independent Living Skills Schedule (ILSS) and the Life Skills Profile
(LSP). Two of these scales, the ILSS and SLOF are designed to used
as questionnaire measures with no interview required. Implications.
The results of this study reflect the current consensus of the field with
regards to the assessment of real-world functional outcomes. All of these
scales are being studied in terms of their convergence with other elements
of outcome and suitability across multiple raters.
ID: 550320
PRELIMINARY VALIDATION OF THE ENGLISH
VERSION OF THE SCHIZOPHRENIA QUALITY OF
LIFE SCALE (S-QOL)
Karina Hansen1, M. C. Simeoni2, P. Auquier2, C. Lancxon3,
C. Sapin1
1Global Outcomes, Risks and Market Acc, H. Lundbeck A/S, Paris,
France; 2Public Health, School of Medicine, Marseilles, France;
3Psychiatry Department, Sainte Marguerite University Hospital,
Marseilles, France
Objectives: This study assesses the validity and responsiveness over changes
of the English version of the S-QoL, first schizophrenia-specific health-re-
lated quality of life scale developed from patients’ viewpoint on the need-
based framework. Methods: The S-QoL, comprising 41 items exploring
eight dimensions (Psychological Well-being, Self-esteem, Relations with
Family, Relations with Friends, Resilience, Physical Well-being, Auton-
omy and Sentimental Life), was first developed and validated in French.
After a standard backward-forward translation process, its English version
was tested in a sample of patients with schizophrenia. Two assessments
were performed: baseline and 12 weeks later. Psychometric properties (val-
idity and sensitivity over changes) were evaluated using methods from Clas-
sical Test Theory, Rasch analyses and structural equation modelling.
Results: A total of 128 patients filled-in the S-QoL. The factorial structure
of the original version was globally retrieved. The questionnaire was well
accepted (missing dimension rates lower than 3%). Cronbach’s alphas were
greater than 0.70 for 6 of the 8 dimensions. The S-QoL dimensions and total
score were statistically correlated with depression assessed with the Calgary
Depression Scale for Schizophrenia (CDSS), and severity of symptoms
measured by the Positive and Negative Symptoms Scale (PANSS). Using
the sub-sample of patients rated ‘‘Very much Improved’’ or ‘‘Improved’’ on
the Clinical Global Impression of Improvement (CGI-I) at Week 12, all the
dimensions and the total score were statistically significantly improved. Five
of the dimensions, as well as the total score, reached an effect size of at least
0.50 indicating an at least moderate change on health status. Conclusions:
These results strengthen the usefulness of assessing the impact of schizo-
phrenia on patients’ everyday life with the S-QoL, specifically designed
for assessing the health-related quality of life of patients with schizophre-
nia. Its sensitivity to changes in health state is of major interest for evalu-
ative purposes.
ID: 550310
ALCOHOL AND ILLICIT DRUG USE AFTER ONE
YEAR COMPARED WITH BASELINE IN NORWE-
GIAN FIRST-EPISODE PSYCHOSIS PATIENTS
Elisabeth H. Lange1, R. Nesva˚g1,3, B. Emilsson1,
O. A. Andreassen1,2, I. Melle1,2, I. Agartz1,3
1Institute of Psychiatry, University of Oslo, Oslo, Norway;
2Division of Psychiatry, Ulleval University Hospital, Oslo, Norway;
3Department of Psychiatric Research, Diakonhjemmet Hospital,
Oslo, Norway
The study investigates stability of alcohol and illicit drug use over the first
year after the first-episode of psychosis using Alcohol Use Disorders Iden-
tification Test (AUDIT) (1) and Drug Use Disorders Identification Test
(DUDIT) (2), self-rating questionnaires that assess level, pattern, and
behavioural consequences of substance use. Thirty-six women and 49 men
with first-episode non-organic psychosis from the Thematic Organized Psy-
chosis study (TOP) at University of Oslo, Norway who met DSM-IV criteria
for schizophrenia spectrum disorder (n = 45), affective psychotic disorder (n =
17) or other psychotic disorder (n = 23) participated. AUDIT and DUDIT
were administered at inclusion and at one year follow up. Maximum score of
AUDIT and DUDIT is 40 and 44, respectively. AUDIT score of 6 for women
and 8 for men are cut-off levels for hazardous or harmful use of alcohol. Cut-
off scores for DUDIT are 6 for men and 2 for women (2). Level of functioning
was assessed with Global Assessment of Functioning scale (GAF), split ver-
sion. At baseline 33 (39%) patients had an AUDIT score above cut-off,
whereas 32 (38%) scored above cut-off for DUDIT. There were no gender
differences in proportion of patients above cut-off. Men scored higher
than women by total DUDIT scores (P = .008), but not by total AUDIT
scores. There was an increase in level of functioning over the year as measured
by GAF-F (from 45.9 (SD 14.7) to 54.0 (SD 16.3), P < .001). At one year
follow up, 22 (26%) patients scored above DUDIT cut-off, a significant re-
duction (P = .002) from baseline. When divided by gender, the reduction was
significant only for men (P = .005). No significant change was seen for AU-
DIT scores at one year follow up. A reduction of hazardous or harmful use of
illicit substances but not of alcohol was found over the first year after first-
episode of psychosis. Levels of alcohol misuse among women were compa-
rable to that of men. The results indicate that treatment strategies should in-
crease focus on reducing alcohol misuse in this patient group.
References
1. Saunders JB, et al. Development of the Alcohol Use Disorders Identi-
fication Test (AUDIT): WHO Collaborative Project on Early Detec-
tion of Persons with Harmful Alcohol Consumption–II. Addiction
1993;88(6):791–804.
2. Berman AH, et al. Evaluation of the Drug Use Disorders Identification
Test (DUDIT) in criminal justice and detoxification settings and in
a Swedish population sample. Eur Addict Res 2005;11(1):22–31.
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INTENSIVE CASE MANAGEMENT OF CLIENTS AT
HIGH RISK FOR SUICIDE: COMPARING OUTCOME
TO TREATMENT AS USUAL IN A SPECIALISED
EARLY PSYCHOSIS PREVENTION PROGRAM
(EPPIC)
Warrick Brewer, K. Witt, J. Dileo, D. Gee, C. Duff, C. Crlenjak,
B. Murphy, T. Lambert, P. McGorry
Psychiatry,University of Melbourne, ORYGEN Youth Health
Research Centre, Parkville, VIC, Australia
Introduction: The first episode of psychosis is a critical period where early
intervention can alter the trajectory of the young person’s ongoing mental
health and general functioning. The Intensive Case Management (ICM)
team was developed as a sub-program of the Early Psychosis Prevention
and Intervention Program (EPPIC- Melbourne Australia) in 2002 to pro-
vide assertive outreach to young people experiencing a first episode of psy-
chosis who are at high risk due to level of risk to self/others, disengagement
or suboptimal recovery. Method: Individual and general service key perfor-
mance outcomes were assessed on 120 consecutive referrals within the first 5
years of operation relative to 50 EPPIC treatment-as-usual (TAU) clients
matched for age, gender, year of entry, and diagnosis. Results: ICM clients
had greater levels of anti-social personality disorder traits (P< .01), utilised
significantly greater levels of illicit substances (P < .03), had no adverse
events, had less days in crisis managed by a crisis assessment (CAT)
team, and had reduced number of inpatients admissions (P < .02) and
days in hospital (P< .03) relative to EPPIC TAU over 2 years. Conclusions:
Our findings support a clinical rationale for incorporating an intensive case
management team within an already unique service program targeted at the
early detection and treatment of psychosis.
ID: 550240
ILLNESS PERCEPTIONS IN PATIENTS WITH
A FIRST-EPISODE PSYCHOSIS AND THE ROLE OF
CHILDHOOD TRAUMA
Connie Markulev1,4, B. Garner1, L. J. Phillips2, Y. Yun1,
R. Parslow1, S. Hammond4, P. D. McGorry1,3
1Psychiatry, ORYGEN Research Centre, Parkville, VIC, Australia;
2School of Behavioural Sciences, University of Melbourne,
Parkville, VIC, Australia; 3ORYGEN Youth Health, Northwestern
Mental Health, Parkville, VIC, Australia; 4Psychology, Australian
Catholic University, Fitzroy, VIC, Australia
Over the past two decades there has been increased interest and research into
the potential causal role of childhood trauma (CT) in psychotic disorders.
Since CT has been found to impact on cognitions and emotions, identifying
the influence of CT on beliefs about current mental health concerns in first-
episode psychosis (FEP) patients may hold important implications for for-
mulation and treatment in this illness group. In this study forty-one (n = 41)
FEP patients (25 males and 16 females, mean age 19.8 years) were recruited
from the Early Psychosis Prevention and Intervention Centre (EPPIC) at
ORYGEN Youth Health and assessed on measures of psychopathology, ret-
rospective accounts of CT, functioning, and current illness perceptions.
Childhood sexual abuse (CSA), physical abuse (CPA) and emotional abuse
(CEA) were reported by 31%, 41% and 63% of the patients, respectively. His-
tories of childhood physical neglect (CPN) and emotional neglect (CEN)
were found in 63% and 36% of patients respectively. There were no signif-
icant differences in illness perception constructs between those patients that
had experienced CSA or CPA and those that had not. FEP patients that had
experienced CEA (M = 18.54, SD = 6.02) were more likely to perceive their
illness as chronic (t39= 2.08,P< .05) compared to those patients that had not
experienced CEA (M=14.40, SD=6.39). Patients that had experienced CEA
were also more likely to perceive their mental health problems as a conse-
quence of difficulties in life (t39 = 2.10, P< .05), and have a less coherent un-
derstanding of their illness (t39 = 2.31, P < .05). Those patients that had
experienced CPN also had a less coherent understanding of their illness com-
pared to those that had not experienced CPN (t39 = 2.05, P< .05). Method-
ological issues in the measurement of CT across research studies remain,
however, the high prevalence rates of CT in our group are comparable
with previous research. Our findings suggest that CT has a clear role in mod-
ifying perceptions of subsequent illness, but that further exploration is re-
quired and an emphasis on CSA or CPA alone may not adequately
address the complex issues related to CT in FEP. Further analysis is planned
in order to determine if there are differences in levels of symptomatology or
short-term functional outcome between those FEP patients that have expe-
rienced CT and those that have not.
ID: 550205
VALIDATING ASSESSMENTS OF REAL-WORLD
OUTCOMES IN SCHIZOPHRENIA
Elizabeth W. Twamley1,2, T. Patterson1,2, P. Harvey3, R. Heaton1
1Psychiatry, University of California, San Diego, San Diego, CA,
USA; 2Psychology Service, VA San Diego Healthcare System,
San Diego, CA, USA; 3Psychiatry, Emory University, Atlanta,
GA, USA
Among people with schizophrenia, impairment in everyday functioning
skills (including social and occupational functioning, independent living,
medication management, and basic self-care) is cognitively mediated. As
new pharmacological and psychosocial treatments for cognitive impair-
ment are tested, the need grows to demonstrate the real-world significance
of neurocognitive gains by patients. The moderate correlations between
neuropsychological measures and functional outcome measures vary
depending on the nature of the functional outcome measures used (eg,
self-report vs. informant report vs. performance-based), and it remains un-
clear which existing measures best characterize the real-world performance
of patients. We have launched a series of three studies whose overall goal is
to improve the assessment of real world functioning in schizophrenia. We
will examine the convergence between a wide range of existing real-world
rating scales and performance-based measures (including neuropsycholog-
ical assessments and functional capacity assessments). In this report of the
first study, we will include data from >100 geographically and ethnically
diverse schizophrenia participants who have undergone assessment using
six, RAND-panel nominated real-world functioning scales (both self-report
and informant-report versions), neuropsychological assessment using the
MATRICS Consensus Cognitive Battery, and the UCSD Performance-
Based Skills Assessment. The RAND-nominated scales include the In-
dependent Living Skills Survey, Life Skills Profile, Quality of Life Scale,
Social Behavior Schedule, Social Functioning Scale, and Specific Level
of Functioning Scale. We will present the correlations between these meas-
ures, including the convergence between self-reports and informant reports
of functioning. Our goal is to identify (1) the best real-world functioning
scale based on convergence with both other real-world outcome measures
and with neuropsychological and functional capacity measures and (2) the
best rater of functioning (eg, patient, relative, case manager, or medical pre-
scriber). This work was supported by linked NIMH R01s, MH078737 (Pat-
terson) and MH078775 (Harvey).
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THE SUBJECTIVE EXPERIENCE OF PEOPLE AT
A HIGH RISK OF DEVELOPING PSYCHOSIS
JOURNEYING INTO AND THROUGH AN EARLY
DETECTION FOR PSYCHOSIS SERVICE
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of Clinical Psychology, University of Liverpool, Liverpool, United
Kingdom; 3Division of Clinical Psychology, University of
Manchester, Manchester, United Kingdom
The study aimed to explore how people who have been assessed as being at
a high risk of developing psychosis entered into services and journeyed
through them. We used a qualitative approach to study the subjective ex-
perience of the individual in keeping with the view that it is important to
empower service users by allowing participants to give voice to their expe-
riences. Individual semi-structured interviews were conducted with ten par-
ticipants ranging in age from 16 to 30 years (mean age 21.8 years) recruited
from an early detection of psychosis service in the United Kingdom. The
interviews initially focused on the participants’ perception of their experi-
ences and their experience of professional involvement and were developed
in line with theoretical sampling as a response to the themes that arose from
the data. The data were analyzed using grounded theory. Three main
themes were identified in the analysis: 1. Perception of needs which encom-
passed how the participants identified the need to access services and what
they required from the service. This led to help seeking as their difficulties
worsened, to an identification of what was required from the service and an
acknowledgement of when these psychological needs were met. 2. Partic-
ipants’ subjective journey into and through the service which was recounted
as at times progressive, regressive or static, and the identification of draw-
ing upon personal resources when this journey became difficult. 3. Partic-
ipants’ orientation toward their personal future which was identified by all
the participants but with a strong recognition that basic needs (such as
housing) have to be met before psychological issues can be addressed.
The study concluded that participants’ journey into and through an early
detection service is multi-faceted. The subjective accounts highlight a strong
perception of needs and an acknowledgement of what is required from the
service to meet these needs. There is also a recognition that the journey is
arduous and at times it is necessary to rely on personal resources. Ulti-
mately participants are orientated towards their future goals but identify
a hierarchy that they must progress through before meeting their psycho-
logical needs. This research furthers our understanding of how people
assessed as being at risk of developing psychosis make sense of their expe-
riences whilst in an early detection service and what they perceive their
needs to be during this time.
ID: 550091
IMPACT OF A SHORT-TERM SKILLS-BASED IN-
TERVENTION PROGRAM ON LEVEL OF INSIGHT
AND ENGAGEMENT IN FOLLOW-UP PSYCHIAT-
RIC CARE
Anna Mia Muller, D. A. Wirshing, L. H. Guzik, Z. D. Erickson,
S. J. Mena
Schizophrenia Research Clinic, West Los Angeles VA Medical
Center, Los Angeles, CA, USA
The purpose of this NARSAD-funded study is to examine the impact of
a psychosocial intervention program on insight into illness and the role
of insight in adherence to rehabilitative efforts among individuals diagnosed
with schizophrenia or schizoaffective disorder. Lack of insight is associated
with treatment non-adherence, higher relapse rates and re-hospitalizations,
and poorer social and occupational functioning. Psychosocial intervention
programs show promising results in improving treatment adherence but re-
search results are inconsistent in describing the role of insight in rehabili-
tation. Outpatients at the West Los Angeles VA Medical Center participate
in the Community Re-Entry Program (CREP), aimed at increasing under-
standing and self-management of illness and improving participants’ ability
to achieve successful community living. Insight into illness is assessed via
two self-report questionnaires before and after participation in the psycho-
social treatment program. Illness-management educational sessions include
exposure to illness symptoms, warning signs of relapse, medication manage-
ment, communicating with health-care professionals, and planning for psy-
chiatric emergencies. Pre-and post tests designed for the CREP program are
administered to assess retention of session content. After completion of the
treatment program, study participants are monitored for six months and are
compared to individuals receiving standard care. Preliminary results con-
ducted with a limited data set yielded no support for the hypothesis that
treatment group participants would report increased level of insight follow-
ing completion of the intervention program (N = 11). The hypotheses that
treatment group participants would report greater insight into illness (N =
21) and demonstrate greater involvement in rehabilitative efforts and lower
relapse rates (N = 9) compared to participants receiving usual care were not
supported. However, CREP test scores suggest that treatment group par-
ticipants increased their knowledge of illness management, retained these
skills after participation in the treatment program, and demonstrated
greater self-management skills than individuals in the comparison condi-
tion. Lack of support for the hypotheses on the outcome variables
may be associated with the small number of subjects to date and a floor
effect due to low relapse rates among study participants during the obser-
vation period.
ID: 550065
METACOGNITION AS A PREDICTOR OF WORK
FUNCTION OVER SIX MONTHS FOR PARTICI-
PANTS WITH SCHIZOPHRENIA
Kelly D. Buck1, P. H. Lysaker1,2
1Roudebush VA Medical Center, Indianapolis, IN, USA;
2Psychiatry, Indiana Univeristy School of Medicine, Indianapolis,
IN, USA
Introduction: It has been widely suggested that impairments in the capacity
for metacognition, or the ability to think about thinking, are a root cause of
psychosocial dysfunction in schizophrenia. To date, however, most of the
literature supporting this has come from cross sectional studies which re-
port significant correlations between assessments of metacognition and
function. Thus it is unclear whether metacognitive capacity is prospectively
linked with behavior in real life settings. To explore this possibility we
sought to determine whether metacognition assessed as baseline predicted
work performance in a vocational rehabilitation program over the follow-
ing six months. Methods: Participants were 56 adults with schizophrenia in
a post acute phase of illness enrolled in a 6 month study of the effects of
cognitive therapy on work outcome, all of whom worked for at least 66% of
the weeks they were assigned work. Metacognitive capacity was assessed
using an abbreviated form of the Metacognition Assessment Scale
(MAS) using personal narratives elicited with the Indiana Psychiatric Ill-
ness Interview. Participants were then assigned to a work placement and
work performance was assessed biweekly using the Work Behavior Inven-
tory (WBI) by raters blind to MAS ratings. Results: Participants were di-
vided into three groups on the basis of their score at baseline on MAS
subscale Awareness of One’s Own Mind: Poor self-awareness (n = 21) Lim-
ited self-awareness (n = 23) and In tact self-awareness (n = 13). A repeated
measures ANOVA was then conducted comparing work performance
across 13 rating points (biweekly for 26 weeks). This analysis revealed sig-
nificant effect for time (f2,12 = 3.77 P < .001) with all groups showing better
work performance over time and a significant group effect (f2,53 = 6.86 P <
.001) with participants rated as having in tact self-awareness having better
ratings of work performance than the groups with poor or limited self-aware-
ness beginning in the fifth week of work. A significant interaction was also
noted (f2,12= 1.57; P < .001) with the group showing limited self-awareness
making an initial gain in work performance which they could not sustain.
When analyses were repeated covarying for executive function using the
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Wisconsin Card Sorting Test, the main group effect was found to persist.
Discussion: Results suggest the deficits in awareness of one’s own thoughts
may be a barrier to effective vocational function over time in schizophrenia.
ID: 549846
EFFECTS OF COGNITIVE BEHAVIORAL THERAPY
ON WORK QUALITY AND QUANTITYFOR ADULTS
WITH SCHIZOPHRENIA
Paul Lysaker1,2, L. W. Davis1,2, G. Bryson3,4, M. D. Bell3,4
1Psychiatry, Roudebush VA Med Center, Indianapolis, IN, USA;
2Psychiatry, Indiana Univeristy School of Medicine, Indianapolis,
IN, USA; 3Psychiatry, VA Connecticut Healthcare, West Haven,
CT, USA; 4Psychiatry, Yale University School of Medicine, West
Haven, CT, USA
The Indianapolis Vocational Intervention Program (IVIP) is a manualized
program of cognitive-behavioral group and individual interventions which
was designed to help persons with schizophrenia to persist and perform bet-
ter at job placements. To date, two studies have supported its feasibility and
revealed high levels of participant satisfaction. However, the effects of IVIP
on work quality and quantity have yet to be tested in a randomized con-
trolled trial. In this study, 100 participants with schizophrenia or schizoaf-
fective disorder were offered a six month job placement and randomized to
receive IVIP (n = 50) or support services (n = 50) matched for treatment
intensity. Assessments revealed groups were equivalent at baseline in terms
of symptom severity and readiness for rehabilitation. Once participants
were working number of hours worked was recorded weekly and job per-
formance was assessed biweekly using the Work Behavior Inventory (WBI)
with raters blind to condition. To examine whether IVIP led to greater lev-
els of work quantity T-tests were performed which revealed that partici-
pants in the IVIP group worked significantly more hours and weeks
than participants in the support condition. To determine whether IVIP
led to greater work quality, repeated measures ANOVA were conducted
comparing biweekly ratings of work performance using the WBI for 56 par-
ticipants who worked for at least two-thirds of the intervention. This anal-
ysis revealed that participants in the IVIP group had generally better work
performance than those in the support condition. Results suggest that re-
ceiving a cognitive-behavioral interventions concurrent with work place-
ment services may improve rehabilitation outcomes in people with
schizophrenia.
ID: 549684
EFFECTS OF THE DURATION OF UNTREATED
PSYCHOSIS ON TREATMENT OUTCOME IN
CHRONICALLY INSTITUTIONALIZED PATIENTS
WITH SCHIZOPHRENIA
Branislav Mancevski1,2, J. G. Keilp1,2, A. S. Brown1,3,
A. J. Dwork2,4
1Psychiatry, College of Physicians and Surgeons of Columbia
University, New York, NY, USA; 2Molecular Imaging and
Neuropathology, New York State Psychiatric Institute, New York,
NY, USA; 3Epidemiology, New York State Psychiatric Institute,
New York, NY, USA; 4Pathology and Cell Biology, Psychiatry,
College of Physicians and Surgeons of Columbia University,
New York, NY, USA
Objective: Duration of untreated psychosis (DUP) is widely cited as a factor
in predicting treatment response in schizophrenia. Studies have found that
longer DUP is associated with more severe negative symptoms and cogni-
tive deficits, and less improvement in positive symptoms during the first 6
months of treatment. Most studies have concentrated on relatively short
DUP and short-term social or vocational outcomes, and they have been
confounded by clinical and socioeconomic factors that interfered with
the onset of the treatment. Our previous study of 101 autopsy subjects
with schizophrenia, chronically hospitalized in psychiatric institutions in
New York State, found that the introduction of antipsychotic medications
in these institutions in 1954 did not reduce the number of positive symptoms
over the years. This failure may have been related to prolonged duration of
illness before antipsychotic treatment. By studying the extensive records of
subjects who were admitted to the state hospitals prior to the widespread
introduction of chlorpromazine in 1954, we have obtained a sample in
which DUP was determined only by the date of onset of psychosis and in-
stitutional initiation of neuroleptic treatment. Method: We have evaluated
positive, negative and cognitive symptoms in 95 schizophrenia subjects: 44
with long DUP, admitted between 1941 and 1943, and 51 with short DUP,
admitted between 1951 and 1953. Diagnoses were determined and positive
and negative symptoms catalogued with the modified Diagnostic Evalua-
tion After Death. Cognitive function was evaluated with the Scales of Cog-
nitive Impairment Rated From Institutional Records. Results: Many of the
short DUP patients experienced a gradual improvement in overall function-
ing. Seventy-one percent were discharged, after a mean duration of treat-
ment of 14 years, to outpatient facilities or to their own custody with a year
of follow-up by a state social worker. According to the registry, they were
not readmitted to the state system. In contrast, 77% of the long DUP
patients never achieved a state of relative independence longer than 6
months and remained hospitalized (P < .00001). Discharges of patients
with long DUP were mostly to nursing homes after a mean treatment du-
ration of 19 years. Conclusions: Earlier treatment with phenothiazines was
associated with better long-term outcome and a very gradual improvement in
symptoms. Acknowedgements: NARSAD Wodecroft Award, MH60877,
Lieber Ctr. for Schizophrenia Res.
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MEASURING FUNCTIONAL OUTCOMES IN
SCHIZOPHRENIA: RESULTS OF AN EXPERT
SURVEY AND RAND PANEL
Feea Leifker1, T. L. Patterson2, R. K. Heaton2, P. D. Harvey1
1Psychiatry and Behavioral Sciences, Emory University, Atlanta,
GA, USA; 2Psychiatry, University of California, San Diego, San
Diego, CA, USA
Recent research on functional outcomes in schizophrenia has highlighted
problems with many of the existing measures. Researchers often use different
outcome measures which evaluate different types of outcomes (social vs.
living skills). Further, there is a often a substantial discrepancy between
the level of functioning reported by a patient when compared to an infor-
mant. It has not been determined whether the discrepancies in ratings orig-
inate from inadequate measures, is the result of differing opinions of the
patient and caregivers, or a combination of these problems. In Fall
2007, 49 experts in the field of schizophrenia and severe mental illness
were asked to nominate what they felt were the best scales measuring
real world outcomes in schizophrenia. Fifty-nine measures were nominated.
The investigators examined the results of the poll and selected 11 scales that
a) were the most highly nominated, b) had the most published validity data,
and c) best represented the domains of interest. Information regarding the
reliability, usefulness, sensitivity to treatment, practicality, and conver-
gence with measures of symptomatology and cognition for the 11 scales
was provided to the 9 experts who served as RAND Panelists. Of the 11
measures selected, panelists were asked to rate each measure in each
area on a 5-point Likert scale. Ratings that were discrepant (determined
by a SD > 2) were discussed by the panelists until each panelist could
agree on a score 61. The two scales that scored the highest in each of
the three domains (Hybrid, Social Functioning, and Everyday Living Skills)
were selected for use in Study 1 of the Validation of Everyday Functioning
in Schizophrenia (VALERO) study. The scales selected were: Quality of
Life Scale (QLS), Specific Levels of Functioning scale(SLOF); Social
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Behavior Schedule, Social Functioning Scale, Independent Living Skills
Schedule (ILSS) and the Life Skills Profile (LSP). The results of the first
phase of the VALERO initiative show that although there are significant
discrepancies in scales used for the assessment of functional outcome, a con-
vergence in opinions is possible. All scales nominated are currently being
evaluated for their usefulness and applicability in measuring functional out-
comes as reported by the patient and informant, as well as performance
based measures of cognition and social and everyday living skills.
NIMH Grant MH 78775.
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OPERATIONALIZING COGNITIVE IMPAIRMENT
ASSOCIATED WITH SCHIZOPHRENIA: MATRICS
CONSENSUS COGNITIVE BATTERY AND
ALTERNATIVES
Michelle Stewart1, M. Stolar1, S. Olderbak2, R. Goldman3,
E. Watsky1
1Pfizer, Inc., New London, CT, USA; 2Psychology Department,
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The NIMH-funded academic-FDA-industry partnership known as
MATRICS delineated seven cognitive domains to assess cognitive impair-
ment associated with schizophrenia (CIAS) and created a consensus test
battery (MCCB), which represents one operationalization of the concept
of CIAS. Fully computerized batteries now commercially available offer
alternative ways to operationalize CIAS. Whether these alternatives assess
the same constructs as MCCB remains to be fully explored. As part of
a noninterventional, cross-sectional study all subjects were tested on the
MCCB (N = 202) while half were randomized to do one of two fully com-
puterized tests, CNS Vital Signs (N = 103) or Cogstate (N = 99). Subjects
were stable, outpatient schizophrenia patients aged 18–65 years under treat-
ment with FDA-approved antipsychotics. Clinical (PANSS, CGI) and
functioning (UPSA-2, SCoRS) measures were administered. Two global
clinician-rated functioning items were also included.The correlational
structure of the computerized batteries and MCCB were examined using
linear regression and factor analytic methods. The influence of symptom
measures on functional endpoints was explored. Correlations between com-
posites for the two fully computerized batteries and the MCCB were fairly
high (r = .75); at the domain level they were in the moderate range (.30–.50).
Fit for a one-factor model was good for MCCB, marginal for CNS Vital
Signs, and poor for Cogstate. Across all three, the domains of working
memory and attention domains were among the highest loadings. The com-
parability of these different operationalizations of CIAS is analyzed in
terms of domain structure and associations with the clinical severity and
functioning measures. Source of Funding: Pfizer, Inc.
ID: 549631
ECOLOGICAL VALIDITY OF COGNITION AND
FUNCTIONING IN SCHIZOPHRENIA: A RELIABLE
METHOD TO ASSESS NATURALISTIC BEHAVIORS
IN EVERYDAY CONTEXTS
Elizabeth Bromley1, J. Brekke2
1Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA,
USA; 2School of Social Work, University of Southern California,
Los Angeles, CA, USA
Objective: Evaluating the ecological validity of the constructs of cognition
and functioning has emerged as an important area in schizophrenia re-
search. Two types of ecological validity, verisimilitude and veridicality,
are relevant. Our focus is on veridicality, which concerns whether cognitive
or functional measures are empirically related to what individuals do when
they are directly observed in their daily lives in naturalistic community set-
tings. The purpose of this study was to develop a reliable and valid method
to rate daily cognitive and functional tasks as they occur in the course of
daily life. Method: Ten subjects with SCID-diagnosed schizophrenia were
videotaped in situ during their usual daily activities over two weeks, yield-
ing approximately 160 hours of video data. Subjects were selected whose
composite score on the MATRICS Consensus Cognitive Battery fell in
the top (n = 5) or bottom (n = 5) third from the mean. A consensus-based
strategy was used to demarcate cognitive and functional behaviors as they
occurred in everyday settings. Three raters blind to subjects’ MATRICS
scores rated cognitive and functional behaviors for complexity, accuracy,
independence, and novelty. A coding strategy was also used to quantify
subjects’ level and range of activity over a unit of time. The coding scheme
was elaborated and refined until adequate inter-rater reliability was
reached. The coding scheme is currently undergoing further validation
in an additional sample of 10 subjects. Results: Everyday behaviors per-
formed by subjects varied substantially, although all subjects performed
a core set of cognitive and functional tasks that were thoroughly captured
on video- and audiotape. We reached adequate levels of inter-rater reliabil-
ity for these daily cognitive and functional tasks. Reliability was reached on
scores of independence, accuracy, complexity (but not novelty), as well as
on the level and range of activity. Preliminary evidence on the validity of the
ratings will also be presented. Conclusions: This pilot study of 10 subjects
with schizophrenia yielded a reliable strategy for rating everyday cognitive
and functional behaviors in naturalistic, community settings. The method
signifies a substantial advance, since it will now be used to assess the ve-
ridicality (ecological validity) of neurocognitive and functional instru-
ments. In addition, the method can be used to clarify moderators and
mediators of everyday disability in schizophrenia.
ID: 549572
MEDIATORS AND MODERATORS BETWEEN
NEUROCOGNITION AND FUNCTIONAL STATUS
IN SCHIZOPHRENIA
Yuri Rassovsky1, J. Lee1,2, M. Sergi1,3, P. Nori1,2, S. Crosby1,2,
M. F. Green1,2
1Psychiatry and Biobehavioral Sciences, UCLA Semel Institute, Los
Angeles, CA, USA; 2VA Greater Los Angeles Healthcare System,
Los Angeles, CA, USA; 3Psychology, California State University,
Northridge, CA, USA
Neurocognitive deficits in schizophrenia have been reliably demonstrated
across studies and consistently reported to affect patients’ functional status.
However, despite the important link between neurocognition and adaptive
functioning, the nature of this relationship is complex and multidimen-
sional. In an effort to better understand this relationship, the present study
utilized the structural equation modeling (SEM) approach to examine po-
tential mediators and moderators hypothesized to influence the connection
between neurocognition and functional outcome. An important advantage
of this approach is that it can be used to simultaneously examine the rela-
tionships among measured variables and their respective latent constructs,
as well as the direct and indirect interconnections among these constructs.
Using data from 180 schizophrenia outpatients, we have tested several
models, examining the direct and indirect relative contributions of visual
information processing, social cognition, anhedonia, and premorbid func-
tioning to functional status in schizophrenia. First, we have replicated, in
a substantially larger sample, our recently reported findings that a direct
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and significant association between visual information processing and func-
tional status was fully mediated by a measure of social perception. Second,
we have found that an inclusion of a measure of anhedonia significantly
improved model fit. This measure explained a significant amount of vari-
ance in functional outcome, especially in the social component of the con-
struct of functional status. Third, we have found that adding a measure of
patients’ premorbid functioning has also significantly improved model fit.
Interestingly, premorbid functioning did not directly affect functional sta-
tus, but rather accounted for unique variance in visual processes and social
perception. These findings thus offer a more comprehensive insight into the
complex nature of the various processes that are influencing adaptive func-
tioning in schizophrenia.
ID: 549480
THE EPIDEMIOLOGY OF SUICIDE ATTEMPTS
AMONG PERSONS WITH A PSYCHOTIC DISORDER
IN THE GENERAL POPULATION
Jaana Suvisaari1,2, J. Suokas1,3, J. Pera¨la¨1,
S. I. Saarni1,3, A. Ostamo1, J. Lo¨nnqvist1,3, H. Heila¨1,4
1Department of Mental Health and Alcohol Research, National
Public Health Institute, Helsinki, Finland; 2Department of Social
Psychiatry, Tampere School of Public Health, University of
Tampere, Tampere, Finland; 3Department of Psychiatry, University
of Helsinki, Helsinki, Finland; 4Department of Pension and Income
Security, The Social Insurance Institution of Finland, Helsinki,
Finland
Objective: We investigated the epidemiology of suicide attempts in a general
population -based sample of middle-aged people with a psychotic disorder
(Pera¨la¨ et al. 2007). Method: The study was based on a nationally repre-
sentative survey of 8028 persons aged 30 years or over from Finland. Psy-
chotic disorders were diagnosed according to DSM-IV-TR criteria using
the SCID-I interview and/or case note data. Lifetime severity of symptoms
and course and outcome of the disorder were assessed using the Major
Symptoms of Schizophrenia Scale and the GAF and SOFAS scales. Based
on information from the interview and case notes, we assessed lifetime his-
tory of suicide attempts. We examined the prevalence of suicide attempt in
different psychotic disorders and clinical differences in persons with psy-
chotic disorder with vs. without a history of suicide attempts. Results:
Of persons with a lifetime history of any psychotic disorder, 30.7% had a his-
tory of at least one suicide attempt. The lifetime prevalences of suicide
attempts in the largest diagnostic groups were as follows: schizophrenia:
33.3%; schizoaffective disorder: 37.5%; delusional disorder: 0%; major de-
pressive disorder: 41.4%; bipolar I disorder 30.5%; and substance-induced
psychotic disorder: 46.3%. The difference in prevalence between persons
with delusional disorder vs. other psychotic disorders was statistically signif-
icant (P = .0059). Persons with psychotic disorder with a lifetime history of
suicide attempt had more severe depressive symptoms (P< .0001) and symp-
toms of avolition (P = .043), but did not differ from those without suicide
attempts in any other symptom measures. The groups did not differ in overall
course and outcome, but the lifetime duration of hospitalizations was longer
in persons with a history of suicide attempts. Conclusions: Suicide attempts
are common in all psychotic disorders except for delusional disorder. Sui-
cide attempts are associated with depressive and negative symptoms but not
with positive or disorganized symptoms. History of suicide attempts is as-
sociated with longer hospitalizations but not with outcome.
Reference
1. Pera¨la¨ J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic
and bipolar I disorders in a general population. Arch Gen Psychiatry.
2007;64:19–28.
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THE MULTIDIMENSIONAL SCALE OF INDEPEN-
DENT FUNCTIONING (MSIF): ASSESSING THE
DISCRIMINATION BETWEEN SCHIZOPHRENIA
PATIENTS AND HEALTHY CONTROLS
Ashley A. Miles, R. W. Heinrichs, N. Ammari
Psychology, York University, Toronto, ON, Canada
The Multidimensional Scale of Independent Functioning (MSIF; Jaeger,
et al., 2003) is a measure of real-life performance among patients with
schizophrenia. It was designed to improve on the shortcomings of existing
scales, such as the Social Adjustment Scale II (SAS II; Schooler et al.
1979), by including multiple dimensions and a global indicator of func-
tional outcome, and relying on both self-report and informant informa-
tion. Moreover, by including separate measures of key domains
sensitive to the schizophrenia illness, it allowed for the detection of mean-
ingful changes in functional status. One shortcoming, however, is that the
authors’ validation study included only patients with schizophrenia, and
so it remains unclear if non-psychiatric adults will perform in the desired
range and whether the measure discriminates meaningfully between pa-
tient and healthy participants. Accordingly, this study had several aims;
1) assess the functional status profile of healthy adult participants, 2) as-
sess the discriminability of the MSIF between psychiatric and healthy
adult populations, 3) assess the stability of the MSIF. Demographic, clin-
ical, and MSIF data were obtained from 156 patients with schizophrenia
or schizoaffective disorder, and 128 were retained for follow-up assess-
ment approximately 10-months later. Demographic and MSIF data
were obtained for 74 healthy adult participants. On the global indicator
of functional independence, healthy adult participants scored in the nor-
mal range (M = 1.78, SD =1.18), whereas the schizophrenia patients scored
in the moderately-to-significantly disabled range (Baseline: M = 4.42, SD =
1.09; Follow-up: M = 4.37, SD = 1.03). Independent samples t-tests
revealed significant differences between the two groups on all domains
of the MSIF, with effect sizes (Cohen’s d) ranging from 0.21–2.58.
Paired-samples t-tests revealed no differences between the two assessment
points. The MSIF demonstrates exceptional discriminative validity;
healthy adults score in the highly independent range, whereas schizophre-
nia patients score in the impaired, dependent range. Moreover, the effect
size differences are extremely large relative to those typically seen in this
field. Researchers should strongly consider including the MSIF in future
research studies aimed at evaluating the functional status of patients with
schizophrenia.
ID: 549263
SUBJECTIVE QUALITY OF LIFE OF NIGERIAN
PATIENTS WITH SCHIZOPHRENIA
Abiodun O. Adewuya1, R. O. Makanjuola2
1Department of Psychiatry, Lagos State University College of
Medicine, Ikeja, Nigeria; 2Department of Mental Health, Obafemi
Awolowo University, IIle-Ife, Nigeria
Objectives: to examine the perceptions of patients with schizophrenia on
their overall QOL and determine the clinical and socio-demographic cor-
relates of the patients’ ratings on the indices of subjective quality of life.
Methods: A total of 99 adult patients (males = 58, females = 41) with schizo-
phrenia completed questionnaires detailing their sociodemographic profiles
and living conditions. Clinical (illness-related and medication-related)
details were obtained by means of rating scales and assessment of their
case files. They also completed the World Health Organisation Quality
of Life Scale—Brief version (WHOQOL-BREF) as a subjective assessment
of their quality of life. Results: Patients had problems relating to physical
health, relationships, work, leisure and finance. Despite these problems,
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their level of satisfaction with items of subjective QOL was generally high,
with the highest satisfaction with self (82.8%) and overall QOL (78.8%).The
highest levels of dissatisfaction were with availability of money for everyday
needs (76.8%) and sex life (71.7%). There was low to moderate correlation
between the patients’ reported living situations and their satisfaction with
their life Poor overall subjective quality of life was significantly determined
by when last worked (OR 4.6, 95% CI 1.9–21.7), poor perceived family sup-
port (OR 6.4, 95% CI 2.0–19.9), multiple relapses or exacerbations of symp-
toms (OR 6.5, 95% CI 1.2–51.6) and negative attitude towards
antipsychotic medication (OR 3.1, 95% CI 1.3–11.5). Conclusion: This
study have showed that despite their deplorable living situations, Nigerian
patients with schizophrenia still have a high level of satisfaction with their
quality of life. Also the subjective QOL was adversely affected by both soci-
odemographic and clinical variables. Functioning in social roles and access
to resources and opportunities are the prerequisite for the possibility that
such well-being and happiness can also be present in the future. In order to
help these patients an appropriate balance between lowering of their expect-
ations and increasing their achievements should be sought. Programmes to
improve the QOL of Nigerian patients with schizophrenia should specifi-
cally focus attention on providing opportunities for equal employment, in-
vestment in drugs with less side effects and increasing the level of social
support from the family and friends.
ID: 549168
PREDICTORS AND CONSEQUENCES SUBSTANCE
USE IN PATIENTS WITH SCHIZOPHRENIA:
A DAILY LIFE STUDY USING ECOLOGICAL
MOMENTARY ASSESSMENT
Catherine Loh1, J. Swendsen3, E. Granholm1,2
1Psychiatry, UCSD, SanDiego, CA, USA; 2Psychology, VASDHS,
San Diego, CA, USA; 3National Scientific Research Center
(CNRS), University of Bordeaux, Bordeaux, France
Background: Investigations of both clinical and community samples have
repeatedly demonstrated high comorbidity between schizophrenia and sub-
stance use disorders, but the mechanisms underlying these association re-
main widely debated. Recent advances in computerized ambulatory
monitoring techniques provide the opportunity to assess the temporal dy-
namics of these variables in a manner which is inaccessible to standard re-
search protocols. Method: 130 adults with schizophrenia participated in an
investigation of daily life experiences and behaviors using Personal Digital
Assistants (PDAs). The PDAs were programmed to administer electronic
interviews four times per day for a one-week period, and to collect infor-
mation concerning the experience of psychotic symptoms, substance use,
and mood states. Results: The sample completed an average of 72% of
all programmed assessments, resulting in 2460 observations collected
across daily life contexts. Multilevel modeling of time-lagged data demon-
strated that psychotic symptoms predicted decreases later alcohol use (P <
.000) and cannabis use (P < .000), while cannabis use itself predicted the
onset of new psychotic symptoms (P = .014). Happy moods were also as-
sociated with increases, and sad moods with decreases, in the use of both
substances over subsequent hours. Only anxious moods were associated
with increases in later alcohol use (P < .000), but with similar decreases
in later cannabis use (P < .000). Mood states were generally not predicted
by earlier substance use, despite some increase in sad mood following can-
nabis use (P = .037). Conclusion: With the exception of the well-established
association of anxious moods and alcohol use, no evidence was found for
self-medication in this sample. Rather, substance use decreased when psy-
chotic symptoms or negative affect was experienced, indicating that the
management of alcohol or cannabis use in this population should empha-
size alternative theories when developing intervention or prevention
strategies.
ID: 549004
THE RELATIONSHIPS AMONG CHANGE IN
NEUROCOGNITION, INTRINSIC MOTIVATION,
AND FUNCTIONAL OUTCOME DURING
COMMUNITY-BASED PSYCHOSOCIAL
REHABILITATION
E. Nakagami, M. Hoe, J. S. Brekke
Social Work, University of Southern California, Los Angeles,
CA, USA
This study included 130 individuals diagnosed with schizophrenia who were
recruited upon admission to community-based psychosocial rehabilitation
and followed prospectively for 12 months. Measures of neurocognition
were taken at baseline and 12 months. Measures of intrinsic motivation,
functioning (social, work, independent living) and symptoms were taken
at baseline, 6, and 12 months. Latent growth modeling was used with con-
structs representing baseline neurocognition (NC), intrinsic motivation and
functional outcome, as well as constructs reflecting change in NC, change in
motivation, and change in functional outcome over time. Two models were
estimated (see Table). There was significant change in NC, motivation, and
functional outcome over time. Both latent models fit the data extremely
well while controlling for symptoms. There were notable findings across
both models. First, in both models motivation at baseline was strongly as-
sociated with functioning at baseline. Second, change in motivation was
strongly related to change in functional outcome. Third, in model 1 baseline
NC was strongly related to both baseline motivation and psychosocial func-
tioning, and to change in psychosocial functioning; however, baseline NC
was not related to change in motivation. In model 2, the findings were very
similar. Change in NC was strongly related to both baseline motivation and
to the rate of change in psychosocial functioning; however, NC change was
not related to change in motivation. These findings suggest that functioning
and motivation are strongly associated both cross-sectionally and dynam-
ically over time. They also suggest that while functioning and motivation
are very closely linked, change in functioning is driven by change in NC,
while change in motivation is related to more non-cognitive contextual fac-
tors such as behavior change. This reflects a theoretical perspective which
suggests that intrinsic motivation is related to an interplay between cogni-
tion, behavior and environmental context (Deci and Ryan 2002). These
results also suggest that interventions designed to facilitate rehabilitative
or NC change should distinctly target cognitive and motivational factors.
Interventions designed to enhance intrinsic motivation should consider
contextual factors that facilitate functional change. The findings also im-
prove our theoretical understanding of the dynamic relationships among
NC, motivation and functional outcome in schizophrenia.
ID: 548971
PREDICTORS OF CHANGE IN LIFE SKILLS
IN SCHIZOPHRENIA AFTER COGNITIVE
REMEDIATION
Matthew Kurtz1,2, B. E. Wexler3, J. C. Seltzer2, M. Fujimoto2,
D. S. Shagan2
1Psychology, Wesleyan University, Middletown, CT, USA;
2Schizophrenia Rehabilitation Program and Resource Center, The
Institute of Living, Hartford, CT, USA; 3Psychiatry, Yale School of
Medicine, New Haven, CT, USA
Few studies have investigated predictors of response to cognitive remedi-
ation interventions in patients with schizophrenia. Predictor studies to
date have selected treatment outcome measures that were either part of
the remediation intervention itself or closely linked to the intervention
with no studies investigating factors that predict generalization to meas-
ures of everyday life-skills as an index of treatment-related improvement.
In the current study we investigated the relationship between four
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measures of neurocognitive function, crystallized verbal ability, auditory
sustained attention and working memory, verbal learning and memory,
and problem-solving, two measures of symptoms, total positive and neg-
ative symptoms, and the process variable of treatment intensity to change
on a performance-based measure of everyday life-skills after a year of
computer-assisted cognitive remediation. Thirty-eight patients with
schizophrenia or schizoaffective disorder were studied. Results of a linear
regression model revealed that auditory attention and working memory
predicted a significant amount of the variance in change in perfor-
mance-based measures of everyday life skills after cognitive remediation,
even when variance for all other neurocognitive variables in the model was
accounted for. Stepwise regression revealed that auditory attention and
working memory predicted change in everyday life-skills across the trial
even when baseline life-skill scores, symptoms and treatment intensity var-
iables were controlled. These findings emphasize the importance of sus-
tained auditory attention and working memory for benefiting from
extended cognitive remediation and suggest the addition of supplementary
training in elementary attention and working memory skills prior to re-
mediation in those patients unlikely to show benefit.
ID: 548920
THE THREE-YEAR COURSE OF FUNCTIONAL
STATUS AND COGNITION IN OLDER PATIENTS
WITH SCHIZOPHRENIA
Gayla Paschall, P. D. Harvey
Department of Psychiatry and Behavioral Science, Emory
University School of Medicine, Atlanta, GA, USA
Background: Cognitive and functional disability is present over the lifespan
in schizophrenia, starting at the time of the first psychotic episode. There
has been some suggestion of functional decline in very poor outcome older
patients with schizophrenia while, better outcome patients did not show this
decline. Earlier longitudinal studies have focused on younger patients sug-
gesting there may be age-associated risks of cognitive decline. Therefore,
the current study is a longitudinal follow-up (36 months) with patients vary-
ing in their history of long term institutional stays. Method: Subjects were
older, ambulatory schizophrenia patients with a history of current active
illness (n = 98, mean age, 60.1 yrs). All were receiving atypical antipsychotic
treatment. The length of the longest consecutive hospital stay ranged from 1
to 330 months (mean = 25.7 months). Patients were divided into two groups
for the purposes of these analyses: 55 Longer Stay (LS) patients, 43 Shorter
Stay (SS) patients, with a 3-month stay as the dividing point. Subjects were
cognitively assessed with a comprehensive neuropsychological (NP) bat-
tery. Functional disability was assessed using the UCSD Performance-
based Skills Assessment (UPSA). Correlations with longest stay were
also calculated for changes in cognition and functional (everyday living)
status. Results: Patients with longer hospitalizations were more impaired
on all cognitive measures, and had more social and functional disabilities
(all P’s < .05; all effect sizes (d) > 0.5). There were no differences found in
age, age at first admission, education, or total number of admissions. In the
NP measures, there was a significant difference between performance after
time between LS and SS patients, with SS patients showing practice effects
and LS patients appearing to worsen, P < .05). On the UPSA, again SS
patients showed a practice effect and LS patients appeared to worsen
(P < .05). There was a significant correlation between UPSA changes and
NP changes, (r = .53,P< .001), with longer stays correlating with more decline.
Discussion: Patients with longer continuous hospitalizations showed evidence
of cognitive and functional changes over 3 years. Patients who never had a long
stay actually improved their performance. While the worsening seen is only
moderate in nature, it is consistent with the results of previous studies exam-
ining institutionalized patients. NIMH Grant #MH 63116.
ID: 548860
DOES MEDICATION EFFICACY PREDICT ADHER-
ENCE IN FIRST EPISODE PSYCHOSIS? A LONGI-
TUDINAL PROSPECTIVE STUDY
Katherine Steger1,2, C. Cassidy1, M. Rabinovitch1, R. Joober1,2,
A. Malla1,2
1PEPP-Montre´al, Douglas Hospital, Montre´al, QC, Canada;
2Psychiatry, McGill University, Montre´al, QC, Canada
Adherence to medication helps achieve and maintain remission in psychotic
illnesses, but efforts to understand and maximize adherence have had lim-
ited success. Cost-benefit models of decision-making suggest that clinical
efficacy should be an important determinant of medication taking, but
the relationship between changing clinical status and adherence has rarely
been examined. This study investigated the link between efficacy and ad-
herence by monitoring clinical status and adherence behaviour in 77 first
episode psychosis patients. Our design employed four time points: clinical
evaluations at months 1 and 6 (including BPRS, SAPS, SANS, GAF, Cal-
gary Depression and Hamilton Anxiety Scales) and adherence assessments
at months 3 and 9. This design allowed us to observe the impact of changing
symptoms on subsequent changes in behaviour. Subjects in our study sam-
ple had been treated for an average of 8.1 months (SD 6.8) and displayed
a range of patterns of adherence and clinical evolution. Examining the en-
tire sample (n = 77), we found no direct correlation between change in ad-
herence behaviour and change in any clinical index. Demographic factors
(age, gender, diagnosis, DUP) also failed to predict adherence in the com-
plete sample. However, analysis of two important subgroups revealed links
between clinical condition and adherence. First, subjects with the poorest
adherence (adherence in the lowest quartile at both time points or dropping
significantly; n = 24) showed an inverse correlation between change in
BPRS and medication-taking: subjects with greater clinical improvement
showed larger reductions in adherence (R =0.467;P< .05). These subjects
differed demographically from the full study population only in age, being
slightly younger (22.7 vs. 24.9 years, P < .02). A second, smaller subgroup
comprised those subjects who maintained very high levels of adherence de-
spite achieving less clinical improvement than the group mean (n = 6). We
found that all subjects in this subgroup had experienced more dramatic clin-
ical improvement before the initiation of our study, demonstrating that
maintenance of high adherence without substantial reduction in psychopa-
thology is extremely rare. Despite this suggestion that medication efficacy is
required to maintain very high levels of adherence, our overall conclusion is
that patients have a variety of behavioural responses—both positive and
negative—to the clinical improvement brought by medications.
ID: 548740
CLINICAL AND COGNITIVE CHARACTERISTICS
OF HIGHLY FAVORABLE AND UNFAVORABLE
FUNCTIONAL OUTCOMES IN SCHIZOPHRENIA
Walter Heinrichs1, N. Ammari1, S. McDermid Vaz2,
A. Miles1
1Psychology, York University, Toronto, ON, Canada; 2Psychiatry
and Behavioral Neurosciences, McMaster University/St.Joseph’s
Healthcare Hamilton, Hamilton, ON, Canada
Cognitive performance rather than symptom severity is regarded as the pri-
mary predictor of functional outcome in schizophrenia. However, contra-
dictory evidence exists and many studies fail to sample from the extremes of
outcome measures. This study tested whether the differential importance
assigned to symptoms and cognitive impairment is supportable in schizo-
phrenia patients with high and low levels of community independence.
Schizophrenia patients with highly unfavourable (n = 24) and highly
favourable (n = 28) functional outcomes as defined by community support
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requirements were drawn from a pool of patients (n = 156) attending a range
of rehabilitation and community treatment programs. Standard cognitive
and symptom measures were analyzed with independent groups compari-
sons and logistic regression methods. Positive, negative and general symp-
tom measures as well as cognitive tasks generated statistically significant
group differences and large effect sizes. Symptom severity and cognitive
data separately predicted community independence at greater than 80% ac-
curacy, with cognition adding new validity over and above the contribution
of symptoms. However,the conditional validity of symptoms was not sig-
nificant. Proportions of patients receiving second generation antipsychotic
medications were statististically similar in the 2 outcome groups, but rates
of anti-Parkinsonian medication were 4 times higher in the unfavorable
outcome group. Results suggest researchers may have underestimated
the role of psychopathology as a determinant of functional status in schizo-
phrenia. Psychotic and non-psychotic symptom severity should be consid-
ered along with cognitive performance as key features and potential
mediators of functional outcome in the illness.
ID: 548678
FUNCTIONAL CAPACITY ASSESSMENTS FOR
SCHIZOPHRENIA CLINICAL TRIALS
Richard Keefe1, K. Hurley2, M. Kraus1, D. Leech1, P. Harvey3,
T. Walker1, A. D. Loebel5, R. Krishnan1, R. Roscigno6,
R. Pietrobon4
1Duke University Medical Center, Durham, NC, USA; 2NeuroCog
Trials, Inc., Durham, NC, USA; 3Psychiatry, Emory University
Medical Center, Atlanta, GA, USA; 4Surgery-Orthopaedic Surgery,
Duke University Medical Center, Durham, NC, USA; 5Dainippon
Sumito Pharma America, Fort Lee, NJ, USA; 6Robert F. Roscigno
PhD Consulting, LLC, Chapel Hill, NC, USA
This presentation will describe the longitudinal stability and validity of two
widely used functional capacity instruments, the UCSD Performance-based
Skills Assessment (UPSA) and the Schizophrenia Cognition Rating Scale
(SCoRS), and a real-world measure of functioning, the Independent Living
Skills Inventory (ILSI). In one study, 60 patients with schizophrenia were
assessed at baseline and 23 assessed after 3 months of care at a rehabilitation
unit at John Umstead Hospital and Duke University. At baseline, the
UPSA was significantly correlated with cognitive performance as assessed
by the Brief Assessment of Cognition in Schizophrenia (BACS) composite
scores (r = .65, df = 55, P < .001), and real-world functional outcome as
assessed by the ILSI (r = .40, df = 56, P < .01). SCoRS global scores
were also correlated with BACS composite scores (r = .54, df = 55, P <
.001) and ILSI total scores (r = .48, df = 56, P < .001). Longitudinal
data analyses suggested that the UPSA had excellent stability (ICC =
0.81) and no practice effect (d = 0.06) over 3 months. The SCoRS rater
mean item scores had better stability (ICC = 0.77) than the SCoRS rater
global scores (ICC = 0.56), and the practice effect for both was small
(d = .08 and d = .25). In the second study, patients were assessed with the
SCoRS and the tests from the MATRICS battery before and after treatment
with lurasidone or ziprasidone. The cognitive measures showed minimal
effects, yet the SCoRS ratings demonstrated significant improvements in
patients treated with lurasidone. These data suggest that interview-based
and performance-based assessments both demonstrate construct validity. In-
terview-based assessments are prone to instability over time, even when
informants are included as sources of information, yet may be sensitive to
treatment effects. Performance-based functional assessments are more stable
over time and have the advantage that they do not require informant involve-
ment. We will also discuss in this session a virtual-reality measure of functional
capacity that could be used as a co-primary measure in clinical trials of cog-
nitive enhancement in schizophrenia. This Virtual Reality Functional Capac-
ity Assessment Tool (VRFCAT) uses a realistic environment simulating daily
activities. Outcome measures are based on error rates and times to completion
for each of the assessment activities. Pilot data on the reliability and feasibility
of this measure in schizophrenia patients will be presented.
ID: 548362
COMPARISON OF CORRELATIONS BETWEEN
FUNCTIONAL CAPACITY, CASE-MANAGER RAT-
INGS, AND REAL-WORLD OUTCOMES IN PEOPLE
WITH SCHIZOPHRENIA IN THE U.S. AND SWEDEN
Thomas L. Patterson1, P. D. Harvey2, L. Helldin3, C. R. Bowie4
1Psychiatry, University of California, San Diego, La Jolla, CA,
USA; 2Psychiatry, Emory University, Atlanta, GA, USA;
3Psychiatry, NU Healthcare, Trollha¨ttan, Sweden; 4Psychology,
Queens University, Kingston, ON, Canada
Functional disability is a central feature of schizophrenia and has been
reported to occur across different countries and systems of care. Recent
advances in the assessment of functional disability have separated the mea-
surement of functional capacity (ability to perform everyday functioning
skills) from that of real-world functional outcomes. In this study, samples
of schizophrenia patients living in generally rural areas in Sweden (n = 146)
and in urban areas in New York (n = 197) performed the brief version of the
UCSD Performance-based Skills Assessment (UPSA-B) and were rated by
their case managers with the Specific Levels of Functioning (SLOF). Infor-
mation from archival records and case managers was used to determine the
occurrence of different real-world outcomes, including living indepen-
dently, employment status, and having ever experienced a stable romantic
relationship. Correlations between these measures were then analyzed for
each sample. Performance on the UPSA-B was essentially identical in the
two samples (mean raw score in New York, 13.8; Sweden, 13.3). Scores on
the case manager ratings of real-world work performance were also strik-
ingly similar for both work (New York: 24; Sweden: 22) and everyday ac-
tivities (New York: 34; Sweden: 33). Further, the correlation between
UPSA-B scores and ratings of everyday activities were quite similar
(New York: r = .43; Sweden: r = .36), as were the correlations between
work outcomes and UPSA-B scores (New York: r = .30; Sweden: r =
.33). The proportion of cases who had never been married or had never
had a close relationship was 66% in New York and 61% in Sweden. In no-
table contrast, 76% of the Swedish patients and 25% of the New York
patients were living independently. Scores on performance-based measures
of functional capacity related to everyday living skills were very similar
across samples of people with schizophrenia living in very different environ-
ments. These results are consistent with previous studies showing that
measures of cognition in people with schizophrenia are also quite similar
across different countries. While measures of functional ability and case
manager estimates of patients’ real-world outcomes were very similar in
level of impairment and correlational structure, real-world residential out-
comes were very different. These data suggest that cultural and social sup-
port systems can lead to very divergent outcomes in individuals who have
evidence of the same levels of ability and potential.
ID: 546640
THE CANADIAN OBJECTIVE ASSESSMENT OF
LIFE SKILLS (COALS): A NEW MEASURE OF
FUNCTIONAL COMPETENCE IN SCHIZOPHRENIA
Stephanie McDermid Vaz1, R. W. Heinrichs2, A. A. Miles2,
N. Ammari2, A. Oman1
1Cleghorn Early Intervention in Psychosis Program, St. Joseph’s
Healthcare Hamilton and McMaster University, Hamilton, ON,
Canada; 2Department of Psychology, York University, Toronto,
ON, Canada
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The purpose of this study is to develop a new instrument for the assessment of
functional competence and life skills in people with schizophrenia. There is
little consensus on the best way to measure functional status, and there are
concerns about the accuracy, reliability and suitability of instruments cur-
rently in use. The Canadian Objective Assessment of Life Skills (COALS)
was undertaken to address limitations of existing measures while building
in features of our own analysis of functional competence. The following
methods were used to generate test items, content and structure for the mea-
sure: 1) focus groups and feedback sessions with clinicians and peer support
workers at clinical settings, 2) review and content analysis of existing instru-
ments including the University of California Performance Skills Assessment
(UPSA), the Test of Adaptive Behaviour in Schizophrenia, the Test of Gro-
cery Shopping Skills and the Medication Management Ability Assessment
and 3) patient feedback and clinical observations during administration of
153 UPSA protocols. We hypothesize two key components in relation to suc-
cessful independent living: (a) procedural knowledge routines (PKR), or
‘‘knowing how’’ to carry out an adaptive action or activity, and (b) executive
operations (EXO), which reflect ‘‘knowing what to do and when to do it’’.
PKR are highly specific to particular tasks and situations and require direc-
tion, cues, prompts and focused probes for assessment. In contrast, EXO in-
volve primarily self-cued and self-initiated behaviours and these are more
readily elicited by novel or ambiguous and therefore less constrained situa-
tions. These two components are evaluated in 5 domains relevant to indepen-
dent functioning in the community: Health and Hygiene, Time Management,
Trip Planning, Crisis Management and Domestic Activities. The COALS
incorporates the advantages of objective, performance based evaluation cri-
teria, along with the insights of cognitive science. Work is in progress to eval-
uate the value of this instrument in measuring treatment and program
effectiveness as well as individual patient needs, vulnerabilities and skill pro-
files. This research is supported by the Ontario Mental Health Foundation.
Reference
1. Heinrichs RW, Ammari N, Miles A McDermid Vaz S. Cognitive per-
formance and functional competence as predictors of community inde-
pendence in schizophrenia. Schizophrenia Bulletin, 2008. in press.
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ANXIETY AND VULNERABILITY TO PSYCHOTIC
EXACERBATIONS IN RESPONSE TO LIFE
STRESSORS
Nancy M. Docherty1, A. St-Hilaire2, J. M. Aakre1,
A. McCleery1
1Department of Psychology, Kent State University, Kent, OH,USA;
2Department of Psychiatry, Harvard Medical School, Boston,
MA, USA
Life events and social environment stressors have been associated with
a higher risk of relapse in schizophrenia patients. Some patients may be
especially vulnerable to psychotic symptom exacerbations in response to
life stressors. The present longitudinal study assessed recent life events
of outpatients with schizophrenia or schizoaffective disorder, and the level
of criticalness of each patient’s ‘‘most influential other’’ person toward the
patient. It tested three main hypotheses: (1) Patients with life stressors in the
form of either high-critical ‘‘most influential others’’ or recent stressful life
events would show increases in psychotic symptoms at the nine-month fol-
low-up session, compared with patients who did not experience either of
these stressors; (2) compared with patients low in anxiety, patients high
in anxiety at the baseline assessment would show increases in psychotic
symptoms at follow-up; and (3) patients with high levels of anxiety at base-
line who experienced either of the stressors would show the greatest exac-
erbation of psychotic symptoms at follow-up. All of these hypotheses were
supported. The results indicate that (a) most patients showed some im-
provement over time, (b) the occurrence of life stressors predicted relative
increases in severity of psychosis, and (c) level of anxiety at baseline pre-
dicted level of vulnerability of psychotic symptoms to stressors.
ID: 539009
CHARACTERIZING INSIGHT IN EARLY
PSYCHOSIS: A PILOT STUDY
Barbara Krishna Stuart1, R. L. Loewy1, M. Fisher1,2,
M. O’Banion2, D. Rose1, S. Vinogradov1,2
1Department of Psychiatry, University of California, San Francisco,
San Francisco, CA, USA; 2University of California, San Francisco
Veterans Affairs Medical Center, San Francisco, CA, USA
It is well known that impaired insight is common among patients with
chronic psychosis, but only in recent years have investigators begun to ex-
amine insight in young people with early psychosis. The objective of this
study was to examine the clinical and cognitive correlates of insight in
young people with recent-onset psychosis and how these differ from find-
ings in chronic phases of the illness. Insight, clinical symptoms, cognitive
performance, and social functioning were assessed in a preliminary sample
of 14 young adults (mean age of 22.2, SD = 4.4) with recent-onset schizo-
phrenia or schizoaffective disorder (first psychotic episode within the prior
3 years). A reference sample of 69 clinically stable outpatients with chronic
schizophrenia or schizoaffective disorder was also assessed (mean age of
43.1, SD = 9.8). There were no differences on clinician ratings of insight
between the recent-onset and chronically ill patients, with mean ratings
of mildly impaired insight in both groups. In the recent-onset sample,
poor insight was associated with lower scores on tests of working memory
(P = .03) and attention (P = .04) and with lower Full Scale IQ (P = .04).
There were no associations between insight and cognitive measures in
chronically ill patients. Poor insight in recent-onset patients was associated
with greater negative symptomatology (P = .01), but not with overall social
functioning or depression. In contrast, poor insight was associated with de-
pression (P = .003) and poor social functioning (P < .001) in chronically ill
patients. The preliminary results from this cross-sectional study suggest
a complex relationship between insight, negative symptoms, cognitive
problems, and depression that may change over the course of a psychotic
illness. Future research requires a prospective longitudinal design.
ID: 550834
RELIABILITY AND VALIDITY OF A BEHAVIORAL
MEASURE OF SOCIAL COGNITION IN AN INTER-
PERSONAL SETTING
Janelle Caponigro1,3, L. M. Valenti2, A. R. Molz2, J. Luther2,
D. M. Paldino2, G. L. Haas1,2
1University of Pittsburgh Medical Center, Western Psychiatric
Institute and Clinic, Pittsburgh, PA, USA; 2VA Pittsburgh
Healthcare System, Mental Illness Research, Education, and
Clinical Center, Pittsburgh, PA, USA; 3Clinical Psychology,
University of California, Berkeley, Berkeley, CA, USA
Social functioning impairments are a hallmark of schizophrenia. It is be-
lieved that studies of social cognition (ie, the application of cognitive skills
to social situations) will lead to better understanding of these impairments.
However, current laboratory measures neglect to include a fundamental
element of the interpersonal context: perspective-taking within an interac-
tive social setting. The Interpersonal Block Assembly Task (IBAT) is
a novel laboratory assessment of social cognition that addresses this deficit
in established measures. Using verbal communication, the participant must
explain to a researcher how to orient blocks in order to successfully
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construct a design. This study aims to establish reliability of the IBAT and
demonstrate its validity as a measure of social cognition. Also of interest is
whether performance on the IBAT is associated with diagnostic group (ie,
schizophrenia versus healthy individuals). A battery of established mea-
sures of social cognition (eg, Theory of Mind (ToM)) and the IBAT
were administered to all participants. The IBAT showed excellent internal
consistency with a Cronbach alpha coefficient of .96. Intraclass correlation
coefficients (ICC) were calculated and demonstrated good inter-rater reli-
ability (ICC = .84). The IBAT demonstrated construct validity through an
association with other established measures of social cognition. Perfor-
mance on the IBAT was found to be positively correlated with first order
ToM (r = .21, P < .05) and second order ToM (r = .47, P < .001). Con-
vergent validity was tested by examining the association between the
IBAT and measures of social functioning and psychiatric diagnosis.
IBAT performance was found to be correlated with educational achieve-
ment (r = .28, P < .01), occupational achievement (r = .41, P < .001),
and financial difficulty (r = .33, P < .05). Diagnosis of schizophrenia
was associated with poor performance on the IBAT (r = 0.29, P <
.01). Non-social cognitive measures were administered to determine dis-
criminant validity; the detectability parameter of the Continuous Perfor-
mance Test was not correlated with the IBAT (r = .04, P = .68). These
findings support the IBAT as a novel, reliable, and valid measure of ex-
pressive social cognition that improves upon the limitations of existing
measures. Findings indicate that the IBAT is a useful tool to distinguish
social cognitive abilities between people with schizophrenia and healthy
individuals.
ID: 551909
IS A DEFICIT OF MENTALIZATION A MISSING
LINK BETWEEN ALEXITHYMIA AND SCHIZO-
PHRENIA?
Rosalie Ouellet1,2, M. Roy1,2, C. Be´gin2
1Centre de recherche universite´ Laval Robert-Giffard, Beauport,
QC, Canada; 2Universite´ Laval, Que´bec, QC, Canada
Difficulties of emotion regulation are known to be very common and so-
cially incapacitating among people suffering from schizophrenia (SZ) and
schizophrenia spectrum psychotic disorders (SZSPD). Alexithymia, which
refers to a deficit of the mentalization of emotions that leads to an impor-
tant difficulty to identify and express one’s feelings, has been found in about
30% of SZ and SZSPD patients. Despite this high prevalence, very few stud-
ies have explored the characteristics of alexithymia in people with SZ, and
most of them that did have provided inconsistent results, particularly on its
relationships with the negative and positive symptoms. The current study
aimed at examining the relationships between alexithymia and other con-
cepts associated to mentalization, such as social cognition and insight,
among 30 patients suffering from SZ or SZSPD and 30 healthy controls.
The relationships between alexithymia and the symptoms of SZ, as well as
the social functioning, have also been explored. Preliminary results showed
a weak negative association between alexithymia and the performance on
social cognition tasks, especially among patients with SZ and SZSPD. Alex-
ithymia was independent from insight, social functioning, and psychotic
symptoms. Significant moderate positive correlations were found between
alexithymia and symptoms associated to general psychopathology among
patient with SZ and SZSPD. The preliminary results showed that the ability
to mentalize emotions may be required to understand accurately the social
interactions and contexts of day to day life. Alexithymia appeared to be
independent from psychotic symptoms while it was associated with depres-
sion and anxiety, the latter association being in line with what is generally
found among other Axis I disorders. The findings support the construct
validity of alexithymia among people suffering from SZ and SZSPD and
encourage further exploration of its characteristics among this population.
ID: 551906
IMPACT OF SCHIZOPHRENIA CANDIDATE GENES
ON SCHIZOTYPY AND COGNITIVE ENDOPHENO-
TYPES AT THE POPULATION LEVEL
Nicholas C. Stefanis
Psychiatry, University Mental Health Research Institute, Athens
Greece and National and Kapodistrian University of Athens, Athens,
Greece
Background: Aspects of cognitive function and schizotypy have been pro-
posed as potential endophenotypes for schizophrenia. It is unknown
whether the expression of these endophenotypes at the population level
is modulated by the genetic variability of candidate susceptibility genes
for schizophrenia. Methods: We examined the potential impact of 23 a pri-
ori selected single nucleotide polymorphisms (SNPs) within the DTNBP1,
NRG1, DAOA/G32, DAAO, COMT and RGS4 genes, on cognition and
self-rated schizotypy, in a representative population of 2243 young male
military conscripts. Single SNP and haplotype associations were evaluated.
Results: a) The DTNBP1 SNPs rs2619522 and rs760761 exhibited several
single marker associations, the minor alleles being associated with lower
attention capacity but also a decrease in positive and paranoid schizotypy
scores. The DTNBP1 haplotype load had borderline associations with non-
verbal IQ, paranoid schizotypy, and sustained attention. b) For individual
NRG1 polymorphisms, isolated but weak signals of association were noted
with sustained attention and working memory but not schizotypy. The risk
allele of functional SNP8NRG243177 was associated with reduced spatial
working memory capacity. However, individual NRG1 risk alleles and hap-
lotypes were associated with stress induced hostility and psychotic symp-
toms at military induction, indicating a potential susceptibility role of
NRG1 under a gene X environment (stress) interaction model. c) An iso-
lated effect of DAAO, RGS4 and COMT variability was noted on negative
schizotypy but not cognition. No convincing association of DAOA/G32
variability was detected. Conclusions: Several candidate susceptibility
genes for psychosis might exert specific modulating effects on subclinical
psychosis and cognitive ability at the population level.
ID: 551901
THE DEVELOPMENT OF THE MENTAL-STATE
REASONING TRAINING (MSR) PROGRAM
Pamela Jane Marsh1, R. Langdon1, J. McGuire1, A. Harris2,
M. Coltheart1
1Macquarie Centre for Cognitive Science, Macquarie University,
Sydney, NSW, Australia; 2Discipline of Psychological Medicine,
University of Sydney, Sydney, NSW, Australia
Social cognition, the cognitive operation that underlies social interactions
and the understanding of the intention of others, is profoundly impaired in
schizophrenia. Thus, improving social disability in schizophrenia is now
a high priority in schizophrenia research. This study describes a group-
based program designed to improve general understanding of other peo-
ple’s thoughts and feelings (mental state reasoning training; MSR). This
is a manual-based program developed around videos, computer games,
and group games and is delivered in ten sessions over five weeks, twice-
weekly. The MSR program is based on errorless learning techniques
and uses probes to target mental-state reasoning aspects of program activ-
ities. Our aim is to examine whether the MSR program produces improve-
ments in social cognitive abilities and social functioning in individuals with
schizophrenia. Participants undergo baseline testing to assess their social
cognitive abilities (emotion recognition, ‘Theory of Mind’, and attribu-
tional style) before entering into the five week training program. Partici-
pants are then retested following completion of the program to assess
potential improvements in social cognitive abilities. To assess the impact
of training on real-world social functioning, participants complete the
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Empathy Quotient at baseline and immediate post-training to examine
whether they self-report any subjective changes in their abilities to relate
with other people. Clinicians with the best knowledge of participants
also complete the Role Functioning Scale at baseline and then again
one month after training to assess objective changes in social functioning.
Initial pilot testing has involved nine individuals with schizophrenia or
schizoaffective disorder. Qualitatively the pilot participants have shown
an increased use of social cognitive language when describing their own
and others’ social experiences. Further empirical findings will be reported.
In conclusion, although the research is in the early stages, the MSR pro-
gram shows good potential for use in clinical practice. The program is
designed to be implemented by any clinical staff (it does not require clinical
psychologists or neuropsychologists) and it provides an enjoyable and non-
threatening environment for participants.
ID: 551880
SOCIAL AND ROLE FUNCTIONING: CRITICAL
OUTCOME DOMAINS INDEPENDENT OF
PSYCHOSIS
Barbara Cornblatt1, T. Lencz1, J. Addington2, K. Cadenhead3,
E. Walker4, L. Baskir1, L. Seidman5, T. Cannon6, D. Perkins7,
S. Woods8, M. Tsuang3, T. McGlashan8, R. Heinssen9
1Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks,
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Diego, CA, USA; 4Psychology, Emory University, Atlanta, GA,
USA; 5Psychiatry, Harvard University, Boston, MA, USA;
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8Psychiatry, Yale University, New Haven, CT, USA; 9NIMH,
Washington, DC, USA
Profound deficits in social and role functioning characterize schizophrenia
and result in the severe disability associated with the illness. Nevertheless,
prevention research in schizophrenia traditionally has not as yet focused on
the underlying biology and characteristics of impaired functioning and few
studies have been concerned with interventions developed specifically to
improve functional outcome. In this report, we analyze pooled data con-
tributed by the 8 sites included in the North American Prodromal Longi-
tudinal Study (NAPLS) consortium. All subjects included met NAPLS
attenuated positive symptom criteria (APS) and had one or more clinical
follow-ups over a two-year period (n = 291). The sample was further divided
into a nested case-control design (total n = 100). Cases are subjects convert-
ing to psychosis over follow-up; controls are matched for APS symptoms at
baseline, age, gender, site and length of follow-up. There were a total of 50
case-control pairs. Of these, 26 pairs had short term follow-up (6 months);
24 longer term follow-up (up to two years). For both short and long out-
come groups, social functioning was found to be significantly impaired
from the outset in converters relative to clinically stable matched controls
and to be stable over time (p ranges from .01 to <.0001). No impact on
functioning resulted from baseline depression, emergence of psychosis,
or treatment with either anti-depressants or anti-psychotics. Role function-
ing followed a very similar course, with the exception that some improve-
ment was shown in the short-term (P = .006 for non-converters). Subjects
converting to psychosis were also significantly impaired in role (school for
adolescents) at baseline and throughout follow-up relative to matched
CHR controls (P = .0004). Level of role functioning remained stable
throughout follow-up and was not impacted by depression, emergence
of psychosis or medication. The current NAPLS findings are supportive
of the hypothesis that the two critical functional domains—role and
social—are long standing traits associated with a vulnerability to schizo-
phrenia and resistant to conventional treatment. Of particular interest,
the finding that entrenched functional level does not further worsen
with the emergence of positive symptoms supports the notion that these
are independent domains, most likely related to different etiologies and de-
velopmental pathways and possibly associated with different parts of the
brain.
ID: 551864
CORRELATES OF THERAPEUTIC ALLIANCE
ACROSS SIX MONTHS OF THERAPY IN
SCHIZOPHRENIA
Louanne W. Davis1,2, P. H. Lysaker1,2
1Roudebush VA Medical Center, Indianapolis, IN, USA;
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Indianapolis, IN, USA
While therapeutic alliance in schizophrenia has been linked with treatment
adherence and outcome, less in known about its clinical correlates. This
study explores neurocognition as a possible predictor of therapeutic alli-
ance in schizophrenia. Participants were 84 persons with diagnoses of
schizophrenia spectrum disorder who participated in a 26-week study of
the effects of cognitive behavior therapy on work outcome. Three measures
of neurocognition were administered at baseline: Hopkins Verbal Learning
Test (HVLT:verbal memory), Continuous Performance Test-II (CPT-II:vi-
gilance) and Wisconsin Card Sorting Test(WCST: executive function). The
Marlowe Crowne Social Desirability Scale (MCSD)was also administered
to detect any bias effects of culturally approved responding. Participants
were randomized to either a CBT intervention designed to enhance
work function or a supportive therapy control condition, both of which
involved attending weekly individual and group therapy sessions. All par-
ticipants were paid for up to 20 hours per week of concurrent work activity.
Participants completed the Working Alliance Inventory, Short Form, Cli-
ent version (WAI-S-C) following one randomly selected individual therapy
session every 4 weeks of the study. Baseline assessments were correlated
with all seven time points of the WAI-S-C therapeutic alliance ratings. Pear-
son Product Moment correlations revealed that there was no significant
relationship between therapeutic alliance and the total score on the
MCSD. Therapeutic alliance ratings were significantly correlated with
CPT-II t-scores measuring omission errors (month 3; r = 284, P = .05)
and a pattern of erratic responding (months 2,3,5, and 7: r =  .403,
P = .05; r = .351, P = .01; r = .336, P = .05; r = .361, P = .05, respec-
tively). The WAI-S-C scores were also significantly correlated with the
WCST t-score for non-perseverative errors in month 1 (r = .270, P =
.05). There were no significant correlations between WAI-S-C scores
and HVLT t-scores for immediate and delayed recall. Findings suggest
that impairments in aspects of vigilance and abstract thinking may be re-
lated to difficulties forming and maintaining the therapeutic alliance during
individual therapy as judged by persons who have schizophrenia. Further
study is needed to understand how these factors and others not measured or
reported here might combine to predict the strength of therapeutic alliance
perceived by persons who have schizophrenia over the course of therapy.
ID: 551857
THE IMPACT OF CANNABIS USE ON ILLNESS
COURSE IN FIRST EPISODE PSYCHOSIS
Isobel Harrison1, T. R. Barnes1, V. Leeson1, S. Mutsatsa1,
E. M. Joyce2
1Psychological Medicine, Imperial College London, London, United
Kingdom; 2Institute of Neurology, University College, London,
United Kingdom
The prevalence of comorbid cannabis use in patients presenting with a first
psychotic illness is high. Studies in people with established schizophrenia
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have implicated cannabis in a worse illness course in terms of relapse and
hospitalisation. However, longitudinal studies of first episode patients who
report substance use at time of first presentation to services indicate the
majority give up illicit substances over time. In a cohort of 109 patients
experiencing their first psychotic episode, we sought to compare outcome
at two years in those reporting different patterns of cannabis use over the
first year of treatment. Self-report data on cannabis use in the three months
prior to first presentation and the use of cannabis in the three months prior
to time of one year follow-up revealed that 65% of the sample were non-
users throughout, 21% gave up cannabis use and 11% persisted with can-
nabis use. A further 3% of the sample had commenced use at time of follow-
up and were excluded from further analysis. When comparing the three
groups, there was a significant difference in terms of total number of
days in hospital, and trend-level differences in whether or not they were
re-admitted to hospital and the number of the readmissions during these
two years. These results reflected longer and more frequent hospitalisations
in the persistent cannabis users than the non-users and those that discon-
tinued use. When just the persistent cannabis users were compared with
those that gave up, the difference in all these measures became highly sig-
nificant. The results suggest that, in patients with comorbid cannabis use at
the time of a first psychotic episode, discontinuing use has a substantial
benefit in terms of hospitalisation.
ID: 551851
PARANOIA STRIKES DEEP: A CONTINUUM OF
SUSPICIOUSNESS AND ITS RELATION TO SOCIAL
ANXIETY AND SCHIZOTYPY
Leslie H. Brown1, I. Myin-Germeys2, T. R. Kwapil1
1Psychology, University of North Carolina–Greensboro,
Greensboro, NC, USA; 2Psychiatry and Neuroscience, Maastricht
University, Maastricht, Netherlands
Paranoia is a key component of schizotypy and schizophrenia. Paranoia
has been alternatively described as part of the positive schizotypy/schizo-
phrenia dimension, given that paranoia is characterized by unusual ideas,
and as a separate dimension of schizotypy/schizophrenia. However, some
studies have found that paranoia is also related to negative schizotypy/
schizophrenia, although it appears that this relation may be due to social
aversiveness resulting from paranoia, not from core ideational components
of paranoid thought. Furthermore, social anxiety commonly co-occurs
with paranoia and positive schizotypy. Paranoia and social anxiety share
many features, including self-consciousness and social fear and discomfort.
Disentangling the overlap and boundaries of positive and negative schiz-
otypy, paranoia, and social anxiety should enhance our understanding
of the etiology and development of schizophrenia and spectrum disorders.
The present study examined: 1) whether paranoia is best conceptualized as
part of positive schizotypy or as separate dimension, 2) the relation of para-
noia with negative schizotypy, 3) the relation of social anxiety with these
dimensions of schizotypy, and 4) the expression of these constructs in daily
life using experience sampling methodology (ESM). Confirmatory factor
analyses tested a series of competing models. The best fit was found for
a four-factor model with positive and negative schizotypy, paranoia,
and social anxiety. As hypothesized, the paranoia factor was most strongly
associated with positive schizotypy. Although some measures of paranoia
correlated with negative schizotypy, measures of core features of paranoid
ideation were minimally associated with negative schizotypy. Social anxiety
comprised a separate factor outside of schizotypy, but was strongly asso-
ciated with positive schizotypy and paranoia. ESM findings indicated that
paranoia and social anxiety are differentially experienced in daily life. The
results are consistent with a multidimensional model of schizotypy/schizo-
phrenia and support the idea that paranoia and social anxiety are differ-
entially experienced within schizotypy. Identification of the
multidimensional structure of schizophrenia (including paranoia) across
a broad continuum of clinical and subclinical manifestations should en-
hance our understanding of relevant etiological factors and lead to better
targets for prophylactic interventions used to prevent the development of
clinical disorders.
ID: 551847
AGE OF SIGN LANGUAGE ACQUISITION,
LINGUISTIC ABILITY, AND COGNITION AMONG
DEAF PEOPLE WITH SCHIZOPHRENIA
Heather Kathleen Horton
School of Social Welfare, University at Albany, Albany, NY, USA
We have an extensive understanding of the cognitive and social cognitive
deficits associated with schizophrenia among hearing people. Similarly,
a large knowledge base exists regarding these domains among nonclinical
deaf samples. Well-established associations found across literatures were
recently manifest in a sample of deaf and hearing people with schizophrenia
(PWS). Cognition significantly predicted outcome (Horton and Silverstein,
2007) and, SC mediated the relationship for both groups (Horton and Sil-
verstein, 2007, in press). Between-group differences fell along lines of the
communication medium upon which each group relied. For deaf subjects,
visuospatial memory (VSM) was the strongest predictor of outcome and,
was most consistently mediated by SC; among hearing subjects, verbal
memory served these same roles. The current study tests relationships be-
tween deafness-related variables, and, the predictors and mediators in the
cognition-outcome relationship. Diverse study participants were recruited
from a community-based psychosocial rehabilitation agency. A quasi-ex-
perimental design was employed. Sixty-five subjects with a SCID-based di-
agnosis of schizophrenia (34 deaf, 31 hearing) were evaluated on linguistic
ability, visuospatial memory (VSM), SC, and functional outcome. SC was
operationalized by measures of Theory of Mind (ToM) and facial affect
processing (FAP). Controlling for illness severity, early SLA significantly
predicted superior linguistic ability among deaf subjects; and, fluent signers
displayed an increased ability to infer another person’s intentions. Al-
though strong signing skills predicted higher levels of functional outcome,
the relationship only approached significance when illness severity was con-
trolled. Deaf and hearing subjects unexpectedly displayed similar levels of
performance on measures of nonlinguistic cognitive processing and FAP.
Like nonclinical samples of deaf people, age of SLA and linguistic ability
are important factors in the lives of deaf PWS. Additionally, a complex
relationship exists between linguistic ability and ToM. Schizophrenia
researchers studying hearing people, and psychologists studying nonclinical
deaf people share common interests that can contribute to expanding our
understanding of deaf PWS. Attending to the linguistic and nonlinguistic
characteristics of tasks may clarify whether pathways to impairment are
similar across groups.
ID: 551808
SUICIDAL BEHAVIOR IN CHILDREN AND
ADOLESCENTS WITH FIRST EPISODE PSYCHOSIS
Tatiana Falcone
Psychiatry and Psychology, Cleveland Clinic, Cleveland, OH, USA
Patients diagnosed with schizophrenia have a 10 to 20 years reduction in life
expectancy compared to the general population. A large proportion of
these premature deaths are accounted for by suicide. Patients in the earlier
phase of the disease (adolescents) have the highest risk for suicide. For
schizophrenic patients, the strongest predictor of suicide risk is a previous
suicide attempt, increasing the risk by 40 times. Adolescents with psychotic
symptoms and a past history of suicide attempts have higher risk of com-
mitting suicide in the next 5 years than an adolescent with no history of
psychosis. Schizophrenia and first-episode psychosis increase risk for de-
pression, self-harm and suicide. Most available reports focus on adult
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patients with schizophrenia and/or first episode psychosis. Our hypothesis
was that first episode psychosis, is associated with an increased risk for de-
pression and suicidal behavior. We studied patients admitted to a pediatric
inpatient psychiatric unit between 2003–2006. Patients (n = 102) were di-
agnosed with new-onset psychosis using DSM-IV TR criteria for Psychosis
NOS, schizophreniform disorder or schizoaffective disorder. A control
group of (n = 102) patients with other psychiatric diagnosis admitted to
the same unit, and match by age, gender and ethnicity was selected. Study
participants were administered the BPRS-C to assess severity of psychiatric
symptoms. The suicidality subscale was analyzed separately. Thirty two
percent of the patients had attempted suicide compared to 28% in the con-
trol group, 104 total suicide attempts in the group of psychotic patients and
51 total suicide attempts in the group of controls. Individuals with depres-
sion were found to be 2.8 times more likely to attempt suicide than those
without in the patient group. Our results are double of those identified in
adult studies. Depression was the second most frequent co morbidity in this
patients (n = 36), and ADHD the first (n = 49).Duration of untreated psy-
chosis has been and independant indicator of self harm. Our sample dem-
onstrated an interesting pattern with patients with the highest suicidality
scores having had 7 months or more of untreated psychosis. It is imperative
to address depressive symptoms in children and adolescents with first ep-
isode psychosis or schizophrenia to prevent potential suicidal behavior.
There should be a low threshold for hospitalization of adolescents with psy-
chosis. The quality of initial treatment is critical.
ID: 551756
COMPARISON OF ACADEMIC AND CONSUMER
DEFINITIONS OF RECOVERY IN SCHIZOPHRENIA:
THE POSSIBILITY OF RECOVERY WITHOUT
REMISSION
Kristen Renee Bradshaw1,2, C. Loh1,2, P. Link1,2, E. Granholm1,2
1VA, San Diego, CA, USA; 2University of California, San Diego,
San Diego, CA, USA
Academic consensus criteria for remission from schizophrenia emphasize
only remission from positive symptoms, whereas academic definitions oper-
ationalize recovery as requiring both symptom remission and adequate
psychosocial functioning. In contrast, consumer models focus on recovery
as a process and identify people as ‘‘in recovery,’’ regardless of whether
symptoms are fully controlled. The current study compares academic
and consumer definitions of recovery and explores the possibility of func-
tional recovery without achieving symptom remission. The study included
141 participants with schizophrenia or schizoaffective disorder (M/F = 92/
49, x age = 56, SD = 8.2 years) who were assessed annually over a period of
three years. Assessments included social functioning (Social Functioning
Scale-SFS), symptoms (Positive and Negative Syndrome Scale- PANSS),
and independent living (Independent Living Skills Survey-ILSS). Approx-
imately one in five people with schizophrenia were found to be in recovery,
according to a consumer definition that included only functional achieve-
ment, as defined by Harrow and Jobe (2007; The Journal of Nervous and
Mental Disease; the following criteria met over two consecutive assess-
ments [ILSS Appearance items 7, 8 about clothing, Personal Hygiene items
7, 8, 11 about skin, hair and nail cleanliness] AND [any 4 Leisure Activity
Items 1–11 OR ILSS Employed], AND SFS Social Engagement and Inter-
personal Communication  1) compared to one in ten who meet academic
definitions of recovery (same functioning criteria þ PANSS  3 on items
P1, G9, P3, P2, G5, N1, N4, N6 over two consecutive assessment points).
One third to half of all participants met consensus criteria for symptom
remission at any given assessment point (PANSS criteria only). The find-
ings showed that functional recovery, from the perspective of consumers,
can be achieved despite the persistence of positive symptoms. This study is
an important preliminary step toward a clinically relevant definition of re-
covery that may be useful for measuring outcomes and change in real world
environments relevant to consumer goals.
ID: 551754
DEFEATIST PERFORMANCE ATTITUDES AND
DIMINISHED MOTIVATION IN SCHIZOPHRENIA
Yuliana Gallegos1, P. Link1, S. Fish1,3, E. Granholm1,2
1Psychology, VA San Diego Healthcare System, San Diego, CA,
USA; 2Psychiatry, UCSD, La Jolla, CA, USA; 3Psychology,
SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San
Diego, CA, USA
This study examined whether defeatist performance attitudes (eg, failure
expectancy) are associated with low performance effort and negative symp-
toms in schizophrenia. Defeatist performance attitudes may be associated
with diminished motivation to apply effort to cognitive and social function-
ing tasks, especially more difficult tasks. Performance attitudes were
assessed in participants with schizophrenia or schizoaffective disorder
(n = 93) and healthy controls (n = 53) using the Defeatist Performance At-
titude Scale. To index the amount of effort applied to a task with varying
difficulty, pupil dilation responses were recorded as an index of cognitive
effort during a digit span recall task with low, moderate and high difficulty
conditions (3, 6, and 9 digit spans). People with schizophrenia showed sig-
nificantly more defeatist attitudes relative to controls, and defeatist atti-
tudes were significantly correlated with poor performance in people with
schizophrenia in the high difficulty condition. People with schizophrenia
were divided into mild, moderate and severe defeatist attitude subgroups
(tertile split). The subgroup with severe defeatist attitudes showed a decrease
in effort (reduction in pupil dilation) when task difficulty increased from
low to moderate load, whereas the mild and moderate subgroups and
healthy controls increased their effort from low to moderate loads.
When challenged by an increase in cognitive task difficulty, therefore, de-
featist performance beliefs in people with schizophrenia were associated
with poor effort and poor performance. Furthermore, the subgroup
with severe defeatist attitudes showed significantly more severe negative
symptoms on the Diminished Motivation factor (but not other factors)
of the Scale for Assessment of Negative Symptoms. Defeatist performance
attitudes, therefore, may be an important treatment target for psychosocial
interventions, like cognitive behavioral therapy, which can be used to mod-
ify defeatist beliefs associated with diminished motivation to perform dif-
ficult social and daily functioning tasks.
ID: 551703
THE PREDICTIVE VALUE OF FIRST-RANK
SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
VERSUS BIPOLAR MANIA WITH PSYCHOSIS
Linda S. Grossman1, C. Rosen1, M. Harrow1, G. Strauss2
1Psychiatry, University of Illinois at Chicago, Chicago, IL, USA;
2Psychiatry, University of Maryland Medical Center, Baltimore,
MD, USA
Objective: This study prospectively examined the degree to which Schnei-
derian First-Rank Symptoms (FRS) predict later psychopathological
symptoms, functional outcome, and periods of recovery over a 20-year pe-
riod in patients with schizophrenia versus bipolar mania with psychosis.
Method: The Chicago Followup Study prospectively examined 59 subjects
with a diagnosis of schizophrenia and 27 subjects with bipolar disorder at
index hospitalization and followed prospectively with 6 subsequent assess-
ments over the next 20 years. The study was designed to evaluate multiple
factors at each time point that provided data on premorbid adjustment,
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phenomenology, severity of illness, course of illness, prognosis, outcome,
and treatment. Results: FRS are not exclusive to schizophrenia; however
they are less frequent in bipolar patients. Schizophrenia patients who have
FRS at the 2-year follow-up are more likely to exhibit future episodes of
psychosis over the next 20 years (P .05). Overall, the reoccurrence of FRS
at follow-up assessments was more likely in schizophrenia patients when
compared to patients with bipolar disorder (P  .05). The data on 6 fol-
low-ups over 20 years showed that patients with schizophrenia were less
likely to experience periods of recovery when compared to patients with
bipolar disorder (P  .05). As expected, when we looked at ‘‘voices com-
menting’’ and ‘‘voices commanding,’’ which are considered two of the more
serious symptoms in DSM IV diagnosis of schizophrenia, we found that
a higher percentage of patients with schizophrenia presented with these
types of FRS (P  .05). Additionally, schizophrenia patient who presented
with FRS at 2-year follow-up were more likely to have future periods of
psychosis and FRS than schizophrenia patients without FRS at the 2-
year follow-up (P  .05). Conclusions: FRS are no longer considered pa-
thognomonic for schizophrenia. Although Schneider’s classic work remains
a useful heuristic tool, FRS should not be used exclusively as criteria for
diagnosis of schizophrenia. FRS at 2-yr follow-up are predictive of a more
severe course of illness, regardless of diagnosis. Current data suggest that
outcome may be predicted by specific patterns of symptoms over time as
well as diagnosis.
ID: 551701
ENVIRONMENTAL SUPPORTS AND TECHNICAL
ADVANCES IMPROVE ADHERENCE TO
MEDICATION IN SCHIZOPHRENIA
Meredith Lee Draper, D. I. Velligan, N. J. Maples, J. L. Ritch,
X. Li, A. L. Miller
Psychiatry, UTHSCSA, San Antonio, TX, USA
Cognitive Adaptation Training (CAT) is a psychosocial treatment that uses
environmental supports such as signs, checklists, alarms and the organiza-
tion of belongings to bypass cognitive deficits and to cue and sequence
adaptive behaviors in the home. CAT has been found to improve multiple
domains of outcome for individuals with schizophrenia. From CAT, our
group has developed a number of interventions to primarily target medi-
cation adherence in schizophrenia. In an ongoing study, 69 outpatients
with schizophrenia (SCID-DSMIV) were randomly assigned for 9 months
to one of three treatment groups; 1) Pharm-CAT–CAT focused only on
medication and appointment adherence 2) MM- A treatment using the
Med-eMonitor; and electronic device with the ability to store up to five
different medications, cue the taking of medication, warn patients when
they are taking the wrong medication or taking it at the wrong time, record
side effect complaints, and through modem hookup promptly alert treat-
ment staff to failures to take medication as prescribed. Early identification
of adherence problems with the monitor was followed with rapid telephone
intervention to overcome barriers to adherence or 3) treatment as usual
(TAU). Data for these participants are available for the first 3 months
of treatment. Medication adherence was assessed during a one month base-
line period and then monthly using in-home pill counts. Symptoms and
functional outcomes were assessed at baseline and at 3 month intervals.
Analysis of covariance for mixed models for pill count adherence indicated
a non-significant trend for treatment group effects. Participants in treat-
ments utilizing environmental supports had better adherence to prescribed
medication (P < .07). Although treatment groups had lower levels of pos-
itive symptoms than TAU, these differences were not significant after 3
months of treatment. These preliminary findings add further evidence to
reinforce the notion that environmental supports targeting medication ad-
herence may improve this behavior.
ID: 551683
THE RELATION OF CORTISOL SECRETION WITH
SOCIAL AND ROLE FUNCTIONING DEFICITS IN
CHR YOUTH
Elaine F. Walker, M. Esterberg, J. Brasfield
Psychology, Emory University, Atlanta, GA, USA
The goal of this study was to test the hypothesis that cortisol elevations
are linked with role functioning impairment in youth at-risk for psychosis.
Functional impairments in social and occupational domains are among
the most debilitating aspects of psychotic disorders. Retrospective and
prospective research indicates that these impairments are present before
the onset of clinical symptoms, however biological and psychosocial
determinants of the deficits are unknown. The present longitudinal study
examines the relation of cortisol secretion with social and role functioning
deficits in adolescents (mean age 14.75 at baseline) who are deemed at
clinical high risk (CHR) for psychosis based on the presence of schizoty-
pal syndrome and/or prodromal symptoms. Multiple measures of salivary
cortisol were obtained at three times; at baseline, interim follow-up, and
1-year follow-up. Area under the curve (AUC) was computed based on
these measures. Role functioning and symptoms were rated using the
Structured Interview for Prodromal symptoms (SIPS) at baseline and
1-year later. There was a positive relationship between cortisol AUC
and ratings of role function deficits at both baseline and one-year fol-
low-up. This relation was not accounted for by reports of stressful life
events. These findings suggest that elevated HPA activity is associated
with impaired role functioning in CHR youth. This relation is assumed
to reflect bidirectional influences that include the stress-inducing effects of
impaired role function, as well as the contribution of stress sensitivity to
impaired functioning.
ID: 551682
EARLY LIFE EXPERIENCES PREDICT
SELF-ESTEEM IN FIRST-EPISODE PSYCHOSIS
Nadia Christine Vracotas, S. N. Iyer, A. K. Malla
Prevention and Early Intervention Program for Psychosis, Douglas
Mental Health University Institute, McGill University, Montreal,
QC, Canada
Low self-esteem seems to be related to the etiology, understanding and
treatment of a wide range of psychiatric conditions, including psychotic
disorders. Vracotas et al. found that distress experienced by individuals
with first-episode psychosis (FEP) was associated with level of self-esteem,
depression, and anxiety, but not positive or negative symptoms. Self-esteem
has repeatedly been implicated in the formation and maintenance of delu-
sions and hallucinations. Moreover, self-esteem seems to predict clinical
outcome in FEP. Little is known about what factors influence the level
of self-esteem in psychosis. It has been well established that the quality
of received parenting has direct and lifelong effects on psychological
well-being. Thus, early life experiences such as parental care and attach-
ment could contribute to the development of self-esteem. Our aim was
to investigate the influence of early life experiences and parenting variables
on the level of self-esteem in a FEP sample. Methods: The study included
a sample of 45 individuals with FEP (non-affective and affective) receiving
treatment at the Prevention and Early Intervention Program for Psychoses
in Montreal, Canada. The Parental Bonding Instrument (PBI; subscales for
Care and Overprotection) and the Measure of Parental Style (MOPS; sub-
scales for Indifference, Abuse, and Overcontrol) were used as indicators of
early life experiences and parenting. Patients completed the PBI and MOPS
retrospectively, separately for their mother and father. The Self-Esteem
Rating Scale was administered during the first six months of treatment.
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Pearson’s bivariate correlations were derived between self-esteem scores,
PBI and MOPS measures. Results: In relation to mothers, self-esteem
was positively correlated with PBI Care (r = .316, P < .05), and negatively
correlated with the PBI Overprotection (r =.510, P< .001), MOPS Over-
control (r = .323, P < .05) and MOPS Abuse (r = .345, P < .05) sub-
scales. There was no association between self-esteem and any father rated
subscales. Conclusions: Better self-esteem is associated with higher levels of
mother care and lower levels of overprotection, overcontrol and abuse. In-
terestingly, none of the father-related parenting variables predicted self-
esteem. Given the relationship between self-esteem, early childhood and
parenting, efforts should be made to assess patients’ early life experiences
and its effects on self-esteem and to provide specialized interventions that
address these issues.
ID: 551633
EXAMINING THE IMPACT OF A WELLNESS-BASED
GROUP INTERVENTION FOR RECENT-ONSET
SCHIZOPHRENIA PATIENTS: PRELIMINARY
RESULTS FROM AN ONGOING TRIAL
Denise Gretchen-Doorly, K. L. Subotnik, R. E. Kite, J. Ventura,
S. K. Carter, K. H. Nuechterlein
Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles,
CA, USA
Despite substantial progress in the treatment of schizophrenia, medical
morbidity remains the domain least improved by recent treatment advan-
ces.1 We can no longer think of wellness programs as adjunctive psycho-
social treatments that are beneficial, but not essential, to recovery. This
poster explains the development, implementation, and preliminary evalu-
ation of a 50-session health behavior training program that is part of the
Developmental Processes in Schizophrenic Disorders Project (PI: Keith
Nuechterlein, Ph.D., ClinicalTrials.gov Identifier: NCT00333177), con-
ducted at the UCLA Aftercare Research Program. We designed this well-
ness program specifically for recent-onset schizophrenia patients, a group
that has received little, if any, attention in the health behavior change lit-
erature. Patients learn skills in (1) relaxation training, including progres-
sive muscle relaxation and diaphragmatic breathing techniques; (2) basic
nutrition and healthy eating habits; and (3) light exercise. For six months,
patients attend three hours of the wellness group per week while receiving
other outpatient case management and psychiatric care. To understand
factors that contribute to and maintain behavior change in this popula-
tion, outcome measures were chosen to assess both subjective health atti-
tudes (ie, quality of life, perceived stress) and objective global health
indicators (ie, physical fitness, metabolic blood tests). Although current
analyses are limited due to a small sample size (n = 13), paired sample
t-tests indicate statistically significant pre-post increases in overall life sat-
isfaction (t = 3.24, df = 12, P = .007) and satisfaction with health (t =
2.76, df = 12, P = .017) as well as a significant decrease in perceived stress
(t = 2.36, df = 12, P = .036) after six months of wellness group training.
Changes in objective health measures are not statistically significant after
six months, but patients are beginning to show improved physical fitness
along with directional tendencies toward decreased LDL and total choles-
terol. Encouraged by these preliminary findings, we plan to evaluate out-
come measures with a larger sample to determine whether patients
sustain changes when treatment exposure is reduced to 1.5 hours per
week for an additional six months.
Reference
1. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality
in schizophrenia: Guidelines for psychiatrists. Journal of Clinical
Psychiatry 2005;66:183–194, .
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HEALTH SERVICES OUTCOMES IN VETERANS
WITH SCHIZOPHRENIA AND TRAUMATIC BRAIN
INJURY
Jacob S. Ballon1,2, J. O. Brooks1,2, R. King2, J. Hoblyn1,2
1Psychiatry and Behavioral Science, Stanford University, Stanford,
CA, USA; 2Department of Psychiatry, Veterans Affairs Palo Alto
Healthcare System, Palo Alto, CA, USA
Of the 1.4 million traumatic brain injuries (TBI) that occur yearly, nearly
100 000 patients have severe, long-term sequelae and still more suffer from
milder, though debilitating, symptoms. TBI is strikingly important among
veterans, as nearly 25% of soldiers returning from Iraq and Afghanistan
report injuries to the face, head, or neck. TBI is associated symptoms
such as headache, irritability, disinhibition, visual changes, poor concentra-
tion, and apathy and, in more severe cases, severe cognitive deficits, sensory
loss, seizures, and paralysis. TBI is associated with increased rates of many
psychiatric illnesses including PTSD, substance use disorders, schizophre-
nia, bipolar disorder, and Alzheimer disease. However, there is a paucity of
research regarding the excess disability imposed by TBI on chronic mental
illness. We sought to address this deficit by examining the excess disability
created by TBI in the face of schizophrenia. Our study extracted data from
the Veterans Affairs (VA) Sierra-Pacific aggregate database for fiscal years
2003 to 2007 for patients with TBI, schizophrenia, and TBIþschizophrenia.
Outcome measures included the number of medical and psychiatric hospi-
talizations and length of hospitalization. The predictors of health service
utilization included pharmacological interventions, medical comorbidities,
psychiatric comorbidities, substance abuse/dependence, marital status,
homelessness, and income. Results are discussed in the context of health
service and treatment implications for patients with TBI and schizophrenia.
Our results are relevant to psychosocial interventions that can benefit
patients with TBI and schizophrenia and provide insight into current psy-
chopharmacological interventions.
References
1. Hoge CW, McGurk D, Thomas JL, et al. Mild traumatic brain
injury in US soldiers returning from Iraq. NEJM. 2008;358(5):453–463.
2. Rogers JM and Read CA. Psychiatric comorbidity following traumatic
brain injury. Brain Injury 2007;21(13):1321–1333.
3. Corrigan JD, Cole TB. Substance Use Disorders and Clinical Manage-
ment of Traumatic Brain Injury and Posttraumatic Stress Disorder.
JAMA 2008;300(6):720–721.
4. Incidence Rates of Hospitalization Related to Traumatic Brain Injury–
12 States, 2002. JAMA 2006;295(15):1764–1765.
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COGNITIVE REMEDIATION IN SCHIZOPHRENIA:
ARE WE PROCEEDING CAUTIOUSLY?
Jason E. Peer1, D. Dickinson1,2
1MIRECC, VA Capitol HealthCare Network, Baltimore,
MD, USA; 2Psychiatry, University of Maryland School of
Medicine, Baltimore, MD, USA
The recognition of the prominent role that cognitive impairment plays in
the functional disability associated with schizophrenia has led to substantial
pharmacological and psychosocial intervention development efforts. Cog-
nitive remediation is one such intervention with a growing research base of
randomized controlled trials (RCT). Recent meta-analyses of cognitive re-
mediation indicate a ‘medium’ effect size for cognitive and functional im-
provement and have been generating considerable enthusiasm and some
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calls for dissemination efforts. Yet these meta-analyses have given limited
attention to the substantial methodological issues that may bias this body of
research. Such concerns include, for example, very small samples, ‘‘treat-
ment as usual’’ control groups, odd or limited outcome measures, un-
blinded assessments, and limited a priori data analytic strategies. As
a result of these concerns, we are in the process of investigating the meth-
odological quality of the evidence for cognitive remediation in schizophre-
nia by conducting several moderator analyses, using previously published
meta-analytic findings supplemented with more recently published studies.
Our primary analysis addresses the relationship of methodological rigor to
treatment effect size using the Clinical Trials Assessment Measure
(CTAM), developed by Tarrier and Wykes (2004). Through pilot work
with a sample of published studies (n = 9) we have established reliable
CTAM ratings (mean CTAM score = 55; s.d. = 13.73; range 32–74). Pilot
analyses revealed a negative correlation between cognitive treatment effect
size and CTAM scores (r = .54), raising the concern that this inverse re-
lationship between effect size and methodological rigor will hold for the
broader literature. In continuing work, we will rate all studies and include
analyses of treatment effects for both cognitive and functional outcome
measures. Additional moderator analyses will evaluate the impact of re-
lated key study design issues such as type of comparison condition (eg,
treatment as usual vs. active comparator) and sample criteria (eg, inpatient
vs. community) on treatment effect sizes. We will also present an evaluation
of whether a publication bias exists in the cognitive remediation literature,
and analyses investigating historical trends in treatment effects and meth-
odological quality. These preliminary findings suggest that a more cautious
evaluation of the evidence for cognitive remediation may be warranted.
ID: 551578
A PRELIMINARY INVESTIGATION INTO THE ROLE
OF FAMILY ENVIRONMENT, PERSONALITY,
AND POSITIVE SCHIZOTYPY IN PREDICTING
SUBSTANCE USE DISORDERS IN SOCIAL
ANHEDONICS AND CONTROLS
Marsha N. Sargeant, J. J. Blanchard
Psychology, University of Maryland, College Park, College Park,
MD, USA
Schizophrenia is characterized by high rates of comorbid substance use dis-
orders (Blanchard et al. 2001). Unfortunately, the factors that give rise to
high substance use in schizophrenia are as yet unknown. It may be produc-
tive to examine how schizophrenia-spectrum characteristics are associated
with substance use in populations that are not yet ill. The current study
examined how social anhedonia (a putative indicator of risk for schizophre-
nia spectrum disorders) is associated with substance use. We also examined
the role of individual differences in family environment and personality
traits. This study utilized participants in the Maryland Longitudinal Study
of Schizotypy, an ongoing study that screened 2,434 18-year-olds in the
community. Two groups were selected based on initial self-report scores:
individuals high in social anhedonia (N = 86) and a healthy control group
with low schizotypy scores (N = 89). Participants completed structured di-
agnostic interviews at a baseline assessment and again at a 3-year follow-up.
Substance use disorders were measured dichotomously (0 = absent, 1 =
threshold). Social anhedonics had significantly less education, less family
cohesion, higher negative affect, and PerAb scores than controls. In social
anhedonics, at baseline, family cohesion and perceptual aberration were
significantly associated with having a substance use disorder (P’s < .05).
Only perceptual aberration was significantly correlated with SUDs at fol-
low-up in this group. Negative affect, disinhibition, and magical ideation
were not significantly associated with SUDs in this group both at baseline
and follow-up. In the control group, disinhibition was associated with
SUDs at baseline and follow-up (P’s< .05). There were no other significant
associations in the control group at baseline or follow-up. These findings
suggest that family environment a may play a role in the development of
substance use disorders in social anhedonics. Implications of other findings
in this study are discussed.
ID: 551518
DISORGANIZED SYMPTOMS AND
NEUROCOGNITIVE DEFICITS, PREDICT
IMPAIRED SOCIAL FUNCTIONING IN INDIVIDU-
ALS AT RISK FOR PSYCHOSIS
Kristin Cadenhead1, A. Eslami2, C. Jahshan1
1Psychiatry, University of California San Diego, La Jolla, CA,
USA; 2Psychiatry, UCLA, Los Angeles, CA, USA
Individuals identified as putatively prodromal or ‘‘at clinical high risk
(CHR)’’ for schizophrenia, based on the Structured Interview for Prodro-
mal Syndromes, have significant neurocognitive and functional deficits at
initial evaluation which may be potential indicators of increased vulnera-
bility for psychosis. We have previously reported that CHR subjects show
neurocognitive (Eastvold et al. 2007) and social functioning (Ballon et al.
2007) deficits at baseline assessment. Here, we present prospective longitu-
dinal data and assess whether baseline clinical, neurocognitive and social
functioning variables can predict social functioning at 1-year follow up.
Twenty-two CHR subjects were assessed at 1-year follow-up using the So-
cial Adjustment Scale. Despite improvement in attenuated positive symp-
toms and some neurocognitive domains, CHR subjects continued to have
impairment in social functioning regardless of whether they converted to
psychosis. To explore predictors of the observed functional disability in
at risk subjects, multiple regression analyses were performed using baseline
social functioning, clinical and neurocognitive variables as predictors to de-
termine which baseline variables were associated with poor functional out-
come. Bizarre and disorganized behavior, along with impaired executive
functioning accounted for a significant amount of the variance in overall
social functioning at follow-up. Work role impairment was accounted for
by deficits in processing speed, whereas social role deficits were related to
high disorganized symptoms. The association of baseline neurocognitive
deficits and disorganized symptoms with impaired functional outcome sug-
gests important treatment targets that may alter the course of illness. Psy-
chosocial treatment efforts that focus on social interaction and cognitive
remediation might improve functional outcome in these help seeking indi-
viduals. Further research, using larger samples and longer follow-up, such
as the North American Prodromal Longitudinal Studies (NAPLS) consor-
tium, will help to elucidate the development of functional deficits and
their relationship to presenting clinical symptoms and neurocognitive
functioning.
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FUNCTIONAL IMPAIRMENT: THE HALLMARK OF
RISK FOR PSYCHOSIS
Jean Addington1, D. Perkins2, S. Woods3, K. Cadenhead8,
T. Cannon7, B. Cornblatt5, L. Seidman4, E. Walker6,
T. McGlashan3, M. Tsuang8, R. Heinssen9
1University of Calgary, Calgary, AB, Canada; 2UNC, Chapel Hill,
NC, USA; 3Yale University, New Haven, CT, USA; 4Harvard
University, Boston, MA, USA; 5Zucker Hillside Hospital,
New York, NY, USA; 6Emory University, Atlanta, GA, USA;
7UCLA, Los Angeles, CA, USA; 8UCSD, San Diego, CA, USA;
9NIMH, Washington, DC, USA
Poor social functioning is a hallmark of schizophrenia. Retrospective stud-
ies have long suggested that social deficits appear before the psychotic
symptoms. By examining functional outcome in individuals who appear
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to be at clinical high risk (CHR) ie, putatively prodromal for psychosis we
can now examine this prospectively. We first present evidence that in a large
sample (n = 86) from the PREDICT (Prodromal Research for Early De-
tection in a Collaborative Team) study, CHR individuals do not differ sig-
nificantly in social and role functioning from a sample of individuals who
are presenting with a first episode of psychosis nor from a sample of indi-
viduals who have a more chronic course of illness. All three patient groups
are significantly impaired compared to a young healthy control group.
These results are supported by evidence of similar functional impairments
in the 371 CHR subjects of the large North American Prodromal Longi-
tudinal Study (NAPLS) consortium. Furthermore, in the NAPLS data set
using cluster analyses, we identified in the CHR group four patterns of so-
cial functioning from early childhood until the onset of the attenuated psy-
chotic symptoms. These patterns of stable-good, stable-moderate,
deteriorating and poor-deteriorating are identical to patterns of premorbid
functioning observed in individuals who have a chronic course of schizo-
phrenia. We explore this further in a third study, ADAPT (Access, Detec-
tion and Psychological Treatments) and demonstrate that in this clinical
high risk group, these young people in addition to functional impairments,
exhibit levels of social defeat and poor self schema. What is of concern is
that these data demonstrate that these clinical high risk individuals do not
differ in their functioning from those with a diagnosed psychotic illness yet
less than one-third are likely to go onto to develop full blown psychosis. The
conclusion from these data is that social impairment is not only a hallmark
of schizophrenia but also of a period of risk. It is from such data in this CHR
period that we will attempt to identify potential targets of intervention.
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DIFFERENTIAL IMPACT OF NEUROCOGNITION
ON THE PREDICTION OF SOCIAL AND ROLE
FUNCTIONAL OUTCOME IN THE SCHIZOPHRENIA
PRODROME
Christopher W. Smith1, L. Baskir1, A. Auther1, D. McLaughlin1,
C. Correll1,2, B. Cornblatt1,2
1Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks,
NY, USA; 2Feinstein Institute for Medical Research, North Shore
Long Island Jewish Health System, Manhasset, NY, USA
The Recognition and Prevention Program is a longitudinal study of ado-
lescents (12–22) considered prodromal for schizophrenia based on attenu-
ated positive symptoms assessed using the Scale of Prodromal Symptoms
(SOPS). In addition to focusing on psychotic outcomes, we prospectively
study cognition, social and school functioning, both as part of the vulner-
ability for schizophrenia and as independent outcomes. This study focuses
on prediction of functional outcome using baseline neurocognitive and clin-
ical variables. Of 102 subjects (mean age = 16.02) with baseline data, 71 had
follow up data at about 2 years. Subjects were evaluated at baseline with
extensive cognitive and clinical batteries. Cognitive scores were calculated
consistent with the MATRICS battery. Clinical measures include positive,
negative, and disorganized symptoms, as well as anxiety and depression.
Functioning was assessed longitudinally with the Global Functioning: So-
cial and Role scales. Pearson’s correlations were used to screen for predic-
tors and multiple regression was used to identify the strongest predictors of
functioning. Social functioning is correlated significantly with processing
speed (r = .31, P = .009), and negative symptoms (trend level: r = .22,
P = .08). Role functioning is significantly correlated with verbal memory
(r = .43,P< .005), executive function (r = .25, P = .04) and working memory
(r = .34, P = .004) and processing speed (trend level: r = .23, P = .06), but not
with clinical features. The relative contribution of cognitive and
clinical domains to functional outcomes was assessed using stepwise
multiple regression with cognitive variables entered first and symptoms en-
tered second. Controlling for intercorrelations among measures, processing
speed predicts social functioning (Adj R2 = .08, FD(1,64) = 6.99, P = .01; b =
.50, t = 2.64. P = .01) and verbal memory predicts role functioning (Adj
R2 = .17, FD(1,64) = 14.15, P< .0005; b = .69, t = 3.76. P< .0005). Consistent
with findings in schizophrenia patients, cognitive and functional deficits are
prominent features of the prodromal phase. Plausible relationships between
cognition and social and role functioning were found: good social function-
ing requires rapid processing of a wide array of inputs (ie, speed of process-
ing), and academic role functioning requires following instructions and
remembering verbal information (ie, verbal learning and memory). Clinical
features did not play a significant role in prediction of functional outcome.
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DIFFERENCES BETWEEN EARLY RESPONDERS
AND EARLY NON-RESPONDERS TO ATYPICAL
ANTIPSYCHOTICS ON FUNCTIONAL OUTCOMES
IN THE TREATMENT OF SCHIZOPHRENIA
Bruce J. Kinon1, L. Chen1, H. Ascher-Svanum1, V. L. Stauffer1,
S. Kollack-Walker1, W. Zhou1, S. Kapur2, J. Kane3, D. Naber4
1Eli Lilly and Company, Indianapolis, IN, USA; 2Institute of
Psychiatry, King’s College of London, London, United Kingdom;
3Zucker Hillside Hospital, New York, NY, USA; 4University of
Hamburg, Hamburg, Germany
Objectives: In this study, we extend the findings from a prospective clinical
trial assessing the effects of early response to an atypical antipsychotic
across multiple functional outcome measures. Methods: This was a ran-
domized, double-blind, flexible-dose, 12-week study that enrolled chroni-
cally-ill patients (n = 630) diagnosed with schizophrenia or schizoaffective
disorder who were experiencing an acute symptom exacerbation. Patients
were initially assigned to risperidone drug therapy (2–6 mg/day), and their
response status at 2 weeks determined. Early responders continued with
risperidone therapy, whereas early non-responders were randomized
(1:1) in a double-blind manner to either continue on risperidone or switch
another atypical antipsychotic for 10 additional weeks of therapy. Subse-
quent improvement in functioning was measured by the Schizophrenia Ob-
jective Functioning Instrument (SOFI), Quality of Life Scale (QLS), and
Subjective Wellbeing under Neuroleptics (SWN) scale. Results: Early re-
sponse to risperidone was observed in 27.6% of patients. Compared to early
non-responders, early responders to risperidone showed significantly more
improvement from baseline to endpoint on the SOFI total score and 4 sub-
domains (P < .001), the QLS total score and 4 subdomains (P < .01), and
the SWN total score and 5 subdomains (P< .05). Most of these differences
in functioning were already evident and significantly different between the
early response and early non-response groups by 2 weeks of treatment.
Conclusion: Patients who show an early response to antipsychotic treat-
ment as measured by improvement in psychiatric symptom severity
show early and consistent improvement across multiple domains of func-
tioning, a finding that was concordant between both physician- and patient-
rated quality of life scales.
ID: 551425
EXPOSURE TO ‘‘THE TROUBLES’’ IN NORTHERN
IRELAND INFLUENCES CLINICAL
PRESENTATION FOLLOWING A FIRST EPISODE
OF PSYCHOSIS
Rosalind McCaul1, T. M. Rushe2, S. J. Cooper1, R. Anderson1,
A. J. Turkington1, C. Mulholland1
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United Kingdom
The effects of violence on the mental health of patients with psychosis has
been under researched (1) but there has been a recent important study in the
literature, this study examined eighty-two participants who had a diagnosis
of schizophrenia and a history of exposure to ‘‘The Troubles’’. This study
found that these patients had significantly higher levels of symptoms com-
pared to those patients with no such exposure. The purpose of this study is
to examine the impact exposure to the troubles made to symptomlogy fol-
lowing a first episode of psychosis. The Global Assessment of Functioning
scales (GAF), the Positive and Negative Syndrome Scale (PANSS), and the
‘‘Troubles’’ survey was administered to 175 patients recruited to the North-
ern Ireland (NI) First Episode Psychosis Study, at one year. The exposure
to the Troubles was based on the responses to two survey questions one
asking about the impact ‘‘.on your area’’; the second about the impact
‘‘. on you or your family’s life’’. Four ordered response categories ranging
from ‘‘not very much at all’’ to ‘‘a lot’’ were possible. Mean age of onset was
30.8yrs 6 10.7; m/f = 115/60.Median DUP was 6 months (IQR = 1–12).
Diagnosis breakdown was non-affective psychosis 66% as apposed to af-
fective psychosis 34% of population sample. While exposure to the troubles
was similar across the sexes and across diagnoses, some effects of the
‘‘Troubles’’ in the patient’s area were observed in 67.4% following their first
episode of psychoses. 32.6% related that the ‘‘The Troubles’’ had ‘‘a lot’’ of
impact on their area. 63.4% of patients related that the ‘‘The Troubles’’ had
some impact on their lives 63.4% responded that they had experienced ‘‘a
lot’’ of impact on their lives or on the lives of their families. Relationships
were observed between the effects on area and the GAF total score (Rho =
.186, P< .005) and between patients who were in remission. (Rho = .205, P<
.005. No significant relationship was observed between the effect of the ‘‘Trou-
bles’’ and the PANSS Scale. While it appears that the population of NI in gen-
eral has shown resilience to the effects of ‘‘The Troubles’’, those suffering from
first episode psychoses who have been directly effected show increased rates of
psychological morbidity and a poorer outcome.
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EVALUATION OF COGNITIVE FUNCTION IN
PATIENTS SWITCHED FROM RISPERIDONE TO
ARIPIPRAZOLE USING DIFFERENT TITRATION
STRATEGIES: AN OPEN-LABEL STUDY
V. Rykmans1, J. P. Kahn2, A. Dillenschneider3, S. Modell4,
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Analyses of secondary endpoints related to cognitive function were per-
formed on data from a 12 week, open-label study of 400 patients with schizo-
phrenia with efficacy and/or safety issues with risperidone who were switched
to aripiprazole (1). Patients were randomized to either a titrated (5 mg/day to
15 mg/day by Week 4) or fixed dose (initiated at 15 mg/day) aripiprazole
switching strategy. Changes in cognitive function were summarized at Weeks
4 and 12 (LOCF) using the Grupo Espan˜ol para la Optimizacio´n y Trata-
miento de la Esquizofrenia (GEOPTE) scale for social cognition and the
PANSS Cognition subscale. The GEOPTE scale (2) is a 15 item scale that
measures both the patient and caregivers’ subjective perception of the
patients’ deficits. A negative change score signifies improvement. The scales’
mean changes were summarized using descriptive statistics with 95% confi-
dence intervals. GEOPTE summary scores and PANSS Cognition subscale
scores were decreased at Weeks 4 and 12 (LOCF) for both switching strat-
egies. Aripiprazole was well tolerated with the most common adverse event
reported being insomnia (8.5%, n = 34/399). Non-optimally treated schizo-
phrenia patients switched from risperidone to aripiprazole showed reductions
in the GEOPTE Patient and Caregiver summary scores, as well as the PANSS
Cognition subscale. Additional research is warranted to evaluate the poten-
tial impact of ariprpazole on cognition.
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Table.
Titrated dosing—mean
change, (95% CI)
Fixed dosing—mean
change, (95% CI)
GEOPTE
patient
summary
Baseline (BL) 37.39, n = 194 37.97, n = 191
Week 4 [Change
from (BL)]
3.2, (4.67, 1.73),
n = 192
2.56 (3.84, 1.29),
n = 188
Week 12 (LOCF)
[Change from (BL)]
5.27, (6.80, 3.73),
n = 194
6.12 (7.84, 4.40),
n = 191
GEOPTE
caregiver
summary
Baseline (BL) 40.98, n = 102 44.31, n = 100
Week 4
[Change from (BL)]
4.17, (6.45, 1.90),
n = 98
7.19, (9.38, 4.99),
n = 95
Week 12 (LOCF)
[Change from (BL)]
5.43, (7.82, 3.04),
n = 102
9.92 (12.79, 7.05),
n = 100
PANSS
Cognition
subscale
Week 4 [Change
from (BL)]
18.27, n = 198 18.79, n = 195
Week 4 [Change
from (BL)]
2.19, (2.69, 1.70),
n = 198
2.72 (3.39, 2.05),
n = 194
Week 12 (LOCF)
[Change from (BL)]
3.36, (3.99, 2.73),
n = 198
3.97 (4.85, 3.09),
n = 195
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ASSESSMENT OF VOCATIONAL CAPACITY IN
SCHIZOPHRENIA
Lea Vella1, N. M. Loebach2, C. Z. Burton3, R. K. Heaton3,
D. V. Jeste3,4, E. W. Twamley3
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COMPASS (Computerized Assessment), a standardized vocational as-
sessment, is a battery of computerized and hands-on tests designed to
measure ability in specific work domains. This assessment was adminis-
tered in a treatment study examining the effectiveness of supported em-
ployment. We expected COMPASS scores to be correlated with baseline
neuropsychological performance, functional capacity, and previous work
history. Eighty-nine unemployed outpatients with schizophrenia or schiz-
oaffective disorder, ranging in age from 22 to 60, all stating a goal of
work, were enrolled in the study. Baseline assessments included the
COMPASS (reasoning development, mathematical development,
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language development, general learning ability, verbal aptitude, numeri-
cal aptitude, spatial aptitude, form perception, clerical perception, motor
coordination, finger dexterity, manual dexterity, eye hand foot coordina-
tion, and color discrimination); neuropsychological tests (attention, pro-
cessing speed, working memory, learning, memory, and executive
functioning); measures of psychiatric symptom severity (positive, nega-
tive, and depressive symptoms); measures of quality of life (physical
and mental); and an assessment of everyday functioning capacity. Past
work variables included recency of last work and percentage of adult life-
time employed. The COMPASS total score was examined as a putative
measure of the participant’s current vocational capacity. Higher COM-
PASS scores were correlated with better performance in every neuropsy-
chological domain (r = .48 to .74, P’s < .001), with the exception of
memory (P = .21). Higher COMPASS scores were also correlated with
greater everyday functioning capacity (r = .49, P = .001). Higher COM-
PASS scores were correlated with younger age, shorter illness duration,
higher levels of education, and ethnic non-minority status (r = .29, .27,
.51, and .37, respectively, P’s  .02). Lower levels of negative symptoms
and greater physical quality of life were also associated with higher
COMPASS scores (r = .32 and .42, respectively, P  .006). Neither re-
cency of last work nor percentage of adult lifetime employed was corre-
lated with COMPASS performance (P  .30). The expected relationships
between the COMPASS total score and neuropsychological and everyday
functioning emerged, but COMPASS performance was not associated
with recent or lifetime work history and may not predict return to
work in work rehabilitation participants.
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PHRENIA: THREE YEAR FUNCTIONAL
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USA; 8Psychiatry, Georgetown University School of Medicine,
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Background: We examined the independent functioning outcomes of first
episode subjects over the first three years of treatment with olanzapine or
risperidone. Method: 112 subjects aged 16 to 40 years old with a first ep-
isode of schizophrenia, schizophreniform or schizoaffective disorder were
randomly assigned to treatment with olanzapine (2.5 to 20 mg daily) or
risperidone (1 to 6 mg daily) and followed for a total of 3 years. Independent
functioning was assessed with the Multidimensional Scale of Independent
Functioning (MSIF). Domains assessed were work, education, combined
work and education role, residential and a global assessment of disability.
Ratings for each domain varied from 1 (normal functioning) to 7 (total dis-
ability). Results: Based upon a RMANCOVA model, overall functioning
improved over time in all areas. For work and education, ratings improved
approximately half a rating point for each year in study. Functioning did
not differ between medication conditions in any area. The least square
mean estimates for functioning with each medication were between 4 (mod-
erately disabled) and 6 (markedly disabled) for all areas. Women compared
with men had better work, residential and global functioning. Older com-
pared with younger subjects also had better work, residential and global
functioning. Marijuana use before study entry was associated with poorer
educational functioning. Subjects at the suburban study site compared with
subjects at the inner city site had better educational, combined work and
educational and global functioning. We also examined the time until sub-
jects achieved a rating of no or very mild disability. A substantial majority
of subjects were able to achieve this on the combined work and education
role. In a multivariate Cox regression model, subjects taking risperidone
compared with those taking olanzapine were approximately half as likely
to achieve good work functioning. Women compared with men were ap-
proximately twice as likely to have good work performance and approxi-
mately eight times as likely to have little or no disability related to
residential functioning. Discussion: Our subjects on average had substan-
tial disabilities during the first 3 years of treatment but improved to a clin-
ically meaningful degree over time. Olanzapine and risperidone treatment
did not differ on overall effect on disability but olanzapine was associated
with more likelihood of achieving little or no work disability.
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RECOVERY FROM SCHIZOPHRENIA: DOES
RESILIENCE MATTER? TEN AND 20-YEAR
FOLLOW-UPS OF FORMER PATIENTS WITH
SCHIZOPHRENIA
Anne-Kari Torgalsboen1, B. R. Rund1,2
1Department of psychology, University of Oslo, Oslo, Norway;
2Asker and Bærum Hospital Trust, Oslo, Norway
The main purpose of this study is to follow up a group of 27 persons with
a former diagnosis of schizophrenia 20 years after first assessment in order
to examine how many are still recovered and to evaluate the impact of
resilience on clinical outcome. A retrospective study of ten persons
who had fully recovered from schizophrenia was carried out in Norway
in the mid-80s. An expansion of this study, with methodological improve-
ments, was designed in 1989/1990. During a 4-year period 20 people were
recruited through several mental hospitals in Norway; 17 fulfilled the in-
clusion criteria. A semi-structured interview is designed for the 20-year
follow up study based on previous research on course and prognosis of
schizophrenia. In addition to the interview, the Global Assessment of
Functioning Scale (GAF) is used to examine each subject’s present overall
psychosocial functioning. To assess remission, the criteria for remission in
schizophrenia by Andreasen and collaborators (2005) will be used as well
the operational criteria for full recovery developed by Liberman et al.
(2002). The Connor-Davidson Resilience Scale (CD-RISC) (2003) is cho-
sen to assess resilience. The scale comprises of 25 items, each rated on a 5-
point scale, with higher scores reflecting greater resilience. The inclusion of
subjects is still going on. Data-analysis is under preparation, but prelim-
inary results (n = 7, mean age 50.6 years) show a significant correlation
between resilience and present GAF score and how the subjects rate their
subjective well-being. There is also a significant difference between fully
recovered subjects and those with remission concerning resilience score.
These results indicate that a majority of the subjects have maintained their
recovery and that subjects who are still fully recovered are more resilient.
Further analyses with the whole sample is needed to see if these tendencies
are confirmed.
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TALKING ABOUT SCHIZOPHRENIA—PSYCHOE-
DUCATION IN THE CONSUMER’S PERSPECTIVE
Rodrigo Affonseca Bressan, J. C. Assis, C. C. Villares
Psychiatry, Universidade Federal de Sa˜o Paulo, Sao Paulo, Brazil
Psychoeducation is very challenging in schizophrenia due to its psychopath-
ological complexity, heterogeneous clinical presentations and outcomes.
Psychiatrists’ descriptions of symptoms and jargons are not well under-
stood by patients and families. There is a need of consumer friendly materi-
als using more appropriate language to the lay public. Objective: To
develop a psychoeducational material from patient’s and parent’s point
of view using illustrative cartoons. Methods: A schizophrenic patient,
a family member and an occupational therapist trained in the WHO
anti-stigma program (Open the Doors), together with a psychiatrist and
a cartoonist where involved in the development of the psychoeducational
material. Instead of communicating psychiatric knowledge to consumers,
the aim of the material was to bring different perspectives together showing
using three characters to express the complexity of schizophrenia with a re-
alistic hope. Results: The content was divided in 6 booklets. The
1st—‘‘How does it occur’’ focused on the prodrome symptoms and the first
psychotic episode; the 2nd, ‘‘The construction of a diagnose’’ focused on
the issues related to the diagnostic criterias; 3rd, ‘‘The relevance of treat-
ment’’ focused on the treatment challenges; 4th, ‘‘Stigma—how people per-
ceive it’’ focused in perception of stigma in real life; 5th, ‘‘Family
environment’’ focusing on the families perspectives, 6th, ‘‘Recover and
new perspectives’’ showing the different aspects of recover and the new sci-
entific advances. Each booklet had 30 000 copies which that were distrib-
uted in most mental health centers all over Brazil by Astra-Zeneca’s
representatives every two-months. Discussion: The booklet was extremely
well accepted by patients and families with several reprint requests. Psychia-
trists also evaluated very positively the material, some clinicians use the
material in their regular appointments. A website was recently developed
(http://proesq.institucional.ws/psicoeducacao) and is widely accessed by
patients and families.
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Durk Wiersma1, A. Wunderink1,2, S. Sytema1
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Introduction: Generally agreed outcome criteria in psychosis are required
to evaluate the effectiveness of new treatment strategies and surmount ther-
apeutic pessimism. The aim of this study is to explore recovery and its re-
lation to symptomatic and functional remission in first episode patients and
to find predictors of recovery. Method: In a sample of first episode patients
(N = 125) symptomatic and functional remission during the last nine
months of a two years follow-up period were examined, as well as recovery
and its predictors. Recovery was clinically defined by the two dimensions of
symptomatic and functional remission. Results: Half the patients (52.0 %)
showed symptomatic remission, a quarter (26.4 %) showed functional re-
mission, while one fifth (19.2 %) met both criteria-sets and were considered
recovered. Functionally remitted patients recovered in 72.7% (OR = 2.7),
symptomatically remitted patients in 36.9% (OR = .6). Recovery was sig-
nificantly associated with short duration of untreated psychosis (OR = .531,
df = 1, P = .008). No recovery occurred in patients with long duration of
untreated psychosis (> 6 months). Another significant predictor of recovery
was better baseline functioning (OR = .858, df = 1, P = .021). Conclusion:
Functional remission is more selectively associated with recovery than
symptomatic remission. Treatment delay reduces chance of recovery. Base-
line functioning levels also significantly predict recovery. Our results clearly
show that social functioning is an important parameter in schizophrenia
outcome research, both as a predictor of future course characteristics,
and as a more selective index of recovery than symptom remission.
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Recent studies suggest that, decades after initial onset of schizophrenia,
a substantial number of patients can achieve full recovery, eg, sustained
improvement in both symptoms and social/work functioning. Patients in
the early course of schizophrenia can also achieve recovery, although
reports indicate that the overall rate of early recovery is low (13.7%; Rob-
inson et al. 2004). Patients in the early course of schizophrenia (N = 73), who
were being treated at UCLA with a first generation antipsychotic medica-
tion and psychosocial interventions, were assessed at 3-month intervals dur-
ing their first post-hospitalization year. Positive and negative symptom
remission required subclinical ratings on all relevant BPRS items (Nuech-
terlein et al. 2006). Modified functional recovery criteria required adequate
social and work functioning. Both had to be met for three months duration.
At 12 months, 51% of the subjects achieved both positive and negative
symptom remission and 19% had adequate social and work functioning.
Only 14 % of subjects showed both symptom remission and functional re-
covery at 12 months. Level of insight predicted recovery, but age at onset,
patient education, parental education, prodromal course of illness, premor-
bid prodromal social and work functioning did not. Patients with good in-
sight or no insight were more likely to recover than patients with partial
insight. Although some schizophrenia patients can achieve both symptom-
atic and functional recovery in the early course of illness, the overall rate
during the first post-hospitalization year might be relatively low. Some tra-
ditional predictors of poor outcome, eg, low levels of education, were not
related to this combination of symptom and functional recovery. The ev-
idence that partial, but not good or poor insight is related to recovery is
consistent with a previously found relationship between insight and neuro-
cognitive functioning.
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CBT FOR SCHIZOPHRENIA: MOLDING TECHNI-
QUES FROM THE UK TO FIT SYSTEMS IN THE USA
CBT FOR SCHIZOPHRENIA: MOLDING TECHNI-
QUES FROM THE UK TO FIT SYSTEMS IN THE US
Page Burkholder
Psychiatry, SUNY Downstate, Brooklyn, NY, USA
The challenges and rewards of adapting and implementing techniques of
CBT for schizophrenia developed in the UK to ‘‘real world’’ clinical settings
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in the USA will be outlined in this presentation. The programs to be dis-
cussed are based upon the results of clinical trials and programs first prac-
ticed in the UK and utilize features (normalizing, reality testing, developing
alternative explanations for delusions, etc.) taught and supervised by
experts from the UK. They have developed within the very different and
less uniform medical system in the USA. Various ways of disseminating
both the specific ‘‘hands on’’ techniques and the paradigm shift required
for conceptualizing ‘‘psychotherapy for schizophrenia’’ to clinicians in
the USA will be discussed. Two clinical trials which grow from and build
upon the UK programs will be presented. One, from Drs. Yulia Landa and.
Paul Chadwich presents a Group Cognitive Behavioral Therapy interven-
tion for paranoid delusions and cognitive biases compared to Treatment as
Usual (TAU). Twenty four patients with Schizophrenia or Schizoaffective
Disorder were randomly assigned to CBT or control, with one group and
one individual session weekly. At week 8 the initial assessment showed sig-
nificant changes in the CBT condition, but not in the TAU condition (re-
duction in delusions, suspiciousness and poor rapport from the PANNS,
reduction in delusional conviction and amount of distress from PSYRATS
and increase in ability to dismiss a paranoid thought and decrease in worry
from the CDRS). A second pilot trial from Drs. Peter Weiden, Douglas
Turkington, Nina Schooler and. Page Burkholder looked at implementing
CBT for schizophrenia in a large public psychiatric clinic in the ‘‘inner city’’
and at medication adherence as an outcome measure for CBT (given the
crucial role adherence to treatment and medication plays in better clinical
outcomes, including the CATIE trial). 16 outpatients with schizophrenia or
schizoaffective disorder were randomized to TAU or CBT-Adherence In-
tervention. While the small sample size and low completion rates (only 4 of
9 CBT patients attended all 12 sessions) the CBT-AI appeared to increase
subsequent medication adherence rates.
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OASIS: FIRST 3 YEARS EXPERIENCE CARING FOR
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OF PSYCHOTIC ILLNESS IN CHAPEL HILL, NORTH
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D. O. Perkins1
1OASIS Program, Psychiatry, University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA; 2Psychology, University of
North Carolina at Chapel Hill, Chapel Hill, NC, USA
There remains hope that appropriate early intervention in the first years of
psychotic illness can reduce chronicity of symptoms and improve function-
ing. In the United States the challenge is to provide these services within
a fee for service system in which this population is particularly at risk
for inadequate mental health insurance. Here we describe the first 3 years
experience of OASIS, a community-based specialty clinic providing com-
prehensive services to teens and young adults (ages 16 to 35) with new onset
psychosis, and those at high risk for developing psychosis. Services include
psychiatric evaluation and management, individual, group, family and mul-
tifamily therapies, as well as keyworker services. Since opening June 2005,
OASIS has admitted 209 clients. Twenty-six (12.4%)were identified as ‘at
high risk’ for developing psychosis. Clients have a mean age of 22.66 years
(SD 4.49), are predominantly male (71%), Caucasian (67.4 %), and single
(93% never married). 25 % were in school (or recently on medical leave from
school) at time of entry into our program, and 67.9 % were unemployed. At
entry into our program, the mean GAF score was 50.82 (SD 11.43) dem-
onstrating the severe symptoms and functional impairment of our clients.
58% of our clients have private insurance, 22% have Medicaid, and 20% are
uninsured. OASIS was founded with the support of two grants, KB Rey-
nolds and Duke Endowment. Data collection at six month intervals shows
improvement from baseline in GAF, symptom response and functional out-
come. Our data highlight the importance of comprehensive treatment of
those at risk for psychosis and those in the early years of illness, where
symptoms adversely affect school, transition to work, and social relation-
ships. Service provision for this population requires coordination of limited
resources.
ID: 551146
SELF-ESTEEM AND PSYCHOTIC SYMPTOMS: A
QUESTIONNAIRE STUDY IN THE GENERAL
POPULATION
Jasper Edwin Palmier-Claus, S. Lewis, G. Dunn
Psychiatry, The University of Manchester, Manchester, United
Kingdom
A component of self-esteem, negative beliefs about the self, may be asso-
ciated with psychotic symptoms in clinical and non-clinical populations
(Barrowclough et al. 2003; Gracie et al. 2007). This study re-examines
whether positive and negative beliefs are associated with paranoia, positive
symptoms, negative symptoms and depression. It also investigates the re-
lationship that self-esteem has with perceived stress, stressful life-events and
schizotypy. 268 healthy volunteers completed several questionnaires online.
These included: the Green et al. Paranoid Thought Scale, designed to be less
confounded by depression than more commonly used measures of para-
noia; an adapted version of the Holmes-Rahe Life Events Scale; and the
Brief Core Schema Scale. Participants will be contacted to complete fol-
low-up questionnaires in October, 2008. Preliminary multiple regression
analyses show that negative, but not positive beliefs about the self, are as-
sociated with paranoia (P < .001), positive symptoms (P < .001) negative
symptoms (P< .001), depression (P< .001) and total symptom scores (P<
.001) at baseline. The number of life events deemed by the participant to be
‘very stressful’ was associated with negative beliefs, whereas life events ap-
praised as even ‘moderately stressful’ were associated with the formation of
psychotic symptoms. Initial consideration of the data confirms that nega-
tive beliefs about the self are strongly associated with the positive, but also
the negative symptoms of psychosis. Future analysis will control for depres-
sion and examine a model of stress, self-esteem and symptom severity using
structural equation modelling. Data from the follow-up assessments will
also be analysed. Negative beliefs about the self may act as a vulnerability
factor for psychosis, and further research is needed to assess its suitability as
a target for intervention in clinical and at risk groups.
ID: 551036
CIBERSAM: THE SPANISH NETWORK ON MENTAL
HEALTH
Celso Arango1,2
1Hospital General Universitario Gregorio Maran˜on, Madrid, Spain;
2Centro de Investigacio´n en Red de Salud Mental, CIBER, Madrid,
Spain
The Center for Biomedical Research in Mental Health (CIBERSAM) is
composed of 25 research groups in the field of psychiatry and neuroscience
(www.cibersam.es). The groups, comprising more than 500 researchers, are
located in public and private hospitals, universities, and research institu-
tions. This virtual center, funded by the Spanish government, has
a main objective of seeking increased efficiency by coordinating basic
and clinical research groups and achieving effective and productive man-
agement of assigned resources. A number of multicenter trials, including
clinical trials assessing the efficacy of antidepressants for the treatment
of negative symptoms (n = 250 patients), gene x environmental interaction
studies in patients and families (n = 1000 patients) , longitudinal studies of
first-episode childhood-onset schizophrenia assessing progressive changes
and oxidative stress markers, the search for new therapeutic targets, and
post-mortem studies, are being conducted, focusing on schizophrenia
and related psychoses. We will present the highlights of those studies
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and will testify on behalf of the benefits of such a structure that includes
both clinical and basic research facilities, working to foster innovation and
the transfer of results to society, the scientific community, and the enter-
prise sector.
ID: 551012
EARLY DETECTION OF FIRST PSYCHOSIS: TIPS
SAMPLE FIVE YEAR OUTCOMES
Ingrid Melle1,2, T. K. Larsen5,6, S. Friis1,2, P. Vaglum3,
J. O. Johannesen5, E. Simonsen7, U. Haahr7, S. Opjordsmoen1,2,
B. R. Rund4, J. I. Rossberg1,2, I. Joa5, W. Hegelstad5,
H. Langeveld5, J. Evensen1, T. H. McGlashan8
1Psychiatry, Ulleval University Hospital, Oslo, Norway; 2Institute
of Psychiatry, University of Oslo, Oslo, Norway; 3Institute of
Behavioral Sciences in Medicine, University of Oslo, Oslo, Norway;
4Institute of Psychology, University of Oslo, Oslo, Norway;
5Psychiatry, Stavanger University Hospital, Stavanger, Norway;
6Clinical Medicine, University of Bergen, Bergen, Norway;
7Psychiatric Research, Zealand Region Psychiatry, Roskilde,
Denmark; 8Psychiatry, Yale University, New Haven, CT, USA
Reducing the duration of untreated psychosis (DUP) through early detec-
tion is associated with better PANSS negative (PNeg), depressive (PDep),
and cognitive (PCog) outcomes at baseline, 1 and 2 year follow-up in the
TIPS first episode psychosis sample. Here we report differences in early
detected (ED) versus non-early detected (NoED) samples at 5 years. A total
of 281 patients with first psychosis (DSM-IV) were recruited to baseline
over 4 years. The two samples entered equivalent treatment programs
for the first 2 years. At 5 year follow-up 193 (69%) of the baseline sample
participated (74% and 64% of ED and NoED samples, respectively). The
PNeg score at 2 years was: ED = 15.7, NoED = 18.7, P = .013 and at 5 years
was ED = 15.8, NoED = 17.0,P = ns. Drop outs between 2 and 5 years in the
NoED group had significantly higher 2 years PNeg than ED drop-outs
(ED = 14.9, NoED = 21.0, P = .008). The PDep score at 2 years was
ED = 8.2, NoED = 9.9, P = .001 and at 5 years was ED = 8.1, NoED =
9.0, P = ns. Again PDep scores at 2 years were higher in NoED dropouts
(ED = 7.7, NoED = 10.1,P = .015). The PCog score at 2 years was ED = 4.3,
NoED=5.6,P= .0001 and at 5 years remained significant (ED=4.2, NoED=
5.4,P= .0001) with no difference in the PCogscores amongdropoutsbetween
2 and 5 years. Treatment utilization was not different across the two groups
for the first 2 years as per the standard protocol. After 2 years treatment
was optional. ED/NoED medication utilization was equivalent at years 3,
4, and 5, but the rate of individual treatment contacts (‘‘talking therapies’’)
wassignificantly lower (P< .01) in theEDgroupatyears3, 4,and5compared
to the NoED group. Overall, ED/NoED baseline differences in negative,
cognitive, and depressive components appear to persist to 5 years. Apparent
attenuation of differences is likely to be secondary to higher drop out rates
of sicker NoED patients between 2 and 5 years. By years 3, 4, and 5 more
ED patients have less structured treatment contacts but continue pharmaco-
therapy suggesting greater treatment selectivity by the ED group.
ID: 550970
THE EFFECT OF NEUROCOGNITIVE CHANGE ON
HETEROGENEOUS TREATMENT RESPONSE
SUBGROUPS OF FUNCTIONAL CHANGE IN
COMMUNITY-BASED PSYCHOSOCIAL
REHABILITATION FOR SCHIZOPHRENIA
Maanse Hoe, J. S. Brekke
School of Social Work, University of Southern California, Los
Angeles, CA, USA
The present study aimed to test two hypotheses. The first hypothesis pro-
posed that there would be heterogeneous subgroups of functional change in
community-based psychosocial rehabilitation. The second hypothesis was
that subgroups in neurocognitive change would predict the subgroups of
individual trajectories of functional change The notion of heterogeneity
in treatment responsiveness has been repeatedly addressed in literature
but the heterogeneity in the impact of community-based psychosocial re-
habilitation across individuals is not well documented. Method: Data were
gathered on 130 individuals diagnosed with schizophrenia recruited upon
admission to community-based psychosocial rehabilitation who were fol-
lowed over a 12 month period. Psychosocial functioning data were gathered
at baseline, 6 and 12 months. Tests of neurocognition and social cognition
were administered at baseline and 12 months by testers blind to the psycho-
social data. Data were analyzed using latent growth mixture models.
Results: Growth mixture modeling showed that there was two latent classes
in functional change that discriminate those individuals who showed
a strong relationship between treatment intensity and functional change
during rehabilitation (treatment responders) and those who did not
show a significant relationship between service intensity and functional
change during rehabilitation (treatment non-responders). The subgroup
of neurocognitive change significantly predicted the treatment response
subgroups, indicating that individuals with neurocognitive enhancement
were five times more likely to belong to the treatment responders than
the trajectory class of the treatment non-responders (OR = 4.978; 95 %
CI = 1.666–14.877). Additional analyses showed that individuals at baseline
who were younger (OR = .919), had more social contacts (OR = 1.566), had
better neurocognition (OR = 1.194) and who had less symptomatology
(OR = .937) were more likely to be in the treatment responder class in which
functional improvement was significantly predicted by treatment intensity.
Implication: These findings suggest a neuro-psycho-social model for under-
standing responsiveness to intensive psychosocial rehabilitation in the com-
munity. This is a multi-factorial model which spans phenomenological
levels, and suggests that comprehensive and interdisciplinary theoretical
approaches are needed to understand complex issues like treatment respon-
siveness in schizophrenia.
ID: 550950
NEGATIVE SOCIAL INTERACTION APPRAISALS,
MOOD AND SOCIAL FUNCTIONING IN
SCHIZOPHRENIA
Eric Granholm1,2, J. Swendsen3, C. Loh1,2
1Psychology, VA San Diego Healthcare System, San Diego,
CA, USA; 2Psychiatry, University of California, San Diego,
San Diego, CA, USA; 3University of Bordeaux, Bordeaux, France
Research on the complex interplay between factors that might contribute to
poor social functioning in schizophrenia has been hampered by limitations
of traditional measures, most notably the ecological validity of retrospec-
tive self-report and interview measures. Computerized Experience Sam-
pling Methods (ESMc) permit the real-time assessment of relationships
between daily life experiences, thoughts, feelings and behaviors. ESMc
was used to assess number of daily social interactions, appraisals of these
interactions (eg, ‘‘I succeeded/failed;’’ ‘‘I was liked/rejected’’), and mood in
outpatients (n = 111) with schizophrenia. Participants completed electronic
questionnaires on a personal digital assistant (PDA) four times per day for
one week. In time-lagged HLM analyses, more negative interaction
appraisals at any point in a day were associated with less positive mood,
which in turn, was a strong predictor of fewer social interactions over sub-
sequent hours. Social isolation, therefore, was linked to defeatist beliefs
about social interactions that were associated with reduced positive
mood. Greater positive mood may have been more reinforcing of prior so-
cial interactions or less likely to activate negative defeatist beliefs that
would interfere with later interactions. The findings may suggest a useful
treatment target for psychosocial interventions, like cognitive behavioral
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therapy, which can be used to challenge defeatist beliefs and improve mood
and, therefore, might improve social functioning in schizophrenia.
ID: 550944
ASSESSING THE ABILITY TO TAKE MEDICATION
Natalie Jean Maples, D. I. Velligan, J. L. Ritch, X. Li, D. Stutes,
A. L. Miller
Psychiatry, UTHSCSA, San Antonio, TX, USA
The Test of Adaptive Behavior in Schizophrenia– Medication subtest
(TABS-MED) assesses a person’s ability to follow medication instructions,
to identify problems such as running out of medication, and to get appro-
priate medication refills. The TABS is designed to assess capacities includ-
ing initiation, planning, problem identification, sequencing, and problem-
solving that are necessary to complete a range of instrumental skills. The
TABS-MED assesses these capacities as they relate to the ability to take
medication as prescribed. As part of an NIMH trial examining the efficacy
of different psychosocial treatments to improve adherence, we examined
the reliability and validity of the TABS Medication Subtest in a sample
of 69 individuals with schizophrenia (DSM-IV-R). At baseline, the
TABS-MED, the Medication Management Ability Assessment
(MMAA)–a performance-based test of medication taking ability from
the UCSD Performance-Based Skills Assessment, and a comprehensive
neuropsychological test battery were administered. Subjects were followed
for one month to examine adherence to medication using randomly scheduled,
unannounced in home pill counts. Results indicated that the TABS and
MMAA were significantly but not strongly correlated (r = .30; P < .01).
Only the TABS was significantly correlated with a summary cognitive func-
tion score (r = .34 <.003) and measures of prospective memory (.46; P <
.0001), working memory (.44; P < .0001), secondary verbal memory (r =
.38; P < .002) processing speed (r = .25; P < .04), sustained attention
(r = .32; P < .01) and card sorting (r = .40 P < .0002). Neither the
TABS nor MMAA was significantly correlated with fluency measures.
Only the TABS was significantly correlated with pill count adherence
(r = .31; P < .03). The relatively weak correlation of the TABS with pill
count adherence underscores the notion that adherence is multi-determined
and ability is only one contributor to taking medication as prescribed. The
TABS-MED may be a useful performance-based assessment for examining
the capacity for adherence in studies where direct assessment of adherence
behavior is not possible.
ID: 550922
ANTIPSYCHOTIC DRUGS AND QUALITY OF LIFE
IN SCHIZOPHRENIA: A META-ANALYSIS
Lakshmi P. Voruganti1, A. G. Awad2
1Psychiatry and Behavioral Neurosciences, McMaster University,
Hamilton, ON, Canada; 2University of Toronto, Toronto,
ON, Canada
Background: Improved quality of life and psychosocial functioning have
been recognized as desirable goals of effective antipsychotic drug therapy;
and second generation antipsychotic drugs held the promise of fulfilling this
need. We sought to review all studies that formally evaluated the impact of
antipsychotic drugs on quality of life of people treated for schizophrenia.
Methods: Clinical trials and other evaluation studies on the effectiveness of
antipsychotic drugs in schizophrenia published between 1953 and July 2008
were identified; and studies that included quality of life or functional out-
come measures were specifically examined to assess the impact of antipsy-
chotic drug therapy on these domains. 67 studies that met the study criteria
were critically reviewed, ascertaining the process and outcome of quality of
life evaluations. Results: There is a dearth of data on quality of life eval-
uation in clinical trials, considering the vast number of published studies on
the efficacy of antipsychotic drugs. Design issues such as lack of an explicit
evaluation strategy, use of disparate quality of life measures and relatively
short duration of trials significantly limit the validity and generalizability of
results. Studies suggested, however, that antipsychotic drug therapy (com-
pared to no treatment) improved quality of life; and second generation an-
tipsychotic drugs fared better in improving functional outcomes.
Conclusions: Measuring quality of life, let alone improving it, remains
a challenge in schizophrenia research and antipsychotic drug evaluation.
The review highlights the need to broaden the scope of evaluation batteries
in clinical trials and develop standard guidelines, and stresses the inclusion
of patient reported outcomes.
ID: 550875
IMPAIRED OLFACTORY IDENTIFICATION
ABILITY IS ASSOCIATED WITH POORER
FUNCTIONAL OUTCOME IN PATIENTS WITH
FIRST EPISODE PSYCHOSIS
Kimberley P. Good1, P. Tibbo1, H. I. Milliken1, D. Whitehorn1,
M. Teehan1, M. Alexiadis1, N. Robertson1, Z. Ursuliak1,
S. Abidi1, L. C. Kopala2
1Psychiatry, Dalhousie University, Halifax, NS, Canada;
2Psychiatry, University of British Columbia, Vancouver, BC,
Canada
Background: Olfactory deficits are found in a significant proportion of
patients with psychotic disorders, however, the full prognostic significance
of these findings has yet to be determined. Our group has previously
reported that patients with olfactory deficits (‘microsmic’) are less likely
to remit on negative and cognitive symptoms of the PANSS in follow-
up (Good et al. 2006, AJP 163(5): 932–933). In the current study, we
identified first episode psychosis patients who were microsmic at first pre-
sentation and compared them to first episode psychosis patients who had
normal olfaction (‘normosmic’), on functional outcome using the SOFAS
and Levels of Functioning Scale (LOFS) after at least 2 years of treatment
in the Nova Scotia Early Psychosis Program (NSEPP). Premorbid func-
tioning, measured with the Premorbid Adjustment Scale (PAS), was com-
pared between groups. Method: Seventy six (76) first episode psychosis
patients (52M; 24F) were assessed with the University of Pennsylvania
Smell Identification Test (UPSIT) as soon as it was clinically feasible at
baseline. UPSIT scores served to classify patients into subgroups. The
PAS was completed by an informed relative (usually the mother) at base-
line. The patients’ psychiatrists completed the SOFAS and the LOFS at
standardized time points post-baseline assessment Results: 40% of the sam-
ple was identified as microsmic. LOFS scores were significantly lower in the
microsmic group than the normosmic group (F9,40 = 3.9, P < .001), specif-
ically on measures assessing level of useful employment and ability to meet
own basic needs. Differences in SOFAS scores missed statistical signifi-
cance (t71 = 1.7, P < .10). PAS scores did not differ between groups. Con-
clusions: Microsmic patients had poorer functional outcome than
normosmics patients despite no differences in premorbid adjustment. Ol-
factory deficits at first episode may provide a marker of poorer outcome.
Testing olfaction is a simple process and could provide clinically valuable in-
formation at first episode to identify those patients early who might benefit
from more intensive biopsychosocial interventions to promote functional
recovery.
ID: 554879
DISSECTING SOCIAL INFORMATION PROCESSING
DEFICITS IN SCHIZOPHRENIA: CONTRIBUTION
OF AFFECTIVE AND NON-AFFECTIVE COGNITIVE
COMPONENTS
Gretchen L. Haas1,2, L. Valenti2, J. Caponigro2, A. Molz2,
G. Goldstein2, J. Luther1,2
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1Psychiatry, University of Pittsburgh School of Medicine, Pitts-
burgh, PA, USA; 2MIRECC, VA Pittsburgh Healthcare System,
Pittsburgh, PA, USA
Deficits in social functioning are a core feature of schizophrenia. A growing
body of research on facial affect recognition in schizophrenia provides
strong evidence for receptive deficits in the processing and interpretation
of emotion expression in the human face. Concurrent with these findings
is the body of evidence for deficits in social perspective-taking and the in-
terpretation of meaning from verbal and non-verbal interpersonal commu-
nication. The current study was designed to investigate specific components
of social information processing, on laboratory measures of facial affect rec-
ognition, and social perspective-taking, in addition to two new measures of
inferential reasoning regarding interpersonal behavior in a social context.
Methods: 43 adults with DSM-IV Schizophrenia or Schizoaffective Disor-
der and 42 Healthy Control Subjects, ages 18–65, matched for age, IQ and
socioeconomic status, were evaluated on a battery of non-affective and af-
fective cognitive tasks, including the Pennsylvania Emotion Recognition
Task (PERT-96), a False Belief Task (FBT) to assess so-called Theory
of Mind perspective-taking abilities, a new videotape equivalent of the
FBT task and a newly validated Movie Clips task that taps inferential rea-
soning regarding the thoughts, feelings and motives of characters in selected
scenes from movies. Results: Participants with schizophrenia not only dem-
onstrated deficits in the accuracy (P < .004) and speed (P < .003) of pro-
cessing facial affect, but deficits on these measures were correlated with
deficits in social perspective-taking on both the videotape (<.01) and story
version (P < .05) of the FBT as well as inferential reasoning regarding the
thoughts, and emotions of characters in the movie scenes. A particularly
interesting finding was that the ability to reflect on personal emotional re-
sponse to watching the movie scene was correlated with accuracy on the
objective measure of affect recognition. Findings provide promising evi-
dence of links between specific information processing deficits and the in-
terpretation of social behavior in a social context.
ID: 554986
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21. 21. Therapeutics: Pharmacologic Probes
IDENTIFICATION OF CLOZAPINE INTERACTIONS
WITH THE PHOSPHATIDYL INOSITOL 3-KINASE
(PI3K) PATHWAY IN CAENORHABDITIS ELEGANS
Rakesh Karmacharya1,3, G. R. Sliwoski2, M. Y. Lundy2, R. F.
Suckow4, B. M. Cohen1,2, E. A. Buttner1,2
1Psychiatry, Harvard Medical School, Boston, MA, USA;
2Mailman Research Center, McLean Hospital, Belmont, MA, USA;
3Chemical Biology Program, Broad Institute of Harvard and MIT,
Cambridge, MA, USA; 4Department of Analytical Psychophar-
macology, New York State Psychiatric Institute, New York,
NY, USA
Clozapine has superior therapeutic efficacy and a unique side effect profile
as an antipsychotic agent, but the mediators of these effects are not known.
We studied behavioral and developmental effects of clozapine in the nem-
atode C. elegans, as a model system to identify previously undiscovered
mechanisms of drug action. C. elegans provides a versatile system that
can be used to identify novel targets and pathways modulated by psycho-
active drugs, as many gene systems of interest in psychiatric illnesses are
conserved between C. elegans and mammals. In our study, we observed
that clozapine induced developmental arrest in early larval stages in C. ele-
gans in a dose-dependent manner. Larval arrest was also seen with the clo-
zapine metabolite N-desmethyl clozapine but was not seen with other
typical or atypical antipsychotic drug tested, including haloperidol, perphe-
nazine, or olanzapine. We then screened for worms with mutations in neu-
rotransmitter and signal transduction systems to dissect pathways involved
in clozapine-induced larval arrest. Experiments with mutants deficient in
neurotransmitter biosynthetic pathways showed that clozapine-induced
larval arrest was not dependent on dopaminergic or serotonergic systems,
which are shared targets for other antipsychotic drugs. We discovered that
age-1 mutants, which have a mutation in the gene coding for phosphatidyl
inositol 3-kinase (PI3K), suppressed clozapine-induced larval arrest. This
result is interesting in the context of recent human genetic studies pointing
to an association between the PI3K target AKT-1 and schizophrenia. It is
known that PI3K plays a pivotal role in the insulin signaling pathway. We
compared the effects of starvation to that of clozapine on the insulin sig-
naling pathway, since both conditions lead to early larval arrest. We studied
the nuclear/cytoplasmic localization of the transcription factor DAF-16,
which is the downstream effector in the insulin signaling pathway. The
DAF-16 localization results showed that starvation results in inhibition
of the insulin signaling pathway, while clozapine-induced larval arrest
results in activaton of the insulin signaling pathway. Our findings demon-
strate a drug-specific novel interaction between clozapine and the PI3K
pathway in C. elegans and hold implications for understanding the unique
therapeutic and/or side effects of clozapine in humans.
ID: 542774
REASONS FOR DISCONTINUATION AND CON-
TINUATION OF ANTIPSYCHOTIC THERAPY FROM
PATIENT AND CLINICIAN PERSPECTIVES
Allen W. Nyhuis1, H. Ascher-Svanum1, V. Stauffer1, B. J. Kinon1,
D. Faries1, G. Phillips1, D. Perkins2
1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis,
IN, USA; 2School of Medicine, University of North Carolina,
Chapel Hill, NC, USA
The purpose of this study was to assess the reasons for discontinuation and
for continuation of antipsychotic medication in the treatment of schizo-
phrenia from patient and clinician perspectives. Two measures were
developed to assess the Reasons for Antipsychotic Discontinuation/
Continuation (RAD), one from patient’s perspective (RAD-I) and the
other from clinician’s perspective (RAD-Q). These measures were admin-
istered to patients enrolled in a 12-week study of antipsychotic medication
in the treatment of schizophrenia (N = 630). Reasons for discontinuation
and reasons for continuation with the assigned antipsychotic during the
study were assessed. Reported reasons were rated as being a primary rea-
son, very important, somewhat important, or of minor importance. The top
primary reasons for medication discontinuation and continuation were
identified from patient and clinician perspectives, and level of concordance
between patients’ and clinicians’ reasons was assessed. The top primary rea-
sons for medication discontinuation differed from the top primary reasons
for continuation on the medication, with a high level of concordance be-
tween patients’ and clinicians’ perspectives. The top 3 primary reasons for
medication discontinuation were insufficient improvement or worsening of
positive symptoms, medication-related adverse events, and insufficient im-
provement or worsening of mood symptoms. The top 3 primary reasons for
medication continuation were improvement in positive symptoms, subjec-
tive perception of improvement, and improvement in level of functioning.
Current findings show that medication efficacy appears to be the core driver
of medication continuation and discontinuation, especially with regard to
positive symptoms. Reasons for medication discontinuation differ some-
what from reasons for continuation, with a high level of concordance
between patients’ and clinicians’ perspectives.
ID: 550806
ORAL SUPPLEMENTATION AND CONCOMITANT
MEDICATION IN THE TREATMENT OF
SCHIZOPHRENIA WITH LONG-ACTING ATYPICAL
ANTIPSYCHOTICS
Haya Ascher-Svanum1, X. Peng1, W. Montgomery2, D. Faries1,
A. Lawson1, M. Witte1, D. Novick3, N. Jemiai3, E. Perrin4,
D. P. McDonnell5
1Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA;
2Health Outcomes, Eli Lilly and Company,MacQuarie Park, NSW,
Australia; 3Health Outcomes, Eli Lilly and Company, Erl Wood
ELCL, United Kingdom; 4Medical, Eli Lilly and Company,
Surenses, France; 5Medical, Eli Lilly and Company, Cork ELCL,
United Kingdom
This study aimed to assess the use of oral antipsychotics and other con-
comitant oral medications—psychotropics and the anticholinergic benztro-
pine—during the 1-year open-label treatment of schizophrenia with
olanzapine long-acting injection (OLAI), and to compare with previously
published rates for risperidone long-acting injection (RLAI). One-year
rates of concomitant oral medication use were drawn from 2 comparable
open-label, single-arm extension studies of patients with schizophrenia
treated with long-acting atypical antipsychotic medications: 1 for OLAI
(n = 931), with extension of 3 OLAI clinical trials, and 1 for RLAI (n =
371), with extension of 2 RLAI clinical trials (based on published 1-year
data—Lindenmayer et al. Eur Neuropsychopharmacol. 2007;17:138–
144). Supplementation with oral olanzapine occurred in 21% of OLAI-
treated patients (median duration 10 days). Oral risperidone was
supplemented—beyond the first 3 weeks of treatment in 45%–83% of
RLAI-treated patients (median duration not reported). Use of the anticho-
linergic benztropine was low among OLAI-treated patients (3%, median
duration 14 days) and higher among RLAI-treated patients (31%–44%, me-
dian duration not reported). Lorazepam was used by 11% of OLAI-treated
patients compared to 24%–55% of RLAI-treated patients. Zolpidem was
used by 4% of OLAI-treated patients and 11%–12% of RLAI-treated
patients. Atypical antipsychotic therapies in long-acting injection formula-
tions were found in this preliminary analysis to differ on concomitant use of
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oral atypical antipsychotic and other oral medications. OLAI therapy may
require less oral supplementation compared to RLAI, thus offering a sim-
pler treatment regimen. Though limited by cross-study comparisons and
the need for replication, the current findings may have important clinical
and economic ramifications as depot formulations are often chosen for per-
sons previously nonadherent to oral medication regimens.
ID: 550676
NEW GENERATION ANTIPSYCHOTICS: ARE THE
DOPAMINE MECHANISMS PARTIAL AGONISM OR
FUNCTIONAL SELECTIVITY?
Richard B. Mailman
Pharmacology, Penn State College of Medicine, Hershey, PA, USA
During the past five years, the concept of receptor functional selectivity has
gone from a controversial hypothesis to an accepted concept of receptor
pharmacology. The demonstration of ligand-induced differential signaling
has been made in dozens of receptor systems, and the involved molecular
mechanisms are under intensive study. It remains unclear, however,
whether functionally selective properties of drugs will be meaningful
in vivo, and if so, how to harness this interesting phenomenon to lead to novel
neuropsychopharmacological drugs. Some of the clearest examples of func-
tional selectivity are with dopamine receptor ligands. Both dihydrexidine
and its analog N-n-propyldihydrexidine bind to D2L receptors with typical
shallow, GTP-sensitive curves, and inhibit adenylate cyclase (ACase) to the
same degree as dopamine in a variety of preparations. Although these
results would normally lead to the conclusion that these compounds are
full D2L agonists, in other assays these drugs behave as pure antagonists.
This functional selectivity is found in both heterologous systems expressing
the D2L receptor and in physiological preparations (eg, brain or pituitary).
In vivo, both compounds cause behavioral effects distinct from that of any
known ligand that also is a full agonist at D2L-mediated adenylate cyclase.
An even more compelling example is the antipsychotic drug aripiprazole
(Abilify). Although commonly thought to be a simple partial agonist, ari-
piprazole is actually a functionally selective ligand. For example, its intrin-
sic activity and potency at D2L-mediated inhibition of ACase are markedly
affected by the D2L receptor milieu. Moreover, sometimes aripiprazole is
a pure antagonist, completely blocking some actions of dopamine or quin-
pirole. These data suggest that aripiprazole is functionally selective D2 li-
gand, not simply a partial agonist, and also explain some of its behavioral
effects. Such examples of functionally selective dopamine receptor ligands
provide support for hypothesis that ligands with functionally selective
properties may have novel clinical effects, even when targeting ‘‘old’’ recep-
tors. If one accepts this hypothesis, the scientific hurdles then become how
best to differentiate potential drug candidates for novel signaling profiles,
and how to select the best clinical candidates from the identified subgroup.
Jumping these hurdles should be of interest and importance both heuristi-
cally and clinically.
ID: 550667
MECHANISM OF ACTION OF SERTINDOLE IN THE
MODULATION OF DOPAMINE NEURON POPULA-
TION ACTIVITY
Anthony A. Grace, O. Valenti
Department of Neuroscience, University of Pittsburgh, Pittsburgh,
PA, USA
Antipsychotic drugs administered acutely are known to increase the pop-
ulation activity (ie, proportion of neurons firing spontaneously) of dopa-
mine (DA) neurons in the ventral tegmental area (VTA). However, the
mechanism by which these drugs alter DA neuron firing is not known.
There are several mechanisms that can account for this effect; ie, blockade
of DA neuron autoreceptors or feedback from blockade of postsynaptic
DA receptors in the accumbens. This was examined using the classical an-
tipsychotic drug haloperidol in comparison with the 2nd generation drug
sertindole. Although both haloperidol and sertindole occupy D2 receptors
rapidly after administration, consistent with previous reports sertindole,
unlike haloperidol, failed to block the inhibition of DA neuron firing pro-
duced by autoreceptor-selective doses of apomorphine. Therefore, it is un-
likely that the change in DA neuron population activity was due to DA
autoreceptor blockade. Our previous studies showed that DA neuron pop-
ulation activity was regulated by a hippocampus subiculum-nucleus accum-
bens-ventral pallidal-VTA pathway. We tested whether the increase in DA
neuron population activity may be due to antipsychotic drug-induced
blockade of D2 receptors in the accumbens, causing accumbens activation,
inhibition of the ventral pallidum, and disinhibition of the VTA. We found
that blockade of the accumbens-ventral pallidal pathway via injection of
the GABA antagonist bicuculline into the ventral pallidum prevented
both haloperidol and sertindole from increasing dopamine neuron popula-
tion activity. Interestingly, VTA DA neuron population activity is also el-
evated at baseline in a developmental disruption model of schizophrenia
using the mitotoxin methylazoxymethanol acetate (MAM), which we pro-
pose is responsible for DA-dependent psychosis. Therefore, we examined
how sertindole affected DA neuron activity in MAM-treated rats. We
found that a single dose of sertindole to MAM-treated rats caused a sub-
stantial decrease in DA neuron population activity, presumably due to in-
duction of depolarization block. Thus, by inducing depolarization block,
antipsychotic drugs are attenuating the abnormally increased DA neuron
population activity proposed to underlie psychosis. Therefore, we propose
that in the MAM-treated rat or the schizophrenia patient, antipsychotic
drugs will produce a rapid induction of depolarization block due to the al-
ready heightened baseline state of the DA system.
ID: 550588
ATYPICAL ANTIPSYCHOTIC METABOLISM/
BIOTRANSFORMATION AND EXCRETION
John Sheehan1, J. Kern-Sliwa2, C. M. Canuso2, A. Grinspan2,
J. C. Amatniek2
1Manager, Medical Communications-Psychiatry, Ortho-McNeil
Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Ortho-
McNeil Janssen Scientific Affairs, Titusville, NJ, USA
Although all atypical antipsychotics (aripiprazole, clozapine, olanzapine,
paliperidone, quetiapine, risperidone, and ziprasidone) share the common
characteristic of dopamine and serotonin receptor modulation, each mol-
ecule has unique pharmacodynamic and pharmacokinetic characteristics.
Reviewed here are some of the pharmacokinetic differences between the
atypical antipsychotics, focusing on the pathways and extent of metabo-
lism/biotransformation, and the routes of excretion. To perform the review
we used each manufacturer’s radiolabeled drug ADME (Absorption, Dis-
tribution, Metabolism, Excretion) study, available in the primary literature
or FDA submission documents, combined with each product’s prescribing
information. All atypical antipsychotics other than paliperidone require ex-
tensive biotransformation (extensive defined as50% of the drug recovered
unchanged). Specifically, quetiapine requires the greatest overall metabo-
lism, with <1% of the dose recovered unchanged; in contrast, 59% of pal-
iperidone is recovered unchanged in the urine. Hepatic CYP450
(cytochrome P450) enzymes are largely responsible for the biotransforma-
tion of atypical antipsychotics. This review delineates the extent of
CYP450-mediated biotransformation of atypical antipsychotics, and the
specific CYP450 enzymes involved in these reactions. After administration
of a radioactive dose, fecal elimination of radioactive compounds
accounted for the majority of the dose for aripiprazole (55%) and ziprasi-
done (66.3%). For the remaining atypical antipsychotics, the majority of
a radioactive dose was recovered in the urine (>50% of recovered radioac-
tivity, 80% for paliperidone). These findings confirm that the routes of
elimination (via metabolism and excretion) of atypical antipsychotic agents
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vary considerably. An understanding of atypical antipsychotic drug metab-
olism and excretion may permit better-informed drug and dose selection in
special populations, such as patients with comorbid conditions (eg, hepa-
titis, substance abuse, diabetes, end-stage renal disease), those with phar-
macogenetic variability, or those at risk for drug-drug interactions. The use
of patient ‘‘tailored’’ atypical antipsychotic drug and dose-selection may
result in greater treatment efficacy as well as a reduction in adverse events.
Supported by Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville,
New Jersey, USA.
ID: 550574
UNDERSTANDING THE ROLE OF PHOSPHORY-
LATION IN PDE10A ACTIVITY AND IN THE
REGULATION OF DOWNSTREAM SIGNALING
Erik Ian Charych1, V. Pulito1, M. Kelly1, F. Liu1, K. Chan1,
K. Marquis1, U. Egerland3, T. Hage3, M. Malamas2, N. Brandon1
1Schizophrenia and Bipolar, Wyeth Research, Princeton, NJ, USA;
2Chemical and Screening Sciences, Wyeth Research, Princeton,
NJ, USA; 3Elbion AG, Radebeul, Germany
Inhibition of PDE10A, a dual cAMP/cGMP phosphodiesterase located pri-
marily in the striatum, may prove to be an effective therapeutic approach to
treating the symptoms of schizophrenia. We have undertaken a biochemical
approach to explore the effects of papaverine (PDE10A IC50 36nM, 9- to
277-fold selectivity over other PDEs) and MP-10 (IC50 0.18nM, >3000-
fold selectivity) in rodents. MP-10 treatment caused increases in phosphor-
ylation levels of striatal CREB(ser133), DARPP-32(thr-34), GluR1(ser845)
and ERK(tyr204) by 2.6-, 3.5-, 4.1-, and 1.4-fold, respectively. Papaverine
treatment resulted in a trend toward higher levels of CREB, DARPP-32
and ERK phosphorylation, particularly with the higher doses. The 10
and 54 mg/kg doses of papaverine resulted in significant increases in
GluR1 phosphorylation of 2.7- and 4.6-fold, respectively. Surface biotiny-
lation was used to determine the extent of S845-phosphorylated GluR1 on
cell surfaces in MP-10-treated striatal slices. The results indicated that there
is a significant increase (2.3-fold) in the levels of phosphorylated GluR1
(S845), but not total GluR1, on cell surfaces of MP-10-treated striatal slices
(1 uM, 30 min) compared to vehicle control. Similar results were obtained
when cultures of dissociated striatal neurons were subjected to these con-
ditions, such that there was a 1.4-fold increase in the levels of phosphor-
ylated GluR1 (S845) on the surface of MP-10-treated neurons (1 uM,
30 min) compared to vehicle control. In order to investigate the regulation
of PDE10A itself by PKA phosphorylation, we have generated an antibody
that targets phosphothreonine 16 of the PDE10A2 polypeptide (anti-
pPDE10A2). Anti-pPDE10A2 specifically reacted with a GST fusion pro-
tein containing the N-terminal portion of PDE10A2 only following phos-
phorylation by protein kinase A (PKA). In contrast, anti-pPDE10A2 did
not react with this fusion protein when it contained an alanine or glutamate
mutation at position 16 (T16A and T16E, respectively), even after treat-
ment with PKA. Using this antibody, we also confirmed by subcellular frac-
tionation and by immunocytochemistry that the reported membrane to
cytosol translocation of PDE10A2 is caused by PKA phosphorylation at
Thr16 of PDE10A2. We are now trying to understand the significance
of these events for the therapeutic effects of PDE10A inhibition and to un-
derstand the key regulatory signals for PDE10A activity.
ID: 550561
A PHASE 2 TRIAL OF AN ALPHA 7 NICOTINIC
ACETYLCHOLINE RECEPTOR AGONIST IN
SCHIZOPHRENIA
Robert Freedman1, A. Olincy1, L. Johnson1, R. W. Buchanan2,
W. R. Kem3
1Psychiatry, University of Colorado, Aurora, CO, USA;
2Psychiatry, Maryland Psychiatric Research Center, Baltimore,
MD, USA; 3Pharmacology, University of Florida, Gainesville,
FL, USA
Nicotinic acetylcholine receptors are possible therapeutic targets for schizo-
phrenia, based on neurobiological and molecular evidence for deficiencies
in expression of alpha 7-nicotinic receptors. Patients’ heavy smoking sug-
gests attempted self-medication through this mechanism. 3-[(2,4-dimethoxy)
benzylidene]anabaseine (DMXB-A) is a partial alpha 7-nicotinic agonist
and can be taken orally. Thirty-one subjects with schizophrenia received
DMXB-A at two different doses and placebo for periods of 4 weeks in
a three-arm, two-site, double-blind, crossover Phase 2 trial. The MATRICS
Consensus Cognitive Battery assessed cognitive effects, and the Scale for
Assessment of Negative Symptoms (SANS) and the Brief Psychiatric Rat-
ing Scale (BPRS) assessed clinical effects. Subjects continued their current
antipsychotic drug during the trial and were non-smokers. There were no
significant changes in the MATRICS cognitive measures compared to pla-
cebo over the three treatment arms, but the patients experienced significant
improvement at the higher DMXB-A dose on SANS total score and a trend
towards improvement on BPRS total score. Improvement was most notable
on the SANS Anhedonia and Alogia subscales. Examination of the first
treatment arm showed effects of DMXB-A on the Attention-Vigilance
and Working Memory MATRICS domains, compared to baseline. Five
subjects developed mild tremor, and nearly half had mild nausea on
DMXB-A. DMXB-A, a nicotinic agonist that activates alpha 7-nicotinic
receptors, improved clinical ratings of negative symptoms that are generally
resistant to treatment with dopamine antagonist antipsychotic drugs. The
clinical utility of this treatment is not yet determined.
ID: 550514
IN VITRO BINDING AND FUNCTIONAL PROFILE
OF ARIPIPRAZOLE AT CLONED HUMAN DOPA-
MINE D3 RECEPTORS
Shaun Jordan1, J. J. Murphy1, K. Regardie1, R. Chen1,
R. Fernalld1, V. Koprivica1, C. Wolff1, J. Kambayashi1,
J. C. Nelson2, Y. Tadori3, H. Kitagawa4, T. Kikuchi3
1Neuroscience Research, Otsuka Maryland Medicinal Labs., Inc.,
Rockville, MD, USA; 2Psychiatry, University of California, San
Francisco, San Francisco, CA, USA; 3Quests Research Institute,
Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan; 4Second In-
stitute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd.,
Tokushima, Japan
Background: The dopamine (DA) D3 receptor has been proposed as a ther-
apeutic target for antipsychotic drugs. Aripiprazole is the only approved
antipsychotic that behaves as a D2 receptor partial agonist, although its
functional profile at the D3 receptor is less well described. The purpose
of this study was to estimate the in vitro binding affinity and functional
characteristics of aripiprazole at cloned human D3 receptors (hD3R)
expressed in CHO cells. Methods: Radioligand binding assays were per-
formed to estimate the binding affinity (KD) of [3H]R(þ)7-OH-DPAT,
density of hD3R expression (BMAX), and binding affinity (Ki and KD)
of aripiprazole at the hD3R expressed on CHO-hD3R cell membranes.
The in vitro potency (pEC50) and intrinsic activity (EMAX) of aripiprazole
were estimated at the hD3R using upstream (forskolin-stimulated cAMP
accumulation) and downstream (serine-9 phosphorylation of GSK-3b)
readouts of CHO-hD3 cell signaling. Results: [3H]R(þ)7-OH-DPAT
bound with high affinity to a single site (KD = 2.28 6 0.40 nM) expressed
at high density (BMAX = 25.05 6 1.63 pmol/mg protein) on CHO-hD3 cell
membranes. Aripiprazole displaced this radioligand and bound to the
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hD3R with high affinity (Ki = 1.62 nM). Aripiprazole potently (pEC50 =
8.23 6 0.17) inhibited cAMP accumulation in CHO-hD3 cells, displaying
lower intrinsic activity (EMAX = 27.6 6 1.4% of 10 lM DA) than OPC-
4392, (-)3-PPP and (þ)terguride (EMAX = 58.0 6 1.8%; 76.76 3.2%; 77.2 6
2.6% respectively). Aripiprazole exhibited a similar potency (pEC50 =
8.16 6 0.31) and intrinsic activity (EMAX = 25.6 6 4.7% of 10 lM DA)
in the CHO-hD3 cell phospho-serine 9 GSK-3b assay. These effects of ari-
piprazole on cAMP and phospho-serine 9 GSK-3b were mediated through
the D3R as they were blocked by the D3R antagonist (-)raclopride. Dis-
cussion: Aripiprazole bound with high affinity to and behaved as a potent
partial agonist at the hD3R. Interestingly, aripiprazole demonstrated lower
intrinsic activity in the cAMP assay than a series of other hD3R partial
agonists that are clinically ineffective as antipsychotics, consistent with
the rank order of intrinsic activity displayed by these compounds at cloned
human D2 receptors. Moreover, aripiprazole produced D3R-mediated
increases in phospho-serine 9 GSK-3b, an inactivated phosphoprotein
that promotes neuronal survival and neurogenesis, which is of interest
as the pathology of schizophrenia has been linked to disordered
GSK-3b regulation.
ID: 550409
REPEATED DOSING OF THE SELECTIVE GLYT1
INHIBITOR, DCCCYB DOES NOT PRODUCE DE-
SENSITIZATION OF GLYT1 OR NMDA RECEPTORS
Julie A. O’Brien1, B. M. Connolly2, D. R. Reiss3, W. Cho4, C. Sur2,
M. A. Jacobson1
1Schizophrenia Research, Merck and Co., West Point, PA, USA;
2Imaging, Merck. and Co., West Point, PA, USA; 3Circadian
Rhythm and Depression, Merck and Co, West Point, PA, USA;
4Clinical Research, Merck and Co, West Point, PA, USA
Hypofunction of NMDA receptors has been implicated in the pathophys-
iology of schizophrenia. Mechanisms which may lead to enhancing NMDA
function are currently being pursued as novel treatments. Selective glycine
transporter subtype 1 (GlyT1) inhibitors are being developed as an ap-
proach to enhance NMDA function via increasing synaptic glycine,
a co-agonist for NMDA as a treatment for positive, negative symptoms
and cognitive impairment in schizophrenia. DCCCyB is a potent and se-
lective GlyT1 inhibitor. Preclinical studies with acute dosing, have demon-
strated that DCCCyB produces increases in extracellular glycine levels in
prefrontal cortex as measured by dialysis, however the potential for desen-
sitization of NMDA receptors or GlyT1 after repeated dosing has not been
evaluated. To address this, male SD rats were dosed with either 5 mg/kg
DCCCyB or vehicle (0.5% methylcelluose) po for eight days. Rat cortex
was collected 1 hour after dosing on day eight and both synaptosomal
and membrane homogenates were prepared. GlyT1 functional activity
was measured by [3H]-glycine uptake and density of GlyT1 was determined
by saturation binding with the selective GlyT1 radiolablel, [3H]-CPyPB.
NMDA receptor density was measured by [3H]-MK801 binding.
NMDA receptors were also localized after repeated dosing by immunocy-
tochemistry measured with a NMDAR2 antibody in sections prepared
from cortex and cerebellum. Plasma was collected at day 8 to confirm
DCCCyB exposures and correlated with 65% GlyT1 receptor occupancy.
Repeated dosing of DCCCyB did not result in a change in either the affinity
(Ki) or the maximum rate of glycine transport (Vmax) compared to vehicle
treated animals. The affinity and density of GlyT1 defined by [3H]-CPyPB
was also unchanged between DCCCyB and vehicle treated groups. Re-
peated dosing did not affect the binding affinity for [3H]-MK801 or expres-
sion level of NMDA receptors. In addition, no evidence of significant
NMDA receptor internalization was observed after repeated dosing with
DCCCyB. These results indicate that neither alterations in GlyT1 function
nor expression and NMDA receptor densensitization occur after 8 days
dosing with DCCCyB, a selective GlyT1 inhibitor.
ID: 549100
A SELECTIVE MGLUR2 POSITIVE ALLOSTERIC
MODULATOR RADIOLIGAND DEFINES THE
MGLUR2 DISTRIBUTION IN RAT, RHESUS AND
HUMAN BRAIN
Marlene Jacobson1, D. M. Pascarella1, E. J. Brnardic2,
T. J. Hartingh2, J. A. O’Brien1, B. C. Magliaro1, Z. Zeng3,
R. M. Garbaccio2, A. Converso2, Y. S. Tang4, M. E. Fraley2,
P. H. Hutson1
1Schizophrenia, Merck Research Labs, West Point, PA, USA;
2Medicinal Chemistry, Merck Research Labs, West Point, PA,
USA; 3Imaging, Merck Research Labs, West Point, PA, USA;
4Drug Metabolism, Merck Research Labs, Rahway, NJ, USA
Preclinical studies have shown that mGluR2/3 agonists and mGluR2 selec-
tive positive allosteric modulators exhibit anti-psychotic activity in rodent
behavioral models. Based on studies with KO mice, the antipsychotic ac-
tivity of mGluR2/3 agonists has been attributed to activation of mGluR2.
Recently, Lilly demonstrated POC with a non-selective mGluR2/3 agonist,
LY404039 showing improvements in positive and negative symptoms in
schizophrenic patients, further validating the mechanism. Therefore, acti-
vation of mGluR2 is a promising, non-dopaminergic therapeutic approach
for the treatment of schizophrenia. Determination of mGluR2 distribution
has been difficult due to lack of subtype selective radioligands and the dis-
tribution in humans is not known. Currently, potent, nonselective mGluR2/
3 radiolabeled agonists and antagonists have been utilized, however the use
of these labels have been unable to definitely measure the specific contri-
bution of mGluR2. We here report the in vitro characterization of a radio-
tracer developed from a potent and selective mGluR2 positive allosteric
modulator TBPCOB, and its use in autoradiographic studies to localize
mGluR2 binding sites in rat, rhesus and human brain. TBPCOB is a potent,
selective, mGluR2 positive allosteric modulator (FLIPR mGluR2 EC50 =
29 nM; mGluR3 EC50 > 30 lM). The compound was amenable to radio-
labeling with tritium and produced low nondisplaceable binding on tissue
homogenates. Kd values of 1.6 and 4 nM, respectively, were determined in
rat and rhesus brain homogenates and the binding fit to a one-site model.
Autoradiographic studies of rat, rhesus and human brain slices with
TBPOC showed high specific binding sites with a nonhomogeneous distri-
bution. High levels of specific binding was measured in the cortex, hippo-
campus and caudate and was similar across species. Furthermore,
GTPc35S autoradiography employing suboptimal concentrations of the
mGluR2/3 agonist, LY379268 with a selective mGluR2 potentiator
revealed a similar distribution. This is the first report of the mGluR2 an-
atomical localization using direct radiolabel binding with a selective
mGluR2 ligand and the first visualization of mGluR2 in human brain
tissue.
ID: 549012
DETECTING ANTIPSYCHOTIC-LIKE COMPOUNDS
WITH A DOPAMINE D3 RECEPTOR-LINKED
MECHANISM OF ACTION USING PREPULSE
INHIBITION OF STARTLE IN RATS
Martin Weber1, R. R. Luedtke2, J. P. Durbin3, P. E. Park1,
R. H. Mach3, N. R. Swerdlow1
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Jolla, CA, USA; 2Pharmacology and Neuroscience, University of
North Texas Health Science Center at Fort Worth, Fort Worth, TX,
USA; 3Radiological Sciences, Washington Univ School of Medicine,
St Louis, MO, USA
Background: Prepulse inhibition of startle (PPI) occurs when a weak lead
stimulus inhibits the response to an intense startling stimulus. PPI is im-
paired in schizophrenia and Tourette Syndrome (TS), among other disor-
ders. In rats, PPI is disrupted by dopamine (DA) agonists, and this effect is
blocked by both typical and atypical antipsychotics. Putative antipsy-
chotics are commonly screened for their ability to prevent PPI deficits in-
duced by the D1/D2 agonist apomorphine (APO). As DA D3 receptor
antagonists or partial agonist might have antipsychotic properties without
D2-related side effects, we developed a PPI-based screening strategy to de-
tect such compounds. WC10, and WC44, two members of a novel panel of
preferential D3-receptor compounds were tested. In in-vitro assays, WC10
is characterized as a D3 antagonist/weak partial agonist and WC44 as a full
D3 agonist (Chu et al. 2005). The sensitivity of these compounds to prevent
PPI deficits induced by the preferential D3 agonist pramipexole (PRA) vs.
the D1/D2 agonist APO was used as functional evidence of D3 vs. D1/D2
selectivity, and to predict potentially novel clinical profiles for these com-
pounds. Methods: Acoustic startle and PPI were measured in Sprague
Dawley rats. First, we tested the ability of the preferential D2-receptor an-
tagonist L741,626 (0, 1, 3, 10 mg/kg) to prevent the PPI-disruptive effects of
APO (0, 0.1, 0.5 mg/kg) and PRA (0, 1 mg/kg), to confirm that D2 receptor
stimulation is preferentially responsible for the PPI-disruptive effects of
APO vs. PRA. Second, we tested the ability of WC10 (0, 1, 3, 10 mg/kg)
and WC44 (0, 1, 3, 10 mg/kg) to prevent the PPI-disruptive effects of
APO and PRA. Haloperidol (0, 0.1 mg/kg) was a positive control. In
some cases, measures of drug effects on generalized motor activity were
also conducted. Results: APO induced PPI deficits and HAL prevented
these deficits, confirming sensitivity of the ‘‘traditional PPI assay’’. WC10,
but not WC44 reversed APO-induced PPI deficits. In contrast, reversal of
PRA-induced PPI deficits was more pronounced for WC44 than for
WC10. Conclusions: The present findings confirm the feasibility of this
screening strategy. The data suggests a conventional (ie, D2-antagonist-
like) antipsychotic profile for WC10. In contrast, WC44 may have novel
antipsychotic-like properties linked to functional D3 receptor antagonism.
Supported by Tourette Syndrome Association and NARSAD Young In-
vestigator awards to MW.
ID: 548979
THE EFFECT OF SMOKING CESSATION DRUG
VARENICLINE ON AUDITORY GATING IN
A MOUSE MODEL OF THE DEFICIT IN SCHIZO-
PHRENIA PATIENTS
Kristin M. Wildeboer1, Karen E. Stevens1,2
1Psychiatry, University of Colorado Denver, Aurora, CO, USA;
2Medical Research, Veterans Affairs Medical Center, Denver,
CO, USA
Varenicline, marketed in the US as Chantix, is an FDA approved smoking
cessation drug. Because of the high incidence of smoking in schizophrenia
patients as compared to the general population the utilization of varenicline
in the schizophrenia population is being explored. Varenicline produces its
effects via specific subtypes of nicotinic acetylcholine receptor (nAChR).
Specifically, it is a partial agonist at the a4b2 nAChR, the high affinity nic-
otine receptor, and a full agonist at the a7 nAChR. Both subtypes of
nAChR are thought to be involved, genetically and physiologically, in
schizophrenia. Selective agonists for both the a7 and a4b2 subtypes pro-
duce improvements in a specific symptom of schizophrenia, the auditory
gating deficit. This deficit prevents patients from filtering extraneous sen-
sory stimuli resulting in ‘sensory stimuli overload’. We utilize a mouse
model, the DBA/2 mouse, which spontaneously exhibits a gating deficit
analogous to the deficit of schizophrenia patients. This study assessed
the effect of varenicline upon the auditory gating deficit of DBA/2 mice
to determine how this smoking cessation drug may impact gating of schizo-
phrenia patients attempting to alleviate their addiction to nicotine. Electro-
physiological auditory evoked potentials (AEPs), in response to paired
identical click stimuli were recorded from the hippocampal CA3 region
of DBA/2 mice before and after administration of varenicline. The measure
of auditory gating (TC ratio) is the ratio of the AEP produced by the second
stimulus (TAMP) divided by the AEP produced by the first stimulus
(CAMP). A TC ratio of >0.4 indicates deficient auditory gating while
a TC ratio of 0.4 is considered normal gating. We tested four different
doses (0.5, 1, 5, 10 mg/kg) of varenicline in the auditory gating paradigm.
All four doses produced significant decreases in TC ratio as compared to
controls. It has been proposed that control of TAMP is via the a7 nAChR
while control of CAMP is in part via the a4b2 nAChR. There were signif-
icant changes in both the TAMP and CAMP at varying doses. Central ad-
ministration of a-bungarotoxin with a dose of varenicline which decreased
TAMP, fully blocked this effect. Taken together, these data indicate activity
of varenicline at both the a4b2 and a7 subtypes. These results indicate that
along with its function as a smoking cessation drug, varenicline may be use-
ful in alleviating the auditory gating deficit in schizophrenia patients.
ID: 547916
IPTAKALIM: A POTENTIAL ANTIPSYCHOTIC
DRUG WITH NOVEL MECHANISMS
Ming Li1, T. Sun1,2, C. Zhao1, G. Hu2
1Psychology, University of Nebraska-Lincoln, Lincoln, NE, USA;
2Pharmacology, Nanjing Medical University, Nanjing, China
Iptakalim is a putative novel adenosine triphosphate (ATP)-sensitive potas-
sium (KATP) channel activator. Centrally, iptakalim acts on the neuronal
and astrocytic plasma membrane and/or mitochondrial KATP channels.
Because it demonstrates an action on the regulation of dopamine and glu-
tamate release in the forebrain regions, we examined its potential antipsy-
chotic efficacy in four preclinical tests. First, we show that acute iptakalim
treatment selectively and dose-dependently disrupts conditioned avoidance
responding, while leaving escape response intact. Second, we show that re-
peated iptakalim treatment gradually loses its inhibition on avoidance
responding, an effect shared only by clozapine, but not by other antipsy-
chotics tested, such as haloperidol, olanzapine and risperidone, indicating
a possible clozapine-like property. Third, we show that iptakalim is effec-
tive in reducing amphetamine- and PCP-induced locomotor activity and
shows a preferential effect in reducing the PCP-induced hyperlocomotion
over the amphetamine-induced one. Finally, we show that iptakalim and
clozapine, but not haloperidol, preferentially induces c-fos expression in
the medial prefrontal cortex and nucleus accumbens, but not in the dorso-
lateral striatum. These findings suggest that iptakalim may be a drug that
possesses an clozapine-like antipsychotic property with a mechanism of ac-
tion distinct from currently available antipsychotics. This study also sug-
gests that neuronal and astrocytic plasma membrane and/or mitochondrial
KATP channels may be a valid target for future antipsychotic drug
research.
ID: 546658
DOSE-RELATED EFFECTS OF ACUTE EXPOSURE
TOD9-THC ON BEHAVIOR, ATTENTION, MEMORY
AND NEURAL SYNCHRONY IN HUMANS
Deepak Cyril D’Souza1,2, M. Ranganathan1,2, N. Singh1,2,
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The mechanisms by which cannabinoids produce transient psychotomi-
metic effects and impairments in attention and memory are not clear. Per-
ceptual, memory and attentional functions are based on distributed
processes that are believed to be ‘‘bound’’ together by synchronous high
frequency oscillatory activity. In humans, macroscopic neural synchrony
can be evaluated noninvasively by entrainment of the EEG to sensory (au-
ditory) stimuli presented of various frequencies. We are studying the dose
related effects of D9-THC on electrophysiological indices of information
processing in humans. Healthy subjects (n = 9) completed 3 test days during
which they received (0, 0.015, 0.03 mg/kg) intravenousD9-THC in a double-
blind, randomized design. The effects of D9-THC on 1) Behavior (Percep-
tual alterations, psychotic-like symptoms), 2) Memory (immediate verbal
recall, spatial working memory and visual object recognition memory),
3) neural synchrony (steady state EEG response to auditory click trains
at 20, 30 and 40 hz), and 4) event related potentials (ERPs) recorded during
performance of ‘‘oddball’’ target detection tasks were measured. D9-THC
induced transient psychotomimetic effects, perceptual alterations, amnestic
effects and attentional impairments. D9-THC reduced EEG power in re-
sponse to auditory click trains. D9-THC reduced target P3b and novel
P3a amplitudes generated during the auditory oddball task even though
subjects responded accurately to target stimuli. D9-THC appeared to affect
target P3b more than novelty P3a. The reductions in target P3b amplitude
may reflect D9-THC induced impairments in the top down allocation of
attention and/or the updating of memory associated with task specific
response selection as well as cognitive slowness and inefficiency.
ID: 550888
PCP-INDUCED EFFECTS UPON VOLUNTARY
SUCROSE INTAKE: IMPACT OF CLOZAPINE
David M. Thomson1,3, A. McVie1,3, B. J. Morris1,3, J. A. Pratt2,3
1Faculty of Biomedical and Life Sciences, University of Glasgow,
Glasgow, United Kingdom; 2Strathclyde Institute of Pharmacy and
Biomedical Sciences, University of Strathclyde, Glasgow, United
Kingdom; 3Psychiatric Research Institute of Neuroscience in
Glasgow, Universities of Glasgow and Strathclyde and NHS Greater
Glasgow and Clyde, Glasgow, United Kingdom
Drug treatment of schizophrenia is hampered by the general lack of effec-
tiveness of existing antipsychotic drugs against the negative symptoms and
cognitive deficits. These symptoms have been correlated with dysfunctional
prefrontal cortex activity. We have shown that repeated PCP treatment to
rats reproduces metabolic abnormalities in the prefrontal cortex activity
(hypofrontality) (Cochran et. al. 2003 Neuropsychopharmacology 28:
265–75). The aim of this study was to examine the effects of repeated
PCP in a behavioural task that may mirror an aspect of negative symptoms
and determine if this is modified by clozapine. The task selected was the
voluntary sucrose consumption test since this is considered to relate to an-
hedonia. Hooded Lister rats were habituated to the sucrose drinking pro-
cedure and then received PCP (2.6 mg/kg i.p.) or vehicle according to our
previous treatment regime. (Cochran et. al. 2003). Following 5 days of PCP
or vehicle treatment, the effects of clozapine were determined. Measures
taken daily were sucrose consumption over 30 min, water consumption
in the remaining 23.5 hrs and body weight. Daily water consumption
did not differ between groups either before or after treatment. The main
effect observed was a reduction in sucrose intake in the groups that received
vehicle/clozapine and the PCP/clozapine group. These groups also showed
parallel reductions in body weight. Taken together these results suggest that
clozapine itself may produce anhedonia. The finding that PCP influences
body weight in parallel with reduced sucrose intake warrants further inves-
tigation of PCP as a potential model to assess anhedonia.
ID: 551874
PSYCHOTOMIMETIC EFFECTS OF THE KAPPA
OPIOID RECEPTOR AGONIST SALVINORIN A IN
HEALTHY HUMANS
Mohini Ranganathan1,2, D. D’Souza1,2
1Psychiatry, Yale University, New Haven, CT, USA; 2Psychiatry,
VACHS, West Haven, CT, USA
Salvinorin A (SA) is the active compound derived from the leaves of the
hallucinogenic plant Salvia divinorum. Salvia divinorum has been used
for centuries in traditional Mexican rituals and ingestion of the leaves is
reported to produce psychotomimetic effects such as depersonalization
and hallucinations. SA is unique in that it does not act at any of the recep-
tors known to be involved in psychotomimetic effects of other drugs (eg,
serotonin, dopamine, glutamate etc) but only at the kappa opioid receptor
(KOR), where it is a highly selective and potent agonist. Thus, the psy-
chotomimetic effects of SA are presumably mediated via agonist effects
at kappa receptors. KOR agonists and Psychosis: Studies with selective
KOR agonists (including SA) in animals have demonstrated development
of behaviors considered analogous to psychosis. Preclinical data suggests
that KOR agonists selectively modulate the dopaminergic output from the
ventral tegmental area. Further, preliminary data from our colleagues
(Zhao and Gelernter) suggests that a specific single nucleotide polymor-
phism (SNP) in the KOR gene might be a risk locus for schizophrenia. Lab-
oratory studies with drugs (amphetamine, ketamine, LSD) have been
critical in advancing some of the better known hypotheses of psychosis.
Thus, SA, a highly selective and potent agonist at the KOR that is known
to be used in humans, is an ideal tool to probe this system and examine its
role in the neurobiology of psychosis. While there is increasing recognition
of the recreational use of SA there are no controlled studies characterizing
the dose related behavioral, cognitive, physiological and endocrine effects
of SA in psychiatrically and medically healthy volunteers. Pilot data suggest
that SA at very small doses produces robust but transient hallucinations,
perceptual alterations, synesthesias, dissociative symptoms, blunted affect
and cognitive deficits. There are no significant changes in heart rate or
blood pressure and no adverse effects. The onset of effects is within 30 sec-
onds to 1 minute with peak effects lasting from 5-10 minutes and a return to
baseline within 30 minutes. These data will be discussed.
ID: 551819
ATYPICAL ANTIPSYCHOTICS: FUNCTIONAL
SELECTIVITY OF LIGANDS AT 5-HT2A AND
5-HT2C RECEPTORS
William P. Clarke, K. A. Berg
Pharmacology, University of Texas Health Science Center, San
Antonio, TX, USA
Drug selectivity is generally ascribed to differential affinity for different re-
ceptor subtypes. High selectivity (ie, large difference in affinity for a target
receptor vs. other receptors) is coveted, as adverse effects of drugs are at-
tributed to actions at non-target receptors. Recent advances in understand-
ing of receptor function indicate that drugs have more selectivity than that
afforded by differential affinity for different receptor subtypes. Evidence
reveals that drugs can selectively activate different cellular signaling cas-
cades coupled to a single receptor subtype. Consequently, drugs acting
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at the same receptor can produce qualitative, not just quantitative, differ-
ences in cellular activity. Importantly, differences in functional selectivity
between drugs acting at the same receptor subtype may underlie differences
in therapeutic efficacy and/or adverse effect liability. The serotonin2A
(5-HT2A) and 5-HT2C receptor subtypes are key targets for atypical anti-
psychotics. Many 5-HT2A/2C ligands have been shown to be functionally
selective for different cellular signaling pathways coupled to these recep-
tors. In fact, very recently differences in behavioral actions of 5-HT2A
agonists have been demonstrated to be due to functional selectivity, indi-
cating the physiological relevance of the process. It is widely believed that
antagonism at 5-HT2A/2C receptors is a prerequisite for atypical anti-
psychotic efficacy. However, most, but not all, atypical antipsychotics
are inverse agonists at 5-HT2A and/or 5-HT2C receptors. Importantly,
the pharmacological characterization of these drugs generally is based
on measurement of a single cellular response (typically calcium changes
in a high-throughput screening system). We have found that many inverse
agonists at 5-HT2C receptors are functionally selective when a range of
cellular responses is measured. Moreover, one 5-HT2C drug, SB 242084,
is a strong inverse agonist for two responses (PLA2 and Gai), but is an
agonist for a third response (PLC) coupled to the receptor. Response-
dependent behavior of drugs acting at a single receptor subtype suggests
that we do not fully understand the mechanism of action of drugs like
the atypical antipsychotics. Understanding the functionally selective
characteristics of atypical antipsychotics should provide better methods
for screening new drugs and may allow for drugs with greater therapeutic
selectivity and improved efficacy for the treatment of schizophrenia.
ID: 551777
FUNCTIONAL SELECTIVITY OF 5-HT2C RECEPTOR
AGONISTS
Mark Pausch
Wyeth Research, Princeton, NJ, USA
Agonists of the serotonin 5-HT2C receptors offer tremendous potential for
the treatment of multiple psychiatric illnesses including schizophrenia. The
signaling properties and regulation of 5-HT2C receptors are highly complex
due to the engagement of multiple signaling pathways and the distinct
functional properties of the many RNA-edited isoforms of 5-HT2C recep-
tors, which are subject to modulation in multiple psychiatric disorders and
following pharmacological or environmental manipulation. In order to un-
derstand at a molecular level the properties of the 5-HT2C agonists that
lead to therapeutic benefit, we have evaluated the impact of 5-HT2C ago-
nists on multiple 5-HT2C receptor isoform across a broad range of signal
transduction outputs in vitro, including measurements of effects on phos-
phatidylinositol and arachidonic acid metabolism, Ca2þ mobilization,
ERK phosphorylation and interactions with b-arrestin2. The studies
have revealed remarkable diversity in signaling patterns produced by the
5-HT2C agonists consistent with the expression of functional selectivity.
The presentation will highlight recent advances in the understanding of
5-HT2C agonist functional selectivity and the potential implications for
the reported therapeutic potential in psychiatric illness.
ID: 551643
THE CANNABINOID HYPOTHESIS OF
SCHIZOPHRENIA: DOPAMINE-CANNABINOID
INTERACTIONS AND PRE-CLINICAL EVIDENCE IN
PCP-TREATED RATS
Andrea Giuffrida, A. Seillier
Pharmacology, University of Texas Health Science Center, San
Antonio, TX, USA
The cannabinoid hypothesis of schizophrenia suggests that over-activity of
the endocannabinoid system contributes to the etiology of psychosis. In
keeping with this hypothesis, schizophrenic patients have increased expres-
sion of CB1 cannabinoid receptors in the brain and elevated anandamide in
the cerebrospinal fluid (CSF), which is negatively correlated to psychotic
symptoms. It is unclear, however, whether these changes contribute to the
development of schizophrenia (eg, via cannabinoid-mediated alterations of
dopaminergic transmission) or if they represent a compensatory adjustment
to the disease. The first scenario is consistent with the observation that ad-
ministration of THC increases dopamine transmission in rodents and
humans. The second is supported by studies showing that activation of do-
pamine D2 receptors elevates anandamide in rat brain and that endocan-
nabinoids counteract dopamine-mediated behavioral responses. To further
address these questions, we studied endocannabinoid transmission in rats
sub-chronically treated with PCP and monitored the development of
schizophrenia-like symptoms using the following behavioral measures:
(1) working memory in a variable-delayed alternation task in a T-maze
(to model cognitive deficit), (2) social withdrawal (negative symptom),
and (3) motor activity in response to d-amphetamine (positive symptom).
Sub-chronic PCP increased endocannabinoids levels in the nucleus accum-
bens and amygdala, increased CB1 receptor-stimulated [35S]GTPcS bind-
ing in the anterior cingulate cortex and decreased it in the hippocampus.
PCP also caused a delay-dependent impairment of working memory, in-
creased social withdrawal and enhanced motor activity. URB597, a drug
that elevates brain anandamide by blocking its metabolism, reversed
PCP-induced social withdrawal, whereas it had no effect on working mem-
ory or motor activity. Pharmacological blockade of CB1 receptors by
AM251 ameliorated the cognitive deficit observed in PCP-treated rats,
but impaired working memory in saline-injected controls. These results in-
dicate that: 1) PCP causes disturbances of endocannabinoid transmission;
2) elevation of endocannabinoids tone may reduce the negative symptoms
of schizophrenia; 3) CB1 receptor antagonism is beneficial for schizophre-
nia-related cognitive deficits, but may have detrimental effects under nor-
mal conditions. Supported by NARSAD (to AG).
ID: 551415
DIFFERENT MECHANISMS UNDERLYING
PARTIAL AGONISM
Arvid Carlsson
University of Gothenburg, Goteborg, Sweden
In theory partial agonism should be an attractive pharmacotherapeutic
principle in a variety of psychiatric and neurological conditions, which
are often chracterized by imbalances of neurocircuitries rather than perma-
nent hyper- or hypoactivities. It is thus remarkable that so few partial ago-
nists are on the market. For example, Abilify is the only partial agonist on
the market for the treatment of psychosis. Partial agonists in the classical
sense are capable of binding to the same site of the receptor as the full (en-
dogenous) agonist and can serve as either agonist or antagonist by compet-
ing or cooperating with this agonist, depending on baseline level. The
compound (-)-OSU6162 is an example of an atypical partial dopamine
D2 agonist, which seems to bind to two different sites of the receptor
with mutually opposite actions. Judging by preclinical as well as early clin-
ical observations such a mechanism seems to provide potential advantages
compared to classical partial agonists.
ID: 551364
FUNCTIONAL SELECTIVITY OF ANTIPSYCHOTICS
AT THEb-ARRESTIN 2-DEPENDENT D2 DOPAMINE
RECEPTOR-MEDIATED AKT/GSK3 SIGNALING
PATHWAY
Marc G. Caron
Cell Biology,Medicine, Neurobiology, Duke University Medical
Center, Durham, NC, USA
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Hyperactivity of the dopaminergic system recapitulates symptoms of psy-
chosis. Several classes of antipsychotics have been developed for the treat-
ment of schizophrenia. Despite their complex pharmacological profiles, all
clinically effective antipsychotics share the ability to interact with D2 class
dopamine receptors (D2R). G protein-coupled receptors (GPCR-7TM) like
the D2Rs can signal not only through the activation of G proteins but also
through the ability of GPCR/b-arrestin 2 (barr2) to scaffold intracellular
signaling complexes. Interestingly, D2Rs mediate their physiological effects
via both of these pathways but the role of these D2R-mediated signaling
events in the actions of antipsychotics remains unclear. In mice, pharma-
cological or genetic activation of D2-like receptors (D2R) modulates not
only the G protein/cAMP-dependent signaling pathway but also engages
an Akt-GSK-3 signaling pathway through the ability of D2R/barr2 com-
plex to scaffold the kinase Akt and the phosphatase PP2A. Thus, in mice
D2R activation leads to a dephosphorylation (inhibition) of Akt (Thr308)
and dephosphorylation of GSK-3 (activation), an effect that is independent
of both cAMP and Ca2þ signaling. Behaviorally, inhibition of GSK-3
inhibits dopaminergic responses. barr2-KO mice show diminished behav-
ioral responses to D2R activation and loose the ability of D2Rs to regulate
Akt/GSK3 phosphorylation with no effects on G protein-mediated
responses. Using the two cellular assays, we demonstrate that a large series
of antipsychotics including haloperidol, clozapine and aripiprazole, uni-
formly and potently antagonize the b-arrestin 2 recruitment to D2R in-
duced by agonists. On the other hand, these antipsychotics have
complex pharmacological profiles on D2R mediated Gi/o protein/cAMP
inhibition with very highly variable efficacies. The higher potency of the
drugs at the b-arrestin-2-dependent D2R signaling ranges from 3 to 150
fold. Interestingly, the mood stabilizer lithium can also regulates Akt/
GSK-3 signaling and related behaviors in mice by disrupting the signaling
complex composed of barr2/Akt/PP2A. These results suggest that the Akt/
GSK-3 signaling pathway plays an important role in the actions of dopa-
mine and that antagonism at the barr2-dependent signaling is a common
property of clinically effective antipsychotics. Thus, barr2-mediated signal-
ing complexes represent interesting novel pharmacological targets for func-
tionally selective agents.
ID: 550919
EFFECTS OF HALOPERIDOL ON THE BEHAV-
IORAL, SUBJECTIVE, COGNITIVE, MOTOR AND
NEUROENDOCRINE EFFECTS OF D9-THC IN
HUMANS
Deepak Cyril D’Souza1,2, S. Bhakta1,2, B. Pittman1,
M. Ranganathan1,2
1Psychiatry, Yale University School of Medicine, West Haven,
CT, USA; 2Psychiatry, VA Connecticut Healthcare System,
West Haven, CT, USA
The extent to which DA D2 mechanisms play a role in the pathophysiology
of D9-THC induced psychotomimetic effects is not known. This study eval-
uated whether pretreatment with a dopamine receptor antagonist, altered
the effects of D9-THC in humans. In a 2 test day double-blind study, 28
subjects including healthy subjects (n = 17) and frequent users of cannabis
(n = 11) were administered active (0.057 mg/kg) or placebo oral haloperidol
in random order followed 90 and 215 minutes later by fixed order intrave-
nous administration of placebo (vehicle) and active (0.0286 mg/kg) D9-
THC, respectively. Consistent with previous reports, intravenous D9-
THC produced psychotomimetic effects, perceptual alterations, and subjec-
tive effects including ‘‘high’’. D9-THC also impaired verbal recall and at-
tention. Haloperidol pretreatment did not reduce any of the behavioral
effects of D9-THC. Haloperidol worsened the immediate free, and delayed
free and cued recall deficits produced by D9-THC. Haloperidol and D9-
THCC worsened distractibility and vigilance. Neither drug impaired per-
formance on a motor screening task, the Stockings of Cambridge task or
the delayed match to sample task. Frequent users had lower baseline
plasma prolactin levels and blunted D9-THC induced memory impair-
ments. The deleterious effects of haloperidol pretreatment on the cognitive
effects ofD9-THC are consistent with the preclinical literature in suggesting
crosstalk between DAergic and CBergic systems. However, it is unlikely
that DA D2 receptor mechanisms play a major role in mediating the psy-
chotomimetic and perceptual altering effects of D9-THC. Further investi-
gation is warranted to understand the basis of the psychotomimetic effects
of D9-THC and to better understand the crosstalk between DAergic and
CBergic systems. Pilot data from an ongoing [11C]PHNO PET study of
extrastriatal DA release induced by intravenous D9-THC in monkeys
will also be presented.
ID: 550909
ALTERATIONS IN HIPPOCAMPAL FUNCTION IN
SCHIZOPHRENIA
Carol A. Tamminga1, B. Thomas1, P. Mihalakos1, H. Kirane1,
H. Lu1, A. Preston2, D. Shohamy3, A. D. Wagner4
1Psychiatry, University of Texas Southwestern Medical Center at
Dallas, Dallas, TX, USA; 2Psychology, The University of Texas at
Austin, Austin, TX, USA; 3Psychology, Columbia University,
New York, NY, USA; 4Psychology, Stanford University, Stanford,
CA, USA
Individuals with schizophrenia express manifestations of their illness in
a number of symptom domains, including psychosis and cognitive dysfunc-
tion. These domains can be viewed as independent, even though the full
extent of their independence is currently unspecified. One of the major areas
of cognition that is affected is declarative memory, particularly in aspects of
relational memory. Although the characterization of the memory defect in
schizophrenia and the involvement of the medial temporal lobe (MTL)
structures in that pathology has been examined for several years, the
role of antipsychotic medication in modulating these cognitive alterations
and hippocampal function in schizophrenia has not been examined. Thus,
we have examined individuals with schizophrenia who are on-(SV-ON) and
off-(SV-OFF) antipsychotic medication (APD) and report that APD med-
ication in schizophrenia affects both performance of declarative memory
tasks and fMRI BOLD activation with memory tasks in MTL structures.
In summary, using the Acquired Equivalence Task or a face-house Asso-
ciative Inference Task, the SV-ON perform either normally or show a mod-
est (though significant) decrement from normals; however, the SV-OFF
show significantly poorer performance than both NV and SV-ON. Using
fMRI BOLD and ASL we have been able to demonstrate functional alter-
ations, particularly in the SV-OFF, with an increase in perfusion and a de-
crease in activation during inferential memory tasks in MTL structures. We
are in the process of localizing these alterations to hippocampal subfields
and have early evidence of CA3 involvement. It is the guiding hypothesis of
this investigation that changes in homeostatic plasticity mechanisms, par-
ticularly in CA3, generate increases in neuronal activity in hippocampus,
associated with production of psychotic symptoms and degradation of
memory process, particularly involving relational memory. Speculatively,
it is the rich network of collateral feedback circuits within CA3, which pro-
vide the necessary neuronal architecture for normal associational memory,
that can generate complex psychotic memories if dysfunctional.
ID: 554707
NOVEL USE OF PRECLINICAL AND CLINICAL
DATA TO PREDICT THERAPEUTIC DOSE RANGES
FOR ITI-007, A POTENTIAL TREATMENT FOR
SCHIZOPHRENIA AND OTHER NEUROPSYCHIAT-
RIC DISORDERS
Kimberly Vanover, A. A. Fienberg, L. P. Wennogle, S. Mates,
R. E. Davis
Intra-Cellular Therapies, Inc., New York, NY, USA
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ITI-007 represents a novel small molecule therapeutic agent with potent 5-
HT2A receptor antagonism, activity as a dopamine receptor protein
phosphorylation modulator (DPPM) consistent with presynaptic D2 re-
ceptor partial agonism in vivo, and inhibition of the serotonin transporter
(SERT). ITI-007 is being developed as a treatment for schizophrenia. As
clinical development of ITI-007 progresses, we have begun to define an-
ticipated therapeutic dose ranges based on clinical biomarkers as well as
safety, tolerability, and pharmacokinetic data. Importantly, because of its
high potency at 5-HT2A receptors as an antagonist relative to its potency
at dopamine receptors, it is possible to fully saturate 5-HT2A receptors
and then by simple dose adjustment titrate the amount of dopamine ac-
tivity. With this unique profile, our hypothesis is that therapeutic efficacy
should be seen at lower dopamine receptor occupancies than with other
antipsychotic drugs. A single ascending dose study and multiple ascending
dose study were conducted to determine safety, tolerability and pharma-
cokinetics of ITI-007. In a separate open-label study, dopamine D2 recep-
tor occupancy for ITI-007 is being determined after a single oral dose in
healthy male volunteers using positron emission tomography (PET). Using
data from in vitro pharmacology assays, animal models, and early clinical
studies, therapeutic dose ranges are projected. ITI-007 is safe and well tol-
erated in healthy volunteers over a wide range of doses thought to span
low, primarily 5-HT2A receptor selective doses, and higher doses expected
to have antipsychotic efficacy mediated through 5-HT2A, dopamine and
SERT pharmacology. Initial data from the PET study suggest that ITI-007
penetrates brain and occupies D2 receptors. Safe and therapeutic dose
ranges of ITI-007 are projected to inform the design of future clinical in-
vestigation. The present results provide a safe range of doses from which to
explore the efficacy of ITI-007. It is anticipated that less than 50% occu-
pancy of D2 receptors will be required for ITI-007 to demonstrate anti-
psychotic efficacy. Additionally, serotonin reuptake inhibition by ITI-
007 predicts activity in mood disorders and contributes to the overall
unique profile of ITI-007. Phase 2 clinical trials in schizophrenia are
planned.
ID: 555224
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22. 22. Therapeutics: Treatment Trials
ARIPIPRAZOLE IN SCHIZOPHRENIA PATIENTS
WITH COMORBID OBSESSIVE-COMPULSIVE
SYMPTOMS: AN OPEN-LABEL STUDY OF
15 PATIENTS
Ira D. Glick1, M. Poyurovsky2, O. Ivanova3, L. M. Koran4
1Psychiatry, Stanford University School of Medicine, Stanford,
CA, USA; 2Psychiatry, Israel Institute of Technology, Haifa, Israel;
3Psychiatry and Behavioral Sciences, Stanford University School
of Medicine, Stanford, CA, USA; 4Psychiatry and Behavioral
Sciences, Stanford University School of Medicine, Stanford,
CA, USA
Background: Approximately 15% of patients with schizophrenia also meet
DSM-IV criteria for obsessive-compulsive disorder (ICD) at some point in
their illness, a rate considerably high than in the general population. This
study examined aripiprazole treatment of patients with comorbid schizo-
phrenia and obsessive-compulsive symptoms (OCS) that did not meet full
criteria for OCD. Method: Physically healthy adults aged 18 to 65 years
with DSM-IV schizophrenia and a minimum score of 16 on the Yale-Brown
Obsessive Compulsive Scale (YBOCS) were eligible to participate in this 6-
week, open-label, flexible-dose trial of aripiprazole monotherapy. Patients
currently taking another antipsychotic medication were concurrently down-
titrated from their current antipsychotic and up-titrated with aripiprazole,
starting with 15 mg/day. Coadministration of the 2 medications lasted from 7
to 14 days, until a stable therapeutic dose of 10 to 30 mg/day as reached.
Subjects were recruited into the study between January 2005 and December
2006. Results: Of 15 eligible patients, 7 completed the trial. All 7 had at least
minimal improvement on the YBOCS, the Clinical Global Impressions
(CGI) scale, and the Positive and Negative Syndrome Scale (PANSS). At
week 6, the mean CGI-Improvement scale score was 2.3 (much improved).
Mean PANSS scores decreased from 75 to 56, a mean decrease of 21% (P<
.05) On the YBOCS, 6 or 7 completers showed a change of greater than 35%
from baseline to week 6. Conclusion: These results suggest that aripiprazole
monotherapy can modestly improve the outcome for some schizophrenia
patients with obsessive-compulsive symptoms. Further studies with aripi-
prazoleunder controlled conditionsare indicated for this patientpopulation.
Overall, even modest improvement in global functioning due to an improve-
ment in OCS component may be clinically meaningful for the difficult-to-
treat subset of schizophrenia patients.
ID: 533323
COGNITIVE REMEDIATION IN EARLY
SCHIZOPHRENIA
Shaun M. Eack1,2, G. E. Hogarty1, S. S. Cooley1, A. L. DiBarry1,
S. S. Hogarty1, D. P. Greenwald1, D. M. Montrose1,
M. S. Keshavan1
1Western Psychiatric Institute and Clinic, University of Pittsburgh,
Pittsburgh, PA, USA; 2School of Social Work, University of
Pittsburgh, Pittsburgh, PA, USA
Background: The early application of cognitive rehabilitation approaches
may afford substantial functional benefits to individuals with schizophrenia
who often experience significant cognitive dysfunction. We examined the
two-year effects of Cognitive Enhancement Therapy (CET; www.Cogniti-
veEnhancementTherapy.com) in a sample of young individuals in the first
years of the illness to evaluate the impact of this intervention on long-term
outcomes when applied early in the course of the disorder. Methods: Stabi-
lized, early course outpatients with schizophrenia or schizoaffective disorder
wererandomlyassignedandtreated ina two-year trial withCET(n=31)oran
active Enriched Supportive Therapy (EST) control (n = 27). CET is an inte-
grated approach to the remediation of social and non-social cognitive deficits
in schizophrenia that utilizes computer-assisted cognitive training and
group-based secondary socialization techniques. EST is an individual ap-
proach that focuses on illness management and stress reduction. Structural
magnetic resonance imaging and a comprehensive battery of measures were
administered annually to assess treatment effects on neurobiology, cogni-
tion, functional outcome, and symptomatology. Results: Intent to treat anal-
yses revealed significant differential effects favoring CET on composite
measures of social cognition, social adjustment, and cognitive style during
the first year of treatment. Strong differential effects (d> 1.00) on these com-
posites remained at year 2, and extended to measures of symptomatology,
particularly negative symptoms. In addition, moderate effects (d = .46) were
observed favoring CET at enhancing neurocognitive function. Preliminary
evidence from analyses of neuroanatomical change indicate a potential pro-
tective neurobiologic prophylaxis associated with CET, such that EST
patients displayed significantly greater gray matter loss over the two years
of study in social-cognitive networks comparedto those receiving CET. Con-
clusions: CET is an effective approach for the remediation of social and non-
social cognitive deficits in early schizophrenia that can serve to reduce
disability among this population. The remediation of such deficits should
be an integral component of early intervention programs treating psychiat-
rically stable outpatients with schizophrenia. CET may serve as an excellent
adjunct to pharmacotherapy in early intervention programs.
ID: 550794
A DOUBLE-BLIND COMPARISON OF THE SAFETY
AND EFFICACY OF LURASIDONE AND ZIPRASI-
DONE IN CLINICALLY STABLE OUTPATIENTS
WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE
DISORDER
Josephine Cucchiaro1, S. G. Potkin2, M. Ogasa1, A. Loebel1
1Dainippon Sumitomo Pharma America, Inc., Fort Lee, NJ, USA;
2Department of Psychiatry and Human Behavior, University of
California at Irvine, Irvine, CA, USA
Background: Lurasidone is a new atypical antipsychotic with high affinity
for D2 and 5-HT2A receptors, as well as for receptors implicated in enhance-
ment of cognitive function (5-HT1A, 5-HT2A, 5-HT7). The current study is
the first to evaluate the comparative safety and efficacy of lurasidone versus
ziprasidone in stable outpatients diagnosed with schizophrenia or schizo-
affective disorder. Methods: Adult outpatients were recruited who met
DSM-IV criteria for schizophrenia or schizoaffective disorder that was
chronic (at least 6 months duration), and stable. After completing a 1-3
day single-blind, placebo run-in period, patients were randomized to 21
days of treatment with a fixed dose of lurasidone 120 mg once daily (starting
dose, 80 mg for 3 days) or ziprasidone 80 mg BID (starting dose, 40 mg BID
for 3 days). Results: The intent-to-treat sample consisted of 150 patients on
lurasidone (mean PANSS total, 68.7) and 151 patients on ziprasidone
(mean PANSS total, 68.9). The proportion of patients reporting at least
one adverse event was lower for lurasidone compared to ziprasidone
(57% vs. 66%; P = .05). The median endpoint change in weight was similar
on both lurasidone and ziprasidone (0.65 vs. 0.35 kg). Treatment with
lurasidone versus ziprasidone was associated with greater reduction in tri-
glycerides (2.6 vs. þ22.4 mg/dL), similar endpoint reduction in total cho-
lesterol (6.4 vs.4.4 mg/dL), and similar change in glucose (þ4.7 vs. þ4.8
mg/dL). Treatment with lurasidone was associated with lower endpoint
change in the QTcF: þ0.3 vs. þ3.3 msec). No patients in either treatment
group had clinically significant elevations in QTcF (>450 msec in males; >
470 msec in females). Treatment with lurasidone versus ziprasidone, respec-
tively, resulted in greater early improvement on the PANSS total score at
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Week 1 (4.1 vs.1.6; P = .048), but not Week 2, (6.0 vs.3.7) or Week 3
(6.2 vs. 4.5; MMRM analysis). At LOCF-endpoint, treatment with lur-
asidone versus ziprasidone resulted in significantly greater improvement on
the PANSS negative symptom subscale (1.3 vs. 0.6; P = .046). Conclu-
sion: Treatment with lurasidone in a dose of 120 mg/d was safe and well-
tolerated, and was not associated with clinically significant changes in
weight, lipids or QTc. In the current study of stable patients, lurasidone
had efficacy that was comparable to ziprasidone 160 mg/d, but with an ear-
lier onset of improvement in the PANSS total score.
ID: 550774
DOUBLE BLIND, RANDOMIZED, CONTROLLED
STUDY OF A PSYCHOTHERAPY DESIGNED TO
IMPROVE MOTIVATION FOR CHANGE, INSIGHT
INTO SCHIZOPHRENIA AND ADHERENCE TO
MEDICATION
Celine Marie Paillot
Universite´ Paris X Nanterre, Larchmont, NY, USA
Most patients with DSM-IV schizophrenia exhibit full or partial non-
adherence to pharmacological treatment (Rummel-Kluge, 2008). Only about
one-third reliably take antipsychotic medication as prescribed (Oehl, 2000).
Poor adherence (ie, both complete and partial non adherence) has been
found to be associated with serious negative outcomes and as such, inter-
ventions aimed at improving and maintaining adherence are of great inter-
est to clinicians, researchers, and policy makers. Objective: To assess the
efficacy of a psychotherapy based on motivational enhancement and cog-
nitive therapies designed to improve patient’s adherence to treatment and
motivation to change (Listen-Empathize-Agree-Partner, or LEAP therapy;
Amador, 2007). Method: 54 patients diagnosed with schizophrenia about
to be discharged following inpatient treatment were included in a six month
repeated measures study. Patients were randomly assigned to either the ex-
perimental or control therapies and were blind to group assignment. All
patients received long acting injectable antipsychotic medications and
were rated as compliant when the injection was confirmed and non com-
pliant if the injection was refused or the appointment was missed. Insight
into schizophrenia and attitudes toward treatment were assessed using the
Scale to assess Unawareness of Mental Disorder, the Birchwood Insight
Scale and the Drug Attitude Inventory, respectively. All assessments
were made by a rater blinded to group assignment. Results show that com-
pared to the control psychotherapy LEAP improved motivation for
change, insight and adherence to treatment. Conclusion: This study found
LEAP to be superior to the control psychotherapy. Strengths of the exper-
imental design include the randomized blinded group assignment, blinded
assessments of the dependent variables and near 100% reliability and val-
idity of the adherence measure. Among the limitations of the present study
was the absence of a LEAP fidelity measure and the fact that the senior
author was the only therapist for all patients and as such could have biased
the results by differentially treating patients depending on which therapy
they were assigned to. This study should be replicated in a larger more het-
erogeneous sample with a longitudinal assessment of fidelity to the LEAP
intervention and a therapist(s) blinded to study hypotheses. Key words:
compliance; poor adherence to treatment, insight, motivation to change,
schizophrenia, Long-acting injectables.
ID: 550761
LONG-ACTING RISPERIDONE FOR SCHIZO-
PHRENIA AND CO-OCCURRING ALCOHOL USE
DISORDER
Meera Narasimhan1, M. F. Brunette2, R. Dawson2,
C. D. O’Keefe2, M. H. Weeks2, P. F. Buckley3, A. I. Green2
1Neuropsychiatry and Behavioral Science, University of South
Carolina, Columbia, SC, USA; 2Psychiatry, Dartmouth Medical
Center, Concord, NH, USA; 3Psychiatry and Health Behavior,
Medical Colllege of Georgia, Augusta, GA, USA
AUD is common in patients with schizophrenia and worsens its course.
Current pharmacological options to limit alcohol use in these patients
are limited. While typical antipsychotics appear not to decrease alcohol
in these patients, preliminary data suggest the atypical antipsychotic cloza-
pine (CLOZ) does. We have suggested that the effects of CLOZ on decreas-
ing alcohol use in these patients is mediated by its weak dopamine (DA) D2
receptor and potent norepinephrine (NE) alpha 2 receptor blockade, which
may ameliorate a dysfunction in brain reward circuitry (Green et al. 1999).
Risperidone, another atypical antipsychotic, is a potent blocker of the NE
alpha 2 receptor. Studies with RISP in comorbid patients, however, have
failed to demonstrate the dramatic effects seen with CLOZ. We have sug-
gested that intramuscular LAR may be important to test in this population
because: 1. patients are more likely to stay on LAR than OR 2. LAR may
allow for a lower blood level of RISP with resulting less potent blocade of
the DA D2 receptor than OR. Moreover, clinically, LAR may offer certain
advantages over OR in minimizing extrapyramidal symptoms (EPS), prolac-
tin elevation, and improve negative symptoms. In this ‘‘proof of concept’’
study conducted at 5 sites, patients with schizophrenia or schizoaffective dis-
order and co-occurring AUD between the ages of 18 and 65, not taking
CLOZ or LAR, are currently being recruited (to achieve a sample of
100). Patients who provide consent and are eligible are randomized to either
the LAR or OR treatment group and followed for 6 months. The dosage of
LAR starts at 25 mg IM/ 2 weeks, with a target dose of 37.5 mg IM/ 2 weeks.
OR is tapered up to a target dose of 4 mg per day. Assessments of diagnosis,
symptoms, cognition and physical health are conducted at baseline. Ratings
for alcohol and other substance use, psychiatric symptoms, EPS, cognition
and overall functioning are performed longitudinally. Blinded independent
raters review data and make a ‘‘consensus rating’’ of substance use at 0, 3
and 6 months. Ninety-four patients have been randomized thus far out of
a target total of 100. The study population has been largely male (73.2%
vs. 26.8%), with a substantial representation of African American patients
(42%). We will present the full baseline dataset of this sample at the meeting
and discuss key issues faced in launching such a multi-site treatment trial of
patients with schizophrenia and AUD.
ID: 550725
PREDICTORS OF ATTENDANCE IN TWO METHODS
OF COGNITIVE REMEDIATION
Gary Joseph Bryson1,2, K. Corey1, C. Dyer1, L. Taylor1
1Psychology, VA Connecticut Healthcare System, Newington,
CT, USA; 2Department of Psychiatry, Yale University School of
Medicine, New Haven, CT, USA
Cognitive remediation has been shown to be an effective treatment of cog-
nitive dysfunction in schizophrenia. However, little research has been con-
ducted on factors effecting attendance in training. This study investigates
the relationships between two cognitive remediation methods (Computer
Based Training-PSS CogRehab, Bracy 1999 or Cognitive Remediation
Therapy-CRT; Wykes, 2001) and initial symptom and cognitive variables.
We predict that initial symptoms, most likely the emotional discomfort
score, will predict the number of session attended in computer training con-
dition, but not the CRT condition. Additionally, we hypothesized that
baseline cognitive test performance will be related to the number of sessions
attended in the computer condition, but not the CRT condition. Methods:
Fifty (50) participants with either schizophrenia or schizoaffective disorder
were randomly assigned to either CRT or Computer Based Training. Intake
symptom and cognitive measures were conducted and participation rates
over a 15 week course of treatment were gathered. Drop out rates were
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also established (stopping participation before week 14). Analysis: Stepwise
linear regressions were conducted (one for each condition with symptoms
predicting the number of sessions. Symptom variables entered were the five
factors (as measured by the Bell et al. 1999) from the PANSS. Additionally,
stepwise linear regressions were conducted (one for each condition with
baseline cognitive test scores predicting the number of sessions. Results:
For participants in the Computer Training Condition symptoms were sig-
nificantly predictive of the number sessions attended, but no such relation-
ship was found between symptoms and sessions for the CRT participants.
Additionally, cognitive test measures were related to attendance in both
conditions. Conclusion: Symptoms interact with training methods to effect
participation while cognitive abilities have a more universal effect on atten-
dance. More specifically, symptoms reduce participation in Computer
Trained group, while the individual therapeutic nature, positive reinforce-
ment, scaffolding and interactive strategizing inherent in CRT may serve to
negate the effects of symptoms on participation.
ID: 550606
DO ALL SCHIZOPHRENIA PATIENTS NEED TO USE
ANTIPSYCHOTIC MEDICATIONS THROUGHOUT
THEIR LIFETIMES: A 26 YEAR MULTI-FOLLOWUP
Martin Harrow, T. H. Jobe, L. S. Grossman,
E. Astrachan-Fletcher, A. Bonner-Jackson
Psychiatry, University of Illinois, College of Medicine, Chicago,
IL, USA
Objectives: Multi-decade research on antipsychotic use has not been readily
available to the field. A central issue in the long-term treatment of schizo-
phrenia is whether all patients with schizophrenia need to use antipsychotic
medications continually throughout their lives. The research also studied
whether antipsychotic medications increase work disability. The current
study of schizophrenia patients assessed 7 times over a 26-year period pro-
vides data on these issues. Method: From the Chicago Followup study, 101
patients with psychotic disorders, including 61 with schizophrenia spectrum
disorders, were assessed at acute hospitalization and then followed up 7
times over 26 years. Using standardized research instruments, patients
were assessed at each followup for positive symptoms, negative symptoms,
depressive syndromes, cognitive impairment, work disability, and treat-
ment. This included assessments of first and second-generation antipsy-
chotic medications. Results: 1) A subgroup of schizophrenia patients
removed themselves from antipsychotics for many years with some leaving
treatment for prolonged periods. 2) Significantly more of the patients who
removed themselves from antipsychotics for prolonged intervals experi-
enced periods of recovery (P < .01). 3) The relatively favorable outcome
of this subgroup of schizophrenia patients who stayed off of antipsychotics
for prolonged periods is partly due to favorable internal characteristics of
these patients, rather than their treatment status (P < .05). 4) Beginning at
the 4.5 year followups and continuing for over 20 years there was surpris-
ingly little work disability among the subgroup of schizophrenia patients
who left treatment for prolonged periods. 5) Schizophrenia patients who
were switched from first generation to second generation antipsychotics
showed reductions of depressive symptoms. Conclusions: The 26 years
of longitudinal data indicate that not all patients with schizophrenia
need to be treated with antipsychotics continuously throughout their lives
and identify specific factors which may contribute to periods of recovery.
The periods of recovery in a subgroup of schizophrenia patients who leave
treatment is partly due to internal premorbid characteristics and premorbid
developmental achievements of these patients, rather than their treatment
status. Antipsychotics, which block dopamine receptors and reduce moti-
vational salience, may also contribute to work disability in schizophrenia.
ID: 550535
INVESTIGATOR EXPERIENCES WITH AND
OPINIONS OF IRBS
Praveen George, B. A. Fischer
Maryland Psychiatric Research Center, Baltimore, MD, USA
Institutional Review Boards (IRBs) oversee human subject protections in
proposed research conducted, funded, or regulated by any U.S. Govern-
ment agency. There is no doubt that human subjects have been mistreated
in the past and that protections offered by IRBs are necessary. However,
there are reports critical of IRBs where IRB ‘‘mission creep’’ is described as
being burdensome and an obstacle to sound, ethical science. Virtually no
work has been done to assess how researchers perceive IRB protections
and/or burdens. Therefore, there is no empiric data on which to base a dis-
cussion of whether IRBs are satisfactorily meeting their mandate. A survey
was developed to assess researcher IRB experiences. The survey was mailed
first to 200 depression researchers and then to 200 schizophrenia research-
ers. Potential participants were identified using ‘‘depression’’ and ‘‘schizo-
phrenia’’ as search terms in the NIH Computer Retrieval of Information on
Scientific Projects (CRISP) database of funded grants. Researchers from
University of Maryland were not removed from the subject pool unless
the Maryland Psychiatric Research Center was their primary appointment.
If, after 4 wks, there was no response to the initial mailing, participants were
emailed the survey. Response rate was approximately 30%. Most respond-
ents were Professor level with at least 15 yrs experience and over $1million
in grant support. Most submitted 3 or more protocols/yr for IRB review.
IRB turn-around time was 3 wks or longer 88% of the time. Protocols were
returned from the IRB for subject safety concerns 46% of the time, and with
bureaucracy concerns 42% of the time (format, etc). No one believed IRB
paperwork was inadequate to evaluate protocols; 30% reported paperwork
was excessive and discouraged scientific advancement, but most reported it
was about right considering the IRB mission. Most agreed the IRB mission
should involve enforcing subject privacy and policing conflict of interest,
but 60% thought it was beyond the scope of the IRB to evaluate study de-
sign. Only 3–8% would not submit a controversial protocol because of dif-
ficulty dealing with an IRB. It appears that IRB review is time-consuming
and time is wasted coordinating between multiple IRBs and in bureaucratic
concerns. However, most researchers believe IRB paperwork is necessary,
the IRB mission should include assessment of subject privacy and conflict
of interest, and that IRBs do not inhibit scientific progress.
ID: 550533
EFFECT OF LURASIDONE ON DEPRESSIVE
SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
Masaaki Ogasa1, A. Loebel1, J. Cucchiaro1, D. A. Phillips1,
J. Severs1, M. Nakamura2, J. Guarino1
1Dainippon Sumitomo Pharma America, Fort Lee, NJ, USA;
2Setsunan University, Osaka, Japan
Background: Clinically significant depression occurs in approximately 25%
of individuals with schizophrenia and is associated with greater functional
impairment and worse outcomes. Lurasidone is a novel psychotropic agent
with high affinity for D2 and 5-HT2A receptors, as well as for receptors im-
plicated in enhancement of cognitive function (partial agonist at 5-HT1A;
antagonist at 5-HT7). The goal of this secondary analysis was to evaluate
the efficacy of lurasidone in patients diagnosed with schizophrenia who
were experiencing clinically significant depressive symptoms. Methods:
Data for this analysis came from a 6-week, placebo-controlled study in
which patients meeting DSM-IV criteria for schizophrenia were random-
ized to 6 weeks of double-blind treatment with a fixed dose of lurasidone
80 mg (N = 90; baseline MADRS score = 14.2; subgroup with MADRS
>12, N = 55) or placebo (N = 90; baseline MADRS score = 14.5; subgroup
with MADRS >12, N = 58). Results: On an ANCOVA analysis, treatment
with lurasidone was associated with significantly greater LOCF-endpoint
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improvement than placebo on the MADRS in the total sample (2.72 and
0.11; P = .026), and in the subgroup with MADRS>12 (6.02 vs.2.77;
P = .04). The Cohen’s d effect size for endpoint change in the MADRS was
0.42 for the depressed subgroup. Treatment with lurasidone was also asso-
ciated with significantly greater improvement than placebo in the PANSS
depression item (G6; 1.03 vs. 0.30; P < .01). Conclusion: These explor-
atory findings from a double-blind, phase 2 study suggest that lurasidone is
effective in the treatment of depressive symptoms associated with schizo-
phrenic illness. Phase 3 double-blind studies are underway to fully charac-
terize lurasidone’s clinical profile and confirm its potential antidepressant
benefit in patients diagnosed with schizophrenia who present with clinically
significant symptoms of depression.
ID: 550473
IMPROVING OUTCOMES FOR SCHIZOPHRENIA
VIA A WEB-BASED FAMILY PSYCHOEDUCATION
INTERVENTION, DESIGNED FOR THOSE WITH
COGNITIVE IMPAIRMENTS
Armando James Rotondi1, G. L. Haas2, R. Ganguli2, S. Eack3,
C. M. Anderson2, C. E. Newhill3, M. B. Spring4, J. B. Rosenstock2
1Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA,
USA; 2Department of Psychiatry, University of Pittsburgh, Pitts-
burgh, PA, USA; 3Department of Social Work, University of
Pittsburgh, Pittsburgh, PA, USA; 4Department of Information
Sciences, University of Pittsburgh, Pittsburgh, PA, USA
The study’s purpose was to: 1) conduct usability studies to determine how
to develop usable websites for persons with SMI and cognitive impair-
ments, and; 2) use this knowledge to create a web-based intervention to
provide multi-family psychoeducational therapy (M-FPE) to persons
with schizophrenia and their family members via home computers. A ran-
domized treatment and control group design was used to evaluate a web-
based M-FPE intervention. Usability studies, conducted with 98 persons
with SMI, revealed that standard website design guidelines produce web-
sites that are poorly suited and confusing to persons with SMI. We iden-
tified an alternative model and set of guidelines for designing websites that
was used to develop the M-FPE website for persons with schizophrenia and
their family members. We found that compared to websites designed via
standard guidelines, and three public mental health websites, users com-
pleted more tasks with our website (P  .0002), and completed them faster
(P  .000007). The intervention website had the following components: an
on-line therapy group for persons with schizophrenia, one for family mem-
bers, and one for both; the ability to ask health professionals a question and
receive a response; a library of previously asked and answered questions,
and; educational materials. At 3 months, participants with schizophrenia in
the intervention group had lower perceived stress (P = .04) and showed
a trend for a higher perceived level of social support (P = .06). The average
number of website page-views per person with schizophrenia was 1 080.7
(SD = 1 812.0, range = 86–6 325). At the end of one-year: the intervention
group had a large reduction in positive symptoms compared to TAU, with
a differential effect size of 0.90 (P = .013); those in the intervention group
had greater knowledge of schizophrenia diagnosis, differential effect size =
0.91 (P = .028), and; those with more severe disease symptoms tended to use
the website more (r = .65, P = .005). Persons with schizophrenia used the site
significantly more than family members. Persons with SMI, and others with
cognitive impairments, can and will use web-based interventions. Our ex-
perience indicates that such users can experience improved outcomes from
the use of on-line treatments, if the applications are designed specifically for
use by persons with cognitive impairments. This provides an opportunity to
increase the receipt of evidence based treatments such as FPE.
ID: 550464
PREVALENCE OF, AND RATIONALE FOR, THE
PRESCRIPTION OF HIGH DOSE AND COMBINED
ANTIPSYCHOTICS IN FORENSIC PSYCHIATRY
INPATIENT SETTINGS IN THE UK: A COMPARISON
WITH ACUTE ADULT INPATIENT SETTINGS
Thomas R. E. Barnes1, D. Brooke2, E. Petch3,
A. Shingleton-Smith4, C. Paton1
1Department of Psychological Medicine, Imperial College London,
London, United Kingdom; 2Oxleas NHS Foundation Trust,
Dartford, United Kingdom; 3West London Mental Health NHS
Trust, London, United Kingdom; 4Centre for Quality Improvement,
Royal College of Psychiatrists, London, United Kingdom
Psychiatric patients in forensic settings are characterised by psychotic ill-
ness with high levels of co-morbidity, and presentation with violence orig-
inating in complex and enduring psychiatric and social problems.
Medication strategies for treatment-resistant psychosis, such as high-
dose and combined antipsychotic prescriptions, might be expected to
be more commonly used in forensic than acute adult inpatient settings.
We used data from two quality improvement programmes to test this
hypothesis. Two audit-based quality improvement programmes on pre-
scribing of high-dose and combined antipsychotic drugs were conducted
in 1. acute adult and psychiatric intensive care wards (baseline audit Jan-
uary 2006, re-audit January 2007), and 2. forensic wards (baseline audit
March 2007, re-audit March 2008). Demographic, clinical and prescribing
data were gathered for all patients prescribed antipsychotic drugs. 32 UK
specialist mental health services (Trusts) participated in the first pro-
gramme, submitting data for 3271 patients at re-audit. 21 Trusts partic-
ipated in the second programme, submitting data for 1997 patients at
re-audit. In acute adult settings, prevalence of high-dose prescribing
was 34% and combined antipsychotics 39%. Corresponding figures for
forensic settings were 32% and 40%. In both settings, the main reason
for combined antipsychotics was to manage behavioural disturbance.
In forensic settings, a quarter of patients were prescribed clozapine alone
or in combination with a second antipsychotic. Almost 10% of antipsy-
chotic combinations were prescribed for the management of persistent
aggression, but few of these included clozapine. The prevalence of
high-dose and combined antipsychotic prescribing was high, and similar
across the two programmes; 3 out of every 10 patients were prescribed
a high dose and 4 out of 10 combined antipsychotics. The clinical reasons
for prescribing combined antipsychotics differed across clinical settings.
Most notably, clozapine augmentation and the management of persistent
aggression were more frequently cited reasons in forensic settings. The
three antipsychotics most frequently augmenting clozapine were ami-
sulpride, haloperidol and sulpiride. These drugs share potent dopamine
D2 antagonism and a relatively low potential to exacerbate the metabolic
side effects of clozapine, suggesting that clinicians employ a common
pharmacological rationale when selecting a second antipsychotic to aug-
ment clozapine.
ID: 550405
MULTI-MODAL COGNITIVE THERAPY FOR
SCHIZOPHRENIA: ADDRESSING COGNITIVE
IMPAIRMENT AND DYSFUNCTIONAL COGNITIVE
SCHEMAS
Dawn Irene Velligan1, D. Turkington3, S. Tai2
1Psychiatry, UTHSCSA, San Antonio, TX, USA; 2Psychology,
University of Manchester, Manchester, United Kingdom;
3Psychiatry, Royal Victoria infirmary, Newcastle upon Tyne,
United Kingdom
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The process of recovery in schizophrenia involves resolving persistent
symptoms and improving functional outcomes. In large randomized, pro-
spective clinical trials, our research group has demonstrated the efficacy of
Cognitive Adaptation Training (CAT—a home-based psychosocial treat-
ment utilizing environmental supports such as medication containers, signs,
checklists and the organization of belongings to bypass deficits in cognitive
functioning and cue and sequence adaptive behavior) for improving adher-
ence to medications and functional outcomes in schizophrenia. The effect of
CAT on levels of symptomatology has been mixed. Early CAT studies uti-
lizing therapists with extensive training in psychotherapy with psychosis
found significant improvements in positive symptoms. More recent ran-
domized trials failed to replicate this finding with CAT technicians not
trained in psychotherapy for psychosis. Persistent psychotic symptoms sub-
stantially impair patients’ ability to adapt to life in the community. Cog-
nitive Behavior Therapy (CBT) is an evidence-based practice in the UK for
addressing persistent positive symptoms and the distress associated with
them. We have demonstrated that CBT decreases symptomatology and
minimizes the negative effect of persisting symptoms upon individuals
with this disorder. We now describe a home delivered, multi-modal cogni-
tive treatment (Mcog) targeting both functional outcomes and persistent
positive symptoms for individuals with schizophrenia. Pilot (n = 14) found
that those seen in CAT by therapists trained in cognitive behavioral tech-
niques for psychosis experienced significant improvement in positive symp-
toms over 9 months (n = 7; (t = 3.03; P< .03; t = 2.52; P< .05; and t = 1.29;
t = 3.58; P < .02; for hallucinations, delusions, and suspiciousness, respect-
fully). Individuals seen by CAT technicians not trained in these techniques
did not improve with respect to positive symptoms (all P’s>.25). By integrat-
ing CAT and CBT elements into one Multi-modal Cognitive Treatment,
CAT techniques such as reviewing audio tapes of CBT conversations
with the therapist can extend the reach of CBT to environments in which
persistent symptoms are particularly problematic (eg, riding the bus).
Moreover, because Mcog is provided on the same home visit, multiple out-
come dimensions can be addressed with minimal additional costs for pro-
viding treatment.
ID: 550398
TOWARDS A COGNITIVE-EMOTIONAL
TREATMENT OF INSIGHT IN PSYCHOSIS
Marieke Pijnenborg1,2, A. Aleman1
1Neuroimaging Centre, University Medical Hospital, Groningen,
Netherlands; 2Psychotic Disorders, GGZ Drenthe, Assen,
Netherlands
Goal: Insight is impaired in many people who suffer from psychosis.
Limited insight has been associated with poorer social functioning, more
violent behavior and poorer outcome of the disease. Therefore, we are de-
veloping a treatment module that aims to enhance insight in psychosis and
thereby participation in daily life. The cognitive-emotional module is based
on research findings and hypotheses regarding the role of executive func-
tion, self-evaluation and self-defense in poor insight. Methods: The treat-
ment module encompasses several cognitive and emotional processes that
are thought to play a role in insight in psychosis and exists of five sub-
modules: introduction and explanation of the treatment’s rational, self-
reflection, emotion regulation, receiving feedback and perspective taking,
and acceptance and goal setting for the future. The effect of the treatment
module on insight, symptoms, social functioning and quality of life will be
evaluated in a multicentre RCT. Results and conclusions: A psychosocial
approach that targets cognitve-emotional processing holds promise for im-
proving patients’ insight in psychotic illness. We present outline and con-
tent of the treatment module, together with results of a pilot study that is
currently being performed.
ID: 550389
CONTINUITY OF TREATMENT AND SUPPORTING
PARENT GROUPS IN EARLY PHASE SCHIZO-
PHRENIA: A 5 YEAR RANDOMISED TRIAL
Donald Linszen, L. Wouters, M. Krikke, D. Nieman,
T. v. Amelsvoort, M. Lenior, P. Dingemans, L. d. Haan
Psychiatry, AMC University Amsterdam, Amsterdam, Netherlands
The beneficial effects of early intervention in first episode schizophrenia
show a return to the predominantly unfavorable course at 5 year
follow-up. Objective: to evaluate the effectiveness of 5 year specialized
continuity of treatment with or without parent groups in early phase
schizophrenia. Methods: randomised controlled trial. Participants were
consecutively admitted patients (n = 198) aged 15–28 years with early
schizophrenia-like disorders. Interventions: Continuity of Treatment by
professionals Specialized in the treatment of early schizophrenia (CST),
Continuity of Specialized Treatment plus Parent groups (CSTþP) and
Continuity of Treatment as Usual (CTU). Outcome measures: rates of first
relapse during 5 years treatment, time to first relapse after remission, sui-
cide, psychosocial functioning, second and third relapse. Analysis: Cumu-
lative relapse rates were estimated using life-table methods. 38 Patients
changed from the assigned condition. The effect of the three interventions
on time to first relapse after remission was compared using Cox regression
analysing both intention to treat (ITT) and actually realized treatment
(ART) grouping. Results: The relapse rate after 5 years was relatively
low (0.49, 95% confidence interval 0.41–0.56). No differences between
the 3 conditions were found in the ITT analysis. However, the ART anal-
yses showed significant lower relapse rates after 5 years for CSTþP (0.30,
95% CI 0.18–0.45) but not for CST (0.53, 95% CI 0.38-0.67) as compared
with CTU(0.56, 95% CI 0.45 0.67). Cox regression showed a significant
positive effect in postponing relapse for CSTþP condition,corrected for
potential confounding factors. Continuity of treatment didn’t affect the
suicide rate (n:7; 3,5%). 109/190 patients started with poor social function-
ing: 71 patients showed improvement (65%) and 38 did not change (35%).
Of the 81 patients who started with good functioning 44 deteriorated (54%)
and 37 did not change (46%). No effects of ITT or ART treatment condi-
tions were found on psychosocial functioning. Conclusion: the basic treat-
ment design offered to all patients, including the parental educational
approach was associated with a reduced relapse rate. We found no differ-
ences in effect between the treatment conditions in the ITT analysis. The
favorable CSTþP result underlined the importance of active participation
of the parents. Psychosocial functioning improved or remained well for
a significant proportion of the patients.
ID: 550291
EFFICACY OF SOCIAL COGNITIVE REMEDIATION
IN SCHIZOPHRENIA PATIENTS: A META-ANALYSIS
Daniel R. Mueller, V. Roder, A. Heuberger
University Hospital of Psychiatry, University of Bern, Bern,
Switzerland
Objective: Increasing interest in social cognition in the last few years led to
the development of several new approaches in social cognitive remediation.
Initial evaluations of these approaches have been made over 20 years ago.
Social cognitive remediation approaches directly intervene in individual or
multiple social cognitive areas (emotional processing, social perception,
Theory of Mind (ToM), social schemata and attribution style) declared
by the NIMH-MATRICES-Initiative. Some of these approaches integrate
social cognitive interventions with therapeutic components intended to
ameliorate neuro-cognitive and social skills or with work rehabilitation.
Until today no meta-analysis on the efficacy of social cognitive remediation
has been presented. Method: 19 controlled studies with randomized patient
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assignment were included in this quantitative analysis. The sample con-
sisted of 961 schizophrenia patients (DSM/ICD). In 74% of the studies so-
cial cognitive remediation was compared to Placebo-Attention-Conditions
and/or to standard care, in 26% of the studies it was compared to other
psychotherapies. Based on the outcome variables from each study effect
sizes (ES) between the compared groups were calculated. Results: Over
an average length of 23 weeks a significant global therapy effect could
be demonstrated (average effect size of all conducted variables). Significant
effects were found in the summarized social cognitive areas and in the sub-
areas of emotional processes, social perception and ToM. The summarized
neuro-cognitive area showed significant evidence of amelioration compared
with the control groups. The largest effects were visible in the MATRICES
areas speed of information processing and planning/problem solving. The
effect sizes for the verbal memory and the working memory reached the
level of significance. There was however no significant effect for the visual
memory. Further significant effects were found for psychopathology and
social functioning. The global therapy effect could be maintained during
a follow-up period at an average of 9.5 months. The setting, the control
groups and the type of intervention were identified as moderators. The
quantitative analysis of the results shows strong evidence that social cog-
nitive remediation has a broad effect on various areas of functioning and
symptoms relevant in schizophrenia.
ID: 550290
RELAPSE PREVENTION IN FIRST-EPISODE
PSYCHOSIS PATIENTS WITH STABLE
MAINTENANCE MEDICATION FOR AT
LEAST ONE YEAR
Eric Chen1, C. Hui1, M. Lam3, C. W. Law2, C. Chiu2, D. Chung3,
S. Tso5, E. Pang3, K. T. Chan5, Y. C. Wong3, K. Chan4,
S. F. Hung4, T. J. Yao6, W. G. Honer7
1Psychiatry, University of Hong Kong, Hong Kong, China;
2Psychiatry, Queen Mary Hospital, Hong Kong, China;
3Psychiatry, Tai PoHospital, Hong Kong, China; 4Psychiatry, Kwai
Chung Hospital, Hong Kong, China; 5Psychiatry, Castle Peak
Hospital, Hong Kong, China; 6Clinical Trials Centre, University of
Hong Kong, Hong Kong, China; 7Psychiatry, University of British
Columbia, Vancouver, BC, Canada
Clinically there is a strong expectation from first-episode psychosis patients
and their carers to discontinue with maintenance medication after a period
of remission. However, there is so far no consensus regarding how long
maintenance medication should be continued. The current study aims to
assess whether this point in time is reached after at least 1 year of mainte-
nance medication. Following a first-episode of schizophrenia and non-af-
fective psychosis (DSM-IV), patients who were remitted well and on
maintenance medication for at least 12 months were randomized to receive
either maintenance medication (quetiapine 400mg/day) or placebo. Relapse
was defined as the re-emergence of positive symptoms. In the overall sample
of 178, 83 patients relapsed during the study. Fewer patients relapsed in the
quetiapine maintenance group (27 of 89, 30%) compared with the placebo
group (56 of 89, 63%). The Kaplan-Meier estimate of the proportion
of relapse at 11 months after randomization was 41 percent (95% CI, 29
to 53%) in the quetiapine maintenance group and 76 percent (95% CI,
66 to 86%) in the placebo group (log-rank test, v2 = 15.65, P < .001).
New data for relapse risks in remitted first-episode psychosis patients is
provided. The risk of relapse after medication discontinuation is still sub-
stantial after receiving maintenance medication for a mean of 22 months
following first-episode psychosis. Supported by investigator initiated trial
award from AstraZeneca and the Research Grants Council Hong Kong
(Project number: 765505).
ID: 550243
OUTCOME OF THE SERTINDOLE COHORT PRO-
SPECTIVE (SCOP) STUDY: ALL-CAUSE MORTALITY
Joseph Peuskens1, P. Tanghøj2, A. Mittoux2
1University Centre St.-Jozef, Kortenberg, Belgium; 2H. Lundbeck
S/A, Copenhagen, Denmark
Sertindole is an efficacious atypical antipsychotic with good tolerability
and is currently launched in approximately 30 countries. A known dose-
dependent QT prolongation gave rise to a cardiac safety concern, and there-
fore, a post-marketing surveillance (PMS) study, SCoP, was initiated to
confirm that under normal conditions of use, sertindole is not associated
with an excess mortality rate compared to other atypical antipsychotics.
This was a prospective, randomised (1:1), partially blinded, active-controlled,
multinational study. The primary endpoint was all-cause mortality. It was
conducted under normal conditions of use and the inclusion criteria
were deliberately broad to ensure patients were representative of patients
to be treated with sertindole on the market. Both for sertindole and for
risperidone, the titration and maintenance dosages and patient manage-
ment was left to the discretion of the investigators, in accordance with
the national Summary of Product Characteristics (SPCs). An Independent
Safety Committee classified the events, using blinded data, and providing
advice to the Independent Management Committee overseeing the study.
Patients were eligible for enrolment if they had a diagnosis of schizophrenia,
were>18 years, and based on the patient’s clinical status, a new or a change
in antipsychotic treatment was indicated. In addition, patients were only
eligible for enrolment if they met all other criteria set out in the national
SPCs for both sertindole and risperidone. Add-on antipsychotic therapy
was allowed and patients were monitored for the entire duration of the
study, including after they started add-on therapy or discontinued study
drug. The SCoP study is one of the largest PMS studies ever conducted
in schizophrenia research. A total of 9 809 patients were treated at 593 sites
in 38 countries with approximately 15 000 patient years of exposure (PYE)
accrued. The all-cause mortality rate for all patients in the study was 0.8
per 100 PYE and the estimated mortality ratio (MR) was 1.081 (90%CI:
[0.801;1.458]) indicating that sertindole is not associated with an excess
mortality compared to risperidone. The withdrawal rates due to serious
adverse events were 2% and 1% for sertindole and risperidone, respectively,
and the withdrawal rate due to lack of efficacy was 8% for both treatments.
In conclusion, sertindole offers a safe and efficacious alternative to other
atypical antipsychotics.
ID: 550242
RELAPSE PREDICTORS FOR DISCONTINUING
AND CONTINUING MAINTENANCE MEDICATION
IN REMITTED FIRST-EPISODE PSYCHOSIS
PATIENTS
Christy Hui1, E. Chen1, M. Lam3, C. W. Law2, C. Chiu2,
D. Chung3, S. Tso5, E. Pang3, K. T. Chan5, Y. C. Wong3,
K. Chan4, S. F. Hung4, T. J. Yao6, W. G. Honer7
1Psychiatry, Univeristy of Hong Kong, Hong Kong, China;
2Psychiatry, Queen Mary Hospital, Hong Kong, China;
3Psychiatry, Tai PoHospital, Hong Kong, China; 4Psychiatry, Kwai
Chung Hospital, Hong Kong, China; 5Psychiatry, Castle Peak
Hospital, Hong Kong, China; 6Clinical Trials Centre, University of
Hong Kong, Hong Kong, China; 7Psychiatry, University of British
Columbia, Vancouver, BC, Canada
After a first-episode psychosis, patients inevitably face a clinical dilemma
regarding whether to continue with maintenance medication after a period
of remission. This decision has to be weighed against the long-term med-
ication side effects and the risk of relapse. In this study, we aim to identify
potential predictors for relapse among patients who have continued with
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maintenance medication, as well as those who have discontinued with main-
tenance medication. This is a double-blind randomized placebo-controlled
study. Patients who were remitted from a first-episode of schizophrenia or
non-affective psychosis (DSM-IV) and had remained well on maintenance
medication for at least 1 year were recruited into this study. Eligible patients
were randomized to either quetiapine (400mg/d) or placebo for 12 months
to detect a relapse. Relapse was defined as re-emergence of definitive positive
symptoms. Baseline clinical and cognitive variables were measured as poten-
tial predictors for relapse. Univariate and multivariate Cox-proportional
hazards models were applied to analyze significant predictors in the mainte-
nance medication and the placebo groups. A total of 178 patients were
recruited. In the placebo group, significant multivariate relapse predictors
were smoking (relative risk 4.317, 95% CI = 1.012–18.417), negative symp-
toms(relative risk 1.030, 95% CI = 1.008–1.053) and verbal fluency (relative
risk 0.880, 95% CI = 0.807–0.960). In the medication group, significant mul-
tivariate relapse predictors were pre-morbid functioning (interest) (relative
risk 1.641, 95% CI = 1.215–2.216), PANSS (general psychopathology)
(relative risk 1.548, 95% CI = 1.089–2.200), logical memory at immediate
recall (relative risk 0.879, 95% CI = 0.782–0.988) and neurological
soft signs (disinhibition) (relative risk 3.423, 95% CI = 1.585–7.390). Impor-
tantly,predictors identified inthetwogroupshelpprovide informationabout
the characteristics of the patients who are more prone to relapse. Future
intervention strategies for relapse prevention can be based on the current
findings. Supported by investigator initiated trial award from AstraZeneca
and the Research Grants Council Hong Kong (Project number: 765505).
ID: 550229
CLOZAPINE’S DISTINCTIVENESS IN THE TIME
COURSE AND PROFILE OF EARLY SYMPTOM RE-
MISSION IN SCHIZOPHRENIA: A QUANTITATIVE
REVIEW
Megan Elizabeth Sherwood1,2, A. E. Thornton1,3, W. G. Honer1
1Psychiatry, Centre for Complex Disorders, University of British
Columbia, Vancouver, BC, Canada; 2Psychiatry, St. Paul’s
Hospital, Vancouver, BC, Canada; 3Psychology, Simon Fraser
University, Burnaby, BC, Canada
In patients with schizophrenia, an early, linear response to antipsychotic
treatment is generally apparent. Nevertheless, the specific response to clo-
zapine treatment has yet to be fully elucidated despite the fact that clozapine
is more efficacious than other agents in treatment-refractory schizophrenia.
Therefore, we conducted a meta-analytic review of randomized, controlled
clinical trials that compared clozapine to comparator antipsychotics using
BPRS or PANSS outcome measures. Seventeen studies enrolling 1463 par-
ticipants were retrieved. Seven of these studies enrolled refractory patients;
ten studies enrolled non-refractory patients. Regression coefficients were
used to estimate linear and quadratic rate of change of the per-item
BPRS or PANSS scores across time, starting from the baseline and ending
after four weeks of treatment. Refractory and non-refractory patient sam-
ples were combined in the analyses to maximize the robustness of the find-
ings. Results revealed significant linear declines for both the clozapine and
comparator treatments (P’s < .001), with a trend towards a greater linear
decline in the clozapine (M = .400, SD = .277) relative to the comparator
(M = .302, SD = .179) arms: t (16) = 1.81, P = .09. Additionally, we
detected a significant attenuation of the linear decline over time for
both clozapine and the comparator (P’s < .01), that did not differ between
the treatments: clozapine arms (M = .041, SD = .044) versus comparator
arms (M = .025, SD = .034), t16 = 1.58, P = .134. These results suggest
that antipsychotic treatments are associated with rapid and robust symp-
tom reduction, which significantly attenuates over time early in the course
of treatment. Furthermore, there appear to be minimal differences in profile
of response in patients undergoing clozapine versus comparator treatments
over four weeks of treatment. Because of a dearth of studies of refractory
patients, the current meta-analytic findings are based upon combined (re-
fractory and non-refractory) patient samples. The implications for refrac-
tory patients alone are consequently limited.
ID: 550196
ADEPT: A DEFINITIVE ESTROGEN PATCH TRIAL
Jayashri Kulkarni1, C. Gurvich1, L. Mu1, S. Chaviaras3,
S. Damodaran3, K. Roberts2, M. Berk2, A. de Castella1,
P. Fitzgerald1, H. Burger4
1Alfred Psychiatry Research Centre, School of Psychology,
Psychiatry and Psychological Medicine, Monash University,
Melbourne, VIC, Australia; 2Department of Clinical and Biomedical
Sciences, University of Melbourne, Melbourne, VIC, Australia;
3Clinical Trials Research Group, School of Psychology, Psychiatry
and Psychological Medicine, Monash University, Melbourne, VIC,
Australia; 4Prince Henry’s Institute, Monash Medical Centre,
Melbourne, VIC, Australia
Accumulating evidence suggests estrogens may have therapeutic effects in
severe mental illnesses, including schizophrenia, via neuromodulatory and
neuroprotective activity. Our previous studies have indicated that women
receiving 100mcg transdermal estradiol improved significantly more than
women receiving placebo, in terms of positive and general psychopathology
symptoms. The aim of the current study was to compare the effectiveness of
adjunctive transdermal estradiol (100 and 200mcg) to adjunctive placebo in
the treatment of acute psychotic symptoms. Women of childbearing age
with a diagnosis of schizophrenia or schizoaffective disorder were invited
to participate in this 8-week three-arm (100mcg/day adjunctive transdermal
estradiol, 200mcg/day adjunctive transdermal estradiol, or adjunctive
transdermal placebo) double-blind, placebo controlled study. All patients
continued to receive standard antipsychotic treatment whilst in the trial.
Psychopathology, mood and cognition were assessed at baseline then at
weekly, fortnightly or monthly intervals using the PANSS, MADRS
and RBANS. Estradiol, progesterone, and gonadotropin levels were
assessed at baseline and days 28 and 56. Preliminary results indicate an im-
provement in psychopathology for the estradiol groups, as compared to the
placebo group. The findings from this multisite ‘proof-of-concept’ study
will determine whether estradiol can be used as an adjunctive treatment
of psychotic symptoms in women with schizophrenia. This research is sup-
ported by The Stanley Medical Research Institute.
ID: 550162
COGNITIVE BEHAVIORAL THERAPY FOR
PARANOIA
Yulia Landa1, P. Chadwick2, L. Alexeenko1, D. Silbersweig1
1Psychiatry, Weill Cornell Medical College, New York, NY, USA;
2Psychiatry, University of Southampton, Southampton, United
Kingdom
Background: Studies have shown that patients’ reasoning styles as well as
cognitive biases underlie the formation and maintenance of paranoid
beliefs. We developed the Group Cognitive Behavioral Therapy (GCBT)
intervention to address specific for paranoid delusions cognitive biases
and to teach patients new, more adaptive ways of processing information.
The aim of this project is to conduct a preliminary controlled study to test
the efficacy of Group CBT for Paranoia. Method: Twenty four paranoid
patients with Schizophrenia or Schizoaffective disorder are randomly
assigned to either CBT or control group with clinical/symptom assessments
conducted at baseline and post-treatment by blind evaluators. Treatment as
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usual (TAU) is used as a control condition. Treatment phase for the CBT
group lasts 15 weeks and includes attending one individual and one group
therapy sessions weekly. Individual sessions support group sessions, and
are conducted by the same therapist. CBT interventions are focused on:
(1) Increasing patients’ cognitive flexibility and changing maladaptive
methods of forming judgments by learning and utilizing meta-cognitive
processes needed for making more accurate judgments; (2) Learning to
identify and correct cognitive biases; and (3) Using learned methods of rea-
soning to analyze and replace patients’ delusional beliefs with more adap-
tive ones. While the focus of therapeutic intervention is on helping patients
learn and apply cognitive operations, principles of cognitive therapy are
applied to create supportive, collaborative and empowering relationships
among group members. Results: The differential treatment effects will
be examined to determine whether there will be a statistically significant
increase in reductions in outcome scores of the CBT for Paranoia treatment
compared to control group. The initial assessment at week 8 showed that
the following significant changes occurred in the CBT condition, but not in
the TAU condition: reduction in delusion, suspiciousness, and poor rap-
port (PANNS); reduction in delusional conviction, and amount of distress
(PSYRATS), increase in ability to dismiss a paranoid thought and decrease
in worry (CDRS), (P < .05). Conclusions: These initial results suggest that
paranoid patients can benefit from learning cognitive operations needed for
making more accurate judgments, and applying these skills to modify their
paranoid beliefs in the context of GCBT.
ID: 550049
ASSESSMENT OF ELEMENTS OF CONSENT OVER
THE COURSE OF REAL CLINICAL TRIALS IN
SCHIZOPHRENIA
Bernard A. Fischer, K. J. Prentice, L. C. Mathews,
W. T. Carpenter
Maryland Psychiatric Research Center, University of Maryland
School of Medicine, Baltimore, MD, USA
Informed consent is not equivalent to merely obtaining a signature and the
process of consent is not complete once a signature is obtained. Ethical re-
search requires that subjects maintain some knowledge of a study during
participation. Continuing or sustained consent has received attention when
progressive cognitive decline is expected over the course of a study (eg, stud-
ies in Alzheimers disease). However, little has been done on sustained con-
sent in schizophrenia (SZ) where a relatively static cognitive insult is
coupled with a fluctuating clinical state. It is unclear what elements of in-
formed consent are lost over the course of a clinical trial in SZ and when
these elements are lost. To address this issue, we followed participants with
SZ enrolled in real clinical trials of 8 wks or longer and assessed their
capacity to consent at set time points. Capacity to consent was assessed
with the modified Evaluation to Sign Consent (mESC); a 23-item scale de-
veloped at the MPRC which measures Understanding, Appreciation, Rea-
soning, and Therapeutic Misconception with a maximum score of 92.
Participants in the Sustained Consent Study reviewed medication trial con-
sent forms and received a baseline mESC at wk 0 of the medication study.
Participants were randomized to receive a follow-up mESC at 1, 4, and 8
wks; 4 and 8 wks; or only at 8 wks. A Brief Psychiatric Rating Scale (BPRS)
was completed with each mESC. The medication trials included studies of
adjunctive agents for treatment-resistant positive symptoms (risperidone
added to clozapine), negative symptoms (rasagiline), and cognitive impair-
ment (atomoxetine and others). This preliminary analysis includes 42 sub-
jects enrolled in the Sustained Consent Study with a mean age of 42 yrs.
Participants were 57% male, 40% non-white, and had an average of 12
yrs education (SD 0.37). Baseline BPRS totals averaged 32.7 6 8.1. Baseline
mESC scores were 77.5 6 10.7. Over the course of 8 wks, there were no
meaningful changes in mean mESC score (Wk 1: 75.1 6 12.6, Wk 4:
76.4 6 12.6, Wk 8: 79.4 6 11.1). BPRS total did not correlate with
mESC score at any time point. This result supports the idea that partici-
pants with SZ can complete clinical trials of up to 8 wks with little change
in baseline capacity to consent. However, it should be recognized that this
sample size is small, participants were largely drawn from a research clinic
(were experienced subjects and clinically stable), and had, on average, com-
pleted high school.
ID: 550044
PILOT PROGRAM FOR MEDICATION
OPTIMIZATION: SOMETIMES LESS IS MORE
Amanda Ernst Wood1,2, A. Kennedy1, L. M. Martin1,2,
N. Kilzieh1,2, V. S. Sellars1, A. Tapp1,2
1VA Puget Sound Health Care System, Tacoma, WA, USA;
2Psychiatry and Behavioral Sciences, University of Washington,
Seattle, WA, USA
Purpose: The Optimization Program (OP) was developed as a clinical pro-
gram to maximize effectiveness of pharmacological treatment in clients
with severe mental illness within the VA Puget Sound Health Care System.
The objectives of the OP were to: 1) identify the most efficacious agents for
the treatment of specific target symptoms; 2) minimize risks to safety as-
sociated with the use of psychiatric medications; and 3) reduce the utiliza-
tion of redundant and/or questionably beneficial medications. Methods:
The OP enrolled clients with a psychiatric disorder who were prescribed
polypharmacy (at least four psychotropic medications). The OP procedures
were developed into a template followed by the client’s prescriber. These
procedures included a five Axis diagnosis, review of current symptoms/
problems, relevant mental status findings, and overall assessment of client.
Each psychotropic medication was then evaluated on a rating scale for tar-
get symptoms, tolerance, safety, compliance, and efficacy. Based on the
medication evaluation, a plan was developed to optimize the pharmacolog-
ical treatment of the client. Results: Assessment of 18 clients who partic-
ipated in this program found that after one OP visit, the number of
psychiatric medications was significantly reduced (P < .000) from an av-
erage of 5.3 to 4.2. During this same time, the GAF ratings remained es-
sentially unchanged from an average of 45.6 to 46.9 (P = .095). Conclusion:
Following a systematic approach to evaluating psychiatric medications, to-
tal number of medications were able to be reduced without apparent in-
crease of symptoms or decompensation of the client. Eliminating
unnecessary medications may decrease the risk of harm to clients and re-
duce overall costs to the medical center.
ID: 550022
PRELIMINARY FINDINGS FROM A COMMUNITY-
BASED EFFECTIVENESS TRIAL OF SOCIAL COG-
NITION AND INTERACTION TRAINING (SCIT)
David Leland Roberts1, D. L. Penn2
1Psychiatry, Yale University, New Haven, CT, USA; 2Psychology,
University of North Carolina, Chapel Hill, NC, USA
Social Cognition and Interaction Training (SCIT) is a manualized, 20-week
psychosocial intervention designed to improve social functioning in schizo-
phrenia by way of enhanced social cognition. The current presentation will
summarize preliminary data from an uncontrolled, pre/post effectiveness
trial of SCIT conducted within a network of outpatient clinics unaffiliated
with the SCIT treatment developers (n = 48). Outcome domains included
Theory of Mind, emotion perception, and attributional bias. Preliminary
results indicate that: 1) SCIT was transportable to and feasible in this en-
vironment; 2) SCIT was associated with improved performance in Theory
of Mind and emotion perception; 3) SCIT was not associated with changes
in attributional bias. It is concluded that SCIT holds promise as a transport-
able intervention, but that measurement limitations may hinder evaluation
of social cognitive treatments.
ID: 549975
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SOCIAL COGNITION AND INTERACTION
TRAINING (SCIT): TREATMENT OUTCOMES AND
POTENTIAL MECHANISMS OF CHANGE
David Leland Roberts1, D. R. Combs2, D. L. Penn3
1Psychiatry, Yale University, New Haven, CT, USA; 2Psychology,
University of Texas, Tyler, TX, USA; 3Psychology, University
of North Carolina, Chapel Hill, NC, USA
The current presentation will report six-month follow-up data from a
previously published trial comparing Social Cognition and Interaction
Training (SCIT; n = 18) to an active treatment control group (n = 10) among
forensic inpatients. Initial outcome results from this study showed SCIT-
related improvements in emotion and social perception, Theory of Mind,
attributional style, interpersonal functioning, and neurocognition. Six-
month follow-up domains included two measures of emotion perception
and interpersonal functioning. At follow-up, both groups declined from
post-test on these measures. However, SCIT participants remained im-
proved relative to baseline, and were similar to non-ill controls on emotion
perception measures. These results suggest that it is possible to improve
social cognition and social functioning with an intervention that empha-
sizes metacognitive awareness and cognitive debiasing rather than neuro-
cognitive remediation techniques.
ID: 549930
NEW RESEARCH IN PSYCHOSOCIAL INTERVEN-
TIONS FOR ADHERENCE: PROSPECTIVE STUDIES
OF THE USE OF ENVIRONMENTAL SUPPORTS VS.
TREATMENT AS USUAL FOR IMPROVING
ADHERENCE AND OUTCOME IN MULTI-EPISODE
PATIENTS
Dawn Irene Velligan, N. J. Maples, J. L. Ritch, E. M. Medellin,
X. Li, A. L. Miller, J. Mintz
Psychiatry, University of Texas Health Science Center,
San Antonio, TX, USA
Cognitive Adaptation Training (CAT) is a psychosocial treatment that uses
environmental supports such as signs, checklists, alarms and the organiza-
tion of belongings to cue and sequence adaptive behaviors in the home. We
present data from two prospective, randomized studies examining different
treatments using environmental supports to target medication adherence
medications. In study I, 95 outpatients with schizophrenia (SCID-DSMIV)
were randomly assigned to 1) Full-CAT (CAT focused on many aspects of
community adaptation including grooming, care of living quarters, leisure
skills, social and role performance and medication adherence), 2) Pharm-
CAT (CAT focused only on medication and appointment adherence) or 3)
treatment as usual (TAU). Treatment lasted for 9 months, and patients
were followed for 6 months after the withdrawal of home visits. In study
II, as part of a larger treatment study, 69 outpatients were randomized to
one of three treatments 1) PharmCAT 2) MM–A treatment using the Med-
eMonitor; an electronic device with the ability to store up to five different
medications, cue the taking of medication, warn patients when they are tak-
ing the wrong medication or taking it at the wrong time, record side effect
complaints, and through modem hookup promptly alert treatment staff to
failures to take medication as prescribed. Early identification of adherence
problems with the monitor was followed with rapid telephone intervention
to overcome barriers to adherence; and 3) TAU. Data are available for the
first 3 months of treatment for study II. For both studies, medication ad-
herence (assessed during unannounced, in-home pill counts) and outcomes
were assessed at 3 month intervals. For Study I, results of mixed effects
regression models indicated that both CAT and PharmCAT treatments
were superior to TAU for improving adherence to prescribed medication
(P < .0001). Effects on medication adherence remained significant when
home visits were withdrawn. Survival time to relapse was significantly lon-
ger in both CAT and PharmCAT in comparison to TAU (.004). For study
II, mixed effects regression models for pill count adherence indicated a non-
significant trend for treatment group effects at 3 months. Participants in
treatments utilizing environmental supports had better adherence to pre-
scribed medications (P < .07). Findings suggest that supports targeting
medication adherence lead to better adherence and outcomes for individ-
uals with schizophrenia.
ID: 549888
INITIAL EFFICACY DATA ON A SOCIAL COGNI-
TIVE SKILLS TRAINING PROGRAM
Michael F. Green1,2, W. P. Horan1,2, K. Shokat-Fadai3,
M. J. Sergi3,1, C. Waldon1,2, A. Ofek1,2, R. S. Kern1,2
1Psychiatry and Biobehavioral Sciences, UCLA—NPI, Los
Angeles, CA, USA; 2MIRECC, VA Greater Los Angeles
Healthcare System, Los Angeles, CA, USA; 3Psychology, Cal State
University Northridge, Northridge, CA, USA
Social cognitive deficits are promising treatment targets for new interven-
tions to improve functional outcome in schizophrenia. This talk will present
data from two studies that are evaluating a new social cognitive skills train-
ing program designed to address four aspects of social cognition (affect per-
ception, social perception, attributional style, Theory of Mind) in stable
outpatients with psychosis, a population for whom such interventions
will likely be very useful. In the first study (Horan et al. in press) 31 clinically
stable outpatients were randomly assigned to a social cognition skills train-
ing intervention or a time-matched control condition (illness self-manage-
ment training and relapse prevention skills training), with both treatments
lasting 12 sessions. Participants completed pre- and post-treatment assess-
ments of social cognition, neurocognition, and symptoms. The social cog-
nition group demonstrated a large improvement in facial affect perception
(within group effect size = .73), which was not present in the control group
(within group effect size = .15) and the between group effect was significant
(P < .05). This improvement was independent of changes in basic neuro-
cognitive functioning or symptoms. Results from this pilot study support
the efficacy of a social cognitive intervention for community-dwelling out-
patients and have led to a subsequent study. A second study is currently
underway and is attempting to disentangle the effects of social cognition
remediation from cognitive remediation. In this study, participants are ran-
domly assigned to one of four types of interventions: social cognitive train-
ing, cognitive remediation, a combination of the social cognitive training
and cognitive remediation, and a control condition, with each treatment
lasing 24 sessions. These validation trials of a new training program for
social cognition are designed to encourage further development of this
treatment approach with the aim of achieving broader improvements in
social cognition and eventual generalization of treatment gains.
ID: 549819
EFFECTIVENESS OF RISPERIDONE LONG-ACTING
INJECTION IN THE EARLY PHASE OF
SCHIZOPHRENIA: RELAPSE PREVENTION AND
FUNCTIONAL OUTCOME
Kenneth L. Subotnik1, K. H. Nuechterlein1,2, J. Ventura1,
D. Gretchen-Doorly1, G. S. Hellemann1, J. S. Luo1,
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CA, USA; 2Psychology, University of California, Los Angeles,
Los Angeles, CA, USA
Returnof psychotic symptoms in the first year of treatment for schizophrenia
patients is a major clinical problem. Short acting antipsychotic medication
requires daily re-commitment to treatment, which is compromised by
patients’ poor awareness of the need for continued antipsychotic treatment.
We are comparing the clinical effectiveness of the long acting injectable form
of risperidone to the oral form in a 12-month randomized controlled trial in
recent-onset schizophrenia patients. This is a preliminary report from Sam-
ple 4 of the project entitled ‘‘Developmental Processes in Schizophrenic Dis-
orders’’ (PI: Keith Nuechterlein, Ph.D., ClinicalTrials.gov Identifier:
NCT00333177), conducted at the UCLA Aftercare Research Program. Par-
ticipantsarealsoreceivingindividualcasemanagement,groupandindividual
psychoeducation, assistance in returning to work or school using Individual
Placement and Support, and random assignment to group training focusing
on either cognitive remediation or healthy behaviors. Among patients in the
risperidone long-acting injectable (RLAI) treatment group, the rate of psy-
chotic relapse is lower, the time to first relapse is longer, and degree of inde-
pendent living is higher than among patients treated with oral risperidone.
The time to discontinuation of treatment with risperidone for any reason
is nonsignificantly longer in the RLAI group. If these findings are confirmed
in the full sample, they will support the view that RLAI, as compared to the
oral form of risperidone, improves both clinical outcome and a key aspect of
community functioning.
ID: 549795
THE TRAINING OF AFFECT RECOGNITION (TAR):
EFFICACY, FUNCTIONAL SPECIFICITY AND
GENERALIZATION OF EFFECTS
Wolfgang Wo¨lwer, N. Frommann
Department of Psychiatry and Psychotherapy, University of
Du¨sseldorf, Du¨sseldorf, Germany
Impairments in affect recognition are well known in schizophrenia. Such
impairments have proven to be a trait-like characteristic in schizophrenia
mostly unaffected by traditional treatment. Moreover they seem to play
a crucial role in patients’ poor social functioning. The present study should
contribute to the still open question of treatment options for these impair-
ments. A special Training of Affect Recognition (TAR) was evaluated in
three consecutive studies using pre-post-control group designs with either
an ‘‘active’’ control treatment (studies 1 and 2), a ‘‘passive’’ treatment as
usual group (study 1), or a waiting group (study 3). The active control treat-
ment consisted of a Cognitive Remediation Training (CRT) aiming at im-
provement of basic neurocognitive functioning. Outcome measures
comprised facial and prosodic affect recognition, basic cognitive function-
ing assessed by a neuropsychological test battery, and social interaction
assessed by a role play test. Analyses revealed specific training effects in
the form of a double dissociation both in studies 1 and 2: the TAR improved
facial and prosodic affect recognition as well as understanding of social
scenes, but had no effects on memory, attention and executive functioning.
Patients under CRT and those without training did not show improvements
in affect recognition, though patients under CRT improved in some mem-
ory functions. Positive effects of the TAR on facial affect recognition could
also be replicated in forensic schizophrenia patients (study 3) and proved to
be stable for at least 4–6 weeks after the end of training (studies 2 and 3).
However, an impact on social interaction could not be found (study 2).
According to these results, improvements in disturbed facial affect recog-
nition in schizophrenia patients are not obtainable with a traditional cog-
nitive remediation program like CRT, but need a functional specific
training like the newly developed TAR.
ID: 549725
EFFICACY OF A BRIEF INTERVENTION TO
IMPROVE AWARENESS OF NEUROCOGNITIVE
DEFICIT IN SCHIZOPHRENIA
Alice Medalia, J. Choi, E. Schwalbe, E. King
Psychiatry, Columbia University, New York, NY, USA
The majority of people with schizophrenia have neuropsychological dys-
function yet about half of them have poor insight into their cognitive impair-
ments (Medalia and Thysen, 2008). As new treatments are developed for the
cognitive problems in schizophrenia, it will be important that patients are
receptive to them and understand why they require yet another intervention.
We developed a brief psycho-educational intervention called Braincheck, to
improve awareness of neurocognitive deficit. Braincheck involves a series of
highly interactive exercises that provide multiple opportunities for partici-
pants to actively explore how cognitive functions can be assessed and
changed. Braincheck begins with a brief cognitive self assessment; and
then continues to psycho-educational exercises intended to improve under-
standing of what cognition is, and how it can be changed. The primary ob-
jective of this investigation was to determine whether Braincheck could help
individuals with schizophrenia and schizoaffective disorder become more
aware of their cognitive dysfunction, and more receptive to the idea that cog-
nition can change and be treated. After a pre-assessment of cognition, insight
and receptiveness to treatment, 20 adults with schizophrenia or achizoaffec-
tive disorder participated in Braincheck, and then were subsequently re-
assessed on the same measures. Results indicated that the participants in
Braincheck made significant improvements in awareness of cognitive deficit
(P< .001) and receptiveness to the idea that cognition is malleable (P< .001).
These results provide the basis for an ongoing randomized controlled trial to
determine if behavioral interventions like Braincheck can help improve
awareness of cognitive dysfunction and receptiveness to cognitive enhancing
treatments. Supported by an investigator-initiated grant from Eli Lilly (PI:
A. Medalia).
Reference
1. Medalia A, Thysen J. Insight into Neuro-cognitive Dysfunction in
Schizophrenia, manuscript, Schizophrenia Bulletin. 2008; doi: 10.1093/
schbul/sbm144.
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‘EXTENDED’ DOSING—REDEFINING INTERMIT-
TENT ANTIPSYCHOTIC THERAPY: A DOUBLE-
BLIND TRIAL
Gary Remington1, S. Mann1, S. Kapur2, P. Seeman3
1Psychiatry, University of Toronto, Toronto, ON, Canada;
2Psycological Medicine, Institute of Psychiatry, London,
United Kingdom; 3Pharmacology, University of Toronto, Toronto,
ON, Canada
The numerous adverse side effects associated with antipsychotic use have
fostered efforts to minimize drug exposure, as evidenced by the reduction
in dose that has been documented over the last several decades. Intermittent
antipsychotic treatment represents another strategy that had been tried in the
past, but evidence of less favourable outcomes with this approach discour-
aged its use. Based on neuroimaging work, specifically positron emission to-
mography (PET) and dopamine D2 occupancy, we postulated that clinical
response could be maintained with ‘extended’ dosing. In contrast with inter-
mittent dosing, which allowed for prolonged intervals without antipsychotic
exposure, extended dosing provides for intermittent but regular dosing (ie,
every 2–3 days). In follow-up to a pilot project that supported such an
approach, we carried out a double-blind trial in stabilized patients with
schizophrenia. Subjects were randomly assigned to one of two groups: (i)
their regular antipsychotic and dose, with placebo interchanged every other
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day; (ii) regular antipsychotic and dose daily. The trial was 6 months in du-
ration. Results indicated no difference in clinical outcome between groups, as
measured by various clinical measures including the Brief Psychiatric Rating
Scale (BPRS), Clinical Global Impression scale (CGI), and Calgary Depres-
sion Scale (CDS). Of note, no differences were noted with respect to side
effects such as exptrapyramidal symptoms (EPS) or subjective response,
as evaluated by the Drug Attitude Inventory (DAI). Our findings will be dis-
cussed in terms of the underlying rationale for this strategy, as well as clinical
implications and practical concerns. Supported by a NARSAD Independent
Investigator Award to GR.
ID: 549676
NEUROPSYCHOLOGICAL EDUCATIONAL
APPROACH TO COGNITIVE REMEDIATION
(NEAR) IN JAPAN
Satoru Ikezawa1, M. Kato1, K. Tamashiro1, I. Nagata1,4,
K. Kaneko1, K. Nakagome1, T. Mogami2, S. Katayama1,3,
I. Sato3, A. Iwasaki3, Y. Hiroe4, Y. Hayami4, M. Umebayashi4,
K. Yamada4, Y. Senda4, C. Komatsu4, M. Kurimura4, T. Kato5,
J. Sasaki5, H. Ohmiya5, I. Kimura6, K. Matsumura6, M. Yoshizawa6
1Division of Neuropsychiatry, Department of Multidisciplinary
Internal Medicine, Tottori University, Yonago, Japan; 2Division of
Clinical Psychology, Graduate School of Medical Sciences, Tottori
University, Yonago, Japan; 3Yasugi Daiichi Hospital, Yasugi,
Japan; 4YowaHospital, Yonago, Japan; 5YonagoHospital, Yonago,
Japan; 6Meiwakai-Medical andWelfare CenterWatanabeHospital,
Tottori, Japan
In Japan, ‘‘Interfering Independence to People with disabilities Law’’ was
enforced in 2006. Although, disabled persons’ employment, deinstitution-
alization, and socialization were promoted by this law, there are actually
many people with psychiatric illness including patients with schizophrenia,
who suffer from social dysfunction. It is widely accepted that cognitive dys-
function in schizophrenia plays a major role in determining social outcome.
With the aim of alleviating many difficulties they encounter in their com-
munity lives, cognitive remediation therapy for patients with schizophrenia
has gradually launched in Japan. After participating in the one-week clini-
cian training of Neuropsychological Educational Approach to Cognitive
Remediation (NEAR) we set up NEAR in Japan. Fifteen patients with
schizophrenia participated in the study. NEAR in Japan consisted of
two sessions a week, lasting one hour each. The subjects completed approx-
imately 6 months of NEAR sessions before being assessed for the efficacy.
In each session, subjects engaged in some computer tasks that involved the
cognitive region according to the profile of subjects’ cognitive dysfunction.
In addition, a group meeting that aimed at promoting motivation and gen-
eralization of cognitive skills to daily life was held once a week. We mea-
sured efficacy by using a) Japanese version of Brief Assessment of
Cognition in Schizophrenia (BACS-J) as a cognitive function scale, b)
Life Assessment Scale for Mental Illness (LASMI) as a social function scale,
c) Positive and Negative Syndrome Scale (PANSS) as a psychiatric symp-
toms scale. The findings of the present study can be summarized as follows;
a) patients showed significant improvement in cognitive function, however,
social function and psychiatric symptoms were not significantly improved,
b) age of onset showed positive correlation with the improvement of atten-
tion, c) the improvement in executive function correlated with the improve-
ment in the skills of daily life, d) younger patients showed greater
improvement than elderly patients in terms of the skills of daily life, e) pre-
morbid IQ negatively correlated with the social function improvement. Al-
though the sample size in the present study was small, NEAR in Japan was
moderately effective on cognition, and some potential predictors of its ef-
ficacy were found.
ID: 549654
ADD-ON D-SERINE TO ANTI-PSYCHOTICS IN
SCHIZOPHRENIA: A RCT FOCUSED ON NEGATIVE
SYMPTOMS AND COGNITION
Mark Weiser1, D. C. Javitt2, U. Heresco-Levy3, Y. Abramovitch4,
A. Teitlebaum5, A. Doron6, Y. Levkovitch7, M. Davidson1
1Psychiatry, Sheba Medical Center, Ramat Gan, Israel; 2Nathan
Kline Institute, New York, NY, USA; 3Sara Herzog Memorial
Hospital, Jerusalem, Israel; 4Beer Yaacov Mental Health Center,
Beer Yaacov, Israel; 5Kfar Shaul Mental Health Center, Jerusalem,
Israel; 6Lev Hasharon Mental Health Center, Pardesiya, Israel;
7Shalvata Mental Health Center, Hod Hasharon, Israel
Negative symptoms and cognitive impairment are commonly observed in
patients with schizophrenia, and have been hypothesized to be caused by
functional under-activity of NMDA receptor-mediated neurotransmission.
Previous studies on sample sizes from 30–60 subjects administered d-serine,
a NMDA agonist, at doses of 2 gm/day, and showed significant improve-
ments in negative symptoms. Based on these previous studies, the Stanley
Medical Research Institute funded a large randomized, placebo-controlled
trial administering d-serine to patients with schizophrenia. Between 2004–7
we randomized 195 subjects with chronic schizophrenia, stabilized on their
anti-psychotic medication, to receive add-on d-serine 2 gm/d, or placebo.
Subjects received double-blind medication for 4 months. The mean age of
the patients was 39.3 6 12.1, mean years of education was 10.9 6 2.7, mean
age of onset of illness was 23.4 6 8.5 years. Mean total PANSS score was
75.5, mean PANSS negative score was 26.4. On symptoms, there were sig-
nificant improvements in both d-serine and placebo groups: total PANSS
scores improvement: for d-serine (þ0.9 effect sizes) vs placebo (þ1.0 effect
sizes), t =0.69,P = .496; SANS scores improvement: d-serine (þ0.65 effect
sizes) vs placebo (þ.86 effect sizes), t = 1.05, P = .296. On cognition, the
MATRICS composite score improved by .30 effect sizes for d-serine vs 0.24
effect sizes for placebo, t = 0.74, P = .46. Treatment was well tolerated;
75% of the subjects completed the 16 week study, and there were no signif-
icant adverse events. D-serine administered at 2 gm/day is not an effective
treatment for schizophrenia. The implications for the NMDA hypothesis of
schizophrenia will be discussed.
ID: 549597
NEUROCOGNITIVE EFFECTIVENESS OF HALO-
PERIDOL, RISPERIDONE AND OLANZAPINE IN
FIRST EPISODE PSYCHOSIS: A RANDOMIZED,
CONTROLLED ONE-YEAR FOLLOW-UP
COMPARISON
Benedicto Crespo-Facorro, J. Rodrı´guez-Sa´nchez,
R. Pe´rez-Iglesias, I. Mata, R. Ayesa, M. Ramirez, O. Martinez,
J. Vazquez-Barquero
HU Marques de Valdecilla, Univeristy of Cantabria,
Santander, Spain
Context: Cognitive impairments determine general functionality in schizo-
phrenia. The beneficial effect of second generation antipsychotics com-
pared to first generation antipsychotics in treating these cognitive
impairments has lately been questioned. Objective. To investigate the
neurocognitive effectiveness of haloperidol, risperidone and olanzapine
in first-episode of schizophrenia-spectrum disorders. Design. This is a pro-
spective, randomized, open-label study. Setting. Data for the present inves-
tigation were obtained from a large epidemiological and three-year
longitudinal intervention program of first-episode psychosis conducted
at the outpatient clinic and the inpatient unit at the University Hospital
Marques de Valdecilla, Santander, Spain. Participants. 104 patients
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randomized to haloperidol (N = 35), olanzapine (N = 30) or risperidone (N =
39) who completed clinical and cognitive evaluations at baseline, 6 months
and 1 year were included in the final analysis. 37 healthy individuals were
also longitudinally assessed. Interventions. A neuropsychological battery
that comprised nine cognitive domains was used. The contribution of clin-
ical changes, concomitant medications and the severity of motor side effects
to cognitive changes was controlled. Main outcome measure. Cognitive
score changes at 1-year follow up. Results. The three treatment groups
showed a significant improvement in cognitive scores after 1 year. The dif-
ferential cognitive effectiveness between antipsychotics was insignificant.
The magnitude of cognitive changes was similar in the three treatment
groups and controls, although a greater improvement in Finger Tapping,
Trail Making Test B and Rey Complex Figure Test was found in the treat-
ment groups. Clinical changes, use of concomitant medications and the
emergence of motor side effects did not significantly account for cognitive
changes over time. Conclusions. Haloperidol, olanzapine and risperidone
were equally effective in treating cognitive deficits of psychosis. The effect
of practice clearly contributes to cognitive score improvements after treat-
ment with antipsychotics. Our results provide important information re-
garding the practical utility of antipsychotic treatments to improve
cognition, and could have implications for developing novel approaches
for cognitive pharmacotherapy in schizophrenia.
ID: 549580
NEW RESEARCH IN PSYCHOPHARMACOLOGIC
INTERVENTIONS FOR ADHERENCE: A PROSPEC-
TIVE STUDY OF LONG-ACTING RISPERIDONE VS.
ORAL SECOND-GENERATION ANTIPSYCHOTIC IN
FIRST-EPISODE SCHIZOPHRENIA
Peter Joseph Weiden1, N. R. Schooler2, A. Sunakawa2, J. Weedon3
1Center for Cognitive Medicine, University of Illinois at Chicago,
Chicago, IL, USA; 2Psychiatry, SUNY Downstate Medical Center,
Brooklyn, NY, USA; 3Biostatistics, SUNY Downstate Medical
Center, Brooklyn, NY, USA
Background: We evaluated the potential effectiveness of long-acting route
(risperidone microspheres) as an alternate approach to oral antipsychotics
help address the adherence problem in first-episode patients. Methods: The
study used an effectiveness approach with adherence attitude and adher-
ence behavior as primary outcomes. Consenting first-episode subjects
were randomized in a 2:1 ratio to either a recommendation of long-acting
risperidone (INJ, n = 26) or staying on oral medication (ORAL, n = 11).
Nonadherence behavior was defined as:1) time until a 14 day medication
gap (GAP), 2) proportion of days adherent/ specific time intervals (0–
12,12–36,36–52 weeks). Two Kaplan-Meier (K-M) analysis of time to
GAP were conducted:Intent to Treat (ITT) and As Actually Treated
(AAT). ANOVA analysis compared INJ and ORAL on proportion of
days adherent. The ROMI was used for adherence attitudes with 2 sub-
scales, ROMI-Adherence (ROMI-A; 9 items) and ROMI-Nonadherence
(ROMI-NA;10 items). Data were analyzed for the 3 major assessment points
(12, 36, and 52 weeks) using mixed linear models, with treatment (INJ/
ORAL), time (12, 36, 52) as fixed factors, and the 2 ROMI subscales as de-
pendent variables. Categorical analyses compared the 19 ROMI items and
treatment groups at each major time point. Results: Most of the INJ patient
(19/26;73%) accepted this recommendation. Most patients (68%) had at
least one GAP over 52 weeks. The INJ acceptance was associated with bet-
ter adherence at 12 weeks (P < .05), but there were no significant between-
group GAP differences at 52 week K-M survival. In contrast, adherence
attitudes at 52 weeks favored the INJ group, with two ROMI-NA items
being significantly higher (less favorable) in ORAL; stigma (IIT) and family
opposition to medication (ITT and AAT). Discussion: Almost 70% of ini-
tially adherent first-episode patients had at least one GAP within a year,
and spent at least 25% of their time without medication. While adherence
behavior did not differ at 1 year, adherence attitudes favored the INJ group.
The initial recommendation of long-acting antipsychotic was for the most
part acceptable to first-episode patients, but the long-acting route does not,
by itself, solve the adherence problem. Possible advantages of the long-act-
ing route in first-episode patients may be associated with more favorable
adherence attitudes compared to oral route, as well as the easier adherence
tracking associated with the long-acting route compared to oral.
ID: 549515
A JAPANESE PROGRAM THAT ADDRESSES MOTI-
VATIONAL AND COGNITIVE DEFICITS IN
CHRONIC SCHIZOPHRENIA
Tamiko Mogami1, S. Ikezawa2, K. Kaneko2, K. Tamashiro2,
K. Nakagome2, I. Nagata2, Y. Hiroe3, I. Kimura4, I. Sato5,
T. Kato6
1Graduate School of Medical Sciences, Tottori University, Yonago,
Japan; 2Department of Multidisciplinary Internal Medicine, School
of Medicine, Tottori University Faculty of Medicine, Yonago,
Japan; 3Yowa Hospital, Yonago, Japan; 4Meiwakai-Medical and
Welfare CenterWatanabeHospital, Tottori, Japan; 5Yasugi Daiichi
Hospital, Yasugi, Japan; 6Yonago Hospital, Yonago, Japan
A cognitive remediation program that targets the motivational and cogni-
tive deficits of schizophrenia was adapted for use with chronic patients in
Japan. This presentation will describe the philosophy behind the program
and the techniques used to enhance intrinsic motivation and cognition.
Also, results will be presented from an ongoing randomized controlled trial
that has so far enrolled 15 patients (8 women and 7 men; mean age = 33.6
years [SD = 10.7] with schizophrenia or schizoaffective disorder with mean
illness duration of 10.6 years. The treatment group received twice-weekly
computer-based cognitive sessions and a once-weekly verbal session for six
months. The treatment sites included outpatient clinics, day treatment, and
inpatient units. The attendance rate, which represented a behavioral mea-
sure of motivation, was 88.0% during the first three months and 89.0% dur-
ing the last three months, indicating high treatment intensity throughout
the program. The average attendance rate was significantly correlated
with improvements in social functioning (r = .86, P < .005), and GAF
(r = .76, P < .05). The control group consisting of patients with compatible
diagnoses and clinical history received outpatient milieu treatment. Data
from PANSS item N4, N6 and G13 also provided measures of motivation
in the two groups. Both the experimental group and control group were
administered a series of tests including Brief Assessment of Cognition in
Schizophrenia (BACS) as a neuropsychological measure at the start and
end of the six months period. The experimental group showed significant
improvement at the post- NEAR program compared to the baseline in ver-
bal memory (t = 3.92, P < .01), working memory (t = 3.57, P < .01),
verbal fluency (t = 2.72, P < .05), and executive function (t = 2.71, P <
.05). The ANOVA comparing the group and treatment effect resulted in
a significant group-by-treatment interaction effect in working memory
(F1,25 = 12.11, P = .05). These findings indicate that people with chronic
schizophrenia can be successfully engaged in cognitively enhancing activ-
ities, and that programs that specifically target motivation and cognition
benefit even people with chronic forms of the illness.
ID: 549414
REMEDIATION OF NEURO AND SOCIAL COGNI-
TION: RESULTS OF AN INTERNATIONAL RAN-
DOMIZED MULTI-CITE STUDY
Volker Roder, D. R. Mueller
University Psychiatric Hospital, Bern, Switzerland
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Objectives: Nowadays the importance of cognitive processes for functional
outcome and recovery is a main topic of interest of researchers and clini-
cians. It seems that neuro-cognitive domains such as attention, vigilance,
memory, and executive functioning have a decisive impact and prognostic
value in these areas. Social cognition (eg, emotion perception, Theory of
Mind, attributional style) might be a significant mediating factor to aug-
ment this neuro-cognitive impact. The NIMH MATRICS initiative estab-
lished a consensus on separate neuro-cognitive and social cognitive
domains that are relevant for the treatment of schizophrenia. Against
this background we developed a cognitive-behavioral group therapy
program (INT: Integrated Neuro-cognitive Therapy) covering these treat-
ment targets. INT is partly computer based and intends to restitute and
compensate neuro-cognitive and social cognitive (dys-) functions. This
‘‘bottom up’’ and ‘‘top down’’ approach puts a strong focus on the patients’
daily life context to promote transfer and generalization. INT additionally
facilitates intrinsic motivation and resources. Methods: INT is currently
evaluated in an international randomized multi-cite study in Switzerland,
Germany and Austria, which is supported by the Swiss National Science
Foundation. INT is compared with treatment as usual (TAU). INT patients
receive 30 therapy sessions twice a week, lasting 90 minutes each. A com-
prehensive assessment battery comprising proximal and distal measures, is
applied before and after therapy and at a 1-year follow-up. Up to now 145
outpatients participate in the study. Results: INT patients obtain medium
effect sizes in neuro-cognitive and social cognitive variables, insight, neg-
ative symptoms and high ones in social functioning after therapy. The
global effect size still augments at follow-up. Only the INT group shows
higher significant correlations between self-rated deficits in neuro-cognition
and objective psychometric test performance after the treatment phase.
A SEM model supports evidence of social cognition as a mediating factor
between basic neurocognition and functional outcome. Finally, a low
drop-out rate of 9% of the INT patients during the study represents
a high acceptance by the patients. Conclusion: Results support the signif-
icance of the MATRICS variables for psychological treatment targets. INT
seems to be successful in improving functional outcome when embedded in
other rehabilitation efforts.
ID: 549356
EARLY PSYCHOTIC RESPONSE INDEX FOR PRE-
DICTING LONG-TERM GLOBAL FUNCTIONING IN
PATIENTS WITH SCHIZOPHRENIA
Ofer Agid1, S. Kapur2, I. Lombardo3, E. Pappadopulos3, C. Siu4
1Center for Addiction and Mental Health, Toronto, ON, Canada;
2Institude of Psychiatry, London, United Kingdom; 3Pfizer Inc.,
New York, NY, USA; 4Data Power, Inc., Ringoes, NJ, USA
Background: The delayed onset of action hypothesis for antipsychotic
drugs in the treatment of schizophrenia spectrum disorders has recently
been rejected. In this analysis, we assess if the combined use of early reduc-
tion in psychosis (within the first 2 weeks) and/or early side-effect measures
are effective in predicting the level of long-term global functioning. Meth-
ods: The analysis data-set was based on a double-blind, 6-month study of
ziprasidone and olanzapine (N = 94), which showed comparable efficacy
between the treatment groups at all time points (2). The generalized additive
model, which models the GAF change scores at Month-6 as nonparametric
smoothed functions of the covariates (BPRS core score at Week-2 and/or
weight change at Week-6), was used to ensure adequate control for any
nonlinearities in the predictive function. A multivariate score function
model was then developed to predict the likelihood of achieving >50% im-
provement in GAF. Results: At Week-2, the majority of ziprasidone (80%)
or olanzapine (83%) patients showed greater than 20% improvement in
BPRS Core symptoms. At up to 6 months of follow-up, 52 (55%) subjects
met the responder criteria for 50% or greater improvement in global func-
tioning. Early responders (Week-2) showed significantly more improve-
ment in global functioning than early non-responders at all time points
(Week-6 and Month-6) (all P < .05), confirming that response within
the first 2 weeks of antipsychotic treatment is an indicator of continued
responsiveness to treatment over at least 6 months. Application of the Gen-
eralized Additive Models revealed a nonlinear functional relationship of
early weight change (6 weeks) to GAF improvement at study endpoint
(Month-6) (P< .05), with large weight gain predicts less GAF improvement
at final visit. A multivariate score function based on baseline scores, early
reduction of psychotic symptoms at 2 weeks (P< .05), and % weight change
observed at 6 weeks (P< .05) showed statistically acceptable predictive per-
formances based on c-statistics (AUC ROC > 0.8; 1-specificity vs. sensitiv-
ity curve). Conclusions: Our findings suggested that very early
improvement in psychotic symptoms predicts long-term global functioning.
An early response score function incorporating core psychotic subscale and
side-effects measures can be useful tool for predicting patient’s likelihood of
achieving favorable long-term treatment outcomes.
ID: 549280
SHORT-TERM IMPROVEMENT BY MINOCYCLINE
ADDED TO OLANZAPINE ANTIPSYCHOTIC
TREATMENT IN PARANOID SCHIZOPHRENIA
Cristiano Chaves1, C. R. Marque1, I. B. Chaudhry2, N. Husain2,
F. Minhas2, J. P. Oliveira1, L. Wichert-Ana1, M. Kato1, S. Dursun2,
P. Richardson2, J. Stirling2, J. F. Deakin2, A. W. Zuardi1,
J. E. Hallak1
1Department of Neuropsychiatry and Medical Psychology, Ribeira˜o
Preto Medical School, University of Sa˜o Paulo, Ribeira˜o Preto,
Brazil; 2Neuroscience and Psychiatry Unit, University of
Manchester, Manchester, United Kingdom
The limited effect of current antipsychotics on the schizophrenia symptoms
has led to the search for novel drugs that can potentiate the treatment of this
disorder. Minocycline is an antibiotic of the tetracycline group, with effi-
cacy in different neurological diseases. Various findings from animal and
human studies suggest that minocycline has possible advantages for the
treatment of schizophrenia, including case reports of beneficial effects in
catatonic schizophrenia. The current study investigated the effects of min-
ocycline as adjuvant therapy in three patients with recent onset paranoid
schizophrenia in use of a stable dose of olanzapine for more than four
months (15, 20 and 20 mg/day respectively). Minocycline was administered
300mg daily, divided in two doses, for a period of eight weeks. Clinical eval-
uation was performed fortnightly by the PANSS and CGI. In this prelim-
inary study, olanzapine augmentation with minocycline considerably
improved the positive (75, 90.9, and 100% respectively) and negative
(86.36, 30, and no symptoms detected respectively) symptoms of paranoid
schizophrenia. There were no significant side effects. In addition, one of
these subjects was also submitted to a SPECT before and after minocycline
treatment. An abnormal increase in regional cerebral blood flow was found
in the posterior cingulate prior to minocycline administration, which was
significantly reduced after minocycline therapy. It is noteworthy that this
patient did not exhibit negative symptoms, and the reduction of the in-
creased rCBF after minocycline treatment was observed together with im-
provement of the positive symptoms. Minocycline may reduce the
neurotoxic consequences of N-methyl-D-aspartate receptor (NMDA-R)
hypofunction implicated in the pathophysiology of schizophrenia. In
fact, this agent reversed several NMDA-R antagonist symptoms in ani-
mal and human studies. It has been previously suggested that NMDA-R
hypofunction may lead to glutamate, serotonin, and dopamine release in
the posterior cingulate cortex. These alterations may underlie the neurotoxic
effects of NMDA-R hypofunction and could be involved in the posterior cin-
gulate overactivation during psychosis exacerbation. Thus, the neuroprotec-
tion by minocycline may be mediated by NMDA-R transmission
modulation. Another possibility is that minocycline is an anti-microglial
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agent, which could reduce a possible inflammatory component of
schizophrenia.
ID: 549262
THE ROLE OF MOTIVATION AND ENGAGEMENT
IN SUCCESSFUL COGNITIVE TRAINING WITH
SCHIZOPHRENIA PATIENTS
Alice Medalia, J. Choi
Psychiatry, Columbia University, New York, NY, USA
Schizophrenia is characterized by impairments in neurocognition that are
known to contribute to decrements in psychosocial functioning in major
areas of life such as work, independent living and social relationships.
Treatments to target these neurocognitive impairments have typically fo-
cused on the content of the intervention, namely the cognitive task, with
little regard to the way the intervention is delivered. Yet, research shows
that intrinsic motivation is a significant mediator in cognitive treatment
outcome. It predicts who will engage in cognitive treatment, the degree
of task engagement, and persistence on the training activities. We will pres-
ent results from several recently completed randomly controlled studies
which examined the impact of motivational variables on neuropsycholog-
ical and functional outcome. Two studies compared the degree and persis-
tence of executive skill acquisition with and without motivational
paradigms incorporated into the teaching approach (N = 42). Another
study examined a psycho-educational intervention called Braincheck to tar-
get beliefs of cognitive malleability and awareness of neurocognitive deficit,
with the premise that engagement on remediation tasks is a function of
patients’ expectancies of success, beliefs of neuroplasticity, and goal value
(N = 20). Results from these trials demonstrated that (a) intrinsic motiva-
tion techniques improved executive skill acquisition (P = .04), attentional
resource allocation (P = .05), task engagement (P = .05), and self-reported
feelings of efficacy (P = .05); (b) although effects on neurocognitive meas-
ures dissipated over time, certain executive skills acquired through motiva-
tional learning remained intact at 132 days post-treatment (P = .05); (c)
baseline perceptions of self competency accounted for 43% of the variance
on post-test executive scores; and (d) Braincheck made significant improve-
ments in awareness of cognitive deficit (P < .001) and receptiveness to the
idea that cognition is malleable (P< .001). Overall, results provide the basis
for incorporating intrinsic motivation instructions and value expectancy
motivators to impact skill acquisition, duration of effects, task engagement,
self-reported feelings of competency and accomplishment, awareness of
cognitive dysfunction, and receptiveness to cognitive enhancing treatments.
ID: 549133
SELECTIVE ATTENTION TRAINING FOR AUDI-
TORY HALLUCINATIONS
Sandra Wilkniss1, A. Hartzell2, V. Vorhies1, T. Schirmer2,
L. Robin1
1Research and Training, Thresholds, Chicago, IL, USA;
2Psychology, Rosalind Franklin University, Chicago, IL, USA
An estimated 30% of individuals with schizophrenia are not responsive to
antipsychotic medication and continue to suffer from distressing positive
symptoms such as hallucinations. Hallucinatory experiences in this popu-
lation negatively impact quality of life and daily functioning in a variety of
ways including reduced ability to maintain attention and focus due to AH,
chronic distress due to the often abusive nature of AH, and in some cases,
serious suicide attempts in response to AH. Targeted rehabilitation of se-
lective attention impairment has been demonstrated in several case exam-
ples to improve functioning and quality of life in schizophrenia patients
with unremitting AH. The goal of the proposed work was to conduct
the first treatment outcome study of selective attention training for auditory
hallucinations in schizophrenia who are receiving optimal pharmacother-
apy . We examined the effects of this treatment on AH dimensions, psycho-
social functioning, self esteem, psychiatric symptoms, and quality of life in
24 individuals with schizophrenia or schizoaffective disorder. Participants
were randomly assigned (stratifying by age and gender) to either the selec-
tive attention training condition or supportive psychotherapy for weekly
sessions totaling 24 hours of exposure. We hypothesized that individuals
in the SAT condition would show significantly greater improvement in
quality of life and self esteem. Results showed that those in the SAT con-
dition showed significant improvement on the quality of life scale (World
Health Organization QOL) and measures of depression. Participants across
conditions showed improvement in self esteem (Rosenberg Self-Esteem
scale). Findings suggest that SAT for auditory hallucinations, while not di-
rectly impacting symptoms, relates to improved quality of life. This suggests
that persons with schizophrenia may use this intervention to better manage
symptoms they are experience resulting in more positive feelings about
quality of life. Second, participants with unremitting AH receiving either
individual intervention showed significantly improved self-esteem suggest-
ing that 1:1 attention in a community-based psychiatric rehabilitation
center is important in improving self esteem. Given the small sample, this
study serves as a feasibility study to further test the interpretations of these
findings.
ID: 549118
CLINICAL AND SUBSTANCE USE OUTCOMES OF
FIRST-EPISODE SCHIZOPHRENIA PATIENTS WITH
A LIFETIME DIAGNOSIS OF CANNABIS USE DIS-
ORDERS RANDOMLY ASSIGNED TO RISPERI-
DONE OR OLANZAPINE FOR 16 WEEKS
Serge Sevy1,2, D. G. Robinson1,3, B. Napolitano1,4, J. Gallego1,
R. C. Patel5, J. M. Soto-Perello5, J. McCormack1, B. Lorell5,
J. M. Kane1,3
1Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks,
NY, USA; 2Psychiatry, Albert Einstein College of Medicine, Bronx,
NY, USA; 3Center for Translational Psychiatry, Feinstein Institi-
tute for Medical Research, Manhasset, NY, USA; 4Biostatistics
Unit, Feinstein Instititute for Medical Research, Manhasset, NY,
USA; 5Psychiatry, Bronx Lebanon Medical Center, Bronx, NY,
USA
Introduction: Cannabis is the most common illicit drug used among indi-
viduals presenting with a first episode of schizophrenia. In this study, we
report 16-week clinical and substance use outcomes of first-episode schizo-
phrenia patients with a lifetime history of cannabis use disorders and trea-
ted with either risperidone or olanzapine. We focused on first-episode
patients to limit the confounding effect of prior exposure to prescribed med-
ications. Methods: Forty-nine first-episode patients with a diagnosis of
schizophrenia, schizophreniform disorder, or schizoaffective disorder
and a co-occurring lifetime diagnosis of cannabis use disorders were ran-
domly assigned to treatment with either olanzapine (2.5 to 20 mg daily) (n =
28) or risperidone (1 to 6 mg daily) (n = 21). Response criteria were: a rating
of 3 (mild) or less on the following SADS-CþPD items: severity of delu-
sions; severity of hallucinations; impaired understandability; derailment;
illogical thinking; bizarre behavior, and a rating of very much improved
or much improved on the CGI improvement item. This level of improve-
ment had to be maintained on two consecutive ratings. Results: Response
rates of positive symptoms were 45% (95% CI: 25%, 65%) with olanzapine
and 54% (95% CI: 29%, 79%) with risperidone. Survival curves did not dif-
fer between groups (log-rank test; P < .95). The percentage of responding
subjects having a subsequent rating not meeting response criteria was high-
er in subjects assigned to olanzapine (60%; 95% CI: 25%, 95%) compared to
subjects assigned to risperidone (20%; 95% CI: 0%, 56%) but did not reach
statistical significance (log-rank test; P < .23). Separate RMANOVA for
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delusions, hallucinations, and thought disorganization showed improve-
ment over time but no differences between study medications. Among neg-
ative symptoms, SANS global asociality-anhedonia showed an
improvement over time but no difference between study medications. Re-
garding rates of cannabis and alcohol use during the study, there were no
differences between treatment groups for cannabis use (56% in the olanza-
pine group vs. 35% in the risperidone group, Chi-square test, P< .1626) or
alcohol use (52% in the olanzapine group vs. 40% in the risperidone group,
Chi-square test, P< .4208). Discussion: Our results suggest that olanzapine
and risperidone have similar efficacy on psychotic symptoms and substance
use in first-episode schizophrenia patients with co-occurring cannabis use
disorders.
ID: 549115
INHALED LOXAPINE IS AN EFFECTIVE AND
RAPID TREATMENT FOR AGITATION IN
SCHIZOPHRENIC PATIENTS
James Cassella, R. Fishman, D. Spyker
Clinical Development, Alexza Pharmaceuticals, Mountain View,
CA, USA
Agitation is a common problem in schizophrenia, often requiring drug ther-
apy in an acute care setting. Experts in behavioral emergencies consider
speed of onset as an important factor in choosing a treatment. This Phase
3 clinical trial describes the speed and effectiveness of treating agitation
with inhaled loxapine. This was a multi-center, randomized, double blind,
parallel group, placebo controlled study. Two doses of inhaled loxapine,
10 mg and 5 mg, and placebo were tested. Study subjects were agitated
patients with schizophrenia who provided informed consent. At baseline,
subjects were required to have a minimum total score of 14 for the five items
of the PANSS Excited Component (PEC) including tension, excitement,
hostility, uncooperativeness and poor impulse control, and a score of at
least 4 (moderate) on at least one item. Subjects were excluded for recent
psychostimulant use or substance dependence within the prior 2 months.
Other antipsychotics, benzodiazepines and hypnotics were not allowed
within 4 hours of study drug administration. The primary endpoint was
the change in the PEC total score at 2 hrs. Additional endpoints included
change in the PEC at 10, 20 30, 45, and 60 minutes as well as at 4 and 24 hrs,
and Clinical Global Impression—Improvement (CGI-I),CGI-I responder,
and ACES at 2 hrs. A total of 344 subjects were randomized to inhaled
placebo (n = 115), inhaled loxapine 5 mg (n = 116) or inhaled loxapine
10 mg (n = 113). Mean PEC scores at entry were similar: 17.4, 17.8 and
17.6, respectively. For the PEC total score at 2 hours (11.9, 9.8, 8.9, respec-
tively), both the 10 mg and 5 mg doses were statistically significantly dif-
ferent from placebo. At each post-dose time point starting at 10 minutes,
the 10 mg dose was statistically superior to placebo. For CGI-I at 2 h, both
the 10 mg and 5 mg doses showed statistically significant differences vs.
placebo. By survival analysis, time to rescue medication over 24 hr was lon-
ger for either dose of loxapine compared to placebo. Median ACES scores
were in the ‘‘normal’’ to ‘‘calm’’ range after loxapine treatment. Both doses
were generally safe and well tolerated. Inhaled loxapine appears to offer
a very rapid and safe alternative to injectable antipsychotics in agitated
schizophrenic patients.
ID: 548921
COGNITIVE REMEDIATION WITH AND WITHOUT
ATOMOXETINE IN SCHIZOPHRENIA
Debra S. Moore1, M. Shepard1, P. Mihalakos1, B. Thomas1,
B. Witte1, M. Cullum1, A. Bellack2, C. Tamminga1
1Psychiatry, UT Southwestern Medical Center at Dallas, Dallas,
TX, USA; 2Psychiatry, University of Maryland School of Medicine,
Baltimore, MD, USA
Cognitive treatments have become a focus of treatment development in
schizophrenia, due to the adverse effect that cognitive dysfunction has
on psychosocial outcome in the illness. However, no known treatment
effects have been demonstrated with drugs known to enhance cognition
preclinically. Therefore, the idea has developed that the implementation
of pharmacological treatments may require a cognitive remediation com-
ponent in order to become manifest. Cognitive remediation is an interven-
tion that has recently and increasingly appeared promising in improving
cognitive functions in individuals with schizophrenia. Moreover, the puta-
tive treatment holds considerable face validity, especially with all that is
known about the mechanisms of brain plasticity and its reliance on repe-
tition to change function. Based on this rationale, we developed a four-cell
intervention designed to test two treatments (atomoxetine and cognitive re-
mediation) alone and together in people with stable schizophrenia and de-
monstrable cognitive dysfunction. We have carried out an interim analysis
with an N = 6 in each of the four groups (atomoxetine [A] þ control [Con];
Aþ cognitive remediation [CACR]; placebo [P]þCon; and PþCACR), to
look both at symptom and cognition outcomes and at potential biomarker
outcomes represented by changes in functional imaging characteristics.
Here we report the outcomes of individuals with schizophrenia who
have participated in cognitive remediation three times weekly (60 minute
sessions) for 12 weeks using CACR-developed software.
We have done a preliminary analysis of the change in outcome measures
with these treatments. This analysis has shown no significant change in any
of the groups on the composite score from our cognitive battery (which is
our primary outcome measure) nor on the total Birchwood SFS score. We
will examine subscale scores in the future. PANSS ratings show a decrease
in symptom manifestation (total PANSS score) with each treatment (atom-
oxetine, CACR, and CACR þ atomoxetine) but not with the placebo/
control task alone, although we did not test for significance yet because
of the very low N. We have not predicted a reduction in psychotic symp-
toms, but continue to follow this outcome. We will report data from a sig-
nificant number of subjects in their response to atomoxetine, cognitive
remediation and both together.
ID: 548845
EFFICACY AND TOLERABILITY OF
ADJUNCTIVE ARMODAFINIL IN PATIENTS WITH
SCHIZOPHRENIA
John M. Kane1, D. C. D’Souza2, A. A. Patkar3, J. M. Youakim4,
J. Tiller4, R. Yang4, R. S. Keefe3
1Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA;
2Psychiatry, Yale University School of Medicine, New Haven,
CT, USA; 3Psychiatry and Behavioral Sciences, Duke University,
Durham, NC, USA; 4Clinical Research, Cephalon, Inc., Frazer,
PA, USA
Armodafinil, the longer lasting enantiomer (R) of modafinil, improves
wakefulness and long term memory in obstructive sleep apnea, shift
work disorder (SWD), and narcolepsy and attention in SWD and narco-
lepsy. A proof-of-concept study evaluated the effect of armodafinil on cog-
nition and symptoms in patients with schizophrenia receiving oral
olanzapine, risperidone, or paliperidone. This 4-wk, double-blind,
placebo-controlled study randomized 60 adult patients 1:1:1:1 to armoda-
finil 50 mg/d, 100 mg/d, or 200 mg/d, or placebo. Dosing began at 50 mg/d,
with 50-mg titration on days 2, 4, and 6 to randomized dosage. Efficacy
measures included the Measurement and Treatment Research to Improve
Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery
(primary) and the Positive and Negative Syndrome Scale (PANSS,
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secondary). Tolerability was assessed. There was no apparent improvement
in measures of cognition. The 200-mg/d dose had a potentially clinical
meaningful effect vs placebo on the PANSS negative scale and total scores.
No evidence of worsening positive symptoms in the armodafinil groups as
assessed by the PANSS positive scale scores was noted. Armodafinil was
generally well tolerated. The most common adverse events vs placebo were
diarrhea (5 [11%] vs 1 [7%]), headache (4 [9%] vs 1 [7%]), and restlessness (3
[7%] vs 0). Adjunctive armodafinil 200 mg/d may improve the negative
symptoms of schizophrenia without worsening positive symptoms in
patients receiving oral olanzapine, risperidone, or paliperidone. Armoda-
finil provided no apparent improvement in the MATRICS measures of cog-
nition. Armodafinil was generally well tolerated. These findings warrant
larger, adequately powered, double-blind, placebo-controlled studies.
Sponsored by Cephalon, Inc.
Table. Baseline-to-Final Visit Score Change
Armodafinil
Placebo
(n = 13)
50 mg
(n = 14)
100 mg
(n = 14)
200 mg
(n = 12)
MATRICS
composite score
Mean change (SD) 2.2 (5.1) 1.9 (6.2) 2.8 (8.0) 2.9 (4.7)
Effect size (95% CI) 0.04
(0.81, 0.73)
0.09
(0.68, 0.86)
0.15
(0.66, 0.95)
PANSS negative
scale score
Mean change (SD) 0.1 (1.9) 0.3 (4.0) 0.3 (3.4) 3.4 (2.1)
Effect size (95% CI) 0.11
(0.65, 0.87)
0.13
(0.63, 0.88)
1.69
(0.78, 2.60)
PANSS positive
scale score*
Mean change (SD) 0.9 (1.2) 0.7 (2.1) 0.1 (3.3) 0.4 (2.7)
PANSS total score
Mean change (SD) 1.7 (4.9) 2.5 (8.6) 0.9 (7.8) 6.3 (7.3)
Effect size (95% CI) 0.11
(0.64, 0.87)
0.11
(0.87, 0.64)
0.73
(0.08, 1.54)
*From safety analysis set.
ID: 548729
PERFORMANCE AND INTERVIEW-BASED
ASSESSMENTS OF COGNITIVE CHANGE IN
A RANDOMIZED, DOUBLE-BLIND COMPARISON
OF LURASIDONE VS. ZIPRASIDONE
Philip D. Harvey1, M. Ogasa2, J. Cucchiaro2, A. Loebel2,
R. Keefe3
1Psychiatry, Emory University School of Medicine, Atlanta,
GA, USA; 2Neuroscience, Dainippon Sumitomo America, Fort Lee,
NJ, USA; 3Psychiatry, Duke University Medical Center, Durham,
NC, USA
Background: Improving cognitive functioning in people with schizophrenia
is a major treatment goal. The FDA has asked for a co-primary measure to
demonstrate clinical relevance of any detected cognitive changes. There are
few data available regarding whether co-primary measures are sensitive to
treatment-related changes. Lurasidone is a new atypical antipsychotic with
affinity for D2 and 5-HT2A receptors, as well as for serotonin receptor sub-
types implicated in cognitive enhancement, including 5-HT7 and 5-HT1A.
Methods: Adult outpatients, ages 18–70 years old, were recruited who met
DSM-IV criteria for schizophrenia or schizoaffective disorder with no hos-
pitalization or acute exacerbation of psychosis in the previous 3 months.
Eligible patients were randomized to 21 days of treatment with lurasidone
120 mg once daily or ziprasidone 80 mg BID. The intent-to-treat sample con-
sisted of 150 patients on lurasidone and 151 patients on ziprasidone. A sim-
ilar proportion of patients completed the study on lurasidone and
ziprasidone [67.5% (n = 123) vs. 69.3% (n = 111)]. Study participants were
tested at baseline and endpoint with the MATRICS consensus cognitive bat-
tery (MCCB) and an interview-based assessment of cognitive functioning the
Schizophrenia Cognition Rating Scale (SCoRS). SCoRS ratings were based
on the interviewer’s best judgment, after interviews with the patient and
a caregiver. Results: There were no between-group differences in MCCB
or SCoRS ratings, although at week 3 lurasidone was superior on the SCoRS
at a trend level (P= .058). On the MCCB, at week 3, lurasidone demonstrated
significant within group-improvement from baseline (P= .026) but not zipra-
sidone (P = .254). There was no significant within-group improvement from
baseline on the SCoRS for the ziprasidone patients (P = .185), although lur-
asidone patients improved significantly (P< .001). Effect size for improvement
on the SCoRS (0.43) was over twice as large for lurasidone as improvement on
the MCCB (0.157). Implications: These data indicate that interview-based,
‘‘co-primary’’ measures of cognitive improvements are more sensitive to
change compared to the MCCB. In contrast to the MCCB, ratings on the
SCoRS are not performance-based, meaningthat practice effects are not a vi-
able explanation for improvements detected. In this 3-weekstudy, lurasidone
showed general trends toward improvement on the MCCB, as well as the
SCoRS, and is being assessed further in ongoing clinical trials.
ID: 548350
TWO DAY TREATMENT OF AUDITORY HALLU-
CINATIONS BY HIGH FREQUENCY RTMS GUIDED
BY CEREBRAL IMAGING
Sonia Dollfus1,2, A. Larmurier-Montagne1, A. Razafimandimby2,
O. Etard3
1Department of Psychiatry, Centre Hospitalier Universitaire, Caen,
France; 2Centre d’Imagerie Neurosciences et d’Applications aux
PathologieS, UMr 6232 CNRS, Caen, France; 3Service
d’explorations fonctionnelles du syste`me nerveux, Centre Hospitalier
Universitaire, Caen, France
Background: Auditory hallucinations are a common and disabling problem
for many patients with schizophrenia that often fail to respond to optimal
antipsychotic therapy. Repetitive transcranial magnetic stimulation
(rTMS) has recently been suggested as an alternative treatment for these
patients. Until now, rTMS has been used at low frequency and has been
most commonly applied to the left temporoparietal cortex. In order to im-
prove the efficiency of this treatment, we conducted a pilot study using high
frequency rTMS guided by anatomical and functional magnetic resonance
imaging (MRI). Methods: Eleven patients with schizophrenia (DSM-IV)
were treated with high frequency (20 Hz) rTMS delivered over 2 days.
The anatomical target was identified by MRI as the highest cluster activa-
tion along the posterior part of the left superior temporal sulcus from the
BOLD signal contrast map of each subject (listening to French vs Tamil
story). Results: A significant reduction in the global severity and frequency
of auditory hallucinations between baseline and post-treatment day 12 was
observed. Seven out of 11 (63.8%) patients had at least 30% improvement in
Auditory Hallucinations Rating Scale scores. For 2 patients, auditory hal-
lucinations disappeared entirely. High frequency rTMS was well tolerated
in all patients. Conclusions: This is the first study reporting the successful
treatment of auditory hallucinations with 20 Hz rTMS combined with an-
atomical and functional MRI. The high rate of efficacy, the safety and short
duration of treatment present a considerable therapeutic gain compared to
low frequency rTMS.
ID: 548330
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ADJUNCTIVE RISPERIDONE IN CLOZAPINE
TREATED PEOPLE WITH TREATMENT-RESISTANT
SCHIZOPHRENIA
Elaine Weiner1,2, M. P. Ball1,2, S. Feldman1,2, R. Conley3,
D. Kelly1,2, J. M. Gold1,2, R. P. McMahon1,2, R. W. Buchanan1,2
1MPRC, Catonsville, MD, USA; 2Psychiatry, University of
Maryland Medical School, Baltimore, MD, USA; 3Neuroscience,
Eli Lilly and Company, Indianapolis, IN, USA
Background: Up to 50% of people adequately treated with clozapine con-
tinue to exhibit significant residual positive and negative symptoms and
cognitive impairments. They represent a major therapeutic challenge, rais-
ing the question as to what treatment options are available for them. In
clinical practice, a second antipsychotic medication is often used, but there
is little empirical evidence to support the validity of this approach. Previous
studies with adjunctive risperidone have produced mixed results. The cur-
rent study was deigned to provide a comprehensive evaluation of adjunctive
risperidone for persistent positive symptoms (primary outcome), negative
symptoms and cognitive impairments (secondary outcomes). Methods: The
study was a 16-week, placebo-controlled, parallel group, RCT of adjunctive
risperidone (4 mg/day). Subjects with DSM-IV schizophrenia or schizoaf-
fective disorder were required to demonstrate at least a minimum level of
illness severity defined as a BPRS (18 item version) total score of 45 or more
and a CGI severity of illness item score of 4 or more, and a minimal level of
positive symptoms defined as a BPRS positive symptom total item score of
8 or more, and a score of 4 or more on any individual item. The BPRS pos-
itive symptoms items and SANS total score were used to assess change in
positive and negative symptoms, respectively and a comprehensive neuropsy-
chological battery was used to assess change in cognition. Results: Eighty-six
subjects signed consent forms and 71 subjects entered the 4-week evaluation
phase. Sixty-five subjects were randomized and entered the double-blind
phase of the study (risperidone: 30/placebo: 35). The majority of subjects
were male: risperidone group: 63.3%; placebo group: 71.4%; and Cauca-
sian: risperidone group: 76.7%; placebo group: 62.9%. The risperidone
group was significantly older: 48.3 (7.2) versus 43.6 (9.6). In September
2008, the last of the randomized subjects completed the trial. Fifty-two sub-
jects completed all 16 weeks of the double-blind study (risperidone: 25/pla-
cebo: 27). The presentation will include complete data for intent to treat
primary analyses for the primary and secondary outcome measures using
mixed model analysis of variance for repeated measures. Discussion: Study
results will provide a comprehensive evaluation of the efficacy and safety of
adjunctive risperidone for persistent positive and negative symptoms and
cognitive impairments.
ID: 547770
RECOMBINANT HUMAN ERYTHROPOIETIN:
APPROACHES TO NEUROPROTECTION AND
NEUROREGENERATION IN SCHIZOPHRENIA
Hannelore Ehrenreich1, P. Falkai2
1Clinical Neuroscience, MPI of Experimental Medicine, Go¨ttingen,
Germany; 2Department of Psychiatry and Psychotherapy,
Georg-August-University, Go¨ttingen, Goettingen, Germany
Mainly due to modern imaging technology, schizophrenia is increasingly rec-
ognized as developmental disease with additional neurodegenerative com-
ponents, comprising cognitive decline and progressive loss of cortical
gray matter. Therefore, neuroprotective/neurotrophic add-on strategies
may deliver promising treatment options. Erythropoietin (EPO) is an ideal
candidate compound for neuroprotection in human brain disease in general
and in schizophrenia in particular, capable of combating a spectrum of path-
ophysiological processes operational during the progression of the disease.
In the nervous system, EPO acts anti-apoptotic, anti-oxidant, anti-
inflammatory, neurotrophic and plasticity modulating. EPO has been found
to be neuroprotective/neuroregenerative in various different animal models
of neuropsychiatric diseases. In preparation of a first trial on EPO in schizo-
phrenia, we tested the capability of EPO to penetrate an intact blood-brain-
barrier. Using indium 111-labeled EPO, we demonstrated that even in
healthy subjects, EPO enriched within the brain. This accumulation was in-
creased in schizophrenic patients as compared to healthy controls, likely
explained by the higher density of EPOR expression found in frontal cortex
and hippocampus of schizophrenics. Importantly, EPO is able to improve
cognitive functioning in mice and to enhance hippocampal long-term poten-
tiation and other determinants of neuronal plasticity, essential for learning
and memory processes. EPO prevents the development of slowly progressing
global brain atrophy in a mouse model of chronic neurodegeneration. Fur-
ther, EPO reduces haloperidol-induced cell death in primary hippocampal
neuronal cultures. Based on these grounds, we performed a double-blind,
placebo-controlled, randomized multicenter trial. Treatment over 12 weeks
with high-dose weekly EPO led to significant improvement of cognitive per-
formance compared to placebo controls. Employing voxel-based morpho-
metrical magnetic resonance imaging analysis, we obtained first evidence
that EPO treatment delays progressive cortical gray matter loss in chronic
schizophrenia. In contrast, over the three months of study duration, we did
not see effects on psychopathology or social functioning. The fact thatEPO is
the first compound ever to exert a beneficial effect on cognition in schizo-
phrenia should encourage further work along these lines. An EPO treatment
trial including patients with first episode schizophrenia has been initiated.
ID: 546968
MODAFINIL FOR CLOZAPINE-TREATED SCHIZO-
PHRENIA PATIENTS. A DOUBLE-BLIND, PLACEBO-
CONTROLLED TRIAL
Oliver Freudenreich, D. C. Henderson, E. A. Macklin, A. E. Evins,
X. Fan, C. Cather, J. P. Walsh, D. C. Goff
Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Rationale: Patients with schizophrenia often suffer from cognitive deficits
and negative symptoms that are poorly responsive to antipsychotics includ-
ing clozapine. Clozapine-induced sedation can worsen cognition and impair
social and occupational functioning. Objectives:To evaluate the efficacy,
tolerability, and safety of modafinil for negative symptoms, cognition
and fatigue in schizophrenia patients treated with clozapine. Methods:
A double-blind, placebo-controlled, flexible-dosed 8-week pilot trial was
conducted, adding modafinil up to 300 mg/day to stabilized schizophrenia
outpatients receiving clozapine. Psychopathology, cognition, and fatigue
were assessed with standard rating scales. Results: 35 patients were ran-
domly assigned to treatment with study drug and included in the analysis.
Modafinil did not improve negative symptoms, cognition, or fatigue com-
pared to placebo. Modafinil was well tolerated and did not worsen psycho-
sis. Conclusions: Results of this pilot trial do not support routine use of
modafinil to treat negative symptoms, cognition, or fatigue in patients
on clozapine. Larger trials are needed to resolve or refute a potential ther-
apeutic effect of uncertain magnitude.
ID: 546739
TEST-RETEST CHARACTERISTICS OF THE
MATRICS CONSENSUS COGNITIVE BATTERY IN A
20-SITE SCHIZOPHRENIA CLINICAL TRIAL OF
R3487/MEM3454 VERSUS PLACEBO
Richard Keefe1, C. Siu2, K. Fox3, D. A. Lowe4, G. Garibaldi5,
L. Santarelli5, S. Murray4
1Psychiatry, Duke University Medical Center, Durham, NC, USA;
2Data Power, Inc., Ringoes, NJ, USA; 3NeuroCog Trials, Inc.,
Durham, NC, USA; 4Memory Pharmaceuticals, Montvale,
NJ, USA; 5Roche Pharmaceuticals, Nutley, NJ, USA
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Background: The Measurement and Treatment Research to Improve Cog-
nition in Schizophrenia (MATRICS) Project produced a battery of tests,
the MATRICS Consensus Cognitive Battery (MCCB), designed to assess
cognitive treatment effects in clinical trials of patients with schizophrenia.
In validation studies, the MCCB demonstrated excellent reliability, min-
imal practice effects and large correlations with measures of functional
capacity. It has been an empirical question whether the MCCB would
demonstrate these favorable characteristics when administered in the con-
text of the type of large multi-site industry trial for which it was designed.
Methods: Patients with schizophrenia maintained on a stable dose of a sec-
ond generation antipsychotic therapy were enrolled into a randomized,
double-blind, placebo-controlled trial of R3487/MEM3454. Testers
from 20 sites were trained and certified, and all MCCB data were reviewed
and re-scored centrally. The MCCB was administered at screening and 7–
14 days later at baseline. A measure of functional capacity, the UCSD
Performance-based Skills Assessment (UPSA) was also measured at base-
line. The MCCB generates a composite score and cognitive domain scores
standardized to a normative population with mean (T) = 50 and SD = 10.
Results: Baseline T-scores for the 7 MCCB cognitive domains and a com-
posite score were determined for 62 male and 21 female subjects, mean age
39.0 years (SD = 8.8), mean PANSS total score 57.7 (SD = 9.6) and mean
UPSA-2 total score 84.9 (SD = 15.3). Only 7 test scores were missing out of
a total of 1800 test assessments for the 10 MCCB tests performed in 90
subjects at 2 occasions (99.6% complete). All 90 (100%) patients had suf-
ficient data for computing a composite score according the MCCB crite-
ria. The mean MCCB composite score was 28.1 at screening and 30.2 at
baseline, with identical SDs of 11.5 at both time points. The test-retest
reliability for the MCCB composite score was very high (ICC = 0.88).
Construct validity was also strong, as the MCCB composite score dem-
onstrated a large correlation with the UPSA composite score (r = .59,
df = 82, P < .001). The practice effect on the composite score was small
(z = 0.17). Discussion: In the context of a 20-site clinical trial in stable
patients with schizophrenia, the MCCB is sensitive to cognitive deficits
in all domains, demonstrates excellent test-retest reliability and construct
validity, and small practice effects.
ID: 546725
OPEN LABEL, PILOT STUDY OF ADJUNCTIVE
SODIUM OXYBATE FOR THE TREATMENT OF
SCHIZOPHRENIA AND ASSOCIATED SLEEP
DISTURBANCES
Joshua Tolkien Kantrowitz1,3, E. Oakman1,2, S. Bickel1,
L. Citrome1,2, D. C. Javitt1,2
1Schizophrenia Research Center, Nathan Kline Institute for
Psychiatric Research, Orangeburg, NY, USA; 2Psychiatry,
New York University, New York, NY, USA; 3Psychiatry,
Albert Einstein College of Medicine, Bronx, NY, USA
Subjective and objective sleep is abnormal in schizophrenia, and associated
with significant distress and cognitive deficits. Gamma-hydroxybutyric acid
(sodium oxybate), a GABAB and GHB agonist, improves deficits in sub-
jective and objective sleep in narcolepsy and fibromylagia, and multiple
lines of evidence link modulation of the dopaminergic system with the
GABAB receptor. We report interim results of an ongoing, four week
open label, 8-patient trial of adjunctive sodium oxybate in patients with
schizophrenia and insomnia related to schizophrenia. 5 patients with
a mean baseline Epworth Sleepiness Scale (ESS) of 9.8, Pittsburgh Sleep
Quality Index (PSQI) of 10.6 and PANSS of 93 have completed. Exclusion
criteria includes: (1) Restless leg syndrome or obstructive sleep apnea (2)
History of alcohol dependence (3) Persistent need for other sedative hyp-
notics. After tapering previous sedative-hypnotic and baseline evaluations,
patients receive 4 weeks of adjunctive sodium oxybate at night, beginning at
4.5 g and increasing by 1.5 g/night/week to 9 g (in divided doses of ½ at
bedtime and ½ four hours later). A two-week taper of sodium oxybate fol-
lowed. Treating psychiatrists were encouraged to keep antipsychotic dosage
stable. Primary outcome was subjective sleep (ESS and PSQI), with clinical/
cognitive scales (PANSS, CGI and MATRICS) and objective sleep (poly-
somnography/actigraphy) secondary. Safety measures included several
EPS scales and weekly vital signs. Through 5 patients, improvements
were noted in the primary subjective outcomes— PSQI (P = .04;Cohen’s
d = 1.34) and the ESS (P < .05;Cohen’s d = 1.29). In an interim analysis,
a majority of polysomnography (n = 3) and actigraphy (n = 4) comparisons
normalized from baseline to study end, particularly in stage III/IV sleep and
REM latency (with increase in total REM) and decreased daytime napping.
No changes were noted on the other clinical, cognitive or safety measures.
Despite no change in objective symptoms, two days before final ratings, one
patient’s antipsychotic was changed from perphenazine to quetiapine by the
treating psychiatrist for subjective worsening of psychosis. The improve-
ment in ESS remains (P < .05) even with exclusion of this patient, but
the PQSI change is reduced (P = .11). The interim results of this study
of sodium oxybate in schizophrenia associated insomnia demonstrate large
effect size improvement in subjective sleep without significant changes in
general psychopathology.
ID: 546447
ATOMOXETINE AND GROUP SUPPORT FOR
TREATMENT OF WEIGHT GAIN IN SUBJECTS
TAKING OLANZAPINE OR CLOZAPINE
M. Patricia Ball, R. W. Buchanan, K. Warren, S. Feldman,
R. McMahon, J. Osing
Maryland Psychiatric Research Center, University of Maryland
Baltimore, Catonsville, MD, USA
Weight loss interventions for those on second generation antipsychotic
medications have demonstrated varying success. We attempted to deter-
mine if atomoxetine, a structured support group, and exercise would result
in significant benefits for this population. The study was a randomized, par-
allel group, double-blind comparison of adjunctive atomoxetine or placebo.
Subjects with schizophrenia or schizoaffective disorder, taking either olan-
zapine or clozapine, who had gained at least 7% of their pre-clozapine or
olanzapine weight were eligible. A weekly diet support group and exercise
program, implemented during a 2-week evaluation period, continued dur-
ing the 24 week double-blind treatment period. Of the 44 subjects who
signed consent, 36 entered treatment and 26 completed the study. Atom-
oxetine did not effect weight loss (F = 0.05, df = 1,28.2, P = .82): both treat-
ment groups showed modest trends in weight loss, averaging about 2 kg (F =
3.77, df = 1, 28.2,P = .062). There was no significant evidence that gender or
baseline antipsychotic modified treatment effects (time x gender x treat-
ment, F = 0.96, P = .34; time x antipsychotic x treatment, F = 2.16, P =
.15). Secondary outcomes evaluated included neuropsychological assess-
ments, symptom assessments (BPRS, SANS) and safety assessments .
Among individual neuropsychological tests, only the Gordon distractibility
test scores were nominally statistically significant (Wilcoxon permutation
test p-value = 0.041, unadjusted for multiple comparisons), although this
difference partly reflected worse performance in the placebo group. Only
one of 26 laboratory measurements, blood C02, showed a nominally sig-
nificant (P = .019, unadjusted for multiple comparisons) reduction (approx
6%) in atomoxetine versus placebo. Of the symptom and safety assess-
ments, only one side effect, tremor, showed nominally significant (P =
.018) differences in incidence of new or worsened symptoms (almost all
‘‘mild’’) between atomoxetine (28%) and placebo (71%). Six placebo and
three atomoxetine subjects achieved exercise levels consistent with current
weight loss recommendations, but this number was too small to evaluate for
significance. Results indicate that adjunctive atomoxetine is not effective
for weight loss in this population, but both olanzapine and clozapine sub-
jects can lose weight with structured group support and exercise. Motiva-
tion to exercise poses the biggest challenge. Supported by Eli Lilly and
Company and an ACISR pilot project grant.
ID: 546250
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PSYCHIATRISTS’ ATTITUDES TO FIRST AND
SECOND GENERATION ANTIPSYCHOTIC
LONG-ACTING INJECTIONS: COMPARISONS OVER
FIVE YEARS
Maxine X. Patel1, P. M. Haddad2, I. B. Chaudhry3,
S. McLoughlin2, N. Husain3, A. S. David1
1Division of Psychological Medicine, Institute of Psychiatry, KCL,
London, United Kingdom; 2Cromwell House, University of
Manchester and Greater Manchester West Mental Health NHS
Foundation Trust, Salford, United Kingdom; 3Lancashire Care
Early Intervention Service, University of Manchester and
Lancashire Care NHS Foundation Trust, Accrington,
United Kingdom
Background: Previously, when only first generation antipsychotic depot
long-acting injections (LAIs) were available, some clinicians perceived
LAIs as having an ‘‘image’’ problem despite them being associated
with reduced rates of rehospitalisation when compared to tablets. This
study investigated psychiatrists’ attitudes and knowledge concerning de-
pot long-acting injections (first and second generation antipsychotics) and
whether they had changed over time. Method: Cross-sectional postal sur-
vey of consultant psychiatrists working in NorthWest England. A pre-
existing questionnaire on clinicians’ attitudes and knowledge regarding
LAIs was updated. Results were compared with a former sample (South-
East England, 2001: N = 143). Results: The sample comprised 102 con-
sultant psychiatrists (response rate 71%). LAI use over the past 5 years
had: decreased (50%), not changed (27%), increased (23%). Most regarded
LAIs as associated with better compliance (89%) than tablets. A substan-
tial proportion believed that LAIs could not be used in first-episode psy-
chosis (38%) and that patients always preferred tablets (33%).
Psychiatrists with decreased LAI use had significantly lower scores for
the side effects knowledge subscale than those who had unchanged or in-
creased rates of LAI use (mean 51.5% vs 54.8%, P = .029). When com-
pared to psychiatrists sampled five years previously, our current
participants scored more favourably on a patient-focused attitude sub-
scale had more favourable patient-focussed attitudes (63.5% vs 60.4%,
P = .034); other subscales did not differ. Item-by-item analysis revealed
specific differences between the two samples including significantly fewer
current participants regarding LAIs as: (i) compromising patient auton-
omy (mean 0.99 vs 1.28, P = .036); being stigmatising (1.88 vs 2.42, P =
.002); being old fashioned (1.49 vs 2.04, P = .002). Conclusions: During
the period that a second generation antipsychotic LAI has been available,
and LAI prescribing rates have reduced, most attitudes and knowledge
have remained fairly stable and consistent in the UK, except for attitudes
regarding the patients who are prescribed LAIs which improved. Con-
cerns about stigma and autonomy with LAI use have decreased. However,
concerns about patient acceptance continue as do negative views about
some aspects of LAI use; these may compromise medication choices of-
fered to patients.
ID: 546172
EXPLORING PLACEBO RESPONSE IN RECENTLY
CONDUCTED VS. EARLIER TRIALS OF PATIENTS
WITH SCHIZOPHRENIA
Cynthia A. Bossie1, L. Alphs1, C. M. Canuso1, I. Turkoz1,
I. D. Glick2
1Scientific Affairs, Ortho-McNeil Janssen, Titusville, NJ, USA;
2Psychiatry and Behavioral Sciences, Stanford University, School of
Medicine, Stanford, CA, USA
Research suggests that the placebo-adjusted effect of antipsychotic treat-
ment in acute schizophrenia trials has diminished over the past several dec-
ades. This may be partly due to an increasing placebo response, which was
the focus of these post-hoc analyses. The analyses were performed using
placebo-arm data from available acute schizophrenia trials that were
denoted as Earlier Trials (late 1980s-mid 1990s: RIS-USA-1, RIS-INT-3
[CR006067], RIS-USA-72) and similarly-designed Later Trials (2004–
2005: CR003379, CR004378, CR004375). PANSS and CGI-S at week
6 (completers) and endpoint (LOCF) were examined. Regression models
assessed the relationship between placebo response (20% or30% reduc-
tion in PANSS total score) and: country, age, gender, illness duration, base-
line PANSS and CGI-S, and enrollment in Later vs. Earlier trials. Results
of the analyses included that the distribution of percentage change in total
PANSS scores over time shifted towards greater improvements with pla-
cebo in Later vs. the Earlier trials at week 6 (P = .012), but not at study
endpoint. Multiple logistic regression models identified ‘‘Later vs. Earlier
Trials’’ as the only variable significantly associated with placebo response.
Placebo-treated patients in Later vs. Earlier Trial were 4.3-times (95% CI,
1.89–9.58, P  .001) and 4.7-times (95% CI, 1.58–13.94, P = .0054) more
likely to experience a20% and30% reduction, respectively, in PANSS at
week 6. In conclusion, placebo-treated patients with schizophrenia enrolled
in more recently-conducted trials are more likely to exhibit a reduction in
PANSS at week 6 than those in earlier-conducted trials. None of the tested
variables were significantly associated with this response, suggesting that
factors not considered (ie, associated with study conduct/other patient
characteristics/etc.), or hidden biases, may underlie this phenomenon.
Supported by Ortho-McNeil Janssen Scientific Affairs, LLC.
ID: 543442
INSIGHT AND ITS RELATIONSHIP TO BASELINE
CHARACTERISTICS OF SCHIZOPHRENIA
PATIENTS RANDOMIZED TO LONG-ACTING
INJECTABLE RISPERIDONE OR ORAL ATYPICAL
ANTIPSYCHOTICS: RESULTS FROM THE
PROACTIVE STUDY
Maju Mathew Koola, J. Bustillo, J. Lauriello
UNM, Albuquerque, NM, USA
a) While the use of long acting antipsychotics is often recommended to in-
crease medication adherence, the relationship between atypical long acting
antipsychotics and relapse is not well established. The purpose of PROAC-
TIVE (Preventing Relapse in schizophrenia: Oral Antipsychotics Com-
pared To Injectables: eValuating Efficacy) study is to compare the
relapse rates of patients receiving the first line oral atypical antipsychotics
vs. the long acting atypical risperidone. A secondary aim is to evaluate the
role of insight in adherence and relapse. This study presents baseline data
on the level of insight, patient presenting symptomatology and previous
relapses. b) The primary outcome variable in this analysis is the level of
insight measured by the modified Scale to Assess Unawareness of Mental
Disorder (SUMD) at baseline. Inclusion Criteria: 1. Schizophrenia and
schizoaffective disorder patients. 2. Exacerbation in the last 12 months. Ex-
clusion 1. First episode patients. c) To date, baseline data have been ana-
lyzed for 78 subjects. The number of patients with good insight = 45 (males=
33, females = 12), with limited insight = 33 (males= 24, females = 9). The age of
patients with good insight (mean = 39.13, SD = 10.44), with limited
insight (mean = 34.97, SD = 12.02). Adherence with good insight =
39 (good = 33, poor = 6), with limited insight = 32 (good = 24,
poor = 8). The number of hospitalizations in patients with good insight
(mean = 12.38, SD = 17.75), number of hospitalizations in patients with
limited insight (mean = 6.43, SD = 8.76). BPRS with good insight
(mean = 2.60, SD = 1.03), BPRS with limited insight (mean = 2.93,
SD = 1.31). SANS with good insight (mean = 2.34, SD = 0.54), SANS
with limited insight (mean = 2.45, SD = 0.57). d) There were no statis-
tically significant differences between those with good and limited
insight on sociodemographic variables or measures of psychopathology.
The only variable that correlated with insight was the previous number of
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hospitalizations; those with good insight had a higher number of prior hos-
pitalizations. This result offers several possible interpretations: first that with
greater experience in treatment patients develop more insight about the ill-
ness. However, it could mean that those with insight at the start of their illness
seek help and utilize resources while those without insight avoid treatment.
Funding from National Institute of Health, Grant No. 5U01MH070008-03.
ID: 540493
TRAJECTORIES AND ANTECEDENTS OF
TREATMENT RESPONSE OVER TIME IN EARLY
EPISODE PSYCHOSIS
Stephen Z. Levine, J. Rabinowitz
Bar Ilan University, Ramat Gan, Israel
Background: Little is known about the extent of heterogeneity of symptom-
atology in treated early onset psychosis. The current study aims to quantify
the extent of heterogeneity in trajectories of treated symptom severity in
early episode psychosis and their antecedents. Methods: Data were from
491 persons with early episode psychosis from a clinical trial of haloperidol
and risperidone. Positive and Negative Syndrome Scale (PANSS) admin-
istrations were used to measure symptom severity trajectories for: (a) rapid
treatment response scores over 4 weeks, and (b) medium-term course over
24 weeks. Baseline antecedents included: sex, DSM-IV diagnosis, age of
onset, the Premorbid Adjustment Scale, and a cognitive test battery. Symp-
tom severity trajectories were calculated with mixed mode latent class re-
gression modeling from which groups were derived. Results: Five groups
based on PANSS scores over time were identified. Over 4 weeks three
groups with varied baseline PANSS scores (54 to 105) did not surpass
30% PANSS improvement. Another group improved and then was stable
(n = 76,15.3%) and another showed marked improvement (n = 94,18.9%).
Logistic regression showed that membership in the best response trajectory
was associated with not having a diagnosis of schizophrenia, good premor-
bid functioning and higher cognitive functioning, whereas membership in
the poor response trajectory was associated with earlier age of onset and
poorer cognitive functioning. Conclusion: Amelioration generally charac-
terizes treated symptom severity. Age of onset, diagnosis, cognitive func-
tioning and premorbid functioning have prognostic value in predicting
treatment response trajectory.
ID: 537757
PRIOR PARTICIPATION IN CLINICAL TRIALS IN
SCHIZOPHRENIA: DOES THE DESIGN OF THE
CLINICAL TRIAL HAVE AN IMPACT?
Penny Randall1,2, A. Kalali1,2, K. Jacobs1,2
1Medical and Scientific Services, Quintiles, San Diego, CA, USA;
2Psychiatry, UCSD, San Diego, CA, USA
Background: As documented in a recent article1, there has been a historical
reduction in the drug-placebo difference in multicenter trials of antipsy-
chotic medications in schizophrenia. Many possible explanations for this
finding have been raised, including the fact that clinical trial subjects
may have different characteristics. One possible difference between subjects
entering clinical trials now and those who entered earlier clinical trials may
be prior participation in a clinical trial examining a treatment for schizo-
phrenia. We examined data obtained from two global clinical trials in
schizophrenia to determine whether protocol design might influence re-
cruitment of subjects with prior participation in clinical trials. Methodol-
ogy: Trial 1 was a 6-week placebo controlled double blind clinical trial in
patients with an acute exacerbation of the symptoms of schizophrenia. It
excluded subjects who had participated in a trial within 6 months of screen-
ing. Trial 2 was a 6-week, outpatient trial in patients with schizophrenia,
who had suboptimal response or adverse events to current therapy. It
excluded subjects who had participated in a clinical trial within 12-months
of screening. Results: Table 1. Percentage of Subjects with Prior Trial
Experience in Region. Conclusions: This data demonstrates that prior trial
experience of subjects is multifactorial and is impacted significantly not
only by geographical region but also by the trial design, as well as factors
not examined in this study.
Reference
1. Aaron S. Kemp, Nina R. Schooler, Amir H. Kalali, et al. Schizophr
Bull. 2008 Aug 22.
ID: 550812
CHANGES IN ADIPOSITY, INSULIN SENSITIVITY
AND LIPID METABOLISM DURING RANDOMIZED
ANTIPSYCHOTIC TREATMENT IN
SCHIZOPHRENIA
John W. Newcomer, D. Haupt, P. Fahnestock, K. Flavin,
G. Nicol, J. Schweiger, E. Westerhaus, A. Stevens, M. Yingling
Psychiatry, Washington University School of Medicine, St. Louis,
MO, USA
Background: Antipsychotic medication treatment can increases or decrease
body weight, as a function of individual medication effects and pretreat-
ment conditions. Interest in treatment effects on body weight is related
to hypothesized changes in adiposity, and glucose and lipid metabolism,
relevant to risk for cardiovascular disease and diabetes. However, few
studies to date have quantified medication effects on direct measures of ad-
iposity, versus weight or surrogate measures like body mass index.
Complicating measurement of medication effects, pre-treatment conditions
can influence treatment response. However, no studies to date have
balanced pre-treatment conditions across randomized treatment
groups. Methods: Schizophrenia patients were randomized to 12 weeks
of treatment with olanzapine, quetiapine, risperidone, or ziprasidone, bal-
ancing prior treatment conditions and baseline adiposity across treatment
groups. Detailed metabolic measurements, including dual energy X-ray
Table 1.
Number of Subjects with Prior Trial
Experience in Region U.S. Ukraine Russia India All Subjects
Trial 1 45/86(52%) 2/49 (4%) 16/75 (21%) 1/60 (2%) 64/270 (24%)
U.S. Ukraine Argentina Colombia Slovak Republic Czech Republic All Subjects
Trial 2 53/101 (52%) 9/13 (69%) 12/35 (34%) 2/11 (18%) 1/20 (5%) 8/25 (32%) 85/205 (41.5%)
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absorptiometry (DEXA), magnetic resonance imaging (MRI), hyperinsu-
linemic, euglycemic clamps, and fasting plasma measurements were used to
quantify whole-body and regional adiposity, insulin sensitivity, and plasma
lipid levels. Results: Preliminary analysis of final results from this study
indicate that significant treatment group-related differences are observed
treatment-related changes in DEXA and MRI-measured adiposity, fasting
plasma triglyceride, fasting cholesterol, and fasting LDL. For example, sig-
nificant time x treatment condition effects are observed on DEXA-mea-
sured total body fat, MRI Visceral Surface Area, MRI Subcutaneous
and Visceral combined, fasting plasma triglyceride, fasting plasma choles-
terol, and fasting plasma LDL, with pretreatment conditions contributing
to differential outcomes in some treatment groups. Discussion: Antipsy-
chotic medications can produce differential effects on direct measures of
adiposity, as well as clinically available measurements relevant to cardio-
metabolic risk. The results are relevant to understanding opportunities to
reduce risk in persons treated with antipsychotic medications. Supported by
MH63985.
ID: 551876
SUBJECTS WITH SCHIZOPHRENIA OR
SCHIZOAFFECTIVE DISORDER AND HEPATIC
ILLNESS: BASELINE CHARACTERISTICS FROM
A TRIAL OF PALIPERIDONE EXTENDED-RELEASE
Joan Amatniek1, C. M. Canuso1, S. Rodriguez1, L. Mao1,
E. A. Youssef2, V. Navarro3, D. C. Henderson4
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville,
NJ, USA; 2At the time of this analysis, was an employee of
Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA;
3Thomas Jefferson University, Philadelphia, PA, USA;
4Massachusetts General Hospital, Harvard Medical School,
Boston, MA, USA
Management of patients with schizophrenia or schizoaffective disorder
(SCH/SCA) is often complicated by comorbidities, including hepatic illness
(HI). This large prospective study of these patients was undertaken to eval-
uate the effects of paliperidone extended-release (ER), which undergoes
limited hepatic metabolism. Interim baseline data from a 9-week, open-
label, single-arm, crossover study of outpatients with stable SCH/SCA
and HI were reviewed to assess the distribution of HI, by etiology and stage,
in the study population. The inclusion criteria were Child-Pugh scores reflect-
ing well-compensated (Class A) to functionally compromised (Class B) HI
and liver tests (LTs) 3x the upper limits of normal (ULN). In this pre/post
comparison, subjects receive treatment as usual for 4 weeks, a 1-week cross-
titration, and paliperidone ER for 4 weeks. The study endpoints were ad-
verse events (primary), laboratory tests, movement disorder scales, Positive
and Negative Syndrome Scale (PANSS), quality of life, and alcohol use.
Study identification number: CR014341. A total of 69 US subjects enrolled;
57 (82.6%) subjects had a diagnosis of schizophrenia and 12 (17.4%) sub-
jects had a diagnosis of schizoaffective disorder. The mean (6SD) age was
48.2 (67.5) years. Most subjects were male 69.6% (n = 48), black 63.8%
(n = 44), with high school education 72.5% (n = 50), unemployed 88.4%
(n=61);44.9%(n=31) livedinsupportedhousing.Themostcommonetiology
of liver disease was viral hepatitis (95.7%, n= 66). Most subjects had a Child-
Pugh rating of A (82.6%, n = 57). LTs (alanine and aspartate aminotransfer-
ase) were just above ULN (44.7 6 23.90 U/L and 39.2 6 17.09 U/L, respec-
tively). The mean (6SD) PANSS total score was 73.8 (612.6). Most subjects
had used tobacco (95.7%, n = 66), alcohol (91.3%, n= 63), marijuana (68.1%,
n= 47), and cocaine (66.7%, n= 46); 43.5% (n= 30) had used heroin. Thus far,
most subjects have mild HI due to viral hepatitis, possibly related to prior
substance abuse. The effects of paliperidone ER in this important patient
population are currently under study. Supported by Ortho-McNeil Janssen
Scientific Affairs, LLC.
ID: 551875
EARLY ANTIPSYCHOTIC RESPONSE AS A
PREDICTOR OF LATER RESPONSE IN FIRST
EPISODE SCHIZOPHRENIA
John M. Kane, D. Robinson, J. Gallego
The Zucker Hillside Hospital, Glen Oaks, NY, USA
Objective: Few studies have examined the time course of response in schizo-
phrenia. Studies with multi episode patients suggest that lack of response
early in treatment predicts longer term non-response. Correll et al. (2003),
in an open label study with multi episode patients found high predictive
power for non-response at 2 weeks to predict non-response at 4 weeks.
Kinon et al. (2008) and Leucht (2007) showed the non-response to antipsy-
chotics early in treatment (1–2 weeks) is predictive of non-response later in
treatment (4–12 weeks). However, Emsley et al. (2006) analyzed data from
522 first episode patients treated with risperidone or haloperidol and found
that time to response varied widely with many patients responding during
the first two weeks but with a significant number of patients responding
after week 8. Given this inconsistency in time course of response between
first episode and chronic patients data which can help to resolve this ques-
tion, would be very valuable. This study examined time course of response
of first episode patients treated with the widely used second generation anti-
psychotics olanzapine or risperidone. Methods: Post hoc analysis of two
different randomized controlled trials in patients with a first episode of
schizophrenia. Prediction models were utilized, using survival analysis, re-
ceiver-operated analysis and sensitivity-specificity models. Results: In an
analysis of data on 225 first episode patients participating in a randomized
controlled trial, early response/non-response at 2 weeks predicted subse-
quent response/non-response at 12 weeks. Early responders achieved a sig-
nificantly greater level of symptom improvement than the early non-
responders at all time points. In a separate 16 week trial, 112 first episode
patients were also evaluated regarding time course of response. We did not
see the same degree of predictive power based on early response in this
cohort. Differences between these cohorts in terms of length of prior treat-
ment, etc., which might impact the results will be discussed. Conclusions:
Response patterns may differ in patients with a first episode of schizophre-
nia compared to more chronic patients. These data are important in inform-
ing treatment decisions as well as providing a framework for biologic and
pharmaco genetic studies.
ID: 551856
LONG-TERM TOLERABILITY AND SAFETY OF
ARIPIPRAZOLE IN THE TREATMENT OF
PEDIATRIC PATIENTS WITH SCHIZOPHRENIA
OR BIPOLAR I DISORDER
Robert A. Forbes1, M. Nyilas1, B. Johnson1, C. Aurang1,
R. Owen2, T. Iwamoto1, W. H. Carson1, C. Correll3
1Global Medical Affairs, Clinical Development, Otsuka
Pharmaceutical Development and Commercialization, Princeton,
NJ, USA; 2Clinical Development, Bristol Myers Squibb,
Wallingford, CT, USA; 3Psychiatry, Zucker Hillside Hospital,
Glen Oaks, NY, USA
Background: There is limited published long-term clinical trial safety data
upon which to guide treatment decisions and expectations in pediatric
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patients with schizophrenia or bipolar disorder. Method: This is a com-
bined safety analysis from double-blind and open-label studies which
assessed the short- and long-term safety and tolerability of aripiprazole
(2–30 mg) in 514 child and adolescent patients (281 schizophrenia and
233 bipolar I mania) over a treatment period of up to 32 weeks. Pooled
data in this analysis was attained from subjects who had participated in
either double-blind parent study: a 6-week, double-blind study in schizo-
phrenia (ages 13–17 years), or a 30-week (4-week acute þ 26-week con-
tinuation) double-blind study in bipolar I disorder (ages 10–17 years).
Also included were tolerability and safety data from subjects who qualified
for and participated in a 6-month, open-label extension study with a com-
bined patient population. Assessments for each patient population in-
cluded frequency and severity of adverse events, discontinuation due to
adverse events, blood chemistries, ECG, and metabolic parameters, in-
cluding body weight and BMI. Results: AEs were generally mild to mod-
erate in severity. Over the course of more than 26 weeks of treatment, 7.2%
of patients discontinued due to AEs (6% and 8.6% in the schizophrenia
and bipolar disorder samples, respectively). The most prominent AEs
in the combined sample included somnolence (23.2%), extrapyramidal dis-
order (21.6%), headache (17.7%) and akathisia (12.3%). There were 4 cases
of suicidal ideation, with no completed suicide. Body weight shift table
analysis showed that 19 subjects had a shift in weight from normal at base-
line to abnormal at the last visit. Mean change in weight z-score was not
clinically significant over >32 weeks of treatment (<0.5 SD). Conclusions:
Aripiprazole was well tolerated, in general, over a treatment period of up
to 32 weeks in pediatric patients with schizophrenia or bipolar disorder.
Incidence and severity of AEs were consistent with respective short-term,
double-blind parent studies. Relative to the normal rate of growth in these
patient populations, mean weight gain observed in the aripiprazole groups
was not clinically significant.
ID: 551855
PREDICTORS OF REMISSION WHEN LONG-
ACTING RISPERIDONE IS ADDED TO STANDARD
CARE IN PATIENTS WITH BIPOLAR DISORDER
WHO RELAPSE FREQUENTLY
Wayne Macfadden1, C. Adler2, N. Turner1, I. Turkoz1,
J. T. Haskins1, L. Alphs1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ,
USA; 2University of Cincinnati College of Medicine, Cincinnati,
OH, USA
Patients with bipolar disorder who relapse frequently can be a challenging
population to treat. Predicting which patients are more likely to achieve
remission may optimize their therapy and improve long-term outcomes.
This analysis examined whether specific patient characteristics at baseline
were associated with achieving remission in symptomatic patients with
bipolar disorder who relapse frequently. Post-hoc analysis was conducted
of the OL phase of an international study (United States and India) that
assessed risperidone long-acting injectable therapy (RLAT) or placebo as
adjuncts to treatment as usual (TAU) for bipolar disorder in delaying time
to relapse. During the 16-week, OL stabilization phase, RLAT (25, 37.7
or 50 mg intramuscular every 2 weeks) was administered adjunctively with
TAU (mood stabilizers, antidepressants and anxiolytics). Patients with
symptoms of depression (MADRS >10) or with manic or mixed symp-
toms (YMRS>10) at baseline were analyzed. Remission was defined as
MADRS 10, YMRS 10 and CGI 3 at the end of the OL stabilization
period (week 16). Subjects were stratified by patients who remitted vs
patients who did not remit. Statistical significance was determined using
Fisher’s exact test (categorical variables) and t test (continuous variables).
Predictors of remission were explored using univariate logistic regression
models. Study identification number: CR004693. Of 275 enrolled patients,
177 (64.4%) were not in remission at OL baseline. At the end of the
16-week, OL stabilization phase, 100 of these 177 patients completed the
16-week, OL phase and remitted (56.5%). A higher percentage of patients
from India vs the United States remitted (70.9% vs 32.8%; OR: 5.0,
95% CI: 2.6–9.6; P < .0001), and a lower percentage of females vs males
remitted (35.2% vs 70.8%; OR: 0.23; 95% CI: 0.12-0.43; P < .0001).
Patients without substance abuse were more likely to remit than those
with substance abuse (62.5% vs 40.8%; OR: 2.4, 95% CI: 1.2–4.7;
P = .01). Patients who remitted had a lower baseline CGI-BP-S score
than patients who did not remit (3.9 vs 4.2; OR: 0.68; 95% CI: 0.48–
0.94; P = .02). These analyses identify several demographic and baseline
clinical characteristics associated with achieving remission after treatment
with RLAT when used adjunctively with TAU in symptomatic patients
with bipolar disorder. Additional analyses are necessary to clarify these
relationships. Supported by Ortho-McNeil Janssen Scientific Affairs,
LLC.
ID: 551841
PATIENT ASSESSED QUALITY OF LIFE (PQ-LES-Q)
VS. CLINICIAN ASSESSMENT (PANSS, CGI) IN
A TRIAL OF ARIPIPRAZOLE IN ADOLESCENT
PATIENTS WITH SCHIZOPHRENIA: TREATMENT
ARM ANALYSIS
Richard Eric Whitehead1, A. Pikalov1, N. Jin2, M. Ali2, E. Kim3,
M. Nyilas4, W. H. Carson4, T. Iwamoto4, S. A. Wisniewski5
1Medical Affairs, Otsuka America Pharmaceutical, Inc., Rockville,
MD, USA; 2Biostatistics, Otsuka Pharmaceutical Development and
Commercialization, Inc., Rockville, MD, USA; 3Health Economics
and Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ,
USA; 4Global Clinical Development, Otsuka Pharmaceutical
Development and Commercialization, Inc., Princeton, NJ, USA;
5Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA
Background: The self administered Pediatric Quality of Life Enjoyment
and Satisfaction Questionnaire (PQ-LES-Q(T)) is made up of 14 items
that assess aspects of quality of life and a 1 item overall (O) assessment.
We previously showed a strong correlation between physician and patient
assessment in treatment improvement. The purpose of this post hoc
analysis was to assess the same correlations by treatment arm. Methods:
302 children (age 13–17) with schizophrenia participated in a 6-week,
multicenter, randomized trial. It examined 2 fixed doses of aripiprazole
(10 and 30 mg/day) vs. placebo. The primary measure was mean change
on PANSS Total score (LOCF). Secondary measures included: mean
changes on CGI-S and PQ-LES-Q(T) and (O). Descriptive statistics of
change from baseline in PQ-LES-Q(T) and (O) score were summarized
by category of change in PANSS and CGI-S. Trend analysis explored
the relationship between the PQ-LES-Q(O) and CGI-S score using the
a Cochran-Mantel-Haenszel correlation. Results: Aripiprazole showed sig-
nificant improvements over placebo in PANSS, CGI-S, and PQ-LES-Q(O)
(week 6; P < .05; LOCF). Strong correlation was found between all meas-
ures when treatment arms were combined. This includes PQ-LES-Q(T) vs.
PANSS Total and PQ-LES-Q(O) vs. CGI-S (r  .37; P  .01). Analysis by
treatment arm (10mg, 30mg and placebo) showed strong correlation be-
tween change in PQ-LES-Q(T) vs. change in PANSS(T) in the 10mg,
30mg, and placebo groups (r  0.269; P < .011; LOCF). Correlation be-
tween change in PQ-LES-Q(O) vs. change in CGI-S was significant in the
10mg group (r =0.277; P = .0063; LOCF) but not for the 30mg and placebo
International Congress on Schizophrenia Research
22. 22. Therapeutics: Treatment Trials 363
 at Cold Spring H
arbor Laboratory-Library on February 20, 2013
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
groups (r  0.084). When the 3 treatment arms were combined and CGI-S
improvement was put into 4 categories (no improvement in CGI-S Score;
improvement of 1; improvement of 2; improvement of 3), change in PQ-
LES-Q(O) correlated with CGI-S change from baseline (P = .0037;
LOCF). When separated by treatment arm, correlation in the 10mg arm
remained significant (P = .002) while the 30mg and placebo arms were
not. Conclusions: There is significant correlation between improvement in
patient assessment (PQ-LES-Q(T)) and clinician disease state assessment
(PANSS Total score). It is seen both when treatment arms are combined
or analyzed separately. There is significant correlation between improvement
in patient assessment (PQ-LES-Q(O)) and clinician global assessment (CGI-
S) for 10mg arm and for treatment arms combined.
ID: 551758
A CLINICAL RESEARCH PROGRAM FOR THE
TREATMENT OF SCHIZOAFFECTIVE DISORDER
Colette Kosik-Gonzalez1, C. M. Canuso1, J. Carothers1,
A. Kalali2,3, J. P. Lindenmayer4, I. Turkoz1, N. Schooler5
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville,
NJ, USA; 2Quintiles Inc., San Diego, CA, USA; 3University of
California-San Diego, San Diego, CA, USA; 4New York University
School of Medicine, New York, NY, USA; 5SUNY Downstate
Medical Center, Brooklyn, NY, USA
Although treatment of schizophrenia and bipolar disorder has been the fo-
cus of extensive clinical research, schizoaffective disorder (SCA) remains
understudied. We present key design elements from the first registration
program in SCA, as well as the demographic and clinical characteristics
of this population at study entry. The registration program consisting of
two international, double-blind, placebo-controlled studies assessed pali-
peridone ER in patients with SCA. Included subjects met SCID-confirmed
DSM-IV criteria for SCA; PANSS total score60, a score of4 on at least
two of the PANSS items of hostility, excitement, tension, uncooperative-
ness and poor impulse control and prominent mood symptoms (16 on
YMRS and/or on HAM-D-21). Concomitant antidepressants and/or
mood stabilizers were permitted, if given at stable dose within 30 days
of screening. The primary endpoint was the PANSS total score change
at endpoint for paliperidone ER vs placebo. Secondary efficacy measures:
the novel CGI-Severity for Schizoaffective Disorder (CGI-S-SCA) and -
Change (CGI-C-SCA) scales, the YMRS and the HAM-D-21 scales. 614
patients were in the combined ITT population; 40.4% were from the US
and 59.6% were ex-US. Mean age was 37.4 years (range 18–61); 60.4%
were male and 48.9% were Caucasian. Mean ages at first psychiatric
and first schizoaffective diagnoses were 25.2 (range 4–56) and 31.7 (range
3–61) years, respectively. Approximately 45% of patients were taking con-
comitant antidepressants and/or mood stabilizers. 68.9% of patients were
diagnosed with bipolar subtype of schizoaffective disorder and 31.1% were
diagnosed with depressive subtype. 31.4% of patients had attempted suicide
in their lifetime; 47.9% of those patients made at least two or more attempts.
Mean (SD) baseline PANSS total score was 92.8 (12.9) and mean (SD)
baseline CGI-S-SCA score was 4.6 (0.6). The percentages of patients
with YMRS 16 or HAM-D-21 16 at baseline were 79.5% and 66.9%,
respectively. The percentage of patients with both YMRS and HAM-D-
2116 at baseline was 46.4%. To our knowledge, this clinical program rep-
resents the first registration trials focused specifically on SCA. Baseline fea-
tures reflect the prominence of psychotic and affective symptoms distinctive
of this disorder. This database will provide valuable information regarding
the characteristics and treatment of this understudied patient population.
Supported by Ortho-McNeil Janssen Scientific Affairs, LLC.
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‘‘TIME COURSE FOR RESPONSE TO OLANZAPINE
AND RISPERIDONE IN FIRST-EPISODE SCHIZO-
PHRENIA’’
Juan Andre Gallego1, D. G. Robinson1,2,
B. Napolitano1,3, M. L. Lesser1,3, S. M. Sevy1,4, J. McCormack1,2,
J. M. Kane1,2
1Psychiatry Research, Zucker Hillside Hospital, Glen Oaks, NY,
USA; 2Center for Translational Psychiatry, The Feinstein Institute
for Medical Research, Glen Oaks, NY, USA; 3Biostatistics Unit,
The Feinstein Institute for Medical Research, Glen Oaks, NY, USA;
4Psychiatry, Albert Einstein College of Medicine, Bronx, NY, USA
Objective: Few studies have examined the time course to response in schizo-
phrenia. Studies with multi episode patients have attempted to identify sub-
jects who will ultimately not meet study response criteria based upon
response during the first weeks of the trial (Correll 2003, Kinon 2008,
Leucht 2007). Very few studies have examined treatment response with
a first episode population. Emsley et al. (2006) analyzed data from 400 first
episode patients who responded within 12 weeks to treatment with either
risperidone or haloperidol. Their finding that time to response varied
widely and that 11.5 % of responding patients improved first after week
8 suggests that first episode patients may have different response patterns
than multi-episode patients. To further knowledge about response patterns
of first episode patients, we examined time to response over a 16 week pe-
riod to treatment with the widely used second generation antipsychotics
olanzapine or risperidone. Methods: 112 subjects (70% male; mean age
23.3 years) with first-episode schizophrenia, schizophreniform disorder
or schizoaffective disorder were randomly assigned to olanzapine (2.5 to
20 mg daily) or risperidone (1 to 6 mg daily). Two different response criteria
models were examined: 1) A model based on absolute criteria, which re-
quired ratings on 2 consecutive visits of mild or better on the SADS-
CþPD psychosis items plus a rating of much or very much improved on
the CGI; 2) A model based on a reduction of more than 20% on the
SADS-CþPD. To allow for comparison with prior studies, the SADS-
CþPD items that correspond to the BPRS items were chosen for this anal-
ysis. Different models of hazard function models (exponential, weibull,
lognormal) were used to analyze time course to response. Results: 49%
(95% CI: 39%, 60%) of patients met response criteria based on the absolute
response criteria at the end of week 16. The cumulative response rate at
week 16 based on a 20% reduction was 93% (95% CI: 87 to 99%). Based
on graphical methods and examination of the Pearson correlation coeffi-
cients, the exponential model compared to the Weibull and Lognormal
models provided the best fit. Conclusion: Time to treatment response to
atypical antipsychotics differ between first episode and multi-episode
patients. The exponential model provided the best fit to describe treatment
response in this study. Our data suggests that treatment trials with first
episode patients should last at least 16 weeks.
ID: 551739
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF FLEXIBLE-DOSE PALI-
PERIDONE ER IN THE TREATMENT OF PATIENTS
WITH SCHIZOAFFECTIVE DISORDER
Carla Canuso1, N. Schooler2, C. Kosik-Gonzalez1, J. Carothers1,
I. Turkoz1, J. P. Lindenmayer3
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville,
NJ, USA; 2SUNYDownstateMedical Center, Brooklyn, NY, USA;
3Georgetown University School of Medicine, Washington, DC, USA
Schizoaffective disorder (SCA) is a common mental illness with no estab-
lished treatment guidelines. Although antipsychotics are the cornerstone of
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treatment for these patients, their use has not been systematically evaluated
in clinical trials either alone or in combination with other psychotropic
agents. Data are presented from one of two registration trials of paliper-
idone extended-release (ER) in patients with schizoaffective disorder.
A randomized, 6-week, international, double-blind, placebo-controlled
study enrolled SCA subjects experiencing acute exacerbation. Inclusion cri-
teria: SCID-confirmed DSM-IV diagnosis of SCA; PANSS total score60;
score 4 on two or more PANSS items of hostility, excitement, tension,
uncooperativeness or poor impulse control; and prominent mood symp-
toms (16 on YMRS and/or on HAM-D-21). Stable doses of antidepres-
sants/mood stabilizers were permitted. Patients were randomized in a 2:1
ratio to 6 mg/day paliperidone ER or placebo. Dosages could be adjusted
(3-12 mg/day) up to day 15; no adjustments could be made thereafter. Pri-
mary endpoint: PANSS total score change at endpoint for paliperidone ER
vs placebo. Secondary endpoints: YMRS and HAM-D-21 scores and ad-
verse events (AEs). Study identification number: CR013099. 311 subjects
were randomized to paliperidone ER (n = 216) or placebo (n = 95);
52.1% received concomitant antidepressants and/or mood stabilizers.
63.5% of paliperidone ER and 55.9% of placebo patients completed the
study. Mean (SD) modal dose of paliperidone ER was 8.6 (2.5) mg/day.
There was significant improvement with paliperidone ER vs placebo on
mean (SD) PANSS total change score (20.0 [18.9] vs 10.8 [18.7.4];
P < .001) and on all five PANSS factor scores (P < .05). Among patients
with prominent manic or depressive symptoms, paliperidone ER showed
significant improvement vs placebo on mean (SD) YMRS (10.6 [10.8]
vs 5.7 [10.0]; P = .001) and HAM-D-21 (10.2 [8.7] vs 6.2 [8.6]; P <
.001) change scores. Most common AEs (5%) for paliperidone ER vs pla-
cebo: headache (15.0% vs 12.6%), akathisia (6.1% vs 1.1%), dizziness (8.4%
vs 5.3%), insomnia (6.5% vs 5.3%) and dyspepsia (5.6% vs 5.3%). This study
demonstrated the efficacy and effective dosing of flexible-dose paliperidone
ER in this understudied population with no unexpected tolerability issues.
These findings were consistent with another similarly designed registration
study of paliperidone ER in SCA. Supported by Ortho-McNeil Janssen Sci-
entific Affairs, LLC.
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A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF TWO DOSE RANGES OF
PALIPERIDONE ER IN THE TREATMENT OF
SUBJECTS WITH SCHIZOAFFECTIVE DISORDER
Jennifer Carothers1, C. M. Canuso1, J. P. Lindenmayer2,
C. Kosik-Gonzalez1, I. Turkoz1, N. Schooler3
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ,
USA; 2Georgetown University School of Medicine, Washington,
DC, USA; 3SUNYDownstateMedical Center, Brooklyn, NY, USA
Schizoaffective disorder (SCA) is common among patients with mental ill-
ness. Although antipsychotics are widely used, they have not been system-
atically studied in this population, and no treatment is specifically indicated
for this disorder. Data are presented from one of two registration trials of
paliperidone extended-release (ER) in patients with SCA. A randomized,
6-week, international, double-blind, placebo-controlled study enrolled
SCA subjects experiencing acute exacerbation. Inclusion criteria: SCID-
confirmed DSM-IV diagnosis of SCA; PANSS total score 60; score
4 on two or more PANSS items of hostility, excitement, tension, unco-
operativeness or poor impulse control; and prominent mood symptoms
(16 on YMRS and/or on HAM-D-21). Stably dosed antidepressants/
mood stabilizers were permitted. Patients were randomized to placebo, pal-
iperidone ER 6 mg/day (lower dose) or 12 mg/day (higher dose). Doses
could be reduced to 3 mg/day and 9 mg/day, in the lower- and higher-
dose groups, respectively, with optional increases to initially assigned
dose; no adjustments after day 15. Primary endpoint: PANSS total score
change at endpoint for each paliperidone ER group vs placebo. Study iden-
tification number: CR010498. 316 subjects were randomized to 6 mg/day
paliperidone ER (n = 109), 12 mg/day paliperidone ER (n = 100) or placebo
(n = 107); 38.9% received concomitant antidepressants and/or mood stabil-
izers. Completion rates were 68.6%, 78.6%, and 59.4%, respectively. Mean
(SD) modal daily doses in the lower- and higher-dose groups were 5.7 (0.9)
and 11.6 (1.0) mg/day, respectively. Mean (SD) PANSS total score was sig-
nificantly improved with higher-dose paliperidone ER vs placebo (30.6
[19.1] vs 21.8 [21.4], P = .003). Change with lower-dose paliperidone
ER (27.4 [22.1]) was similar to placebo (P = .200). Higher-dose paliper-
idone ER was significantly better than placebo on most secondary efficacy
endpoints. Similar findings were observed for mania and depression scores
in patients with prominence of these affective symptoms. Most common
AEs: headache (placebo 16.8%, lower-dose 13.9%, higher-dose 13.3%)
and tremor (3.7%, 12.0%, 11.2%, respectively). This study demonstrated
the efficacy, safety, and effective dosing of paliperidone ER in this under-
studied population. Improvement was consistently observed for higher-
dose paliperidone ER vs placebo. Similar findings were observed in a
second, flexible-dose study. Supported by Ortho-McNeil Janssen Scientific
Affairs, LLC.
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EVALUATION OF THE EFFECTS OF AL-108 ON
NEUROCOGNITION IN SCHIZOPHRENIA: INITIAL
TURNS STUDY RESULTS
Daniel C. Javitt1, R. W. Buchanan2, J. A. Lieberman3,
R. S. Keefe4, S. R. Marder5
1Psychiatry, Nathan Kline Institute/NYU Langone School of
Medicine, Orangeburg, NY, USA; 2Psychiatry, Maryland
Psychiatric Research Center, Baltimore, MD, USA; 3Psychiatry,
New York State Psychiatric Institute, Coumbia University,
New York, NY, USA; 4Psychiatry, Duke University Medical
School, Durham, NC, USA; 5Semel Institute, UCLA, Los Angeles,
CA, USA
Background: Persistent neurocognitive dysfunction is a primary predictor
of impaired long-term outcome in schizophrenia. At present, no treatments
are specifically approved for treatment of cognitive impairments in schizo-
phrenia. TURNS (Treatment Units for Research on Neurocognition and
Schizophrenia) is an NIMH-funded multicenter consortium focused on
identifying and evaluating promising new treatments for persistent neuro-
cognitive dysfunction. AL-108 is an intranasal drug product containing
NAP, an 8 amino-acid peptide (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; NAPV-
SIPQ, MW = 824.9) fragment of the much larger Activity-Dependent Neu-
roprotective Protein (ADNP), which participates in neurodevelopment and
neuroprotection. AL-108 acts, in part, by stabilization of microtubular
structure. AL-108 is active in rodent models of neurodegeneration and
was originally developed for treatment of neurocognitive dysfunction in
Alzheimers disease and mild cognitive impairment. This poster will report
initial results of a multicenter study of AL-108 in schizophrenia. The study
is due for completion in 2/2009, with initial statistical analysis scheduled for
3/2009. Study design: The study consists of a 12-week, parallel group ran-
domized clinical trial of 2 doses of AL-108 (4 and 30 mg/d intranasally) vs.
placebo. Subjects are 18–60 yr old male and female patients with DSM-IV
diagnosis of schizophrenia being treated with oral second generation anti-
psychotics or first generation injectables with controlled positive and neg-
ative symptoms. The primary outcome measure consists of the composite
score of the MATRICS Consensus Cognitive Battery (MCCB). Secondary
outcome measures include BPRS and SANS symptom rating scale scores,
functional capacity scores and safety assessments. Targeted n is 60 subjects.
Results: As of August, 2008, 50 patients had been randomized. The treat-
ment was well tolerated with no medication related SAEs observed across
subjects. The study is projected to complete in 2/2009, with initial statistical
analysis to be performed in 3/09. Study results will be presented. Discussion:
AL-108 is a novel peptide being investigated for treatment of AD. This
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report will provide the first assessment of its clinical effectiveness in
schizophrenia.
ID: 551596
ALL SOURCE VERIFICATION: A NEW TOOL FOR
MEASURING ADHERENCE IN SCHIZOPHRENIA
CLINICAL TRIALS
Nina R. Schooler1, A. Sunakawa1, P. J. Weiden2
1Department of Psychiatry and Behavioral Sciences,
SUNY Downstate Medical Center, Brooklyn, NY, USA;
2Department of Psychiatry, University of Illinos-Chicago,
Chicago, IL, USA
Plasma concentrations and electronic monitoring are the gold standard in
determining adherence to medication but are impractical in many settings.
Other assessment techniques include patient questionnaires, pill counting,
clinician judgments based on patient and caregiver reports and review of
pharmacy records. Each method has limitations and advantages. We
have developed a method—All Source Verification (ASV) that integrates
multiple sources of information. Methods: The ASV includes prescriptions,
pharmacy records, other medication sources (eg, samples) the Treatment
Compliance Interview (TCI), based on patient report, clinician and fam-
ily/caregiver judgments. An integrated rating is based on all available in-
formation. The ASV was used in a randomized clinical trial—PREFER
(PREventing First Episode Relapse—that compared long-acting injectable
risperidone microspheres to oral antipsychotics in first episode schizophre-
nia patients in the community. Adherence was assessed over 52 weeks for all
randomized subjects. Non-adherence was defined by the first 14-day med-
ication gap. The TCI was administered at weeks 12, 36 and 52. We com-
pared the TCI report of adherence with the ASV judgments to determine
whether ASV added information regarding non-adherence. Results: There
were thirty seven subjects in the trial. At week 12, 2 (5.4%) had a gap ac-
cording to TCI compared to 10 (27%) according to ASV (v2 = 5.71 df1, P<
.01. By week 52, the percentages were 29.7% and 70.3% respectively (v2 6.62
df 1, P< .01. Discussion: To our knowledge, this is the first clinical study to
use a multi-pronged approach that includes pharmacy records to assess ad-
herence behavior. In addition to the overall adherence judgment, the ASV
permits comparison of estimate based on each source. In the present study,
ASV significantly increased estimates of non-adherence compared to pa-
tient report. This is consistent with other studies that suggest that patient
report may underestimate non-adherence. Limitations of this study include
its small size, the fact that ASV ratings were made by a non-blind rater and
involved consensus judgments. At present, the method is labor-intensive
and will not be suitable for clinical use or very large RCTs. However,
ASV emphasizes the value of multiple sources of information. It further
underscores the high risk for non-adherence of first episode patients and
the degree to which they fail to report this to clinicians.
ID: 551580
CLOZAPINE VS. RISPERIDONE FOR PEOPLE WITH
FIRST EPISODE SCHIZOPHRENIA AND
CO-OCCURRING CANNABIS USE DISORDER
Douglas Louis Noordsy, J. F. Marshall, J. N. Smith,
A. I. Green
Psychiatry, Dartmouth Medical School, Lebanon, NH, USA
Schizophrenia (SCZ) with comorbid substance use disorder is associated
with increased morbidity and mortality. Early in the course of SCZ, can-
nabis is one of the most commonly abused substances. Patients with SCZ
who use cannabis have an earlier age of onset, higher rate of relapse and
a poorer outcome than those without cannabis use disorder (CUD); and
continued use after anti-psychotic treatment is associated with an even
worse outcome. Repeated relapse has been associated with progression
of SCZ to a more chronic and treatment resistant illness. Clozapine is
the most effective antipsychotic and has been shown to increase time in re-
mission for first episode patients (relative to chlorpromazine), and to de-
crease cannabis use in patients with schizophrenia. Thus, patients with first
episode SCZ and co-occurring CUD may be appropriate candidates for the
use of clozapine, in an attempt to improve the long-term course of this
disorder. This pilot study is assessing whether treating patients with first
episode SCZ and comorbid CUD with clozapine will lead to increased ab-
stinence from cannabis as compared to those treated with risperidone
over 24 weeks of treatment. As a secondary objective, the study is
assessing whether patients treated with clozapine will have improved global
functioning, clinical symptoms, psychosocial functioning and neurocogni-
tive functioning, as compared to those receiving risperidone. The study
population (an eventual sample of 21) includes patients between the
ages of 17–45 who are in their first episode of SCZ and have a comorbid
CUD. Participants are randomized to clozapine or risperidone for 24 weeks
and medication drop-outs are followed in intent-to-treat fashion. Partici-
pants are assessed for: (a) continued cannabis and other substance use each
week using a Time Line Follow Back interview; (b) clinical symptoms every
4 weeks using the BPRS, SANS, and CGI; (c) psychosocial functioning ev-
ery 4 weeks using a structured interview; and (d) neuropsychological func-
tioning every 12 weeks using the BACS. We will present preliminary data on
sample demographics, baseline characteristics, and treatment parameters.
ID: 551539
TRAJECTORIES OF ANTIPSYCHOTIC RESPONSE:
MOVING BEYOND THE RESPONDER/
NON-RESPONDER DICHOTOMY
Shitij Kapur1, T. Arenovich3, O. Agid3, G. Sajeev3, B. Muthen1,
L. C. Chen2, B. Kinon2
1Institute of Psychiatry, London, United Kingdom; 2Eli Lilly,
Indiannapolis, IN, USA; 3Research, CAMH, Toronto, ON, Canada
Objective: When clinical trials are analyzed in groups with a focus on end-
of-trial outcomes, ie, drug versus placebo resulting in responders versus
non-responders, it obscures the tremendous inter-individual variation
across patients. We hypothesized that an approach based on individual tra-
jectories through the trial, rather than an end-point analysis, would provide
a statistically superior and clinically more meaningful way for conceptual-
izing response. Method: We examined data on 420 patients with schizo-
phrenia treated for six weeks in two double-blind placebo-controlled
trials using haloperidol and olanzapine. Their weekly response data
were examined using conventional methods and growth mixture modelling
to identify the optimal number of response trajectories. We examined if
these trajectories were similar across drug and placebo and across different
symptom dimensions. Results: Positive symptoms respond along four dis-
tinct trajectories: the two most common trajectories were the ‘partial re-
sponder’ (48%) and ‘responder’ (22%), to which drug-treated and
placebo-treated patients contribute equally. The most striking drug-
placebo differences were in the ‘dramatic responders’ (10%), who are
exclusively drug-treated patients, and the ‘non-responders’ (20%), who
are predominantly on placebo. The response of negative symptoms was
more modest and did not show such distinct trajectories. Conclusions:
Four distinct trajectories of response, rather than simple responder/non-
responder models, provide a much better statistical and heuristic under-
standing of how antipsychotics work. The data show that there are no
simple ‘‘drug response type’’ versus ‘‘placebo response type’’, thought
the most striking responses are observed only in the drug-treated. Since
this approach is data driven and does not make any apriori categorizations,
we hypothesize that groups defined by such trajectories are much more
likely to correlate to underlying genetics and biology than simple
dichotomous categorizations.
ID: 551471
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DOES CATATONIC SCHIZOPHRENIA IMPROVE
FASTER WITH ELECTROCONVULSIVE THERAPY
THAN OTHER SUBTYPES OF SCHIZOPHRENIA?
Jagadisha Thirthalli, V. H. Phutane, M. Kesavan,
C. Naveen Kumar, M. Bharat, P. Baspure, B. N. Gangadhar
Psychiatry, National Institute of Mental Health and Neurosciences,
Bangalore, India
Treatment guidelines recommend the use of electroconvulsive therapy
(ECT) for catatonic schizophrenia. In the Indian setting, many non-cata-
tonic schizophrenia patients also receive ECT. In this study, we compared
the response to ECT of catatonic schizophrenia versus other subtypes of
schizophrenia. Consecutive schizophrenia inpatients (n = 53) referred for
ECT within three months of starting antipsychotic treatment were studied.
This included 19 with catatonic schizophrenia (Bush Francis Catatonia
Rating Scale  2) and 34 with non-catatonic schizophrenia. Behavioural
observation was assessed using Nurse’s Observation Scale for Inpatient
Evaluation (NOSIE-30) by a trained rater. ECT was administered thrice
weekly and assessments were done at baseline, at the end of 2nd, 4th,
6th, 8th, 10th, 12th and 14th ECT sessions. The treating psychiatrists de-
cided to terminate ECT and the total number of ECTs required to achieve
clinical response was taken as an indirect measure of speed of response.
Changes in NOSIE-30 scores between the groups were compared using re-
peated measures analysis of variance. The total number of ECTs adminis-
tered in each group was compared using survival analysis. Table shows
change of NOSIE scores during the first two weeks of treatment. There
was a significant group X occasion effect in NOSIE total patient asset
scores, suggesting faster response to ECT in the catatonia group (F =
5.42; df = 3, 150; P = .001). Survival analysis suggested that patients
with catatonic schizophrenia required significantly fewer ECTs (one less
ECT session on an average) to achieve clinical improvement (Log-rank sta-
tistic = 5.31;P = .02). Catatonic schizophrenia patients show faster response
to ECT than non-catatonic schizophrenia patients. However, the magni-
tude of the difference is modest.
Table. Comparison of NOSIE total patient asset score across time. Figures
are in mean (SD)
Assessment
Time
Catatonic
Schizophrenia
(n = 19)
Non-catatonic
Schizophrenia
(n = 34)
Baseline 65.2 (12.0) 83.3 (17.4)
After 2nd ECT 100.3 (9.7) 105.1 (17.7)
After 4th ECT 132.8 (14.1) 125.5 (17.5)
After 6th ECT 166.3 (14.8) 142.9 (17.3)
For this analysis, data was taken only from the first 2 weeks, as very few
patients received ECT beyond this time.
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AMISULPRIDE IMPROVES OBSESSIVE-
COMPULSIVE SYMPTOMS IN SCHIZOPHRENIA
PATIENTS TAKING ATYPICAL ANTIPSYCHOTICS:
AN OPEN-LABEL SWITCH STUDY
Sung-Wan Kim, I. S. Shin, J. M. Kim, S. J. Yang, T. Youn,
J. S. Yoon
Chonnam National University Hospital, Gwang-ju, South Korea
Objective: Atypical antipsychotics with a 5-HT2a antagonist effect have
been reported to induce or exacerbate obsessive-compulsive symptoms
(OCS) in patients with schizophrenia. We aimed to evaluate the effect of
amisulpride on OCS that occurred in patients with schizophrenia, who
were taking atypical antipsychotics. Methods: Subjects with a Yale-Brown
Obsessive Compulsive Scale (Y-BOCS) score of 10 or greater and taking
atypical antipsychotics were recruited. Their OCS were observed for
changes 12 weeks after their antipsychotic medications were changed to
amisulpride, which is a selective dopamine D2/D3 receptor antagonist
with a negligible affinity for the 5-HT2a receptor. Results: Thirteen patients
taking risperidone and three patients taking aripiprazole were enrolled and
fifteen patients completed the study. Improvements in the YBOCS scores
were statistically significant. Twelve of the sixteen patients showed 50%
or greater improvement in the YBOCS total score. The scores of the
Positive and Negative Syndrome Scale (PANSS) also significantly de-
creased following the switch to amisulpride, but there was no significant
relationship between the changes of the YBOCS and PANSS scores.
Conclusion: In conclusion, amisulpride was effective at improving OCS re-
lated to the use of risperidone or aripiprazole. This case series supports the
hypothesis that switching from antipsychotics antagonizing 5-HT2a recep-
tors, which have the potential to induce or exacerbate OCS, to amisulpride,
which has a negligible affinity for the serotonin 5-HT2a receptor, may be
a good treatment option for the management of OCS in patients with
schizophrenia.
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EVALUATION OF THE EFFECT OF ARIPIPRAZOLE
ON COGNITIVE FUNCTION AND WEIGHT
CHANGE IN SCHIZOPHRENIA: AN OPEN-LABEL
STUDY
Joseph Peuskens1, A. De Nayer2, H. Mourad3, B. Roussard4,
S. Geerts5, W. Kerselaers6, A. de Patoul6, W. H. Carson7,
R. D. McQuade7, V. Halkin6
1Universitaire Centrum Sint Jozef, Kortenberg, Belgium; 2Hoˆpital
Sainte The´re`se, Montignies-sur-Sambre, Belgium; 3CHP Petit
Bourgogne, Lie`ge, Belgium; 4Virga Jesse Ziekenhuis, Hasselt,
Belgium; 5Algemeen Ziekenhuis Sint Lucas, Brugge, Belgium;
6Bristol-Myers Squibb, Braine-l’Alleud, Belgium; 7Otsuka
Pharmaceutical Development and Commercialization Inc.,
Princeton, NJ, USA
Secondary outcomes related to cognitive function from a 12 week multicen-
ter open-label naturalistic study (1) examining the effectiveness of aripipra-
zole in patients with schizophrenia (DSM-IV) are reported here.
Aripiprazole was started at 15 mg/day and dosing adjustments were allowed
as per clinical judgement in the range of 10-30 mg/day. Cognitive function-
ing was measured by the California Verbal Learning Test (CVLT) indexes
and the letter and category Verbal Fluency (VF) tests. Mean change in cog-
nitive test scores and in body weight from baseline to Week 12 were calcu-
lated (LOCF) using descriptive statistics with 95% confidence intervals.
A total of 361 patients were treated in the study. At the study endpoint
(Week 12) patients showed improvements in all CVLT indexes and VF
tests. The average change in baseline body weight at Week 12 (LOCF)
was 1.5 Kg (95% CI: 1.94, 0.97) n = 328. Aripiprazole was well tol-
erated with the most common treatment related adverse event reported being
insomnia 14.13%N = 51/361. Schizophrenia patients treated with aripiprazole
in a naturalistic setting revealed modest improvements in list learning and
word generation measures of cognitive function. More rigorous, controlled
trials are needed to determine the nature and extent of potential cognitive
improvement with aripiprazole.
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1. Peuskens, et al. Poster presented at the European College of Neuropsy-
chopharmacology, 2008, Barcelona, Spain.
Table.
Baseline
[(BL) , n]
Week 12 (LOCF)
[Mean change
from BL 95% CI, (n)]
Verbal
Fluency
Letter fluency 20.2, n = 345 þ2.9 (2.04, 3.81), n = 301
Category fluency 27.2, n = 345 þ1.7 (0.83, 2.56), n = 301
CVLT
indexes
Free recall 42.2, n = 343 þ9.4 (8.18, 10.60), n = 297
Short delay free recall 8.3, n = 346 þ2.0 (1.62, 2.35), n = 297
Short delay cued recall 9.4, n = 345 þ 2.2 (1.85-2.53), n = 297
Long delay free recall 8.8, n = 345 þ1.9 (1.59, 2.30), n = 297
Long delay cued recall 9.7, n = 346 þ2.1 (1.72, 2.40), n = 295
Semantic clustering
index
1.3, n = 167 þ0.3 (0.15, 0.43), n = 122
Discriminability 89.7, n = 346 3.3 (2.30-4.22), n = 296
ID: 551284
NEUROSTEROIDS AS NOVEL THERAPEUTIC
AGENTS IN SCHIZOPHRENIA AND PTSD
Christine E. Marx1,2, R. S. Keefe1, V. M. Payne1,2, J. D. Kilts1,2,
J. L. Strauss1,2, J. C. Naylor1,2, R. M. Hamer4, R. W. Buchanan3,
J. A. Lieberman5, L. J. Shampine1,2, M. W. Massing2
1Psychiatry and Behavioral Sciences, Duke University Medical
Center, Durham, NC, USA; 2Durham VAMedical Center, Durham,
NC, USA; 3Maryland Psychiatric Research Center, Baltimore,MD,
USA; 4Psychiatry, University of North Carolina, Chapel Hill, NC,
USA; 5Psychiatry, Columbia University College of Physicians and
Surgeons, New York, NY, USA
Background: Many neurosteroids demonstrate pronounced neuroprotec-
tive, anxiolytic, and cognition-enhancing actions in rodents, properties
that suggest therapeutic potential for schizophrenia and PTSD. Further-
more, clozapine and SSRIs markedly elevate brain neurosteroid levels to
physiologically relevant concentrations. Brain neurosteroids are also al-
tered in patients with schizophrenia and reductions in peripheral neuroste-
roid levels are associated with PTSD symptomatology. In addition, certain
neurosteroids are positive NMDA receptor modulators and may poten-
tially ameliorate NMDA receptor hypofunction in schizophrenia. We
therefore conducted two pilot randomized controlled trials (RCTs) utilizing
adjunctive pregnenolone (PREG) in patients with 1.) schizophrenia, and 2.)
PTSD. Methods: Both proof-of-concept investigations randomized
patients to 8 weeks of adjunctive PREG (fixed escalating doses), or placebo,
following a 2-week placebo lead-in phase. Outcomes not reported previ-
ously include the Clinical Global Impressions-Improvement (CGI-I) Scale,
the Heinrich-Carpenter Quality of Life (HC-QOL) Scale, lipid profiles, and
baseline neurosteroid levels in relationship to MATRICS and BACS assess-
ments, among others. Results: 1) Schizophrenia RCT (n = 18; 9 per group):
Patients receiving PREG demonstrate significant improvements in the
CGI-I scale at study completion compared to the placebo group. The
HC-QOL Scale scores were improved by 5.27 points in the PREG group.
Baseline neurosteroid levels are positively correlated with cognitive
improvements, as assessed by MATRICS composite scores. LDL and cho-
lesterol levels (non-fasting) are significantly decreased post-treatment in
patients receiving PREG. 2) PTSD RCT (n = 17; 10 placebo / 7 PREG):
Effect sizes comparing the PREG and placebo completer groups for the
Beck Depression Inventory-II and the Connor-Davidson Resilience Scale
are 0.36 and 0.48, respectively. Increases in serum pregnanolone levels are
correlated with cognitive improvements in BACS composite scores. LDL
levels (non-fasting) are decreased in 6 of the 7 patients receiving PREG.
PREG was well-tolerated in both RCTs. Conclusions: Neurosteroids may
demonstrate promise as mechanistically novel therapeutic agents in schizo-
phrenia and PTSD. Pregnenolone was well-tolerated and associated with
reductions in non-fasting serum LDL levels post-treatment. These molecules
may also have biomarker utility for the assessment of clinical response.
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OUTCOME EVALUATION OF SOLUTIONS FOR
WELLNESS AND TEAM SOLUTIONS PROGRAM IN
PATIENTS WITH SEVERE MENTAL ILLNESS
Anzalee Khan1,2, J. P. Lindenmayer3,1, D. Wance1, N. Maccabee1,
S. Kaushik4
1Manhattan Psychiatric Center, WardsIsland, New York, NY,
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Aim: Obesity is increasing at an alarming rate in the US especially in
patients with schizophrenia. Our study was designed to evaluate retrospec-
tively the outcome of the effectiveness of the Solutions for Wellness and
Team Solutions programs in a large, non selected inpatient sample.
Method: 275 inpatients with DSM-IV mental illness, at a tertiary care psy-
chiatric facility, were included in the 36-week comprehensive and manual-
ized educational programs that encourage healthy lifestyles for people with
chronic mental illness. Each of the eleven 12-week modules was tested be-
fore and after by 30 knowledge questions and levels of metabolic markers,
weight and BMI were recorded at three time points. Results: Of the 275
patients, significant increases in scores were observed for seven of the eleven
knowledge assessment modules. The greatest improvements in scores were
observed for the ‘‘Discharge Preparation (Avoiding Crisis Situations)’’,
‘‘Understanding Your Treatment’’ and ‘‘Fitness and Exercise’’. A signifi-
cant weight loss of 4.88 lbs was observed and a decrease in BMI. Significant
reductions were observed in glucose and triglycerides (P < .05), but not in
cholesterol levels controlling for patients on cholesterol medications.
26.18% presented with DM II, impaired fasting glucose, and/or impaired
glucose tolerance at baseline. Patients with impaired glucose tolerance
showed a significantly greater decrease in glucose level (P = .000). Group
differences were also observed for change in weight, with the DMII group
showing a slightly greater reduction of 5.98 lbs. 10 year CHD risk was com-
puted and 33.3% (n = 23) of patients with Metabolic Syndrome (MetS) at
baseline were at significantly greater risk (>5%) for developing a CHD
event as compared to those without MetS (21.78%, n = 44) (risk ratio =
1.64). Conclusion: Participants gained a significantly greater understanding
of healthy lifestyles with decreases in weight, BMI and key metabolic
markers, which may point to a possible interactive effect, whereby better
understanding of key parameters such as medications and symptoms may
support healthy lifestyles. A structured, manualized program on wellness
and psychoeducation can be successfully implemented in a large psychiatric
naturalistic inpatient setting. Results may help both clinicians and hospital
managers to implement similar programs or to include successful compo-
nents in existing programs addressing weight and metabolic abnormalities.
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PATTERNS AND PREDICTIVE VALUE OF EARLY
TREATMENT RESPONSE IN ADOLESCENTS WITH
SCHIZOPHRENIA-SPECTRUM DISORDERS
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Background: In acutely exacerbated patients with chronic schizophrenia,
the majority of symptomatic response occurs early on in treatment and
early non-response seems to be a reliable marker of later treatment non-
response. However, it is unknown whether these findings extend to adoles-
cents with schizophrenia. Methods: We examined time course and predic-
tive power of early response in 1) a 3-month, observational study of atypical
antipsychotics; and 2) an industry sponsored, 6-week, placebo-controlled
trial (RCT) of aripiprazole. In the ‘‘real-world’’ sample, we assessed
time course of CGI-S and GAF scores, and the prediction of presence/ab-
sence of a CGI-I score of much/very much improved for later/sustained re-
sponse status. In the RCT, we assessed the prediction of a >20% total
PANSS score reduction at week 1 and 2 for response or remission at end-
point. Analyses included survival models, sensitivity and specificity analy-
ses, and Receiver Operating Characteristics (ROC). Results: In 80
adolescents (15.2 years) with first episode schizophrenia (n = 32) or psycho-
sis NOS (n = 48) treated openly for 3 months(mean prior antipsychotic ex-
posure: 2.2 6 3.9 months, 58.4% antipsychotic naı¨ve), CGI-S and GAF
score reductions were significantly more pronounced in the first 4 weeks
vs. the following 8 weeks. The exponential survival model best fit
the response pattern for all patients, the schizophrenia and psychosis
NOS subsamples, and for simple and sustained response (R = 0.92–
0.97). In the RCT, 293 adolescents (15.5 years) were randomized to aripi-
prazole 10 mg (N = 99) or 30 mg (N = 97), or placebo (N = 98). By week 1, 2
and 3, 23–45%, 45–57% and 78–80% of the total PANSS score reduction were
achieved in the aripiprazole arms. A>20% PANSS score reduction at 2 weeks
predicted a >20% PANSS score reduction at study endpoint with 97.8%
specificity (NPV: 59.0%) and 47.5% sensitivity (PPV: 90.3%). In ROC
analyses, the optimum cut-off was a 10% PANSS total score reduction at
week 2 (sensitivity: 80.3%, specificity: 82.6%) for response, and a 13%
reduction at week 2 (sensitivity: 64.7%, specificity: 64.1%) for cross-sectional
‘‘remission’’. Conclusions: Data in adolescents with schizophrenia-
spectrum disorders confirm that most of the treatment response occurs
early. Early non-response was a better predictor of later non-response in
the RCT than in the naturalistic study that used more global outcome meas-
ures. Further studies in adolescents and real-world settings are needed.
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PREDICTORS OF PERSISTENCE ON TREATMENT
WITH OLANZAPINE AND OTHER ATYPICAL AN-
TIPSYCHOTIC MEDICATIONS IN PATIENTS WITH
SCHIZOPHRENIA
Hong Liu-Seifert, D. Lin, O. Osuntokun
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: Poor treatment response is an important factor that contributes
to a lack of persistence on treatment. The goals of this research were to
determine whether improvements in PANSS symptom domains predict
the likelihood of staying on treatment and whether differential responses
to treatment with various atypical antipsychotics in specific symptom
domains account for differences in discontinuation rates or persistence
on treatment. Methods: A post hoc analysis of pooled data from 5 random-
ized, double-blind, 24- to 28-week clinical trials in adult patients with
schizophrenia was conducted that included 1103 olanzapine-treated and
1090 risperidone-, quetiapine-, ziprasidone, or aripiprazole-treated
patients. The 5 factors of the Positive and Negative Syndrome Scale
(PANSS) were tested as potential predictors of persistence on treatment
for all treatment groups combined. Treatment differences in the 5 PANSS
factors and individual items were assessed between olanzapine and the
other 4 atypical antipsychotics combined. Results: Improvement in the
PANSS positive factor was the strongest predictor of persistence on treat-
ment irrespective of the specific medication (based on standardized scores,
hazard ratio [HR] = 1.58; 95% confidence interval [CI] = 1.40 1.79; P <
.0001). Improvement in the PANSS hostility (HR = 1.23; 95% CI =
1.11, 1.37; P = .0001) and depressive (HR = 1.15; 95% CI = 1.05, 1.2;
P = .0021) factors were also significant predictors, to a lesser degree, while
the negative and disorganized thoughts factors were not. Olanzapine-
treated patients showed significantly greater improvements at week 24
on the PANSS positive, hostility and depressive factors compared to
patients treated with other antipsychotics (P < .001 for all 3 factors). In
particular, a significant difference on the hallucination item was observed
at week 2 and was sustained throughout the treatment period. Conclusion:
The results suggest that significant improvement in positive symptoms
may be the best predictor of persistence on treatment, followed by signif-
icant improvement in hostility and depressive symptoms. Patients treated
with olanzapine experienced greater improvements in these specific symp-
tom domains compared to other atypical antipsychotics. These findings
may add to our understanding of why olanzapine-treated patients are
more likely to continue on treatment.
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DOES ZIPRASIDONE WORK BETTER IN LESS SE-
VERELY ILL PATIENTS OR IN OLDER PATIENTS?
Nigel Bark1,2, N. Lawson2, E. Trigoboff3, X. Huang1,2,
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This trial aimed to study State Hospital patients switched to ziprasidone to
see why it was not more widely used. Subjects from three State Hospitals who
needed a change of antipsychotic participated. For reasons unrelated to this
study one site (C) only recruited four subjects; a second (B) only recruited
outpatients; the third (A) only recruited inpatients. All subjects were evalu-
ated before the start and at weeks 1, 2, 4, 6 and 8. If on two antipsychotics one
was stopped before starting ziprasidone the second halved three days after
starting and stopped four days later. Ziprasidone (bid) was 80mg on day 1,
160mg day 2 and could be increased to 240mg after three weeks. 39 subjects
were recruited. The 17 outpatients from site B were very different from the 18
inpatients at site A: aged 53 (32 at A), all but two white (all but two African-
American and Hispanic at A) and with a baseline PANSS of 69 (92 at A).
Fifteen relapsed early. The inpatients that completed at site A barely im-
proved (PANSS 90). At site B the completers improved significantly ending
with PANSS of 56. Reduction in PANSS score was significantly related to
age but not to initial PANSS score or to previous medication dosage. Sub-
jects as a group reduced their prolactin level (45 to 22), improved metabolic
measures but prolonged their QTc (404 to 418). At site B outpatients did well
on ziprasidone. At all sites metabolic indicators improved. Continuing the
original antipsychotic longer could perhaps have prevented relapses. This
study suggests that less severe subjects do not respond better but that older
subjects may do so. However this could be confounded by other differences
between these outpatients and inpatients especially taking the medicine with
food. Such studies in the future should have blood levels to assure equal ab-
sorption. Supported by a grant from Pfizer Inc.
ID: 551168
DISCONTINUATION CHALLENGE IN REMITTED
FIRST EPISODE PSYCHOSIS: RELAPSE RATES AND
FUNCTIONAL OUTCOME COMPARED WITH
MAINTENANCE TREATMENT
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Objective: To compare the consequences of guided discontinuation strategy
and maintenance treatment in remitted first episode psychosis in terms of
relapse rates and functional outcome. Method: The study was conducted
in seven mental health services, covering a catchment area of 3.1 million
inhabitants. A sample of 131 remitted first episode patients, aged 18–45
years, diagnosed with schizophrenia or related psychotic disorder was in-
cluded. After six months of positive symptom remission they were randomly
and openly assigned to discontinuation strategy or maintenance treatment.
Maintenance treatment was carried out according to APA-guidelines, pref-
erably using low dose atypical antipsychotics. Discontinuation strategy was
carried out by gradual symptom-guided tapering of dosage and discontin-
uation if feasible. Follow-up was eighteen months. Main outcome measures
were relapse rates, and social and vocational functioning. Results: Twice as
many relapses occurred in discontinuation strategy (43% vs. 21%, P = .007).
Of patients who received the strategy 20% were successfully discontinued.
Recurrent symptoms caused another 30% to restart antipsychotics, while
in the remaining patients discontinuation was not feasible. The difference
regarding functional outcome was a trend favoring discontinuation strategy
in holding a job 16 hours a week (OR= 2.4,P= .06). Conclusions: Only a lim-
ited number of patients can be successfully discontinued. High relapse rates
do not allow discontinuation strategy to be universal practice. However, if
relapse risk can be carefully managed by close monitoring, in some remitted
first episode patients guided discontinuation strategy may offer a feasible
alternative to maintenance treatment. Further research is needed to find pre-
dictors of successful discontinuation.
ID: 551165
THE OPUS -TRIAL; A RANDOMISED MULTI-
CENTRE TRIAL OF INTEGRATED VERSUS STAN-
DARD TREATMENT FOR PATIENTS WITH A FIRST
EPISODE OF PSYCHOTIC ILLNESS—FIVE-YEARS
FOLLOW-UP
Merete Nordentoft1,2, M. Bertelsen1, A. Thorup1, P. Jeppesen1,2,
L. Petersen1
1Psychiatric Center Bispebjerg, Copenhagen, Denmark; 2Faculty of
Health Sciences, Copenhagen University, Copenhagen, Denmark
Context: Intensive early treatment for first episode psychosis have shown to
be effective. It is unknown if the positive effects are sustainable at five-year
follow-up. Objective: To determine long term effects of intensive early in-
tervention programme (OPUS) for first episode psychotic patients. Design:
Single-blinded randomised controlled clinical trial of two years of intensive
early intervention programme versus standard treatment. Follow-up was
two and five years. Setting: Copenhagen Hospital Corporation and Psychi-
atric Hospital Aarhus, Denmark Patients: 547 patients with a first episode
of psychosis. Participation was 369 patients at two-year follow-up and 301
at five-year follow-up. All 547 patients were followed for five years in the
registers. Interventions: Two years of intensive early intervention pro-
gramme (OPUS) versus standard treatment. OPUS treatment consisted
of ACT with manuals for family involvement and social skills training.
Standard treatment offered contact with a community mental health centre.
Main Outcome Measures: Psychotic and negative symptoms, secondary
outcome measures were service use and social functioning. Results:
Analysis was based on the principles of intention to treat. Assessment
was blinded for previous treatment allocation. At five-year follow-up we
found that the effect of the treatment seen after two years (psychotic dimen-
sion; 0.32 95% CI = 0.58 to 0.06, P = .02, negative dimension; 0.45
95% CI = 0.67 to 0.22, P = .001) had equalized between the treatment
groups. A significant smaller percentage of patients from the experimental
group were living in supported housing (4 % vs. 10%, OR 2.3, 95% CI = 1.1
to 4.8, P = .02) and were hospitalized fewer days (mean days 149 vs. 193,
mean difference 44, 95% CI = 0.15 to 88,12 P = .05) in the entire five-
year period. All other social outcome measures showed no significant dif-
ferences between the groups. Conclusions: The intensive early intervention
programme improved clinical outcome after two years of treatment, but
the effects were not sustainable up to five years after. We found a difference
on supported housing and use of bed days at the five-year follow-up in
favour of intensive early intervention programme.
Five-year follow-up of a randomized multicenter trial of intensive early in-
tervention vs standard treatment for patients with a first episode of psy-
chotic illness: the OPUS trial.
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A RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED, DOSE-RESPONSE
STUDY TO ASSESS EFFICACY AND SAFETY OF
PALIPERIDONE PALMITATE IN ADULT SUBJECTS
WITH SCHIZOPHRENIA
Gahan Pandina1, J. Lindenmayer2, J. Lull1, P. Lim1,
C. Gassmann-Mayer1, E. Yuen1, J. Palumbo1, S. Gopal1
1Pharmaceutical Research and Development LLC, Johnson and
Johnson, Raritan, NJ, USA; 2Department of Psychiatry, New York
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Efficacy and safety of 3 fixed doses of the investigational, injectable atypical
antipsychotic paliperidone palmitate (PALM) vs placebo (PBO) were
assessed in a 13-week, double-blind, multicenter study in subjects with
DSM IV schizophrenia. Adult subjects with acute exacerbation of schizo-
phrenia were randomly assigned in a 1:1:1:1 ratio to fixed dose PALM 25,
100, 150mg eq. or PBO. PALM groups received an initiation dose of PALM
150mg eq. in the deltoid muscle on Day 1, followed by the assigned fixed
dose (deltoid or gluteal muscle) on Day 8, and every 4 wks thereafter. ITT
analysis set (n = 636) included 67% men and 54% white (30% black); mean
(6SD) baseline PANSS total score = 87.1(611.21). Mean (6SD) changes in
PANSS total score from baseline to end point (primary outcome) showed
significant reductions (P  .034) in a dose-related manner for all 3 PALM
groups vs PBO: 25mg eq. =8.06 19.90; 100mg eq. =11.66 17.63; 150mg
eq. = 13.2 6 18.48 vs PBO (2.9 6 19.26). Significant improvement in
PANSS total score was observed at Day 8 for PALM 25mg eq. and
150mg eq., and at Day 22 for all PALM groups vs PBO and maintained
thereafter. Dose-related improvement in mean Personal and Social Perfor-
mance (PSP) scale scores was observed among PALM groups (25mg eq. =
2.9 [P = .509]; 100mg eq. = 6.1 [P = .007]; 150mg eq. = 8.3 [P< .001]) vs PBO
(1.7). Treatment-emergent AEs (TEAEs) occurred at similar rates among
PALM groups (60.0–63.2%) and PBO (65.2%). Among the most common
TEAEs, events that occurred 2% more frequently with PBO than PALM
(total group), were: insomnia (16.5 vs 11.5%) and schizophrenia (11.6 vs
8%). The incidence of serious TEAEs was higher with PBO (14.0%)
than any PALM group (25mg eq. = 9.4%, 100mg eq. = 13.3%, 150mg
eq. = 8.0%). The incidence of EPS-related TEAEs was low; akathisia
was the most frequently reported EPS-related AE across all groups
(PBO = 4.9%, 25mg eq. = 1.3%, 100mg eq. = 4.8%, 150mg eq. = 5.5%). In-
cidence of 7% weight increase was dose-related with PALM (25mg eq. =
6%, 100mg eq. = 8%, 150mg eq. = 13%) vs PBO (5%). Local injection site
tolerability was good. PALM treatment was safe and effective in subjects
with acute exacerbation of schizophrenia when initiated with a 150mg eq.
dose in the deltoid muscle (Day 1) followed by 25–150mg eq. doses
monthly, beginning on Day 8 in deltoid or gluteal muscle. There was
a dose-response in primary and secondary efficacy endpoints (PANSS
and PSP), and there were no unexpected AEs. The benefit/risk profile of
PALM was favorable.
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FAMILY MOTIVATION INTERVENTION IN EARLY
ONSET PSYCHOSIS AND CANNABIS ABUSE:
A RANDOMIZED CLINICAL TRAIL
Maarten Smeerdijk, R. Keet, L. De Haan, G. Schippers,
D. Linszen
Psychiatry, AMC, Amsterdam, Netherlands
There is a high prevalence of cannabis abuse in individuals with schizophre-
nia and related disorders. This is unfortunate as it has been found that can-
nabis abuse is an independent risk factor for aggravation of psychotic
symptoms, longer treatment duration, more re-admissions and poorer
treatment compliance. For relatives of patients with schizophrenia it is of-
ten frustrating that the patient seems unwilling to change the cannabis use,
even when the negative consequences are so obvious. As a result most rel-
atives develop a highly critical attitude towards the cannabis use, which in
turn evokes more resistance to change in the patient. In the Amsterdam
Adolescent Clinic we designed an innovative family group intervention
called Family Motivational Intervention (FMI). FMI combines evidenced
based insights from motivational interviewing, psychoeducation and family
interventions into one integrated approach. We hypothesize that training
parents in a motivational approach will ameliorate their interaction with
the patient and facilitate positive behavioural changes in patients with early
onset psychosis. A total of 85 relatives of 53 patients with early psychosis
were randomly assigned to psychoeducation only (PE) or to FMI. Outcome
measures were changes in cannabis use and in compliance, consequences for
caring and needs, and consequences for the interaction between patient and
carers. Preliminary results of the first two FMI groups show that 44%
patients in the FMI group (n = 15) reached abstinence in cannabis use
at the end of treatment compared to 18% in the PE group (n = 17). Other
benefits of FMI included an increase in percentage of days the patient were
abstinent from cannabis. No significant differences were found between the
groups in changes in use of other substances and in compliance to medi-
cation. With regard to the relatives, there were no significant difference be-
tween PE (n = 22) and the FMI (n = 24) groups concerning consequences for
caring and needs. These preliminary findings suggest that teaching relatives
motivational techniques is beneficial over psychoeducation only in reducing
cannabis use in patients with recent onset psychosis. Although, our family
intervention did not show advantages over psychoeducation in reducing
carers concern and needs. At this moment we are completing the data
set to establish the overall effectiveness of FMI.
ID: 551039
QUETIAPINE FOR THE TREATMENT OF PATIENTS
WITH SCHIZOPHRENIA AND ALCOHOL USE
DISORDERS
Mary Brunette1, A. I. Green1, P. F. Buckley3, C. O’Keefe1,
R. Dawson2
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2Frontier Science and Technology Foundation, Boston, MA, USA;
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Preliminary studies suggest that quetiapine, a mixed dopaminergic and se-
rotonergic agent used for the treatment of psychosis, may decrease sub-
stance use or craving for substances in patients with schizophrenia. We
report here on an open label, 3-month study of 23 patients with schizophre-
nia or schizoaffective and co-occurring alcohol use disorder conducted at
two sites. Results for the 17 study subjects who completed at least one
month of quetiapine treatment (mean dose 472 6 255 mg) revealed that
psychiatric symptoms improved (mean total PANSS changed from
73.41 6 16.9 to 62.94 6 17.72; t = 2.72, df = 16, P = .015). Due to sub-
stantial site differences, drinking outcomes are reported separately for
the two study sites. At Site 1 (N = 11), mean days of drinking each
week did not change significantly (3.18 6 1.63 to 2.71 6 2.32, t = 1.2,
df = 10, P = .26). At site 2 (N = 6) mean days of drinking dropped from
3.42 6 1.32 to 0.37 6 0.35, t = 6.1, df = 5, P = .002. In that site, the majority
of patients (83.3%) were in a psychiatric unit prior to medication initiation.
Additionally, other site differences were present. Conclusion: Quetiapine
may have a positive impact on psychiatric symptoms and on alcohol use
in patients with co-occurring schizophrenia and alcohol use disorder but
significant site differences impact our ability to interpret the findings of
this pilot study. Randomized, controlled trials are needed to clarify, con-
firm and extend these findings.
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PRIOR PARTICIPATION IN CLINICAL TRIALS IN
SCHIZOPHRENIA: HOW COMMON IS IT?
Amir H. Kalali1,2, P. Randall1,2, K. Jacobs1,2
1Quintiles, San Diego, CA, USA; 2Psychiatry, UCSD, San Diego,
CA, USA
Background: As documented in a recent article , there has been a historical
reduction in the drug-placebo difference in multicenter trials of antipsy-
chotic medications in schizophrenia. Many possible explanations for this
finding have been raised, including the fact that clinical trial subjects
may have different characteristics. One possible difference between subjects
entering clinical trials now and those who entered earlier clinical trials may
be prior participation in a clinical trial. We examined data obtained during
screening of patients for a global clinical trial to determine the extent to
which subjects had been involved in a previous clinical trial for schizophre-
nia. Additionally, we describe how subject trial experience varied across
geographical regions. Methodology: The clinical trial examined was of
6-weeks duration and enrolled patients with an acute exacerbation of
schizophrenia. One of the protocol criteria excluded subjects who had par-
ticipated in a trial within 6 months of screening. Screening data included
whether the subject had participated in a prior clinical trial for the treat-
ment of scizophrenia. These forms were examined on all subjects screened.
Results:Number of Subjects (Percentage) with Prior Trial Experience In
Region: US 45/86 (52%) Russia 16/75 (21%) Ukraine 2/49 (4%) India 1/
60 (2%) All Subjects 64/270 (24%). Conclusions: This data demonstrates
that prior trial experience of subjects varies significantly based on geographical
region with over half of the US subjects screened having reported prior par-
ticipation in a clinical trial for the treatment of schizophrenia. These data un-
derscore the importance of further careful study of the characteristics of
clinical subject entering clinical trials.
Reference
1. Aaron S. Kemp, Nina R. Schooler, Amir H. Kalali, et al. Schizophr
Bull. 2008 Aug 22.
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GROUP COGNITIVE BEHAVIORAL SOCIAL SKILLS
TRAINING FOR SCHIZOPHRENIA
Eric Granholm
1Psychology, VA San Diego Healthcare System, San Diego,
CA, USA; 2Psychiatry, University of California, San Diego,
San Diego, CA, USA
The majority of clinical trials of cognitive behavioral therapy (CBT) for
schizophrenia used an individual therapy, but some promising results
have been reported using group therapy. Group CBT tends to be more com-
mon in the U.S. than in the U.K. One important difference between group
and individual CBT is that groups tend to emphasize skills training over
detailed case formulation. There is less time in groups to fully explore the
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unique content and history of each person’s belief system. Group therapy is
also a useful format for behavioral skills training, like social skills training.
Social functioning is also a more common treatment target in the U.S. than
in the U.K., where positive symptom reduction is the predominant primary
treatment target. An example of a more behavioral group CBT approach
that targets psychosocial functioning in the U.S. is cognitive behavioral so-
cial skills training (CBSST). CBSST is a 24 to 36 session weekly group ther-
apy intervention that combines cognitive therapy with social skills training
and problem solving training to improve functioning in people with schizo-
phrenia. Behavioral practice of communication skills and goal-focused
problem-solving skills are combined with practice of thought challenging
skills. A focus of CBSST is on challenging thoughts that interfere with
use of skills in the community (eg, ‘‘I will be harmed if I go out;’’ ‘‘It
won’t be fun;’’ ‘‘I won’t be able to do it’’). By challenging these dysfunc-
tional performance beliefs and illness-related thoughts (eg, paranoia) that
interfere with the execution of everyday activities, participants are more
likely to engage in community functioning activities. In a randomized con-
trolled trial that compared treatment as usual (TAU) with TAU plus group
CBSST in 76 outpatients with chronic schizophrenia, participants in
CBSST groups showed significantly greater self-reported independent com-
munity functioning, but not symptoms, than participants in standard care,
and improvements in functioning were maintained at 1-year follow-up.
Similar greater benefit for functioning than for symptom outcomes was found
at end of treatment in a second trial of 90 people with schizophrenia random-
ized to CBSST or a supportive goal-focused contact control condition. In
contrast to U.K. CBT interventions for psychosis, which typically show
greater benefit for symptoms than for functioning, group CBSST developed
in the U.S. showed greater benefit for functioning than for symptoms.
ID: 550952
A COMPREHENSIVE RETROSPECTIVE AUDIT OF
THE USE OF RISPERDAL CONSTA IN AN AREA
MENTAL HEALTH SERVICE IN MELBOURNE,
AUSTRALIA
Rolet Anthony de Castella, J. Kulkarni, P. B. Fitzgerald,
A. Nicol, C. Furtado, F. Biffin, P. Williams
Alfred Psychiatry Research Centre, Monash University, Prahran,
VIC, Australia
Background: Risperdal Consta is the first depot atypical antipsychotic on
the market. Early use of new medications is often a matter of trial and error,
until real world usage data becomes available. Aim: To investigate how Ris-
perdal Consta has been used during the 1st 12 months after release on the
PBS in patients with schizophrenia, and to describe patient outcomes.
Method: Medical records of all clients initiated on RC during the first
6 months after approval on the PBS were reviewed for 12 months pre
RC, and 12 months post RC. Data captured pre and post RC included;
pharmacotherapy, hospitalisations, adherence, substance use, reason for
switch to RC, start dose of RC, location of initiation, and length of treat-
ment on RC. Results: 141 files were reviewed. Mean age was 40.4 years.
Two thirds were men. Mean duration of illness was 12 years. 85% had
been hospitalised in the 2 years prior to RC, but only 45% were hospitalised
post RC. Previous primary AP’s were oral risperidone 28%, Zuclo deco-
noate 22%, and lanzapine 16%. 70% of clients were initiated on RC while
inpatients, 80% of clients had 2 or less dose changes of RC in the 1st 12
months. More than 35% of clients were continuing on RC after 12 months.
81.5% of clients received some concomitant oral antipsychotics medications
during the 1st 12 months, most commonly oral risperidone (76%). 10.4% of
clients were reported to have good adherence pre RC compared while 70.4%
had good adherence post RC. The most common reason for discontinuation
of RC was inadequate response (43%), and the most common AP post RC
was clozapine (33%). Conclusion: This study provides real world data about
the use of RC in an Area Mental Health Service, which will help guide clini-
cians in the use of this medication in treating patients with schizophrenia.
ID: 550935
TRANSLATION AND CULTURAL ADAPTATION OF
THE MATRICS CONSENSUS COGNITIVE BATTERY
Keith H. Nuechterlein1,2, M. F. Green1,3, R. S. Kern1,3
1Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles,
CA, USA; 2Psychology, UCLA, Los Angeles, CA, USA;
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The development of the MATRICS Consensus Cognitive Battery (MCCB)
established a ‘‘gold standard’’ cognitive endpoint for clinical trials of treat-
ments that target the core cognitive deficits of schizophrenia. Use of this
standard battery allows reliable and valid measurement of seven key cog-
nitive domains and valid comparisons across different clinical trials. The
current applications of the MCCB in English in several clinical trials
have made clear that availability of the MCCB in multiple languages is
now a key issue, as it will be used in numerous international clinical trials.
This presentation describes the steps that have been taken over the last two
years to translate and culturally adapt the MCCB for five initial languages
(simplified Chinese, German, Hindi, Russian, and Spanish), plus three dia-
lects of Spanish for Central and South America. To ensure a high-quality
MCCB version in each language that complies with copyrights, the process
has involved multiple steps of professional forward translation, back trans-
lation, reconciliation of differences, evaluation by native language psychol-
ogists/psychiatrists, review and approval by the original test developers and
intellectual property owners, pilot testing, and page composition/printing.
This presentation will describe examples of issues that arise in translation
and cultural adaptation of cognitive performance measures and ways to
successfully resolve them. The presentation will also focus on the ongoing
steps to develop norms for the MCCB in these languages. The progress of
academic researchers who are translating the MCCB into a number of ad-
ditional languages will be summarized. Together these steps are furthering
a key NIMH goal for the MATRICS initiative—to facilitate the evaluation
of promising new treatments for the core cognitive deficits of schizophrenia.
ID: 550920
FOLLOW UP OF PATIENTS WITH TREATMENT
REFRACTORY SCHIZOPHRENIA AFTER A SOCIAL
LEARNING PROGRAM
Adam J. Savitz, K. C. McGovern, L. Grant, J. English
Psychiatry, Weill Cornell Medical College, White Plains, NY, USA
Since the 1970s, research shows that social learning programs (SLPs, token
economies) effectively transition chronically hospitalized patients with
schizophrenia to the community. A major criticism of SLPs is the benefits
do not continue in the community since the behavioral interventions are no
longer present. The Second Chance Program (SCP) is an inpatient SLP lo-
cated at a private academic hospital. Most patients come from NY state
hospitals (80%). Admission criteria are willingness to come, primary psy-
chotic disorder, and no recent sustained community tenure. Most patients
have been institutionalized the majority of their adult lives, 2/3 are male, 2/3
have substance abuse histories, and approximately 1/2 have criminal histo-
ries. The length of stay is 6 to 12 months. The SLP focuses on skill training
in areas such as ADLs and rewarding community appropriate behaviors.
Pharmacology is optimized with about 2/3s of patients being on clozapine.
For this study, patients received routine clinical care by community
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providers and were tracked in the community. METHODS: Consenting
patients are administered a baseline assessment (T0) upon discharge
from the SCP. This battery assesses symptoms (BPRS and SANS), subjec-
tive well being, independent living skills (ILSS), and quality of life. Patients
are followed at 6 and 12 months post-discharge. Only 6 months data (T1)
are currently available. Results: In the last 5 years, 156 patients have been
discharged from SCP; 86% were discharged to the community; of these,
22% relapsed and returned to SCP. Most of these patients were subse-
quently discharged back to the community. 34 patients consented for
the study. At 6 months, 20 were still in their placements while the others
had been rehospitalized or had left the residential program. Of these, 12
were available and completed their 6-month follow-up. There was no sig-
nificant difference from baseline to 6 months in symptoms, as measured by
the BPRS (T0 = 52.6, T1 = 46.1, P = .119) and SANS (T0 = 28.1, T1 = 29.7,
P = .744). Quality of life remained the same (T0 = 5, T1 = 5.9, P = .121). The
ILSS showed no significant changes in hygiene (T0 = 93.2, T1 = 92.5, P =
.795) or personal appearance (T0 = 96.1, T1 = 97.5, P = .576). Conclusion:
These results show the benefits of a SLP continue in the community even
with no additional reinforcement of the skills learned. Symptoms as well as
important skills such as ADLs are maintained during this time for those
patients, who were available at follow-up.
ID: 550885
LURASIDONE FOR SCHIZOPHRENIA:
SYMPTOMATIC REMISSION DURING
SHORT-TERM TREATMENT
John Guarino1, A. Loebel1, J. Cucchiaro1, M. Ogasa1, R. Silva1,
C. Siu2
1Dainippon Sumitomo Pharma America, Fort Lee, NJ, USA; 2Data
Power, Inc., Ringoes, NJ, USA
Background: Lurasidone is a novel psychotropic agent with high affinity
for D2 and 5-HT2A receptors, as well as for receptors implicated in enhance-
ment of cognitive function (partial agonist at 5-HT1A; antagonist at 5-HT7).
In this analysis, we investigated rates of symptom resolution for lurasidone
treatment, using data from a double-blind, placebo-controlled, 6-week trial
in hospitalized patients with schizophrenia. Methods: Adult outpatients
were recruited who were hospitalized for an acute exacerbation of schizo-
phrenia meeting DSM-IV criteria. After completing a single-blind, 3–7 day
placebo washout period, eligible patients were randomized to 6 weeks of
fixed-dose treatment with lurasidone 40 mg (N = 50; baseline PANSS total,
92.8), lurasidone 120 mg (N = 49; PANSS total, 89.6), or placebo (N = 50;
PANSS total, 93.3). Symptomatic remission was defined, using consensus
criteria (Andreasen et al. Am J Psychiatry 2005;162:441–449), as an LOCF-
endpoint score%3 (mild or less) on 8 core PANSS items (P1-3, G5, G9, N1,
N4, N6). Results: Treatment with lurasidone (40 mg and 120 mg, respec-
tively) was associated with significantly greater LOCF-endpoint improve-
ment than placebo on the PANSS total score (12.9 and 16.1 vs. 5.7;
P < .05 for both comparisons to placebo). Treatment with lurasidone
120 mg or 40 mg was also associated with significantly higher remission
rate at endpoint compared to placebo (31% and 34% vs. 6.1%; P < .01).
Number needed to treat rates (NNT [95%-CI]) for achieving remission
were similar for lurasidone 40 mg (NNT = 4.0 [3, 10]), and lurasidone
120 mg (NNT = 3.6 [2, 8]). A significantly higher proportion of patients
treated with lurasidone 120 mg completed the 6-week study and met criteria
for remission compared to placebo (P = .02), a numeric trend favoring
LUR 40 vs. placebo was found (P = .08). Conclusion: In this short-term, pla-
cebo-controlled, phase 2 trial, the novel psychotropic lurasidone was
associated with higher remission rates than placebo. Further studies are un-
derway to fully characterize lurasidone’s clinical profile and dose-response
characteristics.
ID: 550841
EFFECT OF ARIPIPRAZOLE VS HALOPERIDOL ON
PANSS PROSOCIAL ITEMS IN EARLY EPISODE
PATIENTS WITH SCHIZOPHRENIA
John P. Docherty1, R. A. Baker2, E. Kim2, A. Pikalov3,
J. Eudicone2, S. Mathew3, R. Mankoski2, R. D. McQuade4,
R. N. Marcus5
1Comprehensive Neuroscience Inc., White Plains, NY, USA;
2Bristol-Myers Squibb, Plainsboro, NJ, USA; 3Otsuka America
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Previous work has demonstrated that a certain negative symptoms show
little change with antipsychotic drug treatment. Other work has shown
that relatively small improvement in these symptoms appear to be corre-
lated with larger change in function. Thus these residual symptoms may
pose an important barrier to functional recovery. Clinical reports have sug-
gested a specific benefit from aripirazole in some patients on these ‘‘barrier
symptoms.’’ To assess this observation, we compared the effect of aripipra-
zole vs haloperidol in early episode patients with schizophrenia on relevant
PANSS items using two PANSS scales, the Prosocial scale and a modified
Proscial scale. Early episode was defined as less than or equal to 40 years of
age, and less than or equal to five years since first diagnosis. The PANSS
Prosocial subscale consists of six PANSS items broadly related to social
engagement (1), the modified prosocial subscale consists of four PANSS
items, including difficulty with abstract thinking, anitem not contained
within the prosocial subscale but an empirically demonstrated prominent
residual symptom. Measurements were taken at approximately monthly
intervals for up to one year. Least square mean changes from baseline
in both groups were compared for each subscale using an ANOVA model
with last observation carried forward. Aripiprazole demonstrated signifi-
cant improvements vs haloperidol as early as week 18 on both the prosocial
subscale (4.75 for aripiprazole (n = 237) vs3.78 for haloperidol (n = 123,
P < .05)) and on the modified prosocial subscale (3.16 for aripiprazole
vs 2.27 for haloperidol P < .05). Patients showed similar significant
improvements over time at all remaining testing intervals through week
52 using the modified subscale, but less consistent improvement over
time with the prosocial subscale. Similar significant improvements at weeks
46 and 52 (endpoint) were observed with both subscales. In patients with
early episode schizophrenia, aripiprazole demonstrates greater improve-
ments in prosocial PANSS items than haloperidol. The cognitive and func-
tional implications of these findings remain to be clarified in future
prospective studies.
Reference
1. Purnine DM, et al. J Nerv Ment Dis. 2000;188:653–61.
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MODAFINIL IMPROVES WORKING MEMORY
AND EMOTIONAL FACE RECOGNITION IN FIRST
EPISODE PSYCHOSIS
Linda Scoriels1, J. Barnett1, G. Murray1,2, B. Sahakian1,
S. Cherukuru2, M. Fielding2, F. Cheng2, P. Jones1,2
1Psychiatry, Cambridge University, Cambridge, United Kingdom;
2Cambridgeshire and Peterborough Mental Health NHS Trust,
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Cognitive and emotional impairments are important determinants of
functional outcome in schizophrenia. People suffering from first-episode
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psychosis (FEP) also show these dysfunctions and current antipsychotic
drugs do not help. Modafinil is a wake-promoting drug commonly used
for sleep disorders. Modafinil can enhance mood, attention, memory
and executive functions in healthy volunteers, schizophrenia and bipolar
depression. Following the research into the effects of modafinil in chronic
schizophrenia, we aimed to establish the role of modafinil in the adjuvant
treatment of schizophrenia in the FEP, a time when strict diagnosis is often
difficult to establish but when therapeutic endeavor is arguably most vital.
A within-subject, randomized, double-blind, placebo-controlled crossover
study was carried out. To date, 27 patients attended on two occasions sep-
arated by at least one week. On each occasion, patients received either a sin-
gle dose of 200 mg modafinil or a placebo prior to cognitive assessment. Our
preliminary results show that a single dose of modafinil significantly im-
proved digit backward (P = .016). Modafinil showed significant improve-
ment in face recognition for baseline low performers (P = .028), but not for
high performers. There was a trend for an improvement in emotional face
recognition with modafinil (P = .053) and a significant improvement in rec-
ognition of sad faces (P = .008). Modafinil showed a significant improve-
ment in emotional face recognition (P = .042) for high performers when
groups were segregated. Modafinil improves working memory in the
FEP, confirming the results found in chronic schizophrenia. But, more in-
terestingly, modafinil also improves face recognition for low performers,
who probably have more difficulties in this type of processing. Modafinil
improves emotional face recognition, and this is particularly true for high
performers. Low performers are impaired in face recognition, which is im-
proved by modafinil but does not seem enough to improve their ability in
recognizing emotional faces. Conversely, high performers do not seem to
need help for recognizing faces, but modafinil does help them in the discrim-
ination of emotional faces.
ID: 563567
TELEHEALTH MONITORING OF PATIENTS WITH
SCHIZOPHRENIA AND SUICIDAL BEHAVIOR
John Kasckow1,2, J. Gurklis1, R. Thompson1, R. Crofutt1,3,
T. Murray1,3, I. Richmond1,3, G. Haas1,2
1MIRECC and Behavioral Health, VA Pittsburgh Health Care
System, Pittsburgh, PA, USA; 2Western Psychiatric Institute and
Clinics, University of Pittsburgh Medical Center, Pittsburgh, PA,
USA; 3Nursing Service, VA Pittsburgh Health Care System,
Pittsburgh, PA, USA
Suicide is the leading cause of premature death in patients with schizophre-
nia. This project evaluates feasibility and impact of implementing a special-
ized telemental health case management program using the ‘‘Health
Buddy’’ (HB) to reduce suicidality among patients with schizophrenia.
We hypothesized that use of this device would result in a greater decrease
in psychiatric symptoms for patients with schizophrenia recently hospital-
ized for escalating suicidality. Subjects with ages > 17 years with schizo-
phrenia were admitted for worsening suicidal ideation or recent suicide
attempt. In addition, patients had scores > 0 on items 4 and/or 5 from
the Scale for Suicidal Ideation (SSI). Exclusion criteria: a) MMSE score
< 20, b) a serious active medical or other psychiatric disorder which could
impact diagnosis, safety, or anticipated adherence. Subjects were randomly
assigned to receive 24-week intensive case management (ICM; weekly face-
to-face assessments and twice weekly phone calls for safety monitoring by
outpatient nursing staff) or 24-week ICM with the addition of the HB. Fre-
quency of contact was decreased contingent on suicidal ideation. Subjects
assigned to the HB condition provided daily reports of depressive and sui-
cidal symptoms; this was monitored by inpatient nursing staff twice per
8 hour shift over a 24-hour period. Repeated measures ANOVA was used
to measure treatment differences in symptom change for HB versus control
(CON) cases from baseline to Month 1 and Month 2 on the SSI, the Calgary
Depression Rating Scale , Clinical Global Impressions, and the Scale for
Positive Symptoms. Out of 186 patients screened, 32 had recent escalation
of suicidal ideation or suicide attempt. Seventeen patients signed informed
consent and 13 were randomized to treatments: 7 to the Health Buddy (HB)
group and 6 to the control (CON) group. Preliminary findings reveal rel-
atively good adherence to use of the Health Buddy (rates ranged from 87–
100% over month 1 and 78% to 100% over month 2). After 2 months there
were greater improvements in suicidal ideation (P = .04) and positive symp-
tom (P = .02) scores for HB subjects relative to CON patients. These pre-
liminary findings suggest that patients show relatively high levels of
adherence to HB monitoring and that HB monitoring over 2 months is as-
sociated with more rapid remission of suicidal ideation among patients
with schizophrenia recently discharged from the hospital for treatment
of suicide.
ID: 554174
MULTI-REGIONAL BRIDGING STUDIES: COM-
PARING EFFICACY AND TOLERABILITY OF
INTRAMUSCULAR/ORAL ZIPRASIDONE AND
HALOPERIDOL IN ASIA TO EUROPE/SOUTH
AMERICA
Bruce Parsons1, C. Siu2, G. Cohen1
1Pfizer, Inc., New York, NY, USA; 2Data Power, Inc., Ringoes,
NJ, USA
Background and Aims: Availability of second-generation antipsychotics
(SGAs) in Asian countries has lagged behind in the United States, Europe
and South America because there have been limited numbers of adequate,
well-controlled studies of efficacy and tolerability in these patient popula-
tions. ICH E5 has provided some guidance for use of multi-regional bridg-
ing studies to support global drug development that could remedy this
problem. There are methodological questions about how to design such
studies and combine evidence from studies in different ethnic groups
and regions. Two identically designed randomized clinical trials of IM/
oral ziprasidone and haloperidol conducted in Asia and Europe/South
America provide the opportunity to synthesize results of an initial and rep-
lication bridging study. Methods: IM/oral ziprasidone (N = 130) was com-
pared to IM/oral haloperidol (N = 122) in a 6-week,randomized trial in
acute schizophrenia conducted in Hong Kong, Malaysia, Philippines, Sin-
gapore, Taiwan and Thailand. The study replicated an identically designed
randomized trial conducted in Europe and South America (79% Caucasian,
N = 600) (Brook et al. 2005). The weighted Z-test method (Lan et al. 2005)
was applied to synthesize the ANCOVA results from Asian bridging and
initial European/South American studies. Results: At the end of IM treat-
ment (<= 3 days), mean change in BPRS total score was 7.7 in the zipra-
sidone group compared with 5.8 in the haloperidol group (P = .066), and
the magnitude of treatment difference (LS mean 1.9; 95% CI [3.9, 0.1];
ZAsian = 1.832) was similar to that observed in (Brook et al. 2005) (LS
mean 2; 95% CI [3.3, 0.8]; ZForeign = 3.149). The combined weighted
Z-statistics for the two studies combined was ZWeighted =3.17 (P< .001). At
endpoint, between-group differences in BPRS total score and COVI
scores were not significant (P > .74) within studies and in combined studies.
Ziprasidone was significantly superior to haloperidol in movement disorder
related measures (ESRS and Barnes Akathisia Scales) and EPS adverse event
rates (4.6% vs. 22% in the IM phase; 20% vs. 61% in the IM and oral phases).
Conclusions: These findings demonstrate consistent efficacy and tolerability
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advantages of ziprasidone over haloperidol in different ethnic groups, and
support extrapolation of bridging evidence from the initial European/South
American study to Asian patients with schizophrenia.
ID: 553531
PSYCHOSOCIAL INTERVENTIONS: IGNORE THEM
AT YOUR PERIL
Shon William Lewis1, A. Morrison2, P. French3, R. Bentall4,1,
D. Fowler5, P. Jones6, M. Birchwood7
1Psychiatry Research Group, University of Manchester,
Manchester, United Kingdom; 2Department of Psychological
Sciences, University of Manchester, Manchester, United Kingdom;
3School of Psychological Sciences, University of Manchester,
Manchester, United Kingdom; 4School of Clinical Psychology,
University of Bangor, Bangor, United Kingdom; 5School of
Medicine, Health Policy and Practice, University of East Anglia,
Norwich, United Kingdom; 6Department of Psychiatry, University
of Cambridge, Cambridge, United Kingdom; 7Department of
Clinical Psychology, University of Birmingham, Birmingham,
United Kingdom
The effectiveness of specific psychological interventions, such as cognitive
therapy, for full psychosis is established, although systematic review shows
the effect size to be moderate at best and is smallest in the most rigorously
designed trials. One problem with interpreting the data is that psychological
treatments are always delivered in the presence of antipsychotic drug treat-
ments and the role of non-specific effects and whether the effect might be
explained by improved drug adherence. The use of cognitive therapy in at
risk mental states allows an estimate of the effectiveness of such treatments
for psychotic symptoms in patients who are free of drug treatments, and
also allows for clearer testing of hypotheses about mechanisms of action.
Data from the UK EDIE trial of cognitive therapy in ARMS (n = 58) and 3
year follow-up will be discussed, and the design of the multisite EDIE
2 randomised controlled trial currently in progress will be presented. No
accepted clinical guidelines for the treatment of people with ARMS yet ex-
ist. Several factors suggest psychological interventions, should their effec-
tiveness be confirmed, be the first line approach in a stepped care model.
Trial data suggest them to be more acceptable than drug treatments and
the number needed to harm (NNH) is likely to be lower. Clarification
of the clinical target is important and reduction of current symptoms is
likely to be of more relevance than prevention of full psychosis. Reliable
population attributable risk estimates are still needed to allow the impact
of successful treatment on the wider incidence of psychosis to be assessed.
ID: 552588
RISK VS BENEFIT: CLINICAL STAGING AS A GUIDE
TO THE USE OF ANTIPSYCHOTICS AND OTHER
STRATEGIES IN PREPSYCHOTIC ILLNESS
Patrick McGorry, A. R. Yung
Orygen Research Centre, University of Melbourne, Melbourne,
VIC, Australia
Diagnosis in psychiatry increasingly struggles to fulfill its key purposes,
namely to guide treatment and to predict outcome. The clinical staging
model, widely used in clinical medicine yet virtually ignored in psychiatry,
is proposed as a more refined form of diagnosis which promotes early in-
tervention and also make more sense of the confusing array of biological
research findings in psychiatry by organising data into a coherent clinico-
pathological framework. Clinical staging has immediate potential to im-
prove the logic and timing of interventions in psychiatry just as it does
in many complex and potentially serious medical disorders. In particular
it could prove a crucial guide for determining the sequence and timing
of interventions in subthreshold psychotic and mood disorders disorder.
Interventions can be evaluated in terms of their ability to prevent or delay
progression from earlier to later stages of disorder, and selected on clearcut
risk/benefit criteria. This framework can be used to study the timing of the
use of antipsychotic and other drug and psychosocial therapies in people at
incipient risk of transition to first episode psychosis. This presentation will
review the available studies in UHR/CHR stages of illness and propose clin-
ical guidelines for intervention.
ID: 552572
RELATIONSHIP BETWEEN ERYTHROCYTE MEM-
BRANE FATTY ACIDS AND TRANSITION TO
PSYCHOSIS IN ULTRA-HIGH RISK INDIVIDUALS:
BASIC RESEARCH FINDINGS FROM A RCT
G. Paul Amminger1,2, M. R. Scha¨fer2, K. Papageorgiou2,
C. M. Klier2, A. Mackinnon1, P. D. McGorry1, G. E. Berger3
1Orygen, Parkville, VIC, Australia; 2Child and Adolescent
Psychiatry, Medical University of Vienna, Vienna, Austria;
3Department of Research and Education, The Schlo¨ssli Clinic,
Oetwil am See, Switzerland
Introduction: Reduced erythrocyte membrane fatty acids, particularly
arachidonic acid (AA) and docosahexaenoic acid (DHA), and an elevated
omega-6:omega-3 ratio have been described in different stages of schizo-
phrenia including drug-naive first episode samples. No study has yet exam-
ined (1) the erythrocyte fatty acid composition in the prodromal phase of
psychosis, or (2) the relationship between fatty acids and transition to psy-
chosis in ultra-high risk individuals. Methods: The study sample comprised
81 UHR individuals (according to criteria of Yung et al. 1998) (mean age =
16.4, SD = 2.1 years) who participated in a RCT of 1.2 g/day omega-3 fatty
acids vs. placebo (ClinicalTrials.gov number, NCT00396643). Baseline
measures included the PANSS, the MADRS, and the GAF. Erythrocyte
membrane fatty acids were determined at baseline using gas chromatogra-
phy. The primary outcome of interest, conversion to psychosis was oper-
ationally defined using cut-off points on the PANSS (4 or more on
hallucinations, 4 or more on delusions and 5 or more on conceptual disor-
ganisation), the frequency of symptoms (at least several times a week), and
their duration (more than 1 week). Correlational analysis was used to detect
associations between fatty acid levels and psychiatric measures at baseline.
Cox regression analysis was used to investigate the predictive validity of
baseline fatty acid levels for psychosis status at 12 month follow-up.
Results: Low DHA (P < .05) and high n-6:n-3 ration (P < .01) correlated
with more severe negative symptoms at baseline. Low trans-vaccenic acid
(P< .01) correlated with more severe PANSS global symptoms at baseline.
93.8% participants (76/81) completed the intervention. By study end (12
months), 4.9% (2/41) individuals in the omega-3 group and 27.5% (11/
40) in the placebo group made a transition to psychosis (P = .004). Cox
regression analysis controlling for effects of treatment revealed low baseline
trans-vaccenic acid as a significant predictor of transition to psychosis
among investigated fatty acids in UHR individuals (P < .05), while
both DHA and AA did not predict transition. Conclusions: The most im-
portant finding of the RCT is that a 12-week intervention with omega-3
fatty acids prevented the onset of psychotic disorder. However, the findings
also suggest that abnormal membrane phospholipid metabolism may con-
tribute to the onset of psychosis in UHR individuals. Supported by Stanley
Medical Research Institute Grant 03-T315.
ID: 552510
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PSYCHOLOGICAL AND PHARMACOLOGICAL
INTERVENTIONS IN THE AT-RISK POPULATION.
RESULTS OF COMPLETED AND THE RATIONALE
OF ONGOING TRIALS AT THE FETZ
A. Bechdolf1,2, S. Ruhrmann1, F. Schultze-Lutter1,
J. Klosterkotter1
1Department Psychiatry and Psychotherapy, University of Cologne,
Cologne, Germany; 2Orygen Research Centre, Melbourne, VIC,
Australia
The early detection and intervention center at the University of Cologne
(FETZ) was founded in 1997. The UHR criteria as well as the predictive
validity of the basic symptoms has been intensively researched. Moreover,
one of the focuses has been the evaluation of psychological and pharma-
cological interventions in the at -risk population. CBT as well as antipsy-
chotics (AP) have been found to at least delay the onset of first episode
psychosis in people at risk. Recently the multicenter PREVENT-study
commenced, which explores the differential treatment effects of CBT
and AP in this population. This question has far reaching ethical, accep-
tance and compliance implications of the indicated prevention approach
in general. The results of the intervention studies led by the FETZ will
be presented as well as the rationale and the design of the recent PREVENT
study.
ID: 552497
THE KEY TO EFFECTIVE PREVENTION OF PSY-
CHOSIS IS UNDERSTANDING AND TARGETING
THE MECHANISMS UNDERLYING CLINICAL AND
FUNCTIONAL DETERIORATION
Tyrone D. Cannon1,2
1Psychology, UCLA, Los Angeles, CA, USA; 2Psychiatry and
Biobehavioral Sciences, UCLA, Los Angeles, CA, USA
The psychosis prodrome is a clinical risk construct with modest ability to
predict onset of psychosis. Its long-term promise is to facilitate recruitment
of those at greatest risk into prevention trials. With no demonstrable pro-
phylactic effects, and with little or no effect on motivational symptoms or
functional disability, antipsychotic drug treatment is clearly not the ‘silver
bullet’ of psychosis prevention. Specification of rational preventive inter-
ventions requires knowledge of the mechanisms underlying progression
from prodromal to fully psychotic symptoms. In several recent studies, pro-
dromal patients who progressed to psychosis showed differential profiles of
neurobiological change compared with those who did not. In one study,
converters showed a significantly greater rate of surface contraction in right
prefrontal regions when compared directly with non-converters. The brain
surface contractions in the converters resembled the patterns found in
healthy controls and in first-episode schizophrenia patients. First-episode
patients showed a significantly steeper rate of gray matter reduction than
the healthy subjects, but in the same regions that healthy subjects evidenced
maturation-related decline. In a study of white matter integrity, prodromal
patients failed to show the normal increase in fractional anisotropy (FA)
with age that was observed in the healthy adolescent control group, and
lower FA in the patient group was predictive of poorer functional outcome
at follow-up. Together, these findings suggest that regressive developmental
processes active during late adolescence and early adulthood that are likely
to result in reduced cellular connectivity (synaptic pruning and disrupted
white matter development) may underlie the emergence and early course of
psychotic symptoms. While the results of these studies are provocative in
this regard, they are limited primarily by the small numbers of cases in-
cluded, the uncontrolled nature of treatments received by the patients,
and heterogeneity of outcomes among converters. To deliver on the prom-
ise of a prevention strategy for psychosis, the next wave of prodromal re-
search must use very large samples and incorporate biological measures to
identify the neurobiological mechanisms underlying the clinical and func-
tional deterioration associated with psychosis onset and to develop modes
of intervention that are theoretically predicted to prevent progression from
a prodromal to fully psychotic state.
ID: 552379
THE PRODROMAL SYMPTOMS OF PSYCHOSIS:
EXPERIENCES FROM THE TOPP CLINIC
T. K. Larsen, N. Helland, L. K. Skryten
Stavanger University Hospital, Stavanger, Norway
Background: This project is related to an ongoing international multi-site
study testing the efficacy of Early Treatment and Intervention in schizo-
phrenia (TIPS). Method: The project tests whether ‘‘prodromal’’ people
(symptomatic, pre-psychotic) can be identified who are at very high risk
for developing psychosis. The sample consists of treatment seeking patients
aged 15–65 who are at very high risk for imminent conversion to psychosis.
They are informed of their state of being at risk and recruited for a five year
follow-along study with supportive psychotherapy, and assessment after
3 months, 1, 2 and 5 years. A Norwegian version of the SIPS (Structured
Interview for Prodromal Symptoms) is used to assess conversion to psychosis.
Results: 40 patients are included, during the first year of follow-up 8 cases
have developed psychosis which equals 20%. We see a clear decrease in symp-
toms during the first 3 months of treatment. Approximately 50% participate
in psychotherapy, antipsychotic medication is not prescribed. Conclusion:
The conversion rate is lower than in similar international studies. This might
be an effect of intensive psychotherapy or sample selection. Our experiences
will be discussed with focus on psychotherapeutic processes. The study
is supported by NARSAD (the National Alliance for Research in
Schizophrenia and Depression).
ID: 552116
THE IMPACT OF GEOGRAPHY AND SOCIAL CON-
TEXT ON ULTRA HIGHRISK FOR SCHIZOPHRENIA
RESEARCH IN RURAL AUSTRALIA
Helen J. Stain1,3, K. Crittenden1,2, E. Bennett1,2, M. Startup2,3,
V. Carr2,3, A. Baker2,3, U. Schall2,3, B. Kelly1,2, S. Halpin4,5,
S. Bucci4,5, J. Fleming2,4, R. Sakrouge4
1Centre for Rural and Remote Mental Health, University of
Newcastle, Orange, NSW, Australia; 2Centre for Brain and Mental
Health Research, University of Newcastle, Newcastle,
NSW, Australia; 3Schizophrenia Research Institute, Sydney, NSW,
Australia; 4Hunter Medical Research Institute, Newcastle, NSW,
Australia; 5Psychological Assistance Service, Hunter New England
Area Health Service, Newcastle, NSW, Australia
Introduction: The Detection, Evaluation and Psychological Therapy
(DEPTh) project, an Australian randomised controlled trial of cognitive
behavioural therapy for ultra high risk (UHR) youths, began in 2006 across
rural and urban sites. There are known difficulties in recruitment to UHR
studies1 and a lack of research directed towards early intervention service
delivery for rural youth. Factors that impact on UHR research in rural
areas include limited specialist mental health services2, vast distances cou-
pled with sparse population distribution, and the social context for rural
youth3. Aim: This paper will present findings regarding recruitment and
retention in treatment for DEPTh, focusing on the unique characteristics
of the rural site, where no early intervention service or UHR research pro-
gram existed prior to the study. Method: Recruitment at the rural site in-
volved many non health youth services. Rural recruitment strategies
involved: referrer education about UHR mental states; repeated promotion
of the DEPTh project; extensive travel for staff; provision of comprehensive
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assessment reports to referring agencies; case management; and enhanced
interaction between research staff and referring agencies. Results: Stronger
rural referral rates compared to urban were indicative of a lack of early
intervention services. Rural participants were generally marginalised youth,
often disengaged from ‘‘main stream’’ services, families and education.
Clinical profiles showed some differences compared to the urban sample.
Discussion: Geography, social context and presence of clinical services im-
pact on the rate of recruitment as well as pathways and clinical profiles of
youth for UHR research in rural areas. The use of videoconferencing and
close linkage to existing mental health and youth related services facilitated
recruitment and retention for DEPTh.
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